<SEC-DOCUMENT>0000805928-23-000020.txt : 20230314
<SEC-HEADER>0000805928-23-000020.hdr.sgml : 20230314
<ACCEPTANCE-DATETIME>20230314163839
ACCESSION NUMBER:		0000805928-23-000020
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		103
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230314
DATE AS OF CHANGE:		20230314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Axogen, Inc.
		CENTRAL INDEX KEY:			0000805928
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				411301878
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36046
		FILM NUMBER:		23731577

	BUSINESS ADDRESS:	
		STREET 1:		13631 PROGRESS BLVD.
		STREET 2:		SUITE 400
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615
		BUSINESS PHONE:		(386) 462-6817

	MAIL ADDRESS:	
		STREET 1:		13631 PROGRESS BLVD.
		STREET 2:		SUITE 400
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AxoGen, Inc.
		DATE OF NAME CHANGE:	20111004

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LECTEC CORP /MN/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>axgn-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:008e6d96-0028-47c7-9dfe-7d6d669b55a8,g:6a78ba92-a70c-4cec-a491-e196b80cf77c,d:3b0f4bcd44e346a09eb3f60d2751bcde--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:axgn="http://www.axogeninc.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>axgn-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV80L2ZyYWc6MGNiZjM3Nzc0OTE4NDAwNGI4Zjk4MzY3ZjlmZTFhYzUvdGFibGU6ZjRiNGFjM2M0YWZlNGViMGFlYjA3NGJiYTVhY2JmNGIvdGFibGVyYW5nZTpmNGI0YWMzYzRhZmU0ZWIwYWViMDc0YmJhNWFjYmY0Yl8wLTEtMS0xLTEwMjQzMQ_e7d81657-03b9-45a1-aa35-d1dc60737fb0">0000805928</ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV80L2ZyYWc6MGNiZjM3Nzc0OTE4NDAwNGI4Zjk4MzY3ZjlmZTFhYzUvdGFibGU6ZjRiNGFjM2M0YWZlNGViMGFlYjA3NGJiYTVhY2JmNGIvdGFibGVyYW5nZTpmNGI0YWMzYzRhZmU0ZWIwYWViMDc0YmJhNWFjYmY0Yl8yLTEtMS0xLTEwMjQzMQ_f5bbdde5-c941-4d9c-8e7a-9a66d7064adc">2022</ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV80L2ZyYWc6MGNiZjM3Nzc0OTE4NDAwNGI4Zjk4MzY3ZjlmZTFhYzUvdGFibGU6ZjRiNGFjM2M0YWZlNGViMGFlYjA3NGJiYTVhY2JmNGIvdGFibGVyYW5nZTpmNGI0YWMzYzRhZmU0ZWIwYWViMDc0YmJhNWFjYmY0Yl8zLTEtMS0xLTEwMjQzMQ_67570d5c-4070-4abf-8bc2-d05df6d66a19">FY</ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV80L2ZyYWc6MGNiZjM3Nzc0OTE4NDAwNGI4Zjk4MzY3ZjlmZTFhYzUvdGFibGU6ZjRiNGFjM2M0YWZlNGViMGFlYjA3NGJiYTVhY2JmNGIvdGFibGVyYW5nZTpmNGI0YWMzYzRhZmU0ZWIwYWViMDc0YmJhNWFjYmY0Yl80LTEtMS0xLTEwMjQzMQ_3de4cf71-ea1c-4f3b-bbbf-704677e63628">false</ix:nonNumeric><ix:nonNumeric contextRef="i5efaab989c6841568efb1406dbb75d6c_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg2NTE3MQ_1b1457ed-1497-471b-a70d-aa52a8985c35">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_53f04da6-b4de-4448-a842-3ba64e7044cf">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_d6f381e2-5ace-449f-8744-bd43ca3d4c2a">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_e7410970-08ee-44c3-807d-dbdd552f3cb6">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" name="us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_2ffaa088-42a3-4658-a56e-41bcb91c69e1">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" name="us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_6ac65a1e-f9f2-4c6f-9b60-403fe0960398">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_282ba7ce-3ef3-47fa-b090-df6bc8c1cb62">http://www.axogeninc.com/20221231#LeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_bf9cd539-7ed8-407f-9081-99b74e7abdea">http://www.axogeninc.com/20221231#LeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_43b1e322-811d-4e24-9d5c-24c744c9ffc6">http://www.axogeninc.com/20221231#LeaseLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_90aa3a79-3bec-4569-a69a-52d996616d6a">http://www.axogeninc.com/20221231#LeaseLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_271319ea-950a-424e-8fc3-fea671d857ad">http://www.axogeninc.com/20221231#LeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_51dc3b73-6881-4d4b-ad5d-be166f123d9e">http://www.axogeninc.com/20221231#LeaseLiabilityCurrent</ix:nonNumeric><ix:nonNumeric contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_ad5ae935-b90b-46e6-8d03-aa77e93ca8d3">http://www.axogeninc.com/20221231#LeaseLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_d55777eb-f537-4f2f-82c6-3481b4ecb124">http://www.axogeninc.com/20221231#LeaseLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i289e4e30f0654ba2b3181339326c280d_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI3NjM_61ba867c-4dd3-4803-a6a5-10aa309ff564">P7Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="axgn-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i065152e6a3b64f53bb6e652d3c07713d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib74c767cfa73403094e07d49b29033f0_I20230310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="idb63c57e724a4e6e8ad20ee65119370a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17b0477fc984ecfa301826bf71b2eb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf515d9a7de44eff9aae0e17da62fba2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11a07c1ba89f4e78b9f41a1b28db3e2e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i020f70d532cd4985bbe689c32516cea3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b861abf62b4326b086bd6c32bdcf69_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b02bce882f4530a644cf1f4de1281a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45cc08a71962457c8a2b55f8d7a4d39a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i988505ce34a844a09623ae3c12d8ec87_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f968e20d3bf41eebd5e2ffa7bb615b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied6b9724c05f4cb3a66af446b51ae49e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i404b822cbf2e4fe08c667eb2554e74c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0df7a1efdb049cfa90a2524886d1252_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48bde1d6124b4ea78c970234e62219ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35d0ad377f844a4a7e48534c50caff4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8158cb4740e7427188f9ee3550c9230b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic23f7a20a5a44ab7b5e3f093917b8c03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81e2bc0aacfa402f813dddb588b6267f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec80f298a69e4799b67c597636a9f301_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d3fa1437edd43a5b85f3cf6a86ed7df_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64198b8113a54a908aaacc22c63099fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e263d574089497289c6eefc50c18244_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26cf5637ad1d4822b296d27f9963de73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5efaab989c6841568efb1406dbb75d6c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2097ff736d5343bda084880731e97ad9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4725cd6d9b24bb59307c754dcac2d41_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd68d66cd4242ecb6935259bfbb0bfd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc7ba18f09ee45d587b2fe032937cda5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc6c9dfa31e4dfb90c5dc20212c1ca1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">axgn:ResearchAndDevelopmentGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic68f8ca16e14404a992ae8f0910b911c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">axgn:ResearchAndDevelopmentGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87f90b83c663430ea63bc4f87a3e3a3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">axgn:ResearchAndDevelopmentGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7fac01f992a4a81b65d12402ff03e2f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64abf6623fa944d6afd0f670cf3c2a34_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2511c05b8d24d5498026c37e476c019_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead0e385765c4b64b8993cfd1f3c50a7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">axgn:AviveSoftTissueMembraneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fdfd74ec77440a993b43f1ab043aec4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070dcdc6ab0e4a87856b934b83e36f61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4b7b03e5ad24c209c6e89b463f7c09d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7786e6549f4f2b87fd1be253cbb057_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a1078ddd2ca4d68ba2298c4052ef876_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3763b8b0a3348d59cfaea1445d2bfc8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefef6bfa4d304246b2f3543fef3d3125_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fcdd9ed764541c286b0eaaa84d984ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i981abdd294e44919817cd956d30d31a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i219c4cc0cbd547b3b68a43331493fb1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c791c3ff7e418ab95668e32cc7a1ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d0b4619b6c40f0b1a0de407ee760f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief216639aeea40978d9004092b61999b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i040b86ceb15544419c782b59216a1371_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idffd7fe48ee54e349aaddba79d4382e8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cab5edf539940499d0c87a4b0bfaecf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2057862cc54798a45830a2e34c7672_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i414b5edcb9214fef95168d989218cbd4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65aa335ff06f439d8115f7904b82f8aa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">axgn:PatentsAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib87452ca58634dbaa8dd73c32eb97477_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7f9133c7a74c2bbd041186bedf782a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i883e9d9eb9ba4b5980f84ab0473b72ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cb615006a90448cae97a9c052e1adfb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i108f5fba334f442e831ebcd3d2adaee4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d98f50d860845f4a00f11fe83cde291_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45579dc2f8964009928c3c2e3fef14d8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9f0dbd08bf2403187833c72b32e0021_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73351972eccc4224be149e2d0b567b8c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d33c3cc49e343eb8a823bc5ad30dd10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia545915c6cee4044ae461b4e3af6a345_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id571ec182cbc48dbb46f0902fabfaa4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd5c952fe7147368209c3bdedede315_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe2f9c677cc94813913c444deda1a1fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6afd80e6ff54416977b579d2a685207_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5149fc3ac5624e7ca71842bdab5b8b31_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5473e91ae2d416cae7554133eb8cbb1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d1a0dcac804c06a79caf26d3fdcdf2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43510f63e6ba4c3ca4047759ce1d9771_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7965b9980ab4e319a9eb72458f4e891_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6626e08228454045ae1ff645428d36cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1feb2a1c57d43a8a89b0469ed5f79d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7999f53613c34864ab3d0b6a7527bba5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42db69a16e2a4860a246a776fd8ad30c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife046a9660e8491b9dca4c3123909056_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e456cfb65c14ed1ae258c526b1a5ce9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i614ad5e81ab442e19a8c5e1d2bb61b7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i699ff71d4b5f46c19f42ee43b4ff55ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ba0f9df4d9c44889d4cd22b2ac19083_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i690e6522ce7d426589cbba53994c7d97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id48f1ba541194d20abbd6444602c33bb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12533576801f4002b10b0fe696102c65_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i134277d723964a98be276a7cfd374add_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dc0ea19aecc4d6dbf7f2bb1e1acc8cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07a044804b5b4fb1af23926c78c8ce13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9df50280b6e4544bdb2b7df50822fa9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13c01632c18d4b0fa2a95b893eb9f178_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic339a73d39af4de797a3d83409a67e96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i233781a5f56440c3bd9431cd5d4497ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51dbdd80d2ef4fdcbf34d3331a1740c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f44c5f22b0f4c40813f276fb3c6827e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe9c570ebbd4043946a89fd045c1f82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7407c910a8640d8988cc07ab8eda26d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3799b9b46cfa4242a49caf62d6c4d193_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96fd23a1c75242caaecd4598b4ab2e33_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42df21d43bee4402a8975d2309e802f0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05a09806c9ee410192e276bdee67d4ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i493945d3878542549477456e7e460b75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fb3c6271c204980bf4241e0ed97c838_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i112f623f3210421683f1756809d4475b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib01ca98fb65f484db7aa0441f172af4a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a72a93104ed4eccbc5523f4c0f05191_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df814d0d49f44b38f0402eeabb3552c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02f73cc8149a450c9f9c913738431082_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21ffd851ecc4537b177459b24c9a3d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac001b043861493599ed9f7cf962441d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventBefore2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8843fd82eae4f4092d2b2e26e5f6403_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventBefore2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3218bc21e1b493a82d42491d73cb0ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventIn2024OrAfterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i920e8bfa648d41c7b399a5783bd68c3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventIn2024OrAfterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia49615132a2c496d981625ca85c9c943_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:OptionalPrepaymentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1cad8ff35f4474da61c3d70a7da989b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:OptionalPrepaymentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic393cbccf77f4f7f9ddd00e20e44bfa7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3313bb44c00d456ba559b7c53b18be3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac024fdbce484e7f8e49292e12eb03a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ac361d361b540cbba4353a8b20de144_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2532d10d99c4277927947329d695475_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a116e8bc9eb4403af53f80e4b35086c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e18c269659d4844ac0d512a92bcd2a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1958bf62020547a291e5c09e08fcc45f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventBefore2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if107145343dc4b0daddec46f6ccc3857_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventBefore2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d58523409ee484bae896a42cbecd8b1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventIn2024OrAfterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49673c1dce6f4f2496f2da68cd37b20b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventIn2024OrAfterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic134f7c3e14d4cd7b7811f6e97064116_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:OptionalPrepaymentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81395195766a421e95d3757424963785_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:OptionalPrepaymentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ba9dcd463a4411d98f217af826e1ec3_D20210222-20210222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-22</xbrli:startDate><xbrli:endDate>2021-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic07a04ab4a2a4b3fa3a573b41c2448a6_I20210222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157567aac3fe47c883ab1353f6869f96_D20210712-20210712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-12</xbrli:startDate><xbrli:endDate>2021-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="m"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit><xbrli:context id="i955f3c4847e84499b9e5df9ed14d2f7a_I20210712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b56b68105574c4899488b9442a10226_D20210713-20210713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-13</xbrli:startDate><xbrli:endDate>2021-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c395685d2a24e03a092821152da1c30_I20210713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0581e65b1022415ca3161ab6932a9f19_D20220127-20220127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-27</xbrli:startDate><xbrli:endDate>2022-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4097a733c1714381b903a1dfe340dafe_I20220127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e1fc63be79e43f2ab16a203a1d29645_I20220822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPFirstAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i099064cb7e584aca8bb8c8b521b1be3c_I20220822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf7f7b402ec14835ba2971de3296cb0d_D20220822-20220822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPFirstAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-22</xbrli:startDate><xbrli:endDate>2022-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41dbef148b97433ea98f9c4af34f62f1_D20221231-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPFirstAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a30248ed7b4f40a1fafee657210a01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPFirstAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i312f2d64cb674fdbad24a7fe51918409_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i104179cd76d94a2bb5b480f5d740f348_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe9a8770fa764d7891407778eae23958_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id591cfe573344db49a17900c7f2534ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6403d399211849738490229c7838d26e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if575cb76b14c473cbdc0a317a1e37598_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7f2d0f52ae2425faca15b977fa1eb33_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18a440d8b8744e8f9a6b185b93f909de_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id42e84f255884f7eb85ff88a32cfbec7_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if401beb532c24731a94a6c209f24f06f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc88fe00a2b34650ba8c22e3a5248c9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d1964162f34aa9aff7b7bf6ccd1778_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i271d865b318a4f69926f6640eb4178a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32bc87a417ec436cbde425177f4f1fca_I20201210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7229d1ab938d4b54a5c614ac06b82ab4_D20201210-20201210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-10</xbrli:startDate><xbrli:endDate>2020-12-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i232073fcc6e04d25aa02ac11cc331bfc_I20201210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">axgn:TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i443dfc9e27ca43fa95f569f05a0bbe28_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1655c65194084245be81921c34c77204_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2861cc9701fe4e06bbe34f3f481d4cbb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a546ce46a914aa785e30fa74d23ae15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">axgn:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eb9268062cf4f6cbb9c740dbb809cea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">axgn:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bda4fe5ea904b66952845b8d764cf1b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6204757bdfb4234845eb99fcc2f5bde_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib00632d9ac6845ff94f04e3e98489229_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b8752e11b545e6a8bef12b17eaa002_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a16e53d518446cfbd2024ffdb8a8bf1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36385a5cb9a84a35be78534b6035cd66_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071fd4cf629e4e2280fd669b14f69dee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>axgn:plan</xbrli:measure></xbrli:unit><xbrli:context id="if01e2ccdaa54461098fe9e12370e82c8_D20220525-20220525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-25</xbrli:startDate><xbrli:endDate>2022-05-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1901933b221a4b9b954c7479477f3e4b_I20220525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23829077b773438fa1c9f990db81d62a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ea41484f76d414e87f57fe619eda0d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i265deb6981db4caba802dff7098eaf78_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia017b12b6e4844b9ad5921672e3ad683_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic382dfac5eb34387894011ca21faacb1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5e8c7dd95f4725be7b20b882541185_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad06ab740e97428ab5fa032137f4d319_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353c868d857d4f78b75da6d08d6f5ce8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82f76c354583477ba3582208c4de3e9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906644212cb044e79417f0990512be9f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib865e7888f5b433f95e77cfab871debf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9648970fef2d49fbbf69cb19fe670983_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7956fd5c1234348844e780e82ebc0c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib744e6a9173947e59255d4550e92de8b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee39cce463fb44d0a4bfe365b6681f5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09c0b507e033470891c7ca7da0c6882b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aca85efc69240e1a769914f9dcb9319_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ec881302ae14b18b7a4033a56f38e41_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia801c2b2298a45dd968f3bc35b69132c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab23cd73c6404992b546cccab3d848b9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d35f388c73c4c55b667458fd456bb77_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8fe5d68d40444db8d1a38fee238b7a9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0212c0badd7b46908abba199f97a351e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:DirectorsAndOfficersStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e80010008dd494aa1fc37d1fd76468b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:DirectorsAndOfficersStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">axgn:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i289e4e30f0654ba2b3181339326c280d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b94c6006f54a3db47bc4394457d1e3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic51b16331d104e7e8fdcef21b100803f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id192a5d2ca61416498fadecd34072e03_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1e45b0b246b467fbbfb1b6cd29a64b4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">axgn:DirectorsAndCertainExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42d9032ded3e403885f2e9975a16f6ba_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">axgn:DirectorsAndCertainExecutiveOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id91fc5c40e6640dda04b21132c42f27c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4666913c7daa474b8bbb30f0335d78a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia34eb80cba6046728fa5e0562af47d00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36f58e081cfe4d2ba7361775fbbb25d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0c5b69b5984bf8bec833a99943f9a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie11aa559ad27461e8d53d7d3e811e707_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a311c65bd9478aab63c3835e9f72d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7b8b79e630c433d9fdf51406b61b52d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2655caad891648a1a7b5ffeb3d3a7654_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86095a926657489a9c0c27cdcf148b0a_D20181227-20181227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-27</xbrli:startDate><xbrli:endDate>2018-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4efbb86d561c4296ac6a8acef41fa1c7_D20191217-20191217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-17</xbrli:startDate><xbrli:endDate>2019-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51ad0d1614e74ceda868f8561214b5ae_D20171218-20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-18</xbrli:startDate><xbrli:endDate>2017-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i248e3d8e95cb446ea5448ffd760d6858_D20181227-20181227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-27</xbrli:startDate><xbrli:endDate>2018-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i717731af1dc14019834ae2cebf768ac6_D20191217-20191217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-17</xbrli:startDate><xbrli:endDate>2019-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a2ae8023341421386b40e9ae8b40f59_D20171218-20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-18</xbrli:startDate><xbrli:endDate>2017-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19da80c554e84b1f87236d2a9f78dea3_I20200717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyPerformanceShareUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8234a2e85537460db0ac834d843b9f53_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyPerformanceShareUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3332793e1664f34a11a863a2ac0ea63_I20210316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyOnePerformanceShareUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifeb16850541e4351bd40387578338733_D20210316-20210316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyOnePerformanceShareUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-16</xbrli:startDate><xbrli:endDate>2021-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib665842cd4a641bd996a4f540d05b968_D20210316-20210316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyOnePerformanceShareUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-16</xbrli:startDate><xbrli:endDate>2021-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id572945122984533aa8afff607ed6ec8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyOnePerformanceShareUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2216c948174746b58affe9e729448569_I20210316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyTwoPerformanceShareUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc02d67a57a34782804ce01d01580755_D20220316-20220316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyTwoPerformanceShareUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-16</xbrli:startDate><xbrli:endDate>2022-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia121473080d34c55a59059e23ecccb8d_D20220316-20220316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyTwoPerformanceShareUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-16</xbrli:startDate><xbrli:endDate>2022-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0b64e28b97d45429f64b42130e5f1e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ad8aba17c754a17ae1c1742ee8271fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23c516e6eac4ecd8e34c8640d264ee9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961f19ca53be45ff97d7bd5885e51a53_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf36782fab8f4beda0e41e2bcb53023b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea37731e57ec4ce89a11a90afef95441_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e8e5bdce3b54c78ae99fb00b50a85b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff1fe87cd0546b8b116eabe76752894_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i181cd94e7d834b44b5b5a1f041d09d44_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieed0a63f9da94ba092fa792b834444ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05aa70972d464831a814056c33b271a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefd130037ca64a11bb22c7512ae0a94d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanEmployerMatchingContributionTranche1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i182aaa761ab746c08c115aa520c8ef32_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanEmployerMatchingContributionTranche2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i400f27a4e7ff431998cec2a000a877d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i236f63d48da94326b86bbf56915ef555_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73105f432ef241c4a97fc1d3d88fe6a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:CommunityTissuesServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if781fbbca41e4e539d4a2af2b30d30b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:CommunityTissuesServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a9992aadca401c9da150aec1eb925d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:CommunityTissuesServicesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fde54db694d4428af52e02f60a749f9_D20111201-20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-12-01</xbrli:startDate><xbrli:endDate>2011-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e477a79209414b9802cd7abd1b6b50_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0f3af02aa7447d8f475f07a758e898_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb046ec1c789420aa97b6546383d2a96_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7981a723acd84152a08440913339b2eb_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="acre"><xbrli:measure>utr:acre</xbrli:measure></xbrli:unit><xbrli:context id="ic4c3c23c084b482f91cc7aa41dcd753c_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a73dc524bc0487f8a26096a8e638192_I20190709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d4755bb5df442e0bcbac343dd97c6a5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c09353a39ab44c1abcd20449e840722_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a632239217d41468fa2372519ffc0b1_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9e769962cd54b3b97e7d9fd767e4375_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ca27fff32cc49c8b733f18e1fa356ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i240989f39b9840bca8e3655746971a82_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc7bb6eff8634156ae51a0b363ee7e34_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1483ac9511a64c4ea92e59beedb6290d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i872b209a46c14c878edd3c5a93dc57b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="settlementscenario"><xbrli:measure>axgn:settlementScenario</xbrli:measure></xbrli:unit><xbrli:context id="i63b272a784f043b28b8f70d792398c9d_I20230310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace3449af19a43cd8d67c6135dea1c3f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1eadfa7371f84649a56fada99ffeb49f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i491dd34b56ac4fb6b8ba9809c9f8440d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3669aa557841487bb68d45ebfd6ac73d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if81dc6f294f4481ba24f6cf04a2a5b07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2f4d63cb0a4bdbba2fe027bcca072d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a1d089805140e781df39c5f26229e1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief79fb6a5e3b43748ba8450f97233cc8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff49c4d00f374dc3a6c840d2ead2e75c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66448d92e4ed4bbdabf0e6233a2efd1f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc7ff5c961444d40b57c14dbf3857165_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia96693000e594bfcab99cf6f0f656103_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01ee8be630348558bc989c9e8469302_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i682121d6bec448318e7178b60d411be4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000805928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">____________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU0_1e42d764-f9e2-4192-a28e-4209692de150">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">____________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:494.25pt"><tr><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:477.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGFibGU6YmE2YzJiNjY1ZWQzNGU1M2JlYmQ4MzY1YjdlY2FmNmMvdGFibGVyYW5nZTpiYTZjMmI2NjVlZDM0ZTUzYmViZDgzNjViN2VjYWY2Y18wLTAtMS0xLTEwMjQzMQ_7131b5d4-38e5-4c2e-83ba-ad64b056099c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8yODM_84342b8b-5d96-4bf9-a590-52fcb7df21a2"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8yODM_dc0bcaa2-e036-4b2a-a9b1-214bff2158d5">December 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Or</span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:494.25pt"><tr><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:477.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGFibGU6YzYwMGU4ZWM4MTkyNDQ3N2FlMTM5YTdhOWRkMzQxYTgvdGFibGVyYW5nZTpjNjAwZThlYzgxOTI0NDc3YWUxMzlhN2E5ZGQzNDFhOF8wLTAtMS0xLTEwMjQzMQ_4e2adfa6-cbff-466c-820f-422f30391222">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">____________ to______________&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjYx_5da5044b-a95b-43fc-8e7a-8ad51521eb01">001-36046</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU1_48e727ad-5ac6-423e-b497-63550749d717">AXOGEN,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU2_465f9c89-afbc-49b1-9ffa-70e4d3412ee5">Minnesota</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">incorporation or organization)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjUw_44d59569-9ada-400d-b59e-9ba6e8712e92">13631 Progress Blvd., Suite 400</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjUx_34e63d97-12aa-4a59-8c5f-44059455c35e">Alachua</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQ2_dde48038-1219-405d-b034-4e05de34e8c1">FL</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU3_0fa1e76c-084b-45c4-8e6b-2885acc58088">41-1301878</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Identification No.)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQ1_3ff57000-1fef-4755-a03a-ba86b4a1894a">32615</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Zip Code)</span></div></div></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjM4_2ebcc82e-052b-41af-b2bf-4aeafd3d30cd">386</ix:nonNumeric>) <ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjM5_c5e57656-c3db-4091-a73c-8c5c38e8091e">462-6800</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGFibGU6ZTdmODYxZjNiZDU2NDkwNGI3ZDAwNDg2Nzg4ZDFmYTYvdGFibGVyYW5nZTplN2Y4NjFmM2JkNTY0OTA0YjdkMDA0ODY3ODhkMWZhNl8xLTAtMS0xLTEwMjQzMQ_0765fa90-2838-4b18-a371-69ec317df12f">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGFibGU6ZTdmODYxZjNiZDU2NDkwNGI3ZDAwNDg2Nzg4ZDFmYTYvdGFibGVyYW5nZTplN2Y4NjFmM2JkNTY0OTA0YjdkMDA0ODY3ODhkMWZhNl8xLTItMS0xLTEwMjQzMQ_380fc31b-0e03-4f6e-aa14-fd15c92c198b">AXGN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGFibGU6ZTdmODYxZjNiZDU2NDkwNGI3ZDAwNDg2Nzg4ZDFmYTYvdGFibGVyYW5nZTplN2Y4NjFmM2JkNTY0OTA0YjdkMDA0ODY3ODhkMWZhNl8xLTQtMS0xLTEwMjQzMQ_546d2a6a-b9a9-43ed-bf97-eea18a7f89e4">The Nasdaq Stock Market</ix:nonNumeric></span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Title of class)</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjUz_1aa6c246-0101-431a-b68a-432c638e704d">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQw_891ae001-2e68-4d20-8bb5-8c27d428e42b">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQx_5953c45b-360c-403e-af92-c382c527d452">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU4_4c86a6f8-ed67-43f3-866f-ed37268c6283">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Large accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQz_01fa6268-6125-444b-b69f-c418978d2d14">Accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Smaller reporting company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQ3_c1760eba-23e0-40ae-90e9-41c657e39d03">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU5_cb5e12cb-87ae-4c1b-b419-a32ed2d368f7">&#9744;</ix:nonNumeric></span></div></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQ4_6abf1546-44e0-4fa9-a036-c21ab2405ef6">&#9746;</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9633;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">]</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). &#9633;</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQ0_b9e746d6-3baa-421c-b0d1-fb4804ad93f2">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2022, the last day of the registrant's most recently completed second quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="i065152e6a3b64f53bb6e652d3c07713d_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV81NDk3NTU4MTc1OTA_43f51233-eea0-4761-8f2c-32e9f5be1f13">221,521,729</ix:nonFraction> based upon the last reported sale price of the common stock on the Nasdaq Capital Market.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s common stock as of March&#160;10, 2023, was <ix:nonFraction unitRef="shares" contextRef="ib74c767cfa73403094e07d49b29033f0_I20230310" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV81NDk3NTU4MTc2MjA_fc8ce4e1-cbc5-47c2-8bac-c251fe4d1b69">42,601,918</ix:nonFraction> shares.</span></div><div style="margin-top:3pt;text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjYw_72505d69-aaa2-42dc-9364-f695205fd0f2" escape="true">Portions of the Registrant&#8217;s definitive proxy statement to be filed pursuant to Regulation 14A within 120 days after the end of the Registrant&#8217;s fiscal year are incorporated by reference into Part&#160;III of this Form&#160;10-K.</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTENTS</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_16">PART&#160;I</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_19">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_22">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_22">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_25">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_25">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_28">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_28">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_31">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_31">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_34">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_34">55</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_37">PART&#160;II</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_40">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_40">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_43">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_43">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_43">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_46">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_46">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_70">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_70">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_70">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_73">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_73">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_73">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_148">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_148">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_148">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_151">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_151">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_151">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_154">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_154">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_154">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_157">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_157">&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_154">101</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_160">PART&#160;III</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_163">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_163">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_163">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_166">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_166">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_166">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_169">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_169">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_169">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_172">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_172">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_172">102</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_175">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_175">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_175">102</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_178">PART&#160;IV</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_184">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_184">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_184">103</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_190">Exhibit&#160;Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_190">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_193">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_193">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_193">111</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_196">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_196">112</a></span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, in reports filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) (including this Annual Report on Form 10-K), in press releases, and in other communications to shareholders or the investment community, Axogen, Inc. (including Axogen, Inc.&#8217;s wholly owned subsidiaries, Axogen Corporation, Axogen Processing Corporation and Axogen Europe GmbH, the &#8220;Company,&#8221; &#8220;Axogen,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) may provide forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, concerning possible or anticipated future results of operations or business developments. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as its business plans. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;forecasts,&#8221; &#8220;continue,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;goals,&#8221; and variations of such words and similar expressions are intended to identify such forward-looking statements. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The forward-looking statements in this Form 10-K include, but are not limited to the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Statements regarding estimates of the total addressable market for our current portfolio; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our belief that our total addressable market is comprised of four categories: (1) trauma, (2) oral maxillofacial, (3) breast reconstruction neurotization, and (4) Upper Extremity Compression;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Statements regarding estimates of the market for our current portfolio in each of the four categories; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Statements regarding our beliefs that expanding our products into lower extremity surgery, head and neck surgery, urology, and the surgical treatment of pain could offer us expanded revenue opportunities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that there is a significant patient and societal need to reduce the use of pharmacologic solutions, including opioids such that there is a sufficient market opportunity for our products that justifies us devoting our resources to pursuing the opportunity; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that Avance Nerve Graft is the first off-the-shelf human nerve allograft for bridging nerve transections;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our belief that the data developed in connection with the Biological License Application ("BLA") supports the claim that Avance Nerve Graft is intended for the repair of peripheral nerve discontinuities:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our efforts with respect to returning Avive Soft Tissue Membrane to the market;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our expectation that renovation and validation of the Axogen Processing Center facility will be completed prior to the termination date of the CTS Agreement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our expectation that we will transfer processing of Avance Nerve Grafts to the Axogen Processing Center in mid-2023;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our expectation that we will file the Avance BLA by the end of 2023;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our belief that we met the clinical end point required for our pivotal end point required for our pivotal study to support the BLA and that only one study is sufficient to support the BLA</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our belief that commercial payers and CMS will reimburse our nerve repair products used for various applications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our belief that further innovation and product development is needed to maintain our leadership position and provide expansion opportunities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that the exclusion of use of our products in the oral cavity for endodontic and periodontal applications and OMF surgery from our distribution rights under the Distribution Agreement with Cook Biotech does not limit our identified OMF market;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that we have enough Axotouch Two-Point Discriminator inventory on hand to support sales through 2024;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that there is an opportunity to improve current approaches to peripheral nerve repair; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that our approach to peripheral nerve repair will solidify our position as a leader in the field of peripheral nerve repair;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that we can increase</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">market penetration and share by increasing awareness of the impact of nerve damage on quality of life and improving the adoption of nerve repair techniques and our products through the continued use of educational conferences and presentations, surgical resident and fellow training, scientific publications, digital communication, and a knowledgeable and professional sales team;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that growth can be supported primarily through expanded productivity of our sales force;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that we can provide additional growth by expanding usage of existing accounts and also, by adding new accounts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that we may continue to incur net losses and operate with negative cash flow from our operations for the foreseeable future; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our expectation that the number of direct sales professionals will increase over time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that additional opportunities exist to develop or acquire complementary products in peripheral nerve repair as well as opportunities to expand our existing portfolio of products in new applications of peripheral nerve repair;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that there is a global need for surgical repair of damaged or transected nerves and that a global market exists for our product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that revenue from international distribution and sales has not been material and that there are no material risks associated with foreign operations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Our belief that we do not have dependencies as to international revenue; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our belief that our existing cash and cash equivalents and investments, as well as cash provided by sales of our products will allow us to fund our operations through at least the next 12 months;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Statements regarding our belief that following the completion of the Axogen Processing Center facility ("APC Facility") renovation, we expect a decrease in capital expenditures, and thus in the cash used in investing activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our belief that the Cost of Goods Sold ("COGS") in the APC Facility will not materially differ from our current processing facility;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Statements regarding our assessment of our internal controls over financial reporting;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our expectations regarding the impact of COVID-19 on our business, operations, customers and the economy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Statements regarding our expectations related to inflationary pressures, labor shortages, increasing interest rates, global business disruptions caused by geopolitical factors and other macroeconomic factors impacting our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Statements regarding our expected clinical trial enrollment, timing, and outcomes; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Statements regarding our visibility at and sponsorship of conferences and educational events.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this Form 10-K should be evaluated together with the many uncertainties that affect our business and its market, particularly those discussed in the risk factors and cautionary statements set forth in our filings with the SEC, including as described in &#8220;Risk Factors&#8221; included in Item 1A of this Form 10-K and &#8220;Risk Factor Summary&#8221; included in this Form 10-K. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements contained in this report are based on information that is currently available to us and expectations and assumptions that we deem reasonable at the time the statements were made. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or otherwise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 1. BUSINESS</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries. We provide innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves.&#160;Physical damage to a peripheral nerve&#160;or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform for peripheral nerve repair features a comprehensive portfolio of products, including:</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Avance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Graft, a biologically active off-the-shelf&#160;processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site;&#160;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Axoguard Nerve Connector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a porcine (pig) submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed peripheral nerves;&#160;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Axoguard Nerve Protector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; </span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Axoguard Nerve Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma;</span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Axotouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Two-Point Discriminator, used to measure the innervation density of any surface area of the skin.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We suspended the market availability of Avive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soft Tissue Membrane ("Avive") effective June 1, 2021 and we continue discussions with the U.S. Food and Drug Administration (the "FDA") to determine the appropriate regulatory classification and requirements for Avive. The suspension was not based on any known or reported safety or product performance issues or concerns with Avive. We seek to return Avive to the market, although we are unable to estimate the timeframe or provide any assurances that a return to the market will be achievable. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products is currently available in the U.S., Canada, Germany, United Kingdom ("UK"), Spain and several other European, Asian and Latin American countries.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nerves can be damaged in several ways. When a nerve is cut due to a traumatic injury or inadvertently during a surgical procedure, functionality of the nerve may be compromised, causing the nerve to no longer carry the signals to and from the brain to the muscles and skin thereby reducing or eliminating functionality. The loss of function can impact a person&#8217;s ability to work and perform daily tasks, to properly be aware and respond to their environment (e.g., heat, cold or other dangers), and could negatively impact their ability to experience and enjoy life. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nerve damage or transection of the type described above generally requires a surgical repair. Traditionally, the standard has been to either suture the nerve ends together directly without tension or to bridge the gap between the nerve ends with a less important nerve surgically removed from elsewhere in the patient&#8217;s own body, referred to as nerve autograft. More recently, synthetic or collagen conduits have been used for the repair of short gaps. Nerves that are not repaired or heal abnormally may result in a permanent loss of function and/or sensation. Additionally, abnormal healing can form a neuroma that may send altered signals to the brain resulting in the sensation of pain. This abnormal section of the nerve can, under certain circumstances, be surgically removed and the nerve managed by capping, burying or repairing the nerve.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, compression on a nerve, blunt force trauma or other physical irritations to a nerve can cause nerve damage that may alter the signal conduction of the nerve, result in pain, and may, in some instances, require surgical intervention to address the resulting nerve compression. Finally, when a patient undergoes a mastectomy due to breast cancer or prophylactically due to a genetic predisposition for breast cancer, the nerves are cut to allow the removal of the breast tissue. This can result in a loss of sensation, the potential risk of a symptomatic neuroma, and could negatively impact the patient&#8217;s quality of life. When a patient chooses a breast reconstruction after a mastectomy, sensation and quality of life can, in certain cases, be returned through surgical nerve repair.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To improve the options available for the surgical repair and regeneration of peripheral nerves, we have developed and licensed regenerative medicine technologies. Our innovative approach to regenerative medicine has resulted in first-in-class products that we believe are redefining the peripheral nerve repair market. Our products are used by surgeons during surgical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interventions to repair a wide variety of physical nerve damage or transection throughout the body, which can range from a simple laceration of a finger to a complex brachial plexus injury (an injury to the network of nerves that control the movement and sensation of the shoulder, arm, and hand) as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Peripheral Nerve Regeneration Market Overview</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peripheral nerve injury (&#8220;PNI&#8221;) through damage or transection is a major source of physical disability impairing the ability to move muscles or to feel normal sensations. Patients suffer traumatic bodily injuries every day that may result in damage or transection to peripheral nerves severe enough to require surgical treatment. We break our total addressable market into four categories: (1) trauma ("Trauma"), (2) oral maxillofacial (&#8220;OMF&#8221;), (3) breast reconstruction neurotization ("Breast") and (4) Upper Extremity Compression (together, the "Total Addressable Market").</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that U.S. PNI has a potential Total Addressable Market for our current product portfolio of $2.7 billion. Estimating the Total Addressable Market for nerve repair is challenging as there is not a simple data source for the incidence of peripheral nerve issues. This is further complicated by the fact that nerves can be injured through a variety of traumatic and surgical injuries and can impact a patient from head to toe. In addition, we believe nerves are often one of many structures injured in a trauma (i.e., amputation) or in surgery and the incidence of these nerve injuries are often not coded or tracked. Quantifying the procedures involving nerve repair may also be challenging. While selected trauma and surgical procedures are dedicated to the repair of nerves, most of the incidence of nerve repair is a step in a larger trauma or surgical procedure. Current Procedural Terminology ("CPT") codes exist for surgeons to code for nerve repair; however, we believe the data substantially underestimates the total number of nerves repaired. Physicians are encouraged to document all steps of procedures, but open trauma often involves many surgical steps, and CPT codes may be inclusive of each other or may not be documented or reported in billing records. As a result, we believe CPT coding underrepresents the total number of nerve repairs performed in trauma. Because we believe CPT claims are not fully representative of the true volumes of nerve repair surgery, we follow an &#8220;empirical&#8221; methodology to estimate the Total Addressable Market &#8211; using published clinical literature and procedure databases to make what we believe are the most objective assumptions.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trauma</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trauma portion of the Total Addressable Market encompasses traumatic PNI throughout the body, with approximately 95% of injuries affecting upper and lower extremity nerves. We estimate that the Trauma portion of the Total Addressable Market is approximately $1.9 billion based upon epidemiological studies regarding the general number of trauma patients, clinical literature review reporting PNI incidence, and physician interviews. We have estimated the portion of these nerve repair procedures due to trauma that would require Gap Repair, Primary Repair and/or Nerve Protection and applied, as we believed was appropriate in each procedure segment, the number of units and average sales price of Avance Nerve Graft and the average market price for nerve connectors, and nerve protectors to determine the probable Total Addressable Market.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OMF</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that the OMF portion of the Total Addressable Market is approximately $300 million annually, based upon research indicating that approximately 56,000 PNI occur in the U.S. each year related to third molar surgeries, anesthetic injections, dental implants, orthognathic surgery, and mandibular resection procedures. We have applied the average sales price of the Avance Nerve Graft, Axoguard Nerve Connector, and Axoguard Nerve Protector that address such PNI to derive the OMF portion of the estimated Total Addressable Market.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Breast</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that the Breast portion of the Total Addressable Market is approximately $250 million. Currently, when a patient undergoes autologous breast reconstruction after a mastectomy, the patient receives the shape of a natural breast, but often times experiences little to no return of sensory feeling. In certain cases, sensation can be returned to the breast area with the use of our products through an innovative surgical technique called Resensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the ideal breast reconstruction should restore breast size, shape, symmetry, and softness, as well as sensation, without the potential risks and comorbidity associated with autograft. We believe the Resensation technique incorporates a patient's desire for the opportunity to return sensation to their breasts with a reproducible and efficient surgical approach for reconstructive plastic surgeons.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Upper Extremity Compression</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PNI caused by recurrent carpal tunnel syndrome and cubital tunnel syndrome constitutes the "Upper Extremity Compression" portion of the Total Addressable Market. We estimate that the Upper Extremity Compression portion of the Total Addressable Market is approximately $270 million, or 130,000 procedures</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We estimate there are approximately 488,000 primary carpal tunnel and 95,000 primary cubital tunnel relief surgeries performed annually in the U.S. We estimate that approximately 97,500 carpal tunnel revision surgeries and 32,400 total cubital tunnel procedures are addressable each year in the U.S. to mitigate the recurrence of symptoms. These revision and primary surgeries are required due to compression of the peripheral nerve associated with soft tissue attachments from the surrounding tissue or tissue infiltration entrapping the nerve. To prevent additional recurrences, surgeons will opt for a Nerve Protection which includes a product such as the Axoguard Nerve Protector. To derive the carpal and cubital tunnel revision portion of the Total Addressable Market, we multiplied the average market sales price of Axoguard&#160;Nerve Protectors by the number of estimated procedures. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although distribution and sales of products in the Trauma, OMF, Breast and Upper Extremity Compression portions of the Total Addressable Market constitute our primary revenue sources today, market expansion opportunities in lower extremity surgery, head and neck surgery, urology and the surgical treatment of pain could offer us expanded revenue opportunities. We have begun an expansion into the surgical treatment of pain with an initial focus in the treatment of neuroma in our existing call points. The size of the pain market opportunity is challenging to identify as the cause of the chronic pain is often not diagnosed and there has not historically been a surgical treatment to resolve the cause of the pain. We believe the market opportunity is sufficient to apply selected resources to the opportunity and there is a significant patient and societal need to reduce the use of pharmacologic solutions, including opioids. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Portfolio</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Avance Nerve Graft</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avance Nerve Graft is a biologically active nerve implant with more than ten years of comprehensive clinical evidence and more than 75,000 implants since launch.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avance Nerve Graft is processed nerve allograft (human) intended for surgical repair of peripheral nerve discontinuities to support regeneration across the defect. It is intended to act as a structural bridge in order to guide and support axonal regeneration across a peripheral nerve gap caused by traumatic injury or surgical intervention. Avance Nerve Graft is decellularized and sterile processed human peripheral nerve tissue. We developed Avance Nerve Graft by following the guiding principle that the human body created the optimal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">peripheral nerve structure. We, through our licensing efforts and research, developed the Avance Method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a proprietary method for processing recovered human peripheral nerve tissue in a manner that preserves the essential structure of the ECM while cleansing away cellular and noncellular debris. Avance Nerve Graft provides the natural peripheral nerve structure of a nerve, including the native laminin to guide the regenerating nerve fibers. The nerve ECM is additionally processed to remove a natural inhibitor to regeneration called chondroitin sulphate proteoglycan.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Avance Nerve Graft is the first off-the-shelf human nerve allograft for bridging nerve transections. Avance Nerve Graft is comprised of bundles of small diameter endoneurial tubes that are held together by an outer sheath called the epineurium. Avance Nerve Graft has been processed to remove cellular and noncellular factors such as cells, fat, blood, and axonal debris, while preserving the three-dimensional laminin lined tubular bioscaffold (i.e., microarchitecture), epineurium and microvasculature of the peripheral nerve. After processing, Avance Nerve Graft is flexible and pliable, and its epineurium can be sutured in place allowing for tension-free approximation of the proximal and distal peripheral nerve stumps. During the healing process, the body revascularizes and gradually remodels the graft into the patient&#8217;s own tissue while allowing the processed peripheral nerve allograft to physically support axonal regeneration across the peripheral nerve transection. Avance Nerve Graft does not require immunosuppression for use.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With lengths up to 70 mm and diameters up to 5 mm, Avance Nerve Graft allows surgeons to choose and trim the implant to the correct length for repairing the relevant peripheral nerve gap, as well as to match the diameter to the proximal and distal end of the severed peripheral nerve. Avance Nerve Graft is stored frozen and utilizes packaging that maintains the graft in a sterile condition. The packaging is typical for medical products so the surgical staff is familiar with opening the package for transfer of Avance Nerve Graft into the sterile surgical field. Such packaging also provides protection during shipment and storage and a reservoir for the addition of sterile fluid to aid in thawing the product. Avance Nerve Graft thaws in less than 10 minutes, and once thawed, it is ready for implantation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avance Nerve Graft provides the following key advantages:</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A three-dimensional bioscaffold for bridging a peripheral nerve gap;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A biologically active nerve therapy with more than 10 years of comprehensive clinical evidence;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">No patient donor-nerve surgery, therefore no comorbidities associated with a secondary surgical site;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Available in a variety of diameters up to 5mm to meet a range of anatomical needs;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Available in a variety of lengths up to 70mm, to meet a range of gap lengths;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decellularized and cleansed ECM;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implanted without the need for immunosuppression, remodels into patient&#8217;s own tissue;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Structurally supports the body&#8217;s own regeneration process;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Handles similar to an autograft, and is flexible and pliable;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Alleviates tension at the repair site;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Three-year shelf life; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Supplied sterile.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Axoguard Nerve Connector</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Connector is a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair. The product is in a tubular shape with an open lumen on each end where the severed peripheral nerve ends are placed. It is typically used when the gap between the peripheral nerve ends is 5mm or less in length. Axoguard Nerve Connector is made from a processed porcine ECM that allows the body&#8217;s natural healing process to repair the peripheral nerve while its tube shape isolates and protects the transected nerves during the healing process. During healing, the patient&#8217;s own cells incorporate into the ECM product to remodel and form a tissue similar to the outermost layer of the peripheral nerve (nerve epineurium). Axoguard Nerve Connector is provided sterile, for single use only, and in a variety of sizes to meet the surgeon&#8217;s needs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Axoguard Nerve Connector can be used:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">As an alternative to direct suture repair;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">As a peripheral nerve coaptation; Connector-Assisted Repair</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">To aid coaptation in direct repair, grafting, or cable grafting repairs; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">To reinforce the coaptation site.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Axoguard Nerve Connector has the following advantages:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Processed intact porcine ECM with an open, porous structure that allows for cell infiltration and remodeling;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Designed as a coaptation aid for tensionless repair of transected or severed peripheral nerves;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Alleviates tension at the repair site;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Remodels into the patient&#8217;s own tissue;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Reduces the number of required sutures (versus direct repair with suture);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Allows surgeon to move sutures away from the repair site which may minimize inflammation and aid nerve regeneration;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Reduces potential for fascicular mismatch;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Allows visualization of underlying</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">peripheral nerve ends;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Available in seven different diameters and two different lengths to address a variety of nerve repair situations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Strong and flexible, easy to suture; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Stored at room temperature with a minimum of 18-month shelf life.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Axoguard Nerve Protector</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Axoguard Nerve Protector is a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps while preventing soft tissue attachments. It is designed to protect and isolate the peripheral nerve during the healing process after surgery by creating a barrier between the nerve tissue and the surrounding tissue bed. The product is delivered in a slit tube format allowing it to be wrapped around peripheral nerve structures. Axoguard Nerve Protector is made from a processed porcine ECM. During healing, the ECM remodels allowing the protector to separate the peripheral nerve from the surrounding tissue. Axoguard Nerve Protector competes against off-the-shelf biomaterials such as reconstituted bovine collagen as well as the use of the patient&#8217;s own tissue such as vein and hypothenar fat pad wrapping. Axoguard Nerve Protector is provided sterile, for single use only, and in a variety of sizes to meet the surgeon&#8217;s needs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Axoguard Nerve Protector can be used to:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Separate and protect the nerve from the surrounding tissue during the healing process;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Minimize risk of soft tissue attachments and entrapment in compressed peripheral nerves;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Protect peripheral nerves in a traumatized wound bed; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Reinforce a coaptation site.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Protector has the following advantages:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Processed porcine submucosa ECM used to reinforce a coaptation site, wrap a partially severed peripheral nerve or protect peripheral nerve tissue;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Creates a protective layer that isolates and protects the peripheral nerve in a traumatized wound bed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Remodels into the patient&#8217;s own tissue;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Easily conforms and provides 360-degree wrapping of damaged peripheral nerve tissue;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Allows the body's natural healing process to repair the nerve;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Minimizes the potential for soft tissue attachments and peripheral nerve entrapment by physically isolating the nerve during the healing process;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Allows peripheral nerve gliding;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Strong and flexible, plus easy to suture;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Is available in five different widths and two different lengths to address a variety of peripheral nerve repair situations; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Stored at room temperature with a minimum of 24-month shelf life.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Axoguard Nerve Cap</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Cap is a proprietary porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nerves are often cut in a variety of surgeries and a nerve that is cut and not reconstructed may form an entangled mass of disorganized nerve and fibrous tissue that could cause debilitating pain called a symptomatic neuroma. Neuromas are a potential cause of pain for those patients who complain of chronic post-surgical pain, including in amputees, which may lead to an inability to use their prosthesis. Despite more than 30 different treatment methods, it is our belief that neuromas continue to be an unresolved problem in microsurgery. We believe the Axoguard Nerve Cap can address these painful neuroma and address nerve pain without the complications of traditional methods, including pharmacotherapy and chemical injections, among others. Axoguard Nerve Cap can be used to reduce the development of symptomatic or painful neuroma formation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Axoguard Nerve Cap has the following advantages:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Separates the nerve end from surrounding tissue, neurotrophic factors and mechanical stimulation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Reduces painful neuroma formation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Allows for anchoring of a nerve end or stump to nearby tissue structure;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Material gradually remodels into the patient&#8217;s own tissue to protect the nerve end; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Semi-translucence allows for visualization of nerve ends or stumps and easy visualization for suture placement.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Axotouch Two-Point Discriminator</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Axotouch Two-Point Discriminator tool can be used to measure the innervation density of any surface area of the skin. The discs are useful for determining sensation after damage to a peripheral nerve, following the progression of a repaired peripheral nerve, and during the evaluation of a person with possible peripheral nerve damage, such as compression.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Axotouch Two-Point Discriminator is a Class I 510(k) exempt medical device.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Axotouch Two-Point Discriminator tool is a set of two aluminum discs each containing a series of prongs spaced between two to 15 millimeters apart. Additionally, 20 and 25 millimeter spacing is provided. A circular depression on either side of the disc allows ease of rotation. The discs can be rotated between a single prong for testing one-point and any of the other spaced prongs for testing two-point intervals.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Axotouch Two-Point Discriminator has the following advantages:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Capable of measuring the innervation density of any skin surface;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Portable and easy to use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Strong aluminum design is resistant to bending;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Bright colors allow for clear discrimination between discs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Clear numbering allows users to interpret results; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Reusable carry case protects discs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Avive Soft Tissue Membrane</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We suspended the market availability of Avive Soft Tissue Membrane ("Avive") effective June 1, 2021, and we continue discussions with the FDA to determine the appropriate regulatory classification and requirements for Avive.  The suspension was not based on any known or reported safety or product performance issues or concerns with Avive. We seek to return Avive to the market, although we are unable to estimate the timeframe or provide any assurances that a return to the market will be achievable. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acroval Neurosensory and Motor Testing System</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Effective November 2019, we discontinued all sales of the Acroval Neurosensory and Motor Testing System. We continue to provide service and support for the existing systems in the marketplace. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tissue Recovery and Processing </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Avance Nerve Graft Processing Overview</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed the Avance Method, an advanced and proprietary technique to process Avance Nerve Graft from donated human peripheral nerve tissue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Avance Method requires special training over several months for each manufacturing associate who processes Avance Nerve Grafts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The processing and manufacturing system for Avance Nerve Graft has required significant capital investment, and we seek to continually improve our manufacturing and quality assurance processes and systems.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avance Method is depicted as follows:</span></div><div style="margin-top:10pt;text-align:center"><img src="axgn-20221231_g1.jpg" alt="axgn-20221231_g1.jpg" style="height:281px;margin-bottom:5pt;vertical-align:text-bottom;width:562px"/><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tissue Processing</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Avance Method consists of several steps, including peripheral nerve tissue recovery/acquisition and testing, donor medical review and release, processing, packaging, and sterilization to meet or exceed all applicable FDA, state, and international regulations and American Association of Tissue Banks (&#8220;AATB&#8221;) standards. We have a number of contracts with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recovery and acquisition agencies to supply peripheral nerve tissue and umbilical cord and believe these contracts, and the ability to enter into additional contracts, will provide us with the tissues we require for our Avance implants. As an FDA registered tissue establishment, we utilize both our own personnel and a variety of subcontractors for recovery/acquisition, storage, testing, processing and sterilization of the donated peripheral nerve and umbilical cord tissue. Additionally, we along with our subcontractors have contracted with independent Good Manufacturing Practice ("GMP") and Good Laboratory Practice ("GLP") compliant laboratories to perform testing for product release. The safety of Avance Nerve Graft is supported by donor screening, process validation, process controls, and validated terminal sterilization methods. The Axogen Quality System has built in redundancies that are meant to control the release of each product for implantation only after such product meets our quality control and product requirements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tissue Recovery and Processing Facility</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We partner with other FDA registered tissue establishments and AATB accredited recovery agencies or recovery agencies in compliance with FDA, state and international regulations and AATB standards for human tissue recovery. After consent for donation is obtained, donations are screened and tested in detail for safety in compliance with FDA, state and international regulations and AATB standards on communicable disease transmission. We process and package Avance Nerve Graft using our employees and equipment pursuant to a License and Services Agreement, as amended (the &#8220;CTS Agreement&#8221;) with Community Blood Center (doing business as Community Tissue Services) (&#8220;CTS&#8221;), in Dayton, Ohio. CTS is an FDA registered tissue establishment and an AATB accredited organization. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current CTS Agreement, which was amended in August 2022, terminates December 31, 2023, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#8217;s right to cure, in certain circumstances), or without cause upon 6 months prior notice. Under the CTS Agreement, we pay CTS a facility fee for clean room/manufacturing, storage, and office space. CTS also provides services in support of our manufacturing such as routine sterilization of daily supplies, providing disposable supplies and microbial services, and office support. The service fee is based on a per donor batch rate. The CTS facility provides a cost effective, quality controlled and licensed facility. Our processing methods and process controls have been developed and validated to ensure product uniformity and quality. Pursuant to the CTS Agreement, we pay license fees on a monthly basis to CTS. See "Item 8. Financial Statements and Supplementary Data &#8211; Notes to Consolidated Financial Statements - Note 14 - Commitments and Contingencies - Service Agreements."</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are renovating a property located near the CTS facility, the Axogen Processing Center facility (the "APC Facility") comprised of a 107,000 square foot building on approximately 8.6 acres of land. It is expected that renovation and validation will be completed before the termination date of the CTS Agreement to provide a new processing facility that can be included in our Biologics License Application (&#8220;BLA&#8221;) for Avance Nerve Graft and we expect to transfer processing of Avance Nerve Grafts to the APC Facility in mid-2023. The capacity of the property once operational, along with the ability for expansion, is expected to provide processing capabilities that will meet our intended sales growth. We have obtained certain economic development grants from state and local authorities totaling $2,685 including $1,250 of cash grants to offset costs to acquire and develop the APC Facility.&#160;The economic development grants are subject to certain job creation milestones by 2023 and related contingencies. We have received approximately $1,188 from these grants through December 31, 2022. These grants have claw back clauses if we do not meet these job creation milestones by 2023, we have sent requests  to the grant authorities for extensions of the job creation milestones; however, we have not yet received a decision from the grant authorities regarding whether extensions will be granted. See "Part II, Item 8. Financial Statements and Supplementary Data &#8211; Notes to Consolidated Financial Statements - Note 14 - Commitments and Contingencies - Service Agreements."</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tissue Packaging</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After processing, the packaging operation is performed in a controlled environment at the CTS facility. Each Avance Nerve Graft is visually inspected and organized by size into finished product codes. The tissue implant is then packaged in primary packaging. The outer pouch acts as the primary sterility and moisture barrier.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tissue Sterilization and Labeling</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After being processed and packaged, Avance Nerve Graft is then terminally sterilized and shipped to our Burleson, Texas distribution facility (the &#8220;Distribution Facility&#8221;). There the products receive their final labels and are released following a final stringent technical and quality review. Orders for Avance Nerve Graft and are placed with our customer care team and the products are packaged and shipped from the Distribution Facility.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tissue Product Release</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established quality procedures for review of tissue recovery, relevant donor medical record review and release to processing that meet or exceed FDA requirements as defined in the Code of Federal Regulations ("CFR") 21 CFR Part 1271, state regulations, international regulations and AATB standards. The Axogen Quality System meets the requirements set forth under 21 CFR Part&#160;1271 for Human Cells, Tissues and Cellular and Tissue-Based Products, including Good Tissue Practices (&#8220;GTP&#8221;) and is compliant with the 21 CFR Part&#160;820 Quality System Regulations (&#8220;QSR&#8221;). Furthermore, we utilize validated processes for the handling of raw material components, environmental control, processing, packaging, and terminal sterilization. In addition to ongoing monitoring activities for product conformity to specifications and sterility, shipping methods have been validated in accordance with applicable industry standards.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing of Our Medical Device Classified Products </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing for the Axoguard Product Line</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Axoguard product line is manufactured by Cook Biotech Incorporated, in West Lafayette, Indiana (&#8220;Cook Biotech&#8221;), which was established in 1995 to develop and manufacture implants utilizing porcine ECM. We decided to expand our portfolio of products and felt that the unique ECM material offered by Cook Biotech provided the combination of properties needed in nerve reconstruction. Cook Biotech&#8217;s ECM material is pliable, capable of being sutured, translucent and allows the patient&#8217;s own cells to incorporate into the ECM to remodel and form a tissue similar to the nerve&#8217;s epineurium. Cook Biotech has its own source of the raw material for the ECM material and manufactures Axoguard products from such sources.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Axoguard Nerve Connector and Nerve Protector</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2008, we entered into an agreement with Cook Biotech, amended in February 2012 and February 26, 2018 (the &#8220;Distribution Agreement&#8221;), to distribute its ECM technology in the form of the Surgisis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Cuff, the form of a nerve wrap or patch, or any other mutually agreed to configuration. The Surgisis products were rebranded under our Axoguard name and consist of the Axoguard Nerve Connector and Axoguard Nerve Protector. Our distribution rights are worldwide in the field of the peripheral and central nervous system but excluding use of the products in the oral cavity for endodontic and periodontal applications and OMF surgery solely as they relate to dental, soft or hard tissue repair, or reconstruction. We believe the exclusion does not limit our identified OMF market, but expansion into certain additional OMF market areas could be limited to our other products not subject to the Distribution Agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Axoguard Nerve Cap</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed, patented, and obtained FDA regulatory clearance for the Axoguard Nerve Cap August 8, 2017. This device is made with Cook Biotech&#8217;s ECM material. Pursuant to the Nerve End Cap Supply Agreement dated June 27, 2017 (the &#8220;Supply Agreement&#8221;), as amended on April 6, 2020 (the "Amended Supply Agreement"), Cook Biotech is the exclusive contract manufacturer of the Axoguard Nerve Cap and both parties have provided the other party the necessary licenses to their technologies for operation of the Amended Supply Agreement. Consistent with Axoguard connectors and Axoguard Protectors, we are able to sell the Axoguard Nerve Cap worldwide in the field of the peripheral and central nervous system, but subject to the same exclusions as Axoguard Nerve Connector and Axoguard Nerve Protector.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Distribution Agreement terminates on June 30, 2027. Although the agreement requires certain minimum purchases, through mutual agreement, the parties have not established such minimums and to date have not enforced such provision. The Distribution Agreement also establishes a formula for the transfer cost of the Axoguard Nerve Connector and Axoguard Nerve Protector. The Amended Supply Agreement has a term through August 27, 2027. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing for the Axotouch&#160;Two-Point Discriminator</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Axotouch Two-</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Point Discriminator was contract manufactured by Viron Technologies, doing business as Cybernetics Research Laboratories (&#8220;CRL&#8221;), in Tucson, Arizona. CRL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supplied the Axotouch unpackaged, and they are packaged at our distribution facility in Burleson, Texas. We believe we have enough inventory on hand to support sales through 2024.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on developing the peripheral nerve repair and regeneration market, committed to improving awareness of new surgical peripheral nerve repair options and is building additional scientific and clinical data to assist surgeons and patients in making informed choices with respect to the repair of peripheral nerve injuries. We believe that there is an opportunity to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">improve current approaches to peripheral nerve repair and that our approach will solidify our position as a leader in the field of peripheral nerve repair products. The following provides the key elements of our sales and marketing strategy.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increase Awareness of Our Products</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the introduction of our portfolio of peripheral nerve repair products, surgeons had a limited number of options available to surgically repair damaged or transected peripheral nerves. We entered the market to improve the standard of care for nerve injury patients. We intend to increase market penetration and share by increasing awareness of the impact of nerve damage on quality of life and improving the adoption of nerve repair techniques and our products through the continued use of educational conferences and presentations, surgical resident and fellow training, scientific publications, digital communication, and a knowledgeable and professional sales team. We work to increase the use of our products within active accounts as well as expand the overall customer base by adding new active accounts. We define an active account as an account that has typically gone through the committee approval process, has at least one surgeon who has converted a portion of his or her treatment algorithms for peripheral nerve repair to our portfolio and have ordered our products at least six times in the last 12 months. As our business continues to grow, we have transitioned to reporting a new account metric that we believe demonstrates the strength of adoption and potential revenue growth in accounts that have developed a more consistent use of our products in their nerve repair algorithm. We refer to these as core accounts which are defined as accounts that have purchased at least $100,000 in the past 12 months. We are focused on plastic reconstructive surgeons and orthopedic and plastic hand surgeons who perform surgeries on patients suffering traumatic nerve damage or transection, on oral and maxillofacial surgeons who repair damaged oral nerves, and on plastic reconstructive surgeons who perform breast neurotization.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expand Clinical and Scientific Data Regarding the Performance of Our Products</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generating clinical data is an important component of our marketing strategy. As of December 31, 2022, there have been over two hundred peer reviewed clinical publications related to our products. Certain of these publications contain data on multiple products. We will continue to accept subjects, for which there are more than 2,700 Avance nerve repairs enrolled to date, in our RANGER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical study (defined below in &#8220;Government Regulations&#8221;), a utilization registry of Avance Nerve Graft. An additional arm of the RANGER study has been initiated, tracking neurotization outcomes in breast reconstruction (Sensation-NOW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Eleven of the above-mentioned publications and more than 70 scientific conference presentations have been generated to date from the registry. Rethink Pain&#8482;, a multicenter observational registry in the area of nerve pain and the surgical treatment of pain, has been initiated and enrollment is underway. A number of additional investigator-initiated case reports, studies, and publications have been completed, including breast neurotization, mandible reconstruction, compressive neuropathies, and the surgical treatment of pain. Case series in brachial plexus, neurotization of breast reconstruction, compression injuries and the surgical treatment of pain are also being developed. We also support outside research and will continue to work with investigators on grants with a translational focus.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RECON, a phase 3 pivotal, multicenter, prospective, randomized, comparative study of hollow tube conduits and Avance Nerve Graft to support the transition of Avance to a biological product has completed enrollment, follow-up, and analysis. See &#8220;Government Regulations &#8211; Clinical Trials.&#8221; The pilot phase of REPOSE, a multicenter, prospective, randomized, and subject blinded study of Axoguard Nerve Cap as compared to neurectomy alone for the treatment of symptomatic neuroma, has published and the comparative phase has completed enrollment and is currently in follow-up. Enrollment is underway in REPOSE XL, a study titled, Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends. ASSIST, a registry study of Avive Soft Tissue Membrane in acute trauma completed follow-up of all enrolled subjects in December 2020. Sensation-NOW (defined below in "Axogen Clinical Trials"), a RANGER (defined below in "Government Regulations") study arm for breast neurotization continues to enroll, as does the additional expansion arm Matched Autograft and Tube Conduit Case Control Cohort Arm of RANGER ("MATCH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a contemporary cohort control which provides reference controls for nerve autograft and manufactured conduits from participating clinical study centers.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitment to the Education of Best Practices in Peripheral Nerve Repair</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established educational conferences and presentations and surgical resident and fellow training that we believe have positioned us as a leader in providing peripheral nerve repair best practices. In 2022, we trained more than three-quarters of hand and microsurgery surgeon fellows in the U.S. through such courses and training.] We have historically provided education on peripheral nerve repair through in-person national programs, including its &#8220;Advances and Best Practices in Nerve Repair&#8221; as well as local and regional educational events. In 2022, we utilized virtual education events and in-person educational events. In 2023, we expect to again offer multiple educational programs including virtual and in-person surgeon education programs. Our education efforts also continue to include online tools and discussion forums such as Nerve Matters, an online community of peripheral nerve surgeons where the surgeons can ask questions, present cases, and share findings in the area of peripheral nerve repair.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Focused on developing deeper penetration with our existing accounts through development of long-term users of our algorithm in our largest market opportunity of extremity trauma</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide full sales and distribution services. As of December 31, 2022, we had 115 direct sales professionals in the U.S. Our direct sales force continues to be supplemented by independent sales agencies that represent approximately 10% of our total revenue.We believe that near-term growth can be supported first through expanded productivity of our existing sales force as they go deeper with existing accounts and then by adding additional surgeons and accounts. We expect the number of direct sales professionals to increase over time. Additionally, we have successfully utilized a hybrid commercial approach that includes the use of independent agencies in more remote geographies to provide appropriate local support for surgeons, without the travel time required of a direct sales representative. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are available and sold in 17 countries outside the U.S. through a number of independent in-country distributors. We provide support and resources for independent agencies and distributors both within and outside the U.S, including two contractors in Germany. We provide our products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons to review the benefits of our products. While surgeons make the decision to implant our products in appropriate patients, hospitals make the decision to purchase the products from us. In today&#8217;s budget constrained environment, hospital committees review new technologies for cost effectiveness as well as quality. We believe that we have been successful in meeting the needs of these hospital committees by demonstrating the cost/benefit of our products and providing a fair value to the hospital. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expand the Product Pipeline and Applications in Peripheral Nerve Repair</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and continue to develop new and next generation products to support surgeons in their needs for repairing damaged or transected peripheral nerves. We believe additional opportunities exist to develop or acquire complementary products in peripheral nerve repair. In addition, there are opportunities to expand the existing portfolio of products in new applications of peripheral nerve repair in applications such as lower extremity surgery, head and neck surgery, urology, and the surgical treatment of pain.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Avance Nerve Graft Performance</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have worked with leading institutions, researchers, and surgeons to support innovation in the field of surgical peripheral nerve repair. We believe our RANGER study (defined below in &#8220;Government Regulations&#8221;) is the largest multi-center clinical study conducted in peripheral nerve gap repair. We have completed the RECON study (defined below in "Axogen Clinical Trials"). This study is a phase 3 trial to support our BLA for the Avance Nerve Graft. See &#8220;Government Regulations - Clinical Trials - Axogen Clinical Trials.&#8221;  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Opportunity for Revenue </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently focus primarily on the U.S. market, with additional foreign distribution and sales in Canada, Germany, UK, Spain, and several other European, Asian and Latin American countries. The need for the surgical repair of damaged or transected nerves is a global opportunity. Through our revenue outside the U.S., we have demonstrated the capability to take our current peripheral nerve repair surgical portfolio into new geographical markets. We currently have European Union (&#8220;E.U.&#8221;)-wide registration only for Axoguard Nerve Connector and Axoguard Nerve Protector as approval/registration for Avance Nerve Graft as human tissue is required in each individual country. Avance Nerve Graft has been granted marketing authorization in Germany and direct commercial operations began in 2022. Currently, Axotouch Two-Point Discriminator and Axoguard Nerve Cap are available only in the U.S. Introduction of our products into foreign markets is subject to meeting the appropriate regulatory standards of particular countries and any appropriate E.U.-wide regulation or directive. In addition to regulatory approval, reimbursement approval is necessary to achieve material product adoption in most countries. Avance Nerve graft has achieved NICE approval in the UK for digital nerve repair and reimbursement approval in South Korea for repairs up to 50mm in length for sensory nerves when an autograft is not possible. To date, revenue from international distribution and sales have not been material, there are no material risks associated with foreign operations, and we do not have dependencies as to international revenue. See " Item 1A. Risk Factors &#8211; Our operations must comply with FDA and other governmental requirements." </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we provide the most extensive product portfolio for peripheral nerve injuries available. Our current development focus is to expand clinical data in peripheral nerve repair surgical applications, to develop product line extensions of the Avance and Axoguard products and new technologies/products for peripheral nerve repair. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with academic institutions in the expansion of treatments for peripheral nerve and are involved in a number of grants from government agencies related to nerve repair or use of our products and/or technologies. For the year ended December&#160;31, 2022, we spent approximately $24.2 million on total research and development expenses for product and clinical development, including expenses related to the transition of Avance Nerve Graft to a biological product.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. As such, we cannot predict what products may be offered in the future that may compete with our products. In the peripheral nerve repair market, we compete primarily against all transected and non-transected peripheral nerve repair approaches, including direct suture repair, autograft, and hollow-tube nerve conduits and materials used to wrap and protect damaged peripheral nerve tissue. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the requirements of the biomaterials used in peripheral nerve repair can vary based on the severity and location of the damaged nerve, the size and function of the nerve, surgical technique, and patient preference, our peripheral nerve repair products compete against both autograft materials (nerve in the case of a bridging repair and vein or fat in the case of a nerve protection repair), and a limited number of off-the-shelf alternatives for repairing and protecting. Competitive aspects of our products focus on their overall value proposition and suitability for specific applications and can include composition and structure of the material, ease of use, clinical evidence, handling, and price. Our major competitors for off-the-shelf repair options in hollow-tube conduits and bio-absorbable wraps are Integra LifeSciences Holding Corporation, Baxter International, Inc., and Stryker Corporation.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe any current or future competitors face the following important barriers to market entry as it relates to its peripheral nerve repair products. Our intellectual property (&#8220;IP&#8221;), and that of our partners, including patents, patents-pending, trade secrets, and know how, is believed to be an important barrier for our Avance Nerve Graft and Axoguard products. We have developed knowledge and experience in understanding and meeting FDA regulatory requirements for Avance Nerve Graft, including having made a substantial investment in conducting the pre-clinical and clinical testing necessary to support a submission for an FDA BLA. Additionally, we believe our ability to offer a portfolio of products focused on peripheral nerve repair and the breadth of clinical data associated with the products provides a unique competitive position versus other entities that do not have this breadth of product offering. However, due to our limited resources, our smaller size, and our relatively early stage, we believe we may face competitive challenges from larger entities and market factors that could negatively impact our growth, including competitors&#8217; introduction of new products and competitors&#8217; bundling of products to achieve pricing benefits.(See &#8220;Item 1A. Risk Factors &#8211; Technological change and competition for newly developed products could reduce demand for our products&#8221;; &#8220;Risk Factors &#8211;&#8211; Our operating results could be adversely impacted if we are unable to effectively manage and sustain our future growth or scale our operations&#8221;).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We protect our IP through a combination of patents, trademarks, trade secrets, and copyrights. In addition, we safeguard our trade secrets and other confidential know-how, and carefully protects these and other IP rights when engaging with third parties. For example, we require vendors, contract organizations, consultants, advisors, and employees to execute confidentiality and nondisclosure agreements, and to appropriately protect any information disclosed to them by us so as to preserve confidential and/or trade secret status. We also require consultants, advisors, and employees to assign their rights to any IP arising out of their relationship with us to us.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into license agreements with University of Florida Research Foundation (the &#8220;UFRF&#8221;) and the University of Texas at Austin (&#8220;UTA&#8221;). Under the terms of these license agreements, we hold exclusive worldwide licenses to underlying technologies used by us in our Avance Nerve Graft. The license agreements include both the right to issued patents and patents pending in the U.S. and international markets. The effective term of the license agreements extends through the term of the related patents. Currently, we pay royalties to UFRF and UTA specific to the licensed technologies related to Avance Nerve Graft.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Form&#160;10-K, we own or are the exclusive licensee of about thirty issued U.S. patents, more than thirty-five pending U.S. patent applications (including those for which we have received a notice of allowance) and more than one hundred and forty international patents and patent applications with regard to our peripheral nerve products and other related technologies. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our Avance Nerve Graft, we have patent protection in the U.S. through at least December 2023. [In addition, per Section 351(k)(7) of the Public Health Service (PHS) Act, we believe we will have a period of 12 years total exclusivity in the U.S.</span><span style="color:#1f497d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for reference product,-meaning protection from biosimilars. Pursuant to the PHS Act, periods of reference product exclusivity begins on the date on which the reference product is first licensed (Section 351(i)(4)). In this context we anticipate Avance would be eligible to receive up to 12 years market exclusivity as the first product of its class to be licensed. Finally, we have Enforcement Discretion from the FDA regarding continued distribution under controls applicable to Human Cellular and Tissue-based Products (&#8220;HCT/Ps&#8221;) with an agreed transition plan to a BLA. We believe a competitive processed peripheral nerve allograft would need to successfully complete BLA Phase I, II and III clinical studies prior to clinical release, the completion of which we believe would take at least eight years.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to seek patent protection for, or where strategically preferable, maintain as trade secret, the inventions that we consider important to our products and the development of our business. We have sought, and will continue to seek, patent protection for select proprietary technologies and other inventions emanating from our research and development ("R&amp;D"), including with respect to uses, methods, and compositions, in an effort to further fortify our IP stronghold in areas of importance to us and our growing product portfolio. In instances that patent protection is not possible, product value to our portfolio can still be derived.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademarks, Trade Secrets and Copyrights</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hold a significant portfolio of hundreds of registered and applied-for trademarks in the U.S. and worldwide. Protection of our trademarks allows us to prevent competitors from, for example, using the same or a confusingly similar company name, or the same or confusingly similar product names within identified classes of goods that could otherwise wrongfully allow such competitors to capitalize on our brand, reputation, and goodwill, and thereby improperly bolster their sales or reputations through, for example, consumer confusion, a false indication of our endorsement, or of a false indication of corporate or contractual relationship with us. We police and enforce our marks. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We possess trade secrets and material know-how in the following general subject matters: nerve and tissue processing, nerve repair, product testing methods, and pre-clinical and clinical expertise. We have registered copyrights for training tools and artistic renderings. Additionally, we entered into the Distribution Agreement and Supply Agreement with Cook Biotech for the Axoguard products. Cook Biotech believes it has know-how and trade secrets with respect to its ECM technology that provides certain competitive obstacles that protect our IP.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulations</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Government Regulation Overview</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to regulation throughout their lifecycle by the FDA, as well as other federal and state regulatory bodies in the U.S. and comparable authorities in other countries. In addition, our Avance Nerve Graft must comply with the standards of the tissue bank industry&#8217;s accrediting organization, the AATB.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We distribute Axoguard Nerve Connector and Axoguard Nerve Protector products for Cook Biotech, and Cook Biotech is responsible for the regulatory compliance of these products. These Axoguard products are regulated as medical devices and subject to pre-market notification requirements under section 510(k)&#160;of the Federal Food, Drug, and Cosmetic Act (the &#8220;FD&amp;C Act&#8221;), 21 CFR Part&#160;820 (&#8220;Quality System Regulation&#8221;), and related laws and regulations. Cook Biotech has obtained a 510(k)&#160;pre-market clearance for Axoguard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nerve Connector from the FDA for the use of porcine small intestine submucosa for the repair of peripheral nerve transections where gap closure can be achieved by flexion of the extremity. Cook Biotech has also obtained a 510(k)&#160;pre-market clearance for Axoguard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nerve Protector for the repair of peripheral nerve damage in which there is no gap or where a gap closure is achieved by flexion of the extremity. We sell the 510(k) cleared devices under the trade names Axoguard Nerve Protector and Axoguard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nerve Connector.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also sell the Axoguard Nerve Cap product, which is classified by the FDA as a Class&#160;II device. The Axoguard Nerve Cap was cleared for market under 510(k) K163446. It is classified by FDA under 21 CFR 882.5275 (Nerve Cuff, product code: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JXI). Cook Biotech is the contract manufacturer for our Axoguard Nerve Cap product and we are responsible for the regulatory compliance of this product.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also distribute the Axotouch Two-Point Discriminator. This device is manufactured for us and distributed from the Burleson Facility. It is a Class I device (general controls) that is exempt from pre-market notification and the Quality System Regulation requirements except for the Recordkeeping and Complaint file requirements. It is classified by FDA under 21 CFR 882.1200 (Two-point discriminator, product code: GWI).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for the regulatory compliance of Avive Soft Tissue Membrane, which we suspended the market availability of effective June 1, 2021. We continue discussions with the FDA to determine the appropriate regulatory classification and requirements for Avive. The suspension was not based on any known or reported safety or product performance concerns with Avive. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">FDA &#8212; General</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA regulations govern nearly all the activities that we perform, or that are performed on our behalf, to ensure that medical products distributed domestically or exported internationally are safe and effective for their intended uses. The activities the FDA regulates include the following:</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product design, development, and manufacture;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product safety, testing, labeling, and storage;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pre-clinical testing in animals and in the laboratory;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical investigations in humans;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pre-marketing clearance, approval, or licensing;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Record-keeping and document-retention procedures;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advertising and promotion;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The import and export of products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product marketing, sales, and distribution;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Post-marketing surveillance and medical device reporting, including reporting of deaths, serious injuries, communicable diseases, device malfunctions, or other adverse events; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Corrective actions, removals and recalls.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable FDA regulatory requirements may subject us to a variety of administrative or judicially imposed penalties or sanctions and/or prevent us from obtaining or maintaining required approvals, clearances, or licenses to manufacture and market our products. It could also subject us to enforcement actions or sanctions, such as agency refusal to approve pending applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution of products, injunctions, or civil monetary penalties or criminal prosecution.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA&#8217;s Pre-market Clearance and Approval Requirements - Medical Devices</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an exemption applies, each medical device distributed commercially in the U.S. requires either a 510(k) pre-market notification submission or a Pre-Market Approval (&#8220;PMA&#8221;) Application to the FDA, or other FDA regulatory authorization. Medical devices are classified into one of three classes&#8212;Class I, Class II, or Class III&#8212;depending on the degree of risk, the level of control necessary to assure the safety and effectiveness of each medical device and how much is known about the type of device. For devices first intended for marketing after May 28, 1976, pre-market review and clearance by the FDA for Class&#160;I and II medical devices is accomplished through the 510(k) pre-market notification procedure by finding a device substantially equivalent to a legally marketed Class I or II device, unless the device is exempt. The majority of Class I medical devices are exempt from the 510(k) pre-market notification requirement. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices for which Class&#160;II controls are inadequate to assure safety or effectiveness, and novel devices, including devices deemed not substantially equivalent to a previously cleared 510(k) device, are placed in Class III. Class III devices generally require an approved PMA prior to marketing, unless classified into Class I or Class II through a De Novo request.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A PMA must be supported by extensive data, including, but not limited to, technical, pre-clinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction, and the safety and effectiveness of the device.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investigational New Drug (IND) Application for Drugs and Biologics</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that a new drug be the subject of an approved marketing application and that a biological product be properly licensed before each is introduced or delivered for introduction into interstate commerce. Because a sponsor often </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needs to ship an investigational drug or biological product to clinical investigators in many states, it must seek an exemption from that legal requirement. The IND is the means through which the sponsor obtains this exemption from the FDA. It is additionally the request from a clinical study sponsor to obtain authorization from the FDA to administer an investigational drug or biological product to humans. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two IND categories: Commercial and Research (non-commercial). The IND application must contain information in three broad areas:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans (often foreign use).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing Information - Information pertaining to the composition, manufacturer, stability, and controls used for manufacturing the drug substance and the drug product. This information is assessed to ensure that the company can adequately produce and supply consistent batches of the drug.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical Protocols and Investigator Information - Detailed protocols for proposed clinical studies to assess whether the initial-phase trials will expose subjects to unnecessary risks. Also, information on the qualifications of clinical investigators--professionals (generally physicians) who oversee the administration of the experimental compound--to assess whether they are qualified to fulfill their clinical trial duties. Finally, commitments to obtain informed consent from the research subjects, to obtain review of the study by an institutional review board (IRB), and to adhere to the investigational new drug regulations.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical trials. During this time, the FDA has an opportunity to review the IND for safety to assure that research subjects will not be subjected to unreasonable risk. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about issues such as the conduct of the trials and or supporting pre-clinical data as outlined in the IND. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns or questions before clinical trials can proceed. Therefore, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following regulations apply to the IND application process:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">21CFR Part 201&#160;&#160;&#160;&#160;Drug Labeling</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">21CFR Part 312&#160;&#160;&#160;&#160;Investigational New Drug Application</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">21CFR Part 314&#160;&#160;&#160;&#160;IND and NDA Applications for FDA Approval to Market a New Drug (New Drug Approval)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">21CFR Part 316&#160;&#160;&#160;&#160;Orphan Drugs</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">21CFR Part 50&#160;&#160;&#160;&#160;Protection of Human Subjects</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">21CFR Part 54&#160;&#160;&#160;&#160;Financial Disclosure by Clinical Investigators</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">21CFR Part 56&#160;&#160;&#160;&#160;Institutional Review Boards</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">21CFR Part 58&#160;&#160;&#160;&#160;Good Lab Practice for Nonclinical Laboratory [Animal] Studies</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biological Product License Application (BLA) Pathway</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics License Application (BLA) is a request for permission to introduce, or deliver for introduction, a biological product into interstate commerce (21 CFR 601.2). Form 356h specifies the requirements for a BLA. Biological products require FDA approval of a BLA to be marketed. The application must demonstrate the safety, purity, and potency of the product candidate based on results of pre-clinical studies and clinical trials. A BLA must also contain extensive Chemistry, Manufacturing and Controls ("CMC") and other manufacturing information, as well as Labeling information. The applicant must pass an FDA pre-approval inspection of the manufacturing facility or facilities at which the biological product is produced to assess compliance with the FDA&#8217;s current Good Manufacturing Practice ("cGMP") requirements. Satisfaction of FDA approval requirements for biologics typically takes several years and the actual time required may vary substantially based on the type, complexity, and novelty of the product. We cannot be certain that any BLA approvals for our products will be granted on a timely basis, or at all.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The steps for obtaining FDA approval of a BLA to market a biological product in the U.S. include:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completion of pre-clinical laboratory tests, animal studies, and formulation studies under the FDA&#8217;s good laboratory practices regulations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin and which must include independent Institutional Review Board, ("IRB"), approval at each clinical site before the trials may be initiated;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Performance of an adequate and well-controlled clinical trial in accordance with Good Clinical Practices to establish the safety and efficacy of the product for each indication;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission to the FDA of a BLA, which contains detailed information about the CMC for the product, reports of the outcomes and full data sets from the clinical trials, and proposed labeling and packaging for the product;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Satisfactory review of the contents of the BLA by the FDA, including the satisfactory resolution of any questions raised during the review;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP regulations, to assure that the facilities, methods, and controls are adequate to ensure the product&#8217;s identity, strength, quality, and purity; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA approval of the BLA, including agreement on post-marketing commitments, if applicable.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Avance Nerve Graft Regulatory Classification and Regulatory Pathway</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avance Nerve Graft has been marketed domestically and internationally since 2007. In 2010, the FDA provided us with an enforcement discretion letter, regarding the marketing of Avance so long as we complied with certain terms that focused us on taking the necessary steps to support a BLA submission for the product. The FDA will end the period of enforcement discretion upon a final determination of our future BLA submission or if prior to the BLA submission, the FDA finds that we do not meet the conditions for the enforcement discretion terms or are not exercising due diligence in executing the transition plan. If final action on the BLA is negative or we are found to not meet the conditions for the transition plan or its execution, or if FDA were to revoke the enforcement discretion for any other reason, we may not be able to continue to distribute Avance Nerve Graft. We continue to work diligently to execute the transition plan, including maintaining regular communication with the FDA, and, in this context, continue to distribute Avance Nerve Graft.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We met with the FDA Center for Biologics Evaluation and Research ("CBER") in July 2010 and, between July 2010 and November 2010, provided information to CBER that resulted in the FDA issuing a letter stating the agency&#8217;s intent to exercise enforcement discretion with respect to the continued introduction or delivery for introduction into interstate commerce of Avance Nerve Graft assuming that certain conditions are met relating to the transition of Avance Nerve Graft from regulation as an HCT/P under Section 361 to a biological product under Section 351 of the Public Health Service Act. Specifically, the FDA transition plan outlined that:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We transition to compliance with Section 501(a)(2)(B) of the FD&amp;C Act, the current  cGMP regulations in 21 CFR Parts 210 and 211 and the applicable regulations and standards in 21 CFR Parts 600-610 prior to initiation of a phase 3 clinical trial designed to demonstrate the safety, purity, and potency of Avance Nerve Graft.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">We have performed several gap analyses of our quality system for compliance with 21 CFR Parts 210 and 211 and 600-610 regulations. The gap analyses have identified areas in which our quality system could improve with respect to compliance with the regulations. The transition is in process and we periodically review the 21 CFR Parts 210 and 211 and 600-610 regulations to ensure that we create and implement appropriate changes, including new quality procedures. Through our internal auditing process, we periodically assess our compliance to the regulations. As we complete the BLA submission, we will retain an external audit consultant with experience in auditing to 21 CFR Parts 210 and 211 and 600-610 regulations to verify quality system compliance with the regulations.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We conduct a phase 3 clinical trial to demonstrate safety, purity and potency of Avance Nerve Graft under a Special Protocol Assessment (&#8220;SPA&#8221;). We and the FDA agreed to the SPA in August 2011. </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In accordance with FDA regulations in 21 CFR &#167;Part 312, we submitted IND #15419 to the FDA and it became effective in March 2015.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The phase 3 clinical trial was initiated in the second quarter of 2015. The study completed initial enrollment in January 2019. As required by the SPA and agreed to by FDA and us, an independent statistical analysis was conducted to determine if greater study enrollment was appropriate to maintain the planned statistical power of the trial. As part of that review, the targeted enrollment was increased to 220 subjects, and the number of participating centers was increased to up to 25. The study completed subject enrollment in July 2020. Subject follow-up was completed in August 2021 with topline study data read-out completed during the second quarter of 2022. Topline results showed that this pivotal study met its primary endpoint for the return of nerve function as measured by static two-point discrimination. It also demonstrated that the safety profile was consistent with previously published data. RECON results demonstrated statistical superiority for return of sensory function, as measured by static two-point discrimination, as compared to conduits in gaps greater </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">than 12 mm (p-value &lt;0.05). Avance demonstrated statistical superiority for time to recover of static two-point discrimination over conduits in nerve gaps greater than 10mm (p-value &lt;0.05). </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We continue to comply with the regulations and standards under 21 CFR Part 1271.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.75pt">We were audited by the FDA at the Avance Processing Facility in March 2013, March 2015, October 2016 and September 2022 and at the Avance Distribution Facility in October 2015 with respect to its Human Tissue Quality System under 21 CFR Part 1271 and in July 2022 with respect to Level 1 Quality System Inspection Technique ("QSIT") Medical Device Inspection under 21 CFR 820. At each inspection, the quality systems were found to be in compliance with 21 CFR Part 1271 and no FDA Form 483 observations were issued.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.75pt">In February 2018. we were audited by the FDA with respect to its Medical Device Quality System under 21 CFR Part 820 and its Human Tissue Quality System under 21 CFR Part 1271. Such audit resulted in two Form 483 observations on general procedures on our Medical Device Quality System and no Form 483 observations on our Human Tissue Quality System. We took corrective action to correct these observations and the FDA has accepted the corrective action plan.</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:13.75pt">In November 2018, we were audited again by the FDA at our Distribution Facility with respect to our Human Tissue Quality System under 21 CFR Part 1271. Such audit resulted in one Form 483 observation on tissue tracking. We took corrective action to correct this observation and the FDA has accepted the corrective action plan.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working with the FDA to ensure compliance with applicable regulations regarding the transition of our quality system to 21 CFR Parts 210 and 211 and 600-610 compliance and through audits for compliance to 21 CFR Part 1271. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in regular communication with the FDA regarding the IND and regulatory compliance. FDA will review our regulatory compliance during the pre-license inspection as part of the BLA review. If the FDA does not find us to be in compliance, the BLA might not be approved or could be delayed.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BLA for Avance Nerve Graft, if approved, will require a potentially substantial user fee payment to the FDA, although certain exemptions, waivers and discounts of the user fees may apply, including certain waivers or discounts for small businesses.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In September 2018, the FDA granted a Regenerative Medicine Advanced Therapy ("RMAT") designation for Avance Nerve Graft. A regenerative medicine therapy is eligible for the RMAT designation if it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such a disease or condition. The RMAT designation provides access to a streamlined approval process for regenerative medicine technologies and informal meetings with the FDA in support of the BLA for Avance Nerve Graft, as appropriate. FDA can withdraw the RMAT designation if the designation criteria are no longer met.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that any future, competitive peripheral nerve allograft would be required to follow the standard pathway for biologic licensing, which typically entails multiple clinical trials and takes many years. The FDA provided updated guidance, "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use" in November 2017, which it revised in July 2020. The guidance clarified the FDA's position that any processing that alters the biological characteristics of peripheral nerve tissue would be considered more than minimal manipulation, and therefore require a BLA prior to marketing.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have maintained a collaborative dialogue with the FDA and will continue to work with the FDA as we progress towards our BLA submission. If our BLA submission is approved, we believe Avance Nerve Graft will have 12 years of reference product exclusivity with regard to potential biosimilars with Avance Nerve Graft being designated as the Reference Product.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are a category of clinical research designed to evaluate and test new interventions, medications, or procedures. Clinical trials are often conducted in four phases. The trials at each phase have a different purpose and help answer different questions.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase I trials test an experimental drug or treatment in a small group of people for the first time. The researchers evaluate the treatment&#8217;s safety, determine a safe dosage range, and identify side effects. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In Phase II trials, the experimental drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In Phase III trials, the experimental study drug or treatment is given to large groups of people. Researchers aim to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase IV trials, also known as Post-marketing studies, are conducted after a treatment is approved for use by the FDA, and provide additional information including the treatment or drug&#8217;s risks, benefits, and best use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are required to support a BLA or PMA and are sometimes required for 510(k) clearance or de novo classification. Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators. Clinical trials are conducted under strict requirements to ensure the protection of human subjects participating in the trial and under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring and safety, and the effectiveness criteria to be evaluated. Clinical trials for biological products require the submission and FDA acceptance of an IND and clinical trials for medical devices require the submission and FDA approval of an Investigational Device Exemption ("IDE") application unless the device regulations provide for an exemption from the IDE requirement. Clinical trials for significant risk devices may not begin until the IDE is approved by the FDA and the IRB overseeing the particular clinical trial. If the product is considered a non-significant risk device under FDA regulations, the trial must only be approved by an IRB prior to its initiation. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND or IDE, for significant risk devices. In addition, for these studies, an IRB at each site at which the study is conducted must approve the protocol, subject consent form and any amendments for each site at which the study is conducted. All research subjects must be informed, among other things, about the risks and benefits of the investigational product and provide their informed consent in writing.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials under an IND typically are conducted in three sequential phases, but the phases may overlap or be combined. In our case, we believe that the phase 3 clinical trial study for Avance Nerve Graft represents the only prospective clinical data that will be required to evaluate safety and effectiveness. Phase 3 clinical trials usually further evaluate clinical efficacy and test further for safety in an expanded patient population. Phase 3 clinical trials usually involve comparison with placebo, standard treatments, or other comparators. Usually, multiple well-controlled large phase 3 or pivotal clinical trials demonstrating safety and efficacy are required to support a BLA. These trials are intended to establish the overall risk-benefit profile of the product and provide an adequate basis for physician labeling. Clinical testing may not be completed successfully within any specified period, if at all. Furthermore, we or the FDA may suspend or terminate a clinical trial at any time on various grounds, including a finding that the subjects are exposed to an unacceptable health risk, have experienced a serious and unexpected adverse event, or that continued use in an investigational setting may be unethical. Similarly, an IRB can suspend or terminate approval of research, for example, if the research is not being conducted in accordance with the IRB&#8217;s requirements or if the research has been associated with unexpected serious harm to patients. Additionally clinical data obtained from the observational study, RANGER, will be provided as supportive safety data.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Clinical Trials</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an active clinical research program to gather data on our product portfolio. We have completed three clinical studies, are performing six ongoing clinical studies, and have plans to initiate further clinical studies. The ongoing studies are: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;A Multicenter Retrospective Study of Avance Nerve Graft Utilization, Evaluations, and Outcomes in Peripheral Nerve Injury Repair (&#8220;RANGER&#8221;),"</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">"A Matched Autograft and Tube Conduit Case Control Cohort Arm of RANGER  ("MATCH"),"</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">"Breast Neurotization Outcomes for Women: A Registry Study of Recovery Outcomes, Quality of Life and Patient Satisfaction in Post-Mastectomy Autologous Breast Reconstruction ("Sensation-NOW")," </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">"A Multicenter, Prospective and Subject Blinded Comparative Study of Axoguard Nerve Cap and Neurectomy for the Treatment of Symptomatic Neuroma and Prevention of Recurrent End-Neuroma Pain ("REPOSE")," </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">"Tolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends ("REPOSE-XL")," and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">"An Ambispective, Multicenter, Observational Registry Study of Patients Considering Surgical Treatment for Chronic Neuropathic Pain ("Rethink Pain")."  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our completed studies are "A Multicenter, Prospective, Randomized, Patient and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities (&#8220;RECON&#8221;)," &#8220;A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and Avance Nerve Graft Evaluation Recovery Outcomes of the Nerve Repair in the Hand (&#8220;CHANGE&#8221;)&#8221; published by Means et al and a pilot study to evaluate the use of Avance Nerve Graft in the reconstruction of nerves following prostatectomy.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these clinical research programs, we are developing additional clinical trials in peripheral nerve repair, including mixed and motor nerve repair, breast neurotization and pain.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are subject to extensive recordkeeping and reporting requirements. Our clinical trials must be conducted under the oversight of an IRB for the relevant clinical trial sites and must comply with FDA regulations, including but not limited to, those relating to Good Clinical Practices. We are also required to obtain the patients&#8217; written, informed consent in a form and substance that complies with both FDA requirements and state and federal privacy and human subject protection regulations. We, the FDA or the IRB may suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the biological product or device, or may otherwise not be sufficient to obtain FDA approval to market the product in the U.S. Similarly, in the E.U., the clinical study for a medicine product must be authorized by the Competent Authority in each Member State where the clinical trial is to be conducted and must receive a favorable opinion from an ethics committee. See "Risk Factors - Clinical trials can be long, expensive and results are ultimately uncertain, which could jeopardize our ability to obtain regulatory approval and continue to market our Avance Nerve Graft product."</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RANGER</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RANGER study is an observational study currently in enrollment and is a utilization registry of Avance Nerve Graft. As of December 31, 2022, eleven publications and more than 70 scientific conference presentations have been generated to date from the study. RANGER is designed to allow up to 2,500 subjects. An additional 500 subjects are allowed to be enrolled in Addendum 1, MATCH, and 2,000 enrolled in Addendum 2, Sensation-NOW. Sensation-NOW is a clinical study cohort designed to assess breast sensation following reconstruction with or without neurotization. We resumed enrollment in 2021 at select centers after pausing enrollment due to COVID-19 in 2020. The follow-up for the RANGER study is standard of care with a target of up to 36 months post peripheral nerve repair. At the time of BLA submission for Avance Nerve Graft, we will provide to the FDA Real World Evidence based primarily on Real World Data from the RANGER study data for all qualifying peripheral nerve repairs. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RANGER study database is also utilized to monitor different nerve repair techniques. As part of this, we utilize the database to support additional regulatory submissions for the Axoguard products.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have worked with leading institutions, researchers, and surgeons to support innovation in the field of surgical peripheral nerve repair. We believe that RANGER is currently the largest multi-center observational clinical study conducted in peripheral nerve gap repair. Various reviewers of the RANGER study have found Avance Nerve Graft nerve repairs resulted in meaningful motor and sensory recovery and reduced pain following neuroma excision and reconstruction with no safety concerns identified. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RECON</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RECON study is a prospective, randomized, controlled, patient and evaluator blinded, comparative study of Avance Nerve Graft and Collagen Nerve Cuffs (manufactured conduits) in the repair of peripheral nerve transections in digital nerves with gaps of 5 to 25mm. The study is designed to assess the outcomes of peripheral nerve repair in approximately 170 subjects in up to 20 centers. Subjects were intraoperatively randomized in a 1:1 ratio after stratification by length of the nerve injury by gap length into short gap (5-14mm) and long gap (15-25mm) categories. The primary objective of the study is to evaluate the safety and efficacy of Avance Nerve Graft for non-inferiority and if met, superiority, of static two-point discrimination, a measure of sensory function, at twelve months as compared to nerve cuffs. Given the pooled standard deviation assumptions and a non-inferiority margin of 2mm, approximately 88 patients per treatment group are required to assess non-inferiority with at least 83% power. In addition to non-inferiority, a minimum treatment effect is required to be demonstrated. Based on an agreement with the FDA in the original protocol and an independent statistical analysis of the pooled standard deviation, the number of subjects was increased to 220 in up to 25 centers. Subjects were followed over the course of 12 months (based on the agreed-upon protocol, subjects have up to an additional three months to complete trial requirements) to assess safety and efficacy outcomes with assessments performed at various defined intervals up to 12 months. The study completed subject enrollment in July 2020. Subject follow-up was completed in August 2021with topline study data read-out completed during the second quarter of 2022. Topline results showed that this pivotal study met its primary endpoint for the return of nerve function </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as measured by static two-point discrimination. It also demonstrated that the safety profile was consistent with previously published data. RECON results demonstrated statistical superiority for return of sensory function, as measured by static two-point discrimination, as compared to conduits in gaps greater than 12 mm (p-value &lt;0.05). Avance demonstrated statistical superiority for time to recover of static two-point discrimination over conduits in nerve gaps greater than 10mm (p-value &lt;0.05). The data in this study will support our BLA submission, which we expect to file with FDA in 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">REPOSE</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting a multicenter, prospective, randomized, and subject blinded study of Axoguard Nerve Cap as compared to neurectomy for the treatment of systematic neuroma ("REPOSE"). REPOSE is a two-phase study comparing standard neurectomy to Axoguard Nerve Cap, which leverages our chambered technology to aid in the management of symptomatic neuromas. The first phase, a non-randomized pilot has completed enrollment and one-year follow-up. The second phase, a prospective, randomized controlled study, completed enrollment in 2022. Overall enrollment is designed to target 101 subjects with 15 in the first pilot phase followed by up to 86 in the randomized, comparative phase. The study will assess pain scores, quality of life, neuroma recurrence, and health outcomes over a 12-month follow-up period. Subject follow-up is expected in the third quarter of 2023. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REPOSE XL</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REPOSE-XL is a prospective, multi-center clinical pilot study evaluating the tolerability and feasibility of the Axoguard Large-Diameter Nerve Cap (sizes 5-7 mm) for protecting and preserving terminated nerve endings after limb trauma or amputation when immediate attention to the nerve injuries is not possible. Enrollment in REPOSE-XL started in 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rethink Pain</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rethink Pain is a prospective and retrospective, multicenter, observational clinical study of patients considering surgical treatment for chronic neuropathic pain. Enrollment resumed in 2021 after pausing in 2020 due to COVID-19. Rethink Pain evaluates a patient's healthcare journey and pain history through detailed medical history and record review. For patients who undergo surgical treatment for pain, standardized outcome measures such as post-operative pain, pain medication usage, quality of life outcomes, and functional outcome of associated nerves as compared to pre-operative levels will be assessed.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Market Regulatory Requirements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous regulatory requirements that apply after a product is cleared or approved. For medical devices, these include, but are not limited to the FDA&#8217;s regulations for device labeling (21 CFR Part 801), medical device reporting (21 CFR Part 803), reporting of corrections and removals (21 CFR Part 806), establishment of registration and device listing requirements (21 CFR Part 807), and compliance with the QSR per 21 CFR Part 820. Distribution of medical devices is also subject to license/registration requirements in some states. For tissue and biological products, the regulatory requirements include: the FDA&#8217;s registration and listing requirements, donor eligibility requirements and compliance with GTP in 21 CFR Part 1271 for human tissue products, compliance with the FDA&#8217;s cGMP in 21 CFR Parts 210, 211, and 600 for licensed biological products, and post-market BLA requirements (21 CFR Part 601), including The Drug Supply Chain Security Act (DSCSA). Among other things, these regulations require manufacturers, including third party manufacturers to:</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Follow stringent design, testing, control, documentation, and other quality assurance procedures during all aspects of the manufacturing process;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Comply with labeling regulations and FDA prohibitions against the false or misleading promotion or the promotion of products for uncleared, unapproved or off-label uses, or indications;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Comply with requirements to obtain clearance or approval for certain changes affecting the product, including changes to the product&#8217;s manufacturing, labeling, or intended use;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Report to the FDA certain adverse events, adverse reactions, and deviations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Comply with post-approval restrictions or conditions, including post-approval study commitments and post-market safety and annual reporting requirements;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Follow post-market surveillance regulations that may apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Follow requirements to issue notices of correction or removal, or conduct market withdrawals, or recalls where quality or other issues arise.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Safety Reporting and other Periodic Reporting</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not received any reports of adverse events where the event was determined to be product related for Avance Nerve Graft or Avive Soft Tissue Membrane products. Although we have voluntarily suspended marketing of Avive, the suspension was not due to a recall or any safety concerns. Nine adverse events have been reported by Cook Biotech for the Axoguard products (one each in 2013, 2014, 2015, 2016, and 2020; and two each in 2017 and 2019). We reported three biological deviations (two in 2018 and one in 2019) for quality system issues related to human tissue distribution (no patient safety issues were involved). In December 2020, a user facility presented a Medwatch report for Avance Nerve Graft for a sizing issue and potential delay in procedure. Our follow-up indicated that there was no delay in procedure and we filed information with the FDA and no further action is required. We have not had to submit any Medical Device Reports (&#8220;MDRs&#8221;) or tissue adverse reaction reports to the FDA. Although the Axoguard connector and protector product lines have had just nine adverse events reported to date, there may have been other incidents, including patient deaths, that may have occurred during procedures utilizing our products without us being aware of any such incidents. In addition, there can be no assurance that in the future our products will not cause or contribute to an adverse event that would require us to submit MDRs, biological deviation reports, or tissue adverse reaction reports to the FDA . IND annual reporting remains in compliance. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FDA, the advertising and promotion of medical products are also regulated by the Federal Trade Commission and in some instances by state regulatory and enforcement authorities. Recently, some promotional activities for FDA-regulated products have been the subject of enforcement action brought under healthcare reimbursement laws and consumer protection statutes. In addition, under the Federal Lanham Act and similar state laws, competitors, and others can initiate litigation relating to advertising claims.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Facilities Listing and Registrations</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our facilities are properly registered with the FDA as tissue or medical device establishments. The FDA has broad post-market and regulatory enforcement powers. We are subject to unannounced inspections by the FDA to determine compliance with the GTP, GMP, and other regulations, and these inspections may also include suppliers' manufacturing facilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure by us or our suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA or other federal or state authorities, which may include any of the following sanctions, among others:</span></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Warning letters, fines, injunctions, consent decrees and civil penalties;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Customer notifications, repair, replacement, refunds, recall or seizure of our products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating restrictions, partial suspension, or total shutdown of production;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Suspension or termination of our clinical trials;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Refusing our 501(k), de novo classification request, PMA or BLA for new products, new intended uses, or modifications to existing products;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Withdrawing or suspending pre-market approvals that have already been granted; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Criminal prosecution.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Education Grants, U.S. Anti-kickback, False Claims and Other Healthcare Fraud and Abuse Laws</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Educational Grants</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A medical product manufacturer may provide financial or in-kind support, including support by way of grants, to third parties for the purpose of conducting medical educational activities. If these supported activities are considered by the FDA to be independent of the manufacturer, then the activities fall outside the FDA restrictions on promotion to which the manufacturer is subject.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure that the educational activities we support through our grants program are in accordance with the appropriate criteria for independent educational activities. However, we cannot provide assurance that the FDA or other government authorities would view the programs supported as being independent.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fraud, Abuse and False Claims</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are directly and indirectly subject to various federal and state laws governing relationships with healthcare providers and pertaining to healthcare fraud and abuse, including anti-kickback laws. In particular, the U.S. Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for or recommending a good or service for which payment may be made in whole or part under federal healthcare programs, such as the Medicare and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid programs. Penalties for violations could include criminal penalties and civil sanctions such as fines, imprisonment and possible exclusion from Medicare, Medicaid, and other federal healthcare programs. In implementing the statute, the Office of Inspector General of the U.S. Department of Health and Human Services (&#8220;OIG&#8221;) has issued a series of regulations, known as &#8220;safe harbors.&#8221; These safe harbors set forth provisions that, if all their applicable requirements are met, will assure healthcare providers and other parties that they will not be prosecuted under the Anti-Kickback Statute for activities that fit within a safe harbor. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy each applicable element of a safe harbor may result in increased scrutiny by government enforcement authorities, such as the OIG, and may be &#8220;at risk&#8221; activities unless a favorable advisory opinion is obtained from the OIG.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Federal False Claims Act (&#8220;FCA&#8221;) imposes civil liability on any person or entity that submits, or causes the submission of, a false or fraudulent claim to the U.S. government. Damages under the FCA can be significant and consist of the imposition of fines and penalties. The FCA also allows a private individual or entity with knowledge of past or present fraud against the federal government to sue on behalf of the government to recover the civil penalties and treble damages. The U.S. Department of Justice ("DOJ") has previously alleged that the marketing and promotional practices of pharmaceutical and medical device manufacturers including the off-label promotion of products or the payment of prohibited kickbacks to doctors violated the FCA resulting in the submission of improper claims to federal and state healthcare entitlement programs such as Medicaid. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AdvaMed is one of the primary voluntary U.S. trade associations for medical device manufacturers. PhRMA is another global trade association focused on the pharmaceutical industry. These associations have established guidelines and protocols for medical device and pharmaceutical manufacturers, respectively, in their relationships with healthcare professionals on matters, including research and development, product training and education, grants and charitable contributions, support of third-party educational conferences, and consulting arrangements. Adoption of the AdvaMed or PhRMA Codes by a medical device manufacturer is voluntary, and while the OIG and other federal and state healthcare regulatory agencies encourage its adoption, they do not view adoption of these codes as proof of compliance with applicable laws. Key to the underlying principles of the AdvaMed and PhRMA Codes is the need to focus the relationships between manufacturers and healthcare professionals on matters of training, education and scientific research, and limit payments between manufacturers and healthcare professionals to fair market value for legitimate services provided and payment of modest meal, travel, and other expenses for a healthcare professional under limited circumstances. We have incorporated these principles into our relationships with healthcare professionals under our consulting agreements, payment of travel and lodging expenses, research and educational grant procedures and sponsorship of third-party conferences. In addition, we have conducted and will continue to conduct training sessions on these principles. Finally, the Sunshine Act, as defined below, imposes additional reporting and disclosure requirements on us for any &#8220;transfer of value&#8221; made or distributed to physicians and teaching hospitals, as well as reporting of certain physician ownership interests. We cannot provide any assurance that regulatory or enforcement authorities will view our relationships with physicians or policies as being in compliance with applicable regulations and laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation Outside of the U.S.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution and sales of medical products outside of the U.S. are subject to foreign governmental regulations that vary substantially from country to country. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are restrictions under U.S. law on the export of medical devices and biological products that cannot be legally distributed in the U.S. The FDA has set forth certain requirements for the export of devices outside of the U.S. depending on the class of device and its FDA approval. We currently believe we comply with applicable regulations when exporting our products and we intend to continue such compliance in the event there are any regulatory changes regarding its products in the U.S.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Medicines Agency (EMA) is the decentralized body of the European Union, located in Amsterdam in the Netherlands. It is responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use in the EU. The EMA serves the EU and three countries from the European Economic Area (EEA)&#8212;Iceland, Norway, and Liechtenstein. The EU has adopted numerous directives, regulations, and promulgated voluntary standards regulating the design, manufacture and labeling of, and clinical trials and adverse event reporting for medicinal products including medical devices. Devices that comply with the requirements of a relevant regulation or directive will be entitled to bear CE marking, indicating that the device conforms to the essential requirements of the applicable regulation and directives and can be commercially distributed throughout the member states of the E.U. and other countries that comply. The method for assessing conformity varies depending on the type and class of the device, but normally involves an assessment by the manufacturer and a third-party assessment by a notified body, an independent and neutral institution appointed by a country to conduct the conformity assessment. This third-party assessment may consist of an audit of the manufacturer&#8217;s quality system and specific testing of the manufacturer&#8217;s device. Such an assessment is required for a manufacturer to commercially distribute the product throughout these countries. In the second quarter of 2014, Axogen&#8217;s Quality System became registered to ISO 13485 for Receipt, Handling, Storage and Distribution of Axoguard Nerve Connector and Axoguard Nerve Protector and we will maintain the registration through 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cook Biotech is responsible for all regulatory filings for the Axoguard Nerve Connector and Axoguard Nerve Protector products, including international registrations. We provide the countries for Cook Biotech to register with, and Cook Biotech prepares and submits the product filing documentation to the Ministry of Health (&#8220;MOH&#8221;) for the country. Each country or region has its own regulations and the documentation required for submission varies. It typically takes less than nine months from the initiation of the project to obtain clearance in a given country or region. To date, the Axoguard Nerve Connector and Axoguard Nerve Protector product lines were registered in May 2013 in Canada for distribution and in April 2013 the product lines were awarded the CE Mark allowing distribution into the E.U. and other countries that accept the CE Mark. Cook Biotech received the renewal of the CE Mark for Axoguard Nerve Connector and Axoguard Nerve Protector in May 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the new European Medical Device Regulation (&#8220;E.U. MDR&#8221;) passed in the European Parliament on April 5, 2017 and went into effect on May 25, 2017. The E.U. MDR is an extensive reform of the rules governing the medical device industry in Europe. Under this regulation, manufacturers had through May 2021 to comply with a broad set of new rules for almost every kind of medical device. The E.U. MDR requires changes in the clinical evidence required for medical devices, post-market clinical follow-up evidence, annual reporting of safety information for Class III products, and bi-annual reporting for Class II products, Unique Device Identification (&#8220;UDI&#8221;) for all products, submission of core data elements to a European UDI database prior to placement of a device on the market, reclassification of medical devices, and multiple other labeling changes.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, medical device companies can expect longer lead times to obtain product registrations (i.e., CE Mark Certification) in the E.U. and a substantially costlier pathway to compliance in the E.U. We are not yet able to determine the costs of complying with these regulations, how the E.U. will interpret and enforce them, what the timelines for approvals of products will be and the overall effect of the E.U. MDR on the marketplace. Given the significant additional pre-market and post-market requirements imposed by the E.U. MDR, the overall impact of these new rules could have a material, adverse effect on our international revenue and expenses.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK left the E.U. in January 2020. We register our human tissue products in each individual E.U. country and our distributor in the UK has import authority for our human tissue product. It is expected that licensed UK establishments that import or export tissues or cells will need written agreements with the relevant E.U. licensed establishments to continue importing and exporting with the E.U. As we ship directly to the UK from the U.S., we did not experience and do not expect delays in shipment of human tissue products into the UK. Further, the RANGER clinical trial being performed at select hospitals in the UK was not affected by Brexit (defined below in "Risk Factors - Regulation Outside of the U.S.") as long as the products continue to come directly from the U.S. Beginning in January 2021, new changes became effective as the transition period for the UK&#8217;s exit from the E.U. ended. Specifically, all medical devices placed into the UK market had to be registered, subject to applicable grace periods, with the Medicines and Healthcare products Regulatory Agency ("MHRA"), will need to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appoint a UK Responsible Person, and comply with additional product marking and conformity assessment requirements. Medical devices must be registered with the MHRA if they are being placed in the UK market after May 1, 2021. Cook Biotech is responsible for appointing the UK Responsible Person and registering Axoguard Nerve Connector and Axoguard Nerve Protector in the UK.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tissue products are not currently regulated under the CE Mark</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for all regulatory filings for Avance Nerve Graft and Avive Soft Tissue Membrane (which we have voluntarily suspended from the domestic market). To obtain international approvals, we prepare the product filing documentation and submit this documentation to the MOH for a country.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although some standards of harmonization exist, each country in which we conduct business has its own specific regulatory requirements, which are dynamic in nature and continually changing. We procure and process our tissue for the Avance Nerve Graft and Avive Soft Tissue Membrane in the U.S. and markets the Avance Nerve Graft in Canada, the UK, and certain other countries under compliance with the individual country regulations. We conduct a regulatory review at the time of submission of the product dossier. This involves reviewing the appropriate MOH regulations, discussion with in-country distributors and use of consultants. It typically takes less than nine months from the initiation of the product to develop a product dossier (specific for that country), submission of the documentation and MOH review of the product filing. While we believe that we are in compliance with all existing pertinent international and domestic laws and regulations, there can be no assurance that changes in governmental administrations and regulations will not negatively impact our operations. Avive Soft Tissue Membrane has received regulatory registration allowing for distribution in Canada, Switzerland, UK, and Austria but we do not distribute Avive Soft Tissue Membrane in those countries at this time.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and international regulatory bodies conduct periodic compliance inspections of our U.S. processing facilities. All of our locations are properly registered with CBER as tissue establishments. Other than our APC facility, which AATB will inspect along with all other facilities to bring it under our accreditation certificate in 2023, we are accredited by the AATB and is licensed in the states of Florida, New York, California, Maryland, Delaware, Oregon, and Illinois. We officially notified AATB that the APC facility came online in November of 2022.  We believe that worldwide regulation of tissue products is likely to intensify as the international regulatory community focuses on the growing demand for these implant products and the attendant safety and efficacy issues of recipients. Changes in governing laws and regulations could have a material adverse effect on our financial condition and results of operations. Our management further believes that it can help to mitigate this exposure by continuing to work closely with government and industry regulators.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotech company of our size, we believe our impact on the environment is modest. However, we are continuously evaluating how we can be the best possible stewards of the environment, and follow local, state, and federal environmental regulations. We are taking steps in our operations and facilities to positively impact the environment wherever possible. In 2022, we conducted a new environmental analysis of all our operations and have implemented the following:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Certain recommendations of the Task Force on Climate Related Financial Disclosures.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">An environmental monitoring program by location.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Evaluation and launching new recycling initiatives and programs.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Working toward ISO 14001 certification, which sets out criteria for an environmental management system.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products, as well as the chemicals used in processing these products, are handled and disposed of in accordance with country-specific, federal, state, and local environmental regulations. Since 2007, we have used outside third parties to perform all biohazard waste disposal.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with independent, third parties to perform sterilization of our allografts. Because of the engagement of a third party to perform irradiation services, the requirements for compliance with radiation hazardous waste do not apply, and therefore we do not anticipate that this engagement will have any material adverse effect upon our capital expenditures, results of operations or financial condition. However, we are responsible for assuring that the service is performed in accordance with applicable regulations. Although we believe we are in compliance with all applicable environmental regulations, the failure to fully comply with any such regulations could result in the imposition of penalties, fines or sanctions that could have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December 31, 2022, we had approximately 396 total employees, including approximately 2 part-time employees and 394 full-time employees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Of these employees, 214 work in sales and marketing, 78 work in corporate, 44 work in research and development and 60 work in operations. Approximately 43% of our employees were female and 57% were male. As of the date of this Annual Report on Form 10-K we have not had a work stoppage and no employees are represented by a labor union.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe in creating and maintaining a culture that encourages and rewards honesty, openness, and passionate debate among our employees, respect is the foundation for communication and action, and patient safety is our first priority We are committed to fostering a culture of diversity, equity, and inclusion. Our corporate values support honest and open communication, mutual support, collaboration, passionate debate, empowerment, and respect. Our Equal Employment Policy includes specific training on preventing discrimination and harassment and encourages diversity, equity, and inclusion. We also have an annual Affirmative Action Plan, which is actively implemented and reviewed with management and our Board of Directors and. following such review, adjusted as needed to meet changing conditions. We are committed to advertising our opportunities on each state's job boards in order to reach an increasingly diverse population of candidates, and we conduct routine audits of our existing job postings, advertisements and candidate communications for gender coding, and update any gender specific language to gender neutral language. Additionally, we have a policy that supports employees who are veterans that participate in Honors Guards, who are selected from partnerships with veteran organizations and participating companies and attend by invitation, and military funerals, the Honor Guards. Further, some of our recruitment efforts are to engage with the next generation of scientists and engineers through targeted awareness and internship programs. We work with Women in Life Sciences, Society for Asian Scientists and Engineers, Society of Women Engineers, and BioFlorida to educate students and professionals about career opportunities available at our Company.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to attract and retain talent, we combine a market competitive compensation and benefit package that includes base and incentive compensation in addition to opportunity to participate in long-term incentive program. Our benefits package includes among other things, health and welfare benefits, employee, spouse and dependent life insurance, 401(k) retirement plans with company match, Employee Stock Purchase Plan, Parental and Family Leave, supplemental disability, adoption assistance, holiday and paid time-off, wellness programs, educational reimbursement for advanced degrees, and relocation assistance. We also offer all employees the opportunity to enroll in leadership and career development programs and support external development through continuing education. We provide employees with individual career development plans focused on developing specific skills, including a mix of on-the-job training, advanced external training, stretch assignments, mentoring, and coaching resources. Employees actively participate in annual job performance review. Additionally, we encourage external professional networking, conference, and trade show participation. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All employees are offered the opportunity to contribute to an employee engagement survey annually and, as a result of the survey responses, we believe our relationship with our employees is satisfactory. Employee safety is critical to our operations, and we follow Occupational Safety and Health Administration (OSHA) 29 CFR 1910, and use a series of company-wide policies, trainings, and procedures to protect all employees&#8217; health and safety. We utilize an Environmental Health and Safety committee that meets monthly to analyze potential issues, review any incident data, and implement necessary process or procedural changes that can minimize the work-related injuries and occupational exposure to chemicals, bio-hazards, or illnesses, and eliminate any potential from serious injuries and fatalities. In 2022, across all operations, locations, and employees, we had nine minor injuries or illnesses, only one of which was OSHA reportable, and zero fatalities.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of our board of directors (the "Board of Directors") has oversight of our culture and human capital management, including diversity, equity, and inclusion with respect to our employees.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Available Information </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is http://www.axogeninc.com. We have included our website address as an inactive textual reference only. We make available, free of charge through our website, our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file, or furnish such material to the SEC. We also similarly make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% shareholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. Reference to our website, or any other website, does not constitute incorporation by reference of the information contained on the site and should not be considered part of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_1626"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RISK FACTOR SUMMARY</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Below is a summary of our risk factors. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Form 10-K and our other filings with the SEC before making an investment decision regarding our common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business and Strategy</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Our revenue growth depends on our ability to increase distribution and sales to existing customers and develop new customers, domestically and abroad, and there can be no assurance that these efforts will result in significant increases in sales.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Our revenue depends primarily on four products, which is dependent on the continued acceptance of our products by the medical community.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:14.5pt">The failure of Silicon Valley Bank, as well as the recent turmoil in the banking industry may negatively impact our business, results or operations and financial condition.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Macroeconomic trends, such as the COVID-19 pandemic, inflationary pressures and political instability could continue to have a material adverse effect on our ability to operate, results of operations, financial condition, liquidity, and capital investments.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">There may be significant fluctuations in our operating results.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">We have not consistently experienced positive cash flow from our operations, and the ability to achieve consistent, positive cash flow from operations will depend on increasing revenue from distribution of our products, which may not be achievable.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">We may not experience the operating efficiencies anticipated with the transition to our APC Facility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">We are highly dependent on the continued availability of our facilities and could be harmed if the facilities are unavailable for any prolonged period of time.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Delays, interruptions, or the cessation of production by our third-party suppliers of important materials may prevent or delay our ability to manufacture or process the final products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Surgical technique evolution, technological change and competition could reduce demand for our products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">We must maintain high quality processing of our products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Our revenue depends upon prompt and adequate reimbursement from public and private insurers and national health systems.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">Negative publicity concerning methods of donating human tissue and screening of donated tissue may reduce demand for our products and negatively impact the supply of available donor tissue.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">The failure of third parties to perform many necessary services for the commercialization of our products, including services related to recovery/acquisition, distribution and transportation, would impair our ability to meet commercial demand.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">We are dependent on our relationships with independent agencies to generate a material portion of our revenue.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:13.8pt">If we do not manage product inventory in an effective and efficient manner, it could adversely affect profitability resulting in significant fluctuations in our operating results.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Our operating results could be adversely impacted if we are unable to effectively manage and sustain our future growth or scale our operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">We may be unsuccessful in commercializing our products outside the U.S.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to the Regulatory Environment in which We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Operate  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Our Avance Nerve Graft product is currently distributed pursuant to enforcement discretion and a transition plan with the FDA and we expect to file our BLA by the end of 2023. If our BLA is not approved by the FDA or the use of Avance Nerve Graft is curtailed, our revenues would significantly decrease which would have a material adverse effect on our operations.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Our operations must comply with and our business is subject to continuing regulatory compliance by the FDA and other authorities, which is costly and could result in negative effects on our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">We have suspended market availability of our Avive Soft Tissue Membrane and there is no guarantee it will be placed back on the market.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">The use, misuse or off-label use of our products may harm our reputation or the image of our products and could result in injuries leading to product liability suits, which could be costly to our business, or result in FDA sanctions. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Our business is subject to continuing compliance to standards by various accreditation and registration bodies, which is costly, and loss of accreditation or registration could result in negative effects on our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:13.8pt">Our Axoguard and Axotouch products are subject to FDA and international regulatory requirements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Defective products could lead to recall or other negative business conditions.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Clinical trials can be long and expensive and results are ultimately uncertain which could jeopardize our ability to generate data to support marketing of our products or obtain regulatory approval of our Avance Nerve Graft product.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">We rely on third parties to conduct our clinical trials, and they may not perform as contractually required or expected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">U.S. governmental regulation could restrict the use of our Avance Nerve Graft product, restrict our procurement of tissue or increase costs.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Healthcare law and policy changes may have a material adverse effect on us.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">We could be subject to civil or criminal penalties if we are found to have violated laws protecting the confidentiality of health information, which could increase our liabilities and harm our reputation or our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our IP</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Failure to protect our IP-rights could result in costly and time-consuming litigation and our loss of any potential competitive advantage.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Future protection for our proprietary rights is uncertain and may impact our ability to successfully compete in our industry.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">The patent protection for our products may expire before we are able to maximize their commercial value, which may subject us to increased competition and reduce or eliminate our opportunity to generate product revenue.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Others may claim an ownership interest in our IP which could expose us to litigation and have a significant adverse effect on our prospects.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">We depend on the maintenance of exclusive licenses.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Our trademarks are valuable, and our business may be adversely affected if trademarks are not adequately protected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Financing Our Business </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">Our credit facility and payment obligations under the Revenue Participation Agreement with TPC Investments II LP and Argo SA LLC, each affiliates of Oberland Capital (collectively, &#8220;Oberland Capital&#8221;), contains operating and financial covenants that restrict our business and financing activities, require cash payments over an extended period of time and are subject to acceleration in specified circumstances, which may result in Oberland Capital taking possession and disposing of any collateral.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt">We may need to raise additional funds to finance our future capital or operating needs, which could have adverse impacts on our business, results of operations, and the interests of our shareholders.</span></div><div><span><br/></span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_22"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 1A. RISK FACTORS</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business involves a number of risks, some of which are beyond our control. The risk and uncertainties described below are not the only ones we face. Set forth below is a discussion of the risks and uncertainties that management believes to be material to us and could adversely affect our business, financial condition, results of operations, cash flows, growth prospects and the trading price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business and Strategy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our revenue growth depends on our ability to increase distribution and sales to existing customers and develop new customers, domestically and abroad, and there can be no assurance that these efforts will result in significant increases in sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning in 2020, we adjusted our commercial strategy to focus on deeper penetration of our existing surgeon customers through the development of long-term users of our algorithm of nerve repair in our largest market opportunity of extremity trauma. We believe that near-term growth can be supported first through expanded productivity of our existing sales force with existing accounts and second by adding additional customers. We expect the number of direct sales professionals to increase over time. Additionally, we believe that we have successfully utilized a hybrid commercial approach that includes the use of independent agencies in more remote geographies to provide appropriate local support for customers, without the travel time required of a direct sales representative. We anticipate that we will continue to add to the number of independent sales agencies as it continues to drive higher productivity and efficiency with our direct sales force. We may also need to establish a regional distribution center or centers at some point in the future to account for growth. The incurrence of these expenses may impact our operating results, and there can be no assurance of their effectiveness. If we are unable to increase sales to existing customers and attract new customers, and develop our sales force, there could be a material adverse impact on our business, results of operations, financial condition, and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our revenue depends primarily on four products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Substantially all of our revenue is currently derived from four products, Avance Nerve Graft, Axoguard Nerve Protector, Axoguard Nerve Connector, and Axoguard Nerve Cap for the treatment of peripheral nerve damage. Of these four products, Avance Nerve Graft represents approximately 60% of our total revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Any disruption in our ability to generate revenue from the processing, distribution, and sale of products will have a material adverse impact on our business, results of operations, financial condition, and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Axoguard Nerve Connector and Axoguard Nerve Protector are only available through the Cook Biotech Distribution Agreement. The Distribution Agreement was amended February 26, 2018 to extend the termination date to June 30, 2027. However, there are conditions for continuation of the agreement, including payment terms and minimum purchase requirements, that if breached could result in an earlier termination of the agreement. Through mutual agreement, the parties have not established such minimums and to date have not enforced such minimum purchase provision. Additionally, in the event that Cook Biotech were to enforce minimum purchase quantities and we fail to reach an agreement as to such minimums, Cook Biotech could terminate the agreement if we fail to generate commercially reasonable sales of Axoguard as measured by sales similar to a competitive product at the same stage in its commercial launch as verified by a mutually acceptable third party. We distribute the Axoguard Nerve Connector and Axoguard Nerve Protector for Cook Biotech, and Cook Biotech is the contract manufacturer for our Axoguard Nerve Cap. Although we believe we could develop or obtain products that would replace the Axoguard products obtained through the Cook Biotech agreements, the loss of the ability to sell the Axoguard products could have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Approximately 60% of our total revenues are from sales of Avance Nerve Graft.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Approximately 60% of our total revenues are from sales of Avance Nerve Graft, which the FDA considers to be a biological product subject to BLA approval requirements. The product is currently distributed pursuant to a transition plan with the FDA. Any change in position by the FDA regarding its use of enforcement discretion regarding the sale of Avance Nerve Graft, or if the BLA we intend to submit is not approved, if our indications are narrowed, or use of Avance Nerve is curtailed in any other way, it will have a material negative impact on our revenues and our operations. For additional information see: &#8220;Risk Factors &#8211; Our Avance Nerve Graft product is currently distributed pursuant to a transition plan with the FDA; however, we expect to file a BLA by the end 2023 and if the FDA does not approve our BLA or otherwise limits on use of our Avance Nerve Graft product it would have a significant impact on our revenues and thus would have a material adverse effect on us.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The failure of Silicon Valley Bank as well as the recent turmoil in the banking industry may negatively impact our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 10, 2023, the California Department of Financial Protection and Innovation closed Silicon Valley Bank (&#8220;SVB&#8221;) and appointed Federal Deposit Insurance Corporation (the &#8220;FDIC&#8221;) receiver. On March 12, 2023, the Department of the Treasury, the Federal Reserve, and the FDIC jointly released a statement that depositors at SVB and Signature Bank would have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception. As of March 14, 2023, we have approximately $8.0 million of cash with SVB, our sole depositor until recent events, after which we have made arrangements to open new accounts with JP Morgan Chase. We could experience disruption with customer receivables and vendor payments as we transition to new accounts. The majority of our other cash, cash equivalents and investments, consisting of a variety of short-term and high-credit treasury and corporate bonds and other liquid investments, is held in custodial accounts with U.S. Bank for which SVB Asset Management is the advisor, and we have made arrangements to transfer such cash, cash equivalents and investments to JP Morgan Chase. Despite our proactive measures and the measures taken by the United States federal government, there is great uncertainty in the markets regarding the stability of regional banks and the safety of deposits in excess of the FDIC insured deposit limits. The ultimate outcome of these events, and whether further regulatory actions will be taken, cannot be predicted, but these events may have a material adverse effect on our liquidity and financial condition if our ability to access funds at SVB and our ability to transfer our other cash, cash equivalents and investments to JP Morgan Chase are impaired. Further, these events may make equity or debt financing more difficult to obtain, and additional equity or debt financing might not be available on reasonable terms, if at all; difficulties obtaining equity or debt financing could have a material adverse effect on our financial condition, as well as our ability to continue to grow our operations. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Macroeconomic trends, such as the COVID-19 pandemic, inflationary pressure, recent events associated with SVB and the aftermath thereof, and political instability could continue to have a material adverse effect on our ability to operate, results of operations, financial condition, liquidity, and capital investments.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We continue to actively monitor the impact of various macroeconomic trends, such as recent events associated with SVB and the aftermath thereof, high rates of inflation, increasing interest rates, increasing labor costs, supply chain disruptions, labor shortages, geopolitical instability, and the COVID-19 pandemic on our business. We believe that the COVID-19 pandemic </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">negatively impacted hospital staffing and surgical procedure volumes which has negatively impacted our revenue. Additionally, we have experienced increased costs consistent with rising interest rates, and inflationary pressures. At this time, we cannot predict the specific extent, duration or full impact that recent events associated with SVB and the aftermath thereof, inflationary conditions, supply chain disruptions, geopolitical instability will have on our ongoing and planned clinical trials, our ability to operate, results of operations, financial condition, liquidity, and capital investments.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Economic conditions, such as recent events associated with SVB and the aftermath thereof, rising inflation, higher interest rates, increasing labor costs, supply chain pressures, changes in regulatory laws and monetary exchange rates, and government fiscal policies, can also have a significant effect on the cost of operations including the cost of materials and labor, as well as the interest on our debt. Moreover, negative macroeconomic conditions could adversely impact our ability to obtain financing in the future on terms acceptable to us, or at all. In addition, the geopolitical instability and related sanctions could continue to have significant ramifications on global financial markets, including volatility in the U.S. and global financial markets.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">COVID-19 caused and may continue to cause decreased access to customer channels, slowing or stopping of the development of clinical products or clinical data, decreased employee availability, hospital staffing shortages, adverse economic conditions, border closures and other disruptions to our business, as well as the businesses of our business partners and others. Furthermore, COVID-19 may have the effect of heightening many of the other risks described in this Annual Report on Form 10-K. COVID-19 has also imposed significant burden on the FDA and forced the agency to divert resources from product review and its approval process. The extent of the impact of the COVID-19 pandemic on our business and operations remains uncertain and will depend on certain developments, including the duration and spread of the pandemic and its future impact on elective procedures, third-party manufacturers, and other third parties with which we do business, as well as its impact on regulatory resources, inspections, and review timelines. If we or any of the third parties with whom we engage were to experience additional shutdowns or other prolonged business disruptions due to the COVID-19 pandemic, our ability to conduct our business could have a material adverse impact on our business, results of operation and financial condition.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our success will be dependent on continued acceptance of our products by the medical community.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success is dependent on continued acceptance of our products by the medical community, which will depend on our ability to demonstrate that our products are an attractive alternative to existing or new nerve reconstruction treatment options, including both surgical techniques and products. Our ability to do so will depend on surgeons&#8217; evaluations of clinical safety, efficacy, ease of use, reliability, and cost-effectiveness, including insurance reimbursement, of our nerve repair products. For example, although our Avance Nerve Graft follows stringent safety standards, including sterilization by gamma irradiation, we believe that a small portion of the medical community has lingering concerns over the risk of disease transmission through the use of allografts in general. If the medical community and patients do not ultimately accept our products as safe and effective or we are unable to raise awareness of our products and processes, our ability to sell the products may be materially and adversely affected, and our business, results of operations, financial condition, and prospects may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have not consistently experienced positive cash flow from our operations, and have a history of net losses and our ability to achieve consistent, positive cash flow from operations will depend on increasing revenue from distribution of our products, which may not be achievable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically incurred net losses and operated with negative cash flow from our operations and may continue to incur losses and operate with negative cash flow from operations for the foreseeable future. We have incurred net losses of $28.9 million, $27.0 million and $23.8 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively. As of December 31, 2022, we had an accumulated deficit of approximately $259.6 million. If revenue does not increase as anticipated, then we will continue to incur net losses and experience negative cash flows and adverse operating conditions. In June 2020, we entered into a seven-year $70 million credit facility (the "Credit Facility") with Oberland Capital, from which we drew proceeds of $50 million, which were used and will continue to be used for working capital, capital expenditures and general corporate purposes. As our debt obligations mature or if our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay investments and capital expenditures, sell assets, seek additional capital, or restructure or refinance our indebtedness. Our ability to restructure or refinance our debt will depend on the condition of the capital markets and our financial condition at such time. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. If we raise funds by selling additional equity, such sale would result in dilution to our shareholders. There is no assurance that if we are required to secure funding, we can do so on terms acceptable to us, or at all.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are highly dependent on the continued availability of our facilities and could be harmed if the facilities are unavailable for any prolonged period of time and we may not experience the operating efficiencies anticipated with the transition to our APC Facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our APC Facility is expected to be fully renovated as our new processing facility for Avance Nerve Graft</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">before December 31, 2023, which is the termination date of the CTS Agreement. We anticipate beginning to transfer the processing of Avance </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nerve Graft from CTS to our APC Facility over in mid-2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During this time, both facilities will be operational. However, renovations and the regulatory process for approval of facilities, whether licensed or owned, is time-consuming and unpredictable. We may not experience the anticipated operating efficiencies as we commence processing operations at the APC Facility. It could cause a significant disruption in service to our customers if we were to lose, even temporarily, the availability of our production or distribution facilities. Moreover, changing facilities may require that we conduct additional studies, make notifications to the regulatory authorities, make additional filings to the regulatory authorities, and obtain regulatory authority approval for the new facilities, which may be delayed or which we may never receive. If we are not able to comply with the applicable regulatory requirements or produce product that meets our requirements and specifications, we will be subject to the same risks that we would be subject to should third parties be unable to comply with the applicable regulatory requirements or produce product meeting our requirements or specifications, as described above. If we fail to achieve the operating efficiencies that we anticipate, our business, results of operations, financial condition, and prospects could be adversely impacted.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In operating our new processing facility, we may be forced to devote greater resources and management time than anticipated, particularly in areas relating to operations, quality, raw material supply, regulatory, facilities and information technology. If we experience unanticipated employee turnover in any of these areas, we may not be able to effectively manage our ongoing processing operations and we may not achieve the operating efficiencies that we anticipate from the APC Facility, which may negatively affect our business, results of operations, financial condition, and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the physical infrastructure of our facilities, including the APC Facility and the facility we license from CTS, could lead to significant costs and disruptions that could reduce our revenue and harm both our business reputation and financial results. Any natural or man-made event that impacts our ability to utilize our facilities could have a material impact on our business, results of operations, financial condition, and prospects. Although we have business interruption insurance that would cover certain costs in instances other than service agreement termination, it may not cover all costs nor help to regain our standing in the market. In addition, we may plan to expand the APC facility or open additional office, lab or distributions space in the future, and our ability to license, renovate, rebuild, or find acceptable service facilities takes a considerable amount of time and expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays, interruptions, or the cessation of production by our third-party suppliers of important materials may prevent or delay our ability to manufacture or process the final products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Most of the raw materials used in the process for Avance Nerve Graft are available from more than one supplier. However, there are materials within the manufacturing and production process that come from single suppliers or certain supplies may be difficult to procure due to supply chain shortages or changes in global trade regulations. Macroeconomic factors could cause disruptions in the supply chain and impair our ability to obtain the materials needed for our product line. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not have written contracts that guarantee supply with any of our suppliers, and at any time they could stop supplying our orders. FDA review of a new supplier may be required if these materials become unavailable from our current suppliers. Although there may be other suppliers that have equivalent materials that would be available to us, if FDA review is required, it could take several months or years to obtain, if approval is able to be obtained at all. Any delay, interruption, or cessation of production by our third-party suppliers of important materials, or any delay in qualifying new materials, if necessary, would prevent or delay our ability to manufacture products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, an uncorrected impurity, a supplier&#8217;s variation in a raw material or testing, either unknown to us or incompatible with our manufacturing process, or any other problem with our materials, testing or components, would prevent or delay our ability to process tissue. These delays may limit our ability to meet demand for our products and delay our clinical trials, which would have a material adverse impact on our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Technological change and competition for newly developed products could reduce demand for our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The medical technology industry is intensely competitive. We compete with both U.S. and international entities that engage in the development and production of medical technologies and processes, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">biotechnology, orthopedic, pharmaceutical, biomaterial, chemical, and other companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">academic and scientific institutions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">public and private research organizations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our products compete with autograft, hollow-tube conduits, commercially available wraps, and amnion products, as well as with alternative medical procedures. For the foreseeable future, we believe a significant number of surgeons will continue to choose to perform autograft procedures when feasible, despite the necessity of performing a second operation and its drawbacks. In addition, many members of the medical community will continue to prefer the use of hollow-tube conduits due in part to their familiarity with these products and the procedures required for their use. Also, steady improvements have been </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">made in synthetic human tissue substitutes, which could compete with our products in the future. Unlike allografts, synthetic tissue technologies are not dependent on the availability of human or animal tissue. Although our growth strategy contemplates the introduction of new technologies, the development of these technologies is a complex and uncertain process, which require a high level of innovation, as well as the ability to accurately predict future technology and market trends. We may not be able to respond effectively to technological changes and emerging industry standards, or to successfully identify, develop or support new technologies or enhancements to existing products in a timely and cost-effective manner, if at all. There can be no assurance that in the future our competitors will not develop products that have superior performance or are less expensive relative to our products, rendering our products obsolete or noncompetitive. In this regard, Integra and Baxter each have or will commercialize a product consisting of a hollow tube conduit filled with material which they suggest is superior to their current hollow conduit products. Additionally, in 2022, BioCircuit received 510(k) clearance for a SIS-based nerve wrap with integrated microhooks that enable suture-free coaptation of peripheral nerves potentially allowing for simpler, consistent quick repairs compared to using typical hollow tube conduits and nerve wraps. Also in 2022, L&amp;C Bio Co. LTD from South Korea registered as a human nerve allograft processor and distributor with the FDA, however, such a product is not currently sold in the U.S. market, and we believe such product would require a biologics license for commercialization. Moreover, a Chinese company provides a human peripheral nerve allograft in China; however, such product is not sold in our markets of interest because of the protection afforded by our IP. Due to our resource allocation, size, and relatively early stage, we may face competitive challenges from these new products or existing products and barriers that are difficult to overcome and could negatively impact our growth.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We must maintain high quality processing of our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Avance Nerve Graft is processed through our Avance Method, which requires careful calibration and precise, high-quality processing and manufacturing. Achieving precision and quality control requires skill and diligence by our personnel. If we fail to achieve and maintain these high levels of quality control and processing standards, including avoidance of processing errors, defects, or product failures, we could experience recalls or withdrawals of our product, delays in delivery, cost overruns or other problems that would adversely affect our business. We cannot completely eliminate the risk of errors, defects or failures and could experience quality system issues where corrective actions must be taken. In addition, we may experience difficulties in scaling-up processing of our Avance products, including problems related to yields, quality control and assurance, tissue availability, adequacy of control policies and procedures, and lack of skilled personnel. If we are unable to process and produce our human tissue products on a timely basis, at acceptable quality and costs, and in sufficient quantities, or if we experience unanticipated technological problems or delays in production, our business, results of operations, financial condition, and prospects would be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our revenue depends upon prompt and adequate reimbursement from public and private insurers and national health systems.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Political, societal, economic, and regulatory influences are fundamentally changing the U.S. healthcare industry. The ability of a hospital or an ambulatory surgery center to pay fees for our products depends in part on the availability of adequate coverage and reimbursement from third-party payors for our products specifically, the procedures associated with the use of our products, or both. Providers that purchase our products generally rely on third-party payors to reimburse all or part of the costs and fees associated with the procedures performed with our products or the products themselves. Therefore, adequate coverage and reimbursement from third-party payors, including government payors such as Medicare and Medicaid, are important for obtaining product acceptance and widespread adoption in the marketplace.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">When our products are used in the operating room of a hospital, they are commonly treated as general supplies utilized in surgery, and the cost is included in payment to the facility for the procedure. When Avance Nerve Graft and Axoguard Connector are used in an outpatient setting where the nerve repair is the primary reason for the procedure, facilities may use a Category I CPT code to facilitate payment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2018, the American Medical Association created a Category I CPT code (64912) specific to nerve repair with nerve allograft (Avance Nerve Graft) and a separate code (+64913) for each additional strand of allograft used in a procedure. Category I CPT codes are used by providers to facilitate payment to the provider (either hospital or ambulatory surgery center) for outpatient procedures. Additionally, Category I CPT codes are used to facilitate payment to the surgeon, for both time spent in outpatient and inpatient procedures. Prior to January 2018, there was no designated Category I CPT code for nerve repair cases that included nerve allograft. The Category I CPT code specific to nerve repair with nerve allograft, has allowed for nerve allograft repair cases to be uniquely identified in the Medicare claims data. This in turn allowed CMS visibility to nerve allograft nerve procedure costs, and thereby confirm that nerve allograft qualified as a device intensive procedure.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Another important change in nerve repair reimbursement occurred in January 2020, when most direct repair procedures were moved from the higher paying level 2 nerve repair Ambulatory Payment Category 5432 to the lower paying level 1 Ambulatory Payment Category 5431, thus aligning payment rates more consistently with the lesser costs of a direct repair.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result of the allograft device intensive status and direct repair Ambulatory Payment Category realignment, CMS reimbursement rates for nerve repair in the outpatient setting have changed significantly during the last two years. With the new 2023 CMS reimbursement rates for nerve repair in the outpatient setting that became effective January 1st, reimbursement for procedures using Avance have increased 35% in hospital outpatient centers and 115% in ambulatory surgery centers since 2019. During this same timeframe, reimbursement rates for procedures involving conduits and connectors also increased 35% in hospital outpatient centers and 49% in ambulatory surgery centers. While Medicare patients represent a relatively small percentage of trauma cases, CMS&#8217; direction often influences commercial payor policies and payments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The process for securing coding for a product or procedure is separate from the process of securing coverage and establishing a reimbursement payment rate. In the U.S., coverage and reimbursement for medical devices varies among payors. In addition, payors review coverage policies on an ongoing basis and can change or deny coverage for these new products and procedures without notice. We estimate that commercial payors covering a significant number of U.S. covered lives have legacy non-coverage policies relating to our Avance Nerve Graft and our Axoguard product lines, designating these products investigational or experimental. Some commercial payors do not currently cover or reimburse our products because they have determined insufficient evidence of favorable clinical outcomes is available. Although some payors consider Avance Nerve Graft and our Axoguard product lines investigational or experimental at this time, these payors may in the future determine sufficient evidence has been developed to cover and reimburse our products and related procedures. In partnership with healthcare providers, we are working actively to reverse these non-coverage decisions and have been successful with several regional plans. However, we cannot provide assurance that we will continue to be successful in these efforts. If we are not successful in reversing existing non-coverage policies, or if other third-party payors issue similar policies, this could have a material adverse effect on our business and operations. Further, third-party payors who currently cover and reimburse customers for procedures using our products may in the future choose to decrease current levels of reimbursement or eliminate reimbursement altogether, which would cause our business to suffer.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amount of reimbursement received by our customers from third-party payors is dependent generally on fee schedules established by these payors for the existing CPT codes. For governmental payors, such as Medicare and Medicaid, the fee schedule amount is determined by statutory and regulatory formulas as previously discussed. For commercial payors, the reimbursement amount generally is dependent upon the specific contract terms between the provider and payor. We cannot provide assurance that government or commercial payors will continue to reimburse for procedures with our products using the existing codes, nor can we provide assurance that the payment rates will be adequate. If providers and physicians are unable to obtain reimbursement for the procedure at adequate levels when use of our products is included, this could have a material adverse effect on our business and operations. Hospitals and ambulatory surgery centers may not purchase our products if they do not receive payment sufficient to cover the cost of our products and related procedures. In addition, in the event that the current coding and/or payment methodology for these procedures changes, this could have a material effect on our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, healthcare law and policy changes may have a material adverse effect on our revenues. See: &#8220;Risk Factors &#8211; Healthcare law and policy changes may have a material adverse effect on us.&#8221;</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Negative publicity concerning methods of donating human tissue and screening of donated tissue may reduce demand for our products and negatively impact the supply of available donor tissue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are highly dependent on our ability to recover human peripheral nerve tissue from tissue donors for our Avance Nerve Graft product. The availability of acceptable donors is relatively limited, and this availability is impacted by regulatory changes, general public opinion of the donation process, and our reputation for handling the donation process. Media reports or other negative publicity concerning both improper methods of tissue recovery from donors and disease transmission from donated tissue, including bones and tendons, may limit widespread acceptance of our Avance Nerve Graft. Unfavorable reports of improper or illegal tissue recovery practices, both in the U.S. and internationally, as well as incidents of improperly processed tissue leading to transmission of disease, may broadly affect the rate of future tissue donation and market acceptance of allograft technologies and donated tissue use. Potential patients may not be able to distinguish our products, technologies, and tissue recovery and processing procedures from others engaged in tissue recovery. In addition, unfavorable reports could make families of our potential donors or donors themselves from whom we are required to obtain consent before processing tissue reluctant to agree to donate tissue to for-profit tissue processors. Any disruption in the supply caused by these publicity issues could have a material impact for our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The failure of third parties to perform many necessary services for the commercialization of our products, including services related to recovery/acquisition, distribution, and transportation, would impair our ability to meet commercial demand.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely upon third parties for certain recovery/acquisition, distribution, and transportation services for our products. For example, the Avance Nerve Graft processing consists of several steps, and we use a number of recovery and/or acquisition </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">agencies to supply the human tissue needed for these products. While we believe our current contracts and the ability to enter into future contracts will provide us with the tissues required for the products, we cannot be sure that we will be able to obtain the tissue that we need in the future. Disruptions in the tissue supply may adversely impact both tissue products and our overall business. If any of the third parties that we rely upon in our recovery/acquisition, distribution or transportation process fail to comply with applicable laws and regulations, fail to meet expected deadlines, or otherwise do not carry out their contractual duties, experience delays due to macroeconomic factors, such as the ongoing COVID-19 pandemic, or encounter physical damage or natural disaster at their facilities, our ability to deliver product to meet commercial demand may be significantly impaired, which could have a material adverse impact on our business, results of operations, financial condition or prospects.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are dependent on our relationships with independent agencies to generate a material portion of our revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We derive material revenue through our relationships with independent agencies. In 2022, approximately [10%] of global product revenue was generated through independent agencies. If certain agency relationships were terminated or discontinued for any reason, it could adversely affect our ability to generate revenue and profit. If we require additional agencies, we may not be able to find additional agencies who will agree to market and distribute our products on commercially reasonable terms, if at all. If we are unable to establish new agency relationships or renew certain current distribution agreements on commercially acceptable terms, our business, results of operations, financial condition, and prospects could be materially and adversely impacted.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we do not manage product inventory in an effective and efficient manner, it could adversely affect profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many factors affect the efficient use and planning of product inventory, such as our ability to predict demand for donor tissue, prepare manufacturing to meet that demand and product mix and handle product expiration. We may be unable to manage our inventory efficiently, keep inventory within expected budget goals, keep our work-in-process inventory on hand or manage it efficiently, control expired product or keep sufficient product on hand to meet demand. Finally, we can provide no assurance that we can keep inventory costs within our target levels, particularly in light of overall cost increases due to global inflation. Failure to do so may materially and adversely impact our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operating results could be adversely impacted if we are unable to effectively manage and sustain our future growth or scale our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance that we will be able to manage our future growth efficiently or profitably. Our business is unproven on a large scale, and actual revenue and operating margins, or revenue and margin growth, may be less than expected. If we are unable to scale our production capabilities efficiently or maintain pricing without significant discounting, we may fail to achieve expected operating margins, which would have a material and adverse effect on our operating results. Growth may also stress our ability to adequately manage our operations, quality of products, safety, and regulatory compliance. Failure to implement necessary procedures, equipment, or processes or to hire the necessary personnel in a timely and effective manner could result in higher costs or an inability to meet market demand and could have a material adverse impact on our business, results of operations, financial condition, and prospects. Additionally, our future growth will increase the demands placed on our third-party suppliers, and there is no guarantee that our suppliers will be able to support our anticipated growth. If growth significantly decreases, it will negatively impact our cash reserves, and we may be required to obtain additional financing, which may increase indebtedness or result in dilution to shareholders. Further, there can be no assurance that we would be able to obtain additional financing on acceptable terms, if at all.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There may be significant fluctuations in our operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant quarterly fluctuations in our results of operations may be caused by, among other factors, our volume of revenue, seasonal changes in nerve repair activity, timing of sales force expansion, unforeseen restrictions on our ability to access healthcare providers such as during the COVID-19 pandemic, inflationary pressures, competitive factors and general economic conditions. There can be no assurance that the level of revenue and profit, if any, we achieve in any particular fiscal period, will not be significantly lower than in other comparable fiscal periods. Our expense levels are based, in part, on our expectations as to future revenue. As a result, if future revenue is below expectations, net income or loss may be disproportionately affected by a reduction in revenue, as any corresponding reduction in expenses may not be proportionate to the reduction in revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be unsuccessful in commercializing our products outside the U.S.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have focused our commercialization efforts in the U.S., except for minor revenue in certain foreign countries. We intend to expand distribution and sales outside the U.S. and will need to comply with applicable foreign regulatory requirements, including obtaining the requisite approvals to do so. The regulatory environment for our portfolio of products is complex. Avance Nerve Graft is distributed in Canada, the UK, and certain other countries. We received approval to distribute </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Avance Nerve Graft in Germany in December 2019. Avance use in Spain currently requires approval for each case to be approved by tissue authorities under an alternative therapies designation. The Axoguard Nerve Connector and Nerve Protector CE Mark has been renewed as of May 2021 by Cook Biotech. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2020, the UK exited the E.U. (&#8220;Brexit&#8221;) following a transition period that ended on December 31, 2020. Brexit could continue to disrupt trade between the UK and the E.U. or other nations, as the UK pursues independent trade regulations. It is still unclear exactly how Brexit will affect legislative and regulatory systems within the UK, as many decisions are left to be made that will determine how far the UK will choose to diverge from existing E.U. rules. Therefore, we cannot be sure what changes could occur or the cost of regulatory compliance with both the UK and the E.U. going forward. Until such time as we can obtain, if at all, the necessary registrations and approvals for our products, material expansion beyond the U.S. will be limited. Finally, the cost of regulatory compliance for sales outside the U.S. can be significant and time consuming.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, we will need to either enter into distribution agreements with third parties or develop a direct sales force in foreign markets. If we do not obtain adequate levels of reimbursement from third-party payers outside of the U.S., we may be unable to develop and grow our revenue internationally. Outside of the U.S., reimbursement systems vary significantly by country. Many ex-U.S. markets have government-managed healthcare systems that govern reimbursement for medical devices, implants, and procedures. Some ex-U.S. reimbursement systems provide for limited payments in a given period and therefore result in extended payment periods. If we are unable to successfully commercialize our products internationally, our long-term growth prospects may be limited.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We incur costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a public company, we incur legal, accounting, and other expenses to comply with relevant securities laws and regulations, including without limitation, the requirement of establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management devotes substantial time and financial resources to these compliance initiatives. Failure to comply with public company requirements could have a material adverse effect on our business. In addition, activity by shareholders or others that bring into question aspects of our business, financial reporting, or management&#8217;s integrity, whether based on facts, beliefs or baseless and contrived for individual economic gain, can have a negative impact on the price of our stock and can result in substantial time and financial resources being expended to address the situation. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in the tax code could have a material adverse effect on our results of operations, financial condition, liquidity, and capital investments.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In recent years, political discourse has centered on potential changes in tax laws or tax rulings. Certain of these changes could negatively affect our financial condition. In addition, our ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments may be limited by provisions of the Internal Revenue Code, and it is possible that certain transactions or a combination of certain transactions may result in material additional limitations on our ability to use our net operating loss and tax credit carryforwards.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Regulatory Environment in which We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operate</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to continuing regulatory compliance by the FDA and other authorities, which is costly and could result in negative effects on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to extensive regulation by foreign and domestic government entities, including compliance with regulations governing appropriate relationships with healthcare professionals, such as physicians, hospitals, and those to whom and through whom we may market our products. We are subject to various federal, state, and territorial laws in the U.S. and other jurisdictions in which we conduct business. These include, for example, anti-kickback laws, false claims laws, healthcare fraud, waste, and abuse laws, and anti-bribery laws such as the U.S. Foreign Corrupt Practices Act. Violations of these laws can be punishable by criminal and/or civil sanctions, including, in some instances, fines, imprisonment and, within the U.S., exclusion from participation in government healthcare programs, including Medicare, Medicaid, and Veterans Administration health programs. These laws are administered and enforced by, among others, the DOJ, which issued new compliance guidance in 2020, the Office of Inspector General of the Department of Health and Human Services, state attorneys general, and their respective counterparts in the applicable foreign jurisdictions in which we conduct business. Many of these agencies have increased their enforcement activities with respect to drug and medical device manufacturers in recent years. There can also be changes to the regulations by foreign and domestic government entities that require us to update or upgrade business processes or to perform additional validation activities for product or processes. Compliance with such changes can be costly to implement or result in non-compliance, thus restricting the ability to distribute tissue or sell products, which could have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our products are also subject to regulation by the FDA in the U.S. The FDA regulates the development, pre-clinical and clinical testing, requirements for commercial marketing and distribution, manufacturing and quality, safety, labeling, and promotion of medical products including human cells, tissues and cellular and tissue-based products (HCT/Ps), medical devices, and biological products. The FDA requires the approval of a biological product, like Avance Nerve Graft, through a BLA prior to marketing. Although the Avance Nerve Graft product has not yet been approved by FDA through a BLA, FDA outlined a transition plan subject to FDA enforcement discretion, that we: (1) transition to compliance with section 501(a)(2)(B) of the FD&amp;C Act, the cGMP regulations in 21 CFR Parts 210 and 211 and the applicable regulations and standards in 21 CFR Parts 600-610 prior to initiation of a phase 3 clinical trial designed to demonstrate the safety, purity, and potency of Avance Nerve Graft; (2) conduct a phase 3 clinical trial to demonstrate safety, purity, and potency of Avance Nerve Graft under an SPA; (3) continue to comply with the requirements of 21 CFR Part 1271; and (4) exercise due diligence in executing the transition plan. See &#8220;Business &#8212; Government Regulations &#8212; U.S. Government Regulation Overview.&#8221; </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA also regulates medical devices, for example the Axoguard products, and generally requires them to be cleared through the 510(k) pre-market notification process prior to marketing or through other pre-market approval processes. The FDA&#8217;s pre-market review process for new and modified existing devices that precedes product marketing can be time consuming and expensive. Some of the future products and enhancements to such products that we expect to develop and market may require marketing clearance or approval from the FDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance, however, that clearance or approval will be granted with respect to any of our medical device products or enhancements of marketed products or that our Avance Nerve Graft will meet FDA&#8217;s requirements for continued marketing and transition to a BLA or ultimately an approved BLA. FDA review of our devices or biological products may encounter significant delays during FDA&#8217;s pre-market review process that would adversely affect our ability to market our products or enhancements. In addition, there can be no assurance that our products, including the Avance Nerve Graft, or enhancements will not be subject to a lengthy and expensive approval process with the FDA. In addition, FDA could decide to revoke its enforcement discretion or change the terms of enforcement discretion for Avance Nerve Graft at any time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that if regulatory clearances or approvals to market a product are obtained from the FDA, the clearances or approvals may contain limitations on the indicated uses of such product and other uses may be prohibited. Product approvals by the FDA can also be withdrawn due to failure to comply with regulatory standards or the occurrence of unforeseen problems following initial approval. The FDA may require post marketing clinical studies or other activities that may add cost or limit marketing of the product. Furthermore, the FDA could limit or prevent the distribution of our products, and the FDA has the authority to require the recall of such products. FDA regulations depend heavily on administrative interpretation, and there can be no assurance that future interpretations made by the FDA or other regulatory bodies will not adversely affect our business, results of operations, financial condition, and prospects. We, and our facilities, may be inspected by the FDA from time to time to determine compliance with various regulations relating to specifications, development, documentation, validation, testing, manufacturing, quality control and product labeling. A determination that we are in violation of such regulations could lead to imposition of civil penalties, including fines, product recalls or product seizures and, in certain cases, criminal sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Avance Nerve Graft product is currently distributed pursuant to enforcement discretion and a transition plan with the FDA, however we expect to file a BLA by the end of this year. If the FDA does not approve our BLA or limits use of our Avance Nerve Graft product it would have a significant impact on our revenues and thus would have a material adverse effect on us.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA considers our Avance Nerve Graft product to be a biological product, subject to BLA approval requirements. Although the Avance Nerve Graft product has not yet been approved by the FDA through a BLA, it is currently distributed under the controls applicable to an HCT/P regulated under section 361 of the Public Health Service Act and 21 CFR Part 1271 of FDA&#8217;s regulations, subject to FDA&#8217;s enforcement discretion and our compliance with a transition plan established by the FDA. See &#8220;Business &#8212; Government Regulations &#8212; U.S. Government Regulation Overview.&#8221; We have continued to communicate with CBER since the acceptance of the transition plan on clinical trial design, pre-clinical studies, CMC for Avance Nerve Graft, and other issues related to the effective IND. Subject to the FDA&#8217;s enforcement discretion, we can commercially distribute Avance Nerve Graft until the FDA makes a final determination on an Avance Nerve Graft BLA submission, assuming we remain in compliance with the transition plan and exercise due diligence in executing the transition plan. In the event that the FDA becomes dissatisfied with our progress or actions with respect to the transition plan or the FDA changes its position for any reason regarding its use of enforcement discretion to permit us to distribute the Avance Nerve Graft product in accordance with the transition plan, we would no longer be able to distribute Avance Nerve Graft, which would have a material adverse effect on our operations and financial viability. In addition, if we do not meet the conditions of the transition plan, or fail to comply with applicable regulatory requirements, the FDA could impose civil penalties, including fines, product seizures, injunctions, or product recalls and, in certain cases, criminal sanctions. We plan to submit the BLA by the end of 2023, and if the FDA does not approve the BLA or limits the use of our Avance Nerve Graft product, our operations and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">financial viability would be significantly negatively impacted as we may no longer be able to distribute our Avance Nerve Graft product or the demand for the Avance Nerve Graft product could drop due to limitations on use.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These consequences also would have a material adverse effect on our operations and financial viability. Additionally, approximately 60% of our total revenues are from sales of Avance Nerve Graft, any change in position by the FDA regarding its use of enforcement discretion to permit the sale of Avance Nerve Graft or a negative BLA resolution will have a material negative impact on our revenues and our operations. For additional information see: &#8220;Risk Factors - Approximately 60% of our total revenues are from sales of Avance Nerve Graft.&#8221;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have suspended market availability of our Avive Soft Tissue Membrane and there is no guarantee it will be placed back on the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effective June 1, 2021, we voluntarily suspended the market availability of Avive Soft Tissue Membrane. The decision to suspend market availability of Avive was made following a communication with the FDA on May 14, 2021, regarding the appropriate classification and regulatory approval requirements for Avive. The suspension of market availability was not based on any known or reported patient safety incidents or product performance issues or concerns reported to us associated with the use of Avive Soft Tissue Membrane, a product that had been marketed by us and routinely used by surgeons for patient care since 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Avive is a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier and was processed and distributed in accordance with U.S. FDA requirements for an HCT/P regulated under section 361 of the PHS Act and 21 CFR 1271. In November 2017, the FDA outlined a regenerative medicine policy framework including guidance on the regulatory considerations for HCT/Ps and the potential for relevant products to be classified as a drug, device, or biological product subject to pre-market approval requirements. The policy described FDA's intention to exercise enforcement discretion through May 31, 2021, to give manufacturers time to determine if they need to submit an IND or marketing application for their HCT/Ps. We have been in dialogue with the FDA to determine the appropriate regulatory classification and requirements for Avive. We will continue discussions with the FDA with the goal of returning Avive to the market. There is no guarantee, however, that we will return Avive to the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The use, misuse or off-label use of our products may harm our reputation, the image of our products, result in injuries leading to product liability suits, which could be costly to our business, or result in FDA sanctions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our products are misused or used for off-label purposes, our reputation and our product&#8217;s reputation may suffer, injuries could occur, which may lead to product liability litigation, or we may be subject to FDA sanctions if we are deemed to have engaged in off-label promotion. We are seeking a biologics license through the BLA process for specific uses of Avance Nerve Graft under specific circumstances. Our promotional materials and training methods must comply with FDA requirements and other applicable laws and regulations, including the prohibition against off-label promotion. Our promotion of the Axoguard products, which are regulated as medical devices, also must comply with FDA&#8217;s requirements, and must only use labeling that is consistent with the specific indication(s) for use included in the FDA substantial equivalence order that results in marketing the devices. The FDA does not restrict or regulate a physician&#8217;s use of a medical product within the practice of medicine, and we cannot prevent a physician from using our products for an off-label use. However, the FD&amp;C Act and the FDA&#8217;s regulations restrict the kind of promotional communications that may be made about our products, and if the FDA determines that our promotional or training materials constitute the unlawful promotion of an off-label use, it could request that we modify training or promotional materials and/or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, civil money penalties, seizure, injunction or criminal fines, and penalties. Other federal, state, or foreign governmental authorities might also take action if they consider our promotion or training materials to constitute promotion of an uncleared or unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement, or exclusion from participation in federal health programs. In that event, our reputation could be damaged and our products&#8217; use in the marketplace could be impaired.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There may be increased risk of injury if physicians or others attempt to use our products off-label. Furthermore, the use of our product for indications other than those for which our products have been approved, cleared, or licensed by the FDA may not effectively treat the conditions not referenced in product indications, which could harm our reputation in the marketplace among physicians and patients. Physicians may also misuse our products or use improper techniques if they are not adequately trained in the particular use, potentially leading to injury and an increased risk of product liability litigation. Product liability claims are expensive to defend and could divert management&#8217;s attention from our primary business and result in substantial damage awards against us. Any of these events could harm our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business is subject to continuing compliance to standards by various accreditation and registration bodies, which is costly, and loss of accreditation or registration could result in negative effects on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to accreditation such as that by the AATB and as a National Association of Boards of Pharmacy</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (NABP) Accredited Drug Distributors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We have registration requirements such as that with ISO 13485 registration bodies. These accreditations and regulations can affect distribution and sale of our products on a state-by-state basis, within the U.S. and also affects distribution and sale of our products outside of the U.S. The loss of accreditation or registration could keep us from selling and distributing our products, which may have negative effects on our business, results of operations, financial condition, and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Axoguard products are subject to FDA and international regulatory requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Axoguard product line is regulated as a medical device in the U.S. and international countries where we market Axoguard products. In the U.S., Axoguard product line is regulated under the FD&amp;C Act and subject to pre-market notification and clearance requirements under section 510(k) of the FD&amp;C Act, 21 CFR Part 820 (Quality System Regulation) and other FDA regulations. In the rest of the world, each region (such as the E.U.) or country has their independent international regulations such as the Medical Device Regulations (CE Mark) in Europe, UK Medicines and Healthcare products Regulatory Agency (MHRA), and Taiwan Pharmaceutical Affairs Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We distribute Axoguard Nerve Connector and Axoguard Nerve Protector products for Cook Biotech, and Cook Biotech is responsible for the regulatory compliance of these products. In the U.S., Cook Biotech has obtained a 510(k) pre-market clearance for Axoguard Nerve Connector from the FDA for porcine (pig) small intestine submucosa for the repair of peripheral nerve transections where gap closure can be achieved by flexion of the extremity. Cook Biotech has also obtained a 510(k) pre-market clearance for Axoguard Nerve Protector for the repair of peripheral nerve damage in which there is no gap or where a gap closure is achieved by flexion of the extremity. In countries where Axoguard is marketed, Cook Biotech has obtained regulatory clearance with the same indications except for Europe and the UK. For the CE Mark, the Axoguard Nerve Protector indication is the same; however, for Axoguard Nerve Connector, the indication is more specific - &#8220;The Axoguard Nerve Connector is indicated for the repair of peripheral nerve discontinuities with gaps up to 5 mm.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are responsible for the regulatory compliance of the Axoguard Nerve Cap. We have obtained a 510(k) pre-market clearance for Axoguard Nerve Cap to protect a peripheral nerve end and separate the nerve from the surrounding environment and to prevent or to reduce the development of symptomatic or painful neuroma.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we or Cook Biotech fail to comply with applicable regulatory requirements, the regulatory bodies in each country could deny or withdraw regulatory clearance/approval for the Axoguard products, or impose civil penalties, including fines, product seizures or product recalls and, in certain cases, criminal sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Defective products could lead to recall or other negative business conditions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our products are defective or otherwise pose safety risks, the FDA could require their recall, or we may initiate a voluntary recall of our products. The FDA may require recall of a marketed medical device product, such as the Axoguard products, in the event that it determines the medical device presents a reasonable probability of serious adverse health consequences or death. However, most device recalls do not rise to this level of health significance and result from voluntary action. The FDA has authority to recall biological products when a batch, lot or other quantity of the product presents an imminent or substantial hazard to the public health. However, in such circumstances, the FDA usually initially requests voluntary recalls of biological products, such as the Avance Nerve Graft. If a company does not comply with an FDA request for a recall, the FDA can order one under the above-referenced circumstances or take other enforcement actions, such as product seizure. In addition, manufacturers may, on their own initiative, recall a product to remove or correct a deficiency or to remedy a violation of the FD&amp;C Act that may pose a risk to health. A government-mandated, government-requested, or voluntary recall could occur as a result of an unacceptable risk to health, reports of safety issues, failures, manufacturing errors, design or labeling defects or other deficiencies, and issues. Recalls and other field corrections for any of our products would divert managerial and financial resources and have an adverse effect on our business, results of operations, financial condition, and prospects. A recall could adversely impact our reputation with customers and our sales. If the FDA were to disagree with our internal determinations and decision making relative to potential recalls (including corrections and removal), we could be subject to further regulatory or enforcement action against.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our products cause or contribute to a death, a serious injury, or any adverse reaction involving a communicable disease, or malfunction in certain ways, we will be subject to reporting regulations, which can result in voluntary corrective actions or agency enforcement actions. See &#8220;Business &#8212; Regulation &#8212; Education Grants, U.S. Anti-kickback, False Claims and Other Healthcare Fraud and Abuse Laws.&#8221; If we fail to report these events to the FDA within the required timeframes, or at all, the FDA could take regulatory or enforcement action against us. Any adverse event involving our products could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection, mandatory recall, or other enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">would require the dedication of time and capital, distract management from operating our business, and may adversely impact our reputation, business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our operations must comply with FDA and other governmental requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations require us to comply with the FDA&#8217;s and other governmental authorities&#8217; laws and regulations on the topics including the manufacture and production and sales and marketing of medical products, and compliance efforts related to such laws is costly, and failure to comply could subject us to enforcement action. See &#8220;Business &#8212; Government Regulations &#8212; Education Grants, U.S. Anti-kickback, False Claims and Other Healthcare Fraud and Abuse Laws &#8212; Fraud, Abuse and False Claims." Enforcement actions could impair our ability to produce products in a cost-effective and timely manner to meet customer demands. We may also be required to bear other costs or take other actions that may have an adverse impact on our future revenue and our ability to generate profits. Furthermore, our key material suppliers, licensors and or other contractors may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce products on a timely basis and in the required quantities, if at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Healthcare providers and facilities, and third-party payors, often play a primary role in the recommendation and prescription of any currently marketed products and product candidates for which we may obtain marketing approval. Our current and future arrangements with healthcare providers and facilities, third-party payors and customers, and our sales, marketing, and educational activities, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations (at the federal and state level) that may constrain our business or financial arrangements and relationships through which we market, sell, and distribute our products for which we obtain marketing approval. In addition, our operations are also subject to various federal and state fraud and abuse, and payment transparency laws and regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payments made to physicians and other healthcare providers, and other financial interests, have been the subject of a range of federal and state laws. The federal physician payment transparency requirements, sometimes referred to as the Physician Payments Sunshine Act, or the Sunshine Act, was created under the Affordable Care Act ("ACA"). The Sunshine Act, among other things, imposes reporting requirements on drug manufacturers for payments or other transfers of value made by them to physicians and teaching hospitals, as well as ownership and investment interests held by physicians, other healthcare providers, including physician assistants, nurse practitioners, and other mid-level healthcare practitioners, and their immediate family members. Reporting relative to these mid-level practitioners began in 2022 for payments or other transfers of value in 2021, which could increase the likelihood of a mistake in submission or failure to submit the required information by that group. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year and up to an additional aggregate of $1 million per year for &#8220;knowing failures,&#8221; for all payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, certain states also mandate implementation of compliance programs, impose restrictions on marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians and other HCPs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the federal fraud, waste, and abuse laws noted, there are analogous state laws and regulations, such as state anti-kickback and false claims laws, and other state laws addressing the medical product and healthcare industries, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and in some cases may apply regardless of payor, i.e., even if reimbursement is not available. Some state laws require pharmaceutical or device companies to comply with the industry's voluntary compliance guidelines (the PhRMA Code and AdvaMed Code) and the relevant compliance program guidance promulgated by the federal government (HHS-OIG) in addition to other requirements, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distribution of our human tissue products outside the U.S. are subject to foreign regulatory requirements that vary from country to country. In the E.U., human tissue regulations, if applicable, differ from one E.U. member state to the next. Because of the absence of a harmonized regulatory framework and the proposed regulation for advanced therapy medicinal products in the E.U., as well as for other countries, the approval process for human derived cell or tissue based medical products may be extensive, lengthy, expensive, and unpredictable. Our products are subject to E.U. member states&#8217; regulations that govern the donation, procurement, testing, coding, traceability, processing, preservation, storage, and distribution of human tissues and cells and cellular or tissue-based products. In addition, some E.U. member states have their own tissue banking regulations. The inability to meet foreign regulatory requirements could materially affect our future growth and compliance with such requirements could place a significant financial burden on us. As a result of Brexit, we cannot be sure what changes could occur or the cost of regulatory compliance with the UK. Accordingly, the cost of regulatory compliance for sales outside the U.S. can be significant and time consuming.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Finally, regulations in both the U.S. and other countries are subject to constant change. There can be no assurance that we can meet the requirements of future regulations or that compliance with current regulations assures future capability to distribute and sell our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical trials can be long and expensive, and results are ultimately uncertain. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are required to perform a clinical trial for our Avance Nerve Graft under FDA&#8217;s statutory requirements to obtain approval of a BLA for the product. This trial is subject to FDA approval and there is a risk that the FDA may not agree that the data supports the conclusions of the study which could jeopardize our ability to obtain regulatory approval and continue to market our Avance Nerve Graft product. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The results of pre-clinical studies do not necessarily predict future clinical trial results and predecessor clinical trial results may not be repeated in subsequent clinical trials. Additionally, the FDA may disagree with our interpretation of the data from our pre-clinical studies and clinical trials and may require the company to pursue additional pre-clinical studies or clinical trials, or not approve our BLA. If we are unable to demonstrate the safety, purity and potency of our product through our clinical trials, we will be unable to obtain regulatory approval to market the Avance Nerve Graft, and we will not be able to continue to provide it.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to submit the BLA for the Avance Nerve Graft by the end of 2023 and expect the BLA to cover the use of Avance Nerve Graft in the whole body for peripheral nerve repair. We will provide the FDA with supportive clinical evidence based on published literature and the RANGER study for qualifying peripheral nerve repairs from multiple areas in the body. The FDA may approve the BLA but restrict the Avance Nerve Graft labeling if the FDA does not agree with the additional data. We believe that restrictions to our labeling could have an adverse effect on Avance Nerve Graft commercialization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on third parties to conduct our clinical trials, and they may not perform as contractually required or expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We rely on third parties, such as contract research organizations (&#8220;CROs&#8221;), medical institutions, clinical investigators, and contract laboratories to conduct our clinical trials and certain nonclinical studies. We and our CROs are required to comply with all applicable regulations governing clinical research, including good clinical practice (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">GCP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">). The FDA enforces these regulations through periodic inspections of trial sponsors, principal investigators, CROs and trial sites. If we or our CROs fail to comply with applicable FDA regulations, the data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our applications. We cannot be certain that, upon inspection, the FDA and similar foreign regulatory authorities will determine that our clinical trial complies or complied with clinical trial regulations, including GCP. In addition, our clinical trial must be conducted with product produced under applicable GCP regulations. Failure to comply with the clinical trial regulations, including GCP, may require us to repeat clinical trials, which would delay the regulatory approval process. Further, if these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, need to be replaced, or the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our non-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we would not be able to obtain regulatory approval for our products on a timely basis, if at all, and our business, results of operations, financial condition, and prospects would be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">U.S. governmental regulation could restrict the use of our Avance Nerve Graft product, restrict our procurement of tissue or increase costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the FDA requirements for biological products, Avance Nerve Graft will continue to be subject to various requirements for human tissue under 21 CFR Part 1271. Human tissues intended for transplantation have been regulated by the FDA since 1993. In May 2005, three new comprehensive regulations went into effect that address manufacturing activities associated with HCT/P. The first regulation requires that companies that produce and distribute HCT/Ps register with the FDA. The second regulation provides criteria that must be met for donors to be eligible to donate tissues and is referred to as the &#8220;Donor Eligibility&#8221; rule. The third regulation governs the processing and distribution of the tissues and is often referred to as the &#8220;Current Good Tissue Practices&#8221; rule. The Current Good Tissue Practices rule covers all stages of allograft processing, from procurement of tissue to distribution of final allografts. Together, the three basic requirements of 21 CFR Part 1271 are designed to ensure that sound, high quality practices are followed to reduce the risk of tissue contamination and of communicable disease transmission to recipients. These regulations increased regulatory scrutiny within the industry in which we operate and have led to increased enforcement actions, which affects the conduct of our business. In addition, guidance was issued by the FDA in November 2017 and revised in July 2020 on Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use, which could have potential implications on future HCT/P products being evaluated by us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additional regulations or guidance documents may be implemented by the FDA in the future. These changes may impose new documentation requirements, process changes or testing that could increase costs, and regulatory burden. See &#8220;Business &#8212; Government Regulations.&#8221; These regulations can also increase the cost of tissue recovery activities. Finally, Avance Nerve Graft is subject to certain state and local regulations, as well as compliance with the standards of the tissue bank industry&#8217;s accrediting organization, the AATB.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The procurement and transplantation of allograft nerve tissue is also subject to federal law pursuant to the National Organ Transplant Act (&#8220;NOTA&#8221;), a criminal statute that prohibits the purchase and sale of human organs used in human transplantation, including nerve and related tissue, for &#8220;valuable consideration.&#8221; NOTA only permits reasonable payments associated with the removal, transportation, processing, preservation, quality control, implantation, and storage of human nerve tissue. We make payments to certain of our clients and tissue banks for their services related to recovering allograft nerve and umbilical cord tissue on our behalf. If NOTA is interpreted or enforced in a manner that prevents us from receiving payment for services we render or prevents us from paying tissue banks or certain of our clients for the services they render for us, our business, results of operations, financial condition, and prospects could be materially and adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have engaged, through marketing employees, independent sales agents and sales representatives, in ongoing efforts designed to educate the medical community as to our products&#8217; benefits, and we intend to continue our educational activities. Although we believe that NOTA permits payments in connection with these educational efforts as reasonable payments associated with the processing, transportation and implantation of our products, payments in connection with such education efforts are not exempt from NOTA&#8217;s restrictions and our inability to make such payments in connection with these education efforts may prevent us from paying our sales representatives and could adversely affect our business, results of operations, financial condition, and prospects. No federal agency or court has determined whether NOTA is, or will be, applicable to every allograft nerve tissue-based material that our processing technologies may generate. Assuming that NOTA applies to our processing of allograft nerve and umbilical cord tissue, we believe that we comply with NOTA, but there can be no assurance that more restrictive interpretations of, or amendments to, NOTA will not be adopted in the future, which would call into question one or more aspects of our method of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other regulatory entities include state agencies with statutes covering tissue banking. Regulations issued by Florida, New York, California, and Maryland, among other states, are particularly relevant to our business. Most states do not currently have tissue banking regulations. However, incidents of allograft related issues in the industry may stimulate the development of regulation in other states. It is possible that third parties may make allegations against us or against donor recovery groups or tissue banks about non-compliance with applicable FDA regulations or other relevant statutes or regulations. Allegations like these could cause regulators or other authorities to take investigative or other action or could cause negative publicity for our business and the industry in which we operate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Axotouch product is subject to FDA and other regulatory requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe our Axotouch product is regulated as a Class I exempt medical device under the FD&amp;C Act and not subject to pre-market notification and clearance requirements under section 510(k) of the FD&amp;C Act, 21 CFR Part 820 (Quality System Regulation) and other FDA regulations. If we fail to comply with applicable regulatory requirements, the FDA could require a 510(k) for the product, or impose civil penalties, including fines, product seizures or product recalls and, in certain cases, criminal sanctions, which may adversely affect our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthcare law and policy changes may have a material adverse effect on us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S. there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability, or the ability of our collaborators, to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or our collaborators, may receive for any approved products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since enactment of the ACA in 2010 there have been a number of legal challenges as well as other legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2021, however, the Supreme Court issued its opinion in California v. Texas, upholding the constitutionality of the ACA. The full effects of the ACA may be unknown as the statutory provisions are fully implemented, and CMS, the FDA, and other federal and state agencies issue final applicable regulations or guidance. These developments could potentially alter coverage and marketing requirements, thereby affecting our pricing and market share if individuals lose coverage for certain benefits. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the future, there may continue to be additional proposals relating to the reform of the U.S. healthcare system. Future legislation, federal agency regulations and Presidential Executive Orders may impact the healthcare system in ways important to our business. Adoption of certain proposals could limit the prices we are able to charge for our products or the amounts of reimbursement available for our products and could also limit the acceptance and availability of our products. The adoption of some or all of these proposals could have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, initiatives sponsored by government agencies, legislative bodies, and the private sector in the U.S. and elsewhere to limit the growth of healthcare costs, especially for drugs and biologics, including price regulation and policies regarding generic drugs and biosimilars, are ongoing in markets where we do business. For example, on August 16, 2022, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was signed into law.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The IRA includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government, including allowing Medicare to negotiate prices for certain prescription drugs, requiring drug manufacturers to pay a rebate to the federal government if prices for single-source drugs and biologicals covered under Medicare Part B and nearly all covered drugs under Part D increase faster than the rate of inflation (CPI-U), and limiting out of pocket spending for Medicare Part D enrollees. Additionally, on October 14, 2022, President Biden signed Executive Order 14087 on &#8220;Lowering Prescription Drug Costs for Americans.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Executive Order specifically requests that the Center for Medicare and Medicaid Innovation consider &#8220;models that may lead to lower cost sharing for commonly used drugs and support value-based payment that supports high-quality care.&#8221; Continued government efforts to lower healthcare costs would affect our market materially. We could experience an adverse impact on operating results due to increased pricing pressure in the U.S. and in other markets. Governments, hospitals, pharmacy benefit managers (&#8220;PBMs&#8221;), and other third-party payors could reduce the amount of approved reimbursement for our products, deny coverage altogether, or impose new requirements on manufacturers to justify their prices. Reductions in reimbursement levels or coverage or other cost-containment measures could unfavorably affect our future operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We could be subject to civil or criminal penalties if we are found to have violated laws protecting the confidentiality of health information, which could increase our liabilities and harm our reputation or our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are a number of federal and state laws protecting the confidentiality of certain health information and restricting the use and disclosure of that protected information. In particular, the U.S. Department of Health and Human Services promulgated privacy rules under the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;). These privacy rules protect medical records and other personal health information by limiting their use and disclosure, giving individuals the right to access, amend and seek accounting of their own health information and limiting most use and disclosures of health information to the minimum amount reasonably necessary to accomplish the intended purpose. If we are found to be in violation of the privacy rules under HIPAA, we could be subject to civil or criminal penalties, which could increase our liabilities, harm our reputation, and have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our IP</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Failure to protect our IP rights could result in costly and time-consuming litigation and our loss of any potential competitive advantage.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success will depend, to a large extent, on our ability to successfully obtain and maintain patents, prevent misappropriation or infringement of IP, maintain trade secret protection, and conduct operations without violating or infringing on the IP rights of third parties. See &#8220;Business &#8212; Intellectual Property.&#8221; There can be no assurance that our patented and patent-pending technologies will provide us with a competitive advantage, that we will be able to develop or acquire additional technology that is patentable, or that third parties will not develop and offer technologies which are similar to ours. Moreover, we can provide no assurance that confidentiality agreements with our employees, consultants and other parties, agreements to protect trade secrets or similar agreements intended to protect unpatented technology or prevent unauthorized use, disclosure, or misappropriation will not be breached by those third parties. IP litigation is extremely expensive and time-consuming, and it is often difficult to predict the outcome of such litigation. A failure by us to protect our IP, or a breach by third parties of agreements aimed at protecting our IP, could have a materially adverse effect on our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future protection for our proprietary rights is uncertain and may impact our ability to successfully compete in our industry.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The degree of future protection for our proprietary rights is uncertain. We cannot ensure that:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We, or our licensors, were the first to make the inventions covered by each of our patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We, or our licensors, were the first to file patent applications for these inventions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Others will not independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Any of our pending patent applications will result in issued patents;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Any of our issued patents or those of our licensors are valid and enforceable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Any patents issued to us or our collaborators will provide any competitive advantages or will not be challenged by third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We will develop additional proprietary technologies that are patentable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The patents of others will not have a material adverse effect on our business rights; or</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The measures we rely on to protect our IP underlying our products are adequate to prevent third parties from using, disclosing, or misappropriating that IP, all of which could harm our ability to compete in the market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success depends in part on our ability and the ability of our collaborators and licensors to avoid infringing patents and proprietary rights of third parties, which could expose us or our collaborators and licensors to litigation or commercially unfavorable licensing arrangements. Third parties may accuse us or collaborators and licensors of employing their proprietary technology without authorization in our products, or in the materials or processes used to make our products. Any legal action against our collaborators, licensors or those claiming damages and/or seeking to enjoin our commercial activities relating to the affected products, materials and processes could, in addition to subjecting us to potential liability for damages, require us or our collaborators and licensors to obtain a license to continue to utilize the affected materials or processes or to manufacture or market the affected products. We cannot predict whether we or our collaborators and licensors would prevail in any of these actions or whether any license required under any of these patents would be made available on commercially reasonable terms, if at all. If we were unable to obtain such a license, we and our collaborators and licensors may be unable to continue to utilize the affected materials or processes, or manufacture or market the affected products, or we may be obligated by a court to pay substantial royalties and/or other damages to the patent holder. Even if we were able to obtain such a license, the terms of such a license could substantially reduce the commercial value of the affected product or products and impair our prospects for profitability. Accordingly, we cannot predict whether, or to what extent, the commercial value of the affected product or products or our prospects for profitability may be harmed as a result of any of the liabilities discussed above. Furthermore, infringement and other IP claims, with or without merit, can be expensive and time-consuming to litigate and can divert management&#8217;s attention from our core business. We and our collaborators and licensors may be unable to obtain and enforce IP rights to adequately protect our products and related IP, which could materially and adversely impact our business, results of operations, financial condition, or prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The patent protection for our products may expire before we are able to maximize their commercial value, which may subject us to increased competition and reduce or eliminate our opportunity to generate product revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The patents for our commercialized products and products in development have varying expiration dates and, when these patents expire, we may be subject to increased competition and we may not be able to recover our development costs. For example, the material U.S. patents covering the formulations used in our Axoguard product line, which are held by Cook Biotech, have expired. Expiration of these patents could adversely affect our ability to successfully execute our business strategy to maximize the value of Axoguard products and could materially and adversely impact our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Others may claim an ownership interest in our IP or claim that we infringe on their IP rights, which could expose us to litigation and have a significant adverse effect on our prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A third party may claim an ownership interest in one or more of our patents or other IP. While we believe we own the right, title, and interest in the patents for which we or our licensors have applied and our other IP (including that which is licensed from third parties) and is presently unaware of any claims or assertions by third parties with respect to our patents or IP, we cannot guarantee that a third party will not assert a claim or an interest in any of such patents or IP. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also, a third party may bring legal actions against us claiming we infringed their IP rights and seek monetary damages and/or enjoin clinical testing, manufacturing, and marketing of the affected product or products. There are many issued patents and pending patent applications in the U.S. and in other jurisdictions, owned by third parties, potentially covering various medical devices and biological products. There may be patents owned by third parties that we are currently unaware of, with issued claims that cover one or more of our current or future products or use or manufacture of those products. Since patents may take many years to issue, there may be pending patent applications owned by third parties that may lead to issued claims that cover one or more of our current or future products or use or manufacture of those products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we become involved in any litigation, it could consume a substantial portion of our resources and cause a significant diversion of effort by our technical and management personnel. If any of these actions were successful, in addition to any potential liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product, in which case we may be required to pay substantial royalties or grant cross-licenses to our patents. We cannot, however, assure that any such license will be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other IP rights, which could have a material and adverse effect on our business, results of operations, financial condition, and prospects. Further, the outcome of IP litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of the adverse party. This is especially true in IP cases that may turn on the testimony of experts as to technical facts or the scope or meaning of patent claims upon which experts may reasonably disagree.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We depend on the maintenance of exclusive licenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We depend fundamentally on keeping and satisfying the terms of exclusive licenses of our nerve repair technologies from UFRF and UTA. Nonetheless, a disagreement between us and either licensor could have a negative impact on our ability to effectively operate our business. In addition, we could learn that the technologies we have licensed do not perform as purported, are not efficacious, or are not the property of the licensor, any of which would have an immediate and negative impact on our business.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our trademarks are valuable, and our business may be adversely affected if trademarks are not adequately protected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S. and other countries, we currently hold trademark registrations and have trademark applications pending, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the same. As our products mature, our reliance on our trademarks to protect our brand, increase our name recognition and, in part, differentiate us from our competitors increases. As a result, if our trademark applications are not successful and if we are unable to prevent third parties from adopting, registering, or using trademarks, including trade dress, that infringe, dilute, or otherwise violate our trademark rights, our business, results of operations, financial condition, and prospects could be materially adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">New legislation or court precedent on patent law in the U.S. and in other jurisdictions may increase the uncertainties and costs for us to obtain and enforce patent claims broad enough to exclude others from making, using, or selling our current and future products. These changes in the patent law may also increase the uncertainties associated with the potential third party patent infringement claims against our current and future products. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways to weaken our ability to obtain and enforce patent rights relevant to our products, and/or our ability to defend our business against third party infringement claims in the future.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Financing Our Business </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our credit facility and payment obligations under the Revenue Participation Agreement with Oberland Capital contain operating and financial covenants that restrict our business and financing activities, require cash payments over an extended period of time and are subject to acceleration in specified circumstances, which may result in Oberland Capital taking possession and disposing of any collateral.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our credit facility with Oberland Capital contains restrictions that limit our flexibility in operating our business. Under the terms of the credit facility, we must maintain, and cause our subsidiaries to maintain, certain covenants, including with respect to limitations on new indebtedness, restrictions on the payment of dividends and maintenance of revenue levels. Our credit facility is collateralized by all of our assets including, among other things, our IP.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we breach certain of our debt covenants and are unable to cure such breach, revert to the provided liquidity covenant or are not granted waivers in relation to such breach, it may constitute an event of default under the credit facility, giving Oberland Capital the right to require us to repay the then-outstanding debt immediately. If we are unable to pay the outstanding debt immediately, Oberland Capital could, among other things, foreclose on the collateral granted to them to collateralize such indebtedness. A breach of the covenants contained in the credit facility documents and the acceleration of its repayment obligations by Oberland Capital could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the credit facility, we entered into a Revenue Participation Agreement (&#8220;RPA&#8221;) with Oberland Capital. Pursuant to the RPA, we agreed to pay an additional quarterly royalty payment as a percentage of our net revenue, up to $70 million in any given fiscal year, subject to certain limitations set forth therein, during the period commencing on the later of (i) April 1, 2021 and (ii) the date of funding of a loan under the credit facility and ending on the date upon which all amounts owed under the Term Loan Agreement have been paid in full. Payments commenced on September 30, 2021 with the royalty structure resulting in approximately 1.0% per year of additional payments on the outstanding principal amount of the loans.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The credit facility and RPA could have important negative consequences to the holders of our securities. For example, a portion of our cash flow from operations will be needed to make payments to Oberland Capital and will not be available to fund future operations. Additionally, we may have increased vulnerability to adverse general economic and industry conditions. Payment requirements under the credit facility and RPA will increase our cash outflows. Additionally, the credit facility and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">RPA contain complex provisions, which, if interpreted differently, could materially increase the amount of the payments due to Oberland Capital. Our future operating performance is subject to market conditions and business factors that are beyond our control. If our cash inflows and capital resources are insufficient to allow us to make required payments, we may have to reduce or delay capital expenditures, sell assets, or seek additional capital. If we raise funds by selling additional equity, such sale would result in dilution to our shareholders. There is no assurance that if we are required to secure funding, we can do so on terms acceptable to us, or at all. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, our credit facility uses the London Interbank Offering Rate (&#8220;LIBOR&#8221;) as a benchmark for establishing the interest rate. In March 2021, the U.K. Financial Conduct Authority announced that all LIBOR settings will either cease to be provided by any administrator or no longer be representative immediately after December 31, 2021 for sterling, euro, Swiss franc and Japanese yen settings, as well as the one-week and two-month U.S. dollar settings, and immediately after June 30, 2023 for the remaining U.S. dollar settings. While we have not yet incorporated LIBOR-replacement provisions into our credit facility, we will need to do so before June 30, 2023. The discontinuation and replacement of LIBOR or any other benchmark rates may have an unpredictable impact on contractual mechanics in the credit markets or cause disruption to the broader financial markets. Additionally, uncertainty as to the nature of such potential discontinuation and replacement, including that any benchmark may not be the economic equivalent of LIBOR or not achieve market acceptance similar to LIBOR, may negatively impact the cost of our variable rate debt.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may need to raise additional funds to finance our future capital or operating needs, which could have adverse impacts on our business, results of operations and the interests of our shareholders.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may need to seek to raise funds through the issuance of public or private debt or the sale of equity to achieve our business strategy. If we raise funds, this could dilute the interests of our shareholders. Moreover, the availability of additional capital, whether debt or equity from private capital sources (including banks) or the public capital markets, fluctuates as our financial condition and industry or market conditions in general change. There may be times when the private capital markets and the public debt or equity markets lack sufficient liquidity or when our securities cannot be sold at attractive prices, in which case we would not be able to access capital from these sources on favorable terms, if at all. We can give no assurance as to the terms or availability of additional capital.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Common Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">An active trading market in our common stock may not be maintained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The trading market in our common stock has been volatile. The quotation of our common stock on The Nasdaq Capital Market does not assure that a meaningful, consistent, and liquid trading market will exist. We cannot predict whether an active market for our common stock will be maintained in the future. An absence of an active trading market could adversely affect our shareholders&#8217; ability to sell our common stock at current market prices in short time periods, or possibly at all. Additionally, market visibility for our common stock may be limited and such lack of visibility may have a depressive effect on the market price for our common stock. As of December 31, 2022, approximately 34.9% of our outstanding shares of common stock was held by our officers, directors, beneficial owners of 5% or more of our securities and their respective affiliates, which adversely affects the liquidity of the trading market for our common stock, in as much as federal securities laws restrict sales of our shares by these shareholders. If our affiliates continue to hold their shares of common stock, there will be limited trading volume in our common stock, which may make it more difficult for investors to sell their shares or increase the volatility of our stock price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The price of our common stock could be volatile due to a number of factors, which could lead to losses by investors and costly securities litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is listed on The Nasdaq Capital Market under the symbol &#8220;AXGN.&#8221; The stock market in general, and the market for medical technology companies in particular, have experienced and could in the future experience volatility that has often been unrelated to the operating performance of particular companies. The trading price of our common stock has experienced volatility and is likely to continue to be volatile in response to a number of factors including, without limitation, the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Fluctuations in price and volume due to investor speculation, including short sales, social media speculation and other factors that may not be tied to our financial performance;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our performance in the execution of our business plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Financial viability; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Actual or anticipated variations in our operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Announcements of developments by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Market conditions in our industry;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Adoption of new accounting standards affecting our industry;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Additions or departures of key personnel;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Introduction of new products by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Sales of our common stock or other securities in the open market;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Regulatory developments in both the U.S. and foreign countries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Performance of products sold and advertised by licensees in the marketplace;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Economic and other external factors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Period-to-period fluctuations in financial results; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Other events or factors, including the other factors described in this &#8220;Risk Factors&#8221; section, many of which are beyond our control.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The stock market is subject to significant price and volume fluctuations. Such fluctuations have and could expose us to securities class action litigation, which could adversely impact our business, results of operations, financial condition, and prospects. </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate paying any cash dividends in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The operation and expansion of our business will continue to require funding. We do not anticipate that we will pay any cash dividends on our common stock for the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our Board of Directors and will depend upon results of operations, financial condition, contractual restrictions, restrictions imposed by applicable law, and other factors our board of directors deems relevant. Accordingly, if any investor purchases shares of common stock, realization of a gain on such investment will depend on the appreciation of the price of our common stock, which may never occur. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Anti-takeover provisions in Minnesota law may deter acquisition bids for us that you might consider favorable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are governed by the provisions of Sections 302A.671, 302A.673 and 302A.675 of the Minnesota Business Corporation Act (the &#8220;MBCA&#8221;). These provisions may discourage a negotiated acquisition or unsolicited takeover of us and deprive our shareholders of an opportunity to sell their common stock at a premium over the market price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In general, Section 302A.671 of the MBCA provides that a corporation&#8217;s shares acquired in a control share acquisition have no voting rights unless voting rights are approved in a prescribed manner. A &#8220;control share acquisition&#8221; is a direct or indirect acquisition of beneficial ownership of shares that would, when added to all other shares beneficially owned by the acquiring person, entitle the acquiring person to have voting power of 20% or more in the election of directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In general, Section 302A.673 of the MBCA prohibits a public Minnesota corporation from engaging in a business combination with an interested shareholder for a period of four years after the date of the transaction in which the person became an interested shareholder, unless the business combination is approved in a prescribed manner. The term &#8220;business combination&#8221; includes mergers, asset sales, and other transactions resulting in a financial benefit to the interested shareholder. An &#8220;interested shareholder&#8221; is a person who is the beneficial owner, directly or indirectly, of 10% or more of a corporation&#8217;s voting stock or who is an affiliate or associate of the corporation, and who, at any time within four years before the date in question, was the beneficial owner, directly or indirectly, of 10% or more of the corporation&#8217;s voting stock. Section 302A.673 does not apply if a committee of our Board of Directors consisting of all of its disinterested directors (excluding current and former officers) approves the proposed transaction or the interested shareholder&#8217;s acquisition of shares before the interested shareholder becomes an interested shareholder.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a tender offer is made for our common stock, Section 302A.675 of the MBCA precludes the offeror from acquiring additional shares of stock (including in acquisitions pursuant to mergers, consolidations, or statutory share exchanges) within two years following the completion of the tender offer, unless shareholders selling their shares in the later acquisition are given the opportunity to sell their shares on terms that are substantially the same as those contained in the earlier tender offer. Section 302A.675 does not apply if a committee of our Board of Directors consisting of all of its disinterested directors (excluding its current and former officers) approves the proposed acquisition before any shares are acquired pursuant to the earlier tender offer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Legal proceedings that we become involved in from time to time could adversely affect our business operations or financial condition.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to legal proceedings from time to time. Legal proceedings, if decided adversely to or settled by us, and not covered by insurance, could result in liability material to our financial condition, results of operations or cash flows. Likewise, regardless of outcome, legal proceedings could result in substantial costs and expenses, affect the availability or cost of some of our insurance coverage and significantly divert the attention of our management. There can be no assurance that we will be able to prevail in, or achieve a favorable settlement of, any pending or future legal proceedings to which we become subject. Even claims without merit could subject us to adverse publicity and require us to incur significant legal fees. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may seek to expand our business in ways that could result in diversion of resources and extra expenses.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may in the future pursue acquisitions of businesses, products and technologies, establish joint venture arrangements, or make minority equity investments to expand our business. We are unable to predict whether or when any prospective acquisition, equity investment or joint venture will be completed. The process of negotiating potential acquisitions, joint ventures or equity investments, as well as the integration of acquired or jointly developed businesses, technologies or products may be prolonged due to unforeseen difficulties and may require a disproportionate amount of our resources and management&#8217;s attention. We cannot assure you that we will be able to successfully identify suitable acquisition or investment candidates, complete acquisitions or investments, or integrate acquired businesses or joint ventures with our operations. If we were to make any acquisition or investment or enter into a joint venture, we may not receive the intended benefits of the acquisition, investment or joint venture or such an acquisition, investment or joint venture may not achieve comparable levels of revenues, profitability or productivity as our existing business or otherwise perform as expected. The occurrence of any of these events could harm our business, financial condition or results of operations. Future acquisitions, investments or joint ventures may require substantial capital resources, which may require us to seek additional debt or equity financing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Future acquisitions, joint ventures or minority equity investments by us could result in the following, any of which could seriously harm our results of operations or the price of our stock:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">issuance of equity securities that would dilute our current shareholders&#8217; percentages of ownership;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">large one-time write-offs or equity investment impairment write-offs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">incurrence of debt and contingent liabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">difficulties in the assimilation and integration of operations, personnel, technologies, products and information systems of the acquired companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">inability to realize cost efficiencies or synergies, thereby incurring higher operating expenditures as a result of the acquisition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">diversion of management&#8217;s attention from other business concerns;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">contractual disputes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">risks of entering geographic and business markets in which we have no or only limited prior experience; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">potential loss of key employees of acquired organizations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to future product liability litigation, which could be expensive, and our insurance coverage may not be adequate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we are not currently subject to any product liability proceedings and have no provision for product liability disbursements, we may incur material liabilities relating to product liability claims in the future, including product liability claims arising out of the usage of our products. Although we currently carry product liability insurance in an amount we believe is consistent with industry averages, our insurance coverage and any provision we may maintain in the future for product related liabilities may not be adequate and our business, results of operations, financial conditions, and prospects could suffer material adverse consequences.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss of key members of management, who we need to succeed, could adversely affect our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future success depends on the continued efforts of the members of our executive management team. Competition for experienced management personnel in the healthcare industry is intense. If one or more of our executives or other key personnel are unable or unwilling to continue in their present positions, or if we are unable to attract and retain high quality executives or key personnel in the future, our business, results of operations, financial conditions, and prospects may be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business and financial performance could be adversely affected, directly or indirectly, by natural or man-made disasters or other similar events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Neither the occurrence nor the potential impact of risks such as earthquakes, hurricanes, floods and other natural disasters, fire, power shortages, geopolitical unrest, war, terrorist attacks and other hostile acts, epidemics or pandemics such as COVID-19 pandemic, outbreaks of RSV and the flu, nuclear disasters, international hostilities or other criminal activities and other events beyond our control and the control of the third parties on which we depend can be predicted. However, these occurrences could impact us directly as a result of damage to our facilities or by preventing us from conducting our business in the ordinary course, or indirectly as a result of their impact on our customers, suppliers, or other counterparties. We could also suffer adverse consequences to the extent that these disasters affect the financial markets or the economy in general or in any particular region.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, climate change could present immediate and long-term risks to our industry and our customers. The potential for increased severe weather events could have a material adverse effect on our operations and infrastructure or the operations and infrastructure of our suppliers. In addition, the effects of climate change could include long-term changes in temperature levels and water availability, increased energy costs, and increased supply costs impacted by those increasing energy costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to mitigate the adverse consequences of such occurrences is in part dependent on the quality of our resiliency planning, and our ability, if any, to anticipate the nature of any such event that occurs. The adverse impact of natural or man-made disasters also could be increased to the extent that there is a lack of preparedness on the part of national or regional emergency responders or on the part of other organizations and businesses that we deal with, particularly those that we depend upon but have no control over.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business, results of operations, financial condition, and prospects could be adversely affected, directly or indirectly, by the effects of an increased focus on environmental, social and governance issues.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Recently, shareholders have had an increased focus on environmental, social and governance ("ESG") issues, focusing on how companies are addressing climate change, diversity, and human rights, among other ESG-related issues. Our failure to comply with stakeholder expectations and standards regarding ESG issues, which are still evolving and can vary considerably, or the perception that we have not responded appropriately to ESG-related issues, could result in reputational harm, and could have an adverse effect on our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cost of mitigating or responding to ESG issues could be significant; however, these costs are too uncertain to predict. In addition, the approaches taken by the U.S. or foreign governments to regulate ESG issues, which may include legislative or regulatory changes, and new reporting requirements, could adversely impact our business, results of operations, financial condition, and prospects, and are too uncertain to predict.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, Russia's ongoing invasion of Ukraine and illegal annexation of Ukrainian territories, and record inflation and could materially and adversely affect our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are exposed to the risk of changes in social, geopolitical, legal, and economic conditions. The global economy has been, and may continue to be, negatively impacted by Russia&#8217;s invasion of Ukraine and illegal annexation of Ukrainian territories. The negative impacts arising from the war and sanctions and export restrictions imposed by various countries, including those imposed by Russia, may include reduced consumer demand, supply chain disruptions, increased cybersecurity risks, and increased costs for transportation, energy, and raw materials. Although none of our operations are in Russia or Ukraine, further escalation of geopolitical tensions could have a broader impact that expands into other markets where we do business, which may adversely affect our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, changes in domestic and global economic conditions, supply chain disruptions, labor shortages, as well as other stimulus and spending programs, have led to higher inflation, which is likely to lead to increased costs and may cause changes in fiscal and monetary policy. Additionally, our ability to access capital markets and other funding sources in the future may not be available on commercially reasonable terms, if at all. Impacts from inflationary pressures, such an increasing costs for research and development of our products, administrative and other costs of doing business, could adversely affect our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, our customers could experience financial and operational pressures as a result of labor shortages, the supply chain disruptions, and increased inflation, which could impact their ability to access capital markets and other funding sources, increase cost of funding, or impede their ability to comply with debt covenants, which in turn could impede their ability to provide patient care, conduct further research and development, marketing and commercialization efforts, or impact their profitability. To the extent that our customers continue to face such financial pressures, it could impact their willingness to spend on our products and services, which could adversely affect our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although, to date, our business has not been materially impacted by Russia's ongoing invasion of Ukraine and illegal annexation of Ukrainian territories, geopolitical tensions, or record inflation, it is impossible to predict the extent to which our operations could be impacted in the short and long term, or the ways in which such matters may impact our business. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in U.S. trade policy, threats of international tariffs, and changes to the U.S. political landscape may adversely affect our business, results of operations, financial condition, and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Rising threats of international tariffs, including tariffs applied to goods traded between the U.S. and China, could materially and adversely affect our business, results of operations, financial condition, and prospects. Over the past several years, legislative and executive action from U.S. and foreign leaders has led to both threats of and the imposition of tariffs on certain materials and products. The U.S. and China imposed tariffs or announced proposed tariffs to be applied in the future to certain of each other&#8217;s exports. In November 2022, the Biden Administration extended the tariffs implemented by former President Trump on COVID-19 related products. We cannot be certain, however, if the Biden administration will choose to have these tariffs remain in place or what impact, if any they may have on our business. Changes in political conditions in China and changes in the state of China-U.S. relations, including the current trade tensions, are difficult to predict and could adversely affect our operations or financial condition. We cannot predict the extent to which the U.S. or other countries will impose quotas, duties, tariffs, taxes or other similar restrictions upon the import or export of our products in the future, nor can we predict future trade policy or the terms of any renegotiated trade agreements and their impact on our business. The adoption and expansion of trade restrictions, the occurrence of a trade war, or other governmental action related to tariffs or trade agreements or policies has the potential to adversely impact demand for our products, our costs, our customers, our suppliers, and the U.S. economy, which in turn could have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Biden administration continues to contemplate significant policy changes, including healthcare regulatory changes, which may impact our business, results of operation, financial condition, and prospects. These effects could be exacerbated by volatile economic, political and market conditions, such as social unrest, civil insurrection, and political action.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations could be negatively affected by potential fluctuations in foreign currency exchange rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to the effects of changes in foreign currency exchange rates. We are exposed to the risk of an increase or decrease in the value of the foreign currencies relative to the U.S. Dollar, which could increase the value of our expenses and decrease the value of our revenue when measured in U.S. Dollars. As a result, our results of operation may be influenced by the effects of future exchange rate fluctuations and such effects may have an adverse impact on our common stock price. Global markets and foreign currencies, including the Euro and the British Pound, were adversely impacted, as a result of Brexit and volatility in foreign currencies is expected to continue as a result of Brexit. Changes in the relative values of currencies occur regularly and, in some instances, could materially adversely affect our business, results of operations, financial condition or prospects.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We may have exposure to additional tax liabilities as a result of our foreign operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to income taxes in the United States and various foreign jurisdictions. We have operations in Canada, Germany, UK, Spain, and several other European, Asian, and Latin American countries. Significant judgment is required in determining our worldwide provision for income taxes and other tax liabilities. In the ordinary course of a global business, there are many intercompany transactions and calculations where the ultimate tax determination is uncertain. We are regularly under audit by tax authorities. Our intercompany transfer pricing may be reviewed by the U.S. Internal Revenue Service and by foreign tax jurisdictions. Although we believe that our tax estimates are reasonable, due to the complexity of our corporate structure, the multiple intercompany transactions and the various tax regimes, we cannot assure you that a tax audit or tax dispute to which we may be subject will result in a favorable outcome for us. If taxing authorities do not accept our tax positions and impose higher tax rates on our foreign operations, our overall tax expenses could increase.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to protect our technology systems and comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our business, results of operations, financial condition, and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on information technology systems, including technology from third-party vendors, to process, transmit and store electronic information in our day-to-day operations. Similar to other companies, the size and complexity of our information technology systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy, or other significant disruption. Our information systems require an ongoing commitment of resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards and the increasing need to protect patient and customer information. Any failure by us to maintain or protect our information technology systems and data integrity could result in the unauthorized access to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">patient data and personally identifiable information, theft of intellectual property or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyber-attacks, intrusions, or other breaches could adversely impact our business, results of operations, financial condition, and prospects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S., federal and state privacy and security laws require certain of our operations to protect the confidentiality of personal information, including patient medical records and other health information. Limiting and/or restricting the use of certain personal data and information, as well as added transparency obligations to data subjects is becoming an increasing focus as evidenced by the implementation of the California Consumer Privacy Act (&#8220;CCPA&#8221;) which became effective on January 1, 2020. In Europe, E.U. member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations. Moreover, the collection and use of personal health data in the E.U. is governed by the European Union General Data Protection Regulation (&#8220;GDPR&#8221;). The GDPR imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the E.U. to the U.S., provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to 4% of the annual global revenue of the noncompliant company. The recent implementation of the GDPR has increased our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#8217;s attention and increase our cost of doing business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compliance with applicable data privacy and security laws and regulations (together with applicable industry standards) may increase our costs of doing business. In this regard and in light of the CCPA&#8217;s implementation, we expect that there will be other proposed laws, regulations and industry standards relating to privacy and data protection in the U.S., the E.U. and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business results of operations, financial condition, and prospects.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on internal information and telecommunications systems, and any failure of these systems, including system security breaches, data protection breaches or other cybersecurity attacks, may negatively impact our business and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cyber-attacks and other tactics designed to gain access to and exploit sensitive information by breaching mission critical systems of large organizations are constantly evolving and have been increasing in sophistication in recent years. High profile security breaches leading to unauthorized release of sensitive information have occurred with increasing frequency at a number of major U.S. companies, despite widespread recognition of the cyber-attack threat and improved data protection methods. While to date we have not experienced a significant data loss, significant compromise or any material financial losses related to cybersecurity attacks, our systems, those of our customers, and those of our third-party service providers are under constant threat. Cybercrime, including phishing, social engineering, attempts to overload our servers with denial-of-service attacks, or similar disruptions from unauthorized access to our systems, could cause us critical data loss or the disclosure or use of personal or other confidential information. Outside parties may attempt to fraudulently induce employees to disclose personally identifiable information or other confidential information which could expose us to a risk of loss or misuse of this information.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are dependent on internal information and telecommunications systems, and we are vulnerable to failure of these systems, including through system security breaches, data protection breaches or other cybersecurity attacks. If these events occur, the unauthorized disclosure, loss or unavailability of data and disruption to our business may have a material adverse effect on our reputation and harm our relationships with vendors and customers. Additionally, these events may lead to financial losses from remedial actions, or potential liability from fines, including in relation to noncompliance with the GDPR, as well as possible litigation and punitive damages. Failures of our internal information or telecommunications systems may prevent us from taking customer orders, shipping products and billing customers. Sales may also be impacted if our customers are unable to access our pricing and product availability information. The occurrence of any of these events could have a material adverse impact on our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our management has broad discretion in the use and placement of our cash and cash equivalents and, despite management&#8217;s efforts, cash and cash equivalents may be used in a manner that does not increase the value of shareholders&#8217; investments or placed in otherwise reputable financial institutions that fail..</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management has broad discretion in the use and placement of our cash and cash equivalents, and investors must rely on the judgment of management regarding the use and placement of such cash and cash equivalents. Management may invest our cash and cash equivalents in short-term or long-term, investment-grade, interest-bearing securities. These investments may not yield favorable returns to shareholders. If we do not invest or apply our cash and cash equivalents in ways that enhance shareholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. Furthermore, the most reputable financial institutions may fail, as evidenced by SVB.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Despite the judgment of management regarding the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">placement of cash and cash equivalents in deemed reputable financial institutions, events outside of our control could occur, the result of which could result in us not having access to our cash and cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business and stock price may be adversely affected if our internal controls are not effective.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Section 404 of the Sarbanes-Oxley Act of 2002 requires that public companies conduct a comprehensive evaluation of their internal control over financial reporting. To comply with this statute, each year we are required to document and test our internal control over financial reporting and our management is required to assess and issue a report concerning it.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we have systems in place to strengthen our internal control over financial reporting, we cannot assure you that we will not discover material weaknesses in the future or that no material weakness will result from any difficulties, errors, delays, or disruptions while we implement and transition to new internal systems. The existence of one or more material weaknesses could result in errors in our financial statements, and substantial costs and resources may be required to rectify these or other internal control deficiencies. If we cannot produce reliable financial reports, investors could lose confidence in our reported financial information, the market price of our common stock could decline significantly, we may be unable to obtain additional financing to operate and expand our business and our business, results of operations, financial condition, and prospects could be adversely impacted.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_25"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 1B. UNRESOLVED STAFF COMMENTS</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_28"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 2. PROPERTIES </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our material physical properties consisted of the following as of December 31, 2022:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Character</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Square Feet</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Square Feet Utilized</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alachua, Florida </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Headquarters - General office, warehousing and distribution</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/31/2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tampa, Florida </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Headquarters - General office, medical laboratory, and meeting space</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/31/2034</span></td></tr><tr style="height:30pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Burleson, Texas </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility - Raw material and finished goods warehousing and distribution</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/30/2027</span></td></tr><tr style="height:26pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2027</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vandalia, Ohio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility - Currently under renovation and retrofit: clean-room, manufacturing, warehousing, and office space.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dayton, Ohio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility - Clean-room/manufacturing, warehousing, and office space</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2023</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.444%"><tr><td style="width:1.0%"></td><td style="width:4.937%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property is encumbered by a lease agreement and is collateral to our Credit Facility.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property is collateral to our Credit Facility.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property is encumbered by our CTS Agreement as an embedded lease.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total square feet and utilization varies each month for the use of CTS's clean room/manufacturing, warehousing, and office space in accordance with the CTS Agreement.</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our facilities will be sufficient to operate our business for the next 12 months and that current lease obligations will not change materially.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 3. LEGAL PROCEEDINGS</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item is set forth in Note 14 - Commitments and Contingencies of the Notes to Consolidated Financial Statements in this Annual Report on Form 10-K and is incorporated herein by reference.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_34"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 4. MINE SAFETY DISCLOSURES</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_40"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Capital Market under the symbol &#8220;AXGN.&#8221; On March&#160;10, 2023, the last reported closing sale price of our common stock on the Nasdaq Capital Market was $7.58 per share.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholders</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;10, 2023, we had 42,601,918 shares of common stock outstanding, and approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 226</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common shareholders of record, based upon information received from our stock transfer agent. However, this number does not include beneficial owners whose shares were held of record by nominees or broker dealers. We estimate that there are approximately 11,343 individual owners. Additional information called for by this item is incorporated herein by reference to the following sections of this Report: Note 11 - Stock-Based Compensation of the Notes to Consolidated Financial Statements included in Item 8; and Part III, Item&#160;12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#160;&#8211; Equity Compensation Plan Information&#8221;.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not repurchase any of our securities in the fourth quarter of 2022.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no sales of unregistered securities in 2022.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part III, Item 12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.&#8221;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid and do not anticipate paying or declaring a cash dividend on our common stock. We intend to retain any earnings to finance the growth and development of our business. Our Board of Directors may declare dividends at its discretion.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_43"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 6. [RESERVED]</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following information should be read in conjunction with our consolidated financial statements and the notes thereto contained in Item 8 of Part II in this Form 10-K, &#8220;Forward-Looking Statements&#8221; contained in Part&#160;1 of this Form 10-K, &#8220;Risk Factors&#8221; contained in Item 1A of this Form 10-K, and the other information appearing elsewhere in, or incorporated by reference into, this Form 10-K. Dollar amounts referenced in this Item 7 are in thousands, except per share amounts.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_49"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Overview</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. We are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries. We provide innovative, clinically proven, and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves.&#160;Physical damage to a peripheral nerve&#160;or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Portfolio </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Avance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Axoguard Nerve Connector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a porcine (pig) submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed peripheral nerves; </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Axoguard Nerve Protector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Axoguard Nerve Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Axotouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Two-Point Discriminator, used to measure the innervation density of any surface area of the skin.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our portfolio of products is currently available in the U.S., Canada, Germany, United Kingdom ("UK"), Spain and several other European, Asian and Latin American countries.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from the distribution of our nerve repair products, Avance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Nerve Graft, Axoguard Nerve Connector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Axoguard Nerve Protector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and Axoguard Nerve Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in the United States ("U.S.") is the main contributor to our total reported sales and have been the key component of our growth to date. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously announced, we suspended the market availability of Avive</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soft Tissue Membrane ("Avive") on June 1, 2021 and we continue discussions with the U.S. Food and Drug Administration ("FDA") to determine the appropriate regulatory classification and requirements for Avive. The suspension was not based on any known or reported safety or product performance issues or concerns with Avive. We seek to return Avive to the market, although we are unable to estimate the timeframe or provide any assurances that a return to the market will be achievable. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced that surgeons initially are cautious adopters for peripheral nerve repair products. Surgeons typically start with a few cases and then wait and see the results of these initial cases. Active accounts are usually past this wait period and have developed some level of product reorder. These active accounts have typically gone through the committee approval process, have at least one surgeon who has converted a portion of his or her treatment algorithms of peripheral nerve repair to our portfolio and have ordered our products at least six times in the last twelve months. As of December&#160;31, 2022, we had 968 active accounts, an increase of 2.9% from 941 one year ago. Active accounts are approximately 85% of our revenue. The top 10% of these active accounts continue to represent approximately 35% of our revenue. As our business continues to grow, we have transitioned to reporting a new account metric that we believe demonstrates the strength of adoption and potential revenue growth in accounts that have developed a more consistent use of our products in their nerve repair algorithm. We refer to these as core accounts which we define as accounts that have purchased at least $100 in the past 12 months. As of December&#160;31, 2022, we had 332 core accounts, an increase of 17.7% from 282 one year ago. These core accounts represented approximately 60% of our revenue in  2022, which has remained consistent over the past two years. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Operational and Business Highlights</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net revenue excluding Avive was $138,584 for the year ended December 31, 2022, an increase of $15,301 or 12.4% compared to the year ended December&#160;31, 2021.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gross profit was $114,437 for the year ended December 31, 2022, an increase of $10,010 or 9.6% compared to the year ended December&#160;31, 2021.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We ended the year with 115 direct sales representatives consistent with 2021. We also have independent sales agencies supplementing our direct sales team, and those agencies represent approximately 10% of our total revenue. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During 2022, we surpassed 75,000 Avance Nerve Graft implants since launch.  </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">During 2022, we added an additional 26 peer-reviewed clinical publications bringing our total to 215 from 181 at the end of 2021, which included the following topics extremity trauma, breast, oral maxillofacial and pain.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">We continue to train approximately 75% of the U.S. hand- and micro-surgery fellows each year, a top priority for Axogen in support of improved nerve repair techniques.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2022, RECON Phase 3 Study of Avance met its primary endpoint. This study provided the first ever Level 1 clinical evidence in support of Avance Nerve Graft for peripheral nerve repairs. This data will be used to support our Biologics License Application ("BLA") submission.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We anticipate submitting our BLA for Avance Nerve Graft by the end of 2023. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect that the renovation and validation of our Axogen Processing Center facility ("APC Facility") will be complete in mid-2023 and anticipate transition to the new facility in mid-2023 This facility will be included in our BLA for Avance Nerve Graft and is expected to provide processing capacity that will meet our expected sales growth.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2022 and 2021</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts and as percentages of total revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:53.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(dollars in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,843&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,707)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,416)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivatives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,569)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,948)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,985)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, for the periods indicated, our revenues excluding the impact of Avive:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:55.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(dollars in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from Avive</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues excluding Avive</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">s</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the year ended December&#160;31, 2022, increased, $11,226 or 8.8%, to $138,584 as compared to $127,358 for the year ended December&#160;31, 2021. In 2022, our revenues continued to recover from the impact of the COVID-19 pandemic that began in early 2020 and negatively impacted hospital procedure volumes, as well as contributed to staffing and resources challenges. We saw improvements in revenues during 2022 as hospitals addressed resource and staffing challenges which improved the capacity and consistency of surgical procedure schedules. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues excluding Avive for the year ended December&#160;31, 2022, increased $15,300 or 12.4% to $138,584 as compared to $123,284, for the year ended December&#160;31, 2021. Revenue growth, excluding the impact of Avive in 2021, was driven by an increase in unit volume of approximately 7.3%, as well as the net impact of changes in price and product mix of approximately 3.7%. and 1.7%, respectively. The unit volume increase was attributed to growth in our core and active accounts. As of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, we had 968 active accounts, an increase of 2.9% from 941 from the prior year and 332 core accounts, an increase of 17.7% from 282 at December&#160;31, 2021, excluding the impact of revenues from Avive.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Gross Profit</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit for the year ended December&#160;31, 2022, increased $10,010 or 9.6% to $114,437 as compared to $104,427 for the year ended December&#160;31, 2021. Gross margin as a percentage of revenue increased to 82.6% for the year ended December&#160;31, 2022. as compared to 82.0% for the year ended December&#160;31, 2021. In 2021, we recorded a $1,429 charge reflecting the write-down of inventory and related production costs due to the suspension of Avive, which resulted in a 1.1% decrease in our gross margin.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Costs and Expenses</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total costs and expenses increased, $14,301 or 11.0%, to $144,144 for the year ended December&#160;31, 2022, as compared to $129,843 for the year ended December&#160;31, 2021. The increase in total operating costs was primarily attributable to the following (i) $8,980 in compensation costs of which $4,627 was non-cash stock compensation; (ii) $1,877 in research and development costs; (iii) $1,602 in travel costs; and (iv) $1,475 in occupancy cost and certain other cost.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing expenses increased $6,900, or 9.4%, to $80,228 for the year ended December&#160;31, 2022 as compared to $73,328 for the year ended December&#160;31, 2021. The increase in sales and marketing was due to an increase in compensation costs of $4,694 and $1,118 in travel costs, due to resumed in office and hospital visits during 2022 as the pandemic related restrictions in hospital access were lifted and travel normalized . </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $2,981, or 12.3%, to $27,158 for the year ended December&#160;31, 2022 as compared to $24,177 for the year ended December&#160;31, 2021. The increase was primarily due to product development and clinical expenses. Product development costs include spending for a number of specific programs including the non-clinical expenses related to the BLA for Avance Nerve Graft, a next generation Avance product, as well as product and application innovations across our nerve repair portfolio. It is expected that costs associated with the BLA will continue to increase as we continue to invest in completing the license application. Product development expenses represented approximately 52% and 53% of total research and development expense for the years ended December&#160;31, 2022, and 2021, respectively. Clinical trial expenses represented approximately 48% and 46% of total research and development expense for the years ended December&#160;31, 2022, and 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased $4,420, or 13.7%, to 36,758 for the year ended December&#160;31, 2022 as compared to $32,338 for the year ended December&#160;31, 2021. The increase was primarily due to non-cash stock compensation of $4,475, $241 of travel costs and $463 of occupancy costs, partially offset by lower professional and consulting fees of $1,608.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Income and Expense</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income increased $2,328, or 148.3% to income of $759 for the year ended December&#160;31, 2022, as compared to an expense of $1,569 for the year ended December&#160;31, 2021. The change was primarily due to the decrease in the fair value of the derivative liability of $1,072, the increase in investment income of $476 and decrease in interest expense of $732. In connection with the Credit Facility, we recognized total interest charges of $6,721 and $5,503 for the year ended December&#160;31, 2022, and 2021, respectively, and of this interest we capitalized to the construction of the APC Facility, interest charges of $6,155 and $4,277 for the year ended December&#160;31, 2022, and 2021, respectively. The increase in interest charges related to the Credit Facility was primarily due to our additional borrowings of $15,000 under the Credit Facility in June of 2021 and the increase in investment income was primarily related to the Federal Reserve raising interest rates 425 basis points throughout 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Income Taxes</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no income tax expense or benefit for the years ended December&#160;31, 2022, and 2021, due to the incurrence of net operating losses in both years, the benefits of which have been fully reserved. We do not believe that there are any additional tax expenses or benefits currently available.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_55"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our principal sources of liquidity were our cash and cash equivalents and investments totaling $48,789. Our cash equivalents are comprised of a money market mutual fund and our investments are comprised of short-term commercial paper and U.S. Treasuries. Our cash and cash equivalents and investments decreased $35,297 from $84,086 at December&#160;31, 2021, primarily as a result of continuing renovations of our APC Facility. On December&#160;31, 2022 and 2021, our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current assets exceeded our current assets liabilities by $74,322 and $102,756, respectively. Based on current estimates, we believe that our existing cash and cash equivalents and investments, as well as cash provided by sales of our products will allow us to fund our operations through at least through the next 12 months from the issuance of these financial statements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Information</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of our cash flows from operating, investing and financing activities:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:63.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,066)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,649)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalent</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,472)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,602)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Cash Used in Operating Activities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $16,066 and $13,405 during the years ended December&#160;31, 2022 and 2021, respectively. The unfavorable change in net cash used in operating activities of $2,661 or 19.9% was due to the following: (i) the net unfavorable change of $3,282 in working capital accounts and (ii) the increase in net loss of $1,963.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of net cash used in operating activities during the year ended December&#160;31, 2020 can be found in Item 7 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed on February 25, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Cash Used in Investing Activities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $3,200 as compared to $23,649 of for the years ended December&#160;31, 2022 and 2021, respectively, a decrease $20,449 or 86%. The change in net cash used in investing activities was due to the decrease in the net purchase and sale of investments totaling $14,252 and capital expenditures, primarily related to the renovation of the APC Facility, of $7,733. Capital expenditures was a significant use of cash in investing activities due to the renovation of the APC Facility, which we are scheduled to complete in the first half of 2023. Following the completion of the APC Facility renovation, we expect a decrease in capital expenditures, and thus in the cash used in investing activities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of net cash provided by investing activities during the year ended December&#160;31, 2020 can be found in Item 7 of our  Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed on February 25, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $1,794 as compared to $20,452 for the years ended December&#160;31, 2022, and 2021, respectively, a decrease of $18,658 or 91%. The change in net cash provided by financing activities was primarily due to no additional proceeds from draws on the Credit Facility during 2022 compared to a $15,000 drawdown of the Credit Facility in the second quarter of in 2021, and a decrease of $3,661 in proceeds from the exercise of stock options year-over-year.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of net cash provided by financing activities during the year ended December&#160;31, 2020 can be found in Item 7 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, filed on February 25, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Capital </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expected future capital requirements may depend on many factors including expanding our customer base and sales force and timing and extent of spending in obtaining regulatory approval and introduction of new products. Additional sources of liquidity available to us include issuance of additional equity securities through public or private equity offerings, debt financings or from other sources. The sale of additional equity may result in dilution to our shareholders. There is no assurance that we will be able to secure funding on terms acceptable to us, or at all. The increasing need for capital could also make it more difficult to obtain funding through either equity or debt. Should additional capital not become available to us as needed, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may be required to take certain actions, such as slowing sales and marketing expansion, delaying regulatory approvals, or reducing headcount.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations and Forward-Looking Cash Requirement</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">On July 9, 2019, we entered into a Standard Form of Agreement Between Owner and Design-Builder (the &#8220;Design-Build Agreement&#8221;) with CRB Builders, L.L.C., a Missouri limited liability company (&#8220;CRB&#8221;), pursuant to which CRB will renovate and retrofit the APC Facility. We anticipate spending between $3,500 and $4,500 in 2023. See Note 14 - Commitments and Contingencies. in the Notes to the Consolidated Financial Statements Part II, Item 8 of this Form 10-K.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">In addition to the APC capital expenditures, other capital expenditures on an annual basis generally range from $4,000 to $5,000 as a use of cash.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">We lease facilities in Florida, Ohio and Texas, as of December&#160;31, 2022, our total remaining obligation related to operating and financing lease payments was $37,352, of which $3,519 is due in 2023. See Note 8 - Leases in the Notes to the Consolidated Financial Statements Part II, Item 8 of this Form 10-K.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had $50,000 outstanding in indebtedness under a credit facility; $35,000 maturing on June 30, 2027 and $15,000 maturing on June 30, 2028. Quarterly interest only and revenue participation payments are due through each of the maturity dates. Interest is calculated as 7.5% plus the greater of the London Interbank Offered Rate ("LIBOR") or 2.0% (11.24% as of December&#160;31, 2022). Revenue participation payments are calculated as a percentage of our net revenues, up to $70,000 in any given year, adding approximately 1.0% per year of additional interest payments on the outstanding indebtedness. Upon each maturity date or upon such date earlier repayment occurs, we will repay the principal balance and provide a make-whole payment calculated to generate an internal rate of return to the lender equal to 11.5%, less the total of all quarterly interest and revenue participation payments previously paid. See Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees and Note 14 - Commitments and Contingencies in the Notes to the Consolidated Financial Statements Part II, Item 8 of this Form 10-K.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_58"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Contractual Obligations and Commitments</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8 - Leases and Note 14 - Commitments and Contingencies in the Notes to the Consolidated Financial Statements Part II, Item 8 of this Form 10-K, for further information.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_64"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our financial statements in accordance with generally accepted accounting principles, there are certain accounting policies, which may require substantial judgment or estimation in their application. We believe these accounting policies and the others set forth in Note 2 - Summary of Significant Accounting Policies in the Notes to the Consolidated Financial Statements Part II Item 8 of this Form 10-K are critical to understanding our results of operations and financial condition. Actual results could differ from our estimates and assumptions, and any such differences could be material to our results of operations and financial condition.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisting of purchased materials, direct labor and manufacturing overhead, are stated at the lower of cost or net realizable value, as determined by the first-in, first-out method. At each balance sheet date, we evaluate inventories for excess quantities, obsolescence or shelf-life. The evaluation includes analysis of historical sales levels by product, projection of future demand, general market conditions, a review of the shelf life based on the expiration dates for products. To the extent we determine there are excess or obsolete inventory or quantities with a shelf life that is too close its expiration for us to reasonably expect that we can sell those products prior to their expiration, we adjust the carrying value to the estimate net realizable value. While we believe the assumptions used to estimate the net realizable value are reasonable, there can be no assurance that the forecasted sales will be realized. As a result, additional reserves against inventories which would have been recognized in earlier periods may not be recognized until later periods if actual sales and net realizable values deviate unfavorably from forecasted sales estimates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review debt instruments to determine whether there are embedded derivative instruments, which are required to be bifurcated and accounted for separately as a derivative financial instrument. Embedded derivatives that are not clearly and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">closely related to the debt host are bifurcated and are recognized at fair value on the consolidated balance sheet with changes in fair value recognized as either a gain or loss on the consolidated statement of operations each reporting period. The fair value of embedded derivatives are measured based on equity markets and interest rates, as well as an estimate of our nonperformance risk adjustment. This estimate includes an option adjusted spread and an estimate of our risk-free rate.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation is in the form of stock options, restricted stock units ("RSU"), performance stock units ("PSU"), and recognized at, or above, the fair market value of our common stock on the date of grant.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of each stock option award on the date of grant using a multiple-point Black-Scholes option-pricing model. In addition, we measure stock options granted to employees at a premium price based on market conditions, such as the trading price of our common stock, using a Monte Carlo Simulation option-pricing model in estimating the fair value at the grant date.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the PSU grants is based on our closing stock price on the grant date. The number of PSU's that will ultimately be earned is based upon our performance as measured against specified targets over the measurement period. Expectations related to the achievement of performance goals associated with PSU grants is assessed as of each reporting period and is used to determine whether PSU grants are expected to vest. If performance-based milestones related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense related to the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) based on the estimated fair value of the options on the date of grant. We estimate the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of fair value using option-pricing models, as indicated above, is affected by our stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, our expected stock price volatility over the expected term of the awards. We determine the expected term of each award giving consideration to the contractual terms, vesting schedules, and post-vesting forfeitures. We use the risk-free interest rate on the implied yield available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected term of the award. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our consolidated statements of operations. Expense is reduced for forfeitures as they occur.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_67"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 - Summary of Significant Accounting Policies in the Notes to the Consolidated Financial Statements, Part II Item 8 of this Form 10-K for further information.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_70"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 7A.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to market risk from exposure to changes in interest rates based upon our investing and cash management activities. For our cash equivalents and investments, a change in interest rates affects the amount of interest income that can be earned.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into derivative transactions related to cash and cash equivalents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect changes in interest rates to have a material adverse effect on our income or our cash flows in 2023. However, we give no assurance that interest rates will not significantly change in the future. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have interest rate exposure as a result of the Credit Facility. As of December 31, 2022, the outstanding principal amount of our loans under the Credit Facility was $50,000. Interest on our loans under the Credit Facility is payable quarterly during the term of the loans and is calculated as 7.5% plus the greater of LIBOR or 2.0% (11.24% as of December&#160;31, 2022); provided that the interest rate shall never be less than 9.5%. Changes in the LIBOR rate may therefore affect our interest expense associated with the loans. An increase of 100 basis points in interest rates would increase expense by approximately $500 annually based on the amounts currently outstanding and would not materially affect our results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to credit risk consist of cash and cash equivalent balances, investments in commercial paper and accounts receivable. Certain of our cash and cash equivalents balances exceed Federal Deposit Insurance Corporation ("FDIC") insured limits or are invested in money market accounts with investment banks that are not FDIC-insured. As of March 14, 2023, we have approximately $8.0 million of cash at SVB, which funds are available to us. On March 12, 2023 by the U.S. Treasury, Federal Reserve, and FDIC announced that SVB depositors will have access to all of their money starting March 13, 2023, including those funds exceeding the FDIC insured limits. Our investment portfolio currently does not contain any securities of SVB. As of December&#160;31, 2022, $15,034 of the cash and cash equivalents balance was in excess of FDIC limits.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest our cash primarily in commercial paper, money market accounts, and U.S. government securities. Although we believe our cash is invested in a conservative manner, with cash preservation being the primary investment objective, the value of the commercial paper held will fluctuate with changes in the financial markets, including, among other things, changes in interest rates, credit quality and general volatility. This risk is managed by investing in high quality investment grade commercial paper with short-term maturities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to accounts receivable, we perform credit evaluations of our customers and do not require collateral. There have been no material losses on accounts receivable. Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up our customer base, thus spreading the trade credit risk. We also control credit risk through credit approvals and monitoring procedures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of the U.S. dollar compared to the foreign currencies of the countries where we distribute our products has little to no effect on our financial results. In our international markets, we distribute our products and services to independent distributors who, in turn, distribute and market to medical clinics. The revenue from the distribution of our products in our international markets through independent distributors is denominated in U.S. dollars. As a result, we have minimal exposure related to foreign exchange rate fluctuations. Our portfolio of products is currently available in the U.S., Canada, Germany, United Kingdom ("UK"), Spain and several other European, Asian and Latin American countries.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTENTS</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:93.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_76">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID No</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83My9mcmFnOmUzZWU4NDhiNTEzNTQ5M2U4NGY1OTUzZDJmYjMzYjczL3RhYmxlOjlhODZjYmU2YjMyMjQ1YWU5Zjc2YjFiZDM1NTM1ZTNmL3RhYmxlcmFuZ2U6OWE4NmNiZTZiMzIyNDVhZTlmNzZiMWJkMzU1MzVlM2ZfMi0wLTEtMS0xMDI0MzEvdGV4dHJlZ2lvbjozNzcyZmRlMmE4ZDc0ZDljODM0MmIwZmQ4YTA5ZGI4Y183NA_33cc46e0-6f0a-455d-a76d-cca3558fee53">34</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_76">)  </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_76">66</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_79">CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2022 AND 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_79">68</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_82">CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2022, 2021 AND 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_82">69</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_85">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY FOR THE YEARS ENDED DECEMBER 31, 2022, 2021 AND 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_85">70</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_88">CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2022, 2021 AND 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_88">71</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_91">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_91">73</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_181">SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_181">103</a></span></div></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:83%">To the shareholders and the Board of Directors of Axogen, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:91%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Axogen, Inc and subsidiaries (the "Company") as of December 31, 2022 and 2021, the related consolidated statements of operations, shareholders&#8217; equity, and cash flows, for each of the three years in the period ended December 31, 2022, and the related notes and the schedule listed in the Index at Item 15(a)(2) (collectively referred to as the "financial statements"). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021 and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America, Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:91%">Basis for Opinions</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on these financial statements and an opinion on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Definition and Limitations of Internal Control over Financial Reporting </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:83%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:91%">Inventory &#8211; Valuation Associated with Excess and Obsolete (E&amp;O) Inventory &#8212; Refer to Notes 2 and 3 to the financial statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or net realizable value. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf-life.The Company monitors the shelf-life of its products and historical expiration and spoilage trends and writes down inventory based on the estimated amount of inventory that will not be distributed before expiration or spoilage. To estimate the amount of inventory that will expire prior to being distributed, the Company reviews inventory quantities on hand, historical and projected distribution levels, and historical expiration trends. The Company&#8217;s calculation of the amount of inventory that will expire prior to distribution has two components: 1) a demand or consumption-based component that compares projected distribution to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being distributed. The Company&#8217;s model assumes that inventory will be distributed on a first-in-first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that a significant portion of the Company&#8217;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written down involves significant judgments and estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant judgments associated with evaluating the valuation of E&amp;O inventory, auditing the reasonableness of management&#8217;s estimates and assumptions involved especially subjective judgment and an increased extent of effort.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:91%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Our audit procedures related to the Company&#8217;s valuation of E&amp;O inventory included the following, among others: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">We tested the design, implementation and operating effectiveness of controls over the E&amp;O inventory valuation. The controls we tested included those over the calculation and accuracy and completeness of underlying data used in the calculation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">We performed procedures to evaluate management&#8217;s ability to accurately forecast by comparing the historical expiring inventory estimates to subsequent inventory destructions and expirations.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%;padding-left:14.5pt">We obtained the Company&#8217;s E&amp;O calculation and tested the mathematical accuracy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">We assessed the reasonableness of the assumptions used in the E&amp;O calculation by developing an independent expectation and comparing our independent expectation to the results of the Company&#8217;s calculation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">We tested the accuracy and completeness of the underlying data used in the calculation of the Company&#8217;s expiring inventory model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:95%;padding-left:14.5pt">We made inquiries of the Company&#8217;s employees outside of the accounting department and evaluated other areas of the audit to identify business, product, or industry changes that may impact the inputs in the inventory valuation calculation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:95%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ <ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83Ni9mcmFnOmZhYWVjNTJjNGMyZjRmY2E4YzNhNWVjYTQ2MzBiMjgzL3RleHRyZWdpb246ZmFhZWM1MmM0YzJmNGZjYThjM2E1ZWNhNDYzMGIyODNfOTQwOA_cb819397-327a-48da-a63e-1d2482011a84">Deloitte &amp; Touche LLP</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83Ni9mcmFnOmZhYWVjNTJjNGMyZjRmY2E4YzNhNWVjYTQ2MzBiMjgzL3RleHRyZWdpb246ZmFhZWM1MmM0YzJmNGZjYThjM2E1ZWNhNDYzMGIyODNfOTQwOQ_c148733b-9959-4349-bdd4-5a3c58b096ce">Miami, Florida</ix:nonNumeric> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 14, 2023</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have served as the Company's auditor since 2018.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AXOGEN,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022 and 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Thousands, Except Share and Per Share Amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMy0xLTEtMS0xMDI0MzE_727c03af-7854-4db2-9474-48b01d0e1dad">15,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMy0zLTEtMS0xMDI0MzE_65c41896-6b75-426b-8c4d-f50873845bc1">32,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNC0xLTEtMS0xMDI0MzE_76afe812-3128-4829-b733-b34673ac0769">6,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNC0zLTEtMS0xMDI0MzE_ed397614-46f7-4dcc-a28f-82457df6c72d">6,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNS0xLTEtMS0xMDI0MzE_a9654362-6100-4575-b009-401d968ef1e8">33,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNS0zLTEtMS0xMDI0MzE_6ceb5b00-114c-4e7e-bac0-13c27ccdadc7">51,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNi0wLTEtMS0xMDI0MzEvdGV4dHJlZ2lvbjpmOTgxYTA5OTVjMDk0N2RmOTQ5ZTg0YmMwYmQ5NTNjYl82Nw_f2a1b32d-a00c-4a1c-9506-7443b4cf1ee6">650</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNi0wLTEtMS0xMDI0MzEvdGV4dHJlZ2lvbjpmOTgxYTA5OTVjMDk0N2RmOTQ5ZTg0YmMwYmQ5NTNjYl83NA_2a7c569b-0d0e-4bb9-b5a3-db4fcd68abc7">276</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNi0xLTEtMS0xMDI0MzE_8ef9b5e2-c795-4a34-aa75-b50ddec67320">22,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNi0zLTEtMS0xMDI0MzE_f95f28ed-f9b0-4b71-be90-6678f53ce13f">18,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNy0xLTEtMS0xMDI0MzE_313a0b55-8eb0-4e12-98fa-21315ab68ad9">18,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNy0zLTEtMS0xMDI0MzE_0e84d523-829a-4ca5-baf5-fe38e8d9e5ff">16,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfOC0xLTEtMS0xMDI0MzE_8cf99c54-cfbd-4437-b60e-1ddcd09d0206">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfOC0zLTEtMS0xMDI0MzE_4511d28e-1179-44ef-982a-1dd2a35c1061">1,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfOS0xLTEtMS0xMDI0MzE_8e7deb34-4f44-4538-8bef-cc21bc973eb4">98,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfOS0zLTEtMS0xMDI0MzE_6d77bad5-629c-4a69-af81-9d7d70dbb279">127,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTAtMS0xLTEtMTAyNDMx_e6607ed9-04cb-45d5-8bb0-a02a80e6446c">79,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTAtMy0xLTEtMTAyNDMx_e1898430-88d3-45a2-b33d-96f70ee9a4f7">62,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTEtMS0xLTEtMTAyNDMx_0eeecafd-2b26-4b3e-9bcf-887ef5e04176">14,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTEtMy0xLTEtMTAyNDMx_aca204c8-8ea2-4fd7-bf94-ceacd31cb852">15,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTMtMS0xLTEtMTAyNDMx_bf25044b-3578-4de2-8670-114ef2f945d4">3,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTMtMy0xLTEtMTAyNDMx_8aa0db78-4b6b-4e35-bbcb-d16137127d9f">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTQtMS0xLTEtMTAyNDMx_2f21bf40-bb17-4524-b747-0c2560ecd61a">195,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTQtMy0xLTEtMTAyNDMx_234e30ee-dbb8-480d-84fd-2e09ff394910">208,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTgtMS0xLTEtMTAyNDMx_ab6950e0-da9f-4a7c-a752-dcd0ed131e07">22,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTgtMy0xLTEtMTAyNDMx_05aef2c0-66e6-441b-aa1d-88989aa580fe">22,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current maturities of long-term lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:LeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTktMS0xLTEtMTAyNDMx_3456f161-d703-4b7a-a819-cb1f49dfa6da">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="axgn:LeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTktMy0xLTEtMTAyNDMx_c71c7198-abc0-4164-acee-3af9d716593e">1,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjAtMS0xLTEtMTAyNDMx_f339e8df-1078-4b89-a49c-4614d6a8bcc5">23,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjAtMy0xLTEtMTAyNDMx_e31a202f-0ec6-43b6-ac0e-2b104cecc8d2">24,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-term debt, net of debt discount and financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjItMS0xLTEtMTAyNDMx_3b26eba8-af57-434d-8cc3-050d93d329b6">45,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjItMy0xLTEtMTAyNDMx_a4fa2744-2815-43eb-a63f-77e64cc0ea88">44,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-term lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:LeaseLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjMtMS0xLTEtMTAyNDMx_90db9367-1171-468d-aeaa-d89f22e95b37">20,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="axgn:LeaseLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjMtMy0xLTEtMTAyNDMx_46ac090c-9878-4702-b39b-a62135d53592">20,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjQtMS0xLTEtMTAyNDMx_4035a704-8ee3-4ea8-8934-bbff138a657f">4,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjQtMy0xLTEtMTAyNDMx_5ad8bbe2-be8a-4951-9d3d-36fb0d5dcdb1">5,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjYtMS0xLTEtMTAyNDMx_8c02185b-f743-4316-948f-02e28d15736b">94,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjYtMy0xLTEtMTAyNDMx_c63a7c91-bcff-49d7-897d-53ded37a9a6e">95,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 19pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and contingencies - see Note 14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjgtMS0xLTEtMTAyNDMx_edd4c5d0-3c60-4f03-8020-7745eb512644"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjgtMy0xLTEtMTAyNDMx_4cd8c0d8-94b4-4280-a587-bd5abe683450"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfMTg_a4fd23d6-1357-4e95-b511-7b36939e91eb"><ix:nonFraction unitRef="usdPerShare" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfMTg_dc291027-212d-4f6c-b674-59657727485e">0.01</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNDI_6e8d6e16-92dd-4ac5-85fd-8e4ee0467f76"><ix:nonFraction unitRef="shares" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNDI_7a23e93b-00ad-41a0-b560-1d585de11de1">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNjQ_323be743-8480-4cba-8153-247dcb699b38"><ix:nonFraction unitRef="shares" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNjQ_d118c35b-9b17-4077-9198-6606879997f2">42,445,517</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNzE_7f73b344-9964-4d10-81ab-48e457aae899"><ix:nonFraction unitRef="shares" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNzE_da2191ed-42c9-46bb-a354-7bbfcea8fdcd">41,736,950</ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMS0xLTEtMTAyNDMx_74ff4c8e-541c-4bab-8de9-f8b067d0465f">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMy0xLTEtMTAyNDMx_40afa51a-6661-4b65-845e-215879ae04d6">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzItMS0xLTEtMTAyNDMx_a728f3b4-e2aa-4f7a-a05c-c2fd2e3985e3">360,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzItMy0xLTEtMTAyNDMx_271b7c84-effe-464c-a383-eb055be5940e">342,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzMtMS0xLTEtMTAyNDMx_f1828f09-9e11-4468-95c4-d70719e84290">259,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzMtMy0xLTEtMTAyNDMx_4e0ba9e8-2cfc-451a-a5a3-b5704b35aebb">230,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzQtMS0xLTEtMTAyNDMx_2d1760fe-fabe-443c-9d00-1624e2b58ea5">100,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzQtMy0xLTEtMTAyNDMx_18762176-b457-40cf-8941-55ad5fe2c15f">112,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzUtMS0xLTEtMTAyNDMx_9423556a-1f36-4598-b938-002b8920d6b1">195,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzUtMy0xLTEtMTAyNDMx_974d7a70-e5de-4904-abbd-4cb8ea361aa5">208,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AXOGEN,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December&#160;31, 2022, 2021 and 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Thousands, Except Share and Per Share Amounts)</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMS0xLTEtMS0xMDI0MzE_fc072238-ec48-45cf-b145-4edda981d0ad">138,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMS0zLTEtMS0xMDI0MzE_b7c5bcb9-cf8b-4c00-970c-e2d451b5ed7a">127,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMS01LTEtMS0xMDI0MzE_c0f3bbdb-2a23-43d2-9536-29af467c75cd">112,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMi0xLTEtMS0xMDI0MzE_f223d375-e73b-4c4c-b82b-67ee665d4efc">24,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMi0zLTEtMS0xMDI0MzE_9652658e-85c1-42a9-9f16-15db968944a9">22,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMi01LTEtMS0xMDI0MzE_9732542d-5f46-4f74-9756-1a19a0913f59">21,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMy0xLTEtMS0xMDI0MzE_c8469871-b775-416f-9225-bb7229375a49">114,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMy0zLTEtMS0xMDI0MzE_5ac6e3ec-c092-4d33-adec-25486ae3b97a">104,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMy01LTEtMS0xMDI0MzE_ffea8db7-9019-45f1-b95e-6d050eb255a2">90,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNS0xLTEtMS0xMDI0MzE_be5bea32-cc1b-4c76-ad09-86e2b0fefd45">80,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNS0zLTEtMS0xMDI0MzE_6794fb71-504c-41d7-b5f6-4d6f1a7e7058">73,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNS01LTEtMS0xMDI0MzE_738b833b-541f-4d41-9866-42d1f15b521b">69,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNi0xLTEtMS0xMDI0MzE_3a4debff-7055-45a7-9530-bdd69e7ab0cc">27,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNi0zLTEtMS0xMDI0MzE_a799b220-8eb2-4693-aacf-62e1e8ff7d8a">24,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNi01LTEtMS0xMDI0MzE_889d65c8-1ddd-41f2-a8e9-3664aaec302d">17,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNy0xLTEtMS0xMDI0MzE_1f82f7ff-49eb-47da-920d-b47a326f1130">36,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNy0zLTEtMS0xMDI0MzE_a724f7de-7ed0-47c2-a499-c329c8c9e2d7">32,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNy01LTEtMS0xMDI0MzE_5451ed91-508a-4843-a60c-d934c89d778c">26,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOC0xLTEtMS0xMDI0MzE_3e1561ab-3634-4d34-9ab5-18b2743e0fe7">144,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOC0zLTEtMS0xMDI0MzE_b0cf5324-632c-4282-99de-fd09a61657d8">129,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOC01LTEtMS0xMDI0MzE_805255ff-1e6c-4605-9e87-5d4f40a589e2">113,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOS0xLTEtMS0xMDI0MzE_f235fbef-48f1-4bf2-802e-a440a34be3c9">29,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOS0zLTEtMS0xMDI0MzE_c6c4d727-4b0e-46cd-b7d2-ad5fe2ab0a2f">25,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOS01LTEtMS0xMDI0MzE_0752a88c-c154-4d6d-91b4-49e8681569a7">23,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTEtMS0xLTEtMTAyNDMx_f7c1c635-2737-46ac-bf72-7a8b954f861b">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTEtMy0xLTEtMTAyNDMx_b6903d1e-2921-434e-9977-169986b36558">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTEtNS0xLTEtMTAyNDMx_4b7d166b-ee4a-4e61-86f1-0836e603bb02">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTItMS0xLTEtMTAyNDMx_75eb3519-a37c-4b68-bd0a-8c501a7f8e36">624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTItMy0xLTEtMTAyNDMx_5c36c5d4-9edd-4dd1-92e9-c204fd3caeb2">1,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTItNS0xLTEtMTAyNDMx_e39d925b-14d1-4ca9-9bbf-f9c70abf9e87">1,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of derivatives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTMtMS0xLTEtMTAyNDMx_c0ffd297-fcaf-48aa-93de-f453edc2c5b6">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTMtMy0xLTEtMTAyNDMx_1bed0613-57ea-4df9-b117-a3b055d5095a">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTMtNS0xLTEtMTAyNDMx_f98b8af2-81ce-4a0b-92e8-8807c480f69d">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTUtMS0xLTEtMTAyNDMx_8578d1dc-b3b3-4dc5-a41c-98ee72e98989">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTUtMy0xLTEtMTAyNDMx_11de82fd-f666-48f5-8128-5557982b7914">278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTUtNS0xLTEtMTAyNDMx_5089c735-9b36-43f3-802f-3cd5fdcba726">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTYtMS0xLTEtMTAyNDMx_850dfbd3-e14f-4889-8b4c-35fc914af770">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTYtMy0xLTEtMTAyNDMx_73bc7637-e09c-4504-b2ea-2cc6893809f2">1,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTYtNS0xLTEtMTAyNDMx_ec0bdb5b-d7bf-4ba1-9f00-e481d6305744">604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTctMS0xLTEtMTAyNDMx_a80f770a-bc04-495d-8d35-8047859901b4">28,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTctMy0xLTEtMTAyNDMx_07326441-74f6-45d2-ad5d-c1b3b1f76c2a">26,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTctNS0xLTEtMTAyNDMx_f7d02799-eb65-49ea-b948-669fa3230e59">23,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average common shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMS0xLTEtMTAyNDMx_2d448aa0-8bbf-4519-be72-34d2e6721c48"><ix:nonFraction unitRef="shares" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMS0xLTEtMTAyNDMx_513e9d47-1a2b-4b26-b372-21e6bb23e38d"><ix:nonFraction unitRef="shares" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMS0xLTEtMTAyNDMx_84179dbf-4da7-4e7f-b270-4d8a281f5bd1"><ix:nonFraction unitRef="shares" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMS0xLTEtMTAyNDMx_b055903e-52ce-4473-9a18-8fcb0276264d">42,083,125</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMy0xLTEtMTAyNDMx_0f98db8a-b32b-454d-97c0-899d0c733c75"><ix:nonFraction unitRef="shares" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMy0xLTEtMTAyNDMx_e121a3d8-aaa8-4c90-b193-7140b912bed9">41,214,889</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktNS0xLTEtMTAyNDMx_385258be-71be-442a-ae66-afba20e3ad90"><ix:nonFraction unitRef="shares" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktNS0xLTEtMTAyNDMx_a62741fb-290a-4852-a606-4d2c92e16914">39,966,937</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtMS0xLTEtMTAyNDMx_1ae5018d-3e61-411f-80a0-2a3c63c363af"><ix:nonFraction unitRef="usdPerShare" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtMS0xLTEtMTAyNDMx_df915d32-3620-416a-8f2b-afbf0146b118">0.69</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtMy0xLTEtMTAyNDMx_18009c9a-81bc-4859-8651-d033587728e7"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtMy0xLTEtMTAyNDMx_1d16f6fd-ece4-43ea-97af-2f6c57fcd9fd">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtNS0xLTEtMTAyNDMx_8484f0db-6850-449c-9186-2f6b3c0c7f34"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtNS0xLTEtMTAyNDMx_8492cad2-44c4-444f-a507-c9df09b5e33f">0.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AXOGEN,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December&#160;31, 2022, 2021 and 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Shareholders&#8217;<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idf515d9a7de44eff9aae0e17da62fba2_I20191231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMi0xLTEtMS0xMDI0MzE_1061258c-9d16-4a10-8f6f-836157471e1e">39,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idf515d9a7de44eff9aae0e17da62fba2_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMi0zLTEtMS0xMDI0MzE_004bf029-571b-43a4-8f8d-0772a12b039d">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i11a07c1ba89f4e78b9f41a1b28db3e2e_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMi01LTEtMS0xMDI0MzE_31249b1a-63e7-48b1-8550-8051bfea984a">311,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i020f70d532cd4985bbe689c32516cea3_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMi03LTEtMS0xMDI0MzE_a0100628-36b0-43c7-a860-f418fdef21de">179,861</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i91b861abf62b4326b086bd6c32bdcf69_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMi05LTEtMS0xMDI0MzE_73256970-e6d3-4e37-a945-700e32a98376">132,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNC01LTEtMS0xMDI0MzE_3a6db523-a627-43c0-99a3-2571a8693d9c">8,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNC05LTEtMS0xMDI0MzE_806ebd56-096c-42c2-89ea-c6e57e3e84c3">8,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of restricted and performance stock units </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS0xLTEtMS0xMTY4NzA_7430532d-1aa4-49e6-a4b0-9ab2b7a0ba76">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS0zLTEtMS0xMTY4NzY_88ed2c2d-f8c5-4b62-ac3a-447d16606495">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS01LTEtMS0xMTY4ODY_72b9580c-89fa-4c84-a2ee-e4f1d7dac2ea">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS05LTEtMS0xMTY4OTg_949f0769-d629-4ee1-afbe-010cf9daa2e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares surrendered by employees to pay tax withholdings </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi0xLTEtMS0xMTY5MDY_220dc78c-6677-4633-b9e5-2301da75827e">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi01LTEtMS0xMTY5MjI_da63131b-7b89-479e-99da-8aa02b397e15">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi05LTEtMS0xMTY5Mzg_cc93261d-7b21-4b06-8109-e39777d6f092">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of stock options and employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231" decimals="-3" name="axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS0xLTEtMS0xMDI0MzE_67db38b5-590d-449d-8052-47712a080fcf">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231" decimals="-3" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS0zLTEtMS0xMDI0MzE_50aaff58-aef6-4ddb-9ff1-09fb07338c42">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231" decimals="-3" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS01LTEtMS0xMDI0MzE_a42ef17a-cd7d-478b-9e5e-f0e10da6ce8c">3,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS05LTEtMS0xMDI0MzE_3073232e-4ebe-4cbc-b19d-3dc1b4c5bca3">3,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercise of Credit Facility Option, net of settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231" decimals="-3" name="axgn:StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi0xLTEtMS0xMDI0MzE_b4cf6932-b13a-4611-a81c-c91df6262972">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231" decimals="-3" name="axgn:StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi0zLTEtMS0xMDI0MzE_db3d073a-7c35-4370-82e3-ef377e5a7d55">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231" decimals="-3" name="axgn:StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi01LTEtMS0xMDI0MzE_0c0388a3-8e7c-411f-9ed3-6c2c17e749a3">3,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="axgn:StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi05LTEtMS0xMDI0MzE_01aff42b-3af2-4f8b-9485-ed27fc2f6658">3,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i70b02bce882f4530a644cf1f4de1281a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNy03LTEtMS0xMDI0MzE_2976496c-41d8-4c42-b83a-398a2d921e6b">23,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNy05LTEtMS0xMDI0MzE_c5f0eacd-e8f8-455d-b60e-b42245635fe4">23,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i45cc08a71962457c8a2b55f8d7a4d39a_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfOS0xLTEtMS0xMDI0MzE_e9d565c3-fed1-426b-b492-0d3360709d1c">40,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i45cc08a71962457c8a2b55f8d7a4d39a_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfOS0zLTEtMS0xMDI0MzE_8b9722bd-779a-4ae4-8c15-775554baa128">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i988505ce34a844a09623ae3c12d8ec87_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfOS01LTEtMS0xMDI0MzE_46a33800-7d64-4c5e-8521-34b40b1afe0e">326,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8f968e20d3bf41eebd5e2ffa7bb615b7_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfOS03LTEtMS0xMDI0MzE_82bdcd1f-a7af-486e-8ed6-0be09dc266b0">203,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ied6b9724c05f4cb3a66af446b51ae49e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfOS05LTEtMS0xMDI0MzE_c84edd43-0da7-44d3-aac4-616d734cb038">123,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i404b822cbf2e4fe08c667eb2554e74c4_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTEtNS0xLTEtMTAyNDMx_5dbfae0a-5ac6-4dfe-be57-01cbbc351796">10,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTEtOS0xLTEtMTAyNDMx_c417361c-84fd-4729-ade6-c8aff8a25489">10,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted and performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if0df7a1efdb049cfa90a2524886d1252_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTItMS0xLTEtMTAyNDMx_e3007f81-c994-4d9d-9eb0-a96dbfc643b8">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0df7a1efdb049cfa90a2524886d1252_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTItMy0xLTEtMTAyNDMx_1a81e9ad-b3d1-4697-b0e8-c75a4b7f62ca">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i404b822cbf2e4fe08c667eb2554e74c4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTItNS0xLTEtMTAyNDMx_0a77c2d4-1ab4-4a7e-b92e-f37c6929a65d">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTItOS0xLTEtMTAyNDMx_6bff7f6c-4db1-4bd2-961a-e890ddd8a37c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="if0df7a1efdb049cfa90a2524886d1252_D20210101-20211231" decimals="-3" name="axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTQtMS0xLTEtMTAyNDMx_84953b93-14cb-45c4-8e1e-1530813b6648">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if0df7a1efdb049cfa90a2524886d1252_D20210101-20211231" decimals="-3" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTQtMy0xLTEtMTAyNDMx_d77e222a-decf-45fb-8771-88c03b2dbd91">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i404b822cbf2e4fe08c667eb2554e74c4_D20210101-20211231" decimals="-3" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTQtNS0xLTEtMTAyNDMx_79985777-e1ab-444c-a815-3637283c6e40">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTQtOS0xLTEtMTAyNDMx_7b53e416-4ad6-4d72-83e4-b18316ebb2f9">5,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i48bde1d6124b4ea78c970234e62219ab_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTYtNy0xLTEtMTAyNDMx_ed6d1a1d-1861-475d-ba23-05a6d719492d">26,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTYtOS0xLTEtMTAyNDMx_39e49eb7-30dc-4424-b814-b8ef4847e9f0">26,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie35d0ad377f844a4a7e48534c50caff4_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTgtMS0xLTEtMTAyNDMx_d07ef018-3543-4c77-bb2e-02e318fa3540">41,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie35d0ad377f844a4a7e48534c50caff4_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTgtMy0xLTEtMTAyNDMx_7cd85176-90d9-454c-96d6-498764f864cf">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8158cb4740e7427188f9ee3550c9230b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTgtNS0xLTEtMTAyNDMx_e0f4c7ea-4109-45c4-b93e-3766e1fbeeb2">342,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic23f7a20a5a44ab7b5e3f093917b8c03_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTgtNy0xLTEtMTAyNDMx_7e4180c7-bb70-45a8-9d00-b95d8904a782">230,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTgtOS0xLTEtMTAyNDMx_9fb1a56e-7980-4353-b82b-4c68ea5cfeb7">112,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e2bc0aacfa402f813dddb588b6267f_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjAtNS0xLTEtMTAyNDMx_c645b670-260f-4af6-ac36-8ef029d5206b">15,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjAtOS0xLTEtMTAyNDMx_65371581-d027-4bc1-b0eb-d313e17c64e1">15,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of restricted and performance stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec80f298a69e4799b67c597636a9f301_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjEtMS0xLTEtMTAyNDMx_f26f55e7-6b37-40b3-bff8-b1e94662fda4">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec80f298a69e4799b67c597636a9f301_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjEtMy0xLTEtMTAyNDMx_dbb1a249-66ef-41a8-8898-67d32a604f0a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81e2bc0aacfa402f813dddb588b6267f_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjEtNS0xLTEtMTAyNDMx_0c211a7b-98c0-497b-b704-95e47e6715f8">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjEtOS0xLTEtMTAyNDMx_018d5eed-4505-41ea-9be2-b3ee09cf09cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise of stock options and employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec80f298a69e4799b67c597636a9f301_D20220101-20221231" decimals="-3" name="axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjMtMS0xLTEtMTAyNDMx_d5678cc7-f4f0-4ff4-b243-5cc8cd06db1e">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec80f298a69e4799b67c597636a9f301_D20220101-20221231" decimals="-3" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjMtMy0xLTEtMTAyNDMx_e4f4cf16-e55f-4c4d-9455-d6897fb4c47f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e2bc0aacfa402f813dddb588b6267f_D20220101-20221231" decimals="-3" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjMtNS0xLTEtMTAyNDMx_d0f2a974-ee2a-4ca4-950d-f16919e71a22">1,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjMtOS0xLTEtMTAyNDMx_6801f60e-55da-495c-b0cb-680bff40dce7">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d3fa1437edd43a5b85f3cf6a86ed7df_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjUtNy0xLTEtMTAyNDMx_a7b10e5b-8a98-4b54-a4a8-5a250ec25abe">28,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjUtOS0xLTEtMTAyNDMx_e6fa335c-b755-45ab-88d5-adfaa4d4cddb">28,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i64198b8113a54a908aaacc22c63099fa_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjctMS0xLTEtMTAyNDMx_0c97ca34-6d83-4451-ada8-a264cf597d7b">42,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i64198b8113a54a908aaacc22c63099fa_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjctMy0xLTEtMTAyNDMx_edc0d993-9895-432e-b4d5-91bd89989a12">424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0e263d574089497289c6eefc50c18244_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjctNS0xLTEtMTAyNDMx_dfc36e00-5d53-4c9e-88fb-70003c25890e">360,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i26cf5637ad1d4822b296d27f9963de73_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjctNy0xLTEtMTAyNDMx_a278f94c-3f54-43e3-848d-95bf9fa909a6">259,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjctOS0xLTEtMTAyNDMx_bbc27fbc-0471-4a6a-bf22-bda42deab64d">100,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AXOGEN,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December&#160;31, 2022, 2021 and 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMi0xLTEtMS0xMDI0MzE_c6f4f912-ceec-4aa5-a1f2-85027feac5b7">28,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMi0zLTEtMS0xMDI0MzE_fd3b2ba8-7267-4751-a29c-658e3fa394fc">26,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMi01LTEtMS0xMDI0MzE_f5e96c8c-45ab-4186-bf90-2cdc1086e067">23,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNC0xLTEtMS0xMDI0MzE_0180378a-853d-4ec8-87c5-680583eb961e">2,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNC0zLTEtMS0xMDI0MzE_8b306db5-9a3c-4e61-931b-da739475fa1d">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNC01LTEtMS0xMDI0MzE_54227d74-dc0c-4bf0-9e7c-903cdcd5d674">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="axgn:RightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNS0xLTEtMS0xMDI0MzE_46c47474-d8c0-44a7-9053-8c64ceb7e772">1,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="axgn:RightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNS0zLTEtMS0xMDI0MzE_56135db2-0a10-4124-8b35-79392e466f0a">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="axgn:RightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNS01LTEtMS0xMDI0MzE_c5a16100-d4dc-474c-b919-73138669ff65">1,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNi0xLTEtMS0xMDI0MzE_4f770e4c-dfb1-46dc-b82e-0bb20a6a333b">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNi0zLTEtMS0xMDI0MzE_fba0c675-47c3-443e-8024-e53c2661f294">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNi01LTEtMS0xMDI0MzE_569fe9d4-3ffb-45c9-b04d-bdd3f514f846">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Amortization of debt discount and deferred financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOC0xLTEtMS0xMDI0MzE_ae2a6e1b-45d7-496b-ab88-2a666c4c3427">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOC0zLTEtMS0xMDI0MzE_f11846c4-987f-4d07-90a6-69b9dcfec8e6">831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOC01LTEtMS0xMDI0MzE_11128781-b7e2-41e6-8791-2aaa6061e227">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Loss on disposal of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOS0xLTEtMS0xMDI0MzE_12bf95fa-b463-4abc-8b0b-00e9fc4d234c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOS0zLTEtMS0xMDI0MzE_dceb88e4-c76b-4567-b880-80352dea40a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOS01LTEtMS0xMDI0MzE_f3702fc4-0b3e-4eec-a553-9d7687fbff52">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Provision for bad debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTEtMS0xLTEtMTAyNDMx_1dde4aa4-96b7-47e7-8d44-dc9c1e6d8abe">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTEtMy0xLTEtMTAyNDMx_b25d0931-014b-4ba4-a303-2289905fce9d">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTEtNS0xLTEtMTAyNDMx_e3354cb8-d616-4dc6-94ac-afe83f75673a">105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Provision for inventory write-down</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTItMS0xLTEtMTAyNDMx_039827a0-9299-45f5-ab29-84dba7bb82c9">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTItMy0xLTEtMTAyNDMx_b2002297-8fe1-455f-86a3-58d171a5da38">3,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTItNS0xLTEtMTAyNDMx_96ec12bf-d83e-41d3-a708-334864bbb080">2,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Investment losses (gains)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTMtMS0xLTEtMTAyNDMx_3847b3b8-b679-4b97-b5f7-7042696287d4">228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTMtMy0xLTEtMTAyNDMx_ce84cae8-1400-4280-a309-1893951f3b5d">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTMtNS0xLTEtMTAyNDMx_a561f563-ceae-461d-8a0b-2e627a450e93">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Change in fair value of derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTQtMS0xLTEtMTAyNDMx_cff45f06-9288-4c5f-8f47-6397a8b5b76a">1,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTQtMy0xLTEtMTAyNDMx_9022d5b8-836a-4753-a09e-49e04e26aa75">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTQtNS0xLTEtMTAyNDMx_c9c52ec8-3bcc-42bb-92eb-d37b7fa54000">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTUtMS0xLTEtMTAyNDMx_be1c65e1-7085-4dc4-834b-d23e5854cfd6">15,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTUtMy0xLTEtMTAyNDMx_7ff27f0f-2ef7-4b2b-8f07-07d689ec5ee8">10,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTUtNS0xLTEtMTAyNDMx_adcd4b18-6f91-4ea9-818a-27dd7a62c6b3">8,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTctMS0xLTEtMTAyNDMx_c78daaaa-7a0a-40ef-9643-086e811a9031">4,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTctMy0xLTEtMTAyNDMx_e195bf51-9df5-4933-898f-1273ccd1b7a1">499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTctNS0xLTEtMTAyNDMx_c1931ed5-beea-4ed6-8544-725e31e4ed10">635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTgtMS0xLTEtMTAyNDMx_8107e9b8-c9e0-4ed0-ac28-90fd4372831c">3,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTgtMy0xLTEtMTAyNDMx_08315cfd-e376-4b4f-b678-919dda3b7a33">7,478</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTgtNS0xLTEtMTAyNDMx_eb07af45-c77e-4b34-a052-2a861b3c4e19">910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTktMS0xLTEtMTAyNDMx_29a5a43b-70ab-4272-875a-85b4e6183584">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTktMy0xLTEtMTAyNDMx_294cf3c8-7b4f-442c-8993-5e933eb3f5c1">2,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTktNS0xLTEtMTAyNDMx_917fdf2b-a791-4217-8fa2-e99ce33f4b4f">2,524</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjAtMS0xLTEtMTAyNDMx_87d9f6d0-34f2-4c2f-8baa-8c62a4d1c15f">660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjAtMy0xLTEtMTAyNDMx_4b82767a-deb7-4350-bb9d-ffab232e014e">270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjAtNS0xLTEtMTAyNDMx_3c998379-0650-495d-8d39-395a0f251bae">4,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Operating lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="axgn:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjEtMS0xLTEtMTAyNDMx_7c3c9005-ddb3-4b1b-9619-71a3aa05498f">1,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="axgn:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjEtMy0xLTEtMTAyNDMx_dfee9e78-c9c3-4d0a-b4d7-c30d7c6b6645">463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="axgn:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjEtNS0xLTEtMTAyNDMx_8776b6c5-f79d-4b7c-a924-0ffcceb72e1c">1,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash paid for interest portion of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjItMS0xLTEtMTAyNDMx_ef566182-3741-43b0-b4a6-6e3691efe67e">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjItMy0xLTEtMTAyNDMx_04e188f7-f574-4615-90ef-7657795eb15a">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjItNS0xLTEtMTAyNDMx_ad3c9196-21f8-433d-959c-cf932ecb9de9">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contract and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjMtMS0xLTEtMTAyNDMx_b2ed0793-d779-4231-96cf-9ce688706cb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjMtMy0xLTEtMTAyNDMx_7a3e9a61-96d1-45be-afb9-d5a7dbfd726e">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjMtNS0xLTEtMTAyNDMx_71164109-b72f-4f2c-9156-456961f83e9f">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjQtMS0xLTEtMTAyNDMx_03f1241d-537e-4186-a2d0-068710f3c3dd">16,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjQtMy0xLTEtMTAyNDMx_d18a3d0e-0236-4220-8ffe-ce780ef83fd7">13,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjQtNS0xLTEtMTAyNDMx_c6ef31ea-22c0-4055-9ec7-0079de08ed15">9,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjctMS0xLTEtMTAyNDMx_36d803b4-a76c-4ef0-8461-ae398ddd3a7e">20,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjctMy0xLTEtMTAyNDMx_9f831bfd-d7b0-44b3-b1c6-f7cc9685ae72">27,811</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjctNS0xLTEtMTAyNDMx_4db2a703-7860-4d52-abf6-c46d753aa79f">21,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Economic development grant proceeds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="axgn:ProceedsFromGrantorsInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjgtMS0xLTEtMTAyNDMx_eb4c7363-b96a-48b5-a58f-d926bbbbcb2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="axgn:ProceedsFromGrantorsInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjgtMy0xLTEtMTAyNDMx_8a386825-e280-427d-8c7b-1bfd7487beed">950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="axgn:ProceedsFromGrantorsInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjgtNS0xLTEtMTAyNDMx_4d61c5ae-65da-4cf5-a399-f541ce5b8a79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Purchase of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjktMS0xLTEtMTAyNDMx_c750a55b-00c0-420c-81e6-7acc03196e54">39,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjktMy0xLTEtMTAyNDMx_a7c20178-7203-44da-88db-028100caec33">68,699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjktNS0xLTEtMTAyNDMx_3f931067-1399-43d1-9ccb-f4140566a041">77,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from sale of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzAtMS0xLTEtMTAyNDMx_5e5daff5-238c-4f5f-9957-613504cd9eaa">57,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzAtMy0xLTEtMTAyNDMx_845c8931-c5d8-49c8-944d-66193fb277ea">72,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzAtNS0xLTEtMTAyNDMx_c9eea86e-db89-4074-b5f9-410d5a95b38b">83,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash payments for intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzEtMS0xLTEtMTAyNDMx_ad3c4ac8-62b0-4f90-b7f0-45a8b26a27a2">1,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzEtMy0xLTEtMTAyNDMx_235133c1-c63b-4cdb-8c4f-6f1de18dfb2b">589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzEtNS0xLTEtMTAyNDMx_bfde27f4-1448-4da8-9188-f3026eaf4b1d">692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Net cash used in  investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzItMS0xLTEtMTAyNDMx_1acf0a70-fd42-4c0a-b8a8-14373e60922c">3,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzItMy0xLTEtMTAyNDMx_c146cc2d-c19a-420f-b58d-57d872f62c0a">23,649</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzItNS0xLTEtMTAyNDMx_bc25d414-1353-4608-8f24-47ca6d4268f1">16,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from issuance of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzUtMS0xLTEtMTAyNDMx_b94f1169-9480-4679-86d8-45cca0a6e612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzUtMy0xLTEtMTAyNDMx_5537ccd1-38fc-4684-9bee-524c2a0d628e">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzUtNS0xLTEtMTAyNDMx_a8c71295-f12b-4eeb-92ba-3cce17bc6b43">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from the paycheck protection program loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzYtMS0xLTEtMTAyNDMx_78227440-aac0-4651-8b40-53e658860126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzYtMy0xLTEtMTAyNDMx_a1d4aefe-716a-42cf-930a-4ff8f71c893e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzYtNS0xLTEtMTAyNDMx_896b1fde-d797-4406-8014-220a8bf587e9">7,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Repayment of the paycheck protection program loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzctMS0xLTEtMTAyNDMx_b8442098-b243-49da-92ae-0baf68d97651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzctMy0xLTEtMTAyNDMx_ec955d55-5518-41cb-8adb-fc2e353784ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzctNS0xLTEtMTAyNDMx_bd881a11-f9de-402f-bcf1-20ff120a036f">7,820</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzgtMS0xLTEtMTAyNDMx_e9b286e0-3e4a-48a7-92de-e1e78c273b2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzgtMy0xLTEtMTAyNDMx_0f6508be-cb48-4d5f-b8dc-dc291124c126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzgtNS0xLTEtMTAyNDMx_cf5240e5-b223-4803-85b9-5a6d599b5d15">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Payments for debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzktMS0xLTEtMTAyNDMx_59a26f45-f95f-4e91-bfb3-33b80b1335cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzktMy0xLTEtMTAyNDMx_ab127bbf-ad4f-44bf-9a57-bd0b7d8f3afa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzktNS0xLTEtMTAyNDMx_a453f86b-e923-4ed2-b52b-d3937a43a811">642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash paid for debt portion of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDMtMS0xLTEtMTAyNDMx_b9c9aadd-84f2-4be3-ab7b-fcfd1a06620a">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDMtMy0xLTEtMTAyNDMx_2f19fb64-7140-4017-8965-3e32f10f23cb">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDMtNS0xLTEtMTAyNDMx_e7d0c4b0-838f-4624-956c-ef9a4c7e8114">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from exercise of stock options and ESPP stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDQtMS0xLTEtMTAyNDMx_4a21efbf-3632-4fee-96ae-4f74e3504dfd">1,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDQtMy0xLTEtMTAyNDMx_de93bfb4-2e29-4dbd-9994-759da24ac695">5,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDQtNS0xLTEtMTAyNDMx_28956cdc-f0dc-4b01-a3a5-b4b2ce4accb3">3,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Payments of employee tax withholdings in exchange of common stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDUtMS0xLTEtMTAyNDMx_0eba33a1-040d-4426-8fd7-c3009c5be078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDUtMy0xLTEtMTAyNDMx_434478fc-4e48-4ff2-a5fb-e7ab690d041c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDUtNS0xLTEtMTAyNDMx_1b579e3d-daa2-41cb-8c99-6af607b4689d">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDYtMS0xLTEtMTAyNDMx_a51587ec-9a68-40a5-b330-abc0f5d63a19">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDYtMy0xLTEtMTAyNDMx_fc3b0a45-ed0f-4155-a95d-5c58e51b16c5">20,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDYtNS0xLTEtMTAyNDMx_bfd89a5e-2bd8-4c5f-902c-8f2e787eaf15">40,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDctMS0xLTEtMTAyNDMx_aeca7b96-d976-4bc9-8f35-a2618ef98c70">17,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDctMy0xLTEtMTAyNDMx_12b22eee-588d-4836-aa99-a955d63b3e2e">16,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDctNS0xLTEtMTAyNDMx_9b5bec2a-1168-4a8e-a62f-5268d1f1e993">13,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDgtMS0xLTEtMTAyNDMx_3410e33a-d553-42a0-82f4-5d125fd79514">39,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6b9724c05f4cb3a66af446b51ae49e_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDgtMy0xLTEtMTAyNDMx_5c86f527-7e35-4442-8e08-d27e7b925584">55,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b861abf62b4326b086bd6c32bdcf69_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDgtNS0xLTEtMTAyNDMx_30040338-a2d3-4ac9-bf2f-bba6f0e052b7">41,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDktMS0xLTEtMTAyNDMx_eb1cb457-71c9-4d41-9300-116506e05fd0">21,535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDktMy0xLTEtMTAyNDMx_4815656f-f406-4d80-936a-ccf1eed35eb6">39,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied6b9724c05f4cb3a66af446b51ae49e_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDktNS0xLTEtMTAyNDMx_54a8825d-4b93-46c5-b216-96a82ca7fb6e">55,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AXOGEN,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ended December&#160;31, 2022, 2021 and 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In Thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Supplemental disclosures of cash flow activity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash paid for interest, net of capitalized interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfMi0xLTEtMS0xMDI0MzE_4f60bfba-7667-43d3-b607-7ec728a78a83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfMi0zLTEtMS0xMDI0MzE_a20c0326-ec91-4ea6-a264-db9ad1919593">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfMi01LTEtMS0xMDI0MzE_6eb26768-91a1-44d5-a1ca-a0e0a13a1a8d">822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acquisition of fixed assets in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNC0xLTEtMS0xMDI0MzE_ad8d9d19-7656-4be1-aaa1-b01b432c43a0">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNC0zLTEtMS0xMDI0MzE_47477324-386c-4fd7-8aac-ba71af2a1a27">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNC01LTEtMS0xMDI0MzE_34ac8846-d7e7-4327-a191-16177b1049f3">1,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acquisition of leasehold asset</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNS0xLTEtMS0xMDI0MzE_762d2d35-245b-43c9-94cf-78ad1c41de67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNS0zLTEtMS0xMDI0MzE_2cef6aac-dad4-4708-aeb5-447145c1ba41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNS01LTEtMS0xMDI0MzE_7e0ebb43-9265-422a-8d8f-31e12ed8cae0">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Embedded derivative associated with the long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="axgn:EmbeddedDerivativeAssociatedWithTheLongTermDebt" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNi0xLTEtMS0xMDI0MzE_b8f5ee5d-4ac3-4337-92e9-d1044f4033a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="axgn:EmbeddedDerivativeAssociatedWithTheLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNi0zLTEtMS0xMDI0MzE_9c4bd0c4-3b63-4eb2-8b0a-178c1d1fca97">3,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="axgn:EmbeddedDerivativeAssociatedWithTheLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNi01LTEtMS0xMDI0MzE_360277f5-61c8-4dcc-9c6b-ada3e55731c3">2,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Obtaining a right-of-use asset in exchange for a lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNy0xLTEtMS0xMDI0MzE_30d0e721-d5ab-4317-b0fb-4dea43d7a1cd">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNy0zLTEtMS0xMDI0MzE_0e71f64c-3199-4b51-9432-041b2baa8e75">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNy01LTEtMS0xMDI0MzE_d3877d94-5d96-4524-b51e-d27a776f6194">14,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Conversion of the Credit Facility option</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="axgn:NoncashOrPartNoncashConversionOption" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOC0xLTEtMS0xMDI0MzE_2430b8a0-1cfd-497e-bb2f-7894f4ea0f8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="axgn:NoncashOrPartNoncashConversionOption" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOC0zLTEtMS0xMDI0MzE_cf3a88db-2d6c-4671-b738-386bb4d66d36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="axgn:NoncashOrPartNoncashConversionOption" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOC01LTEtMS0xMDI0MzE_3c02b596-0e93-4c26-8198-2d55215f8814">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acquisition of intangible assets in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOS0xLTEtMS0xMDI0MzE_f3eff573-2a0e-4734-8661-fcaef33157c6">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOS0zLTEtMS0xMDI0MzE_64978910-8bc4-4a90-81f3-dd0a2aef3dc6">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOS01LTEtMS0xMDI0MzE_e34522ca-fb0a-4718-a53c-b4fb1f6de726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AXOGEN,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December&#160;31, 2022, 2021 and 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In Thousands)</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_94"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV85NC9mcmFnOjk0Y2YxYTI4Yjk3MzQxYzNhZmQyNTllNjUyNmNmNjYyL3RleHRyZWdpb246OTRjZjFhMjhiOTczNDFjM2FmZDI1OWU2NTI2Y2Y2NjJfNTcy_2f6fecd1-7405-465e-bd8d-1ed68fe35638" continuedAt="ib605a79952554b5988799fb76d5067ef" escape="true">Nature of Business &#160;&#160;&#160;&#160;</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:18pt"><ix:continuation id="ib605a79952554b5988799fb76d5067ef" continuedAt="i662ca8553aa943088ccf76621cb23507"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axogen,&#160;Inc. (together with its wholly-owned subsidiaries, the &#8220;Company&#8221;) was incorporated in Minnesota and is the leader in the science, development and commercialization of the technologies used for the peripheral nerve regeneration and repair. The Company's products include Avance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Graft, Axoguard Nerve Connector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Protector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axotouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Two-Point Discriminator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is headquartered in Florida. The Company has processing, warehousing, and distribution facilities in Texas and Ohio.</span></ix:continuation></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i662ca8553aa943088ccf76621cb23507">The Company manages its operations as a single operating segment. Substantially all of the Company's assets are maintained in the United States. The Company derives substantially all of its revenues from sales to customers in the United States.</ix:continuation> </span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_100"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDE1_f4435292-fd0c-40dc-9c68-5023e6e62b53" continuedAt="i8f54a5c3852f4ee69e96e87c5ad16c95" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8f54a5c3852f4ee69e96e87c5ad16c95" continuedAt="idf26cb2a94ee40a4853f0563497aa792"> </ix:continuation></span></div><ix:continuation id="idf26cb2a94ee40a4853f0563497aa792" continuedAt="i7090baa97205494b909dc6e45337c2fb"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2Njk0MTU_bd2b59b3-8ea2-4250-b1d4-f20d46aa81f0" continuedAt="if7bb76cb864540ecbe074007fc0b3918" escape="true">Basis of Presentation </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if7bb76cb864540ecbe074007fc0b3918">The accompanying consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). All intercompany accounts and transactions have been eliminated in consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMjM_5f50ea9a-6349-4b21-a257-bf3e00503ea7" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant estimates affecting the amounts reported or disclosed in the consolidated financial statements include the realizable value of inventories, the valuation of stock-based compensation and the valuation of derivative instruments and the fair value of debt instruments. Other estimates that affect the amounts reported or disclosed in the consolidated financial statements include the allowance for doubtful accounts, the useful life and recoverability of long-lived assets, incremental borrowing rates for operating leases, accounting for income taxes including the realizability of deferred tax assets and the related valuation allowance. The Company bases its estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3MjYzNzg_3b02c09f-40f7-4411-94db-72900d0b6682" continuedAt="if645c0b990df405d82516fb4dbb8fe13" escape="true">Reclassifications</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if645c0b990df405d82516fb4dbb8fe13">Certain prior year amounts have been reclassified for consistency with the current year presentation. Specifically, finance lease right-of-use assets which were presented separately in 2021, and are now included in property and equipment. In addition, the debt derivative liability was included in net operating loss carryforwards in deferred assets in 2021, it is presented separately as debt derivative liability in deferred tax assets. See Note 12 - Income Taxes.</ix:continuation> </span></div><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="axgn:RisksAndUncertaintiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0MzQxODI_516e6727-e98a-4cbe-91ac-ebcf5a86e37b" continuedAt="id44a823a25a84e9f853191fba4484a7c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk and Uncertainties</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020, and the virus has continued to spread through 2022. The related responses by public health and governmental authorities to contain and combat the outbreak and spread of the virus, have adversely impacted global commercial activity, hospital staffing, elective surgeries, supply chains and contributed to significant volatility in financial markets. The Company experienced a decrease in demand for its products and services during 2020 and 2021, due to the lack of access to hospitals and health care facilities and the reallocation of resources from surgical procedures to COVID-19 patient care as well as the related staffing shortages in health care had a material adverse effect on the Company's results of operations. This negative impact began to improve in 2022, particularly in the second half of the year; however, the inflationary pressure and the ensuing recession may have a negative effect on the demand for the Company's products, services and the Company's operating results.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on its suppliers, including single source suppliers, and the inability of these suppliers to deliver necessary components of its products in a timely manner at prices, quality levels and volumes acceptable to the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="i7090baa97205494b909dc6e45337c2fb" continuedAt="ife20ffadebf549f2bbb9d9f9dea68e68"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id44a823a25a84e9f853191fba4484a7c">Company, or its inability to efficiently manage these components from these suppliers, could have a material adverse effect on its business, financial condition and operating results.</ix:continuation></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3NTkxNjg_9f60166e-bbd9-4b22-adc1-92c2f2769df5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of acquisition. Certain of the Company's cash and cash equivalents balances exceed Federal Deposit Insurance Corporation ("FDIC") insured limits or are invested in money market accounts with investment banks that are not FDIC-insured. The Company places its cash and cash equivalents in what they believe to be credit-worthy financial institutions. As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzEwOTk1MTE4MDAyMTA_f8bca0c4-be8b-486d-b383-945779735bec">15,034</ix:nonFraction> of the cash and cash equivalents balance was in excess of FDIC limits. </span></div><div style="margin-top:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent those required to be set aside to meet contractual terms of a lease agreement held by the Company.See Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDA3_4e73b416-6745-4622-91d6-9e213acb3ca9" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same reported in the consolidated statements of cash flows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:72.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzEtMS0xLTEtMTAyNDMx_9ef34c7c-76d5-40f2-b395-24b64322cf3e">15,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzEtMy0xLTEtMTAyNDMx_b3dfad29-2e9d-4d92-8a1f-60c3be77af81">32,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzItMS0xLTEtMTAyNDMx_85c30433-a133-4797-8043-49db86a72679">6,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzItMy0xLTEtMTAyNDMx_87b04915-21c5-4955-819e-62811513f6ac">6,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzMtMS0xLTEtMTAyNDMx_adc2a537-52af-4199-af16-a7b5df11c948">21,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzMtMy0xLTEtMTAyNDMx_53f01ff5-9f4b-4c9f-aa24-bf3d6a708c1e">39,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMjY_35c94acf-5ead-4d99-945a-edeb8d2d4f8e" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments consist of commercial paper and U.S. government securities, are classified as available-for-sale and have maturities less than one year as of each balance sheet date. Investments are carried at fair value based upon quoted market prices. The Company elected the fair value option ("FVO") for all of its available-for-sale investments. The FVO election results in all changes in unrealized gains and losses being included in investment income in the consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMjc_d45df68d-90da-4fd1-8a3c-c3007eadcbf0" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Account receivables are recorded at invoiced amounts and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or other security to support its receivables.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance for doubtful accounts is established for estimated uncollectible receivables based on the Company's assessment of the collectability of customer accounts and recognizes the provision in general and administrative on the consolidated statements of operations. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. Uncollectible receivables are written off against the allowance for doubtful accounts when all attempts to collect the receivable have been exhausted. The provision for bad debts is recorded as a component of general and administrative expenses on the consolidated statement of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3MjYzODE_0805a4fa-b6c9-42b0-9a00-4a301bf6b8f1" continuedAt="i15939740eb9b4d32959b3a7f9f405258" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration Risk</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions and trade receivables. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i15939740eb9b4d32959b3a7f9f405258">The Company's products are sold on an uncollateralized basis and on credit terms.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the Company's customers accounted for 10% or more of the consolidated revenues during the years ended December&#160;31, 2022, 2021 and 2020.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="ife20ffadebf549f2bbb9d9f9dea68e68" continuedAt="i37669cf7156d44cab82cfff16719bac0"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDE4_311bc830-e22f-4f24-b367-4489865eb237" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisting of materials, direct labor and manufacturing overhead, are stated at the lower of cost or net realizable value. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf-life. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage. To estimate the amount of inventory that will expire prior to being distributed, the Company reviews inventory quantities on hand, historical and projected distribution levels, and historical expiration trends. The Company&#8217;s calculation of the amount of inventory that will expire prior to distribution has two components: 1) a demand or consumption-based component that compares projected distribution to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being distributed. The Company&#8217;s model assumes that inventory will be distributed on a first-in, first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that significant portions of the Company&#8217;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written down involves significant judgments and estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMjk_1a47dd4a-e5b7-4749-bc7e-279efb88b6ff" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are stated at historical cost less accumulated depreciation and amortization. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset&#8217;s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg2NTE3MQ_1b1457ed-1497-471b-a70d-aa52a8985c35">three</span> to <ix:nonNumeric contextRef="i2097ff736d5343bda084880731e97ad9_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg2NTE3Mg_3865462a-ee02-4a5d-abf4-a31b5c596e3e">seven years</ix:nonNumeric>. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains or losses on the disposition of property and equipment are recorded in the period incurred and recorded general and administrative expenses on the consolidated statement of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:InterestCapitalizationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3MjYzODM_79585d1c-dd86-455c-831a-c1c2bcf66930" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Interest</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest cost on capital projects, including facilities build-outs, is capitalized and included in the cost of the project. Capitalization begins with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. For the years ended December&#160;31, 2022, and 2021, the Company capitalized $<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk2NTYzNQ_2aef9d37-3777-4587-8890-3fa80412ac30">6,155</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk2NTYzOA_90cd61ae-c781-47e2-bc84-726728d90886">4,277</ix:nonFraction>, respectively, of interest expense into property and equipment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3NDQ4NjQ_d4078e94-b884-4f76-8d56-9e971317a669" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes long-lived assets (asset groups), including property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. The Company tests annually, in the third quarter, for impairments. An impairment is recognized when the estimated undiscounted cash flows generated by those assets is less than the carrying amounts of such assets. If it is determined that long-live asset (asset groups) is not recoverable, an impairment loss would be calculated based on the excess of the carrying value of the long-lived asset (asset groups) over the fair value of the long-lived asset (asset groups). There have been no impairments of long-lived assets during the years ended December&#160;31, 2022, 2021, and 2020. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are not subject to amortization, however, annually in the third quarter or whenever an event occurs or circumstances indicate that the indefinite-lived intangible assets may be impaired, the Company evaluates qualitative factors to determine whether it is more likely or not that the fair value of the indefinite lived asset is less than its carrying amount. The Company's qualitative evaluation includes an assessment of factors, including specific operating results as well as industry, market and general economic conditions. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzA_0eb8e146-f502-48e3-8b1f-93806a4c796d" continuedAt="i0c2997aba8c04acbbf370285d52e2ded" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, net</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are recorded at cost and include patents and patent application costs, licenses, and trademarks. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives and reported net of accumulated </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="i37669cf7156d44cab82cfff16719bac0" continuedAt="i3c0d1447b1c1407d8a0b4132003b5f10"><ix:continuation id="i0c2997aba8c04acbbf370285d52e2ded"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortization. Amortization expense is recorded in general and administrative expenses on the consolidated statements of operations. The useful lives of intangible assets are as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">License agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: <ix:nonNumeric contextRef="ie4725cd6d9b24bb59307c754dcac2d41_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTkzMzUyNw_3429978c-5402-4359-b431-a1499b6d6ae8">17</ix:nonNumeric> to <ix:nonNumeric contextRef="i2dd68d66cd4242ecb6935259bfbb0bfd_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTkzMzUzMg_5aacec6e-cbe0-4f19-af08-21c2c5bd9bae">20</ix:nonNumeric> years</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patents: up to <ix:nonNumeric contextRef="idc7ba18f09ee45d587b2fe032937cda5_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTkwMjk2MQ_9c143285-a0ba-413f-8eaa-87bf30f35d2f">20</ix:nonNumeric> years. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trademarks: indefinite lived</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company pays royalty fees based on net sales of the licensed products, which are recorded in sales and marketing on the consolidated statements of operation.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Nerve Foundation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company may make contributions to the Global Nerve Foundation ("GNF"), a related party, due to certain executives of the Company being members of GNF's board of directors. The GNF was incorporated in 2021 exclusively for charitable, educational, and scientific purposes and qualifies under IRC 501(c)(3) as an exempt private foundation. Under its charter, the GNF engages in activities that focus on improving the awareness and care of patients with peripheral nerve injuries through grants, contributions and other appropriate means. The GNF is a separate legal entity and is not a subsidiary of the Company; therefore, its results are not included in the accompanying consolidated financial statements. The Company contributed $<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="axgn:ContributionsToCharitableOrganization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTkwNDQ1OQ_72bade99-e337-4d29-ad1b-48fd7c08cf44">700</ix:nonFraction> to the GNF during the year ended December&#160;31, 2022, no amounts were contributed previously. These contributions were recorded in sales and marketing expense on the consolidated statement of operations.</span></div><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3NDQ4NjU_ef569045-19f4-4924-8359-1725c499d581" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Cash equivalents, investments and derivative instruments are recorded at fair value on a recurring basis. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for classification and disclosure of fair value measurements as follows:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDIz_3e1c7717-9a04-4f02-aa54-e7882e908745" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its debt instruments in determining whether there are embedded derivative instruments, which are required to be bifurcated and accounted for separately as a derivative financial instrument. Embedded derivatives that are not clearly and closely related to the debt host are bifurcated and are recognized at fair value on the consolidated balance sheet with changes in fair value recognized as either a gain or loss on the consolidated statement of operations each reporting period. The fair value of embedded derivatives are measured based on equity markets and interest rates, as well as an estimate of the Company's nonperformance risk adjustment. This estimate includes an option adjusted spread and an estimate of the Company's risk-free rate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzM_8ebb20a9-279e-49b0-8f53-0827787918ac" continuedAt="iead7130490474db192da21bb5994a760" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if a contract contains a lease at the inception date and determines the lease classification, recognition, and measurement at commencement date. All operating lease commitments with a lease term greater than 12 months are recognized as right-of-use assets and obligations on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies a lease based on whether the arrangement is effectively a purchase of the underlying asset. Leases that transfer the control of the underlying asset are classified as finance leases and all others are classified as operating leases. Interest and amortization expense are recognized for operating leases on a straight-line basis. If a change to the lease term leads </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="i3c0d1447b1c1407d8a0b4132003b5f10" continuedAt="ife09c6c2bbd1473fbc93dca046bbbf09"><ix:continuation id="iead7130490474db192da21bb5994a760"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to a reassessment of the lease classification and remeasurement, assumptions such as the discount rate and variable rents based on a rate or index will be updated as of the remeasurement date. If an arrangement is modified, the Company will reassess whether the arrangement contains a lease. Any subsequent changes in lease payments are recognized when incurred, unless the change requires a remeasurement of the lease liability.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's leases include options for the Company to extend the lease term. The exercise of lease renewal option is generally at the Company's sole discretion. Certain of the Company's lease agreements include provisions for the Company to reimburse the lessor for common area maintenance, real estate taxes, and insurance, which the Company accounts for as variable lease costs. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></div></ix:continuation><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDA5_ff8235ed-77b6-48fc-800f-327051429043" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection. Revenue is recognized when the Company transfers of control of the products and services to the Company&#8217;s customers when the product is shipped or when it is delivered to the customer depending on the agreement. Products are primarily transferred to customer at a point in time. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract. These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#8217;s cost. The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and therefore, the Company has determined it is appropriate to recognize revenue when: i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement. Determining the timing of revenue recognition for such contracts is subject to judgment, because an evaluation must be made regarding the distributor&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company. Changes in these assessments could have an impact on the timing of revenue recognition from sales to distributors. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing, and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#8217;s contracts vary; however, as a common business practice, payment terms are typically due in full within <ix:nonNumeric contextRef="i2097ff736d5343bda084880731e97ad9_D20220101-20221231" name="axgn:AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk1OTc1OA_1bad6082-9843-480f-adda-a3186cd7f538">30</ix:nonNumeric> days of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material. The Company has several contracts with distributors in international markets that include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3MjYzODQ_578f7e20-5fb0-4dfc-8b40-f4a92e64aa3d" continuedAt="i0907f65468e8478f828c23137c7d6c4d" escape="true">Government Assistance</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><ix:continuation id="i0907f65468e8478f828c23137c7d6c4d" continuedAt="if80f7da531374ff08d70c76958c6218f"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As there is no authoritative guidance under U.S. GAAP for accounting for grants to for-profit business entities, the Company accounts for the grants by analogy to International Accounting Standard ("IAS") 20 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20")</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="if80f7da531374ff08d70c76958c6218f"> Government assistance and grants are recognized when there is reasonable assurance that the Company has met the requirements of the assistance and there is reasonable assurance that the grant will be received. The Company received government grants of $<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MTg1NA_c2a41f2f-b2e4-4ed6-a48d-845bdc6649b3">158</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MTg1OQ_74b5598c-fb16-4875-bd98-58596b5ee9e8">1,164</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MTg2Nw_893f7fea-2665-4d08-93e3-1ea5e696261c">628</ix:nonFraction> during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="ife09c6c2bbd1473fbc93dca046bbbf09" continuedAt="i68ced1d243424319aa6d31e578d79783"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzQ_1bbbc0f3-588e-4e90-841c-7d2df3389ecb" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Costs of Goods Sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes direct labor and materials costs related to each product sold or produced, including processing, quality assurance labor and scrap, inbound freight costs, as well as facility and warehousing overhead supporting the Company's manufacturing operations. All of the Company's manufacturing costs are included in cost of goods sold on the consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDE3_74c90991-6e79-407c-8cec-3eea930028c8" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Costs of research and development activities relate to product development, clinical trial expenses for the improvement of existing products, and technical support of products. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment. The Company received certain government grants totaling $<ix:nonFraction unitRef="usd" contextRef="i1bc6c9dfa31e4dfb90c5dc20212c1ca1_D20220101-20221231" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MjYxNg_f8f9b0a6-3ca0-40df-a84c-9e2f2a219936">158</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ic68f8ca16e14404a992ae8f0910b911c_D20210101-20211231" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MjYyMQ_ea5e779e-1a72-46d0-89d7-0e71a594eca4">214</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i87f90b83c663430ea63bc4f87a3e3a3e_D20200101-20201231" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MjYyOQ_5ca20c8c-8a37-47a2-a58e-ce2995c5b718">390</ix:nonFraction> which were recorded as an <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_53f04da6-b4de-4448-a842-3ba64e7044cf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_d6f381e2-5ace-449f-8744-bd43ca3d4c2a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_e7410970-08ee-44c3-807d-dbdd552f3cb6">offset to research and development</span></span></span> in the consolidated statement of operations during the years ended December&#160;31, 2022, 2021 and 2020, respectively</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ShippingAndHandlingCostPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzU_2e68fdce-b300-4cc5-a081-e154d6903733" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shipping and handling costs, including facility and warehousing overhead, directly related to bringing the Company&#8217;s products to their final selling destination are included in sales and marketing expenses on the consolidated statements of operations were $<ix:nonFraction unitRef="usd" contextRef="ib7fac01f992a4a81b65d12402ff03e2f_D20220101-20221231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg4OTk3OA_99520c95-275a-4169-bf8b-bacfe309a5c5">5,271</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i64abf6623fa944d6afd0f670cf3c2a34_D20210101-20211231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg4OTk3NA_2fcbee68-9a32-4f26-b525-0196668bb561">4,883</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="ic2511c05b8d24d5498026c37e476c019_D20200101-20201231" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg4OTk3MQ_320f1bf0-c7af-4b17-9f23-a87762a90490">3,912</ix:nonFraction> for the December&#160;31, 2022, 2021, and 2020, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzY_75f28b22-aac5-4bea-adfa-41319e6143a2" continuedAt="ia46c5f19088641d78fabec7161582359" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. </span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia46c5f19088641d78fabec7161582359">The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the consolidated balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.</ix:continuation> </span></div><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDE0_151150f2-173f-42f2-abb2-26a88e3c1785" continuedAt="iaf161b475d2a4663a0fe0b15ce4df46a" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation is in the form of stock options, restricted stock units ("RSU"), performance stock units ("PSU"), and recognized at, or above, the fair market value of the Company's common stock on the date of grant.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of each stock option award on the date of grant using a multiple-point Black-Scholes option-pricing model. In addition, the Company measures stock options granted to employees at a premium price based on market conditions, such as the trading price of the Company&#8217;s common stock, using a Monte Carlo Simulation option-pricing model in estimating the fair value at the grant date.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of RSU grants based upon the grant date closing market price of the Company&#8217;s common stock.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the PSU grants is based on the Company&#8217;s closing stock price on the grant date. The number of PSUs that will ultimately be earned is based upon the Company&#8217;s performance as measured against specified targets over the measurement period. Expectations related to the achievement of performance goals associated with PSU grants is assessed as of each reporting period and is used to determine whether PSU grants are expected to vest. If performance-based milestones </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="i68ced1d243424319aa6d31e578d79783"><ix:continuation id="iaf161b475d2a4663a0fe0b15ce4df46a"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for all stock-based compensation awards, including stock options, RSUs, and PSUs granted to employees eligible for retirement, as defined within the award notice and allowing for continued vesting post-retirement, over the retirement notice period and continuously updates its estimate of expense over the notice period each reporting period if a retirement notice has not been provided. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense related to the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) based on the estimated fair value of the options on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of fair value using option-pricing models, as indicated above, is affected by the Company&#8217;s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company&#8217;s expected stock price volatility over the expected term of the awards. The Company determines the expected term of each award giving consideration to the contractual terms, vesting schedules, and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected term of the award. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. The expense is reduced for forfeitures as they occur.</span></div></ix:continuation><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzk_533b504c-7745-4297-b395-fb7919f771d9" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic net loss per common share is computed by dividing reported net loss by the weighted average number of common shares outstanding during the period without consideration of potentially dilutive securities. Diluted net loss per share reflects the potential dilution that could occur if contracts to issue common stock were exercised or converted into common stock of the Company. Diluted net loss per share is the same as basic net loss per common share for all periods presented, since the effect of the potentially dilutive securities are anti-dilutive. Potential dilutive common share equivalents consist of the incremental common shares issuable upon exercise of vested stock options, RSUs, and PSUs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDIy_8c45e561-95ea-420c-b031-7113b94299e6" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Financial Accounting Standards Board ("FASB") amended Accounting Standards Codification ("ASC") 848 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (issued under Accounting Standards Update ("ASU") 2020 - 4, Reference Rate Reform). The amendment in this update defers the sunset date of Topic 848 from December 31, 2022, to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. The Company has not yet assessed the impact of the deferral on its consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, FASB amended ASC 832, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (issued under ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosures by Business Entities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">bout Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). This amendment requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy, including, (1) the types of transactions; (2) the financial statement line items affected by the transaction: and (3) significant terms and conditions associated with the transactions. The Company adopted the guidance on January 1, 2022, and the adoption of ASU 2021-10 had no impact on the Company's consolidated financial condition, results of operations and an immaterial impact on disclosures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other ASUs issued and not yet effective as of December 31, 2022, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company&#8217;s current or future financial position or results of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90ZXh0cmVnaW9uOjJkMjg2NWEzNzMyYTQzOWFiMWM5ZjhiNjQyMDcyYmNmXzI1OQ_2cdd56ad-b61e-44e1-b752-5dc74e5a21d2" continuedAt="ib182613d6b1f4e528983e82e72312da0" escape="true">Inventory</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:continuation id="ib182613d6b1f4e528983e82e72312da0" continuedAt="i8a3a3b868ba84ff6bb4f6331b8d23411"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90ZXh0cmVnaW9uOjJkMjg2NWEzNzMyYTQzOWFiMWM5ZjhiNjQyMDcyYmNmXzI1OA_ad59c2b2-76c7-4eed-beb1-43a8e1e6fa5f" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzEtMS0xLTEtMTAyNDMx_7edaf3b3-0d60-4483-ac62-663e75852c00">12,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzEtMy0xLTEtMTAyNDMx_2a179898-0ad6-4781-9a6b-16629cc96272">11,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzItMS0xLTEtMTAyNDMx_8f852d42-aa09-4f48-8555-801029f81228">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzItMy0xLTEtMTAyNDMx_99f46ac8-d4a8-4e20-b96c-f4e257622c01">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzMtMS0xLTEtMTAyNDMx_f5e194f8-70e7-4c8a-b848-1f01249cd412">5,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzMtMy0xLTEtMTAyNDMx_a92447de-9e8e-4af3-a769-c994bfe16722">4,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzQtMS0xLTEtMTAyNDMx_e5b687d8-0a5b-4d64-90f6-c98445a0f820">18,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzQtMy0xLTEtMTAyNDMx_c6665425-b5db-4707-ab35-348bf891578e">16,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for inventory write-down is for the years ended as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:44.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.863%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for inventory write-down</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpiZmZhNzgzMTcwYjk0NjBkYjkzYjI3MGMyYWEwZjQ3ZS90YWJsZXJhbmdlOmJmZmE3ODMxNzBiOTQ2MGRiOTNiMjcwYzJhYTBmNDdlXzItMS0xLTEtMTExMDkz_1eab7fc5-1664-431f-9371-58e62fdaddd4">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpiZmZhNzgzMTcwYjk0NjBkYjkzYjI3MGMyYWEwZjQ3ZS90YWJsZXJhbmdlOmJmZmE3ODMxNzBiOTQ2MGRiOTNiMjcwYzJhYTBmNDdlXzItMy0xLTEtMTExMDkz_e8f87198-c749-4dc3-be3c-b19d55998672">3,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpiZmZhNzgzMTcwYjk0NjBkYjkzYjI3MGMyYWEwZjQ3ZS90YWJsZXJhbmdlOmJmZmE3ODMxNzBiOTQ2MGRiOTNiMjcwYzJhYTBmNDdlXzItNS0xLTEtMTExMDkz_67b5555a-6ecc-4e40-85e3-91193e96a104">2,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i8a3a3b868ba84ff6bb4f6331b8d23411">The provision for inventory write-down for the year ended December&#160;31, 2021, included the Avive write-down of $<ix:nonFraction unitRef="usd" contextRef="iead0e385765c4b64b8993cfd1f3c50a7_D20210101-20211231" decimals="-3" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90ZXh0cmVnaW9uOjJkMjg2NWEzNzMyYTQzOWFiMWM5ZjhiNjQyMDcyYmNmXzI1Ng_81df0635-f429-40a9-8f81-13f6ad7cb3fe">1,251</ix:nonFraction>. The Avive write-down resulted from the Company announcing on May 17, 2021, it was suspending market availability of Avive effective June 1, 2021.</ix:continuation> </span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_112"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzMwNw_b22de966-6d51-4c85-afa2-c45b66728aec" continuedAt="i97321b5d20bf4cc390fc12947d6c4b63" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="i97321b5d20bf4cc390fc12947d6c4b63"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzMwOA_4c5a185e-5f87-4a33-81c0-2de038ebb3f5" escape="true"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i8fdfd74ec77440a993b43f1ab043aec4_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzEtMS0xLTEtMTAyNDMx_23ccce70-3476-4923-a132-7799e6365784">5,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i070dcdc6ab0e4a87856b934b83e36f61_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzEtMy0xLTEtMTAyNDMx_4ac910cb-6eb5-4409-b648-6a064df093b2">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic4b7b03e5ad24c209c6e89b463f7c09d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzItMS0xLTEtMTAyNDMx_89a665cc-bac2-4607-bcc6-0f8126d32970">15,482</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9d7786e6549f4f2b87fd1be253cbb057_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzItMy0xLTEtMTAyNDMx_9798e3a7-e2a7-476a-aeaa-1874a5640f73">14,952</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Processing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4a1078ddd2ca4d68ba2298c4052ef876_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzMtMS0xLTEtMTAyNDMx_3a9e77ea-19c7-4c16-bf4b-d723313e0db5">4,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia3763b8b0a3348d59cfaea1445d2bfc8_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzMtMy0xLTEtMTAyNDMx_d1a4cbea-a544-4361-ac43-83e4adeafb71">3,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iefef6bfa4d304246b2f3543fef3d3125_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzQtMS0xLTEtMTAyNDMx_17809717-788e-449b-bf3d-add13afc3dd4">731</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6fcdd9ed764541c286b0eaaa84d984ce_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzQtMy0xLTEtMTAyNDMx_bb5f1013-a56a-432b-a2d0-d747e7c5290e">731</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzUtMS0xLTEtMTExNDM5_173624ae-8600-4764-9f37-e761bf6636a3">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzUtMy0xLTEtMTExNDU1_9234632a-d109-436c-b8e8-fb8e3ad3556e">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projects in process </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i981abdd294e44919817cd956d30d31a2_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzUtMS0xLTEtMTAyNDMx_3a2f5cd1-44c9-4f33-bbf6-c334cc4e391d">63,703</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i219c4cc0cbd547b3b68a43331493fb1d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzUtMy0xLTEtMTAyNDMx_2ba98659-44cd-42ec-91ef-b354e3ae98e4">45,660</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzYtMS0xLTEtMTAyNDMx_90d0a345-19b3-4058-ab46-dcc2cb79a266">89,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzYtMy0xLTEtMTAyNDMx_4975f35a-1695-44c9-9bec-2f21eeec4219">70,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzctMS0xLTEtMTAyNDMx_a6e68b11-147e-45d5-ab97-e3da0f7793e6">10,296</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzctMy0xLTEtMTAyNDMx_f922fe72-09ca-444a-ad08-9beed2afecc7">7,614</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzgtMS0xLTEtMTAyNDMx_35e6857b-badc-4576-b250-0420997a1e55">79,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzgtMy0xLTEtMTAyNDMx_ce8fd659-a389-4d98-b0c7-105c6f4b90cc">62,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_2ffaa088-42a3-4658-a56e-41bcb91c69e1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_6ac65a1e-f9f2-4c6f-9b60-403fe0960398">projects in process</span></span> is a government grant received totaling $<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:GovernmentAssistanceAmountCumulative" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzM1NzM0MTI3OTA2MzU3_37090f13-b11c-4f59-ac02-8c86d257b6de"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:GovernmentAssistanceAmountCumulative" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzM1NzM0MTI3OTA2MzU3_94556d80-0d70-43e6-961d-001f11fbddd0">1,188</ix:nonFraction></ix:nonFraction> as of December 31, 2022 and December 31, 2021, which was recorded as an offset, and $<ix:nonFraction unitRef="usd" contextRef="i20c791c3ff7e418ab95668e32cc7a1ec_I20221231" decimals="-3" name="us-gaap:AccumulatedCapitalizedInterestCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzU0OTc1NTgxNzQ2MQ_3e87801a-5e13-4c7d-9358-ffe04f136f83">11,429</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i93d0b4619b6c40f0b1a0de407ee760f7_I20211231" decimals="-3" name="us-gaap:AccumulatedCapitalizedInterestCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzU0OTc1NTgxNzY4NQ_1082f4ec-3469-4e0e-a932-2e917f4b57f0">5,274</ix:nonFraction> of capitalized interest as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation expense is as follows for the years ended:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:43.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZTowYjkyYjg1MzJjNDI0NDRiYWJkMTNmZjlhN2U1ZDE4NC90YWJsZXJhbmdlOjBiOTJiODUzMmM0MjQ0NGJhYmQxM2ZmOWE3ZTVkMTg0XzItMS0xLTEtMTExMDg5_882f482d-9c5e-4856-a35d-dc428606e757">2,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZTowYjkyYjg1MzJjNDI0NDRiYWJkMTNmZjlhN2U1ZDE4NC90YWJsZXJhbmdlOjBiOTJiODUzMmM0MjQ0NGJhYmQxM2ZmOWE3ZTVkMTg0XzItMy0xLTEtMTExMDg5_c3b8af9d-2bca-475c-aa59-f68cce1b3eda">2,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZTowYjkyYjg1MzJjNDI0NDRiYWJkMTNmZjlhN2U1ZDE4NC90YWJsZXJhbmdlOjBiOTJiODUzMmM0MjQ0NGJhYmQxM2ZmOWE3ZTVkMTg0XzItNS0xLTEtMTExMDg5_a62a5706-2820-4150-a489-4bcb7528b33b">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzM2Mjg_b25b05b9-f7e5-48f7-b8e9-2001ca32676d" continuedAt="i9a817a1c3ebd4b398f481bcb668d0318" escape="true">Intangible Assets, Net </ix:nonNumeric></span></div><ix:continuation id="i9a817a1c3ebd4b398f481bcb668d0318"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzM2Mjk_240a4155-67bb-4ab1-9c76-edf8bc7f9876" escape="true"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzM2Mjk_51bcfcb1-bb01-4c84-8faf-0565f697e2d3" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:32.477%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.317%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ief216639aeea40978d9004092b61999b_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtMi0xLTEtMTAyNDMx_7578871c-8a51-4358-8488-af6a89b44aff">3,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ief216639aeea40978d9004092b61999b_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtNC0xLTEtMTAyNDMx_dca387ec-c7b9-49d5-998e-6f3900026631">621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ief216639aeea40978d9004092b61999b_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtNi0xLTEtMTAyNDMx_c7da22b0-4cd8-4f17-946a-3121404e95ff">3,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i040b86ceb15544419c782b59216a1371_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtOC0xLTEtMTAyNDMx_73956ab4-36e9-459a-82c9-923766503dae">2,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i040b86ceb15544419c782b59216a1371_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtMTAtMS0xLTEwMjQzMQ_00ebfb8d-1aeb-4459-be4a-1d812c1747e8">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i040b86ceb15544419c782b59216a1371_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtMTItMS0xLTEwMjQzMQ_c919e2d5-9873-4159-9049-a39630b6573f">2,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">License agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idffd7fe48ee54e349aaddba79d4382e8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtMi0xLTEtMTAyNDMx_9bba1feb-6a06-4a3f-ace8-4c1469a3a808">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="idffd7fe48ee54e349aaddba79d4382e8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtNC0xLTEtMTAyNDMx_c8808253-0b38-4709-9e73-f1b6045e1600">1,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idffd7fe48ee54e349aaddba79d4382e8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtNi0xLTEtMTAyNDMx_cf6031cb-85c1-4260-9934-e736ecb7fe3b">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i6cab5edf539940499d0c87a4b0bfaecf_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtOC0xLTEtMTAyNDMx_0f9d04ec-8c8e-457c-990f-70c82e55582f">1,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i6cab5edf539940499d0c87a4b0bfaecf_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtMTAtMS0xLTEwMjQzMQ_c4b01498-96d5-40de-807d-b35de70ef8df">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i6cab5edf539940499d0c87a4b0bfaecf_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtMTItMS0xLTEwMjQzMQ_1202d54b-c477-46c2-ba0b-e15bc2d15d20">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total amortizable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtMi0xLTEtMTAyNDMx_25187651-a93d-4447-b220-7dc1a5ae7456">4,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtNC0xLTEtMTAyNDMx_416ccdfc-e98f-4419-8e91-2159b7f6b3a4">1,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtNi0xLTEtMTAyNDMx_12706ed5-76ff-4de3-bd0d-5496b01db7ca">3,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtOC0xLTEtMTAyNDMx_08370c61-6f73-465d-8bb7-ac6df34238bc">3,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtMTAtMS0xLTEwMjQzMQ_d18f5723-b254-4fc2-b9bc-b173559d776f">1,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtMTItMS0xLTEwMjQzMQ_84d51ae0-554f-4772-9621-371e4dfb5149">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ifa2057862cc54798a45830a2e34c7672_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzgtMi0xLTEtMTAyNDMx_8bf4ca13-c93b-4c76-a49c-c60ce3513d30">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ifa2057862cc54798a45830a2e34c7672_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzgtNi0xLTEtMTAyNDMx_1226a6a3-43e1-4dd9-88e9-15355dd78ccd">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i414b5edcb9214fef95168d989218cbd4_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzgtOC0xLTEtMTAyNDMx_16fe0bb3-f571-4a8e-97fd-9e09efe65280">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i414b5edcb9214fef95168d989218cbd4_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzgtMTItMS0xLTEwMjQzMQ_799d205d-8c67-408d-91cd-34b0cfb254f4">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktMi0xLTEtMTAyNDMx_c9798524-25c9-43c6-aa12-bcee109aec47">5,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktNC0xLTEtMTAyNDMx_db48da74-103e-42a5-a5b1-2da58025fb3d">1,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktNi0xLTEtMTAyNDMx_db600225-ee36-4eff-b3a0-90e2b9dd666b">3,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktOC0xLTEtMTAyNDMx_d937dabe-e51a-4429-aae3-3039231b02b1">3,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktMTAtMS0xLTEwMjQzMQ_ba0a84d2-a6ee-4eb1-92b9-9fcc460d9793">1,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktMTItMS0xLTEwMjQzMQ_23328192-82a2-43a3-bb1b-ad055f5a1c07">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0Xzg3OTYwOTMwMjcxMjI_93f49630-8da8-45ed-98c4-60695bbdb25b" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amortization expense is as follows for the years ended:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:44.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTo4ZTI4YWRkNTdhZWE0ODY2YmZmYjZiZDhiMTVjM2NhMC90YWJsZXJhbmdlOjhlMjhhZGQ1N2FlYTQ4NjZiZmZiNmJkOGIxNWMzY2EwXzItMS0xLTEtMTExMjYz_50f3e9a0-b462-42c9-bdfc-05ba66f7f455">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTo4ZTI4YWRkNTdhZWE0ODY2YmZmYjZiZDhiMTVjM2NhMC90YWJsZXJhbmdlOjhlMjhhZGQ1N2FlYTQ4NjZiZmZiNmJkOGIxNWMzY2EwXzItMy0xLTEtMTExMjY3_2f56eea9-48d0-4ecd-ad90-4f00c0b4b49b">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTo4ZTI4YWRkNTdhZWE0ODY2YmZmYjZiZDhiMTVjM2NhMC90YWJsZXJhbmdlOjhlMjhhZGQ1N2FlYTQ4NjZiZmZiNmJkOGIxNWMzY2EwXzItNS0xLTEtMTExMjcx_ea7ac959-93f6-40e2-8941-b416238dbb83">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzM2Mjc_67556e50-1e9b-47ec-b190-2675c88cfbcc" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, future amortization of patents and license agreements are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:85.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzEtMS0xLTEtMTAyNDMx_e1690428-f3d7-4b3e-85e8-d316fe48342f">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzItMS0xLTEtMTAyNDMx_e45628df-c9aa-4d8d-8953-6074d047b70b">181</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzMtMS0xLTEtMTAyNDMx_b5514337-483f-48b0-a0d1-93d5e579c1b2">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzQtMS0xLTEtMTAyNDMx_9021cfea-2ff0-4674-a052-f7dd24d9b999">180</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzUtMS0xLTEtMTAyNDMx_9567a67b-02e0-44e0-883f-fd00b0476155">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzYtMS0xLTEtMTAyNDMx_5d0adee4-8f0e-4ab0-8d85-91923823197c">2,290</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzctMS0xLTEtMTAyNDMx_bcf6c0d9-31a9-4caa-b522-6700c78dd8a9">3,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">License Agreements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has multiple license agreements with the University of Florida Research Foundation and the University of Texas at Austin (the "License Agreements") in which the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the U.S. and international markets. The effective term of the License Agreements extends through the term of the related patents.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays royalty fees ranging from <ix:nonFraction unitRef="number" contextRef="ie4725cd6d9b24bb59307c754dcac2d41_D20220101-20221231" decimals="2" name="axgn:RoyaltyFeesPercentageUnderLicenseAgreements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzE1ODc_f4b34b9e-90ab-4b37-ae22-e3720d545f3d">1</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i2dd68d66cd4242ecb6935259bfbb0bfd_D20220101-20221231" decimals="2" name="axgn:RoyaltyFeesPercentageUnderLicenseAgreements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzE1OTM_978fa674-2d3a-4df9-ac36-e4c3c8e77f40">3</ix:nonFraction>% under the License Agreements based on net sales of licensed products. Also, when the Company pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at <ix:nonFraction unitRef="number" contextRef="i2dd68d66cd4242ecb6935259bfbb0bfd_D20220101-20221231" decimals="4" name="axgn:PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzIwMjM_74048cef-0d70-4561-abd8-862d25339529">3.75</ix:nonFraction>%. </span></div><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="axgn:ScheduleOfRoyaltyExpensesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzkzNDU4NDg4NDEwMDk_a54a3779-2a97-4b84-ab92-0446ad0a9995" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty fees included in sales and marketing on the consolidated statement of operations are as follows for the years ended:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:44.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty fees </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87452ca58634dbaa8dd73c32eb97477_D20220101-20221231" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTpiOTZkZGM3YzQ4MmU0MWEyYTlkYTE2ZTNlYmNiZDVmNS90YWJsZXJhbmdlOmI5NmRkYzdjNDgyZTQxYTJhOWRhMTZlM2ViY2JkNWY1XzItMS0xLTEtMTExMjkz_a1e685d3-fe04-43f9-ba0a-635b33c4cc51">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7f9133c7a74c2bbd041186bedf782a_D20210101-20211231" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTpiOTZkZGM3YzQ4MmU0MWEyYTlkYTE2ZTNlYmNiZDVmNS90YWJsZXJhbmdlOmI5NmRkYzdjNDgyZTQxYTJhOWRhMTZlM2ViY2JkNWY1XzItMy0xLTEtMTExMjkz_e17ab038-f84b-4456-8ce1-be57ea32f838">2,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i883e9d9eb9ba4b5980f84ab0473b72ff_D20200101-20201231" decimals="-3" name="us-gaap:RoyaltyExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTpiOTZkZGM3YzQ4MmU0MWEyYTlkYTE2ZTNlYmNiZDVmNS90YWJsZXJhbmdlOmI5NmRkYzdjNDgyZTQxYTJhOWRhMTZlM2ViY2JkNWY1XzItNS0xLTEtMTExMjkz_82c64502-d6d7-4997-b139-9a2cb1b8f74f">2,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzQ4Nzk_ddd76579-95c1-4e06-b824-d48fd58961c6" continuedAt="i27486a7e066f421b8bb5a96fdcf9a0c9" escape="true">Fair Value Measurement </ix:nonNumeric></span></div><ix:continuation id="i27486a7e066f421b8bb5a96fdcf9a0c9" continuedAt="ib378eabf5cd2460ab516f1899cb934ec"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzQ4ODI_3a8dc70a-36df-4c80-93ac-f318314168d1" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2022, and 2021:</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1cb615006a90448cae97a9c052e1adfb_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzMtMS0xLTEtMTAyNDMx_baa9b789-8371-4e7d-9513-830fbe6f90af">10,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i108f5fba334f442e831ebcd3d2adaee4_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzMtMy0xLTEtMTAyNDMx_8d00112c-ca92-420b-94f1-4a371d4cd7ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2d98f50d860845f4a00f11fe83cde291_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzMtNS0xLTEtMTAyNDMx_5c9b2bc5-3e04-4f8b-8972-220a9e2385e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i45579dc2f8964009928c3c2e3fef14d8_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzMtNy0xLTEtMTAyNDMx_fe188fff-6e08-47ec-8c0a-b9f64ba78b50">10,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie9f0dbd08bf2403187833c72b32e0021_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzQtMS0xLTEtMTAyNDMx_d71a8856-6e21-4efd-a8ff-f30ecd299a06">12,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73351972eccc4224be149e2d0b567b8c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzQtMy0xLTEtMTAyNDMx_cc657ba7-9112-45c2-8f66-f2f99523fa8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4d33c3cc49e343eb8a823bc5ad30dd10_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzQtNS0xLTEtMTAyNDMx_8c3ebd3f-1f15-42e0-97ae-0febb0f748d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia545915c6cee4044ae461b4e3af6a345_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzQtNy0xLTEtMTAyNDMx_ef7c41e3-43a2-4bab-8eea-daebf4d946d5">12,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id571ec182cbc48dbb46f0902fabfaa4e_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzYtMS0xLTEtMTAyNDMx_14dbde92-b716-4f4c-b4c9-2e61a6be4d14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0fd5c952fe7147368209c3bdedede315_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzYtMy0xLTEtMTAyNDMx_08c80317-efe0-4aff-9ce0-333f4ca05409">21,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibe2f9c677cc94813913c444deda1a1fd_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzYtNS0xLTEtMTAyNDMx_938e5b60-92d9-405a-b898-e40cfdaf8b17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie6afd80e6ff54416977b579d2a685207_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzYtNy0xLTEtMTAyNDMx_8b70cfba-2a71-44f4-bbb1-2c128a937d9e">21,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5149fc3ac5624e7ca71842bdab5b8b31_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzctMS0xLTEtMTAyNDMx_747722c5-a0da-4649-abed-682dba142595">22,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5473e91ae2d416cae7554133eb8cbb1_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzctMy0xLTEtMTAyNDMx_9bac9c7b-3600-4e29-bc43-3a14cc3f02a4">21,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d1a0dcac804c06a79caf26d3fdcdf2_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzctNS0xLTEtMTAyNDMx_ee7b0152-5f9e-4a81-946a-20ce14a7fb3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43510f63e6ba4c3ca4047759ce1d9771_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzctNy0xLTEtMTAyNDMx_8a2922cd-7bc6-44ed-9318-c78dfc75afff">43,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7965b9980ab4e319a9eb72458f4e891_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzExLTEtMS0xLTEwMjQzMQ_ea542e60-91dc-4abd-9b7a-8c9e70871ee3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6626e08228454045ae1ff645428d36cd_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzExLTMtMS0xLTEwMjQzMQ_a0f44ab9-2ca0-4e09-8228-61f9cdde18fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1feb2a1c57d43a8a89b0469ed5f79d3_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzExLTUtMS0xLTEwMjQzMQ_c116eee9-a0a6-41da-bd01-5c738dc015a4">4,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7999f53613c34864ab3d0b6a7527bba5_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzExLTctMS0xLTEwMjQzMQ_cf03cc62-f771-4656-9942-be903519316e">4,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5149fc3ac5624e7ca71842bdab5b8b31_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzEyLTEtMS0xLTEwMjQzMQ_367b55b3-b925-4c7e-9e36-ab189031d2aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5473e91ae2d416cae7554133eb8cbb1_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzEyLTMtMS0xLTEwMjQzMQ_38dba40e-daf9-41d9-b517-bc6e7897d595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79d1a0dcac804c06a79caf26d3fdcdf2_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzEyLTUtMS0xLTEwMjQzMQ_452343a9-2bd9-4c9e-81f7-b8590f28605c">4,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43510f63e6ba4c3ca4047759ce1d9771_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzEyLTctMS0xLTEwMjQzMQ_72ab6800-ee98-46d0-a3ec-d7c238f966fc">4,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i42db69a16e2a4860a246a776fd8ad30c_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzMtMS0xLTEtMTAyNDMx_3b96e12d-20bb-4c01-8f0d-b9e112d07da5">22,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ife046a9660e8491b9dca4c3123909056_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzMtMy0xLTEtMTAyNDMx_26c1071c-9e71-4289-afda-a5d4ec9ae15b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6e456cfb65c14ed1ae258c526b1a5ce9_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzMtNS0xLTEtMTAyNDMx_c2fcf7ca-bdad-43c5-9bf1-8f48df4d3540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i614ad5e81ab442e19a8c5e1d2bb61b7f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzMtNy0xLTEtMTAyNDMx_81f22b80-b0b1-4d1b-bd43-341a511706e7">22,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i699ff71d4b5f46c19f42ee43b4ff55ff_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzQtMS0xLTEtMTAyNDMx_233544f4-de31-4d71-a7ca-aafdf2e59178">12,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3ba0f9df4d9c44889d4cd22b2ac19083_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzQtMy0xLTEtMTAyNDMx_d0f0d809-b039-4587-b1eb-2b97b68b3d66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i690e6522ce7d426589cbba53994c7d97_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzQtNS0xLTEtMTAyNDMx_f94bf3ec-adca-4286-96fc-ba35cc993c90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id48f1ba541194d20abbd6444602c33bb_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzQtNy0xLTEtMTAyNDMx_3e5012ea-50d2-4944-aeb7-0528b45a683d">12,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i12533576801f4002b10b0fe696102c65_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzYtMS0xLTEtMTAyNDMx_53b49c34-9167-4400-aefe-d826d1460652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i134277d723964a98be276a7cfd374add_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzYtMy0xLTEtMTAyNDMx_0de0c71d-a729-450d-92e3-9030ed515fb7">39,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7dc0ea19aecc4d6dbf7f2bb1e1acc8cc_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzYtNS0xLTEtMTAyNDMx_c0d0671b-2d9d-48ab-b823-4beb62b32601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i07a044804b5b4fb1af23926c78c8ce13_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzYtNy0xLTEtMTAyNDMx_51fba7d6-7349-44c6-a037-0baacb9ce3c6">39,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9df50280b6e4544bdb2b7df50822fa9_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctMS0xLTEtMTAyNDMx_091ae009-f7e0-42e4-bdbf-46be4995b40d"><ix:nonFraction unitRef="usd" contextRef="id9df50280b6e4544bdb2b7df50822fa9_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctMS0xLTEtMTAyNDMx_f514860e-ea59-4917-b263-644efc696f13">34,093</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c01632c18d4b0fa2a95b893eb9f178_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctMy0xLTEtMTAyNDMx_716bc0a8-b9e8-410e-b3a1-c1a8320403a5"><ix:nonFraction unitRef="usd" contextRef="i13c01632c18d4b0fa2a95b893eb9f178_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctMy0xLTEtMTAyNDMx_b35d2bf7-0ede-43f3-ac7c-cd45b81b3c71">39,249</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic339a73d39af4de797a3d83409a67e96_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctNS0xLTEtMTAyNDMx_4fe08155-6181-44d2-943a-44650c1c1b18"><ix:nonFraction unitRef="usd" contextRef="ic339a73d39af4de797a3d83409a67e96_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctNS0xLTEtMTAyNDMx_e3bc5e51-7bec-4db8-9c6a-c5e5db575571">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233781a5f56440c3bd9431cd5d4497ec_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctNy0xLTEtMTAyNDMx_2c53c075-54c2-46a8-8162-b63f77ac615b"><ix:nonFraction unitRef="usd" contextRef="i233781a5f56440c3bd9431cd5d4497ec_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctNy0xLTEtMTAyNDMx_ec9f68df-f655-485b-a6c9-e68ee5174996">73,342</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt derivative liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51dbdd80d2ef4fdcbf34d3331a1740c8_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzExLTEtMS0xLTEwMjQzMQ_f5a7d407-adb9-45c3-a5b6-9a3489eedb8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f44c5f22b0f4c40813f276fb3c6827e_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzExLTMtMS0xLTEwMjQzMQ_c64ced99-bbb1-4a5e-9a54-03ac95399643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe9c570ebbd4043946a89fd045c1f82_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzExLTUtMS0xLTEwMjQzMQ_ac07a7c6-65a2-4e45-a631-dd9417e6498c">5,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7407c910a8640d8988cc07ab8eda26d_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzExLTctMS0xLTEwMjQzMQ_3eb9cbc0-898a-4068-b01c-81ae5b893653">5,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9df50280b6e4544bdb2b7df50822fa9_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzEyLTEtMS0xLTEwMjQzMQ_ee6b439e-f7e8-4e19-b0c5-e25f5a5ce25e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c01632c18d4b0fa2a95b893eb9f178_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzEyLTMtMS0xLTEwMjQzMQ_de49267c-6070-4e1d-925d-2d7d3b6e3e3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic339a73d39af4de797a3d83409a67e96_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzEyLTUtMS0xLTEwMjQzMQ_443934f2-fa7d-4a93-9dbd-047c8701a13d">5,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233781a5f56440c3bd9431cd5d4497ec_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzEyLTctMS0xLTEwMjQzMQ_0813ac54-1af6-4753-ba9b-1d10249da1b9">5,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzQ4ODM_e2fb25b8-afa5-4eed-bbe1-1ea2cd3147ef" escape="true"><div style="margin-top:10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Level 3 liabilities measured at fair value on a recurring basis were as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"></td><td style="width:74.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Derivative Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3799b9b46cfa4242a49caf62d6c4d193_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzEtNC0xLTEtMTAyNDMx_b4ed9ac0-172c-45f3-b515-c40e4bc4fbe8">2,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd23a1c75242caaecd4598b4ab2e33_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzItNC0xLTEtMTAyNDMx_152827d8-cab7-421f-a3ae-68485fcdb361">3,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96fd23a1c75242caaecd4598b4ab2e33_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzMtNC0xLTEtMTAyNDMx_4747ac56-b1e3-40a2-94be-7bdc520215ab">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe9c570ebbd4043946a89fd045c1f82_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzUtNC0xLTEtMTAyNDMx_79ddf741-e5ed-4055-983b-0adad96cb66b">5,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42df21d43bee4402a8975d2309e802f0_D20220101-20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzctNC0xLTEtMTAyNDMx_80a47eaa-dc65-4390-9807-c3aacc4a1e33">1,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1feb2a1c57d43a8a89b0469ed5f79d3_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzgtNC0xLTEtMTAyNDMx_c13ced83-1e9f-4212-9a51-a4555c0e6bee">4,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no changes in the levels or methodology of the measurement of financial assets or liabilities during the years ended December&#160;31, 2022, and 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of cash, restricted cash, accounts receivable, accounts payable and accrued expenses approximates the carrying values because of the short-term nature of these instruments. The carrying value and fair value of the Credit Facility were $<ix:nonFraction unitRef="usd" contextRef="i05a09806c9ee410192e276bdee67d4ec_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzIxOTkwMjMyNjA5MjA_73ad5050-b514-4d61-b3f3-e9f8f19774fa">45,712</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i05a09806c9ee410192e276bdee67d4ec_I20221231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzEwOTk1MTE2MzI5NTA_8fcfc2f9-d4fd-4399-bd8d-e3a33dca0e6b">50,293</ix:nonFraction> at December&#160;31, 2022, respectively, $<ix:nonFraction unitRef="usd" contextRef="i493945d3878542549477456e7e460b75_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzU0OTc1NTgxOTIxNw_865b5f26-c870-488b-a236-d60b83839645">45,325</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i493945d3878542549477456e7e460b75_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzU0OTc1NTgxOTIxMw_f17d9edf-af70-47e4-bb48-ebbeb999130b">52,605</ix:nonFraction> at December&#160;31, 2021, respectively. See Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees .</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The debt derivative liabilities are measured using a &#8216;with and without&#8217; valuation model to compare the fair value of each tranche of the Credit Facility including the identified embedded derivative feature and the fair value of a plain vanilla note with the same terms. The fair value of the Credit Facility including the embedded derivative features was determined using a probability-weighted expected return model based on four potential settlement scenarios for the Credit Facility included in the table below. The estimated settlement value of each scenario, which would include any required make-whole payment (see </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="ib378eabf5cd2460ab516f1899cb934ec"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees ), is then discounted to present value using a discount rate that is derived based on the initial terms of the Credit Facility at issuance and corroborated utilizing a synthetic credit rating analysis. </span></div><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzcxNDY4MjU1OTIzODc_885ced90-2356-4d81-9783-dd9828b6e3fc" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant inputs that are included in the valuation of the debt derivative liability - first tranche include:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Input</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Remaining term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4fb3c6271c204980bf4241e0ed97c838_I20221231" decimals="1" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzItMS0xLTEtMTIxNjA5_e2c9bc1e-3995-4f7b-af29-d79600d8981b">4.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i112f623f3210421683f1756809d4475b_I20211231" decimals="1" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzItMy0xLTEtMTIxNjA5_7b4a026c-9a6c-4497-901c-1a4b7bf95cce">5.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturity date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Coupon rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib01ca98fb65f484db7aa0441f172af4a_I20221231" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzQtMS0xLTEtMTIxNjA5L3RleHRyZWdpb246OWM2ZGNhMzI5NGJlNGVhNjg1ZDc5MTlkMjZhNDdkOTJfNTQ5NzU1ODEzOTA4_ec6585ba-84fe-49d2-bbad-8a934537959b">9.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i6a72a93104ed4eccbc5523f4c0f05191_I20221231" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzQtMS0xLTEtMTIxNjA5L3RleHRyZWdpb246OWM2ZGNhMzI5NGJlNGVhNjg1ZDc5MTlkMjZhNDdkOTJfNTQ5NzU1ODEzOTE2_8811d8ba-7c0f-4678-9ea1-3e45dbd9be60">12.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7df814d0d49f44b38f0402eeabb3552c_I20211231" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzQtMy0xLTEtMTIxNjA5_55340763-daa0-45c0-93eb-1abc5df2a292">9.50</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue participation payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02f73cc8149a450c9f9c913738431082_I20221231" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzYtMS0xLTEtMTIxNjA5_79a0f4b5-8986-4739-b8ff-d7dac53112f0">13.90</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie21ffd851ecc4537b177459b24c9a3d5_I20211231" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzYtMy0xLTEtMTIxNjA5_92d2021a-7c40-429b-92e1-74f5733fbd49">10.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Probability of mandatory prepayment before 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac001b043861493599ed9f7cf962441d_I20221231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzctMS0xLTEtMTIxNjA5_abb6fbf7-3a75-4ffe-9b3c-8586b24672af">5.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8843fd82eae4f4092d2b2e26e5f6403_I20211231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzctMy0xLTEtMTIxNjA5_d258bc39-1ad4-45d8-995b-2a1eea15c958">5.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated timing of mandatory prepayment event before 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Probability of mandatory prepayment 2024 or after</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3218bc21e1b493a82d42491d73cb0ea_I20221231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzktMS0xLTEtMTIxNjA5_3bc1cb96-c88e-4bde-a105-39d2c58fe646">15.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i920e8bfa648d41c7b399a5783bd68c3c_I20211231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzktMy0xLTEtMTIxNjA5_f7bf2a96-1366-4eb7-8030-91db8f4f0bd8">15.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated timing of mandatory prepayment event 2024 or after</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Probability of optional prepayment event</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia49615132a2c496d981625ca85c9c943_I20221231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzExLTEtMS0xLTEyMTYwOQ_50f2e9f0-3903-4f53-93ae-078f2e234a58">5.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1cad8ff35f4474da61c3d70a7da989b_I20211231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzExLTMtMS0xLTEyMTYwOQ_2b798d57-5cce-4d39-bb18-c19a795d8a15">5.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated timing of optional prepayment event</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents a significant unobservable input.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant inputs that are included in the valuation of the debt derivative liability - second tranche include: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Input</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic393cbccf77f4f7f9ddd00e20e44bfa7_I20221231" decimals="1" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzItMS0xLTEtMTIxNjA5_3b5c841e-c249-4760-b8fc-c0ff9d7b395c">5.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3313bb44c00d456ba559b7c53b18be3d_I20211231" decimals="1" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzItMy0xLTEtMTIxNjA5_7cf8ae60-564e-41bf-aede-486fb780d38f">6.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coupon rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac024fdbce484e7f8e49292e12eb03a3_I20221231" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzQtMS0xLTEtMTIxNjA5L3RleHRyZWdpb246Zjk0NjVhM2M0ZTI2NDU0YzgyNmE2Nzk0MzRmY2Y1ZjRfNTQ5NzU1ODEzOTA4_cb839e26-85f5-4898-bf3e-73e5b53002ba">9.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i2ac361d361b540cbba4353a8b20de144_I20221231" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzQtMS0xLTEtMTIxNjA5L3RleHRyZWdpb246Zjk0NjVhM2M0ZTI2NDU0YzgyNmE2Nzk0MzRmY2Y1ZjRfNTQ5NzU1ODEzOTE2_db519634-9bd3-4dc9-806c-3502e3e4ea68">12.7</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if2532d10d99c4277927947329d695475_I20211231" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzQtMy0xLTEtMTIxNjA5_d7154a17-365f-4ccf-a4bc-9cb7eea6d680">9.50</ix:nonFraction>%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue participation payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a116e8bc9eb4403af53f80e4b35086c_I20221231" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzYtMS0xLTEtMTIxNjA5_5dd653b7-5951-4ad3-986d-c434ade24250">17.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e18c269659d4844ac0d512a92bcd2a2_I20211231" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzYtMy0xLTEtMTIxNjA5_b51d71f9-3605-4037-82e7-01c48117b671">13.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of mandatory prepayment before 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1958bf62020547a291e5c09e08fcc45f_I20221231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzctMS0xLTEtMTIxNjA5_c4124a9f-603b-4a86-9fe6-049c302826fe">5.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if107145343dc4b0daddec46f6ccc3857_I20211231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzctMy0xLTEtMTIxNjA5_22b0f8a2-90c9-4484-9ff4-149bea3392fe">5.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated timing of mandatory prepayment event before 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of mandatory prepayment 2024 or after</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d58523409ee484bae896a42cbecd8b1_I20221231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzktMS0xLTEtMTIxNjA5_2a0e868d-29f0-4c2c-92dc-48ec0a7ce5e2">15.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i49673c1dce6f4f2496f2da68cd37b20b_I20211231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzktMy0xLTEtMTIxNjA5_a4e240a7-013e-4b3b-9d2b-086500a165c7">15.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated timing of mandatory prepayment event 2024 or after</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of optional prepayment event</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic134f7c3e14d4cd7b7811f6e97064116_I20221231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzExLTEtMS0xLTEyMTYwOQ_3485ab32-943a-4ba8-8cc0-bdc8d548228c">5.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81395195766a421e95d3757424963785_I20211231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzExLTMtMS0xLTEyMTYwOQ_508fa3f6-614b-43ff-8e16-892e8cafcb7e">5.0</ix:nonFraction>%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated timing of optional prepayment event</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents a significant unobservable input.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90ZXh0cmVnaW9uOjhlOTlkMGFjMGQ5ZTQ1ZDlhNGE3MmIwZjRkMzNlYmI0XzExMA_362d9b80-fdf1-44df-9676-f18a6f079b8d" continuedAt="ie810d4004ade4d2eaf28405811838961" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:continuation id="ie810d4004ade4d2eaf28405811838961"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90ZXh0cmVnaW9uOjhlOTlkMGFjMGQ5ZTQ1ZDlhNGE3MmIwZjRkMzNlYmI0XzExMQ_8e660596-642b-4805-90a5-4e650910a6b5" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzEtMS0xLTEtMTAyNDMx_89aabe29-72c8-4927-868b-f183dfe91b68">8,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzEtMy0xLTEtMTAyNDMx_86f714ab-cafd-48c4-be7b-7041e3af5c6d">5,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzItMS0xLTEtMTAyNDMx_83c4d3b2-af44-4b36-bba7-f34710c18655">4,520</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzItMy0xLTEtMTAyNDMx_e0d39b4f-fc5f-49a9-a707-0454ae4d39ce">6,863</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzMtMS0xLTEtMTAyNDMx_06187804-abe6-4363-8614-866c70775256">8,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzMtMy0xLTEtMTAyNDMx_70a326b9-b28a-4359-a738-f99ce0710503">9,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts payable and accrued expenses</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzQtMS0xLTEtMTAyNDMx_effb3b48-1695-4948-8fc3-f350026d1c96">22,443</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzQtMy0xLTEtMTAyNDMx_dad34bca-7da1-4f35-ac2a-d3615ee3137a">22,459</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_109"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzQyMA_0159b1f3-de3e-4d56-8b7e-fd6e089170d6" continuedAt="i0b8ea66a2b0e490e8174c1562d46c775" escape="true"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzQyMA_71cfc386-98e1-4791-8390-89cfd5909456" continuedAt="i50cf573958b04b9781d1bde631553715" escape="true">Leases </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i0b8ea66a2b0e490e8174c1562d46c775" continuedAt="ie3a2c08d6235480d8dbeab5110d2d5a0"><ix:continuation id="i50cf573958b04b9781d1bde631553715" continuedAt="ic95ecdce1d014b3e8145a48661d84599"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases administrative, manufacturing, research and distribution facilities through operating leases. Several leases include fixed payments including rent and non-lease components such as common-area or other maintenance costs. </span></div><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzcxNDY4MjU1OTE5NTc_b3a6efee-3cb7-4d35-ba1b-8d8ecaad65cd" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of total lease expense for the years ended were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzMtMS0xLTEtMTIwNTY1_d922bc6d-a803-45ff-94b1-1a4dabf3302c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzMtMy0xLTEtMTIwNTY1_749e710a-fbd6-4368-9df6-44837cfc160d">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzMtNS0xLTEtMTIwNTY1_2497e5e5-1d89-4aa9-8158-addd376e3e36">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzQtMS0xLTEtMTIwNTY1_ce708d9e-05a4-462e-95b4-0151af79d7c2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzQtMy0xLTEtMTIwNTY1_7d8d5539-1e5c-47d8-8002-5b129034bbc1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzQtNS0xLTEtMTIwNTY1_45204e41-bfef-4bdd-8358-6a8c3e87999c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzYtMS0xLTEtMTIwNTY1_6acbe7d4-c1b7-4c48-b2d5-e595169bf1f9">4,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzYtMy0xLTEtMTIwNTY1_8242c0b6-1b76-4c44-a5d0-188b6e1ec4ce">4,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzYtNS0xLTEtMTIwNTY1_e6418dfe-5a8a-4221-9132-50a2d11c3aa6">2,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzctMS0xLTEtMTIwNTY1_e16cb15c-f407-44d2-a9bb-3840e569f6b4">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzctMy0xLTEtMTIwNTY1_0d98dab1-fa96-4bc2-8bf2-be0f337cf9e5">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzctNS0xLTEtMTIwNTY1_661524ef-ac8e-403f-975a-db16e1274c07">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzgtMS0xLTEtMTIwNTY1_3fa2d6d3-cdde-479b-b3ca-c2585f106458">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzgtMy0xLTEtMTIwNTY1_d5fa2358-8f91-4b90-b892-4a1e91003164">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzgtNS0xLTEtMTIwNTY1_679adb4b-30fa-4cb6-b423-dd49ad8964b9">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzktMS0xLTEtMTIwNTY1_ba4296e2-e028-448f-b1c2-e3eb728c3262">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzktMy0xLTEtMTIwNTY1_1b5d7bee-4de8-4384-89ee-0c49549d3963">5,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzktNS0xLTEtMTIwNTY1_3ea4bd2d-17b1-4231-a2fc-5a308fbb1af8">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="axgn:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzkzNDU4NDg4NDAyOTI_6e1cb6b8-6092-4b2d-8dea-a486f50540cd" continuedAt="i0b7dd47a201941a0bbfda62d38c3b782" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the operating and financing leases is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except lease term and discount rate)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use operating assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzItMS0xLTEtMTEwNTU4_332ead80-84d5-412a-998a-2a8611ba8eda">14,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzItMy0xLTEtMTEwNjUw_12f8362e-ec2b-40eb-b6e0-c24fb2d8b0fe">15,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_282ba7ce-3ef3-47fa-b090-df6bc8c1cb62"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_bf9cd539-7ed8-407f-9081-99b74e7abdea">Current maturities of long-term lease obligations</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMS0xLTEtMTEwNTY2_ae84cc38-279d-48cd-aa4a-418d1465c013">1,303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMy0xLTEtMTEwNjU0_b4d8fbcb-2c83-418f-bf97-4292428270ba">1,825</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_43b1e322-811d-4e24-9d5c-24c744c9ffc6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_90aa3a79-3bec-4569-a69a-52d996616d6a">Long-term lease obligations</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMS0xLTEtMTEwNTc0_7c2b0e22-2672-4eeb-a9b9-59f1187e80ef">20,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMy0xLTEtMTEwNjU4_d342f8e9-4fd7-4e87-8e7e-4d86f9ef263e">20,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Leases </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use financing leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzYtMS0xLTEtMTEwNTgy_9e12c6fb-bcc3-4407-8f39-802ba145e60e">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzYtMy0xLTEtMTEwNjY0_ee2179c1-009c-4746-b140-b9bedb0efe02">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_271319ea-950a-424e-8fc3-fea671d857ad"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_51dc3b73-6881-4d4b-ad5d-be166f123d9e">Current maturities of long-term lease obligations</span></span> </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMS0xLTEtMTEwNTkw_d8d82436-24d4-40e7-9782-ebf4e85e897e">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMy0xLTEtMTEwNjcy_5537896f-109d-42ab-bc26-091071678d13">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_ad5ae935-b90b-46e6-8d03-aa77e93ca8d3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_d55777eb-f537-4f2f-82c6-3481b4ecb124">Long-term lease obligations</span></span> </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMS0xLTEtMTEwNTk4_c15eebe6-7b81-4e8d-8e36-48f4059159d7">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMy0xLTEtMTEwNjc2_47de2c5d-dd5e-44bb-89d6-c874259d4146">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average operating lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzEwLTEtMS0xLTExMDYwNg_c12304e3-6a33-44b8-bd4e-37152d15345d">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzEwLTMtMS0xLTExMDY4MA_e0426ffe-c37b-45c5-827f-ce6d2237d204">12</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average financing term (in years):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzExLTEtMS0xLTExMDYxNA_8bd07bc9-6d96-4761-acbd-f68852ccaf9b">4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzExLTMtMS0xLTExMDY4NA_24520201-2683-4991-bbaa-005b8edaa67a">2</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzEzLTEtMS0xLTExMDYzNg_a08b7995-02b5-4f17-b68b-f2aa4c0e4f99">10.58</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzEzLTMtMS0xLTExMDY4OA_c53670b4-628f-4a8d-9054-fda68060c276">10.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate financing leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzE0LTEtMS0xLTExMDY0Mg_926d4ef9-d3b1-4eec-9bca-e57619fc361c">11.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzE0LTMtMS0xLTExMDY5Mg_d79d6a5f-9d05-4a60-9ee0-f1f30c182004">7.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i0b7dd47a201941a0bbfda62d38c3b782" continuedAt="i798e2b55bf2247bdb8d25431374a4344"> (1)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i798e2b55bf2247bdb8d25431374a4344"> Financing leases are included in property and equipment, net on the consolidated balance sheets.</ix:continuation> </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="ie3a2c08d6235480d8dbeab5110d2d5a0" continuedAt="i3f5cc2880b9c40db8367ee8bec15d8f1"><ix:continuation id="ic95ecdce1d014b3e8145a48661d84599" continuedAt="i1c241362588d4a589fd84a505ae42624"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzkzNDU4NDg4NDAyOTM_676d662e-1ce5-4cb9-9154-84fd8faf5899" escape="true"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzkzNDU4NDg4NDAyOTM_e17ea2aa-fc22-4d92-8b1c-1d821ef1b617" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating and financing leases as of December&#160;31, 2022, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzEtMS0xLTEtMTEwMTA2_5a0ac686-cc12-4c5c-9b22-c349bc77cc60">3,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzItMS0xLTEtMTEwMTA2_c6894fbb-8dfd-476d-bf6d-f6fbc9b66cb0">3,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzMtMS0xLTEtMTEwMTA2_6122bd9f-3883-4a25-940a-f61281ce6991">3,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzQtMS0xLTEtMTEwMTA2_07294201-449d-4726-8a45-dd6b9818e7b0">3,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzUtMS0xLTEtMTEwMTA2_81204ac8-950a-497b-88b5-ebca3bc2bf60">2,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzctMS0xLTEtMTEwMTA2_52a11026-3e48-4cd6-a128-beec3b1878ad">20,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzgtMS0xLTEtMTEwNDUy_d271ac02-de59-4ca2-9b83-06211b006f66">37,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzktMS0xLTEtMTEwMTA2_89d91ea2-8566-4139-89f1-634aa7425c6f">15,637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:OperatingAndFinancingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzEwLTEtMS0xLTExMDQ2OA_694b207b-e297-4253-a65e-745d04efc4c4">21,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:OperatingAndFinancingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzExLTEtMS0xLTExMDEwNg_8b2e72cc-4acf-4648-81bd-034ea116b020">1,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:OperatingAndFinancingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzEyLTEtMS0xLTExMDQ4NA_c25dbf24-9ca2-44a7-ae71-e9785c706688">20,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease modifications</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for lease revisions as a lease modification in accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the modification effectively terminates the existing lease and creates a new lease.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2021, the Company entered into the Seventh Amendment to a License and Services Agreement ("Seventh Amendment") with Community Blood Center (doing business as Community Tissue Services) ("CTS"), with an effective date of February 22, 2021, pursuant to the original agreement dated August 6, 2015, as amended ("CTS Agreement"). The CTS Agreement is for processing of the Avance Nerve Graft in Dayton, Ohio. The Seventh Amendment extended the term of the agreement to December 31, 2023. Under the CTS Agreement, the Company pays CTS a facility fee for use of clean room/manufacturing, storage, and office space, which the Company accounts for as an embedded lease. The Company valued the CTS Agreement using a <ix:nonFraction unitRef="number" contextRef="i7ba9dcd463a4411d98f217af826e1ec3_D20210222-20210222" decimals="3" name="axgn:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTc4MQ_9e47e466-9d77-418b-8ef9-05e8d5fd88d7">6.3</ix:nonFraction>% incremental borrowing rate and recorded a right-of-use asset  and a lease liability of $<ix:nonFraction unitRef="usd" contextRef="ic07a04ab4a2a4b3fa3a573b41c2448a6_I20210222" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTc5MA_436563e9-d106-4026-9dcc-bb7316f86091"><ix:nonFraction unitRef="usd" contextRef="ic07a04ab4a2a4b3fa3a573b41c2448a6_I20210222" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTc5MA_823bf9fa-5709-4b77-b4a5-72ed91f8bae1">272</ix:nonFraction></ix:nonFraction> as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, the Company entered into the First Amendment to Office Lease ("Heights Union First Amendment") with Cousins Heights Union, LLC (as successor in interest to Heights Union I, LLC), with an effective date of July 12, 2021, pursuant to the original lease dated September 20, 2018, as amended ("Heights Union Lease"). The Heights Union Lease is for the general office, medical laboratory, training, and meeting purposes located in Tampa, Florida. The Heights Union First Amendment revises the commencement date of the Heights Union Lease to mean October 30, 2020 and revises the termination date of the Heights Union Lease to be October 31, 2034. Pursuant to the Heights Union First Amendment, the Company was entitled to an additional <ix:nonFraction unitRef="m" contextRef="i157567aac3fe47c883ab1353f6869f96_D20210712-20210712" decimals="INF" name="axgn:LesseeOperatingLeaseNumberOfRentFreeMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTgzMw_f1d23b36-c64b-4536-9712-ccaef57f2ce3">1.5</ix:nonFraction> months of free rent. The Company valued the Height Union Lease using a <ix:nonFraction unitRef="number" contextRef="i157567aac3fe47c883ab1353f6869f96_D20210712-20210712" decimals="3" name="axgn:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg0MQ_dff6090a-21c2-4c62-8abe-8ca282b8cb08">10.6</ix:nonFraction>% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $<ix:nonFraction unitRef="usd" contextRef="i955f3c4847e84499b9e5df9ed14d2f7a_I20210712" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg1MA_992e8b67-97a9-4e5c-9bd2-983a6299fb59"><ix:nonFraction unitRef="usd" contextRef="i955f3c4847e84499b9e5df9ed14d2f7a_I20210712" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg1MA_efb0da20-0998-4f7c-9a57-01594df2278c">299</ix:nonFraction></ix:nonFraction> as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 13, 2021, the Company entered into a Sixth Amendment to Lease ("Sixth Amendment") with Alachua Copeland Park Investments, LLC (as successor in interest to Ology Bioservices Holdings, LLC, who was successor in interest to SNH Medical Office Properties Trust), with an effective date of July 13, 2021, pursuant to the original lease agreement dated February 6, 2007, as amended ("Alachua Lease"). The Alachua Lease is for the Company's corporate headquarters in Alachua, Florida. The Sixth Amendment extended the term of the Alachua Lease to October 31, 2026. The Company valued the Alachua Lease using a <ix:nonFraction unitRef="number" contextRef="i0b56b68105574c4899488b9442a10226_D20210713-20210713" decimals="3" name="axgn:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg4Mw_7e7f73bc-588f-40d0-8ff0-cf018bca582f">10.6</ix:nonFraction>% incremental borrowing rate and recorded a right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="i7c395685d2a24e03a092821152da1c30_I20210713" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg3Mw_bf4dc910-cdce-4da7-bb98-534f5dd3ef84">1,335</ix:nonFraction> and a lease liability of $<ix:nonFraction unitRef="usd" contextRef="i7c395685d2a24e03a092821152da1c30_I20210713" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg2OQ_fde74962-e8e8-43ef-abf6-79958c195913">1,370</ix:nonFraction> as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2022, the Company entered into a Commercial Lease Amendment ("Amendment") with JA-Cole L.P., with an effective date of February 1, 2022, pursuant to the original Commercial Lease dated April 21, 2015, as amended (the "2015 JA-Cole Lease"). The 2015 JA-Cole Lease is for the office and warehouse facility located in Burleson, Texas. The Amendment revised the commencement date to May 1, 2022, and the expiration date to April 30, 2027. The Company valued the 2015 JA-Cole Lease using a <ix:nonFraction unitRef="number" contextRef="i0581e65b1022415ca3161ab6932a9f19_D20220127-20220127" decimals="3" name="axgn:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg4Nw_7d059a42-6bfd-4712-b3fb-ab4e87a8fd76">11.3</ix:nonFraction>% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $<ix:nonFraction unitRef="usd" contextRef="i4097a733c1714381b903a1dfe340dafe_I20220127" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg5MQ_b88f7e5f-1256-45f3-bd1f-d37a75f5db71"><ix:nonFraction unitRef="usd" contextRef="i4097a733c1714381b903a1dfe340dafe_I20220127" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg5MQ_f5465a31-3c6c-49fe-b44a-4c5effaf46d9">641</ix:nonFraction></ix:nonFraction> as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2022, the Company entered into the First Amendment to Lease Agreement (the &#8220;First Amendment&#8221;) with JA-Cole, L.P. with an effective date of October 1, 2022, pursuant to the original Commercial Lease dated October 1, 2020, as amended (the "2020 JA-Cole Lease"). The 2020 JA-Cole Lease is for the office and warehouse facility located in Burleson, </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="i3f5cc2880b9c40db8367ee8bec15d8f1"><ix:continuation id="i1c241362588d4a589fd84a505ae42624"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Texas. The First Amendment adds an additional <ix:nonFraction unitRef="sqft" contextRef="i2e1fc63be79e43f2ab16a203a1d29645_I20220822" decimals="-2" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzE4NjkxNjk3NjgxMDYy_3f239645-8c4f-4112-a82e-4064fcf146f0">2,500</ix:nonFraction> square feet to the Leased Premises, for a total of <ix:nonFraction unitRef="sqft" contextRef="i099064cb7e584aca8bb8c8b521b1be3c_I20220822" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzE4NjkxNjk3NjgxMTE3_d6b54d0d-e873-49ad-b213-c0730d61f680">5,000</ix:nonFraction> square feet and revises the expiration date of the 2020 JA-Cole Lease to mean September 30, 2027. The Company valued the 2020 JA Cole Lease using a <ix:nonFraction unitRef="number" contextRef="icf7f7b402ec14835ba2971de3296cb0d_D20220822-20220822" decimals="3" name="axgn:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzE2OQ_e0b7547f-7252-4113-b0d8-6c23338a0a35">12.8</ix:nonFraction>% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $<ix:nonFraction unitRef="usd" contextRef="i2e1fc63be79e43f2ab16a203a1d29645_I20220822" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzE3Mw_10384ee1-c28d-4b5d-b391-3fda9e320bed"><ix:nonFraction unitRef="usd" contextRef="i2e1fc63be79e43f2ab16a203a1d29645_I20220822" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzE3Mw_c9417503-d307-44bf-8bf5-f24f4f08516f">221</ix:nonFraction></ix:nonFraction> as a result of this amendment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2022, the Company entered into the Second Amendment to Lease Agreement (the "Second Amendment") with SNH Medical Office Properties Trust n/k/a Nucleic Acids Licensing, LLC with an effective date of January 1, 2023, pursuant to the original lease agreement on November 19, 2018, as amended (the "2018 Nucleic Lease"). The 2018 Nucleic Lease is for medical laboratory space in Alachua, Florida. The Second Amendment extends the term of the 2018 Nucleic Lease one year; to December 31, 2023, with the option to extend the term for one additional year. The Company valued the 2018 Nucleic Lease using a <ix:nonFraction unitRef="number" contextRef="i41dbef148b97433ea98f9c4af34f62f1_D20221231-20221231" decimals="3" name="axgn:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzIwMg_75ee95ad-5384-4eac-82fa-92085684c059">14.0</ix:nonFraction>% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $<ix:nonFraction unitRef="usd" contextRef="ic9a30248ed7b4f40a1fafee657210a01_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzE5OA_46bbd2ac-8ec4-4083-a5f7-5a30f3803f4b"><ix:nonFraction unitRef="usd" contextRef="ic9a30248ed7b4f40a1fafee657210a01_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzE5OA_da17c0e9-c3ca-498a-a679-2db44c0ef850">75</ix:nonFraction></ix:nonFraction> as a result of this amendment.</span></div></ix:continuation></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_121"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzk1Mjk_48615156-20b2-443a-b4df-00d55ba88053" continuedAt="i1bcff229090d43228607a4127574b718" escape="true">Long-Term Debt, Net of Debt Discount and Financing Fees</ix:nonNumeric></span></div><ix:continuation id="i1bcff229090d43228607a4127574b718" continuedAt="i4843f7eebdcb4cff99bb7c7dffe1663d"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzk1Mjc_63042330-6be4-4fb4-a57c-468253a8e289" escape="true"><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of debt discount and financing fees consists of the following:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Facility - first tranche</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i312f2d64cb674fdbad24a7fe51918409_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzEtMS0xLTEtMTAyNDMx_52b9c84f-e3df-4ac6-a34c-30af9bc70a22">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i104179cd76d94a2bb5b480f5d740f348_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzEtMy0xLTEtMTAyNDMx_15a3821d-30fc-4579-b54a-8b3e1b7dcd64">35,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Facility - second tranche</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe9a8770fa764d7891407778eae23958_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzItMS0xLTEtMTAyNDMx_3a157a3f-c69b-49f2-a018-865f9a653a65">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id591cfe573344db49a17900c7f2534ed_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzItMy0xLTEtMTAyNDMx_2e986249-9614-4ffc-89c6-3600bfd163f1">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less - unamortized debt discount and deferred financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzMtMS0xLTEtMTAyNDMx_ca1534ec-385b-431e-95d9-a74c69cb5e69">4,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzMtMy0xLTEtMTAyNDMx_af1fca65-38e7-442a-ad8b-b5a02faed250">5,179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, net of debt discount and financing fees</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzQtMS0xLTEtMTAyNDMx_fc85768c-6f85-46b8-a86c-0e14b57b5a22">45,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzQtMy0xLTEtMTAyNDMx_fe6330ba-2a6c-49c9-8167-77872f0f9844">44,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company entered into a <ix:nonNumeric contextRef="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzk1MjY_47f2f728-ef61-4715-ab67-77965382880a">seven-year</ix:nonNumeric> financing agreement (the &#8220;Credit Facility&#8221;) with Oberland Capital and its affiliates TPC Investments II LP and Argo SA LLC (collectively, the "Lender") and obtained the first tranche of $<ix:nonFraction unitRef="usd" contextRef="i6403d399211849738490229c7838d26e_I20200630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzI4Nw_0619661b-ef5d-4fc2-a058-613a86f529cd">35,000</ix:nonFraction> at closing. On June 30, 2021, the second tranche of $<ix:nonFraction unitRef="usd" contextRef="if575cb76b14c473cbdc0a317a1e37598_I20210630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzM0Mg_61b3514c-4454-4ab7-adb0-daad2e29ce30">15,000</ix:nonFraction> was drawn down by the Company. The financing costs for this facility were $<ix:nonFraction unitRef="usd" contextRef="ia7f2d0f52ae2425faca15b977fa1eb33_I20210630" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzQxOQ_1f80427c-f6b5-4631-8c2c-9c2c94ba28b2">642</ix:nonFraction> and were recorded as a contra liability to the long-term debt on the consolidated balance sheet. The financing costs were paid as of December&#160;31, 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each tranche under the Credit Facility requires quarterly interest payments for <ix:nonNumeric contextRef="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630" name="axgn:DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzYwOA_2482f7e0-baf8-4f28-b898-b7dc945eaa2b">seven years</ix:nonNumeric>. Interest is calculated as <ix:nonFraction unitRef="number" contextRef="i18a440d8b8744e8f9a6b185b93f909de_I20200630" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzYzOA_a30e1591-f046-4a60-a76b-1ddfcf7ae1fb">7.5</ix:nonFraction>% plus the greater of the London Interbank Offered Rate ("LIBOR") or <ix:nonFraction unitRef="number" contextRef="id42e84f255884f7eb85ff88a32cfbec7_D20200630-20200630" decimals="3" name="axgn:DebtInstrumentAdditionalInterestFloorRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzcwOA_fb2e43d5-df91-43d5-9fb8-44a46196ca29">2.0</ix:nonFraction>% (<ix:nonFraction unitRef="number" contextRef="i05a09806c9ee410192e276bdee67d4ec_I20221231" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgzMDY0Nw_21fa732e-21a7-400a-9bc2-0e111314f28d">11.24</ix:nonFraction>% as of December&#160;31, 2022). Each tranche of the Credit Facility has a term of <ix:nonNumeric contextRef="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzc3OA_205d735a-994a-4587-bc3a-4958e164fef2">seven years</ix:nonNumeric> from the date of issuance (with the first tranche issued on June 30, 2020, maturing on June 30, 2027, and the second tranche issued on June 30, 2021, maturing on June 30, 2028). In connection with the Credit Facility, the Company entered into a revenue participation agreement (the &#8220;Revenue Participation Agreement&#8221;) with the Lender, which provided that, among other things, a quarterly royalty payment as a percentage of the Company&#8217;s net revenues up to $<ix:nonFraction unitRef="usd" contextRef="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630" decimals="-6" name="axgn:RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzEyMDI_a112e498-f01a-458b-a1f6-151ab994d623">70</ix:nonFraction>&#160;million in any given year, after April 1, 2021, ending on the date upon which all amounts owed under the Credit Facility have been paid in full. This structure results in approximately <ix:nonFraction unitRef="number" contextRef="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630" decimals="3" name="axgn:DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzE2MzM_67b18528-4624-4d18-94a7-ec81a7154858">1.0</ix:nonFraction>% per year of additional interest payments on the outstanding loan amount. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="if401beb532c24731a94a6c209f24f06f_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDU1Mg_b2ef07e4-9ea0-4a71-92c0-a127acf5e5a8">756</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="icc88fe00a2b34650ba8c22e3a5248c9a_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDU2MA_ecb662cf-90f5-4c8f-b8ea-6e3df8e62578">646</ix:nonFraction> as interest expense for this Revenue Participation Agreement for the years ended December&#160;31, 2022, and 2021, respectively. The Company pays the quarterly debt interest on the last day of the quarter, and for the years ended December&#160;31, 2022, and 2021, paid $<ix:nonFraction unitRef="usd" contextRef="if401beb532c24731a94a6c209f24f06f_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDYxMg_3963edbd-8939-491b-8292-c84eb9dab427">5,074</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="icc88fe00a2b34650ba8c22e3a5248c9a_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDYxNQ_7434ee33-ba83-42cf-b9a0-e3049244e270">4,103</ix:nonFraction>, respectively, to the Lender. The Company capitalized interest of $<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDYyNw_2aef9d37-3777-4587-8890-3fa80412ac30">6,155</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDY0NQ_90cd61ae-c781-47e2-bc84-726728d90886">4,277</ix:nonFraction> for the years ended December&#160;31, 2022, and 2021, respectively, towards the costs to construct and retrofit its APC Facility in Vandalia, OH. See Note 14 - Commitments and Contingencies. To date, the Company has capitalized interest of $<ix:nonFraction unitRef="usd" contextRef="i20c791c3ff7e418ab95668e32cc7a1ec_I20221231" decimals="-3" name="us-gaap:AccumulatedCapitalizedInterestCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgzMjY0Mg_3e87801a-5e13-4c7d-9358-ffe04f136f83">11,429</ix:nonFraction> related to this project. The capitalized interest is recorded as part of property and equipment in the consolidated balance sheets. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Lender had the right to purchase up to $<ix:nonFraction unitRef="usd" contextRef="ia2d1964162f34aa9aff7b7bf6ccd1778_I20200630" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzI0MTA_b53175ab-4aa5-42cd-b427-afa50ff268c5">3,500</ix:nonFraction> worth of the Company's common stock from the Company in one transaction at any time after closing of the Credit Facility until the later of (i) the date all amounts due under the Credit Facility are repaid and (ii) June 30, 2027 (the &#8220;Credit Facility Option&#8221;). The purchase price of the common stock was calculated based on the <ix:nonNumeric contextRef="i271d865b318a4f69926f6640eb4178a3_D20220101-20221231" name="axgn:PurchasePriceOfCommonStockCalculationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzk1Mjg_345625bc-e42e-4059-ae89-8c26cef3699d">45-day</ix:nonNumeric> moving average of the closing stock price on the day prior to the purchase. On December 10, 2020, the Lender exercised in full its option under the Credit Facility Option. The exercise price was determined to be $<ix:nonFraction unitRef="usdPerShare" contextRef="i32bc87a417ec436cbde425177f4f1fca_I20201210" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzI5NTY_c6ae716d-90a8-4aed-bc4b-40ced0464d7c">14.13</ix:nonFraction>, resulting in gross proceeds to the Company of $<ix:nonFraction unitRef="usd" contextRef="i7229d1ab938d4b54a5c614ac06b82ab4_D20201210-20201210" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzMwMDY_9a8e0fac-2d39-43e2-a64f-aa642a37ff6d">3,500</ix:nonFraction> and the issuance of <ix:nonFraction unitRef="shares" contextRef="i232073fcc6e04d25aa02ac11cc331bfc_I20201210" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzMwMjk_b765c184-5eab-456a-9ff1-c5af65f447ae">247,699</ix:nonFraction> shares to a wholly owned subsidiary of the Lender. In conjunction with the issuance of the shares, the Lender received certain protective rights (including protection from down-round stock issuances) for a period of one year subsequent to the issuance. These rights expired on December 10, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="i4843f7eebdcb4cff99bb7c7dffe1663d" continuedAt="i55e02b1d96dc4cf2916c4370eb35eede"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts outstanding under the Credit Facility may be accelerated upon certain events, including: (a) required mandatory prepayments upon an asset sale; (b) in the event the Company is subject to (i) any litigation brought by a Governmental Authority (as defined in the Credit Facility) including intervention after litigation is commenced by a Person (as defined in the Credit Facility), or (ii) any final administrative action by a Governmental Authority, in each case arising out of or in connection with any of the Company&#8217;s registry studies, payments made to doctors or training activities with respect to healthcare professionals (excluding certain final administrative actions that have been fully and finally resolved by the parties pursuant to a settlement agreement) or (c) upon the occurrence of an event of default (either automatically or at the option of the Lender depending on the nature of the event). In addition, the Company has the right to prepay any amounts outstanding under the Credit Facility. Upon maturity or upon such earlier repayment of the Credit Facility, the Company will repay the principal balance and provide a make-whole payment calculated to generate an internal rate of return to the Lender equal to <ix:nonFraction unitRef="number" contextRef="i18a440d8b8744e8f9a6b185b93f909de_I20200630" decimals="3" name="axgn:DebtInstrumentMinimumRequiredInternalRateOfReturn" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzQ2Mjk_9cbe7eeb-4b3c-4dae-9a77-e95665ca20e2">11.5</ix:nonFraction>%, less the total of all quarterly interest and royalty payments previously paid to the Lender. See Note 14 - Commitments and Contingencies for further information related to the make-whole payment calculation.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of an event of default, the interest rate incurred on amounts outstanding under the Credit Facility will be increased by <ix:nonFraction unitRef="number" contextRef="i18a440d8b8744e8f9a6b185b93f909de_I20200630" decimals="INF" name="axgn:DebtInstrumentInterestRateEventOfDefaultIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzQ5MDc_949676b9-251e-4211-8e5c-f255342c3e3e">4</ix:nonFraction>%. The Credit Facility includes a financial covenant requiring the Company to achieve certain revenue targets each quarter. As of December&#160;31, 2022, the Company was in compliance with all the covenants. In the event of a failure to meet such covenant the Company may avoid a default by electing to be subject to a liquidity covenant and meeting all of the obligations required by such covenant. The borrowings under the Credit Facility are secured by substantially all of the assets of the Company. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that Credit Facility included separable embedded features on a combined basis as a single derivative feature. The Company estimated the fair value of these features as $<ix:nonFraction unitRef="usd" contextRef="i443dfc9e27ca43fa95f569f05a0bbe28_I20200630" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzcyMTk_9944c825-7fbe-455b-80ac-43301f036306">2,387</ix:nonFraction> as of the date of issuance of the Credit Facility and recorded this value as a debt derivative liability. As a result of the second tranche draw on June 30, 2021, the Company recorded an additional derivative and estimated the fair value to be $<ix:nonFraction unitRef="usd" contextRef="i1655c65194084245be81921c34c77204_I20210630" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDY2OQ_3868eebb-2c71-4e2f-94fb-665b23f30ecf">1,961</ix:nonFraction>, along with an increase of $<ix:nonFraction unitRef="usd" contextRef="i2861cc9701fe4e06bbe34f3f481d4cbb_I20210630" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDY1Mw_dae62985-26c9-467d-b482-b2f5fb6f7d93">1,076</ix:nonFraction> related to the first tranche derivative. See Note 6 - Fair Value Measurement. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt derivative liabilities are recorded at fair value, with the change in fair value reported in change in the fair value of the derivative on the consolidated statements of operations at each reporting date. See Note 6 - Fair Value Measurement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unamortized Debt Discount and Financing Fees</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unamortized debt discount consists of the remaining initial fair values of the embedded derivatives related to the Credit Facility. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financing fees for the Credit Facility were $<ix:nonFraction unitRef="usd" contextRef="i18a440d8b8744e8f9a6b185b93f909de_I20200630" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNzQ4NQ_7ed47f01-df94-4f8b-88b1-d176fcc9c474">642</ix:nonFraction> and were recorded as a contra liability to long-term debt on the consolidated balance sheet. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt discount and deferred financing fees for the years ended December&#160;31, 2022, 2021 and 2020, was $<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyODAzNw_cf0de251-7e1b-4d33-8ed0-bc7c906fc9c9">891</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyODA0MQ_258917a1-9d21-44b3-9b7b-efced9205a4c">831</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyODIyNA_c5d0c0d1-969c-4c8d-9226-d9c8ebe63fe4">232</ix:nonFraction>, respectively, and recorded in interest expense using the effective interest rate method.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Credit Facilities</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i55e02b1d96dc4cf2916c4370eb35eede">The Company had restricted cash of $<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzkyMzU_85c30433-a133-4797-8043-49db86a72679">6,251</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDUwMg_ed397614-46f7-4dcc-a28f-82457df6c72d">6,251</ix:nonFraction> at December&#160;31, 2022, and 2021, respectively. The December&#160;31, 2022, and 2021 balances both include $<ix:nonFraction unitRef="usd" contextRef="i8a546ce46a914aa785e30fa74d23ae15_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCollateralAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzkzMDk_127d150a-d056-4cd0-a3d1-25a5fd02fd2e"><ix:nonFraction unitRef="usd" contextRef="i6eb9268062cf4f6cbb9c740dbb809cea_I20221231" decimals="-3" name="us-gaap:DebtInstrumentCollateralAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzkzMDk_c995e120-9f53-4b2a-b013-5fffda4c2d2a">6,000</ix:nonFraction></ix:nonFraction>, which represents collateral for an irrevocable standby letter of credit. In March 2021, the Company entered into an agreement which required an additional irrevocable standby letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i2bda4fe5ea904b66952845b8d764cf1b_I20210331" decimals="-3" name="us-gaap:DebtInstrumentCollateralAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzk1MjM_3f63c8a0-48f9-41cb-a243-6bfa524b2358">250</ix:nonFraction>.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90ZXh0cmVnaW9uOjRjNjg0MjhlOTc2YzQ0NjM4NjA1NTIxMTc3ZGNjZDVjXzcxNDY4MjU1ODIwMTE_77482fbb-6e68-4c72-953d-93b5e66f8b08" continuedAt="ic5fb8699ee674810990674c3ae2950e6" escape="true">Basic and Diluted Loss per Common Share</ix:nonNumeric></span></div><ix:continuation id="ic5fb8699ee674810990674c3ae2950e6"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90ZXh0cmVnaW9uOjRjNjg0MjhlOTc2YzQ0NjM4NjA1NTIxMTc3ZGNjZDVjXzcxNDY4MjU1ODIwMTM_f20f5aa1-5059-497b-9a33-b849e9624cc7" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two-class method as of:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzMtMi0xLTEtMTA1OTQ3_a80f770a-bc04-495d-8d35-8047859901b4">28,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzMtNC0xLTEtMTA1OTQ3_07326441-74f6-45d2-ad5d-c1b3b1f76c2a">26,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzMtNi0xLTEtMTEyMTMw_f7d02799-eb65-49ea-b948-669fa3230e59">23,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted-average common shares outstanding (Basic)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtMi0xLTEtMTA1OTQ3_2d448aa0-8bbf-4519-be72-34d2e6721c48"><ix:nonFraction unitRef="shares" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtMi0xLTEtMTA1OTQ3_513e9d47-1a2b-4b26-b372-21e6bb23e38d"><ix:nonFraction unitRef="shares" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtMi0xLTEtMTA1OTQ3_84179dbf-4da7-4e7f-b270-4d8a281f5bd1"><ix:nonFraction unitRef="shares" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtMi0xLTEtMTA1OTQ3_b055903e-52ce-4473-9a18-8fcb0276264d">42,083,125</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtNC0xLTEtMTA1OTQ3_0f98db8a-b32b-454d-97c0-899d0c733c75"><ix:nonFraction unitRef="shares" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtNC0xLTEtMTA1OTQ3_e121a3d8-aaa8-4c90-b193-7140b912bed9">41,214,889</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtNi0xLTEtMTEyMTcx_385258be-71be-442a-ae66-afba20e3ad90"><ix:nonFraction unitRef="shares" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtNi0xLTEtMTEyMTcx_a62741fb-290a-4852-a606-4d2c92e16914">39,966,937</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding (Diluted)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzYtMi0xLTEtMTA1OTQ3_18d93ce1-4fde-4a85-bea7-2e892f96b064">42,083,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzYtNC0xLTEtMTA1OTQ3_62fd2e09-725a-49ea-bc76-5802ef2862da">41,214,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzYtNi0xLTEtMTEyMTc5_358bb6f6-c305-4e3c-9388-f8d9a7b84f24">39,966,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per common share (Basic and Diluted)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctMi0xLTEtMTA1OTQ3_cbd0789b-9163-4653-96b0-af345323b1be"><ix:nonFraction unitRef="usdPerShare" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctMi0xLTEtMTA1OTQ3_ccb9521c-9d44-45a8-841c-c15a24420787">0.69</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctNC0xLTEtMTA1OTQ3_441486ef-7d48-4599-acf7-75116327194d"><ix:nonFraction unitRef="usdPerShare" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctNC0xLTEtMTA1OTQ3_e216db2e-6ed3-4003-bd8b-ab7b6029a076">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctNi0xLTEtMTEyMjI3_3b14e3c3-2fc4-44ef-837a-b981c55f419f"><ix:nonFraction unitRef="usdPerShare" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctNi0xLTEtMTEyMjI3_ff9db9ed-4c11-40d9-937d-842dfe5958a2">0.60</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-dilutive shares excluded from the calculation of diluted earnings per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6204757bdfb4234845eb99fcc2f5bde_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzEwLTItMS0xLTEwNTk0Nw_baed45ce-9ed8-458e-ab5b-661483bee045">3,133,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib00632d9ac6845ff94f04e3e98489229_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzEwLTQtMS0xLTEwNTk0Nw_90de40af-bcb1-425d-bdab-1e3caf422c3c">1,364,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88b8752e11b545e6a8bef12b17eaa002_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzEwLTYtMS0xLTExMjI3NQ_a1bee83a-ad42-4de5-8519-35f383ef8735">1,618,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a16e53d518446cfbd2024ffdb8a8bf1_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzExLTItMS0xLTEwNTk0Nw_a6c52547-32d3-4f2b-8326-5d0f49fb6306">454,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36385a5cb9a84a35be78534b6035cd66_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzExLTQtMS0xLTEwNTk0Nw_9ce7e1d1-f877-4b7d-922e-0c40a022953f">333,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i071fd4cf629e4e2280fd669b14f69dee_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzExLTYtMS0xLTExMjI4Mw_edb9713f-593c-4a94-863e-98c3c4df00cb">188,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> These common equivalent shares are not included in the diluted per share calculations as they would be anti-dilutive if the Company was in a net income position.</span></div></ix:nonNumeric></ix:continuation><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_127"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzODU_caf72d51-2618-4168-b51d-000cc4b36979" continuedAt="i519e5c86cbbd4d91a140940850138579" escape="true">Stock-Based Compensation </ix:nonNumeric></span></div><ix:continuation id="i519e5c86cbbd4d91a140940850138579" continuedAt="id3012a7ba1304a77aeef5e679f5eaaab"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains <ix:nonFraction unitRef="plan" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="INF" name="axgn:ShareBasePaymentArrangementNumberOfPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzYw_0e18381f-e388-4165-b14d-ed51512e4ab3">two</ix:nonFraction> stock-based incentive plans: the Axogen, Inc. 2019 Amended and Restated Long-Term Incentive Plan, as amended ("2019 Plan") approved by shareholders on May 25, 2022, which provides incentives through the grants of stock options, non-qualified stock options, PSUs and RSUs to employees, directors, and consultants which replaced the Company's 2010 Stock Incentive Plan ("2010 Plan") and the Axogen 2017 Employee Stock Purchase Plan (&#8220;2017 ESPP&#8221;).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the May 25, 2022, Annual Shareholder Meeting, approval was received to increase the number of shares available under the 2019 Plan by <ix:nonFraction unitRef="shares" contextRef="if01e2ccdaa54461098fe9e12370e82c8_D20220525-20220525" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0Mjc2NQ_72f676e0-dce1-401d-b75d-3725d1ad59d5">2,500,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="i1901933b221a4b9b954c7479477f3e4b_I20220525" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NTE4Mw_fd713148-b54b-404b-b390-61ec9064804b">8,000,000</ix:nonFraction>. The 2019 Plan replaced the 2010 Plan, accordingly, no new grants have been issued under the 2010 Plan.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i23829077b773438fa1c9f990db81d62a_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NTY3OA_19506bdc-175c-444e-ada2-2089f51c3795">3,374,881</ix:nonFraction> shares of common stock for future grant under the 2019 Plan.</span></div><div style="margin-top:10pt;text-indent:18pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzcxNDY4MjU2MDQ3NTA_2a4518d0-7389-4fa6-9114-7e38f0b62e19" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is included in the following line items in the accompanying consolidated statements of operations for the years ended:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Costs of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ea41484f76d414e87f57fe619eda0d3_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzItMi0xLTEtMTEzNTIy_6c87c499-e7d3-4611-9cea-e3ec4d8f0dc1">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265deb6981db4caba802dff7098eaf78_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzItNC0xLTEtMTEzNTIy_c2a05b42-bfac-466a-b634-87c365afc1eb">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia017b12b6e4844b9ad5921672e3ad683_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzItNi0xLTEtMTEzNTIy_69d7ba6a-9d2f-44f6-b08c-e59d3a6175ae">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic382dfac5eb34387894011ca21faacb1_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzMtMi0xLTEtMTEzNTIy_d08dcf52-cc5b-4300-aeff-ac5dc552c0b8">2,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a5e8c7dd95f4725be7b20b882541185_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzMtNC0xLTEtMTEzNTIy_27d07a8d-9222-4831-b421-fef2af3a8aa9">2,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad06ab740e97428ab5fa032137f4d319_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzMtNi0xLTEtMTEzNTIy_3fa88b40-0aa8-446f-ad47-fdbb0d78a2ad">2,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353c868d857d4f78b75da6d08d6f5ce8_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzQtMi0xLTEtMTEzNTIy_cb0cd594-ce39-4207-b074-7496ca52b463">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82f76c354583477ba3582208c4de3e9f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzQtNC0xLTEtMTEzNTIy_b1f57b77-154a-4f1a-9641-5ef188fb2d33">1,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906644212cb044e79417f0990512be9f_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzQtNi0xLTEtMTEzNTIy_fecfbccd-0664-44ba-b2b2-1eef970b81f0">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib865e7888f5b433f95e77cfab871debf_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzUtMi0xLTEtMTEzNTIy_d353ab87-7dbf-435b-820e-566418b3b804">10,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9648970fef2d49fbbf69cb19fe670983_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzUtNC0xLTEtMTEzNTIy_505a9ff3-27cb-442e-a585-d93680d6fb32">5,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7956fd5c1234348844e780e82ebc0c1_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzUtNi0xLTEtMTEzNTIy_90b93401-dd94-43d4-b8b7-2e7fc25fb6c0">4,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total  stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib744e6a9173947e59255d4550e92de8b_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzYtMi0xLTEtMTEzNTIy_89aee083-8160-403e-83b3-08f614d07150">15,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee39cce463fb44d0a4bfe365b6681f5d_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzYtNC0xLTEtMTEzNTIy_881da139-e3c5-4b6c-8fa8-1cef3b9c5f93">10,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09c0b507e033470891c7ca7da0c6882b_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzYtNi0xLTEtMTEzNTIy_a74877b8-5f0d-4aab-8e6f-ba2e6d5ba047">8,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted to employees prior to July 1, 2017, typically vest <ix:nonFraction unitRef="number" contextRef="i9aca85efc69240e1a769914f9dcb9319_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzIyNDI_e35a5a33-dbff-47fe-9823-584b1355fd81">25</ix:nonFraction>% <ix:nonNumeric contextRef="i9aca85efc69240e1a769914f9dcb9319_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzIyNDU_a445d788-4868-4de5-b7d4-4cc9c1edd18b">one year</ix:nonNumeric> after the grant date and <ix:nonFraction unitRef="number" contextRef="i2ec881302ae14b18b7a4033a56f38e41_D20220101-20221231" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzIyNzM_b0746739-398e-4db3-a408-cb54032694be">12.5</ix:nonFraction>% every six months thereafter for the remaining <ix:nonNumeric contextRef="i2ec881302ae14b18b7a4033a56f38e41_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzODM_26bcee2d-8fb4-4406-b6eb-b421e83b240b">three-year</ix:nonNumeric> period until fully vested after <ix:nonNumeric contextRef="ia801c2b2298a45dd968f3bc35b69132c_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzIzNjI_4fabd0ee-3fed-4da1-8537-b91793e4fead">four years</ix:nonNumeric>. The options granted to employees after July 1, 2017, typically vest <ix:nonFraction unitRef="number" contextRef="iab23cd73c6404992b546cccab3d848b9_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI0MzM_abbd4fef-343d-4f33-a301-8cd654caea55">50</ix:nonFraction>% <ix:nonNumeric contextRef="iab23cd73c6404992b546cccab3d848b9_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI0MzY_d00087d3-bd5f-4900-a667-6ab65ccf7388">two years</ix:nonNumeric> after the grant date and <ix:nonFraction unitRef="number" contextRef="i8d35f388c73c4c55b667458fd456bb77_D20220101-20221231" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI0NjQ_3a2e16ef-e0d1-40b5-a068-628f33ca3080">12.5</ix:nonFraction>% every six months thereafter for the remaining <ix:nonNumeric contextRef="i8d35f388c73c4c55b667458fd456bb77_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzODg_ad825771-7592-441b-a6b4-50573e512948">two-year</ix:nonNumeric> period until fully vested after <ix:nonNumeric contextRef="ie8fe5d68d40444db8d1a38fee238b7a9_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI1NTM_81ed86ea-f5c7-45d4-af95-fd46b568b54a">four years</ix:nonNumeric>. The options granted to directors and certain options granted from time to time to certain executive officers have vested ratably over <ix:nonNumeric contextRef="i0212c0badd7b46908abba199f97a351e_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI2OTE_f17252cc-a88f-4b0e-8531-a614c7e3e28b">three years</ix:nonNumeric> or <ix:nonFraction unitRef="number" contextRef="i5e80010008dd494aa1fc37d1fd76468b_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI2OTc_a8e163a2-b2c9-43f9-bbbe-1e07e080621e">25</ix:nonFraction>% per quarter over <ix:nonNumeric contextRef="i5e80010008dd494aa1fc37d1fd76468b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI3MTc_5fd5b7ba-ceea-44d4-8fcc-385c9b9b3a7d">one year</ix:nonNumeric>. Options typically have terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI3NjM_61ba867c-4dd3-4803-a6a5-10aa309ff564">seven</span> to <ix:nonNumeric contextRef="ic0b94c6006f54a3db47bc4394457d1e3_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI3Njk_e9dc7e22-0299-473d-a7e9-c0a7ee7b88ff">ten years</ix:nonNumeric>. The Company estimates the fair value of each option award on the date of grant using a multiple-point Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur. The value of the portion of the award that is ultimately expected to vest is recognized as </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="id3012a7ba1304a77aeef5e679f5eaaab" continuedAt="i4a129185ef9641559dd01bd31ee1f25f"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur.</span></div><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzcxNDY4MjU2MDQ3NTI_fcdc4fdd-7102-4bf7-947a-134e15fa1379" continuedAt="i22acc32389a7403bb1cd7c504c2c8507" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used in the calculation of fair value for stock options granted for the following periods:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:54.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.667%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzMtMi0xLTEtMTEyNDM1_4391b5ea-963f-4940-89c3-9db0fab1d7fc">6.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzMtNC0xLTEtMTEyNDM1_d6f03cef-ecae-425b-8378-6bec3c6d68a9">5.88</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzMtNi0xLTEtMTEyNDM1_17eaf099-b030-4e86-a292-9a9555b505e4">5.88</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzQtMi0xLTEtMTEyNDM1_3ed77748-4f1f-4d06-998c-0c7f227c631e">61.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzQtNC0xLTEtMTEyNDM1_768737f6-b8a0-4633-aa14-b96a77793714">58.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzQtNi0xLTEtMTEyNDM1_7bf895d9-ebe2-4c2c-8d25-916ae550c043">58.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzUtMi0xLTEtMTEyNDM1_c311bd87-ef8b-425c-82b6-7800eb739654">2.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzUtNC0xLTEtMTEyNDM1_915d7f37-e1a2-47c8-8f93-867dc0c95376">1.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzUtNi0xLTEtMTEyNDM1_7ff6c3be-4af2-4f63-8231-5a62f2c5b3f5">0.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzYtMi0xLTEtMTEyNDM1_7232c9b4-c35a-4316-b22c-a00f2c747d6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzYtNC0xLTEtMTEyNDM1_d69b981f-988c-485a-9cef-dedc212d4e28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzYtNi0xLTEtMTEyNDM1_d24ad8b3-6cb1-4a8b-a7f7-af9ce96d16a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzODQ_03e9a32d-9a6d-4310-8f5a-0ae430e3d203" escape="true"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's stock option activity for the year ended December&#160;31, 2022:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value              (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic51b16331d104e7e8fdcef21b100803f_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzUtMS0xLTEtMTAyNDMx_fd798028-ba29-4ce4-bcce-fbf2da7a46ad">3,194,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic51b16331d104e7e8fdcef21b100803f_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzUtMy0xLTEtMTAyNDMx_f011fb51-741e-43d7-ac2a-57a97e9b5a3c">15.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzUtNS0xLTEtMTAyNDMx_72c3bb45-d503-4fcc-a6ef-fc031ee31ee4">6.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic51b16331d104e7e8fdcef21b100803f_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzUtNy0xLTEtMTAyNDMx_b2d8bbfe-e211-4fda-b33f-1d919e2589ca">2,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzYtMS0xLTEtMTAyNDMx_cf77a471-417e-4bb1-974b-306a28efee2b">1,228,920</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzYtMy0xLTEtMTAyNDMx_e469e27d-f573-4f49-aa6b-716b1c9456c0">9.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzctMS0xLTEtMTAyNDMx_e174c496-6353-48e8-85c8-cb3f21b3b5f9">267,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzctMy0xLTEtMTAyNDMx_5355195a-06f9-4dd0-8d10-29eb6b7f641c">14.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzgtMS0xLTEtMTAyNDMx_5408342f-0859-41d1-adc1-faec80abb6d3">260,963</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzgtMy0xLTEtMTAyNDMx_8df062d8-cfe3-4fa2-b20b-e29b95082dd4">4.97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id192a5d2ca61416498fadecd34072e03_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzktMS0xLTEtMTAyNDMx_1827f4b0-db2b-4a15-8dd3-ed7dff0d28cf">3,894,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id192a5d2ca61416498fadecd34072e03_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzktMy0xLTEtMTAyNDMx_8719ee42-8746-4fa9-8faf-26d3b89e3002">14.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzktNS0xLTEtMTAyNDMx_aac64738-9737-43dd-9c34-f10ee83c2ba4">6.78</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id192a5d2ca61416498fadecd34072e03_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzktNy0xLTEtMTAyNDMx_7c8b45da-2c7b-4d9b-8378-f7234b893e29">2,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id192a5d2ca61416498fadecd34072e03_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzExLTEtMS0xLTEwMjQzMQ_89640a08-f726-451f-acde-452bbaed11ae">2,034,249</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="id192a5d2ca61416498fadecd34072e03_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzExLTMtMS0xLTEwMjQzMQ_abacf09b-f1cd-40a0-90f2-9dc859e6308c">16.31</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzExLTUtMS0xLTEwMjQzMQ_7d6f42af-400e-4793-8951-2359ff4dc610">4.94</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id192a5d2ca61416498fadecd34072e03_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzExLTctMS0xLTEwMjQzMQ_27216d46-6868-4b88-8780-8db53a39d7f3">1,462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of stock options granted during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzEwOTk1MTE2NjA4NDg_a8c055ce-fbf4-492a-814b-0090e6767d86">4.65</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzEwOTk1MTE2NjA4OTA_9927ff77-b8cc-459e-8540-7dcb76d314a8">10.53</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzEwOTk1MTE2NjA4OTM_b2ef5544-ba46-4b85-bd78-102a5f5780e3">4.73</ix:nonFraction>, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised for the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDM0Nw_7a97a95a-e2ca-4f6d-92c4-4c70c03c63fb">2,643</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDM1Mg_eb178971-ea98-4bf8-b3be-081bb72d6c44">14,167</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDM2MA_110cfe2c-521e-4eb8-9a52-bede2e8d5d6c">5,595</ix:nonFraction>, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="id192a5d2ca61416498fadecd34072e03_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDIzNQ_ef96b089-72bb-406b-b978-999d49f906b9">6,839</ix:nonFraction> of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDI0NQ_dfca83f9-0931-4f7b-82bf-32c3713dd336">2.4</ix:nonNumeric> years. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted to employees have a requisite service period of <ix:nonNumeric contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzcxNDY4MjU1ODk5ODM_345caf88-7d92-471a-b62a-5dcec8d892ed">four years</ix:nonNumeric>. The RSUs granted to directors and certain RSUs granted from time to time to certain executive officers have a requisite service period of <ix:nonNumeric contextRef="id1e45b0b246b467fbbfb1b6cd29a64b4_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzM2Nzk_cc4585dc-3564-4d1f-bce2-4b4cdc75617a">three years</ix:nonNumeric>, while certain of these RSUs have a requisite service period of <ix:nonNumeric contextRef="i42d9032ded3e403885f2e9975a16f6ba_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzM3NDY_dc1d90f4-e2d1-45c1-8b95-46bb65dc59b4">one year</ix:nonNumeric>. The Company expenses the fair value of RSUs on a straight-line basis over the requisite service period. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="i4a129185ef9641559dd01bd31ee1f25f" continuedAt="i210c03c3a3ec4bd2a7c2f1e5656626f0"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzODY_a891e6e1-d18a-4d7b-9552-8c76b070e0ca" continuedAt="id91c9cf8493d4b3c82f42548030fec78" escape="true">The following table summarizes the activity for restricted stock units for the indicated periods:</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><ix:continuation id="id91c9cf8493d4b3c82f42548030fec78" continuedAt="icebc0cdd0cc049518adfce023734e3bc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:47.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding Restricted and Performance Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Units</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Fair Value at Date of Grant per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Vesting Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id91fc5c40e6640dda04b21132c42f27c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzYtMS0xLTEtMTAyNDMx_394efc51-4b45-4816-933a-0eeb59b32b3e">967,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id91fc5c40e6640dda04b21132c42f27c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzYtMy0xLTEtMTAyNDMx_16a4eb0c-526c-4164-909a-903d86a742f9">16.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4666913c7daa474b8bbb30f0335d78a8_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzYtNS0xLTEtMTAyNDMx_bfe06336-8e8d-4847-a785-a0d13aaf6b2f">1.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id91fc5c40e6640dda04b21132c42f27c_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzYtNy0xLTEtMTAyNDMx_dae9d092-55a4-498a-9dd9-a7746dc4d41c">9,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzctMS0xLTEtMTAyNDMx_c9260d81-c8b9-4345-8ce1-7a54fd2f89bd">1,413,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzctMy0xLTEtMTAyNDMx_aec53efc-02cf-4d24-9ad2-ebda88f91bab">8.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzgtMS0xLTEtMTAyNDMx_421a3a87-f912-458b-94bc-55bbae1a5732">265,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzgtMy0xLTEtMTAyNDMx_0f00569a-b7f0-48f8-80e0-2ea7e316381b">13.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzktMS0xLTEtMTAyNDMx_90a332c2-36d1-4710-bdee-d68388bd7b39">254,297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzktMy0xLTEtMTAyNDMx_51f09a7d-3c61-42cb-ae49-eea2531f48df">12.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia34eb80cba6046728fa5e0562af47d00_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzEwLTEtMS0xLTEwMjQzMQ_ad4237e1-8cbb-4ad2-8fc6-c41107c08335">1,861,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia34eb80cba6046728fa5e0562af47d00_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzEwLTMtMS0xLTEwMjQzMQ_a93f9305-bc43-4f60-8bbc-e6961aed0f4e">11.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzEwLTUtMS0xLTEwMjQzMQ_57ee8c8c-a202-49d6-b4ed-bd29fb262001">1.60</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia34eb80cba6046728fa5e0562af47d00_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzEwLTctMS0xLTEwMjQzMQ_bb328ab9-b8e1-4f2e-bff3-7f7dde5c5fe8">18,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of restricted stock units granted during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ2OA_e20e559d-e9e6-47c5-ad53-0c7cd2bb69d3">8.40</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4666913c7daa474b8bbb30f0335d78a8_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ3Mg_71c77f68-7852-4eee-a007-a3029aac5d1f">20.13</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i36f58e081cfe4d2ba7361775fbbb25d5_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ4Mg_46bb9d67-c5cc-43de-823f-7e603d3fe89a">9.55</ix:nonFraction>, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ia34eb80cba6046728fa5e0562af47d00_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDkyOA_159f6c14-9849-45b7-9e0e-579ca76c1c27">13,756</ix:nonFraction> of total unrecognized compensation costs related to unvested restricted stock. These costs are expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDkzMg_bfbe706d-5f6d-4ab9-8d41-2c953de4f52b">2.74</ix:nonNumeric> years. The total fair market value of restricted stock vested during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjExMQ_c400c10b-d0b7-4cf7-a397-20a3d6ff467d">2,288</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i4666913c7daa474b8bbb30f0335d78a8_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjExNg_17a3ba49-d611-4f4b-8de6-f30c13ef3a82">2,179</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i36f58e081cfe4d2ba7361775fbbb25d5_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjUwNQ_35247e57-5c0e-425d-bc97-646c784c8ab0">2,699</ix:nonFraction>, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Stock Units</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of the PSUs based on its closing stock price at the time of grant and its estimate of achieving such performance target and records compensation expense as the milestones are achieved. PSUs generally have a requisite service period of <ix:nonNumeric contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzQ1MTg_69916784-5360-4e97-8820-fbfe40781731">three years</ix:nonNumeric> and are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses their fair value over the requisite service period. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense will be adjusted based upon the Company&#8217;s estimate of achieving such performance target. The number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on the actual performance metrics as set forth in the applicable PSU award agreement. The amount actually awarded will be based upon achievement of the performance measures.</span></div><ix:continuation id="icebc0cdd0cc049518adfce023734e3bc"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for performance stock units for the indicated periods:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding Restricted and Performance Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Units</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Fair Value at Date of Grant per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Vesting Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd0c5b69b5984bf8bec833a99943f9a5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzItMS0xLTEtMTE0MjIz_a2486409-919b-4862-b516-4f5b0aa34753">763,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd0c5b69b5984bf8bec833a99943f9a5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzItMy0xLTEtMTE0MjI5_37189a3b-9a5d-4136-8c41-57c775e1251d">21.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie11aa559ad27461e8d53d7d3e811e707_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzItNS0xLTEtMTE0MjM3_e9ddfbbe-3f83-4dbd-b22e-061fd04bbb08">2.36</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0c5b69b5984bf8bec833a99943f9a5_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzItNy0xLTEtMTE0MjQz_94acd830-fd43-4888-b6d8-97bfe4a2a0ef">7,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzMtMS0xLTEtMTE0MjIz_2ebdbc97-670b-4a51-b9aa-458ef9f2400d">530,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzMtMy0xLTEtMTE0MjI5_9602602d-18b7-49bc-b1b0-a98ec488bc9e">8.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzQtMS0xLTEtMTE0MjIz_b9014000-4572-4144-8027-c063f965959d">77,671</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzQtMy0xLTEtMTE0MjI5_455418f4-78d9-418d-9032-d348a31edb20">18.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzUtMS0xLTEtMTE0MjIz_923a86da-c0f4-4fac-b139-34ec7ffdc6c6">104,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzUtMy0xLTEtMTE0MjI5_f362af69-e0fc-4349-9320-0c6dba6e5c3a">16.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i59a311c65bd9478aab63c3835e9f72d2_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzYtMS0xLTEtMTE0MjIz_080e09df-b9da-44cd-a79d-5c1f0a10ce2a">1,112,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i59a311c65bd9478aab63c3835e9f72d2_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzYtMy0xLTEtMTE0MjI5_a4e87ae7-2f2e-4e78-addd-fbe5abd45471">15.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzYtNS0xLTEtMTE0MjM3_1eabf1b1-8bca-4099-9107-ea630e72d5ae">1.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a311c65bd9478aab63c3835e9f72d2_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzYtNy0xLTEtMTE0MjQz_88c3b532-28cb-42f7-a88b-68f7763827e9">11,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of performance stock units during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjMxMg_c0200d81-38fc-47e2-8bd0-f70342560a8b">8.23</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie11aa559ad27461e8d53d7d3e811e707_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ2MQ_595080ec-cae7-4d4c-bf2e-14ee975764fe">20.70</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="id7b8b79e630c433d9fdf51406b61b52d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ2NA_03effe25-d863-4c00-886b-202e8732adfc">9.58</ix:nonFraction>, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i59a311c65bd9478aab63c3835e9f72d2_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNTYwMw_45109cbb-6d04-452c-aea7-942cc07a8610">1,723</ix:nonFraction> of total unrecognized compensation costs related to unvested performance stock. These costs are expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNTYwNg_c3521ba7-1f97-4afc-96f8-2b3c78051d28">1.86</ix:nonNumeric> years. The total fair market value of performance stock vested during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ4OA_a445ca7a-b695-460c-b08d-21b8bf853841">673</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ie11aa559ad27461e8d53d7d3e811e707_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ5MQ_f6ba6823-2ae6-422e-bc33-9baeb21e6038">2,302</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id7b8b79e630c433d9fdf51406b61b52d_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ5Nw_92ea3a35-f8a9-4d49-b162-968be17b0951">1,112</ix:nonFraction>, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PSU Awards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2017, December 27, 2018, and December 17, 2019, the Compensation Committee of the Board of Directors approved PSU awards to certain employees related to their work on the Company&#8217;s Biologics License Application </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="i210c03c3a3ec4bd2a7c2f1e5656626f0" continuedAt="i10056512db224c009d34c11d45581b7f"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("BLA"). As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i2655caad891648a1a7b5ffeb3d3a7654_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0MzUwOA_5e9afd12-afb8-4850-bd67-60fecf1f41c8">294,968</ix:nonFraction> PSU awards were available to vest. The number of shares is allocated to certain milestones related to the BLA submission to and approval by the FDA. These awards are expected to vest beginning when the BLA is submitted to the FDA, which is not expected to be until the second half of 2023. The performance measure is based upon achieving each of the specific milestones and will vest <ix:nonFraction unitRef="number" contextRef="i86095a926657489a9c0c27cdcf148b0a_D20181227-20181227" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU4OTE_02677928-a463-4cf1-bd02-7fad9064fb65"><ix:nonFraction unitRef="number" contextRef="i4efbb86d561c4296ac6a8acef41fa1c7_D20191217-20191217" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU4OTE_8eb2dcb8-6432-4564-86b6-944a60a7b6d6"><ix:nonFraction unitRef="number" contextRef="i51ad0d1614e74ceda868f8561214b5ae_D20171218-20171218" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU4OTE_9203d020-9222-4091-aaee-1b84eacf48e0">50</ix:nonFraction></ix:nonFraction></ix:nonFraction>% upon achieving each of the milestones and <ix:nonFraction unitRef="number" contextRef="i248e3d8e95cb446ea5448ffd760d6858_D20181227-20181227" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5MzY_120068d9-bd4e-4586-8a6c-3b85f8a05d1d"><ix:nonFraction unitRef="number" contextRef="i717731af1dc14019834ae2cebf768ac6_D20191217-20191217" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5MzY_726a05dc-7d4a-4bd0-a319-d092e85075e2"><ix:nonFraction unitRef="number" contextRef="i7a2ae8023341421386b40e9ae8b40f59_D20171218-20171218" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5MzY_cf358f0d-f866-4181-81ac-0bdd0d013dfa">50</ix:nonFraction></ix:nonFraction></ix:nonFraction>% <ix:nonNumeric contextRef="i717731af1dc14019834ae2cebf768ac6_D20191217-20191217" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5Mzk_1d1851b3-a7cd-4045-a22f-68f90ebce28f"><ix:nonNumeric contextRef="i7a2ae8023341421386b40e9ae8b40f59_D20171218-20171218" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5Mzk_3fd50f82-8dc5-465c-aba9-cc70ac5c3837"><ix:nonNumeric contextRef="i248e3d8e95cb446ea5448ffd760d6858_D20181227-20181227" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5Mzk_dca8cb76-5ce7-4ead-99bd-41856488587d">one year</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> later. No expense has been recognized on these awards. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, the Compensation Committee of the Board of Directors approved PSU awards of <ix:nonFraction unitRef="shares" contextRef="i19da80c554e84b1f87236d2a9f78dea3_I20200717" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3Xzc1ODY_ae90b4c4-7ec8-4857-aa47-97bee4f4a5fe">144,300</ix:nonFraction> shares tied to 2020 revenue. These awards were granted in mid-year with certain revenue targets adjusted for the impact of COVID-19. These 2020 awards granted in July reached <ix:nonFraction unitRef="number" contextRef="i8234a2e85537460db0ac834d843b9f53_D20200701-20200731" decimals="3" name="axgn:PercentageOfAchievementOfAwardIssued" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3Xzc3NjQ_40b4156f-2399-407e-a286-b84b1226f118">110</ix:nonFraction>% achievement of revenue targets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 16, 2021, the Compensation Committee of the Board of Directors approved PSU awards of <ix:nonFraction unitRef="shares" contextRef="ia3332793e1664f34a11a863a2ac0ea63_I20210316" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3Xzc4OTQ_574c759a-59e6-4025-a271-11ace65da7f7">332,200</ix:nonFraction> shares tied to 2022 revenue, with a payout ranging from <ix:nonFraction unitRef="number" contextRef="ifeb16850541e4351bd40387578338733_D20210316-20210316" decimals="3" name="axgn:PerformanceStockUnitPayoutOpportunity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NTY2Nw_b53e5016-5664-47ee-a633-9242a0447b6e">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ib665842cd4a641bd996a4f540d05b968_D20210316-20210316" decimals="3" name="axgn:PerformanceStockUnitPayoutOpportunity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3Xzc5NTg_bfc68709-fd63-4204-bcfe-7e67864f8afd">200</ix:nonFraction>% upon achievement of specific revenue goals. In the fourth quarter of 2021, it was determined that the performance metrics tied to 2022 revenue were no longer probable; therefore, stock compensation expense related to these awards of $<ix:nonFraction unitRef="usd" contextRef="id572945122984533aa8afff607ed6ec8_D20210101-20211231" decimals="-3" name="axgn:ShareBasedCompensationExpenseForfeitedOrReversed" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzgxOTQ_1c914019-7a0a-4cea-a9f4-d41ef6c021df">1,831</ix:nonFraction> was reversed in 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 16, 2022, the Compensation Committee of the Board of Directors approved PSU awards of <ix:nonFraction unitRef="shares" contextRef="i2216c948174746b58affe9e729448569_I20210316" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NTQzNg_f84aebae-307b-4990-acfd-007df62dc6dc">526,467</ix:nonFraction> shares tied to revenue from 2022 to 2024 with a pay-out range from <ix:nonFraction unitRef="number" contextRef="ifc02d67a57a34782804ce01d01580755_D20220316-20220316" decimals="3" name="axgn:PerformanceStockUnitPayoutOpportunity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzMxNzYz_233f41d1-d5a1-4abf-8b6b-295361607080">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia121473080d34c55a59059e23ecccb8d_D20220316-20220316" decimals="3" name="axgn:PerformanceStockUnitPayoutOpportunity" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NTYxNQ_59112cf3-9a31-4f37-8d7c-c141b4be0fec">150</ix:nonFraction>% upon achievement of specific revenue targets.At December&#160;31, 2022, the total future stock compensation expense related to non-vested performance awards is expected to be $<ix:nonFraction unitRef="usd" contextRef="i59a311c65bd9478aab63c3835e9f72d2_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzgzMjk_182c7a6e-0547-4d08-a034-f6cb2218ff69">1,693</ix:nonFraction> for those awards issued on March 16, 2022. Future stock compensation expense has not been calculated on the awards for which expensing has not yet begun which include the BLA awards.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017 ESPP</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 ESPP allows eligible employees to acquire shares of the Company's common stock through payroll deductions at a discount to market price (currently <ix:nonFraction unitRef="number" contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231" decimals="4" name="axgn:EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjU0OQ_f05e9140-2823-4df9-ae76-335bc2d8a5ba">15.0</ix:nonFraction>%) of the lesser of the closing price of the Company&#8217;s common stock on the first day or last day of the offering period. The offering period is currently <ix:nonNumeric contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231" name="axgn:EmployeeStockPurchasePlanOfferingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjcwNQ_500ace81-ae71-48b3-abb3-dcab09ef65d2">6</ix:nonNumeric> months. Participants may not purchase more than $<ix:nonFraction unitRef="usd" contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231" decimals="-3" name="axgn:EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjc5Ng_8fc35ed8-ad1f-48ed-b80f-27bd9e0f0092">25</ix:nonFraction> or <ix:nonFraction unitRef="shares" contextRef="ia0b64e28b97d45429f64b42130e5f1e9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzNDU4NDg4NjY2Mjc_cc0c747a-b704-4a10-81bb-cc705d445657">3,000</ix:nonFraction> shares of the Company&#8217;s common stock in a calendar year through the ESPP. Stock-based compensation expense related to the 2017 ESPP, included in total stock-based compensation expense, was $<ix:nonFraction unitRef="usd" contextRef="i5ad8aba17c754a17ae1c1742ee8271fc_D20220101-20221231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjk2NQ_631f7563-41ca-4498-8516-5d1c867fb55d">844</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="id23c516e6eac4ecd8e34c8640d264ee9_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjk3MA_30be87d1-11ae-426c-bfa1-6f4ef25bec8f">401</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i961f19ca53be45ff97d7bd5885e51a53_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjk3OA_379edf3e-7ad6-4232-b4ee-da4d1d1fdf89">493</ix:nonFraction> for the years ended December&#160;31, 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ibf36782fab8f4beda0e41e2bcb53023b_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNzA1Ng_acc05c68-6fee-48c0-9ed8-c64a10fed57c">600,000</ix:nonFraction> shares of the Company's common stock authorized for issuance under the 2017 ESPP and <ix:nonFraction unitRef="shares" contextRef="ibf36782fab8f4beda0e41e2bcb53023b_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNzE0NQ_82d484dd-a858-4db7-9c9e-42687198cf8e">69,155</ix:nonFraction> shares remain available for issuance.</span></div><ix:continuation id="i22acc32389a7403bb1cd7c504c2c8507"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the weighted average assumptions used in the valuation of ESPP options for the years ended December 31:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"></td><td style="width:43.773%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.472%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzMtMi0xLTEtMTEyMzc3_0f3f63e9-5eb1-43d7-a0bc-83e97259c09e">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iea37731e57ec4ce89a11a90afef95441_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzMtNC0xLTEtMTEyMzc3_cfd552c3-810b-44e5-a151-fc39cd057c95">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e8e5bdce3b54c78ae99fb00b50a85b4_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzMtNi0xLTEtMTE0OTI4_02d8be47-e8a7-4e8f-9c42-7f91c0c4c332">0.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzQtMi0xLTEtMTEyMzc3_98b767bf-115e-4713-854a-b4c592af720d">66.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea37731e57ec4ce89a11a90afef95441_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzQtNC0xLTEtMTEyMzc3_e1c3a723-0c66-422d-9931-50c0d8fc0683">48.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e8e5bdce3b54c78ae99fb00b50a85b4_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzQtNi0xLTEtMTE0OTI4_af0c78a1-a414-4248-9e8b-aa9a10fc767a">81.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzUtMi0xLTEtMTEyMzc3_7be3dc15-2bc7-4866-8a91-e9911220997c">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea37731e57ec4ce89a11a90afef95441_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzUtNC0xLTEtMTEyMzc3_a9901985-6f9c-4f76-8398-ac6b485e6234">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e8e5bdce3b54c78ae99fb00b50a85b4_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzUtNi0xLTEtMTE0OTI4_be948f65-f31c-427c-a768-7ec19f448460">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzYtMi0xLTEtMTEyMzc3_5ffc2116-6894-4de0-923c-3cf0384b15a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iea37731e57ec4ce89a11a90afef95441_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzYtNC0xLTEtMTEyMzc3_b5b531ee-2fa2-4fd5-b765-c9dc938d3b47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e8e5bdce3b54c78ae99fb00b50a85b4_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzYtNi0xLTEtMTE0OTI4_6ce579d0-dcd9-4b75-982d-f4867f9eec9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i10056512db224c009d34c11d45581b7f">The weighted-average grant-date fair value of ESPP options during the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ff1fe87cd0546b8b116eabe76752894_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzEwOTk1MTE2NjA5MDA_4423c98c-b15c-470b-a593-8d8b18847ca6">2.87</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i181cd94e7d834b44b5b5a1f041d09d44_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzEwOTk1MTE2NjA5MDQ_a5d00814-3b69-4846-858d-c3c87ebf0a45">5.18</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ieed0a63f9da94ba092fa792b834444ee_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NzA0OA_b426fb02-6815-42b7-b458-ff59fba70814">5.24</ix:nonFraction> respectively.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQ1NDE_ce468346-ef7f-4dfe-b20f-173d92e1c75a" continuedAt="ia75668b698524754a3e17451e3784bbd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:nonNumeric></div><ix:continuation id="ia75668b698524754a3e17451e3784bbd" continuedAt="ia500ff01c5f541d0859dbe6b8a335449"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQ1NDI_598b1d67-9b50-434f-bd56-e6d0c586a874" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities, as measured by enacted state and federal tax rates. Deferred tax assets and deferred tax liabilities are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzItMS0xLTEtMTAyNDMx_e951dcf2-8428-4150-8653-ab1d50060a39">42,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzItMy0xLTEtMTAyNDMx_ec299c50-e150-4722-b685-a85cceedd8c3">47,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzMtMS0xLTEtMTAyNDMx_7d71fe4b-e06c-4719-b3e0-e709d0d9d1c5">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzMtMy0xLTEtMTAyNDMx_0b003da5-8e77-4b50-a11d-0517ffb149b2">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:DeferredTaxAssetsInterestLimitation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzYtMS0xLTEtMTAyNDMx_23edc4bb-e339-4783-a5dd-064775a446cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="axgn:DeferredTaxAssetsInterestLimitation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzYtMy0xLTEtMTAyNDMx_336a9c94-d685-4548-ac59-008fc8faf658">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzctMS0xLTEtMTAyNDMx_63982fbd-cbe1-4365-a35d-5bc86a4dfb23">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzctMy0xLTEtMTAyNDMx_74279027-0245-4470-a079-760e4310ba74">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:DeferredTaxAssetsLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzgtMS0xLTEtMTAyNDMx_743cbe96-fc89-4328-91a7-faf18b9304cb">5,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="axgn:DeferredTaxAssetsLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzgtMy0xLTEtMTAyNDMx_e1682cc9-657c-42c0-bb00-28567b423b9f">5,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzktMS0xLTEtMTAyNDMx_557350ec-fded-4c7a-9dd6-303ac250a8b4">5,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzktMy0xLTEtMTAyNDMx_0f4a044e-cc4c-4f28-b490-3ed6548d0b23">3,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEwLTEtMS0xLTEwMjQzMQ_d9047ff9-bd7c-461e-a216-1ec9c25b5a07">6,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEwLTMtMS0xLTEwMjQzMQ_1decbdba-1fd2-4374-8a06-9dd54d47af89">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzExLTEtMS0xLTEyODQ5OA_16df90ee-0741-459f-9514-1fab1d581b8a">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" sign="-" name="us-gaap:DeferredTaxAssetsDerivativeInstruments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzExLTMtMS0xLTEyODUwMA_5f51f969-348b-4a81-8531-9b85c2e894fd">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charitable contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEyLTEtMS0xLTEyODUwMg_7ccf7495-1470-4a88-b600-7cfbcaf49faa">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEyLTMtMS0xLTEyODUwNA_4f8a2ec6-cb1e-4fd2-b71b-e3724756d3d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEzLTEtMS0xLTE0MjIyNQ_92b3d2f8-8141-487a-a5ba-51324b0f3121">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEzLTMtMS0xLTE0MjIzOQ_37429062-345f-47c3-bd8d-c081637dce1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzExLTEtMS0xLTEwMjQzMQ_a5b24140-9ad6-4e30-8011-f4a54572b946">63,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzExLTMtMS0xLTEwMjQzMQ_1c1b4b1a-38a9-4e90-aa09-c7754b9586d8">58,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEzLTEtMS0xLTEwMjQzMQ_448cebfb-b209-4cb5-a5fd-28260084b767">983</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEzLTMtMS0xLTEwMjQzMQ_40d2266c-5b2b-4e66-84bc-fbd251c7b0b6">692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE0LTEtMS0xLTEwMjQzMQ_76f5968c-12ee-41cf-8475-1777b0793530">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE0LTMtMS0xLTEwMjQzMQ_42ee2bd3-7576-4d5e-8663-09935951fb95">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE1LTEtMS0xLTEwMjQzMQ_4a7268b2-5159-4a1e-a6d9-52451d3bc3e4">3,744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="axgn:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE1LTMtMS0xLTEwMjQzMQ_1d731dd8-5b4a-4df9-a1ae-7aed1a2eb39c">3,861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" sign="-" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE2LTEtMS0xLTEwMjQzMQ_36dc46e7-0e43-4154-97d2-5101f3966dc7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE2LTMtMS0xLTEwMjQzMQ_68fbc230-cb9c-4e73-94be-ea7b0daf2ae5">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE3LTEtMS0xLTEwMjQzMQ_536d557f-8918-4990-8b5f-7d586df46d51">4,740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE3LTMtMS0xLTEwMjQzMQ_26be3394-2cf2-49b5-b005-0b76415a13c6">4,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="axgn:DeferredTaxAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE4LTEtMS0xLTEwMjQzMQ_f9bdc1af-65e3-4bbb-997b-026bba1265f1">58,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="axgn:DeferredTaxAssetsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE4LTMtMS0xLTEwMjQzMQ_4ad23510-3c26-4dc5-8b05-49f9f8195bb2">54,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE5LTEtMS0xLTEwMjQzMQ_b743db17-9dd3-43ba-8f70-88cdd242fe1f">58,309</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE5LTMtMS0xLTEwMjQzMQ_80528c89-d16b-42a6-9b6b-233ef0aeb717">53,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is provided to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more-likely-than-not that a portion or none of the deferred tax assets will be realized. As of December&#160;31, 2022 and 2021, management assessed the realizability of deferred tax assets. After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management determined that a full valuation allowance was necessary as of December&#160;31, 2022 and2021. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3Xzk5MQ_56ba2b97-c625-4a5c-83ac-6a4271e0ecaf">5,058</ix:nonFraction> during 2022, primarily as a result of the increase in the capitalized research and development costs. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzM1NzM0MTI3OTA4MDgw_0f086cb9-2d2a-482b-8c87-235fbe72cfc1">6,734</ix:nonFraction> during 2021, primarily as a result of the increase in the net operating loss carryforward. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Section 174 of the Tax Cuts and Jobs Act of 2017 ("TCJA") which requires taxpayers to capitalize and amortize research and development expenditures for the tax years beginning after December&#160;31, 2021. This rule became effective for the Company during 2022 and resulted in capitalized research and development costs of $<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzU0OTc1NTgyMzQ1OA_d9047ff9-bd7c-461e-a216-1ec9c25b5a07">6,357</ix:nonFraction> being recorded to deferred tax assets as of December&#160;31, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the financial statement income tax benefit and the income tax benefit using statutory rates is primarily due to the valuation allowance. <ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQ1NDM_cc069902-0e9d-47aa-b679-98ffb85b52d5" continuedAt="i1b2e8b7b5ff340e8acaba88107b48eb1" escape="true">The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate for the years ended December&#160;31, 2022, 2021, and 2020 as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="ia500ff01c5f541d0859dbe6b8a335449"><div style="margin-top:10pt"><ix:continuation id="i1b2e8b7b5ff340e8acaba88107b48eb1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzItMS0xLTEtMTAyNDMx_b29d0636-8939-4519-a27a-ff915a0feb57">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzItMy0xLTEtMTAyNDMx_27e53e19-8a1a-44b4-ae70-4bbfff2c2595">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzItNS0xLTEtMTAyNDMx_3de65890-0103-4469-aeb3-b947191b7053">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes - net of Federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzMtMS0xLTEtMTAyNDMx_7cf256e0-0ba6-4212-95f8-d29715b2d6ae">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzMtMy0xLTEtMTAyNDMx_ec5bcc19-5238-4356-aebd-e743c9cc3fd5">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzMtNS0xLTEtMTAyNDMx_ce9c8488-1dc8-40e3-ac3f-47400b7347be">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items and other deductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzQtMS0xLTEtMTAyNDMx_4af27b40-5aaa-442e-b05e-27d2ef3d73a4">7.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzQtMy0xLTEtMTAyNDMx_3a95b0e3-7084-421b-8079-6a80622ec875">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzQtNS0xLTEtMTAyNDMx_fce532e0-61ea-4d47-9c7f-3f806522d3d9">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtMS0xLTEtMTQxOTY4_7ce66956-d4ca-4356-9b6c-987d06a5c788">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtMy0xLTEtMTQxOTc4_61bc7b9f-ea23-426b-8134-eeefb3b0b291">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtNS0xLTEtMTQxOTg2_da3164c3-d3c9-4d42-9ca1-b63349e2c671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtMS0xLTEtMTAyNDMx_24905a4f-8bbf-4b6d-a281-444c51ccd5a4">17.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtMy0xLTEtMTAyNDMx_0474a93e-ad56-488a-9d95-6f06dc7efcad">24.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtNS0xLTEtMTAyNDMx_1fd03116-b51a-414e-aa93-8a8b8837136a">27.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzYtMS0xLTEtMTAyNDMx_7c38ff95-4378-4b7b-b68c-28b4607a8330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzYtMy0xLTEtMTAyNDMx_bdb0c94e-7376-480c-b3a0-f7c8d271a6e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzYtNS0xLTEtMTAyNDMx_d5a9f134-0191-438d-9edd-a806e69b6ca8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had tax-effected net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzIxNjA_cc12c7b7-9c36-4295-aba5-61ffdf48f0c7">42,716</ix:nonFraction> to offset future taxable income. Net operating losses incurred in tax years beginning on or after January 1, 2018, are carried forward indefinitely. Net operating losses incurred in tax years prior to January 1, 2018, are subject to a twenty year carryforward before expiring. A portion of the net operating loss carryforwards may expire due to limitations imposed by Section 382 of the Internal Revenue Code. Future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section&#160;382 as a result of changes in ownership.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. In the normal course of business, the Company is subject to examination by taxing authorities throughout the U.S. These examinations could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with federal, state, and local laws. The Company&#8217;s remaining open tax years subject to examination by federal tax authorities include the years ended December&#160;31, 2019, through 2022. The Company's remaining open tax years subject to examination by state and foreign tax authorities include the years ended December&#160;31, 2018, through 2022. However, for tax years 2004 through 2017, federal and state taxing authorities may examine and adjust loss carryforwards in the years in which those loss carryforwards are ultimately utilized.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation enacted in 2018, titled the Tax Cuts and Jobs Act of 2017, subjects a U.S. shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Global Intangible Low-Taxed Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to account for GILTI in the year the tax is incurred.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="usd" contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQyNjA_07ab836d-b1c9-4c4c-85ac-4f08668e9993"><ix:nonFraction unitRef="usd" contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQyNjA_8bd51aad-ed84-4716-b360-279d1f19f1e5"><ix:nonFraction unitRef="usd" contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQyNjA_a609d776-3806-4688-b70c-14a31c908544">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> recorded income tax expense or income tax benefit for the years ended December&#160;31, 2022, 2021, and 2020 due to the generation of net operating losses, the benefits of which have been fully reserved. The Company does not believe there are any additional tax refund opportunities currently available.</span></div></ix:continuation><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_133"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzkwOA_61cc76c1-e7e9-4aa9-948f-698935086ffb" continuedAt="i7414f4437d094ff983c563db83468ae7" escape="true">Retirement Plan</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7414f4437d094ff983c563db83468ae7">The Company sponsors the Axogen 401(k) plan (the "401(k) Plan"), a defined contribution plan covering substantially all employees of the Company. All full-time employees who have attained the age of <ix:nonFraction unitRef="number" contextRef="i05aa70972d464831a814056c33b271a3_D20220101-20221231" decimals="INF" name="axgn:DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzIyNQ_b6912c62-cacf-421d-863b-a7de68a1574c">18</ix:nonFraction> are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of <ix:nonFraction unitRef="number" contextRef="iefd130037ca64a11bb22c7512ae0a94d_D20220101-20221231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzU2NQ_529563c7-07f8-4c36-a7e9-878d6c501b0d">3</ix:nonFraction>% on the first <ix:nonFraction unitRef="number" contextRef="iefd130037ca64a11bb22c7512ae0a94d_D20220101-20221231" decimals="2" name="axgn:DefinedContributionPlanEmployeeContributionPercentMatched" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzU4MQ_31404cb5-1a87-4090-a0d5-b6a1c9615e92">3</ix:nonFraction>% of the employee&#8217;s annual salary and <ix:nonFraction unitRef="number" contextRef="i182aaa761ab746c08c115aa520c8ef32_D20220101-20221231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzYyMA_d2e732fa-840e-4936-a61a-7e233d459d13">1</ix:nonFraction>% on the next <ix:nonFraction unitRef="number" contextRef="i182aaa761ab746c08c115aa520c8ef32_D20220101-20221231" decimals="2" name="axgn:DefinedContributionPlanEmployeeContributionPercentMatched" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzYzNQ_341b1327-870a-458c-b140-9a7be32889c5">2</ix:nonFraction>% of the employee&#8217;s annual salary as long as the employee participates in the 401(k) Plan. Both employee contributions and Company contributions vest immediately. Employer contributions to the 401(k) Plan were $<ix:nonFraction unitRef="usd" contextRef="i05aa70972d464831a814056c33b271a3_D20220101-20221231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1Xzg0Ng_57ac059e-620b-454a-92d1-046c914b1158">1,409</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i400f27a4e7ff431998cec2a000a877d7_D20210101-20211231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1Xzg1MA_2f3cff34-eef9-4873-898d-99658eae1da2">1,346</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i236f63d48da94326b86bbf56915ef555_D20200101-20201231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1Xzg1Nw_dd986ef3-f199-493c-b23b-7223359fd70c">1,141</ix:nonFraction> for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</ix:continuation></span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_136"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzIwMjIw_36347bd7-fbc1-47b0-9969-d827ab67fe4a" continuedAt="i1a63c8ef8b54401f92558bca11e2c60a" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i1a63c8ef8b54401f92558bca11e2c60a" continuedAt="i11b65ecb2d654609a31ebb327eb7a4ca"><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service Agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays CTS a facility fee for the use of clean room/manufacturing, storage, and office space and for services in support of its product process including for routine sterilization of daily supplies, providing disposable supplies and microbial services, and office support. Pursuant to the CTS Agreement, the Company recorded expenses of $<ix:nonFraction unitRef="usd" contextRef="i73105f432ef241c4a97fc1d3d88fe6a3_D20220101-20221231" decimals="-3" name="axgn:LicenseFeeAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0NjM_c24931f6-f198-4aaa-9845-cea33f887da5">2,278</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="if781fbbca41e4e539d4a2af2b30d30b6_D20210101-20211231" decimals="-3" name="axgn:LicenseFeeAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0Njc_899df575-684f-4199-ade0-590c0c9b8f14">2,466</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i07a9992aadca401c9da150aec1eb925d_D20200101-20201231" decimals="-3" name="axgn:LicenseFeeAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0NzQ_bc4090dc-ff62-4671-9219-ebf89c7e7a04">1,739</ix:nonFraction> for the years ended December&#160;31, 2022, 2021, and 2020, respectively, in sales and marketing expenses. The CTS Agreement terminates December 31, 2023, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#8217;s right to cure, in certain circumstances), or without cause upon <ix:nonNumeric contextRef="i73105f432ef241c4a97fc1d3d88fe6a3_D20220101-20221231" name="axgn:NoticePeriodForTerminationOfAgreement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU3ODA_3805ecf3-ac5d-4822-b82d-42c7019db45b">6</ix:nonNumeric> months prior notice. We expect to reduce our utilization of CTS in the second half of 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="i11b65ecb2d654609a31ebb327eb7a4ca" continuedAt="i03b703fc81e34cd1b060e6bbab2ab25f"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2011, the Company entered into a Master Services Agreement for Clinical Research and Related Services. The Company was required to pay $<ix:nonFraction unitRef="usd" contextRef="i1fde54db694d4428af52e02f60a749f9_D20111201-20111231" decimals="-3" name="axgn:ServiceAgreementAmountPaidUponExecutionOfAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU5NDQ_5b2a5579-a4a1-4c6f-9816-b1e8a22cc713">151</ix:nonFraction> upon execution of this agreement and the remainder monthly based on activities associated with the execution of Axogen&#8217;s phase 3 pivotal clinical trial to support the BLA for Avance Nerve Graft. Payments made under this agreement were $<ix:nonFraction unitRef="usd" contextRef="if5e477a79209414b9802cd7abd1b6b50_D20220101-20221231" decimals="-3" name="axgn:PaymentForServiceFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg0OTM1Mg_6c931c25-187c-44cc-b033-07c00c59f1f0">1,254</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i7e0f3af02aa7447d8f475f07a758e898_D20210101-20211231" decimals="-3" name="axgn:PaymentForServiceFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg0OTM1NQ_361a7800-9ef4-4323-8704-c9b587e4a92b">1,100</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ibb046ec1c789420aa97b6546383d2a96_D20200101-20201231" decimals="-3" name="axgn:PaymentForServiceFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg0OTM1OA_8023b993-cbe4-4f3c-afa5-c9d74140d495">1,136</ix:nonFraction> for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Distribution and Supply Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2008, the Company entered into an exclusive distribution agreement with Cook Biotech to distribute the Axoguard Nerve Connector and Axoguard Nerve Protector products worldwide and the parties subsequently amended the agreement on February 26, 2018. Pursuant to the February 2018 amendment, the agreement expires on June 30, 2027. The Cook Biotech agreement establishes a formula for the transfer cost of the Axoguard products and requires certain minimum purchases by the Company, although, through mutual agreement, the parties have not established such minimums; and, to date, have not enforced such provision. Under the Cook Biotech agreement, the Company provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders. The agreement allows for termination provisions for both parties. The loss of the ability to sell the Axoguard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products could have a material adverse effect on the Company's business until other replacement products would be available.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, the Company entered into the Nerve End Cap Supply Agreement (the "Supply Agreement") with Cook Biotech whereby Cook Biotech is the exclusive contract manufacturer of the Axoguard Nerve Cap and both parties have provided the other party the necessary licenses to their technologies for operation of the Supply Agreement. The Supply Agreement expires on August 27, 2027. Under the Supply Agreement the Company provides purchase orders to Cook Biotech and Cook Biotech fulfills the purchase orders.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Axogen Processing Center Facility</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on the continued availability of its processing facilities at the Community Blood Center facility (&#8220;CTS&#8221;) in Dayton, Ohio and could be harmed if the physical infrastructure of this facility is unavailable for any prolonged period of time. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2018, the Company purchased the APC Facility in Vandalia, Ohio, located near the CTS processing facility where Avance Nerve Graft is currently processed. The APC Facility, when and if operational, will be the new processing facility for Avance Nerve Graft to provide continued capacity for growth and to support the transition of Avance Nerve Graft from a Human Cellular and Tissue-based Product pursuant to Section 361 of the Public Health Service Act (PHSA) to a biologic product under section 351 of the PHSA. The APC Facility is comprised of a <ix:nonFraction unitRef="sqft" contextRef="i7981a723acd84152a08440913339b2eb_I20180731" decimals="-3" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzcxNDY4MjU2MTgwOTQ_4baae2db-05bb-45b1-85b1-e5eca6720fde">107,000</ix:nonFraction> square foot building on approximately <ix:nonFraction unitRef="acre" contextRef="i7981a723acd84152a08440913339b2eb_I20180731" decimals="1" name="us-gaap:AreaOfLand" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzkzNzQ_32fee55b-cadb-4172-9769-898f21886f72">8.6</ix:nonFraction> acres of land. The Company paid $<ix:nonFraction unitRef="usd" contextRef="ic4c3c23c084b482f91cc7aa41dcd753c_D20180701-20180731" decimals="-3" name="us-gaap:PaymentsToAcquireLandHeldForUse" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2Xzk0MDk_6dcd011a-65ea-40ac-8562-abfe0038d8f2">731</ix:nonFraction> for the land and this is recorded as land within Property and equipment, net on the consolidated balance sheets. The Company paid $<ix:nonFraction unitRef="usd" contextRef="ic4c3c23c084b482f91cc7aa41dcd753c_D20180701-20180731" decimals="-3" name="us-gaap:PaymentsToAcquireBuildings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2Xzk1MzY_a3be26a7-6e68-4e48-becc-e4fcb7f4220d">4,300</ix:nonFraction> for the building and this is recorded in projects in process within Property and equipment, net on the consolidated balance sheets. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 9, 2019, the Company&#160;entered into a Standard Form of Agreement Between Owner and Design-Builder (the &#8220;Design-Build Agreement&#8221;) with CRB Builders, L.L.C., a Missouri limited liability company (&#8220;CRB&#8221;), pursuant to which CRB will renovate and retrofit the APC Facility. The estimated cost pursuant to the Design-Build Agreement was $<ix:nonFraction unitRef="usd" contextRef="i7a73dc524bc0487f8a26096a8e638192_I20190709" decimals="-3" name="axgn:EstimatedCostRelatingToDesignBuildAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEwMjc5_a7a0f219-e803-40df-bf74-2e137a570a7e">29,300</ix:nonFraction>. Additional costs associated with the renovation, validation and certification of the APC Facility are estimated to be $<ix:nonFraction unitRef="usd" contextRef="i7a73dc524bc0487f8a26096a8e638192_I20190709" decimals="-3" name="axgn:AdditionalCostsAssociatedWithDesignBuildAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEwNDAx_f58bef83-a5b5-4e1a-9b46-2a1e35f1d07c">20,900</ix:nonFraction>. For the year ended December&#160;31, 2022, the Company has recorded $<ix:nonFraction unitRef="usd" contextRef="i5d4755bb5df442e0bcbac343dd97c6a5_D20220101-20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEwOTk1MTE2NjYzNjU_bfdc2729-ee5c-457b-9e9f-262952d33bb3">10,938</ix:nonFraction> related to renovations and design and build in projects in progress. The Company has recorded $<ix:nonFraction unitRef="usd" contextRef="i6c09353a39ab44c1abcd20449e840722_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MDgzMw_31b9488e-0ee8-4d07-a707-08574e26acd2">46,354</ix:nonFraction> to date related to this project. In addition to these project costs, the Company has capitalized interest of $<ix:nonFraction unitRef="usd" contextRef="i5d4755bb5df442e0bcbac343dd97c6a5_D20220101-20221231" decimals="-3" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MDg1Nw_b3f9d816-b464-44f1-a029-f778f9d66616">6,155</ix:nonFraction> for the year ended December&#160;31, 2022. To date, the Company has capitalized interest of $<ix:nonFraction unitRef="usd" contextRef="i6c09353a39ab44c1abcd20449e840722_I20221231" decimals="-3" name="us-gaap:AccumulatedCapitalizedInterestCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MDg0Nw_3ceef902-0f25-4d52-9625-f47b7ba7f950">11,429</ix:nonFraction> related to this project. These items are recorded as projects in process in property and equipment, net on the consolidated balance sheet. The Company anticipates recording an additional $<ix:nonFraction unitRef="usd" contextRef="i7a632239217d41468fa2372519ffc0b1_I20231231" decimals="-3" name="axgn:AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MjQzNA_b74f7d6c-a67b-4bd5-a135-f930ce496ddb">4,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="ic9e769962cd54b3b97e7d9fd767e4375_I20231231" decimals="-3" name="axgn:AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MjQ0OQ_4ee9adae-ea0b-43f2-b72a-669d45d3b8da">5,000</ix:nonFraction> in 2023. The Company anticipates completion of construction, validation of systems and processes in the first half of 2023 and commence processing in mid- 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company obtained certain economic development grants from state and local authorities totaling up to $<ix:nonFraction unitRef="usd" contextRef="i6ca27fff32cc49c8b733f18e1fa356ad_I20221231" decimals="-3" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzExNjI5_712ea7ad-71d3-4b3c-8c5a-1919b08e0195">2,685</ix:nonFraction> including $<ix:nonFraction unitRef="usd" contextRef="i6ca27fff32cc49c8b733f18e1fa356ad_I20221231" decimals="-3" name="axgn:CashGrantsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzExNjQy_fe6449b7-283e-426a-904d-0aed0a4523e0">1,250</ix:nonFraction> of cash grants to offset costs to acquire and develop the APC Facility. The economic development grants are subject to certain job creation milestones by 2023 and related contingencies. The Company received <ix:nonFraction unitRef="usd" contextRef="i240989f39b9840bca8e3655746971a82_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromGrantors" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MDk1OQ_793d8a36-b38d-45fa-b53e-70cfa45ca718">zero</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ibc7bb6eff8634156ae51a0b363ee7e34_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromGrantors" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzExODUy_7915b5ca-2b5a-4f68-abcd-88d8c24af947">950</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1483ac9511a64c4ea92e59beedb6290d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromGrantors" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzExODU5_bbb62255-82bd-4ec9-84ed-8006238fede7">238</ix:nonFraction> from these grants in the years ended December&#160;31, 2022, 2021 and 2020, respectively. These grants have claw back clauses if the Company does not meet these job creation milestones by 2023, the Company has sent requests to the grant authorities for extensions of the job creation milestones; however, the Company has not yet received a decision from the grant authorities regarding whether extensions will be granted. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><ix:continuation id="i03b703fc81e34cd1b060e6bbab2ab25f" continuedAt="i62bb64e4337d441eb9bbd2cddf77e6f3"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value of the Debt Derivative Liabilities  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt derivative liabilities is $<ix:nonFraction unitRef="usd" contextRef="i43510f63e6ba4c3ca4047759ce1d9771_I20221231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MzE4NQ_72ab6800-ee98-46d0-a3ec-d7c238f966fc">4,518</ix:nonFraction> as of December&#160;31, 2022. The fair value of the debt derivative liabilities was determined using a probability-weighted expected return model based upon the <ix:nonFraction unitRef="settlementscenario" contextRef="i872b209a46c14c878edd3c5a93dc57b8_I20221231" decimals="INF" name="axgn:NumberOfPotentialSettlementScenarios" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEyMjcz_8ff68c64-62ae-4ec6-a738-a248ee25a716">four</ix:nonFraction> potential settlement scenarios for the Credit Facility which are described in Note 2 - Summary of Significant Accounting Policies &#8211; Derivative Instruments. The estimated settlement value of each scenario, which includes any required make-whole payment see Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees , is then discounted to present value using a discount rate that is derived based upon the initial terms of the Credit Facility at issuance and corroborated utilizing a synthetic rating analysis. The calculated fair values under the <ix:nonFraction unitRef="settlementscenario" contextRef="i872b209a46c14c878edd3c5a93dc57b8_I20221231" decimals="INF" name="axgn:NumberOfPotentialSettlementScenarios" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEyNzI3_8ff68c64-62ae-4ec6-a738-a248ee25a716">four</ix:nonFraction> scenarios are then compared to the fair value of a plain vanilla note, with the difference reflecting the fair value of the Debt Derivative Liabilities. The Company estimated the make-whole payments required under each scenario according to the terms of the Credit Facility to generate an internal rate of return equal to <ix:nonFraction unitRef="number" contextRef="i872b209a46c14c878edd3c5a93dc57b8_I20221231" decimals="3" name="axgn:DebtInstrumentInternalRateOfReturnUnderSettlementScenarios" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEzMDU0_5c248ea7-da9c-44c9-801e-91e3d4eba90e">11.5</ix:nonFraction>% through the scheduled maturity dates, less the total of all quarterly interest and royalty payments previously paid to the Lender. The calculation utilized the XIRR function in Microsoft Excel as required by the Credit Facility. If the debt is not prepaid but instead is held to its scheduled maturities, the Company&#8217;s estimate of the make-whole payment for the first and second tranches of the Credit Facility due on June 30, 2027, and June 30, 2028, respectively, are approximately <ix:nonFraction unitRef="usd" contextRef="i312f2d64cb674fdbad24a7fe51918409_I20221231" decimals="INF" name="axgn:DebtInstrumentHeldToMaturityMakeWholePayment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEzNTk1_f5af8bf9-e2b8-4b44-afc5-a6db443151fc">zero</ix:nonFraction>. The Company has consistently applied this approach since the inception of the debt agreement on June 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has become aware that the Lender may have an alternative interpretation of the calculation of the make-whole payments that the Company believes does not properly utilize the same methodology utilized by the XIRR function in Microsoft Excel as described in the Credit Facility. The Company estimates the top end of the range of the make-whole payments if the debt is held to scheduled maturity under an alternative interpretation to be approximately $<ix:nonFraction unitRef="usd" contextRef="i312f2d64cb674fdbad24a7fe51918409_I20221231" decimals="-3" name="axgn:DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MTQ2MQ_744261e7-6827-4c39-94a7-fe77766ac75f">9,000</ix:nonFraction> for the first tranche of the Credit Facility on June 30, 2027, and approximately $<ix:nonFraction unitRef="usd" contextRef="ibe9a8770fa764d7891407778eae23958_I20221231" decimals="-3" name="axgn:DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MTQ2Ng_270889df-d458-425e-a5d0-d294eaff3b53">4,000</ix:nonFraction> for the second tranche of the Credit Facility on June 30, 2028. Further, if the debt is prepaid prior to the scheduled maturity dates and subject to the alternative interpretation, the make-whole payment would be larger than the amounts herein.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Commitments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive officers of the Company are parties to employment contracts. Such contracts have severance payments for certain conditions including change of control.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Legal Proceedings </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and may be subject to various claims, lawsuits, and proceedings in the ordinary course of the Company's business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Comp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any's financial condition, results of operations or cash flows. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2019, Plaintiff Neil Einhorn, on behalf of himself and others similarly situated, filed a putative class action complaint in the United States District Court for the Middle District of Florida alleging violations of the federal securities laws against Axogen, Inc., certain of its directors and officers (&#8220;Individual Defendants&#8221;), and Axogen&#8217;s 2017 Offering Underwriters and 2018 Offering Underwriters (collectively, with the Individual Defendants, the &#8220;Defendants&#8221;), captioned Einhorn v. Axogen, Inc., et al., No. 8:19-cv-00069 (M.D. Fla.). Plaintiff asserts that Defendants made false or misleading statements in connection with the Company&#8217;s November 2017 registration statement issued regarding its secondary public offering in November 2017 and May 2018 registration statement issued regarding its secondary public offering in May 2018, and during a class period of August 7, 2017 to December 18, 2018. In particular, Plaintiff asserts that Defendants issued false and misleading statements and failed to disclose to investors: (1) that the Company aggressively increased prices to mask lower sales; (2) that the Company&#8217;s pricing alienated customers and threatened the Company&#8217;s future growth; (3) that ambulatory surgery centers form a significant part of the market for the Company&#8217;s products; (4) that such centers were especially sensitive to price increases; (5) that the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) that the Company&#8217;s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the Company&#8217;s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the Company&#8217;s key operating metrics, such as the number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. Axogen was served on January 15, 2019. On February 4, 2019, the Court granted the parties&#8217; stipulated motion which provided that Axogen is not required to file a response to the complaint until thirty days after Plaintiff files a consolidated amended complaint. On </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i62bb64e4337d441eb9bbd2cddf77e6f3">June 19, 2019, Plaintiff filed an Amended Class Action Complaint, and on July 22, 2019, Defendants filed a motion to dismiss. Plaintiff filed opposing papers on August 12, 2019. The Court held a status hearing on September 11, 2019 and stayed all deadlines regarding the parties&#8217; obligations to file a case management report. On December 4, 2019, the parties presented oral arguments. On April 21, 2020, the Court dismissed the complaint without prejudice, finding the Plaintiff failed to state a claim upon which relief could be granted. The Plaintiff filed a Second Amended Class Action Complaint on June 22, 2020. Axogen filed a motion to dismiss on August 6, 2020. The Plaintiff filed an opposition on September 20, 2020. The Court held oral argument on February 25, 2021. On March 19, 2021, the Court dismissed the Second Amended Complaint with prejudice, finding again that the Plaintiff failed to state a claim upon which relief could be granted. On April 14, 2021, Plaintiff filed a notice of appeal. Plaintiff filed its opening brief on June 28, 2021. The Company filed its appellee brief on August 11, 2021. The Plaintiff filed a reply brief on September 14, 2021. The Eleventh Circuit heard oral argument the week of March 8, 2022. On August 1, 2022, the Eleventh Circuit affirmed the dismissal of the complaint with prejudice.</ix:continuation> </span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_145"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xNDUvZnJhZzo2OTllYjIwYzJmNzU0OTdiYTg0ZDhmMjVmNTczNzZkOS90ZXh0cmVnaW9uOjY5OWViMjBjMmY3NTQ5N2JhODRkOGYyNWY1NzM3NmQ5XzMyNQ_493256e0-247e-4336-911a-b7749e54c4b1" continuedAt="i262071bf3aa74c52b774197fffe66449" escape="true">Subsequent Event</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i262071bf3aa74c52b774197fffe66449">Silicon Valley Bank (&#8220;SVB&#8221;) was closed on March 10, 2023 by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver. At the time of closing, the Company maintained approximately $<ix:nonFraction unitRef="usd" contextRef="i63b272a784f043b28b8f70d792398c9d_I20230310" decimals="-5" name="axgn:CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xNDUvZnJhZzo2OTllYjIwYzJmNzU0OTdiYTg0ZDhmMjVmNTczNzZkOS90ZXh0cmVnaW9uOjY5OWViMjBjMmY3NTQ5N2JhODRkOGYyNWY1NzM3NmQ5XzcxNDY4MjU1ODU2MjE_7e04e522-a0c0-4a59-a6f5-19a52f1235ad">8.0</ix:nonFraction>&#160;million of its cash in deposit accounts with SVB. The vast majority of the Company&#8217;s cash, cash equivalents and short-term investments reside in custodial accounts held by U.S. Bank for which SVB Asset Management is the advisor. The Company&#8217;s investment portfolio currently does not contain any securities of SVB. On March 12, 2023, the U.S. Treasury, Federal Reserve, and FDIC announced that SVB depositors will have access to all of their money starting March 13, 2023. As of March 14, 2023, the Company had access to all of its money held at SVB.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_151"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 9A. CONTROLS AND PROCEDURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures&#8221; as defined in Rules 13a-15&#8364; and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, and Board of Directors, as appropriate, to allow timely decisions regarding required disclosure.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2022, and concluded that our disclosure controls and procedures were effective.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the three months ended December&#160;31, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(as defined in Rules 13a-15(d) or 15d-15(f) of the Exchange Act)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> internal control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with US GAAP and includes those policies and procedures that:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of inherent limitations, a system of internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate due to a change in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our internal control over financial reporting as of December&#160;31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on their evaluation, the principal executive officer and principal financial officer concluded that our internal controls over financial reporting were effective.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, Deloitte &amp; Touche LLP, who audited the consolidated financial statements included in this Annual Report on Form 10-K, has issued an attestation report on the effectiveness of management's internal control over financial reporting as of December&#160;31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_154"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 9B. OTHER INFORMATION</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_157"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTION</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">S</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_163"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item concerning our directors will be set forth under the caption &#8220;Election of Directors&#8221; in our definitive proxy statement for our 2023 annual meeting, which will be filed no later than 120 days after December&#160;31, 2022, and is incorporated herein by reference.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If applicable, information required by this item concerning compliance with Section 16(a) of the Exchange Act, as amended, will be set forth under the caption "Security Ownership of Certain Beneficial Owners and Management &#8212; Delinquent  Section 16(a) Reports&#8221; in our definitive proxy statement for our 2023 annual meeting, and is incorporated herein by reference.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item concerning our audit committee, our audit committee financial expert and any material changes to the way in which security holders may recommend nominees our Board of Directors will be set forth under the caption &#8220;Corporate Governance&#8221; in our definitive proxy statement for our 2023 annual meeting and is incorporated herein by reference.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors adopted a Code of Business Conduct and Ethics, which is posted on our website https://ir.axogeninc.com/governance-docs that is applicable to all employees and directors. We will provide copies of our Code of Business Conduct and Ethics without charge upon request. To obtain a copy, please visit our website or send your written request to Investors Relations, 13631 Progress Blvd., Suite 400, Alachua, FL 32615. With respect to any amendments or waivers of this Code of Business Conduct and Ethics (to the extent applicable to our chief executive officer, principal accounting officer or controller, or persons performing similar functions) we intend to either post such amendments or waivers on our website or disclose such amendments or waivers pursuant to a Current Report on Form 8-K.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_166"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 11. EXECUTIVE COMPENSATION.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item will be set forth under the caption &#8220;Executive Compensation&#8221; in our definitive proxy statement for our 2023 annual meeting, which will be filed no later than 120 days after December&#160;31, 2022 and is incorporated herein by reference.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_169"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item concerning ownership will be set forth under the caption &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information&#8221; in our definitive proxy statement for our 2023 annual meeting, which will be filed no later than 120 days after December&#160;31, 2022 and is incorporated herein by reference.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_172"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item concerning ownership will be set forth under the caption &#8220;Corporate Governance &#8212; Director Independence&#8221; and &#8220;Certain Relationships and Related Transactions&#8221; in our definitive proxy statement for our 2023 annual meeting, which will be filed no later than 120 days after December&#160;31, 2022 and is incorporated herein by reference.</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_175"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item concerning ownership will be set forth under the caption &#8220;Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; in our definitive proxy statement for our 2023 annual meeting, which will be filed no later than 120 days after December&#160;31, 2022 and is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_181"></div><ix:nonNumeric contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90ZXh0cmVnaW9uOmM5ZjA1YjJmOWQyZDRkOWM5ZWFiN2ExYWU2N2FhMTVjXzE0Nw_72324d26-33e3-41f4-bb7c-d79af1656ed7" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule II &#8211; Valuation and Qualifying Accounts - to </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AXOGEN, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II &#8211; VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THREE YEARS ENDED DECEMBER&#160;31, 2022, 2021 AND 2020</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions (Charge-offs)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace3449af19a43cd8d67c6135dea1c3f_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzItMS0xLTEtMTAyNDMx_3e78763d-a5ac-4394-97f7-a549aa49b87b">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eadfa7371f84649a56fada99ffeb49f_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzItMy0xLTEtMTAyNDMx_9bd8c40f-805e-4772-bbf7-b3a1d8999981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1eadfa7371f84649a56fada99ffeb49f_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzItNS0xLTEtMTAyNDMx_6167469d-1d4e-47b2-b673-b29744f98171">676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491dd34b56ac4fb6b8ba9809c9f8440d_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzItNy0xLTEtMTAyNDMx_0246ae01-5d97-4ea3-8877-1c4eeb99e77e">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i491dd34b56ac4fb6b8ba9809c9f8440d_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzMtMS0xLTEtMTAyNDMx_9389338f-fd59-415a-a747-34c295b820c6">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3669aa557841487bb68d45ebfd6ac73d_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzMtMy0xLTEtMTAyNDMx_933d10f3-ab88-4f08-bc19-203f7d52f56c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3669aa557841487bb68d45ebfd6ac73d_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzMtNS0xLTEtMTAyNDMx_c73e6d5f-4be8-477b-a99f-49c9f9060aee">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81dc6f294f4481ba24f6cf04a2a5b07_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzMtNy0xLTEtMTAyNDMx_a4b1aa9f-c71c-448e-bab9-d8a3376314f3">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81dc6f294f4481ba24f6cf04a2a5b07_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzQtMS0xLTEtMTAyNDMx_1f060de5-0239-48c2-8bd4-ecbb2c1c055d">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2f4d63cb0a4bdbba2fe027bcca072d_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzQtMy0xLTEtMTAyNDMx_d6945f24-fe3d-46d3-9bd2-a78a3158a36b">612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e2f4d63cb0a4bdbba2fe027bcca072d_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzQtNS0xLTEtMTAyNDMx_0660e681-3167-423f-899c-c35e9efd5055">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a1d089805140e781df39c5f26229e1_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzQtNy0xLTEtMTAyNDMx_75918ad0-32c0-4e0e-8e31-0e4a93e7c194">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief79fb6a5e3b43748ba8450f97233cc8_I20191231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzctMS0xLTEtMTAyNDMx_87122a2f-916c-4655-8130-3e8a1c658cde">39,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff49c4d00f374dc3a6c840d2ead2e75c_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzctMy0xLTEtMTAyNDMx_af360efa-4da2-4b74-b3f1-bbedc4555807">6,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="iff49c4d00f374dc3a6c840d2ead2e75c_D20200101-20201231" sign="-" xsi:nil="true" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzctNS0xLTEtMTAyNDMx_c7aaed8e-a7ad-4613-a04d-23de09a18fed"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66448d92e4ed4bbdabf0e6233a2efd1f_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzctNy0xLTEtMTAyNDMx_a719f736-b237-4478-9722-5fd57645687b">46,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66448d92e4ed4bbdabf0e6233a2efd1f_I20201231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzgtMS0xLTEtMTAyNDMx_ea857a4d-6878-4391-ba37-f86d5aa06d49">46,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc7ff5c961444d40b57c14dbf3857165_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzgtMy0xLTEtMTAyNDMx_b4972c86-850b-44a3-969b-6b76b8676f90">6,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc7ff5c961444d40b57c14dbf3857165_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzgtNS0xLTEtMTAyNDMx_d4519035-717a-465c-af50-c62a56a48d08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96693000e594bfcab99cf6f0f656103_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzgtNy0xLTEtMTAyNDMx_a1bbfb88-a4a0-4680-9b68-c1e747ff2055">53,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96693000e594bfcab99cf6f0f656103_I20211231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzktMS0xLTEtMTAyNDMx_436f4ce9-2b62-40ad-94e3-88231c321f5c">53,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01ee8be630348558bc989c9e8469302_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzktMy0xLTEtMTAyNDMx_bf314236-fe6f-498a-8aed-316b728d1854">5,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01ee8be630348558bc989c9e8469302_D20220101-20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzktNS0xLTEtMTAyNDMx_25ebc5ee-81db-4597-b62a-ebf7d9f18ab5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i682121d6bec448318e7178b60d411be4_I20221231" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzktNy0xLTEtMTAyNDMx_a1a79755-2043-4464-b993-fa8f853a729d">58,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_184"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_187"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Financial Statements and Financial Statement Schedules</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required by Item 15(a) are filed in Part II Item 8 of this Annual Report on Form 10-K. Schedules not included have been omitted because they are not applicable or because the required information is included in the Consolidated Financial Statements and notes thereto.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="-sec-extract:summary;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are included in this Annual Report on Form 10-K or incorporated by reference in the Form 10-K.</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837019010165/ex-3d1.htm">Amended and Restated Articles of Incorporation of Axogen, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q, filed on November 6, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837019003793/ex-3d2.htm">Axogen, Inc. Amended and Restated Bylaws. (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, filed on May 2, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020001238/ex-4d1.htm">Description of Securities of Axogen, Inc. (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed on February 24, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018001268/axgn-20171231ex429a90a9a.htm">Registration Rights Agreement, dated as of August 26, 2015, between Axogen, Inc. and Essex Woodlands Fund IX, L.P. (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex101.htm">Patent License Agreement, dated as of August 3, 2005, by and between Axogen Corporation and the Board of Regents of the University of Texas System (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*10.2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex102.htm">Amended and Restated Standard Exclusive License Agreement with Sublicensing Terms, dated as of February 21, 2006, by and between Axogen Corporation and the University of Florida Research Foundation, Inc. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837016006614/axgn-20160705ex1021b4b12.htm">Second Amendment to the Amended and Restated Standard Exclusive License Agreement No. A5140, effective as of July 5, 2016, by and between Axogen Corporation and the University of Florida Research Foundation, Inc. (incorporated by reference to Exhibit 10.2.1 to the Company&#8217;s Current Report on Form 8-K filed on July 11, 2016).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+10.2.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1023thirdamendmen.htm">Third Amendment to the Amended and Restated Standard Exclusive License Agreement No. A5140 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1023thirdamendmen.htm">effective</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1023thirdamendmen.htm"> as</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1023thirdamendmen.htm"> of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1023thirdamendmen.htm"> October 19, 2021, by and between AxoGen, Inc.and the University of Florida Research Foundation, Inc. </a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex103.htm">Sid Martin Biotechnology Development Institute Incubator License Agreement, dated as of September 26, 2006, by and between Axogen, Inc. and the University of Florida Research Foundation, Inc. (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*10.4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex1041.htm">Amended and Restated Nerve Tissue Processing Agreement, dated as of February 27, 2008, by and between Axogen Corporation and LifeNet Health (incorporated by reference to Exhibit 10.4.1 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*10.4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex1042.htm">Second Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of August 9, 2011, by and between Axogen Corporation and LifeNet Health (incorporated by reference to Exhibit 10.4.2 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*10.4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312512116287/d311224dex1043.htm">Third Amendment to Amended and Restated Nerve Tissue Processing Agreement, dated as of March 12, 2012, by and between Axogen Corporation and LifeNet Health (incorporated by reference to Exhibit 10.4.3 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 15, 2012).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*10.5.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312511265684/d239706dex105.htm">Distribution Agreement, dated as of August 27, 2008, by and between Axogen, Inc. and Cook Biotech Incorporated (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed on October 6, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.5.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312512116287/d311224dex1052.htm">Amendment No. 1 to Distribution Agreement, dated as of February 24, 2012, by and between Axogen, Inc. and Cook Biotech Incorporated (incorporated by reference to Exhibit 10.5.2 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 15, 2012).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.5.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018001268/axgn-20171231ex1053f032c.htm">Amendment No. 2 to Distribution Agreement, dated as of February 26, 2018, by and between Axogen, Inc. and Cook Biotech Incorporated (incorporated by reference to Exhibit 10.5.3 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312511311516/d253759dex1010.htm">Lease dated as of February 6, 2007, by and between Axogen Corporation and WIGSHAW, LLC (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, filed on November 14, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312512116287/d311224dex1023.htm">Amendment dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312512116287/d311224dex1023.htm"> February 27, 2012 to lease dated as of February 6, 2007, by and between Axogen Corporation and WIGSHAW, LLC, its successors and assigns (incorporated by reference to Exhibit 10.23 to the Company's Annual Report on Form 10-K for the year ended December 31, 2011, filed on March 15, 2012).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000119312513103379/d445191dex1023.htm">Second Amendment to Lease, dated as of February 27, 2013 to lease dated as of February 6, 2007, by and between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2012, filed on March 12, 2013).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000110465914017051/a14-5254_1ex10d10d3.htm">Third Amendment to Lease, dated November 12, 2013 to lease dated as of February 6, 2007, by and between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.10.3 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2013, filed on March 6, 2014).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837016004242/axgn-20160316ex10104d7c3.htm">Fourth Amendment to Lease, dated as of March 16, 2016, by and between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.10.4 to the Company&#8217;s Current Report on Form 8-K filed on March 18, 2016).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020014190/axgn-20201130xex10d9d5.htm">Fifth Amendment to Lease, dated as of November 30, 2020, by and between AxoGen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.9.5 to the Company&#8217;s Current Report on Form 8-K, filed on December 4, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592821000128/sixthamendmenttoleaseaxoge.htm">Sixth Amendment to Lease, dated as of July 13, 2021, by and between Axogen Corporation and Ology Bioservices Holdings, LLC (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K, filed on July 16, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018002975/ex-10d1.htm">Current Premises Election Notice, dated as of April 10, 2018, by and between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 13, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.6.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018007510/ex-10d1.htm">Letter Agreement effective September 20, 2018 by between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on September 21, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837016004559/axgn-20160526xdef14a.htm">Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 (incorporated by reference to Appendix A to the Company&#8217;s Proxy Statement filed on April 8, 2016).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.8.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000095013707014632/c18884exv99w2.htm">Form of Employee Incentive Stock Option Agreement (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed on September 26, 2007).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.8.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837017001241/axgn-20161231ex101028e10.htm">Amended Form of Employee Incentive Stock Option Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 (incorporated by reference to Exhibit 10.10.2 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.9.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000110465915029417/a15-9591_1ex10d1.htm">Commercial Lease, dated April 21, 2015, by and between Axogen Corporation and Ja-Cole, L.P. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 22, 2015).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.9.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000110465915029417/a15-9591_1ex10d2.htm">Addendum to Commercial Lease, dated April 21, 2015 by and between Axogen Corporation and Ja-Cole, L.P. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on April 22, 2015).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.9.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837016008901/axgn-20161025ex1021766d8.htm">Commercial Lease Amendment 2, dated as of October 25, 2016, by and between Axogen Corporation and Ja-Cole L.P. (incorporated by reference to Exhibit 10.2.1 to the Company&#8217;s Current Report on Form 8-K filed on October 31, 2016).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.9.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018009452/ex-10d1.htm">Commercial Lease Amendment 3, dated November 21, 2018 by and between Ja-Cole L.P. and Axogen Corporation (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on November 26, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.9.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837019004464/axgn-20190331ex101f8ceb7.htm">Commercial Lease Amendment 4, dated March 12, 2019, by and between Ja-Cole L.P. and Axogen Corporation (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, filed on May 8, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592822000006/axogencommercialleaseame.htm">Commercial Lease Amendment, dated as of January 27, 2022, by and between Ja-Cole L.P. and Axogen Corporation (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on January 31, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837015002338/axgn-20150930ex1034b785d.htm">License and Services Agreement, dated as of August 6, 2015, by and between Axogen Corporation and Community Blood Center (d/b/a Community Tissue Services) (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed on November 5, 2015).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837019001095/axgn-20181231ex10131074a.htm">Fourth Amendment to License and Services Agreement, dated as of February 22, 2019, by and between Axogen Corporation and Community Blood Center (d/b/a Community Tissue Services). (incorporated by reference to Exhibit 10.13.1 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, filed on February 26, 2019)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592821000042/ctsseventhamendment.htm">Seventh Amendment to License and Services Agreement, dated as of February 22, 2021, by and between Axogen Corporation and Community Blood Center (d/b/a Community Tissue Services) (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed on February 26, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000114036122030901/brhc10041274_ex10-2.htm">Eighth Amendment to License and Services Agreement, dated as of August 22, 2022, by and between Axogen Corporation and Community Blood Center(d/b/a Community Tissue Services) ( incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K, filed on August 25,</a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000114036122030901/brhc10041274_ex10-2.htm"> </a><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000114036122030901/brhc10041274_ex10-2.htm">2022).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837017001241/axgn-20161231ex102219b9a.htm">Form of Non-Incentive Stock Option Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 (incorporated by reference to Exhibit 10.22 to the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837017001241/axgn-20161231ex1023b18e9.htm">Form of Performance Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of May 26, 2016 (incorporated by reference to Exhibit 10.23 to the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837017001241/axgn-20161231ex10240391a.htm">Retention Stock Unit Award Agreement, dated December 29, 2016, by and between Axogen, Inc. and Karen Zaderej, pursuant to Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 (incorporated by reference to Exhibit 10.24 to the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018001268/axgn-20171231ex1026fc96d.htm">Form of 2018 Performance Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 (incorporated by reference to Exhibit 10.26 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017, filed on March 1, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018001268/axgn-20171231ex1028ea35c.htm">Form of Restricted Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of March 23, 2016 (incorporated by reference to Exhibit 10.28 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016, filed on March 1, 2017).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018002975/ex-10d1.htm">Current Premises Election Notice, dated as of April 10, 2018, by and between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 13, 2018).</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018007510/ex-10d1.htm">Letter Agreement effective September 20, 2018 by between Axogen Corporation and SNH Medical Office Properties Trust (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on September 21, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.20.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018007510/ex-10d2.htm">Office Lease dated September 20, 2018 by and between Axogen, Inc., Axogen Corporation and Heights Union, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on September 21, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.20.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592821000128/firstamendmenttolease-axog.htm">First Amendment to Office Lease, dated as of July 12, 2021, by and among Axogen, Inc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592821000128/firstamendmenttolease-axog.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592821000128/firstamendmenttolease-axog.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592821000128/firstamendmenttolease-axog.htm"> Axogen Corporation, and Heights Union I, LLC (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed on July 16, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018007978/ex-10d3.htm">Form of Incentive Stock Option Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of October 29, 2018 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on October 29, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018007978/ex-10d4.htm">Form of Restricted Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of October 29, 2018 (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed on October 29, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837017002511/axgn-20170524xdef14a.htm#APPENDIXB_920672">Axogen, Inc. 2017 Employee Stock Purchase Plan (incorporated by reference to Appendix B to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837017002511/axgn-20170524xdef14a.htm#APPENDIXB_920672">'</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837017002511/axgn-20170524xdef14a.htm#APPENDIXB_920672">s Proxy Statement filed on April 7, 2017).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.25.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018009452/ex-10d3.htm">Lease, dated November 19, 2018 by and between SNH Medical Office Properties Trust and Axogen Corporation (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on November 26, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.25.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837018009452/ex-10d4.htm">First Amendment to Lease dated as of November 19, 2018 by and between SNH Medical Office Properties Trust and Axogen Corporation (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed on November 26, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+10.25.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="exhibit10253secondamendm.htm">Second Amendment to Lease dated as of January 1, 2023 by and between SNH Medical Office Properties Trust and Axogen Corporation.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837019000195/ex-10d2.htm">Form of Non-Qualified Stock Option Inducement Award Agreement to be granted by Axogen, Inc. to Eric Sandberg on January 22, 2019 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on January 22, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837019001095/axgn-20181231ex1047ad382.htm">Form of Performance Stock Unit Award Agreement pursuant to the Axogen, Inc. 2010 Stock Incentive Plan, as amended and restated as of April 5, 2017 (incorporated by reference to Exhibit 10.47 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, filed on February 26, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837019006084/ex-10d1.htm">Standard Form of Agreement Between Owner and Design-Builder, dated as of July 9, 2019, by and between Axogen Corporation and CRB Builders, L.L.C. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on July 9, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837019010165/ex-10d2.htm">Axogen Inc. 2019 Long-Term Incentive Plan and forms of award notices and agreements thereunder (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed on November 6, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">***10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020001238/ex-10d51.htm">Nerve End Cap Supply Agreement, dated June 27, 2017, by and between Cook Biotech Incorporated and Axogen Corporation (incorporated by reference to Exhibit 10.51 to the Company&#8217;s Annual Report on Form 10-K, filed on February 24, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+10.30.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10301firstamendme.htm">First Amendment to Nerve End Cap Supply Agreement, dated April 6, 2020, by and between Cook Biotech Incorporated, and AxoGen Corporation.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020007908/axgn-20200630xex10d1.htm">Term Loan Agreement, dated June 30, 2020, among Axogen, Inc., Axogen Corporation, AxoGen Processing Corporation, TPC Investments II LP and Argo SA LLC. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on July 1, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020007908/axgn-20200630xex10d2.htm">Security Agreement, dated June 30, 2020, among Axogen, Inc., Axogen Corporation, AxoGen Processing Corporation, and Argo SA LLC. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on July 1, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020007908/axgn-20200630xex10d3.htm">Revenue Participation Agreement, dated June 30, 2020, between Axogen, Inc. and Argo SA LLC. (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed on July 1, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020007908/axgn-20200630xex10d4.htm">Option Agreement, dated June 30, 2020, between Axogen, Inc. and TPC Investments II LP. (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed on July 1, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020012062/axgn-20201029xex10d1.htm">Amended and Restated Employment Agreement, dated November 1, 2020, by and between Axogen Corporation and Karen Zaderej (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on October 29, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020012062/axgn-20201029xex10d2.htm">Amended and Restated Employment Agreement, dated November 1, 2020, by and between Axogen Corporation and Peter Mariani (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on October 29, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020012062/axgn-20201029xex10d4.htm">Amended and Restated Employment Agreement, dated November 1, 2020, by and between Axogen Corporation and Maria Martinez (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed on October 29, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020012062/axgn-20201029xex10d5.htm">Amended and Restated Employment Agreement, dated November 1, 2020, by and between Axogen Corporation and Isabelle Billet (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K, filed on October 29, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020012062/axgn-20201029xex10d6.htm">Amended and Restated Employment Agreement, dated November 1, 2020, by and between Axogen Corporation and Bradley Ottinger (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K, filed on October 29, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837021000059/axgn-20210104xex10d1.htm">Second Amended and Restated Employment Agreement, dated January 4, 2021, by and between Axogen Corporation and Angelo Scopelianos (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on January 6, 2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.42.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000155837020012154/axgn-20200930xex10d1.htm">Commercial Lease, dated October 1, 2020, by and between Axogen Corporation and Ja-Cole, L.P (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed on October 30, 2020.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000114036122030901/brhc10041274_ex10-1.htm">First Amendment to Lease Agreement dated as of August 22, 2022, by and between Axogen Corporation and Ja-Cole, L.P. (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed on August 25, 2022)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">**10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592822000117/exhibit103ericsandberg_s.htm">Confidential Separation Agreement and Release of Claims dated July 19, 2022 by and between Axogen Corporation and Eric Sandberg (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed on November 8, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;text-indent:27pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592822000045/exhibit101prsu.htm">Form of Performance-Based Restricted Stock Units Notice and Performance-Based Restricted Stock Units Agreement under the Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on April 1, 2022).</a></span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592822000045/exhibit102rsu.htm">Form of Restricted Stock Units Notice and Restricted Stock Units Agreement under the Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on April 1, 2022)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**10.48</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592822000045/exhibit103iso.htm">Form of Incentive Stock Options Notice and Incentive Stock Option Agreement under the Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed on April 1, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**10.49</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592822000045/exhibit104piso.htm">Form of Premium Incentive Stock Options Notice and Premium Incentive Stock Option Agreement under the Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K, filed on April 1, 2022).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**10.50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/805928/000080592822000051/axgn_proxyx20211.htm#ic90c6bf17bf9481e81ae12deffcdc8e4_178">Axogen, Inc. Second Amended and Restated 2019 Long-Term Incentive Plan (incorporated by reference to Appendix A to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 14, 2022).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="subsidiariesofaxogen123120.htm">Subsidiaries of the Registrant.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="a2022consent.htm">Consent of Deloitte &amp; Touche, LLP.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">++24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Power of Attorney.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="axgnfy22q4ex311.htm">Certification of Principal Executive Officer.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="axgnfy22q4ex312.htm">Certification of Principal Financial Officer.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+++32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="axgnfy21q4ex32.htm">Chief Executive Officer and Chief Financial Officer Certifications pursuant to 18 U.S.C. 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Instance Document &#8211; The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Extension Labels Linkbase.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">+101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline XBRL f</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Confidential treatment has been granted for portions of this Exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as amended. The confidential portions have been deleted and filed separately with the U.S. Securities and Exchange Commission.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contract or compensatory plan or arrangement.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Confidential treatment has been requested as to certain portions, which portions have been omitted and filed separately with the Securities and Exchange Commission.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included on signature page.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnished herewith.</span></td></tr></table></div><div><span><br/></span></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_193"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">ITEM 16. Form 10-K Summary</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i3b0f4bcd44e346a09eb3f60d2751bcde_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AXOGEN, INC</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Zaderej</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President and Chairman of the Board</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Karen Zaderej (with full power to act alone), as his or her true and lawful attorney-in-fact and agent, with full powers of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the Annual Report on Form 10-K of Axogen, Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or their substitute or substitutes, lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Karen Zaderej, Chief Executive Officer, President and Chairman of the Board<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peter J. Mariani, Executive Vice President and Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">William P. Burke</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gregory G. Freitag</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Joseph A. Tyndall</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">John H. Johnson</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alan M. Levine<br/>Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guido J. Neels<br/>Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paul G. Thomas<br/>Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i3b0f4bcd44e346a09eb3f60d2751bcde_7">Table of Content</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amy Wendell<br/>Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10. 25 3
<SEQUENCE>2
<FILENAME>exhibit10253secondamendm.htm
<DESCRIPTION>EX-10. 25 3
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit10253secondamendm</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit10253secondamendm001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit10253secondamendm001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit10253secondamendm002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit10253secondamendm002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2 3
<SEQUENCE>3
<FILENAME>exhibit1023thirdamendmen.htm
<DESCRIPTION>EX-10.2 3
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit1023thirdamendmen</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit1023thirdamendmen001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1023thirdamendmen001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1023thirdamendmen002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1023thirdamendmen002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1023thirdamendmen003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1023thirdamendmen003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30 1
<SEQUENCE>4
<FILENAME>exhibit10301firstamendme.htm
<DESCRIPTION>EX-10.30 1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit10301firstamendme</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1365;"><!-- exhibit10301firstamendme001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit10301firstamendme001.jpg" title="slide1" width="1365" height="1055">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>subsidiariesofaxogen123120.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3736c3dd19c74428b5eb698f3eaaf151_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 21.1</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:125%">SUBSIDIARIES OF AXOGEN, INC.</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">As of December 31, 2021, Axogen, Inc. had three sole subsidiaries&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.66pt">Axogen Corporation, a Delaware corporation&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.66pt">Axogen Europe GmbH, an Austrian corporation&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%;padding-left:9.66pt">Axogen Processing Corporation, a Delaware corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>a2022consent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3279bba7bc114cae9f04b7d968abb206_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in Registration Statement Nos. 333-220770, 333-224713 and 333-255807 on Form S-3 and Registration Statement Nos. 333-173539, 333-177980, 333-201238, 333-211660, 333-218290, 333-230418, 333-233416, 333-222019, 333-255992 and 333-265321 on Form S-8 of our report dated March 14, 2023, relating to the financial statements of Axogen, Inc., and the effectiveness of Axogen, Inc.'s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2022.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#47;s&#47; DELOITTE &#38; TOUCHE LLP</font></div><div><font><br></font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Miami, Florida </font></div><div><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 14, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>axgnfy22q4ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i58e26b6307b34ffe830446046f8ef8c0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Karen Zaderej, certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Axogen, Inc.&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:289.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:168.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 14, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Karen Zaderej</font></td></tr><tr style="height:38pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Zaderej<br>Chief Executive Officer, President and Chairman of the Board</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>axgnfy22q4ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iaac9379ab649463d9c4b1b7bc0a8b8ca_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter J. Mariani, certify that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Axogen, Inc.&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:289.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:168.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter J. Mariani</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter J. Mariani</font></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>axgnfy21q4ex32.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1d6f68d1fc1842259d0e0262fe282e51_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (SUBSECTIONS (A) AND (B) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE)</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K (the &#8220;Report&#8221;) of Axogen, Inc. (the &#8220;Company&#8221;), Karen Zaderej, Chief Executive Officer and President of the Company and Peter J. Mariani, Executive Vice President and Chief Financial Officer of the Company, each certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of her&#47;his knowledge that&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:289.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:168.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; March 14, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Karen Zaderej</font></td></tr><tr style="height:48pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Zaderej<br>Chief Executive Officer,  President and Chairman of the Board<br>(Principal Executive Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Peter J. Mariani</font></td></tr><tr style="height:51pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter J. Mariani<br>Executive Vice President and Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>axgn-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:008e6d96-0028-47c7-9dfe-7d6d669b55a8,g:6a78ba92-a70c-4cec-a491-e196b80cf77c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:axgn="http://www.axogeninc.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.axogeninc.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axgn-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axgn-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axgn-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="axgn-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.axogeninc.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.axogeninc.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" roleURI="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://www.axogeninc.com/role/NatureofBusiness">
        <link:definition>0000008 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.axogeninc.com/role/Inventory">
        <link:definition>0000010 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.axogeninc.com/role/FairValueMeasurement">
        <link:definition>0000011 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.axogeninc.com/role/Leases">
        <link:definition>0000012 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNet">
        <link:definition>0000013 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.axogeninc.com/role/IntangibleAssetsNet">
        <link:definition>0000014 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.axogeninc.com/role/AccountsPayableandAccruedExpenses">
        <link:definition>0000015 - Disclosure - Accounts Payable and Accrued Expenses&#8203;</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetofDebtDiscountandFinancingFees" roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFees">
        <link:definition>0000016 - Disclosure - Long-Term Debt&#8203;, Net of Debt Discount and Financing Fees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedLossperCommonShare" roleURI="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShare">
        <link:definition>0000017 - Disclosure - Basic and Diluted Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.axogeninc.com/role/StockBasedCompensation">
        <link:definition>0000018 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.axogeninc.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlan" roleURI="http://www.axogeninc.com/role/RetirementPlan">
        <link:definition>0000020 - Disclosure - Retirement Plan&#8203;</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.axogeninc.com/role/CommitmentsandContingencies">
        <link:definition>0000021 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.axogeninc.com/role/SubsequentEvent">
        <link:definition>0000022 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccounts" roleURI="http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccounts">
        <link:definition>0000023 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.axogeninc.com/role/InventoryTables">
        <link:definition>0000026 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.axogeninc.com/role/FairValueMeasurementTables">
        <link:definition>0000027 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.axogeninc.com/role/LeasesTables">
        <link:definition>0000028 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000029 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetTables">
        <link:definition>0000030 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>0000031 - Disclosure - Accounts Payable and Accrued Expenses&#8203; (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetofDebtDiscountandFinancingFeesTables" roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesTables">
        <link:definition>0000032 - Disclosure - Long-Term Debt&#8203;, Net of Debt Discount and Financing Fees (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedLossperCommonShareTables" roleURI="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareTables">
        <link:definition>0000033 - Disclosure - Basic and Diluted Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.axogeninc.com/role/StockBasedCompensationTables">
        <link:definition>0000034 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.axogeninc.com/role/IncomeTaxesTables">
        <link:definition>0000035 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000036 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesReconciliationofCashDetails" roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails">
        <link:definition>0000037 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.axogeninc.com/role/InventoryDetails">
        <link:definition>0000038 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000039 - Disclosure - Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details" roleURI="http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details">
        <link:definition>0000040 - Disclosure - Fair Value Measurement - Fair Value of Instruments Classified as Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNarrativeDetails" roleURI="http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails">
        <link:definition>0000041 - Disclosure - Fair Value Measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails" roleURI="http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails">
        <link:definition>0000042 - Disclosure - Fair Value Measurement - Significant Inputs Included in the Valuation of the Debt Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofTotalLeaseExpenseDetails" roleURI="http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails">
        <link:definition>0000043 - Disclosure - Leases- Components of Total Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>0000044 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>0000045 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.axogeninc.com/role/LeasesNarrativeDetails">
        <link:definition>0000046 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails" roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails">
        <link:definition>0000047 - Disclosure - Property and Equipment, Net -Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNetDetails">
        <link:definition>0000048 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails" roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails">
        <link:definition>0000049 - Disclosure - Intangible Assets, Net - Components of Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1" roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1">
        <link:definition>0000049 - Disclosure - Intangible Assets, Net - Components of Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetAmortizationExpenseDetails" roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetAmortizationExpenseDetails">
        <link:definition>0000050 - Disclosure - Intangible Assets, Net - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails" roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails">
        <link:definition>0000051 - Disclosure - Intangible Assets, Net - Future Amortization of Patents and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetNarrativeDetails" roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails">
        <link:definition>0000052 - Disclosure - Intangible Assets, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetRoyaltyFeesDetails" roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails">
        <link:definition>0000053 - Disclosure - Intangible Assets, Net - Royalty Fees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesDetails" roleURI="http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails">
        <link:definition>0000054 - Disclosure - Accounts Payable and Accrued Expenses&#8203; (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails" roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails">
        <link:definition>0000055 - Disclosure - Long-Term Debt&#8203;, Net of Debt Discount and Financing Fees - Schedule of Carrying Values of Outstanding Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails" roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails">
        <link:definition>0000056 - Disclosure - Long-Term Debt&#8203;, Net of Debt Discount and Financing Fees - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedLossperCommonShareDetails" roleURI="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails">
        <link:definition>0000057 - Disclosure - Basic and Diluted Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails" roleURI="http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails">
        <link:definition>0000058 - Disclosure - Stock-Based Compensation - Overview of Equity Incentive Plans Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails" roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails">
        <link:definition>0000059 - Disclosure - Stock-Based Compensation - Summary of consolidated statements of operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionsNarrativeDetails" roleURI="http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails">
        <link:definition>0000060 - Disclosure - Stock-Based Compensation - Stock Options Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails" roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails">
        <link:definition>0000061 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions Used (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>0000062 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails" roleURI="http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails">
        <link:definition>0000063 - Disclosure - Stock-Based Compensation - Restricted and Performance Stock Units Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails" roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails">
        <link:definition>0000064 - Disclosure - Stock-Based Compensation - Summary of Restricted and Performance Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>0000065 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails" roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails">
        <link:definition>0000066 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions Used For 2017 ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTemporaryDifferencesDetails" roleURI="http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails">
        <link:definition>0000067 - Disclosure - Income Taxes - Temporary Differences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.axogeninc.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000068 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>0000069 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RetirementPlanDetails" roleURI="http://www.axogeninc.com/role/RetirementPlanDetails">
        <link:definition>0000070 - Disclosure - Retirement Plan&#8203; (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesServiceAgreementsNarrativeDetails" roleURI="http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails">
        <link:definition>0000071 - Disclosure - Commitments and Contingencies - Service Agreements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails" roleURI="http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails">
        <link:definition>0000072 - Disclosure - Commitments and Contingencies - Axogen Processing Center Facility Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails" roleURI="http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails">
        <link:definition>0000073 - Disclosure - Commitments and Contingencies - Fair Value of Debt Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.axogeninc.com/role/SubsequentEventDetails">
        <link:definition>0000074 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsDetails" roleURI="http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails">
        <link:definition>0000075 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation" abstract="false" name="CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_DefinedContributionPlanEmployeeContributionPercentMatched" abstract="false" name="DefinedContributionPlanEmployeeContributionPercentMatched" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" abstract="false" name="AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure" abstract="false" name="DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_DirectorsAndOfficersStockOptionsMember" abstract="true" name="DirectorsAndOfficersStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_AxoGen2010StockIncentivePlanMember" abstract="true" name="AxoGen2010StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_CommercialLeaseWithJAColeLPMember" abstract="true" name="CommercialLeaseWithJAColeLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive" abstract="false" name="LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_AviveSoftTissueMembraneMember" abstract="true" name="AviveSoftTissueMembraneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_RestrictedCashMember" abstract="true" name="RestrictedCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_PurchasePriceOfCommonStockCalculationPeriod" abstract="false" name="PurchasePriceOfCommonStockCalculationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="axgn_CreditFacilityTrancheTwoMember" abstract="true" name="CreditFacilityTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_DeferredTaxAssetsLiabilities" abstract="false" name="DeferredTaxAssetsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_TwoThousandTwentyOnePerformanceShareUnitMember" abstract="true" name="TwoThousandTwentyOnePerformanceShareUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_RightOfUseAssetAmortization" abstract="false" name="RightOfUseAssetAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo" abstract="false" name="LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_LicenseFeeAmount" abstract="false" name="LicenseFeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_PerformanceStockUnitPayoutOpportunity" abstract="false" name="PerformanceStockUnitPayoutOpportunity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt" abstract="false" name="EmbeddedDerivativeAssociatedWithTheLongTermDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_OptionalPrepaymentEventMember" abstract="true" name="OptionalPrepaymentEventMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_ShareBasePaymentArrangementNumberOfPlans" abstract="false" name="ShareBasePaymentArrangementNumberOfPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="axgn_PatentsAndLicenseAgreementsMember" abstract="true" name="PatentsAndLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_LeaseLiabilityCurrent" abstract="false" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract" abstract="true" name="EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation" abstract="false" name="DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_ShareBasedCompensationExpenseForfeitedOrReversed" abstract="false" name="ShareBasedCompensationExpenseForfeitedOrReversed" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" abstract="false" name="PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_RisksAndUncertaintiesPolicyTextBlock" abstract="false" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="axgn_MeasurementInputCouponRateMember" abstract="true" name="MeasurementInputCouponRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour" abstract="false" name="LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_APCFacilityMember" abstract="true" name="APCFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_OperatingAndFinancingLeaseLiabilityCurrent" abstract="false" name="OperatingAndFinancingLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_NoticePeriodForTerminationOfAgreement" abstract="false" name="NoticePeriodForTerminationOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="axgn_LesseeOperatingLeaseNumberOfRentFreeMonths" abstract="false" name="LesseeOperatingLeaseNumberOfRentFreeMonths" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="axgn_Axogen2017EmployeeStockPurchasePlanMember" abstract="true" name="Axogen2017EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios" abstract="false" name="DebtInstrumentInternalRateOfReturnUnderSettlementScenarios" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" abstract="false" name="DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="axgn_MandatoryPrepaymentEventIn2024OrAfterMember" abstract="true" name="MandatoryPrepaymentEventIn2024OrAfterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_DebtInstrumentHeldToMaturityMakeWholePayment" abstract="false" name="DebtInstrumentHeldToMaturityMakeWholePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_ProceedsFromGrantorsInvestingActivities" abstract="false" name="ProceedsFromGrantorsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" abstract="true" name="Axogen401kPlanEmployerMatchingContributionTranche1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_OperatingAndFinancingLeaseLiability" abstract="false" name="OperatingAndFinancingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_DebtDerivativeLiabilityMember" abstract="true" name="DebtDerivativeLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_DebtInstrumentInterestRateEventOfDefaultIncrease" abstract="false" name="DebtInstrumentInterestRateEventOfDefaultIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_MandatoryPrepaymentEventBefore2024Member" abstract="true" name="MandatoryPrepaymentEventBefore2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree" abstract="false" name="LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_DesignBuildAgreementMember" abstract="true" name="DesignBuildAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne" abstract="false" name="AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_Axogen401kPlanMember" abstract="true" name="Axogen401kPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_MeasurementInputMandatoryPrepaymentRateMember" abstract="true" name="MeasurementInputMandatoryPrepaymentRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_ShareBasedCompensationAwardTrancheFourMember" abstract="true" name="ShareBasedCompensationAwardTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" abstract="true" name="MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne" abstract="false" name="LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_ScheduleOfRoyaltyExpensesTableTextBlock" abstract="false" name="ScheduleOfRoyaltyExpensesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="axgn_OperatingAndFinancingLeaseLiabilityNoncurrent" abstract="false" name="OperatingAndFinancingLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_CreditFacilityMember" abstract="true" name="CreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount" abstract="false" name="LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember" abstract="true" name="TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_PercentageOfAchievementOfAwardIssued" abstract="false" name="PercentageOfAchievementOfAwardIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" abstract="false" name="EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_OperatingLeaseIncrementalBorrowingRate" abstract="false" name="OperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_EmployeeStockPurchasePlanOfferingPeriod" abstract="false" name="EmployeeStockPurchasePlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="axgn_PaymentForServiceFees" abstract="false" name="PaymentForServiceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights" abstract="false" name="StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="axgn_DeferredTaxAssetsInterestLimitation" abstract="false" name="DeferredTaxAssetsInterestLimitation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive" abstract="false" name="LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_TwoThousandTwentyTwoPerformanceShareUnitMember" abstract="true" name="TwoThousandTwentyTwoPerformanceShareUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_CommunityTissuesServicesAgreementMember" abstract="true" name="CommunityTissuesServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_DebtInstrumentAdditionalInterestFloorRate" abstract="false" name="DebtInstrumentAdditionalInterestFloorRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_PrepaymentProbabilityEventDomain" abstract="true" name="PrepaymentProbabilityEventDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_CreditFacilityTrancheOneMember" abstract="true" name="CreditFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" abstract="false" name="ServiceAgreementAmountPaidUponExecutionOfAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_OperatingLeasesAbstract" abstract="true" name="OperatingLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="axgn_ContributionsToCharitableOrganization" abstract="false" name="ContributionsToCharitableOrganization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_CashGrantsReceivable" abstract="false" name="CashGrantsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_PerformanceSharesBiologicLicenseApplicationMember" abstract="true" name="PerformanceSharesBiologicLicenseApplicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade" abstract="false" name="DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember" abstract="true" name="CommercialLeaseWithJAColeLPFirstAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember" abstract="true" name="Axogen2019LongTermIncentivePlanNewAxogenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" abstract="false" name="EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_NoncashOrPartNoncashConversionOption" abstract="false" name="NoncashOrPartNoncashConversionOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" abstract="false" name="AdditionalCostsAssociatedWithDesignBuildAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_ResearchAndDevelopmentGrantsMember" abstract="true" name="ResearchAndDevelopmentGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_TwoThousandTwentyPerformanceShareUnitMember" abstract="true" name="TwoThousandTwentyPerformanceShareUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn" abstract="false" name="DebtInstrumentMinimumRequiredInternalRateOfReturn" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_EstimatedCostRelatingToDesignBuildAgreement" abstract="false" name="EstimatedCostRelatingToDesignBuildAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid" abstract="false" name="LesseeOperatingAndFinancingLeaseLiabilityToBePaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_LeaseLiabilitiesNoncurrent" abstract="false" name="LeaseLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" abstract="false" name="StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="axgn_RoyaltyFeesPercentageUnderLicenseAgreements" abstract="false" name="RoyaltyFeesPercentageUnderLicenseAgreements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="axgn_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="axgn_NumberOfPotentialSettlementScenarios" abstract="false" name="NumberOfPotentialSettlementScenarios" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" abstract="true" name="Axogen401kPlanEmployerMatchingContributionTranche2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" abstract="false" name="NoncashRightOfUseAssetsAndOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_LeasesFinanceAbstract" abstract="true" name="LeasesFinanceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="axgn_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_PrepaymentProbabilityEventAxis" abstract="true" name="PrepaymentProbabilityEventAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="axgn_DirectorsAndCertainExecutiveOfficersMember" abstract="true" name="DirectorsAndCertainExecutiveOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="axgn_DeferredTaxAssetsLeaseObligations" abstract="false" name="DeferredTaxAssetsLeaseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty" abstract="false" name="RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>axgn-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:008e6d96-0028-47c7-9dfe-7d6d669b55a8,g:6a78ba92-a70c-4cec-a491-e196b80cf77c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="axgn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3aed1afc-6b3e-41e6-8887-f12653ca6fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_469c593c-7427-497d-9826-4cf72107c12c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3aed1afc-6b3e-41e6-8887-f12653ca6fe3" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_469c593c-7427-497d-9826-4cf72107c12c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LeaseLiabilityCurrent_511104c2-006c-4e8a-bb61-c6fa31f05524" xlink:href="axgn-20221231.xsd#axgn_LeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3aed1afc-6b3e-41e6-8887-f12653ca6fe3" xlink:to="loc_axgn_LeaseLiabilityCurrent_511104c2-006c-4e8a-bb61-c6fa31f05524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_638a7b91-1de4-47d8-a58d-9a6f0bedc573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2f271766-e599-4751-8d51-4efd4b34e5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_638a7b91-1de4-47d8-a58d-9a6f0bedc573" xlink:to="loc_us-gaap_Liabilities_2f271766-e599-4751-8d51-4efd4b34e5cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d15b2c82-3171-4e64-aedd-83a47a83b2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_638a7b91-1de4-47d8-a58d-9a6f0bedc573" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d15b2c82-3171-4e64-aedd-83a47a83b2d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8ba6abec-f8ba-4309-9b4c-fe9e960b331a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_638a7b91-1de4-47d8-a58d-9a6f0bedc573" xlink:to="loc_us-gaap_StockholdersEquity_8ba6abec-f8ba-4309-9b4c-fe9e960b331a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_898c9473-0a0c-4c5f-87b2-89564edebbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7c6f9b52-b7dc-4249-9792-b78dd5046613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_898c9473-0a0c-4c5f-87b2-89564edebbbd" xlink:to="loc_us-gaap_LiabilitiesCurrent_7c6f9b52-b7dc-4249-9792-b78dd5046613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1c542180-bb13-4de0-891f-e212353f6fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_898c9473-0a0c-4c5f-87b2-89564edebbbd" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1c542180-bb13-4de0-891f-e212353f6fe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LeaseLiabilitiesNoncurrent_4786cfeb-0017-450a-a7ba-804d60e6358f" xlink:href="axgn-20221231.xsd#axgn_LeaseLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_898c9473-0a0c-4c5f-87b2-89564edebbbd" xlink:to="loc_axgn_LeaseLiabilitiesNoncurrent_4786cfeb-0017-450a-a7ba-804d60e6358f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_4db6c99d-fcf1-4a6a-86d3-989f9b0b85ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_898c9473-0a0c-4c5f-87b2-89564edebbbd" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_4db6c99d-fcf1-4a6a-86d3-989f9b0b85ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_45054230-35dd-4c83-9c6f-55d099a704e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1911d2ec-8d50-49cc-aca6-79c1aafa097f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45054230-35dd-4c83-9c6f-55d099a704e5" xlink:to="loc_us-gaap_AssetsCurrent_1911d2ec-8d50-49cc-aca6-79c1aafa097f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_13ae2121-efc2-4af2-98bd-e243516496f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45054230-35dd-4c83-9c6f-55d099a704e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_13ae2121-efc2-4af2-98bd-e243516496f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f8f2deeb-65c8-43f5-a407-65036a94e879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45054230-35dd-4c83-9c6f-55d099a704e5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f8f2deeb-65c8-43f5-a407-65036a94e879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4f25f0d5-9d64-4867-8e43-12c549cca1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_45054230-35dd-4c83-9c6f-55d099a704e5" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4f25f0d5-9d64-4867-8e43-12c549cca1de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_57b2f056-b0ce-4a67-8a7d-f77cee186496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0a9cbcc3-0c07-47d1-8ab1-f32789b6dce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57b2f056-b0ce-4a67-8a7d-f77cee186496" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0a9cbcc3-0c07-47d1-8ab1-f32789b6dce1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_690e3878-3faf-4971-8ead-a0021fd7b57a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57b2f056-b0ce-4a67-8a7d-f77cee186496" xlink:to="loc_us-gaap_RestrictedCash_690e3878-3faf-4971-8ead-a0021fd7b57a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_2bf6dd46-d231-458c-b194-3a6d7e095a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57b2f056-b0ce-4a67-8a7d-f77cee186496" xlink:to="loc_us-gaap_ShortTermInvestments_2bf6dd46-d231-458c-b194-3a6d7e095a2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_df3637c6-e60e-4630-9a5a-f5727eb52085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57b2f056-b0ce-4a67-8a7d-f77cee186496" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_df3637c6-e60e-4630-9a5a-f5727eb52085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6cedd886-1cd0-44a2-b109-17f2dceaba19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57b2f056-b0ce-4a67-8a7d-f77cee186496" xlink:to="loc_us-gaap_InventoryNet_6cedd886-1cd0-44a2-b109-17f2dceaba19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7522d11d-b81c-4bb5-8a4d-6bd5ed58697d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_57b2f056-b0ce-4a67-8a7d-f77cee186496" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7522d11d-b81c-4bb5-8a4d-6bd5ed58697d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9ccdaeaf-ce2e-4617-946e-a7210ce0ba85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4fb4b238-d9f4-414c-bcd8-8e642afa2e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9ccdaeaf-ce2e-4617-946e-a7210ce0ba85" xlink:to="loc_us-gaap_CommonStockValue_4fb4b238-d9f4-414c-bcd8-8e642afa2e08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f3240bf4-fc89-4636-92af-d758021ea55b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9ccdaeaf-ce2e-4617-946e-a7210ce0ba85" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f3240bf4-fc89-4636-92af-d758021ea55b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a17ad930-7644-4fdb-811e-fc7ee488b157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9ccdaeaf-ce2e-4617-946e-a7210ce0ba85" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a17ad930-7644-4fdb-811e-fc7ee488b157" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="axgn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_df6edd27-528f-4612-9821-c15bf75833cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_31b6105c-9290-4a9f-84bf-bc94e7f4c2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_df6edd27-528f-4612-9821-c15bf75833cb" xlink:to="loc_us-gaap_OperatingIncomeLoss_31b6105c-9290-4a9f-84bf-bc94e7f4c2cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1571cb69-bc00-4bf9-9d96-9fbdffffb1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_df6edd27-528f-4612-9821-c15bf75833cb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_1571cb69-bc00-4bf9-9d96-9fbdffffb1d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_9b40531c-c8a3-4fa5-b627-71fbd9a66bff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b2ec8d6f-f815-4190-8945-8ca9f2295efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_9b40531c-c8a3-4fa5-b627-71fbd9a66bff" xlink:to="loc_us-gaap_Revenues_b2ec8d6f-f815-4190-8945-8ca9f2295efe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_96968ffc-8406-48ef-8b1e-82d5f63a95ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_9b40531c-c8a3-4fa5-b627-71fbd9a66bff" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_96968ffc-8406-48ef-8b1e-82d5f63a95ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1698cb0f-4cef-403a-a380-f7e505db4000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_9f84a8c8-12a6-4c9e-b3e8-b6a17c8a59b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1698cb0f-4cef-403a-a380-f7e505db4000" xlink:to="loc_us-gaap_SellingAndMarketingExpense_9f84a8c8-12a6-4c9e-b3e8-b6a17c8a59b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_12734577-7140-4485-8d94-30f6b7521819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1698cb0f-4cef-403a-a380-f7e505db4000" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_12734577-7140-4485-8d94-30f6b7521819" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0b0afc8e-0045-4a58-b888-1c0fc3af6e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1698cb0f-4cef-403a-a380-f7e505db4000" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0b0afc8e-0045-4a58-b888-1c0fc3af6e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_69e9da5c-5c7a-4daa-9a43-bb9bad1e3f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_13ffabfe-55b4-403f-9915-54e4833e4334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_69e9da5c-5c7a-4daa-9a43-bb9bad1e3f95" xlink:to="loc_us-gaap_GrossProfit_13ffabfe-55b4-403f-9915-54e4833e4334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ad66fbf0-af1c-4b94-aa93-e2ac4a6343ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_69e9da5c-5c7a-4daa-9a43-bb9bad1e3f95" xlink:to="loc_us-gaap_CostsAndExpenses_ad66fbf0-af1c-4b94-aa93-e2ac4a6343ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_cc22deac-6ed8-4880-957f-62707f491d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_07e6423b-211c-402c-9cd9-9e0d4b3c6022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cc22deac-6ed8-4880-957f-62707f491d32" xlink:to="loc_us-gaap_InterestExpense_07e6423b-211c-402c-9cd9-9e0d4b3c6022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_982882fd-31d3-4cb3-bbf3-a62d416a52de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cc22deac-6ed8-4880-957f-62707f491d32" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_982882fd-31d3-4cb3-bbf3-a62d416a52de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a8f26b91-bb31-42f1-9200-bc893bc7a9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cc22deac-6ed8-4880-957f-62707f491d32" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_a8f26b91-bb31-42f1-9200-bc893bc7a9b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_6e89af33-4f58-4c54-8996-592fbf9d30a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_cc22deac-6ed8-4880-957f-62707f491d32" xlink:to="loc_us-gaap_InvestmentIncomeNet_6e89af33-4f58-4c54-8996-592fbf9d30a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="axgn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8011c8c-fa87-447c-a39f-af5ded222abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11feea5f-8f4c-4f6c-9ffc-f1bdaad61245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8011c8c-fa87-447c-a39f-af5ded222abb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11feea5f-8f4c-4f6c-9ffc-f1bdaad61245" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_0090b76a-001c-4cfd-82bd-2f3a4750427b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8011c8c-fa87-447c-a39f-af5ded222abb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_0090b76a-001c-4cfd-82bd-2f3a4750427b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_72a6003b-3416-488b-80cd-d20c5f792424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8011c8c-fa87-447c-a39f-af5ded222abb" xlink:to="loc_us-gaap_RepaymentsOfDebt_72a6003b-3416-488b-80cd-d20c5f792424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b6d41bbb-05db-46e6-87d0-65d50bf5ebb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8011c8c-fa87-447c-a39f-af5ded222abb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b6d41bbb-05db-46e6-87d0-65d50bf5ebb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4bdce12d-829a-41f2-a4eb-3260d7bc92db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8011c8c-fa87-447c-a39f-af5ded222abb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4bdce12d-829a-41f2-a4eb-3260d7bc92db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_d9325a94-a4c4-49e8-bfa7-e0ae0d0f8672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8011c8c-fa87-447c-a39f-af5ded222abb" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_d9325a94-a4c4-49e8-bfa7-e0ae0d0f8672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_df0256f5-e578-4db8-a836-6f4c772134a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8011c8c-fa87-447c-a39f-af5ded222abb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_df0256f5-e578-4db8-a836-6f4c772134a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_4c2dc3a0-0c26-4aec-8991-6dfcba1a459f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8011c8c-fa87-447c-a39f-af5ded222abb" xlink:to="loc_us-gaap_ProceedsFromStockPlans_4c2dc3a0-0c26-4aec-8991-6dfcba1a459f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f0b9052b-6a73-483c-a0af-3f94685fa7ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ebc700b0-ac87-44c0-bdc7-21fc7730d5de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f0b9052b-6a73-483c-a0af-3f94685fa7ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ebc700b0-ac87-44c0-bdc7-21fc7730d5de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_179cc847-c35f-4a9f-8087-d4b623886b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f0b9052b-6a73-483c-a0af-3f94685fa7ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_179cc847-c35f-4a9f-8087-d4b623886b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1582ace3-05c2-4157-9ff5-fc407885798d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f0b9052b-6a73-483c-a0af-3f94685fa7ca" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1582ace3-05c2-4157-9ff5-fc407885798d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_68e9fa09-69fd-4f53-84a0-934341f86fef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_68e9fa09-69fd-4f53-84a0-934341f86fef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dcb55424-8bb8-4aa0-bfaf-5434c3bbed01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dcb55424-8bb8-4aa0-bfaf-5434c3bbed01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c6e48438-c96b-4e07-b22c-79583290cb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c6e48438-c96b-4e07-b22c-79583290cb2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_03e92f33-e6e1-4bcc-b88b-4402dd26f265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_NetIncomeLoss_03e92f33-e6e1-4bcc-b88b-4402dd26f265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b068d75a-8519-424e-ba5d-0af3fd0626f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b068d75a-8519-424e-ba5d-0af3fd0626f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_0bc8fc4c-21e6-41c2-bbf8-13be904da718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_InventoryWriteDown_0bc8fc4c-21e6-41c2-bbf8-13be904da718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_02a1a02e-5825-43eb-a282-9f621adcf2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_02a1a02e-5825-43eb-a282-9f621adcf2cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_4f5f0070-1395-41b8-9473-2888309b60be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_4f5f0070-1395-41b8-9473-2888309b60be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f9ca3d10-4467-4770-8452-18f454178814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f9ca3d10-4467-4770-8452-18f454178814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c9c91369-ef52-4d2f-877f-1005159ae982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_ShareBasedCompensation_c9c91369-ef52-4d2f-877f-1005159ae982" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_be21d3d2-e260-4d58-bd6b-a17dc317907a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_be21d3d2-e260-4d58-bd6b-a17dc317907a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RightOfUseAssetAmortization_a22f3af0-9033-466c-8503-14a1ad88c5d1" xlink:href="axgn-20221231.xsd#axgn_RightOfUseAssetAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_axgn_RightOfUseAssetAmortization_a22f3af0-9033-466c-8503-14a1ad88c5d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_67f88966-d67e-4c00-8dd4-50b9a9ec3b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_67f88966-d67e-4c00-8dd4-50b9a9ec3b40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4f379589-f6d8-42fd-bc4c-7f0d6dc92839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4f379589-f6d8-42fd-bc4c-7f0d6dc92839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3cceb456-c9bf-4e4c-9afb-3f240bf50620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3cceb456-c9bf-4e4c-9afb-3f240bf50620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_IncreaseDecreaseInOperatingLeaseLiabilities_dd411145-1393-470e-9d47-6e8e47ddc160" xlink:href="axgn-20221231.xsd#axgn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_axgn_IncreaseDecreaseInOperatingLeaseLiabilities_dd411145-1393-470e-9d47-6e8e47ddc160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_b0b49580-3ad6-4fb4-939a-38d6f9a360cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_b0b49580-3ad6-4fb4-939a-38d6f9a360cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a0c31f1c-a6f1-4a22-b664-fbe7cfd35550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_827bc66c-7989-454d-9545-3577e1c5c4e6" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a0c31f1c-a6f1-4a22-b664-fbe7cfd35550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a118ac7b-5ff4-4fa6-a723-ad30bef1a334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_718d5001-c9a4-4511-8f14-7cc254eaf092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a118ac7b-5ff4-4fa6-a723-ad30bef1a334" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_718d5001-c9a4-4511-8f14-7cc254eaf092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ProceedsFromGrantorsInvestingActivities_d8fc9eda-78c4-4dba-9541-6c8f1d7a4349" xlink:href="axgn-20221231.xsd#axgn_ProceedsFromGrantorsInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a118ac7b-5ff4-4fa6-a723-ad30bef1a334" xlink:to="loc_axgn_ProceedsFromGrantorsInvestingActivities_d8fc9eda-78c4-4dba-9541-6c8f1d7a4349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_6f70552a-3bbe-4e1a-a878-d954e550f67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a118ac7b-5ff4-4fa6-a723-ad30bef1a334" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_6f70552a-3bbe-4e1a-a878-d954e550f67b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_37939e10-5a99-4137-a7de-336033ec359c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a118ac7b-5ff4-4fa6-a723-ad30bef1a334" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_37939e10-5a99-4137-a7de-336033ec359c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0c9b265e-4aed-4105-bcd8-482d9cde469c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a118ac7b-5ff4-4fa6-a723-ad30bef1a334" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_0c9b265e-4aed-4105-bcd8-482d9cde469c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40de7bab-96f5-4845-819e-94ec1b1c1483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e27a8af-910b-4701-b8b7-c8a215eb994c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40de7bab-96f5-4845-819e-94ec1b1c1483" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8e27a8af-910b-4701-b8b7-c8a215eb994c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_0a47a415-e540-47e3-9b3e-86f2b007299a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40de7bab-96f5-4845-819e-94ec1b1c1483" xlink:to="loc_us-gaap_RestrictedCash_0a47a415-e540-47e3-9b3e-86f2b007299a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/InventoryDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0ca9f801-2f6f-4ce5-9173-202ddd4edddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2d1aae88-f285-49f1-aca3-7aabf1c0033c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0ca9f801-2f6f-4ce5-9173-202ddd4edddb" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2d1aae88-f285-49f1-aca3-7aabf1c0033c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_89f37c4e-8bb5-40c9-a3fe-5b126e646f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0ca9f801-2f6f-4ce5-9173-202ddd4edddb" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_89f37c4e-8bb5-40c9-a3fe-5b126e646f81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3b3ef3ce-a869-4938-9163-badf1b46ad12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_0ca9f801-2f6f-4ce5-9173-202ddd4edddb" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3b3ef3ce-a869-4938-9163-badf1b46ad12" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2cf0937a-4140-406a-91d4-8c4674ce29ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_2e13c1f5-4888-43ae-94e6-e86f8e44b76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_2cf0937a-4140-406a-91d4-8c4674ce29ea" xlink:to="loc_us-gaap_DerivativeLiabilities_2e13c1f5-4888-43ae-94e6-e86f8e44b76b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LeasesComponentsofTotalLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_4d7ad627-2d89-4a4c-aac3-4e67268837b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_10537d74-beac-411b-9cda-aeec9554e259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4d7ad627-2d89-4a4c-aac3-4e67268837b2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_10537d74-beac-411b-9cda-aeec9554e259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_7eb1b6e0-e568-49fe-8390-570ca9c48619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4d7ad627-2d89-4a4c-aac3-4e67268837b2" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_7eb1b6e0-e568-49fe-8390-570ca9c48619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c296a330-ccab-4a2c-8245-80a8df42e20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4d7ad627-2d89-4a4c-aac3-4e67268837b2" xlink:to="loc_us-gaap_OperatingLeaseCost_c296a330-ccab-4a2c-8245-80a8df42e20f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_8dfbf80d-1eee-44f6-b6b8-945c1e406555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4d7ad627-2d89-4a4c-aac3-4e67268837b2" xlink:to="loc_us-gaap_ShortTermLeaseCost_8dfbf80d-1eee-44f6-b6b8-945c1e406555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_04bd7c89-fd25-4d23-9c24-f45635bc77e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4d7ad627-2d89-4a4c-aac3-4e67268837b2" xlink:to="loc_us-gaap_VariableLeaseCost_04bd7c89-fd25-4d23-9c24-f45635bc77e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_7cb50076-8189-4dbe-9032-ae8f506e440b" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne_77454550-2a95-444b-bff7-5a6ff3101a5d" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_7cb50076-8189-4dbe-9032-ae8f506e440b" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne_77454550-2a95-444b-bff7-5a6ff3101a5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo_d769c191-3f87-46b3-b354-c46e1005f3c8" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_7cb50076-8189-4dbe-9032-ae8f506e440b" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo_d769c191-3f87-46b3-b354-c46e1005f3c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree_47cd79e9-8187-4d45-af34-1881a86ae88c" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_7cb50076-8189-4dbe-9032-ae8f506e440b" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree_47cd79e9-8187-4d45-af34-1881a86ae88c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour_ae404066-7bf1-4827-a7c1-3daf9da538d1" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_7cb50076-8189-4dbe-9032-ae8f506e440b" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour_ae404066-7bf1-4827-a7c1-3daf9da538d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive_02f25e13-5658-421a-b48e-4724bee610ba" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_7cb50076-8189-4dbe-9032-ae8f506e440b" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive_02f25e13-5658-421a-b48e-4724bee610ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive_170acb74-ebd3-40a4-8d00-bd0c5bb16e73" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_7cb50076-8189-4dbe-9032-ae8f506e440b" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive_170acb74-ebd3-40a4-8d00-bd0c5bb16e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingAndFinancingLeaseLiability_0c9f57ed-bd91-44b8-add6-1fbb76c01c38" xlink:href="axgn-20221231.xsd#axgn_OperatingAndFinancingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingAndFinancingLeaseLiabilityCurrent_1f707e72-d066-492f-a323-b82752ba3a26" xlink:href="axgn-20221231.xsd#axgn_OperatingAndFinancingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_axgn_OperatingAndFinancingLeaseLiability_0c9f57ed-bd91-44b8-add6-1fbb76c01c38" xlink:to="loc_axgn_OperatingAndFinancingLeaseLiabilityCurrent_1f707e72-d066-492f-a323-b82752ba3a26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent_be636425-43d4-4dd6-bb1d-d8bca146b92d" xlink:href="axgn-20221231.xsd#axgn_OperatingAndFinancingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_axgn_OperatingAndFinancingLeaseLiability_0c9f57ed-bd91-44b8-add6-1fbb76c01c38" xlink:to="loc_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent_be636425-43d4-4dd6-bb1d-d8bca146b92d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_88fd9d56-256d-4263-a226-56b94a8cf27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_ee41f4b2-4dfd-4827-8f18-95888a5db35c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_88fd9d56-256d-4263-a226-56b94a8cf27d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_ee41f4b2-4dfd-4827-8f18-95888a5db35c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9cebcac0-6b4e-493f-a834-ab45fc97a7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_88fd9d56-256d-4263-a226-56b94a8cf27d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_9cebcac0-6b4e-493f-a834-ab45fc97a7d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_16d8e73e-4de9-402d-bd5b-b6387911b0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_08c38b56-8c13-4d1f-8b70-caf8edc10419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_16d8e73e-4de9-402d-bd5b-b6387911b0cf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_08c38b56-8c13-4d1f-8b70-caf8edc10419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6efe19cc-a85e-469f-8c42-9d2233c79e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_16d8e73e-4de9-402d-bd5b-b6387911b0cf" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_6efe19cc-a85e-469f-8c42-9d2233c79e22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dbd66939-88f3-424c-bc68-844faa43f929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d305b668-048e-46f9-879b-5ebc866aa63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dbd66939-88f3-424c-bc68-844faa43f929" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d305b668-048e-46f9-879b-5ebc866aa63d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6efe2690-7db5-4804-9349-a8fc02b95e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dbd66939-88f3-424c-bc68-844faa43f929" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6efe2690-7db5-4804-9349-a8fc02b95e2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c160e2bf-4072-413a-ac3b-9529f393c32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c759d6dd-6cd3-4e1b-931b-9fd7b942ea7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c160e2bf-4072-413a-ac3b-9529f393c32d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c759d6dd-6cd3-4e1b-931b-9fd7b942ea7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a40c19c-e748-40e9-8eb1-1f8e3575e102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_c160e2bf-4072-413a-ac3b-9529f393c32d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a40c19c-e748-40e9-8eb1-1f8e3575e102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_159fe2c9-0033-41ef-95be-ac6d66658103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e46048b7-382e-44a9-ba3b-20bcf6370867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_159fe2c9-0033-41ef-95be-ac6d66658103" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e46048b7-382e-44a9-ba3b-20bcf6370867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9148b55d-96b5-4043-a951-c8ad94f1d870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_159fe2c9-0033-41ef-95be-ac6d66658103" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9148b55d-96b5-4043-a951-c8ad94f1d870" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29dbdf2b-f707-485e-9105-215eeb1c1b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6a8b0125-7f06-4f84-9202-a1171bcaeac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29dbdf2b-f707-485e-9105-215eeb1c1b9c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_6a8b0125-7f06-4f84-9202-a1171bcaeac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bbc434fe-e6dc-46b5-9883-addaf25ae517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29dbdf2b-f707-485e-9105-215eeb1c1b9c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_bbc434fe-e6dc-46b5-9883-addaf25ae517" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3caf8cef-bde4-46b7-8c80-48233d88826c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f848dc90-4cff-4c1c-95e7-39aa5d8063d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3caf8cef-bde4-46b7-8c80-48233d88826c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_f848dc90-4cff-4c1c-95e7-39aa5d8063d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_50ea44e5-3514-4f9e-bb8a-2bf16f418912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3caf8cef-bde4-46b7-8c80-48233d88826c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_50ea44e5-3514-4f9e-bb8a-2bf16f418912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e149a8a8-796a-4efe-88a6-c448ae63b00e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3caf8cef-bde4-46b7-8c80-48233d88826c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e149a8a8-796a-4efe-88a6-c448ae63b00e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e1be146b-b4f6-4c64-9f84-b63c345d27f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3caf8cef-bde4-46b7-8c80-48233d88826c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e1be146b-b4f6-4c64-9f84-b63c345d27f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ed2cd7e1-4cbf-41ae-b547-51fc78e88c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3caf8cef-bde4-46b7-8c80-48233d88826c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ed2cd7e1-4cbf-41ae-b547-51fc78e88c3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ed9088fd-28fd-46d4-a735-61ff19e1d59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3caf8cef-bde4-46b7-8c80-48233d88826c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_ed9088fd-28fd-46d4-a735-61ff19e1d59a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#AccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2e9acada-1408-47a2-be16-7040658286d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3bd289b5-8b93-49e4-a827-fc20a80189cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2e9acada-1408-47a2-be16-7040658286d6" xlink:to="loc_us-gaap_AccountsPayableCurrent_3bd289b5-8b93-49e4-a827-fc20a80189cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f888938b-e768-4849-aa7e-93eeb0550e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2e9acada-1408-47a2-be16-7040658286d6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f888938b-e768-4849-aa7e-93eeb0550e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_1ce9723a-0413-4cdc-92c8-5b007b806178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2e9acada-1408-47a2-be16-7040658286d6" xlink:to="loc_us-gaap_AccruedSalariesCurrent_1ce9723a-0413-4cdc-92c8-5b007b806178" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2d1ec823-4690-49b1-8a65-d27f9dc3fa95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6d7a0e84-e407-484e-a738-1384759e3322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2d1ec823-4690-49b1-8a65-d27f9dc3fa95" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6d7a0e84-e407-484e-a738-1384759e3322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ed42c0f0-00ab-4cd8-a25a-a4b9ad4c258f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_2d1ec823-4690-49b1-8a65-d27f9dc3fa95" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_ed42c0f0-00ab-4cd8-a25a-a4b9ad4c258f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IncomeTaxesTemporaryDifferencesDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxAssetsLiabilities_c4ce6281-f509-4049-bca3-5b4b479dc404" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxAssetsLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8b56c26a-35a5-439e-b740-1e418a870071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_axgn_DeferredTaxAssetsLiabilities_c4ce6281-f509-4049-bca3-5b4b479dc404" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8b56c26a-35a5-439e-b740-1e418a870071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a15d83eb-a706-4422-a760-28088919ad96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_axgn_DeferredTaxAssetsLiabilities_c4ce6281-f509-4049-bca3-5b4b479dc404" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a15d83eb-a706-4422-a760-28088919ad96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a526cc44-614b-4e5f-a8db-6d42b56432b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_790c790a-2c03-4001-9489-082340a02b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a526cc44-614b-4e5f-a8db-6d42b56432b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_790c790a-2c03-4001-9489-082340a02b24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_c913a451-59e4-4a6b-a6a6-41f7491decf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a526cc44-614b-4e5f-a8db-6d42b56432b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_c913a451-59e4-4a6b-a6a6-41f7491decf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxLiabilitiesRightOfUseAsset_165994b5-e853-4555-b301-370051e120f4" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a526cc44-614b-4e5f-a8db-6d42b56432b1" xlink:to="loc_axgn_DeferredTaxLiabilitiesRightOfUseAsset_165994b5-e853-4555-b301-370051e120f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_7b20615d-7198-456f-95e7-be51957b567b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_a526cc44-614b-4e5f-a8db-6d42b56432b1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_7b20615d-7198-456f-95e7-be51957b567b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30dfb36f-c866-48e5-bd23-0fe015f66b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_30dfb36f-c866-48e5-bd23-0fe015f66b20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_0c91af38-a4ef-4ebc-b878-7bdf91db47ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_0c91af38-a4ef-4ebc-b878-7bdf91db47ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxAssetsInterestLimitation_1c9e2f9a-f897-4ebb-8881-b98a20c17608" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxAssetsInterestLimitation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:to="loc_axgn_DeferredTaxAssetsInterestLimitation_1c9e2f9a-f897-4ebb-8881-b98a20c17608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_eca47692-65b0-4d48-b59b-183357e4fc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_eca47692-65b0-4d48-b59b-183357e4fc5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxAssetsLeaseObligations_4dab738f-dd50-42dc-a9fa-23899c4de19f" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxAssetsLeaseObligations"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:to="loc_axgn_DeferredTaxAssetsLeaseObligations_4dab738f-dd50-42dc-a9fa-23899c4de19f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2c97873b-dc2d-4e79-a25b-3380e636149d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2c97873b-dc2d-4e79-a25b-3380e636149d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_0f40e04f-b45b-4006-9d5d-7ba643b164d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_0f40e04f-b45b-4006-9d5d-7ba643b164d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_28aa1c54-0cc3-45b6-9507-0b565e34967a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_28aa1c54-0cc3-45b6-9507-0b565e34967a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_216f978b-4774-470c-b859-3a7f2b865887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_216f978b-4774-470c-b859-3a7f2b865887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_97275e8b-b632-4039-a816-b375891ff307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_44744b7b-83f3-44ff-8340-abe7f6728194" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_97275e8b-b632-4039-a816-b375891ff307" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec9fe76d-8754-4f07-9d24-73d33e70029c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_62f5edb1-20dd-4cf4-9acc-5137d26565ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec9fe76d-8754-4f07-9d24-73d33e70029c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_62f5edb1-20dd-4cf4-9acc-5137d26565ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_af6bb203-e7ec-4ef7-8bd9-c6767d7ea33c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec9fe76d-8754-4f07-9d24-73d33e70029c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_af6bb203-e7ec-4ef7-8bd9-c6767d7ea33c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_925fe356-c316-4655-bc95-529b3c3362cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec9fe76d-8754-4f07-9d24-73d33e70029c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_925fe356-c316-4655-bc95-529b3c3362cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a14494ee-6bb0-4b4e-9cf4-533249af32bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec9fe76d-8754-4f07-9d24-73d33e70029c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a14494ee-6bb0-4b4e-9cf4-533249af32bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4900a9d4-58b5-418c-95ab-0b892055ea56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ec9fe76d-8754-4f07-9d24-73d33e70029c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4900a9d4-58b5-418c-95ab-0b892055ea56" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>axgn-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:008e6d96-0028-47c7-9dfe-7d6d669b55a8,g:6a78ba92-a70c-4cec-a491-e196b80cf77c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="axgn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended" id="i31ddc6032a7b41a2a279235dd2eda43c_CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a329ac24-8c7c-4218-abbf-6fcf5964241c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a329ac24-8c7c-4218-abbf-6fcf5964241c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5f413bc7-bc53-4d16-a853-fa2750d2e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5f413bc7-bc53-4d16-a853-fa2750d2e5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7c0d2c66-af66-49c5-9cec-c303e77bea11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockholdersEquity_7c0d2c66-af66-49c5-9cec-c303e77bea11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5eb149e-acbf-4814-bc31-6062b1a9cd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5eb149e-acbf-4814-bc31-6062b1a9cd2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2ee97bbc-71d2-4a9a-b317-497053389858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2ee97bbc-71d2-4a9a-b317-497053389858" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_e960ac8d-2267-487c-a1ea-3a0bea45701b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_e960ac8d-2267-487c-a1ea-3a0bea45701b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_f5ba89d5-c012-48d9-937d-c311d67373cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_f5ba89d5-c012-48d9-937d-c311d67373cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_3705ad98-32ff-48c1-a5aa-659b2b7b1719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_3705ad98-32ff-48c1-a5aa-659b2b7b1719" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_88df4255-8b46-4e3a-93f6-df86e61c5b28" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_88df4255-8b46-4e3a-93f6-df86e61c5b28" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_01302e48-b187-4f6f-92d9-aa000d7165e3" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_01302e48-b187-4f6f-92d9-aa000d7165e3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights_2467e379-5807-41bf-98c1-8f01d51f932b" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights_2467e379-5807-41bf-98c1-8f01d51f932b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue_cfb2bf16-6e18-4722-86b4-f6d37ea26bcf" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue_cfb2bf16-6e18-4722-86b4-f6d37ea26bcf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6fada46-0e3d-4ca0-9178-45c852609fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_NetIncomeLoss_b6fada46-0e3d-4ca0-9178-45c852609fba" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_82be6152-60c6-40ca-89d7-09b68f9601f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_704ba6c7-13b2-4656-a233-b56ec24bac32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ccd5757b-0ffc-458a-b16c-b12d0cbb6765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a329ac24-8c7c-4218-abbf-6fcf5964241c" xlink:to="loc_us-gaap_StatementTable_ccd5757b-0ffc-458a-b16c-b12d0cbb6765" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9eff7980-8500-4357-a030-b0a1537278ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ccd5757b-0ffc-458a-b16c-b12d0cbb6765" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9eff7980-8500-4357-a030-b0a1537278ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9eff7980-8500-4357-a030-b0a1537278ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9eff7980-8500-4357-a030-b0a1537278ff" xlink:to="loc_us-gaap_EquityComponentDomain_9eff7980-8500-4357-a030-b0a1537278ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c6dfc028-2546-4076-9738-99946062e2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9eff7980-8500-4357-a030-b0a1537278ff" xlink:to="loc_us-gaap_EquityComponentDomain_c6dfc028-2546-4076-9738-99946062e2e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9905d4e0-7594-49c4-8f2c-952260a30b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6dfc028-2546-4076-9738-99946062e2e5" xlink:to="loc_us-gaap_CommonStockMember_9905d4e0-7594-49c4-8f2c-952260a30b0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1215f47d-4394-4b4b-a9eb-f0321b167727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6dfc028-2546-4076-9738-99946062e2e5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1215f47d-4394-4b4b-a9eb-f0321b167727" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_51726c62-f583-409e-8177-4a2e8e4d39c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c6dfc028-2546-4076-9738-99946062e2e5" xlink:to="loc_us-gaap_RetainedEarningsMember_51726c62-f583-409e-8177-4a2e8e4d39c9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i6e6051dff82a419589eb433349e539ea_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_df0e1a15-ee69-4a6f-bbc2-9c07462f753e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_CashUninsuredAmount_df0e1a15-ee69-4a6f-bbc2-9c07462f753e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0bf5fa46-b35d-4473-8a36-4396b995d4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0bf5fa46-b35d-4473-8a36-4396b995d4f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_61e960c2-810f-4684-bf5a-91521fd9760d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_InterestCostsCapitalized_61e960c2-810f-4684-bf5a-91521fd9760d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_f07dff67-87d7-401a-9b5b-0f6916b5d3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_f07dff67-87d7-401a-9b5b-0f6916b5d3f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ContributionsToCharitableOrganization_d3228707-4b25-41f9-a320-c07a5aad49b5" xlink:href="axgn-20221231.xsd#axgn_ContributionsToCharitableOrganization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_axgn_ContributionsToCharitableOrganization_d3228707-4b25-41f9-a320-c07a5aad49b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_e21a2d2a-d42d-4ab1-842d-b2291e6f35ac" xlink:href="axgn-20221231.xsd#axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_e21a2d2a-d42d-4ab1-842d-b2291e6f35ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_2b8996e9-2164-460a-b529-aad4c8b842c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_2b8996e9-2164-460a-b529-aad4c8b842c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3396b84e-a6b0-4098-a08b-8c01a2365542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3396b84e-a6b0-4098-a08b-8c01a2365542" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_66e47a89-c151-4440-97d2-f1aa3bf7f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_SellingAndMarketingExpense_66e47a89-c151-4440-97d2-f1aa3bf7f3a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04b0fe4d-522c-4f62-8305-f52842e3bd43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:to="loc_srt_RangeAxis_04b0fe4d-522c-4f62-8305-f52842e3bd43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04b0fe4d-522c-4f62-8305-f52842e3bd43_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_04b0fe4d-522c-4f62-8305-f52842e3bd43" xlink:to="loc_srt_RangeMember_04b0fe4d-522c-4f62-8305-f52842e3bd43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30293b98-0e59-4a00-a3e1-f4078fe6c3b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_04b0fe4d-522c-4f62-8305-f52842e3bd43" xlink:to="loc_srt_RangeMember_30293b98-0e59-4a00-a3e1-f4078fe6c3b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0627b824-8b97-4564-82bf-7ff40843854e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_30293b98-0e59-4a00-a3e1-f4078fe6c3b0" xlink:to="loc_srt_MinimumMember_0627b824-8b97-4564-82bf-7ff40843854e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae92bc12-a1f7-43df-b8c3-d5343da120f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_30293b98-0e59-4a00-a3e1-f4078fe6c3b0" xlink:to="loc_srt_MaximumMember_ae92bc12-a1f7-43df-b8c3-d5343da120f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_96aaec81-832a-442d-ba8f-2a9dc9dafc97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:to="loc_srt_ProductOrServiceAxis_96aaec81-832a-442d-ba8f-2a9dc9dafc97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96aaec81-832a-442d-ba8f-2a9dc9dafc97_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_96aaec81-832a-442d-ba8f-2a9dc9dafc97" xlink:to="loc_srt_ProductsAndServicesDomain_96aaec81-832a-442d-ba8f-2a9dc9dafc97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_12c82eb1-8f55-42e1-a0cb-0fc5272d0cb5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_96aaec81-832a-442d-ba8f-2a9dc9dafc97" xlink:to="loc_srt_ProductsAndServicesDomain_12c82eb1-8f55-42e1-a0cb-0fc5272d0cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_758b0aa2-0aa5-4a99-bbcf-029b84e1782e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_12c82eb1-8f55-42e1-a0cb-0fc5272d0cb5" xlink:to="loc_us-gaap_ShippingAndHandlingMember_758b0aa2-0aa5-4a99-bbcf-029b84e1782e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f2da945-713d-427e-9598-633000dad15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f2da945-713d-427e-9598-633000dad15a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2f2da945-713d-427e-9598-633000dad15a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f2da945-713d-427e-9598-633000dad15a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2f2da945-713d-427e-9598-633000dad15a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_565c109b-48ac-4b8c-a829-f70d064bab39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f2da945-713d-427e-9598-633000dad15a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_565c109b-48ac-4b8c-a829-f70d064bab39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_4edb8562-d156-4486-99aa-27174230e4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_565c109b-48ac-4b8c-a829-f70d064bab39" xlink:to="loc_us-gaap_LicensingAgreementsMember_4edb8562-d156-4486-99aa-27174230e4f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_0db347d4-8ee4-4740-bdc6-0d542e7168e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_565c109b-48ac-4b8c-a829-f70d064bab39" xlink:to="loc_us-gaap_PatentsMember_0db347d4-8ee4-4740-bdc6-0d542e7168e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis_eedcfddf-4b33-459d-9032-6e5396257565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:to="loc_us-gaap_GovernmentAssistanceTypeAxis_eedcfddf-4b33-459d-9032-6e5396257565" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_eedcfddf-4b33-459d-9032-6e5396257565_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_eedcfddf-4b33-459d-9032-6e5396257565" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_eedcfddf-4b33-459d-9032-6e5396257565_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_864471b8-6bfd-4903-8dee-b1f1c4c0d397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_eedcfddf-4b33-459d-9032-6e5396257565" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_864471b8-6bfd-4903-8dee-b1f1c4c0d397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ResearchAndDevelopmentGrantsMember_94c14c3c-bd2f-4ee3-9c22-e20cbd27f3a6" xlink:href="axgn-20221231.xsd#axgn_ResearchAndDevelopmentGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_864471b8-6bfd-4903-8dee-b1f1c4c0d397" xlink:to="loc_axgn_ResearchAndDevelopmentGrantsMember_94c14c3c-bd2f-4ee3-9c22-e20cbd27f3a6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/InventoryDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/InventoryDetails" xlink:type="extended" id="if9bf44b311a848108fe12c5755172241_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7ac818b3-420f-4716-aaae-6b03709bd13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7ac818b3-420f-4716-aaae-6b03709bd13b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2623cdc6-ebb4-4f53-8915-5d397d542ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2623cdc6-ebb4-4f53-8915-5d397d542ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_89f3c964-80cd-4e81-829f-f2866ede274e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_89f3c964-80cd-4e81-829f-f2866ede274e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f343e994-be5a-465a-9abe-09f8a7d87e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryNet_f343e994-be5a-465a-9abe-09f8a7d87e0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f6064d63-4c18-4e48-bc7b-e3961422ae9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryWriteDown_f6064d63-4c18-4e48-bc7b-e3961422ae9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_f1ce82a4-d55f-4112-8351-204883745f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryCurrentTable_f1ce82a4-d55f-4112-8351-204883745f38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_b6f73f22-262d-4223-ab93-296eddec18a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_f1ce82a4-d55f-4112-8351-204883745f38" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_b6f73f22-262d-4223-ab93-296eddec18a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_b6f73f22-262d-4223-ab93-296eddec18a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_b6f73f22-262d-4223-ab93-296eddec18a0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_b6f73f22-262d-4223-ab93-296eddec18a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_94b17c05-6721-47dd-bfa9-e1e763f1cf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_b6f73f22-262d-4223-ab93-296eddec18a0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_94b17c05-6721-47dd-bfa9-e1e763f1cf6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AviveSoftTissueMembraneMember_df4dc0f9-2abe-4624-b0a1-85c769be0d05" xlink:href="axgn-20221231.xsd#axgn_AviveSoftTissueMembraneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_94b17c05-6721-47dd-bfa9-e1e763f1cf6d" xlink:to="loc_axgn_AviveSoftTissueMembraneMember_df4dc0f9-2abe-4624-b0a1-85c769be0d05" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i3b759bf693ca410c90f2f1460cb91979_FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19ead6e0-5063-44b2-a94b-cdf2e6c0d11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5feb3da8-894a-46ff-a138-f2bfa5b95287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19ead6e0-5063-44b2-a94b-cdf2e6c0d11a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5feb3da8-894a-46ff-a138-f2bfa5b95287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_2bbeba34-bf60-4b17-9404-9cd3ccd09a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19ead6e0-5063-44b2-a94b-cdf2e6c0d11a" xlink:to="loc_us-gaap_DerivativeLiabilities_2bbeba34-bf60-4b17-9404-9cd3ccd09a55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_8cc965a8-fd5e-4bd1-a80a-491935dd3c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19ead6e0-5063-44b2-a94b-cdf2e6c0d11a" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_8cc965a8-fd5e-4bd1-a80a-491935dd3c7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19ead6e0-5063-44b2-a94b-cdf2e6c0d11a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c87f2a22-fc77-40b3-92b9-3a39e4eff228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c87f2a22-fc77-40b3-92b9-3a39e4eff228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c87f2a22-fc77-40b3-92b9-3a39e4eff228_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c87f2a22-fc77-40b3-92b9-3a39e4eff228" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c87f2a22-fc77-40b3-92b9-3a39e4eff228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_552f234a-ea2f-4baf-a2b3-d3fa390ac3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c87f2a22-fc77-40b3-92b9-3a39e4eff228" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_552f234a-ea2f-4baf-a2b3-d3fa390ac3ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c1426374-215c-421d-a64b-aa30063e9e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_552f234a-ea2f-4baf-a2b3-d3fa390ac3ce" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c1426374-215c-421d-a64b-aa30063e9e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f95f2f4c-a8a6-496c-bdc9-9859da09d22c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f95f2f4c-a8a6-496c-bdc9-9859da09d22c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f95f2f4c-a8a6-496c-bdc9-9859da09d22c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f95f2f4c-a8a6-496c-bdc9-9859da09d22c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f95f2f4c-a8a6-496c-bdc9-9859da09d22c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e75a77d-7105-4549-a0c9-df92b51468ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f95f2f4c-a8a6-496c-bdc9-9859da09d22c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e75a77d-7105-4549-a0c9-df92b51468ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e9525ac2-cdd6-4bf5-a7dd-7941ad3e2223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e75a77d-7105-4549-a0c9-df92b51468ea" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e9525ac2-cdd6-4bf5-a7dd-7941ad3e2223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ba1743b6-3ae1-42b4-9108-8057321460e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e75a77d-7105-4549-a0c9-df92b51468ea" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ba1743b6-3ae1-42b4-9108-8057321460e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_38bcdaf3-f051-415f-857b-145a0d956cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e75a77d-7105-4549-a0c9-df92b51468ea" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_38bcdaf3-f051-415f-857b-145a0d956cba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5294af63-5c6f-4f0e-88e5-df65afcd4931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5294af63-5c6f-4f0e-88e5-df65afcd4931" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5294af63-5c6f-4f0e-88e5-df65afcd4931_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5294af63-5c6f-4f0e-88e5-df65afcd4931" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5294af63-5c6f-4f0e-88e5-df65afcd4931_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5294af63-5c6f-4f0e-88e5-df65afcd4931" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_86c7bff9-0c8c-4665-b6ab-c4270b9b4cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_86c7bff9-0c8c-4665-b6ab-c4270b9b4cab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_47e19f82-d867-4375-a63f-d8da26ffd1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_47e19f82-d867-4375-a63f-d8da26ffd1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8b30c62e-1841-455d-9d40-f6e71e75e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:to="loc_us-gaap_CommercialPaperMember_8b30c62e-1841-455d-9d40-f6e71e75e74b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember_ef45ce8f-0241-4dec-b334-3a019fd257df" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:to="loc_axgn_DebtDerivativeLiabilityMember_ef45ce8f-0241-4dec-b334-3a019fd257df" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details" xlink:type="extended" id="i35b860c3a0d443a8b415099dc6be8347_FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_322047ac-4d03-47e4-8ec3-fc17d6f0b5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_322047ac-4d03-47e4-8ec3-fc17d6f0b5cc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70fcc18d-1518-4b37-94ab-ed4fd2fb1a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70fcc18d-1518-4b37-94ab-ed4fd2fb1a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cfb81263-a486-4869-822d-d6043fac272f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cfb81263-a486-4869-822d-d6043fac272f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8f6e79ff-6e8d-4587-b54e-b7be0fa52446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8f6e79ff-6e8d-4587-b54e-b7be0fa52446" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d923b29a-a6b0-4d3d-814f-c0edade4d2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_322047ac-4d03-47e4-8ec3-fc17d6f0b5cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8c45036c-171f-482c-96a2-43c851088791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8c45036c-171f-482c-96a2-43c851088791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8c45036c-171f-482c-96a2-43c851088791_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8c45036c-171f-482c-96a2-43c851088791" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8c45036c-171f-482c-96a2-43c851088791_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a00ffb39-3b60-4b6d-8053-8cd01bc3b985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8c45036c-171f-482c-96a2-43c851088791" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a00ffb39-3b60-4b6d-8053-8cd01bc3b985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a2d6cea4-82b1-4d69-a75f-b8a5299cc47f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a00ffb39-3b60-4b6d-8053-8cd01bc3b985" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a2d6cea4-82b1-4d69-a75f-b8a5299cc47f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bc5fb08-bf6d-495c-bcf9-6d2d7fdc3bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bc5fb08-bf6d-495c-bcf9-6d2d7fdc3bed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7bc5fb08-bf6d-495c-bcf9-6d2d7fdc3bed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bc5fb08-bf6d-495c-bcf9-6d2d7fdc3bed" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7bc5fb08-bf6d-495c-bcf9-6d2d7fdc3bed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8f1d329d-00d8-488b-b0da-2b8ca9a64b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bc5fb08-bf6d-495c-bcf9-6d2d7fdc3bed" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8f1d329d-00d8-488b-b0da-2b8ca9a64b76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2b04ed68-6557-44b1-8f4f-b2089201d6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8f1d329d-00d8-488b-b0da-2b8ca9a64b76" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2b04ed68-6557-44b1-8f4f-b2089201d6c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2369e0e3-7ba8-48de-a1ba-90f60d9d631a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2369e0e3-7ba8-48de-a1ba-90f60d9d631a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2369e0e3-7ba8-48de-a1ba-90f60d9d631a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2369e0e3-7ba8-48de-a1ba-90f60d9d631a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2369e0e3-7ba8-48de-a1ba-90f60d9d631a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_209d06d0-6429-410c-b379-25568884ae5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2369e0e3-7ba8-48de-a1ba-90f60d9d631a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_209d06d0-6429-410c-b379-25568884ae5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember_3763b304-f856-45de-b250-10b23d0319c9" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_209d06d0-6429-410c-b379-25568884ae5d" xlink:to="loc_axgn_DebtDerivativeLiabilityMember_3763b304-f856-45de-b250-10b23d0319c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended" id="i628f70aec588432aab5eac69dc92fc3c_FairValueMeasurementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9a2efff8-cf25-486d-a585-64e62a732bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_efc24096-2ce4-4edc-bf26-2e4aa0df7602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9a2efff8-cf25-486d-a585-64e62a732bd2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_efc24096-2ce4-4edc-bf26-2e4aa0df7602" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_937cf620-8ecc-45de-b321-6b7826bf4a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9a2efff8-cf25-486d-a585-64e62a732bd2" xlink:to="loc_us-gaap_LongTermDebtFairValue_937cf620-8ecc-45de-b321-6b7826bf4a7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bd8d6ed-588b-413a-9010-5151166f0975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9a2efff8-cf25-486d-a585-64e62a732bd2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bd8d6ed-588b-413a-9010-5151166f0975" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e0d62e4c-e519-4d2f-b168-4f0943930186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bd8d6ed-588b-413a-9010-5151166f0975" xlink:to="loc_us-gaap_DebtInstrumentAxis_e0d62e4c-e519-4d2f-b168-4f0943930186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e0d62e4c-e519-4d2f-b168-4f0943930186_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e0d62e4c-e519-4d2f-b168-4f0943930186" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e0d62e4c-e519-4d2f-b168-4f0943930186_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a9010018-b19f-4841-b330-2b59dd20d1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e0d62e4c-e519-4d2f-b168-4f0943930186" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a9010018-b19f-4841-b330-2b59dd20d1a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityMember_7f2689b0-85fa-4f59-b494-b9591660a2f4" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a9010018-b19f-4841-b330-2b59dd20d1a0" xlink:to="loc_axgn_CreditFacilityMember_7f2689b0-85fa-4f59-b494-b9591660a2f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails" xlink:type="extended" id="i81e089765fa04478ac0866048fdffb30_FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83db5e17-a251-4b6f-a128-69f1ac3e433b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_32ff8eec-e000-44d3-be00-900d1ff6a212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83db5e17-a251-4b6f-a128-69f1ac3e433b" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_32ff8eec-e000-44d3-be00-900d1ff6a212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83db5e17-a251-4b6f-a128-69f1ac3e433b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e36e647a-7bcf-41d7-bd4b-08b0f298acca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e36e647a-7bcf-41d7-bd4b-08b0f298acca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e36e647a-7bcf-41d7-bd4b-08b0f298acca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e36e647a-7bcf-41d7-bd4b-08b0f298acca" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e36e647a-7bcf-41d7-bd4b-08b0f298acca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_65f15f86-b0f8-4815-a287-8977df65d28a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e36e647a-7bcf-41d7-bd4b-08b0f298acca" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_65f15f86-b0f8-4815-a287-8977df65d28a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember_ddf7bbfb-5a71-4f6e-88d4-e554646109fd" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_65f15f86-b0f8-4815-a287-8977df65d28a" xlink:to="loc_axgn_DebtDerivativeLiabilityMember_ddf7bbfb-5a71-4f6e-88d4-e554646109fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b8288d79-ff9c-4d3b-9c51-37869a3d66a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_us-gaap_DebtInstrumentAxis_b8288d79-ff9c-4d3b-9c51-37869a3d66a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b8288d79-ff9c-4d3b-9c51-37869a3d66a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b8288d79-ff9c-4d3b-9c51-37869a3d66a0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b8288d79-ff9c-4d3b-9c51-37869a3d66a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ef667601-cc9a-40fd-bf72-360f32d2d60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b8288d79-ff9c-4d3b-9c51-37869a3d66a0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ef667601-cc9a-40fd-bf72-360f32d2d60b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityMember_cc056d32-9828-4013-985a-8f53d3b96be8" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ef667601-cc9a-40fd-bf72-360f32d2d60b" xlink:to="loc_axgn_CreditFacilityMember_cc056d32-9828-4013-985a-8f53d3b96be8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheOneMember_3cfe0b00-9428-401c-ae0a-b2382aa6ae91" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axgn_CreditFacilityMember_cc056d32-9828-4013-985a-8f53d3b96be8" xlink:to="loc_axgn_CreditFacilityTrancheOneMember_3cfe0b00-9428-401c-ae0a-b2382aa6ae91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheTwoMember_53af7f4c-f957-4913-8a80-b2eaa8f0255c" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axgn_CreditFacilityMember_cc056d32-9828-4013-985a-8f53d3b96be8" xlink:to="loc_axgn_CreditFacilityTrancheTwoMember_53af7f4c-f957-4913-8a80-b2eaa8f0255c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4dbe94b4-ea4b-4c6b-8f92-80b99c074285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4dbe94b4-ea4b-4c6b-8f92-80b99c074285" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4dbe94b4-ea4b-4c6b-8f92-80b99c074285_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4dbe94b4-ea4b-4c6b-8f92-80b99c074285" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4dbe94b4-ea4b-4c6b-8f92-80b99c074285_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4dbe94b4-ea4b-4c6b-8f92-80b99c074285" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_ed02250b-edc0-4700-868e-1788d2a28271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_ed02250b-edc0-4700-868e-1788d2a28271" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MeasurementInputCouponRateMember_bfe5d223-c4ac-439e-8447-422d3eb4d7b4" xlink:href="axgn-20221231.xsd#axgn_MeasurementInputCouponRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:to="loc_axgn_MeasurementInputCouponRateMember_bfe5d223-c4ac-439e-8447-422d3eb4d7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d3894d15-9462-474c-b1b8-4c86e86e937f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d3894d15-9462-474c-b1b8-4c86e86e937f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MeasurementInputMandatoryPrepaymentRateMember_da908f82-ce39-460d-ae5a-cc1d354c5588" xlink:href="axgn-20221231.xsd#axgn_MeasurementInputMandatoryPrepaymentRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:to="loc_axgn_MeasurementInputMandatoryPrepaymentRateMember_da908f82-ce39-460d-ae5a-cc1d354c5588" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PrepaymentProbabilityEventAxis_edba5039-47cb-4865-8f43-f492944eaaad" xlink:href="axgn-20221231.xsd#axgn_PrepaymentProbabilityEventAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_axgn_PrepaymentProbabilityEventAxis_edba5039-47cb-4865-8f43-f492944eaaad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PrepaymentProbabilityEventDomain_edba5039-47cb-4865-8f43-f492944eaaad_default" xlink:href="axgn-20221231.xsd#axgn_PrepaymentProbabilityEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_axgn_PrepaymentProbabilityEventAxis_edba5039-47cb-4865-8f43-f492944eaaad" xlink:to="loc_axgn_PrepaymentProbabilityEventDomain_edba5039-47cb-4865-8f43-f492944eaaad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PrepaymentProbabilityEventDomain_6e55f5f4-72b9-4314-9e48-088cc4bfd6ab" xlink:href="axgn-20221231.xsd#axgn_PrepaymentProbabilityEventDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_axgn_PrepaymentProbabilityEventAxis_edba5039-47cb-4865-8f43-f492944eaaad" xlink:to="loc_axgn_PrepaymentProbabilityEventDomain_6e55f5f4-72b9-4314-9e48-088cc4bfd6ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MandatoryPrepaymentEventBefore2024Member_2590a78e-c53b-40c7-9cfc-f5eff0230965" xlink:href="axgn-20221231.xsd#axgn_MandatoryPrepaymentEventBefore2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axgn_PrepaymentProbabilityEventDomain_6e55f5f4-72b9-4314-9e48-088cc4bfd6ab" xlink:to="loc_axgn_MandatoryPrepaymentEventBefore2024Member_2590a78e-c53b-40c7-9cfc-f5eff0230965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MandatoryPrepaymentEventIn2024OrAfterMember_ff1298c9-de65-4649-ac5e-b6f03b9fa851" xlink:href="axgn-20221231.xsd#axgn_MandatoryPrepaymentEventIn2024OrAfterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axgn_PrepaymentProbabilityEventDomain_6e55f5f4-72b9-4314-9e48-088cc4bfd6ab" xlink:to="loc_axgn_MandatoryPrepaymentEventIn2024OrAfterMember_ff1298c9-de65-4649-ac5e-b6f03b9fa851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OptionalPrepaymentEventMember_6d96eff5-1135-4877-a18e-4a73a0193c7f" xlink:href="axgn-20221231.xsd#axgn_OptionalPrepaymentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axgn_PrepaymentProbabilityEventDomain_6e55f5f4-72b9-4314-9e48-088cc4bfd6ab" xlink:to="loc_axgn_OptionalPrepaymentEventMember_6d96eff5-1135-4877-a18e-4a73a0193c7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38bbc05b-224a-48dd-a10a-3fb47ca6ebb7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_srt_RangeAxis_38bbc05b-224a-48dd-a10a-3fb47ca6ebb7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_38bbc05b-224a-48dd-a10a-3fb47ca6ebb7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_38bbc05b-224a-48dd-a10a-3fb47ca6ebb7" xlink:to="loc_srt_RangeMember_38bbc05b-224a-48dd-a10a-3fb47ca6ebb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb8236c3-30a1-497e-a856-2208af38da78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_38bbc05b-224a-48dd-a10a-3fb47ca6ebb7" xlink:to="loc_srt_RangeMember_fb8236c3-30a1-497e-a856-2208af38da78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9ce20ea7-1126-448b-b74d-642def540d9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb8236c3-30a1-497e-a856-2208af38da78" xlink:to="loc_srt_MinimumMember_9ce20ea7-1126-448b-b74d-642def540d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a2f95594-0e79-4c02-9e86-68c9315287e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb8236c3-30a1-497e-a856-2208af38da78" xlink:to="loc_srt_MaximumMember_a2f95594-0e79-4c02-9e86-68c9315287e5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ie8f7e6ddb7b1472d8a5dad5763b89888_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingLeaseIncrementalBorrowingRate_139a37d1-5c98-4467-abfc-75e899a4498c" xlink:href="axgn-20221231.xsd#axgn_OperatingLeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_axgn_OperatingLeaseIncrementalBorrowingRate_139a37d1-5c98-4467-abfc-75e899a4498c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_86713ed1-eee1-4dfb-951a-77ff88c50084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_86713ed1-eee1-4dfb-951a-77ff88c50084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bc26380c-3f44-456d-84c1-05639b735fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_us-gaap_OperatingLeaseLiability_bc26380c-3f44-456d-84c1-05639b735fbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths_6793a0ae-2392-4451-8382-16425dc29497" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingLeaseNumberOfRentFreeMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths_6793a0ae-2392-4451-8382-16425dc29497" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c77f8bb8-a23d-47ba-afcd-d7189fa01723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c77f8bb8-a23d-47ba-afcd-d7189fa01723" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_08c0c590-8622-4dc5-b6ae-5449675da268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_08c0c590-8622-4dc5-b6ae-5449675da268" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_673eed56-c673-45b1-bcd0-2a0a54b99ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_08c0c590-8622-4dc5-b6ae-5449675da268" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_673eed56-c673-45b1-bcd0-2a0a54b99ffe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_673eed56-c673-45b1-bcd0-2a0a54b99ffe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_673eed56-c673-45b1-bcd0-2a0a54b99ffe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_673eed56-c673-45b1-bcd0-2a0a54b99ffe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b26e0653-4b5c-46b3-8450-a5360ac303c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_673eed56-c673-45b1-bcd0-2a0a54b99ffe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b26e0653-4b5c-46b3-8450-a5360ac303c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CommercialLeaseWithJAColeLPMember_016833ee-76d6-485a-b8fb-c2d8fb914c04" xlink:href="axgn-20221231.xsd#axgn_CommercialLeaseWithJAColeLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b26e0653-4b5c-46b3-8450-a5360ac303c7" xlink:to="loc_axgn_CommercialLeaseWithJAColeLPMember_016833ee-76d6-485a-b8fb-c2d8fb914c04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember_d598e5b0-64a9-4c38-b53d-921ca373b89e" xlink:href="axgn-20221231.xsd#axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axgn_CommercialLeaseWithJAColeLPMember_016833ee-76d6-485a-b8fb-c2d8fb914c04" xlink:to="loc_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember_d598e5b0-64a9-4c38-b53d-921ca373b89e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="i321fbb145b7d409e9f40d8ba6fd0ff85_PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2096f348-19f3-4da4-ba94-187bf1f7fb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2096f348-19f3-4da4-ba94-187bf1f7fb3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_112b9cc7-e995-46bd-9b52-08dc7203e505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_112b9cc7-e995-46bd-9b52-08dc7203e505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_6f282f67-2267-4283-856b-4b428a521a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_6f282f67-2267-4283-856b-4b428a521a00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_7ccdbda0-4637-4559-a943-9d974856970e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_7ccdbda0-4637-4559-a943-9d974856970e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e554a4cd-be80-4dfe-a12e-10b0db784205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e554a4cd-be80-4dfe-a12e-10b0db784205" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration_28915655-681e-4be1-ba42-b046656ff407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration_28915655-681e-4be1-ba42-b046656ff407" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_659e62a5-adfc-4cbb-9aba-0a3670faf2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_659e62a5-adfc-4cbb-9aba-0a3670faf2ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93fbf79e-1a2b-42e8-a084-58a0dee98c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_659e62a5-adfc-4cbb-9aba-0a3670faf2ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93fbf79e-1a2b-42e8-a084-58a0dee98c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_93fbf79e-1a2b-42e8-a084-58a0dee98c89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93fbf79e-1a2b-42e8-a084-58a0dee98c89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_93fbf79e-1a2b-42e8-a084-58a0dee98c89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93fbf79e-1a2b-42e8-a084-58a0dee98c89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_FurnitureAndOfficeEquipmentMember_b4ca23a9-82e0-495b-9972-07daad85eb96" xlink:href="axgn-20221231.xsd#axgn_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:to="loc_axgn_FurnitureAndOfficeEquipmentMember_b4ca23a9-82e0-495b-9972-07daad85eb96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ba6e1bc7-e9b6-47ea-aaa4-01b324c4de40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ba6e1bc7-e9b6-47ea-aaa4-01b324c4de40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_b15e85ca-aee8-40bc-96ff-641b26bac425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:to="loc_us-gaap_EquipmentMember_b15e85ca-aee8-40bc-96ff-641b26bac425" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3ad67a1d-0c6f-4577-97da-731f517a5d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:to="loc_us-gaap_LandMember_3ad67a1d-0c6f-4577-97da-731f517a5d2b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e3af87dd-2ca1-42bd-9721-1a9a6e69440d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:to="loc_us-gaap_ConstructionInProgressMember_e3af87dd-2ca1-42bd-9721-1a9a6e69440d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="i55b9525ef6b04aec909e918e280ad2a4_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e8e0f680-b2b4-402e-b873-f2ad4370971a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulative_55468004-4d71-4ae9-9605-ff07da4d1d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmountCumulative"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e8e0f680-b2b4-402e-b873-f2ad4370971a" xlink:to="loc_us-gaap_GovernmentAssistanceAmountCumulative_55468004-4d71-4ae9-9605-ff07da4d1d43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts_de1a616c-5966-491c-81b5-53b634c150b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e8e0f680-b2b4-402e-b873-f2ad4370971a" xlink:to="loc_us-gaap_AccumulatedCapitalizedInterestCosts_de1a616c-5966-491c-81b5-53b634c150b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4069bcc4-e28c-4b3b-b517-021ee683f695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e8e0f680-b2b4-402e-b873-f2ad4370971a" xlink:to="loc_us-gaap_Depreciation_4069bcc4-e28c-4b3b-b517-021ee683f695" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_356d453f-fc4b-494a-9c0b-92a59886de05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e8e0f680-b2b4-402e-b873-f2ad4370971a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_356d453f-fc4b-494a-9c0b-92a59886de05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4270810d-00c5-4137-ac14-3b6653462b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_356d453f-fc4b-494a-9c0b-92a59886de05" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4270810d-00c5-4137-ac14-3b6653462b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4270810d-00c5-4137-ac14-3b6653462b68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4270810d-00c5-4137-ac14-3b6653462b68" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4270810d-00c5-4137-ac14-3b6653462b68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_50838114-4abd-40d1-b4be-23ae7b7f9eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4270810d-00c5-4137-ac14-3b6653462b68" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_50838114-4abd-40d1-b4be-23ae7b7f9eb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_7ac6ca86-5241-4468-9ed4-32156eac9360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_50838114-4abd-40d1-b4be-23ae7b7f9eb1" xlink:to="loc_us-gaap_OtherAssetsMember_7ac6ca86-5241-4468-9ed4-32156eac9360" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails" xlink:type="extended" id="i152d3f7cf3204ad686a37891995427e7_IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_609ad7ff-91ec-497e-aa68-c0d47bcdbd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_da7deb5c-9b1d-4f9e-ad8b-588be2e26972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_609ad7ff-91ec-497e-aa68-c0d47bcdbd56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_da7deb5c-9b1d-4f9e-ad8b-588be2e26972" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62c38386-42b2-463a-a769-fd16238e95dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_da7deb5c-9b1d-4f9e-ad8b-588be2e26972" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62c38386-42b2-463a-a769-fd16238e95dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fad0dcd4-df6e-4394-9f2d-08bff8c73eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_da7deb5c-9b1d-4f9e-ad8b-588be2e26972" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fad0dcd4-df6e-4394-9f2d-08bff8c73eea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb9c18dd-4979-46ee-a048-db65e94aadfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_da7deb5c-9b1d-4f9e-ad8b-588be2e26972" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb9c18dd-4979-46ee-a048-db65e94aadfe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fcd019fa-89c8-4bd6-9ab9-62fd40c60c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_609ad7ff-91ec-497e-aa68-c0d47bcdbd56" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fcd019fa-89c8-4bd6-9ab9-62fd40c60c0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c2b5c5ce-c274-4393-afb9-d52de500fe69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fcd019fa-89c8-4bd6-9ab9-62fd40c60c0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c2b5c5ce-c274-4393-afb9-d52de500fe69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2b5c5ce-c274-4393-afb9-d52de500fe69_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c2b5c5ce-c274-4393-afb9-d52de500fe69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2b5c5ce-c274-4393-afb9-d52de500fe69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d467698c-6f5b-4594-b920-a9975b826cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c2b5c5ce-c274-4393-afb9-d52de500fe69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d467698c-6f5b-4594-b920-a9975b826cfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_1590533e-ac5c-4c6d-aed3-d63b0775c728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d467698c-6f5b-4594-b920-a9975b826cfd" xlink:to="loc_us-gaap_PatentsMember_1590533e-ac5c-4c6d-aed3-d63b0775c728" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b361c391-35d5-4894-8a56-021b4538bf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d467698c-6f5b-4594-b920-a9975b826cfd" xlink:to="loc_us-gaap_LicensingAgreementsMember_b361c391-35d5-4894-8a56-021b4538bf5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ecaeff2-7376-4ad9-85f6-6f7c99c38f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_a841b68a-e3bf-40fa-902c-fabccb11dc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ecaeff2-7376-4ad9-85f6-6f7c99c38f59" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_a841b68a-e3bf-40fa-902c-fabccb11dc07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a3370c62-6ef5-419f-a9cd-a3c44af2bc44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_a841b68a-e3bf-40fa-902c-fabccb11dc07" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a3370c62-6ef5-419f-a9cd-a3c44af2bc44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_bee47304-e8e9-41f1-8725-3b9269591ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ecaeff2-7376-4ad9-85f6-6f7c99c38f59" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_bee47304-e8e9-41f1-8725-3b9269591ce3" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fff47b-b4e1-4bc0-8000-84e1c191926d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_bee47304-e8e9-41f1-8725-3b9269591ce3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fff47b-b4e1-4bc0-8000-84e1c191926d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96fff47b-b4e1-4bc0-8000-84e1c191926d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fff47b-b4e1-4bc0-8000-84e1c191926d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_96fff47b-b4e1-4bc0-8000-84e1c191926d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_156a6815-3140-45af-a096-759ab90569b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fff47b-b4e1-4bc0-8000-84e1c191926d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_156a6815-3140-45af-a096-759ab90569b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_5d20b08d-c939-45a2-8d1f-e6b6d284af1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_156a6815-3140-45af-a096-759ab90569b3" xlink:to="loc_us-gaap_TrademarksMember_5d20b08d-c939-45a2-8d1f-e6b6d284af1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails" xlink:type="extended" id="id0bec3d4aadc463996fecb8a00fd1567_IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_30384c2f-6f2e-4a58-a694-6db328a37f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_30384c2f-6f2e-4a58-a694-6db328a37f17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2a7f0018-c0e9-42e9-94fe-0b2f356416fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2a7f0018-c0e9-42e9-94fe-0b2f356416fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6f02f7e8-100b-4cad-98fc-d8db5d8db8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6f02f7e8-100b-4cad-98fc-d8db5d8db8a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c91bb56-2f9b-4e75-b097-9e43b2f46757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c91bb56-2f9b-4e75-b097-9e43b2f46757" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ab76686f-4adc-40e4-b5c5-a3efddaa54d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ab76686f-4adc-40e4-b5c5-a3efddaa54d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5657c258-babb-468e-95a7-c992248b6a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5657c258-babb-468e-95a7-c992248b6a2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b8c5a2a9-fd2f-46d6-81d5-4be85c497fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b8c5a2a9-fd2f-46d6-81d5-4be85c497fe5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f0c5933-de1a-4716-a94a-c4bd2b625b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f0c5933-de1a-4716-a94a-c4bd2b625b71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50e1f388-18f4-480a-accd-e0a77d57d242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f0c5933-de1a-4716-a94a-c4bd2b625b71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50e1f388-18f4-480a-accd-e0a77d57d242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_50e1f388-18f4-480a-accd-e0a77d57d242_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50e1f388-18f4-480a-accd-e0a77d57d242" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_50e1f388-18f4-480a-accd-e0a77d57d242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8201c541-8328-4c0c-9267-2aa2a47ca179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50e1f388-18f4-480a-accd-e0a77d57d242" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8201c541-8328-4c0c-9267-2aa2a47ca179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PatentsAndLicenseAgreementsMember_ab444f0f-1ad0-4775-a43f-3d8c8ae1fbfc" xlink:href="axgn-20221231.xsd#axgn_PatentsAndLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8201c541-8328-4c0c-9267-2aa2a47ca179" xlink:to="loc_axgn_PatentsAndLicenseAgreementsMember_ab444f0f-1ad0-4775-a43f-3d8c8ae1fbfc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails" xlink:type="extended" id="i3510366a2f4c41f7ba6f9add3658110e_IntangibleAssetsNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ff512c45-a784-413e-9ca2-05119747797f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RoyaltyFeesPercentageUnderLicenseAgreements_8fffbc04-9baf-47bd-a9b8-bd96b4ef310e" xlink:href="axgn-20221231.xsd#axgn_RoyaltyFeesPercentageUnderLicenseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ff512c45-a784-413e-9ca2-05119747797f" xlink:to="loc_axgn_RoyaltyFeesPercentageUnderLicenseAgreements_8fffbc04-9baf-47bd-a9b8-bd96b4ef310e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_6ba08c3f-a599-45ab-b391-54f2634f2082" xlink:href="axgn-20221231.xsd#axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ff512c45-a784-413e-9ca2-05119747797f" xlink:to="loc_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_6ba08c3f-a599-45ab-b391-54f2634f2082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e7613805-06b4-454c-a586-9a55359cd748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ff512c45-a784-413e-9ca2-05119747797f" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e7613805-06b4-454c-a586-9a55359cd748" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ce4e1f3-2063-436f-bbf7-7c08bb85d197" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e7613805-06b4-454c-a586-9a55359cd748" xlink:to="loc_srt_RangeAxis_9ce4e1f3-2063-436f-bbf7-7c08bb85d197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ce4e1f3-2063-436f-bbf7-7c08bb85d197_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9ce4e1f3-2063-436f-bbf7-7c08bb85d197" xlink:to="loc_srt_RangeMember_9ce4e1f3-2063-436f-bbf7-7c08bb85d197_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af38b8ea-0988-4f98-bd10-60396bbd366e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9ce4e1f3-2063-436f-bbf7-7c08bb85d197" xlink:to="loc_srt_RangeMember_af38b8ea-0988-4f98-bd10-60396bbd366e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8bd80538-b638-44f3-a806-20f4d64cbc5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_af38b8ea-0988-4f98-bd10-60396bbd366e" xlink:to="loc_srt_MinimumMember_8bd80538-b638-44f3-a806-20f4d64cbc5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ea3c671a-83a7-4cc3-bcba-5d3081084086" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_af38b8ea-0988-4f98-bd10-60396bbd366e" xlink:to="loc_srt_MaximumMember_ea3c671a-83a7-4cc3-bcba-5d3081084086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c83fd5f7-a43c-473d-ba5a-5dce93bba1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e7613805-06b4-454c-a586-9a55359cd748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c83fd5f7-a43c-473d-ba5a-5dce93bba1e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c83fd5f7-a43c-473d-ba5a-5dce93bba1e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c83fd5f7-a43c-473d-ba5a-5dce93bba1e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c83fd5f7-a43c-473d-ba5a-5dce93bba1e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_134d8c38-3722-4579-85e8-1aebb3b06c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c83fd5f7-a43c-473d-ba5a-5dce93bba1e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_134d8c38-3722-4579-85e8-1aebb3b06c76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_a734b249-9970-4363-8ae0-f47b61a9fc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_134d8c38-3722-4579-85e8-1aebb3b06c76" xlink:to="loc_us-gaap_LicensingAgreementsMember_a734b249-9970-4363-8ae0-f47b61a9fc1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetRoyaltyFeesDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails" xlink:type="extended" id="i5a01acc4bc874d2cbf8bafc66c354776_IntangibleAssetsNetRoyaltyFeesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f03462e5-eb33-46b5-b537-7341938da62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_4644c1f6-d7b1-4a06-a93c-741d00e67f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f03462e5-eb33-46b5-b537-7341938da62e" xlink:to="loc_us-gaap_RoyaltyExpense_4644c1f6-d7b1-4a06-a93c-741d00e67f78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18a5c8b2-760c-4b2a-9017-defda6158b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f03462e5-eb33-46b5-b537-7341938da62e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18a5c8b2-760c-4b2a-9017-defda6158b74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c292e557-0eef-4931-90bb-08d23d61e944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18a5c8b2-760c-4b2a-9017-defda6158b74" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c292e557-0eef-4931-90bb-08d23d61e944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c292e557-0eef-4931-90bb-08d23d61e944_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c292e557-0eef-4931-90bb-08d23d61e944" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c292e557-0eef-4931-90bb-08d23d61e944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_afd0178b-7a87-4b3c-a60c-41ce36904e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c292e557-0eef-4931-90bb-08d23d61e944" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_afd0178b-7a87-4b3c-a60c-41ce36904e8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_13861c7d-7cef-4c94-9fb8-abadc6bc39fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afd0178b-7a87-4b3c-a60c-41ce36904e8f" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_13861c7d-7cef-4c94-9fb8-abadc6bc39fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails" xlink:type="extended" id="i562efc41a7f44897a011b8261c8b96e6_LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7fcde607-bae8-453c-b528-cfffd13ac905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7ee90d42-0d08-421c-94ea-e0b95028c69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7fcde607-bae8-453c-b528-cfffd13ac905" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7ee90d42-0d08-421c-94ea-e0b95028c69d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_88653875-2d78-4e7d-9b00-60a0ceb762ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7fcde607-bae8-453c-b528-cfffd13ac905" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_88653875-2d78-4e7d-9b00-60a0ceb762ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_30a099fb-8a2d-4a35-85cd-272cdeac7783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7fcde607-bae8-453c-b528-cfffd13ac905" xlink:to="loc_us-gaap_LongTermDebt_30a099fb-8a2d-4a35-85cd-272cdeac7783" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ce61c970-d6bf-4863-9917-6fa8deadd691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7fcde607-bae8-453c-b528-cfffd13ac905" xlink:to="loc_us-gaap_DebtInstrumentTable_ce61c970-d6bf-4863-9917-6fa8deadd691" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_362ce821-1b1b-40de-8cc5-11bd3d2ed68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ce61c970-d6bf-4863-9917-6fa8deadd691" xlink:to="loc_us-gaap_DebtInstrumentAxis_362ce821-1b1b-40de-8cc5-11bd3d2ed68b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_362ce821-1b1b-40de-8cc5-11bd3d2ed68b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_362ce821-1b1b-40de-8cc5-11bd3d2ed68b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_362ce821-1b1b-40de-8cc5-11bd3d2ed68b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c579968b-9e1c-406a-94fd-fa067da42cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_362ce821-1b1b-40de-8cc5-11bd3d2ed68b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c579968b-9e1c-406a-94fd-fa067da42cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheOneMember_641ced90-3819-478b-ba2a-4f1b9dedad99" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c579968b-9e1c-406a-94fd-fa067da42cea" xlink:to="loc_axgn_CreditFacilityTrancheOneMember_641ced90-3819-478b-ba2a-4f1b9dedad99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheTwoMember_bece1912-decb-4f61-9449-a7588c0e2773" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c579968b-9e1c-406a-94fd-fa067da42cea" xlink:to="loc_axgn_CreditFacilityTrancheTwoMember_bece1912-decb-4f61-9449-a7588c0e2773" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails" xlink:type="extended" id="ic02a1335b34e4cdb9e2072b7ac4bbd80_LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_4ea8be9f-a799-439e-aad9-37f4403369b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DebtInstrumentTerm_4ea8be9f-a799-439e-aad9-37f4403369b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6cc4cf3e-c385-4d50-9cab-768f42d03da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6cc4cf3e-c385-4d50-9cab-768f42d03da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_d4c7f11a-7882-4880-b209-6c71f1158124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_d4c7f11a-7882-4880-b209-6c71f1158124" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade_5cdb814d-f63a-445f-a963-ce36d27235ff" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade_5cdb814d-f63a-445f-a963-ce36d27235ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c8db7c4a-5fb2-4400-9351-4977c650afbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c8db7c4a-5fb2-4400-9351-4977c650afbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentAdditionalInterestFloorRate_0b1d2141-3ff3-48b1-b566-8cf40bec93a4" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentAdditionalInterestFloorRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_DebtInstrumentAdditionalInterestFloorRate_0b1d2141-3ff3-48b1-b566-8cf40bec93a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_c39df72d-f99b-4836-9dc4-f8dc8b0cc3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_c39df72d-f99b-4836-9dc4-f8dc8b0cc3cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty_9dea008d-42aa-413c-9d0f-4a4f5357630b" xlink:href="axgn-20221231.xsd#axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty_9dea008d-42aa-413c-9d0f-4a4f5357630b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure_4e48f5e3-2b59-4c8a-a84a-ec7a4cdd6eda" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure_4e48f5e3-2b59-4c8a-a84a-ec7a4cdd6eda" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_62604bc1-7ca0-46f9-ba06-22240edd9ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_InterestExpense_62604bc1-7ca0-46f9-ba06-22240edd9ceb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_2afb1dd2-9adc-4057-ae0a-1e501f3f339a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_InterestPaid_2afb1dd2-9adc-4057-ae0a-1e501f3f339a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_ffb58584-25fb-4137-bba0-006359ca58bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_InterestCostsCapitalized_ffb58584-25fb-4137-bba0-006359ca58bf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts_e3cab26e-8730-43ea-93df-d83dc36d3db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_AccumulatedCapitalizedInterestCosts_e3cab26e-8730-43ea-93df-d83dc36d3db4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_2b09dc70-0b18-4de1-a185-a8edf132a3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_2b09dc70-0b18-4de1-a185-a8edf132a3c5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PurchasePriceOfCommonStockCalculationPeriod_0cfdd1bd-a1ba-4b00-9996-556e2acf7f24" xlink:href="axgn-20221231.xsd#axgn_PurchasePriceOfCommonStockCalculationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_PurchasePriceOfCommonStockCalculationPeriod_0cfdd1bd-a1ba-4b00-9996-556e2acf7f24" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6aecb8e9-7721-4ebc-a67e-e7bccb43f0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6aecb8e9-7721-4ebc-a67e-e7bccb43f0fa" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_a215cb0b-4505-4bde-ae80-7d61419e4237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_a215cb0b-4505-4bde-ae80-7d61419e4237" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_96311935-99a4-4fce-8637-6b540696aed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_96311935-99a4-4fce-8637-6b540696aed8" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn_7bd84218-86f1-4b0f-b9d5-c0ec6c357633" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn_7bd84218-86f1-4b0f-b9d5-c0ec6c357633" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease_9d151e6c-52f2-4801-821b-9149e006a9c8" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentInterestRateEventOfDefaultIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease_9d151e6c-52f2-4801-821b-9149e006a9c8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_bac1ca25-6aa7-4ed5-b6b3-e0802dcacfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DerivativeLiabilities_bac1ca25-6aa7-4ed5-b6b3-e0802dcacfd9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f834b650-aa75-40de-a062-90aefbfab71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f834b650-aa75-40de-a062-90aefbfab71d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_afadefc9-7542-45af-93b7-ce2d3ea8f277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_RestrictedCash_afadefc9-7542-45af-93b7-ce2d3ea8f277" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount_3141ee23-28be-461e-a49c-e6937fbb0e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DebtInstrumentCollateralAmount_3141ee23-28be-461e-a49c-e6937fbb0e09" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8c06689d-ff33-424f-9451-cb908dc38c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_DebtInstrumentAxis_8c06689d-ff33-424f-9451-cb908dc38c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8c06689d-ff33-424f-9451-cb908dc38c01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8c06689d-ff33-424f-9451-cb908dc38c01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8c06689d-ff33-424f-9451-cb908dc38c01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa91fc9b-54a6-4f92-b00e-cf94b6d13062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8c06689d-ff33-424f-9451-cb908dc38c01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa91fc9b-54a6-4f92-b00e-cf94b6d13062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityMember_7e39f26e-0792-40f5-a699-5d4226fb6ffb" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa91fc9b-54a6-4f92-b00e-cf94b6d13062" xlink:to="loc_axgn_CreditFacilityMember_7e39f26e-0792-40f5-a699-5d4226fb6ffb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheOneMember_610112ca-3e01-429e-9466-aa0d53e29119" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axgn_CreditFacilityMember_7e39f26e-0792-40f5-a699-5d4226fb6ffb" xlink:to="loc_axgn_CreditFacilityTrancheOneMember_610112ca-3e01-429e-9466-aa0d53e29119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheTwoMember_234e456a-2172-412e-a322-25956e15d62f" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axgn_CreditFacilityMember_7e39f26e-0792-40f5-a699-5d4226fb6ffb" xlink:to="loc_axgn_CreditFacilityTrancheTwoMember_234e456a-2172-412e-a322-25956e15d62f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_b36d2b65-3127-4f5f-a16a-cd9712ae4f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_VariableRateAxis_b36d2b65-3127-4f5f-a16a-cd9712ae4f37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b36d2b65-3127-4f5f-a16a-cd9712ae4f37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_b36d2b65-3127-4f5f-a16a-cd9712ae4f37" xlink:to="loc_us-gaap_VariableRateDomain_b36d2b65-3127-4f5f-a16a-cd9712ae4f37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_daa97d7d-7a5f-4fbc-9a59-eb934c67ba18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_b36d2b65-3127-4f5f-a16a-cd9712ae4f37" xlink:to="loc_us-gaap_VariableRateDomain_daa97d7d-7a5f-4fbc-9a59-eb934c67ba18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_2ccdf81f-0f3c-43ff-a4b9-c36bc400fba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_daa97d7d-7a5f-4fbc-9a59-eb934c67ba18" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_2ccdf81f-0f3c-43ff-a4b9-c36bc400fba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bf630e0f-f036-47e6-a48c-4935fed883a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_InvestmentTypeAxis_bf630e0f-f036-47e6-a48c-4935fed883a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bf630e0f-f036-47e6-a48c-4935fed883a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_bf630e0f-f036-47e6-a48c-4935fed883a6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bf630e0f-f036-47e6-a48c-4935fed883a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bba418e3-7f34-4ec1-9710-59694d145c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_bf630e0f-f036-47e6-a48c-4935fed883a6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bba418e3-7f34-4ec1-9710-59694d145c6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_85a1b5e6-786e-48f6-89da-217de4ba1789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bba418e3-7f34-4ec1-9710-59694d145c6a" xlink:to="loc_us-gaap_StockOptionMember_85a1b5e6-786e-48f6-89da-217de4ba1789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0e3b52c5-376a-482b-bac5-1fe66921844d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_srt_OwnershipAxis_0e3b52c5-376a-482b-bac5-1fe66921844d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_0e3b52c5-376a-482b-bac5-1fe66921844d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_0e3b52c5-376a-482b-bac5-1fe66921844d" xlink:to="loc_srt_OwnershipDomain_0e3b52c5-376a-482b-bac5-1fe66921844d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8ebd533c-b2ab-47c3-a698-fdbcbe160cdb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_0e3b52c5-376a-482b-bac5-1fe66921844d" xlink:to="loc_srt_OwnershipDomain_8ebd533c-b2ab-47c3-a698-fdbcbe160cdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember_f049028f-7915-4e95-8ba4-a1e10ebe7c90" xlink:href="axgn-20221231.xsd#axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_8ebd533c-b2ab-47c3-a698-fdbcbe160cdb" xlink:to="loc_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember_f049028f-7915-4e95-8ba4-a1e10ebe7c90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d8520976-8cce-4562-b7c5-a493b6af0bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d8520976-8cce-4562-b7c5-a493b6af0bb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8520976-8cce-4562-b7c5-a493b6af0bb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d8520976-8cce-4562-b7c5-a493b6af0bb2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d8520976-8cce-4562-b7c5-a493b6af0bb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_67a11790-266c-42de-b1f2-31a6aed4101e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d8520976-8cce-4562-b7c5-a493b6af0bb2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_67a11790-266c-42de-b1f2-31a6aed4101e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember_e5300ee7-eac9-4cf0-9250-888bdc7e3429" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_67a11790-266c-42de-b1f2-31a6aed4101e" xlink:to="loc_axgn_DebtDerivativeLiabilityMember_e5300ee7-eac9-4cf0-9250-888bdc7e3429" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_60549f09-c993-48ed-bc5b-66c84afa882b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_60549f09-c993-48ed-bc5b-66c84afa882b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_60549f09-c993-48ed-bc5b-66c84afa882b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_60549f09-c993-48ed-bc5b-66c84afa882b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_60549f09-c993-48ed-bc5b-66c84afa882b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_43086f39-fe37-4033-bbb6-c24d5badb88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_60549f09-c993-48ed-bc5b-66c84afa882b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_43086f39-fe37-4033-bbb6-c24d5badb88b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RestrictedCashMember_728fbcea-3651-43ba-9ca6-722c899b7748" xlink:href="axgn-20221231.xsd#axgn_RestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_43086f39-fe37-4033-bbb6-c24d5badb88b" xlink:to="loc_axgn_RestrictedCashMember_728fbcea-3651-43ba-9ca6-722c899b7748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2c1c22d8-8920-4a2a-a12e-b1ccdcb9fa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_CreditFacilityAxis_2c1c22d8-8920-4a2a-a12e-b1ccdcb9fa8d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2c1c22d8-8920-4a2a-a12e-b1ccdcb9fa8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2c1c22d8-8920-4a2a-a12e-b1ccdcb9fa8d" xlink:to="loc_us-gaap_CreditFacilityDomain_2c1c22d8-8920-4a2a-a12e-b1ccdcb9fa8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5957b5e5-234e-4fe0-86e5-a1c8a4cd75a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2c1c22d8-8920-4a2a-a12e-b1ccdcb9fa8d" xlink:to="loc_us-gaap_CreditFacilityDomain_5957b5e5-234e-4fe0-86e5-a1c8a4cd75a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_89106009-a14c-4ac3-a529-a91b8881e66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5957b5e5-234e-4fe0-86e5-a1c8a4cd75a8" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_89106009-a14c-4ac3-a529-a91b8881e66a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#BasicandDilutedLossperCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails" xlink:type="extended" id="i1e9129658d884cf29d92409abb105fb0_BasicandDilutedLossperCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0508a10-ce40-4ff1-95ae-cd5a710a64b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bce8763-eb0e-4c95-8184-4803014fd0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0508a10-ce40-4ff1-95ae-cd5a710a64b1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bce8763-eb0e-4c95-8184-4803014fd0ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abb564ab-7842-42aa-aecc-58ff32bec2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0508a10-ce40-4ff1-95ae-cd5a710a64b1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abb564ab-7842-42aa-aecc-58ff32bec2dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93e3431e-c28f-437f-9842-6decf3df3530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abb564ab-7842-42aa-aecc-58ff32bec2dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93e3431e-c28f-437f-9842-6decf3df3530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93e3431e-c28f-437f-9842-6decf3df3530_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93e3431e-c28f-437f-9842-6decf3df3530" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_93e3431e-c28f-437f-9842-6decf3df3530_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76189e7c-0c91-490b-a39a-3be46f48b6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93e3431e-c28f-437f-9842-6decf3df3530" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76189e7c-0c91-490b-a39a-3be46f48b6bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aa7a38ad-fd05-4805-a503-5984174e6ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76189e7c-0c91-490b-a39a-3be46f48b6bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aa7a38ad-fd05-4805-a503-5984174e6ffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_770a3711-8c40-481c-9c54-8d6efe95ad11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76189e7c-0c91-490b-a39a-3be46f48b6bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_770a3711-8c40-481c-9c54-8d6efe95ad11" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails" xlink:type="extended" id="iddc55c83991e4c0ba234199036fc9811_StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2158e716-65f6-4a94-84d7-ed5b479db66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ShareBasePaymentArrangementNumberOfPlans_570f9a7b-745d-4cdd-ae7a-94ecfe433ff9" xlink:href="axgn-20221231.xsd#axgn_ShareBasePaymentArrangementNumberOfPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2158e716-65f6-4a94-84d7-ed5b479db66c" xlink:to="loc_axgn_ShareBasePaymentArrangementNumberOfPlans_570f9a7b-745d-4cdd-ae7a-94ecfe433ff9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_74d047cf-9094-4431-8792-30a72206ed01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2158e716-65f6-4a94-84d7-ed5b479db66c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_74d047cf-9094-4431-8792-30a72206ed01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1b41ba8a-8bcb-4b8c-ad99-d3a5996f6c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2158e716-65f6-4a94-84d7-ed5b479db66c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1b41ba8a-8bcb-4b8c-ad99-d3a5996f6c9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_159efd18-952a-4616-b359-87765edbcef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2158e716-65f6-4a94-84d7-ed5b479db66c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_159efd18-952a-4616-b359-87765edbcef3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0edd9d62-a4d1-4b13-89b9-cc5bc8802176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_159efd18-952a-4616-b359-87765edbcef3" xlink:to="loc_us-gaap_PlanNameAxis_0edd9d62-a4d1-4b13-89b9-cc5bc8802176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0edd9d62-a4d1-4b13-89b9-cc5bc8802176_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0edd9d62-a4d1-4b13-89b9-cc5bc8802176" xlink:to="loc_us-gaap_PlanNameDomain_0edd9d62-a4d1-4b13-89b9-cc5bc8802176_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_392c96e8-fbf3-4cae-ac26-051f19383ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0edd9d62-a4d1-4b13-89b9-cc5bc8802176" xlink:to="loc_us-gaap_PlanNameDomain_392c96e8-fbf3-4cae-ac26-051f19383ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_5a4feace-d38a-491e-aedc-f8a1dbd686d6" xlink:href="axgn-20221231.xsd#axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_392c96e8-fbf3-4cae-ac26-051f19383ee6" xlink:to="loc_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_5a4feace-d38a-491e-aedc-f8a1dbd686d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ca7bbccf-b49b-4cc8-9e87-ae11d5df34f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_159efd18-952a-4616-b359-87765edbcef3" xlink:to="loc_srt_RangeAxis_ca7bbccf-b49b-4cc8-9e87-ae11d5df34f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca7bbccf-b49b-4cc8-9e87-ae11d5df34f9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ca7bbccf-b49b-4cc8-9e87-ae11d5df34f9" xlink:to="loc_srt_RangeMember_ca7bbccf-b49b-4cc8-9e87-ae11d5df34f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65db7bf4-c228-4331-a26d-844171572a57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ca7bbccf-b49b-4cc8-9e87-ae11d5df34f9" xlink:to="loc_srt_RangeMember_65db7bf4-c228-4331-a26d-844171572a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9bf22b3f-b83e-4ca3-90b1-407f28520074" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65db7bf4-c228-4331-a26d-844171572a57" xlink:to="loc_srt_MinimumMember_9bf22b3f-b83e-4ca3-90b1-407f28520074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_807148ae-5959-4820-aaff-f4fee5b4b12d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_65db7bf4-c228-4331-a26d-844171572a57" xlink:to="loc_srt_MaximumMember_807148ae-5959-4820-aaff-f4fee5b4b12d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails" xlink:type="extended" id="ibbb86298039d488aa3f167e55ad7e997_StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16e9632-597a-4e41-bd73-12324114ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c768aeb-544f-4e64-89e8-aea4f6addab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16e9632-597a-4e41-bd73-12324114ce7c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c768aeb-544f-4e64-89e8-aea4f6addab5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0682577-97f2-4e14-a816-29c908013779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16e9632-597a-4e41-bd73-12324114ce7c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0682577-97f2-4e14-a816-29c908013779" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7781ff2f-d1ab-460a-b5c8-06b225c56d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0682577-97f2-4e14-a816-29c908013779" xlink:to="loc_us-gaap_PlanNameAxis_7781ff2f-d1ab-460a-b5c8-06b225c56d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7781ff2f-d1ab-460a-b5c8-06b225c56d2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7781ff2f-d1ab-460a-b5c8-06b225c56d2b" xlink:to="loc_us-gaap_PlanNameDomain_7781ff2f-d1ab-460a-b5c8-06b225c56d2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e49f7915-ec37-406d-838a-580b7f3fb911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7781ff2f-d1ab-460a-b5c8-06b225c56d2b" xlink:to="loc_us-gaap_PlanNameDomain_e49f7915-ec37-406d-838a-580b7f3fb911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_bfccf5b4-0832-40be-9335-1f4cc2f8469a" xlink:href="axgn-20221231.xsd#axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e49f7915-ec37-406d-838a-580b7f3fb911" xlink:to="loc_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_bfccf5b4-0832-40be-9335-1f4cc2f8469a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5c3e3f04-84ca-483d-a515-ecd4a1f57a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0682577-97f2-4e14-a816-29c908013779" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5c3e3f04-84ca-483d-a515-ecd4a1f57a26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5c3e3f04-84ca-483d-a515-ecd4a1f57a26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5c3e3f04-84ca-483d-a515-ecd4a1f57a26" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5c3e3f04-84ca-483d-a515-ecd4a1f57a26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5c3e3f04-84ca-483d-a515-ecd4a1f57a26" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_17fff00d-7db3-44f2-ad57-e0331d91e745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:to="loc_us-gaap_CostOfSalesMember_17fff00d-7db3-44f2-ad57-e0331d91e745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_f8aa9cb0-7b50-4141-a8d3-3773b084b11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_f8aa9cb0-7b50-4141-a8d3-3773b084b11e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_24211681-15ce-43b3-8479-d05f1dd4bf40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_24211681-15ce-43b3-8479-d05f1dd4bf40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9c278260-cf05-449d-a63e-a01e11eff72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9c278260-cf05-449d-a63e-a01e11eff72f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationStockOptionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails" xlink:type="extended" id="ic7bdcedb517c4101b4fec119af028f26_StockBasedCompensationStockOptionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cd94469f-eb1e-4d19-85e2-61d109228097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cd94469f-eb1e-4d19-85e2-61d109228097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3166fd9b-263e-4105-89c1-c3f9b96c91a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3166fd9b-263e-4105-89c1-c3f9b96c91a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_223ced39-fa9d-427b-87f5-228bf46ab898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_223ced39-fa9d-427b-87f5-228bf46ab898" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ae26355b-82bc-4deb-8da3-bdc1d57d7a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ae26355b-82bc-4deb-8da3-bdc1d57d7a51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_586b6a0e-c092-4c95-930e-f394beb25ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_586b6a0e-c092-4c95-930e-f394beb25ec7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af2d2113-5199-42ac-9a64-d7941a007250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af2d2113-5199-42ac-9a64-d7941a007250" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_85bd7adb-5d1e-419a-843a-b7e55fbd5025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:to="loc_us-gaap_AwardTypeAxis_85bd7adb-5d1e-419a-843a-b7e55fbd5025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85bd7adb-5d1e-419a-843a-b7e55fbd5025_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_85bd7adb-5d1e-419a-843a-b7e55fbd5025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85bd7adb-5d1e-419a-843a-b7e55fbd5025_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_85bd7adb-5d1e-419a-843a-b7e55fbd5025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6e207658-cd1c-4b25-9244-9f3ed793b80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6e207658-cd1c-4b25-9244-9f3ed793b80e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DirectorsAndOfficersStockOptionsMember_7783754a-e7bc-444f-8761-87eccff58fb2" xlink:href="axgn-20221231.xsd#axgn_DirectorsAndOfficersStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:to="loc_axgn_DirectorsAndOfficersStockOptionsMember_7783754a-e7bc-444f-8761-87eccff58fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c70188d4-62f0-4480-bf48-44dc0567fd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c70188d4-62f0-4480-bf48-44dc0567fd8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_30692c86-ffe6-4f73-ad32-14c7e775dc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:to="loc_us-gaap_PerformanceSharesMember_30692c86-ffe6-4f73-ad32-14c7e775dc2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d42575f6-44a9-42f7-90d6-029346c95249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:to="loc_us-gaap_PlanNameAxis_d42575f6-44a9-42f7-90d6-029346c95249" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d42575f6-44a9-42f7-90d6-029346c95249_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d42575f6-44a9-42f7-90d6-029346c95249" xlink:to="loc_us-gaap_PlanNameDomain_d42575f6-44a9-42f7-90d6-029346c95249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4548ca85-5eff-48d9-aa2c-9f0729b54ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d42575f6-44a9-42f7-90d6-029346c95249" xlink:to="loc_us-gaap_PlanNameDomain_4548ca85-5eff-48d9-aa2c-9f0729b54ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AxoGen2010StockIncentivePlanMember_58851929-d1e5-4c38-8521-21d608e63596" xlink:href="axgn-20221231.xsd#axgn_AxoGen2010StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4548ca85-5eff-48d9-aa2c-9f0729b54ea6" xlink:to="loc_axgn_AxoGen2010StockIncentivePlanMember_58851929-d1e5-4c38-8521-21d608e63596" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_f1078fe9-f206-4e12-9831-566e78023e0e" xlink:href="axgn-20221231.xsd#axgn_Axogen2017EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4548ca85-5eff-48d9-aa2c-9f0729b54ea6" xlink:to="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_f1078fe9-f206-4e12-9831-566e78023e0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_52cb132a-0754-4dcd-a446-dc191300d423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:to="loc_us-gaap_VestingAxis_52cb132a-0754-4dcd-a446-dc191300d423" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_52cb132a-0754-4dcd-a446-dc191300d423_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_52cb132a-0754-4dcd-a446-dc191300d423" xlink:to="loc_us-gaap_VestingDomain_52cb132a-0754-4dcd-a446-dc191300d423_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_52cb132a-0754-4dcd-a446-dc191300d423" xlink:to="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_00132d66-ca6b-405a-8fed-419ca1a82be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_00132d66-ca6b-405a-8fed-419ca1a82be5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d540d84a-88d5-44e0-9991-a1139fda25ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d540d84a-88d5-44e0-9991-a1139fda25ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_368ac0e1-c359-4885-bc78-3d2adbe92b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_368ac0e1-c359-4885-bc78-3d2adbe92b4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ShareBasedCompensationAwardTrancheFourMember_0183b844-be9e-4274-84c7-40e1ac743225" xlink:href="axgn-20221231.xsd#axgn_ShareBasedCompensationAwardTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:to="loc_axgn_ShareBasedCompensationAwardTrancheFourMember_0183b844-be9e-4274-84c7-40e1ac743225" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_560449a4-a700-4c62-a3a7-ff3dc616baa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:to="loc_srt_RangeAxis_560449a4-a700-4c62-a3a7-ff3dc616baa3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_560449a4-a700-4c62-a3a7-ff3dc616baa3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_560449a4-a700-4c62-a3a7-ff3dc616baa3" xlink:to="loc_srt_RangeMember_560449a4-a700-4c62-a3a7-ff3dc616baa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c74a9990-4011-4d0d-889c-1541f710de34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_560449a4-a700-4c62-a3a7-ff3dc616baa3" xlink:to="loc_srt_RangeMember_c74a9990-4011-4d0d-889c-1541f710de34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e38167bc-eb6b-42c4-bd89-c19dd3d431fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c74a9990-4011-4d0d-889c-1541f710de34" xlink:to="loc_srt_MinimumMember_e38167bc-eb6b-42c4-bd89-c19dd3d431fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee614172-eeb2-4762-a975-6d8565ba1587" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c74a9990-4011-4d0d-889c-1541f710de34" xlink:to="loc_srt_MaximumMember_ee614172-eeb2-4762-a975-6d8565ba1587" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails" xlink:type="extended" id="i5b1b7b415a714762b5db8479c44e6de3_StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c140ab04-d3f7-44a2-bb02-8fa3977b39a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c140ab04-d3f7-44a2-bb02-8fa3977b39a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1e6faae9-96fe-444d-8ff4-523648dfa380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1e6faae9-96fe-444d-8ff4-523648dfa380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35048b2f-6fa0-49b5-a083-9c4bfb8d6fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35048b2f-6fa0-49b5-a083-9c4bfb8d6fbf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a4115249-c740-49a9-8768-a09eb7fd400e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a4115249-c740-49a9-8768-a09eb7fd400e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fb67839-180f-48ea-a1e7-9d4079525caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fb67839-180f-48ea-a1e7-9d4079525caa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad3dde8d-f6b2-480b-b8a7-72fc0c7edab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fb67839-180f-48ea-a1e7-9d4079525caa" xlink:to="loc_us-gaap_AwardTypeAxis_ad3dde8d-f6b2-480b-b8a7-72fc0c7edab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad3dde8d-f6b2-480b-b8a7-72fc0c7edab3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ad3dde8d-f6b2-480b-b8a7-72fc0c7edab3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad3dde8d-f6b2-480b-b8a7-72fc0c7edab3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41ddfce3-f19b-4ac1-b9e0-b1f493d5af0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ad3dde8d-f6b2-480b-b8a7-72fc0c7edab3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41ddfce3-f19b-4ac1-b9e0-b1f493d5af0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5c5ae65-68be-4bf1-9479-0140057037e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41ddfce3-f19b-4ac1-b9e0-b1f493d5af0b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5c5ae65-68be-4bf1-9479-0140057037e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended" id="i9b7beb7fd22744b28606e797aa63cc34_StockBasedCompensationSummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5493040c-4ec5-4f59-80c3-935bdf44a470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5493040c-4ec5-4f59-80c3-935bdf44a470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e37c74ad-4d5d-47a4-a0d5-c7c6311f1cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e37c74ad-4d5d-47a4-a0d5-c7c6311f1cbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f178a419-c1e2-452c-99d7-12999dd8032d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f178a419-c1e2-452c-99d7-12999dd8032d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7804c1b4-b7a1-4414-bbf8-b409eb3f1740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7804c1b4-b7a1-4414-bbf8-b409eb3f1740" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ca6970c3-fdf0-4941-9893-019620d3e267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78ba2044-bc0b-4301-9532-bb1845f03581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78ba2044-bc0b-4301-9532-bb1845f03581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d5b478d-353b-4d97-b132-a17233e6d749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d5b478d-353b-4d97-b132-a17233e6d749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb23a740-c509-46ec-8140-42a42cf4cf50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb23a740-c509-46ec-8140-42a42cf4cf50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7adab0d5-01a2-4689-8c37-b5c719a8ed83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7adab0d5-01a2-4689-8c37-b5c719a8ed83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b51cb1f6-9a69-4c25-801d-a2f5d506df32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b51cb1f6-9a69-4c25-801d-a2f5d506df32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c6815e9a-9c9a-4cbb-a982-54b8278bb88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_11a983f0-0598-4768-a1bb-6f8091b0ff20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_11a983f0-0598-4768-a1bb-6f8091b0ff20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50fa0ed0-fd66-481f-b4e1-e601b0114c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50fa0ed0-fd66-481f-b4e1-e601b0114c6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b3ea9262-4bcb-4922-baca-c01398029737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b3ea9262-4bcb-4922-baca-c01398029737" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6e7681af-365e-43b8-b0e5-0c15bfc22bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6e7681af-365e-43b8-b0e5-0c15bfc22bde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_49fb8b4c-3489-4cb1-8c12-d84f0018f614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_49fb8b4c-3489-4cb1-8c12-d84f0018f614" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d5e5ee-f1eb-45fd-bae1-0a0569c5e71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d5e5ee-f1eb-45fd-bae1-0a0569c5e71a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d3ae078-2670-475d-8d0c-abaa0324da61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d5e5ee-f1eb-45fd-bae1-0a0569c5e71a" xlink:to="loc_us-gaap_AwardTypeAxis_2d3ae078-2670-475d-8d0c-abaa0324da61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d3ae078-2670-475d-8d0c-abaa0324da61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2d3ae078-2670-475d-8d0c-abaa0324da61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d3ae078-2670-475d-8d0c-abaa0324da61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c13627-a3e1-4e77-aa68-2f50af199cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2d3ae078-2670-475d-8d0c-abaa0324da61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c13627-a3e1-4e77-aa68-2f50af199cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a514c852-296f-4cab-ab31-205bc07220ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c13627-a3e1-4e77-aa68-2f50af199cca" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a514c852-296f-4cab-ab31-205bc07220ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails" xlink:type="extended" id="i8a5f6f6198a74191b99e7daea83e7b7c_StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4339b93b-95ee-4402-86c8-08bff4510855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4339b93b-95ee-4402-86c8-08bff4510855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2ace89a6-d634-4cea-8661-da01ab401bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2ace89a6-d634-4cea-8661-da01ab401bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5ea34a2d-d521-400f-8569-b3322579ab63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5ea34a2d-d521-400f-8569-b3322579ab63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6dd7c50d-5a11-478d-bef3-50b26aa2c433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6dd7c50d-5a11-478d-bef3-50b26aa2c433" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16f093db-58b5-480f-b15b-5f68d1c125ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16f093db-58b5-480f-b15b-5f68d1c125ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_95c34386-76ea-439a-b44b-aed2a9846652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_95c34386-76ea-439a-b44b-aed2a9846652" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PercentageOfAchievementOfAwardIssued_b4f5304c-8dfc-4570-97bc-5ee3714abcea" xlink:href="axgn-20221231.xsd#axgn_PercentageOfAchievementOfAwardIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_axgn_PercentageOfAchievementOfAwardIssued_b4f5304c-8dfc-4570-97bc-5ee3714abcea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ShareBasedCompensationExpenseForfeitedOrReversed_0a413850-b709-42c7-907f-c223d94d7959" xlink:href="axgn-20221231.xsd#axgn_ShareBasedCompensationExpenseForfeitedOrReversed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_axgn_ShareBasedCompensationExpenseForfeitedOrReversed_0a413850-b709-42c7-907f-c223d94d7959" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PerformanceStockUnitPayoutOpportunity_e59191e6-8bcf-4942-912f-8efa976058e4" xlink:href="axgn-20221231.xsd#axgn_PerformanceStockUnitPayoutOpportunity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_axgn_PerformanceStockUnitPayoutOpportunity_e59191e6-8bcf-4942-912f-8efa976058e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_46a88e1c-0a77-4ec6-b746-d7d1e77ecb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_46a88e1c-0a77-4ec6-b746-d7d1e77ecb58" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c934d18-6df9-4077-ad8a-e82c0910f247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:to="loc_us-gaap_AwardTypeAxis_0c934d18-6df9-4077-ad8a-e82c0910f247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c934d18-6df9-4077-ad8a-e82c0910f247_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0c934d18-6df9-4077-ad8a-e82c0910f247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c934d18-6df9-4077-ad8a-e82c0910f247_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06daabf7-492d-49c7-902c-07fbdd06789a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0c934d18-6df9-4077-ad8a-e82c0910f247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06daabf7-492d-49c7-902c-07fbdd06789a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2ca197e6-0d3d-46e8-99bd-4bbbd9fdd168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06daabf7-492d-49c7-902c-07fbdd06789a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2ca197e6-0d3d-46e8-99bd-4bbbd9fdd168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06daabf7-492d-49c7-902c-07fbdd06789a" xlink:to="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PerformanceSharesBiologicLicenseApplicationMember_cecefa0e-49b4-4563-9398-7c1f6af5f3cd" xlink:href="axgn-20221231.xsd#axgn_PerformanceSharesBiologicLicenseApplicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:to="loc_axgn_PerformanceSharesBiologicLicenseApplicationMember_cecefa0e-49b4-4563-9398-7c1f6af5f3cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TwoThousandTwentyPerformanceShareUnitMember_03281ce7-0a95-4035-9ecb-dc11fa22574b" xlink:href="axgn-20221231.xsd#axgn_TwoThousandTwentyPerformanceShareUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:to="loc_axgn_TwoThousandTwentyPerformanceShareUnitMember_03281ce7-0a95-4035-9ecb-dc11fa22574b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TwoThousandTwentyOnePerformanceShareUnitMember_d2a3458e-9221-49f9-ae0f-a4a9d30d88f0" xlink:href="axgn-20221231.xsd#axgn_TwoThousandTwentyOnePerformanceShareUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:to="loc_axgn_TwoThousandTwentyOnePerformanceShareUnitMember_d2a3458e-9221-49f9-ae0f-a4a9d30d88f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember_f41934c1-a3a5-4c54-8dc1-bc6e8ea6569e" xlink:href="axgn-20221231.xsd#axgn_TwoThousandTwentyTwoPerformanceShareUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:to="loc_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember_f41934c1-a3a5-4c54-8dc1-bc6e8ea6569e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d67f8c69-b1cd-4980-ac65-ee421bb71968" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:to="loc_srt_TitleOfIndividualAxis_d67f8c69-b1cd-4980-ac65-ee421bb71968" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d67f8c69-b1cd-4980-ac65-ee421bb71968_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_d67f8c69-b1cd-4980-ac65-ee421bb71968" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d67f8c69-b1cd-4980-ac65-ee421bb71968_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eccffc8d-86ff-4e23-8406-49bd89a23798" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_d67f8c69-b1cd-4980-ac65-ee421bb71968" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eccffc8d-86ff-4e23-8406-49bd89a23798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DirectorsAndCertainExecutiveOfficersMember_7bfb2a7a-0581-4684-9298-031a8e77e6b0" xlink:href="axgn-20221231.xsd#axgn_DirectorsAndCertainExecutiveOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eccffc8d-86ff-4e23-8406-49bd89a23798" xlink:to="loc_axgn_DirectorsAndCertainExecutiveOfficersMember_7bfb2a7a-0581-4684-9298-031a8e77e6b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5ff07b53-6aee-4c10-affc-fbe15b01b2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:to="loc_us-gaap_VestingAxis_5ff07b53-6aee-4c10-affc-fbe15b01b2dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_5ff07b53-6aee-4c10-affc-fbe15b01b2dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_5ff07b53-6aee-4c10-affc-fbe15b01b2dc" xlink:to="loc_us-gaap_VestingDomain_5ff07b53-6aee-4c10-affc-fbe15b01b2dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f069c216-f921-4cef-b57e-f3bbf0449a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_5ff07b53-6aee-4c10-affc-fbe15b01b2dc" xlink:to="loc_us-gaap_VestingDomain_f069c216-f921-4cef-b57e-f3bbf0449a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_940c7633-f5a2-4b66-b719-cc520e39c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f069c216-f921-4cef-b57e-f3bbf0449a52" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_940c7633-f5a2-4b66-b719-cc520e39c90a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e9f02280-0c60-44cc-bb04-27b18b80c72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f069c216-f921-4cef-b57e-f3bbf0449a52" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e9f02280-0c60-44cc-bb04-27b18b80c72f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c666dc4-bde3-4d8b-a776-271bb7f64df1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:to="loc_srt_RangeAxis_7c666dc4-bde3-4d8b-a776-271bb7f64df1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7c666dc4-bde3-4d8b-a776-271bb7f64df1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7c666dc4-bde3-4d8b-a776-271bb7f64df1" xlink:to="loc_srt_RangeMember_7c666dc4-bde3-4d8b-a776-271bb7f64df1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f81407d2-75bd-48c7-bee2-83ce8c43dd95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7c666dc4-bde3-4d8b-a776-271bb7f64df1" xlink:to="loc_srt_RangeMember_f81407d2-75bd-48c7-bee2-83ce8c43dd95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0ad0343c-9331-4a93-924e-944bfbce10e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f81407d2-75bd-48c7-bee2-83ce8c43dd95" xlink:to="loc_srt_MinimumMember_0ad0343c-9331-4a93-924e-944bfbce10e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_002dc68b-aa2e-4fb1-aebb-7c0382cc29bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f81407d2-75bd-48c7-bee2-83ce8c43dd95" xlink:to="loc_srt_MaximumMember_002dc68b-aa2e-4fb1-aebb-7c0382cc29bb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails" xlink:type="extended" id="i1a44165d94c8417695ba0585620c1a9b_StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4473a691-4b72-42ac-923b-110c3c9384d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4473a691-4b72-42ac-923b-110c3c9384d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2aeb8f91-3553-4fd3-acac-4c8591c11414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2aeb8f91-3553-4fd3-acac-4c8591c11414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c0858af5-31fb-4074-8561-6ba78ebfa30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c0858af5-31fb-4074-8561-6ba78ebfa30c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_799fb555-824e-4043-91b8-dcb26c1ffa52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_799fb555-824e-4043-91b8-dcb26c1ffa52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc489a54-8889-4e05-8530-a2768e19d2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc489a54-8889-4e05-8530-a2768e19d2c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a73ed3d8-9ca0-40d6-aadc-e1ab207df9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4473a691-4b72-42ac-923b-110c3c9384d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cefd89bd-a394-4bbd-a298-49f24519246f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cefd89bd-a394-4bbd-a298-49f24519246f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_37d6fdcb-0130-49f8-b050-85645a6c1fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_37d6fdcb-0130-49f8-b050-85645a6c1fb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5e390bac-f471-43ec-b9f5-cb2f3aec3fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5e390bac-f471-43ec-b9f5-cb2f3aec3fd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_66aaa645-4bfe-4b33-b2ec-3e6dbbecb486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_66aaa645-4bfe-4b33-b2ec-3e6dbbecb486" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_64221bc3-fe1d-43bf-8f14-f6d5489aadce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4a4b01b4-520f-4700-a09b-cfc32d57b773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4473a691-4b72-42ac-923b-110c3c9384d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4a4b01b4-520f-4700-a09b-cfc32d57b773" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b4dc400c-275b-4658-afa7-1319edb40720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4a4b01b4-520f-4700-a09b-cfc32d57b773" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b4dc400c-275b-4658-afa7-1319edb40720" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_28b9f4f2-4d60-4e0d-8ab5-750a8f826902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4a4b01b4-520f-4700-a09b-cfc32d57b773" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_28b9f4f2-4d60-4e0d-8ab5-750a8f826902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b47e5789-1f96-451c-accb-eb0264e09b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4473a691-4b72-42ac-923b-110c3c9384d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b47e5789-1f96-451c-accb-eb0264e09b2a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_535f25de-7227-417b-b669-79aa3ddcb886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b47e5789-1f96-451c-accb-eb0264e09b2a" xlink:to="loc_us-gaap_AwardTypeAxis_535f25de-7227-417b-b669-79aa3ddcb886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_535f25de-7227-417b-b669-79aa3ddcb886_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_535f25de-7227-417b-b669-79aa3ddcb886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_535f25de-7227-417b-b669-79aa3ddcb886_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8abede84-ad2c-4c3b-99b9-8175a1420860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_535f25de-7227-417b-b669-79aa3ddcb886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8abede84-ad2c-4c3b-99b9-8175a1420860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_56be8b6a-21db-4971-87c0-fa42f939f84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8abede84-ad2c-4c3b-99b9-8175a1420860" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_56be8b6a-21db-4971-87c0-fa42f939f84d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e3a4fb85-191c-4888-aa72-b0f46b7eac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8abede84-ad2c-4c3b-99b9-8175a1420860" xlink:to="loc_us-gaap_PerformanceSharesMember_e3a4fb85-191c-4888-aa72-b0f46b7eac1a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" id="i468caa0ce21e4fc09f60f3df49a7fb4c_StockBasedCompensationEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_7c322ecd-4760-4594-9397-59ca6e5938fa" xlink:href="axgn-20221231.xsd#axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_7c322ecd-4760-4594-9397-59ca6e5938fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmployeeStockPurchasePlanOfferingPeriod_f0ef9973-89e4-46e7-a2a0-404579b7834b" xlink:href="axgn-20221231.xsd#axgn_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_axgn_EmployeeStockPurchasePlanOfferingPeriod_f0ef9973-89e4-46e7-a2a0-404579b7834b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_698d6af2-2a68-4204-b3ef-a923ac4cb663" xlink:href="axgn-20221231.xsd#axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_698d6af2-2a68-4204-b3ef-a923ac4cb663" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b07a56d-88df-49af-bbdb-1ccfffe8c2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b07a56d-88df-49af-bbdb-1ccfffe8c2b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639142b8-2b2a-4d2e-a4f5-0c2998c7aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639142b8-2b2a-4d2e-a4f5-0c2998c7aec0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fc4763cf-ec04-4177-8c17-a26d4affbec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fc4763cf-ec04-4177-8c17-a26d4affbec2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9da85aaf-910e-40f1-9eec-5e8fe6a95d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9da85aaf-910e-40f1-9eec-5e8fe6a95d36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9be1f7d-c8f9-423b-b11f-1663c031cca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9be1f7d-c8f9-423b-b11f-1663c031cca3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_80ee08fa-7107-4e8a-9e21-d8c2d634e968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9be1f7d-c8f9-423b-b11f-1663c031cca3" xlink:to="loc_us-gaap_PlanNameAxis_80ee08fa-7107-4e8a-9e21-d8c2d634e968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_80ee08fa-7107-4e8a-9e21-d8c2d634e968_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_80ee08fa-7107-4e8a-9e21-d8c2d634e968" xlink:to="loc_us-gaap_PlanNameDomain_80ee08fa-7107-4e8a-9e21-d8c2d634e968_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7411e5a5-c4a3-4060-bfaa-3edaf5fba9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_80ee08fa-7107-4e8a-9e21-d8c2d634e968" xlink:to="loc_us-gaap_PlanNameDomain_7411e5a5-c4a3-4060-bfaa-3edaf5fba9a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_7077866d-53df-4495-b287-8c3c0d10eadb" xlink:href="axgn-20221231.xsd#axgn_Axogen2017EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7411e5a5-c4a3-4060-bfaa-3edaf5fba9a6" xlink:to="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_7077866d-53df-4495-b287-8c3c0d10eadb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f2f5028b-34c1-4931-92eb-d0bd1d151777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9be1f7d-c8f9-423b-b11f-1663c031cca3" xlink:to="loc_us-gaap_AwardTypeAxis_f2f5028b-34c1-4931-92eb-d0bd1d151777" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2f5028b-34c1-4931-92eb-d0bd1d151777_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f2f5028b-34c1-4931-92eb-d0bd1d151777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f2f5028b-34c1-4931-92eb-d0bd1d151777_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44e81a64-e91f-4e99-9f00-4039ce8ea7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f2f5028b-34c1-4931-92eb-d0bd1d151777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44e81a64-e91f-4e99-9f00-4039ce8ea7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ce9ffea4-55cf-49e9-9c7a-eedf3b06d7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44e81a64-e91f-4e99-9f00-4039ce8ea7fe" xlink:to="loc_us-gaap_EmployeeStockMember_ce9ffea4-55cf-49e9-9c7a-eedf3b06d7b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails" xlink:type="extended" id="if4751c471dbe49f89034bfdd96fc6ad9_StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_467e1bc0-a426-4247-9b14-4714c15a8509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_467e1bc0-a426-4247-9b14-4714c15a8509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953b1b5e-549e-4bff-9fba-6ecbe4ccb304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953b1b5e-549e-4bff-9fba-6ecbe4ccb304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a412b061-a1b1-4652-adce-2cf2296aa4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a412b061-a1b1-4652-adce-2cf2296aa4da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15525d42-cf68-4879-be8c-1015b3ae70c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15525d42-cf68-4879-be8c-1015b3ae70c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15ba763b-621c-45ac-8704-9d79240d46dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15ba763b-621c-45ac-8704-9d79240d46dd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f57a4f71-e27f-4e08-9fcf-04d6a8b21758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15ba763b-621c-45ac-8704-9d79240d46dd" xlink:to="loc_us-gaap_PlanNameAxis_f57a4f71-e27f-4e08-9fcf-04d6a8b21758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f57a4f71-e27f-4e08-9fcf-04d6a8b21758_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f57a4f71-e27f-4e08-9fcf-04d6a8b21758" xlink:to="loc_us-gaap_PlanNameDomain_f57a4f71-e27f-4e08-9fcf-04d6a8b21758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cda3a30d-57d2-4b8a-b320-3b43ec55d156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f57a4f71-e27f-4e08-9fcf-04d6a8b21758" xlink:to="loc_us-gaap_PlanNameDomain_cda3a30d-57d2-4b8a-b320-3b43ec55d156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_c065f17a-f99c-4b8e-a050-c34fa26d61d6" xlink:href="axgn-20221231.xsd#axgn_Axogen2017EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cda3a30d-57d2-4b8a-b320-3b43ec55d156" xlink:to="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_c065f17a-f99c-4b8e-a050-c34fa26d61d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#RetirementPlanDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/RetirementPlanDetails" xlink:type="extended" id="i112ae41418bf42e3aba5b63652b7d3e2_RetirementPlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_027531ba-04cb-476e-b77c-866e8c83755e" xlink:href="axgn-20221231.xsd#axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:to="loc_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_027531ba-04cb-476e-b77c-866e8c83755e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_c865d4bf-c377-4aa4-87de-81b0c753062b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_c865d4bf-c377-4aa4-87de-81b0c753062b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DefinedContributionPlanEmployeeContributionPercentMatched_8932b33a-a483-4b08-baad-0e78b3bb4c80" xlink:href="axgn-20221231.xsd#axgn_DefinedContributionPlanEmployeeContributionPercentMatched"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:to="loc_axgn_DefinedContributionPlanEmployeeContributionPercentMatched_8932b33a-a483-4b08-baad-0e78b3bb4c80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_8cd6c87c-7ea2-4031-9f89-6db51866e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_8cd6c87c-7ea2-4031-9f89-6db51866e21b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_6e774886-d4ac-42ba-8855-923c9d49536c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:to="loc_us-gaap_DefinedContributionPlanTable_6e774886-d4ac-42ba-8855-923c9d49536c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_6ab72722-0c7a-44a8-a1cf-ebc2f592d5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_6e774886-d4ac-42ba-8855-923c9d49536c" xlink:to="loc_us-gaap_RetirementPlanNameAxis_6ab72722-0c7a-44a8-a1cf-ebc2f592d5dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_6ab72722-0c7a-44a8-a1cf-ebc2f592d5dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanNameAxis_6ab72722-0c7a-44a8-a1cf-ebc2f592d5dc" xlink:to="loc_us-gaap_RetirementPlanNameDomain_6ab72722-0c7a-44a8-a1cf-ebc2f592d5dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_e224e3b0-92da-4d96-92bc-72bbc3994c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanNameAxis_6ab72722-0c7a-44a8-a1cf-ebc2f592d5dc" xlink:to="loc_us-gaap_RetirementPlanNameDomain_e224e3b0-92da-4d96-92bc-72bbc3994c7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen401kPlanMember_720d1a8e-9ef8-4b5c-b5a8-6244e9034f03" xlink:href="axgn-20221231.xsd#axgn_Axogen401kPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_e224e3b0-92da-4d96-92bc-72bbc3994c7a" xlink:to="loc_axgn_Axogen401kPlanMember_720d1a8e-9ef8-4b5c-b5a8-6244e9034f03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8dd5f932-f9be-4409-85d4-bfbe09d98d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_6e774886-d4ac-42ba-8855-923c9d49536c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8dd5f932-f9be-4409-85d4-bfbe09d98d2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8dd5f932-f9be-4409-85d4-bfbe09d98d2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8dd5f932-f9be-4409-85d4-bfbe09d98d2d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8dd5f932-f9be-4409-85d4-bfbe09d98d2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_17c819ff-3939-4737-9fd4-6053b8cff4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8dd5f932-f9be-4409-85d4-bfbe09d98d2d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_17c819ff-3939-4737-9fd4-6053b8cff4c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_db119f59-82e9-40a2-8dff-5b96db4ad7e2" xlink:href="axgn-20221231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_17c819ff-3939-4737-9fd4-6053b8cff4c6" xlink:to="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_db119f59-82e9-40a2-8dff-5b96db4ad7e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_bde8218c-f9fe-466e-9b5f-1f7cc83cffec" xlink:href="axgn-20221231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_17c819ff-3939-4737-9fd4-6053b8cff4c6" xlink:to="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_bde8218c-f9fe-466e-9b5f-1f7cc83cffec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#CommitmentsandContingenciesServiceAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails" xlink:type="extended" id="i347a5900b7a146c3bb52c6c5a536d498_CommitmentsandContingenciesServiceAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LicenseFeeAmount_8ac8c11d-03bf-4f49-9e4d-d722c19cd8aa" xlink:href="axgn-20221231.xsd#axgn_LicenseFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:to="loc_axgn_LicenseFeeAmount_8ac8c11d-03bf-4f49-9e4d-d722c19cd8aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_NoticePeriodForTerminationOfAgreement_7a2f19e5-724a-4355-b746-632773ce1b19" xlink:href="axgn-20221231.xsd#axgn_NoticePeriodForTerminationOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:to="loc_axgn_NoticePeriodForTerminationOfAgreement_7a2f19e5-724a-4355-b746-632773ce1b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_a3627858-9a17-4e15-b085-2dff6f170cc6" xlink:href="axgn-20221231.xsd#axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:to="loc_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_a3627858-9a17-4e15-b085-2dff6f170cc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PaymentForServiceFees_ba6325f2-5937-4267-902b-efe97f8f3d73" xlink:href="axgn-20221231.xsd#axgn_PaymentForServiceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:to="loc_axgn_PaymentForServiceFees_ba6325f2-5937-4267-902b-efe97f8f3d73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ea5127a5-09ed-4d89-9818-595271e52f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ea5127a5-09ed-4d89-9818-595271e52f91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_45ac8479-af85-452a-9232-4a22f70de013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ea5127a5-09ed-4d89-9818-595271e52f91" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_45ac8479-af85-452a-9232-4a22f70de013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_45ac8479-af85-452a-9232-4a22f70de013_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_45ac8479-af85-452a-9232-4a22f70de013" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_45ac8479-af85-452a-9232-4a22f70de013_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_682949f5-928e-4949-92d1-a036d3f2b8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_45ac8479-af85-452a-9232-4a22f70de013" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_682949f5-928e-4949-92d1-a036d3f2b8f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CommunityTissuesServicesAgreementMember_7ad174f3-505e-44e5-97df-9f69255af569" xlink:href="axgn-20221231.xsd#axgn_CommunityTissuesServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_682949f5-928e-4949-92d1-a036d3f2b8f9" xlink:to="loc_axgn_CommunityTissuesServicesAgreementMember_7ad174f3-505e-44e5-97df-9f69255af569" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_b92146c0-d007-4463-9a8c-9680b178f760" xlink:href="axgn-20221231.xsd#axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_682949f5-928e-4949-92d1-a036d3f2b8f9" xlink:to="loc_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_b92146c0-d007-4463-9a8c-9680b178f760" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails" xlink:type="extended" id="ic52e30a7ecde492eb4876dee3fe6806f_CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_fe27eda1-7c75-42c8-a767-1cea3ff86627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_fe27eda1-7c75-42c8-a767-1cea3ff86627" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_89962f7a-73e0-4d2f-854a-fa4e2169d0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_AreaOfLand_89962f7a-73e0-4d2f-854a-fa4e2169d0a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLandHeldForUse_1dfdb6d9-00f4-480b-8f99-477cc7693060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLandHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_PaymentsToAcquireLandHeldForUse_1dfdb6d9-00f4-480b-8f99-477cc7693060" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBuildings_36685a74-e98d-44a5-bca0-543f0488d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBuildings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_PaymentsToAcquireBuildings_36685a74-e98d-44a5-bca0-543f0488d4dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EstimatedCostRelatingToDesignBuildAgreement_ab0a817e-7dcd-491b-84d1-7772d4a48deb" xlink:href="axgn-20221231.xsd#axgn_EstimatedCostRelatingToDesignBuildAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_axgn_EstimatedCostRelatingToDesignBuildAgreement_ab0a817e-7dcd-491b-84d1-7772d4a48deb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_d6ac7dde-bbf9-49c9-9fa5-c994c09963ef" xlink:href="axgn-20221231.xsd#axgn_AdditionalCostsAssociatedWithDesignBuildAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_d6ac7dde-bbf9-49c9-9fa5-c994c09963ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_98f07884-049b-4c96-a3e7-096f46c849f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_98f07884-049b-4c96-a3e7-096f46c849f5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e0e75b95-4488-4007-8da5-1a629770972b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e0e75b95-4488-4007-8da5-1a629770972b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_6f77e801-0e80-428d-97c8-9229b0cb7ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_InterestCostsCapitalized_6f77e801-0e80-428d-97c8-9229b0cb7ac6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts_67025594-8507-46ad-8800-b414eb106952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_AccumulatedCapitalizedInterestCosts_67025594-8507-46ad-8800-b414eb106952" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_f847cdba-546f-43b4-88f6-17c0b29336f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_GrantsReceivable_f847cdba-546f-43b4-88f6-17c0b29336f6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CashGrantsReceivable_a1a16918-e9e7-44f2-87b3-39ea3445ffb2" xlink:href="axgn-20221231.xsd#axgn_CashGrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_axgn_CashGrantsReceivable_a1a16918-e9e7-44f2-87b3-39ea3445ffb2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromGrantors_f8bcb96a-e47a-45bd-a8c8-02f19de662e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromGrantors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_ProceedsFromGrantors_f8bcb96a-e47a-45bd-a8c8-02f19de662e2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne_fc60b9b9-28a6-4d4d-9a1e-195ff30ea06c" xlink:href="axgn-20221231.xsd#axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne_fc60b9b9-28a6-4d4d-9a1e-195ff30ea06c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cbea40d4-3c8f-4538-89fc-a5e75e780988" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cbea40d4-3c8f-4538-89fc-a5e75e780988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cbea40d4-3c8f-4538-89fc-a5e75e780988_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cbea40d4-3c8f-4538-89fc-a5e75e780988" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cbea40d4-3c8f-4538-89fc-a5e75e780988_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d94514a7-5b57-4e09-b303-a0e23270d623" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cbea40d4-3c8f-4538-89fc-a5e75e780988" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d94514a7-5b57-4e09-b303-a0e23270d623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_APCFacilityMember_4bcac1a0-c114-424f-b047-4ba94ad6ba34" xlink:href="axgn-20221231.xsd#axgn_APCFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d94514a7-5b57-4e09-b303-a0e23270d623" xlink:to="loc_axgn_APCFacilityMember_4bcac1a0-c114-424f-b047-4ba94ad6ba34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_90a345ce-c916-44a7-871b-0dc60b77a5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_90a345ce-c916-44a7-871b-0dc60b77a5d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_90a345ce-c916-44a7-871b-0dc60b77a5d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_90a345ce-c916-44a7-871b-0dc60b77a5d2" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_90a345ce-c916-44a7-871b-0dc60b77a5d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_54fb9c4b-2249-4514-b043-c769fd089690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_90a345ce-c916-44a7-871b-0dc60b77a5d2" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_54fb9c4b-2249-4514-b043-c769fd089690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DesignBuildAgreementMember_3cec22e4-9dd1-40b5-953d-f208d2e20959" xlink:href="axgn-20221231.xsd#axgn_DesignBuildAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_54fb9c4b-2249-4514-b043-c769fd089690" xlink:to="loc_axgn_DesignBuildAgreementMember_3cec22e4-9dd1-40b5-953d-f208d2e20959" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4d5fd53a-e60f-4d27-851f-50acf88ab27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4d5fd53a-e60f-4d27-851f-50acf88ab27f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4d5fd53a-e60f-4d27-851f-50acf88ab27f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4d5fd53a-e60f-4d27-851f-50acf88ab27f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4d5fd53a-e60f-4d27-851f-50acf88ab27f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_449481e3-21ca-49a9-bfca-83e6067a6338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4d5fd53a-e60f-4d27-851f-50acf88ab27f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_449481e3-21ca-49a9-bfca-83e6067a6338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_f9578004-a76c-467f-a1c6-f2a01119e9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_449481e3-21ca-49a9-bfca-83e6067a6338" xlink:to="loc_us-gaap_ConstructionInProgressMember_f9578004-a76c-467f-a1c6-f2a01119e9ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_b5410186-8f5d-49fe-8a0d-f25f89e57a33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_b5410186-8f5d-49fe-8a0d-f25f89e57a33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_b5410186-8f5d-49fe-8a0d-f25f89e57a33_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_b5410186-8f5d-49fe-8a0d-f25f89e57a33" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_b5410186-8f5d-49fe-8a0d-f25f89e57a33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_cd7fcb86-ce26-43ba-827e-8b10e704ab20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_b5410186-8f5d-49fe-8a0d-f25f89e57a33" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_cd7fcb86-ce26-43ba-827e-8b10e704ab20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_62730b80-1507-46ab-b8d9-c1a7e8c21730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_cd7fcb86-ce26-43ba-827e-8b10e704ab20" xlink:to="loc_us-gaap_ConstructionInProgressMember_62730b80-1507-46ab-b8d9-c1a7e8c21730" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e694e946-fe2d-4f25-8fbc-fb9819471c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e694e946-fe2d-4f25-8fbc-fb9819471c0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e694e946-fe2d-4f25-8fbc-fb9819471c0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e694e946-fe2d-4f25-8fbc-fb9819471c0b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e694e946-fe2d-4f25-8fbc-fb9819471c0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1beacf1c-13c5-4a59-aaf2-bcc328b2d1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e694e946-fe2d-4f25-8fbc-fb9819471c0b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1beacf1c-13c5-4a59-aaf2-bcc328b2d1b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5720e359-cc98-4c11-b0b4-4cb66d62042a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1beacf1c-13c5-4a59-aaf2-bcc328b2d1b5" xlink:to="loc_us-gaap_SubsequentEventMember_5720e359-cc98-4c11-b0b4-4cb66d62042a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_293b56f4-75e7-42fe-9431-d5af6cf5be8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_srt_RangeAxis_293b56f4-75e7-42fe-9431-d5af6cf5be8c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_293b56f4-75e7-42fe-9431-d5af6cf5be8c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_293b56f4-75e7-42fe-9431-d5af6cf5be8c" xlink:to="loc_srt_RangeMember_293b56f4-75e7-42fe-9431-d5af6cf5be8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a1c9721-137f-444d-9f97-e7ea7d281097" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_293b56f4-75e7-42fe-9431-d5af6cf5be8c" xlink:to="loc_srt_RangeMember_5a1c9721-137f-444d-9f97-e7ea7d281097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1e71ce40-5053-4bdd-ae89-def068dfeda1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a1c9721-137f-444d-9f97-e7ea7d281097" xlink:to="loc_srt_MinimumMember_1e71ce40-5053-4bdd-ae89-def068dfeda1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee09fee7-a29d-4359-b093-b9424d721e0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5a1c9721-137f-444d-9f97-e7ea7d281097" xlink:to="loc_srt_MaximumMember_ee09fee7-a29d-4359-b093-b9424d721e0a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails" xlink:type="extended" id="i7ef74697636946bc8fde6a52dc71f4f6_CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_NumberOfPotentialSettlementScenarios_3e4a9bda-a138-4934-969b-46ac6988c677" xlink:href="axgn-20221231.xsd#axgn_NumberOfPotentialSettlementScenarios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_axgn_NumberOfPotentialSettlementScenarios_3e4a9bda-a138-4934-969b-46ac6988c677" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios_589631d4-8ac8-4dc2-a51a-1f1a95a4119f" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios_589631d4-8ac8-4dc2-a51a-1f1a95a4119f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePayment_84b37f0c-bcc3-4387-8a88-aba11760bc63" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentHeldToMaturityMakeWholePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePayment_84b37f0c-bcc3-4387-8a88-aba11760bc63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_31b1a2b3-e733-401c-b170-34d61e48f6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_31b1a2b3-e733-401c-b170-34d61e48f6e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation_fa428bd1-a997-4608-8800-e077eb5cd831" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation_fa428bd1-a997-4608-8800-e077eb5cd831" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea333d04-6ccb-4aba-bdbe-801d9e426a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea333d04-6ccb-4aba-bdbe-801d9e426a21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ea333d04-6ccb-4aba-bdbe-801d9e426a21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea333d04-6ccb-4aba-bdbe-801d9e426a21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ea333d04-6ccb-4aba-bdbe-801d9e426a21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fa33ea96-d07c-4f5d-8f9b-0e7eb60ab145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea333d04-6ccb-4aba-bdbe-801d9e426a21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fa33ea96-d07c-4f5d-8f9b-0e7eb60ab145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityMember_b2599442-048c-4d70-b411-04ddc8e5d9f4" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fa33ea96-d07c-4f5d-8f9b-0e7eb60ab145" xlink:to="loc_axgn_CreditFacilityMember_b2599442-048c-4d70-b411-04ddc8e5d9f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheOneMember_6b7b82e7-bdc8-4ed2-a762-f410bc4e2af9" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axgn_CreditFacilityMember_b2599442-048c-4d70-b411-04ddc8e5d9f4" xlink:to="loc_axgn_CreditFacilityTrancheOneMember_6b7b82e7-bdc8-4ed2-a762-f410bc4e2af9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheTwoMember_70a3bc2a-c49e-4e2c-a59c-271c066cca3b" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_axgn_CreditFacilityMember_b2599442-048c-4d70-b411-04ddc8e5d9f4" xlink:to="loc_axgn_CreditFacilityTrancheTwoMember_70a3bc2a-c49e-4e2c-a59c-271c066cca3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b677da1e-957f-4e4f-8cf1-536aa45c3174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b677da1e-957f-4e4f-8cf1-536aa45c3174" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b677da1e-957f-4e4f-8cf1-536aa45c3174_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b677da1e-957f-4e4f-8cf1-536aa45c3174" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b677da1e-957f-4e4f-8cf1-536aa45c3174_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b622b936-0a5f-4805-9643-c915cc8bf26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b677da1e-957f-4e4f-8cf1-536aa45c3174" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b622b936-0a5f-4805-9643-c915cc8bf26e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember_aed7969b-b669-4407-8161-83668453a718" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b622b936-0a5f-4805-9643-c915cc8bf26e" xlink:to="loc_axgn_DebtDerivativeLiabilityMember_aed7969b-b669-4407-8161-83668453a718" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d957ea0d-c750-48e5-9753-96a89312deb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d957ea0d-c750-48e5-9753-96a89312deb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d957ea0d-c750-48e5-9753-96a89312deb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d957ea0d-c750-48e5-9753-96a89312deb7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d957ea0d-c750-48e5-9753-96a89312deb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_948eaab6-0ae8-4981-a68d-e1f7a2e59313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d957ea0d-c750-48e5-9753-96a89312deb7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_948eaab6-0ae8-4981-a68d-e1f7a2e59313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_72dc7949-d709-4289-868a-d6d9234b628a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_948eaab6-0ae8-4981-a68d-e1f7a2e59313" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_72dc7949-d709-4289-868a-d6d9234b628a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/SubsequentEventDetails" xlink:type="extended" id="ie3f03ebfed234ee198664589384e7869_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_20c9524a-4789-4e06-8e1e-d59b741bb99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation_69aacd4a-ef2c-4f71-8a08-0898e2387a4f" xlink:href="axgn-20221231.xsd#axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_20c9524a-4789-4e06-8e1e-d59b741bb99d" xlink:to="loc_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation_69aacd4a-ef2c-4f71-8a08-0898e2387a4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_180a1182-a20f-48a6-ab09-a14ebf5f1d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_20c9524a-4789-4e06-8e1e-d59b741bb99d" xlink:to="loc_us-gaap_SubsequentEventTable_180a1182-a20f-48a6-ab09-a14ebf5f1d83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2612fcfd-06c6-423b-9647-e6c6f4716428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_180a1182-a20f-48a6-ab09-a14ebf5f1d83" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2612fcfd-06c6-423b-9647-e6c6f4716428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2612fcfd-06c6-423b-9647-e6c6f4716428_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2612fcfd-06c6-423b-9647-e6c6f4716428" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2612fcfd-06c6-423b-9647-e6c6f4716428_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80c6095c-ecf3-4965-bff5-c1c019205b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2612fcfd-06c6-423b-9647-e6c6f4716428" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80c6095c-ecf3-4965-bff5-c1c019205b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b1770c19-788b-436f-a03b-ad79bd9f8114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_80c6095c-ecf3-4965-bff5-c1c019205b23" xlink:to="loc_us-gaap_SubsequentEventMember_b1770c19-788b-436f-a03b-ad79bd9f8114" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended" id="ie0f5114974c44bcb86c84bb171a5185a_ScheduleIIValuationandQualifyingAccountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2a1895ff-e204-4e76-8196-26056720efbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2a1895ff-e204-4e76-8196-26056720efbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_a0fec75f-7287-47ea-8c48-71e3bf4a8cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_a0fec75f-7287-47ea-8c48-71e3bf4a8cca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9f4ababb-718a-44f2-a923-9af8903a7573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9f4ababb-718a-44f2-a923-9af8903a7573" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_dde6bcf3-f668-46f2-a76f-de8375b046f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_384c6775-8ffa-4c8f-8a61-e9f54b362e95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_384c6775-8ffa-4c8f-8a61-e9f54b362e95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_41247db8-b3b5-421e-9e63-74baf06e9e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_384c6775-8ffa-4c8f-8a61-e9f54b362e95" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_41247db8-b3b5-421e-9e63-74baf06e9e52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_41247db8-b3b5-421e-9e63-74baf06e9e52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_41247db8-b3b5-421e-9e63-74baf06e9e52" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_41247db8-b3b5-421e-9e63-74baf06e9e52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d6f5451e-3f1f-4b26-93a7-27b8724f897c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_41247db8-b3b5-421e-9e63-74baf06e9e52" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d6f5451e-3f1f-4b26-93a7-27b8724f897c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_b6419d79-bd0d-4932-8b82-56a86b728eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d6f5451e-3f1f-4b26-93a7-27b8724f897c" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_b6419d79-bd0d-4932-8b82-56a86b728eef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_3320ce51-3cc2-4164-a8ed-4cb5ded762ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d6f5451e-3f1f-4b26-93a7-27b8724f897c" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_3320ce51-3cc2-4164-a8ed-4cb5ded762ed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LeaseLiabilityCurrent_7ffb1d16-08cb-4961-a53c-6d3162a4ef56" xlink:href="axgn-20221231.xsd#axgn_LeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_axgn_LeaseLiabilityCurrent_7ffb1d16-08cb-4961-a53c-6d3162a4ef56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LeaseLiabilitiesNoncurrent_5ce937b5-ef7c-47a7-8c35-fc498af82aca" xlink:href="axgn-20221231.xsd#axgn_LeaseLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="loc_axgn_LeaseLiabilitiesNoncurrent_5ce937b5-ef7c-47a7-8c35-fc498af82aca" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>axgn-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:008e6d96-0028-47c7-9dfe-7d6d669b55a8,g:6a78ba92-a70c-4cec-a491-e196b80cf77c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_075ddfa7-a90a-45b4-a9a6-18e136dc1905_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt derivative liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Derivative Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:to="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_d4db8036-4ebc-46f1-a3b1-f0b058592efd_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of intangible assets in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_226ed691-3245-443a-9595-9e1d84bf57b7_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e082a51f-3923-43fd-9a84-fcaabd565c56_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a2c03762-ec3b-4324-9aca-19f7f36c40a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_1f0d1b45-8d66-482e-bb23-b01174650f45_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debt</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_f0506749-1477-4131-995c-ce67ee2b7225_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_403c340d-651a-46d4-ae49-be04d0b22293_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d66d90b2-7220-42f5-af8d-a9f61b58e27e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeDomain_168f4269-4ec3-4250-a41e-325dde36c5dd_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeDomain_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain" xlink:to="lab_us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_3fa9cd35-58d2-49ec-b6a2-d805aaec2f81_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_f6ce754c-9313-42ea-8fd5-80b92b3c022a_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Size of building space</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_7ae6b02e-a689-435a-a322-5c2b1d3b08d8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3a928fca-6195-47b3-a33e-c497de8ed8ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_4f3f9f1f-a64d-45c8-868b-359704ad637c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_be318f30-7614-4e23-87ad-b778d4a0fec4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_Axogen2017EmployeeStockPurchasePlanMember_81619679-5b01-4d3f-882b-83426417238f_terseLabel_en-US" xlink:label="lab_axgn_Axogen2017EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 ESPP</link:label>
    <link:label id="lab_axgn_Axogen2017EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_axgn_Axogen2017EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Axogen2017 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_axgn_Axogen2017EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_axgn_Axogen2017EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AxoGen 2017 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember" xlink:href="axgn-20221231.xsd#axgn_Axogen2017EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember" xlink:to="lab_axgn_Axogen2017EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_20ad180b-1215-4d34-8f0b-bfcb51c5424b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_432f88f2-2154-4a6a-98e4-c23b72655adb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to improvements in current year</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e44a3000-19b6-4cd7-90ff-3da05cfc6c28_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_f27761fd-e7bb-4802-9bc8-7c6d2fb527bb_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions (Charge-offs)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmountCumulative_1a01417e-b658-4405-835c-1a174ef4c37b_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmountCumulative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants received</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmountCumulative_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmountCumulative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Amount, Cumulative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulative" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmountCumulative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmountCumulative" xlink:to="lab_us-gaap_GovernmentAssistanceAmountCumulative" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DeferredTaxAssetsLeaseObligations_8caa721e-26a6-47c4-bbe1-a21f4d36ebef_terseLabel_en-US" xlink:label="lab_axgn_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligations</link:label>
    <link:label id="lab_axgn_DeferredTaxAssetsLeaseObligations_label_en-US" xlink:label="lab_axgn_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Obligations</link:label>
    <link:label id="lab_axgn_DeferredTaxAssetsLeaseObligations_documentation_en-US" xlink:label="lab_axgn_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from right-of-use liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxAssetsLeaseObligations" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxAssetsLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DeferredTaxAssetsLeaseObligations" xlink:to="lab_axgn_DeferredTaxAssetsLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_e1c06af6-d3c9-4c15-84ab-e4da0bfddd0c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_MeasurementInputCouponRateMember_15c0ac3e-053f-4d88-8a0d-6d9831bfd0a3_terseLabel_en-US" xlink:label="lab_axgn_MeasurementInputCouponRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coupon rate</link:label>
    <link:label id="lab_axgn_MeasurementInputCouponRateMember_label_en-US" xlink:label="lab_axgn_MeasurementInputCouponRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Coupon Rate [Member]</link:label>
    <link:label id="lab_axgn_MeasurementInputCouponRateMember_documentation_en-US" xlink:label="lab_axgn_MeasurementInputCouponRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Coupon Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MeasurementInputCouponRateMember" xlink:href="axgn-20221231.xsd#axgn_MeasurementInputCouponRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_MeasurementInputCouponRateMember" xlink:to="lab_axgn_MeasurementInputCouponRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_f973c629-6d84-49ea-9521-5ceb5742edca_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonus</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8d2253ea-70b8-4ff9-9aca-e473ea551478_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DesignBuildAgreementMember_9e8071d1-7322-4d3c-879b-e67e3360ce3e_terseLabel_en-US" xlink:label="lab_axgn_DesignBuildAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Design Build Agreement</link:label>
    <link:label id="lab_axgn_DesignBuildAgreementMember_label_en-US" xlink:label="lab_axgn_DesignBuildAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Design Build Agreement [Member]</link:label>
    <link:label id="lab_axgn_DesignBuildAgreementMember_documentation_en-US" xlink:label="lab_axgn_DesignBuildAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to design build agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DesignBuildAgreementMember" xlink:href="axgn-20221231.xsd#axgn_DesignBuildAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DesignBuildAgreementMember" xlink:to="lab_axgn_DesignBuildAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a1baaeba-cd2a-426f-8f46-d7ade8666fb8_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_0af8c63b-df99-4142-9cf1-c15258864183_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_88020386-62c9-4a94-9e98-d44427684d62_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_4c61b7bd-a669-41c4-b263-51c556f582c6_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8cb98e2b-5f93-486b-b771-8fb7f9a76dc2_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_c3ebf658-4939-4136-8175-bc7f15af517d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_5b245b07-f072-45e7-b04b-20a3fbcdc5e3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the paycheck protection program loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_6b9f45b1-7958-449d-bc4e-a0d811f6920d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a8018d18-562c-45e2-b65e-24e54d7c7fc9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d6c3a63-7f8f-472f-923a-f7f4f600c49f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c7d334f0-77b9-4572-be7c-3f6006c955f9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount_57c13085-5234-4961-8798-9d928a35ad98_negatedTerseLabel_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount_documentation_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_a7d61b43-93e3-4167-bd00-f7deeafd09fe_terseLabel_en-US" xlink:label="lab_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Services Agreement For Clinical Research and Related Services</link:label>
    <link:label id="lab_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_label_en-US" xlink:label="lab_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Services Agreement For Clinical Research And Related Services [Member]</link:label>
    <link:label id="lab_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_documentation_en-US" xlink:label="lab_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment for clinical research and related services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xlink:href="axgn-20221231.xsd#axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xlink:to="lab_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_f4475bea-db2e-49f0-9221-18f3b7bffb90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of the paycheck protection program loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b4fac556-a327-49fc-b622-12a48ddbdb87_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_678cd54e-aa82-4514-83a8-6866f7f54f5a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7e481ee2-2aa9-423d-9bc7-765a4eef2f9b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_14e09e87-d6a0-4e52-96e1-7f32c7ed881e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_7b5d89b0-15fa-4652-a2b3-afd1fc6fdb9e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_9b61dc3b-97eb-4565-b5c9-daba569a5a95_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_82d14e4c-74af-4fbc-9cc0-cadbc9a9bb1a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7acea96a-5859-4b86-914d-1dd7f932e940_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from computation of net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_b142e8ed-02df-435b-991e-e6ba6f2b12a4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_CreditFacilityMember_197d30ee-0cf9-4719-94c9-bf3707fadb1f_terseLabel_en-US" xlink:label="lab_axgn_CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_axgn_CreditFacilityMember_label_en-US" xlink:label="lab_axgn_CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Member]</link:label>
    <link:label id="lab_axgn_CreditFacilityMember_documentation_en-US" xlink:label="lab_axgn_CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityMember" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_CreditFacilityMember" xlink:to="lab_axgn_CreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_af521339-8f9a-4064-96a0-f63159ee138b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne_a6b09ea3-8ea4-4a68-8433-918f3d1fafd9_terseLabel_en-US" xlink:label="lab_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated costs associated with design build agreement, in 2022</link:label>
    <link:label id="lab_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne_label_en-US" xlink:label="lab_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated Costs Associated with Design Build Agreement, Year One</link:label>
    <link:label id="lab_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne_documentation_en-US" xlink:label="lab_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anticipated Costs Associated with Design Build Agreement, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne" xlink:href="axgn-20221231.xsd#axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne" xlink:to="lab_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9f24cf1b-6d9c-47b8-bda3-a7dadf935d27_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ec784052-3523-40a3-8211-a3016590c19a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_79a359af-dcb3-434e-8b0e-0c3fd2ab3976_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_0fcf4ace-8647-4329-9f0d-0b7b95a6aabd_terseLabel_en-US" xlink:label="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer's Contribution, Second Tranche</link:label>
    <link:label id="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_label_en-US" xlink:label="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Axogen401k Plan Employer Matching Contribution Tranche2 [Member]</link:label>
    <link:label id="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_documentation_en-US" xlink:label="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the second tranche of the AxoGen 401K plan where the employer matches a percent of employee contributions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xlink:href="axgn-20221231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xlink:to="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_881b4735-4815-4c54-bfdb-d1fcbce42512_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_CreditFacilityTrancheOneMember_d2923f13-e600-4f88-836c-3e1831622077_terseLabel_en-US" xlink:label="lab_axgn_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Tranche</link:label>
    <link:label id="lab_axgn_CreditFacilityTrancheOneMember_label_en-US" xlink:label="lab_axgn_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche One [Member]</link:label>
    <link:label id="lab_axgn_CreditFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_axgn_CreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheOneMember" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_CreditFacilityTrancheOneMember" xlink:to="lab_axgn_CreditFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_1f68e932-d37c-4e0d-a53e-771f5d8e09b1_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_33a9116a-9984-4f1b-8714-a19653b1594c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_44a29d0c-b9a3-4dbc-838f-cfad0d77bb64_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_bef3f9ab-87fc-4ef9-b8a5-2055fe57281b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a4472586-a80e-4af8-86ce-c97ccab17f2f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_d52a4ccb-ca2b-4c16-bc38-3c91edaa5fae_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_fedae3ad-3cc7-4611-8c45-47ec2f163cda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_bb05282b-3bd2-403e-8554-675382005f54_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_f7674b62-dbf6-4131-8292-dd0b6bad8ede_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_e6d0b47f-724b-4a0d-aa5b-d37f4b640038_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt_ad323bdf-d599-4996-9195-a82ee4f9907f_terseLabel_en-US" xlink:label="lab_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded derivative associated with the long-term debt</link:label>
    <link:label id="lab_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt_label_en-US" xlink:label="lab_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative Associated With The Long Term Debt</link:label>
    <link:label id="lab_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt_documentation_en-US" xlink:label="lab_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative Associated With The Long Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt" xlink:href="axgn-20221231.xsd#axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt" xlink:to="lab_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_a9538a4f-1f67-4a2d-a1d4-466ff4c07ffe_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow activity:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_484cc170-214f-428e-9b36-fc12cab90456_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_f5d88a3e-a5c6-49fd-9673-ebe5cb416c65_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_c823007c-9a2b-4206-a323-d2382965f72f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_60ffdb1f-b153-4765-b79b-6c8c72764121_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_11baa75a-a135-4505-8f03-b0dd1b777fcc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7d6ad855-3b9b-49dc-a9f9-186a30cc27ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_OptionalPrepaymentEventMember_b1ad5352-e9f6-4170-8c89-e43fbeea62b8_terseLabel_en-US" xlink:label="lab_axgn_OptionalPrepaymentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of optional prepayment event</link:label>
    <link:label id="lab_axgn_OptionalPrepaymentEventMember_label_en-US" xlink:label="lab_axgn_OptionalPrepaymentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optional Prepayment Event [Member]</link:label>
    <link:label id="lab_axgn_OptionalPrepaymentEventMember_documentation_en-US" xlink:label="lab_axgn_OptionalPrepaymentEventMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Optional Prepayment Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OptionalPrepaymentEventMember" xlink:href="axgn-20221231.xsd#axgn_OptionalPrepaymentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_OptionalPrepaymentEventMember" xlink:to="lab_axgn_OptionalPrepaymentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_006b17d9-62a1-46a3-9be9-102767c30abe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_6c391fb6-945d-4c7b-8d8b-51c094f9a97d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c5ea8cba-7651-4802-9a25-3745d6ea6db0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life, Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ea466f49-670f-4c6a-aaaf-6e58fc201dc7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_0c9905ff-a680-4f9b-8698-54513bb2a86a_verboseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of land where building resides</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbfe33da-9a1e-451c-870c-c69c59f9f34c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f51583a6-2783-48d2-ba96-8c6c78cddf18_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of long-term lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_Axogen401kPlanMember_d214fd9a-555a-44e5-9487-ae8beb06e989_terseLabel_en-US" xlink:label="lab_axgn_Axogen401kPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AxoGen 401K Plan</link:label>
    <link:label id="lab_axgn_Axogen401kPlanMember_label_en-US" xlink:label="lab_axgn_Axogen401kPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Axogen401k Plan [Member]</link:label>
    <link:label id="lab_axgn_Axogen401kPlanMember_documentation_en-US" xlink:label="lab_axgn_Axogen401kPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the AxoGen 401K plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen401kPlanMember" xlink:href="axgn-20221231.xsd#axgn_Axogen401kPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_Axogen401kPlanMember" xlink:to="lab_axgn_Axogen401kPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_OperatingAndFinancingLeaseLiabilityCurrent_7f29a896-d9c1-4303-818a-1b08ca2c6d98_negatedTerseLabel_en-US" xlink:label="lab_axgn_OperatingAndFinancingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current lease liability</link:label>
    <link:label id="lab_axgn_OperatingAndFinancingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_axgn_OperatingAndFinancingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Financing Lease, Liability, Current</link:label>
    <link:label id="lab_axgn_OperatingAndFinancingLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_axgn_OperatingAndFinancingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Financing Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingAndFinancingLeaseLiabilityCurrent" xlink:href="axgn-20221231.xsd#axgn_OperatingAndFinancingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_OperatingAndFinancingLeaseLiabilityCurrent" xlink:to="lab_axgn_OperatingAndFinancingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_d7e1c3a4-7f81-4c85-bf67-e99faad90ae3_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9d7b819b-ad9f-47b3-abac-d187d37e9fb7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_91b7892c-031a-48e9-9c7d-4e5c20aacd0f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_72c31808-6810-4398-baee-adbc37a09aa6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_aa0f7b46-514b-4cce-b930-481197486824_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e10fd4b6-557f-49cc-b147-a37493210e63_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of debt discount and financing fees</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_83b0b0ee-2cce-40ed-8208-37d90d141924_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3b37a896-7eed-4099-8d05-b7aee25fb4fd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average operating lease term (in years):</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_03331ad5-dedf-4bb0-bf4b-41b8e34dd572_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DebtDerivativeLiabilityMember_9109a015-fead-4fc5-8bff-c1d30c46a58d_terseLabel_en-US" xlink:label="lab_axgn_DebtDerivativeLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt derivative liabilities</link:label>
    <link:label id="lab_axgn_DebtDerivativeLiabilityMember_label_en-US" xlink:label="lab_axgn_DebtDerivativeLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Derivative Liability [Member]</link:label>
    <link:label id="lab_axgn_DebtDerivativeLiabilityMember_documentation_en-US" xlink:label="lab_axgn_DebtDerivativeLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DebtDerivativeLiabilityMember" xlink:to="lab_axgn_DebtDerivativeLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d3948f18-1ad4-4bcf-9262-f5f130ead6f9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_660d6534-95e4-4703-9e94-49ec86844add_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_7b44bb08-9ad7-4ad8-a0d7-787fb6fa0642_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable and Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_RisksAndUncertaintiesPolicyTextBlock_0fe1e1bc-9497-4a16-9fe3-7096bcdf8626_terseLabel_en-US" xlink:label="lab_axgn_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_axgn_RisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_axgn_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_axgn_RisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_axgn_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Uncertainties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RisksAndUncertaintiesPolicyTextBlock" xlink:href="axgn-20221231.xsd#axgn_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_axgn_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_c04e086b-855e-4cfd-ac55-5b2bc5ecdd78_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_296cbda0-985b-4f0e-922b-a0ab538e733b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dcea5a1d-fb0c-4395-998b-92fa6cd8614b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4933e081-3b08-44c2-9e22-c112a8bbf882_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_5e03a767-b289-4d9f-92ae-e90f43fff7c3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt&#8203;, Net of Debt Discount and Financing Fees</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_70b20888-63de-4170-8365-2b00f3269e84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted and Performance Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0a7a0d8d-9059-4a07-b849-93fbc0911f9a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DirectorsAndCertainExecutiveOfficersMember_21e1f762-41fe-4d99-a763-133b85b87bf6_terseLabel_en-US" xlink:label="lab_axgn_DirectorsAndCertainExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors And Certain Executive Officers</link:label>
    <link:label id="lab_axgn_DirectorsAndCertainExecutiveOfficersMember_label_en-US" xlink:label="lab_axgn_DirectorsAndCertainExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors And Certain Executive Officers [Member]</link:label>
    <link:label id="lab_axgn_DirectorsAndCertainExecutiveOfficersMember_documentation_en-US" xlink:label="lab_axgn_DirectorsAndCertainExecutiveOfficersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors And Certain Executive Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DirectorsAndCertainExecutiveOfficersMember" xlink:href="axgn-20221231.xsd#axgn_DirectorsAndCertainExecutiveOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DirectorsAndCertainExecutiveOfficersMember" xlink:to="lab_axgn_DirectorsAndCertainExecutiveOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_51f95b1c-10da-422a-9c51-0adb96db4a33_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_090f024a-c875-4e25-a215-14396e23d932_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ead55242-390f-4876-8c2a-bb1e9635b517_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_105f17ca-23c8-4b30-9db2-b02955212008_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c8159bc4-830b-443f-ad15-44bce8b7b903_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_775ca7ea-bc86-4a67-bd39-0a93bff28511_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromGrantors_dfef079c-7e30-426d-9be3-331b4daae97b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromGrantors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from grantors</link:label>
    <link:label id="lab_us-gaap_ProceedsFromGrantors_label_en-US" xlink:label="lab_us-gaap_ProceedsFromGrantors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Grantors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromGrantors" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromGrantors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromGrantors" xlink:to="lab_us-gaap_ProceedsFromGrantors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_1d761b9e-c1e3-42c8-b540-b20f9d099981_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_dead1d37-4abf-4055-aaaf-b3945cdaf2fb_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_5758c97f-702a-4a23-b278-7c5e3beac5bd_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_9689e776-d5a1-4731-b87b-c297be43efb2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_9d372071-7430-4bf1-8704-ccb74c3c7e01_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_e723cc6c-21c6-4cc4-93a5-898deddfbaf2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_00ec77e6-a319-489c-97cb-58dd0998dd0a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_d894827e-9d42-43b2-b050-5148c18e5a3e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_e7962abe-2d06-4a20-a19e-a9803cd489e8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1d523871-d8fc-41ff-a804-d0a080853f25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_f15af806-23aa-4dc8-b435-fbb99650737c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameDomain_198e123d-3377-4543-a631-c5d417d4f413_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameDomain" xlink:to="lab_us-gaap_RetirementPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract_47b32c54-8abe-4865-bdea-fc624982680f_terseLabel_en-US" xlink:label="lab_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract_label_en-US" xlink:label="lab_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosure1 [Abstract]</link:label>
    <link:label id="lab_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract_documentation_en-US" xlink:label="lab_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosure1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract" xlink:href="axgn-20221231.xsd#axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract" xlink:to="lab_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_AviveSoftTissueMembraneMember_2406622d-bf5e-466b-b245-d7378bf416c4_terseLabel_en-US" xlink:label="lab_axgn_AviveSoftTissueMembraneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avive</link:label>
    <link:label id="lab_axgn_AviveSoftTissueMembraneMember_label_en-US" xlink:label="lab_axgn_AviveSoftTissueMembraneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avive Soft Tissue Membrane [Member]</link:label>
    <link:label id="lab_axgn_AviveSoftTissueMembraneMember_documentation_en-US" xlink:label="lab_axgn_AviveSoftTissueMembraneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Avive Soft Tissue Membrane</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AviveSoftTissueMembraneMember" xlink:href="axgn-20221231.xsd#axgn_AviveSoftTissueMembraneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_AviveSoftTissueMembraneMember" xlink:to="lab_axgn_AviveSoftTissueMembraneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DirectorsAndOfficersStockOptionsMember_08e0a785-0ff9-4156-91da-21b5c90fcf1a_terseLabel_en-US" xlink:label="lab_axgn_DirectorsAndOfficersStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors And Officers Stock Options</link:label>
    <link:label id="lab_axgn_DirectorsAndOfficersStockOptionsMember_label_en-US" xlink:label="lab_axgn_DirectorsAndOfficersStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors And Officers Stock Options [Member]</link:label>
    <link:label id="lab_axgn_DirectorsAndOfficersStockOptionsMember_documentation_en-US" xlink:label="lab_axgn_DirectorsAndOfficersStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An arrangement whereby an officer or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DirectorsAndOfficersStockOptionsMember" xlink:href="axgn-20221231.xsd#axgn_DirectorsAndOfficersStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DirectorsAndOfficersStockOptionsMember" xlink:to="lab_axgn_DirectorsAndOfficersStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a4f3ff18-5c28-4f40-8fd0-b5c574b0fe31_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_366fa86d-cdeb-4929-b871-fb2a51eff0d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b7098e4c-c6c9-44e8-a941-45e3c12396b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember_d95a5131-dce9-4134-b5b6-07ed7fa40db8_terseLabel_en-US" xlink:label="lab_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Lease With JA-Cole L.P, First Amendment</link:label>
    <link:label id="lab_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember_label_en-US" xlink:label="lab_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Lease With JA-Cole L.P, First Amendment [Member]</link:label>
    <link:label id="lab_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember_documentation_en-US" xlink:label="lab_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Lease With JA-Cole L.P, First Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember" xlink:href="axgn-20221231.xsd#axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember" xlink:to="lab_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_f18a1237-8654-470d-a4d3-7aa5d0b1a326_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Year After Grant Date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_e49b19b2-202f-4634-bf8d-dbae33aecb1b_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_931db032-04c9-40f4-92a6-09b95b337842_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_613b266f-3d99-4784-8ac4-f5fed12b1a27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_210d59ad-89f1-41c6-97f7-ec800153e852_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f4aa3dd9-8db9-4f62-b502-8c315976b05b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_721c8843-6da0-4083-a4bc-ed492acb7ceb_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_2e32d513-7e83-4c8b-b798-dab727ed5fb6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_f820cbce-99b5-4f13-9b44-af776991f168_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_80450c87-c232-4c58-8a8c-725457485abc_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fccc4fcd-50fb-4b42-a564-29406b00177d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive_6a2a0dbc-5b3b-412d-b968-66b1e591accd_terseLabel_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive_label_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, Year Five</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive_documentation_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive" xlink:to="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1714555d-e4bd-4e4f-8558-078ec833fa8c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_f66cd32c-4afb-4ebb-8db4-fad0884a0e81_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_21462e45-51be-40bc-9baa-3483d5d0ff4b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_387017e8-43bf-4300-9226-1504642870df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted-average assumptions for options granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd1bdcaf-9507-475b-857f-d65a090426d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fefb2adc-25df-48bc-9c9e-2f41eb351de7_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1f45562e-94f1-4a51-a8fb-13fc8c7066ce_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a538231a-85da-4a57-b169-8824281914f2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period of recognition of unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5b9cb6ea-88d9-4626-a577-2cef15116e7f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life, Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e92df354-3bee-45db-9c94-0ea3796d1e1f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_bf064025-2835-4322-92a5-4899e1f1c71f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and ESPP stock purchases</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_3217ccb8-da22-4f82-b6c0-2487c964c43f_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_1ea444d2-998b-48c9-9493-ac853d6323d8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7cf08a8e-0500-42f6-9c9f-fcc594dd1110_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_ScheduleOfRoyaltyExpensesTableTextBlock_7907808c-fd08-47c1-adc4-650601f3ffbb_terseLabel_en-US" xlink:label="lab_axgn_ScheduleOfRoyaltyExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of royalty expenses</link:label>
    <link:label id="lab_axgn_ScheduleOfRoyaltyExpensesTableTextBlock_label_en-US" xlink:label="lab_axgn_ScheduleOfRoyaltyExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Royalty Expenses [Table Text Block]</link:label>
    <link:label id="lab_axgn_ScheduleOfRoyaltyExpensesTableTextBlock_documentation_en-US" xlink:label="lab_axgn_ScheduleOfRoyaltyExpensesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Royalty Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ScheduleOfRoyaltyExpensesTableTextBlock" xlink:href="axgn-20221231.xsd#axgn_ScheduleOfRoyaltyExpensesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_ScheduleOfRoyaltyExpensesTableTextBlock" xlink:to="lab_axgn_ScheduleOfRoyaltyExpensesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation_c58c92c6-cb4b-4e99-829d-fb3987f1093b_terseLabel_en-US" xlink:label="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity make-whole payment, alternative interpretation</link:label>
    <link:label id="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation_label_en-US" xlink:label="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Held To Maturity Make-Whole Payment, Alternative Interpretation</link:label>
    <link:label id="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation_documentation_en-US" xlink:label="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Held To Maturity Make-Whole Payment, Alternative Interpretation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation" xlink:to="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_695fa83a-a85f-460a-84a6-89855f882a9d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_173c6927-86d3-4a88-a689-6b2553615d39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_d8d20157-5e46-4599-bf31-e05379e35d42_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants received</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmount" xlink:to="lab_us-gaap_GovernmentAssistanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_af3a15ee-587a-49ff-b397-ce70a0c7929b_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e890b16f-2fc1-47f0-83c0-dd7d9c236303_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_cdaa2a1b-942a-493a-a5e6-53d43b4bdef1_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan&#8203;</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_3c78f984-d521-4fbb-9e3b-8e2017d4ae77_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_EmployeeStockPurchasePlanOfferingPeriod_0102f6f7-3eaf-4cd1-b9ec-769b70cc1ad1_terseLabel_en-US" xlink:label="lab_axgn_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_axgn_EmployeeStockPurchasePlanOfferingPeriod_label_en-US" xlink:label="lab_axgn_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Offering Period</link:label>
    <link:label id="lab_axgn_EmployeeStockPurchasePlanOfferingPeriod_documentation_en-US" xlink:label="lab_axgn_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmployeeStockPurchasePlanOfferingPeriod" xlink:href="axgn-20221231.xsd#axgn_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_EmployeeStockPurchasePlanOfferingPeriod" xlink:to="lab_axgn_EmployeeStockPurchasePlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_f904c950-e268-4c38-a725-9401c129bd11_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining term (years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_92c039c1-00c6-4e9c-8a34-5a0b9626551b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_NoticePeriodForTerminationOfAgreement_230270a3-b700-405d-8512-89c5b2282664_terseLabel_en-US" xlink:label="lab_axgn_NoticePeriodForTerminationOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notice period for termination of agreement</link:label>
    <link:label id="lab_axgn_NoticePeriodForTerminationOfAgreement_label_en-US" xlink:label="lab_axgn_NoticePeriodForTerminationOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notice Period For Termination Of Agreement</link:label>
    <link:label id="lab_axgn_NoticePeriodForTerminationOfAgreement_documentation_en-US" xlink:label="lab_axgn_NoticePeriodForTerminationOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the notice period for termination of the agreement by either parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_NoticePeriodForTerminationOfAgreement" xlink:href="axgn-20221231.xsd#axgn_NoticePeriodForTerminationOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_NoticePeriodForTerminationOfAgreement" xlink:to="lab_axgn_NoticePeriodForTerminationOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2ec987cf-3aab-4767-b48f-c12923e5d0ca_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_0f2e3688-6e4d-4b31-a84a-c9ed12fae1e2_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_58a26641-2841-4e21-9c41-e3f4be783799_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f89336c9-2f84-44a6-8a2a-489819717edf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5ac5b4af-e709-491b-8f87-267aacd5efcd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_c7d5702a-5ca9-4c3f-93c1-c405f68ce534_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_fb11ceb3-4067-4e3a-82e7-69be3fe84e6a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBuildings_2573b0b4-53e7-4768-90c2-dc533ef32ca0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBuildings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire Building</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBuildings_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBuildings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Buildings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBuildings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBuildings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBuildings" xlink:to="lab_us-gaap_PaymentsToAcquireBuildings" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_d623ecd5-2047-4567-ae34-2d2b026cd467_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LicenseFeeAmount_646d92aa-1683-4e8e-92ff-1dbf18a6a778_terseLabel_en-US" xlink:label="lab_axgn_LicenseFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee amount</link:label>
    <link:label id="lab_axgn_LicenseFeeAmount_label_en-US" xlink:label="lab_axgn_LicenseFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee amount</link:label>
    <link:label id="lab_axgn_LicenseFeeAmount_documentation_en-US" xlink:label="lab_axgn_LicenseFeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LicenseFeeAmount" xlink:href="axgn-20221231.xsd#axgn_LicenseFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LicenseFeeAmount" xlink:to="lab_axgn_LicenseFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7dfcdf4-e3ef-472f-b8af-b4992b05f859_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a604458c-d21f-4439-acad-91c61f8e8472_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7ed63124-0c24-4abf-b8bd-8c635bc0eab8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2727376f-2f0f-4050-830a-d7809c1ac946_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0842ba85-74e3-4984-96e4-95ebe24e283c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_11db6dc9-c810-47db-b48d-b95ceae8515f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive_797a1cbd-fa37-42ce-9391-03b8dcb88088_terseLabel_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive_label_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive_documentation_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive" xlink:to="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_c2832ebe-ab6a-47a7-9ef1-858e190e5438_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_17eb3927-e339-41ec-aa36-68ad5a2d4391_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a2e4fe2e-f1db-4e74-a104-31af25deb750_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_31cae98d-8b02-4d6a-a469-50d162b8a663_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Processing equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_RestrictedCashMember_cdbb48b6-7ac8-4b16-9630-2f596e584b29_terseLabel_en-US" xlink:label="lab_axgn_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_axgn_RestrictedCashMember_label_en-US" xlink:label="lab_axgn_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Member]</link:label>
    <link:label id="lab_axgn_RestrictedCashMember_documentation_en-US" xlink:label="lab_axgn_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RestrictedCashMember" xlink:href="axgn-20221231.xsd#axgn_RestrictedCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_RestrictedCashMember" xlink:to="lab_axgn_RestrictedCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_afc491a6-25a8-4fb8-9718-fbff15d9fd8c_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_ShareBasedCompensationAwardTrancheFourMember_da836e65-f392-495d-98e1-b4dbead2ca37_terseLabel_en-US" xlink:label="lab_axgn_ShareBasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Quarter, Over One Year</link:label>
    <link:label id="lab_axgn_ShareBasedCompensationAwardTrancheFourMember_label_en-US" xlink:label="lab_axgn_ShareBasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Award Tranche Four [Member]</link:label>
    <link:label id="lab_axgn_ShareBasedCompensationAwardTrancheFourMember_documentation_en-US" xlink:label="lab_axgn_ShareBasedCompensationAwardTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fourth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ShareBasedCompensationAwardTrancheFourMember" xlink:href="axgn-20221231.xsd#axgn_ShareBasedCompensationAwardTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_ShareBasedCompensationAwardTrancheFourMember" xlink:to="lab_axgn_ShareBasedCompensationAwardTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_af679259-296d-409f-b442-a7406089a17c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_669f4f76-41d8-4f8a-aab9-56a396523582_terseLabel_en-US" xlink:label="lab_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional costs associated with design build agreement</link:label>
    <link:label id="lab_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_label_en-US" xlink:label="lab_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Costs Associated with Design Build Agreement</link:label>
    <link:label id="lab_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_documentation_en-US" xlink:label="lab_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Costs Associated with Design Build Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xlink:href="axgn-20221231.xsd#axgn_AdditionalCostsAssociatedWithDesignBuildAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xlink:to="lab_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1c786bc1-e444-4b9a-bd34-512a31b6daed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_19358f6f-8b23-4250-a2f1-c9c2a0966da8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0ff09094-a327-4ce7-9e48-f1394774534b_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_4974aabb-9ede-4bd9-9483-023a975cda3f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_330f43bc-980c-41e1-b7e6-8735085781c6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_36a3a0f7-e905-4958-9987-2ac5395b1624_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oberland Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_c412c10e-f58e-492e-a646-e2d6428e1a0f_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_835cb636-98f3-46be-aacf-83a3e051f84f_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7f0444e4-aa6e-438c-a358-f6b4066a3dc5_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_bc148878-906e-4082-ad07-849e239e3b91_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ad10ca6a-883c-4efa-a2cc-48d8cd8e2db6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_abc28cba-c82a-4c20-ba3d-796481b03ce7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_d5bebb95-00c9-4ba1-92c5-9dc7f304e20e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_9e62c7d2-3ca1-452c-97f6-77a51222e5b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_b91896c6-0e43-4f23-b575-8fd28451303a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_a4f18289-f21d-4628-af35-caffcc22d906_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_306739e2-09cb-4f07-b627-25c50a885886_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0df7ce7f-334c-4ea2-bcbc-593089f19d51_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_9d561021-fde3-4d5c-b91d-c71e10f3486d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b3a7ce5c-a58b-4dae-8ab1-4a3ca5b51ebd_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5c99a051-8623-45c0-81ce-b8e25468a28a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_d6d910a6-fbc6-43f8-abb4-c1b6e92f6173_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest, net of capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5a322604-bd04-480d-8b5b-bb4cdd8def82_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share - basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_522fb05d-b349-44a6-ac9d-8b4d12ef8935_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_70d8c517-2392-495d-9d84-7359591e86f8_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreements</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_cbdad2c5-e43d-45e6-92f7-18df810d78fd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_8235545a-d98c-4bb6-ad90-8160a19dea02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of restricted stock vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_0ce7832f-0034-407d-85c2-972a89fe1f6f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_7152ae32-37ea-41bb-a42a-007584378dd5_terseLabel_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options Exercised and Employee Stock Purchase Plan</link:label>
    <link:label id="lab_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options Exercised and Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:to="lab_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_ca86622f-c984-4aab-8ad4-83df8e7d7d00_terseLabel_en-US" xlink:label="lab_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount available to participants per year</link:label>
    <link:label id="lab_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_label_en-US" xlink:label="lab_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Amount Available to Participants Per Year</link:label>
    <link:label id="lab_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_documentation_en-US" xlink:label="lab_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Amount Available to Participants Per Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xlink:href="axgn-20221231.xsd#axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xlink:to="lab_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_0aa950e2-5c9f-4e38-80f6-b447137ea9f1_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Axis]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_dbdc4efb-f971-434b-b457-85d3e5e96390_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_81a399ff-321f-49ff-abbf-3d32a9f50878_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_3f355cdc-ff44-4718-a12a-283180cc93e6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_debbe170-810b-48f4-95df-3f85e67375cf_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3381fd7d-9628-472a-917c-915a91bc3d1a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2ca3bcee-fee2-4be2-8141-1456cb6aedba_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e7863fac-9703-4b5b-833b-c97933ccc341_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_049243b1-611b-4db1-823a-0eb39eb16665_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade_9d15f285-312f-4f4e-a798-891e2d086e12_terseLabel_en-US" xlink:label="lab_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for which quarterly interest payments are required</link:label>
    <link:label id="lab_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade_label_en-US" xlink:label="lab_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period For Which Quarterly Interest Payments Should Be Made</link:label>
    <link:label id="lab_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade_documentation_en-US" xlink:label="lab_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Period For Which Quarterly Interest Payments Should Be Made</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade" xlink:to="lab_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_e73206b4-9f1f-4a2c-8a56-7a1db9efb112_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_e9fc6cd1-23fa-48e1-a999-dabc87617026_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6a4dec63-304a-4e35-87aa-ce3063114f6e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_MandatoryPrepaymentEventBefore2024Member_dabac7dc-4146-477a-97ba-c22757d826a0_terseLabel_en-US" xlink:label="lab_axgn_MandatoryPrepaymentEventBefore2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of mandatory prepayment before 2024</link:label>
    <link:label id="lab_axgn_MandatoryPrepaymentEventBefore2024Member_label_en-US" xlink:label="lab_axgn_MandatoryPrepaymentEventBefore2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mandatory Prepayment Event Before 2024 [Member]</link:label>
    <link:label id="lab_axgn_MandatoryPrepaymentEventBefore2024Member_documentation_en-US" xlink:label="lab_axgn_MandatoryPrepaymentEventBefore2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mandatory Prepayment Event Before 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MandatoryPrepaymentEventBefore2024Member" xlink:href="axgn-20221231.xsd#axgn_MandatoryPrepaymentEventBefore2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_MandatoryPrepaymentEventBefore2024Member" xlink:to="lab_axgn_MandatoryPrepaymentEventBefore2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a2e6ee1f-e6d6-4c8a-83fc-2cbc77875415_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5983171f-3f98-4bf1-8667-00adfee699bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e1006dd3-695f-459a-827d-4dc8dd69859e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_72f1e555-08d5-4cc4-8f69-3bfe1261648f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3d5cc22f-f77f-4e47-b9cb-f389572e3c40_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value instruments classified Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_f015e885-4145-4b97-80ea-0c82ec35addb_terseLabel_en-US" xlink:label="lab_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service agreement amount paid upon execution of agreement</link:label>
    <link:label id="lab_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_label_en-US" xlink:label="lab_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement Amount Paid Upon Execution Of Agreement</link:label>
    <link:label id="lab_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_documentation_en-US" xlink:label="lab_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement Amount Paid Upon Execution Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xlink:href="axgn-20221231.xsd#axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xlink:to="lab_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_APCFacilityMember_f8d0fbf8-63ff-4cb1-a06b-be8c077fed3d_terseLabel_en-US" xlink:label="lab_axgn_APCFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Facility</link:label>
    <link:label id="lab_axgn_APCFacilityMember_label_en-US" xlink:label="lab_axgn_APCFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Facility [Member]</link:label>
    <link:label id="lab_axgn_APCFacilityMember_documentation_en-US" xlink:label="lab_axgn_APCFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_APCFacilityMember" xlink:href="axgn-20221231.xsd#axgn_APCFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_APCFacilityMember" xlink:to="lab_axgn_APCFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9228d255-892c-41f3-ab1a-9fd67af3870d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2978c6e8-a7c4-46d5-b915-f5ead6cd68cf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_5cf21442-73f2-45d9-ae34-9c1c1691ce5b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_78bdb8e3-b8e6-4c26-b07e-e782ca91bab5_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5a289afc-4b76-4794-b3cd-c226722c8c45_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7e5033b7-29b9-4da3-aaf5-828a79c4f3b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense of consolidated statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_06041d2f-884b-48a4-9463-19062428e806_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9b8c59fa-495f-4236-8319-266dad52cd39_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_28961ba2-843d-4465-b912-207e31d6b83b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1b48950b-c29a-45a2-8d98-96236d4158eb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_27d8afbf-8907-4587-92f1-a31412d1463c_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Domain]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_abda1771-8647-4380-954b-f963465ee2bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree_f8e82f05-bdae-40fe-aa1f-ab7e3999ed2e_terseLabel_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree_label_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, Year Three</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree_documentation_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree" xlink:to="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_NoncashOrPartNoncashConversionOption_a0db2e92-83b9-4a9b-baaa-4ef643aa9543_terseLabel_en-US" xlink:label="lab_axgn_NoncashOrPartNoncashConversionOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of the Credit Facility option</link:label>
    <link:label id="lab_axgn_NoncashOrPartNoncashConversionOption_label_en-US" xlink:label="lab_axgn_NoncashOrPartNoncashConversionOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Conversion, Option</link:label>
    <link:label id="lab_axgn_NoncashOrPartNoncashConversionOption_documentation_en-US" xlink:label="lab_axgn_NoncashOrPartNoncashConversionOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Conversion, Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_NoncashOrPartNoncashConversionOption" xlink:href="axgn-20221231.xsd#axgn_NoncashOrPartNoncashConversionOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_NoncashOrPartNoncashConversionOption" xlink:to="lab_axgn_NoncashOrPartNoncashConversionOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_15ca2e93-ffdc-42e0-ac72-66625904efdb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c26706ee-22b8-4ead-96d5-c68007055fcf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_67f90c2b-df25-4281-801f-b7972280fde9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant inputs in liability valuation</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_b29d22b0-9ed1-411a-b53c-f6575223d436_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_03f0fc2c-fb4b-400c-9ffc-dace17a8f007_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_cf1ded60-6f34-4cb7-b7e1-0a8683aaabba_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-term Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Excluding Long-Term Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:to="lab_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_PercentageOfAchievementOfAwardIssued_84cb6167-c300-4239-8f83-b5b77339cea3_terseLabel_en-US" xlink:label="lab_axgn_PercentageOfAchievementOfAwardIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of award issued (as a percent)</link:label>
    <link:label id="lab_axgn_PercentageOfAchievementOfAwardIssued_label_en-US" xlink:label="lab_axgn_PercentageOfAchievementOfAwardIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Achievement Of Award Issued</link:label>
    <link:label id="lab_axgn_PercentageOfAchievementOfAwardIssued_documentation_en-US" xlink:label="lab_axgn_PercentageOfAchievementOfAwardIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Achievement Of Award Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PercentageOfAchievementOfAwardIssued" xlink:href="axgn-20221231.xsd#axgn_PercentageOfAchievementOfAwardIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_PercentageOfAchievementOfAwardIssued" xlink:to="lab_axgn_PercentageOfAchievementOfAwardIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_4fa6a47d-3189-4470-8637-8ed23b145c17_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_45ea0cbb-2af0-4889-952d-fa05ca221fd1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e99b6626-7c0b-47cc-9181-ecce902b12d7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7422e28a-51de-41ad-8a0a-2950c8b3f4eb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $650 and $276, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_76dac391-73ff-402b-b14f-3e4bcae85a70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_38257e2f-f1e5-4aab-8794-5e88b1924ca4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_ae132aaa-c67e-47ab-a8db-fbbfe812faaa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_c458394c-6466-484b-ab60-41e4168be730_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_77d37fbc-9f33-4356-8951-6528592825dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_ProceedsFromGrantorsInvestingActivities_51e8f219-9c8a-4027-a86f-cd0186df6dec_terseLabel_en-US" xlink:label="lab_axgn_ProceedsFromGrantorsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic development grant proceeds</link:label>
    <link:label id="lab_axgn_ProceedsFromGrantorsInvestingActivities_label_en-US" xlink:label="lab_axgn_ProceedsFromGrantorsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Grantors, Investing Activities</link:label>
    <link:label id="lab_axgn_ProceedsFromGrantorsInvestingActivities_documentation_en-US" xlink:label="lab_axgn_ProceedsFromGrantorsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Grantors, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ProceedsFromGrantorsInvestingActivities" xlink:href="axgn-20221231.xsd#axgn_ProceedsFromGrantorsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_ProceedsFromGrantorsInvestingActivities" xlink:to="lab_axgn_ProceedsFromGrantorsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ad98537e-5e57-4d38-81ff-315bae93700c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_efc75c26-8dce-44e5-81aa-4a28537a40cd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_2856fba1-ce89-44da-9043-3c5bbb1ffde5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1a69fae1-6d6d-4536-a63c-f0976c1499a5_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_0ad688a1-dab4-4061-b716-89d01cf8af62_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_4de90f33-f884-4df0-b4d4-5e405a16823d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for debt portion of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7cb364c4-57e5-4f5f-a720-876ba442396a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_28b572fa-6004-4693-b584-b4ceddf22709_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_57c786eb-aad2-4403-ac7a-3653c760b9e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_19ec3825-9857-4126-96df-209ebaf7a2c1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_861cbe34-06c7-4197-bf0f-b28988258daf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_819a42c7-82f3-4897-9672-469fe10398f6_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_07b41433-93b6-43d5-957e-e1e8859764aa_terseLabel_en-US" xlink:label="lab_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount from market value on common stock</link:label>
    <link:label id="lab_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_label_en-US" xlink:label="lab_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Discount from Market Value on Common Stock</link:label>
    <link:label id="lab_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_documentation_en-US" xlink:label="lab_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Discount from Market Value on Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xlink:href="axgn-20221231.xsd#axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xlink:to="lab_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_50c25fc9-060d-4e2f-856b-dfb15b0b0161_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_17d1614d-0e88-48eb-a41d-d6b3a88795a3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6d2c7b74-d40d-4768-aecf-29b5f0254696_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_bec1d6f7-03be-4da9-b664-4f9bda3c4bc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_1432df79-fe06-4894-824b-ec865256b389_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent items and other deductions</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DeferredTaxLiabilitiesRightOfUseAsset_c224cc3d-5dd4-434f-b021-7b63b5f1f8f2_negatedLabel_en-US" xlink:label="lab_axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_axgn_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Asset</link:label>
    <link:label id="lab_axgn_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax consequences attributable to taxable temporary differences derived from right-of-use asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_axgn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_cac7b7c1-3992-4998-bbc4-5b81e035580e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_4a98d363-3abf-4d97-8738-492ba8f386da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered by employees to pay tax withholdings</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_accc2810-617c-4483-83da-075a87e9a866_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_5fc82aab-da5e-4d59-89f6-15f66c72ddb8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_08041c7b-3070-457c-9099-05a7c4b65761_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_32cf30cd-6633-4d67-8133-bea7bd7f9588_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_0244b0dd-8850-4a24-b112-f859a3a56527_terseLabel_en-US" xlink:label="lab_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty stack cap for royalties paid to more than one licensor for sales of the same product</link:label>
    <link:label id="lab_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_label_en-US" xlink:label="lab_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Capping Royalties for Multiple Royalty Payments to Licensors</link:label>
    <link:label id="lab_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_documentation_en-US" xlink:label="lab_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xlink:href="axgn-20221231.xsd#axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xlink:to="lab_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_d794f246-d1d0-48d0-9020-cd84bbc49552_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized intangible assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_13a67df8-6f44-426f-9f6e-28b4e7c4a0b6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_265ccfc8-3e9a-4d09-8c7e-f5ef5a9e959f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_374d8483-251b-4a35-a67e-ee4b403de9c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock unit activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_c43e4460-6d74-4a2d-aa4b-b7abfb1824e4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_c582eb9c-b20a-46c6-9094-76a18fc52519_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5d7137d7-8ed5-4d38-9115-3c719e49345e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2598175d-5d69-4cc4-a340-61c489f4c17e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_90ee5627-e949-48d9-9767-f97e4d5d1db6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_70881cd9-076d-496f-b81a-54da468721ed_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e7c5d385-e42f-42bc-96ac-884fa39c2c66_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2ac31985-bbbc-4c21-9e7c-34f81b2130d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6386bbd8-06f4-496e-b619-9c91921bb67f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_c3ca03b9-0d12-4bdd-8fa5-7f4defa36451_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares surrendered by employees to pay tax withholdings (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_fd686e71-76df-4b16-9b99-81c663e7e6aa_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_e9cafbce-d542-4c50-a3d1-709d47a84480_terseLabel_en-US" xlink:label="lab_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obtaining a right-of-use asset in exchange for a lease liability</link:label>
    <link:label id="lab_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_label_en-US" xlink:label="lab_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Right of Use Assets and Operating Lease Liability</link:label>
    <link:label id="lab_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_documentation_en-US" xlink:label="lab_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the noncash amount of right of use assets and operating lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" xlink:href="axgn-20221231.xsd#axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" xlink:to="lab_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90b48ff1-27de-48e7-b4d8-b5e26d5a4c24_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_58fa6ef8-f468-47f0-ba87-341eaac4b9d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLandHeldForUse_efe5b0fe-848e-4a21-bcae-fd473bd2c0b3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLandHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire Land</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLandHeldForUse_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLandHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Land Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLandHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLandHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLandHeldForUse" xlink:to="lab_us-gaap_PaymentsToAcquireLandHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1f323c96-afca-4de4-ab92-4061318b4236_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_496971c4-748c-494c-8b39-cdf4d1ab5c54_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9f12fd7e-39a8-4649-b3bd-ddc0fc64a538_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_065a64ab-34ad-46e3-84a1-0b8ebdf0dd85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_184ce814-30a9-4b23-83a0-5f3aa1f3136e_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_PurchasePriceOfCommonStockCalculationPeriod_ba21d7f5-5db6-4522-b039-bf77fd650f29_terseLabel_en-US" xlink:label="lab_axgn_PurchasePriceOfCommonStockCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Moving average of closing stock</link:label>
    <link:label id="lab_axgn_PurchasePriceOfCommonStockCalculationPeriod_label_en-US" xlink:label="lab_axgn_PurchasePriceOfCommonStockCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Common Stock Calculation Period</link:label>
    <link:label id="lab_axgn_PurchasePriceOfCommonStockCalculationPeriod_documentation_en-US" xlink:label="lab_axgn_PurchasePriceOfCommonStockCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Price Of Common Stock Calculation Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PurchasePriceOfCommonStockCalculationPeriod" xlink:href="axgn-20221231.xsd#axgn_PurchasePriceOfCommonStockCalculationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_PurchasePriceOfCommonStockCalculationPeriod" xlink:to="lab_axgn_PurchasePriceOfCommonStockCalculationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_51655153-fe07-4499-af38-26669f87c675_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_053a68ca-d31b-4792-acd7-72a8cca3abe5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_552bfddc-0a3d-4952-8370-578de905a335_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_42d0bde9-f212-4071-884b-58620ebdcc6d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_50ccd772-62c4-40d7-9958-3755cef41531_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1b34cae3-5008-4f9b-956e-2a0a2a702e26_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DefinedContributionPlanEmployeeContributionPercentMatched_7e48b784-18c9-4c65-b2d8-e083ee745c6d_terseLabel_en-US" xlink:label="lab_axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contribution matched, percent</link:label>
    <link:label id="lab_axgn_DefinedContributionPlanEmployeeContributionPercentMatched_label_en-US" xlink:label="lab_axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employee Contribution, Percent Matched</link:label>
    <link:label id="lab_axgn_DefinedContributionPlanEmployeeContributionPercentMatched_documentation_en-US" xlink:label="lab_axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contribution, as a percent of annual salary, that is matched by the employer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xlink:href="axgn-20221231.xsd#axgn_DefinedContributionPlanEmployeeContributionPercentMatched"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xlink:to="lab_axgn_DefinedContributionPlanEmployeeContributionPercentMatched" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_db3ade2c-8215-4fc0-b91d-9a69ac640021_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_3861e35b-48a0-4e58-8b07-a3b1efc7d1a1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_a13f8280-0b75-47a1-9861-7f7df4fad386_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DeferredTaxAssetsLiabilities_15275dc6-70ef-4e1f-9bf2-ea6ea7b8dbdb_totalLabel_en-US" xlink:label="lab_axgn_DeferredTaxAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_axgn_DeferredTaxAssetsLiabilities_label_en-US" xlink:label="lab_axgn_DeferredTaxAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets (Liabilities)</link:label>
    <link:label id="lab_axgn_DeferredTaxAssetsLiabilities_documentation_en-US" xlink:label="lab_axgn_DeferredTaxAssetsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxAssetsLiabilities" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxAssetsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DeferredTaxAssetsLiabilities" xlink:to="lab_axgn_DeferredTaxAssetsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_93cdb5f2-9091-42fe-be23-e4e15767bcd2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2d7efdcb-82a8-4598-9541-82d3ac4e7e9d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_47f42612-7298-4036-b08f-699b66ad2b2d_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_EstimatedCostRelatingToDesignBuildAgreement_df92a2c4-e608-4ea3-b626-058a56716e01_terseLabel_en-US" xlink:label="lab_axgn_EstimatedCostRelatingToDesignBuildAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated cost relating to design build agreement</link:label>
    <link:label id="lab_axgn_EstimatedCostRelatingToDesignBuildAgreement_label_en-US" xlink:label="lab_axgn_EstimatedCostRelatingToDesignBuildAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Cost Relating to Design Build Agreement</link:label>
    <link:label id="lab_axgn_EstimatedCostRelatingToDesignBuildAgreement_documentation_en-US" xlink:label="lab_axgn_EstimatedCostRelatingToDesignBuildAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Cost Relating to Design Build Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EstimatedCostRelatingToDesignBuildAgreement" xlink:href="axgn-20221231.xsd#axgn_EstimatedCostRelatingToDesignBuildAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_EstimatedCostRelatingToDesignBuildAgreement" xlink:to="lab_axgn_EstimatedCostRelatingToDesignBuildAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_9b4c0727-2c31-4bab-bf3f-1f976f3af2de_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charitable contributions</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_756f4939-0d21-4937-b354-4103382b13b7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_OperatingLeasesAbstract_ad726a4c-b3f1-4c85-8bb4-83c5bdb24236_terseLabel_en-US" xlink:label="lab_axgn_OperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_axgn_OperatingLeasesAbstract_label_en-US" xlink:label="lab_axgn_OperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases [Abstract]</link:label>
    <link:label id="lab_axgn_OperatingLeasesAbstract_documentation_en-US" xlink:label="lab_axgn_OperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingLeasesAbstract" xlink:href="axgn-20221231.xsd#axgn_OperatingLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_OperatingLeasesAbstract" xlink:to="lab_axgn_OperatingLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_17c854de-7e68-48b4-be54-6ff6cb291105_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_128b0d1c-6efb-4208-8a8d-5e56b4f93c8a_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_58e7d530-1656-4fe6-ae2f-d414ad2d3066_terseLabel_en-US" xlink:label="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer's Contribution, First Tranche</link:label>
    <link:label id="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_label_en-US" xlink:label="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Axogen401k Plan Employer Matching Contribution Tranche1 [Member]</link:label>
    <link:label id="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_documentation_en-US" xlink:label="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the first tranche of the AxoGen 401K plan where the employer matches a percent of employee contributions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xlink:href="axgn-20221231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xlink:to="lab_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2cf877b8-de3d-4584-8b6e-735db25d192b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value per share; 100,000,000 shares authorized; 42,445,517 and 41,736,950 shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5babec7e-f2ed-4b29-9b0b-c149cccaa5f4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_TwoThousandTwentyOnePerformanceShareUnitMember_160b01ce-2be1-43cd-a263-3e2c1db37ce1_terseLabel_en-US" xlink:label="lab_axgn_TwoThousandTwentyOnePerformanceShareUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 PSUs</link:label>
    <link:label id="lab_axgn_TwoThousandTwentyOnePerformanceShareUnitMember_label_en-US" xlink:label="lab_axgn_TwoThousandTwentyOnePerformanceShareUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty-One Performance Share Unit [Member]</link:label>
    <link:label id="lab_axgn_TwoThousandTwentyOnePerformanceShareUnitMember_documentation_en-US" xlink:label="lab_axgn_TwoThousandTwentyOnePerformanceShareUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty-One Performance Share Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TwoThousandTwentyOnePerformanceShareUnitMember" xlink:href="axgn-20221231.xsd#axgn_TwoThousandTwentyOnePerformanceShareUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_TwoThousandTwentyOnePerformanceShareUnitMember" xlink:to="lab_axgn_TwoThousandTwentyOnePerformanceShareUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1f1b65c4-6006-4679-ae28-b4c582732e47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_PerformanceSharesBiologicLicenseApplicationMember_01760ef2-e393-4b70-aec7-73f41517902f_terseLabel_en-US" xlink:label="lab_axgn_PerformanceSharesBiologicLicenseApplicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSU - BLA Milestones</link:label>
    <link:label id="lab_axgn_PerformanceSharesBiologicLicenseApplicationMember_label_en-US" xlink:label="lab_axgn_PerformanceSharesBiologicLicenseApplicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares Biologic License Application [Member]</link:label>
    <link:label id="lab_axgn_PerformanceSharesBiologicLicenseApplicationMember_documentation_en-US" xlink:label="lab_axgn_PerformanceSharesBiologicLicenseApplicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares or units awarded based on Biologic License Application milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PerformanceSharesBiologicLicenseApplicationMember" xlink:href="axgn-20221231.xsd#axgn_PerformanceSharesBiologicLicenseApplicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_PerformanceSharesBiologicLicenseApplicationMember" xlink:to="lab_axgn_PerformanceSharesBiologicLicenseApplicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7b112a48-603f-4e94-9edf-7a582c85ce29_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_27e951e2-a549-4b10-8a2c-fc9286da243d_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease costs</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1619f1d-185d-429d-a5c9-23561012aef0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43605ecc-52a1-4411-82d1-2a29b600c725_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d18e156-0dc0-4ceb-9238-1d4bfffbca83_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_423dcd3b-0cb2-41aa-a4c3-f092714e4733_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_OperatingAndFinancingLeaseLiability_866a5999-8dee-4fef-b66d-18e388d5ad3a_totalLabel_en-US" xlink:label="lab_axgn_OperatingAndFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liability</link:label>
    <link:label id="lab_axgn_OperatingAndFinancingLeaseLiability_label_en-US" xlink:label="lab_axgn_OperatingAndFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Financing Lease, Liability</link:label>
    <link:label id="lab_axgn_OperatingAndFinancingLeaseLiability_documentation_en-US" xlink:label="lab_axgn_OperatingAndFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Financing Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingAndFinancingLeaseLiability" xlink:href="axgn-20221231.xsd#axgn_OperatingAndFinancingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_OperatingAndFinancingLeaseLiability" xlink:to="lab_axgn_OperatingAndFinancingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_35ff72a5-1c3e-4b89-a7d8-be48c758fd52_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d34e489a-857c-4b45-a593-958ddd78248f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0a8db325-2117-4cd4-a2b6-074331e70518_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f6725e91-7cbb-4697-b6e9-4a25db0440da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_9802b190-5a3c-470c-b35a-0475882260b4_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable economic development grants from state and local authorities (up to)</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_337635f7-a264-4512-99bc-2be4c3b5967d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_8b4468b9-870f-4a28-bcb5-b379f4066266_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1499852c-35ee-4692-9ad9-0e7ad7bafcce_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of fixed assets in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_7b107257-a214-4779-9d7e-b66886f245d8_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_3bddb343-3159-4ef2-b71e-6128a5cfa64c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of warrants outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f4b96fee-a8ab-4b97-9686-ee02d58b0a77_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_7d241f0a-42a9-4192-945a-7271fa3b55fd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of long-term lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_9bc87ed5-2b86-4ede-b2ef-6a4edb4a8932_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Vesting Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31420aaf-8202-4950-84d6-bfa179339765_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_67b13f75-3236-4534-af55-8cb95a3e7af0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2925a39f-d8d7-4122-8a1b-2fb1e8402d3b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d690ee63-2134-4065-a702-8094f1659e34_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_27b31912-3e81-4bac-8419-411bddf99a5c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_3c66c1de-577a-4823-a913-cd30bff1155b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period of intangible assets (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_bd261a17-97c2-47db-99c6-c45305ee9919_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_20408b37-843a-4b8d-8740-bd3dae83bd9d_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_TwoThousandTwentyPerformanceShareUnitMember_541734ba-9f8a-4052-8431-608dc0cc5337_terseLabel_en-US" xlink:label="lab_axgn_TwoThousandTwentyPerformanceShareUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 PSUs</link:label>
    <link:label id="lab_axgn_TwoThousandTwentyPerformanceShareUnitMember_label_en-US" xlink:label="lab_axgn_TwoThousandTwentyPerformanceShareUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Performance Share Unit [Member]</link:label>
    <link:label id="lab_axgn_TwoThousandTwentyPerformanceShareUnitMember_documentation_en-US" xlink:label="lab_axgn_TwoThousandTwentyPerformanceShareUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty Performance Share Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TwoThousandTwentyPerformanceShareUnitMember" xlink:href="axgn-20221231.xsd#axgn_TwoThousandTwentyPerformanceShareUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_TwoThousandTwentyPerformanceShareUnitMember" xlink:to="lab_axgn_TwoThousandTwentyPerformanceShareUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_0dc405f9-feba-462c-a271-2bc5893eda43_verboseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projects in Process</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_98ccd4ef-7168-4d1b-9a4c-526836ea7d9d_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0f5541c1-6e40-48fa-b2ee-974d4cb7f781_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c0b97472-5d8a-4b96-adf8-8bb7202a3d42_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5bcd45ba-361d-42a4-aaae-361ffbb41c75_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_7147d368-cd26-4aeb-97a5-48f768d5a593_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fb1ae1f1-ce25-4890-ac4f-72acd81e9ec6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_58664d5d-dcea-48b4-885e-97e411453d59_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3e9a5e88-c462-48f1-b597-8c41ec8f6ab2_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e8f53ab1-c3ec-44c5-bbad-abe47fe7db03_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_AxoGen2010StockIncentivePlanMember_dd9eeedb-ebdb-487f-99f0-61cc0048fdb2_terseLabel_en-US" xlink:label="lab_axgn_AxoGen2010StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Axogen Plan</link:label>
    <link:label id="lab_axgn_AxoGen2010StockIncentivePlanMember_label_en-US" xlink:label="lab_axgn_AxoGen2010StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Axo Gen2010 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_axgn_AxoGen2010StockIncentivePlanMember_documentation_en-US" xlink:label="lab_axgn_AxoGen2010StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The AxoGen 2010 Stock Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AxoGen2010StockIncentivePlanMember" xlink:href="axgn-20221231.xsd#axgn_AxoGen2010StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_AxoGen2010StockIncentivePlanMember" xlink:to="lab_axgn_AxoGen2010StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_PatentsAndLicenseAgreementsMember_8e5a5c51-313b-4afd-94bf-9e833a730829_terseLabel_en-US" xlink:label="lab_axgn_PatentsAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And License Agreements</link:label>
    <link:label id="lab_axgn_PatentsAndLicenseAgreementsMember_label_en-US" xlink:label="lab_axgn_PatentsAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And License Agreements [Member]</link:label>
    <link:label id="lab_axgn_PatentsAndLicenseAgreementsMember_documentation_en-US" xlink:label="lab_axgn_PatentsAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And License Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PatentsAndLicenseAgreementsMember" xlink:href="axgn-20221231.xsd#axgn_PatentsAndLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_PatentsAndLicenseAgreementsMember" xlink:to="lab_axgn_PatentsAndLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_AssetsAndLiabilitiesLesseeTableTextBlock_a99f849a-abf9-47d4-b12f-832ceaf68618_terseLabel_en-US" xlink:label="lab_axgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental balance sheet information</link:label>
    <link:label id="lab_axgn_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_axgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_axgn_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_axgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="axgn-20221231.xsd#axgn_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_axgn_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_920bda2a-def6-4c0f-ab07-5c16f4be3b40_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_00aa44a2-0fa9-410e-afa2-216476693cdc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1df8df24-f09f-4cb8-8581-b70b2988c420_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less - unamortized debt discount and deferred financing fees</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_PrepaymentProbabilityEventDomain_8a4feb2c-57f5-4495-adbd-880a269d0a54_terseLabel_en-US" xlink:label="lab_axgn_PrepaymentProbabilityEventDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Probability Event [Domain]</link:label>
    <link:label id="lab_axgn_PrepaymentProbabilityEventDomain_label_en-US" xlink:label="lab_axgn_PrepaymentProbabilityEventDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Probability Event [Domain]</link:label>
    <link:label id="lab_axgn_PrepaymentProbabilityEventDomain_documentation_en-US" xlink:label="lab_axgn_PrepaymentProbabilityEventDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Probability Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PrepaymentProbabilityEventDomain" xlink:href="axgn-20221231.xsd#axgn_PrepaymentProbabilityEventDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_PrepaymentProbabilityEventDomain" xlink:to="lab_axgn_PrepaymentProbabilityEventDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember_acec6d60-c018-4b1c-ad68-ca02ebf6ff43_terseLabel_en-US" xlink:label="lab_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TPC Investments II LP</link:label>
    <link:label id="lab_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember_label_en-US" xlink:label="lab_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TPC Investments II LP, A Wholly Owned Subsidiary Of Oberland Capital [Member]</link:label>
    <link:label id="lab_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember_documentation_en-US" xlink:label="lab_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TPC Investments II LP, A Wholly Owned Subsidiary Of Oberland Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember" xlink:href="axgn-20221231.xsd#axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember" xlink:to="lab_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_42ed2b71-ef60-4e7a-8c29-d43d2c742689_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ae49a99c-9126-4c79-8579-99fa032a3e94_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes - net of Federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights_ed4c8df2-858f-4573-b0da-32a3ee6d51b4_terseLabel_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of Credit Facility Option, net of settlement (in shares)</link:label>
    <link:label id="lab_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights_label_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Settlement of Warrants and Rights</link:label>
    <link:label id="lab_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights_documentation_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Settlement of Warrants and Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights" xlink:to="lab_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0d5100de-892e-4af7-88ac-e297fdffec0d_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Differences between the carrying amount of assets and liabilities for financial reporting purposes</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8cac3843-8bdb-44af-a420-2e4d8724d1bf_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn_95d381ca-baa5-45a2-a0f0-f7c97c0fd883_terseLabel_en-US" xlink:label="lab_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Make-whole payment, minimum required internal rate of return</link:label>
    <link:label id="lab_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn_label_en-US" xlink:label="lab_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Minimum Required Internal Rate Of Return</link:label>
    <link:label id="lab_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn_documentation_en-US" xlink:label="lab_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Minimum Required Internal Rate Of Return</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn" xlink:to="lab_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c3eeb52d-3fe8-492c-91e8-edd66cd36660_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future amortization</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_54253718-05d3-4d3b-959a-c3a2762e5c22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value included in net loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b0812a7b-b10c-42ec-8927-417f1978ed9a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_b9303c70-bfc7-49ad-8f9d-5ee9407e111f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_6239cc40-4e6c-4899-9d41-f4b352a581e6_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_42e5ce57-e483-4322-9853-471a5e148799_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ff58440c-1a3d-4da9-8c14-41350bc8afbe_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_172acad7-2cc5-4e0a-986c-d66592a7d015_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b0f62ab7-5e88-4dbc-b208-a040a77ceb6a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_a2a3588c-114b-41ae-9e4c-71811682a651_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of debt discount and financing fees</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f340eef0-904f-4f3e-92af-ac5c21bfc747_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e3844918-22b9-47d7-9af6-bfb5872ea59b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a23b5079-c4a6-4ee0-8d9b-dbf3235d7d5f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_466597b7-6b23-4168-b0ac-6eca413927c7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_a362d411-db4a-44c6-885e-5e5bf8aa7297_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_cb76d24f-abe7-4c08-8ee9-1076f6ced880_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d0c265da-c7ba-4c4c-9157-7c4749490945_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a993db57-bdd2-4241-9038-3a1c54317f3e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3bb682bf-50c1-4485-be47-dd4f70efcdf1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation_3cf796e8-638d-43fb-a6e4-f60367bdbb4b_terseLabel_en-US" xlink:label="lab_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash previously deposited at bank closed by California Department of Financial Protection and Innovation</link:label>
    <link:label id="lab_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation_label_en-US" xlink:label="lab_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Deposited At Bank Closed By California Department Of Financial Protection And Innovation</link:label>
    <link:label id="lab_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation_documentation_en-US" xlink:label="lab_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Deposited At Bank Closed By California Department Of Financial Protection And Innovation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation" xlink:href="axgn-20221231.xsd#axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation" xlink:to="lab_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeAxis_f58ac16a-a40f-4310-97a1-d4df1a41a54a_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeAxis_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis" xlink:to="lab_us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ab19dd68-c134-4f39-9722-7436f9fbb82f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_c44623a8-e01e-4db2-8a9c-a9ec132d46d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Amounts Attributable to Parent, Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_962df6f4-641d-4604-b375-287e92df88d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_NumberOfPotentialSettlementScenarios_5c7dcffd-352d-4e6e-a641-e88c8cb7f1fd_terseLabel_en-US" xlink:label="lab_axgn_NumberOfPotentialSettlementScenarios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential settlement scenarios</link:label>
    <link:label id="lab_axgn_NumberOfPotentialSettlementScenarios_label_en-US" xlink:label="lab_axgn_NumberOfPotentialSettlementScenarios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Potential Settlement Scenarios</link:label>
    <link:label id="lab_axgn_NumberOfPotentialSettlementScenarios_documentation_en-US" xlink:label="lab_axgn_NumberOfPotentialSettlementScenarios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Potential Settlement Scenarios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_NumberOfPotentialSettlementScenarios" xlink:href="axgn-20221231.xsd#axgn_NumberOfPotentialSettlementScenarios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_NumberOfPotentialSettlementScenarios" xlink:to="lab_axgn_NumberOfPotentialSettlementScenarios" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_4ea9ca3f-f36e-42da-9ef2-cdedf4202811_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_63aa9ab0-e5ff-4698-9d92-9f8ea057294d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d081b845-beb7-425d-8a27-0d1a7fa2f0dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value financial assets measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_cad1a1b4-6a3c-4118-9226-8e4934b9f6f4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4f1c8e51-4d2f-4358-abe4-455954a81778_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8496f884-ecc3-40f6-bd9e-4d6830bcac84_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs related to non-vested stock options and restricted stock awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_c39833f5-a2cb-417e-a993-a92370d4c1e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_154d2070-842a-4afb-ae12-af672e7e0243_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_79677c2c-1dcd-405c-a0a9-f203c64020c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9436dfa8-4700-4316-884b-c6505ced733d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_858ac9db-a3de-49b4-ae52-48d568d7da49_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_5c1c30a8-242a-4aec-8aa1-92053d14725a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_032f68d1-8eda-4dfe-94ac-8dcb8664c53a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_d79cc0d4-2537-47b7-9876-de4201fce300_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_c95c2615-edb1-4ccc-9517-7fb9825c2c1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_4233ecff-a48f-4d7a-9d18-0adc56315d47_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_ShareBasedCompensationExpenseForfeitedOrReversed_06ff5dbe-4e7f-4ab0-95e2-8f6a2492489e_terseLabel_en-US" xlink:label="lab_axgn_ShareBasedCompensationExpenseForfeitedOrReversed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of grants reversed</link:label>
    <link:label id="lab_axgn_ShareBasedCompensationExpenseForfeitedOrReversed_label_en-US" xlink:label="lab_axgn_ShareBasedCompensationExpenseForfeitedOrReversed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense, Forfeited Or Reversed</link:label>
    <link:label id="lab_axgn_ShareBasedCompensationExpenseForfeitedOrReversed_documentation_en-US" xlink:label="lab_axgn_ShareBasedCompensationExpenseForfeitedOrReversed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense, Forfeited Or Reversed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ShareBasedCompensationExpenseForfeitedOrReversed" xlink:href="axgn-20221231.xsd#axgn_ShareBasedCompensationExpenseForfeitedOrReversed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_ShareBasedCompensationExpenseForfeitedOrReversed" xlink:to="lab_axgn_ShareBasedCompensationExpenseForfeitedOrReversed" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure_a1d68a52-4105-477c-bca8-d688e76d3809_terseLabel_en-US" xlink:label="lab_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payment percentage</link:label>
    <link:label id="lab_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure_label_en-US" xlink:label="lab_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percentage Of Additional Payment On Outstanding Loan Based On Royalty Structure</link:label>
    <link:label id="lab_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure_documentation_en-US" xlink:label="lab_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Percentage Of Additional Payment On Outstanding Loan Based On Royalty Structure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure" xlink:to="lab_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_fcffed2f-301c-4a47-82dc-b4d6dc4d8217_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_ef8374bd-cf7f-405a-a9d6-f33272471e2d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DeferredTaxAssetsInterestLimitation_a62e4e0a-8283-44bf-89bd-845964116811_terseLabel_en-US" xlink:label="lab_axgn_DeferredTaxAssetsInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest limitation</link:label>
    <link:label id="lab_axgn_DeferredTaxAssetsInterestLimitation_label_en-US" xlink:label="lab_axgn_DeferredTaxAssetsInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Limitation</link:label>
    <link:label id="lab_axgn_DeferredTaxAssetsInterestLimitation_documentation_en-US" xlink:label="lab_axgn_DeferredTaxAssetsInterestLimitation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Interest Limitation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxAssetsInterestLimitation" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxAssetsInterestLimitation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DeferredTaxAssetsInterestLimitation" xlink:to="lab_axgn_DeferredTaxAssetsInterestLimitation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e1927368-cca7-447e-acab-4345966fa61d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_2a001466-2d02-4232-91b2-d80f0d07ef46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ac61b3a0-83f4-445f-893c-8e7100314bcd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_18e56391-9e91-4ffb-8db3-e1d6966e0aac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at Beginning of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_ed1e723f-c05e-43d2-a981-786e0d351b2c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at End of Year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_CashGrantsReceivable_e6d3e77b-ba6f-4b04-acaf-bbbb7dde532e_terseLabel_en-US" xlink:label="lab_axgn_CashGrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash grants receivable (up to)</link:label>
    <link:label id="lab_axgn_CashGrantsReceivable_label_en-US" xlink:label="lab_axgn_CashGrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Grants Receivable</link:label>
    <link:label id="lab_axgn_CashGrantsReceivable_documentation_en-US" xlink:label="lab_axgn_CashGrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of cash grants receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CashGrantsReceivable" xlink:href="axgn-20221231.xsd#axgn_CashGrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_CashGrantsReceivable" xlink:to="lab_axgn_CashGrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_486063e4-8a15-42af-955d-47858e189044_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_523f634b-451b-4e88-95f6-54ff39f3a13d_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finance lease maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b73a1b7e-bcf4-4b96-bcee-5a53f5253227_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_RightOfUseAssetAmortization_3e1df5c8-6be1-4a02-a540-d3b008bfdacb_terseLabel_en-US" xlink:label="lab_axgn_RightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_axgn_RightOfUseAssetAmortization_label_en-US" xlink:label="lab_axgn_RightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right Of Use Asset Amortization</link:label>
    <link:label id="lab_axgn_RightOfUseAssetAmortization_documentation_en-US" xlink:label="lab_axgn_RightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of amortization expense attributable to right-of-use asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RightOfUseAssetAmortization" xlink:href="axgn-20221231.xsd#axgn_RightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_RightOfUseAssetAmortization" xlink:to="lab_axgn_RightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_598a6b3a-9b38-41f6-8805-8c8545af94d2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_554a251b-8848-4759-b340-48d867be71cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_01bb3bce-6f69-4456-957f-cbc103cef189_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents balance outside of FDIC limit</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_db5bca1e-da68-432f-9e52-dcaa609f51bf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b64e4f73-7f29-43e5-8157-e2723b6ec22c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c9f39217-4936-4ee7-a664-cecd99c4a58a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6ab864c9-0a71-482c-92e9-3991b79794d7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_CreditFacilityTrancheTwoMember_8796f675-d3ea-4f08-9b5d-5afb3e3ecc94_terseLabel_en-US" xlink:label="lab_axgn_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Tranche</link:label>
    <link:label id="lab_axgn_CreditFacilityTrancheTwoMember_label_en-US" xlink:label="lab_axgn_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility. Tranche Two [Member]</link:label>
    <link:label id="lab_axgn_CreditFacilityTrancheTwoMember_documentation_en-US" xlink:label="lab_axgn_CreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility. Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheTwoMember" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_CreditFacilityTrancheTwoMember" xlink:to="lab_axgn_CreditFacilityTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_AuditInformationAbstract_label_en-US" xlink:label="lab_axgn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_axgn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_axgn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AuditInformationAbstract" xlink:href="axgn-20221231.xsd#axgn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_AuditInformationAbstract" xlink:to="lab_axgn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_d41ffb62-78ff-47c7-81a4-e03c730a1b0a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_ea362960-b80d-4a0b-9ae9-1a372fe9c91c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a78d40d2-ccf3-4bad-8574-6777070a9cf5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_MeasurementInputMandatoryPrepaymentRateMember_640c0b0d-3b14-4acb-a99a-11ba19d2c3cf_terseLabel_en-US" xlink:label="lab_axgn_MeasurementInputMandatoryPrepaymentRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mandatory Prepayment Rate</link:label>
    <link:label id="lab_axgn_MeasurementInputMandatoryPrepaymentRateMember_label_en-US" xlink:label="lab_axgn_MeasurementInputMandatoryPrepaymentRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Mandatory Prepayment Rate [Member]</link:label>
    <link:label id="lab_axgn_MeasurementInputMandatoryPrepaymentRateMember_documentation_en-US" xlink:label="lab_axgn_MeasurementInputMandatoryPrepaymentRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Mandatory Prepayment Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MeasurementInputMandatoryPrepaymentRateMember" xlink:href="axgn-20221231.xsd#axgn_MeasurementInputMandatoryPrepaymentRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_MeasurementInputMandatoryPrepaymentRateMember" xlink:to="lab_axgn_MeasurementInputMandatoryPrepaymentRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_a491ebba-da2a-4334-a020-680f711eb06e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DebtInstrumentAdditionalInterestFloorRate_b77e89f1-a37a-4ffe-8b83-ee54dedec489_terseLabel_en-US" xlink:label="lab_axgn_DebtInstrumentAdditionalInterestFloorRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest floor rate</link:label>
    <link:label id="lab_axgn_DebtInstrumentAdditionalInterestFloorRate_label_en-US" xlink:label="lab_axgn_DebtInstrumentAdditionalInterestFloorRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Interest, Floor Rate</link:label>
    <link:label id="lab_axgn_DebtInstrumentAdditionalInterestFloorRate_documentation_en-US" xlink:label="lab_axgn_DebtInstrumentAdditionalInterestFloorRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Additional Interest, Floor Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentAdditionalInterestFloorRate" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentAdditionalInterestFloorRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DebtInstrumentAdditionalInterestFloorRate" xlink:to="lab_axgn_DebtInstrumentAdditionalInterestFloorRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_b3259551-9b5e-4dab-b3bd-7f0850ba13b9_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_ab5b66a6-3d97-4f3f-8158-2b433d196e62_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature&#8203; of&#8203; Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne_e2ca2f86-3245-4760-bc75-122bbe4c2641_terseLabel_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne_label_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, Year One</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne_documentation_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne" xlink:to="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_32a4093d-6f40-49fc-9c3b-e29a9b6dcb84_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1e36962a-0b44-4a35-bf64-950571426e20_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_97b98aeb-9231-413e-ac8a-9b691d987e06_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCollateralAmount_3f3f12f0-b8f0-42b2-b39c-6a6e90e06f09_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCollateralAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCollateralAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCollateralAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Collateral Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCollateralAmount" xlink:to="lab_us-gaap_DebtInstrumentCollateralAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_CommunityTissuesServicesAgreementMember_70d05e7d-88fd-4f63-b281-cea8e1f33948_terseLabel_en-US" xlink:label="lab_axgn_CommunityTissuesServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CTS Agreement</link:label>
    <link:label id="lab_axgn_CommunityTissuesServicesAgreementMember_label_en-US" xlink:label="lab_axgn_CommunityTissuesServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Community Tissues Services Agreement [Member]</link:label>
    <link:label id="lab_axgn_CommunityTissuesServicesAgreementMember_documentation_en-US" xlink:label="lab_axgn_CommunityTissuesServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Community Tissues Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CommunityTissuesServicesAgreementMember" xlink:href="axgn-20221231.xsd#axgn_CommunityTissuesServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_CommunityTissuesServicesAgreementMember" xlink:to="lab_axgn_CommunityTissuesServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedCapitalizedInterestCosts_b8eed02f-63c7-45f9-b7f0-be7a274a14fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated capitalized interest costs</link:label>
    <link:label id="lab_us-gaap_AccumulatedCapitalizedInterestCosts_label_en-US" xlink:label="lab_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Capitalized Interest Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:to="lab_us-gaap_AccumulatedCapitalizedInterestCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_553dba8a-1b9f-4c62-a61e-d73a19ec0464_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_74af3e2b-64ae-4686-9c77-65e8cabade93_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies - see Note 14</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2197235d-08dd-4e07-b60e-1a3500d8561a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c6085e38-5130-44da-8968-ce1791dcc1d7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_92f6d2cf-c4bf-4509-a80d-cc8d192253db_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_0e212550-5d1a-41f2-b99b-7025a7f1103e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_MandatoryPrepaymentEventIn2024OrAfterMember_be223272-dd8a-401a-9045-73803312e5a7_terseLabel_en-US" xlink:label="lab_axgn_MandatoryPrepaymentEventIn2024OrAfterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of mandatory prepayment 2024 or after</link:label>
    <link:label id="lab_axgn_MandatoryPrepaymentEventIn2024OrAfterMember_label_en-US" xlink:label="lab_axgn_MandatoryPrepaymentEventIn2024OrAfterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mandatory Prepayment Event In 2024 Or After [Member]</link:label>
    <link:label id="lab_axgn_MandatoryPrepaymentEventIn2024OrAfterMember_documentation_en-US" xlink:label="lab_axgn_MandatoryPrepaymentEventIn2024OrAfterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mandatory Prepayment Event In 2024 Or After</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MandatoryPrepaymentEventIn2024OrAfterMember" xlink:href="axgn-20221231.xsd#axgn_MandatoryPrepaymentEventIn2024OrAfterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_MandatoryPrepaymentEventIn2024OrAfterMember" xlink:to="lab_axgn_MandatoryPrepaymentEventIn2024OrAfterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_a6ee7e3a-4c07-455b-b05e-220ecf7198df_terseLabel_en-US" xlink:label="lab_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Age of doubtful accounts</link:label>
    <link:label id="lab_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_label_en-US" xlink:label="lab_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts Receivable Age of Accounts Receivable</link:label>
    <link:label id="lab_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_documentation_en-US" xlink:label="lab_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the age of specific types of trade accounts and notes receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xlink:href="axgn-20221231.xsd#axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xlink:to="lab_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_891e2141-4420-418c-b1ba-fdc3c4d536d2_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e93bf192-8791-420c-823c-b7b563715cc0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_286ec035-c6d9-4ac3-a36d-a3576603c9a6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_5f55ec89-cd54-4f3b-985d-af3bcb967365_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_1748a222-3490-4923-8821-39832fb1c578_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_830e51e1-7afa-41c7-ae7e-a437e683d9c0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_54650b50-276b-4065-bb58-7508f9a65d47_terseLabel_en-US" xlink:label="lab_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Age limit for eligibility to participate in the plan</link:label>
    <link:label id="lab_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_label_en-US" xlink:label="lab_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Minimum Age Limit For Eligibility To Participate In Plan</link:label>
    <link:label id="lab_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_documentation_en-US" xlink:label="lab_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan minimum age limit for eligibility to participate in plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xlink:href="axgn-20221231.xsd#axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xlink:to="lab_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios_ef392aa0-8506-45c8-b3b7-9e9c97f17b34_terseLabel_en-US" xlink:label="lab_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Make-whole payment required under each scenario, internal rate of return</link:label>
    <link:label id="lab_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios_label_en-US" xlink:label="lab_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Internal Rate Of Return Under Settlement Scenarios</link:label>
    <link:label id="lab_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios_documentation_en-US" xlink:label="lab_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Internal Rate Of Return Under Settlement Scenarios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios" xlink:to="lab_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_da4f9a69-408a-4e3a-a106-d39d925407fa_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_740f18f6-7203-402a-94d9-1ab77a22f1eb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_a80a3cf1-23fc-47ff-a3a8-84b71222c2c3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest costs capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_e13ed204-4cb0-4489-a81a-81548f89fcc2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9bea2b4f-19e0-4a0e-98a8-3390ca9157e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_9f8871e5-6c8a-430b-b347-723af4c705ee_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cbb2f6bb-0b4a-4056-9d7c-eb4c4c573374_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue_281137e6-7c65-4deb-b988-ba8ef911e45c_terseLabel_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of Credit Facility Option, net of settlement</link:label>
    <link:label id="lab_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue_label_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Settlement of Warrants and Rights, Value</link:label>
    <link:label id="lab_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue_documentation_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Settlement of Warrants and Rights, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" xlink:to="lab_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_9f8df91d-0c94-43a0-aff9-1242e070043f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_43c25b0c-d290-4755-b22d-f2c891ec495a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate financing leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePayment_4f924618-fe46-43f9-a0b0-f49ed9ebbb8f_terseLabel_en-US" xlink:label="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity make-whole payment</link:label>
    <link:label id="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePayment_label_en-US" xlink:label="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Held To Maturity Make-Whole Payment</link:label>
    <link:label id="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePayment_documentation_en-US" xlink:label="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Held To Maturity Make-Whole Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePayment" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentHeldToMaturityMakeWholePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePayment" xlink:to="lab_axgn_DebtInstrumentHeldToMaturityMakeWholePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember_d9a6426d-32b4-45d3-af31-62526e9c52c4_terseLabel_en-US" xlink:label="lab_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 PSUs</link:label>
    <link:label id="lab_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember_label_en-US" xlink:label="lab_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty-Two Performance Share Unit [Member]</link:label>
    <link:label id="lab_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember_documentation_en-US" xlink:label="lab_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty-Two Performance Share Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember" xlink:href="axgn-20221231.xsd#axgn_TwoThousandTwentyTwoPerformanceShareUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember" xlink:to="lab_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_8d9248e8-31e6-4582-b2fa-bca00e339575_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_1a0e2052-ba75-44dc-b97a-836996473959_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_e04e4241-b894-49c0-a5da-7b47de0377c2_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty fees</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_363590ef-e0e2-4463-918a-c95df299da0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_58889489-55cc-4a5e-a8ea-1979401467a4_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameAxis_d6203ca8-92a9-474a-afb1-113041888684_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanNameAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameAxis" xlink:to="lab_us-gaap_RetirementPlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f2a56236-7aad-4bd0-b18c-73fca9a5ba90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of employee tax withholdings in exchange of common stock awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7cfe6645-1997-4a62-bfff-ac2e54541506_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_524a44bf-8437-4657-a7fb-2ec1ccf07d14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_5972f779-05f7-4651-8046-c50d752d7746_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective income tax basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_4f1ea8ab-5acb-4bf2-9824-a16ab9e75b1b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and deferred financing fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_bb033b71-d7af-410d-b381-c19c1db6a6a7_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_d5a79e04-0166-4df9-ab10-00a37b617b35_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ed08f0a-2b0a-41c5-bca7-fde1c9fba2d9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_774bb5ba-5371-40be-bdca-04d98d995b0f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_PerformanceStockUnitPayoutOpportunity_74e813f1-a9c3-4981-a929-413ad2008767_terseLabel_en-US" xlink:label="lab_axgn_PerformanceStockUnitPayoutOpportunity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock unit, payout opportunity</link:label>
    <link:label id="lab_axgn_PerformanceStockUnitPayoutOpportunity_label_en-US" xlink:label="lab_axgn_PerformanceStockUnitPayoutOpportunity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Payout Opportunity</link:label>
    <link:label id="lab_axgn_PerformanceStockUnitPayoutOpportunity_documentation_en-US" xlink:label="lab_axgn_PerformanceStockUnitPayoutOpportunity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit, Payout Opportunity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PerformanceStockUnitPayoutOpportunity" xlink:href="axgn-20221231.xsd#axgn_PerformanceStockUnitPayoutOpportunity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_PerformanceStockUnitPayoutOpportunity" xlink:to="lab_axgn_PerformanceStockUnitPayoutOpportunity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_31046ac6-46b2-4909-8f85-915db7719113_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_3d52ac44-70ff-4556-ae50-d56b7ebb84a0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_67390bd8-9847-43b1-b318-5bf59bf67ef7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_0d75460f-9c37-4f05-8e95-42e04ff97514_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_2eb9963b-90a4-4e9e-a9a0-c00681c460ab_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_5db78ae1-3c12-4ad3-9e32-5bb246843178_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_358a3794-c03f-43d7-b46e-3aa7fa7b8aa5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6603d1a1-b367-442a-a5f3-552f83b644d1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per common share - diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_14e39646-0b83-4d26-b7f8-a81815403441_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e754449b-eedc-4042-bcb5-fd5c1e9968dd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_93d40b2a-66f1-44c2-b0b8-c28c1ac5e03a_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_1dea6b13-81f9-4a0d-b461-6bfd501a03cc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LeasesFinanceAbstract_790c9e23-c9c0-4972-9b78-9cf60892a608_terseLabel_en-US" xlink:label="lab_axgn_LeasesFinanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Leases</link:label>
    <link:label id="lab_axgn_LeasesFinanceAbstract_label_en-US" xlink:label="lab_axgn_LeasesFinanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases Finance Abstract</link:label>
    <link:label id="lab_axgn_LeasesFinanceAbstract_documentation_en-US" xlink:label="lab_axgn_LeasesFinanceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LeasesFinanceAbstract" xlink:href="axgn-20221231.xsd#axgn_LeasesFinanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LeasesFinanceAbstract" xlink:to="lab_axgn_LeasesFinanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_df604c99-af54-4ca8-ad45-8a15a6b50b20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9405f6fc-400e-479e-bac4-20ebc5301eb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_OperatingLeaseIncrementalBorrowingRate_d4096ff4-acba-4623-90f4-ec7502e03f5e_terseLabel_en-US" xlink:label="lab_axgn_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, incremental borrowing rate</link:label>
    <link:label id="lab_axgn_OperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_axgn_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:label id="lab_axgn_OperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_axgn_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingLeaseIncrementalBorrowingRate" xlink:href="axgn-20221231.xsd#axgn_OperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_OperatingLeaseIncrementalBorrowingRate" xlink:to="lab_axgn_OperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo_419dc4ed-a056-4e42-8977-edb2aae1ffce_terseLabel_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo_label_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, Year Two</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo_documentation_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo" xlink:to="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths_7c160936-a741-4557-ba3b-2e1b3cb396a7_terseLabel_en-US" xlink:label="lab_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent-free period (in months)</link:label>
    <link:label id="lab_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths_label_en-US" xlink:label="lab_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Rent-Free Months</link:label>
    <link:label id="lab_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths_documentation_en-US" xlink:label="lab_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Rent-Free Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingLeaseNumberOfRentFreeMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths" xlink:to="lab_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_a83b869d-0861-45f5-9831-09ad415430ed_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2a872b92-1b37-4392-a96a-e06a0c8a51d2_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d60b4456-2072-47c1-ad49-bae1b817ef30_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6ba4f16b-e587-4653-821c-161234e3cdca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract_8be0eff3-bb60-469c-a55c-affa61fbd7f3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease costs</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_961f0635-01e9-4b0a-9dc3-cf78e0232424_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_235050e4-5693-4f5e-8db3-5a80156142b1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_ResearchAndDevelopmentGrantsMember_225a695f-875c-4bb8-bfcb-91349fc02eab_terseLabel_en-US" xlink:label="lab_axgn_ResearchAndDevelopmentGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Grants</link:label>
    <link:label id="lab_axgn_ResearchAndDevelopmentGrantsMember_label_en-US" xlink:label="lab_axgn_ResearchAndDevelopmentGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Grants [Member]</link:label>
    <link:label id="lab_axgn_ResearchAndDevelopmentGrantsMember_documentation_en-US" xlink:label="lab_axgn_ResearchAndDevelopmentGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ResearchAndDevelopmentGrantsMember" xlink:href="axgn-20221231.xsd#axgn_ResearchAndDevelopmentGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_ResearchAndDevelopmentGrantsMember" xlink:to="lab_axgn_ResearchAndDevelopmentGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_f8ef94b2-d007-40af-bd48-eefb069b8b07_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_570cef91-e89c-46b6-9412-dc936fd00eb2_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LeaseLiabilitiesNoncurrent_9a3b92c7-ed74-4fb7-8773-4a7903ddde53_terseLabel_en-US" xlink:label="lab_axgn_LeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease obligations</link:label>
    <link:label id="lab_axgn_LeaseLiabilitiesNoncurrent_label_en-US" xlink:label="lab_axgn_LeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liabilities, Noncurrent</link:label>
    <link:label id="lab_axgn_LeaseLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_axgn_LeaseLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LeaseLiabilitiesNoncurrent" xlink:href="axgn-20221231.xsd#axgn_LeaseLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LeaseLiabilitiesNoncurrent" xlink:to="lab_axgn_LeaseLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_FurnitureAndOfficeEquipmentMember_4da81076-8a79-4651-b20f-4d53e2120c92_terseLabel_en-US" xlink:label="lab_axgn_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_axgn_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_axgn_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_axgn_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_axgn_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment and tangible personal property commonly used in offices.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_FurnitureAndOfficeEquipmentMember" xlink:href="axgn-20221231.xsd#axgn_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_FurnitureAndOfficeEquipmentMember" xlink:to="lab_axgn_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8bafbf9f-6840-45c2-93da-988072f4abc9_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of operating lease maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_IncreaseDecreaseInOperatingLeaseLiabilities_2feb8bfe-a188-4dc2-b492-20c9073a9301_negatedTerseLabel_en-US" xlink:label="lab_axgn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease obligations</link:label>
    <link:label id="lab_axgn_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_axgn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_axgn_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_axgn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="axgn-20221231.xsd#axgn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_axgn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_594788f1-a4d2-4490-ac27-6a24aeace4f4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_788e0fdd-39a3-4e08-be89-e82722644365_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment losses (gains)</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_ShareBasePaymentArrangementNumberOfPlans_ccd905b9-ae70-4acf-8fc9-343a9130946d_terseLabel_en-US" xlink:label="lab_axgn_ShareBasePaymentArrangementNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share-based incentive plans</link:label>
    <link:label id="lab_axgn_ShareBasePaymentArrangementNumberOfPlans_label_en-US" xlink:label="lab_axgn_ShareBasePaymentArrangementNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-base Payment Arrangement, Number Of Plans</link:label>
    <link:label id="lab_axgn_ShareBasePaymentArrangementNumberOfPlans_documentation_en-US" xlink:label="lab_axgn_ShareBasePaymentArrangementNumberOfPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-base Payment Arrangement, Number Of Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ShareBasePaymentArrangementNumberOfPlans" xlink:href="axgn-20221231.xsd#axgn_ShareBasePaymentArrangementNumberOfPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_ShareBasePaymentArrangementNumberOfPlans" xlink:to="lab_axgn_ShareBasePaymentArrangementNumberOfPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_08ec89bc-fb47-4e31-8e6a-bc5d48c8c3f8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_c6712469-bd3d-4d6a-b16c-8aed6fda20f5_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_2c219513-0d0a-4191-89e6-9e3d1eea9d24_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average financing term (in years):</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a7260aed-6271-439c-991d-1dcbcaa3b546_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent_29527fa5-ee26-43a2-9c0c-0c1c3e435480_terseLabel_en-US" xlink:label="lab_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liability</link:label>
    <link:label id="lab_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Financing Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Financing Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent" xlink:href="axgn-20221231.xsd#axgn_OperatingAndFinancingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent" xlink:to="lab_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b5dbc5ed-cb3b-4af2-b448-1b71a2395a30_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_4679ed1e-fcc3-493b-a3cd-bed19f14e354_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_0e635722-8ae4-46c9-b263-b30afca36efc_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_1e58a672-2a8d-49c8-aae2-44a61817a3f1_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_bf3d540d-10a4-4e49-a8dc-62fd1e5fffc1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_75089fe6-aec7-4a95-90bf-596df415d8c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt, net of financing fees</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_7774b409-1494-4ef3-92fc-c41db4183c56_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCapitalizationPolicyPolicyTextBlock_8f968ed2-7747-4c39-9c9f-f65486fcdf29_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCapitalizationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Interest</link:label>
    <link:label id="lab_us-gaap_InterestCapitalizationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestCapitalizationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Capitalization, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCapitalizationPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCapitalizationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCapitalizationPolicyPolicyTextBlock" xlink:to="lab_us-gaap_InterestCapitalizationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cb0a04f2-9a5b-4c58-aee4-cc43be0a376f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_18d048f2-7337-4226-a4f2-babc960eb08c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_6ce555b3-d589-4e60-960e-47adaeed38a0_terseLabel_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and employee stock purchase plan</link:label>
    <link:label id="lab_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Purchase Plan</link:label>
    <link:label id="lab_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_documentation_en-US" xlink:label="lab_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:to="lab_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_df46501b-5fa2-44d1-b4f5-532993c9cde5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a2f05321-f957-4ff4-a19e-701e0b72f94f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5a95466e-2cdb-49ac-9fc3-53ce74a919e2_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_ee8f6051-5d18-4e80-b616-5e38e6b9d5ec_terseLabel_en-US" xlink:label="lab_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:label id="lab_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_label_en-US" xlink:label="lab_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Axogen 2019 Long-Term Incentive Plan, New Axogen Plan [Member]</link:label>
    <link:label id="lab_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_documentation_en-US" xlink:label="lab_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information relating to New Axogen Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember" xlink:href="axgn-20221231.xsd#axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember" xlink:to="lab_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_89b7c3a0-4e74-4dd8-abc4-33fea74e46c5_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration_0c2ef672-352a-44fe-87b5-2556e3dc1fab_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_8c0d9198-7f14-4ff7-a954-95be59d65cd2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted and performance stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_f68cc723-3e9e-4927-8366-113dcc036036_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_91ceabbb-3f78-4ec8-b7e8-72a24255ebc7_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest portion of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_4dc26bc5-bed9-4ad5-947d-43d999d02bd6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_481a4e68-d807-44e0-a329-1d93e271cfdb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_CommercialLeaseWithJAColeLPMember_94299afc-ab24-4511-ac81-3e12b74701bf_terseLabel_en-US" xlink:label="lab_axgn_CommercialLeaseWithJAColeLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Lease With JA-Cole L.P</link:label>
    <link:label id="lab_axgn_CommercialLeaseWithJAColeLPMember_label_en-US" xlink:label="lab_axgn_CommercialLeaseWithJAColeLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Lease With JA-Cole L.P [Member]</link:label>
    <link:label id="lab_axgn_CommercialLeaseWithJAColeLPMember_documentation_en-US" xlink:label="lab_axgn_CommercialLeaseWithJAColeLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Lease With JA-Cole L.P</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CommercialLeaseWithJAColeLPMember" xlink:href="axgn-20221231.xsd#axgn_CommercialLeaseWithJAColeLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_CommercialLeaseWithJAColeLPMember" xlink:to="lab_axgn_CommercialLeaseWithJAColeLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0f95262f-665e-44cb-92ae-e40be3fef6d4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_PaymentForServiceFees_5c8540cc-4cab-4ad5-bd41-552b42ceacaf_terseLabel_en-US" xlink:label="lab_axgn_PaymentForServiceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for service fees</link:label>
    <link:label id="lab_axgn_PaymentForServiceFees_label_en-US" xlink:label="lab_axgn_PaymentForServiceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Service Fees</link:label>
    <link:label id="lab_axgn_PaymentForServiceFees_documentation_en-US" xlink:label="lab_axgn_PaymentForServiceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PaymentForServiceFees" xlink:href="axgn-20221231.xsd#axgn_PaymentForServiceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_PaymentForServiceFees" xlink:to="lab_axgn_PaymentForServiceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_2ca10389-38d0-40fb-8bd2-c00a6cf9f6e8_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_7b2d5e8b-c6c4-45d9-87a3-f1368c126a7d_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_637c7450-79ca-4778-a108-d03cbd4c22b5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_07632507-7f70-4edf-912c-150c60b2d70f_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4b2630de-9450-49ab-b724-d80a69772a98_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2aab8a97-7fb8-4e79-853c-067facb099c0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a4e11f69-adaa-46c5-a6e6-d222748eca2d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_8a8cd934-c6c0-4ecc-b6e7-53303baa954e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of leasehold asset</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d63f8b16-3ac7-4f8f-80b4-18a2c4ff5209_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_45d725a1-0609-4840-9d36-1599ebe46cf2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_43c59492-2514-407f-8530-d714f53c7f17_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_73a6c85b-3228-4317-9241-d821d56faf6d_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_790b5b64-d575-4a6b-824a-4a0e2dbcd85d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0a87fc4c-5080-4cc8-b2c3-79da53cd710a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_09ae1340-411b-4af6-8422-dba6ad38010e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, measurement input</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_bbd6e300-1cba-44ce-91ec-2da1b000500f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_19d9eb94-98a8-404e-a652-7c84edac18d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_883fd3bc-59f1-4719-bb78-018acb5a1f2c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_18c447db-9141-47d2-88e9-41e00b49d9b2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b5047f38-70d8-452f-a8e5-603feb824b1e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_81913c91-1c1c-4d72-8133-9dd445b48df4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_30704207-2ef0-49f6-8f80-b0ae11c2c973_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_ContributionsToCharitableOrganization_0627d8a6-81b6-4e5c-8fbd-ec1d051f2976_terseLabel_en-US" xlink:label="lab_axgn_ContributionsToCharitableOrganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions to charitable organization</link:label>
    <link:label id="lab_axgn_ContributionsToCharitableOrganization_label_en-US" xlink:label="lab_axgn_ContributionsToCharitableOrganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions to Charitable Organization</link:label>
    <link:label id="lab_axgn_ContributionsToCharitableOrganization_documentation_en-US" xlink:label="lab_axgn_ContributionsToCharitableOrganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions to Charitable Organization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ContributionsToCharitableOrganization" xlink:href="axgn-20221231.xsd#axgn_ContributionsToCharitableOrganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_ContributionsToCharitableOrganization" xlink:to="lab_axgn_ContributionsToCharitableOrganization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_648f207e-3658-4d43-af8e-1b3441980cdd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease_e501798e-6a98-435d-befc-e497c10534d2_terseLabel_en-US" xlink:label="lab_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate increase in the event of default</link:label>
    <link:label id="lab_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease_label_en-US" xlink:label="lab_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Event of Default, Increase</link:label>
    <link:label id="lab_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease_documentation_en-US" xlink:label="lab_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Event of Default, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentInterestRateEventOfDefaultIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease" xlink:to="lab_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_PrepaymentProbabilityEventAxis_dd49b26e-18e9-415b-88a0-29c9bc623c29_terseLabel_en-US" xlink:label="lab_axgn_PrepaymentProbabilityEventAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Probability Event [Axis]</link:label>
    <link:label id="lab_axgn_PrepaymentProbabilityEventAxis_label_en-US" xlink:label="lab_axgn_PrepaymentProbabilityEventAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Probability Event [Axis]</link:label>
    <link:label id="lab_axgn_PrepaymentProbabilityEventAxis_documentation_en-US" xlink:label="lab_axgn_PrepaymentProbabilityEventAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Probability Event</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PrepaymentProbabilityEventAxis" xlink:href="axgn-20221231.xsd#axgn_PrepaymentProbabilityEventAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_PrepaymentProbabilityEventAxis" xlink:to="lab_axgn_PrepaymentProbabilityEventAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LeaseLiabilityCurrent_5fc8b71b-8f3c-4fe1-9897-16ec03061e37_terseLabel_en-US" xlink:label="lab_axgn_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of long-term lease obligations</link:label>
    <link:label id="lab_axgn_LeaseLiabilityCurrent_label_en-US" xlink:label="lab_axgn_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability, Current</link:label>
    <link:label id="lab_axgn_LeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_axgn_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LeaseLiabilityCurrent" xlink:href="axgn-20221231.xsd#axgn_LeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LeaseLiabilityCurrent" xlink:to="lab_axgn_LeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty_928e6da2-c7e3-4b52-9058-56d398efa4ad_terseLabel_en-US" xlink:label="lab_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold revenue achievement for payment of additional quarterly royalty</link:label>
    <link:label id="lab_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty_label_en-US" xlink:label="lab_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Participation Agreement, Threshold Revenue Achievement For Payment Of Additional Quarterly Royalty</link:label>
    <link:label id="lab_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty_documentation_en-US" xlink:label="lab_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Participation Agreement, Threshold Revenue Achievement For Payment Of Additional Quarterly Royalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty" xlink:href="axgn-20221231.xsd#axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty" xlink:to="lab_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_505c248e-ec21-45c2-aaa6-95429a6a22b7_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_8ad768d4-f96e-436d-8d9a-94f619c09c98_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1c44381a-e593-427d-932b-662371691e35_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share&#8203;</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_RoyaltyFeesPercentageUnderLicenseAgreements_16b9ac84-7ae7-41c2-bde0-47806142e040_terseLabel_en-US" xlink:label="lab_axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty fees range under the license agreements</link:label>
    <link:label id="lab_axgn_RoyaltyFeesPercentageUnderLicenseAgreements_label_en-US" xlink:label="lab_axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Fees Percentage under License Agreements</link:label>
    <link:label id="lab_axgn_RoyaltyFeesPercentageUnderLicenseAgreements_documentation_en-US" xlink:label="lab_axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty fees percentage under license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xlink:href="axgn-20221231.xsd#axgn_RoyaltyFeesPercentageUnderLicenseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xlink:to="lab_axgn_RoyaltyFeesPercentageUnderLicenseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29f1e166-5950-4662-8fce-94c8c0fc4ee7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ada8bcb1-b743-47ea-84b5-2afb6c67c6a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_51b06926-4900-4076-8be2-9884e7360f8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_0bc52db9-6603-4cc2-93e3-86f3b080f50b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted and performance stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_3083c0e4-84a5-482d-a30d-40f80b21d466_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_8121f2bf-1537-4d5f-b7f1-b5ade81a0d75_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate, Type of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="lab_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_85ed524f-aaff-480e-98cd-369e8ac20b52_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b00556e9-cac2-4eb5-a406-8f31ab218cda_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4eb783e8-e64a-4272-9320-a2c9a555c7c4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_2ef5368c-f6e5-4abb-838a-78d47b8be963_totalLabel_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_label_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_documentation_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid" xlink:to="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f9bd63f1-691b-4d1d-88f5-409b0a1cad2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net loss per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_3c98b136-aa8d-42dd-bfc8-b70272323845_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate at period end</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour_038124d4-0a5f-4808-aedf-c5c53c8d93f5_terseLabel_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour_label_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, Year Four</link:label>
    <link:label id="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour_documentation_en-US" xlink:label="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating and Financing Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour" xlink:to="lab_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_f66c983f-bde5-4828-8980-0707fb048104_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_f3215651-3ce3-4adb-bdc3-afb4e6a3e653_terseLabel_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:label id="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_label_en-US" xlink:label="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lab_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_8d029b8e-012d-44e3-87a3-886400fce65f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>axgn-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:008e6d96-0028-47c7-9dfe-7d6d669b55a8,g:6a78ba92-a70c-4cec-a491-e196b80cf77c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.axogeninc.com/role/Cover" xlink:type="simple" xlink:href="axgn-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_35a3d742-f127-4f85-a40b-032a8a23f596" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_DocumentType_35a3d742-f127-4f85-a40b-032a8a23f596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_5f971e8a-5239-4149-9c4e-ad3b24074959" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_DocumentAnnualReport_5f971e8a-5239-4149-9c4e-ad3b24074959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4d72d4ab-f5c9-45dc-aa18-f8c531d9cdf8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_DocumentPeriodEndDate_4d72d4ab-f5c9-45dc-aa18-f8c531d9cdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dcfdbf0f-39dd-43ec-ab53-2a39150ba2f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_CurrentFiscalYearEndDate_dcfdbf0f-39dd-43ec-ab53-2a39150ba2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_41096828-7a96-4986-8502-a7b2dc822d29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_DocumentTransitionReport_41096828-7a96-4986-8502-a7b2dc822d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2f7b09f6-0f6d-4794-b387-e29857069f1c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityFileNumber_2f7b09f6-0f6d-4794-b387-e29857069f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_78ed2875-f52c-4f75-9f13-df02ca5c6590" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityRegistrantName_78ed2875-f52c-4f75-9f13-df02ca5c6590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8bae0285-7918-450e-baf7-80415ac11a2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8bae0285-7918-450e-baf7-80415ac11a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b3b52108-d031-48a0-b87a-64fab86bd0f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityTaxIdentificationNumber_b3b52108-d031-48a0-b87a-64fab86bd0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b21268aa-3039-42e6-a42e-1c11bab6ce29" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityAddressAddressLine1_b21268aa-3039-42e6-a42e-1c11bab6ce29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a3cf1709-ace0-4087-ac6e-3746bce34cd3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityAddressCityOrTown_a3cf1709-ace0-4087-ac6e-3746bce34cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b106284e-c465-432c-8de6-fbc2e896bf93" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityAddressStateOrProvince_b106284e-c465-432c-8de6-fbc2e896bf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_10f91a65-e1cb-4889-bc2a-48486f48f870" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityAddressPostalZipCode_10f91a65-e1cb-4889-bc2a-48486f48f870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_64184968-c2a1-45a7-8a52-f99de8419c4e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_CityAreaCode_64184968-c2a1-45a7-8a52-f99de8419c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_781a67e3-5637-4f23-9088-d4611dda53b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_LocalPhoneNumber_781a67e3-5637-4f23-9088-d4611dda53b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_edf08286-3257-4d60-8647-e24c4109188c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_Security12bTitle_edf08286-3257-4d60-8647-e24c4109188c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d71a284f-9bcd-4176-8be2-28d3fe1fd2dc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_TradingSymbol_d71a284f-9bcd-4176-8be2-28d3fe1fd2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_5b2d9c19-94e7-42c0-aae3-d1682d930ef8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_SecurityExchangeName_5b2d9c19-94e7-42c0-aae3-d1682d930ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a993c84d-fe31-4f70-9508-efbfed1e3950" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a993c84d-fe31-4f70-9508-efbfed1e3950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_bc00ad66-f635-4aad-9b74-8b481729a68e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityVoluntaryFilers_bc00ad66-f635-4aad-9b74-8b481729a68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1a223983-987f-427c-96c5-cdcb3a90c958" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityCurrentReportingStatus_1a223983-987f-427c-96c5-cdcb3a90c958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2b81a529-4d00-40cf-97b5-1c5fcc157ecf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityInteractiveDataCurrent_2b81a529-4d00-40cf-97b5-1c5fcc157ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_faabd47b-d840-4275-be4f-23691ddd875a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityFilerCategory_faabd47b-d840-4275-be4f-23691ddd875a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6bf4ad25-13d0-4c88-9f10-25752a3326d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntitySmallBusiness_6bf4ad25-13d0-4c88-9f10-25752a3326d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0a208ad2-61fb-4e60-82b9-763aaff4b821" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityEmergingGrowthCompany_0a208ad2-61fb-4e60-82b9-763aaff4b821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_c91bfcea-caec-4313-8eb9-965e41461314" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_c91bfcea-caec-4313-8eb9-965e41461314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_38cf38c1-6e07-408d-9870-4f39abb1680e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityShellCompany_38cf38c1-6e07-408d-9870-4f39abb1680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_7abf7582-6d7e-4f46-872a-43d60058fd6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityPublicFloat_7abf7582-6d7e-4f46-872a-43d60058fd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_75d08385-bae7-4191-b12d-3d2e19639506" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_75d08385-bae7-4191-b12d-3d2e19639506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2966100d-661a-4f30-b74a-57b2d6599929" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_2966100d-661a-4f30-b74a-57b2d6599929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_430b9396-66fa-4c68-bb5a-83490aa1c2b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_EntityCentralIndexKey_430b9396-66fa-4c68-bb5a-83490aa1c2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_001dbe3a-302d-4bd7-bc3f-136ef1327534" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_DocumentFiscalYearFocus_001dbe3a-302d-4bd7-bc3f-136ef1327534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_841cbbdf-2db8-436a-b6dd-ee67250e1f9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_841cbbdf-2db8-436a-b6dd-ee67250e1f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_766ca5bb-0a6f-4d61-bfe0-0c5eec421a00" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb312978-fb0f-4ccc-abe0-65663adee52e" xlink:to="loc_dei_AmendmentFlag_766ca5bb-0a6f-4d61-bfe0-0c5eec421a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/AuditInformation" xlink:type="simple" xlink:href="axgn-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AuditInformationAbstract_fc281472-cdb7-410e-aa46-cf6526fac898" xlink:href="axgn-20221231.xsd#axgn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_ef36ce2f-e1be-48b2-b307-d67243f1f4d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_AuditInformationAbstract_fc281472-cdb7-410e-aa46-cf6526fac898" xlink:to="loc_dei_AuditorFirmId_ef36ce2f-e1be-48b2-b307-d67243f1f4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_90a1b67a-c6e1-4daa-987a-3cfa5eea945d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_AuditInformationAbstract_fc281472-cdb7-410e-aa46-cf6526fac898" xlink:to="loc_dei_AuditorName_90a1b67a-c6e1-4daa-987a-3cfa5eea945d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_36c865c2-db9b-4140-a80d-7f422afd9b61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_AuditInformationAbstract_fc281472-cdb7-410e-aa46-cf6526fac898" xlink:to="loc_dei_AuditorLocation_36c865c2-db9b-4140-a80d-7f422afd9b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="axgn-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a81478fe-5874-4f06-80c4-cf8b4d52af56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ef5f0297-4a30-444d-8f12-366df72826ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a81478fe-5874-4f06-80c4-cf8b4d52af56" xlink:to="loc_us-gaap_AssetsAbstract_ef5f0297-4a30-444d-8f12-366df72826ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_00d50abd-3e83-4dc6-8b9e-be17cced2fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef5f0297-4a30-444d-8f12-366df72826ee" xlink:to="loc_us-gaap_AssetsCurrentAbstract_00d50abd-3e83-4dc6-8b9e-be17cced2fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e412e594-c237-4b3c-887b-e5f56cd3cf2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00d50abd-3e83-4dc6-8b9e-be17cced2fa1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e412e594-c237-4b3c-887b-e5f56cd3cf2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_9e47880a-78c2-417d-9f68-1f08fdad7510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00d50abd-3e83-4dc6-8b9e-be17cced2fa1" xlink:to="loc_us-gaap_RestrictedCash_9e47880a-78c2-417d-9f68-1f08fdad7510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_2b588f91-7b54-4b63-86ba-e76eaa49bfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00d50abd-3e83-4dc6-8b9e-be17cced2fa1" xlink:to="loc_us-gaap_ShortTermInvestments_2b588f91-7b54-4b63-86ba-e76eaa49bfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_238792d4-b20b-4a13-9b15-abfc51bc3fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00d50abd-3e83-4dc6-8b9e-be17cced2fa1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_238792d4-b20b-4a13-9b15-abfc51bc3fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4d2bc0ed-8a99-4f15-b570-95d89a0db8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00d50abd-3e83-4dc6-8b9e-be17cced2fa1" xlink:to="loc_us-gaap_InventoryNet_4d2bc0ed-8a99-4f15-b570-95d89a0db8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1dd7df0b-0f55-4320-9a3b-c3552622e02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00d50abd-3e83-4dc6-8b9e-be17cced2fa1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1dd7df0b-0f55-4320-9a3b-c3552622e02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_15d2c26c-e910-4afc-9835-c49f0444a964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_00d50abd-3e83-4dc6-8b9e-be17cced2fa1" xlink:to="loc_us-gaap_AssetsCurrent_15d2c26c-e910-4afc-9835-c49f0444a964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b9834b7b-43a1-4f0d-b9cf-3aee4a6c4177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef5f0297-4a30-444d-8f12-366df72826ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_b9834b7b-43a1-4f0d-b9cf-3aee4a6c4177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8ff14823-ca6a-44c6-b6d0-630ef5863dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef5f0297-4a30-444d-8f12-366df72826ee" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8ff14823-ca6a-44c6-b6d0-630ef5863dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_92dc485a-2f33-4d7a-b7b4-c7e4dbeda514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef5f0297-4a30-444d-8f12-366df72826ee" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_92dc485a-2f33-4d7a-b7b4-c7e4dbeda514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9589294d-41a2-4362-9b86-aa50ea0401e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ef5f0297-4a30-444d-8f12-366df72826ee" xlink:to="loc_us-gaap_Assets_9589294d-41a2-4362-9b86-aa50ea0401e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64ee6097-1bc7-4103-8f59-723a25cb2648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a81478fe-5874-4f06-80c4-cf8b4d52af56" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64ee6097-1bc7-4103-8f59-723a25cb2648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_12e6bef1-4809-4837-8b5a-a7fa4b61bbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64ee6097-1bc7-4103-8f59-723a25cb2648" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_12e6bef1-4809-4837-8b5a-a7fa4b61bbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c1a1da5f-050d-42c2-bdc9-88ddd45928cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_12e6bef1-4809-4837-8b5a-a7fa4b61bbf3" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c1a1da5f-050d-42c2-bdc9-88ddd45928cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LeaseLiabilityCurrent_3692621b-7a8c-4aeb-b36a-d6702e806078" xlink:href="axgn-20221231.xsd#axgn_LeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_12e6bef1-4809-4837-8b5a-a7fa4b61bbf3" xlink:to="loc_axgn_LeaseLiabilityCurrent_3692621b-7a8c-4aeb-b36a-d6702e806078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4e951669-1073-4a04-86b5-e46b2c095ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_12e6bef1-4809-4837-8b5a-a7fa4b61bbf3" xlink:to="loc_us-gaap_LiabilitiesCurrent_4e951669-1073-4a04-86b5-e46b2c095ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cdc2ba57-6850-4620-a231-8bcbd4d67f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64ee6097-1bc7-4103-8f59-723a25cb2648" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cdc2ba57-6850-4620-a231-8bcbd4d67f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LeaseLiabilitiesNoncurrent_e2280bc0-8812-41bd-87e3-2d81fb4f1806" xlink:href="axgn-20221231.xsd#axgn_LeaseLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64ee6097-1bc7-4103-8f59-723a25cb2648" xlink:to="loc_axgn_LeaseLiabilitiesNoncurrent_e2280bc0-8812-41bd-87e3-2d81fb4f1806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_4d306cd0-19fc-4eff-ba38-bdf0223c2125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64ee6097-1bc7-4103-8f59-723a25cb2648" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_4d306cd0-19fc-4eff-ba38-bdf0223c2125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cad0dfda-2045-4c5b-ab7e-a02fcf69caba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64ee6097-1bc7-4103-8f59-723a25cb2648" xlink:to="loc_us-gaap_Liabilities_cad0dfda-2045-4c5b-ab7e-a02fcf69caba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_158cf724-c814-40cb-9db3-1daf9424b56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64ee6097-1bc7-4103-8f59-723a25cb2648" xlink:to="loc_us-gaap_CommitmentsAndContingencies_158cf724-c814-40cb-9db3-1daf9424b56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_cc71102e-fa17-41e4-a853-fa4eb3c51e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64ee6097-1bc7-4103-8f59-723a25cb2648" xlink:to="loc_us-gaap_StockholdersEquityAbstract_cc71102e-fa17-41e4-a853-fa4eb3c51e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2d871454-c58c-4c2c-ae9b-0080515bcf44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc71102e-fa17-41e4-a853-fa4eb3c51e36" xlink:to="loc_us-gaap_CommonStockValue_2d871454-c58c-4c2c-ae9b-0080515bcf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_059094a0-eb3f-4fd1-8ea9-638e57a8032d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc71102e-fa17-41e4-a853-fa4eb3c51e36" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_059094a0-eb3f-4fd1-8ea9-638e57a8032d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c98ef9f0-bb9a-42a2-8b79-e6578d7238bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc71102e-fa17-41e4-a853-fa4eb3c51e36" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c98ef9f0-bb9a-42a2-8b79-e6578d7238bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c2b90271-458d-4b83-90ba-66003d2d83d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc71102e-fa17-41e4-a853-fa4eb3c51e36" xlink:to="loc_us-gaap_StockholdersEquity_c2b90271-458d-4b83-90ba-66003d2d83d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec491747-ca3c-43c9-a103-627d159362f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64ee6097-1bc7-4103-8f59-723a25cb2648" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ec491747-ca3c-43c9-a103-627d159362f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="axgn-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_68f61043-abce-462d-b30c-29e18ec4cf54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_63965e1a-4ce4-41f1-9c45-b490c3921de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68f61043-abce-462d-b30c-29e18ec4cf54" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_63965e1a-4ce4-41f1-9c45-b490c3921de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_068b8a69-5a1e-41d5-b3b3-7e3ed4aad67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68f61043-abce-462d-b30c-29e18ec4cf54" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_068b8a69-5a1e-41d5-b3b3-7e3ed4aad67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_646954ce-46aa-4d34-a28c-79bd411c78e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68f61043-abce-462d-b30c-29e18ec4cf54" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_646954ce-46aa-4d34-a28c-79bd411c78e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d270c143-28f4-41ed-a061-0eadf7a37c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68f61043-abce-462d-b30c-29e18ec4cf54" xlink:to="loc_us-gaap_CommonStockSharesIssued_d270c143-28f4-41ed-a061-0eadf7a37c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b9e90770-0766-43ca-9b62-a77d219931c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68f61043-abce-462d-b30c-29e18ec4cf54" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b9e90770-0766-43ca-9b62-a77d219931c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="axgn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9c5edad2-032f-40c4-825e-a5dd30adce7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_Revenues_9c5edad2-032f-40c4-825e-a5dd30adce7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f841b6ae-04fd-46ac-9cbd-8459376e23f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f841b6ae-04fd-46ac-9cbd-8459376e23f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_96c39a13-ebd4-48e1-80b5-9b5523d60095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_GrossProfit_96c39a13-ebd4-48e1-80b5-9b5523d60095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ab72ac74-e299-479d-89ff-ac8b8dd7fd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ab72ac74-e299-479d-89ff-ac8b8dd7fd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_9b3a0376-1feb-4fd7-8fe6-1c06591d6ead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab72ac74-e299-479d-89ff-ac8b8dd7fd30" xlink:to="loc_us-gaap_SellingAndMarketingExpense_9b3a0376-1feb-4fd7-8fe6-1c06591d6ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3406f4c7-5784-4d42-bf59-ba4fa0b4d2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab72ac74-e299-479d-89ff-ac8b8dd7fd30" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3406f4c7-5784-4d42-bf59-ba4fa0b4d2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7d93f69a-6ca3-45d9-a130-e152fd11a7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab72ac74-e299-479d-89ff-ac8b8dd7fd30" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7d93f69a-6ca3-45d9-a130-e152fd11a7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_13895d66-77e2-4fbc-be6d-54f778b5cbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ab72ac74-e299-479d-89ff-ac8b8dd7fd30" xlink:to="loc_us-gaap_CostsAndExpenses_13895d66-77e2-4fbc-be6d-54f778b5cbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ab06ba0f-b56d-4ca8-91b7-b25e68ce9700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_OperatingIncomeLoss_ab06ba0f-b56d-4ca8-91b7-b25e68ce9700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6a0c8c23-2994-4acc-9001-92df6bc9e3de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6a0c8c23-2994-4acc-9001-92df6bc9e3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_456c64db-8ec0-4883-8e0c-6c80b6ed1b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6a0c8c23-2994-4acc-9001-92df6bc9e3de" xlink:to="loc_us-gaap_InvestmentIncomeNet_456c64db-8ec0-4883-8e0c-6c80b6ed1b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_999cbe21-aedf-4bea-b214-67f781c7e0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6a0c8c23-2994-4acc-9001-92df6bc9e3de" xlink:to="loc_us-gaap_InterestExpense_999cbe21-aedf-4bea-b214-67f781c7e0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_deda8aea-f072-4987-8496-fcf1494219f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6a0c8c23-2994-4acc-9001-92df6bc9e3de" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_deda8aea-f072-4987-8496-fcf1494219f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b859b478-a82e-4667-9b3a-825586c590a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6a0c8c23-2994-4acc-9001-92df6bc9e3de" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b859b478-a82e-4667-9b3a-825586c590a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8e8ee5bf-072c-446a-b746-29679e6539a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6a0c8c23-2994-4acc-9001-92df6bc9e3de" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8e8ee5bf-072c-446a-b746-29679e6539a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87cc4bd6-8066-4977-ae2a-409517a1bc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_NetIncomeLoss_87cc4bd6-8066-4977-ae2a-409517a1bc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67ecf583-8f6e-4435-86eb-c6a08f442939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_67ecf583-8f6e-4435-86eb-c6a08f442939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d81f69d7-0061-4f42-9a6a-ea6642457f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d81f69d7-0061-4f42-9a6a-ea6642457f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7b81dc27-ad12-40ef-bb32-aa27af755c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_EarningsPerShareBasic_7b81dc27-ad12-40ef-bb32-aa27af755c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3893c9ae-cd24-43a1-8d16-20042f65c17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_07c603f2-673c-4d8d-9884-cdc7cef7b139" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3893c9ae-cd24-43a1-8d16-20042f65c17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="axgn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b8da9ab3-c24a-427f-a41d-bc1aae8cf1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ccd5757b-0ffc-458a-b16c-b12d0cbb6765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b8da9ab3-c24a-427f-a41d-bc1aae8cf1fe" xlink:to="loc_us-gaap_StatementTable_ccd5757b-0ffc-458a-b16c-b12d0cbb6765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9eff7980-8500-4357-a030-b0a1537278ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ccd5757b-0ffc-458a-b16c-b12d0cbb6765" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9eff7980-8500-4357-a030-b0a1537278ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c6dfc028-2546-4076-9738-99946062e2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9eff7980-8500-4357-a030-b0a1537278ff" xlink:to="loc_us-gaap_EquityComponentDomain_c6dfc028-2546-4076-9738-99946062e2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9905d4e0-7594-49c4-8f2c-952260a30b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6dfc028-2546-4076-9738-99946062e2e5" xlink:to="loc_us-gaap_CommonStockMember_9905d4e0-7594-49c4-8f2c-952260a30b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1215f47d-4394-4b4b-a9eb-f0321b167727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6dfc028-2546-4076-9738-99946062e2e5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1215f47d-4394-4b4b-a9eb-f0321b167727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_51726c62-f583-409e-8177-4a2e8e4d39c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c6dfc028-2546-4076-9738-99946062e2e5" xlink:to="loc_us-gaap_RetainedEarningsMember_51726c62-f583-409e-8177-4a2e8e4d39c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a329ac24-8c7c-4218-abbf-6fcf5964241c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ccd5757b-0ffc-458a-b16c-b12d0cbb6765" xlink:to="loc_us-gaap_StatementLineItems_a329ac24-8c7c-4218-abbf-6fcf5964241c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a329ac24-8c7c-4218-abbf-6fcf5964241c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5f413bc7-bc53-4d16-a853-fa2750d2e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5f413bc7-bc53-4d16-a853-fa2750d2e5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7c0d2c66-af66-49c5-9cec-c303e77bea11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockholdersEquity_7c0d2c66-af66-49c5-9cec-c303e77bea11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5eb149e-acbf-4814-bc31-6062b1a9cd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c5eb149e-acbf-4814-bc31-6062b1a9cd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2ee97bbc-71d2-4a9a-b317-497053389858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2ee97bbc-71d2-4a9a-b317-497053389858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_e960ac8d-2267-487c-a1ea-3a0bea45701b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_e960ac8d-2267-487c-a1ea-3a0bea45701b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_f5ba89d5-c012-48d9-937d-c311d67373cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_f5ba89d5-c012-48d9-937d-c311d67373cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_3705ad98-32ff-48c1-a5aa-659b2b7b1719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_3705ad98-32ff-48c1-a5aa-659b2b7b1719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_88df4255-8b46-4e3a-93f6-df86e61c5b28" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan_88df4255-8b46-4e3a-93f6-df86e61c5b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_01302e48-b187-4f6f-92d9-aa000d7165e3" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan_01302e48-b187-4f6f-92d9-aa000d7165e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights_2467e379-5807-41bf-98c1-8f01d51f932b" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights_2467e379-5807-41bf-98c1-8f01d51f932b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue_cfb2bf16-6e18-4722-86b4-f6d37ea26bcf" xlink:href="axgn-20221231.xsd#axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue_cfb2bf16-6e18-4722-86b4-f6d37ea26bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6fada46-0e3d-4ca0-9178-45c852609fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_NetIncomeLoss_b6fada46-0e3d-4ca0-9178-45c852609fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_82be6152-60c6-40ca-89d7-09b68f9601f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_82be6152-60c6-40ca-89d7-09b68f9601f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_704ba6c7-13b2-4656-a233-b56ec24bac32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62f7cbff-7384-4ab4-a32b-5a4cfe8a2c2b" xlink:to="loc_us-gaap_StockholdersEquity_704ba6c7-13b2-4656-a233-b56ec24bac32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="axgn-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_34dbbac3-46e9-43bf-894f-dd32147bcee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8cffe2ff-9fec-4ccc-abaf-7f507f68473b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34dbbac3-46e9-43bf-894f-dd32147bcee7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8cffe2ff-9fec-4ccc-abaf-7f507f68473b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3e11a41-ed3b-4c04-823a-35fd6fff45a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8cffe2ff-9fec-4ccc-abaf-7f507f68473b" xlink:to="loc_us-gaap_NetIncomeLoss_a3e11a41-ed3b-4c04-823a-35fd6fff45a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8cffe2ff-9fec-4ccc-abaf-7f507f68473b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8c9f281e-bfe7-40ab-87e7-871d53b05599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8c9f281e-bfe7-40ab-87e7-871d53b05599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RightOfUseAssetAmortization_a73a2e5b-30fc-41af-802e-7f5da4e7f095" xlink:href="axgn-20221231.xsd#axgn_RightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_axgn_RightOfUseAssetAmortization_a73a2e5b-30fc-41af-802e-7f5da4e7f095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1366be9b-7019-4492-8b11-622e20d94f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1366be9b-7019-4492-8b11-622e20d94f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_be8a38d7-d5e4-4a07-91f6-dcebc0c4e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_be8a38d7-d5e4-4a07-91f6-dcebc0c4e1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3eac8d89-bd8a-4157-9ec7-9f0396e773b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3eac8d89-bd8a-4157-9ec7-9f0396e773b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_0bed8b9b-1bdc-4708-ab67-4b9ea27de46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_0bed8b9b-1bdc-4708-ab67-4b9ea27de46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_c455ef43-06f9-46b5-b279-013f1c1239f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_us-gaap_InventoryWriteDown_c455ef43-06f9-46b5-b279-013f1c1239f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_eaf0690f-2555-4f37-b038-eb88fdb98b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_eaf0690f-2555-4f37-b038-eb88fdb98b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_92ff1bf6-44f9-43b1-9856-ac4bb970ab4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_92ff1bf6-44f9-43b1-9856-ac4bb970ab4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dfed0dd9-6432-417b-873a-c32544e978c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_us-gaap_ShareBasedCompensation_dfed0dd9-6432-417b-873a-c32544e978c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c112ff7-d08c-4bc4-af6a-be60fac08e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53d5fa1b-3237-41c7-88ca-f8dc24f7aab8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c112ff7-d08c-4bc4-af6a-be60fac08e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b8406736-2f63-4de1-bae9-2625593d542e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c112ff7-d08c-4bc4-af6a-be60fac08e23" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b8406736-2f63-4de1-bae9-2625593d542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9f986ea4-97f3-431c-a0e4-32bb65b56a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c112ff7-d08c-4bc4-af6a-be60fac08e23" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9f986ea4-97f3-431c-a0e4-32bb65b56a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c421be0c-caac-4d51-9326-86f084141551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c112ff7-d08c-4bc4-af6a-be60fac08e23" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c421be0c-caac-4d51-9326-86f084141551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b2d22d35-daa9-44df-b311-54c1c69aa405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c112ff7-d08c-4bc4-af6a-be60fac08e23" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b2d22d35-daa9-44df-b311-54c1c69aa405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_IncreaseDecreaseInOperatingLeaseLiabilities_f1ee9df1-7feb-47bd-9cec-d8c8546f13a4" xlink:href="axgn-20221231.xsd#axgn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c112ff7-d08c-4bc4-af6a-be60fac08e23" xlink:to="loc_axgn_IncreaseDecreaseInOperatingLeaseLiabilities_f1ee9df1-7feb-47bd-9cec-d8c8546f13a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_f9832da2-bcaa-418c-9228-bc9c581839ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c112ff7-d08c-4bc4-af6a-be60fac08e23" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_f9832da2-bcaa-418c-9228-bc9c581839ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9f0f0c50-6c77-4336-b0f3-b45427b7733a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5c112ff7-d08c-4bc4-af6a-be60fac08e23" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9f0f0c50-6c77-4336-b0f3-b45427b7733a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a93cc9be-6465-4d0e-b006-8f0b48f37d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8cffe2ff-9fec-4ccc-abaf-7f507f68473b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a93cc9be-6465-4d0e-b006-8f0b48f37d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5265beca-b8b7-4640-b60d-c8a1d05dfc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34dbbac3-46e9-43bf-894f-dd32147bcee7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5265beca-b8b7-4640-b60d-c8a1d05dfc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17f77b45-92e8-4a7d-989e-9ad4467a11a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5265beca-b8b7-4640-b60d-c8a1d05dfc27" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17f77b45-92e8-4a7d-989e-9ad4467a11a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ProceedsFromGrantorsInvestingActivities_8c3e7349-b3ab-43d9-87a0-674ee7bcd1b7" xlink:href="axgn-20221231.xsd#axgn_ProceedsFromGrantorsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5265beca-b8b7-4640-b60d-c8a1d05dfc27" xlink:to="loc_axgn_ProceedsFromGrantorsInvestingActivities_8c3e7349-b3ab-43d9-87a0-674ee7bcd1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5a8313b5-c205-44af-8ca5-a7e93ac35da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5265beca-b8b7-4640-b60d-c8a1d05dfc27" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5a8313b5-c205-44af-8ca5-a7e93ac35da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_bb20ec59-85b9-4805-a9d8-6fc6e876b041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5265beca-b8b7-4640-b60d-c8a1d05dfc27" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_bb20ec59-85b9-4805-a9d8-6fc6e876b041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_15d420cb-22cb-4f4c-97ad-d1383e6f5f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5265beca-b8b7-4640-b60d-c8a1d05dfc27" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_15d420cb-22cb-4f4c-97ad-d1383e6f5f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39710e82-7601-4346-8064-537cfdfb90aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5265beca-b8b7-4640-b60d-c8a1d05dfc27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_39710e82-7601-4346-8064-537cfdfb90aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34dbbac3-46e9-43bf-894f-dd32147bcee7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e2c98217-15fd-4c23-b296-c8981529bd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e2c98217-15fd-4c23-b296-c8981529bd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2caf4cde-0432-458e-a873-61af145aa86f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2caf4cde-0432-458e-a873-61af145aa86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_039289d0-eebe-407b-ac22-ec2f5c4d13c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:to="loc_us-gaap_RepaymentsOfDebt_039289d0-eebe-407b-ac22-ec2f5c4d13c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_47efefc5-1363-4d8d-9312-ca1d57e0dc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_47efefc5-1363-4d8d-9312-ca1d57e0dc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_a0bdf432-ab5a-4a50-a53a-bd3a1e33682b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_a0bdf432-ab5a-4a50-a53a-bd3a1e33682b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_570259c5-338d-4d5e-9529-7ec7497fc8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_570259c5-338d-4d5e-9529-7ec7497fc8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_3295dbb0-646b-4950-9a04-e47de1e5fb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:to="loc_us-gaap_ProceedsFromStockPlans_3295dbb0-646b-4950-9a04-e47de1e5fb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e9f4a99b-b8a7-4b8c-a495-e109d11b910c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e9f4a99b-b8a7-4b8c-a495-e109d11b910c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d9a9bad4-ee00-498b-9e9a-76654cef257f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_14ad6a78-5b52-4784-829f-480819f4bb47" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d9a9bad4-ee00-498b-9e9a-76654cef257f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50dd0ef3-3bfa-4602-8d08-62a4f2376b28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34dbbac3-46e9-43bf-894f-dd32147bcee7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50dd0ef3-3bfa-4602-8d08-62a4f2376b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6aa2cf71-532e-4d9b-9dc6-a02748a5a311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34dbbac3-46e9-43bf-894f-dd32147bcee7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6aa2cf71-532e-4d9b-9dc6-a02748a5a311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7d2f5e16-3f46-462f-9c0d-0cff75db2169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34dbbac3-46e9-43bf-894f-dd32147bcee7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7d2f5e16-3f46-462f-9c0d-0cff75db2169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e6d02a24-c7a5-4e44-8d6b-9f6758286480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34dbbac3-46e9-43bf-894f-dd32147bcee7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e6d02a24-c7a5-4e44-8d6b-9f6758286480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1e2dc9b4-8d14-450d-9ed3-79c6070ac3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e6d02a24-c7a5-4e44-8d6b-9f6758286480" xlink:to="loc_us-gaap_InterestPaidNet_1e2dc9b4-8d14-450d-9ed3-79c6070ac3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_078eceb1-a677-4e6f-b67b-477694941623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_34dbbac3-46e9-43bf-894f-dd32147bcee7" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_078eceb1-a677-4e6f-b67b-477694941623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_16e3bf71-a771-45e5-9662-bf31812a85b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_078eceb1-a677-4e6f-b67b-477694941623" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_16e3bf71-a771-45e5-9662-bf31812a85b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_68d00a2b-bf99-42fd-b382-0a38836cdede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_078eceb1-a677-4e6f-b67b-477694941623" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_68d00a2b-bf99-42fd-b382-0a38836cdede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt_7583114c-a86a-435e-ab0b-841c899d6987" xlink:href="axgn-20221231.xsd#axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_078eceb1-a677-4e6f-b67b-477694941623" xlink:to="loc_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt_7583114c-a86a-435e-ab0b-841c899d6987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_d78e1f8c-4bd0-4b16-8d54-cdd61e35cd64" xlink:href="axgn-20221231.xsd#axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_078eceb1-a677-4e6f-b67b-477694941623" xlink:to="loc_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability_d78e1f8c-4bd0-4b16-8d54-cdd61e35cd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_NoncashOrPartNoncashConversionOption_89a99018-9b6a-44e4-9be3-13e059e932ee" xlink:href="axgn-20221231.xsd#axgn_NoncashOrPartNoncashConversionOption"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_078eceb1-a677-4e6f-b67b-477694941623" xlink:to="loc_axgn_NoncashOrPartNoncashConversionOption_89a99018-9b6a-44e4-9be3-13e059e932ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_ab4010f5-be77-42ec-8668-0bc30a086ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_078eceb1-a677-4e6f-b67b-477694941623" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_ab4010f5-be77-42ec-8668-0bc30a086ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/NatureofBusiness" xlink:type="simple" xlink:href="axgn-20221231.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81e4f6f8-e44d-401d-a0be-7a4ec614869d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_7a54f16d-cb23-455b-bc70-1b26cd3ceb97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81e4f6f8-e44d-401d-a0be-7a4ec614869d" xlink:to="loc_us-gaap_NatureOfOperations_7a54f16d-cb23-455b-bc70-1b26cd3ceb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="axgn-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0846a3e0-22a0-409a-bda8-505fe8cc4deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3e4380be-6717-41be-aeb7-e6dfa22ba789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0846a3e0-22a0-409a-bda8-505fe8cc4deb" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_3e4380be-6717-41be-aeb7-e6dfa22ba789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/Inventory" xlink:type="simple" xlink:href="axgn-20221231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_193cafa9-12c5-4537-a7a2-47ba5da900ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_69d94cc8-d157-4cee-b355-0bd709c84cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_193cafa9-12c5-4537-a7a2-47ba5da900ac" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_69d94cc8-d157-4cee-b355-0bd709c84cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4dbc50e7-3f13-4971-b056-48cfd891791c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f2d17eed-5af8-42f6-aec1-de2aea07edd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4dbc50e7-3f13-4971-b056-48cfd891791c" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f2d17eed-5af8-42f6-aec1-de2aea07edd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/Leases" xlink:type="simple" xlink:href="axgn-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d8e5bb74-8630-4fd7-804c-db29b1d03ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_4fc4662a-d471-465d-a951-aeb0318613a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d8e5bb74-8630-4fd7-804c-db29b1d03ef2" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_4fc4662a-d471-465d-a951-aeb0318613a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_f4a8fac7-5a32-438d-9f07-33372310829d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d8e5bb74-8630-4fd7-804c-db29b1d03ef2" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_f4a8fac7-5a32-438d-9f07-33372310829d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="axgn-20221231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1fc7899a-f128-48ef-a8d6-94fdef81e20d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cdfb6c30-a0ce-4aa4-9a38-5ada3612ba68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1fc7899a-f128-48ef-a8d6-94fdef81e20d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_cdfb6c30-a0ce-4aa4-9a38-5ada3612ba68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_416cd279-0f10-42c0-8d69-14b35eb23d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b4ce5a5f-3fdc-4d3f-aaa5-e6973f2fa151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_416cd279-0f10-42c0-8d69-14b35eb23d3e" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b4ce5a5f-3fdc-4d3f-aaa5-e6973f2fa151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="axgn-20221231.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_368ac5aa-d994-48f3-bd35-aa227ce84d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e8076ea6-7241-4806-b624-74050794de48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_368ac5aa-d994-48f3-bd35-aa227ce84d4f" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e8076ea6-7241-4806-b624-74050794de48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFees" xlink:type="simple" xlink:href="axgn-20221231.xsd#LongTermDebtNetofDebtDiscountandFinancingFees"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a418a226-0bab-4bd8-917b-1a0e231cbe91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_ab6f2941-1c8c-479b-85f1-98b7f9ea57fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a418a226-0bab-4bd8-917b-1a0e231cbe91" xlink:to="loc_us-gaap_LongTermDebtTextBlock_ab6f2941-1c8c-479b-85f1-98b7f9ea57fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShare" xlink:type="simple" xlink:href="axgn-20221231.xsd#BasicandDilutedLossperCommonShare"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_905e23a2-e0ec-4691-8d93-173822298b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_07bc7cf9-0900-457c-9e49-61a9136acec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_905e23a2-e0ec-4691-8d93-173822298b84" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_07bc7cf9-0900-457c-9e49-61a9136acec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cafc4cf0-a1da-46c2-b26e-d35029eae1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_efd6f68b-9976-4626-9e62-8615f5c4371f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cafc4cf0-a1da-46c2-b26e-d35029eae1c9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_efd6f68b-9976-4626-9e62-8615f5c4371f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IncomeTaxes" xlink:type="simple" xlink:href="axgn-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4184c2c6-05a1-49aa-9bee-45a162fa1906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6a9400a5-7169-4449-98e0-5079c133b078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4184c2c6-05a1-49aa-9bee-45a162fa1906" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_6a9400a5-7169-4449-98e0-5079c133b078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/RetirementPlan" xlink:type="simple" xlink:href="axgn-20221231.xsd#RetirementPlan"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/RetirementPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01822d06-9b49-46de-99db-e4f35cc9839a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_bd57d48e-5db4-4fd6-953b-70161a581a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01822d06-9b49-46de-99db-e4f35cc9839a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_bd57d48e-5db4-4fd6-953b-70161a581a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="axgn-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fb9559ee-1cc5-473d-8176-9380c951da97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_143009cf-70fe-407b-8985-01b80a253e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fb9559ee-1cc5-473d-8176-9380c951da97" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_143009cf-70fe-407b-8985-01b80a253e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/SubsequentEvent" xlink:type="simple" xlink:href="axgn-20221231.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2640b03e-7365-45d5-94c2-96e81cce3955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_eb019c07-bf46-4a86-8135-2593da29c646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2640b03e-7365-45d5-94c2-96e81cce3955" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_eb019c07-bf46-4a86-8135-2593da29c646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="simple" xlink:href="axgn-20221231.xsd#ScheduleIIValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_27d99d8d-a7dd-4169-bf95-23c5655a5ae5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_f4ca8e2f-2f98-49d5-97d2-8047a9d34d8d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_27d99d8d-a7dd-4169-bf95-23c5655a5ae5" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_f4ca8e2f-2f98-49d5-97d2-8047a9d34d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="axgn-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0d7625c1-e87f-46e7-a920-2f937e807a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0d7625c1-e87f-46e7-a920-2f937e807a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_13fd4f8c-f0ad-420c-9735-48d715a137c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_UseOfEstimates_13fd4f8c-f0ad-420c-9735-48d715a137c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_08406ab9-007c-4c4f-a8c7-d933a4dd3c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_08406ab9-007c-4c4f-a8c7-d933a4dd3c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RisksAndUncertaintiesPolicyTextBlock_efeef7d6-f67c-40d9-b026-cd721d62258e" xlink:href="axgn-20221231.xsd#axgn_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_axgn_RisksAndUncertaintiesPolicyTextBlock_efeef7d6-f67c-40d9-b026-cd721d62258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_7e0fbc79-3514-46ff-86c8-2d8555234788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_7e0fbc79-3514-46ff-86c8-2d8555234788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_9def1c27-618b-4d10-acfd-b1620e763c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_9def1c27-618b-4d10-acfd-b1620e763c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_3671921d-0181-41e5-a7c9-081ad1ad289a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_3671921d-0181-41e5-a7c9-081ad1ad289a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_6651e96b-e28f-4567-9d96-8880e8a7f5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_6651e96b-e28f-4567-9d96-8880e8a7f5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_60efff91-1841-4352-a44f-bf536ca2a6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_60efff91-1841-4352-a44f-bf536ca2a6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f8fdc379-4456-4806-954c-798f5e30d563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f8fdc379-4456-4806-954c-798f5e30d563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCapitalizationPolicyPolicyTextBlock_5f9aef47-6551-43d0-a054-afe8de32b728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCapitalizationPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_InterestCapitalizationPolicyPolicyTextBlock_5f9aef47-6551-43d0-a054-afe8de32b728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_dadfe77a-17f3-492f-b1ed-bbe9517d402f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_dadfe77a-17f3-492f-b1ed-bbe9517d402f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_9b29e8ed-06c0-4a03-b4f3-8fee05efb8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_9b29e8ed-06c0-4a03-b4f3-8fee05efb8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_67143c4e-2ef9-4d4e-a29e-821523d44de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_67143c4e-2ef9-4d4e-a29e-821523d44de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_de1c49e9-e222-4e34-b498-6255e4538d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_de1c49e9-e222-4e34-b498-6255e4538d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_b12f5275-9d61-41f7-b15e-bdb098d2eccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_b12f5275-9d61-41f7-b15e-bdb098d2eccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_90c695ae-8b27-4ecb-91bd-c5fc7c267fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_90c695ae-8b27-4ecb-91bd-c5fc7c267fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock_29a98188-9e4a-4a95-b51d-7563fad933bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_GovernmentAssistancePolicyTextBlock_29a98188-9e4a-4a95-b51d-7563fad933bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_6405e2d8-035b-4b8e-b699-f5abed8b163f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_6405e2d8-035b-4b8e-b699-f5abed8b163f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a2d7bbd4-78dd-43eb-8b7d-bcda8239bdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_a2d7bbd4-78dd-43eb-8b7d-bcda8239bdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_b3f24ad0-5ef8-4f06-8c4a-f748e5249cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_b3f24ad0-5ef8-4f06-8c4a-f748e5249cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_664261fc-29d4-4949-9288-fc21bf9bd1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_664261fc-29d4-4949-9288-fc21bf9bd1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f02651c9-6b41-4e3c-9335-1a3212f25e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f02651c9-6b41-4e3c-9335-1a3212f25e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_019eefac-cc5b-445a-96a4-3c3090ef0aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_019eefac-cc5b-445a-96a4-3c3090ef0aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6bcfbb02-116d-49f7-8ac7-89fa7d0d8a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c3800e23-7cd8-4f45-aff4-7c51ca89f41c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6bcfbb02-116d-49f7-8ac7-89fa7d0d8a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f14e53ff-5a65-444c-8917-f7cdfb46e4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b070bb5a-d531-450a-9d31-bed6af282ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f14e53ff-5a65-444c-8917-f7cdfb46e4b1" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b070bb5a-d531-450a-9d31-bed6af282ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/InventoryTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8f0a696f-f50f-4c45-b154-4cae768e2221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_935c9ce0-f5f6-4114-82af-b86f8e867e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8f0a696f-f50f-4c45-b154-4cae768e2221" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_935c9ce0-f5f6-4114-82af-b86f8e867e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_78df02a3-12cc-44c6-8df5-c74fb66f6888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1b1b9db0-dc8f-45b9-98f2-827b9dfd01a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_78df02a3-12cc-44c6-8df5-c74fb66f6888" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1b1b9db0-dc8f-45b9-98f2-827b9dfd01a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23efeca1-8b3d-429c-ba5e-f37fcc21a08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_78df02a3-12cc-44c6-8df5-c74fb66f6888" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_23efeca1-8b3d-429c-ba5e-f37fcc21a08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_fbe78d0b-7471-4b29-977e-6c59596f529d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_78df02a3-12cc-44c6-8df5-c74fb66f6888" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_fbe78d0b-7471-4b29-977e-6c59596f529d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LeasesTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_62e4ad50-841a-4c87-8ca7-26283ad05ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_62880fdb-9462-4dfd-a3c9-322f208f36af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_62e4ad50-841a-4c87-8ca7-26283ad05ad2" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_62880fdb-9462-4dfd-a3c9-322f208f36af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AssetsAndLiabilitiesLesseeTableTextBlock_ef809a4d-1644-44b1-affc-52e48c2c6e56" xlink:href="axgn-20221231.xsd#axgn_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_62e4ad50-841a-4c87-8ca7-26283ad05ad2" xlink:to="loc_axgn_AssetsAndLiabilitiesLesseeTableTextBlock_ef809a4d-1644-44b1-affc-52e48c2c6e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2b7da288-485c-4f76-9ee3-56d04e96ccec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_62e4ad50-841a-4c87-8ca7-26283ad05ad2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2b7da288-485c-4f76-9ee3-56d04e96ccec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_51056e7f-f9b6-488d-83f2-16a4bed0fd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_62e4ad50-841a-4c87-8ca7-26283ad05ad2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_51056e7f-f9b6-488d-83f2-16a4bed0fd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1804f8a3-85d7-458c-b2c4-96d738e98306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_538bebb3-a7c4-4929-86a8-565a6f8224e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1804f8a3-85d7-458c-b2c4-96d738e98306" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_538bebb3-a7c4-4929-86a8-565a6f8224e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_792f4f5c-2142-4fbf-b9ca-2a5a013178a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f053017f-e8c7-4d1b-b13c-2d7aa037c760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_792f4f5c-2142-4fbf-b9ca-2a5a013178a5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f053017f-e8c7-4d1b-b13c-2d7aa037c760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_e40994eb-9629-4de6-98a1-069993fe3818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_792f4f5c-2142-4fbf-b9ca-2a5a013178a5" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_e40994eb-9629-4de6-98a1-069993fe3818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_82691459-e924-4b88-b194-1997c0ee6432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_792f4f5c-2142-4fbf-b9ca-2a5a013178a5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_82691459-e924-4b88-b194-1997c0ee6432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_150d30a7-317e-4cf0-98ea-fb041539bd63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_792f4f5c-2142-4fbf-b9ca-2a5a013178a5" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_150d30a7-317e-4cf0-98ea-fb041539bd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ScheduleOfRoyaltyExpensesTableTextBlock_f8ddcee3-381e-433f-9b65-0bdd0a47279b" xlink:href="axgn-20221231.xsd#axgn_ScheduleOfRoyaltyExpensesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_792f4f5c-2142-4fbf-b9ca-2a5a013178a5" xlink:to="loc_axgn_ScheduleOfRoyaltyExpensesTableTextBlock_f8ddcee3-381e-433f-9b65-0bdd0a47279b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e058c7e4-e808-4af7-ab48-5e1a43b8ccae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_c6174b27-f48a-4743-9a42-994b86dc0ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e058c7e4-e808-4af7-ab48-5e1a43b8ccae" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_c6174b27-f48a-4743-9a42-994b86dc0ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#LongTermDebtNetofDebtDiscountandFinancingFeesTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bdda0767-6e26-44a5-9316-89c6f70439bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_02e84aea-19c5-408e-9f07-e59d3b658aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bdda0767-6e26-44a5-9316-89c6f70439bd" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_02e84aea-19c5-408e-9f07-e59d3b658aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#BasicandDilutedLossperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_70db82cb-22cf-4ed7-8b06-f8b9529a2bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4d61537c-4c5f-4166-b044-073114788119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70db82cb-22cf-4ed7-8b06-f8b9529a2bf7" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4d61537c-4c5f-4166-b044-073114788119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_679ede55-df20-4118-9fba-5296065adee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f90333a5-5872-42c1-9781-ea04df829558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_679ede55-df20-4118-9fba-5296065adee9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_f90333a5-5872-42c1-9781-ea04df829558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_99d12fda-9615-4e3c-aec4-57c7c1f777d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_679ede55-df20-4118-9fba-5296065adee9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_99d12fda-9615-4e3c-aec4-57c7c1f777d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_04f62a04-68c3-4f5e-90cf-1494480caf9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_679ede55-df20-4118-9fba-5296065adee9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_04f62a04-68c3-4f5e-90cf-1494480caf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_a82399a4-7984-4376-9bf1-59c12010eae8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_679ede55-df20-4118-9fba-5296065adee9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_a82399a4-7984-4376-9bf1-59c12010eae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="axgn-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_79041a36-b196-48c9-8909-10ba32584c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_41856bec-9359-419c-a2f1-6cafa2eb1221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79041a36-b196-48c9-8909-10ba32584c52" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_41856bec-9359-419c-a2f1-6cafa2eb1221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0ad0dbe2-5c9a-41c0-9253-d783b4a312f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79041a36-b196-48c9-8909-10ba32584c52" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_0ad0dbe2-5c9a-41c0-9253-d783b4a312f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6b45a013-d8e9-4f8d-9542-5ecd30184605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6b45a013-d8e9-4f8d-9542-5ecd30184605" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04b0fe4d-522c-4f62-8305-f52842e3bd43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:to="loc_srt_RangeAxis_04b0fe4d-522c-4f62-8305-f52842e3bd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30293b98-0e59-4a00-a3e1-f4078fe6c3b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_04b0fe4d-522c-4f62-8305-f52842e3bd43" xlink:to="loc_srt_RangeMember_30293b98-0e59-4a00-a3e1-f4078fe6c3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0627b824-8b97-4564-82bf-7ff40843854e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_30293b98-0e59-4a00-a3e1-f4078fe6c3b0" xlink:to="loc_srt_MinimumMember_0627b824-8b97-4564-82bf-7ff40843854e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae92bc12-a1f7-43df-b8c3-d5343da120f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_30293b98-0e59-4a00-a3e1-f4078fe6c3b0" xlink:to="loc_srt_MaximumMember_ae92bc12-a1f7-43df-b8c3-d5343da120f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_96aaec81-832a-442d-ba8f-2a9dc9dafc97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:to="loc_srt_ProductOrServiceAxis_96aaec81-832a-442d-ba8f-2a9dc9dafc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_12c82eb1-8f55-42e1-a0cb-0fc5272d0cb5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_96aaec81-832a-442d-ba8f-2a9dc9dafc97" xlink:to="loc_srt_ProductsAndServicesDomain_12c82eb1-8f55-42e1-a0cb-0fc5272d0cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_758b0aa2-0aa5-4a99-bbcf-029b84e1782e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_12c82eb1-8f55-42e1-a0cb-0fc5272d0cb5" xlink:to="loc_us-gaap_ShippingAndHandlingMember_758b0aa2-0aa5-4a99-bbcf-029b84e1782e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f2da945-713d-427e-9598-633000dad15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f2da945-713d-427e-9598-633000dad15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_565c109b-48ac-4b8c-a829-f70d064bab39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f2da945-713d-427e-9598-633000dad15a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_565c109b-48ac-4b8c-a829-f70d064bab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_4edb8562-d156-4486-99aa-27174230e4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_565c109b-48ac-4b8c-a829-f70d064bab39" xlink:to="loc_us-gaap_LicensingAgreementsMember_4edb8562-d156-4486-99aa-27174230e4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_0db347d4-8ee4-4740-bdc6-0d542e7168e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_565c109b-48ac-4b8c-a829-f70d064bab39" xlink:to="loc_us-gaap_PatentsMember_0db347d4-8ee4-4740-bdc6-0d542e7168e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis_eedcfddf-4b33-459d-9032-6e5396257565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:to="loc_us-gaap_GovernmentAssistanceTypeAxis_eedcfddf-4b33-459d-9032-6e5396257565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_864471b8-6bfd-4903-8dee-b1f1c4c0d397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_eedcfddf-4b33-459d-9032-6e5396257565" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_864471b8-6bfd-4903-8dee-b1f1c4c0d397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ResearchAndDevelopmentGrantsMember_94c14c3c-bd2f-4ee3-9c22-e20cbd27f3a6" xlink:href="axgn-20221231.xsd#axgn_ResearchAndDevelopmentGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_864471b8-6bfd-4903-8dee-b1f1c4c0d397" xlink:to="loc_axgn_ResearchAndDevelopmentGrantsMember_94c14c3c-bd2f-4ee3-9c22-e20cbd27f3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_3226671c-7754-4a41-abf7-83a226c0fb6e" xlink:to="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_df0e1a15-ee69-4a6f-bbc2-9c07462f753e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_CashUninsuredAmount_df0e1a15-ee69-4a6f-bbc2-9c07462f753e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0bf5fa46-b35d-4473-8a36-4396b995d4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_0bf5fa46-b35d-4473-8a36-4396b995d4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_61e960c2-810f-4684-bf5a-91521fd9760d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_InterestCostsCapitalized_61e960c2-810f-4684-bf5a-91521fd9760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_f07dff67-87d7-401a-9b5b-0f6916b5d3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_f07dff67-87d7-401a-9b5b-0f6916b5d3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ContributionsToCharitableOrganization_d3228707-4b25-41f9-a320-c07a5aad49b5" xlink:href="axgn-20221231.xsd#axgn_ContributionsToCharitableOrganization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_axgn_ContributionsToCharitableOrganization_d3228707-4b25-41f9-a320-c07a5aad49b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_e21a2d2a-d42d-4ab1-842d-b2291e6f35ac" xlink:href="axgn-20221231.xsd#axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable_e21a2d2a-d42d-4ab1-842d-b2291e6f35ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_2b8996e9-2164-460a-b529-aad4c8b842c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_2b8996e9-2164-460a-b529-aad4c8b842c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3396b84e-a6b0-4098-a08b-8c01a2365542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_3396b84e-a6b0-4098-a08b-8c01a2365542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_66e47a89-c151-4440-97d2-f1aa3bf7f3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ee56fa8-87ba-49ec-8ac4-e84bfc3be78d" xlink:to="loc_us-gaap_SellingAndMarketingExpense_66e47a89-c151-4440-97d2-f1aa3bf7f3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e08bde5b-4f0d-4e28-be0c-f20c3f549abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d66ab3ca-734e-42a5-bdbc-4fb1b2eefb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e08bde5b-4f0d-4e28-be0c-f20c3f549abf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d66ab3ca-734e-42a5-bdbc-4fb1b2eefb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_2a91a3d4-37fb-4990-be44-3b13851f9b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e08bde5b-4f0d-4e28-be0c-f20c3f549abf" xlink:to="loc_us-gaap_RestrictedCash_2a91a3d4-37fb-4990-be44-3b13851f9b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d336bb37-e141-4ac2-ba3e-65c6be8a1d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e08bde5b-4f0d-4e28-be0c-f20c3f549abf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d336bb37-e141-4ac2-ba3e-65c6be8a1d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/InventoryDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5bd8d38a-0e2f-45d0-afdb-1ebd3efa6e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_f1ce82a4-d55f-4112-8351-204883745f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5bd8d38a-0e2f-45d0-afdb-1ebd3efa6e98" xlink:to="loc_us-gaap_InventoryCurrentTable_f1ce82a4-d55f-4112-8351-204883745f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_b6f73f22-262d-4223-ab93-296eddec18a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_f1ce82a4-d55f-4112-8351-204883745f38" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_b6f73f22-262d-4223-ab93-296eddec18a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_94b17c05-6721-47dd-bfa9-e1e763f1cf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_b6f73f22-262d-4223-ab93-296eddec18a0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_94b17c05-6721-47dd-bfa9-e1e763f1cf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AviveSoftTissueMembraneMember_df4dc0f9-2abe-4624-b0a1-85c769be0d05" xlink:href="axgn-20221231.xsd#axgn_AviveSoftTissueMembraneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_94b17c05-6721-47dd-bfa9-e1e763f1cf6d" xlink:to="loc_axgn_AviveSoftTissueMembraneMember_df4dc0f9-2abe-4624-b0a1-85c769be0d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_f1ce82a4-d55f-4112-8351-204883745f38" xlink:to="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7ac818b3-420f-4716-aaae-6b03709bd13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7ac818b3-420f-4716-aaae-6b03709bd13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2623cdc6-ebb4-4f53-8915-5d397d542ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2623cdc6-ebb4-4f53-8915-5d397d542ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_89f3c964-80cd-4e81-829f-f2866ede274e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_89f3c964-80cd-4e81-829f-f2866ede274e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f343e994-be5a-465a-9abe-09f8a7d87e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryNet_f343e994-be5a-465a-9abe-09f8a7d87e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f6064d63-4c18-4e48-bc7b-e3961422ae9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_1831afc6-ad2b-45ac-a456-520776cdb0e4" xlink:to="loc_us-gaap_InventoryWriteDown_f6064d63-4c18-4e48-bc7b-e3961422ae9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c3d6d7dd-c1b3-4933-9cfe-dd74c8b27544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c3d6d7dd-c1b3-4933-9cfe-dd74c8b27544" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c87f2a22-fc77-40b3-92b9-3a39e4eff228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c87f2a22-fc77-40b3-92b9-3a39e4eff228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_552f234a-ea2f-4baf-a2b3-d3fa390ac3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c87f2a22-fc77-40b3-92b9-3a39e4eff228" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_552f234a-ea2f-4baf-a2b3-d3fa390ac3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c1426374-215c-421d-a64b-aa30063e9e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_552f234a-ea2f-4baf-a2b3-d3fa390ac3ce" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c1426374-215c-421d-a64b-aa30063e9e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f95f2f4c-a8a6-496c-bdc9-9859da09d22c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f95f2f4c-a8a6-496c-bdc9-9859da09d22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e75a77d-7105-4549-a0c9-df92b51468ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f95f2f4c-a8a6-496c-bdc9-9859da09d22c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e75a77d-7105-4549-a0c9-df92b51468ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e9525ac2-cdd6-4bf5-a7dd-7941ad3e2223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e75a77d-7105-4549-a0c9-df92b51468ea" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e9525ac2-cdd6-4bf5-a7dd-7941ad3e2223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_ba1743b6-3ae1-42b4-9108-8057321460e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e75a77d-7105-4549-a0c9-df92b51468ea" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_ba1743b6-3ae1-42b4-9108-8057321460e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_38bcdaf3-f051-415f-857b-145a0d956cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8e75a77d-7105-4549-a0c9-df92b51468ea" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_38bcdaf3-f051-415f-857b-145a0d956cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5294af63-5c6f-4f0e-88e5-df65afcd4931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5294af63-5c6f-4f0e-88e5-df65afcd4931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5294af63-5c6f-4f0e-88e5-df65afcd4931" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_86c7bff9-0c8c-4665-b6ab-c4270b9b4cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_86c7bff9-0c8c-4665-b6ab-c4270b9b4cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_47e19f82-d867-4375-a63f-d8da26ffd1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_47e19f82-d867-4375-a63f-d8da26ffd1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_8b30c62e-1841-455d-9d40-f6e71e75e74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:to="loc_us-gaap_CommercialPaperMember_8b30c62e-1841-455d-9d40-f6e71e75e74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember_ef45ce8f-0241-4dec-b334-3a019fd257df" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fce97db-3064-4ab4-af7a-3646416d38c0" xlink:to="loc_axgn_DebtDerivativeLiabilityMember_ef45ce8f-0241-4dec-b334-3a019fd257df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19ead6e0-5063-44b2-a94b-cdf2e6c0d11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_58412047-bc3c-4938-9b74-fd4d1518ec4c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19ead6e0-5063-44b2-a94b-cdf2e6c0d11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5feb3da8-894a-46ff-a138-f2bfa5b95287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19ead6e0-5063-44b2-a94b-cdf2e6c0d11a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5feb3da8-894a-46ff-a138-f2bfa5b95287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_2bbeba34-bf60-4b17-9404-9cd3ccd09a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19ead6e0-5063-44b2-a94b-cdf2e6c0d11a" xlink:to="loc_us-gaap_DerivativeLiabilities_2bbeba34-bf60-4b17-9404-9cd3ccd09a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_8cc965a8-fd5e-4bd1-a80a-491935dd3c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19ead6e0-5063-44b2-a94b-cdf2e6c0d11a" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_8cc965a8-fd5e-4bd1-a80a-491935dd3c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9bfd4e6e-0b36-4ec6-b87a-7fd09cac0663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9bfd4e6e-0b36-4ec6-b87a-7fd09cac0663" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8c45036c-171f-482c-96a2-43c851088791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8c45036c-171f-482c-96a2-43c851088791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a00ffb39-3b60-4b6d-8053-8cd01bc3b985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8c45036c-171f-482c-96a2-43c851088791" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a00ffb39-3b60-4b6d-8053-8cd01bc3b985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a2d6cea4-82b1-4d69-a75f-b8a5299cc47f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a00ffb39-3b60-4b6d-8053-8cd01bc3b985" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a2d6cea4-82b1-4d69-a75f-b8a5299cc47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bc5fb08-bf6d-495c-bcf9-6d2d7fdc3bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bc5fb08-bf6d-495c-bcf9-6d2d7fdc3bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8f1d329d-00d8-488b-b0da-2b8ca9a64b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7bc5fb08-bf6d-495c-bcf9-6d2d7fdc3bed" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8f1d329d-00d8-488b-b0da-2b8ca9a64b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2b04ed68-6557-44b1-8f4f-b2089201d6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8f1d329d-00d8-488b-b0da-2b8ca9a64b76" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2b04ed68-6557-44b1-8f4f-b2089201d6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2369e0e3-7ba8-48de-a1ba-90f60d9d631a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2369e0e3-7ba8-48de-a1ba-90f60d9d631a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_209d06d0-6429-410c-b379-25568884ae5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2369e0e3-7ba8-48de-a1ba-90f60d9d631a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_209d06d0-6429-410c-b379-25568884ae5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember_3763b304-f856-45de-b250-10b23d0319c9" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_209d06d0-6429-410c-b379-25568884ae5d" xlink:to="loc_axgn_DebtDerivativeLiabilityMember_3763b304-f856-45de-b250-10b23d0319c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_322047ac-4d03-47e4-8ec3-fc17d6f0b5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e8a426b5-d23e-44c8-9b31-f90262e12d5f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_322047ac-4d03-47e4-8ec3-fc17d6f0b5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_322047ac-4d03-47e4-8ec3-fc17d6f0b5cc" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70fcc18d-1518-4b37-94ab-ed4fd2fb1a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_70fcc18d-1518-4b37-94ab-ed4fd2fb1a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cfb81263-a486-4869-822d-d6043fac272f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cfb81263-a486-4869-822d-d6043fac272f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8f6e79ff-6e8d-4587-b54e-b7be0fa52446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8f6e79ff-6e8d-4587-b54e-b7be0fa52446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d923b29a-a6b0-4d3d-814f-c0edade4d2c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_478d9f2e-c10d-42e1-8110-851007e7fd57" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d923b29a-a6b0-4d3d-814f-c0edade4d2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8fccec0c-c66f-4bdd-95ec-82a5c8002020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bd8d6ed-588b-413a-9010-5151166f0975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8fccec0c-c66f-4bdd-95ec-82a5c8002020" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bd8d6ed-588b-413a-9010-5151166f0975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e0d62e4c-e519-4d2f-b168-4f0943930186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bd8d6ed-588b-413a-9010-5151166f0975" xlink:to="loc_us-gaap_DebtInstrumentAxis_e0d62e4c-e519-4d2f-b168-4f0943930186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a9010018-b19f-4841-b330-2b59dd20d1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e0d62e4c-e519-4d2f-b168-4f0943930186" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a9010018-b19f-4841-b330-2b59dd20d1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityMember_7f2689b0-85fa-4f59-b494-b9591660a2f4" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a9010018-b19f-4841-b330-2b59dd20d1a0" xlink:to="loc_axgn_CreditFacilityMember_7f2689b0-85fa-4f59-b494-b9591660a2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9a2efff8-cf25-486d-a585-64e62a732bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8bd8d6ed-588b-413a-9010-5151166f0975" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9a2efff8-cf25-486d-a585-64e62a732bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_efc24096-2ce4-4edc-bf26-2e4aa0df7602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9a2efff8-cf25-486d-a585-64e62a732bd2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_efc24096-2ce4-4edc-bf26-2e4aa0df7602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_937cf620-8ecc-45de-b321-6b7826bf4a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9a2efff8-cf25-486d-a585-64e62a732bd2" xlink:to="loc_us-gaap_LongTermDebtFairValue_937cf620-8ecc-45de-b321-6b7826bf4a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dd25c161-d855-4fe9-811d-5b5713e7a070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dd25c161-d855-4fe9-811d-5b5713e7a070" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e36e647a-7bcf-41d7-bd4b-08b0f298acca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e36e647a-7bcf-41d7-bd4b-08b0f298acca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_65f15f86-b0f8-4815-a287-8977df65d28a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e36e647a-7bcf-41d7-bd4b-08b0f298acca" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_65f15f86-b0f8-4815-a287-8977df65d28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember_ddf7bbfb-5a71-4f6e-88d4-e554646109fd" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_65f15f86-b0f8-4815-a287-8977df65d28a" xlink:to="loc_axgn_DebtDerivativeLiabilityMember_ddf7bbfb-5a71-4f6e-88d4-e554646109fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b8288d79-ff9c-4d3b-9c51-37869a3d66a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_us-gaap_DebtInstrumentAxis_b8288d79-ff9c-4d3b-9c51-37869a3d66a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ef667601-cc9a-40fd-bf72-360f32d2d60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b8288d79-ff9c-4d3b-9c51-37869a3d66a0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ef667601-cc9a-40fd-bf72-360f32d2d60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityMember_cc056d32-9828-4013-985a-8f53d3b96be8" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ef667601-cc9a-40fd-bf72-360f32d2d60b" xlink:to="loc_axgn_CreditFacilityMember_cc056d32-9828-4013-985a-8f53d3b96be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheOneMember_3cfe0b00-9428-401c-ae0a-b2382aa6ae91" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_CreditFacilityMember_cc056d32-9828-4013-985a-8f53d3b96be8" xlink:to="loc_axgn_CreditFacilityTrancheOneMember_3cfe0b00-9428-401c-ae0a-b2382aa6ae91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheTwoMember_53af7f4c-f957-4913-8a80-b2eaa8f0255c" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_CreditFacilityMember_cc056d32-9828-4013-985a-8f53d3b96be8" xlink:to="loc_axgn_CreditFacilityTrancheTwoMember_53af7f4c-f957-4913-8a80-b2eaa8f0255c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_4dbe94b4-ea4b-4c6b-8f92-80b99c074285" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_4dbe94b4-ea4b-4c6b-8f92-80b99c074285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_4dbe94b4-ea4b-4c6b-8f92-80b99c074285" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_ed02250b-edc0-4700-868e-1788d2a28271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_ed02250b-edc0-4700-868e-1788d2a28271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MeasurementInputCouponRateMember_bfe5d223-c4ac-439e-8447-422d3eb4d7b4" xlink:href="axgn-20221231.xsd#axgn_MeasurementInputCouponRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:to="loc_axgn_MeasurementInputCouponRateMember_bfe5d223-c4ac-439e-8447-422d3eb4d7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d3894d15-9462-474c-b1b8-4c86e86e937f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d3894d15-9462-474c-b1b8-4c86e86e937f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MeasurementInputMandatoryPrepaymentRateMember_da908f82-ce39-460d-ae5a-cc1d354c5588" xlink:href="axgn-20221231.xsd#axgn_MeasurementInputMandatoryPrepaymentRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_9762b1f0-34e9-4f5f-a340-c85599313915" xlink:to="loc_axgn_MeasurementInputMandatoryPrepaymentRateMember_da908f82-ce39-460d-ae5a-cc1d354c5588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PrepaymentProbabilityEventAxis_edba5039-47cb-4865-8f43-f492944eaaad" xlink:href="axgn-20221231.xsd#axgn_PrepaymentProbabilityEventAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_axgn_PrepaymentProbabilityEventAxis_edba5039-47cb-4865-8f43-f492944eaaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PrepaymentProbabilityEventDomain_6e55f5f4-72b9-4314-9e48-088cc4bfd6ab" xlink:href="axgn-20221231.xsd#axgn_PrepaymentProbabilityEventDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_PrepaymentProbabilityEventAxis_edba5039-47cb-4865-8f43-f492944eaaad" xlink:to="loc_axgn_PrepaymentProbabilityEventDomain_6e55f5f4-72b9-4314-9e48-088cc4bfd6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MandatoryPrepaymentEventBefore2024Member_2590a78e-c53b-40c7-9cfc-f5eff0230965" xlink:href="axgn-20221231.xsd#axgn_MandatoryPrepaymentEventBefore2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_PrepaymentProbabilityEventDomain_6e55f5f4-72b9-4314-9e48-088cc4bfd6ab" xlink:to="loc_axgn_MandatoryPrepaymentEventBefore2024Member_2590a78e-c53b-40c7-9cfc-f5eff0230965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MandatoryPrepaymentEventIn2024OrAfterMember_ff1298c9-de65-4649-ac5e-b6f03b9fa851" xlink:href="axgn-20221231.xsd#axgn_MandatoryPrepaymentEventIn2024OrAfterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_PrepaymentProbabilityEventDomain_6e55f5f4-72b9-4314-9e48-088cc4bfd6ab" xlink:to="loc_axgn_MandatoryPrepaymentEventIn2024OrAfterMember_ff1298c9-de65-4649-ac5e-b6f03b9fa851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OptionalPrepaymentEventMember_6d96eff5-1135-4877-a18e-4a73a0193c7f" xlink:href="axgn-20221231.xsd#axgn_OptionalPrepaymentEventMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_PrepaymentProbabilityEventDomain_6e55f5f4-72b9-4314-9e48-088cc4bfd6ab" xlink:to="loc_axgn_OptionalPrepaymentEventMember_6d96eff5-1135-4877-a18e-4a73a0193c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38bbc05b-224a-48dd-a10a-3fb47ca6ebb7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_srt_RangeAxis_38bbc05b-224a-48dd-a10a-3fb47ca6ebb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb8236c3-30a1-497e-a856-2208af38da78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_38bbc05b-224a-48dd-a10a-3fb47ca6ebb7" xlink:to="loc_srt_RangeMember_fb8236c3-30a1-497e-a856-2208af38da78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9ce20ea7-1126-448b-b74d-642def540d9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb8236c3-30a1-497e-a856-2208af38da78" xlink:to="loc_srt_MinimumMember_9ce20ea7-1126-448b-b74d-642def540d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a2f95594-0e79-4c02-9e86-68c9315287e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb8236c3-30a1-497e-a856-2208af38da78" xlink:to="loc_srt_MaximumMember_a2f95594-0e79-4c02-9e86-68c9315287e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83db5e17-a251-4b6f-a128-69f1ac3e433b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bf54bdb3-102c-4ad5-9368-d0041af9302d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83db5e17-a251-4b6f-a128-69f1ac3e433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_32ff8eec-e000-44d3-be00-900d1ff6a212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83db5e17-a251-4b6f-a128-69f1ac3e433b" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_32ff8eec-e000-44d3-be00-900d1ff6a212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LeasesComponentsofTotalLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0f619ed2-116d-43df-8564-3564c567f31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_ed628638-17cb-4d61-8581-d199340df10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f619ed2-116d-43df-8564-3564c567f31f" xlink:to="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_ed628638-17cb-4d61-8581-d199340df10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3489a487-e5a2-4a3a-a4ce-b8d2a7bd4b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_ed628638-17cb-4d61-8581-d199340df10d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3489a487-e5a2-4a3a-a4ce-b8d2a7bd4b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_2b8ab31e-b629-4bf6-a4a6-eb876873ff68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_ed628638-17cb-4d61-8581-d199340df10d" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_2b8ab31e-b629-4bf6-a4a6-eb876873ff68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_d848c0ab-63a3-47e8-8197-300093881545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f619ed2-116d-43df-8564-3564c567f31f" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_d848c0ab-63a3-47e8-8197-300093881545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_aa294305-e877-4efe-8077-e6d98d53023b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_d848c0ab-63a3-47e8-8197-300093881545" xlink:to="loc_us-gaap_OperatingLeaseCost_aa294305-e877-4efe-8077-e6d98d53023b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_628a1e7b-f57d-41ff-9eb4-9799e2659744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_d848c0ab-63a3-47e8-8197-300093881545" xlink:to="loc_us-gaap_ShortTermLeaseCost_628a1e7b-f57d-41ff-9eb4-9799e2659744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_14343ea8-e738-4fb0-8f69-513bc126cc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_d848c0ab-63a3-47e8-8197-300093881545" xlink:to="loc_us-gaap_VariableLeaseCost_14343ea8-e738-4fb0-8f69-513bc126cc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_901343cd-a274-4535-be19-a40229eed04c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0f619ed2-116d-43df-8564-3564c567f31f" xlink:to="loc_us-gaap_LeaseCost_901343cd-a274-4535-be19-a40229eed04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_97b246e5-99e3-4dbc-828c-d59efb7c361e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_97b246e5-99e3-4dbc-828c-d59efb7c361e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_8f7ff05d-b49c-4d48-97e7-5434d9c3dd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_8f7ff05d-b49c-4d48-97e7-5434d9c3dd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_cab71654-d616-4566-9a35-7dbbc7f01aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_cab71654-d616-4566-9a35-7dbbc7f01aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_8c84278f-5958-4721-966c-2657ea3e5ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_8c84278f-5958-4721-966c-2657ea3e5ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingLeasesAbstract_4e49a3b7-aca5-4726-b1bb-45db6847f629" xlink:href="axgn-20221231.xsd#axgn_OperatingLeasesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:to="loc_axgn_OperatingLeasesAbstract_4e49a3b7-aca5-4726-b1bb-45db6847f629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e40e617b-ebf5-40fd-a430-becaa4ecf36d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_OperatingLeasesAbstract_4e49a3b7-aca5-4726-b1bb-45db6847f629" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e40e617b-ebf5-40fd-a430-becaa4ecf36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b64e3144-5f69-4eef-9b02-f8c4bc71a4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_OperatingLeasesAbstract_4e49a3b7-aca5-4726-b1bb-45db6847f629" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b64e3144-5f69-4eef-9b02-f8c4bc71a4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_23d02c59-94ee-4ea9-ac7e-49491c6cb486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_OperatingLeasesAbstract_4e49a3b7-aca5-4726-b1bb-45db6847f629" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_23d02c59-94ee-4ea9-ac7e-49491c6cb486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LeasesFinanceAbstract_62024d5e-4bbf-4c6a-9036-8b512cfad109" xlink:href="axgn-20221231.xsd#axgn_LeasesFinanceAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:to="loc_axgn_LeasesFinanceAbstract_62024d5e-4bbf-4c6a-9036-8b512cfad109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_a8874365-0d74-4944-b42e-afa23fe2045a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_LeasesFinanceAbstract_62024d5e-4bbf-4c6a-9036-8b512cfad109" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_a8874365-0d74-4944-b42e-afa23fe2045a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_246cea3b-4a16-43ad-9591-7e90b5778de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_LeasesFinanceAbstract_62024d5e-4bbf-4c6a-9036-8b512cfad109" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_246cea3b-4a16-43ad-9591-7e90b5778de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8dc3c604-d0fa-461b-abaa-4a011ad87887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_LeasesFinanceAbstract_62024d5e-4bbf-4c6a-9036-8b512cfad109" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8dc3c604-d0fa-461b-abaa-4a011ad87887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ad5b26fb-35bb-46b6-92f8-6a93d290218e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ad5b26fb-35bb-46b6-92f8-6a93d290218e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_e656b073-75bb-47bd-930c-b7f3284f7db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_e656b073-75bb-47bd-930c-b7f3284f7db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_39524528-cc3f-46f3-81e6-4021bf68eb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_39524528-cc3f-46f3-81e6-4021bf68eb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a672c155-6bd9-414e-a688-0de51cf66586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ac844b3-184f-4578-893d-807b7294cce8" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a672c155-6bd9-414e-a688-0de51cf66586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne_6eb18dae-6514-4a82-8039-db7c767ace40" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne_6eb18dae-6514-4a82-8039-db7c767ace40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo_c4a7b945-623c-47d3-bd78-19f2a79d7022" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo_c4a7b945-623c-47d3-bd78-19f2a79d7022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree_6dadd509-6f3d-46a5-9d78-5187ef31bdb6" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree_6dadd509-6f3d-46a5-9d78-5187ef31bdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour_cd8f4932-ade3-4a15-9fa9-df6624723f4d" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour_cd8f4932-ade3-4a15-9fa9-df6624723f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive_88b855aa-e6c8-459b-9939-68d41069d236" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive_88b855aa-e6c8-459b-9939-68d41069d236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive_56987624-6995-4243-a9c6-0e628b67d08a" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive_56987624-6995-4243-a9c6-0e628b67d08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_9ce961e7-2ff2-4f18-aecf-a6203c843dc3" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid_9ce961e7-2ff2-4f18-aecf-a6203c843dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount_36c950a9-20be-4857-ba33-256e0cc95091" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount_36c950a9-20be-4857-ba33-256e0cc95091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingAndFinancingLeaseLiability_23fe937b-fdcf-4fde-8720-79060b2c1db4" xlink:href="axgn-20221231.xsd#axgn_OperatingAndFinancingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_OperatingAndFinancingLeaseLiability_23fe937b-fdcf-4fde-8720-79060b2c1db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingAndFinancingLeaseLiabilityCurrent_7ae862d2-d7db-4307-a2ba-81818412ed24" xlink:href="axgn-20221231.xsd#axgn_OperatingAndFinancingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_OperatingAndFinancingLeaseLiabilityCurrent_7ae862d2-d7db-4307-a2ba-81818412ed24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent_e0905ea7-4ced-41ac-b076-fc462b8c8046" xlink:href="axgn-20221231.xsd#axgn_OperatingAndFinancingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_fcdf09c5-fab3-413c-8ca5-c23917e70e08" xlink:to="loc_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent_e0905ea7-4ced-41ac-b076-fc462b8c8046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1a4a1de5-916b-4cfd-8039-26d225be4986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_08c0c590-8622-4dc5-b6ae-5449675da268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a4a1de5-916b-4cfd-8039-26d225be4986" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_08c0c590-8622-4dc5-b6ae-5449675da268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_673eed56-c673-45b1-bcd0-2a0a54b99ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_08c0c590-8622-4dc5-b6ae-5449675da268" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_673eed56-c673-45b1-bcd0-2a0a54b99ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b26e0653-4b5c-46b3-8450-a5360ac303c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_673eed56-c673-45b1-bcd0-2a0a54b99ffe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b26e0653-4b5c-46b3-8450-a5360ac303c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CommercialLeaseWithJAColeLPMember_016833ee-76d6-485a-b8fb-c2d8fb914c04" xlink:href="axgn-20221231.xsd#axgn_CommercialLeaseWithJAColeLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b26e0653-4b5c-46b3-8450-a5360ac303c7" xlink:to="loc_axgn_CommercialLeaseWithJAColeLPMember_016833ee-76d6-485a-b8fb-c2d8fb914c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember_d598e5b0-64a9-4c38-b53d-921ca373b89e" xlink:href="axgn-20221231.xsd#axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_CommercialLeaseWithJAColeLPMember_016833ee-76d6-485a-b8fb-c2d8fb914c04" xlink:to="loc_axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember_d598e5b0-64a9-4c38-b53d-921ca373b89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_08c0c590-8622-4dc5-b6ae-5449675da268" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_OperatingLeaseIncrementalBorrowingRate_139a37d1-5c98-4467-abfc-75e899a4498c" xlink:href="axgn-20221231.xsd#axgn_OperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_axgn_OperatingLeaseIncrementalBorrowingRate_139a37d1-5c98-4467-abfc-75e899a4498c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_86713ed1-eee1-4dfb-951a-77ff88c50084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_86713ed1-eee1-4dfb-951a-77ff88c50084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bc26380c-3f44-456d-84c1-05639b735fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_us-gaap_OperatingLeaseLiability_bc26380c-3f44-456d-84c1-05639b735fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths_6793a0ae-2392-4451-8382-16425dc29497" xlink:href="axgn-20221231.xsd#axgn_LesseeOperatingLeaseNumberOfRentFreeMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths_6793a0ae-2392-4451-8382-16425dc29497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c77f8bb8-a23d-47ba-afcd-d7189fa01723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_70797a55-6e71-4861-a1bf-bc0e81c72d56" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c77f8bb8-a23d-47ba-afcd-d7189fa01723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2afdfaed-b3b9-4387-84d6-039300a7afad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_659e62a5-adfc-4cbb-9aba-0a3670faf2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2afdfaed-b3b9-4387-84d6-039300a7afad" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_659e62a5-adfc-4cbb-9aba-0a3670faf2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93fbf79e-1a2b-42e8-a084-58a0dee98c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_659e62a5-adfc-4cbb-9aba-0a3670faf2ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93fbf79e-1a2b-42e8-a084-58a0dee98c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_93fbf79e-1a2b-42e8-a084-58a0dee98c89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_FurnitureAndOfficeEquipmentMember_b4ca23a9-82e0-495b-9972-07daad85eb96" xlink:href="axgn-20221231.xsd#axgn_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:to="loc_axgn_FurnitureAndOfficeEquipmentMember_b4ca23a9-82e0-495b-9972-07daad85eb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_ba6e1bc7-e9b6-47ea-aaa4-01b324c4de40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_ba6e1bc7-e9b6-47ea-aaa4-01b324c4de40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_b15e85ca-aee8-40bc-96ff-641b26bac425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:to="loc_us-gaap_EquipmentMember_b15e85ca-aee8-40bc-96ff-641b26bac425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3ad67a1d-0c6f-4577-97da-731f517a5d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:to="loc_us-gaap_LandMember_3ad67a1d-0c6f-4577-97da-731f517a5d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e3af87dd-2ca1-42bd-9721-1a9a6e69440d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_53c9890a-77a0-4e3f-814e-c79438d6c044" xlink:to="loc_us-gaap_ConstructionInProgressMember_e3af87dd-2ca1-42bd-9721-1a9a6e69440d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_659e62a5-adfc-4cbb-9aba-0a3670faf2ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2096f348-19f3-4da4-ba94-187bf1f7fb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2096f348-19f3-4da4-ba94-187bf1f7fb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_112b9cc7-e995-46bd-9b52-08dc7203e505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_112b9cc7-e995-46bd-9b52-08dc7203e505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_6f282f67-2267-4283-856b-4b428a521a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_6f282f67-2267-4283-856b-4b428a521a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_7ccdbda0-4637-4559-a943-9d974856970e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_7ccdbda0-4637-4559-a943-9d974856970e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e554a4cd-be80-4dfe-a12e-10b0db784205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e554a4cd-be80-4dfe-a12e-10b0db784205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration_28915655-681e-4be1-ba42-b046656ff407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e088a3fe-0200-4b21-a7df-f0b715195a55" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration_28915655-681e-4be1-ba42-b046656ff407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e26bb37c-09d0-48d1-a2e2-92261687a57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_356d453f-fc4b-494a-9c0b-92a59886de05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e26bb37c-09d0-48d1-a2e2-92261687a57c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_356d453f-fc4b-494a-9c0b-92a59886de05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4270810d-00c5-4137-ac14-3b6653462b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_356d453f-fc4b-494a-9c0b-92a59886de05" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4270810d-00c5-4137-ac14-3b6653462b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_50838114-4abd-40d1-b4be-23ae7b7f9eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4270810d-00c5-4137-ac14-3b6653462b68" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_50838114-4abd-40d1-b4be-23ae7b7f9eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_7ac6ca86-5241-4468-9ed4-32156eac9360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_50838114-4abd-40d1-b4be-23ae7b7f9eb1" xlink:to="loc_us-gaap_OtherAssetsMember_7ac6ca86-5241-4468-9ed4-32156eac9360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e8e0f680-b2b4-402e-b873-f2ad4370971a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_356d453f-fc4b-494a-9c0b-92a59886de05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e8e0f680-b2b4-402e-b873-f2ad4370971a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmountCumulative_55468004-4d71-4ae9-9605-ff07da4d1d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GovernmentAssistanceAmountCumulative"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e8e0f680-b2b4-402e-b873-f2ad4370971a" xlink:to="loc_us-gaap_GovernmentAssistanceAmountCumulative_55468004-4d71-4ae9-9605-ff07da4d1d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts_de1a616c-5966-491c-81b5-53b634c150b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e8e0f680-b2b4-402e-b873-f2ad4370971a" xlink:to="loc_us-gaap_AccumulatedCapitalizedInterestCosts_de1a616c-5966-491c-81b5-53b634c150b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4069bcc4-e28c-4b3b-b517-021ee683f695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e8e0f680-b2b4-402e-b873-f2ad4370971a" xlink:to="loc_us-gaap_Depreciation_4069bcc4-e28c-4b3b-b517-021ee683f695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3dbd20b5-d56f-4565-b1f1-a552844120bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fcd019fa-89c8-4bd6-9ab9-62fd40c60c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3dbd20b5-d56f-4565-b1f1-a552844120bb" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fcd019fa-89c8-4bd6-9ab9-62fd40c60c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c2b5c5ce-c274-4393-afb9-d52de500fe69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fcd019fa-89c8-4bd6-9ab9-62fd40c60c0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c2b5c5ce-c274-4393-afb9-d52de500fe69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d467698c-6f5b-4594-b920-a9975b826cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c2b5c5ce-c274-4393-afb9-d52de500fe69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d467698c-6f5b-4594-b920-a9975b826cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_1590533e-ac5c-4c6d-aed3-d63b0775c728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d467698c-6f5b-4594-b920-a9975b826cfd" xlink:to="loc_us-gaap_PatentsMember_1590533e-ac5c-4c6d-aed3-d63b0775c728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b361c391-35d5-4894-8a56-021b4538bf5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d467698c-6f5b-4594-b920-a9975b826cfd" xlink:to="loc_us-gaap_LicensingAgreementsMember_b361c391-35d5-4894-8a56-021b4538bf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_609ad7ff-91ec-497e-aa68-c0d47bcdbd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_fcd019fa-89c8-4bd6-9ab9-62fd40c60c0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_609ad7ff-91ec-497e-aa68-c0d47bcdbd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_da7deb5c-9b1d-4f9e-ad8b-588be2e26972" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_609ad7ff-91ec-497e-aa68-c0d47bcdbd56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_da7deb5c-9b1d-4f9e-ad8b-588be2e26972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62c38386-42b2-463a-a769-fd16238e95dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_da7deb5c-9b1d-4f9e-ad8b-588be2e26972" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_62c38386-42b2-463a-a769-fd16238e95dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fad0dcd4-df6e-4394-9f2d-08bff8c73eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_da7deb5c-9b1d-4f9e-ad8b-588be2e26972" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fad0dcd4-df6e-4394-9f2d-08bff8c73eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb9c18dd-4979-46ee-a048-db65e94aadfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_da7deb5c-9b1d-4f9e-ad8b-588be2e26972" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_eb9c18dd-4979-46ee-a048-db65e94aadfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_bee47304-e8e9-41f1-8725-3b9269591ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3dbd20b5-d56f-4565-b1f1-a552844120bb" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_bee47304-e8e9-41f1-8725-3b9269591ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fff47b-b4e1-4bc0-8000-84e1c191926d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_bee47304-e8e9-41f1-8725-3b9269591ce3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fff47b-b4e1-4bc0-8000-84e1c191926d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_156a6815-3140-45af-a096-759ab90569b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_96fff47b-b4e1-4bc0-8000-84e1c191926d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_156a6815-3140-45af-a096-759ab90569b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_5d20b08d-c939-45a2-8d1f-e6b6d284af1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_156a6815-3140-45af-a096-759ab90569b3" xlink:to="loc_us-gaap_TrademarksMember_5d20b08d-c939-45a2-8d1f-e6b6d284af1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ecaeff2-7376-4ad9-85f6-6f7c99c38f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_bee47304-e8e9-41f1-8725-3b9269591ce3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ecaeff2-7376-4ad9-85f6-6f7c99c38f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_a841b68a-e3bf-40fa-902c-fabccb11dc07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7ecaeff2-7376-4ad9-85f6-6f7c99c38f59" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_a841b68a-e3bf-40fa-902c-fabccb11dc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a3370c62-6ef5-419f-a9cd-a3c44af2bc44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_a841b68a-e3bf-40fa-902c-fabccb11dc07" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a3370c62-6ef5-419f-a9cd-a3c44af2bc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_78b0d7c5-b9cb-42f5-90a0-a047c94e4c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3dbd20b5-d56f-4565-b1f1-a552844120bb" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_78b0d7c5-b9cb-42f5-90a0-a047c94e4c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3dbd129a-acfc-41fb-ae54-42ade6b9b498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3dbd20b5-d56f-4565-b1f1-a552844120bb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3dbd129a-acfc-41fb-ae54-42ade6b9b498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetAmortizationExpenseDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41f8d0c9-32eb-4736-82a8-3671c705378a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fd1f1104-b452-4e3b-8961-d23a56a5df8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41f8d0c9-32eb-4736-82a8-3671c705378a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fd1f1104-b452-4e3b-8961-d23a56a5df8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8eb62ae-e303-4750-b811-64a411e1838c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f0c5933-de1a-4716-a94a-c4bd2b625b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8eb62ae-e303-4750-b811-64a411e1838c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f0c5933-de1a-4716-a94a-c4bd2b625b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50e1f388-18f4-480a-accd-e0a77d57d242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f0c5933-de1a-4716-a94a-c4bd2b625b71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50e1f388-18f4-480a-accd-e0a77d57d242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8201c541-8328-4c0c-9267-2aa2a47ca179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50e1f388-18f4-480a-accd-e0a77d57d242" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8201c541-8328-4c0c-9267-2aa2a47ca179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PatentsAndLicenseAgreementsMember_ab444f0f-1ad0-4775-a43f-3d8c8ae1fbfc" xlink:href="axgn-20221231.xsd#axgn_PatentsAndLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8201c541-8328-4c0c-9267-2aa2a47ca179" xlink:to="loc_axgn_PatentsAndLicenseAgreementsMember_ab444f0f-1ad0-4775-a43f-3d8c8ae1fbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f0c5933-de1a-4716-a94a-c4bd2b625b71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_30384c2f-6f2e-4a58-a694-6db328a37f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_30384c2f-6f2e-4a58-a694-6db328a37f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2a7f0018-c0e9-42e9-94fe-0b2f356416fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2a7f0018-c0e9-42e9-94fe-0b2f356416fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6f02f7e8-100b-4cad-98fc-d8db5d8db8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6f02f7e8-100b-4cad-98fc-d8db5d8db8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c91bb56-2f9b-4e75-b097-9e43b2f46757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_8c91bb56-2f9b-4e75-b097-9e43b2f46757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ab76686f-4adc-40e4-b5c5-a3efddaa54d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ab76686f-4adc-40e4-b5c5-a3efddaa54d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5657c258-babb-468e-95a7-c992248b6a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5657c258-babb-468e-95a7-c992248b6a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b8c5a2a9-fd2f-46d6-81d5-4be85c497fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_a87eed53-baf6-4006-ad94-9db1abda5e7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b8c5a2a9-fd2f-46d6-81d5-4be85c497fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_79c50b2f-83f8-4719-98da-a53d1259a38e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e7613805-06b4-454c-a586-9a55359cd748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_79c50b2f-83f8-4719-98da-a53d1259a38e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e7613805-06b4-454c-a586-9a55359cd748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ce4e1f3-2063-436f-bbf7-7c08bb85d197" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e7613805-06b4-454c-a586-9a55359cd748" xlink:to="loc_srt_RangeAxis_9ce4e1f3-2063-436f-bbf7-7c08bb85d197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_af38b8ea-0988-4f98-bd10-60396bbd366e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9ce4e1f3-2063-436f-bbf7-7c08bb85d197" xlink:to="loc_srt_RangeMember_af38b8ea-0988-4f98-bd10-60396bbd366e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8bd80538-b638-44f3-a806-20f4d64cbc5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_af38b8ea-0988-4f98-bd10-60396bbd366e" xlink:to="loc_srt_MinimumMember_8bd80538-b638-44f3-a806-20f4d64cbc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ea3c671a-83a7-4cc3-bcba-5d3081084086" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_af38b8ea-0988-4f98-bd10-60396bbd366e" xlink:to="loc_srt_MaximumMember_ea3c671a-83a7-4cc3-bcba-5d3081084086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c83fd5f7-a43c-473d-ba5a-5dce93bba1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e7613805-06b4-454c-a586-9a55359cd748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c83fd5f7-a43c-473d-ba5a-5dce93bba1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_134d8c38-3722-4579-85e8-1aebb3b06c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c83fd5f7-a43c-473d-ba5a-5dce93bba1e8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_134d8c38-3722-4579-85e8-1aebb3b06c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_a734b249-9970-4363-8ae0-f47b61a9fc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_134d8c38-3722-4579-85e8-1aebb3b06c76" xlink:to="loc_us-gaap_LicensingAgreementsMember_a734b249-9970-4363-8ae0-f47b61a9fc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ff512c45-a784-413e-9ca2-05119747797f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e7613805-06b4-454c-a586-9a55359cd748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ff512c45-a784-413e-9ca2-05119747797f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RoyaltyFeesPercentageUnderLicenseAgreements_8fffbc04-9baf-47bd-a9b8-bd96b4ef310e" xlink:href="axgn-20221231.xsd#axgn_RoyaltyFeesPercentageUnderLicenseAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ff512c45-a784-413e-9ca2-05119747797f" xlink:to="loc_axgn_RoyaltyFeesPercentageUnderLicenseAgreements_8fffbc04-9baf-47bd-a9b8-bd96b4ef310e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_6ba08c3f-a599-45ab-b391-54f2634f2082" xlink:href="axgn-20221231.xsd#axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ff512c45-a784-413e-9ca2-05119747797f" xlink:to="loc_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors_6ba08c3f-a599-45ab-b391-54f2634f2082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IntangibleAssetsNetRoyaltyFeesDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_752338dd-7162-4f7c-b6f2-05d70df08106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18a5c8b2-760c-4b2a-9017-defda6158b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_752338dd-7162-4f7c-b6f2-05d70df08106" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18a5c8b2-760c-4b2a-9017-defda6158b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c292e557-0eef-4931-90bb-08d23d61e944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18a5c8b2-760c-4b2a-9017-defda6158b74" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c292e557-0eef-4931-90bb-08d23d61e944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_afd0178b-7a87-4b3c-a60c-41ce36904e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c292e557-0eef-4931-90bb-08d23d61e944" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_afd0178b-7a87-4b3c-a60c-41ce36904e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_13861c7d-7cef-4c94-9fb8-abadc6bc39fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_afd0178b-7a87-4b3c-a60c-41ce36904e8f" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_13861c7d-7cef-4c94-9fb8-abadc6bc39fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f03462e5-eb33-46b5-b537-7341938da62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_18a5c8b2-760c-4b2a-9017-defda6158b74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f03462e5-eb33-46b5-b537-7341938da62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_4644c1f6-d7b1-4a06-a93c-741d00e67f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f03462e5-eb33-46b5-b537-7341938da62e" xlink:to="loc_us-gaap_RoyaltyExpense_4644c1f6-d7b1-4a06-a93c-741d00e67f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#AccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_781c1e02-68fe-40ac-b515-9426a4ca1ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0dd395cb-3964-469e-8b64-f37c1c1dff29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_781c1e02-68fe-40ac-b515-9426a4ca1ce0" xlink:to="loc_us-gaap_AccountsPayableCurrent_0dd395cb-3964-469e-8b64-f37c1c1dff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a0944fc3-ba9d-4c9c-bf89-6b2b21636225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_781c1e02-68fe-40ac-b515-9426a4ca1ce0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a0944fc3-ba9d-4c9c-bf89-6b2b21636225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_c171d82b-24e4-41c4-8986-f9cbae0f8778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_781c1e02-68fe-40ac-b515-9426a4ca1ce0" xlink:to="loc_us-gaap_AccruedSalariesCurrent_c171d82b-24e4-41c4-8986-f9cbae0f8778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_20c87168-60ce-4446-95bd-bf6241fb7090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_781c1e02-68fe-40ac-b515-9426a4ca1ce0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_20c87168-60ce-4446-95bd-bf6241fb7090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a70df1a2-4a4a-46a2-a93d-d0e9bb9576de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ce61c970-d6bf-4863-9917-6fa8deadd691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a70df1a2-4a4a-46a2-a93d-d0e9bb9576de" xlink:to="loc_us-gaap_DebtInstrumentTable_ce61c970-d6bf-4863-9917-6fa8deadd691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_362ce821-1b1b-40de-8cc5-11bd3d2ed68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ce61c970-d6bf-4863-9917-6fa8deadd691" xlink:to="loc_us-gaap_DebtInstrumentAxis_362ce821-1b1b-40de-8cc5-11bd3d2ed68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c579968b-9e1c-406a-94fd-fa067da42cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_362ce821-1b1b-40de-8cc5-11bd3d2ed68b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c579968b-9e1c-406a-94fd-fa067da42cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheOneMember_641ced90-3819-478b-ba2a-4f1b9dedad99" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c579968b-9e1c-406a-94fd-fa067da42cea" xlink:to="loc_axgn_CreditFacilityTrancheOneMember_641ced90-3819-478b-ba2a-4f1b9dedad99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheTwoMember_bece1912-decb-4f61-9449-a7588c0e2773" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c579968b-9e1c-406a-94fd-fa067da42cea" xlink:to="loc_axgn_CreditFacilityTrancheTwoMember_bece1912-decb-4f61-9449-a7588c0e2773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7fcde607-bae8-453c-b528-cfffd13ac905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ce61c970-d6bf-4863-9917-6fa8deadd691" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7fcde607-bae8-453c-b528-cfffd13ac905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7ee90d42-0d08-421c-94ea-e0b95028c69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7fcde607-bae8-453c-b528-cfffd13ac905" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7ee90d42-0d08-421c-94ea-e0b95028c69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_88653875-2d78-4e7d-9b00-60a0ceb762ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7fcde607-bae8-453c-b528-cfffd13ac905" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_88653875-2d78-4e7d-9b00-60a0ceb762ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_30a099fb-8a2d-4a35-85cd-272cdeac7783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7fcde607-bae8-453c-b528-cfffd13ac905" xlink:to="loc_us-gaap_LongTermDebt_30a099fb-8a2d-4a35-85cd-272cdeac7783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_43d87b43-60b3-4d96-b588-4f615784c557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_43d87b43-60b3-4d96-b588-4f615784c557" xlink:to="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8c06689d-ff33-424f-9451-cb908dc38c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_DebtInstrumentAxis_8c06689d-ff33-424f-9451-cb908dc38c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_aa91fc9b-54a6-4f92-b00e-cf94b6d13062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8c06689d-ff33-424f-9451-cb908dc38c01" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_aa91fc9b-54a6-4f92-b00e-cf94b6d13062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityMember_7e39f26e-0792-40f5-a699-5d4226fb6ffb" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_aa91fc9b-54a6-4f92-b00e-cf94b6d13062" xlink:to="loc_axgn_CreditFacilityMember_7e39f26e-0792-40f5-a699-5d4226fb6ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheOneMember_610112ca-3e01-429e-9466-aa0d53e29119" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_CreditFacilityMember_7e39f26e-0792-40f5-a699-5d4226fb6ffb" xlink:to="loc_axgn_CreditFacilityTrancheOneMember_610112ca-3e01-429e-9466-aa0d53e29119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheTwoMember_234e456a-2172-412e-a322-25956e15d62f" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_CreditFacilityMember_7e39f26e-0792-40f5-a699-5d4226fb6ffb" xlink:to="loc_axgn_CreditFacilityTrancheTwoMember_234e456a-2172-412e-a322-25956e15d62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_b36d2b65-3127-4f5f-a16a-cd9712ae4f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_VariableRateAxis_b36d2b65-3127-4f5f-a16a-cd9712ae4f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_daa97d7d-7a5f-4fbc-9a59-eb934c67ba18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_b36d2b65-3127-4f5f-a16a-cd9712ae4f37" xlink:to="loc_us-gaap_VariableRateDomain_daa97d7d-7a5f-4fbc-9a59-eb934c67ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_2ccdf81f-0f3c-43ff-a4b9-c36bc400fba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_daa97d7d-7a5f-4fbc-9a59-eb934c67ba18" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_2ccdf81f-0f3c-43ff-a4b9-c36bc400fba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bf630e0f-f036-47e6-a48c-4935fed883a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_InvestmentTypeAxis_bf630e0f-f036-47e6-a48c-4935fed883a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bba418e3-7f34-4ec1-9710-59694d145c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_bf630e0f-f036-47e6-a48c-4935fed883a6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bba418e3-7f34-4ec1-9710-59694d145c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_85a1b5e6-786e-48f6-89da-217de4ba1789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_bba418e3-7f34-4ec1-9710-59694d145c6a" xlink:to="loc_us-gaap_StockOptionMember_85a1b5e6-786e-48f6-89da-217de4ba1789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_0e3b52c5-376a-482b-bac5-1fe66921844d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_srt_OwnershipAxis_0e3b52c5-376a-482b-bac5-1fe66921844d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_8ebd533c-b2ab-47c3-a698-fdbcbe160cdb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_0e3b52c5-376a-482b-bac5-1fe66921844d" xlink:to="loc_srt_OwnershipDomain_8ebd533c-b2ab-47c3-a698-fdbcbe160cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember_f049028f-7915-4e95-8ba4-a1e10ebe7c90" xlink:href="axgn-20221231.xsd#axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_8ebd533c-b2ab-47c3-a698-fdbcbe160cdb" xlink:to="loc_axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember_f049028f-7915-4e95-8ba4-a1e10ebe7c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d8520976-8cce-4562-b7c5-a493b6af0bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d8520976-8cce-4562-b7c5-a493b6af0bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_67a11790-266c-42de-b1f2-31a6aed4101e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d8520976-8cce-4562-b7c5-a493b6af0bb2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_67a11790-266c-42de-b1f2-31a6aed4101e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember_e5300ee7-eac9-4cf0-9250-888bdc7e3429" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_67a11790-266c-42de-b1f2-31a6aed4101e" xlink:to="loc_axgn_DebtDerivativeLiabilityMember_e5300ee7-eac9-4cf0-9250-888bdc7e3429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_60549f09-c993-48ed-bc5b-66c84afa882b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_60549f09-c993-48ed-bc5b-66c84afa882b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_43086f39-fe37-4033-bbb6-c24d5badb88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_60549f09-c993-48ed-bc5b-66c84afa882b" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_43086f39-fe37-4033-bbb6-c24d5badb88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RestrictedCashMember_728fbcea-3651-43ba-9ca6-722c899b7748" xlink:href="axgn-20221231.xsd#axgn_RestrictedCashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_43086f39-fe37-4033-bbb6-c24d5badb88b" xlink:to="loc_axgn_RestrictedCashMember_728fbcea-3651-43ba-9ca6-722c899b7748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_2c1c22d8-8920-4a2a-a12e-b1ccdcb9fa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_CreditFacilityAxis_2c1c22d8-8920-4a2a-a12e-b1ccdcb9fa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5957b5e5-234e-4fe0-86e5-a1c8a4cd75a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2c1c22d8-8920-4a2a-a12e-b1ccdcb9fa8d" xlink:to="loc_us-gaap_CreditFacilityDomain_5957b5e5-234e-4fe0-86e5-a1c8a4cd75a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_89106009-a14c-4ac3-a529-a91b8881e66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5957b5e5-234e-4fe0-86e5-a1c8a4cd75a8" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_89106009-a14c-4ac3-a529-a91b8881e66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6841ea5-6e0e-4309-9df6-48956842d1c1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_4ea8be9f-a799-439e-aad9-37f4403369b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DebtInstrumentTerm_4ea8be9f-a799-439e-aad9-37f4403369b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6cc4cf3e-c385-4d50-9cab-768f42d03da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6cc4cf3e-c385-4d50-9cab-768f42d03da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_d4c7f11a-7882-4880-b209-6c71f1158124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_d4c7f11a-7882-4880-b209-6c71f1158124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade_5cdb814d-f63a-445f-a963-ce36d27235ff" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade_5cdb814d-f63a-445f-a963-ce36d27235ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c8db7c4a-5fb2-4400-9351-4977c650afbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_c8db7c4a-5fb2-4400-9351-4977c650afbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentAdditionalInterestFloorRate_0b1d2141-3ff3-48b1-b566-8cf40bec93a4" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentAdditionalInterestFloorRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_DebtInstrumentAdditionalInterestFloorRate_0b1d2141-3ff3-48b1-b566-8cf40bec93a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_c39df72d-f99b-4836-9dc4-f8dc8b0cc3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_c39df72d-f99b-4836-9dc4-f8dc8b0cc3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty_9dea008d-42aa-413c-9d0f-4a4f5357630b" xlink:href="axgn-20221231.xsd#axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty_9dea008d-42aa-413c-9d0f-4a4f5357630b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure_4e48f5e3-2b59-4c8a-a84a-ec7a4cdd6eda" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure_4e48f5e3-2b59-4c8a-a84a-ec7a4cdd6eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_62604bc1-7ca0-46f9-ba06-22240edd9ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_InterestExpense_62604bc1-7ca0-46f9-ba06-22240edd9ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_2afb1dd2-9adc-4057-ae0a-1e501f3f339a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_InterestPaid_2afb1dd2-9adc-4057-ae0a-1e501f3f339a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_ffb58584-25fb-4137-bba0-006359ca58bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_InterestCostsCapitalized_ffb58584-25fb-4137-bba0-006359ca58bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts_e3cab26e-8730-43ea-93df-d83dc36d3db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_AccumulatedCapitalizedInterestCosts_e3cab26e-8730-43ea-93df-d83dc36d3db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_2b09dc70-0b18-4de1-a185-a8edf132a3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_2b09dc70-0b18-4de1-a185-a8edf132a3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PurchasePriceOfCommonStockCalculationPeriod_0cfdd1bd-a1ba-4b00-9996-556e2acf7f24" xlink:href="axgn-20221231.xsd#axgn_PurchasePriceOfCommonStockCalculationPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_PurchasePriceOfCommonStockCalculationPeriod_0cfdd1bd-a1ba-4b00-9996-556e2acf7f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6aecb8e9-7721-4ebc-a67e-e7bccb43f0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6aecb8e9-7721-4ebc-a67e-e7bccb43f0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_a215cb0b-4505-4bde-ae80-7d61419e4237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_a215cb0b-4505-4bde-ae80-7d61419e4237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_96311935-99a4-4fce-8637-6b540696aed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_96311935-99a4-4fce-8637-6b540696aed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn_7bd84218-86f1-4b0f-b9d5-c0ec6c357633" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn_7bd84218-86f1-4b0f-b9d5-c0ec6c357633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease_9d151e6c-52f2-4801-821b-9149e006a9c8" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentInterestRateEventOfDefaultIncrease"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease_9d151e6c-52f2-4801-821b-9149e006a9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_bac1ca25-6aa7-4ed5-b6b3-e0802dcacfd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DerivativeLiabilities_bac1ca25-6aa7-4ed5-b6b3-e0802dcacfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f834b650-aa75-40de-a062-90aefbfab71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f834b650-aa75-40de-a062-90aefbfab71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_afadefc9-7542-45af-93b7-ce2d3ea8f277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_RestrictedCash_afadefc9-7542-45af-93b7-ce2d3ea8f277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount_3141ee23-28be-461e-a49c-e6937fbb0e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_f47dc399-1bb7-439a-b384-f1a87b661a1f" xlink:to="loc_us-gaap_DebtInstrumentCollateralAmount_3141ee23-28be-461e-a49c-e6937fbb0e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#BasicandDilutedLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bd6e3cc0-b1c2-47ac-83db-32aeab04447c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_60349ee4-2578-4795-9e8f-287b841f95fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bd6e3cc0-b1c2-47ac-83db-32aeab04447c" xlink:to="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_60349ee4-2578-4795-9e8f-287b841f95fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_43914953-4318-4649-89a8-bd8184302292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_60349ee4-2578-4795-9e8f-287b841f95fd" xlink:to="loc_us-gaap_NetIncomeLoss_43914953-4318-4649-89a8-bd8184302292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract_766d393b-d82c-4cd3-b3e4-2e77dc0ac0dc" xlink:href="axgn-20221231.xsd#axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bd6e3cc0-b1c2-47ac-83db-32aeab04447c" xlink:to="loc_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract_766d393b-d82c-4cd3-b3e4-2e77dc0ac0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c9f1a3e-5ebe-4671-9f55-2fab4c26b624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract_766d393b-d82c-4cd3-b3e4-2e77dc0ac0dc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c9f1a3e-5ebe-4671-9f55-2fab4c26b624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e6a3492-eaef-43b6-8c77-824f992da143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract_766d393b-d82c-4cd3-b3e4-2e77dc0ac0dc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4e6a3492-eaef-43b6-8c77-824f992da143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_58a95dd5-5d73-4d4e-bb82-d9e6f1e95ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract_766d393b-d82c-4cd3-b3e4-2e77dc0ac0dc" xlink:to="loc_us-gaap_EarningsPerShareBasic_58a95dd5-5d73-4d4e-bb82-d9e6f1e95ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ca877aed-0d47-453e-b61a-1a4471427e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract_766d393b-d82c-4cd3-b3e4-2e77dc0ac0dc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ca877aed-0d47-453e-b61a-1a4471427e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abb564ab-7842-42aa-aecc-58ff32bec2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bd6e3cc0-b1c2-47ac-83db-32aeab04447c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abb564ab-7842-42aa-aecc-58ff32bec2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93e3431e-c28f-437f-9842-6decf3df3530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abb564ab-7842-42aa-aecc-58ff32bec2dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93e3431e-c28f-437f-9842-6decf3df3530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76189e7c-0c91-490b-a39a-3be46f48b6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_93e3431e-c28f-437f-9842-6decf3df3530" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76189e7c-0c91-490b-a39a-3be46f48b6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_aa7a38ad-fd05-4805-a503-5984174e6ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76189e7c-0c91-490b-a39a-3be46f48b6bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_aa7a38ad-fd05-4805-a503-5984174e6ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_770a3711-8c40-481c-9c54-8d6efe95ad11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_76189e7c-0c91-490b-a39a-3be46f48b6bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_770a3711-8c40-481c-9c54-8d6efe95ad11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0508a10-ce40-4ff1-95ae-cd5a710a64b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_abb564ab-7842-42aa-aecc-58ff32bec2dd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0508a10-ce40-4ff1-95ae-cd5a710a64b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bce8763-eb0e-4c95-8184-4803014fd0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c0508a10-ce40-4ff1-95ae-cd5a710a64b1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bce8763-eb0e-4c95-8184-4803014fd0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6f88b6e-e0f1-4d11-aa5d-86bb51da1003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_159efd18-952a-4616-b359-87765edbcef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6f88b6e-e0f1-4d11-aa5d-86bb51da1003" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_159efd18-952a-4616-b359-87765edbcef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0edd9d62-a4d1-4b13-89b9-cc5bc8802176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_159efd18-952a-4616-b359-87765edbcef3" xlink:to="loc_us-gaap_PlanNameAxis_0edd9d62-a4d1-4b13-89b9-cc5bc8802176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_392c96e8-fbf3-4cae-ac26-051f19383ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0edd9d62-a4d1-4b13-89b9-cc5bc8802176" xlink:to="loc_us-gaap_PlanNameDomain_392c96e8-fbf3-4cae-ac26-051f19383ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_5a4feace-d38a-491e-aedc-f8a1dbd686d6" xlink:href="axgn-20221231.xsd#axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_392c96e8-fbf3-4cae-ac26-051f19383ee6" xlink:to="loc_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_5a4feace-d38a-491e-aedc-f8a1dbd686d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ca7bbccf-b49b-4cc8-9e87-ae11d5df34f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_159efd18-952a-4616-b359-87765edbcef3" xlink:to="loc_srt_RangeAxis_ca7bbccf-b49b-4cc8-9e87-ae11d5df34f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_65db7bf4-c228-4331-a26d-844171572a57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ca7bbccf-b49b-4cc8-9e87-ae11d5df34f9" xlink:to="loc_srt_RangeMember_65db7bf4-c228-4331-a26d-844171572a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9bf22b3f-b83e-4ca3-90b1-407f28520074" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65db7bf4-c228-4331-a26d-844171572a57" xlink:to="loc_srt_MinimumMember_9bf22b3f-b83e-4ca3-90b1-407f28520074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_807148ae-5959-4820-aaff-f4fee5b4b12d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_65db7bf4-c228-4331-a26d-844171572a57" xlink:to="loc_srt_MaximumMember_807148ae-5959-4820-aaff-f4fee5b4b12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2158e716-65f6-4a94-84d7-ed5b479db66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_159efd18-952a-4616-b359-87765edbcef3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2158e716-65f6-4a94-84d7-ed5b479db66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ShareBasePaymentArrangementNumberOfPlans_570f9a7b-745d-4cdd-ae7a-94ecfe433ff9" xlink:href="axgn-20221231.xsd#axgn_ShareBasePaymentArrangementNumberOfPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2158e716-65f6-4a94-84d7-ed5b479db66c" xlink:to="loc_axgn_ShareBasePaymentArrangementNumberOfPlans_570f9a7b-745d-4cdd-ae7a-94ecfe433ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_74d047cf-9094-4431-8792-30a72206ed01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2158e716-65f6-4a94-84d7-ed5b479db66c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_74d047cf-9094-4431-8792-30a72206ed01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1b41ba8a-8bcb-4b8c-ad99-d3a5996f6c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2158e716-65f6-4a94-84d7-ed5b479db66c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1b41ba8a-8bcb-4b8c-ad99-d3a5996f6c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_adcc55f5-b383-4117-8580-350875c402e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0682577-97f2-4e14-a816-29c908013779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_adcc55f5-b383-4117-8580-350875c402e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0682577-97f2-4e14-a816-29c908013779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7781ff2f-d1ab-460a-b5c8-06b225c56d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0682577-97f2-4e14-a816-29c908013779" xlink:to="loc_us-gaap_PlanNameAxis_7781ff2f-d1ab-460a-b5c8-06b225c56d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e49f7915-ec37-406d-838a-580b7f3fb911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7781ff2f-d1ab-460a-b5c8-06b225c56d2b" xlink:to="loc_us-gaap_PlanNameDomain_e49f7915-ec37-406d-838a-580b7f3fb911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_bfccf5b4-0832-40be-9335-1f4cc2f8469a" xlink:href="axgn-20221231.xsd#axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e49f7915-ec37-406d-838a-580b7f3fb911" xlink:to="loc_axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember_bfccf5b4-0832-40be-9335-1f4cc2f8469a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5c3e3f04-84ca-483d-a515-ecd4a1f57a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0682577-97f2-4e14-a816-29c908013779" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5c3e3f04-84ca-483d-a515-ecd4a1f57a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5c3e3f04-84ca-483d-a515-ecd4a1f57a26" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_17fff00d-7db3-44f2-ad57-e0331d91e745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:to="loc_us-gaap_CostOfSalesMember_17fff00d-7db3-44f2-ad57-e0331d91e745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_f8aa9cb0-7b50-4141-a8d3-3773b084b11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_f8aa9cb0-7b50-4141-a8d3-3773b084b11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_24211681-15ce-43b3-8479-d05f1dd4bf40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_24211681-15ce-43b3-8479-d05f1dd4bf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9c278260-cf05-449d-a63e-a01e11eff72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7ab08cfd-7669-48fe-b2d2-01ffafeb0f12" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_9c278260-cf05-449d-a63e-a01e11eff72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16e9632-597a-4e41-bd73-12324114ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0682577-97f2-4e14-a816-29c908013779" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16e9632-597a-4e41-bd73-12324114ce7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c768aeb-544f-4e64-89e8-aea4f6addab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b16e9632-597a-4e41-bd73-12324114ce7c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7c768aeb-544f-4e64-89e8-aea4f6addab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationStockOptionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9993a7cb-908e-46ff-8e4f-8fb04641784f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9993a7cb-908e-46ff-8e4f-8fb04641784f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_85bd7adb-5d1e-419a-843a-b7e55fbd5025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:to="loc_us-gaap_AwardTypeAxis_85bd7adb-5d1e-419a-843a-b7e55fbd5025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_85bd7adb-5d1e-419a-843a-b7e55fbd5025" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6e207658-cd1c-4b25-9244-9f3ed793b80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6e207658-cd1c-4b25-9244-9f3ed793b80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DirectorsAndOfficersStockOptionsMember_7783754a-e7bc-444f-8761-87eccff58fb2" xlink:href="axgn-20221231.xsd#axgn_DirectorsAndOfficersStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:to="loc_axgn_DirectorsAndOfficersStockOptionsMember_7783754a-e7bc-444f-8761-87eccff58fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c70188d4-62f0-4480-bf48-44dc0567fd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c70188d4-62f0-4480-bf48-44dc0567fd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_30692c86-ffe6-4f73-ad32-14c7e775dc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c5f038-977b-4ec1-9ff1-d523984c52ea" xlink:to="loc_us-gaap_PerformanceSharesMember_30692c86-ffe6-4f73-ad32-14c7e775dc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d42575f6-44a9-42f7-90d6-029346c95249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:to="loc_us-gaap_PlanNameAxis_d42575f6-44a9-42f7-90d6-029346c95249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4548ca85-5eff-48d9-aa2c-9f0729b54ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d42575f6-44a9-42f7-90d6-029346c95249" xlink:to="loc_us-gaap_PlanNameDomain_4548ca85-5eff-48d9-aa2c-9f0729b54ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AxoGen2010StockIncentivePlanMember_58851929-d1e5-4c38-8521-21d608e63596" xlink:href="axgn-20221231.xsd#axgn_AxoGen2010StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4548ca85-5eff-48d9-aa2c-9f0729b54ea6" xlink:to="loc_axgn_AxoGen2010StockIncentivePlanMember_58851929-d1e5-4c38-8521-21d608e63596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_f1078fe9-f206-4e12-9831-566e78023e0e" xlink:href="axgn-20221231.xsd#axgn_Axogen2017EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4548ca85-5eff-48d9-aa2c-9f0729b54ea6" xlink:to="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_f1078fe9-f206-4e12-9831-566e78023e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_52cb132a-0754-4dcd-a446-dc191300d423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:to="loc_us-gaap_VestingAxis_52cb132a-0754-4dcd-a446-dc191300d423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_52cb132a-0754-4dcd-a446-dc191300d423" xlink:to="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_00132d66-ca6b-405a-8fed-419ca1a82be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_00132d66-ca6b-405a-8fed-419ca1a82be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d540d84a-88d5-44e0-9991-a1139fda25ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_d540d84a-88d5-44e0-9991-a1139fda25ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_368ac0e1-c359-4885-bc78-3d2adbe92b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_368ac0e1-c359-4885-bc78-3d2adbe92b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ShareBasedCompensationAwardTrancheFourMember_0183b844-be9e-4274-84c7-40e1ac743225" xlink:href="axgn-20221231.xsd#axgn_ShareBasedCompensationAwardTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_7685f5b1-935c-4952-9ca0-9b94175b629e" xlink:to="loc_axgn_ShareBasedCompensationAwardTrancheFourMember_0183b844-be9e-4274-84c7-40e1ac743225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_560449a4-a700-4c62-a3a7-ff3dc616baa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:to="loc_srt_RangeAxis_560449a4-a700-4c62-a3a7-ff3dc616baa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c74a9990-4011-4d0d-889c-1541f710de34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_560449a4-a700-4c62-a3a7-ff3dc616baa3" xlink:to="loc_srt_RangeMember_c74a9990-4011-4d0d-889c-1541f710de34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e38167bc-eb6b-42c4-bd89-c19dd3d431fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c74a9990-4011-4d0d-889c-1541f710de34" xlink:to="loc_srt_MinimumMember_e38167bc-eb6b-42c4-bd89-c19dd3d431fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee614172-eeb2-4762-a975-6d8565ba1587" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c74a9990-4011-4d0d-889c-1541f710de34" xlink:to="loc_srt_MaximumMember_ee614172-eeb2-4762-a975-6d8565ba1587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5beedf49-b4c1-4100-9684-fd05543c0c85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cd94469f-eb1e-4d19-85e2-61d109228097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cd94469f-eb1e-4d19-85e2-61d109228097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3166fd9b-263e-4105-89c1-c3f9b96c91a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3166fd9b-263e-4105-89c1-c3f9b96c91a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_223ced39-fa9d-427b-87f5-228bf46ab898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_223ced39-fa9d-427b-87f5-228bf46ab898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ae26355b-82bc-4deb-8da3-bdc1d57d7a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ae26355b-82bc-4deb-8da3-bdc1d57d7a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_586b6a0e-c092-4c95-930e-f394beb25ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_586b6a0e-c092-4c95-930e-f394beb25ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af2d2113-5199-42ac-9a64-d7941a007250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64f16f5f-b80f-4c5e-85d1-6c44ef7e1077" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_af2d2113-5199-42ac-9a64-d7941a007250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_967aad97-ffbb-46f8-b1ac-0f53c3465b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fb67839-180f-48ea-a1e7-9d4079525caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_967aad97-ffbb-46f8-b1ac-0f53c3465b3b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fb67839-180f-48ea-a1e7-9d4079525caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ad3dde8d-f6b2-480b-b8a7-72fc0c7edab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fb67839-180f-48ea-a1e7-9d4079525caa" xlink:to="loc_us-gaap_AwardTypeAxis_ad3dde8d-f6b2-480b-b8a7-72fc0c7edab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41ddfce3-f19b-4ac1-b9e0-b1f493d5af0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ad3dde8d-f6b2-480b-b8a7-72fc0c7edab3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41ddfce3-f19b-4ac1-b9e0-b1f493d5af0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f5c5ae65-68be-4bf1-9479-0140057037e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41ddfce3-f19b-4ac1-b9e0-b1f493d5af0b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f5c5ae65-68be-4bf1-9479-0140057037e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fb67839-180f-48ea-a1e7-9d4079525caa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c140ab04-d3f7-44a2-bb02-8fa3977b39a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c140ab04-d3f7-44a2-bb02-8fa3977b39a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1e6faae9-96fe-444d-8ff4-523648dfa380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1e6faae9-96fe-444d-8ff4-523648dfa380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35048b2f-6fa0-49b5-a083-9c4bfb8d6fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_35048b2f-6fa0-49b5-a083-9c4bfb8d6fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a4115249-c740-49a9-8768-a09eb7fd400e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4b9b6be1-557b-489c-bbb9-dd4a5b8f4a17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a4115249-c740-49a9-8768-a09eb7fd400e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db5262d7-5631-49e6-8416-262a78478301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d5e5ee-f1eb-45fd-bae1-0a0569c5e71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_db5262d7-5631-49e6-8416-262a78478301" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d5e5ee-f1eb-45fd-bae1-0a0569c5e71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d3ae078-2670-475d-8d0c-abaa0324da61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d5e5ee-f1eb-45fd-bae1-0a0569c5e71a" xlink:to="loc_us-gaap_AwardTypeAxis_2d3ae078-2670-475d-8d0c-abaa0324da61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c13627-a3e1-4e77-aa68-2f50af199cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2d3ae078-2670-475d-8d0c-abaa0324da61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c13627-a3e1-4e77-aa68-2f50af199cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a514c852-296f-4cab-ab31-205bc07220ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c13627-a3e1-4e77-aa68-2f50af199cca" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a514c852-296f-4cab-ab31-205bc07220ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d5e5ee-f1eb-45fd-bae1-0a0569c5e71a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5493040c-4ec5-4f59-80c3-935bdf44a470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5493040c-4ec5-4f59-80c3-935bdf44a470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e37c74ad-4d5d-47a4-a0d5-c7c6311f1cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e37c74ad-4d5d-47a4-a0d5-c7c6311f1cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f178a419-c1e2-452c-99d7-12999dd8032d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f178a419-c1e2-452c-99d7-12999dd8032d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7804c1b4-b7a1-4414-bbf8-b409eb3f1740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7804c1b4-b7a1-4414-bbf8-b409eb3f1740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ca6970c3-fdf0-4941-9893-019620d3e267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec23a229-7f11-4109-a936-7194d209f50c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ca6970c3-fdf0-4941-9893-019620d3e267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78ba2044-bc0b-4301-9532-bb1845f03581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78ba2044-bc0b-4301-9532-bb1845f03581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d5b478d-353b-4d97-b132-a17233e6d749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d5b478d-353b-4d97-b132-a17233e6d749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb23a740-c509-46ec-8140-42a42cf4cf50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fb23a740-c509-46ec-8140-42a42cf4cf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7adab0d5-01a2-4689-8c37-b5c719a8ed83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7adab0d5-01a2-4689-8c37-b5c719a8ed83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b51cb1f6-9a69-4c25-801d-a2f5d506df32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b51cb1f6-9a69-4c25-801d-a2f5d506df32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c6815e9a-9c9a-4cbb-a982-54b8278bb88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5aa13717-db9f-44d1-b811-d37a21a194cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c6815e9a-9c9a-4cbb-a982-54b8278bb88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_11a983f0-0598-4768-a1bb-6f8091b0ff20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_11a983f0-0598-4768-a1bb-6f8091b0ff20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_946401f9-9b6c-409d-bd67-8e40b0f5af38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50fa0ed0-fd66-481f-b4e1-e601b0114c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50fa0ed0-fd66-481f-b4e1-e601b0114c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b3ea9262-4bcb-4922-baca-c01398029737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b3ea9262-4bcb-4922-baca-c01398029737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6e7681af-365e-43b8-b0e5-0c15bfc22bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6e7681af-365e-43b8-b0e5-0c15bfc22bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_49fb8b4c-3489-4cb1-8c12-d84f0018f614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4e9d613d-ca57-4ab3-aa4e-da414acf2c54" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_49fb8b4c-3489-4cb1-8c12-d84f0018f614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1552418-7463-4448-9397-e03704b2775d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1552418-7463-4448-9397-e03704b2775d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c934d18-6df9-4077-ad8a-e82c0910f247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:to="loc_us-gaap_AwardTypeAxis_0c934d18-6df9-4077-ad8a-e82c0910f247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06daabf7-492d-49c7-902c-07fbdd06789a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0c934d18-6df9-4077-ad8a-e82c0910f247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06daabf7-492d-49c7-902c-07fbdd06789a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2ca197e6-0d3d-46e8-99bd-4bbbd9fdd168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06daabf7-492d-49c7-902c-07fbdd06789a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2ca197e6-0d3d-46e8-99bd-4bbbd9fdd168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06daabf7-492d-49c7-902c-07fbdd06789a" xlink:to="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PerformanceSharesBiologicLicenseApplicationMember_cecefa0e-49b4-4563-9398-7c1f6af5f3cd" xlink:href="axgn-20221231.xsd#axgn_PerformanceSharesBiologicLicenseApplicationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:to="loc_axgn_PerformanceSharesBiologicLicenseApplicationMember_cecefa0e-49b4-4563-9398-7c1f6af5f3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TwoThousandTwentyPerformanceShareUnitMember_03281ce7-0a95-4035-9ecb-dc11fa22574b" xlink:href="axgn-20221231.xsd#axgn_TwoThousandTwentyPerformanceShareUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:to="loc_axgn_TwoThousandTwentyPerformanceShareUnitMember_03281ce7-0a95-4035-9ecb-dc11fa22574b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TwoThousandTwentyOnePerformanceShareUnitMember_d2a3458e-9221-49f9-ae0f-a4a9d30d88f0" xlink:href="axgn-20221231.xsd#axgn_TwoThousandTwentyOnePerformanceShareUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:to="loc_axgn_TwoThousandTwentyOnePerformanceShareUnitMember_d2a3458e-9221-49f9-ae0f-a4a9d30d88f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember_f41934c1-a3a5-4c54-8dc1-bc6e8ea6569e" xlink:href="axgn-20221231.xsd#axgn_TwoThousandTwentyTwoPerformanceShareUnitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PerformanceSharesMember_47a8d00b-acda-4908-afea-191b71895378" xlink:to="loc_axgn_TwoThousandTwentyTwoPerformanceShareUnitMember_f41934c1-a3a5-4c54-8dc1-bc6e8ea6569e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d67f8c69-b1cd-4980-ac65-ee421bb71968" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:to="loc_srt_TitleOfIndividualAxis_d67f8c69-b1cd-4980-ac65-ee421bb71968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eccffc8d-86ff-4e23-8406-49bd89a23798" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_d67f8c69-b1cd-4980-ac65-ee421bb71968" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eccffc8d-86ff-4e23-8406-49bd89a23798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DirectorsAndCertainExecutiveOfficersMember_7bfb2a7a-0581-4684-9298-031a8e77e6b0" xlink:href="axgn-20221231.xsd#axgn_DirectorsAndCertainExecutiveOfficersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eccffc8d-86ff-4e23-8406-49bd89a23798" xlink:to="loc_axgn_DirectorsAndCertainExecutiveOfficersMember_7bfb2a7a-0581-4684-9298-031a8e77e6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_5ff07b53-6aee-4c10-affc-fbe15b01b2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:to="loc_us-gaap_VestingAxis_5ff07b53-6aee-4c10-affc-fbe15b01b2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f069c216-f921-4cef-b57e-f3bbf0449a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_5ff07b53-6aee-4c10-affc-fbe15b01b2dc" xlink:to="loc_us-gaap_VestingDomain_f069c216-f921-4cef-b57e-f3bbf0449a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_940c7633-f5a2-4b66-b719-cc520e39c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f069c216-f921-4cef-b57e-f3bbf0449a52" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_940c7633-f5a2-4b66-b719-cc520e39c90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e9f02280-0c60-44cc-bb04-27b18b80c72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f069c216-f921-4cef-b57e-f3bbf0449a52" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e9f02280-0c60-44cc-bb04-27b18b80c72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7c666dc4-bde3-4d8b-a776-271bb7f64df1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:to="loc_srt_RangeAxis_7c666dc4-bde3-4d8b-a776-271bb7f64df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f81407d2-75bd-48c7-bee2-83ce8c43dd95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7c666dc4-bde3-4d8b-a776-271bb7f64df1" xlink:to="loc_srt_RangeMember_f81407d2-75bd-48c7-bee2-83ce8c43dd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0ad0343c-9331-4a93-924e-944bfbce10e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f81407d2-75bd-48c7-bee2-83ce8c43dd95" xlink:to="loc_srt_MinimumMember_0ad0343c-9331-4a93-924e-944bfbce10e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_002dc68b-aa2e-4fb1-aebb-7c0382cc29bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f81407d2-75bd-48c7-bee2-83ce8c43dd95" xlink:to="loc_srt_MaximumMember_002dc68b-aa2e-4fb1-aebb-7c0382cc29bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_436c09ae-d837-4e3e-b4a9-1fbb0a857e4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4339b93b-95ee-4402-86c8-08bff4510855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4339b93b-95ee-4402-86c8-08bff4510855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2ace89a6-d634-4cea-8661-da01ab401bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2ace89a6-d634-4cea-8661-da01ab401bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5ea34a2d-d521-400f-8569-b3322579ab63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5ea34a2d-d521-400f-8569-b3322579ab63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6dd7c50d-5a11-478d-bef3-50b26aa2c433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6dd7c50d-5a11-478d-bef3-50b26aa2c433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16f093db-58b5-480f-b15b-5f68d1c125ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16f093db-58b5-480f-b15b-5f68d1c125ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_95c34386-76ea-439a-b44b-aed2a9846652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_95c34386-76ea-439a-b44b-aed2a9846652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PercentageOfAchievementOfAwardIssued_b4f5304c-8dfc-4570-97bc-5ee3714abcea" xlink:href="axgn-20221231.xsd#axgn_PercentageOfAchievementOfAwardIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_axgn_PercentageOfAchievementOfAwardIssued_b4f5304c-8dfc-4570-97bc-5ee3714abcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ShareBasedCompensationExpenseForfeitedOrReversed_0a413850-b709-42c7-907f-c223d94d7959" xlink:href="axgn-20221231.xsd#axgn_ShareBasedCompensationExpenseForfeitedOrReversed"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_axgn_ShareBasedCompensationExpenseForfeitedOrReversed_0a413850-b709-42c7-907f-c223d94d7959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PerformanceStockUnitPayoutOpportunity_e59191e6-8bcf-4942-912f-8efa976058e4" xlink:href="axgn-20221231.xsd#axgn_PerformanceStockUnitPayoutOpportunity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_axgn_PerformanceStockUnitPayoutOpportunity_e59191e6-8bcf-4942-912f-8efa976058e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_46a88e1c-0a77-4ec6-b746-d7d1e77ecb58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7caac1c8-4715-412c-a9d9-761c599c7469" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_46a88e1c-0a77-4ec6-b746-d7d1e77ecb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_841e8665-2942-4d09-afbb-cc687718d347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b47e5789-1f96-451c-accb-eb0264e09b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_841e8665-2942-4d09-afbb-cc687718d347" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b47e5789-1f96-451c-accb-eb0264e09b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_535f25de-7227-417b-b669-79aa3ddcb886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b47e5789-1f96-451c-accb-eb0264e09b2a" xlink:to="loc_us-gaap_AwardTypeAxis_535f25de-7227-417b-b669-79aa3ddcb886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8abede84-ad2c-4c3b-99b9-8175a1420860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_535f25de-7227-417b-b669-79aa3ddcb886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8abede84-ad2c-4c3b-99b9-8175a1420860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_56be8b6a-21db-4971-87c0-fa42f939f84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8abede84-ad2c-4c3b-99b9-8175a1420860" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_56be8b6a-21db-4971-87c0-fa42f939f84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e3a4fb85-191c-4888-aa72-b0f46b7eac1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8abede84-ad2c-4c3b-99b9-8175a1420860" xlink:to="loc_us-gaap_PerformanceSharesMember_e3a4fb85-191c-4888-aa72-b0f46b7eac1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4473a691-4b72-42ac-923b-110c3c9384d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b47e5789-1f96-451c-accb-eb0264e09b2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4473a691-4b72-42ac-923b-110c3c9384d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4473a691-4b72-42ac-923b-110c3c9384d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2aeb8f91-3553-4fd3-acac-4c8591c11414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2aeb8f91-3553-4fd3-acac-4c8591c11414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c0858af5-31fb-4074-8561-6ba78ebfa30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c0858af5-31fb-4074-8561-6ba78ebfa30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_799fb555-824e-4043-91b8-dcb26c1ffa52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_799fb555-824e-4043-91b8-dcb26c1ffa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc489a54-8889-4e05-8530-a2768e19d2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cc489a54-8889-4e05-8530-a2768e19d2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a73ed3d8-9ca0-40d6-aadc-e1ab207df9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_74e5784c-2108-4581-b787-672b14528d89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a73ed3d8-9ca0-40d6-aadc-e1ab207df9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4473a691-4b72-42ac-923b-110c3c9384d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cefd89bd-a394-4bbd-a298-49f24519246f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cefd89bd-a394-4bbd-a298-49f24519246f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_37d6fdcb-0130-49f8-b050-85645a6c1fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_37d6fdcb-0130-49f8-b050-85645a6c1fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5e390bac-f471-43ec-b9f5-cb2f3aec3fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5e390bac-f471-43ec-b9f5-cb2f3aec3fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_66aaa645-4bfe-4b33-b2ec-3e6dbbecb486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_66aaa645-4bfe-4b33-b2ec-3e6dbbecb486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_64221bc3-fe1d-43bf-8f14-f6d5489aadce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_83af4386-79e3-4043-893b-ffa368eb0589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_64221bc3-fe1d-43bf-8f14-f6d5489aadce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4a4b01b4-520f-4700-a09b-cfc32d57b773" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4473a691-4b72-42ac-923b-110c3c9384d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4a4b01b4-520f-4700-a09b-cfc32d57b773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b4dc400c-275b-4658-afa7-1319edb40720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4a4b01b4-520f-4700-a09b-cfc32d57b773" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b4dc400c-275b-4658-afa7-1319edb40720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_28b9f4f2-4d60-4e0d-8ab5-750a8f826902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_4a4b01b4-520f-4700-a09b-cfc32d57b773" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_28b9f4f2-4d60-4e0d-8ab5-750a8f826902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82319033-7119-431f-ae8f-558f4674af92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9be1f7d-c8f9-423b-b11f-1663c031cca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82319033-7119-431f-ae8f-558f4674af92" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9be1f7d-c8f9-423b-b11f-1663c031cca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_80ee08fa-7107-4e8a-9e21-d8c2d634e968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9be1f7d-c8f9-423b-b11f-1663c031cca3" xlink:to="loc_us-gaap_PlanNameAxis_80ee08fa-7107-4e8a-9e21-d8c2d634e968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7411e5a5-c4a3-4060-bfaa-3edaf5fba9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_80ee08fa-7107-4e8a-9e21-d8c2d634e968" xlink:to="loc_us-gaap_PlanNameDomain_7411e5a5-c4a3-4060-bfaa-3edaf5fba9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_7077866d-53df-4495-b287-8c3c0d10eadb" xlink:href="axgn-20221231.xsd#axgn_Axogen2017EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7411e5a5-c4a3-4060-bfaa-3edaf5fba9a6" xlink:to="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_7077866d-53df-4495-b287-8c3c0d10eadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f2f5028b-34c1-4931-92eb-d0bd1d151777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9be1f7d-c8f9-423b-b11f-1663c031cca3" xlink:to="loc_us-gaap_AwardTypeAxis_f2f5028b-34c1-4931-92eb-d0bd1d151777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44e81a64-e91f-4e99-9f00-4039ce8ea7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f2f5028b-34c1-4931-92eb-d0bd1d151777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44e81a64-e91f-4e99-9f00-4039ce8ea7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ce9ffea4-55cf-49e9-9c7a-eedf3b06d7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44e81a64-e91f-4e99-9f00-4039ce8ea7fe" xlink:to="loc_us-gaap_EmployeeStockMember_ce9ffea4-55cf-49e9-9c7a-eedf3b06d7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9be1f7d-c8f9-423b-b11f-1663c031cca3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_7c322ecd-4760-4594-9397-59ca6e5938fa" xlink:href="axgn-20221231.xsd#axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock_7c322ecd-4760-4594-9397-59ca6e5938fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmployeeStockPurchasePlanOfferingPeriod_f0ef9973-89e4-46e7-a2a0-404579b7834b" xlink:href="axgn-20221231.xsd#axgn_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_axgn_EmployeeStockPurchasePlanOfferingPeriod_f0ef9973-89e4-46e7-a2a0-404579b7834b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_698d6af2-2a68-4204-b3ef-a923ac4cb663" xlink:href="axgn-20221231.xsd#axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear_698d6af2-2a68-4204-b3ef-a923ac4cb663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b07a56d-88df-49af-bbdb-1ccfffe8c2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b07a56d-88df-49af-bbdb-1ccfffe8c2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639142b8-2b2a-4d2e-a4f5-0c2998c7aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_639142b8-2b2a-4d2e-a4f5-0c2998c7aec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fc4763cf-ec04-4177-8c17-a26d4affbec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fc4763cf-ec04-4177-8c17-a26d4affbec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9da85aaf-910e-40f1-9eec-5e8fe6a95d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49c1c17a-cf92-4266-b652-126baddcbc3d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9da85aaf-910e-40f1-9eec-5e8fe6a95d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_451f0bd6-e9eb-4e33-bfab-7e8be69fb855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15ba763b-621c-45ac-8704-9d79240d46dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_451f0bd6-e9eb-4e33-bfab-7e8be69fb855" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15ba763b-621c-45ac-8704-9d79240d46dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f57a4f71-e27f-4e08-9fcf-04d6a8b21758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15ba763b-621c-45ac-8704-9d79240d46dd" xlink:to="loc_us-gaap_PlanNameAxis_f57a4f71-e27f-4e08-9fcf-04d6a8b21758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cda3a30d-57d2-4b8a-b320-3b43ec55d156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f57a4f71-e27f-4e08-9fcf-04d6a8b21758" xlink:to="loc_us-gaap_PlanNameDomain_cda3a30d-57d2-4b8a-b320-3b43ec55d156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_c065f17a-f99c-4b8e-a050-c34fa26d61d6" xlink:href="axgn-20221231.xsd#axgn_Axogen2017EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cda3a30d-57d2-4b8a-b320-3b43ec55d156" xlink:to="loc_axgn_Axogen2017EmployeeStockPurchasePlanMember_c065f17a-f99c-4b8e-a050-c34fa26d61d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_15ba763b-621c-45ac-8704-9d79240d46dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_467e1bc0-a426-4247-9b14-4714c15a8509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_467e1bc0-a426-4247-9b14-4714c15a8509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953b1b5e-549e-4bff-9fba-6ecbe4ccb304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_953b1b5e-549e-4bff-9fba-6ecbe4ccb304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a412b061-a1b1-4652-adce-2cf2296aa4da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a412b061-a1b1-4652-adce-2cf2296aa4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15525d42-cf68-4879-be8c-1015b3ae70c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2040d3ad-32ed-42cf-8098-90c2c2614fd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15525d42-cf68-4879-be8c-1015b3ae70c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IncomeTaxesTemporaryDifferencesDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_53a8aa7b-0663-4f0e-afac-4110cd516bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_5e334410-1793-4b09-931d-109e51ed44d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_53a8aa7b-0663-4f0e-afac-4110cd516bd5" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_5e334410-1793-4b09-931d-109e51ed44d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_5e334410-1793-4b09-931d-109e51ed44d6" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_786d367e-1897-471e-ae2c-f237176bcf05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_786d367e-1897-471e-ae2c-f237176bcf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_e9b0b433-b089-4037-a1f9-53203152dcab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_e9b0b433-b089-4037-a1f9-53203152dcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxAssetsInterestLimitation_247f9985-8376-4d2c-aaa6-9c7fb54ebaea" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxAssetsInterestLimitation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:to="loc_axgn_DeferredTaxAssetsInterestLimitation_247f9985-8376-4d2c-aaa6-9c7fb54ebaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_46e3e7bd-a487-4802-8be1-0f7ce71aa2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_46e3e7bd-a487-4802-8be1-0f7ce71aa2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxAssetsLeaseObligations_d7e7d073-8abc-493e-b120-e87358dfdf11" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxAssetsLeaseObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:to="loc_axgn_DeferredTaxAssetsLeaseObligations_d7e7d073-8abc-493e-b120-e87358dfdf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bc6dbf10-abb3-4c79-b900-52f8da043fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bc6dbf10-abb3-4c79-b900-52f8da043fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_9e690c22-a24c-47fd-8ca0-8044be85afec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_9e690c22-a24c-47fd-8ca0-8044be85afec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_11efdaff-ea72-414e-b876-752fb47a149e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_11efdaff-ea72-414e-b876-752fb47a149e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_0ce59d96-32f2-4fcd-bc9b-53204b06401d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:to="loc_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_0ce59d96-32f2-4fcd-bc9b-53204b06401d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_5e4c4713-922d-4156-83c7-a2ac55954162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c329e087-9ce9-441a-a95d-4f2aa256e8c7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_5e4c4713-922d-4156-83c7-a2ac55954162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fdd97264-aea9-48d5-a6e5-581acffda892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_5e334410-1793-4b09-931d-109e51ed44d6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fdd97264-aea9-48d5-a6e5-581acffda892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_d889b7cd-0ebe-4b12-9488-fa9f964183d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_5e334410-1793-4b09-931d-109e51ed44d6" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_d889b7cd-0ebe-4b12-9488-fa9f964183d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_bc29e614-d860-46ae-9571-16b86d56d44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_d889b7cd-0ebe-4b12-9488-fa9f964183d1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_bc29e614-d860-46ae-9571-16b86d56d44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_e69376a0-b670-43cc-a677-a9be74d61039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_d889b7cd-0ebe-4b12-9488-fa9f964183d1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_e69376a0-b670-43cc-a677-a9be74d61039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxLiabilitiesRightOfUseAsset_6fd92e4a-872b-44f6-9ef8-40fb5133cabc" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_d889b7cd-0ebe-4b12-9488-fa9f964183d1" xlink:to="loc_axgn_DeferredTaxLiabilitiesRightOfUseAsset_6fd92e4a-872b-44f6-9ef8-40fb5133cabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_8fb8a2c1-c1b2-4cb5-ae8f-cf41f1cc69a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_d889b7cd-0ebe-4b12-9488-fa9f964183d1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_8fb8a2c1-c1b2-4cb5-ae8f-cf41f1cc69a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_6e04f95d-137b-454c-996f-9911f334f816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_d889b7cd-0ebe-4b12-9488-fa9f964183d1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_6e04f95d-137b-454c-996f-9911f334f816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DeferredTaxAssetsLiabilities_a8277906-9f85-4955-bb08-e4310b18c7d0" xlink:href="axgn-20221231.xsd#axgn_DeferredTaxAssetsLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_5e334410-1793-4b09-931d-109e51ed44d6" xlink:to="loc_axgn_DeferredTaxAssetsLiabilities_a8277906-9f85-4955-bb08-e4310b18c7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_86cdb368-7b3c-499e-af28-e9d72143c22c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_5e334410-1793-4b09-931d-109e51ed44d6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_86cdb368-7b3c-499e-af28-e9d72143c22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7d59c027-0be6-4475-a7c3-37f97928151c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4c22f9a1-151a-42be-b94e-77fd040f9ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d59c027-0be6-4475-a7c3-37f97928151c" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4c22f9a1-151a-42be-b94e-77fd040f9ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_68c67b4f-b1fb-4d92-85e1-605c835e31f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d59c027-0be6-4475-a7c3-37f97928151c" xlink:to="loc_us-gaap_OperatingLossCarryforwards_68c67b4f-b1fb-4d92-85e1-605c835e31f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4b608b1f-3b61-4ccb-8ca5-afac621cd7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d59c027-0be6-4475-a7c3-37f97928151c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4b608b1f-3b61-4ccb-8ca5-afac621cd7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_194f94fa-ba78-4fdd-b7d1-e7a97ce2174a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d02188ae-08e1-4beb-84bc-d09629ba5470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_194f94fa-ba78-4fdd-b7d1-e7a97ce2174a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d02188ae-08e1-4beb-84bc-d09629ba5470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_52310025-7d43-415d-af84-2d62897a8871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_194f94fa-ba78-4fdd-b7d1-e7a97ce2174a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_52310025-7d43-415d-af84-2d62897a8871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_8dbcc0a8-233f-482e-bc03-d8420721240a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_194f94fa-ba78-4fdd-b7d1-e7a97ce2174a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_8dbcc0a8-233f-482e-bc03-d8420721240a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6302b39b-d23e-4d5e-b9d1-4282bb831d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_194f94fa-ba78-4fdd-b7d1-e7a97ce2174a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6302b39b-d23e-4d5e-b9d1-4282bb831d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dfadcc43-7452-443f-bce4-2eb6dc932a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_194f94fa-ba78-4fdd-b7d1-e7a97ce2174a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dfadcc43-7452-443f-bce4-2eb6dc932a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7397f55-7f6f-40d4-a7ea-b8b24770131d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_194f94fa-ba78-4fdd-b7d1-e7a97ce2174a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d7397f55-7f6f-40d4-a7ea-b8b24770131d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/RetirementPlanDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#RetirementPlanDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/RetirementPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_999af208-4d63-4933-9a9a-207ec731594c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_6e774886-d4ac-42ba-8855-923c9d49536c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_999af208-4d63-4933-9a9a-207ec731594c" xlink:to="loc_us-gaap_DefinedContributionPlanTable_6e774886-d4ac-42ba-8855-923c9d49536c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_6ab72722-0c7a-44a8-a1cf-ebc2f592d5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_6e774886-d4ac-42ba-8855-923c9d49536c" xlink:to="loc_us-gaap_RetirementPlanNameAxis_6ab72722-0c7a-44a8-a1cf-ebc2f592d5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_e224e3b0-92da-4d96-92bc-72bbc3994c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameAxis_6ab72722-0c7a-44a8-a1cf-ebc2f592d5dc" xlink:to="loc_us-gaap_RetirementPlanNameDomain_e224e3b0-92da-4d96-92bc-72bbc3994c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen401kPlanMember_720d1a8e-9ef8-4b5c-b5a8-6244e9034f03" xlink:href="axgn-20221231.xsd#axgn_Axogen401kPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_e224e3b0-92da-4d96-92bc-72bbc3994c7a" xlink:to="loc_axgn_Axogen401kPlanMember_720d1a8e-9ef8-4b5c-b5a8-6244e9034f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8dd5f932-f9be-4409-85d4-bfbe09d98d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_6e774886-d4ac-42ba-8855-923c9d49536c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8dd5f932-f9be-4409-85d4-bfbe09d98d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_17c819ff-3939-4737-9fd4-6053b8cff4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8dd5f932-f9be-4409-85d4-bfbe09d98d2d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_17c819ff-3939-4737-9fd4-6053b8cff4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_db119f59-82e9-40a2-8dff-5b96db4ad7e2" xlink:href="axgn-20221231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_17c819ff-3939-4737-9fd4-6053b8cff4c6" xlink:to="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member_db119f59-82e9-40a2-8dff-5b96db4ad7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_bde8218c-f9fe-466e-9b5f-1f7cc83cffec" xlink:href="axgn-20221231.xsd#axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_17c819ff-3939-4737-9fd4-6053b8cff4c6" xlink:to="loc_axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member_bde8218c-f9fe-466e-9b5f-1f7cc83cffec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_6e774886-d4ac-42ba-8855-923c9d49536c" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_027531ba-04cb-476e-b77c-866e8c83755e" xlink:href="axgn-20221231.xsd#axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:to="loc_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan_027531ba-04cb-476e-b77c-866e8c83755e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_c865d4bf-c377-4aa4-87de-81b0c753062b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_c865d4bf-c377-4aa4-87de-81b0c753062b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DefinedContributionPlanEmployeeContributionPercentMatched_8932b33a-a483-4b08-baad-0e78b3bb4c80" xlink:href="axgn-20221231.xsd#axgn_DefinedContributionPlanEmployeeContributionPercentMatched"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:to="loc_axgn_DefinedContributionPlanEmployeeContributionPercentMatched_8932b33a-a483-4b08-baad-0e78b3bb4c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_8cd6c87c-7ea2-4031-9f89-6db51866e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_587b5816-098e-4ff6-bf72-607bdd826b81" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_8cd6c87c-7ea2-4031-9f89-6db51866e21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#CommitmentsandContingenciesServiceAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_448ce808-94be-4ebf-a2c0-bfe532015b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ea5127a5-09ed-4d89-9818-595271e52f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_448ce808-94be-4ebf-a2c0-bfe532015b2f" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ea5127a5-09ed-4d89-9818-595271e52f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_45ac8479-af85-452a-9232-4a22f70de013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ea5127a5-09ed-4d89-9818-595271e52f91" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_45ac8479-af85-452a-9232-4a22f70de013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_682949f5-928e-4949-92d1-a036d3f2b8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_45ac8479-af85-452a-9232-4a22f70de013" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_682949f5-928e-4949-92d1-a036d3f2b8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CommunityTissuesServicesAgreementMember_7ad174f3-505e-44e5-97df-9f69255af569" xlink:href="axgn-20221231.xsd#axgn_CommunityTissuesServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_682949f5-928e-4949-92d1-a036d3f2b8f9" xlink:to="loc_axgn_CommunityTissuesServicesAgreementMember_7ad174f3-505e-44e5-97df-9f69255af569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_b92146c0-d007-4463-9a8c-9680b178f760" xlink:href="axgn-20221231.xsd#axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_682949f5-928e-4949-92d1-a036d3f2b8f9" xlink:to="loc_axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember_b92146c0-d007-4463-9a8c-9680b178f760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable_ea5127a5-09ed-4d89-9818-595271e52f91" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_LicenseFeeAmount_8ac8c11d-03bf-4f49-9e4d-d722c19cd8aa" xlink:href="axgn-20221231.xsd#axgn_LicenseFeeAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:to="loc_axgn_LicenseFeeAmount_8ac8c11d-03bf-4f49-9e4d-d722c19cd8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_NoticePeriodForTerminationOfAgreement_7a2f19e5-724a-4355-b746-632773ce1b19" xlink:href="axgn-20221231.xsd#axgn_NoticePeriodForTerminationOfAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:to="loc_axgn_NoticePeriodForTerminationOfAgreement_7a2f19e5-724a-4355-b746-632773ce1b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_a3627858-9a17-4e15-b085-2dff6f170cc6" xlink:href="axgn-20221231.xsd#axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:to="loc_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement_a3627858-9a17-4e15-b085-2dff6f170cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_PaymentForServiceFees_ba6325f2-5937-4267-902b-efe97f8f3d73" xlink:href="axgn-20221231.xsd#axgn_PaymentForServiceFees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems_176654b1-b05f-43f7-ae0c-ba87e0b40fe8" xlink:to="loc_axgn_PaymentForServiceFees_ba6325f2-5937-4267-902b-efe97f8f3d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9a68f1e-e104-4dfb-9d3b-95474931fbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9a68f1e-e104-4dfb-9d3b-95474931fbd4" xlink:to="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cbea40d4-3c8f-4538-89fc-a5e75e780988" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cbea40d4-3c8f-4538-89fc-a5e75e780988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d94514a7-5b57-4e09-b303-a0e23270d623" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_cbea40d4-3c8f-4538-89fc-a5e75e780988" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d94514a7-5b57-4e09-b303-a0e23270d623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_APCFacilityMember_4bcac1a0-c114-424f-b047-4ba94ad6ba34" xlink:href="axgn-20221231.xsd#axgn_APCFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_d94514a7-5b57-4e09-b303-a0e23270d623" xlink:to="loc_axgn_APCFacilityMember_4bcac1a0-c114-424f-b047-4ba94ad6ba34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_90a345ce-c916-44a7-871b-0dc60b77a5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_90a345ce-c916-44a7-871b-0dc60b77a5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_54fb9c4b-2249-4514-b043-c769fd089690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_90a345ce-c916-44a7-871b-0dc60b77a5d2" xlink:to="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_54fb9c4b-2249-4514-b043-c769fd089690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DesignBuildAgreementMember_3cec22e4-9dd1-40b5-953d-f208d2e20959" xlink:href="axgn-20221231.xsd#axgn_DesignBuildAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_54fb9c4b-2249-4514-b043-c769fd089690" xlink:to="loc_axgn_DesignBuildAgreementMember_3cec22e4-9dd1-40b5-953d-f208d2e20959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4d5fd53a-e60f-4d27-851f-50acf88ab27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4d5fd53a-e60f-4d27-851f-50acf88ab27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_449481e3-21ca-49a9-bfca-83e6067a6338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4d5fd53a-e60f-4d27-851f-50acf88ab27f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_449481e3-21ca-49a9-bfca-83e6067a6338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_f9578004-a76c-467f-a1c6-f2a01119e9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_449481e3-21ca-49a9-bfca-83e6067a6338" xlink:to="loc_us-gaap_ConstructionInProgressMember_f9578004-a76c-467f-a1c6-f2a01119e9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_b5410186-8f5d-49fe-8a0d-f25f89e57a33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_b5410186-8f5d-49fe-8a0d-f25f89e57a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_cd7fcb86-ce26-43ba-827e-8b10e704ab20" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_b5410186-8f5d-49fe-8a0d-f25f89e57a33" xlink:to="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_cd7fcb86-ce26-43ba-827e-8b10e704ab20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_62730b80-1507-46ab-b8d9-c1a7e8c21730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_cd7fcb86-ce26-43ba-827e-8b10e704ab20" xlink:to="loc_us-gaap_ConstructionInProgressMember_62730b80-1507-46ab-b8d9-c1a7e8c21730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e694e946-fe2d-4f25-8fbc-fb9819471c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e694e946-fe2d-4f25-8fbc-fb9819471c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1beacf1c-13c5-4a59-aaf2-bcc328b2d1b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e694e946-fe2d-4f25-8fbc-fb9819471c0b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1beacf1c-13c5-4a59-aaf2-bcc328b2d1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5720e359-cc98-4c11-b0b4-4cb66d62042a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1beacf1c-13c5-4a59-aaf2-bcc328b2d1b5" xlink:to="loc_us-gaap_SubsequentEventMember_5720e359-cc98-4c11-b0b4-4cb66d62042a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_293b56f4-75e7-42fe-9431-d5af6cf5be8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_srt_RangeAxis_293b56f4-75e7-42fe-9431-d5af6cf5be8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a1c9721-137f-444d-9f97-e7ea7d281097" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_293b56f4-75e7-42fe-9431-d5af6cf5be8c" xlink:to="loc_srt_RangeMember_5a1c9721-137f-444d-9f97-e7ea7d281097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1e71ce40-5053-4bdd-ae89-def068dfeda1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a1c9721-137f-444d-9f97-e7ea7d281097" xlink:to="loc_srt_MinimumMember_1e71ce40-5053-4bdd-ae89-def068dfeda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee09fee7-a29d-4359-b093-b9424d721e0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5a1c9721-137f-444d-9f97-e7ea7d281097" xlink:to="loc_srt_MaximumMember_ee09fee7-a29d-4359-b093-b9424d721e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a9b4c57e-7869-4f83-a512-4a81c6172675" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_fe27eda1-7c75-42c8-a767-1cea3ff86627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_fe27eda1-7c75-42c8-a767-1cea3ff86627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_89962f7a-73e0-4d2f-854a-fa4e2169d0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_AreaOfLand_89962f7a-73e0-4d2f-854a-fa4e2169d0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLandHeldForUse_1dfdb6d9-00f4-480b-8f99-477cc7693060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLandHeldForUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_PaymentsToAcquireLandHeldForUse_1dfdb6d9-00f4-480b-8f99-477cc7693060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBuildings_36685a74-e98d-44a5-bca0-543f0488d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBuildings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_PaymentsToAcquireBuildings_36685a74-e98d-44a5-bca0-543f0488d4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_EstimatedCostRelatingToDesignBuildAgreement_ab0a817e-7dcd-491b-84d1-7772d4a48deb" xlink:href="axgn-20221231.xsd#axgn_EstimatedCostRelatingToDesignBuildAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_axgn_EstimatedCostRelatingToDesignBuildAgreement_ab0a817e-7dcd-491b-84d1-7772d4a48deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_d6ac7dde-bbf9-49c9-9fa5-c994c09963ef" xlink:href="axgn-20221231.xsd#axgn_AdditionalCostsAssociatedWithDesignBuildAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement_d6ac7dde-bbf9-49c9-9fa5-c994c09963ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_98f07884-049b-4c96-a3e7-096f46c849f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_98f07884-049b-4c96-a3e7-096f46c849f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e0e75b95-4488-4007-8da5-1a629770972b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e0e75b95-4488-4007-8da5-1a629770972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_6f77e801-0e80-428d-97c8-9229b0cb7ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_InterestCostsCapitalized_6f77e801-0e80-428d-97c8-9229b0cb7ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedCapitalizedInterestCosts_67025594-8507-46ad-8800-b414eb106952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedCapitalizedInterestCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_AccumulatedCapitalizedInterestCosts_67025594-8507-46ad-8800-b414eb106952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_f847cdba-546f-43b4-88f6-17c0b29336f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_GrantsReceivable_f847cdba-546f-43b4-88f6-17c0b29336f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CashGrantsReceivable_a1a16918-e9e7-44f2-87b3-39ea3445ffb2" xlink:href="axgn-20221231.xsd#axgn_CashGrantsReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_axgn_CashGrantsReceivable_a1a16918-e9e7-44f2-87b3-39ea3445ffb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromGrantors_f8bcb96a-e47a-45bd-a8c8-02f19de662e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromGrantors"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_us-gaap_ProceedsFromGrantors_f8bcb96a-e47a-45bd-a8c8-02f19de662e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne_fc60b9b9-28a6-4d4d-9a1e-195ff30ea06c" xlink:href="axgn-20221231.xsd#axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b04fde-ac94-469c-a1e6-a98f2484c507" xlink:to="loc_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne_fc60b9b9-28a6-4d4d-9a1e-195ff30ea06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d2e915d9-f5e3-4857-b651-13c2b2a1a9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d2e915d9-f5e3-4857-b651-13c2b2a1a9a1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ea333d04-6ccb-4aba-bdbe-801d9e426a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:to="loc_us-gaap_DebtInstrumentAxis_ea333d04-6ccb-4aba-bdbe-801d9e426a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fa33ea96-d07c-4f5d-8f9b-0e7eb60ab145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ea333d04-6ccb-4aba-bdbe-801d9e426a21" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fa33ea96-d07c-4f5d-8f9b-0e7eb60ab145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityMember_b2599442-048c-4d70-b411-04ddc8e5d9f4" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fa33ea96-d07c-4f5d-8f9b-0e7eb60ab145" xlink:to="loc_axgn_CreditFacilityMember_b2599442-048c-4d70-b411-04ddc8e5d9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheOneMember_6b7b82e7-bdc8-4ed2-a762-f410bc4e2af9" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_CreditFacilityMember_b2599442-048c-4d70-b411-04ddc8e5d9f4" xlink:to="loc_axgn_CreditFacilityTrancheOneMember_6b7b82e7-bdc8-4ed2-a762-f410bc4e2af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CreditFacilityTrancheTwoMember_70a3bc2a-c49e-4e2c-a59c-271c066cca3b" xlink:href="axgn-20221231.xsd#axgn_CreditFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_axgn_CreditFacilityMember_b2599442-048c-4d70-b411-04ddc8e5d9f4" xlink:to="loc_axgn_CreditFacilityTrancheTwoMember_70a3bc2a-c49e-4e2c-a59c-271c066cca3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b677da1e-957f-4e4f-8cf1-536aa45c3174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b677da1e-957f-4e4f-8cf1-536aa45c3174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b622b936-0a5f-4805-9643-c915cc8bf26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b677da1e-957f-4e4f-8cf1-536aa45c3174" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b622b936-0a5f-4805-9643-c915cc8bf26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtDerivativeLiabilityMember_aed7969b-b669-4407-8161-83668453a718" xlink:href="axgn-20221231.xsd#axgn_DebtDerivativeLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b622b936-0a5f-4805-9643-c915cc8bf26e" xlink:to="loc_axgn_DebtDerivativeLiabilityMember_aed7969b-b669-4407-8161-83668453a718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d957ea0d-c750-48e5-9753-96a89312deb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d957ea0d-c750-48e5-9753-96a89312deb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_948eaab6-0ae8-4981-a68d-e1f7a2e59313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d957ea0d-c750-48e5-9753-96a89312deb7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_948eaab6-0ae8-4981-a68d-e1f7a2e59313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_72dc7949-d709-4289-868a-d6d9234b628a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_948eaab6-0ae8-4981-a68d-e1f7a2e59313" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_72dc7949-d709-4289-868a-d6d9234b628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f92ae937-66ca-41cf-8abc-aed12e1b2cd4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_NumberOfPotentialSettlementScenarios_3e4a9bda-a138-4934-969b-46ac6988c677" xlink:href="axgn-20221231.xsd#axgn_NumberOfPotentialSettlementScenarios"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_axgn_NumberOfPotentialSettlementScenarios_3e4a9bda-a138-4934-969b-46ac6988c677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios_589631d4-8ac8-4dc2-a51a-1f1a95a4119f" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios_589631d4-8ac8-4dc2-a51a-1f1a95a4119f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePayment_84b37f0c-bcc3-4387-8a88-aba11760bc63" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentHeldToMaturityMakeWholePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePayment_84b37f0c-bcc3-4387-8a88-aba11760bc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_31b1a2b3-e733-401c-b170-34d61e48f6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_31b1a2b3-e733-401c-b170-34d61e48f6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation_fa428bd1-a997-4608-8800-e077eb5cd831" xlink:href="axgn-20221231.xsd#axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_96c04384-a648-4637-8c27-8f5cdb82e41c" xlink:to="loc_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation_fa428bd1-a997-4608-8800-e077eb5cd831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_df5d2328-59a8-4876-bb32-37112797165f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_180a1182-a20f-48a6-ab09-a14ebf5f1d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_df5d2328-59a8-4876-bb32-37112797165f" xlink:to="loc_us-gaap_SubsequentEventTable_180a1182-a20f-48a6-ab09-a14ebf5f1d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2612fcfd-06c6-423b-9647-e6c6f4716428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_180a1182-a20f-48a6-ab09-a14ebf5f1d83" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2612fcfd-06c6-423b-9647-e6c6f4716428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_80c6095c-ecf3-4965-bff5-c1c019205b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2612fcfd-06c6-423b-9647-e6c6f4716428" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_80c6095c-ecf3-4965-bff5-c1c019205b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b1770c19-788b-436f-a03b-ad79bd9f8114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_80c6095c-ecf3-4965-bff5-c1c019205b23" xlink:to="loc_us-gaap_SubsequentEventMember_b1770c19-788b-436f-a03b-ad79bd9f8114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_20c9524a-4789-4e06-8e1e-d59b741bb99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_180a1182-a20f-48a6-ab09-a14ebf5f1d83" xlink:to="loc_us-gaap_SubsequentEventLineItems_20c9524a-4789-4e06-8e1e-d59b741bb99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation_69aacd4a-ef2c-4f71-8a08-0898e2387a4f" xlink:href="axgn-20221231.xsd#axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_20c9524a-4789-4e06-8e1e-d59b741bb99d" xlink:to="loc_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation_69aacd4a-ef2c-4f71-8a08-0898e2387a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="axgn-20221231.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_0083a2f9-57fc-4648-8897-46d85df387fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_384c6775-8ffa-4c8f-8a61-e9f54b362e95" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_0083a2f9-57fc-4648-8897-46d85df387fa" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_384c6775-8ffa-4c8f-8a61-e9f54b362e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_41247db8-b3b5-421e-9e63-74baf06e9e52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_384c6775-8ffa-4c8f-8a61-e9f54b362e95" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_41247db8-b3b5-421e-9e63-74baf06e9e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d6f5451e-3f1f-4b26-93a7-27b8724f897c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_41247db8-b3b5-421e-9e63-74baf06e9e52" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d6f5451e-3f1f-4b26-93a7-27b8724f897c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_b6419d79-bd0d-4932-8b82-56a86b728eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d6f5451e-3f1f-4b26-93a7-27b8724f897c" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_b6419d79-bd0d-4932-8b82-56a86b728eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_3320ce51-3cc2-4164-a8ed-4cb5ded762ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d6f5451e-3f1f-4b26-93a7-27b8724f897c" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_3320ce51-3cc2-4164-a8ed-4cb5ded762ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_384c6775-8ffa-4c8f-8a61-e9f54b362e95" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_2a1895ff-e204-4e76-8196-26056720efbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_2a1895ff-e204-4e76-8196-26056720efbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_a0fec75f-7287-47ea-8c48-71e3bf4a8cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_a0fec75f-7287-47ea-8c48-71e3bf4a8cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9f4ababb-718a-44f2-a923-9af8903a7573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_9f4ababb-718a-44f2-a923-9af8903a7573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_dde6bcf3-f668-46f2-a76f-de8375b046f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_28f4f146-013a-4f26-b971-cee628543907" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_dde6bcf3-f668-46f2-a76f-de8375b046f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>axgn-20221231_g1.jpg
<TEXT>
begin 644 axgn-20221231_g1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &F TT# 2(  A$! Q$!_\0
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M:E?.4TG22PSC<P+G\AP*V--\$:18@-+&;J0=6EZ?]\]*Z*.-(D"1HJ(.BJ,
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MVJ:A;ZQ,DMK<6, DSU^4Y(QUQ^'2L7QWI^KQ>-X/%$L7B;3]/OM/C!?1?]?
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M%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M9.JZI-IUW:A(/.A<,90O+@#'*COC/3\JTH)XKF%)H9%>-QE64\&LK5_^0G9?
M[DG]*II)-I4SW%NK26[G=-;@9Y_O)[^H[_7KKR7BK$<UF=+145O<0W4"3P2+
M)$XRK*>#4M9%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?VS?_P#0,B_\"O\ [&FT4<L>P7?<=_;-_P#] R+_ ,"O_L:/[9O_ /H&1?\
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M_GF?^^V_QH_L^V_YYG_OMO\ &CV?F',=-17,_P!GVW_/,_\ ?;?XT?V?;?\
M/,_]]M_C1[/S#F.FHKF?[/MO^>9_[[;_ !H^P6P.0C ^HD8?UH]GYAS'345S
M!M'3)M[^]@8]UF+@?\!?</TJQ'?:M;X#-!>(/[R^6_YC(/Y"DZ;Z#YC?HK,M
M-;M;B86\H>UN3TCF&-W^ZW1OP.?:M.H::W*3N%%%%( HHHH **** "BBB@ H
MHHH BNK=+JUEMY!E)$*G\:XCP%.]IJ&HZ3(>48L ?4'!_I7>5P3C^S?BBI&
MESS_ -]+_P#%"N[">_3J4O*_W'EX]>SK4:ZZ2Y7Z2.]HHHKA/4.:\>,1X7E
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M5[:>[:/S%B4G)&,\9[XZCJ.]&G]?/_@AJ,M_ _AZVL+BQ73]]M< !XY97D&
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MNM/6Z<KL#B/ R[Y;&<GH":V(/"BP0>(HOMA8:S([D^7CR=R!,=?FZ9[5F+X
MGM5TB33=>FLKJRLEL9IDMU;SXACC:Q(4Y&<\XI:V^[\G^MANW3S_ $,+PSXY
MMO#_ ,/]+EU R7%W=SW C26=(R0)6SN>1@HP/4^U="OQ%L)M-TR\M+&ZNFU"
MX>VCAA*,PD49(SG:1[@X[U3/PQC30M.LH-5*WFGR2M#=36B2JPD8L0T;<'KU
MXYY]JU(?!GEC0RVH;GTRY>Y8BV1!,S*00%7 4<^AIZMLE^7F4D^(\?E-+-H.
MIPQ07(M;R1PFVWD)  .&^;DC[N>M+KGQ.T;0]9FTZ1#*;;;]H<3Q(4R 0 C,
M&<X(^Z#5NY\%BXTS5K+[>5_M"^6\W^3GR\,IVXW<_=Z\=:J:C\/%NM?GU.TU
M)+9+LJUU"]C%.7( &49P2F0/>E[V@]!VH_$2"SOM2M[?1[^\73X8YYY8=NU8
MV7=NY(Z#MUJ.V\;W][XVM=+M-(:;3+BP2[2<,H<*Q'SG+?=&<8QG/M5Y_!:-
M=>(IEOB!K-HEMM\K_4[4*9Z_-USCBH[;P5-8ZKHVH6>L/#)8V2V,Z_9U87,2
MD'N?D.1UYJEOK_6__ !VMI_6W_!.NHHIKND4;22,%11EF8X 'J:!%>8/:3&_
MMF5)5'[Q6.$E4=F]/8]OI46FW2WTM]=(CHLLX<+(N&&8H^HJY96+ZHZW-TI6
MS',4+#!D/9F]O0?B:BB_Y"6J_P#7U_[32A-78-,L4444 %9NN:8VJZ>8$U&^
ML"K;_-LI C\ \9(/%:5(R[D*^HQ2:N@1Y%:-?VGPVN?$5SXGUUYV+18\U'"8
MEV@JI YP/7N:[D>+XV\3-H4%A<W#P[!/.K(!'N&0=I.XCW P*JR>!ED\!R>&
M/[1(#N7^T>3TS)O^[N_#K2ZEX)DU3Q-:ZK/JS"WMI%E2W6V0.&'82_>V_P"S
M1V#H2:9XXM]5FU'[/IUU]FLA*#<%DPS1_>4J#N4^F0,U/:^,+6Z3P^RVTR_V
MTK-%DC]WA=WS?_6JC9^ S%XAN=5O=6>Z,L,D*(MND1"OP=[+S(1V)J'2? %S
MIU[I$T_B">[@TIG%K;O;HJK&R[0I(Y)']X_E25[:A+K82T^*.C7FO1Z;&A,<
MLYMXYQ/$2SYQ_JPV\#@\D8JK\3]7?3+CP]&^KWFEV-Q=.MU/:-AP@7M@'O[&
MK>E?#M=(UA9[?4U_L])3-':FQB,BL3G'G8W;?;K[UMZWX=76=7T6_-R8CI=P
MTX0)N\S*XQG/'ZTK-I7'=)NWF<AX?\87VD:%)<:JNHZC9S:D+73)Y(@L\\;#
MY21@9YXSCG-=!<^-)8;E+*'0-0N=1$ N+BUC:/-NA) W,6VDG'0$FM+Q!H U
MW^S<W)@^Q7L5W]S=OV'.WJ,9]:S]9\(W5YK;ZOI&N3:5=SPB"YVP+*LJ#..&
MZ-SU_2F[V_KM_GN"M_7K_D0CX@V-U;Z<VDV-WJ5S?Q--';0A59$4X8L6( P>
M/>H==^)>EZ%>):36\AN!"L\\;S10M"K#.,.PW-_LKDTG_"O$L(]+;0-7N--N
M["%K<3F)9O-C8[FW*<#)/.>WI1JOP^-]JJ:E;ZMY-R\20W33V45QYP48W#</
MD;'<>W%#OT#0M'QY9RZS::;96-S=M/!'<,Z%%V1OT.UB"WOM!Q4MMXOCU#7;
MW2K:PNBEJSQ2789"$<#/*YW >A(Q535_ 3:M?6#OK#I9VGEGR1:QE\ICE9,
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M31.X^BBBH&%%%% !1110 4444 %<%XK7R_&^C3+P2T0S])/_ *]=[7!>-/\
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M7_&C^U-/_P"?^U_[_+_C72^3%_SR3_OD4>3%_P \D_[Y%'M%V#E.:_M33_\
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M+=7L92W4AH;=^I/]YQ_(=NO7IO5$YVT148]6%<G]NM+?5M52:Z@C?[2#M>0
M_P"K3UKK*88HV.612?4BIA+E')7.:_M33_\ G_M?^_R_XT?VII__ #_VO_?Y
M?\:Z7R8O^>2?]\BCR8O^>2?]\BJ]HNPN4YK^U-/_ .?^U_[_ "_XT?VII_\
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MI?)B_P">2?\ ?(H\F+_GDG_?(H]HNP<IS7]J:?\ \_\ :_\ ?Y?\:/[4T_\
MY_[7_O\ +_C72^3%_P \D_[Y%'DQ?\\D_P"^11[1=@Y3FO[4T_\ Y_[7_O\
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M<9<J9+5Q;*R@L+<0P+@9W,Q.2['J2>YJQ114;E!1110 4444 %%%% !1110
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M@P>]=E11TM_77_,//^NG^1YSI?@SQ&TOA^TU>;2ET[0I!)!):%S+.0I4;@0
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MJT_!FCZGH&AG2M1GAGCMIG6TD1B6,&<H'R!\PSCOP!S7144(&%%%% !1110
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M*[LO_C?)_D>9F_\ NWSC^:.]HHHKA/3.9\>_\BQ)_P!=4_G6OH7_ "+^F_\
M7K%_Z *R/'O_ "+$G_75/YUKZ%_R+^F_]>L7_H KLE_ND?\ $_R1YL/^1A/_
M  K\V7Z***XST@HHHH *#12,0JDGM0!%<3+#$6)Y[5AW-PX.?XFZFK-S<B1F
MD<_NTX ]345E:O>2^=+PE:)6,6[Z_<3Z3:!5\TJ0"<C-:K#<C+ZC%"J%  &
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M.-Q'(R.I->KO%')C?&K8Z;AG%*T:. '16 Y (S3O_7W@CPVXU_4;KP9+=_\
M"37%JG]MW1 FNI('GA#?+$LN"8R,C"\9Z5ZYX5O6U'PKI=XZW*M+;HQ%UCS>
MG5L=3[]ZU3#$R[3&A&<X*CKZT_&!@4=+>GY ]7<****0!1110 4444 %%%%
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MRT=XJ?<^W1'_ &7)KKPTHTY<[LWYG#BXRJQY(W7I;_ASI\8]J4#UK &IW/\
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M7B+QGX+U#39YDL[JUOBT9;&2J8Y .#@CK1OM_5@VW/3&M+=YTG>WB:5.%D*
MLOT/:@VEL=V;>([GWM\@Y;U/O[UY;X/\;G1/ 7AV"6UN=2U"_>X\M?.12P65
M\_-(P!..@SDUZI;R^?;QR^6\>]0VQQAESV/O5-6;$G<Q_$_AJ#Q)HUQ8&=[.
M28HQN(44ME#E=P(PPSV-4/"G@H>'+Z[U&ZU)]0U"Z18GE^SQVZ!%S@!(P!WZ
MUU=%2M!O4C-O TZSM#&9E&%D*C<!Z ]:;%9VT$KR0V\,<C_?9$ +?4CK4U%
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ME[_;&G_98Y/*>?[2FQ7SC:6S@'/;K1TM_78?]?J8FA>#;JRU<ZMKFNRZS>K
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M[987#J<'!P1QU!%3TVWK<04444AA1110 445BZ_J\]C;2PZ=")]0,32(AZ*
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M"P4Z<^:IT.V'' I:**\P]<**** "N"\:?\C3H_\ O+_Z&*[VN"\:?\C3H_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJG\ZU= ;=X=TT_\ 3M&/_'179+_=(_XG^1YL/^1A/_"OS9HT445QGI!1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ_\  ^\UO''CW2_#^EZK9PZK'#K<=E)+ @C+['VDIN."H).,!NOO4M]XCO\
M3_A3_P )"#'-?IIJ7!,B_*SE022!CN>V*PM9\#^(FOO%*:6^F26?B& +))=,
MPD@81[,  '(_$8K?U/PU?7GPN?PW&\(OCIZ6VYF.S>% ZXSCCTI/X';?3]1Q
MMS*^W_#&)X=\<:L=?M=.URYTJZ@NM.-^;BQ5D%L  =L@+-Z]<BNJT?QIX>UV
M:YBT[45DDMEWRJ\;Q$+_ 'AO RON,BJ,/@V#3O!=QI>BV]GIFHSV8A:YMX@N
M9-N"Q(&3S7(:'\+]3@N;][L6MFM[I,EA(T%Y-<,9&_Y:9DZ9ZX& *J6[M_6_
M_#$1V3?E^G_#FQXJ^(EC+X,U>\\+ZLK7UF$.\0G !<#*[UPPYZC(KJ'\6:)"
MM]YM^H_L\*+IO+8K&S=%W8P6_P!D9/M7'WGA/Q7JGP_N/#=W%H\31P1P6\D,
MC_O-K*<ME?EX'09Y[T7/@77[?0=9T/2[N!;&>Z6ZM6>9UD(+;I(G8#(![,"3
M0[6T_K8%OJ=5:>.?#5]I%UJL.JQ_8[0A9WDC>-HR>@*L W/&..>U8E]\2](O
MM(NIO#NJ6YN+:6%)3>V=PB('8#&-@))[8_'BN$U[PC>^$O!VO27"6=M'JEW9
M"*..YEE6$JPW$RR?,N,9WGIZ=*GT#39O$FA:SH-AY-Q?+=VUW/JAU$W<5SAA
MQYNT?,%7& *%9O[OTN$KI'I>I?$#PMH][-9W^KQPW,#JDL?E.Q0L,@G"G _V
MNGO2ZYX^\,>')4CU34Q$[QB4".&27"'HQV*< ]LUD7G@V_N#XU(^S$ZU&BVQ
M9CQA"OS<<<^F:\Y\7C[+XKNK>ZN[=8;/3[6*YLSJ9M#>[5R4"[29O;&.N*FX
MSWNTNH;ZSAN[=BT,R!T8J5RI&1P>1^-354TJY%YI-G<K ]N)84<0N.4R.A^E
M6ZIJSL).ZN%%%%(8445YQXNBU>_\5ZA;6NMZII]K;:-]J5+)PH>57.,D@_B!
MC-*X'H]%>$>,O$OBI/["E;4KO3K:33(9UGC,J+)<D?-O\N&3=CCY3@<UU.BV
M^M^(_$^MQWFOZE;Q06=J8H[5S'$TDD!W,,C=@'D 8YYJK/7R!.]CTZBO$X=?
M\9:AH.I7%NU\E[H=B+&5 &_?W!DP\N,'<0BY!P?O&N@^$6JZEJ-OJ:7>K2:A
M;Q,GE>>\KR1D@[@7DBC)'M@XHMV!Z;GI;,%4LQ  &23VH1UD0.C!E89# Y!%
M>-/<:IJ_B?Q+I!U?7+D36\X\N%7B2VP,HFUH\ GH"K'<"<BH?#<=W=V?@C2=
M/\0:]!;30W*WS;F1T=%C/EC>O"@Y XZ9P:4=?Z]?\AM?J>V4$@ DG '>O(+S
MQ-J5I<:CHCW.J_VDOB&-HR(I2JVC2+C]X!M"$9&,]ZD@GO-:U_7=.U+7/$5K
MJKM<0Q6%O$4MUMP#L=6V8R?[V[)Z8I7]VZ_K1/\ 7\P:L[?UU_R/64=)$#HR
MLC#(93D&G5XOX:U<>'?"'A&Z^WZR]A#=/#J0EBE<PL8\"/8%R4#8QP1GO4EC
M>Z[KNH:+:_VOK-C;WNJ:DLKKN240K\T:D.#MQ@ 9&1VJK7=D2GI=_P!;_P"1
M[)17AMAKWBM?BE'9WNJW-NW]H& 65QYOER6V< A5A*9(Y#[QSUKN/B%J>J>'
MY=.U?3VN9(BLMI);1Y*L\B_NG*CT88S[TNB:ZCZM/H=M-/%;0///(L<4:EG=
MS@*!U)-1I?6LD GCN(WC,7G!D;=E,9W#'45Y)I]UXED&HZ1?7]](_A[3KD3W
M&Y@+N5_]42?XL+D]\&BUL_)\;:3>WFI:PDEYH*>5$I8PRR",[HVPI &/FP2/
MFY]J'_7X_P"0+?\ KR_S/6=.U&UU;3H-0L9?-M9T#QOM*[E/?! (_&JTUSI%
M]K2:7.L4U_:HMXD<D1;RQDJ'5B, ]1P<UYOX"M]4TBX\( ZKJ,]MJ-A+Y]K/
MCRH=@4IL4 ;3R>3R:B\?S?8_'=[<OJ>LZ:G]D(L4VF0,QDF\QBB,P1L GMQG
MUIRT?W_A<-3UE;VU>]DLEN(FNHT$CPAQO53T)'4 X-3UY)_:?BR*WU6X"SG5
MU\/V<A14R5E);S&5>FX#)QZBLI=;O(])UM]*UCQ/JNC+:1M)=S;XIX+DOA@C
MF/<%"\D!3@=*&K.P>?\ 73_,]PIID19%C+J';)52>3CK@5X=H?B'Q(W@75S)
MJ.JR0Q7\"?; ))9XK9P"[(7C5CCUV\=JLW$-I)XD\'ZI_P )%XGFTQFF@BO)
M4=79N-BM^[SACD$D#('MFBVMOZV$W97/8K2^M+])'M+F*=8Y&B<Q.&"N.JG'
M0CTJQ7D UO5?#]BWB"22]FM+;6[R"YMUW-NB8X0[>^& P?>L/Q9JOC'2K71$
MN=4O[.VFLS<O<K)*,W+,3Y;,D4APJD80@#%+HGZ?E<:U_'\['O=<%XT_Y&G1
M_P#>7_T,5U7AVXNKOPUIEQ>RI+=2VL;RR1J55V*@D@$ C/H0/I7*^-/^1IT?
M_>7_ -#%=^ 5J]O)_D>7FSOA;^<?S1WM%%%<!ZAS/CW_ )%B3_KJG\ZU/#W_
M "+FG?\ 7LG\A67X]_Y%B3_KJG\ZTO#C!O#>G$?\^Z#\A7;+_=(_XG^1YL/^
M1C+_  +\V:E%%%<1Z04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,EABN(FBFC22-
MN"CJ"#^!I(((;:(1011Q1CHD:A0/P%244 %%%% !6;=:NMM>M:K:S3.B*[%"
MH #$XZD?W36E7/W/_(PW?_7O#_.2K@DWJ*3L:EAJ"W_F@0R1-$P5E?'<9[$U
M<K'T7_CZU#_?3_T&MBE)6=@3N@HHHJ1C)8HYHVCEC62-AAE89!'N*;!;06L0
MBMX8X8Q_#&H4?D*EHH *@FL;2XF2::U@DE3[KO&"R_0GI4]% !1110 4444
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M<21]X%CZY-9>O>._$OA_2[*&2UTR]U:\G*QG3XI9XU38&YC!WD_0^_M1+1M
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MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2^6[6-E#P^8NU2I^;MW Z\]*AL/B!+!/X<TZ739C%J%G!)]MN[M5+,ZCA3L
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MH\G3[7JW8J#R?Q->BJH50JC  P!7?7_<4%1ZO5_HCR<*_K6*EB?LQ]V/ZO\
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M/3BO3O\ A8FC_P#/"]_[]K_\51_PL31_^>%[_P!^U_\ BJ:P6(_D8O[4P?\
MS\1YT?#LD7P2U/4A#?/K-P&B;?)(S"-;GA53. ,#/ [FI?%-G?&Y\=O%;7!,
MNGZ>(RB-\Q&<@>N*] _X6)H__/"]_P"_:_\ Q5'_  L31_\ GA>_]^U_^*IK
M!XA._(Q_VK@[6]HOZM_D<9K5MH-W\7;*2ZM[RUFLQ%(TZ17#_:YB!L0;0455
MX)/&3^-<]I4>I2?$;3=3\N]M[M]4:"]@:&Y9DB.X#?*S>6RD<@*../2O5/\
MA8FC_P#/"]_[]K_\51_PL31_^>%[_P!^U_\ BJ2P6(5O<>@GF>#::]HCSA-
MT[2=/^(5K;:;>0ZR?/-N0LS![9@A&T\J3NS_ +7X58UFVM9+]E\56VL2P#2[
M?^QQ:K.468)\W^KZ/NQRW%=__P +$T?_ )X7O_?M?_BJ/^%B:/\ \\+W_OVO
M_P 52^I8BUN1]/PN/^U,'>_M%U_&W^1QEKX<O]<UOP[8^*%OY - ?[4JS21A
MWWKA9"A&2 >1GJ*[7X;"Z3P+8Q79F,D32QCS\[]JR,%SGGH!3?\ A8FC_P#/
M"]_[]K_\51_PL31_^>%[_P!^U_\ BJIX/$?R/^FW^I*S/!_\_%_2.NHKD?\
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AV192-(QA$51[#%.HHJ2PHHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exhibit1023thirdamendmen001.jpg
<TEXT>
begin 644 exhibit1023thirdamendmen001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ'I<=[]B8)<R33^4 Y4-M7"MN."/3K6)JW@S63J,=W::H\[27J2R>8B95%#
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MCD1$+A6)SW#=#WK*O/"UY=:P8H]/NHH5U,7I877[C"R^:&";NK8Y&, MGC%
M'3S^+(8?%\6A>0Q1HQNN<_*LA)PF/7C-/UOQ3;:-J=AI_E--<7<@7"G C7!^
M8GZX'XURLW@C6KG1KV]&HS1:M/=&]6WQ&464?*OS8S]T#OWJ74?"6O7-S!J$
M5ZWFSWB7$L3HA,*\_*#CD+G'6@#8O/&C6NKS0"Q#6<%TEI+-YN)/,95;*ICE
M<,.<]<\5TE]>PZ=92W<^[RXQD[1DGL !]:\ZU#POJ4VHW;MIKS:I)>)-;ZD)
M0$C0*H!(SV(/&.:[NPTRXL[N>:74[BZ23[L4H4*G/; S0!4TKQ/;:AX8DUV:
M)[:WC\TNK_>58V923_WSFJFG>-+>Z\-WFKW=L]J;20QS0DY(.0!SZ$FLN7P[
MJMSX330O+,*W5_,US(K*=D#3LQZ\'*GI5'6?!&KNVHV5O=27MIJ=JHFDEV(4
MDBD5D&% Z@OS]* .@7Q=<0:=J%U?Z<D1MK<W">5<"17XX0G PV>",8]ZO:1K
M=U>6MS<WUI;V\42!P8KCS<\$G/ QT%<I'X?OGN+RZM?#T-O:FR2)["5U"W$H
M;+'"G&<<9/7'/%1S>'M6N)=2;2]*_LFUOTAMFB0HNW&\O)M'''RCU.?:@#H]
M%\:VVK:/J.H-;20BQC,S1]6:(KO1A_O)@X]\5#9>-M_G?;[-( +8741BF\P%
M,D?-P-K<=.>M9-YX0UO3+B4:1>2727EA)9R-((T\K$9$9& .X5<]JKV?AB_1
MV-AHBVR"P:"ZANI=R74F<KT.<#YSGC[P]* .ETWQ-?WFG2WLNEQA!$'C2"Y$
MCLQQA2,#'6H5\;?9H[]-2L?)N[5$D$4,OF*X?.T!B!\V5(([5G6.EZG;ZS+J
MVD:%#IJQV/DFT8JJSR;T).%.,A0P!/?':LR_\(ZCK$FIW%MIKV,$J1/]EDF&
M9YT+%B.?ER"HSQTH [&Q\1RFUO9M3LEM_LH4EK>7SD?/0*< YZ#IWHTWQ7;7
MWALZW+!-!"'=/+(W/\KE1P.YQ5+POI4UMKFI7T>F#2["=$6.U!4 L.K;5X']
M<UI>%=/N=-TAX+I-DANIY ,@_*TK,#^1% %>R\17FJ^'(-5T[3 [RGF&:;9M
M7&<D@&I_"^NS^(+":ZFLA;*DS1)B3>'VG!(.!QD$?A67;:9J]C\/Y;&"'_B8
M$;53>.A8 \].F:Z;3+&/3=,M;*( )!$L8QWP,9H M4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !52YTNQO)XY[BVCDECY5B.15NB@  P,#I1110 444
M4 %%%% ",H92K#((P138HDAC$<:A4'0#M3Z* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA_P?;36>\7,M[NDFWL&;)^OX5VOBCPKIFF^%-=O;.(Q-+9$,H=L9&"".>/\
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MQAHZVKS^<Y$<PMW0+\RR'/RX]>#5-/B%H4MY=VB/<-<6:[KB,1<QC&<GGTH
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MU'P#I6J^&;7P_=3WC6%LP9 '4-D9QD[?<UT.G62:;IUO91/(\5O&L2&0@MM
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MI+V[GN)4\LSRLNX#V 4+^E8NC?#[3_#]K=VVEZAJ5M%=2&64*\9RQZG)0XH
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MDA*97GOQ^73MBO4UT5!J=M?F\NFE@A:%02FTJ2"<C;ZJ*=/H=A<ZW::P\/\
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M_84DCCOT\]R"K '<>>W/YUTVJ0G4_$6G6T5Q,B6^ZXG\J4J&7& AP>Y8'\*
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MQKH#KVCC4AIIU:Q%^3M%L;A/-SZ;<Y_2K+7UHEXEFUU"+IP2L)D&]@.<A>M
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M* ..\?Z=?:I!I,=E9O<&WOXKB3'38IY_&M1+NXEU &VT>:W5H_WTTR $@=%
M!YSD\YXK9:XA5G5I4!0;G!8?*/4^E4;CQ#HMG(T=UK&GP.BAF66Y12 >Y!/2
M@#E/"2:QH6CWEJVCSO=37<TT62%CP[$C<W)'7T-:_@WPU-H$%_<WLJ2ZAJ-R
MUS<%/NJ2  H/<  <\5HGQ-H(CED&M:>RQ+O?;<H=JYQDX/3)'YUI12I/"DT3
M!XY%#*PZ$'D&@#-UN?4+=;1[&T^U)Y^+B,'!\O:W3CDYV\5S>A^'3'X\N=?L
M["73+.6V$<T,HPTTN3\VT9 &,<Y[5V-G?VFHQ-+9SI-&KF-F0Y 8=15@D $D
MX H X\:??#XI'5?LDGV'^SVMO-_VRRG\L*:O:K92:MX@M+:XM)3I]N#(9!]U
MY,< ^PX.?45LV.HV>IQ/+8W,5Q&CF-GB8, PZC(^M3R2)%&TDC!40%F9C@ #
MJ30!PXT2[T'XA1ZAI-E(^G7EMY=\%/\ &I)1AZ_>;/3M6E:Z,FKZ5K&F:K92
M);W=Q*PW<95F)!'H1P:Z:.1)HUDC=71AD,IR#3J //=*\-ZSH_@_Q!I=RYOI
MII)%M'48+1E%"[OH015BPAUR/P'9^'[736AOELEM9)[@[8X_EVEAC);O@<5W
M5% '$V_AI]-TS0_#2P27&GPYDN[@#&Y]VX?@6)S[5#J?A^XTGQOI6MZ+922+
MY;V]ZH/WHS@C\0RC]:[RJM_J5EI=N)[ZZBMXBP0-(P4%CP />@#AYO"[ZWXT
M\0/J6GRC3-1LH[>.0]58  GVQVJ98/$)\&:EH6HVCW-XD30P74?W9QV)'8_G
M7=@@@$=#2T <-:1:[_P@-EX=M-.>"^73H[*2XN#B.,B,(S#&2V.2!QGU%=)X
M;T2+P[X?M-+B?>($PSXQN;N:U:* .,\36-[-XT\/ZC#82W%K8-(TVP D[HG0
M8'?EA6I'?W:W,\MOHD\4*IN(8 /,_8 #@8QUSWK==UC1G=@J*"69C@ >IJ@F
MOZ/*MLR:K9,+IBD!$ZGS6'4+SR1Z"@#C]:\,7FM>'O[6>"2+Q(DBW-N!SY+@
M_<]UP2">,]<=JEU;1]8\0Z9H>KFU6VUW2)1+Y$K?)*>-P# < XZXXKN(9XKB
M,20R*Z'NIS4=U?6MBL;74Z1"218T+G&YB< 4 9UIJU]J 6--)NK.3J[W(&T#
MOMP?F_3U]JYVTAU/3OB#KNK-I-S+9WD<21&/&[*HH.1Z9![UW=% '&^(M*U3
MQ7X9F0P"TN8[A9K>&0YSL]3VSGT.,5;FN]0UVV@LCI%S9LTD;7$D^ BA6!8*
M1][."!TZUT]% '-:D]R;JZL[[1I=0TIXD$?E ,V[YMP(..,;><^M<F_A#4[+
MX9:EHUM;LSW5V9;6U#9\B(R[U4GV7CZUZC51-3L9-2?34NHFO4C\UH P+*N0
M,D=N2* *4^F1ZQX4;3+R)D6:V\IT8<@[<5G^!=%U#1M!0:Q*)M2952611@%4
M&%_'%=110!PFE6M[IWC3Q%J5SI-S+;7SQ^08T#'Y5 .02,5U6C/<O9GS[,6:
M*Q6&#.2J#H3[^W:M&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#@_BK'&^@Z:716/\ :MH.1GCSDKN8U5844* N
M , <5S_B_P -S^)K&WM8KM;98;B.XW;<DLC!A^&0*EBTS67N;=[O5$>&$[O+
MCC"[F[9..G7B@#S6[O)-(\/?$.YL@(9FU18!(@P4628(Q'X,:]0TG1[!/#UI
M;?9HWC:!=Q902Q(R23ZUCV/@A5B\06VI3I=6NM2M++'MQL)R>..V>#[5>TS1
M=8TVU2P&KB6TB&V.1T!E5>P]_KF@#E]=L8]/^(?A"VMK1+D0VDT2I(0-P"$#
M)Q[5T/D)=Z5K4MWI$%I(JM % #!T"!@>@[LWY4FI^%KRZ\2Z9J]M?+$=/B:.
M-'&[<&!!))'O5N32-6N%N_M&I*YEA\J- N%CSG+=.3S^E '#Z/<3>!88]&U*
M1IM U&$BQN).3#)C/E-[$9P?]FM'4](U5]$T'5="@@N)M.+R-82<)<*W!&1T
M;&<<'FMCQ)%I5IX*?3O$9>:W:(H6AMWE.0,AL*IQC'7BJ2+;V'A#1=9L]7E@
MLK"VRA>(MYZD8 9<$Y^@SF@!/#VM:1KUIKKPV+6.I" )>V4JCY"JO@].>IYK
M,\#F7_A -&B_L*">&5EB>8D$A6?!;&.P/K6EH2Q:QJFKW+2/%K<]LD31S1;-
MD/S8(X^;J?R&:;;:;J?A?2--\-V^J%VG)AB:.,;U')9CG&,#)S[<<T =\H"J
M .@&!7EWC_44FO9M1@O/+N/#TD<T,(/$S94R?^.%UKL(_$^G2ZFOA^UFG&H-
M"[(TENZK\NT$[F !^\.F:RGUNS\-Z?=:1>M+?31(\M[+# 66,/EBSC'?=G R
M<4 4?'OB%KGP-ILUG,T4.J2Q1R3(<%$;J!_GM70>)_[,T'PG<32Z8DME"BJ\
M<8 8*2%!'!R<D5EZ-X+M;KP3+HM]>C4-,N&,ULP&#$&Y 7TQV^IJA>M>:SX2
MO-.FNKF[L5G^R&X2$&:;8W) Z8ROWB1F@"'Q!- /$O@V[;3VD5H)"(542.5V
MKM],\5>^&]N;Z76/$,92.PU216ALU.1%MSG/H3GIBHD-IJ]W9ZS%?M9Q>'%,
M,\%S$5=,(I);C^[M.1FET":V/BJ]GTB>XL5OH3<&QNH"J28(S(G'!RW(X//2
M@#.\'236VAZZ]OH<%YLU.ZP6(_YZ-VV_UJ_XOMXX/%G@M8;*.4K+(HB. "-G
M3.#53P_<7.A7TFD)>36[:C>3202W%KA7=F)(!QQR>,XS4^L"&3Q;X<L?[5G_
M +1LY&5&>U<K+(5.27*[>@/0T =''$+BVUN2YTB&S>.%H4*X/F)L#9Z#N3^5
M<KX)O1X0O=0T"Y;%D\'V^P+'L3M=/P.S_OJNRDTK5[@SFXU)&5X&BCC5,*I.
M06/'/!JK=^"[?5(M&.HR;Y],E+JZ# D4XRI]C@?D* .:\'VC?\+0UFYO$S<W
M5BD[JXR8]Y4[/^ @[?PJKX.EN+/P_K\MKH<%Z4U2;;N('\*<8VFNR@\-WEOX
MQO\ 7TNXR;J$0B$KPH&,'./855T'PMJWA^UO(+75(F%S<O<DM&/E9@!@<?[-
M %/QEX6CU2?2+73Y/L5W;9:TFC RI1&PI_V3C!^M5]-\0+X@ETZTU.V2'6K"
M[$5U PR1T(89[$$'\ZZ6/1+Z.\TV=KX2FU4^:7',K%2&/MU)Q1J'A2POO$UC
MKX7R[ZU&PNH_UB9R ?7'/YT <YXVTRQM+WPC#!:PJG]J[3\@Y'D3=?6NZM;"
MULFF-M D7G/O<(, G &?R K%\2>';C7;S2IH[I85T^Y^TJ"N=[;&3!]L.:Z%
M<[1NQNQSCUH X'Q3%#X?\>:+XE9$6VN%DL+MBH_B&]3_ ..$?C6'X=U0Z!KG
MB+3_ +/'"NI![W3UQP[,=BCZ%AG\:]#\3^'[?Q/H4VEW)VI(RL' Y4@@Y'ZC
M\:KWWA'3[W5-%O67#:7Q&,?> 7"@_0\T <KX]TFUTWPMX<M(H4"1ZM .5'=7
M)J_\2M-LK?P+?216L2R/=6K,^P9.;F///XUL>+?#<_B6WL8([I;=;6Z6ZSMR
M6900!].34GBG0;GQ)X?.E_:4@WO$\D@&>4=7X_%: ,SQ1IME%X U.>.UB222
MP57*H!N"C(S_ -]'\ZYW69Y6^"<<)TO$0TZWP^1C^#G&*[K5]&N-4\+2Z1]H
M2-Y81$\H&<#U JA>^%KJ\\!IX:-XBD01P&<+SM3'.,=3M% &UH:*F@:>J*%'
MV:/@#'\(KSW6)-0\):MJ\^J:4NJ>'M1D9WNHQ^]M0V<@@YRHS@=*]&TRVELM
M,M[6:19'AC$>Y1U &!6/)H6J"/4+>'4U:VO9)&*RH"8@_4+QSU[T <KKW]FW
M>H_#V:Q"2V;7&(7*]5 7&:['Q#!%+<Z()(T?&H#&Y0?^64E4KCP3:G0M+L+2
M=H)M+<2VLX4'#@[B2/0GJ*OPZ7?W%Y;W&IWB2+;-OCBB7 WX(W$X]">/>@#C
MH/\ 1_BQXD,.E)=_Z)"=@P.=B>QK,T-X[CP)XPBF_=SK([R:>_/V3(X'/K@U
MV4?AC4H/%>H:[!J,:/>HL;1F/(55  QQUXJ)/ H@TS6XX[YI+_62#=74B@$@
M @8 XXR?SH TO R)'X!\.[%5<Z9;$X&,_NEKFM0=+/XLWMU' C21Z'$X '4^
M9-6SI_AW6[#1K'25UE/LMK%% 2L0#-&@ QG'!(&,^]2IX9N%\9G7FNT9#:):
M& K_  *6(.<=?G- &=\,K>*[\$V>I7(6XN[X?:)Y9!N)9_F(Y[ GI67\2M*M
M=,\+626ENI5M9MY!&<8!)Y ] <?K70Z5X6O/#IEMM'U!4TV21I%MI5SY)8Y(
M3CIZ#I1XE\)W.OZ7;60U IY-RETTC#)9U.1QV% %JUC-QK*Q7.AP6T<<1D25
M2&W'(&.@[$UP]J+GP/._B.WW2Z'=W,PU*#_G@1*RB1,=L 9'M7?#3]8DNX);
MC44,4)+>5&N YP0-W'3G-2:3I,EIILUC?/%<Q2/(Q4KP0[%B",<CDT <E)I+
M>(O"6M1Z--#'-+J;RQ/M^63!!"G&.#3O#GB&VU#Q+;:=K6C_ -D>(H(VVQKS
M',F""5.!QC)Q6IIW@>/1M!?2M+OI;5/MK7<3@9,8/\(]JM_\(]<W>N6>J:E<
M1226086Z(F!D@C<3CWZ4 <WX:LK675?'L;V\3*;LC!0=-AK-\*7,_@F#2]*U
M&1I]!U6",V<TG/D2.@/E'V)) _"NMTSPM?Z;<ZY.M]&[:K)YC97_ %;8QQQS
M5YO#4%[X/3P]J>VXB%LMN7 _N@!6'H1@'V- '"WEQYE]X*T$@)I][)<2SJO
ME*,-JG';YC75>,[O3M(LK'[5I@EBENX8HVA(5DDW#;VZ9'-/N? ]G<^']-TX
MSR1SZ:=UK=I_K(CZ@_EGZ4NJ^&;_ %^.R@U2^C\FUN$N-T*_-(R'(SQQSZ4
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M%7B$76B*\%@8]7C<(H# PNNWDG=\PP3Q@=.M2V7BO5YK._BFALQ=6-\+6>X
M81!,CY]F2?NGINZ]ZM?\(E=^;H+_ &U/^)3NQ\O^LR!UXXZ53D\!73WMQ=KJ
MOERR:BM^@"94,,?*0>HP/SH CMO'TYTK49)88);JVU(:? 4RB2L5# X.2._<
M]*I27EQHOQ.U._U P3>1H#2 PQF/?B1.""6[\5H3?#HW-KJT4^K2F2]O%ODD
M5 IBE QD8]JL?\(5<WNK3W^KZF+@W&GM831I$ &5B#D<<'(S0!9T_6=>FU>S
M2;3Q)IUU%O,R0F,P-Q@$ECN!!]!TK3U_4+O3K:![5(0'E"2S39VPK@_-@8SS
M@8R.M9_A[P[JND^7#>ZY+?6EN,6\;( P';<W4X[59\1^'Y=;;3I8+UK::QN?
M/0[0RM\K*00>#PQ_&@#GH?'T_P#PCU_J$\<6++4!:23HA*!,*?,VYS@!NF>U
M=1X>U&75=--U)/;7"-*WE2VP(5X_X3@DX/XUCZ=X2O\ 2_[0:WU<NUW>"[(>
M, $[5!4X[';6GX<\.P>'H;M80B_:IVG:.-=J(3V4#M0!MT444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%<W$=K;27$
MK 1QJ68^PKF?$NHRIXFT'2I'>&QO)'$T@; <A&*IGW('UK F-T&\9:/)--)I
MUK!%-;L7/R,P?<F?0;0<>] '7Z/KTVK20.--ECLKFV6Y@N=VY65@" 1CY3@]
M*VZY_P #0)!X'T/8S'?80,=S9ZQCI704 %%%% &7XCDC3PWJ>]E4FTE R?\
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M4QP0<'VQ0!Z5D5$+F%KEK<2*9E4,R \@&O))7O(_#6J:M_:=ZUU9:N5A)G;
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MU:*.T,(P9V"G<%R0 #D<Y[4_4I)+GPUXSL+F;,5I>0F&))BPC!920/8'MVH
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M75SK][X@M_[4BL+RQN=L+O.5:!5 (8+CD$#/OFO1+7=]DAWR"1M@RX_B..M
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MA[HC*SDR6<1.YLX^4=/2@#K:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH IZCI=EJL*17MNLJHP=.2"K#H01@@_2HCH
M.FM8S61MLP3?ZT>8VY_JV<G\ZP_'NM:GH5A87&G7$,1FO8+:3S8MXVO(%)ZC
MIFK0DU=9+@KK%I<1QVSLRK;;6C?^ _>.1PW% &U8:?:Z7916=G&8[>)0B)N+
M;0. !DFFW]Q>6\:FSL?M;$\KYHCQ^)K"\*^(?M'@C2]4U>X437$*L[ 'YF/H
M!DUI/XFT:/3)-1>_C6TC;:\A!^4^A&,B@"+^T]<_Z%[_ ,G4_P *#J>NXX\/
M?^3J?X5%<:_IUY/:)::RD++=F)E\ICYI"ME.V.F<\_=JOXT\2Q:-X?U-K:]2
M+4(+9I(P8RX!P2 <<#\Z +O]IZY_T+W_ ).I_A1_:>N?]"]_Y.I_A20^(["T
MTVT?4;Q8YI(1(WRD\<<G ..HK8CD6>!987#)(H9''(((X- &1_:>N?\ 0O?^
M3J?X4?VGKN?^1=_\G4_PKD8?$WB.2'Q3,=2L5&D7;0Q*]M@2 >IW<'\*Z_1O
M$$=]X6L=8O4^R?:(5=D;)P2.@[F@!#J>N]O#O_DZG^%!U/7/^A>_\G4_PJ>'
MQ%I-Q9M=Q7J-"K^63M8$-Z8QG/X5(NMZ<]@;U;D&WW%-VUL[@<$8QGJ/2@"I
M_:>N?]"]_P"3J?X4?VGKG_0O?^3J?X5/'XBTF6P-\EZAMP_EEL'.[TQC.?PI
MK>)]&6P-\U_&ML)1"7(88?.,$8R.>* (O[3US_H7O_)U/\*/[3UW/_(N_P#D
MZG^%31^)-(EM#=)>*T(D,60C9W#&1C&>XK \0>*3!>>&;K3[Z-M-OKTQ3$(?
MF7RI&Z]1RHXQ0!L_VGKG_0O?^3J?X4'4]= X\.Y/_7ZG^%7M,U>PUFW:?3[A
M9XT<HQ (PP[$$ US'B#6M7LO'.C:/:WUM!:7\$\CM);[BI0ICG<.N[]* -DZ
MGKF/^1>_\G4_PH_M/7/^A>_\G4_PI=/N[BV@NKG4=3MKFT#_ +J:.+9C'!!&
M3D[@>E3)XCTF2">9;Q=EOCS<JP*9Z9!&: (/[3US_H7O_)U/\*/[3US/_(O?
M^3J?X5<_MK3C-;P_:E\RYC\V$8/SKMW9''IS52/Q;H4L\$*:C&SSN8XP%;!8
M=LXP#]: $_M/7<_\B[Q_U^I_A1_:>N?]"]_Y.I_A5?Q9XA@TG1=0\F]2&^BM
MVD3,9?! R,XZ9^M.L?$ME;Z#I]QJEVL<\ULLS?*2<8Y. #Q0!,=3UW''AW/_
M &^I_A0-3US'_(O?^3J?X5'=>+]+MM:L-,\TO+>(9$94)4*!UR!W)%3:=J$#
MW&K2'5DN(H)L.FPI]FPBY4DGGUS[T -&IZ[CGP[C_M]3_"C^T]<_Z%[_ ,G4
M_P *LV_B#2[EI5BNU+1+O=2K*0OK@CD?2H;;Q5H=Y=06UOJ$<DMP"8@%;#XZ
MX.,=J +>GW-]<>9]MT[['MQL_?K)NZYZ=,<?G3]2T^#5=,N;"Z7=!<1M&X]B
M,<>]6JY#6M:U:S\?Z%I-O<P)8WRRM*K0;F&Q&;@Y[E: -:/0XKS18]+U:%;B
M* @(VXC<%^Z>#D$=*?\ \(SI'VJ>Y^R$33Q>3(PE?YD_N]>G%0GQ?H"L$;4H
M\F8P?=; < $@G''45<O]<TW2VVWMTL1P"?E)P"<<X''XT 49_!GAZYL+>RET
MU6@MB6A'F.&0DY.&!W?K6Q:VL%E;);VT:QQ(,*H[5(CK)&KHP96&01W%.H *
MJWJWKQ 6+VZ/GYC.C,,?@159_$.DI?BQ:]07!D$6W:<;SC SC&>1WJY>7EO8
M6KW-U*(H8QEG/04 <[8>'+_2[N>[L_[,BGN&W2MLG;>>F2#(1V%1-X3NGDO7
M9=,W7H N3MG_ '@'3/[SW-;5GXCTC4+Y;*UO4DN&C$JH%890C(()&#Q2GQ!I
M0O%M3>()F;8HP<%O3=C'ZT 8D?A.ZAFM)HUTQ9+2+R8&"S_NTQC _>^E2V7A
MN]T^SN+2V325M[ABTL;PS.K$]>&D-7-.\5Z?J?B'4-&@9_M%DP1R4(!;;DXX
M[4[Q=X@3PSX:O=49=SPQED3!^8^G% &/9^"Y+">WFMH=+62V),)9;AO+R",+
MF4X&"1CI6YY?B+_GYTO_ ,!Y/_BZS],U,VT8O[W5UFL[A!L0PL'63&6QWQU[
M5IOXCT>.PBOGOXUMI7\M)#G!;TZ<'ZT 9]IHNJV5[<WEN^F+<7./-<QS-NQT
MX,F*JMX4NGU*?42NF"[N%V2RJLX+#&,'$N*Z33]2M-5M?M-E,)8=Q7=M(Y'4
M<BLV\\8:!822I=:E'&T+^7(-K'8V <' ]Q0!E#P?.MK:6HCTP06C[X$VSXC;
M&,C][Z$_G3V\)W$DM[))%I$C7J[;CS(IF$@QCD&3'0"MB\\3Z+83+%<W\:2-
M%YP7!.4R!D8'JP_.G7'B+2;4J)KQ5W!6!VL0 W3) XZCK0!@P>#)+;39M/AA
MTI;:;'F)LG)8#H-QDSCGIFID\+W:75K<A=+\VTC\N!BDYV+C&,&3!&/6CQ/X
MG2PU32M*AN/*>^=M\JH6VH .F.Y)_2F6>M#1+35[G5M>6_\ L";Y(H[<JT2@
M<9Y.21C\30!!_P (-@MBVTD*91-L"S[0X_B"^;@'GL*G_P"$1N"M\NS3,7QS
M<C;/^]^O[VM_1=7M]<TN*_ML^7(.A!&/S_"FW'B#2K6[%K/>(DI<)@@XW'H,
MXQF@#$'A:\$UG-C3/,LUVVY*SGRQZ#]Y4=EX.ETZ_DO;2WT>&=\DE89L GJ0
MOF84^X K?O=?TO3YC%=7:QN,$_*2!GID@8'XTR\\2Z/87#6]S?1I*(_,*X)^
M7(&>!ZL/SH PF\&2M9S6ABTLV\\OFR)MGPS]<_ZVKB:#J*:DNHK_ &4+M8Q$
M)?*FSM'0']YS^-6)?&OAV$$R:I$H601,=K<,0#@\<<$5?O=;T[3PIN;I4W+N
M&%+<>O /% %?R_$7_/SI?_@/)_\ %UB#P;.MY/=H-/2XN,>=(C7*E\9QG$O;
M)_.MZY\1Z19QP23WT:).I>(\G> ,\8'M43>*]#6*.4Z@FR1 ZG8WW2< GCC\
M: ,J7PG=3Z<MA*NF/;+)YNPK/DONW9)\S).[GDTZ;PQ>SWEK=R_V:UQ:J4@D
M*SY0'KC]YWP/RJ]-XMTV'Q+#H9=C<21>;N"': >G.._%2:5J=M]AO;J35DNX
M8[EE,GEE!%POR>^.N?>@#)D\(2RZO_:KV^C_ &TG<9!#, Q]2HDP3[D4MSX1
MGN]5_M.>#1VO, -((9AN Z;@),-^(-;D7B#2IX;B6.\7;;C=+E6!0>N",XIE
MIXGT:_O8[.VOTDGD3S$4*PW+[$C% &;+X>OYM0EOW&D_:I8_*DD$4P++C&#B
M3]:DL-$U/3-/^P6ATI+7+'RC#*PY.3UD/6M^XN(;2!YYY!'$@RS'M7&6OC!6
M\=:E;R7RMI-OIT5P#Y3*8V+R!L]SPH.<4 :AT343I(THIHQL @C$!MI"NT=!
M]^HM(\.7V@Q-'IJZ5 K=?W4SGZ9:0G'MTK;&L6#3V]NMTOG72%X!@_./45S?
MA[Q04LM4N-=O45(-0>W2380 !C P,T ;3P^(9$*-<Z7@C!Q!(/\ V>L2'P7+
M;^=Y2:<HG<O*H-QAV)R21YN#DDYKJCJ%JMS#;&4>=,I>-<'Y@,9/ZC\Z+W4+
M73XU>ZF$88X'!)/T YH P+OP[>WNFKIT\6C&T0AEB2WD0*1T(VN,&H4\)W"+
M=*L&CXNU"3YAF/F =,_O.O'7K6S)XDT>+3O[0>_C6UW;/,(/#>A&,@T)XDTB
M2W\]+U6C\UH<A6R7&<@#&3T/Y4 85YX,DO[>V@N;?2'6VXA/ESAE'IN$F?UK
MIM,MIK.R2WF%L-@PHMT*J!]"359/$NCR6K7*7T9B5@A8 _>],8SF@^)-'%@;
MXWT8MA)Y1<@C#YQ@C&1S0 FO:6VN67]FR "SFXN#GED[K^(XIHT"V'B./6$7
M9+';F ;6;YAD=1G'&/2I+3Q#I5^]U':WJ.]L,RC:PVCUY'(^E5M.UJRM]&LY
M;C51>"5?EN%A8>9[[1G% &[64WAO2&NY;DV8\R5M\@WML=O4IG:3^%$'B/2+
MFVEN8;U7BB?RW8*W#>F,9S3X-?TNYL'OHKQ&MXVVNV""I]"",Y_"@#.OK/4]
M6UH6=W8VZ:+;RQSI-N#/(R88#'\.' _ 5T?2N0T/Q%+JGCK5;&.Z6:Q@MT>)
M1&4*DXSG/7J:Z*_U>PTLQB\N!$T@)1=I8D#&> #ZB@ U/2+#6;9;?4+<31JX
MD4;BI5AT((((-9\O@WP_,DZOIRE;A@\H$CC>P& 3@]< 59D\1Z1%%:R/?1A+
MM=T!P?G&TMQQZ FG6FOZ7?:=)?VUXCVL3%7?!&TCJ"",]Z &_P#".Z5]O>]-
MKNN'B,+.\C-N0]5()P1P*JP>#/#]M+#)#IX5H',D0,SD1L>NT%L#Z#BL[2?$
M<FI?$"[T^&Z66QCLO-5/**%6W(.<]>I[5TM]J5IIL8DNYA&IZ?*6)_  F@"U
M69=>']+O;UKR>US<.FQW61DWKZ-M(S^-,/B;1A!;3&_C\NZ.V%L'#'TZ<'ZU
M'J>LV3:'?SQ:HMHL*O&UT8RPA8#DXXSB@"35/#6C:S!!!?V$4J6YS#M)0Q_0
MJ013I?#NDSVMI;262&*S;? ,D%&]<YS]<]>]27&L6&GI&MU= ,R[LA"<CUP
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M%CMK\^%]2>ULKAQ;Z^;F2V$+;I8=BC*KC+#.>GI7KRO&^0K*VW@X.<4H '0
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MQ:WM?.LM4^UR_P"D<;/.,G'R]<'%2:EX,U75;_Q)(QAMUOEMVM)%DW$/%O\
MO# X._UH V[WQ!-]BU>'4-!O$CM[)IV&1ME3;\RAP<;@">,YXJFOC"+3[;0K
M2RT6YE_M*!WM8TD7C9C*DD\?>')XJ<0>*=4\.:A;:I:V4%U+9O;QQPSEED=E
M*[RQ'RCG.,'ZUSEW;:CI.M> K1[>%[N"*Z1HQ-A3_JNC8_I0!T5AXY%]IUU)
M_9%Y'J%K="UGLL;F1R<9)'&W&3G.,"LGQ3K\6O?#[Q2$C>"YTY9(G"RYPPC#
M@AE.",,*EO?"VMF"^O;00"]O;^.>>U,NU&B7(";\=<8.<=O>JMUX2U^;2O%M
MFEM9I_;!W0[9CA,PI&0>.VS.>^>U 'HEK_QZQ?[HJGK&KP:/;1R2@O+-(L,,
M2GYI'8@ #\2.>E6K,2K9Q"9%24*-RJVX _7O6)XNT*YUFSM)K&15OK"X2Y@5
M_N.RL#M;T!QC/:@!A\4N;J_TR2QDAU2"V-Q%"74^:G0LISC@D9R>]<(]Q=?\
M*X;Q$+&X75=LR?;%N K%69@2<-SC.!GI@8Q@5VG]AZA>:Y/KMU;PPW:V#V<,
M"3;E.\@L2V!C[H[5E-X9UUOAC_8'V:V^W?,/^/CY,%R<YV^] $T*:5I?BG2G
MDT26VO;^%V643CRUV;=QV!L G>.<<X]JV!XJ>66&2UTJZN;"6Z-K]JB&X AM
MA8J.=NX=<8QSTYJIJFBZIJ&NZ!=BW@6"RBF2?]_R-^SIQS]PU7\/:3XGT*>3
M1U6S?1Q<O+#>&0^:L;.7V%.A/.W.??':@";4/B!8V+/(L/GVT4_D221RJ6!]
M0F=Q ]A785P.G>'O$6CZC>6%O!IUSI5S.9H[N8XE@SC*[,?-TSU'4UWU &1J
MVM/IUS'!%92SLT;2-)D)&@7U8X&3]:YJ;QU<7K>$KG2[)VM=8F(=690P'E.V
MWGOQG/M6IKVF:S<^([*[M(X+FP2%D>"64IL<G[_0[N,<<=.M<[IO@[7]/T7P
MI'Y=H]UHMT6>/S<*Z&-TSNQU^8'&/QH ])4DJ"5VDCD>E8^N:#::T =0GN!:
MQ(3Y<4[QC/\ >.TC./?UK87=L7=C=CG'K7->*$\1W$D$&DV%I<6GWI_.NC$6
M/9?NGC_"@#.\)Z/>ZAX/CL]5O+Q[<7,WEDS,LDD D;RP7!W$%<=^12>$]*N+
M/5?$=E#=W3:+NB6TWS,YC?Y_,"L23C[G>KD[^,6\/LD.G:=%?/)L$:7)"Q18
MQPVWENN....N*?I!\3VUE<)-I&G6_E1C[-!'=%O-<GG<^WY?R/7VH RM _L^
MS^(U_8V-Y>0@6PWVETTI\U\@^8GF=>.I'6N^KF[72;S4-?L];U.SAL[BUB9%
MCAF\W<6!!RVT<<GC%=)0!PTE[+X@^)=SH4LTBZ;IMJ)I(4<J)I&QC=CD@!CQ
MTR!6A,='TSQ7:0V\TL%X8'*V,0<1R@X^;:/DR,=?SJ/4?#=[:^,%\4:,8Y+B
M2'[/=6DK;%E3C!#<X(P.QSBFG1]6U#QK9Z[<VL%M%:6DD*QK-O+LWX#&,>]
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M]XCUJ6QU/1M*@;RY=3F93+C)15 SCW^85@:EJFH$>*_#UU<R/]GTZ2YM[I0
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MT <XW@^T$]_Y$\D-KJ$ADN[=?NR,3DG.>,GKZY-3#PS#'KW]K07#1RBT6S1
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M'%;E% %#1M,&CZ7#8),TL<(VH6'.*S;KPL+CQ'_;B7\L5T(C"NT<!"02.O\
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M;Z7/#JTLDY2X<6\\L8226/LS  <GWYH Z2BBB@ HHHH **** "BBB@ HHHH
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M<*%Y75%'=C@4D<\4L?F1R*R?W@>*Y3QYI&L:M:VO]GVFG7UK YEGLKWI/@8
M'&#U/7OBI-!DTS4O 3+::7#8V_ERQRV2Q*JQNK,'&!Q]X&@#9U72K+Q#IJP3
MLYB+"1)(FP58="#^)J#2]'M=-NMAO[J]NE7<INI S(IXXP!Q6)X2U.VT7X5Z
M-=W,BQQI:(HW' )/ %<]INHQ6GQ UN]_M&"YNWT7S?DF5QO!SL7![  <>F:
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M@YZU:@TC['H<MA:R*LL@=FD=<@NY+,< CC)/%-M]?M[GQ'=:((9EN+>(3,[
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MQ\4:KJTMY!)%?;/W2PE63:,#G<<_E4?C7PW=>*=$73[:\BM2)EE+R1%\[>V
M1724R5S'$[JC.5!(5<9/MS0!5OM/74](GL+L@B>(QNR#'4=17/\ A_P]K^G0
MII^HZQ!<Z;;)Y=NL<!25EQA=[;B#@8Z =*U/#OB.V\2VKW5G!.D"N4WR #+
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M#]:UM-.K+XBU&&XEA?2E2/[*$B*M&<892V2#T!Z#K6Y3!-&9FA#J9%4,5SR
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M:!=^'[75K5=+>[2XM_-MV:2,+,L@4D, 1\N.E==8^([.]NXK8K)!).ADM_-
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M6#Q_>KJF\)V#WM_=F6[\Z_B\J<^=U7&,#\*I7/P^T.[LK*V<7(-ED03)+B5
M3DC=CI[4 8);Q%'J_AK2[S79/,F::&Y>!4^?;&Y!/!^;*\]O:JMOXDU.RTPZ
M9)?R22R:\--6[D"[TC98V)Z8R/,...U=LWA/33=:?<(9XY+ $0>7)@#*E23Z
MD@FJ[^!M%EL+ZRF2:6&\F^T2"23)$F -R\<' '/M0!R5Y<2>&_&?B2\BFDE\
MO3(B@E(.S+H.OMG//I6A+?:UHUD_B$7/FV*Z:]P]O+(KF9UC+!EQC&>,BM^U
M\%Z5;74]RYN;J:>#[/*]S+YA=/0YZ]*-&\$Z-H8E6VBD>.0%1',^]44]54=A
MSTH Y2\BFGN/ ^IRW\T[W%\&D#8VL3#(<@ <8Y_.M[XF GP5.%."9X,'T_>+
M4UO\/]%MC;[&NREM-YUO&TV4B;!'RC' P:W=3TRUUC3Y+&\C\R"0<CT(Z$>X
MH XE(-8TOQ7;:4NMWEW;:K82R#S0FZWDC* ,I"@8/F="#TIWA[5]0OUM= GO
M93JMC=.FH2@#<40L5<C&,/A?^^JZ>+2(M&BGO+6*XOKP1;4\Z0-(P'10QQ@5
M7\/:?,U[>:Y>V*V=[?! T1(+HJ@##$<$\#H: ,OXIQNW@B<I/+'M=<[#C=]:
MH:GI\MQ\4+6TCU"X@;^Q)LSIMWG]['ZC'Z5VVKZ3::YIDVGWT9>WE&& .#^%
M4$\)V":I'J2RW8NH[<VX?SCRAQG/N2 ?K0!R6A:U?:IX?T6.YU*62Z>:ZC>%
M% DN0DA522/N@ <G%9,MYJ&K^%_"TUY?7 G_ +9^SNRL 6 23K@8)XKN(? .
MBV\-K'$;I#;2O+$XFPP+G+#..A/./<U(O@;0TTW[ D#I +C[2@5L%'YY7TZD
M?C0!/XLU:;P[X.U'48/WDUK;,R%QGD#J<5EW+7FC6AUN/5WN+8V9+6\H!\R0
MX(<$=,#=QTKJ9;*WGL&LIHQ+;O'Y3HXR&7&"#ZUD:-X.TC0UD6U25U=#&!,^
M\(AZJOH.G'M0!A:>FN72V&JQZD\5K<VFZ8,Z/O9DR&3C@@D>O2N9,.IZC\(Y
M==O->OY9GMN8P45,B3 /"YS^-=[I7@71M&>9K(7$8D#!4\WY8MW78/X>IJS:
M^%-,M/#DF@JLKZ>ZE2DC[L G.!^- '-:W<7=K9RP6FISRS6^E/,L* !HW R)
M&;&,#L,<\4B:SJDT_@F5KZ15O5<7,8"[9"-N">,]STK>?P-HTC1LRSY6W-NY
M\S_6H1C#\?-3D\%Z5%_9OEFY3^SBQMPLN,$XSGUZ#\J .)NKS6_[+\2WXUZ\
M#Z9J>R! L>TKYH7:WR\C&17J-I*T]A!*WWGB5C]2,UA/X)TI[34+5I+ORK^;
MSIQYWWFW;L_G6Y%:)#8+:))*$5-@;=\P'UH Y#X5_P#(H2?]?T__ *%3]2U.
MZU?Q/=:+9RR(D5H)%:&548N689Y!SC'YBK-KX TVQM'M;34-6@MW)9HH[LA2
M3UXQWJ?4_ VBZHMEYR31RV48CAFADV2;?0MW[_F: .5BM=3;X@>'8-1U.22Z
M&F7(F>$@*65XAG'(SS5/3=3NM \.:S?1W4TCR:W]DW2L#L5Y@A;)'! /?CCI
M7H$WA;2YKC3Y_*9)+!&2 H<84XR#ZC@?E49\'Z,R:C&]N7BU DSQ,<KD]2!V
M/>@#F=9C\0Z5IVL7::I)!;-:K);QEDD=)%/S$''W2&'&.PKIO"UE=0:9'=W6
MIW-[)=Q1RE9MNV,E!D+@#CZYJM;>!-'M=)N=.1KLPW "R,TV7VCHH..G/2M^
MQLX]/L8+.)G:.% B%VW' &!DT <YXF7^UM2@TAK1KNTCC\^ZC7W)$8/ME7_*
ML;P5J%ZO@W5-$N)9(=0T57MU<XW[%!\MN1Z 5V=AHUOI]]=W<4MPTETP:022
M;AD>@[50?P?IK:S>:KYMVMU>1F*8K-@,AXQB@#B;>\UL:9X5O_[<NS+J%U]E
MG4JFW:9"N0-O6I&\1:GHEWKNF-?37*0WMM!#-,5#H)=Y/(&/X0.G>NO'@G2U
ML]/M1)>"*PE\ZW_?<JV<Y_.G2^"](GDU1ITEF&IA1<K(^X';]T@=B.U '+^(
M_P#A(=%\-^);Q-5EAC2S,]JFY'DB8*<\XY4X]/6I#J6IZ'XJM%DU*XO(+O2)
M[IXI0N%>,QXVX /\9K>B\!Z-%H=SI&;I[:Y79*7ERY3^[G'3VJW_ ,(IIYU*
MTOW>Y>>U@:WCWRY&QL9!'?.!^5 '!ZBT^IZ'X0UJ:^EEEN]4M973(V#=*I"@
M8_ASC\.:L7D^L2IXND&NWB'3)E-N%"<<=#\O(_QKI4^'FAQ[%7[4((K@7,4'
MG?NXI V[*KCCFK1\&Z:4U)#+=XU$@W'[[[V* .4?6M5TG4=&OVU">Z74-,EN
MIK>0+L#K T@"X (&5 Z]*OZ4VMZG_9&L07[16T^[[2'D1EE!/&T8X(P:WU\(
MZ:MSILY>Y9].C\J -+D!=NW!'?@XJ'3/ VBZ1?RW=FDR%V+"/S/W:,>I5>QH
M X2+5-<@\+QZV^N7<LT&N&T\ME38\9N/*^;"^C=JZ?P[;N/B-XD9KJ=P@B 1
MF!&"H..E:/\ P@FD?V4=-WW?V8W/VHKYW_+3=OST_O<_6KDOABP-_<Z@JR_:
M;B 0R$28#@#@GW]Z -OM7D7B:\N/$?PW\4ZG+>2H89)X4@3&U%C)7:>.^,_C
M7I/A[23HFBP6!D:01# W.6VCTR>H%95[\/\ 0[Z6_9Q<QQ7_ #<P12[8I#C&
MXKCK[T 8?B?4;V*'49+#4)6EM+6!EBA 46Y)Y+,002W0#V-16\MQ-\1;2]>Z
MG);P_'=-$K#:6W'(QCOC]:Z:X\#:+<S2R2)-^^A6&5!)\L@7H6'<CUJQ%X2T
MJ&\L+N..0364(@B;=U0$D!O7DYH Y;2;[7=7TO2_$5O>"-"S/=*\BM')'S\H
M7&5/ YSW-9VKW,_B'X>W&N2WLRL^I(JP+C8J+=J@7&,] ,GU_*NRT_P-H>F:
MJ]_:PR(S-O$._P#=*W]X+T!]ZBN/A_HEQ)>$_:4ANY1/-;QR[8C(&#;MN,9W
M#- &GJ-S]C\,27'VN.T\NW!^T2#*Q\#DBN-TK4]97Q1=Z9'<3-&^B-=0&XQE
MI@44.1CY<EB2#ZUW=WI5I?:1)I=S'YEI)'Y;(W.5K(M_ VC6]PEPHG:9;5K0
MR/)EFC88P3WQQCZ"@#+\'ZU+=ZS-9:@UW::DENIDLI^5;D_O4; R#T]!BKVH
MZC->>.+;P_Y\EM;FRDN6:/ :1@R*%R>WSD\>@K5T_0+/3KD7"-/-,L0B62>3
M>509X![=:=JF@V6K3VUQ/YD=S;$F*>%MCKD8(!]#0!YKKE]J&H>"O$MA>W,K
MG2[_ .SQS# ,J%4<;N.HW8X]*]5L83!911F5Y"%'S/C)X]JRKWPCI=_HS:7*
M)EMY'WR;),-(V<Y8]ZV(8!!;K"'D8*NT,S9;\Z /-;G0KVW,WBK0$)U6UN9?
M/@'2[B#G*'WQT/TH7QM')X7OM9TML"[U!8 Y',1(Y)'J,?K7?Z7H\&DK*L$M
MPXE<R,)9-W).3BH6\-Z4UE>VAM$\B\<R3)@8+'O]>* .?NI-0T[QG9Z-%?W$
MEIJ=M)EWVEH)%4G>IQWQT.1S57P[K%_?VZZ+=7DW]JV5Y(EU)P&=$ .2,8&0
MP_(UUFFZ#::9*LJ//-*D8B22XDWLJ#L#V%3P:59VVJ76HQ0JMS<HB2N!]X*6
M(_\ 0C0!P]A>ZYXAM%U6QO/L[Q7[HY:13'Y:N5,97&<X[YSD52O[C67L/&DZ
MZ]>(^DSEK;:(\<01N ?EY&6-=='X&T2+7)-6CAD2:60RR1*^(G<\[BO<YYSZ
MT]_!NFR0ZG$TMV4U-MUT/.^^=H7^0 _"@#FI[S4;76M/\S49YXM4T^=YH9 N
MQ&"@@K@ CN.2>M8MD=6T/PEH>NV6K7+!KTP/8,$\IT:9P0.-V>O?O7H1\):<
MUU8W#R73O91F*(-+D;2,$$=Z=9>%--L9(S&)GBBD,L4$C[HXF)SE5[<\T <M
M;WVN^)H+ZZTZZ-K/:7[1*V]=B(IY5E(R<@]<]A4^FQ:IJOC;5H)=>O$MK&>W
MECBB$>U@8XW*'Y?NDD^_/6MJ;P-HDVN/JWDR)/(=TJ(^(Y6]67N:OV7A^SL-
M8O-4A>X-Q=X\W?)E3@ #CV  _"@"[?\ _(.NO^N3_P C7F4PE/P G$1(_<-O
MQ_<\WYO_ !W->H7,"W5M) [.JR*5)0X.#Z&J&E^'['2=&.DPB22S*LICF;?\
MK9R/IR: .1UD$^(OA^+?[VV0\?\ //;%N_#I7H595EX>L;"<31B221$,<1E;
M=Y2GJ%] >/R%1^&]#_L&PEMQ([*\SR*K2%]H))QDT 5O$ULFJ:;/X?MT3S+U
M"LQ _P!5&W!<^_IZXK'TZ V_Q:GCY\A=(VVP)R-H>/=C\<5H7G@'2KZ^GNY;
MG41+.<OMN2 >,=,5J3>'+":"UC DB-JGEQ21-M<)C!7/I_A0!R7@\2_\(OXG
M+9\DW]SY/IM[X_X%NJWHVH7&F_"S19;6UN+B5[6*/%O"964$<MM'/;]174_V
M/:#2#I<8>&V*E3Y;;3SR3GU))/XTND:5;Z+IL.GVK2F"%0L8D?<5 Z"@#S_P
MG?VR_$S4((+#4H0]C&";BT=#NSDL^1QDYK?\53.WC'PE8G_CWEGGF=>Q9$ 7
M/_?;5T,6DVD.LSZJB$74\:Q.V>"HZ55U[2'U'[%=6Y47EA/YT);@'*E64GT(
M/Y@4 8,%O(WQ=NV^USA1IJ/Y>X;?O@8QCI7*:/)?Z5X8TO5+;49U']JF!K;"
M^6R,3G/&<\#O7I,^@V=_J4.K2I-#>+#Y>4?:<'L<=<'D>XJB/ NDC3(M/$EX
M+:*?[0J^=T?UZ?YS0!A&^UOQ&=7?3KIK6XL-0>!'\Q=B+'(0=RD9.Y0>_?BN
MVNK"#5M)-G?HLT4T860 D Y'."#D5D7/@?1;G6_[6:.5+EL>8$?"RD=W'\5=
M& %4 # ' % &'+X;TJR5[V"V*7$-HT"/YC'Y N #D\].IKE_A]!K$OA+3_*G
MM/L/VN8R1^4?,*>>^1N+8]>U=SJL$]SID\%L%,LB[0&D,8P>OS $CCVKG="T
M?7/#UC]CL;.P,&XL%EOY&P2<G'[OU)- %*ZO-27Q+XHLUU.=8H-/2># 3]TQ
M#$XX]AUS5&T7Q$/!MCK-MJ%WJ5U=10236A*+N08+B/"YW%<^O7BM*;PWK$^H
M7U\UM:":]B\F8KJ,@!3L!^[X[_G3H_#VLQ:/:Z9':V:P6K!H6&HR!UP<CGR^
ME '-:KJ$>L:;X?FMM1O@PU]89(I?D>+,;G8PQSC;QGU->L(/*B52Q;:N"S=3
MCN:XFX\+ZC=60M9M-TYA]I%UYGVZ3>90"-V[RNN":TKNU\0WFER:>]GIR0R1
M^43'?2*VW&.OE^E '&^*4O[RTF\4VEE*U[9W(DLY1T\A<C;CW);/T%=%XCU>
MXO;+PQ?:5J,MO;ZC=0AO+"G=&ZD]P>>E78[#Q!%I']FK:V'D[-FXW\F_'U\N
ML:V\%:A:6%C90VML+>QF$UNG]I2?(PZ?\LNE %,#5WOO$^FG7[X16"">!P(]
MX+ \$[>GR_J:DTKQ!JOB=+2Q$CI<-I4=T6BD5"7=5^;D'(!/3WK1'AC5A=:A
M<"VM/,OT"3G^T9.0,_\ 3+W-4[CP)=7%II]NVG6*G3UV02IJ$@D5.FW=Y73V
MH 8[Z_\ \)'X8TJZUR4-<VURMRT"IABF<,,@\XQ[9'2JNG>)=332[?2YK^1I
M9==ET[[8P7>L2*S#MC)V =.YK</AO5?[0L+U;&PCEL$,<&R_D  /WN/+[]ZJ
MMX*O7TRYL)-.L)(;BX^U,7U"0LLO]]3Y7!YZT 9=_%<Z7X@\<2VFH7"30:-Y
M\,IVED*QY Y'(R.]6M^KQZIX<4:Y>%=5@E6X4A,+C9@K\O!Y/7/6K(\%ZC_I
MA>UMI)+VW^S7$KZE(7DCQC!/E>G%6/\ A&-7\[3I?LUKOT\%;<_VC)\H.,_\
MLO84 8UKXDU.S<Z+)=2W&[6'LDN)&59-F2P7.,9/W>GZU)XC;Q'H?AO5Y3J\
MD>V>)[504=XT;(*L<<CCCOUJ]+X+O)[34+:?3;"6.^E\Z7??R$A\YW*?*X.0
M*&\&7[Z(VDM8V;6[.'=CJ,A=R.F3Y7(% $%X^HVNO>(-'DU:ZGMVT:2\5GVA
MHW! ^4@# Y-;O@JPCD\':6;AWG*YD4R'[IR?3^M5/^$>U<ZM)J3V=C)<26QM
M7WZA(0T9Z@CR^?6MGPQI,VBZ:;.2"&)%<E!'.TO!]RJX^E #]=L;=?#FL[8P
M&EMI6=NY(4D'/MV]*K^!KN:]\$Z5/.29##M)/4[25!_("K^N6T]_I<UA ,&Z
M4Q/(3@(AX8_7&<>]9J^%(8=0T::VD>---A\H8D(W#T*XP<]^: )?%%RT45A#
M'>M;O/=!/+C3<\XV.=B^G0'/HIKD[#5O$<_AO4%@62ZN;/5#&8=X\QX!M9D#
M8Y."0.,]*[C6=!LM=CMUNQ(K6\HFBDB;:Z-@C@_1B*H0^"M)MQ+]G^T0M+.+
MAFCEVG> .0?P% !X.U2#5=*FEAN;B4K.P>.Y7;)">/D(P.E8\-DTGQ9O_P#2
MYU']FHV 1_?Z=.E==IVF6VF1RK;AB97,DCN<L['N3WJHGAVS3Q!)K2RW/VN1
M!&W[WY2H[8]* .&CUW5CX'T^^.H2_:3J?D/)A<LG/!X]JT-.M]4U?7?$4<VO
MWR06-V!%'&(Q\ICSM)V].?K6N_P_T-Q(C+<&)YQ<"+S?DC?U48XSW^@K3TSP
M[9Z5?7EW;O<&2\;=,))-RL>F<?3B@#RN&"4_"[PXQNYF>36T 9R#MQ+(../Y
MUO7&NZGX<O/%5JU_->1V@M6A>?;NC\UE5CD #C?GD=JZ4^ M%^QQVBBY2".X
M^THB2X"OG(QQT!)/XFK1\):7)>ZA=3":9]0C$5PLK[E91T&/:@#FM177[*PO
MKZ'5)(;633S(BLZ2/YH!.]#C&""N1@]*WO!UK>#2+?4+S5+J\DN[>-S'+MV1
MG'.W ![]R:99> ]&L-.N;&'[3Y-PI0[I<E%_NJ<<#GI6YIFGPZ5I\-C;M(T,
M*A$\QMQ ';- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** (;F\M;*/S+JXA@CSC=*X49^IJ(ZKIX@BG-_:B&8XCD\
MY=KGT!SS7.^++Z&UUK1$EC\MVD<I>.A=(3L;^$=21QVZUY]$(9?!FE6\JN[Q
M>(%)#1D$*5//TH ]</B#11;O<'5[ 0QOY;R?:4VJW3!.< ^U6+C4K&TMUGN;
MVWAA<9622554CV)->=3VEB?%?C3]RNTZ<-ORG!/E <>]9^EZI!IUQH<FK27,
M.FS:9Y44Z [8Y5DDW!N">5,?Y4 >J/JNG1",R7]J@E7?&6F4;UQG(YY&.:=#
MJ-C<V1O8+RWEM0"?/2563 Z_,#CBO-4TO1[7Q#X0MK2&8V*R3,AN,DE/*?:<
M]ATQFLN29[/3;MHHI#IUOXF26ZC13GR=D1)QW&=U '>Z5XFEU'QOJ.F)<6<V
MGV]JLL;P'<<DC.XY([UT%MJ=A>320VM[;3RQ_?2*569?J >*\QU2Z2[\5>))
M](#222Z5'M:-"-^UD+ ''7&:EC?3M9TDZAH,E])KUOI4L,:,2! _ED!6!'7=
MG&* .HUOQ0;77]#L;"\L94N[PP7,8<-(HV,W&#QROI75UY,-3TVYMO [0*RS
M6MX%F0QMNB_=."#QZXKUF@#EKSQ'-I_C=-.O;BT@TLV3S^9(=A#*RCEB<8YK
M=_M?3?+@D_M"UV7&/);SEQ+GIMYY_"N1UN"S;XE6$NI1 VIT^959U)7=N3CZ
MXS61:^&9G\':K+9Q^7]FU"6_TE&!&U4E+@#T# 8^C4 >F"YMVN#;B>,S!0QC
M#C<!ZXZXX-2,RHC.[!549))P *YSPA)/J=G)KEY"8I[P*JHW5(UZ*?\ @1<_
MB*Z2@#A]<\=QOX6O-4\/7-I,]M-Y3;SNX'4@ ^N>OI776^IV%W)/';7UM,\'
M$RQRJQC_ -[!X_&O(9I(T^&&M6#HPN5U"4M'Y9SAFR.U;NIO9V'C/56BM3-;
MG0Y T40(\SYH\#/TS^M '?)K.ERK,T>HVCB%=TI693L'JW/ ^M0Z'KUAXAT]
M;W3YTEB/]U@2/KZ5Y]H%W%+XRT*1),PR:4(EC6%E6+AL1DGJ1D#/%=%\,)4/
M@FSMP"LT V2HRD%3Z<T =E56WU.PNYV@M[VVFF09:..568#W -4?%D=Y-X1U
MB/3\_:VLYA%CJ6V'&/>N5L=1TC7M*MYM+M7_ +7M[.2-5*%3!G&X-]2HH [9
M-5TZ2Y>V2_M6GC!+Q+,I90.N1G(Q5'4/%N@Z;9R7-QJUELC3S"%G4L1G&0,\
M\@_E7$^&)- U:UT#[0U__;&FP[)+>3(\EA&4DW<8*_>_2J5CI=K+\'M7D@M
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M [GPOJ,^K^&;#4+G;YT\6]]HP,Y/2M2::*WB:6:1(XT&6=V  'N37/> 75_
MVE8!&V'!!!!!R?6CQQ=0VGAPO/;-/&;FW''2,^:F';')"G#$=\8H V$U?39;
M:2YCU"T:",[7E692JGT)S@4MOJFGWER]O;7]K-.@W/'',K,H]2 <@5Y)=RQ2
M6'CJ)Y#/Y]O \;+"RJYR^2H_*M22);;Q#H/]F((YVT*5%*@_?\LE0?QQ0!TO
MBSQ4VDSZ7#I]W8O+/J$5M/$S!I K'L >/QKK:\8EU&RG\&>&8BCK?6NL1&XC
M:-MZ'S&+$\=.0:]G!!&1TH Y/Q;K^L:/JFBVNFI8LFH7 @8W*.2IR.1M(]:=
MHOB6^G\6WWAO5(;?[5;P+<I-; A&0G&#DD@UE?$0H^M^%(S)(G_$P!9H\Y49
M7G/:J_AM3X6UO5-$O@7N[P-/::B5)^T+V5CV89'UR: .\_M33S>_8OMUM]J_
MYX>:N_\ [YSFD;5]-25XFU"U$J ED\Y=P Z\9KS;P\^CZG!I^GZF=076K'43
M)]FY&)!*6#YQC:>#UZ5/HIN[+5+*""5=2TBZ,OD!XRD]FP7G=U#*>G;M0!VV
ME>)](U?39+^VOK?[/'(\;.95P-KE,DYZ$CCUR*;JOBO1M)T6759;^WDMHVV;
MHY5;<W]T8/7GI7 V&HVMEX-MK6>V9IX]9E#,R';;M]K8J[#'('!QW]1UK)U
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M&.B@5SOQ6*GX=ZE%R6D:$*H!)/[U"?T!H T[6Z\1'[%-</I303;3(D:.KA2
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MCG5['5_!6L):[IE@V#>%/W]RG ]: .QFU&SL8(GOKZVAWKD-)($#=,D9/O\
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M*** "BBB@!KQI)C>BM@Y&1G!IC6T#XW0QM@YY4'FBZN8[.TFN9CB*%&D<^@
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MA"C'Y5Q.O:S]L\6Z#I:PSS:=>0RROY8XF&S*D<]!UKKM,L%TS3X;-)IYEC7
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ME!)(L$L)CE:(K*,'*]Q[4 7:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M#VI6/B7PLT%HTUEI=DUO-.)$')3:" 3D_E7:7#3);2-!&))@I*(3@$^E2T4
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M%@!@H'(&.#^=:/\ 8^IIXD\.W::7%';VB3>>+=HT2+S P "Y&<9&<#UKM"0
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M&/FVYYY&170K&B$E5 +<D^M.H \UT_PQJ*:=K=AJ'AY9[2]U(7"1+-'GRRB
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MPM(=4TF__M"2273R[9E4$RLRLK%L8_O$\8K.N/A]'<V-Y"VH2I-+?C4(9XU
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M=N>G%:I\.S'7['5C=KYEI:FV";.&!'4\^M &!IWC6]O;73K)D"ZC=2W$9DC
M( BV9(!]=XXIMYXG\4:?ID)NK"**=M26T621AB:,D[7P,XR ./>K#_#K%C$M
MOJT]O?6UU)<VUW&HRA?;N4@Y!!VBK]YX1N+_ $^T@NM6FFGANDNGF=!EV7HN
M!@!>?K[T 86K^(->BTKQ;8O=11WNFVWVF*YB7^$IG;C Y!!YKM/#RW":%:"Y
MG$TAC!W[<<5E7/@Y;V[UR:XNVVZO:BVE1%QL !&5]^>];6CV,NFZ7#:373W+
MQKCS& &?P% ')^*/%6HZ(^HW"M$(K-T\N!5WF92 6+$ [.I SZ9J2^UW7I?$
M=]IED;6&.&Q6Z21\D\YXQCVI=5^'YU)];"ZQ<PP:JRR21A5.Q@H7@D9Q\HX^
MM:$7A:6+6)]1-^9))K(69#H.@_BXQS0!FZ;XPN=:31+*';;WU] TTLF-P15W
M D#ODJ?SIW@!9TO/$RW+J\PU1M[*, G:M)%X :T@TJ2RU22&_P!-W+'<; 1)
M&Q)*L.X^8],5L>'?#C:%<ZE.]_-=-?3^>P=5 4XQQ@>U &5XQT_6X]7T_P 0
M:$L5W<6*,)+!V"F9#D':3P#S[5GZ;XTTU=%U/4;/3Y+34S<K'=64Z[669AP3
MVP0.OM76:AI5Y-JL.HV6H&"2*(QF%TW1R G/S#@_D161-X#M+ZQU:.^N)&NM
M4=7EGA 385'R[!SC&3USUH JW/B?6M"&H2ZG9O+811QF"[8*F9'D2,(5!SU?
M.?05<O-9U;0+6]U+4O*N=,ALOM/F( K!QDE .XP!S[T)X-FO-%NM.UW6;G4O
M/B$0<JJ; "&#  ?>RH.:?8^$)O[+GT_6M7N-4@DA-NJR*JA4(QV')QW]J *M
MSXAU71[G17O3%/;ZM)]GP@QY$I1G7D#++\I&:RX_%_B#^RDU>46HMHM3-G+"
MO+.OG>7D''&*Z"T\)R)'ID5_?&\CTL[[0NF&+[2H9SW(#'ICK54^!F.@R:5_
M:!V/>F]W[.0WF>9CZ9_2@"KJVLWFO:=XCBT^5(8=.5H'#J#YCX.[/H!BN@\'
M?\B5H?\ UX0?^@"LF;P/(M]J4UCJLMK!J:_Z7"$# OS\ZYZ'DYZUT.AZ9_8N
MB6>F_:'G%M$L0D<#) &!TH YWQSY.K11Z TLJ)*C33M%&[X"X"J=H.-Q)(_W
M#4'A+Q#<W'PZF8D-JFDP26\RRY&7B!4$\9^8+G\:Z73]+EM-3OKZ:X$SW6P8
MVXV!<X ]OF-9">#GAUC7;Z"_*1ZQ&4E@V?*AV;=P_P!KN?QH R(?%'B(IX=N
M6^QM'JI:$Q\C8V>&SM_2GQ>,]0M$U6QO5CFOK2_CLXY$& _F#<#C'9?S(K43
MP<Z6NAP"^_Y!,ADC)3_6'_:_^M5>]\ 17YUHS7\J/J5Q'=+)$ &@DCQM*DY[
M#G.>IH I:KXD\3Z-I&NW$MDK1V4 GMKN7:OF<'*[1G!&/UJXWB;4M)U^6#5O
M(>U?3I;Z,0]4\LH"O09SN_2IIO!U[?\ AV]TS4M<GNY;N/R6F9%&U,'H .O)
MY-6KSPI_:&K0WMU<AE2RDLGC5,!DDV[C]?E% '+ZO=ZAJO\ PB&JRS1_9KO4
M89%@"C,:EUV\]SC&:GNO%7B+[)XAN(?LB#2;ORPIY\Q=V,=.*NP_#^XCM].L
MSKMP;/3KE9[50B[E 8,%)QSC'%6V\&,UGKEN;\XU:;SG;9S&<YP/_KT 4_\
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M8W;HMSH,D\@+?('!3#;>G&32>&KNYM/$UOIVL6]Q'?2)*\-TDS/;W29SP"2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA*ZGM;+=917T42W/GX)*W"HQ"@<C((Z].:G3PCK']G^%[9_LO_$JD9IR'/S
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M+\W49WMA%+AL'CKQ5G4O".HZMJ4)N/LZ6;:2^G388EOG5E)''3YJ +B>-_\
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M+J8 22A!N8>YJU110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,T?FG^#<-WY4TWEJIP;F$'=MY<=?3Z\T 3T51_MBQ.K_ -EBX0W8C,ACW#(
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M8*RGS).&QR#BO7K.TBL;&"SA!$4$:Q(#_=48'\JB;2K!DV&SA*[M^-HQN]:
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MUV2*ZOO%FD2ZI8_:[BX3[/<3WD<;VF8DP &8' /S<=<^N:U8]'TN[^)']GS
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M(_$+!9_,.5!NCD#G@$=O>MNX\C^V/',9E^7[' ^/,/#8?)Z\<XKO_P"R-/\
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MK9X5VGS%0R JV[..1CC'?K6MJ6OWT5[XJBLK6UMKNPM(Y4N"NXR AOO=.F*
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MU&*(#[.I_=21[2K G'1D!J]#X?\ $%QHMQ9ZIJD$\IB\F$QJ57']YN.3P/\
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MV_K70_:Y/[4-G]EE\ORA)]HQ\F22-OUXS^-6J . @\"ZLEIIEDVJ0"VTZ_\
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M8)(H1$3M+. "YR!@XSP/6JZ>#9V^'TOAF:ZC$A20).@)&69F&1CL6_2NPHH
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MU&\\ WE]DW3I=;R1C<04&?QQ7;S>%='GNY+IK>02S((YBEQ(HE4 * P#8;@
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M0Z?)>7%HNGA4A6)]IY!/F>_I_P !KF;FZO/$/ASP1?:C<3I=2:B(W:)]H?\
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ML[?4+*:SNXA+;S(4D0_Q UCV_@O0;6:":&TF$L$9BB=KN9BJ'^')?ISQZ=J
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MXOHD75-B^;< XA)B0?*<<C&",9Y)KTNVAM/^$:6*R,4UM]FQ&8\%7&W@C'%
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MBEC&DVDVF!POS.J H9%]R%/(]:;X:N)[74KBTU)K74]/6Q5DOXXP6$>3^[D
M&"1SQCO0!Z%!/%<P1SPN'BD4,C#H0>]253TF2RFTBTDTU%2R:)3 J1[ $QQA
M>,<=JN4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 UXTDQO16P<C(SBD\J,J5\M-IZC:,&GT4
M1F"$H$,2;1T7:,"D-O 2288R3ZJ*EHH C$$(*D1)E>AVCBE\J,2;Q&F_^]M&
M:?10 A )!(&1THVK@C:,'J,=:6B@"/R(@A01)L/5=HP:7RHQ'Y?EIL_NXX_*
MGT4 9NK:/'J>DW%C&YM3,FWS(E *UG:?X>OUEB;5;ZTN4A8-&+>S\DDCH6.Y
ML_ABNCHH 8(8ED,BQH'/5@HR?QI#;PLQ8PQECU)49-244 54T^"/4)+T+F=T
M"$\<*.WZFK#(CXW*K8Y&1G%.HH C^SP8(\F/!Z_*.:&@A;;NB0[?NY4<?2I*
M* *]_;R75A<6\4BQO+&R!V7<!D8SC(S6;X7T(^'M!M=-DFCN'MU*B98MA()S
MTR?7UK:HH 9Y,62?*3).2=HY-"Q1H24C12>I"@9I]% $9@A(P8HR,YP5'6E:
M&)RI>)&*],J#BGT4 ,:&)GWM&A;U*C-0I80)?R7H!,TBA"3C@#M5FB@!C11N
MP9HU9AT)&2*;]F@P1Y,>"<D;14M% #1&@8,$7(& <=J:((E+%8D!;[Q"CGZU
M)10!%]F@P!Y,>!R!M%*T$+MN:)&;&,E034E% $9@B+!C$F1P#M%)]F@V[?)C
MP#G&T5+10!RG_"+ZG!J=U-:ZK;?9;F7S'BN;/S'7@#"MN  X]#71V-G%8645
MK#GRXE"C-6** &>5'M*^6NUNHQP:5$2-<(JJ/0#%.HH 8\4<H D17QTW#-*8
MT9-C(I7^Z1Q3J* &HBQJ%10JCH ,"D$48<N(U#GJV.:?10!5NK"*XL[FW7]R
M9XV1I(P PR,9KG;#PI?PPI9W^I6MU81@*JK9[)64=F?<<_4 5UE% $8MX0/]
M4G/7Y1S1Y$.6/E)ENIVCFI** ,75=%NM0N;=8=0^S:>H(GMDB&9>1CYL\=#V
M[ULJH10J@!0, #M2T4 ,>&*1@SQHQ'0E0<4KQI(NUT5AZ,,TZB@!IC0IL**4
M_ND<4WR(<$>5'@C!&T=*DHH C$$(*D1("O0[1Q1]GA+%C#'N/4[1DU)10!5B
ML((KZ6\"YGD4(6..%':IS#$S[VC0MZE1FGT4 1^1"$*>4FP]5VC!H,$)0(8H
MRHZ#:,"I** &/%'(H5XT91T#*"*&BC=0KQJRCH",BGT4 9>LZ=?7]K#!I^H_
M8-LF9&6(-O3!!4<C'4<^U7;.UCL;.*VBSMC&,GJ3W)]R>:GHH :T:.P9D5B.
MA(SBN?UKP]=WM_;WVFZA%:2PIL\J:W\V)ADG.T%3GGKFNBHH RM,T5+/S9;D
MPSW4P42.D(1/ESC"\XZGO6D\4<B!'C1E'0,,BGT4 ,:*-TV-&K)_=(R*<JA5
M"J  .@ Z4M% $9@B)),2$MU)4<TODQ;]_EIN_O;1FGT4 -=%D7:ZAE]",TGD
MQ>7Y?EIL_N[1C\J?10 PPQ%-AC0I_=VC%'DQ!@WEIN' .T9%/HH 9Y,8D\P1
MIO\ [VT9_.G8!() R.AI:* $VK@C:,'J,=::L,2 A8T4'J H&:?10 BJ%4*H
M 4<  =*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45EZAXATO3)7BN[I4:
M-0TG^P"< GTR:TD=9(U=&#*P!!'<4 .HHHH **X4>(I;_P 7:KH\^IG3+BU*
MK9Q$#$ZD9+G/WAGC QTZ\\=':ZA)I^B6+:S,GVYHE$NQ<;Y-N6VC\": ->BL
MN+Q%I4^GI?17D;P.YC4J>K@X*_7-9NJ>.-*L-.@NXG-P)KD6P5/X7[[O3&#0
M!TU%8L&HVUQXC>&+5-S+;*S66/NY)^<GWZ?A4L?B/2I;J*W6[3?+D1$]'(Z@
M'O0!JT5@2^-?#T+2*^I0_NYA YSPK^A_.MQBS1$Q$%B/E)Z4 /HKCK*XUVT\
M;0V%QJ<%]:SPM)-&L>PP$=,<GC.!SZUUL_F>0_E,JR8^5F&0#]* )**YOP+J
MM[K/AE+O4)$DN3-(C,B[1PV.!4GC?4+_ $GP=JFHZ=-'%<6MN\P,B;@=H)QU
M% '045A:SKW]CZ##=LOF7$[QPQ)_>=SC]!D_A5N348-*MH8[^Y#7++D@#ECU
M.!Z"@#2HKF]6\1Q66E6_B"UN%N-,W*)MO(VL<!@?7)'YUN75Q%%82W#SB*(1
MEC+V48^]_6@"Q16'INLV4.AV,LFI?;1,C&.? S* >3CVR*U;:ZAO[-+BVE#1
M2KE''<>M $]%<+X5\8PBVGAUK4E-R=0DAB+C'R@+@?SKI[_Q#I>F.5N[I(]I
M4.QZ(6.!GTR2* -.BL.Y\8:#:WKVDNHQ"= A9!R0'SM_/%3S>(M*ANTM9+Q$
MDDD\E">A?^[GUX/Y4 :M%<#HGC:VL;S6K?7]453%J)A@+C 5-BD?ADFNLBU[
M39M5;3([I&O%C\TQ#KL]?I0!I455L=0MM2A::TE$D:NT98?WE."/P(-4QXET
MEKR.U%XF^20Q(<\,XY*@^M &M16#+XS\/PM('U*(>5-Y,ASPKYQ@^G/%6;3Q
M)I%]J#V-O>QO<*GF;,]5]10!JT5DQ^)M(DNUM1>()71I$!_C4#)(]>*KV_C/
MP_=2VL<.I0N;I]D)!X9L[<?7(Q0!O45ROC+Q'%IN@ZD+6]$5[;Q;MRC/ED],
M_6K=GXAM;7P[IUSJ-R/.DLHYY#WY0$L?;K0!OT5FRZ[IJVT$RW:,MRNZ$H<E
MQCJ*Q?A_J]UK6C7=Q=7)N"E]/%&^,?(KD+^@% '645DW7B32;.Z:WGNT1U=8
MW)Z(QS@'T)P:BO?%VA:=/<P7.H1)+;#,R=T'O^'- &W16?+K>GQVUO/]I5EN
M1F';R7'M^=8G@75[G6+34Y;BZ-PL5_/%$Y&/D61@OZ 4 =716)<>+=#MK]K&
M6_C%RCJC1CJI;IFIG\1Z4E[%:/=HLDKF.,D\,X_A!]>#^5 &K168NOZ:URMN
MMP"[;PF.C%?O8^E9NC^-=,U32I=19C;PK.85$G5O3\3SQ0!TM%<WJGC32]/T
M&XU2-S.L,GDE$ZB3I@^G45H3:_I]O:QSRS!1(F\+W"CJ?IS0!J45EOK^F&SM
M[B.\1TNDW0&,Y+C&<C\.:R/ &KW6M:/>W%U<FX*7TD<;D8^0!<#]30!U=%8(
MUBQ@UG4GEUA2EK$&FMB.( ,?,3_GK4MGXKT34+V&TMK^.2:9"\8'\0]O\]Z
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M--Q- $]%<)X?UZ36+>'7I-9-O;I/,L]HR HR;V2, \$-]WGG)["M^XUNVO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M';VY"S(.LA<##GM@DD>E:LD<DWB;Q3=?8;D1W.F!(F-NWSGRQ\HXZ^U>AT4
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MLULHD=/+EC*'(8@G!['&<]\U?HH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"W6XC2 $B522,#/<$#/U%5+#Q/J\7BBVT;7-+CMC>J[6LD+[A\JEBK<GG -
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M9>W=^+>#[-=O;[D;"$*%(.2?>M*_US3=-L8[RYNXE@D=(XWWC#LS!0!Z\D4
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MSSS4WAGQ9;Z_;7ADC-K<V5P;>XCD(P& !R#Z'-;;7ELL!G:XB$0."Y<8S]:
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MH;_SQF@##^(21O\ #W7]X!Q8RE<^NTXKGM5AM8K3P1+$J*WVY 2I_A,$F?U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1O%>GW,RW%MHLUJ4$MHB[8Y<\[@5/4%>?:J[:=IVFWWA69+:9-'BN9V+W(W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*K-?VJK*QF7$3;'.>C>GU]J+Z_M=,LY+N]G2"WCQND<X R0!^I H LT4V.19
M8UD0Y1P&4CN#5:[U.RL9[6"YN(XY;J3RX$8X+M@G _ &@"W14<\\5M!)//(L
M<4:EG=S@*!U)-9>C^*=$UZ>6'3-1@N98AET1P2!ZX]* -BBBB@ HK,GU_3+?
M5HM*EN56^E&8X#]YQZ@=Q5N^O8-.L9KRY8K!"NYR!G H L44V.198DD0Y5@&
M!]C3J "BBB@ HHHH **** "BJFIZG9Z/I\M]?S+#;1#+NW058AE2>".:,Y21
M0RGU!H ?12$A023@"L;_ (2S1?[,?4?MJ?94G^SF3MOSMQ^= &U134<.BNIR
MK#(IU !1110 4444 %%%% !16?'K>GRZI<Z:EPK7=M'YLL8ZJO\ DU8L;Z#4
M;1;JV8M$Q8 D8Y4E3^H- %BBBB@ HHHH **** "BBB@ HILCK'&SL<*HR:AL
MKV#4;*&[MF+0S*'0D8R#0!8HHHH **** "BBB@ HHHH ***RM2\1:9I,FR\N
M-F"H<@$B/<<#<>WXT :M%("& (.0>12T %%%9>I^(=-TAB+R?9MV[R%)" D
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M_E&+&\BVC91G/ Z5Z57._P#"(6DEUK4MS<S7$>L+LN87"A<>6(^, $?*H[T
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M Y^;"K^5:-V(HK_PE=^'Y#(E[,8[D1MN$\!C8EG_ +V&"_,>><9YH ]#\V/
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MHEU"ZALO/L=.E$-S.),,&S@A5QSC(SR.M4/A_)%INB-]NN8;=M1U&YDM(Y9
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MS>:#9N^#D_W@#^ K,U&]L]6^&EW?ZC/&=86^=9C(^)(R&(5/4+MVG'0YSWH
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M'0C(QGKFNAL=1FAO=7?4;U3:VKJ$S&%V _3D]A0!?DT33)8(8'LXC'#_ *L
M8V?0CFK<,$5O$L4,:HB]%48JC8Z]INHW3VMM<$SHH<QR1/&Q4]" P&1P>16E
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF.-=T&Z*XVK_ *EU(ZDY'!!YK<L4O'^(\=Q=64J*VE^7)(L9\O?N7Y<UW-%
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M >;PPW"ZAX)9;"Y46\4RSGR2!%G9C=Z9P?RKT&^EE@L+F6!-\R1,R+C.6 )
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1W^CW&FS,QCGA:%F/)P1C/UKF+7PGJ#Z5IVBZA+;O8:?.DJ2HQ+RA&W(&4C
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MC:6/'!P3S6GJVI>(O#%O?7D]U;RV,J1K;EYC(\4A)!8_* 5Z'\Z .^) !).
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M:.9XU/0LH)_#FK@N83-Y(E7S,9VYYH RK'PU:VDD,DTDEV]O&88&G.XQH1C
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MLJ@(?LJS_:5M<_NUE_O8_#..F<GN:UA=VY) GCR%W$;NWK3EN(7A\Y9%,?\
M>!XH RKSPU8W=W<3_/%]K4+=JA($ZCH&_P ]"1W-0:OH@U3^S],2$1Z9:R1R
MR#& ?+(*(!Z<<UM+=6[1"43(8SP&SQ0;NW$32><FQ203GO0 Z:"*>W>"5 \3
MJ593T(KEH/A]I<"VD0N+UK>SG$]M";F3;$0<@#YNF>U;]]/<!+9K*2WPTH$A
MEYRF#G;@]<X_6K+7,"3")I4$C=%)YH YN[\!:5=F_1Y+I;>]D$LD"3NJ;^[
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MY[UMT[)*PW'IV/''I6A>ZU8Z>UFL\Z@WDHBA /WFQFK<ES#$RB255+' R>M
M&,_@W1&T6ZTH6I$%T2TSEV,CL1C<7)W$_C44'@S38KN:ZDDNYYI[8VTS2W,C
M>8A&#G+>E;LEU;Q;O,F1=HR<GH*JW6M6-IJ%E8R3#[1>DB)1W 4DGZ<4 8T_
M@+29](MM/+W2FT<O:SK<.)(#Q]QMV0.!P#BMO2]+ATJT$$4DTK'EY9I&D=SZ
MEF)-6?M$/F^5YB[_ .[GFI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]SLOV;SP#F Q+_J\_P"UNX'?->B111P1B.*-(T'147 'X4V2UMYG#RP1.P&
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M*VDTO5)]8TKQ#>/;ZFMYYD:"',K+M78T3XSZ]#P0:[SQBU['X-U)K$.UR(>
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M6M-E_HL+V<>Y ,R\;L9_V1'@^YKT..*.%=L4:(OHHP*541-VU57<<G QD^M
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M9@FGAT^PFAGF520KL4( _P"^35271M4;P9KEDNFW'VBXU)YXD\L_,ADR#^5
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M,%)%<?;Z[J%EJGA866I37XOXS]MMFD,I4;,[\\[<$ ?C78>-[:XOO!6L65I
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MNRGI_NT 84'@J]COX[R36U:46$EB^VT 4JQ4Y W<$;12Q>!YXM.T2T_M?/\
M9=QYX;[,/WGS[L8W<5V-% '%R>!)I=*UVQ.L<:M=?:6?[,/W9W!L ;N>@JS)
MX0NAK*:C:ZJ(G>Q6QN ;?=YBCN/F^4_G75T4 </8^ +G3K71HK?6SNTV&:W!
M>V#!TD*D\;N"-O7WI\7@*>+3-/L1K)*65^;Q&-L"6_>%]I^;WZUVM% #'5FA
M9 P#$8W8_I7&OX"F?PE;:"=8^6"[2Z\[[,,G;+Y@&-WJ!SFNUHH Y-_"-]!X
MAN]3TO6S:)?;3=PFW#AV "[E.X;20 ._2DN?!UU#KTFJ:+K+V#7$:QW4;0^:
ML@48!'(PW7GWKK:RO$.M#P_I#ZBUL]Q&CHKJC $!F"YY]R* *(\,3KXDM]87
M4CF&U^S^6T.=W+$L6SZL>U4],\&W>EZ9'8IJR3PJ9-Z26HVR!L=MW&,=:ZN"
M43V\<H& ZAL>F1FI* .&3X=G3HM/DT75GLKVS\Q1*T.]'1W9RA7(X!<XYKK]
M.M9;.T6.>Y:YF)W/*5V[C[#M5JB@#GV\.3_\)/=ZTFHA?M%K]F$)@SM'KG=S
MR/2LP>!)QX>TW2!K'RV-U]I63[*,L020,;N/O&NSJIJ%U<6L,;VUE)=LT@1D
M1@I53U;GL* .0?X?7)@:W77#Y0U$ZA'FV!96+EBI.[D<D5?D\'SR7^MW7]J@
M'5+=82OV<?N\ C/WN>OM75T4 <G#X,FBE\/.=5W#1E*@?9P/-^4KS\W'7WJM
M-\/O.TNXL?[6D3_36OK25(@&MY"=WK\W/TKM:* .2O?"6I:MX<NM-U+7?-GG
MV#SUM@ BJP; 7=U) YS2:AX*EU&_-S)JQ0-IC:<52  X8,-X.[@_-G%==10!
MQMKX)O8+^QO'UL/+;6DUH<6H 9)"AZ;N"-@I(O D\>C:5I_]L9&GW@N@_P!F
M'SD2;]N-W'I79T4 <A:>#+O3M2O6L-:>#3;V7SY[7R 2'Q@E'S\N<#L>E.;P
M?>VVN7=[I6M-9VE\^^ZMC 'RW<J<C:3]#UKK:IZKJ=OH^FRWUTVV*/:/J6(5
M1^)('XT 6D39&J D[1C)KDX_!&^PURSO-2::+59C.2D.PQ/NW CDYP<?E6UI
M6J75_-/'<Z9/9^7M*.Y#+(",Y!'\JOW%S#:Q>;/*L:9"[F.!DG 'YF@#EXO!
MUW=Z)<:5KNLOJ%O)"8(]L/E%5(QDG)R??BKN@:'JNFE%U+7&U&.%=L*^1Y9'
MNQR<G\NM6+?7A-XINM#:UDCD@MTN!*6!5U8L. .G*FMB@#'\4:(_B/P_=Z2M
MW]E%S&8VE\O>0",'C(JG/X8F.KV6KVU^(M0MX&MY',.5FC.TX(SQ@J#^==)5
M+4[^2P@C>*TENI))!&L<9 .<$YR> ..] '.W7@;S[=!%J/E7!U!-0GE\C=YC
MK(' QD8' 'TKKE!"@,<G')QC-<G!XVEN+O4;:/0[II-.8"Z E0F/*AN.?FX.
M>,UI:-XB75]5U*P^R2P/8B,DN0=X?=C&.GW: ,RX\%S2QZ]##JOE0:N69D-N
M&,;-P3G=SU/%3?\ "(S/J&CW4FI!ETZW:W\O[/CS0P )SNXX4>M;L]U<1ZA;
M6Z64DD$N[S+@, L6 2,CJ<D <>M6Z .2\/\ A"^T'R[)-<>71X#^XM&A 91V
M4OGD#Z=JW]7L)-3TR:TBN6MI)!A9E&2A]0*J:CX@73O$&EZ4]K(W]H,ZI,&&
MU2JEN1U[5LT <W<^&KG5+S3Y-5OHYXK&7SHTC@V%WVLH).3@88\54T_P;>Z3
M?SI8ZV\>D3SM.UD806!8[G"OG@$DGIWKI=2U&WTG3;B_NW"00)O=C2:7J5OJ
M^EVVH6KAH+B,2*1[]OJ.E '.VO@^\TW5;N73M:>WTZ\E\Z:T, 8AN^U\\9^A
MZ5.OA.2'6=9OK;4?+CU2-5>$P[MC"(1@@YYX .*Z:B@#C8/ C6MKHIAU(_;]
M($BPW!AP'1R"RLN?8=ZEU#P2=0L+Z-M0\N\OKF&>:X$.1^Z=650N>GR@=:ZV
MB@#GH/#4T7BM=<;4 ^+-;0P^1C(4L<YS_M'M6W=PM<6<T"2>6TB%0^W=C(ZX
MK,\2:^OAS3X[Q[62X1I5B(1@-N>_-;- &#HV@76B^&#I,6I!Y5$GE7/DXV%F
M+9VYYP3ZTWQ!X=N/$'AC^QYM1\MW\LRW AW;BK!ONYXR0.]=!10!G7%E?/;V
M<=OJ A:&1&F;RL^:@(RN,\9'&>:H>(?"-AKVFO:;4MV9U<RK'N/!STS705%]
MIA^U?9A*IGV[R@/('KB@!\<:11K'&H5%& !VKG]%\,S:1XBUC5FU$3C4F0M#
MY&W9LW8P=QS]X]JZ*N>E\4,/$<VAPZ9--=Q0K.<2(HV,6 .2?530 S5_"\^H
M>($U6WU(VY^R/:21-#O#(QSD<C!JA:>!9[2ST6*/6#YNE22E)#;CYTD()4C=
MQTZUN-KR6VF7=[J%K)9BV.&20@Y],$<'/'YUGMXND@G6"ZTFX@DF>-+7+*1.
M7]".!COGID4 0VOA"^T[5[J73]<>'3+N8SRV9@#$,3EMKYX!)]*23P5*Y\0X
MU7:NL*%(^S@^4 @7^]SP/:N@TF^N-0L_-NK":QF#LC0RD$\'&01P0?6KU ')
MP>#9K;5-/U"'52LUK8M92?N!^\1BIR/F^4Y0>M30>%&_MNQU6\NTGN;,.J2)
M#L9PV0 W)Z9KH#=0"Z%KYJ_:"AD$>>=H(!/ZC\ZBTVZN+RU,MS926<@D=1&[
M!B0&(#<>H&?QH I^(] @\1Z5]BFD:)DD66*11DHZ]#C\34$&@3G4H]3O;U)[
MZ& PPNL.U4SG+8SR3DUO44 8GA;0)/#>D?V>][]K4.SJ_E;,9YQC)J'Q'X:F
MUZ^TJX341;+I]S]H5/(W[VVE<$Y&.&-=#7,P>+9;O4M0L;31KF:6P?9-B5!S
MU&,GGCTH U-=TM]9T*[TT7/D&YB,9EV;L9'7&15#4/"D6J>%(-$NKEF,(CVW
M")M8%"#D#/'3'XU;T/Q%8:\DXM799[=]D]O*I22)NO*D _0]#6H[K&C.[!44
M$LQ. !ZT <[KOA,:I9:<MI?/9WNG'=;7(3=@\9R,C.<>M:FDV5W9V[?;[[[9
M<N07D$?EK] N3C\ZN0S1W$*RPN'C895AT-24 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 </\4<#P[IXX _M.#^9I_P 4DW>$$4$J6U"S&Y>H_?I71ZOH
M5AKD<4>H1-*D;;U7>0 W8X]:=J6BV6KV<=K>HTL,;*X!<_>7D$^I!Y^M 'GN
MJ:I?^%=7\5Q6,\]RL&CQWT2S-NVRDR GCMA%XK2OWETO4?"T^FW,MQ%J,YMK
ME6;/G(8V?>?<%!^9KK$\/Z<FI2WYA+W$L0AD:1BV]!T4@]1R?S-&G>'=-TMT
M:U@($:[8E9BRQ#T0'A1],4 >?'4KI? S3F\D%Q#KIA5]W(3[45V_3;Q5V]U.
MZTW7V;58Y'T^6[Q;ZC;R9\DX.(73'3WS74R^"] GDN'DT^-O/E$SJ1\N\'.X
M#H#QSZU93PUI:3O*(#AY/-:(L?++_P![9TS[XH \_P!2U6>.ZL[ZQO9)U;78
M[:2Z9MGRF8(T83G*@97.1TI][#<W-[XR9]4O0+$1/ %D "G#>WM7:2>"O#TK
MR,^FPGS)Q<$;1@2 [MP'8Y&3ZU-_PBVE9O3Y+C[: +C$A_> =,_G0!RVC:M+
MXAURST_49F6-=(AN<*V/-D=%);\-Q_*K_P ,4$?A1XPY8+>3#).3UK7F\(Z+
M.EB'M!NL5"6[AB'1,8V[NNW'&.E7M*T:PT2V:WT^V2")G+L%&,D]Z (?$G_(
MK:O_ ->4W_H!K"\+7=G9_"^QGOF06R6C&3=T*Y.:ZF^LH=1LY+2X#&&4;756
M(R.XX[5E0>#]$@AC@^QB6WB.8X)SYD:_16R!0!YU\/GOH--\):!J0DBM;JVN
M+C:3@OMV[$/MAB?^ BIM=NKQ?#'CC29I6FM+"=4MI7/(5HT<K^!8UZ=J.CV6
MJI$+J++0MOBD0[7C.,95AR."1QV-07'AS2[K2WTV:WW6TAW2*3S(?5C_ !'Z
MT <O<.(_B?ICE]@70+DEO[OSP\UFZ9?3CQ%X<:WNI7M;\W"O</)AIQM<@E.=
MN#C')Z"NZ_X1W3CJ$5\T3M<Q0F!79R3Y9ZJ?4' _(55A\%>'[<P&+3HE:"1I
M(2!S&3UVGL.>@H X[P[87][X6O\ 4TUB[-_%)-%"9I!Y?5#\PQ[8S[UO>#-2
M^TZA?V=U9SZ?J,*J9[1Y/,C' ^9&P,@]>G>MNV\,Z7::9<:=% 1:W!S)&7)!
M/K['_"K5CI5II[O)"K&5P TLCEW('0;CSB@":\=X[*9XEW.J$J/>N)\)V5AJ
MGPDL(-4?]Q>VT;3N3@^8^TYSZ[R/QKO2 00>AKG[#PW#:Z?<Z--$LVF/(985
M/\'S;@OMM(&,=,4 <QX.N=3\/ZS'X;OF6]L9_->SO&.)5VXW*XZ'M@\?2I9O
M#Y\*>(M+OM!O;AH;ZZ,-U9R/N1U*LVY?0@K[]375Z;X;T_3&D=$>:5P5\R=S
M(P4_P@GD#VIVE>'-,T8 6<!7:,)O8ML'HN>@^E &!\3P9O!4WEL"L5S"\VT]
M$#@MG\*QO&L%S>^+](33\^;'I%VSE>RGRL#\:[&Q\,V=K>ZK<-!$4U$_OH<;
MD<8QE@>"2./I5ZQTBST]G>",EW 4O(Q9MHZ+D\X]J /-+Q#/\//!,%J#Y_VV
MR  Z@K(N_P#+!S3-/1[;X0>(;>YS]J6YE20'J7)3']*]*MM"TZTN_M,-N%<,
MS(O\,;-]XJO12<G)'7)HET'3IKTW<ENI<L'9?X&8=&*]"?<T <9K'VK3[GX>
M$DB\$RP3#^\# 0P/ZFO1:QYM(-]XBMM2NE&RQ#?9ESGYF4J6/X$BMB@#B+J[
M_M?QGK.DW<K)#960:&(-C<6 )?ZC./QKFO"\\EIH?@=89W5)+JZBE^;[X$YP
M#^9_.O1M1\-:5JM]'>W5J#<QJ4$J':Q4]5)')'MTJ ^#]".EPZ<MA'';P2F:
M(1_*4<G)((Y!H XBXU^[T_\ MN*.Y/DG5TM@S-Q%&2W3V. /QKK/#>G7=AK%
M^SZC'+:SHDD5HF2(3T)#9Z''2KZ>$]"2VO;<:9;^3>_\?"&,$/\ 6IM&\/Z9
MX?MV@TVU6%&.21R3^- %N^F>WT^YFC7<\<3.H]2!FO-'U*\_X0;1O%%I=2-J
M<M[")5+<2!Y@K1D>@!('TKU,@$8(R*R;?PUI5K<^=#;!1YAE$6?W2N3G<$Z!
ML\Y SGF@#SZ[BN[C_A,)GU2^#6+QO HD&$//M7I.B7$EWH.G7,IS)-:Q2.?4
ME0351O"VE-]NS%)_IV#<_O#^\QTSZ]:T[.TBL;.&U@!6&% B*3G"C@"@#E_&
M.J3VNK:'IJLB07TD@D9R0"5V[5)]#N/Y5DO#<:5:+I]YK33^=J(%O;1+R5(9
MQ"6ST &<^B]*[76-$T[7K$V>IVL=Q 3G:Z@X/J/0U3?PEHCZ7!IS6,?V>"02
MQ\?,KC^+/7/)Y]S0!P,/B*^L-$NH9YVBB_X2)+)W$F\P0-'&2 <#NS<XK7\7
MZ;'8>&==$&HR20SFW9+;J(,3)DJ??-=0/".@BVO;;^S+8PWAW3H8P0YP!G&.
MN!3(_"&B1:4^FI:!;9V5I &.7(.1N/4X/3- &!HJRZ7XYM[&.[N);>ZTN.=T
ME;.'RXR... /RKO*RXM T^'4HM05)#<Q1"%':0G"#^'Z<G\ZU* /*M;U2>.:
M._L+R2?&NV]N]RS[-JF5$:(+SE<9!.1SFGW<-S=ZKXSWZI>A;**"6!5D "L?
M,]O:NSF\%^'[AYWETV%O.E6=QM&/,!!W =CD=:F'A;2@]ZZPNIO5"7&)"/,
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M]JC?7=*00%M0MP)T+Q9<?.H!;(]> 37 7?V;P_KVE-<V^IV^B/I_DP20F1C
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M",Y^M4+"Y\0/X@ACNQ:_V>]GOD6-&#Q3 CJV<8()XQVK5MM4MKN^GLX_,\Z
M*7W1LH^8 C!(P>".E7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF,;5QZ8IU% "!0"2 ,GJ<=:6BB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH'YFK] !1110 450U;6;'0[,76H3B&$NJ!B"<L3@"K] !1110 44A('4@4M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#E9M3U+5]8U73M*NUM7TY(SDHK>8[EN#N!P/E[>M='9-<
M-8P&Z""Y\M?-"'*A\?-C\<US^J>#4O=>_MBSU2\TZXDC$5P+<C$R@Y&<CJ,G
MGWK5BTEX=1M[B._N!!#!Y/V8D;'/]\^] &E1110!YSJL/B'PMK^IZSHUJ-:T
MR]D#WEDA!EA<  [>YXV\?IS5JS\407UKHFF>&08XKJT,L94*&B1 !M ?C()
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M +FXU,VDA,8QMV,>!C_9K3?4O$C7]QH4-T)K^UMS,UQ$L:[F9CL!5AC !49
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-#O=-M#:3S/>S"-62,L!Z].^.U<_IWBQ-*\0^(XM6OIY8()HA$"@/E*0V<X
MP.G)H [^BL%]3L)?$]G$NJ2B9K8R+:IM\N1",[SQGI[U;M=>LKN[BMHO-W3*
M[1,R$*X7 ;![XR* -.BF32I!#)-(VU(U+,?0#DUQWA+Q1?:AXAU72M5B$,N5
MN[-?6W8;1C_@2,?QH [2BLJ_\1:=ITLT4\K%X(_-F"+N\M/5O0<U0N/'?A^V
M6W+7N[[1$TT6Q<[U SQ^5 '245B77BS2K2W^T2RR>0 K22*A*QAN%W'MFI+_
M ,2Z;IT3RS2.\<<8FD>)"PC0C.YB.@QSF@#7HK!N/&.BV]U]E-UYDWD^>$C7
M<2GJ/6HH/'.@W)LO*NRRWCB.)PORASP%8]CGC'K0!T=%8U]XHTK3G87,S+&D
M@BDF"YCC?^ZS= >GYU5N_'.@V<][!)=$RV3!;A40DIGN?;GK0!T=%<[-XM@7
MQ)8:3#;3RB[MS<"9(R5V]L'^==%0 45@MJEA'XFNT;4YO-@M5:6UX\M5RWS]
M,Y/U["H['QOH6HW%E#;71<WN?(;;\K'&=N?7 )Q[4 =%161XGO+6Q\/7DUY?
MRV,(C;=<0XWIQU&01G\*IGQ3%#XGM]#%O<ONM&N&G,9Q@%0.>G<Y_"@#HZ*S
M+?7K*YNXK>,RYE+")RA"/MSG![]#5F]U""P5#,6+2':B(-S,?0#O0!:HKG7\
M;Z!%9+=R7H2,W'V9@PPR29P58=B"#3+CQOI::5J=[ )IVTY29H1&0X&,@X]#
MZT =+17*C7K2^N/#[SWMU8W-R[,EJ% 68^6Q(;()QC)&".@JW#XST.>^>TCN
M]TJ3&!_EX5@ 3D_\"% &_16'_P )9IGVC[/NF$S0M/$AC(\Y%QDI_>ZCI5#2
MO'=A>:19W]W%/:B\N3;0AHSAF\PHH^IX_&@#JZ*JIJ$$FHR6*EC/'&)&&W@
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MF>UN"D;Q.A 'SEF!!!!['K5AK"Z34?'9^QR;+ZW$=J0HQ(1"$P/3YO6O1J*
M/.].M+^SUGPQ>-I]Q)%%I[6TNS;F-_?)''TKK]'UR/6);R);2YMI+63RW6=5
M&>N",$\<5HF>$3B RH)F&X1[AN(]<4D-O%;AO*3;N.6.<DGZF@#DYX9D^(EW
M?&WD-K_9B0B0#@N'D8C\F%<_9Z;?1>$O!MHUE*+BQO4DN$P,QJ(I%)SGGEEZ
M5ZC10!S?CZVGOO VKVEK"TUQ/:R1Q1KU9BI Z_6LN:&[A\9Z?J(T^>>UDTN2
MW)3;\KYC.&!(ZX-=Q10!YWX=TZ^L?$UF^FFZ739FE>]L;KE;1BK',9SC!?'
M[&M#QQ:WD>J:)K4.G-J-K8^<ES;)M+E9-F&4,0"1L/?O782SPP%!+*B;V"KN
M8#<?0>]24 >;ZS8"[T:SFTSP^UDLVIPW+Q"-%D*ALL[A21[]2:=J6EWU[K'C
M'[/:R%+[3(X;=C@"1P'R/;J.M>C44 >=RQ7EW=>"+C^S[F-+.=FN X7,:^2Z
M9.">[#I4EEHUY?:%XUTT1-;SZC=S-;2/P"K01H&R.GS*?RKT"FLZJ0&8 MP
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MW5N5<3@-YBMN##M@^GTJ>@#RMO#NH6EM!+]E<FY\02:AY2X/E0L[D$]LX89
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M:C]L$4F]EC3S-PC3G@ <5<U_PIJ.NQSSM>P0ZC"X;39T#?Z-CJ?<GOZX'I0
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MK9W2C^(,"RGZC8?^^C7>LRHC.Q 51DD]A7(:]HR:KJ&@:3:J/LNG7(NY]O1
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M-A]GDM18B^F,BG.\IYS;ATQZU'K%UJUE\2M<N='@AGN8](5O+DSDC<F=OJ:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]<F1L]"3A$'XJJUR&JRZP/%GA^XNM'VROJ1PXFR-OE2# X[ Y]\4 >G4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exhibit1023thirdamendmen002.jpg
<TEXT>
begin 644 exhibit1023thirdamendmen002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;=V JHIPV.O:IK[PEX@GN;?4;?4L37.HPWDT4ELC-;J <+NW?,J9P .N2>]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1BBB@ HQ110 8JG<Z3IM[<QW%WI]I//%_J
MY9859D^A(R*N44 &!Z4444 &*,444 %&*** $P#VIL4,4$210QI'&@VJB* %
M'H *?10 4444 %&*** #%&*** # ]**** "C%%% !1110 4444 %%%% !BBB
MB@ HHHH **** "C%%% !1110 4444 &*,444 %&*** "C HHH **** #%&**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHYI/)A>38[[1
MG:@R3]!5'0=9@\0:):ZM:K(MO=)OC$@PV,XY'X4 :5%%% !15'6-7L]"TFXU
M+4)A%:P+N=SVYP/U(JY'(LL2R(P9&&58="#WH =1110 4444 %%%8$/BB&YM
M]8DMK*]FDTN8PR0)$/,D;8KX09YX8>E &_134;<@;!&1G!IU !1574M0M]*T
MVYU"[D$=O;1M+(Y[*!DT^SNX;^R@N[=Q)!/&LD;CHRL,@_D: )Z*IZG?-IUA
M+=+:7%V4Q^YMDW2-D@<#/OGZ U;!R : %HIDC^7&S[6; SA1DGZ5G^'];M_$
M6BP:I:I*D$Q;:)5PW#%>1GVH TZ*** "BD=MB%L$X&<#J:RO#VO6_B/3Y+VU
MCFCC2XD@*S*%;<C%3QGU% &M1110 4444 %%%% !114%[=+964UTZ.Z1(794
M7+$#T% $]%4=&U2'6]%LM4ME=8+N%9HPXPP5AD9]^:NG@4 +165H^NV^M3ZC
M%!'-&UA<_9I1*NW+;5;CGIAA6K0 4444 %%9%IX@MKSQ)?:(D4RW%G#'-(SK
MA2KE@-ISS]TUKT %%%% !13/.C\[R=Z^9MW;,\XZ9^E/Z4 %%,CECE!,;A@"
M5)!S@@X(_.GT %%9/]OVW_"5_P#"/>7,+K[&;S>5^0H&5>#GDY;T[5:U*^.G
M69N!:W%T0RKY5NFYSD@9QZ#.3[ T 7**!R** "BJ<%\TU_=6S6L\:V^S$TBX
M27<"?D/?&.:M1R)-$DL;!XW4,K*<@@]"* '4444 %%%1M/$LZP&11*ZEU0GD
MJ, D#T&X?F* )**I:=?MJ$4SM:7-MY<SQ;;A-I;:<;AZJ>H-7: "BF/+'&R!
MW"EVVJ">IZX'Y&GT %%%% !1110 444R66.")Y97"1H"S,QP !WH ?116#?^
M*;>SO9K:&TN[UK9HUNS:QA_(\S[I(SD\<G:#@<F@#>HI <@&@D 9/2@!:*Q;
M_P 2VECJ6D61265M5D*6\L:@Q\(7Y.?05M4 %%%% !1161KWB.S\.16TM\DY
M2YG6WC,4>[,C'"K^- &O163!KL<NH06<EE>V\DX;RVFAPIVC)&03@XK6H **
MR=&U^VUNXU*&WCF1M/N?LTOFKMRVT-QSTPPJQ/J#0ZFEH+.Z=6A:8SHF8Q@@
M;"<_>.>![4 7J*R_#VNVWB31HM4LUE6"5G51*NUOE8J<CZJ:G@OS-J%W:M:W
M$:VX0B>1,1R[AGY#WQT- %VBFQR)-$DL;!T<!E93D$'H16=>:]96.L6&ES-*
M+F^9EA B8J2JECEL8' Z9S0!IT444 %%1_:(LR#S%S']_G[O?GTIR.LD:NC!
MD8 JP/!'K0 ZBBLC6?$%MHD^FPW,<S'4+M+2%HUR [9(W'/ P#^5 &O1110
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ML+B]LHX&ENXX&C'S."D8.]E!'WV]BJFLGP=J=Z_@+4]'GFGMM6T%9+1W^4N
MBYB;N.5QZ]#7:V&B6NFWE[=0-.9;V023&24N"P  P#TX &!Z5D7_ (5LK2;6
M=9LHKM]3O[<QRJDQ(E^7:HVD[>.Q[4 <E!>Z_I^F>"_$!UR\O#JKVMK=V<H7
MRRLL?WU &0P(SDDYY[<57EN?$3>#]=\01^);X7.C7UR88B$\N5(F^[( .<@8
MXQBNN\(>&DLO#NAF_BNQ=Z?:HJV\\F]89=FUBHR1Z@')P#@8%9_A3PJTEMJJ
M:Q;7L,<^J370MI)!Y<JE]R$@$\<#*]#CD&@"O)J'B'Q3J&NV>F7"V5Q8"%(
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M5DU2!KR2]DA6"2:XNGD+J"2,Y.#UJQJGA^QUB[L;J[\[S;&7SK<QRE KXQG
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M.J+X,T[Q9?Z9:G3+F<13)!*WF0 R&,-R,,,@<<=:])EEC@B:6:1(XU&6=VP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;OQ>\MGME9/]'?=@C!'4J2#[\=: /6;'Q"M[XEU+1OLDD3V,<4AD=@1('SC
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MN[1XKMX)K6]?,D$O!,>23D<C'/0BNIH *R-#\2:?XA;4%L)=_P!AN6M9?]X
M'(]N>#[4GB6^GL](=+(;K^Y86]JN?^6C=&^BC+'V4UQ-O#)X-^(>GSO9+9:7
MK=NFG,JR[Q]HC'[IB<#DKE?<T =DGB/S/$U]HBV,WFVEJER'W+B4,2 %Y]0>
MN*G\-ZXGB/0K?58X'@2??B-R"5VL5YQQVK#LS_Q=S5?^P1;_ /HR2G_#(_\
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M36O\+U$?@.UB#L^RZO%W,<D_Z5+R3ZT =C1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &1K?AC1O$?D_P!KV$=V(<^6
M)"<+GKC!JO!X*\.6ND7>E0:3;I879!GA4'$A&,9YSV%:]Y?6UA$)+F4(K-M4
M8)+-Z*!R3UX%<SXF\<6&F^#9];TZYAN23Y4)&6'F%@AW#MM)R0<=,4 =: %4
M*. !@4M>;ZCXCN])U33[%O$+W-KJUQB.=[55FM8UC<M@A=K990!E>!G.>*Z6
MRUNUT>VCL]:UV*YNA($^T-%Y?WS^[#[?E5B"/3/84 ='169J'B#2M*9EO;V.
M'8 SE@<1@G +D#"@G@$XS5./Q;I\OB]_#J,3<QVZS,VTXR20%''/ )S0!OT4
M5G:G#J<\UNMA=QVT8+&9VB\PGT &1CUS[4 9\^E:G_;3ZE;I8>;M\M))))MV
MS.=I .,=\8H>PUI[Z.]:'1C=1QM&DNV3<$8@D9]"5'Y5A^%=5\2Z_!?SMJ%M
M_H.L2V1C^S "2*-P"<YX8KG\:7PUXUMXI=6MO$.L6R7":U-96H<"/*+M"C ]
MR>3W/6@"[#X9O8+HW$=EHRN9OM&P&;R_-_YZ;,[0W^UC-:V/$G_4*_*2F1ZC
M WBRZ@&MPN(;16DT\*N83N/[QFZC((&#]:NV6M:=J,Y@M;D/+Y8EVE&4E"<!
MAD#*GU'% '.R>%KR4S;K32A'.Q>>%))UBE8]2\8(5L]\@YJSJ&B:EJEA'8WM
MGHDUM&RO'&5D 0K]TC'3'M707XNFT^Y%DR+=F)O)+C*A\?*2.XSBN,EU'Q%%
MX^M/#?\ :T!BFTY[MIOL8W!E<+@#=TYH N#PS?+<7,ZVNE+)=1"&9EDG&]!P
M%.#T X JM>^"3J&EVNF7>EZ'+9VA_P!'C8S?NO93G('MFH;CQ#J6B>+]*M-<
MU*WCLGT^XEN"(PBLZ2(JMGDC(;[H[GO6S?Z_IU[IVEW=CXCMK6&\NXU@E 5_
MM/S8,2@]R>,CD4 53X8O"=/(LM&3^SO^/0(9E$/;Y0#@<?G6I)'XCEB:-CI>
MUA@[3*I_,<BB;Q?X=MKY[&;6+1;I)8X'B\P%ED?.U3CN<&L+QSXM73=+_P")
M5J<<=XM[!;OB+>"6D0,FXC:&"L3CJ!0!IV&E:SIEBME91Z7#;(,+&&F.T>V3
MQ^%9B^"72PDL4T[1UM)91.\(DGVM(#D,1NZYP<^P]*[@=*SM<U(Z5I%Q=(@D
MF "0QDX\R5CM1?Q8@?C0!B_V!J?]HMJ/DZ9]M:'R&G\Z?<8_[N=W3//UYZU1
MG\#_ &K1X])GTK0Y+&)S)%"WG$1L>25.<KDD]/4UK>"O$3>(/"-MJ-X%AO(]
MT-ZGW1',A*N#Z<C/T-3+XT\-/);(FM6;&ZD,4.V3(=@Q7 /3J"!ZD<4 9G_"
M+W8@L(%LM'2*P.ZU2-ID$3<_,,$<\GGKR:4^&+QA?A[+1I%U#_C[60S.)N,#
M<"2.@ ]L5MZ?XCT;5I+I+#4;>=K7'GA&^X#G!/MP>>G%,C\4:'(TZ_VE A@B
M$\@E/EXB/1_FQE/]H<>] '/VO@N2SF2>#3M&6=(3 LI>=G6,_P (8G(J0>$K
ME;2RM%LM)6WL9/-M8Q).!"_JO/!'/TR:V;'Q;X?U*]AL[+5K:>XGC\V*-&Y9
M<9R/P(..N.:Q/'GBM=*T&[.FZDD-_#-%'GRMXW,RY3)&T-M)..OM0!,?#-Z\
MVH2O9:-(VHJ%N_,,KB< 8 8$X.!P/3M5:S\$G3]*N=,M-+T2*RNO]?$IF_>#
MT8YR1[=*WKWQ=X?TZ2ZBN]7M8Y+0+YZ;\M'G. 0._!X]J=#XKT&XU&WL(=5M
M9+JY3S(8T?.]<;N#TZ<XZXYH RU\.ZBEY:78M]+^T6D9BMY#+.3&AZJ.>AP/
MR%5T\'S11E(=.T6(>?\ :08C,A63GY@000?F;I_>/K70R^(=)@OX[*6^C2>2
M3R4#9"F3&=F[&-V/X<Y]JIS>-_#$!82:W9C;-Y#$29 ?C@D?4<]!F@!MIX<B
MDME@U2SLG6*Y6[A\HN3YP.=[%CDMGN:Z&L)O%>G+XK'AXN?M7D><3M.!D@*N
M<8.<GZ8]ZW: *5WI-G?7=M=7$;--;,6A82,NPD8)&#UP2/H<5%JV@:9KJ0)J
M=J+A()!+$K,P"..C#!ZCUJ#Q/XDL_"VCMJ%YN*[UC154G<[' ''0>]3S:_IE
MO!%-+= +*AD0*C,Q5?O-M SM'&3C S0 B:!IR:C+J"PL+R6(0O,)7W,@Z G/
M^3S4VEZ39:+9+9Z? (+=22L88D+DY.,GCG)_&FG6M-%A!?"]A:UN-HAD1MPE
M+?="X^\3Z"H+?Q/H=TERT.K6C?9?^/A?- :'G'SJ>5YXY% #KWP]I=_>_;)[
M4&X,7DM(CLA>/^XVTC<OL<BEN_#VDWLUG+<V$#O9<6Q*X\H8 P,=N!QTX%4-
M2\;:+IVB:CJ9N?,2P&)H@C"17(RJE2,C/J1CO6-J'BXV_BS06.HQ0Z+=VES+
M.'0#YDVX^8\]6Q@=>* -]O"&AO8W-DUB&MKJ7SYXC*Y623^\W/)X'Y#TINJ>
M#/#VMW-O<:GI4%U-;J$CDERS;1V)S\P]CGK5RV\0:3=Z2FJ6]_#+8N=J3*<A
MCG;@#J3GC'7/%0?\)9H LS=/JMM'$LWV=O,;8RRYQL*GD-R.,9H L)H6G1ZO
M_:J6X6^\KR?-#MGR_P"[C.-N><5<NK6"]M)K6YB66"9"DD;C(92,$&JVEZSI
MVMP23Z9>1744<C1.\1R XZBEO=7L-.N+:WO+E89;I_+@5@<R-Z#U/M0!F7O@
MCPWJ.F6VG76D6\MK;,6A0@Y0GKALYY^M63X9T<OI[BR13IPQ9["5$'&#M .!
MD<'UJ2/Q%I,JWQ2]0BQS]J^4_N<#)W<<<<_2J']NV/\ ;4T@UR-XH;$326"Q
M@L@SGS3CYN00 M &@VA:>VI3:CY3"\FC\IYEE<,4&<+P>@R3^-55\(Z(EC:6
M2V06VLY1-;1"1]L3CHRC/!'/TR?6N<OO&IU'1] U;2KL06UUJ<$-PKQC/E,3
MG);IP.WKUKKM)UW2]=BFDTN^BNEA?RY#&?NMUP: ([7PYI5E.DL%KM,<C2HI
M=F5';.YE4G )W'D#/)]:L:KI%AK5D;/4;:.X@W!]C]F!R"".01ZBGZC?V^EZ
M=/?73E(($+NP4L0![#DUPMUXX>Z_X0_4[6[2UT[49C]MC=!\H\AI,%CTP<=*
M .E/@GPX4NT_LFW"WBJEQMR/-5>@;!YZ#/KWJVOA_35U"WO_ +.3=V\7DQ2M
M(Q*IW7D].E%EXCT?4=,EU*TU&"6SB8I),&P$8=0<]#R./>IM.UG3]5:=+*Y6
M62W;9-'@J\;=0&4@$?B* ,J/P)X9C92NCV^U9_M"(<E$D]57.!U["M^:"*YM
MY+>>-)(9%*/&XR&4\$$>E25QNK^,)M,\=:9II@4Z5<-]DFN?[MTXW1I_WR/_
M !\4 ;&B^$]!\/).FE:9;VRS\2!1G</3G/')XZ5)8>&M)TR2-[2T6/R@RPKN
M8K"&ZA 20@/^SBKUW?6UA"LMU,L:,P1<]68\!0!R2?05E2>-/#,4,\DFN6*"
MW;;,C3 /&V<89#\P.>,$9H #X/T)M/FL#8*;2>;[1+"9'VO)G.XC/7.#]1FE
MO?"&A:A>M>76GQR7#P^1)(68&1,8VO@_-^.:E@\4Z)<V\L]OJ,4\<4YMF\K+
MGS0,E  ,DXYXSQ4L7B#29]-CU&&^BDM9&V)(AW;GSC: .2V01MQF@""+PKHL
M#Z>\-BD9TX$6FQF40@C!V@'N.#Z]Z1_">AR)J"-IT.W46+78&1YQ/7.#W[^O
M>G?\)7H/V2&Z.JVRPS3_ &>,L^TM+G&S!YW9ZCJ*K_\ "<^&/(N9_P"V[0QV
MK!)B'R5)!(XZD$ G(XP#Z4 6Y_#FEW*68DMOFLAMMI5D99(AC!"N"& (XQFD
MF\,Z1/#9PO9)Y=G)YUNJLRB.3GYQ@_>Y//7D^M2RZ]ID5G!=F[1H;A-\)C!<
MR+C.5"@DC'.1VJNWBSP^D=K(VLV02Z1I(#YP_>*H)+#V !Y]J "3PKHTLUY*
M]F&DO61[AS(^9&3&PDYZK@8/;M5ZQTRUT[S3;Q[7E;=)(S%W<XP"S,23P .3
MVK$U#QWH=GX<;6X+M;JV\SR$,0)S)G&T\?+R1UKH;:XBN[=)X6W1N,JV,9H
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M$=TPE<&50, 'GICCZ<4Z?Q'I%M?+9S7\23-((0#G;YA&0A;H&((^4G/(K4H
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MC/2D\->([/Q/I*:A9D^6Y.%92"!N(&<^H&:SOB#JM_HOA5[[3KA8)DN($+%
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M\"+'O,9XR<J2,'JM=CX0.CWVH7FKZ58ZA&T\:1SW-]YJM(5Z*!(<G;D\].<
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MHYXVC1/*8(<*P*8^;'7KBO5J* /*]7M[K2]0N)]":=+Q/LT,^BW,1F@O%"(
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M?DWM]I-C=V\%Y-YKRW9D#SOC!?;(=P'09.,X],$]-10 4444 %%%% !1110
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M9+>*U23<8XD1SDGN2S=A@8 JU>:-K]I=Z/KFA1VTUS%IZV5W974AC$B<,"&
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M62[BMVM;FRN9"BRQLP;AP#A@P].]1ZCH.N7.I:%XB#6\FIZ>TPEM Y6-XI5
M**Y'5< @D<G/2@"OKOC*XD\(>*6LX'M=6TB*1)XV<9B.PLLBG'S*1@CI]!6M
MX4T&RM+>#58]/2TO;BTCBE,4A*RJ "&8# +<]2,^]8^H^$M2O=*\6SK%"NI>
M((EA$1D^2!%C\M<MCD]2<#N!VS716AUFWM]&MQ9VXC1?+O2TQ)0*F%*8'S98
M=\<4 ;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %*\TG
M3]0N(+B[LX9IK<[H9'4%HSZJ>Q^E7:** "BBB@ HHHH **** "BBB@ HHHH
M**** $90RE2,@C!JII^E6&DQ/%I]I#;1NQ=DB0*"QZG [FKE% !1110 4444
M %%%% !1110 4444 %%%% %&[T;3;^[ANKNPMI[B$$1R21!F0'G@D<5> Q11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/!*.4./;*GF@"[12!@PR#FEH **H:G=7UN+=;"R2ZEEDV,))3&J+M)W$A6]
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M?S)(C"I5WSG<1CDYYR: /.;UM)UKQ!XCT;5-0T^S$4<36#S1@F*W,*XD@8L
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M@D@N+>SCBECD7:RLJ@$4 =#1110 4444 %%%% !1110 4444 %%%% !1110
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MR0:7!"T41W  >4T@[]3GD_3TJ[#XQNY_^$/(LX0GB"(LXWG,+"$R\>HXQVH
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M;5X8X93)(%?9(RL!M^4[N#U"]1G%=N#D9H @FO;6WN8+>:>*.>X+"&-G :3
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MBB>-9RQVB/#CAMQ ZD8.: .M:^M([U+-KB$74BEDA+C>RCJ0.N*LUYY.+_\
MX6YX=>_BM5=]-NR&@SUS'E3GKCC![YZ"O0Z *>H:KI^E1J^H7MO:HYVJT\JH
M"?;)JPP$T/[N0J'7Y73!QGN.U<&XO;[XJZG8W26T]D-'C!@D4L#&\KAA@\9.
MT9[<"I]-\6W%OK.A:+/86ML+Z.5/LL3_ #V7EKN5'QE3E1T&,>] '2Z#H5MX
M>TQ-/LY)GMT9F02L&*[B2><#N2?QI-*T"WTB]U"ZAGN))+^7SI_-8$%\!<C
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ML9'33VLVC6%E!)8/N'S' R ,<\=ZRX/!&KP>'M*TL:A9%K#4_M_F&%L/B1I
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MG/3_ /77144 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2"&YWZ?N^S,]W*WEAL949;[O ^7I0!Q.H?\ )-O'/_8<N/\ T>E>KQ?ZA/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]>?VK%+):K!#DL8P=R\GA@1C%37GCBRLK":]DL[PP6J(][A%#6NY0VUU)R6
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MA(&,9W-@LN=H.,^QI-2\:6&F279E@N6MK*:*&ZN$4;8GDV[1@G)^\N2 <9H
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MIPL:<\MGC'X].: .KR**X/1KZYN/BSJ<,L=Y;QKI,+_9YY=RAC(PW* Q49
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MVE=P) SDD'\Z]'HH XO2K36)OB-<:Y<Z3)9V4VEQ6P\V:-G5UD9B"%)]?7_
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M$DLRYY)))/(R2>E<U:_#N:U\*V7A_P#MQWMK.[CNH7>V&Y=C[PGWON[OQQ0
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M7PT\:ZEXLLM6366M[;4]/N&AEMXXRHC 'WCDG/(8?A0!Z%17FWB3Q5XD\/\
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MB&ZMXS&4QNX92S?W#SGN*SH_&?B"7XGZWX5:]L+>TTVT%W]J>U9CMVQL01O
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M>*O!5_=6[066OZ:C&ZM9D+ %1U"Y!VG]#Q7HT"RI"HFD$D@'S,%V@GUQDXH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!YW\;-'OM:^'%S#86TEQ+%-',8XQN8J"<X'?&<_
MA5BWU_3_ !)X;T>QTFX6ZN?-LI)8T!S"L4L;N7_NX"$<]3@"N\QFD"*.@ H
MY&=-)USQ3KVC7ABN(Y]/MH9(6_B(><L![C<IXY&17+_#[P[JW@GQ=JFD7]R\
MNAV]JTVG3RD8",ZEP3V((&1^/>O5MH]*, G.* /'_@Q(D?B/QLLAV&YU'S8
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MV_SLX\O/7;ST]Z^@,"C ]* .5^&DL;_#G0HU<%X;...1>Z,!R".QKJZ,"B@
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MX/$NNW_Q=M=+TG5)+GPP8/.N9X(8W2)MKG9Y@7@$JHY.>:]2(!ZB@*H&  *
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MLC;1G8K=&8\],XQSBK?A[6H_$6@6>K0P301W4>]8YEPZ\XY'X5I;5QC'%*
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M*")O-XR3[=?T]ZWZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBL[6=0&DZ1<WNS>T:_(F<;V/"K^)(%1^'9+N;P[I\M^^^[D@225L8^8C/]:
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M,E0W^TQ)9O=J .NB7;&J[F;:,98Y)^M/I%Z4M !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ I&Z4M(WW30!QOC027\UCI$;A5F;,O_ CL7\LN_\ P"NN
M1%CC5$&U5   Z 5PEGJ-K>>-)K^\NA&D<_V>V3KO8;HU '7C]ZQ[ .":Z73O
M%&C:K->16=_%*UGGSNHVCUR>HXZCB@"WJ=\-/L'N/+,C\)'&#@NY. /S/7MU
MK@[UOM<MG!-J*6UI=3&:\U)F""[,>#LC)_A!("^N"1TYVGF_X2G7K>UEBEAT
MV&)KE<DJUR#\@R.H3EO<^PZWM;EEN%&AZ4D7VMD&Z0@;;-#D!\>O!"@?7H*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSJZ-JDVI^:TATTJF #97QN!GW^1<?K0!J@!0 .@I:** "BBB@ HHHH ****
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M#>J?]_(__B*UZ* ,C^PY?^@WJG_?R/\ ^(H_L.7_ *#>J?\ ?R/_ .(K7HH
MR/[#E_Z#>J?]_(__ (BC^PY?^@WJG_?<?_Q%:]% &1_8<O\ T&]4_P"^X_\
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M\<+P#[U;M/"UY;9W^*-8E!(.&$"_A\L0KE=.UA_#GB?Q[J%_#$TJ3:>@2W!
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M *#>J?\ ?R/_ .(K7HH R/[#E_Z#>J?]_(__ (BC^PY?^@WJG_?<?_Q%:]%
M&1_8<N?^0WJG_?<?_P 11_8<O_0;U3_ON/\ ^(K7HH R#H<Q_P"8YJO_ '\C
M_P#B*/[#E_Z#>J?]]Q__ !%:]% &1_8<O_0;U3_ON/\ ^(H_L.7_ *#>J?\
M?R/_ .(K7HH R/[#E_Z#>J?]]Q__ !%']ARY_P"0WJG_ 'W'_P#$5KT4 9']
MAR_]!O5/^^X__B*/[$ES_P AO5#_ ,#C_P#B*UZ*  # Q1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &7K&GW=^]BUM/#$+>X6=O,C+[L C'!&.O7FL[Q-X.L_$5WI=^S>1?:==
M13QS(O+(KAFC/JIQ^!P:U=1UW2](DACU"_@MGF!,:RN 7QC./ID?G56T\7>'
MK^XB@M-9LYI9FVQJDH)<^@]3P: .=UGP'J&IOXBCCUB*.WUCRV_>6I>2(H
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M6.+,<>T9^=OX<]!ZFK] !1110 4453U74%TK39[YX+B=85W&*WCWR-[*O<T
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M%C\/[C3+Z>*S\07<>@3RM*^D^4A7YCEE$A^94))R!ZUT^O@GPYJ8'7[)+_Z
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M+3[W5;/4YXI&N[,,('$SJ$W8W?*#@YP,Y':J4O@S09H=1A>S?RM1=I+I!<2
M2,QRW ;Y<GDXQGO0!@WMS=:MXGE\/+,\,<.F0W$82\>V=V=G#."@);;M7@\
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M:6YD=S%S\FXMD#DYP>>]0W'@W0[FVTZ![60#31MLY([B1)(1C& X8-C QC-
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M +FYDF6-AT8!V(R.QZBMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** #&:*** "BBB@ HHHH **** "BBB@ HHHH **** "@@$8(R#
M110  8'%%%% !1110 4444 %%%% !1110 4444 %%%% !00#UHHH :J*OW5
M^@IU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 9NJZY9Z,]JMWYP-U*(8?+B9]SD$A>!UP#^5366IP7T
MDL<:3QO%C<LT+1G!Z$;@,C@]*Y?XA2HC^&%-VMJQUJ(B4E?E_=R\\\59_MR#
M2K/46DUF'4;E65HN54 N L<9*\ EP<?4F@#H+/4[._ENXK:=)'M)O)G"G[CX
M#8/X$51/B;3A<",?:&0SBV$ZP.8C*6V;=X&/O<9Z9XSFN0LH7\&^-;!KQH8[
M?7(/LTSB8MYEW'EED;*C!<,X^H%03N^B7C:IH&J1WNF3ZGY=UHLY#,DS38<P
MGJK;\OM/'4T =A<>,-+M;N.VD2]\V69[>(+9RD2.@)8*=N&P%8\>AJ_IFLVN
MK0R2VWF@1OL998RC _[IYZY'U!KGO%4D,7BSP4K2(I.HS'!('_+M*,_F1^=;
M<Z"S\06LX.([N,V[@#JXRZ'\O,_,4 2VVNZ?=VMY=1SX@LI'CN'=2@0J 6SD
M= #UI;/6;6]F:%!+'*(Q*$FC*%D/&X ]OY=ZY73I[?\ L3QLSP_;8DOKHR6Z
M')E7R4RG'KR*H>'(/[,GN[76=1AOM.ETL21ZD9R#!!G!B9L]/FR'R"0#GI0!
MVFE>(+'69YXK,7!\G[SR6[HC>A5F ##CJ,T#Q%IC2:B@N5)TYE6Y(!.QB,@<
M=3[#OQUKE;"#4-,35;3PS>R:M8^1$UFLMR)/L\A8JZK(V<@)A@"3C@=#5;PU
MJ)TO7O$KZMIJ:78VZ6[RRS72.(V"#&3W)Y;/K[F@#JK;QCH]U8WET))X_L3!
M;B":W=)D)^[^[(W?-VP.>U%EXPTG4!=^2;L-:HKRI+:2QOAB0N%906)((  [
M51\,WND:KJVHZG:WMG<WMTL6^.WF60PQ)D(&*D@-EF/XXYQFIM(NK-;._P!>
MN;F&WCO[@^7/*P5?+7]W%@GC!QN'^_0!:M_%FE76ES:A&\^R&4P20F!_.64?
MP>7C=NY'&.AIL7C#1YM'?4XY9FACE\B2,0.9DD_N&/&X-SG&.G-8&AZE%X?A
MU^XUF]M);2*_\R#4"JQ_:'=%RO7!9?N9'88XP:U?"LVDRP:C?VE]:74US<FY
MNWMY1(D;%0H7<..$51[]>] &KHVO6.NI.UE]H'D.$D6>W>(JQ .,, >A!_&I
M+S6+*QU"RL)Y@MS>LRP1]2Q52Q^@P*S-"NH;+11J6HW$<#ZI<^>#*=O,A B3
MGOL$:_45R&H3:['XO\/W%[X?V3R:BX$@NT8%!%(%4=P I+>YSZT >HT4@Z"E
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH BFM;>X(\Z".3;TWH#C\Z9_9]GL*?9(-I.<>6,9]:L44 12VT$Y4S0Q
MR%?N[U!Q]*8+&T$XG%K")ATDV#</QZU8HH BDMH)G5Y8(W9?NEE!(I[(KXW*
M#@Y&>QIU% $4=M!#N\J&./=][:H&::MG:HCHEO$J29WJ$ #?4=ZGHH CA@AM
MXQ'!$D<8Z*BX _ 4CVT$H<20QN'QN#*#G'3-2T4 0Q6EO!N\F"*/=UV(!G\J
M&M+=[?[.T$30 !?+* K@=L=*FHH @-G:M"L+6\1B7[J%!M'X4J6MO%&T<<$:
M(WWE50 ?J*FHH C:"%T5'B1E4@J"H(!'0CZ4YD1F5F4$J<J2.E.HH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit1023thirdamendmen003.jpg
<TEXT>
begin 644 exhibit1023thirdamendmen003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M< ZR2;=NV/&67YUR<CO@'%8+>!M:F\/2WQU.YCUM[DZFMF#&81< Y5,[<XP
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M]UBZM)K5[%BEQ:$AI%; *@=,[@5QTZUDR>&M6N?!UOX?*M;K<ZE,]W*CKF.
MSO*,9R"6^48P>IS5/6? NK-+JEM:7L][;ZK9@2R7+HACGB8&/[@'##*YQD8%
M '0MXNN;32M4O=3T@VXL;?SU\JY65)#S^[W #:^< C'<<FKVCZY=7UI<75_8
MP6<$*YWQWBSC@9;.T#&*Y3_A&[J<ZG<6?A>TL[66SBA.EW#*$NG63<6(0X&%
MX!/4]>*BN_#6J:BVI_V?I/\ 8MKJ<4%E+"K1@JH8F27"DKG8=H[G\* .ET+Q
MG;ZQH=]J<EI-:_8U,LD#$,YCV"16'^\I!QZ\56M?'):"YDO],-L4TTZI$([A
M90\/H2 -K=..1[UF7G@[6]-U.:XT75+FX:_T][*:2X*+Y#*,Q.-JCH<K^-5K
M+PM=1"Y_L[PU#I]NVG-!<VEU,&2]ER-H.TG@?-\QP3NH Z/3?%.H7VE7&H2:
M'A(X@Z16UXD\CL<80@ ;3SWZ4T>,C;0ZFNI::\%Y8"(F"&82B0RG$85L#DG@
M@@8K+LM+U6#5)M7TCP];Z2T5@(!:.Z!;F3>#SL.,!00">[>E9UYX/O\ 5H-:
M:WTHZ;:W/V>46$DRG[1-')O9B5)"[@ N<\]Z .PLO$<K6=]<:GIS6@M=IW02
M?:$E#= A4 E@>",=2*9I/BZWU+PLVO2VES;PK(\?D%"\N5?8!M'<G''O57PK
MI,UIK&J7RZ2ND65Q'"D=D"G+KNW2$(=HSE1[[>:N^#M,NM)T)K:\C"2FZGDP
M"#\K2,PZ>Q% $=CXCO\ 5_#-EK&EZ,9GN6;-O+<B(QJ&89)(//'3WJ?PMK\_
MB+3YKN;3OL:).T49$PE64+P64@#C.1^%95KI.L67PSDTN"/9J;1RQJ X^4O(
MW.>G1LUU&GV4.G:;;65N@2&WB6)%'8 8H LT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5&ZT;3+ZZBNKO3[:>XB_U<LD2LR]^":O44 %%%% !1110
M4444 (0&!!&0>"*;##%;PI##&L<2#:J(,!1Z 4^B@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=1:);5;MW6WR$C.<$\]<*3BI-(\66>LFR-O:WR0WT7FV\TL&U'&-W7L<<X-
M&]15'5]5M=$TNXU&\,@MX$+N8T+D =>!5BTN8[VS@NHL^7-&LBY'.",C^= $
MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 9^NQI+X?U%)$5U-M)D,,C[IKPWP7HME?_ +/VKW3Q(EW:
M&YN(+E1MDC>,;AAASVQ^->R^+M8T_2- F.HZA#8QW(-NDTR,R[F4]EYZ G\*
M\@T>3PQIO@F;PFWQ L_[.N)&:>2*QD69E8C* DD#..N#0!M^$?BA=OX*\,I?
M;9=4U*Y>T6>;.T)'UD;').,<=S6CJWQ+UJP\'OKT.C1.MG?&TOED#J N<+*G
MJIR/SK"UVX^'USI>A0:#XJM]+NM#E$EG*8'<=LAA@9SCK71R>.?!NI>'+K2]
M;\4VEV]W$T<S1V[H@R,?*N#C'7DGF@#7U;QP-(T;4M<=(9],MK:)X3$3NFED
M (7/0#!7GW]JP]3\6W.KZ%XBTB^M(G5]"DNXKF!&\K)C.Z,EOX@>E9?]H_#I
M_AHO@V3Q1'Y?D!#<B-RWF#G?C'J.GIQ26?BK1O\ A$+K0M2\>V%R7LVLX9$L
MI%PI7;N?NQ ],?C0!)X,\7/HW@;P)H5G$DFH:LKJK2YV1(';+$#DGT%7]0^*
MEU9^&?$-VEC;OJ.@W_V.XB9F\N4;BH=3U&<=#7.6<_@NQTSPP(O&%FVI>'W;
MR9FMI DR,22K+U'7J#6/XKU#PG:^ ?$D=AK\.H:SK-Z+N81Q.HR7W;5!'0 G
MJ: /2K3QYJD'C+2-#U:QM(X]9L_M%I+;NQV-@DH^>O3J/6N>D^+NNQ^&KS7F
MTFP-K8ZI]@F197WR#.,KV'XU2TS6_"USXBT7Q#K'B^R>32[ 6]K;Q6LB[6*X
M+.><GG'''%9$MIX2E\(:CH!\=V(6]U+[>9OL4N5/7;C/TYH ])TSQY?-XZGT
M'5K2VA@_LT:C%+ [,47NK9 R<9Y'I570_B9<:Q-HUPM@IL=5GDA58U9I+?&=
MC.>F#CGTR*YZ#5_!X\<)XAN?%]C)'_9HTZ2V6VE&Y<8)W?\ UJ/!FO>'O!\)
MTR/Q[:7&BQRM+!$UFXF )SM+],9]ORH GN?BWKEMH^L:J=*T\VVDZDME,!*^
MZ0$XRHQP?J:U=9\0Z_+\7]!T:REMDLGM'NUCD#88E"#NQU(&<=JX:YMO"=SX
M=US2&\=V*C5K];UI!92_NR#G:!GGMS717FN^$9_&.C>)8?&=I#<V-J;66,VL
MC+(I!!*^AY/7- '>?$:-)/AUK_F(K8LI",C.#CK7DGASP_JFN:#X"F\/V,MI
M/9L9+S4BHC4Q[ONYZOW[&N[\3^/?!VO^&[[28?$]I ;N%H6E>&1MH(P2  .:
MK^#/&G@[PMX7L]%E\56ER+52B2I!(FX9)Y&#ZT 9_AVY?3/BW\1[FVLWN9(8
M()$MX0 TC; <#W)K<T+XAW=_XSM/#]Y:VZM=V'VH&,D-;R?Q1.,G)&.U<G_:
M/A7^W?%>J)XZMH'UZ 0@PVT@:WP,*0>_'7I5;0Y/"FC:_HFK?\)[:3/IMD;-
MH_L#*'7)/&.AYY)S0!KM\7-<31+W5WTFP^RV.L?V;,%E?<X_O*,<?B:]@C<2
MQ)(.C*&'XU\]26OA.3PSJ6C'QW8@7VJ_VFTOV*7Y6_N8STZ<U[YI=Q%=Z39W
M$$RS0RPHZ2H" ZD#! /.#0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "HYK>&X4+/#'*H.0'4,,_C
M4E% #8XTB0)&BH@Z*HP!3J** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,N]U^SL;XV<B7,DP02$0P,^ 20,X'L:A_X2>S_Y]=1_\ Y/\*+;
M_D<=0_Z\X/\ T*2MJ@#%_P"$GL_^?74?_ .3_"C_ (2>S_Y]=1_\ Y/\*VJ*
M ,7_ (2>S_Y]=1_\ Y/\*/\ A)[/_GUU'_P#D_PK:HH Q?\ A)[/_GUU'_P#
MD_PH_P"$GL_^?74?_ .3_"MJB@#%_P"$GL_^?74?_ .3_"C_ (2>S_Y]=1_\
M Y/\*VJ* ,7_ (2>S_Y]=1_\ Y/\*/\ A)[/_GUU'_P#D_PK:HH Q?\ A)[/
M_GUU'_P#D_PH_P"$GL_^?74?_ .3_"MJB@#%_P"$GL_^?74?_ .3_"C_ (2>
MS_Y]=1_\ Y/\*VJ* ,7_ (2>S_Y]=1_\ Y/\*/\ A)[/_GUU'_P#D_PK:HH
MQ?\ A)[/_GUU'_P#D_PH_P"$GL_^?74?_ .3_"MJLS7]1N=)T6>^M;9;F6(
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M^$GL_P#GUU'_ , Y/\*/^$GL_P#GUU'_ , Y/\*VJ* ,7_A)[/\ Y]=1_P#
M.3_"C_A)[/\ Y]=1_P# .3_"MJB@#%_X2>S_ .?74?\ P#D_PH_X2>S_ .?7
M4?\ P#D_PK:HH Q?^$GL_P#GUU'_ , Y/\*/^$GL_P#GUU'_ , Y/\*VJ* ,
M)O%FGJZ1M#?*[YVJ;1P6QUP,<T__ (2>S_Y]=1_\ Y/\*-2_Y&;0_P#MO_Z
M*VJ ,7_A)[/_ )]=1_\  .3_  H_X2>S_P"?74?_  #D_P *VJ* ,7_A)[/_
M )]=1_\  .3_  H_X2>S_P"?74?_  #D_P *VJ* ,7_A)[/_ )]=1_\  .3_
M  H_X2>S_P"?74?_  #D_P *VJ* ,7_A)[/_ )]=1_\  .3_  H_X2>S_P"?
M74?_  #D_P *VJ* ,7_A)[/_ )]=1_\  .3_  H_X2>S_P"?74?_  #D_P *
MVJ* ,7_A)[/_ )]=1_\  .3_  H_X2>S_P"?74?_  #D_P *VJ* ,7_A)[/_
M )]=1_\  .3_  H_X2>S_P"?74?_  #D_P *VJ* ,7_A)[/_ )]=1_\  .3_
M  H_X2>S_P"?74?_  #D_P *VJ1CM4G&<#.* ,;_ (2>S_Y]=1_\ Y/\*/\
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MD+!>PR^8BN0#M<$ KUZUV,UU;VY433Q1EONAW S],T 97_"3V?\ SZZC_P"
M<G^%'_"3V?\ SZZC_P" <G^%2:KXCTS1[RPL[NY1;F^E$4$>X9/&2Q] ,=:T
M7N((W1'FC5G^X&8 M]/6@#*_X2>S_P"?74?_  #D_P */^$GL_\ GUU'_P
MY/\ "MJB@#%_X2>S_P"?74?_  #D_P */^$GL_\ GUU'_P  Y/\ "MJB@#%_
MX2>S_P"?74?_  #D_P */^$GL_\ GUU'_P  Y/\ "MJB@#%_X2>S_P"?74?_
M  #D_P */^$GL_\ GUU'_P  Y/\ "MJB@#%_X2>S_P"?74?_  #D_P */^$G
ML_\ GUU'_P  Y/\ "MJB@#%_X2>S_P"?74?_  #D_P */^$GL_\ GUU'_P
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M^U=:_P"A;E_\"XO\: -NBL3^U=:_Z%N7_P "XO\ &C^U=:_Z%N7_ ,"XO\:
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M&N[-Y&D%K*$1W.6*E0P!/?&<9]J -*BN%^('A]]6O-%DTV9;+5UN'-O=JOS
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M $=NLBV\2R[?,"@-MZ9QVKG/'6@W_B3P^-.L&@1S/'*7F8@ (P;' [XKIZ*
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M=N\2NPR%)'!-846@:TVM>'-0N#9G^S+>2*98W;YBRA1MR.V,_C78T4 ><?\
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M3_OZ*/\ A)]#_P"@M:?]_10!K45D_P#"3Z'_ -!:T_[^BC_A)]#_ .@M:?\
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MM977&<E03GW':J^L:E=>)?#OC5Q>R6T6G>;:10Q8P=D8+,V1SN)./85??2O
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MH/\ IHU:MM;0V=ND$"E8TX4%B<?B>:RT_P"1UE_[!Z?^C&H VJ*** "BBB@
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M6JFW-]I]O<&W.82Z F/Z>E2Z?I=AI,!@T^TAMHF8N4B0*"3U/%6Z* ,74O\
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M8#)+$=,CY:@\$W5S#I&F>'-2\/W8U+3&\MKB:W_< *3^]20\$D= .<FO0Z*
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M9(Y6A8([)NW ,1CC(KHK34UNIKZ/[+=0BTE\LM+$0). =R?WASU%7J* ./\
MA\);;0]16XM;F%_[2NY@DL+(61I&92 0,Y%33Z??^)6L-;L=2N]((@95M[BT
M!=23R2K?=/ 'TKJJ* .)^&>DZII6AW::E/*Q>^N&2*6$1D#S6._W#=:HZQ8"
M^^,>FSW&G7$VGQZ5);O,;=S&)"X(&[&.E>B44 <AXGC_ +'MM%MM,T@_8A=[
M9'L[7>]JNUOF10."3QN[9-<:=.U&/PYK\0TK4BR>)(KY0\19Y(<PY9?[Q^4]
M/2O8:* /-;^0V/B_4+C5-"U>\TW5H8F@>TCD?RR%VM'(B'C/7)XY-6[2T^P^
M.]):+2I[2R@T62$*D+ND)+A@FX C. :[^B@#Q_2+/4+70/#DSZ7?_P"A:]--
M-$+9]ZQN9-K;<9(^8<UZ^IW(&P1D9P>HI:* "BBB@ HHHH **** ,74O^1FT
M/_MO_P"@"M'4/^0;=?\ 7%_Y&L[4O^1FT/\ [;_^@"M2[M_M=G-;^;)$)4*%
MX\;ESZ9!'Z4 >5Z':'7_  %X%LK2VG6>TFM[F29H&58D0$L0Q&#G@  G.:U=
M,TR\U#2/'5C##/:W%_>3M;R30M&'5D 4@D#@D$5VF@Z-#X?T2UTJVGGF@M4$
M<;3E2VT= 2H _2M&@#S62UNO$.C^$;%-/N[2]TZYMY+DRP,BP"( -AB,$-C
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M.@=0Z[6&>Q'8UGI_R.LO_8/3_P!&-6O%$D,211($C0!551@ #M60G_(ZR_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAN;AX(A-.EK'O:*,G 8C.2.#P,G@\5L(ZR1JZ_=8 CC'%>?VL5Q;_$KQ//\
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MH&YZ5R?PD_Y)];?]?%Q_Z-:K%_KE[:>.TMTNC+IW]DS77D*B\NC 9W8R?SH
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M]:JWDUY%):BUMDF1Y@L[-)L\M,'YAQ\QSCCWH I?\)9X=_Z#NF_^!2?XT?\
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MR0!DG%+0!C_\)9X=_P"@[IO_ (%)_C1_PEGAW_H.Z;_X%)_C6Q2$@#)( ]Z
M,C_A+/#O_0=TW_P*3_&C_A+/#O\ T'=-_P# I/\ &M@D 9)P*,C&<\4 8_\
MPEGAW_H.Z;_X%)_C1_PEGAW_ *#NF_\ @4G^-:^X<\CCK[4N: ,?_A+/#O\
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M^5=9D9QD9]*6@#AVC\$F:]*Z[:);7TGFW5JEZ@BE?N2N>^!G'7O6Y)XG\./
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M&,8]Z=X7UY_$6F3W<EJ+9HKN:V,8??\ ZMBN<X'7% #_ /A+/#O_ $'=-_\
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MG:CH&CZM/#/J.EV=W-"<QO/"KLGT)% '#W4[Q^);"WU*^.I6#Z'A$5A&YFW
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MA6YC9I YW-,9PCQ,/3!*[?3%>L(6**6&&P,CWJC'H6DQ7S7L>FVJW+-O,HB
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M,%FQTR>^.V>E7Z .&\56-K<?$7P=YT08R/=!LD\@0,169O&L67C=M0FD@O\
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M_L*2^;71J-O]ID0713;SOP(P .<'@8ZU=M_$.E75M<SQWB!+:3RIPZE&C?\
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M;VZ;9-$R$JTSLI&1R,$4 :VI?\C-H?\ VW_] %;)(4$D@ <DFL;4O^1FT/\
M[;_^@"K'B&TN-0\-:I96;;+FXM)8HFSC#LA _4T 1)XATN_N/L%KJ 6ZFB9X
M3L(WJ.K(6&UP/;-<UX"\;6^H>&M'36=31M7O7F0;EQO82N ,@;0=JC ZG%2>
M%M7AO[+3(;C0KNVO],MS%</<6Q46^$VD(W1MQ ^[GBN5TJTN+?X;>$K5[*X2
MZMM:$TT?D-NC7S93N(QP-K#GWH ],E\3:/#>?99+U1)YXMRVQB@E.,(7QM#<
MC@G/-13>,/#\&HO82:I"+I)4A:,9)5V^Z#@<5Y[KLEW>VU['_9=_#+;:]#,;
M:VM6\MHEE4^<6 ^=F SP3CT[UTFD!CXY\777V&5Q/!;- )(BHE*1$%02,9!P
M* .CL_$VCW]W#:VUZKRSAS#\C!9@OWMC$8?'L30_B71XKV.T>^19993#&2K;
M&D'5 ^-I;VSFO.M+ENKG5/!5X=/U"+[-)<1W%NEFT<-FS1%0BC'(!_BR?J.E
M:?A"Y>#2K/PSJVA7<NJZ?<D[Y("83\Y(G$G3H<^N>U '3Z1XQTW5I-6P7ACT
MZY:!Y)8V0':J$G)&!RQ&.O&>]3_\);H2QWCR:@D/V-!)<+.C1-&IZ,58 X/8
M@5P=Y9:K_97C&RMM/NY+O^W%U&.((RK<0CR3A7Z$G8W .>*M7K:;K6@ZUJ6G
M:-J:7CZ9):M-=Q2!R3TB56Y;GN./>@#H-1\6Z'>VBK:>)4LV6Y@4RI'N+%SE
M4 (YW=,CI6K?^)](TPW'VRZ:-;;_ %S^2Y6/@'E@N!P1WKC/%%N\OPV\/PVU
MI,TJ3V#/&D+;E$94MD8R,8-6O$$JZ_XD32KJ&XAT"S*W-TP@<_;9>JH,#E1@
M$^IP* .EG\7:%;Q^9+?J$$2SNPC<B.-ONL^!\@/JV*9)XKL4\6P^'PLIF>U-
MR9!&Q4#<JJ 0,<Y//08]ZX/Q/<76JIXGM(M&O;8W.F(;7[/:MNO/W><2/CY=
MA.-O'X]*W+%IH_'FBZ@]E>"VN-!^RJY@;Y9!(K8;CY>!GYL?G0!T&EZSI_V+
M4;QM=2\MHKMU:1@%6$\#RAC[V"?<G-64\2Z.\=VYO4C^QKNN$F5HWB7L65@"
M >QQS7G#6.I/IU_=6UG<2+:>*%U&2#RR&F@5E)90?O="1CKBM;5+1]4\5WVO
MV4<OV%-#EM7?RV!FD8Y50",DCZ=\4 =98^+="U.]M[2SU**6>XA\Z%0&'F)@
M'()&"<$''45M5YAI\$L=O\-$^RSJUG!LN1Y+#R3Y 4AN./FXYKT^@# UGQ99
M:-KVE:3.DS3:@SX9(F8*JJ3G@')R ,>^:M7?B32+&X6"YO%C8R+%N*-L5VZ*
MSXVJQ]"0:Y_Q;%/%XV\(:D+6XEM;::X69X8C)L+Q%5R!SR>,U@0P1?:M8\.Z
M_H>IW<US?RW%L4#F"X1WW*2P.U=O?/3'>@#T.77=-@N_LKW!\SS%A.(G*AVZ
M*6 V@\C@FL>V\9:;JMGKNVZDL(]/EDMVNI8F 3:BDO\ ,,<%CQUX]ZP+Z"]L
M_%<MWH<ESOGU&);[3+F$M%,OR@SQMCY2!SD'&5IUHD]KI7CZQFL[I9I[RZN(
MOW+%9$>) FTXP22#P.: .GB\4:+8VUC!=:S'-/-:B9'92'F0 9?:!W]/>K<'
MB31[G2%U6&_B>R9MBR#/+YQMQC.[/&,9S7$Z5&ZZ[X'DDMI@MMI,L<S-"V(G
M*H &XX.5-8T<+VWA.^EEM[R.:'Q.UY;JMNS$@R[E;9U92,].: /4K'7M+U*[
MFM+2\1[J#_6P$%9(_P#>4@$?B*T:XKP;?:9>Z_K5['//_:-^8Y)();66 (D:
MA!MW@;O<^]=K0!D7?B?1K&YDM[B^5'B=4E(1BL3-]T.P&%)SW(J6\U[3;"9X
MKFX*M'M\PK$[+'N^Z&8 A2>V37F?C WM];>+;%=*O(9A-$\,=K:L5NE&W]Z[
MX^8\8V@CIT-:7B)+Q=7O]5T!KN/4)#"DVF75N6AU!-JX(R/E8 D$YXV\XH ]
M,J"\O;;3[9KF[F6*%< LWJ> /<GTJ922@+##8Y'H:Y#X@Q7HM-&O[6VENH+#
M4XKF[@A7<[1!6!('?!(./:@!NC^(WN_'.O6LE\YTZTM(90D\7E&%B6W9! /0
M \UN0>)='N)YH$O566*+SV65&C/E_P!\;@,K[C(KS[68KS7]6\5R:1:7;?:]
M*MA;N]N\2S,CEF3+ 8)''..M:%M)I'B"UFO9?#NKBZAL9(;G[2LBM&K#YHDR
M?F)]L]* .VM]=TVY^T;;@I]GC667SHVBVHV<-\P'!VGGVJO_ ,)7H8%R7OTB
M^RQ">43(T96,]' 8 E>.HR*\\N=-\1S:+K6DZ?/)J]BME%):7%Q%Y<^5DS]F
M<X&_Y<\XXS@]:Z&[U>V\1>'=6O+71;R*X_LR6!Y+BU:.0,5.(E!&6Y/;C\Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME3$Q(Q)(7QR.V<5T-% !7,ZQH=_?>-= UB P?9M-6=9%=B&?S5"\<=L5TU%
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M_07LO^_Z_P"-'_"2:'_T%[+_ +_K_C0!J45E_P#"2:'_ -!>R_[_ *_XT?\
M"2:'_P!!>R_[_K_C0!J45E_\))H?_07LO^_Z_P"-'_"2:'_T%[+_ +_K_C0!
MJ45E_P#"2:'_ -!>R_[_ *_XT?\ "2:'_P!!>R_[_K_C0!J45E_\))H?_07L
MO^_Z_P"-'_"2:'_T%[+_ +_K_C0!J45E_P#"2:'_ -!>R_[_ *_XT?\ "2:'
M_P!!>R_[_K_C0!J45E_\))H?_07LO^_Z_P"-'_"2:'_T%[+_ +_K_C0!J45E
M_P#"2:'_ -!>R_[_ *_XT?\ "2:'_P!!>R_[_K_C0!J45E_\))H?_07LO^_Z
M_P"-'_"2:'_T%[+_ +_K_C0!J45E_P#"2:'_ -!>R_[_ *_XT?\ "2:'_P!!
M>R_[_K_C0!J45E_\))H?_07LO^_Z_P"-'_"2:'_T%[+_ +_K_C0!J45E_P#"
M2:'_ -!>R_[_ *_XT?\ "2:'_P!!>R_[_K_C0!J45E_\))H?_07LO^_Z_P"-
M'_"2:'_T%[+_ +_K_C0!#J7_ ",VA_\ ;?\ ] %:5\]Q'I]R]JJ-<K$QB#G"
ME\'&?;.*YS4->TA_$.C2KJ=HT<?G[V$RX7*#&>:T+S6] OK&XM)=8M!'/&T3
M%+A00&&#@^O- '*Z9XJN;BPU19=2DT_5K6QW36FK1;/(D_YZ@@?,A]L]JDM=
M8U.77-4THW=XMN='^UQ2S(JRJ^=I*\< ^A%3W.E^$M0M[F+4O$ OFFM?LGG3
M748>./(;"E0.<@')R>*=8Z?X4LM3346\1/=72VIM'>XOPWFH3GY@,#CVP/;/
M- &+INH:KI7P^\'7-OJ4K&[NK6*<2*K;DD8 C.,^O/7FM>_\1W=CXM-AJ<]S
MI\4MY$MC<>6&M9X_EW1LV/ED)WCDCJ*C31?"4>CV&EIXDD%M8W"W$&;U&*LI
M!09(/ QP/SS5R>#PU=32?:/$8EM9;A;I[-[F(Q&12&!^[N RH. P&1[F@"C:
MPSP?$KQ/-_:++Y6G6[@S[1'_ ,M" W'W13=+\2:E;Z]IT-Q<S7=K<Z3+=R.T
M857DCVDM$, [#N.,]L5?>U\+2ZIJ=_-KZ2MJ4 M[F)KF/8T8!    (QD\@YJ
MM8:/X1L+O3;H>(Y9YM/A:")IM0#9C./D8# (&T8''OF@"YH4^M:WIFBZ['JT
M26]XA>ZMV4%0K@[1&<<,&QUZ\US.@ZU?:-X&AN?MTTUSJ&M/9+)/AA&6F<%^
MG)P#UXSBMS1-*\(:!?&:SU]C;JYDAL9+\-;P,>I1.W4]2<=L4)H_@I=+OM-;
M6$DM+N<SB-[T8@<MNS'_ '<-SWH DO-5U;2O$]WHGVUYH9],>]MKAT4O Z'!
M4\8*G(/-9D$GBVZ^'L7B.WUR26\>SBN?LBVZ ''+@'&<E?UK:B3PZB7+S>)A
M<W=Q!]F:[FN(O,6+GY5PH4=3SC)[G@5"/$.A>#?#EG86-S)JD,1$$<<<L;NJ
M]LG@;1ZF@#2T;6#X@U6.[L+IVTR.T1F& 1)(XW 9]0O7ZBLW7TN9/B=X9B2_
MN(H7MKMS$A&W*A.<$=PQ'\JL^%KKP_H.@PV::AI\+LS32HDZX#NQ8CKT&<#V
M IVJ/X7U;4].U&;6XHKFP+^4T-VJ;E<#<K>H.T?E0!BR^)-6O?!^M^*+.[\I
M]-N+CR[0H"C1P,0RMWRP4G.>,BN]L+K[;I]M=["GG1+)M/49&<5Q[Z?X2,][
MLUY8K._D\V[L4N8_)F?N3D;AG R%8 ]ZZ"37]#:W,4>M6D.5VJT<R97Z9R/T
MH Y_X2?\D_MO^OBX_P#1K59O]=O+/QTELMSYNG?V3-=F%5'WT8#@CFL[3]'\
M-Z5IATZQ\8WD%J2S;$OHA@L<G!VY')-7XH/"L.KVFHIKL0>TM/L<<1N8RGE=
MP1C))P#G.: $T6YUG5--T3Q#'JL0MKE/.O+9T!0JP^58R.0P.!R>:IZ7JGB3
M7+/2]<L)46">X/VB&5T\H0[BI"_Q;UP.O4YI^BZ3X0T*],UIX@<VRN9(;&2_
M#6\#'.2B?B>I..U-L-&\'Z9J\M]:^('C@DE,W]G_ &\?9ED)SO">N><9Q[4
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M^_8H^Q6G_/K#_P!^Q7E^F7:1P+H\UW=RB/Q#<VUI;-.=LJ("1'(YR=BYSW/
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M#L?L5I_SZP_]^Q1]BM/^?6'_ +]BLKQA>06'A+4KBXN[BTB$6TS6_P#K%)(
MV^A)(&?>N=\.32VOQ)O=.RD%L^CP3BU2X,BB3S)%+'/&XJ!G'MUZT =L;*UP
M<6L!/;*#_"L'P[J]OX@NM4A&CQ6XTZZ:TD9BK;W7!)4 =.1UQ]*Z:N%^'SH-
M1\8Y91_Q/)N_^RM '47,!CO+2.#2K>:"1F$\I*J80%)! Q\V3@?C5O[%:?\
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M^'@T%O*\<]L&3S8]K[&)XQP>>O3FM^]NX;6RL)XM*MIWO)4B5%8#!89SG;R
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M^SNW()P3GUZ5A3WMUJ'PTU?Q";N>#Q!:7<Y#+(P:%DE(6+;G[I7;\N.<YZT
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M%AA!$:] S%C^9YK*3_D=9?\ L'I_Z,:@#:HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#%MO^1QU#_KS@_]"DK1O]/M-4M&M;ZW2XMW^]'(,JWU%9UM_P C
MCJ'_ %YP?^A25'XTU"\TGP=JNI6$JQW-I;O,A9 P)49P0: +,'AG1+:2*2+3
M+96A_P!42F=GTSTI=4\-:)K5Q#<:GI=I=S0?ZMYH@Q6N3C\4:QI>M>%K>^N8
M;ZVUR$EPL(CD@<1A]PP<%:Z2T\8^'KZZ%M;:K;R2E9&P#V3[YSTXH P/$/A:
MZU+Q+)>76@Z5K5BT*10)<2>6]MC);^$[@2<_A6QI'A#3K2PAAN;"WS%.;B")
M262V)QPA/IC\R:T;/Q!I=]>+:6]VK7#1^:D; J73^\N1R/I2+XBTEK^*R%['
MY\KM'&.<.R_>4-T)'I0 C>'-'<W9;3H";S'VG*_ZW'][UJ_;6T-G;1V]O&L<
M,:A41>B@=A5&7Q%I4%]'9RWB)-)+Y*9!VF3^YNZ;O;-.&O::UZEH+D&9Y&B0
M;3AG7JH.,9&#0!)J&D:?JOE?;[2*X\EM\?F#.UO4>]1W>@:3?W4%S=Z?;S3V
MZ[8I)$R5'IGTI;?7-.NKQ+6&Y#RN&* *<.%.&P<8.*L7E];6$(EN91&K,$7/
M)9CT '4F@"BOAC0T2T1=+ME6T.ZW"ICRCZKZ&K5MI-A9WEQ>6UK'%<7!S-(H
MYD/OZU!%XATF>P>^COHC;I(868G!60'!0CKNSQCK3#XGT9;*[O'OD2&S.+DL
M"##QGYAC(X[T :<T,=Q"\,R*\4BE75AD,#U!JI9Z-IU@&%K9Q1[D$9P,Y4?P
M\]O:E&KV#+9L+@%;TXMR%/[SC/''H":KIXDTA[Y+,7T8FDW>6#D"3;][:3PV
M/:@!-/\ #&A:5'<QV&DVENET")UCB $@/4'U'/2DMO"V@V;0-;Z3:1-;AA$R
M1 % W7!J*V\8^'KRY%O;ZK;R2$2' /:/A^?:K5GK^EWUW):07:FXCC$K1N"C
M;#_$ 0,CWH 8/#6BC2Y-+_LRV-C(VY[<H"A/7.*LZ9I.GZ+9+9Z;9PVELIR(
MX4"C-<MJ7BHR>+_#=GIFH!K6]DE$T8BXE4(2&5B.1GTJYXZU:]T73M-NK2[6
MV5M3MH9RR*0T3R ,,GIQGF@#H;VQM=2M)+2]@2>WD&'C<95AZ$56&@:4+BWG
M%C%YULFR%\<QKZ ]A5.V\9^';NWO9X-5@>.Q&;DC.8AZD8SCWJZNMZ<]O97"
MW2F*^8+;, <2DC(QQZ F@"LWA/0'B:-])M61IO/(9,YD_O\ UYZTYO"N@M%)
M&=)M-DDOG.HC #/V8X[U=OM1M--B22[F6,2.(T!Y+L>@ ')-)IVI6>JVOVFR
MG6:(.R$C^%@<$$'H1Z4 1IHFF1WLMXME#]IFC\J23&2Z?W3ZCVJM:>%- L6@
M:UTBTB:W8M"5B&4)ZD>G2L.[\22S>.[GPZ^J+I31P1R6H:)2;HMG."W! X&!
MS6WIM]>6.AQR>(9HEO/-=&:-" _SG9M7D\K@XH FC\.Z/#'=QIIUN$O,_:%V
MY$N>NX=Z2S\.:+831S6FEVL,L<9B1TC (0]1GTI8/$.E7.GO?Q7L9MTD,3MR
M"KYQL(Z[LD<=>:S-5\=:-IFE2WRS-/Y=REJ\:(VY)&( ##&5ZYYH TM+\-:)
MHL\T^F:7:VDL_P#K'AC"EN]-/A?0FTU]..DVGV-Y/-,/E#;O_O8]:B_M2WG\
M16,$.KA3);O)]@\L9E'&')(W#'I[U,/$FD&\BM?MT8DED,49.0KN.JANA/MF
M@!C>%=!>.>,Z1:;+@*LP\L?O H  /J  *L7.B:9>6MO;7-E%+#;L&B1QD(1T
M(]Q5&X\:>'+629)M5@5H)1%+U/EL>QXXZCGI6Z"" 0<@]* ,X^']),UU*;"'
MS+M=MPV.91Z-ZUR^O^$&FU"S6WT#2M2TBWM_*CL[AO+,#ELEE.""",#'&,5J
M:3JVHW'CG7=*NI(FM;2&"2 (F"-^[.3GGH*Z1]Q1MA ;'!(R,T 8OAC0DT*S
MFCCMH;1)I/,%K Q:.'@# )^F3@"M>YMH+RVDM[F))89%*O&XRK#T(K \$ZO?
MZSHUS/J+QO<17UQ;YC3:N$D*CC\*V-3OUT^T,FPR3.0D,0ZR.>BC_'L,F@!E
MGHNFZ?&\=I9QQ*Z[&VCDKV&?3VIVG:38:1$T6GVD=M&QW%(Q@$^N*QO NKZA
MK?AU[K5&C-TMY<0MY0PH"2LH _ =:SM4U;6O^%F6GAZTU%(+2XTZ2[)-NKLK
M*X7&3VYH [&[M+>_M);2[@2>WE7;)'(N58>A%4K/P]H^GW,=Q::;;0SQ1^4D
MB1@,J9SC/IR:Y[PGXU;4--OSK3P1W%EJ4FG"6$';<LO0HO)R?3GH:OZIXXT?
M3]&74HY6N(WN5M0(T8D2%@"&X^7&<\T =(0&4@]",&L4>#_#H>5QI%J&E8O(
M0O+D]2?4U/>>(=+L(!-<W6Q#&)2=C$JG]YAC*CZU%<^+-"M)5BEU.#S'@^T*
MJDL6CXPPQUSGM0!/_P (_I -F1I\ -D,6V%QY/\ N^E,/AK1&UK^V#I5H=2_
MY^?*&_ZY]:S[_P <:/:1Z1+%,;B+5)A'!)$A9<8))) ]NG6ND5@RAAT(R* ,
MN;PUHEQK":O-I5I)J,>-MRT0+C'3FE/AS1V>\<Z= 6O1BY.W_7#_ &O6M2B@
M#*/AG12$']G082,1*,?P Y"_3D\4:GX9T/66MVU+2K2Z-O\ ZDRQ [/I6K10
M!G7^@:3JDEO)?:?;SO;_ .I9T&4]@?3VJ;3],L=)MOLVGVD-M#N+;(D"C)Y)
MXJW10!BZE_R,VA_]M_\ T 5M5BZE_P C-H?_ &W_ /0!6I=7,=G:2W,V[RXD
M+MM4L<#T Y- "FVA-TMR8D,ZH4$F.0I.2,^G HBMH()9I(HD1YF#RLHP7; &
M3^  _"N#O_'#7ND>%]9TVZ-K9WVI0PW*21#F-@QQEAQPHY'KUKK;'Q%I.I6]
MU<6M]&\=JVV<G*^6<9Y!P1Q0!+'HFF13W<Z64(EO!MN&V_ZT8QAO7@FH8O#.
MB0FU,6F6Z&TR+?:F/*SUV^F<U+8:WIVIW,]M:W(>>  R1,I5E!Z'! .#ZUH$
MX&3TH R&\+Z&UO<0-I=N8KF3S9T*\2/ZMZFIAH6EB\^UBRB%SY?D^;CYMG]W
M/I5*+Q#;))J5Y<:E8#2K9UB#JQ#1.!\XD)XZ],5HVVKZ?=W\UC;WD,MU H>6
M)6RR ]"10 [3],LM)M?LUA;1V\ )81QC R>O%%_IEEJD217UM'.B,'4.,[6'
M<'L:M,RHA=CA0,D^E4$UW2I+&*^2_@-K++Y*2A_E9]VW;GUSQ0 V?P_I-U8+
M83Z?!):JV\1,N5W=<^Y]Z>NB:8M\;T647VEH_*,I&6*?W3[>U9__  D=I!>:
MA/=:IIZ:9;F.+.XAXY3DL')XZ%<5KF_M%OC9-<1BZ$7G&(M\PCSC=],@T 4]
M*\-Z)H<LTNEZ7:V<DW^L:&,*6^M:,T,=Q!)#,BO%(I1T89# C!!JI:ZQI][<
M>1;7<<DI7>J@_>7ID>H]Q5Z@#*T?23IND_V3(1+9PCRX"3SY793]!QGN,5-:
MZ;;Z1I[6^DVD,"C)2)?E3)/7\SFHSX@TP7'D?:<R;G4 (Q#,H)8 XP2,'BLS
M2?'>BZGHR:H\YMH)+AX%,R,O(E:-<G&,G _/% &KHNDQ:-I_V=&WR22/-/*1
MS)*YW,WXD_@,5%KK:WY4,>BP6CF1BDSW,A7RE(^\  =Q![<59CU:PEU"YL$N
MD-U;())HCP44YP3GMP:Y;4_%N_Q;X;M=-U$-9WCS>>@AR)46,D,K$<C('W:
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M,D@G/(R<9K4M=*36?'&K:DD3_P!D76EQV<HDC*"XDW.2<$#.$(&?PKM:* .
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MV!XX7F0HL.SRMP!P0<]>O6NL\!K)'X#T.&:"6"6*RBC>.5"C*0H!R#S7144
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M %YP?^A25M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!BZE_R,VA_]M__ $ 5IWLDT-C/);(CS)&619&*J2!QD@'
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MK>1IFPMI2\8E&=T@R !G(& .U2:SHVLW7BVPU.TELYK"&W:)K6Z+8BE)R)E
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M $8U &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &+;?\ (XZA_P!><'_H
M4E;58MM_R..H?]><'_H4E;5 !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3Q)*,A)XS&XYQRIY%6J\WM?$NO/X$\.ZNZW5ZLN]]2>R1/M&P;@&5,8(!QG
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MPM:ZM=Q1022M(&1"=J[791R?I0 [2/"]KI&KWNJ+=WEQ>7J1K.\\N0VP8!P
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M]_Z%O5?^^K?_ ..T?VU>_P#0MZK_ -]6_P#\=H V**Q_[:O?^A;U7_OJW_\
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M[_T+>J_]]6__ ,=H V**Q_[:O?\ H6]5_P"^K?\ ^.T?VU>_]"WJO_?5O_\
M': -BBL?^VKW_H6]5_[ZM_\ X[1_;5[_ -"WJO\ WU;_ /QV@#8HK'_MJ]_Z
M%O5?^^K?_P".T?VU>_\ 0MZK_P!]6_\ \=H V**Q_P"VKW_H6]5_[ZM__CM'
M]M7O_0MZK_WU;_\ QV@#8HK'_MJ]_P"A;U7_ +ZM_P#X[1_;5[_T+>J_]]6_
M_P =H ;J7_(S:'_VW_\ 0!6CJ()TR[ Y/DO_ .@FL"[N]1N-7TZ\7P]J02U\
MS>K/!N;<N!C][C\\5H?VU>_]"WJO_?5O_P#': /,-&TBP_X1GP)?Z0B#73-
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M9 YSMR9!T]10 63R'XD:;%J+K]L/AM1<*6&=_F?-^N:YC3=2CT[P-IDLC_\
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M!/KUXJ]HUO>VM\;^[\(&"X\IH=FGQ6Z*58@G<3+EN@^G-;,5RMOL\GP=>Q[
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M$.HZO'')HUXNAJ$=[<+!YKNK;L%O.QMR%XQV([UN_P!M7O\ T+>J_P#?5O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#.U36[+1WM4NS*&NI?)A$<3/N?!.W@=<
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MBKJ-Y*D+:G<&<&1MNXR$"->>^T( *Y&_EU]/&/AVXOM#03R:A*%D%XI!3R9
M% QP I)]SGUH ].HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exhibit10253secondamendm001.jpg
<TEXT>
begin 644 exhibit10253secondamendm001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3;A$BCE"O&Z\ -N8?+C&".00: )-8\;6.E>&[/6%@FG^VJCP6X^5RK8))]
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M<"3>V2IPH  "^^2:CU'P==ZP;^[M]#33H"+5DTXNB_:'BD+,3L.T94[0?SH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS9C.[=TQCG- $]%9MQXAT6TM8+JYUC3X;>X&899+E%60?[))P?PJU9W]GJ,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@'@[_H5=%_\  &/_  H_X0#P=_T*NB_^ ,?^%='10!SG_" >#O\ H5=%_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%8^OGQ&(H?^$=CTMY,GSO[0DD48[;=B
MGWZT ;%%><>$O$_CCQ,ANQ9^'XK*"\>VN/WTWF81L.4&W!XSC)'OBM+PEX_T
M_5=)MCJVHV%MJ4\\T:V_F!20LK(O!/<** .UHK$DUICXM@TF"XT]D$#R7$;3
M?Z0IXVX3T]34UAXFT/5;V2RL-6L[FYCSNBBF#,,=>* -6BN;\:^)9_#6EVKV
M=M'<7M[=):6ZROMC#MGECV  -6M!/B,+<#Q"NF<$&%[%G(([[@P&,4 ;5%9-
MCXHT'4[Y[*QU>RN+I,YBBF5FXZ\=Z+_Q/H6EWJ6=_J]E;7+XQ%+,JMSTX/2@
M#6HK,U/Q%HVC)$VI:I:6JS?ZLRRA=_N/45--K&F6\$$\U_;1PS@M%(TH"N ,
MD@]#QS0!=HJAI>MZ7K<#S:7?V]Y&C;7:&0-M/H<=*YCQ+\0-/L'L[;2-2L+J
M^DU"&VFA$@9E1B0QP#U% ';445RD7C6WE^(TWA14_P!7:B03=C+U9/P4J?QH
M ZNBLO4?$>BZ0774=4M+5DV[EEE"D;NG'O@TQ?%7A]KV"S76K%KB=0T48G4E
MP>F.>] &O16;JOB'1]#,8U34[6S,OW!-*%+?3-2S:QIMO!#/-?VT<,ZEHI&E
M 5P%W$@]#P": +M%4=+UK3-;@:?2[^WO(D;:S0N& /H<5R^O^/["TU#2K#2=
M1L+JZN-4@L[B)9 S(CMM8@ ]10!VU%9%YXIT#3WV7FL64#^88MLDR@AQC(^H
MR/SJ2W\1Z+=ZFVFVVJV<MZHR8$F4M^5 &G165?\ B;0]*O8[._U:SMKF3&V*
M6958_@:FOM<TK3 3?:C;6P$?FGS90ORYQGGMF@"_17-ZYXXT;1_",WB1+F*\
MLT&(_(D4^:W]T'UK6TO6-/UJU^TZ=>0W40.&:%PP!],CO0!>HKF-:\=Z-H/B
M:RT2_N(X9;F)Y6EDE55B Q@-GN<\?0UJ:EXBT;1XH9=1U.UM4FYB,LH7>/4>
MM &G14<$\-S D\$J2PR ,CHP*L/4$=:P;7Q#//X_U#P\T,8@MK&*Z64$[BSL
M00?;B@#HJ*K7^H6>EVCW=_=0VUNGWI)7"J/Q-066NZ3J5B]]9:E:SVL?WYDE
M!5/J>WXT :%%9FE>(]%UQY$TO5+2\>/[ZPRABOX4EKXDT2]U1],MM5LYKY,A
MH$F!<8Z\>U &I163+XHT&#5!IDNL627Q.WR&F4-GTQZ^U:U !16%'XCCGUK5
M;2&/=;Z5"&N90>?,(+;%'LHR?J*Y32OB>NIOX8B5($DUV>;!(;;#&A("'U<\
M#/2@#TBBN8TOQYHFJ>)-0T..ZB2ZM)5A4-*N9VP2P0>V,&L[PK\0;'4;25=:
MU"PM+TWTUO#"9 A=5;:IP3WH [BBL*[UMT\6:?I%M<:<PD1WN8I)\7"@+E2B
M=QP<^U6;3Q)HE_J4FG6FJV<U['D/!'*"PQUX]J -2BBN4\)>-;?Q3JFMV<,>
MP:?<;(F_YZQ\KO'MN5Q^% '5T5CW7BOP_93K!<ZS8PRM(T01YU!W X(Z\8/%
M2VGB/1;_ %*33K35;2>\CSO@CE!88Z\4 :=%9-YXGT+3]173[S5[*"[;&(9)
ME5N>G':I=0U[2=*W?;]2M;;8@D/FRA<*3@'Z9H T:*J6^J6%WIPU&WO()+(J
M7^T+("FT=3GIQ7+Q>.[/4?&^FZ1I-]97EE/;3RSR1/N9&3&!P>.IH [.BL<>
M+/#QNX;4:U8>?,,QQ^>N6'MS4VF>(-'UJ26/3-3M;MX?]8L,H8K^5 &E164O
MB?0FU;^REU>R-_G;]G$R[\^F/7VHU#Q-H>DEUU#5K.V9&",LLH4@D9 Q].:
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M= TN\2TO]8LK:X?!$<LRJW/3CM5J]UC3=.$9O;ZWMQ(K.AED"A@HR2,^@(H
MNT5GZ;KNE:P2-.U"WNB$#D1."=I. ?IQ5FWO;6[DGCM[B.5X'\N4(V2C>A]#
M0!/17'>.?'L/A"W6.*SFO+U]I"JA\N)6;:&=NPST'4UV- !117G_ (D\3^+_
M  W;WNMW6FZ6-%M9MOD"=C</%NQO!QM!.<XH ] HKC];\4:H_B2W\-^'+:UD
MU![7[9-->,PCAB)VC(49+$CI573_ !1XFUO298-.TRPCUJTOGLKX3S-Y,.T9
MWK@;F!XP* .ZHKD?#/B75M1U'7-$U.UM%U72MGSV[L890ZEEZC(]ZI6WBCQ)
MI7BS2M$\26FG,NJJY@EL'<^4R#)5@P&1[B@#NZ*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *.U
M%% 'GOPE_P"18U7_ +"]W_Z&:Y*'2[!OV?\ 6+LV<'VGS;R;SM@W[UG?:V>N
M1@5[/:6%I81/%:6\4$;N798U !8]3]348TG3QISZ<+* 63[MT&P;#N.3D>Y)
M- '!7,$,_P 1O#OG843Z#.)I!P2"%!)/TJEX-N%\+^(-(\,B72=7L+F&4Z=J
M%F%$\2+@D2XR"#D?,,9Q^7IK:=9//'.UK"TL<9B1R@)5#U4>WM573O#FBZ1<
M/<:=I5I:S.,,\,04D?44 5_%5GH.HZ*UGXC>W2QFD509Y1& _5<,2,-QQ7D^
ML7NJVFC^,O#>CZQ/K&G6MA'-#<;_ #9( S8>(N/O?+D^N*]HU'3+'5[0VNHV
MD-U 3DQS(&&?7FFZ=I&G:1:FVTZQM[6 G)2&,*#]<=: /,;7P[+JX\/-#XG\
M-+%;3Q7%H+&Q$<K!>2BGS">5R",?6KG@"304TK6CKSV"ZM_:5P=0^VE _P!\
M[,[OX=NW':NZL_#.A:=>F]L](LH+DY)ECA4-^>*+[PUH>I7JWE]I-G<7*XQ+
M+"K-Q[F@#C-,?2Q\4O%$FL-:#-K;?83<%=GV;RQNV9XQNSG%<5IUM#=IX1A>
M%9-*D\379LHY%RIM_F*8!_A]*]LU'P_H^KK$NH:9:70B_P!6)8@VSZ>E3OIE
MB_V7=:0'[(=UO\@_='&/E].* /*?%4<^G^)/'":-%Y,TGAV*7; N"6WNI8 =
M]H-&N?\ ",#P;X/716T\XU*S\ORBGF?[6<<Y]?UKUD65J+Q[P6\?VF2,1O+M
M&YD!R%)].36=#X3\/6]R;F'1;!)BX<NL"@[@<YZ4 7=3U&WTC2[K4;IML%M$
MTKGV S7ABW.LV'AC3O$T_A[4([R'4SK%S>DQ^6T4G##[V['EE1T[5[O=V=M?
MVLEK=P)/!(,/'(,JP]Q2RVMO-:-:2PH]NZ>6T3+E2N,8QZ8H X'3+;3]6^+6
MNW,MO!<QMI-J8VD0-\K;LXSZBN)&G647P!@NH[2%+A+WS%E5 &#"<@'/7H,5
M[?;:98V4IEMK2&&0QK$61 #L7[J_04S^QM,_LX:?]AM_L8.?(\L;,YST^O-
M'E:P:A/\2?% EU31K.<B(0KJMIYI>WV?\LR74;<YR!3!X:BTI? ^FW%]::M:
M3:U-/$T4>(0C1LP51EAM#9/7O7JFIZ!I&LF,ZGIMK=F/[AFB#%?IFIO[,L,6
MH%G !:'-N @ B.,?+Z<4 >3>*H[K3]=\?)H<1AG?1;:3; N"3N8%@!WVYJ75
MO^$9&B> %T5K XU>Q\ORBOF?>&[..<YZ^]>L+96JWDEVMO&+F5 CR[?F91T!
M/IR:SH/"GA^VNOM4&BV,<_F"3S%@4,&!R"#C@YH \\L--L;FU^)TT]I!+*;N
M==[Q@G CR!D^_-1-86EGX4^%US;6T4,YO;53)&@5B'@<MDCKD@$UZLFFV4:W
M2I:PJ+IBTX"#]Z2,$MZTATRQ:&UA-I"8K1E:W38,1$# *^F 2* /&=#LKZ^_
MX2F*_P!9\/VEP]_.M[%J=EOE"$G:=QD7Y-OW>,"M;3= CL/B+X1TN^FBU/['
MH4NR=TR'(9=K '/8UZ/?^&]$U2[2[O\ 2K.YN$^[)+"K,/Q-6_[/L_MD=W]F
MB^T11F))=HW*A_A!["@#QO6K2./PE\4K2"!1#%>AXXE7A"40D@=N]>O:1<:?
M<6$;:=+;/$45CY!4CD=\5,FGV<9N2MK"#=',_P @_>G&/F]>.*ATS1-+T6.1
M-,L+>T20[G$*!0Q]3B@#C/%)LH/BOX6FO1 D,EI=1[Y@ I;Y"!D]^M16$FF?
M\+8\12:L]K@V5M_9[7!78;?9\^PGC&_.<5W6IZ/INLP+!J5C;W<2G<JS(& /
MJ,U!>>&]$U"V@M[S2K2>&W 6%)(@1&/0>@H Y/X2@_V)J[0!AIC:K<&P_N^3
MNXV_[/I4<>IV&F?&K67O[ZVM%?1[<*T\JQACO;@9->@PPQ6\*0PQI'$@VJB#
M 4>@%9NH>&=#U:Y^TZAI-G=3[0OF31!FP.@R: //O'EX-4\7>%9;/5=,&F;I
MU6YN%%Q;"XVC:&PP&[!.,GK4<ELWA>/Q-XJN;_2-8 L!!<:?I]L(XV;<-K2#
M>W8D?0UZ.GAS14TQ],72K06+MO:W\H;"WKCUI]EH6DZ=9R6EGIMK!;RC$D4<
M0"O]1WH \KLH+BS^*/AAKS5M'GGN;2X5X=,MEA6--@(4D,2PXX) Z&I='E'A
M#6+30M/ETO5[+4#<_P!FW5OM-U;2;68AR,[ESQGCWKTFU\+Z#9",6NCV4/ER
M>:FR%05?&,CWI]EX<T73;U[VRTJSM[E\[I8H55CGKR* /&/#VBSZU\/VLKCQ
M!X<M1.SI=I=67^DQSESG<YD!WYZ''I7N.G6\MIIEI;3SF>6&%(WF(QYC!0"W
MXGFJ4WAC0KC4?[0FT>RDO,[O.:!2V?7..M:U ' ?#$/YWC 3\S_V]-OSUQL3
M%=PMG:IY6VVA7RB3'A -A/7'I6;9:&-.\1ZAJ5LX6'4%1IX2/^6J\!Q]5X/T
M%;- 'GOA9K"V^(_C**<VT5PUS;/"LFU68&,C*YZY/I7*Z7I=A+\'/&MS)9P-
M.;B^?S2@W;DY4YZ\$<5ZY=:%I-[J,&H76G6TUY 08IWC!="#D8/L:D32M/CL
MIK)+.!;6<L98@@VN6^]D=\T ><RJLOC[X=RN!YDNFW'F/T9OW'<U#X5F@\(^
M)-*T"";2]7TR_:<Z?>6VW[3;_P 3+(1G<.<;N/?TKTXZ;8F:VF-I"9;92D#[
M!F-2,$#T&.*K6/AS1=,O'N['2K.VN'SNEBA"L<^XH R_B#KDF@^#+ZXMP6O9
ME%M:(.K32?*N/IG/X5YY8SW?A#Q+X2N9=#OM-L# -'O)KDQE9&;YD;Y6/.\$
MY/J?6O8KJQM+TPFZMXYC#()8MZYV..C#WHO+&TU&#R+RWCGBW!MDBAAD'(/U
M% 'D)TZRF\%?$VXDM('F_M&]_>,@+?*<CGVK2U&PM;)OAI-9VL,$WGH@:- I
M(:W8D''8FO2!I6GBWN;<6</DW3,TZ;!B0MU+#OFGOI]G)]EWVT3?92&@RH_=
M$#&5]..* /$O#VFW6I>'-7@O]<\.VDLMW<+J$6I66Z=&+M@LYD';!4XXKI-%
MT**T^)6CZ=?O%J+V/AD*L\D8(9A*J[@#G'!_6N]O/#.AZA?"]O-(LI[H8_>R
M0JS<>Y%7A8VJW@O!;QBY$?E"4*-P3.=N?3(Z4 >(7*QVWAK4[61?+T1/&@CO
M47A$M_W18''1<GGZUU5Z=(/Q6T+^RC9$#2;K=]E*_=P-N=O;KBO01I=@L%S
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M#4)_B=XI$FJ:-938A$"ZI:>:7M]G_+,EU 7.<@>U4O[%M] U#P9:ZQJ=I?\
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M2G=@_0$#\*=XL\.W_B=K;3FN+:+1"Z2W:F,M-(4<,%4YPH.!D]:Z95"J%4
M#  [4 <+\7O^2?7'_7Q!_P"C%KKM4U:PT6S^UZE=Q6MOO5/,D.!N)P!4UY96
MNH6YM[R".>$D$I(N02.1Q5#Q%H<?B+3/[-N'5;621&G&W)95.< ]B2!SZ9H
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ME'?C[;NSMZ_=Y^E.N=%31/&.M7&KZ;KMS9ZDZ7%M<:8\QP=@5HW6,\$8X)H
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MQ/<WQ\0Q:A?M"I81L[EG)QV&>M:#3:GX$\;ZS='2+W4-"UB1;GS;*(RO!-M
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ME0=&$F?/;_@),?Y5NZ];0^*/BMIVAZ@!-I5CIW]H&V;E)Y6<JI8=&  SCWH
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M=VP /<T]6#*&4@J1D$=Q7'_%7_DE^O\ _7N/_0EKI=)_Y MC_P!>\?\ Z"*
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M%]-Y@B5QAL<#)(XR<U!;_#;2X9+:)[[49],M91-;Z;+-F"-@<CC&2 >@)P*
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M-'%<ZA*X-R5."45>BYR,FKGB;Q1KNAZ'H4D>FV?]K:E>QV<D$DS&.-F1V.&
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MRQH9-J)\>6;GC/7C=MVXK*\2):RQ^.(]-6-M&;4--7$7^J,WF1^9MQQ]<=Z
M/9['7M'U2ZFM;#5+.ZN(?];%#.KLGU /%7I94@A>:5@D<:EF8] !R37G^I6%
MIIGQ,\%FQMHK;S;>[B?RD"[E$:D XZX-;_Q",P^'?B$V^?,^P3=.N-IS^F:
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M'UH ] O?$.BZ;:0W5]JUE;6\P!BEFG55<>Q)YJPFI6,FG_V@EY;M9[=_V@2
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M0D61-6@9Y/L__+/!W ;-N.GO5A/#<5GKGPZTF_N(=3B@2\=) ,QN,*R8!)R
M",?04 >GZ=K>E:ON_LW4;6[VJ'/D3*^%/0\'H<&I)=3L(+$WTM[;I: X,[2
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M&BZ>+JX5EFE^S)ND###!CCG/?UJW)I>GRVUO;26%J]O;LK01-"I6(J,*5&,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &I&D2!(T5%'0*,
M"G444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !117.^*O$,_AQ]'F$$<EG=7R6ER[$
MYB#Y"L/^!8'/K0!T5%<Q<^,;:W^(=GX4*@R7%F]P7ST8'Y5_$!C^5<]K'Q&O
M[*#7;NTLK>2ST_4X-.B=R<R,Q42$X]">* /2**YWQCXBG\-Z5:7<$,<K3WT%
MJ5<G $CA2>.XS6%+XF\6ZEXSUO0]!M-%\K2Q"7DOI94+>8I(QL4_W3Z=J ._
MHK@=:\1>+],D\/Z4MOHO]L:I--&Q\R4P($4L,':&Z#TZT_3O&6L176NZ3KMA
M:1:KI=@;Y'M9&>&9,''4 CD8H [NBN T#6/B#KNEV&J1VGAI+.[190K7$_F!
M#[;,9Q[UJ>,O&MOX2N-(BEC\S[;=+')C_EE%D!G_  +*/QH ZNBN5\6^)+_3
M+S1])T>&VDU'5I72*2Z8B*-57<Q..2?0"M?0SK7V$C7EL1=AR ;-F*,O8_,
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M%U9QS,!PNYD!_+)KB-3\2?$#2]<TK2I;+PTTVJ2/' R7$^U2J%SN^3C@=@:
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MX&J]IHFEV%A)8VFGVT%K("'ACC 5L]<CO0!D^ M.L['P/H7V:WCC+V$+,RJ
M6+(&.3WY-9OC'5'/B;2-"MX]-@N+B*6<7^H1"1857 *HI(RQSZCC-=I##';P
MQPPHL<4:A411@*!P !534M&TW6(TCU*PM[M$;<@FC#;3[9H \)N&A3X;>*+=
MKJUN;>'Q&G[R% D)4R(257) 4\\9Q7:^(?[.F\=^$W\.M:MJ($WGFS*G_1_*
M/W]O;=MQFN^/A_1RDB?V9:;)2A=?)7#;/NY'?':ETW0M)T=Y'TW3;6T:7[YA
MB"EOKB@#R*U?0U^ U]'>-;?VNT<PF1L?:#>;VV\?>W;L8]O:M[PG?)I?CS6/
M[:NHK6XETBP<FXD";BJN'.3UP3S7>/X<T634QJ3Z59M? [O/,*[\^N<=:??Z
M'I6JS13:AIUK=20_ZMYH@Q7Z9H \7$MK<_#6:_RCVH\7&;S6' C-SDMST&*]
MQLY+26W!LG@> ' ,)!4'\.*B_LG3OL4UG]AM_LLY9I8?+&URW))'?-.T[3+'
M2;06NGVD-K;@EA'$H5<GJ<"@#S>?P^OB/QUXTM5F-O=Q"RGM+D#F&98SM8?R
M/L37'W-UJE_I/C&?5K)[.0ZK8+J4*Y($2A5D(_V2!GZ&O?([2VBN9KF."-9Y
ML>;(% 9\<#)[XH-I;,TS&",F=0LI*@[P!C!]>M 'F^O?V9<_$7P;'H/V624>
M;]I^R;2HM"F/FV_PYQC/>LS2M.NI?$=O\/98G_L_1KYM3,I'RR6Y.^%/^^W(
M_P" >U>HZ;H.DZ.TC:;IMK:-)]\PQ!2WUQ5P6\*W#7 B03.H5G Y('09_$T
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M&S_OGI0!Y?J^@O!IGB[6CKNEWDDNDM;SV^GVXB 8<J[X=N<9'T-:USI-G;?
MB2.ULX@QT17.V,;F/EAB3ZG.37;VN@:18V,ME:Z9:PVLHQ)$D0"N/<=ZNQP1
M16ZP)&JPJNQ4 ^4+C&,>E 'GM]X@TW3OAMI36$&FWK70M+?;*5,,<C[0'EQV
M!&>?2L_PO#Y'Q>OK6?4=-OGFT=3.+*W6),B08#*&;) /4]B*] @\,:%;6MS:
MP:191V]S_KXEA4+)]1WJ6ST#2-/:%K/3+6W: ,(VBB"E0W7!'K0!XQIUM!<>
M /"MO-$DD+>*RK1LN5(S+P1Z5W<$$-E\;I4MHDA2?0HWD6-0H9A,X!('?  _
M"NP31]-CABA2QMUBBE\Z-!&,))S\P]#R>?>IOL=M]M^V^1']J\OR_.VC=LSG
M;GTR30!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7(?$;4[W2M LI["Y>"5]2M8F9.I1I &'
MXBNOKA_BI!<S>%;9K:TN+IH=1MIFCMXS(^U9 20!ST% '9W-S#9VLUU<2+'!
M"ADD=C@*H&23^%<C!\2=,DEM6N--U:SL+R016VH7-N%@D8_=YW$@'L2!5'6M
M='C?P[JWA^PTO6;6ZN[.18I+RQ>&/=C(!8C ST_&N?T;2-&U>'3M)U*Q\8?:
ME,8FM[AIC;Q.F#DL?D*@CC% ':ZWX\MM N[E+O1=::SM2!/?Q6P,"9 .<[LD
M#/) -2:MXYL=-U2'3;:PU'5+N2W^U&.PB5]D6<!CN8=<]LUY[XFM;_59O%5K
MJ=KX@N-19Y(M+M[59!;>3CY&R/E)/?)]JMZ_]E;P_HL\5EX@M/$%OI48M+RQ
MLY"2X7'DR8'3<.0V!S0!W>J^,K33;BULXM/U&^U"YA$ZV5I"&E2/^\^2 HSQ
MR>M7?#_B.R\1VLTMJD\,MO(8;BVN4V2PN/X6'/UX)%>8WNF:C!XFMM>\26^M
M+'?Z7!%-)H[2;H)TSE76/G:<Y]CFN\\$:7IMI9W=_I\&J1M?2[I6U,MYTA4;
M0Q#<XQTS0 _QYK-UH_AB4:<<:G>NMG9?]=7. ?P&3^%5]'\:6G_"NX/$FJNT
M8AC"70"Y83*VQE '4E^,>]8_B&S\0>(OB39QZ:J6EGH<!G6XN[=GBFGD^7"X
M(R57OGC)]:YR[T+6;#2?&.@7]K<7BSO%JUG/86[!/-+J650<\AE!*YSC/K0!
MW>E^/K?4M?@T>31=6L;F:W>Y0WD2(#&N.1ASGKTZBC0_B%I_B&..YLM-U1=/
M9':2^FA5(8MH)(8[O;L"*Y+POJ$^H^,[&Z\2SW*:H+&2WL(FTZ2WC?@%SE^2
MV!TP*U?#7A^^N_@>-#:)[2^GLYH@DRE"K%FQD'D9X_.@#3M_B3IDTEM))INK
M6VG74@B@U*>W"P2,3A>=VX GH2!5K4_'5G8ZG<V%IIFJ:I+: &Z-A KK!D9P
MQ+#G'.!DUPNA:1I.I6NFZ-JEEXO6[7RXY[>9YC;1LF#NW'Y-F5!&/:HX]$3P
M[XDU^+64\3>7>WKW=I<:2TS1RJ_.UA'T<=.: .ZN?B)HL,.D26\=[>G5XI)+
M-+6'>S[-NY2"1@_,.O'!R15$?%/3VANV30=?:6Q8B^A%JNZV &<M\^,8YX)/
M%4(/#R:;XI\#?V787L>GPV][))YREFA:01,!(>Q)S^1JWINGWB:G\06>UF5;
MIU\@E#B7]R1\OKSQQ0!M7_C?2[2STV:VBNM1FU./S;2VLXP\LB8!W8)   (R
M215;_A8NC1Z+?ZC<P7UJVG2+'>6LT($T);H2N<$'KD$]*\]C\/7=A;>#]6U&
MUUI;*+14LKE=.+K/;2<,"RK\Q4]"/85?UKP_:7/@'7KS0['79;N]>&-_[061
MII1&<@A6^;'S&@#N-/\ '5G>ZU'I4NF:I93SQ/+:F[@"+<JO79\Q.>1P0.M9
MO@+QOJ'B:YU."]TF]B$-_-#'/Y*K%&BA<(YW$[^3GC'(JSXBL[J;Q[X.N(K>
M5X8#<^;(J$K'F, ;CVR:R_ EU+H6MZYH&H:??QW%WK$]U!,+9V@>-E4@^8!M
M'W2.3UQ0!VGB#6K?P[H%[J]SS%:Q&0@=SV'XG%<IJ=WXI/@W09;6.XNKR]N8
M)-0-MA7CA<[G5#V !VYZU;^*NGSZG\--:M[92THA#A1U(4@G] :Z/0ITNO#^
MFW$9!CEM8G4CT*@T >>ZQJ_BBS\.>/M0NTO+&6V.--EW#RQ$. 4'KW)/7(]*
M]'T^5I-*M996RS0(S,>YV@DU@?$FUN+WX<Z[;6L$D\\EJRI%&I9F.1P .M9E
MEXJBUK2DT!-)UVUN+FU-L)Y]/D2.-BF,EB.!0!.WQ-TD*UTNGZK)I"R>6VJI
M;@VP.<9SNW%<_P 6W%7];\9)HUR8UT/6=0B2(327%E;J\:H<\Y+#/3MFO-?#
M^A64&AVWAO7K'Q:M\G^C306[S-:N"V-RD?)LQS6OKEO+_P )1J%AJL7B![""
MVBBTBWTX2>5(-F"79.-V[CYB,4 ==>?$#2X+?27LK:^U.758S-:P6409V0#)
M8[B ,?6I[_QI9:?I^GSR6.HO=Z@2+?3T@!N&(ZY7.!CN2<<UYY9VEC%\.O#M
MIK&G:_::E9B98KNQM9&FM9 YX.T9PP(]C44^G^(KN'PMXC\36NK'RK>:VO!I
MQ9+F(%LI(53GD=0* /08_$\7B/1M:M+.#4K'5;:!E>UDC"7,;,IVLHR0<]CG
M%9/A_1O%MOK7AHZCJ=W)%9Z:XU+>^8YI6SM'^TPSR?\ 9]ZO^"-,TE;F]U>P
MAUH32A8&EU4OOD5>1M#\XR3794 <OH&M7+^*=<\/7\OF36A2YMW( +029P#Z
ME2"/IBM;6]8&BV(N38WMZS.$6&SB\QV)]B0 /<FN4TJ)KGXUZ[>Q\PVVE06S
MGMO9]V/P"_K4_P 2)=52PTQ+(WZ:?)=JNI2:>I:=(<?P[>>O4CF@"Y9^/=-N
M=/U:YFL]0LY])3S+NSN8@LRKC(( 8@@CIS4-K\1-.N;[3X7TW5;:VU%Q':7M
MQ;A(96(R #NW#(SC(YK@X-,<77C,:=IFLBTOM%46C7D<C/,R[@P&[)!R1@'!
M]JZC7=.O9?"7@>&.TG>6VO;%ID6,DQA8R&+#L!WS0!JZOX\M+6\O].L=-U74
MI;1"+F6QA#I;L1G#$L.>^!FIOAO>7.H?#O0[N\GDGN);8-)+(VYF.3R2:YC1
MM0G\(3>(]'U'2-3FEO+Z>[M;BUM&F2=9 ,#<HP",8YQVKI?AK:W%C\.=#MKN
M"2">.V"O%*I5E.3P0>E #=1\?V-EJ-Y96VEZKJ36/_'Y)8P*Z0'&<$EAD@<X
M&:==_$'1X/[+%K#>Z@^J6[SV:6<.\R!<9')&#\W? X/-<]I>IS^"-0\26=]H
M^IW3WFHS7UI):6K2I.LAR%+ ?*0>.:I>$O#.J:'K7@B*[M9,V^G7GVAE4E(6
M=D8(3T!_P- '>^&_%%IXECN_)M[JTN;.7R;FUNT"21MC(R 2,$="#2>(/%=E
MX>FM+62"ZO+^\)%O9VD8>60#J<$@ #U)K+\+V=S;^//&=Q+;RQPSS6IAD9"%
MDQ$0=I[X-4?$T-SHWQ'TKQ4UE<W>FK8RV4_V:(RO Q8,&VCD@XQQ0!HGXBZ/
M'H&IZK<6]];G3'6.\M)8@)XBQ 7*YP0<YR#ZUK:'KXUWSGCTS4+6! ICFNX@
MBS YY09)QQW ZBO,-<TW4]?TOQKKL&EWL<.H_8X+2WDA9991$XW.4Z@<]_0U
M[)$-L*#&,*!B@#%UWQ*=$GB@CT35M2DD4N?L,"N$ ]2S 9]JY3Q3XSCO/#?A
M[6]'EO!!+K$$<L,:E96 8AXBO<\8Q2^,7N9/&D$.JC6QH M-T*Z6DA$L^[D2
M&/G@= >*Y2RL=0L?"%C'_8^J;[+Q5]K>!H6>7R=^\-_M?+WR>?>@#TS2?&]C
MJ6J2Z9=65_I5_'$9Q!J$00O&.K*0Q! [\U03XFZ2XBN6T_58])EE$,>JO;@6
MS,3M!SNW!2> 2N*Q-3BN/'_B>UN-.L;ZTL[&PNHFN;RW: O)*FU54, 2!U)Z
M5F75S?:C\,K;P+%H6IIK)ABLI-ULP@BV,,R>9C:5PN1@YYH ].T_Q!9ZEJ6J
MV$"RB73'1)RR@*2RAAM.>>#[5R&M_$ETTWPUJ.C:=>SVVJ7PB<>2I?8&P5 W
M8#GM]#TJ"RN[CPGXO\2176E:E<C4?(DLY+2V:19"L00J6'"G([XZUC6NG:G8
M_#7P==2Z9>%]+U1+JZMDB)E2,2-DA.IQG- 'KEE<F\LH;EK>>V,B[C#.H5T]
MF )&?QKB;'QC._QAU/P[,[?81:((,C@3* [@'U*N#^ KLM+U&+5M.BOH([B.
M.7.U;B%HG&"1RK $=/RKR;4/#VMWGAS7-=L+6>'6CKLMS:(Z$.8_]2..N-AS
M^ H Z'P#XYE\077BS[3YLD=C=&:U54RS6Y4A0H'7F-B/]ZMK2O'5IJ.LP:5<
MZ5JVEW-RC/;?;X%03!1D[2&/('.#BN0OM!UCPCK)'ARTEE:3PT;1'2,E1/"<
M@GMN(;@'J16=IMHI\4^$-0MK7Q)<-!,ZW]UJ$<N%=XR!PW3G/(&!QS0!W]CX
M]LM4U>XTZPTO5+A[6[>TN9EA410LIP69BW3CMS[4RT^(%IJ-RHT[1M9O+%IO
M)&H0VP,!.<9!+!BH/<#%4_!^DW1TKQ;:S12VKWFK7OE.Z%<JYPKCU'O5+P9X
MC;P_X>TWPWJ.A:O'J5IMMF6&S=XFYQO$@&W;WZT 5]/\<3:1K_BZ.[LM8U*"
MUO\ (-M%YB6T009^\PP.IP,FO1=-U&UU?3;;4+*42VMS&)(G'=3TKC-#L+N*
M?Q\9+69!<W;M!N0CS1Y0&5]>>.*T_AK:W%E\.M$MKN"2">.WP\<JE64[CP0>
ME &/XX\0>)=-U_1;>SBAM=)GU*WMY9R^Z6?<PR%&/E7L2>37H5<3\1+*ZO7\
M-?9;:6;RM9MY)/+0ML4,,L<= /6MSQ!XBC\/MIWFV=Q.E[=I:[X0"(F;H6R>
MF?2@#8<,R,%;:Q! ;&<'UKR[6HM>\(ZOX<,/BC4=3OM2U!8+BUN-IBDC/+LJ
M ?(%'I7J3,$0L<X R<#->0:3XF:;QKJ/B+6_#_B#S%_T7385TV1A#"#R^<?>
M8_D!0!NR#5O&7BK7K6UUV]TJRT<I;PK9D*9)RNXLY(.0,@8H\/'5_'GA#2[F
M?7[S3W@>6&]-B%1YY$8J#NQ\HXR0/6JZZA=^"?%_B62?2-1O+;5FCN[.2SMF
ME!DV;61L?=.0.O%9=XNM^#_A39:/:V%\^K:F[M</:P-+]D61BSD[1]X X'O0
M!T?@/6=6N= UMI)9=7%A?S6]A,Y57N43&,MT/.1NJ3P%K.O:IK/B:#7FA$UG
M<Q1QP0',<0*9P#C)//)J_P"!K[3WT=-*TW3-2LH-/B1!]MM&A\S.>1N^\<@D
M_7WJKX/LKJV\7^,YI[>6**>^B:%W0@2 1X)4]Q0!8^).HWFD^ -4OK"X>WNH
MA'LE3JN9%!_0FNFMV+6L3L224!)]>*Y7XHVMS>_#G5[>TMY;B=ECVQ0H69L2
M*> .3P*BM/&S7]J;+3]$UF._-NP@:[L)(XO,"':&8C &0* )K7X@V<NJVEC=
MZ/K&GK>R^3:W%Y;!(Y7[+D,2">V0*;>_$2PM;S4K6WTG6+Z739"EU]EMU81C
M:&W9+ $8/UXZ5YM]FN;F'PY?3VGB:[UBUU6WN=4DN8I?+A D&X*IX(';:#Q7
MH'AVQNX=4\=-+;3(MS>;H2R$"0>2!E?49XXH T[WQUI%IHVF:C"MS>_VH ;*
MVM8]TTV1GA21C'?)XKA+_P 5:G>O\0IX_P"T].^R:5"\%O<G8\#[7RR@$@9P
M.0:CT>TU+PW;>"=>NM*OI[:TL9[2ZAA@9Y;<NQ(?9UQV.*GN[>^\377Q!N;'
M3+^..^TF&*U^TV[1&9E5\A0P^GYT =M<^+;30M&T9;I+J\U"^A006MLF^:9M
M@+$ D#W))%0_\+$TF/1=6U&YM;^VDTD*;RRFB43Q@]#C=@@]B#7+O)=1ZGX0
M\7C2M1>QM;&2RNX/LS>?;MPN[R^I&5(X['-9OB2PU+Q)8>-]=M-+O8[>[L(+
M.TAD@999RC99]F,XYP,B@#OT\=Z>-+O-5NK+4++3K=%=+FYA"K<;L@",9+$\
M=P.HKG/^$NO-6^)/AJU2QUC2[:6&X>2"\01K,-ORG"L0<>_(K7^(.F7UWX9T
M^>PM6NGTV]MKU[1!\TJ1L"R@=SCM60=5?Q+\2?#-_9Z5JL5K;0W FENK-XE1
MF7@984 >@ZG?KI>G37CV]Q<"(9\JVCWR-[ =ZQ-%\:VNKZI+IDVFZEIE_'#]
MH%O?PJC21YP64JQ!P:3X@2ZO#X1N&T83_:#)&)&MEW2I$6&]D'=@N<5Q&B64
M$7Q%TR]TVQUXV#6$]N]UJ"2G=*<$??Y''? !- '1Q_%;1Y+.UU#^S=832[AU
MC_M![8"&-V. &.[/7C(!%:^L>-+/2M672H+#4-4U#RQ,\%A$',2'HS$L ,]A
MG)K@YM'U(_LZQZ:-/N3?#R?]&\IO,XN48_+C/09^E:]O=S^$/'VM7FH:9J%Q
M9ZO%;O;W-I;--M9(PAC8*"5Y&1VYH UOAAJESK'A.6\NYIY7:_N0OGD[U42'
M:ISTP.,=JP?B99ZUH>E3:U8>*M6A:6[BC%NK+Y:*[ $#C-;OPOM[FW\*3?:[
M2>UDDU"ZE$4\91PK2$C(/L:C^*]C=ZAX+$%G;37$OVVW;9$A9L!P2<#L* +B
MA/ NFW.H:QK^IZE$[)'&EP [ER<!4"@9)J33/'%G?:I_9EUINIZ7>M"TT4-]
M"J><B]=I5B"1Z9S6=\4-%O-6T;3;BTBN9_[/OX[J6"U<K*\8!#;"/XAG(_&L
M_P /Z9HFIZLMY;0>)Y+BS@D>*75?."*6&TJ/,ZL<]O2@#0M?BEI%U#87:Z;J
M\>FWKI$E_);!85=C@*QW9Z\9 (]ZTM>\:1Z!=RQ2:'K-W#!&))KFUM@T4:GO
MDL"<=\ UQ)TC4O\ A0>CZ?\ 8+G[;&UL6M_*;S%Q,"<KC(P.:D\31W=]XFUZ
MVU>#7Y4\E4TBWT]9! X*<LS+QNW==QX% '8ZEX]TG3SHX6*\O&UB%IK(6D.\
MR!0K8ZC!(8>W7)%4+OX@QR^$O$&H6.G7T6I:3&PEL[F$!XGVDJS -@IW)!Z
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MA6V,D;1OQ&5) 0;L*WJ:A\6^/=7\,7UY*VH^'I(;9P1IP9_M+QY'\6<!O;%
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MI ZJ3SWQ7J= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&=L#G &30!YY'\/M5.GV\MQ=VLFJ3:[%JU\REA& K#Y$XR<  #.*](KB=/\
MBIX=OVM?,34;*&[8+;W%Y:-'%*3T ?D<UVU '-0>';F/XBWOB%VA-I/IT5JB
M9.\.KLQ)&,8P?6G>+= NM=_L;[*\2?8M2BNY/,)&47.0, \\UT=% '*>,/#=
M_JE[I6LZ-+;)JNENYC2Z!\J:-P Z-CD9P,&JM_HOB77_  =KNFZE#I%K<WL!
MAMEMF<JF1SO8CU]!7:T4 <A>>%KVXE\'LDL &C2!KC+'YAY6SY>.>?7%17'A
M*_EU/QG<K+;[-;LDM[8%CE6$3)EN.!DCIFNTHH \^U3PYXG;PK8Z!:VFA7MH
M+!;:<7K/E)0,;UPO('YYJM;>!-=\.G1[_1[JROM0M; 6%Y'?%@DZ!MP*L 2"
M#P,]J]*K(\0^)=,\,627.I2L/-<1PQ1(7DE<_P *J.2: ,YXO%P\.DI;Z$=5
M:7+PY?R#%_=SC);'?&*@\!>&;[P[;ZI)?BTA>_NS<+:61/DVXP!A<@<G&3Q6
MIH'B:+Q TZ)INJ6,D(4LM_:F$D'.",]>AK;H Y#4O!<6L>.FU?4(;6XT]M+>
MR\N09<.S@DCC ^7(SG/-94'@K7MWAF*ZO+6>+0M0>1)6=M\EML*H#\OWQD ]
MN.M>B55N=2LK.ZM;:XN8XY[IBD$;'YI"!DX% '):WX&EUWQ!KUQ<31I9:EI,
M=BNTGS$D5V;=C&,#([]JI'PSXNUS^R-.\02:6FF:=/'/)):LYDNFC^YP1A1G
MDUZ)10!R">"(A\2IO%#.IA>U"K!_TWY4OCI]S S[FL_1?AV=#T'Q38V\J-+J
MID2V9V.(H=A$:'C@ ENGK7?US&M>.;#1=;_LAK#5;V\$ N&6QM3-LC)(R<'C
MD&@"CJ'A&_N_!OAW1XY;<7&FSVLDS,QVL(A\VWC/TZ5TFOZ8^L^'M1TR.X:W
M>ZMWA65?X"P(S2Z)K=AXATJ+4M-F\VWD) )4J58'!4@\@@]JT* /+K;P=XL,
M?AF*6#0[>WT&XB?R[=WW7  VLV=N%."3CG)JYJWA;Q1X@\1:?-?0Z+;P6-^+
MF/4+<O\ :3$I)$?([YP><5T5SXST^VLHKIX+Q4DU%=- >$H?,+;0<'JN>]='
M0!2U8:D=*N!I!MQJ&W]R;G/E[O\ :QSBN.L?#?B;6_$]IK7BC^S;86-M+!;P
M6#,Q<R !F8MVP!@5N1^,;"33=6OA!=M'IEW):3+'%O=G1MI*@=1FNA5@RAAG
M!&>1@T >42>"/&K^"!X/6XT9=/MV18[@M)YDL:R!U!&,*>.3ST_&NRMO#UW#
MX^?76DA-JVEK9A03OWAPV<8QC ]:Z:B@#S71? VN6OAF_P#!NHFPDT*59A#=
MQ.WGC<=R94C&0??M6KH-CXUM9;&SU*+0&L[;"2W46\RS(!@87&%;IGFNUHH
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MT^]@DUQI3,9&CW+-/(^2JKWSG KT.JMY?V5E);1W=Q'$]S*(H%<\R/@G ]\
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MZL[FT*RH]O)L).=N&]1ST]A7;5E>(]!MO$V@W6D7<DD<%P &:,@,,$'C/TH
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M7PJT+2K[SA UM!<;H7VMOP'SGZDU8U+PGINC6?BG6;0W'VK4;)A.'E+)\L9
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M[4K^Z"W,=T;B:0-(61PX'3 &1T H T-$T;^QH)4.H7U[),V]Y+N7><X_AX
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M19/%'CA_$OV7[2+@+_I1'%IY8V;<]NO2@#T.ZU;3K)8FNK^V@652T9DE50X
MR2,GD <UE'Q/;7>L:5;:3?Z3=P76]I2+M3)L .#&H^]R"#]#7ENAV/\ :<'P
MRM]3B,L'FWK0I+_%$HS'GU& /PQ7:>);2WM?B-X*-M;Q1MF[4;$ X\K('';)
M/YT ;OBCQ=IGA[3[P-J5@FI1V[RPVL\RAG(!(&W()Z=J6T\6Z;%X<TG4M;U&
MPT^2^M8YL33"-2S*"0NX],FO-].&C7/P^\8W&K_96UUY[L78N"/,4@D1@9Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5!=V-I?Q+%>6L-Q&KK(J31AP&!R&
M /<'H:GHH 0@$$$9!Z@U#:6=K86JVUG;0V]NF=L4*!%&3DX XZDFIZ* ,JV\
M,Z#9:BVHVNC6$-ZQ),\=NBOD]>0,\UR'B#P3K&J:GJ#PV/A*:&]!47-W8'[3
M$I&.H!WD>I(KT2B@#(T+P]::)I]A"%2>[M+5;7[8\8\UD';=UQGG&:FU30-'
MUL1_VKI=G>^7]PW$*N5^F1Q6C10!EW7AO0[ZPAL+K1[":T@_U4#VZE(_]T8P
M/PIESX5\/7EE!97&B:=+:V_^IA:V0K'Z[1CC\*UZ* (;6TMK&UCM;2WBM[>,
M82*) JJ/0 <"LV\\*>'-1O&O+W0-+N;E\;IIK.-W..F6(S6Q10!4N=*T^]T\
MV%U8VTUF0!]GDB5DP.GRD8J/3M$TK2;5[;3M.M+2!^7CAA5%;Z@#G\:OT4 8
MUMX2\.6;A[;0=,B82"4%+5 0XZ,..",G\ZNKI6GIJ$NH+8VZWDJ>7).(@'=?
M0GJ1]:N44 9%EX6\/Z;?&^LM$T^VNB2?.BMD5QGK@@<9K2:V@:Z2Z:&,W"(4
M64J-RJ2"0#Z' _*I:* ,V]\.Z+J5]'>WVDV5S=1#"330*[*!TY(IT&A:3;"
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M&9'\Q)([1 RMZ@XX/TK:HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF?EP.*Z^XT37M8UOPIJVH0V5O-ILUP]U%#,74!D*KM) SVSTJ.7PEJ-EK?B
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MZI%$+JWNIFB,<D8(#*P4Y!!Y&* .%THS'PCX;-PJ+-_PF/[P(<J&\YLX]J]
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MCE&XXR,<]B*Z[P]#K'GS2ZMH^DZ>NT");.0R/GOEMJ\=.,4 =#1110 4444
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MMEMV9E?<.^W(;\#76Z%J%SKOCS6;J*[D.DZ?%'9Q1H_[N28_.[XZ$@%1GW-
M'845P7Q$@ULW>EW-JVJMHL/F&_BTF8QW&<#:PQRP'.0*P-2\1S:G+X;T30[W
M6+[3KFTENI;FTE5+N<(VW:78KMP<YQSQ0!ZO<W,-G:RW-S(L4$2EY'8\*HY)
M-+;W$5U;17$#AX94#HXZ,I&0?RKR&]M/$'_"*>+K._&M1:.-/,UI)?W"M.K@
M'=&65B64C'7WKO? >E+IGA+3BMY>7/GVL,I^TSF39F,?*N>B^U %SQ#XDM/#
ML%LT\-S<SW4ODV]M;(&DE;&< $@< 9R2*T[2=KFTAG:"6!I$#&*4 .F1T;!(
MR/K7G7CW11J'Q$\'$ZCJ%OY[SQXM[@ILVQELKCH3G!/<5.%O/%WCO6M+FU74
M;&PTB.)(XK*X,+2NX)+LPY(XP!TZT >B56NM0M+&6VCN9TB>YD\J%6/+OUP*
M\>;7?$%_IVB::NM7$5S'XBETR2]C.&FB4'DCH3@_3(S6IXS\+1V^J>#K0:OK
M+B34V4RR7SM(-RDY#'H1C ]!F@#O[CQ%:6_BFS\/O%,;JZMWN$< ; JG!!.<
MY_"M>O+M>T4W/Q1\-Z6NI7\*II,RM<1S$3NH(ZOUR>YZUN> ;F\CO?$>BW5]
M<7L>F7PCMYKE]\FQD#;6;O@YY- '07.OVMKXFL=!>.8W-[!+/&Z@; L>,@G.
M<_,,<5JUYSXNTS^UOBIX;M#>7=HK:?=EI+24QR$ Q\!AR/PK$U#Q/K?A"Q\6
MZ1%?3Z@^GM:_8KJX(>6,7#;<,3]XKU!/XT >PUD>'?$5IXFL)KRSBFCCAN9+
M9A, "60X)&">*X/2;?Q/8^(-)ELX/$KV\DH34?[5NHY8FC(Y=0&.T@\X48K+
MTG6;S1/A5JT^GR>5=3Z[+;),1GRO,F"EOP!/XXH ]GHKS+4[6_\ "'B3P[:V
M^NZI>6^LRO974=W<&0@E,B5">4(/IQ6$?&GB*#2+/1[1Y+K6=$N9I=6+,2TE
MM W?W=6&/7% 'M5%<1X2UN3Q9XJU?6+2[E;1;:..SMD#'RY),;W?'3(W*,UV
M] !1110 4444 %%%% !1110 4444 5I=.LIKZ*]EM('NHEVQS-&"Z#T!ZBK-
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5CZYX<M/$,VFO>R2^787(NEA4C9(X&%W9'(&<UL
M44 8FL>%M/UB?3;APUO/I]TMU#);A5.X?PGCE2."*\MO],O;6XO1X?LO&EMK
MC7#-;^8J&V!+9RTF,%#[D\<5[;10!C:7H$5CK%[K+22-?7\,*7"Y&P&,$?*,
M>YK+O/ 5M)JUUJ.FZMJ>D2WA#7:64H"3'INPP.&]Q76T4 <YJ_@VRU:&P;[9
M?6U]IZ[;:_@EQ,H(P0200P/?(J*?P3!>^&;[1-1U;4[U+W!EGGE4N,8X7Y<*
M..F*ZBB@#*OM M=0UK2=5E>43Z9YODJI&UO, !W<?[(K/N/ VCWBZXET)I4U
MB1)9U+XV,@ 4H0,@C /UKI:* .=T/PM)HUX)Y=?U?4 D9CCBNYE**IQV"C)X
MZFHT\#Z;'X*N/"PFN?L4X<,^X>8-S;C@XQU]JZ:B@#F=9\%V^J7UC?V^I7VG
M7UG";=+BU<!FB/56!!!Y&:Z"2UCGLGM)\RQ/&8WW=6!&#GZU-10!P;?"VQ>Q
MMK.36]8D@L9$DL(VF7;;%3E<#;\V.GS9XJ_J'@*WU75#<7VL:K/9&X6Y.GO,
M/)\Q3D=L[<CIFNMHH K:C91ZEIMS8S,RQ7$31.5Z@$8.*Q9_!FGW&E:!I[37
M BT-X7MB&&6,:;%W<<\=<8KHZ* ,*Z\):9>ZOJ.H72R3'4+(6,\+$;#&"3Z9
MSSZUF6/P]L[:]L9KK5=3U"#3VWV5K=RAHX6 P#P 6('3/2NPHH RM&T&UT.7
M49+9Y6-_=O=R^80<.W4# Z5B+\/K:VO)GT[6M7TZRGE,TMC:SA8BQ.3C()4'
MN ?RKL**  <#%9&F>';/2Y]6EC:23^U+@W$ZR$$9( (''3 K7HH X$_"?2VT
MX:6VKZP=,BD$EO9FX'EPD-NP/ER1GUS_ %K?;PG:#Q7+X@BN;J*:XA$-U K_
M +J< 84L,=0/0UOT4 </=Z';>$/!=]I-G:ZIJ]K>,\,%D@\TQ;PQV@\;4SGD
M],UH_#_PRWA/P98Z7+@W04R7# YS(QR>>^.GX5T]% &'K_AV76W@DAUO4M->
M(,I^QR* X/7<"#GIP:S&^'.CIH^FV-G/>V<^FEVMKV"7$ZLY)<DD8.XDD@C'
MTKKZ* ,.Q\,Q0:3>Z??:A?ZHEZI6=KR4,2I&"%P %&/2D\,^&CX:M6M5U:_O
MH JI#'=NK"%5Z!< ?KZ5NT4 96HZ#:ZEK.DZI,\JS:8\CPJI&UBZ[3NX]*S]
M8\&0:EJQU6SU*_TJ_DB$,TUDX'G(.@8$$9&>#UKI:* .7A\!:/;6FC6UOY\<
M>E71NXCORTDA!R7)'.<DGI5[Q+X9M?$UG!%-/<6L]M,L]M<V[!9(I!W&<COT
MK:HH YZT\)00:QIVK3W]Y=WUC;26RRSLI\P.<DM@#GL,=JN:7H-KI.I:K?0/
M*TNI3+-,'((5@H7Y>.F!6K10!S?B#P?#KVK6>J#4KZPO;.)XH9;1PI <C.<@
MYZ8Q3+3P)H\&C:AIUT)[_P#M([KVXNI-TLS=B2,8QVQTKIZ* .;T3PF^C7:3
M/X@UB^CB4I#!=3*44>^%!8^YJ"/X?:/';:Q9%[E].U1_-EM&D^2*3.2\?=3D
M _45U=% '*Z7X%M;'5[?5+W4]1U6ZM$*6AO9 P@!&#M  Y(XR:T[/PWIMCK6
MJZM%#_I6IA%N">A" @ ?GS6O10!A:5X2T[1?#,V@Z?YL%K*) 6C;#J7SD@]B
M,\?2KVB:4FAZ+::9'<3W"6R;!+</N=O<FK]% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&9R-@_>)CGY3W%9LXU_5/AMXPL/+U2^L54)I4E[;LMU*N 6!4C<V#D D9(H
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M\/:3?S2Z!IDES#YD_P#:$SJ%8\A% Z\'D^M ';SW,%JJM<3QPJS!%,CA06/
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MG%+'/$DL,B21N-RNC AAZ@CK3Z\HT'Q)XC\,>#?#VH:E9Z?+H#Q00.;=V\Z
M/A5<YX(R1D#IFNFMO&X@@\3_ -JQQPSZ([.50G]Y"5W1MSZ]/J* .QHK-\/W
M=]?>'["[U*%(;R>%9)8DSA"1G'-<-XF\?ZMX7U25KJ;0'M(YE4V27#?:S&6
MW8Z9YSM]* /2ZBDN8(IHH9)XTEESY:,X#/CDX'>N1OO$VLZCXEGT+PS:VA>S
MA2:[N[UFV1E\E$55Y)(!/M6'XKU671_$G@W4O$CVMLUO]L>X:!B8P!%QC(!Y
MXX]30!Z?17G]SXYUBW\"/XH;3;=5GNH4LK9I#N,3R*@+L. QSGCI5FV\4ZWI
MGBVWT;Q);V"Q7MM+<6\UFS'R_+&65MW7CN* .WHKS7_A.O$A\.GQ>--L?^$?
M#;_(+M]I,&[;YF?NY[[?UJ_)\0&L1XE%_!&&TV*.YLQ'G_289!^[_$MA?J:
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M#;%8CV/08K<GT3Q%H?B^_P!9T&"RO;;5(XENK>YF,31R1@@,I .1@G(KN:*
M/+8/A[K2>'+-W;3_ .V['59M0BC8EX)!(3E"<9&03SBNDM=/UJ_TO58;_1=)
MTYYK1X;<6TN]BS*0=QV@ <BNHNKJWL;66ZNIHX+>)2\DLC!551U))Z5)'(DT
M221L&1P&5AT(/0T <4OA'4G^$$?A7[1'!J L%MS(K$IN'49'.#C!]C69!X8\
M1S>(_"^IR:5I.GVND,T;6UO.68JZ%"X.T#C.<=?>O2J* .+T;2-?T'Q;JYAM
MK2YTC5+S[69S.5DARH#+LQ\W(XYK'7X?ZM_8U\$FMH]1CUY]7L2S$HWS9"O@
M9&02#Z5Z910!P:^'M?U_Q)%K>NP6=DME:2P6EK!,92TD@P79L# QP!4#^"]5
M;X4Z-X;'D?;[22U:3Y_DQ'*K-@X]!79ZQK-MH=FEU=).\;RI"!#&7.YC@<#M
M[UH4 <Y-JNJ+X^M-*@6WDTUK)YK@@'S(7! 4D],-G@>Q]*V[ZV%[I]S:EMHF
MB://ID$?UI+F[LK!HWN9H8&GD6)"[!3(YZ*/4^U6: /,!X6\5W'PVF\(75I8
M*;>".&VNH[DD3;'!R5V_+\H_.NHUW0;S4=?\+WL'E^5ID\DD^YL'!CVC'KS7
M3T4 >:Z/X7\1>%K5]&T_2-$U&Q65FM;NZD*/&C'.UUVDL1GJ#7I$:".)4"J@
M QM4<#Z54U?4X=%T:]U.X5FAM(6F<(,DJHR<?E56+Q'9RSZ1"([C?JD1E@(B
M)50%W?,>@XH S?"7ANXTK0M5T_40A%Y?W4V(VS^[E<D?C@UAZ!X=\2^'[6VT
M0:1H5]9V[A8]0E<JYASG#)L)+XXZXKT6B@#A[G0_$&@^+=0UGP[;65Y:ZFD8
MN+2>8PM'(@VAE;!&,=J@UGPQKU]J6C^)X[?2Y-9M8'M[JQD<F"6-CG"N5R&'
M')%=_5=;^T>_DL%N8FNXT$CPA@753P"1V!P: .;.EZOJ7A+7+2[TO3-/O+RU
ME@@CM9-PPT94;VVCN>W:N1N[76=#\7>"+2RM;:ZU"VTFYC>*28HK8\L'#8//
MX5ZU5>2QM9;Z&]>WC:ZA5DCE*_,BMC(!]\"@#BK'P=JM_!XGO=;EMH=2UV 6
MZQ6Y+I;QJI"C) R<L2:V?!L6OV>CPZ=KEE:0?8H(H(9;><R>=M&TL00-O1>/
M<UH:5KUKJ]]JEI DBR:;<?9YBPX+;0W'M@UJ4 <5XBT'6'\;6/B'3K*RU&.&
MS:U%M=S&,0N6)\Q3M/4'![\5@Q^ _$'_  C;Z;,+(S?\) NIAXI"$:,G<P (
MR".F*]3K(U3Q#::3J^D:;.DAFU25XH2HX!5=QS^% &1K?A:XUCQC!?.4&GG2
MKBQF^;Y\R'L/IFN7NO"_CB?P.?!SV^DR6\0CCCO_ +2REXT=6'R;>&P/7%>K
M44 1[9$MML>TRA,+N/&<<9]J\\M/"FNZEXSAUK4M/TW2A':S6]RUC,7:]+C
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M%JNH/I<RR6JSLNU0!C;@#GZGFM>W\'VEMH6LZ2MQ,8M5FFFE<XRAD ! ^F*
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MK6=EV8P0 Q R^,\9/4"JUQ\/BNH7DVD^(M5TFVO9#+<6MHRA"Y^\RDC*$^U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M67XAU"_TS1Y;C2],?4;W(2*W5MH))QDGL!U- &I17!?";Q!J_B3P]J=YK4JO
M=QZK-#M0?+&%5/E7V!)KO: "BBN6^(?B&3PUX+O;RV/^G2[;>T4=3*YVKCZ9
M)_"@#J:*X?X>>*I]4\!&ZU<O_:6F>9!?J?O;X\G/U*X/US6;_P +N\-+#;W4
MEIJT=A.=JWC6C>47[J&[D>U 'I5%<EX=^(6E>(=4N-,%M?:?>PQ>?Y-_ 86:
M/^^ >U9C_&#PZD[NL&I2:9'+Y,FJ):,;97SC!>@#T"BN.UOXD:3HNM#2/LFH
M7U\\"SQ165N9C(K>F/SJQIGQ!T#4_"]YX@%P]O:6+,ETLZ%7A<8^4KZ\C'KF
M@#J:*\<U;XDRZ[XI\'6^EV^L:?:W.HKYC7$!B2ZB.,8/\0KH+WXQ:#9SWR?8
M-6F33[A[>\FAM2T<!5BN6;H <'% 'H=%</I7Q3T+5M:L].CM]1@%_D65S<VS
M1Q7)'78QZT[6/BAHNE:K=:?%:ZCJ,EES>/8VS2I;?[[#@8H [:BN.U7XF^'M
M*L-'OC)<7-OJZN;1K:(N6*XRN.N<MC'KFH[#XDZ=J=EK!@L-2AU'3(?.ET^X
MMF6<KV(3J: .UHKS_P"&'C^[\9:/"=0TZ[CNRLCO<BV*6S@2$!4;H2!@?4&E
M^)GCJ]\&C14L;.69KR]2.5Q 7'E_Q*N/^6A[#ZT =_17(7WQ$TO3=%L;^\L]
M1BN+^0QVNGM;-]IE8'D"/KW'YBKOA?QGIOBHW4-LES;7MFP6XL[N(QRQYZ94
M]J .BHKS?XL^(=1T4:%;6^HOI.GWUV8KS4D3<T*@9 &>!GG\JV]"QX6\.7FI
M:OXK?5].'[^.\F"_)'CH"OWLG^= '6T5P^D_%/1-3U.SLI;74K#[<<64U[:M
M''<GML8\'-/UCXFZ1I>L7.F6]EJ>IW%F,W?]GVK3+!_O$=* .UHKS#Q!\4+O
M2O'FEZ5#I&H36$UH9Y4CLV::0D97:/0=_3FM*V\3?;OBLNF_;-2M5CTTR&PG
MM0D4GS9\T.3GOMZ?PGF@#O:*X"3XO^'8[ESY.HMIL<_V=]46U8VROG&-]7]=
M^(VE:%K2Z.;34+V^D@6>*&RMS*9%)[ ?3- '845A^%O%>F^+]+>^TTR!8Y3#
M-%*FUXG'56'8\BH/&FLZSHNB--H>E?;[M@W+MMCA4*278^G'3O0!T=%<C\,=
M7OM=^'VF:EJ,YGNYQ(TCD8S^\8#]*Z34KJ6RTNZNH+62[FAB9TMX_O2L!D*/
M<]* +5%>;?#[Q/XBUWQIXCM=>B2T-HD0CLHV#+#G)Y;NW(R:ZCQW?W6E^!-:
MOK*9H;F"U=XY%ZJP[T =#17GMO\ $:ST/PUX7&L+>W>HZK8++&+>'S'F<*N1
M@=R6JPGQ-L+WP[KE[96-^FH:5'F6PN+9EF4G[I*=<>OH : .ZHKS?PG\3_[0
M\"S:YK.GWT36=OY]Q,+8I%+EB/W1/#8P*U=(^)6DZM9W6H?8]1M-,MK?[0U]
M=6YCA=>F%)^\<\<4 =G17#Z3\4M%U34[*RDL]3L1?G%E/>6ICCN#V"L>N?ZT
MSQ'\3-+TN^O](L[74M0O;6(FX:PMC*ML2."Y'3'Z4 =W17F'@#QRL?A/PO%K
M$]S=7^M3SQQ2M\W*L3\Q[<$5V)\6Z:OBJX\/.9$NK>U^UR2,,1A/K0!O45Q&
MF_$_2M8U*&WT_3=7N+2:;R8]02S;[.S_ ._TK(\,_$^\U?QKK&D7.CZA]GAN
M%AMS'9M^Y&#DRG^$G'% 'IU%><>#_&UG)I_BC6=1U:^-G9W6YXKZV$36@Q_J
MP 22<\=N<<5IZ'\3-'UK5K;36M-1T^:\4O9M?6QB6X _N$]: .THKSZ\^+^A
MVMQ?Q+I^KW T^9X;R2"T+I!M.-S,. #S7<:??VVJ:?;W]G*);:X021N.ZF@"
MS17(>)/B#9^&+Z2"\TC6)+:%5>:]@M&>",'U?I2ZW\1M#T2+2I7^TW2:K&7M
M#:Q&0R< @ #G)R,4 ==17,>&_'>E>)!?HB7-C<Z?S=6]]$8I(EQG<0>W%>>^
M./BO%J6@(OAQ-7@1[Z*)-26W9(9 &^90_O0![3156YFFATJ:>"/SIT@9XX_[
M[!<@?B:\F^&]SJ_B\P:S+XZN/ML4Y-]I'E(%1<G"8Z@>] 'L=%8>G>*K#4]5
MUK3H%E$VD,%N"RX!)!/R^O2O/?%_Q$^U:3X6UO1Y+Z.RFU4Q3PQ)^\F5>J[1
MUR>U 'KU%<MX:\>Z7XEU"YTV."\L=2MU#O9WT!BDV^H![5B^#O&$&IZMXHO+
MK4-0BMK7RY7M-0MA!]B7:<]\G.,\XH ]#HK@K+XM:#=WEJCVFIVME=R>5;:A
M<6C);S-V <\<U>UWXBZ7HVLMI$-GJ.J:A&GF30:=;-,T2^K8Z4 =?17EWB7X
MJ7&F:]X8AL=)OY++44:>9?L;&9UQPJ#^\#R1Z8KTFQNA>V,%T(981,@?RYEV
MNN1T8=C0!8HKY\76_$5U:>*]:;Q[+I\FE7T\=O92JA655)*K@X//0=:]'T_X
MB06?P^T37/$"2+?ZB@6.UMXBTD\F<#8GOP?QH [RBN*M?B7IEYIVJ21V.I1Z
MCIT8DFTV:V9;C!Z$)U(YS]*Y3X:^*9;[3=3\7^(M6U:.*-7+QW";+-5+''E<
M?,PVXX/?% 'L%%<1I'Q1T;5-3L[*2SU.P^W'%E->VK11W)]$8\'M^=1GXIZ7
M)K=UI%GI>KWMW:W'D3"VM2ZQ\XW$C@#/<T =W17"M\4M+?7[O1;33-6O+VTN
M?L\XMK8NL?.W<2. N>YJ36/B?HNE:I<V$5KJ.HR68S>-86S2I;#_ &R.G>@#
MMJ*Y74_B)X=TOPW9ZXUVT]M>D+:I A:29C_"%]?6N7\+>,;SQ'\8;VWV:E9V
M,6CAA8WL1B*2>8OS;3Z@]: /4J*YWQ3H.L:T+8Z5XFN=%\H-YGD0+)YN<8SN
MZ8P?SKSWX;6OB[Q3IJZS=^.+Y8X+YX7M?LZ%9%0CJ>",T >R45P=_P#%K0+&
M]NHQ;ZE<V=G+Y5U?V]JSV\+=,%Q6IJ7CK3--UK0]-\NXN#K(#6T\*;H]IZ$G
M_"@#J**** "BN,\4ZO?V/C[P;86UR\=K>O="YC&,2!40KGZ$FFW7Q,TNV%\Z
M:=JEQ!I\SPWL\-L6CM]IP2Q],<\=NM ':T5%;7$5W;17,#AXI5#HPZ$'D5RM
M]\0;+3+YX[W2=7M[*.?[.U_):$0!MVW.[^[GC=TH Z^BN=UKQC9:3J46F0VE
MYJ.HR1^=]FLHM[)'TW-V ^M,O?&MA8:397EQ:7Z7%Z_EVU@;<_:9'[@)^N?2
M@#I:*YH^-;&VT.ZU75+._P!+BMW"-'=P%7=CT" 9W9Z<=Z32O&UGJ.I'3KBQ
MO]-O6A-Q%#>P[#-&.I7GG'<=10!TU%<EH/C_ $_Q&L<UA8ZA]B*NTE[)#MAB
M*CD%B>OTKD_&/Q#;4-%LI-%M]6M[>;4H(XM1\DI#,N_# -UP>?8XH ]9HKEM
M=\<0:!=SQSZ/J\UM;*'N+N&U+11J1G.[O@=<=*DU;QOIFES:9"(KJ\EU.%YK
M-+2(R&4+M.!Z<,#SQP: .EHKEK7Q_HLVAZAJET9[%=.D\J[@N8]LL3\87;W)
MR,8ZYJ?2/%J:I*XETC5=/A$)G6XO;?RXR@[[L\'G.#S0!T5%<9#\2M*D:"=[
M'4X=+N)1%#J4ML5@<DX!SU"D]"1BNSH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *0]#2T4 >=_""RN]/\.ZVMW:S0.^M7,BK(A4LI"8(SV.*Z3PGXH_
MX2FTNY_[,N[#[/<-!MN5P7QW%=!10 5Y7\0+#7O%/C_1-&TA$AM]-7^T)+JZ
MA9H#*#\JG&,GV]Z]4KBO$/@*^US6IM0@\9^(-,CD"@6MG<%(TPH' ]\9^IH
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M0HD7 &,^V*DTW2M07P-\2X6LK@2W.IW;P(8SF52>"H[@UN?\*LU3_HH_BO\
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M[^#NGW=EX&N[>[MY;:5]0N"%E0J<$C!P:C_X59JG_11_%?\ X%FC_A5FJ?\
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M)IS7D$_(;=&?WBGG!P,$5U-<AX\\%_\ "7PZ8L<WD26UR#(X."T# K*GXJ:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX;V^E=U7GOA:_71/&GB/2;^VNXY]0U,W%JXMV:.1&0<[P,#H0<UZ%0 4444
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MW;<.V>.?3-)K'C^;2OB#%H7]EW]S:&R\YFMK4R.SEA@K@\H >3ZUSL&FWO\
MPS]J=D;*X^U,LVV Q'>?WN1A<9K5U6[/A_Q[H>M7UM=FP;1VM&EA@:39+N#8
M8*"1D4 -D\<OHOQ!\2VEW#JU_!%';/!;6<!E\E3$"[8X"C)YYJ_KOB;[<_@F
M^T:]D%EJ6IJK[#M\R,QN=K#ZCD>HJ7PU%*_Q&\5WIMYDM[F*S:*22,J''E#.
M,^G<=JXJSM;W2_ G@R_GT^\,>F:R\]U&D#&2.,^:-VS&<<C\Z /5;#Q'8:@=
M4$;2(VES-#<K*NTJ0H;(]00>#4VAZS:^(-'M]4LA*+:X!:,R+M) )&<>AQD5
MYK\0K>_L/$R0Z2C;/%L":=,5X\N16'[S_OT7'MBO4=.L8=,TVVL+9=L-O$L2
M#V Q0!QFE>+9+*X\<7FL7,LEAI%\%C54!,<?EJ2 !C/)K1TWX@Z1J6MP:6MO
MJ-N]TK-:SW-L8XKD*,GRV/7CGH*XS4].OG\/?%)%L[@O<W1,"B)LRCRT&5X^
M;\*Z+Q#9W$FJ^ 7CMI6$%WF4JA/EKY##YO09XYH T-+^(.EZSJWV&QLM4FB,
MCQ+>BT/V=G0$LH?/7@]JH^#/'L_B35=2L;C2[^+R;V:&&7[*5C1$Z"1B>'XZ
M>M<]IEW_ &=XUL;;PE'J\5I=7C_VEIMU:NL$*G.Z568?*<\\'!K3\+ZF^A:U
MXFT>>SNEU"ZU6XNK/-NYBE5_F0[P, =CSQ0!L6GQ'TBYU>WT^2RU:T^U2^1;
MW-W9F.&9_P"ZK$]3VR!5:PU6_D\5^.;=[N5H;.& VR%N(B8F)V^F2,UY]=37
M>I:?HE[>R^([O6;;5;>YU"%XI1;VJK*-V$QMX'0C)[UV]K'/:_$/Q=:2VMP/
M[6M(I+.81DQOLC*L-W0')Z&@";0_&MMHWPV\-:KK]S<2R7Z1P^:$,CO(RL1G
M'/\ ":>OQ4TAI9[8:1KWV^$!FL?L!\XH?X\9QMXZDUR$,5U=> _ M@NGWJW6
MEZU;PW<3V[ QE%DRW3[O(YZ<UVUK:SCXOZE<F"00-H\2"4H=I;S#QGIGVH O
M-X[T,>%K?Q"LTKVERVR&-(R99),XV!.I;((Q[5'IWC[2K^._\RWU"QN;&'[1
M-:7MOY4WE_W@N>1^->:+H.HIX9T/4);?5([;3M9O9+F.S#)<)&\CA9$&,G&0
M>!T-=!;Z7I&HV6MZMIL_B*^O8]-DM4DU(2$,K\[4#*"3E1TH Z*Q^)>B7]_8
M6\=OJ4<.H$+:WDUJ4@E<C(4.>_X8JGH_Q!N+[Q_K.@S:5??9[:2&*"2.U/R%
M@=S2MGY5.!@^E9U_87;?#OX>PK:3F:WN-,,J",[H]JKN+#MCG.>E3V-\/#?Q
M6\2'4;6[$.L"T-G-%;O(CE5*L"5!P03WH WM*\>Z9K6L?V?966IR1F5X5OOL
MI^S.Z9W /GM@]NU=57DVF79T_P ;V=KX335DL[F\D_M/3;JU=8(!R6E1F'RY
M/. <'->LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %<]JOAR_U"_DNH/%&JV$; 8@M_*V+@8XW(3SUZUT-07O\ QXW'_7)OY4 <
MM'X2U*5 \?CK6W4]&7R"/_1=/_X0[5?^AWUW\H/_ (W7->#;_4M-^#^E7&FR
M:;"1<7(EFU"1ECC3SY>>.IS@8]ZM6/Q(NI_"'B74'BL9K_1" 6MI"T$X(RK
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M8Y$[Q1K@-Z@,V<>U/TSPYI+>.O$WA1K0?V)+;6M\+-6*QK)N8' !Z':"1T-
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M&KOX?%AO?2K9F:]W8QEB  OK4TGQ/EBT413V5O!X@_M!M->"6;$"2*-Q<O\
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M%%% !1110 R9#+!)&LC1LRE0Z]5)'49[URO_  AVJ_\ 0[Z[^4'_ ,;KK:*
M.2_X0[5?^AWUW\H/_C='_"':K_T.^N_E!_\ &ZZVB@#DO^$.U7_H=]=_*#_X
MW5#4-(DTJ6UCOOB%K,#74GEQ;S -S8)_YY\< UWE>3^*;6PTGQY?ZOXOT9]1
MT*[MXHK:[\KSDL\##*R=5!/.0* .J7PAJC*&7QQKA4\@CR.?_(=+_P (=JO_
M $.^N_E!_P#&ZZ'2C8G2;0Z88S8^4OD>7]W9CC'MBKE ' 7?P]D.H0ZO>^-M
M;\ZT#>5+*\(6+(P2,I@''&:NP>%[ZZB$MOX]UF:,]'C:!A^8CKI=5TRPU:P>
MUU&S2[M\AS"Z[@Q7D<=ZX#X<+:GQCXH?3[5]*L\Q(NE2KL=& YE*=%#>WI0!
MN2>$M2AC:23QUK:(HR6;R !^/EU#!X>N+F3R[?XA:K*^,[8Y+=CCZ!*U/'NG
M76K>!-9L+&$S75Q;,D48(!9CVYKC?#?V70/$$.C7'@ZTT36+JQD-E=V[I()B
MJC<I(Z'.#0!T \-W9N3;#X@:N;@#)B#V^[\MF:;+X=N8)U@F^(6K1RM]V-WM
MPQ^@*5Y(VI>'],^'R&5&B\>P7J,SLC?:/.\X;B6_NE,CKCG%>C_$#0_#-GX8
MU/5[S2HI]8U)5CA9LM(\[ *@3)^7!YXQT- &Y_PAVJ_]#OKOY0?_ !NJ\_AZ
MXMI/+N/B%JL3XSMDDMU./H4KI/#]K=6/AS3+2^E,MW#:QQS.3G<X4 G/?FL#
MQUHOA1-+OO$>O:-:7DMK;\/*F6;'W5'U)Q^- #(O#=W/$TD/Q U>2-/O,CVY
M"_4A*6W\,7MW'YEMX^UB9,XW1M;L/S"5PB^&1HWA[P?X<EC6 :]J1N=3CB^4
M,-N[RN/X1E1C_9KJ].T^T\,_%U=.TFW2ULM0TDS36\0PGF(^ P'0''% &M_P
MAVJ_]#OKOY0?_&Z/^$.U7_H=]=_*#_XW76T4 <E_PAVJ_P#0[Z[^4'_QNC_A
M#M5_Z'?7?R@_^-UUM% '*P>$]3AN(Y7\9:W*J,&,;B':X!Z'"=#75444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<MXD'C$7CK
MH4.FW5C/;^64N9&C>&3GY\@'<N"./:NIIKNL<;.QPJ@D_2@#S63P#JFGZ!X5
MMK9+/5&T>226YLIY#'%</)N)8'!Y5F)&14?_  A/B&?3O&4$T&FPOKL,30+;
MR'9$Z@@H<J.V#D"O0=&UBRU[2HM2T^0R6LI<(Q4C)5BIX/NIJ_0!R>K>'+Z]
MO/",L1BVZ3<>9<;FQD>44^7CGDUS:^$O%VG:-K_AW3H],EL-1GGGAO)IF#()
M.J% O)]\XKU"B@#S4>$==T[5-)OXM/T[5OL^D0V'DW4Y1;:1 -SI\IR#],\5
M#8> ]=@T.QT^?[%YEKXB74R\3D(T6_>=HQD$$D >U>H44 <=\3_LG_""WKW%
MU%;7$.VXLW=@#YR$,NWU)(Q@>M7/ 6D3:/X0LTO#G4+H&[O&/4S2'>V?H3C\
M*V[K3K*^E@DN[2&=[=M\+2H&\MO49Z&K5 &3XHTZ?6/">L:9;%!/=V4T$9<X
M7<R%1D^F35"<WOAOX=XCDMDOK&P55:4DQ^8J@ <<G)X_&MV_O[73+&:]O;B.
MWMH5+R22-@*!1;7%OJ-C#<Q8D@F19$)'4'D'!_"@"'1;B\NM"T^XU"$0WLMO
M&\\:]$D*@L/P.:XGQ3HGB[4O&UAJ=I9:9=:9IH+6MO<W+)F8_P#+1@%/(Z#T
MZUZ)7+ZO\0- T349K*ZDN6DMP&N'@MGD2 'H78#"\<T 9NL:)XFU$Z#XABAT
M^+7]+DEWVGG,898WRI4/C(.-IZ=:AAT#Q9%;^(-<06$?B354CA@C64F*UC0$
M#YB.3R3TQFNHU3Q/I&D:1#JES=@VT^T0&)2[3%N@11RQ/M5&'Q]X>ET6ZU4W
M;QPVL@BGBEA998W/12A&[)[<4 8O@+1_%7AJRM=*N],TI+0;GN+J.[=YI9#R
M7(*C))]ZBU[1?&?BV*#1]2M=)L[!+I)I;N"=G=U1MP"*5&"<=S73:#XQTCQ%
M=36EH]Q%>0H)'MKJ!H9-AZ,%8 D>]:.IZQ8:-#%+?W"0K+*D,8)Y=V(  '?K
M0!(VF6#WJWK6=NUVO2<Q@N/^!=:\_L] \<Z/J?B!=(CT9;?5+UKA+FXF<M$"
MH7[@7D\>M>E5Q]W\3O#%CJ-S97%S<(UK)Y4\@MG,<;>[ 8'6@##N_AA)9Z)H
M8TJ:WNM3TJ>2X?[<O[N\:3/F!NN,YX/..*U%\+W>O:%JVGZMHNE:0MY;F"-K
M)O,D&>I8[0,9 X%=G;74%[;1W-K,DT$JADDC;*L#W!J6@#D-#;QM!]CT[4K#
M23;P@1S7L=RV9$ QE4V\,>.IQ6!I/@[7/#5NVCV>A:!J=FLK&VO;I]CHC'.U
MUV$L1GJ#7IU% ',6WAZYM_B"^M*L"6)TM+-40X(<.6X&.F#7/Q^!M67X:^)/
M#Y:W^V:C=7$T)WG8%=P5R<<<"O1Z* . ET;Q1I/C"ZUK2K&PO(9[""T,<UR8
MF#)G)'RD8K-F^&VJ2Z>FIR2V$WB+^TWU)XY 3;/N7:8NF<;1UQUKOX=<LY_$
M%UHB%_MEM"D\@*_+M8D#!_"M*@#CM-TG5+BUU$7N@:-IC2VS10?97WR;F!!W
M': %Z=*U_".E7&A^$=+TN[*&XM;=8Y"ARN1Z&MJB@#)UV;78((9-"M+.ZD#_
M +V*YE,>Y<?PD \Y]:Q_!WA[5-.U/6];UDVR7NK2HYM[9BR0JB[0,D#)]36W
MKFO6?A^T2XO$N7$C^6B6T#2NS8)P%4$] :30?$.F^)+%KO3)S(B.8Y$92CQN
M.JLIY!H S?#^@7FF>+/$VISF(P:E+ \ 5LL B$'(QQR:?X?U;4]0U_7[>Z%L
M^GVDZ1VDT.?FRN64D]2O&<>M:EEK.GZC?WME9W4<T]D56X5#GRRV< GUX/%7
M418UVHH4>@&* .;\=V?B'4O#,VG^&S;QW=S^[DFFE*>7&?O;< \GI^-8^F^'
M=<NO"EUX5U33-+T_2VL6MH7L[AI'#8P"05'?DGUKJ-?\1Z;X:M(KC4977SI/
M+BCBC:1Y&ZX51R34>A^*M)\06]S-93LIM#MN8IXS%)"<9^96P1P#^5 ')6WA
MKQ;JPT/3/$":='INDS1SO-;RL[W;1CY!M(&T9P3FH1HOCJ+QSJ'B+^S=&NV=
M?(LEGNW'V:'T "]6ZD_A72:;\0_#NJZG#86US,'N&*V\LD#I%.1U".1AOPJ)
MOB5X:2_-J]Q<+&)OL_VLVSBW\S.-OF8VYSQ0!8U2Z\91+;G3M,TJX$ENHF22
MZ9#%-WP=OS)^O%.\#>&Y_"WA>'3KJ=)KDR233-&"$#NQ8A<]AG%=&754+LP"
M@9+$\ 54TK5;+6M/2^T^=9[:0L$D7HV"0<>V10!<HHHH *BN?/\ LTOV81F?
M8?+$A(7=CC..V:EKC[OXC:3:^)3I"Q75PD9\N>[MX7DCAF) $;$#&3GUXQ0!
MAQVOBGQ?XHL(M9LK#3H?#]XMQ)-;R,[3N4. A(&%PW/TKTRBB@#$UGPCH/B&
MZAN=5TZ.YGA4I&[,P*@]0,$5S?A[P1<^%;WQ-?:1:V2W-W*#IZRRN5$85<J_
M4CY@?6N_JCINL6&K_:387"3K;3&"1D.0' !(![XS0!R-EH'B+6?'&G^(]>@L
MK"/38)(H;>VF,K2%^I9L  <# K9\-ZKJFI:MK\5XMNUE:78BLYH <.-N6!SU
M*D@''?([5JKJ]B^M-I"7"M?)#Y[Q#DJF< GTR:NJBHNU%"CT Q0!S5IH%Y!\
M1]2UYS%]CN=/AMD ;Y]ZLQ.1CIR*C\5>';W6M>\,7MJ8A%IEZ9Y][8)4H1\O
M')S6Y/J]C;:K::7+<*+V[#M##_$P49)]A6%>_$;PWI^I264]W*/)E$,UPL#M
M!$Y_A:0#:#^- &7X[T+Q1KNMZ5_9UKI]QH]DXN)+>ZN&3SYAG;N 4_*O!]S6
MM--XVD\,SM#9Z1!K0E411^<SPF/(R2< YQFI=9\<:+H6JKIETUU)=M +C9;V
MSR_(20#\H/=36UIU_#J>GPWL"RK%,NY1+&4;'NIY% &5JG@S0-=O$OM6TR*X
MO%C$?F[W! ]!@CC-<3#\*I;;P]JUO9_9K746U47UA)O9E"H08U;T_B'?KWKL
M]>\;:/X<O4M+_P"U^:R!QY-L\@QG'51[4_P]XQT;Q/!>3:=-*8[-@L[31-&$
M.,X^;T'7TH R-+T7Q#JGBZSU_P 1PV-JNGP/%:VUK*9"7<89V) QQD >]=M6
M;HNO:?XAM'N],E::V60QB780KD=2I/WA[BM*@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KB?%VI^++74$T_3=)TV[LM0/V>"::5P8W*DL9%"D;>#T]J[:N4
M\1^/=-\.ZK;Z<\-S>7#8>X2UB:1K:(@X=@H/&0!CCKF@#0\'Z"_AGPGIVC23
MB>2UBVM(!@$DDG'MSQ6W4-G=17UG#=P%C%,@="RE3@C(X/2IJ ,W6Y-8BL-^
MB06D]TK@F*ZD**R]P" <']*YWP]H6M-XOO\ Q5KR6EI--:):16MM(7"HK%MS
ML0,G)_*NEUC5[70].>^O!,8E8+MAB:1V).  J@DU4T'Q1I7B9+A;&23S;<[9
M[>XB:.6//3<C#(S0!F^'M5\1ZMX6O;IH[!M16XFCLWRRP3(K85\\G:0.O>J5
MCHGB/6?&6GZ_XAM[&RBTR&2.VMK:8RL[R8#,QP !@<"NJU;5;30=+>^NQ(+:
M+ (AC+D9.!A1S7/Z?\2_#FIZM:Z9;R7@N[IBL226DB;L#)Y(Z 4 ,UGPK>^(
M_%]I/J M8]"L&6=(4YDNIAT+\<*I[9.:R?$>@^+]0\>VVL06.EW>G:<A%C;W
M-TR;9".9& 4\]AZ5O2?$7PW%JOV!KR3B80-<B%C;K(?X#+C;G\:GUSQQHGA^
M]%G=R7$MR(_->.U@:8Q)_>?:#M'N: "ZD\7R:7IKVUOI<5^;E?ML;2,T:PY^
M;8<9)Q4/B_P_?>)+O1;16B&DPW8N;]6;YI @RB@8Y!;&:Z&PO[75+""^LITG
MMIT#QR(<A@:G9@JEF("@9)/04 <KXX\-7VNP:7=Z1+#%J>E7:W5N)LA'P""A
M(Z \<^U1>']$UF?Q5<^)O$,=K!<FU6SM;6VD,@BCW%F)8@9)/IVK3F\9:#!X
M?.NO?I_9YD:))5!/F.&*X4#EB2#C'6E\/^+-*\2O<Q6+S+<6Q7SK>XA:*1 >
MA*L <'!H W**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *@O?\ CPN/^N3?R-3US'B'PI>ZQ?FZL?$5_I?F0?9Y
MXX51TD3)[,#M;DC(YH X3P_>PV_PE\/VKZGJMI/<W=RL,.E*IN+G]_*2JY!P
M.A)XZ>]+:>)==M_!7CBWENM02YTC:;6:]V?:45UR Q7@D8//O78S?#^VBTW0
MX-)OY]/N=&W"UN559"0X(?<K#!W9)J!?ATAL_$$$^M7EP=<B1;J25$W!US\R
MX  X.,=.* ,PMJ^@^(_"=T^OW]]'K,C0WEO<%?*!,1<&-0!MP1[\4F@Z[JES
M\,_$VH37LKW=M<WJ0RD_,@0_*!]*ZZ_\,07]QH,S7$BG1Y?-C  _>'84P?3K
MFL"?X:EH]5LK/Q#?V>D:E))--8QHA =_O8<C< 3VS0!DZAJ;ZEIWAVW&K^(W
MU.72HKB2TT;8'8LJ_O9'88 SVSS6<GBCQ'?^ -$==1FM]3;7UTV2X9 &91(R
M_.HXSC&1[5V)\!R6MU9W>D:[<Z?<PV$5A,ZPQR>='& %.&! /TJ.T^'%M::=
M;V(U.ZDAM]6758VD"E]X.XJ3W!;)SUYH K:I%?\ @J_T74#K6I7VFR7AM[\7
MDH?:)0%1A@  !P/^^JTO"6H7FM:UXAU)[AVTU;O['919^0"+(=Q]6SSZ 4GQ
M'=9_"=SI2V%W>7.H(8K9+:(MMD&"K,W10#@Y/I6KX4T1?#GA;3=)!R]O HE;
M^_(>7;\6)- &-\3=$L=4\$:O=7D32O9:?<RP*7(4/Y9PQ'0D8XSTK9\)?\B?
MHW_7E%_Z"*M:WIB:WH6H:5)(T<=[;26[.HR5#J5)'YUFZGIDUGX$FTJQDNVF
MCM!;P26YVR[L!5(/;G&3V&: .AKCOB%JAM-$;1K")9-7UW=96T>/[PVM(WLJ
MG.3[5T>BVUU9:%I]K?7!N+N&WCCGF)R9'"@,WXG)KEM<\ WFK>+!XAM_%%[8
MW,<7DPI%!&XB0]0-P/4]30!ESZ7'HWCCX>Z*6+V]G9W*Q[N\BQJ ?K@M5[2E
MC7XP>*.$\C^SK22;(X$@+X)]\#]*T+_P3+J.E::ESKMXVL:;*TMOJHC02 L3
MD%0-I&T[<8[5#_P@!.A:M9MKEXVHZL1]LU(HOF.H&-H P%&.,#UH S?#UW'K
M_B[5_')W#2+*U:QLG523.B$M)( .2,\#UK@/$WB*R\0S6'B#4Y[B&XBU6W%E
M8&"0"V@#_,S?+@NV,]\# %>I>&/!&H^&FM(5\57MSIUJFQ;)[:)4(Q@<JN??
MK6SXB\.0>(K.UMY96A%O=Q70**"24.0/H: &?\)&[:Y!I\6C:G)!,JL+]81Y
M !&>23D?E7-_#U$DU'QLDJJT;:PX8,,@CRUSFO0*X)_AM-_:&J2P>*=4M;/4
MYS-<VMNJ*&) ! ?&X<#'% ' Z1XCU'3?#NGZ'I#7:6M_K5Y%#+9QB29;5#G$
M0;C.=V#V K?'B'Q%X6BUF[6WUVYTB#37GC?6XUWQW ( 4,O52"3CVKLK_P
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MQXE?Q3J)O=%NIH8$&P12K$X'[Q=OS$YZYKU:/P]%'XM?Q#]HD:9[);,QD#&
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MQ5SX-WMK<_#NSM[9B3;/(CJ4(VY=B.HYXQTKN+>V:*QA@GF-Q*D2H\[J TA
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M5/+=SV%=%+X.BCT32-)TO4;S3;?3IHY ;=OFF"G)5SWR>372,BL#E1S[4 >
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU%%<9H_Q0\-:UJD&GPS7$$MR<6S7-N\23_[C$8-/UOXF>'=#U67399+FYNH
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M_&5OLT4BK-X7E@6<*=HD,CX!;IGD5Y_H&EQIX=C\):[>^,+.X:0PRZ=;6RM
MV7^\#L/'?.:]A_X1GQ?_ -% NO\ P5VW_P 31_PC/B__ **!=?\ @KMO_B:
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M^-FL3);R"&71!&)-IVLV1QGIFMG_ (1GQ?\ ]% NO_!7;?\ Q-'_  C/B_\
MZ*!=?^"NV_\ B: .>^#.L)9^&K/PC=V5];ZK8^>9A+;LL8'FLPPW0\,*N?&&
M"Y.BZ%?P6LUS'IVLP7=PL*;F$:ALD#OU'YUJ_P#",^+_ /HH%U_X*[;_ .)H
M_P"$9\7_ /10+K_P5VW_ ,30!R7B+5UO?%/A7QW;:?J%SHEIY]O./LS>9"3T
MDV=<'U]JO^"DN=>^)FN^+H+*YM-)GMXK>$W$9C:X90,MM/.!BM[_ (1GQ?\
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MM#/';W7A1D29XR-C/(Y /HPR.*Z+_A&?%_\ T4"Z_P#!7;?_ !-'_",^+_\
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M:_%NTGNM-\/+;P22[-:MF8(A;:H/)..U:?\ PC/B_P#Z*!=?^"NV_P#B:/\
MA&?%_P#T4"Z_\%=M_P#$T 9DEI/_ ,+^BNQ;R?9_[#V&78=N[S&XSTS63X(O
M3X5\ >)]0U#3+F:*+5)W^S+%\TBEE P#U'/Y5U/_  C/B_\ Z*!=?^"NV_\
MB:U]#TK6-/:<ZMXAEU=9  BR6D4/EXSG[@&<\=?2@"[I%^FJ:-97\4$D$=S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "J[6%HU^E^UM$;Q(S$LY0;PA.2H/7&0.*L44 %%%% !1
M110!CW7A/P[>W_V^ZT/3IKO.?.DMD9\^N<5L    # '0444 %5Y["SNKJWN9
M[:*6>V),$CH"T9/7:>V<"K%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHVACB.)&$RX0^_/%6X9HKB%9H9$DC<95T8$$>Q% #Z*KW=]:6$8DO+F&W0G
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M5W%?V-O>09,5Q$LJ9&#M89'\ZGH **** "BBB@ HHHH **** "BBB@ HHHH
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M&@Z5X@M!:ZM8PW<*MN42#E3Z@]1^% 'E'B+PQ>Z)X,\:7$DVEPVMS;QJ;'3
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MT7S&C0!I"!P6/5CR>3ZFFZ];1:IIMQI7]JRZ?/-'N$MO*$E101EA[=B?>M0
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M"/I6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC97%PK-;?;;1H5G &3L)Z\<]JKWGQ+T*SDO5\G4IUL)W@O)(+-G2W*G!+L.
M*X*W)N->\(ZD)?$E]/#=YU">]CE\J%F0C 0C"\\?*, =:Z33+&Z7PM\1(WM9
M@]Q>Z@T2F,YD!4X*COGMB@#1\2>/7TCQ'X?L[.QNKRSU%'F>2WMFE,B;<J(\
M=3W([ CUKMH9?.@CE".F]0VUUVL,]B.QKRRY%QI%E\.M7N;.[:UT^%H[ORH6
M=XB\0 )4#.,C%>GV5W'?V4-W")!',@=1(A1L'U!Y'XT <C<?%+P];K+*R:BU
MK!,T%S=)9N8K=PVW#MT'X9J]I?CS2-4UJ+2DCO[:XGC,ML;NU:);A!U*$]1^
M5<--IUZ?@QXOM197'VB6^NFCB\IM[@R@@@8R<UT?B*TN7\:^"IH;:1UA$^]@
MA(3,7&X]N: -$_$+1X]42RN+?4[9))_L\=W/9ND#R9P%#GU/'3%;-CKUCJ&H
M:E8Q,Z7&G2!+A9%VXRNX,/4$'K7BVL2:AJ_AUI=1/B.X\017T<MQ:+%(+:WC
M28$X4#:0%'!&23S72_$=-0TK6;:^T=26\26W]CRXXVR'F.0_1=X^E 'HVAZU
M:>(-)AU.Q\PVLV?+:1=I8 XSCTXK'U3Q]I&F7]Q9^1J%XUK_ ,?<EE:-,EOQ
MGYV'0XYP,UO:9I\&DZ5::?;+M@MHEB0>P&*\DMK&/P]JNNV6N3^)X'N;Z2Y@
M;3#(T-S&^,?<!^;L0?:@#TJ/Q=H\MWID"7!9-4B,MG<;?W4N!DKN[-CG!]*Y
MOQ5\1TL/!]QK.AV\UR$NOLJ3- 6B8@X9A@\KU /0FLGQ'X82]\,Z/X"\/VES
M&K@W?VV[5C]C3<6)+<?.68KCT)I-8COM8^$-UI4.BRVNHZ6R12V<<9"MY9',
M7]Y2!D8H [:X\8Z=9:+'J=[!?V@EE\F*VGMF6XE?LJQ]3FHK#QUI%\E\'CO;
M.YLH#<36EY;M%*(Q_$%/4?0UR'BZY7Q,^@>)+"/6?[-TVZD2[6VA>&YC#QX#
MHI&2!D9Q[BI(--TC4[/6M5TZ3Q#>7L6F36R2ZB),,KC)5 P!)RHZ4 ='9_$C
M0;R[L846_C@OR%M;R:T9()6(SM#GO^E/U[QSIFEW=SIL<5_>7D,)>86-LTHM
MP0<%R.GKZURNL:?>/\,_ <*6D[3P7&FF2,1DM& %W9&,C'?-2Z?J)\(ZOXKL
M-5T_4'EU*\>[M+FWM7F6=&0*$RH."I!X/K0!T_PXO[G5/A]H][>7$EQ<31,S
MRR'+-\[=3]*H6WCFX?XBZEX>DTR^:VMT@$<D5HQPSE@6=N@3@8/L:N?#*":V
M^'.C17$,D,JQ-NCE4JR_.W4'I63+?CPW\5=4O+^UO#:ZG96T=O-!;O*I="P9
M3M!P?F'6@"GI/C^/2-3\51ZM_:EY':ZH^&AMWF2U@\M.6(X5<[N/KQ77ZGXQ
MTC3+2RF,DUV]\H:TM[.(RRSC&<JH[8[G%<WH-G<II_Q!62VE4W&H7#1!HR/,
M4P( 5]1G(XKD(M%O-.'@_6]0768=/31$LYWT[>)K:3@_,H&[:>AX]* /6M \
M3:?XBCN/L?GQSVS[+BVN8C'+"QY 936)XP\9W'AOQ#H%A#875S%?2N)S#;-(
MQ4(2%3'5L@$CTI_@C3M*$VH:QI[ZQ++=E(I9M4WAI F=I4, <?,>:K>/S+9:
MUX5UHVUQ-9Z??.;DP1F1HU>-E#;1SC)% &OJGC/3=)^R12P7TU]=Q^9%86]L
MTEQM[DH.F/>J[_$+P_'X?FUJ6::.WMYUMKB.2$K+!(Q  =3R.H_"N-UU%/CF
M/Q/.VO1:-J&GQQ1W.GK(DD#*S';(@&X Y';K3=:T*QF\$W5[I$&LW4E_JMFT
MYU!':60)*@W;2,[=O<CH* .SD^(.D6]DMY>6VIVEN]PMO$]Q9NIE9E)&Q?O$
M''IU(JJOQ.T=YI[4:?K?]H0@,]C_ &>_G!/[^WIM]R:=X_MI[BX\+&&"241Z
MW [[$+;5&<DXZ#WHL;:=?B_K%RT$@@?2;=%E*':6$CY /3/2@#H]$UJQ\0Z1
M!JFG2F2VF!VEE*D$$@@@]"""*X3Q1XBN;[XAZ=X7CDURRM/*:2:2PA*O*Q8*
MIWX.(QDY(_&MCX8VT]IX4FBN()(7_M"Z8+(A4X,K$'![475M.?C#87(AD-NN
MC2(90AVAO-!QGIGVH LZCX]TC2KVXL1#J-ZUD!]KEM+5IDM^,_.P[XY.,T^_
M\?:%8?V;^]GN?[2A,UF+6$R&8#'  YR<]*Y;2]4_X0M_$VF:GINH37%W?S7=
MJ]O:O*MTDBJ% 8# ((P0<8JKX5\/:CI&L^!(+VTD#VUC>M*0I*PL[%@I/0$!
ML?A0!ZCI]X-0L(;L6\]N)5W>5<)LD7V8=C7-7WQ'T*QN;I&2_FMK.3R[J]@M
M&>"!NX9QZ9&<9Q77'D5Y!8W\OAKP7K'A2[T?4+C5WFN5A2*U9TNA*Q*OO VX
MPW.3QB@#NM2\=:/IU]'9!;R\NI;=;F&&RMVF:6,DC*X^G?%/@\<:%-X9?7S=
M/%91N8G$D9$BR X,93KNSQBN4\'Z'?Z-XTTNWNXI";;PU';R3;24\P2<KNZ9
MK!U'P_J=UH6JRPVE]ML_%DE\\5N"DLL(+ M'ZGYMP]<4 >DZ-XSTW6-2_LW[
M/?V-\8S*EO?VS0M(@ZLN>"*U-8U6#1=-DOKB.XDC0J-EO"TCL2< !1[FN*\,
M6>AZMXCM]1MKGQ)=W-C&QCDU/S!&F\;2HWJ,G';VK7^(5YJMEX>B?3&N8U>[
MC2[GM8]\T,!/SL@P>>GTS0!=T'QAIGB"6[@A6ZM;NT :>VO83#(BGHQ![<'F
MN+\7_$:WO-(A70CJB![^")-02W=()1Y@#*LG?(S[&L>PTR2]\8:W%IG]M-!J
M6@26]M>:EYA\R4,,C<_('UQWQ2W^L?;?AYHWAR+1M4AU.SGM(IX#9/M0QNH9
MMV,8.,YSWH ]'UGQKI>C:H-,,-]>WHC$LD%C;-,T2'^)\=!^M<1HGBZ9_ 6A
MS7^JZI#/?:BR+>1P>;D"8@1N6^Z",#UK2L]1/@_QYXC;5;"^DBU66.>TNK>V
M>964+M\LE0<$'L:YZUT^^?X4:#%]ANEF&N)*T30L'5?M!.2,9 QS0!V-CXYN
M)_B'JOA^33+YK:V\A(I([1CM9MVYI&Z!.!@^@-3Z3XILI=5\2W5SJ5[%;:<(
M_.M[RW$2VPP>5/5@V,_E6<+X>'?BKK,]_:WGV?5;:U2UFAMWD0LFY6!*@X/S
M#K6-KV@:GJUS\1K>UM93)<?89( 5($_EX9E4]#D*1^- '9:7X^TC4]0MK/R;
M^S>[!:T>]M6B2Y _N$]>.<'!JI-\4/#\(ED\O4I+:WG:"YN8[-VBMV5MIWMT
M'/IFL'5;]O&^H>%K'2=.OH7T^^CO;N6XMGA6W5%(*98#+$MT'I45II]V/A#X
MPMFLY_/EN]0:.(Q'<X,A*D#&3GM0!W&M^+K+0Y($>SU*]::/S1]AM&F 3^\2
M./ZU@>)_%"WVD^$]3T*_D%K?ZS%$SQDH739+N1AU^\O(/<5D:E=WT>JZ58ZM
M-K=GHJZ5"T(TM) T\^,,KL@W @8PO%85I:7UE\.=%9M-U%FTGQ(US<P-"S3+
M%^]^;'5OOKR,]Z /;KB86]M+.RNXC0N5098X&< >M8K^,-'3PG'XE\YVTZ55
M9"J9=BQ"@;?7)QBMJ&5+FWCF0'9(@8!A@X(SR#TKR"RTZ['Q"7P.T1.D6-\=
M;1OX?*/*1X]!*2: .[U/Q[I6FW\MD+;4;R>W4/="RM&E%L",CS". <<XY-2W
M7C;2H=)L=1M8K[4H;X$P"PM6E9@.N1_#CT.#^5>?K9)X>\3>(8M:N/$UO]LO
M6NK:;3#(T4Z,!Q\@/S#I@U<U"W_L"#P]IMI)KMCX8GCEGN)+=7-SYK$,J.5&
MY!R>G?B@#L?^$]T(^%+CQ'YTWV&VD\J<&(B2)\@%64\@@D5H:)K]OKRS/:VM
M[%#&1MEN8#$LP/1DSR1[XKR%=/NC\.O&UA%8ZH7FU:.X@CNXG::2)C%ACGEO
MNG/<8YKV#6]6B\.^';G4Y+6>>*TBWM%;J"Y ] 2!Q0!J457L+R/4=/MKV$,(
M[B-95#C! (R,CUJQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>(9KVWDEO/)95=V9?+D[/CU]Z]?JGJ6E:?K%H;74K."Z@)SLF0,,^HST- '
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MJ:+8VFHV>JK$TT,MSY+PRH@3(.""I 'O7;27EM#=0VLEQ$EQ/GRHF<!GP,G
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M* .,\+Z3KJ>,M;U[6+*VM$OK>WBBAAN/-*[-^=QP.?F%=G110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>:^-=';4OBCX34:IJ-IYL-RF;68(
M4VQDY7(."<X/J *]*KGO$OA<Z[<Z??6NHS:=J6GNS6]S$BO@,NU@58$$$&@#
MDKS1)M1^+<EDFL:A:)'H<>^:W=1-+B0@98@X]3@<UCW/C?7=.\)QZ<+BZNK]
MM<FTD7D,0><QH3\P7@%]HQ]:]'T_PR;3Q NMW&H2W=Z;!;*1G15#X;=OPO )
M/8<5G2?#S39M*O;*2XN-\^H/J,5PA"R6\S-N!0^U &%X4OM<A\86UI#;^*9-
M&GA?[0^NP*#%(!E2CCL>1@UH?&&T-S\/K@BYGA\NX@.(FP'S*HPW'(&<_4"N
MAT/1M4TZ>274O$=WJI9 BI)#'$J\]<(HR?>K'B+0K;Q+H-UI-VSI%<*/GC.&
M0@@AA[@@&@#A/&.IZEX4L?#^@Z??:S=R:G/)YMTBK/=B-0I*IP!GYACTP:J6
M&J^(;.36(H(O$HTD:7-,D^M0A9()U!QM<=01V/<5U5SX&EU/2;>#5=>O+G4+
M.?S[/4$CCBD@;&, *,$>N>M7;7PWJ!TW4;35?$-WJ1O83#N>&.,1 @C*J@'/
M- '%D:U8_"6X\53^(M1GU1]($JC>!%&2 00H'WAZDG.32:C:ZY8:]X7@B\6:
ML1KJNMYN*$+A5;,0VX3J1WKN+GPG;W/@0^%&N91;FS%IYP W;0 ,XZ9XIU[X
M7M[W4=!O&N)%;1RWEJ ,294+S^5 &/X)N+^W\1^)] NM1N;^#3I('MYKI@TH
M616)4L ,X*_K4GCV]@ACL+0ZEK,-S/(WE6FCA?M%Q@<\D'"CJ36UIWA^'3?$
M&L:NDSO)J?D^8A PGEA@,?7=57Q!X7;6-4L-5L]3FTW4K)7CCGCC60%'QN4J
MP([#F@#S2ZU#4M;^$_C&SU*ZU%9-+N&CC:XVK.R85@DN,@]><=:].\&Z6=+\
M-6:'4+Z]\V*.3==RARF47Y5P!A?:L^P\ 6MM9:[97>H75]!K1#W/G;0WF;<,
MP( ZX!QT&*T_#.B7V@V1M+O6Y]3B142#SH40Q(HP!E0-W&.3Z4 <?XQT5M1^
M*OAD#5M2M//MKD9M9@GE[5'W<J<9SSZX%,ET2;5OBWK%JFL:A8QQZ1:[WM'5
M9)#N<#+$'W/'6NM\2>%CKEYI^H6FI3Z;J5@SF"YB17^5AAE*L"""*ETWPT+#
MQ!/K4M]+<W=Q9PVDI=%4-Y9)WX'0DL>.E 'FLOC77K;PM9:8US>7-_)K5QI;
MWEK"'N&BB)RRJ>-Y Z_4UM^$=0UZ+Q?'9);>)I-#F@9I9-<@ >&4=-KCJ#Z&
MMM_AWI[Z5<6GVRY2=M2DU.WNH\+);S.Q;*]B!DCGJ*U]#TC4].DEDU+Q!=:J
M[J%42PQQ*@'H$ Y]Z *GC[Q"?#/@R_U"-U6XV>3;[CC]Z_RK^IS^%<7\/I-,
M\,^+;KPSIVI6]W:WEA'=QO%,''GH-LO0]6X;'M7>:_X8MO$=YI4E[*QMK"X-
MQ]FV@I,^"%W9],G\Z@U'P7IEYJ>E:A:HEA<Z?.95:WB5?,4C#(WL?Z4 >=QS
MZ_)\,I?&)\3ZG]OLY)&C@#+Y+(DQ7:RXRV1W)KH6.I^)?']YI9US4+"P72K:
MZ\NR=4;S&+CAB#@>OK@5NQ^!K2/P)<>%!=S&WF$F9L#<-[ESQTZFKUAX9@L/
M$<^LI/(TLME#9F,@8"QDD'ZG- 'GFF^)];FT7P_'/J,KSQ>)WTR:8<&XB02?
M?]<X&?I75WVK7%O\3Y+.6_>#34T$W+@M\B,)6!DY[@#]*1OAQ9_V)+81:C<Q
M3?VF^J072!=\,S$G@'@@9(P?6G0_#^.34;R_U;6+S4Y[W3GT^<RJJ QL3G:%
M "]3T^M '&:9X@O[+Q3X?EL;_P 2WFFZE=&VDFU5$$$X()#1  %>1D<<BNI^
M'7_(;\:_]AI__013X_AW<8TH7/B:^N!I,R2V2-#&JH%XPP ^;CC)K9TCPK'H
MOB35-5M+Z?R-2/F363 %!-Q^\!QD< C'3F@#FOBC]L_M/P=_9_D_:_[6_=>?
MG9NV'KCG%;-_%XBD\':O_:]Y!:7:1-)!/I3,C+M&[J^>I&/H36GKGAR#7+[1
M[J6>2-M,NOM*!0"'.",'VYK2O[1;_3KFS=BJSQ-$6'4!AC/ZT >9WNOZMHOP
MZ\,>-/[0EN#%9P?;[267"W:N@R1G_EH"<@]^:9JVOZ]HW@G3+IK^XNM2\0WJ
M#?9J)OLT;C.R!>A(48'J>:ZN#P):*N@P75W+=6.BVZQ06DBC8\BKM$C>I S@
M=.:B_P"%=:?_ &+<:2+RY6T%T+NQ"$!K"0'(\MO0'G!H Y;2M;US2-=22&U\
M5SZ.;6>2\.N0*/+=$+*R..F2-N/>LOQ'I^J:M\))?%.H^(-0>XOHHKDV<;J+
M9$=E*H$QG@$<YSD5Z=I/A_4K5IO[7\17>KQ21&+R9H(HT /4D(HR?>N=F^%\
MLFC2Z"GBC44T(G,5EY4;>6-VX*'(W%0>V: .\_Y<_P#MG_2OGW2]1UB3X=0^
M'9+&U@T;5]1GLSJLLA;R2TS$Y3'!R, YZXKZ&V#RO+SQMVYKEK+P%IMMX)N/
M"TTDEQ:3O*Y=P RL[E\C'0@GCZ4 <GXCUF^A\5P>%;8Z_P#V=I^GQRR'185>
M>5C\J[F/W5P.W4U1FU[Q7:^&+J-Y-7LQ'J]I#8WFHP!)WAD;#*XZ-@\>X-=I
M<>!96?3[VSUZ\M-9M+86K7Z(C&XC':1&!4_6K5WX0DU+08-.U/6;N\ECO([L
MW,B(K%D8,% 4 !>* ,2.#4= ^(&GZ-_;VIWMEJUC<-)]JD5GBDCV_,A"C;][
MI[57^#^CM:Z)/?'4]1F!NKF'[/-*&B&)?OA<?>XZY[FNRO/#\-YXGTS7&F=9
M;"&:)(P!M82;<D_3;6?H7A"?P]JL\EEK=S_94LTD_P#9K1(55WZX?&[&><9H
M =XYOK>RT%?/U/4+%IIECC_LY0UQ.Q_Y9H"#R:X?P_K'BF67Q9H-G+J?VJ"P
M6XTX:N$^T1NP(P2O!!/3->@^)O#:^(H;-DO);*\L;@7-K<Q*&,;@$<JW!!!(
MP:R[7P+/;:G?:I_PD=^^H7UI]FGN"B @@_*R #"X]* *?PYOXK@7-O-JVLRZ
MI'&GVO3]6(\R!N[*,#Y2?J.E/^(\FLP?V5-:2:FFCI*_]I'2L?:%7 V,.#\H
M.<XK3T#PA)I>N7&MZCK%QJNI2VZVPFEB2,)$#G 5 !G/>KVO:1J6J?9VTW7K
MG2I(MVXQ1)(L@./O!P1QCCZT >?Z]XLE6W\,Z1HNIZOJ-IJ$<LTU]81K)=R1
MI@;5S@ Y/)QD8JI)-KEWX>\5Z;<#Q'%HZZ=Y]M<ZI$(YUD&=T>X<,I 'O@D5
MUZ_#:PM]$TRSL;^[M;[39'FMM03:9 [G+Y!&TACU4C%;%EX?N/[*OK'6=8N=
M6%XI1VEC2,*I&,*$  H S?AKIAT_P1I,IU"^NOM-E!($N90RQ?(/E0 # ]N:
MP_B/H[W_ (Q\'L-5U&U$UZ8=MM*JB,B.1MZY4X?MGT[5U7A7PW=^&K3[$^MW
M%_8Q(L5K#-$B^0BYP-RC+<8'/I5G6/#\.L:GH]]),\;Z9<&XC50,.2A7!_[Z
MH Y:5=0\2^.M2T$:UJ%AI^CVT'-I($EGE==VYF(/ &./6N<NO$7B-]&MM*36
M)$O[3Q0NE-?JHW31;)#EAT)Z?B!7>ZOX1DN]<;6M)UBYTC4)81!/)#&DBS(/
MNY5P1D9X(JM#\/-.M]*TVRCNK@M9ZD-3DG<AGN)L,"7/ON[>@H Y;Q[X9:VE
M\)V_]O:S*7U=5,LER"XW?Q [>",<>F35SQ%HLTGQ!\(Z7'K&H1%;*[5[P.IN
M'4!<_,1@$^N*['Q1X9A\36,$37,MI<VLZW%M<Q %HI%/!P>#]#5>V\*RC6-)
MU;4-6FO;[3XIHO,:)$$HDQU"@ 8P!Q0!G>"KG4+;Q!XE\.WFH3ZA%IDT)MY[
MD@R[)(P^UB ,XSC-0^.+B^L/%?A&:TU*\ABNM0%K/;)(!%(FUFR1C.>!WZ5T
M>G^'X=.\1:QK"3.\NIF(R1D#">6@08^H&:;KOAR#7;W1[F6>2-M,NQ=(% (<
M[2N#[<T <&J:UK<'C.[_ .$EU.U.DW\Z6<5NZJJ[8T<;L@EADXQ]?6N^\*:E
M-K'A#1]3N<>?=V44TF!@;F0$_J:KV7A2WL;77H%N)&&LW$EQ(2!^[+HJ$#\%
MK1T/2H]#T&PTF*1I([*W2!78<L%4 $_E0!P/@O0V'Q%\77/]KZF1;W\9,)F'
MER[HL_.-O.,X'3  KG-.L]2L_ 7B/Q'9:_J%K-I^H7L\%M$5$)V2L2'7&6SS
MWKT@^$)[?Q5<ZUIFMW-DEZT;WMJL2.DQ08!RPRO'!Q21^"+6/PCJWAX7<QAU
M)[AWEP-R>:Q)Q],T 8UQ>ZE_PL'PQ+#J5T(=4L)GELV?]P'6+*D+C/4^M4_
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MX'- 'EUOXDU[Q#I]SK,?_"8K>O)+]B73;5&LD"L54$'E^GS$]\^E=%:W&O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5SMYXZ\.6/AN'Q!+J,9T^? A= 6:1C_"%')/M6#J7Q3T^/PEJVK6%E?BXLE
M$-U9R1_,P)4GC[O!YH ] HKE_ OBZ/Q=H,5UY-Q'<I&GG^9 T:EB,G83]X>X
MKJ* "BN-T_7+NP\<>(]+U6Z+VT=O'J%F6  2'!#CZ!EKFM,^(][>_"O6]8EW
M1ZK;3O#"C* V96'D<?1U'X4 >KT5PMAK,T/BO3-'O-6O6O+;2B]S;&T^2Z<
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MGT^4QW?D6CN(,=68@8"^_L?2GV7Q&T"^U*RLXFNU6^;;:7,MLZ0SMZ*Y&":
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MVF>&YFBM':.!E;:=S8P.1^5 '9T5@:UXPTK1&M(I6GN;B\7?;V]I$99)%_O
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M"6QAU.6.3]_*SQD 86,$8V=.N.]=+XV\13>%?"EUJ]O;I<2PE (F. VY@O\
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MC[I% &K'_P EZD_[%UO_ $>E;7CVYU*S\#ZQ<Z5Y(N(K61RTK%=JA26*X_B
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH BN;:"\MY+>YA2:&0;7CD4%6'H0:RM)\(^'M"N6N-+T:SM)FZR11
M -^=;5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!,\9PZQR!BOUQTH L455&I6)O/L@O;<W/_/'S1O_ "SFBXU*QM=_VB\MXMA
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M?UKV:SO[34$=[.YBN$1S&S1.&"L.H..]0V^C:=::K=ZI!:(E[=A1/,,YD"C
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M;E#%!SM0J<KCZ&H-5\):#K=_#?:CID,]U" (YCE6 !R!D$9Y]: /+M'T6_\
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MAKUF3PGH,FA+HC:5;G35.Y;<+@ YSD'J#GOUI--\):!I%P+C3]+@MYA$82Z
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M_9U8-GS!L5LGTZXKA-3\8^(M9L?!.I:7;V\']H7K"2 W#*KL-P"L0/N\9^M
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MZ5<SAEV;\JR2%<;A].YKJ?#-E-:V4LEUHNGZ5/*_,-FP;Y1TW,%&3R>E;E%
M''Z_HVL6_C"T\4Z);07LJ69LKFTEF\HNFXLK*V" 02>OK7.7G@37]3TCQ!>W
M8M5UC6+RUE%O'+E((H9$(7<1RVU3^->G6]S!=P+/;31S0M]V2-@RGZ$5+0!R
MNN>';K4_&7A_4 J&RL[:[AN<MAOWJH!@=_NFN8T+PAK&@6L.B-X7T+4K>%]L
M>IS2!28L_P :;"2P'IQ7J-% $;18MC#"1%\FU"H^[QQ@>U>.R^ _$Q\-QZ5'
MH>E?:[6\6[DU)KK,EZ5DW<?+E21UW&O9J* .6T?0[ZU\:^(=7G1%MM0@MDA
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M!.F^&OMTOE6,\<RS;!N8H^_!'Z5IP^&(8O%VHZ^T[NU]:1VKP$<!5)YS[YH
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M75K1+66(#&Q5!&0?7F@#B-5\3WVF>&/ VA:<UY#+J=A&TT]E;&>9(HXD)"(
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M:*YA>XAQYL2N"T>>FX=1GWKFOB'?6EIX<B@N=,AU)[V[BM8+:<XC:4DE2Q[
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MC*VT9Q +2:P:\-TTF ,-MQZ8]ZWEN(&MQ<+-&82-WF!AMQZYZ5YWJNA:3?\
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MB1S.BD7"R*T:GA]PX&?3M5J+4["<$PWUM(%7>2DJG"YQG@],UX<;5(/ 5MF
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MER\AN+I9'ACBC+LRHNYC@>WZD"@"OH_@_0- NFN=-TV*"=EV>9EF8+_=!8G
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M,TOQEI.JI=.GVNV2VB\Z1KRUD@ C_O N!D4 :4^C:=<Q644UI&Z6+I); _\
M+-EX4CZ53N_"6A7NMIK,^GHVH)MQ.K,I.W[N<'!Q[U1TSX@:!JM_;V<$MS&]
MT2+9Y[9XHY\<_(S !J@N_B9X:LGN%DGNF6VF:&YDCM9'2!E.#O8#"C- %V\\
M"^&;_4GU"YTB![F1MTC9($A]64'#'ZBM<:79#5?[4%NGVWR1;^=_%Y8.=OTR
M<UBZ;X\T#5=6BTVVGG$TZEK=Y;=TCN .IC8@!OPJE)\4/#,9E)FO###*T,\Z
MV<ABA93@[W P.: -\^'=(-A>V)T^%K6^D:6YB8965VQDGWX%.T;0=-\/VC6N
MEVWD0LVXKO9N>G5B:2+7M.GUB/2HI]]U):_;$"@E6BR%W ].I%<[XM^(-IH7
MA[6KRPC:ZN],F6VDC,3;5D(##)';!Z].U &UK/A+0O$$\<^IZ=%/,B[%DR5;
M;_=RI!(]NE6'\/Z2^G6NGFPA%G:.LD$*KA8V7E2 /2J?_"7Z3'H#ZS=//:6B
M/Y?^DV[QNS<8"H1DYSQ@<U'IGC?1=5:ZCBDN()[6$SRP75N\,@C'\05@"1[B
M@#HJQ;[PEH6I:S%J]UIZ/J$6W;.&96^4Y7.",X/KFJ^A>-M&\27,<6E-<SJ\
M9D$WV9Q$,8R"Y&-W(XZU9U_Q1IGAM;?[>\IEN7*0001-+)(0,G"J"3B@"Q'H
M.EQ6%Y8I9QK;7CN]Q&,XD9_O$_6JVH>$M!U6QM;*\TV*2"T 6W'*M$ ,85@0
M1Q[TECXKTK4+NQM8I)DGO87F@2:%HRRH<,.1P1Z=:KZIXXT'1Y[V"[N7$MFT
M22(D3.2\@)1% 'S,0,X% &MI6D6&B60L]-M4M[<$ML3N3U)SU-<OKO@F/Q#X
M]M-2U&UCGTR+3G@.9"KB4N",8P>F><U'XD^(UOI?@V37+"TNI'\X0+%<6LB%
M6R,[@1D<'\:VIO&.D6VAKJ]TUS;V[R>4B36[I*[YP%6,C<2?84 31^$M AT*
M31(]*METV3EX O#'.<D]<Y[]:CL/!GA[2[J&ZLM,CBN8=P28,Q?#8!!8G)'
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M<D^O-,N/#&B75K?6L^G0O#?R^=<J0?WC\?-['@<BJ&E>/="U?48;&"2YBFN
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KA]3BW_&;09"F0FE71#8^Z=Z#^1-=Q10!Y/XBBCTCXH7VI:OJVIZ3I
M]]90I;7MIC9N3.Z-CL;'7<.G4U2U31+.STO2O$>CR:GJNG)K0U&_:X0F1QMV
M&0*%4D# /3WKV0@$8(!'O2T >=^+=;L?'7@77=+\,W,E[="W20B*)AN =6*
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MKQ#I-P[S:A->WT<5DD+LTY=V"A<#!SG%>TUB>&?#D7ANPGM8YVG$MU+<[F4
M@R,6(_#- 'G6CG_A!O$'AF?Q$TEO!_PCOV)IV1F59@Z-L) .#@'\JHW7G:]X
M1^)DUC:W#>??))$C1,KNHCC.0I&>@S7MI /49I: /*/&FJV?BG2="UG1[R[F
MT_2]122^>R0^; I0_. 5/*Y!Z&I[.U\/ZO)J.KZ?XAU;6+RSTV>(/<?ZM5=3
ME<^6N3P.,UZ>  ,  #VH  &  ![4 <G\,8A#\-- 39L/V4$C&.2235;X@KH
M73I]6U*YTJ\BD9K*_MU),3XY!X(P?0]:[:D(!&" 1[T >276I:O?_#C3/&5[
M"3J>B7C7"NL1C-Q;!BC-M/3=&<_A[TMG9:3<?#P:YXLEN+*;6=1&H?:(0=]M
M(<B$@@'&$ ZC'.*[_P 2^'6\2VT=E+J-Q;6!)%U! %'VA?[I8C('TZULQQ1Q
M0K"B!8T4*JCH .U 'CM]J.L^(OA/XA$QEU*.RO%6UO%@*-=P(RL7V]\<\CKB
MKOC+5+'Q!<^'/$FG:A>-HVGW4L=Y<V*'S+8O'@/@J>!N )P>IKUC&!BD  &
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MH/2KF!C':B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exhibit10253secondamendm002.jpg
<TEXT>
begin 644 exhibit10253secondamendm002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZLYGE=MH3( "G<1U]?:N;B\)W\\^HZDVEW-W_H*6D=IKERLCW'[T2."58JH
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MGV^92.?2N@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 %&*** #%4[G2=-
MO;F.XN]/M)YXO]7++"K,GT)&15RB@ P/2BBB@ Q1BBB@ HQ110 F >U-BAB@
MB2*&-(XT&U410 H] !3Z* "BBB@ HHHH *,#THHH *,444 %&!Z444 %%%%
M!1110 4444 %%%% !1BBB@ HHHH **** "BBB@ HHHH *,444 %%%% !BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHKFZM[. SW4\<,2D
MO(P4#)P.3[T 2T4P31M*T0D4R* S*#R <X)'X'\J:MU;O<O;K-&9T4,T88;E
M!Z$CJ!0!+14+W=O'<QV[S1K/("4C+ ,P'4@=\4\31M*8@ZF10&*YY .<''X'
M\J 'T54.J:>)&C-[;AUE$)7S1D.>B]>I].M5I?$FA0RO%+K.GQR(2K(UR@*D
M=01F@#4HJE;:QIEZ,VFH6LXW;/W4RM\V"<<'K@$_A4\UU;V[1+-/'&TK;(P[
M %V]!ZF@":BLR;Q%HEO,\,^L6$4J'#H]RBLI]"">*==:_H]C9Q7EWJME!:R_
MZN:6=51_HQ.#0!HT52EUC3(-.&HS:A:QV) (N7F41D?[V<5)8ZC9:G;"YL+N
M"Z@8X$L$@=3^(XH LT5"EW;R7,ELD\;3Q &2)7!9 >F1U&:>DT<N_P N16*-
MM;:<[3Z'T/(H ?152#5=/NGC2WOK:5I0S1B.56+A3@D8/.#P:E-W;+="U:>,
M7!0N(BPW%1QG'7'O0!-163_PE&@9Q_;FFY]/M2?XTZY\2:'9W7V6YUG3X;CC
M]U)<HK<C(X)SR"* -2BJUUJ-E96ZW%W>000L0%DED"J2>1@FH;36]*U"8PV6
MIV=S*!NV0SJ[8]< T 7Z*S6\0Z*FI?V:VK6*W_\ S[&X42?]\YS4][JNGZ=L
M^W7UM:^9G9Y\JINQUQD\]10!;HJG9:OINI,RV.H6MTR#+""97*CWP:N4 %%)
MD U7@U"SNKNYM8+F*2XMBHGC5@6C+#(W#MD<T 6:*** "BHIKJWMWB2:>.-I
M6V1AV +MZ#/4^U2T %%%% !116<-?T@Q"4:E:[&N?L8;S1@SYQY?^]GM0!HT
M444 %%%5H]0LY;^6QCN8FNX45Y(0PWHIZ$CL#@T 6:*** "BBHYYXK:"2::1
M8XHU+N[' 4 9))H DHJ*WN(;NVBN;>598)4#QR(<JRD9!!]"*SO^$I\/_P#0
M<TW_ ,"D_P : -:BJ]G?V>HPF:RNH;F(-M+PR!P#Z9'?D58H **** "BBD)
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MEW8>*8]#;3+FV>)A8&7S"6X_CXQ@M^E &5IOP]\.2_#N&TFT^VEFFLQ*]ZR
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MJ/,6YM&F9CY:]"'7''L: .QO?&MO9:)87\FEZG]IU"7R;;3C %N6?G@J3A<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'HD9R$!]6YQVH [6B@=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGB&&PTVT@T_3])6?SKU(+55DEQC:JD#Y<\Y/6NX    P /2EH CBACAA2*-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,31_87B#_H;KG_P"@_^)KHZ* .<_L+Q!_T-US_X!0?_ !-']A>(/^ANN?\
MP"@_^)KHZ* .<_L+Q!_T-US_ . 4'_Q-']A>(/\ H;KG_P  H/\ XFNCHH Y
MS^PO$'_0W7/_ (!0?_$T?V%X@_Z&ZY_\ H/_ (FNCHH YS^PO$'_ $-US_X!
M0?\ Q-']A>(/^ANN?_ *#_XFNCHH YS^PO$'_0W7/_@%!_\ $T?V%X@_Z&ZY
M_P# *#_XFNCHH YLZ%X@(_Y&ZY_\ H/_ (FC^PO$ _YFZY_\ H/_ (FNDHH
MYS^PO$'_ $-US_X!0?\ Q-']A>(/^ANN?_ *#_XFNCHH YS^P]?_ .AMN3_V
MY0?_ !-']A>(/^ANN?\ P"@_^)KHZ* .<_L+Q!_T-US_ . 4'_Q-(-"\0?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !113))HXL>8ZKN(4;CC)/04 /HJ*6XAMPGG31Q^8P1-[ ;F/0#/4^U2
MT %%%% !1110 4444 %%4(=;TJYN/L\&I6<LV<>6DZEL_0'-7Z "BBB@ HHH
MH ***BM[F"ZC,EO-'*@)4M&P89'4<4 2T44P2QF5H@Z^8H#%<\@'.#C\#^5
M#Z*8DT<C.J.K,AVN <E3C.#Z<$4^@ HH/%117,,[.L4J.8VV.%8':WH?0^U
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8Y=R5*D< # )S3O#FFZ1X6\6ZA=:;KFG?V-?P(9(IM0,LPN%)&[+$Y!4]S0
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M5IH7AFUT275M-N;Q99FQ;7 ?=ND9QCN>#Z4 =B.E%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %,FABN(7AGC26)U*NCJ"K ]00
M>HI]% &/_P (EX;_ .A?TK_P#C_PH_X1+PW_ -"_I7_@''_A6Q10!C_\(EX;
M_P"A?TK_ , X_P#"C_A$O#?_ $+^E?\ @''_ (5L44 8_P#PB7AO_H7]*_\
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M* ,?_A$O#?\ T+^E?^ <?^%'_")>&_\ H7]*_P# ./\ PK8HH Q_^$2\-_\
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M#U]*N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVPL['XD6VG>*;F"\:TT."+3I;L#RY6!Q*ZAN-YP/?%6OB#%H(T/PW-8Q:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M- ^<C#+G((..AYS5+P;XDU70_A3_ ,)#KEQ!=64%N\D00/Y[MYC##LQ(.3@
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M_B*ZFB@#EO\ A8OAG_G\N?\ P G_ /B*/^%B^&?^?RY_\ 9__B*ZFB@#EO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exhibit10301firstamendme001.jpg
<TEXT>
begin 644 exhibit10301firstamendme001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0?!54# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *J-')_:R2A_W7D,I3=WW#!Q^?-6ZSYG?_ (2"S0(3&;:8
ME@_ .Z/ (_/GV- &A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50GDQKUE'M
M4[K>=MQZC#1]/S_05?K-N"/^$CL!@9^S7'/I\T5 &E1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5FW'_ ",EA_UZW'_H45:595TX7Q/IJE@"UM<8![_-%0!J
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %8>H8_X3#1.3GR+K Q_USK<JA=H
MAU?3I"JEU\P!L<@%>1^@_*@"_1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F
MWK;=9TO+D!FE4+C()V9_#@'\_I6E5&Z_Y"=A]9/_ $&@"]1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5CZK_ ,AO0N<?Z1(,>O[F2MBL[4(U;4-)<@92Y;'M
MF&2@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HWW_ !^:9_U\M_Z*DJ]6
M5J\KQ7^B!3P]\5;Z>1*?Z4 :M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/
MK?\ R$-!_P"P@?\ T1-6Q63K&S[=HN[K]N^7GOY,OMZ9]/Z4 :U%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !6?J4:O<Z:S $I=;E/H?+<?R)K0K)UR1XCIK(
M<$WT:GCL<@_H: -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)UQG7^SF0X
M/VZ('GL<@_SK6K(UY&9=.*C.V_A)^F<?UH UZ*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "L_5O\ 4VWS;?\ 2H>/7YQQ6A5#5F"P6X/>ZA X_P!L4 7Z***
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M^??'%OXF\=>-[C3[VRU8^%=/NFC0:;;;S(R@9))(!/49.0.F,U]!5YO:>*M9
MM=5\4ZG?M>7NDZ7>M;Q6-C;P[E54#,[%BK,.>@.?PH Y/QYJVGZ#\(;G0M+\
M*:QIMK-LA$EW;A%!W!BS-N)+''>O1/A7_P DO\/?]>H_F:\V^*^JW>O?#O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5X+J?PMTKQ?XNUZ^G\6QV,
M[ZA(OV15!9<!<YW,OL> 1C'->]5XI\0/@M+KGBF\\20WGGQ7!#SV>\0.,*%^
M20AE[9P0/K0!Q'C7X2:5X8\)7FK6GBM;^6V,8%N$49W.%[,<?>)Z5[E\*_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M< QIQG+9!&..3VZCFO,/#.K:AJ&LZ9IT7Q5M[^*&XC_T0:6(/M"HPRBRXYR
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGGBMRL?P[IEYIEK="_FAEN+F[DN&,*E54,>%&>> *V* "BBB@ HHHH ****
M"BBB@ HHJMJ$\UMIMU<6\/G3Q0N\<6<;V )"_B>* +-%>,6_C^]T[P;JM_?^
M([2]UF*\AFM;:$J!('CB8VX09)4%G7/7(SD&O8K>1IK6*5XS&[H&9#U4D=*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1(V?I@9]: /7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N12YUC4OB#?VEIJ0M]*TZ*#[1%]G1FDE<%MH8\A=N,GU/%==7G7CJR
M\8Z1K \3>#4ANV> 0WVGS#<)0I)1U&0<C<W0@].M ''^.M9^(5AJWBJ33+<W
M/AB!MMP;DH=@,*;@@8AMO.?E!&2?>NB_9^N3/\,Q'MP(+V6/.?O?=;/_ (]C
M\*Y6\U/XG^.=$U&SUG2[;0]%CA>2[E\EHGD106V+O9LYQU  ]^U=)^SRY;X;
MS XPNHR@8 '\"'\>M 'K-%%% !1110 4444 >3:G;>)O"FLZG=:#HNFWT<HF
M,FH27L<31&5PX,X;!;;T'/W<=*[GP/HLWA_P9IFFW%PMQ/'&6DE3[K,[%SC'
M;+8'L*YR5=3\*7^M-IOA*YU2ZU2=Y_ML4\>QR<[%<,P*A>G'&._.*V_AU87>
MF>!--M+Z>*:Y17\PQ2;T0EV.P'_9SM]L8H /%6CZ]+<0ZOX8OK>#4X(S"\%T
MFZ&YC)SM;'((/((]3ZUR\&C_ !$\6SQ6?BTZ7IVB)(LEQ!9?-)=;3N"$DMA2
M0,].!7H^HW\&EZ9=:A<EA!;1--(5&3M49.!]!7$)\1=5N=.^W6G@76V@>/S(
MY9#$JE=NX,?FSC'/ - 'H   P.@KFKOXA>#[&>6"Z\1Z='-$Y22,S#<K X((
MZ]:Z6N/\3>%K)X[:[T_3=-:\CO\ [88;@*BW;[6RI;!YYW#W44 9&H>*_#_C
M+7="T[1O&CP-]H9Y+:S+HUP C$ N,;0",X/!]#Q7H,$<HLTBN)!)+LVNZC&X
M^N.U>>V]KKFL>*M)<>#;;0K*PF,\]T\L322'8R[$\OL2W4]<#I7H[,$0L<X
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MCPOXA\00>)IO"OBN.U:\%N;FSOK<A5NXPV#E,_*PST]CQW(!W%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO=^>)H6D/1&*CY2>V>M '?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNO\ KB_\C7A6II>^*]6^''AO19_L]YI>F0:C-<LF](/W<90E21NP5'_?0]Z
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M'<4 >H5P/CK[5;>)M!N+#Q%9Z/=W DLX1-:F9KEW*;4P/X>^3P"!ZUWU>?\
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MQ8U.VFGBN/"")%/+ V]9\YC<HQXS@94]><5V7@K5KK6_"&G:A>R0274J$3/
M?D+JQ4XX'<5YAXIM[?Q-K^HOI/@?5KV*"X:VN[JRU(6B7,B<,KI_%CINX)KU
M'P:%3PCIT:Z8VEK'&8Q9,Y8PA6(VDGJ>.O>@#=HHHH **** "BBB@ HHHH *
M*** "BBB@ K"\9Q^9X.U4>2\["W9EBC&6=AR !W.0,5NUC^*M3DT;PQJ%_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKB?3;1TW,Y^8A-P.QSSG!P2?KG:\7)<+I4-_;6;WLFGW"7?V6,9>4+D$+_M
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MF.6YMXQY]Q+O&UB<9"[1R"3SW.* +6AZ7K>D:@;2?4DO=%CM]EMOB59HV!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCU)/>M?3=*T[1[8VVF6-M90%BYBMHEC7<>IP!C/3\J +E%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0ANKB*<0IY<@.$.3AS@'MQV]O2J\K\>WVCZ3XP-S?>.=1T:::SC06=C#YCL
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M$GA6*\BUV7[5X.LM !MCMDM9HW\[YQP=@&,<=1WX[T =I1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5FZ_HEKXBT6XTJ^#&UN-HD"]2 P./;.,5I
M5E>)-7;0O#M[J4</GRPQYBBSC>Y.%7\6(% &9!\.O"=K'LM]&BA7!&(I'7K]
M&KR36/"FE>%/V@?"T6DQ/#!=!9FB9RX5OG4X+$G'RCJ:O3>!_C+J]X-3F\5V
M]C*7WBV2]E1(^^W:B%2!TYS6"NH>(+CXX^%=/\3K$=6TXK!)-#]V92&97'3D
MAN>!TH ^DZ*** "BBB@ HHHH A_T:RMS_JX(5))Z*HR<D_B3^M51JNE37L%L
MM]:273Y,4:R*SG .2 .>F>:Y+XJPQ2Z-I33Z/=ZQ%'J,;-8VZ[O.&Q\AAD'&
M,D=>0.*P_")TJ/Q;ID=G\.KOP]*PDQ>7$03($;97(Y.>.M 'JES<P6=O)<7,
MT<,,:[GDD8*JCU)/2N!\16.GKXFN+MO%&E:>M[#%(\=PR>:LL63#*A+#Y0<$
M@\'!]:Z[Q)@>&]0+:6-500L6L3SYX'51P<GT&.M>977B"[UG6#;W?P>2\O;>
M",,+B:&3RHB6VC+(0.=W'6@#I_AO))<G6[RYU_3=8NKBY1Y6TT'R8\(% ![D
M@9-=V:X7X;W1G&M0S>%[/P[<P7*(]I;;>04!#-M '.3SCG\*[J@#QFX;P7H5
M[?0>*?#&H:AK5S/)))//8&Y,P+';Y3] N,  8QWYKTKP<UVWA+3VO;9[69HR
M1;R'+11[CY:'W";0<\\5%;>--'OM4U;3;&26[NM+0-<+!'N]<JI_B88Y ^G6
MM?3=1M-7TZ#4+"99K6=-\<B]"/Z'L1V- #=5AFN-(O8;>3RYY('2-]V-K%2
M<]N:\3,6I-X5N_!^@^$-6@-UJ$;P74R;H+=0(RTHFW$,=ZL00<<Y'I7MFJVS
M7ND7MJFS=/ \8WYVY92.<=N:\;T/_A/-.\*10V/C#PJ+"U(LD:)=X23@!&?;
MM#9( )ZDCUH ]N0,(U#-N8#DXQDUSGCN2PMO"\U]?7ALS:.LUO<K")6CFSA2
MJ?Q$Y(QW!/2ND7[HSUKG?&OD#0T>6\^Q2)<1O!<-$9$CD!^4NO=?7TZ\8S0!
MPW@O2;LZ[X8NO$&O07"V^FYT*VAMS$KJ8P&8D\LXCP2O;.>QKURO+O"W@SQ#
M<ZKX?U'7M7TFYT_0H#'IT6F!B),IL#NQ[X X'']?4: "BBB@ KS#XBFWUOQ%
M#X=B\%_\)!?1V8NVE^WBS,,9<J 'ZGD'C^?;T^O(OB#-I4?Q'M?[>\4WVAV0
MTH^0]A,T,ID,OS!F522I '&>J]NX!T7PYL[O28[S3)/"<?ARUC"210I<_:3*
MS%MS&4=3P!CJ /0BN[KSCX;S:!-K6K?V%XCU+70+> 23W\KRLGS2856;''?&
M._4YP/1Z "BBB@ HHJCK-E/J.CW=G:WDME<31%8[B(X:-NQ% %+5/"6B:SJD
M>I7]BLMU' ]OOW, T;@AE8 X888]>F>*;X9\):7X3ANHM,$Y%S())&GF,C$@
M  9/. !@5YY=:)<Z5XGN-.UCXF:U86IMHY;22XNXXS,V6$@W,,?+A..OS5N?
M"Z<M>>)[:'7+W6[&"]C$%_<SB42$Q*7"L!V/'!QTQ[@'HE%%% !1110 4$X%
M%% 'E6K_ !-U^_U'4-(\*^'C%<V,337%SJY\KRT /*Q9W-TX.?PQ6S\/M#UA
M$B\3:SKLNIW6J62.8V0(D ;#JJ*.!P>?<5UNJZ+INN6IMM2LXKF,@@;QRN>N
M".1^%9FB^'KW0]31(-6GGT1+8Q0V=P0S0,"NW:V,LNT$?,21[Y. #HJ*** "
MBBB@ HHHH **R]7\2:)H(C_M;5;.R,GW!/,J%OH#R:NV=[:ZC:I=65S#<V[_
M ')89 Z-]".#0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ[B['  ]<^E<1XCTOQI_PEW]J>%5\/K%)9+!,^I+)N8AV8 %,G SQTZGKQ@
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M:,[<X.">G2@#D?'%]<S^*-*TB:UTR?13)!]MBO(P[S>:[(-@(( 4KDGW%7_
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MK#(/;GTKJM!U_P 9:AK\-MK?A--&L3#(QE%]'<%W&W:/E^[P6Z]: .THHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\-[BWUGQ;JNN7GB&PU77);<1>5IR.(+:W#9"@L 22?7T[UZG0 4444 %%%%
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M<UH'_(V^*_\ KYM__2=*Z6N=T2/R_%?B=LYWSV[?3]RH_I0!T5%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)JSI6K^-++QSI6E^*+O03#?6UP8XM.67<63:<G>/3./JWM0!Z'1110 4444
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M+9V.?]K@J?<9[T ;]8&D _\ "6>(VSQOMQC_ +9"M^N;T:9CXU\30%<*HM9
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M*IA_=M\Z.JD,?X2/]OD8KF?AY+X-3QO;IH5UK&M7C6SQ?:[]7/V.- -BKE%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR:6)S("YQ\Y)VX''R^F?H >UZ)_:0T6T_M@QG4?+'V@Q?<W]]OMZ5Y_\3O\
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MG>(=!DEUB/2M#5I9+V>0*%D<!?+B9VX4-EC[[<=:K^&O$\&N>.];M=*OEO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0JCRV0_=(QGH/O9YZT :WB/Q-I/A32VU#6+GR+<':IVEBS8S@ =^*X&X\?\
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M?N(([JVEMYE#12H4=3W!&"*YW1H$O]#NO#6JCS)K-?LTN>#)'C]W(/J .>S
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MRGA\@A=P_NDC% 'AUG?>&;."QM+;XD^)7MP8X8[1[>01GD+M;*C"9[9Z<5]
MUYM?:+\2=:LUTK4KSPW%:-(C2W<$<K2X#;LJK# 8$#!]17I- !1110 &N6T_
MP-IUMX<N-!O,7NGR7;W,:2+@IN?S ,YY(;//'%=37EOA7Q;XXU+2+G4TTVPU
MBWBOIK?R(Y/L]P%5L#!/R-USSMZ=Z .MN_LTOQ$TP'4(EN8+"=EL_+8NZNR
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MI6H>-+!H+;QA/*UG++!<ZY*QC1#MY09(.X$<Y]/7@ ]<HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_)2]6_[!%E_Z.N: ..\8^-=+O=;73TBURU33;KRY-?LH,PV<I&UE9B"",,
M<^OM73:5X'.F^)8=476KN:PMDD%EIS ".W,F-V&'5>.%(PO;H*YN[\*>/KC1
MM9T2RG\/0:3?3W843I+YXCEE<Y)7Y<X;CCIBNBT>U\=0:OI_]M7>D2Z:BLLB
M6$4B-NV';N+$Y7\N<<4 =E1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSV)S\\# @Y]?ESZUYQXCU>W\3_#2[O#X(ATY[6XC\K5+.V2"*3+ 889SR&Z
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MUQOPZU:ZUK2+Z\:.X73&O9/[,>Y),DEOQ@DMR1G=C/.,>E=E0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[/&,$YS]>HKJ+.ZAOK*"[MW#P3QK)&P[J1D'\C7-_$&W^U^%GAG:9=.:>/\
MM#R WF?9]WSXV\^F<?PYH Q- G\476OZ?_:/@_1K&RCD8M=6MRDKQ'RW P%Z
M9SCZ&O1:\A\.-X(B\9Z3:^ (&:969K^XMS*T(@\MOE<L<9+!,>XKUZ@#*U:'
M09);8:S%IK22.([?[8J$LYZ*F[J?85>MY[67?%;2POY#>6Z1L#Y9 ^Z0.AQC
MBO/_ !_I,LGB/3=7M]._M6ZM1%)#;1W"K+"(YU=W1&(W;E^4GM\O8FKOA"'7
MM3\5ZIXEU73&T>VGMX[2&Q=PTDFQB?-<C@'D@#T^F2 =U7E>JZ!*NMZDVE?#
M#2+\?:MWVV]EC7S244L55ER!DXX.,@UZI7BOC$VTGC?4;6+5O'E]=YCDELM
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&\AMT?F;$SM/<8V_CFNE;[IP<''6@#QJ:+4O$DQ\1:=\,='GDG)DAO+N\02
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M6\ID52J[2Q8J.3QV_A%5;S_DJND?]@>[_P#1L%=77*7G_)5=(_[ ]W_Z-@H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:SN-Q/.>2>_I0!Z"Y8(Q0 MC@$X!/UKRNXUC78_$>J37/PQ_M&<2+&MRL\3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5N1D%<=N/K755PGP[BT.VN-5M](TO6;.51"]Q)JRR+++G>% $AS@8/MS7=T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML7+X 5@#@;>OO725&(8UG><(HE=0C/CD@9('X;C^=24 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %1I;PQS2S1Q(LLI!D<* 7P,#)[\5)10 R2))5"NH8!@V#Z@@@_F!3R 1
M@C(-%% #4C2*-8XT5$4!551@ #H *4HI8,5!8=#CD4M% !1110 4444 %-2-
M(D"(H51T &!3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515709024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 10, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AXOGEN,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-1301878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">13631 Progress Blvd., Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alachua<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">32615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">462-6800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AXGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,521,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,601,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Registrant&#8217;s definitive proxy statement to be filed pursuant to Regulation 14A within 120 days after the end of the Registrant&#8217;s fiscal year are incorporated by reference into Part&#160;III of this Form&#160;10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000805928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515585312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Miami, Florida<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512638160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,284<span></span>
</td>
<td class="nump">$ 32,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">6,251<span></span>
</td>
<td class="nump">6,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments</a></td>
<td class="nump">33,505<span></span>
</td>
<td class="nump">51,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $650 and $276, respectively</a></td>
<td class="nump">22,186<span></span>
</td>
<td class="nump">18,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">18,905<span></span>
</td>
<td class="nump">16,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">98,075<span></span>
</td>
<td class="nump">127,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">79,294<span></span>
</td>
<td class="nump">62,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">14,369<span></span>
</td>
<td class="nump">15,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,649<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">195,387<span></span>
</td>
<td class="nump">208,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">22,443<span></span>
</td>
<td class="nump">22,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LeaseLiabilityCurrent', window );">Current maturities of long-term lease obligations</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,834<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">23,753<span></span>
</td>
<td class="nump">24,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of debt discount and financing fees</a></td>
<td class="nump">45,712<span></span>
</td>
<td class="nump">44,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LeaseLiabilitiesNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">20,405<span></span>
</td>
<td class="nump">20,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Debt derivative liabilities</a></td>
<td class="nump">4,518<span></span>
</td>
<td class="nump">5,562<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">94,388<span></span>
</td>
<td class="nump">95,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies - see Note 14</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value per share; 100,000,000 shares authorized; 42,445,517 and 41,736,950 shares issued and outstanding</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">360,155<span></span>
</td>
<td class="nump">342,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(259,580)<span></span>
</td>
<td class="num">(230,632)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">100,999<span></span>
</td>
<td class="nump">112,550<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 195,387<span></span>
</td>
<td class="nump">$ 208,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LeaseLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LeaseLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512997072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for doubtful accounts</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">42,445,517<span></span>
</td>
<td class="nump">41,736,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,445,517<span></span>
</td>
<td class="nump">41,736,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515720336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 138,584<span></span>
</td>
<td class="nump">$ 127,358<span></span>
</td>
<td class="nump">$ 112,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">24,147<span></span>
</td>
<td class="nump">22,931<span></span>
</td>
<td class="nump">21,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">114,437<span></span>
</td>
<td class="nump">104,427<span></span>
</td>
<td class="nump">90,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">80,228<span></span>
</td>
<td class="nump">73,328<span></span>
</td>
<td class="nump">69,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">27,158<span></span>
</td>
<td class="nump">24,177<span></span>
</td>
<td class="nump">17,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">36,758<span></span>
</td>
<td class="nump">32,338<span></span>
</td>
<td class="nump">26,396<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">144,144<span></span>
</td>
<td class="nump">129,843<span></span>
</td>
<td class="nump">113,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(29,707)<span></span>
</td>
<td class="num">(25,416)<span></span>
</td>
<td class="num">(23,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(624)<span></span>
</td>
<td class="num">(1,356)<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivatives</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="nump">759<span></span>
</td>
<td class="num">(1,569)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,948)<span></span>
</td>
<td class="num">$ (26,985)<span></span>
</td>
<td class="num">$ (23,786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">42,083,125<span></span>
</td>
<td class="nump">41,214,889<span></span>
</td>
<td class="nump">39,966,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">42,083,125<span></span>
</td>
<td class="nump">41,214,889<span></span>
</td>
<td class="nump">39,966,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share - basic (in USD per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share - diluted (in USD per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512367072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 132,153<span></span>
</td>
<td class="nump">$ 396<span></span>
</td>
<td class="nump">$ 311,618<span></span>
</td>
<td class="num">$ (179,861)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of restricted and performance stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of restricted and performance stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares surrendered by employees to pay tax withholdings (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares surrendered by employees to pay tax withholdings</a></td>
<td class="num">(670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">3,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights', window );">Exercise of Credit Facility Option, net of settlement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue', window );">Exercise of Credit Facility Option, net of settlement</a></td>
<td class="nump">3,682<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">3,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,786)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,619,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">123,149<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">326,390<span></span>
</td>
<td class="num">(203,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of restricted and performance stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of restricted and performance stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">5,467<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">5,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,985)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">41,736,950<span></span>
</td>
<td class="nump">41,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 112,550<span></span>
</td>
<td class="nump">$ 417<span></span>
</td>
<td class="nump">342,765<span></span>
</td>
<td class="num">(230,632)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">15,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of restricted and performance stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of restricted and performance stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of stock options and employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan', window );">Exercise of stock options and employee stock purchase plan</a></td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,948)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">42,445,517<span></span>
</td>
<td class="nump">42,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 100,999<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="nump">$ 360,155<span></span>
</td>
<td class="num">$ (259,580)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Settlement of Warrants and Rights, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Settlement of Warrants and Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Options Exercised and Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446509345744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,948)<span></span>
</td>
<td class="num">$ (26,985)<span></span>
</td>
<td class="num">$ (23,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,827<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_RightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1,761<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and deferred financing fees</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debt</a></td>
<td class="nump">612<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory write-down</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">3,314<span></span>
</td>
<td class="nump">2,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Investment losses (gains)</a></td>
<td class="num">(228)<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivatives</a></td>
<td class="num">(1,044)<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">15,591<span></span>
</td>
<td class="nump">10,919<span></span>
</td>
<td class="nump">8,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(4,639)<span></span>
</td>
<td class="num">(499)<span></span>
</td>
<td class="num">(635)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,656)<span></span>
</td>
<td class="num">(7,478)<span></span>
</td>
<td class="num">(910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(84)<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
<td class="num">(2,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">660<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease obligations</a></td>
<td class="num">(1,841)<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="num">(1,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Cash paid for interest portion of finance leases</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract and other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,066)<span></span>
</td>
<td class="num">(13,405)<span></span>
</td>
<td class="num">(9,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(20,078)<span></span>
</td>
<td class="num">(27,811)<span></span>
</td>
<td class="num">(21,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_ProceedsFromGrantorsInvestingActivities', window );">Economic development grant proceeds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">950<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(39,247)<span></span>
</td>
<td class="num">(68,699)<span></span>
</td>
<td class="num">(77,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of investments</a></td>
<td class="nump">57,300<span></span>
</td>
<td class="nump">72,500<span></span>
</td>
<td class="nump">83,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Cash payments for intangible assets</a></td>
<td class="num">(1,175)<span></span>
</td>
<td class="num">(589)<span></span>
</td>
<td class="num">(692)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(3,200)<span></span>
</td>
<td class="num">(23,649)<span></span>
</td>
<td class="num">(16,963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from the paycheck protection program loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of the paycheck protection program loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(642)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Cash paid for debt portion of finance leases</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from exercise of stock options and ESPP stock purchases</a></td>
<td class="nump">1,806<span></span>
</td>
<td class="nump">5,467<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of employee tax withholdings in exchange of common stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">20,452<span></span>
</td>
<td class="nump">40,474<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(17,472)<span></span>
</td>
<td class="num">(16,602)<span></span>
</td>
<td class="nump">13,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">39,007<span></span>
</td>
<td class="nump">55,609<span></span>
</td>
<td class="nump">41,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">21,535<span></span>
</td>
<td class="nump">39,007<span></span>
</td>
<td class="nump">55,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest, net of capitalized interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="nump">822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Acquisition of fixed assets in accounts payable and accrued expenses</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Acquisition of leasehold asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt', window );">Embedded derivative associated with the long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
<td class="nump">2,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability', window );">Obtaining a right-of-use asset in exchange for a lease liability</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">14,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_NoncashOrPartNoncashConversionOption', window );">Conversion of the Credit Facility option</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Acquisition of intangible assets in accounts payable and accrued expenses</a></td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Embedded Derivative Associated With The Long Term Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_NoncashOrPartNoncashConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Conversion, Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_NoncashOrPartNoncashConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the noncash amount of right of use assets and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ProceedsFromGrantorsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Grantors, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ProceedsFromGrantorsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_RightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_RightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512851408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature&#8203; of&#8203; Business</a></td>
<td class="text">Nature of Business &#160;&#160;&#160;&#160;<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axogen,&#160;Inc. (together with its wholly-owned subsidiaries, the &#8220;Company&#8221;) was incorporated in Minnesota and is the leader in the science, development and commercialization of the technologies used for the peripheral nerve regeneration and repair. The Company's products include Avance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Nerve Graft, Axoguard Nerve Connector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Protector</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axoguard Nerve Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Axotouch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Two-Point Discriminator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is headquartered in Florida. The Company has processing, warehousing, and distribution facilities in Texas and Ohio.</span>The Company manages its operations as a single operating segment. Substantially all of the Company's assets are maintained in the United States. The Company derives substantially all of its revenues from sales to customers in the United States.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446600329056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). All intercompany accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant estimates affecting the amounts reported or disclosed in the consolidated financial statements include the realizable value of inventories, the valuation of stock-based compensation and the valuation of derivative instruments and the fair value of debt instruments. Other estimates that affect the amounts reported or disclosed in the consolidated financial statements include the allowance for doubtful accounts, the useful life and recoverability of long-lived assets, incremental borrowing rates for operating leases, accounting for income taxes including the realizability of deferred tax assets and the related valuation allowance. The Company bases its estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified for consistency with the current year presentation. Specifically, finance lease right-of-use assets which were presented separately in 2021, and are now included in property and equipment. In addition, the debt derivative liability was included in net operating loss carryforwards in deferred assets in 2021, it is presented separately as debt derivative liability in deferred tax assets. See Note 12 - Income Taxes. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk and Uncertainties</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020, and the virus has continued to spread through 2022. The related responses by public health and governmental authorities to contain and combat the outbreak and spread of the virus, have adversely impacted global commercial activity, hospital staffing, elective surgeries, supply chains and contributed to significant volatility in financial markets. The Company experienced a decrease in demand for its products and services during 2020 and 2021, due to the lack of access to hospitals and health care facilities and the reallocation of resources from surgical procedures to COVID-19 patient care as well as the related staffing shortages in health care had a material adverse effect on the Company's results of operations. This negative impact began to improve in 2022, particularly in the second half of the year; however, the inflationary pressure and the ensuing recession may have a negative effect on the demand for the Company's products, services and the Company's operating results.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on its suppliers, including single source suppliers, and the inability of these suppliers to deliver necessary components of its products in a timely manner at prices, quality levels and volumes acceptable to the </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company, or its inability to efficiently manage these components from these suppliers, could have a material adverse effect on its business, financial condition and operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of acquisition. Certain of the Company's cash and cash equivalents balances exceed Federal Deposit Insurance Corporation ("FDIC") insured limits or are invested in money market accounts with investment banks that are not FDIC-insured. The Company places its cash and cash equivalents in what they believe to be credit-worthy financial institutions. As of December&#160;31, 2022, $15,034 of the cash and cash equivalents balance was in excess of FDIC limits. </span></div><div style="margin-top:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent those required to be set aside to meet contractual terms of a lease agreement held by the Company.See Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same reported in the consolidated statements of cash flows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:72.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,007&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments consist of commercial paper and U.S. government securities, are classified as available-for-sale and have maturities less than one year as of each balance sheet date. Investments are carried at fair value based upon quoted market prices. The Company elected the fair value option ("FVO") for all of its available-for-sale investments. The FVO election results in all changes in unrealized gains and losses being included in investment income in the consolidated statements of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Account receivables are recorded at invoiced amounts and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or other security to support its receivables.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance for doubtful accounts is established for estimated uncollectible receivables based on the Company's assessment of the collectability of customer accounts and recognizes the provision in general and administrative on the consolidated statements of operations. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. Uncollectible receivables are written off against the allowance for doubtful accounts when all attempts to collect the receivable have been exhausted. The provision for bad debts is recorded as a component of general and administrative expenses on the consolidated statement of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration Risk</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions and trade receivables. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products are sold on an uncollateralized basis and on credit terms. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the Company's customers accounted for 10% or more of the consolidated revenues during the years ended December&#160;31, 2022, 2021 and 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisting of materials, direct labor and manufacturing overhead, are stated at the lower of cost or net realizable value. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf-life. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage. To estimate the amount of inventory that will expire prior to being distributed, the Company reviews inventory quantities on hand, historical and projected distribution levels, and historical expiration trends. The Company&#8217;s calculation of the amount of inventory that will expire prior to distribution has two components: 1) a demand or consumption-based component that compares projected distribution to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being distributed. The Company&#8217;s model assumes that inventory will be distributed on a first-in, first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that significant portions of the Company&#8217;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written down involves significant judgments and estimates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are stated at historical cost less accumulated depreciation and amortization. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset&#8217;s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg2NTE3MQ_1b1457ed-1497-471b-a70d-aa52a8985c35">three</span> to seven years. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains or losses on the disposition of property and equipment are recorded in the period incurred and recorded general and administrative expenses on the consolidated statement of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Interest</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest cost on capital projects, including facilities build-outs, is capitalized and included in the cost of the project. Capitalization begins with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. For the years ended December&#160;31, 2022, and 2021, the Company capitalized $6,155 and $4,277, respectively, of interest expense into property and equipment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes long-lived assets (asset groups), including property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. The Company tests annually, in the third quarter, for impairments. An impairment is recognized when the estimated undiscounted cash flows generated by those assets is less than the carrying amounts of such assets. If it is determined that long-live asset (asset groups) is not recoverable, an impairment loss would be calculated based on the excess of the carrying value of the long-lived asset (asset groups) over the fair value of the long-lived asset (asset groups). There have been no impairments of long-lived assets during the years ended December&#160;31, 2022, 2021, and 2020. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are not subject to amortization, however, annually in the third quarter or whenever an event occurs or circumstances indicate that the indefinite-lived intangible assets may be impaired, the Company evaluates qualitative factors to determine whether it is more likely or not that the fair value of the indefinite lived asset is less than its carrying amount. The Company's qualitative evaluation includes an assessment of factors, including specific operating results as well as industry, market and general economic conditions. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, net</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are recorded at cost and include patents and patent application costs, licenses, and trademarks. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives and reported net of accumulated </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortization. Amortization expense is recorded in general and administrative expenses on the consolidated statements of operations. The useful lives of intangible assets are as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">License agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: 17 to 20 years</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patents: up to 20 years. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trademarks: indefinite lived</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company pays royalty fees based on net sales of the licensed products, which are recorded in sales and marketing on the consolidated statements of operation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Nerve Foundation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company may make contributions to the Global Nerve Foundation ("GNF"), a related party, due to certain executives of the Company being members of GNF's board of directors. The GNF was incorporated in 2021 exclusively for charitable, educational, and scientific purposes and qualifies under IRC 501(c)(3) as an exempt private foundation. Under its charter, the GNF engages in activities that focus on improving the awareness and care of patients with peripheral nerve injuries through grants, contributions and other appropriate means. The GNF is a separate legal entity and is not a subsidiary of the Company; therefore, its results are not included in the accompanying consolidated financial statements. The Company contributed $700 to the GNF during the year ended December&#160;31, 2022, no amounts were contributed previously. These contributions were recorded in sales and marketing expense on the consolidated statement of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Cash equivalents, investments and derivative instruments are recorded at fair value on a recurring basis. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for classification and disclosure of fair value measurements as follows:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its debt instruments in determining whether there are embedded derivative instruments, which are required to be bifurcated and accounted for separately as a derivative financial instrument. Embedded derivatives that are not clearly and closely related to the debt host are bifurcated and are recognized at fair value on the consolidated balance sheet with changes in fair value recognized as either a gain or loss on the consolidated statement of operations each reporting period. The fair value of embedded derivatives are measured based on equity markets and interest rates, as well as an estimate of the Company's nonperformance risk adjustment. This estimate includes an option adjusted spread and an estimate of the Company's risk-free rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if a contract contains a lease at the inception date and determines the lease classification, recognition, and measurement at commencement date. All operating lease commitments with a lease term greater than 12 months are recognized as right-of-use assets and obligations on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies a lease based on whether the arrangement is effectively a purchase of the underlying asset. Leases that transfer the control of the underlying asset are classified as finance leases and all others are classified as operating leases. Interest and amortization expense are recognized for operating leases on a straight-line basis. If a change to the lease term leads </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to a reassessment of the lease classification and remeasurement, assumptions such as the discount rate and variable rents based on a rate or index will be updated as of the remeasurement date. If an arrangement is modified, the Company will reassess whether the arrangement contains a lease. Any subsequent changes in lease payments are recognized when incurred, unless the change requires a remeasurement of the lease liability.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's leases include options for the Company to extend the lease term. The exercise of lease renewal option is generally at the Company's sole discretion. Certain of the Company's lease agreements include provisions for the Company to reimburse the lessor for common area maintenance, real estate taxes, and insurance, which the Company accounts for as variable lease costs. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection. Revenue is recognized when the Company transfers of control of the products and services to the Company&#8217;s customers when the product is shipped or when it is delivered to the customer depending on the agreement. Products are primarily transferred to customer at a point in time. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract. These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#8217;s cost. The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and therefore, the Company has determined it is appropriate to recognize revenue when: i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement. Determining the timing of revenue recognition for such contracts is subject to judgment, because an evaluation must be made regarding the distributor&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company. Changes in these assessments could have an impact on the timing of revenue recognition from sales to distributors. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing, and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#8217;s contracts vary; however, as a common business practice, payment terms are typically due in full within 30 days of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material. The Company has several contracts with distributors in international markets that include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Government Assistance</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As there is no authoritative guidance under U.S. GAAP for accounting for grants to for-profit business entities, the Company accounts for the grants by analogy to International Accounting Standard ("IAS") 20 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20")</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Government assistance and grants are recognized when there is reasonable assurance that the Company has met the requirements of the assistance and there is reasonable assurance that the grant will be received. The Company received government grants of $158, $1,164 and $628 during the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Costs of Goods Sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes direct labor and materials costs related to each product sold or produced, including processing, quality assurance labor and scrap, inbound freight costs, as well as facility and warehousing overhead supporting the Company's manufacturing operations. All of the Company's manufacturing costs are included in cost of goods sold on the consolidated statements of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Costs of research and development activities relate to product development, clinical trial expenses for the improvement of existing products, and technical support of products. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment. The Company received certain government grants totaling $158, $214, and $390 which were recorded as an <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_53f04da6-b4de-4448-a842-3ba64e7044cf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_d6f381e2-5ace-449f-8744-bd43ca3d4c2a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_e7410970-08ee-44c3-807d-dbdd552f3cb6">offset to research and development</span></span></span> in the consolidated statement of operations during the years ended December&#160;31, 2022, 2021 and 2020, respectively</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shipping and handling costs, including facility and warehousing overhead, directly related to bringing the Company&#8217;s products to their final selling destination are included in sales and marketing expenses on the consolidated statements of operations were $5,271, $4,883, and $3,912 for the December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the consolidated balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation is in the form of stock options, restricted stock units ("RSU"), performance stock units ("PSU"), and recognized at, or above, the fair market value of the Company's common stock on the date of grant.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of each stock option award on the date of grant using a multiple-point Black-Scholes option-pricing model. In addition, the Company measures stock options granted to employees at a premium price based on market conditions, such as the trading price of the Company&#8217;s common stock, using a Monte Carlo Simulation option-pricing model in estimating the fair value at the grant date.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of RSU grants based upon the grant date closing market price of the Company&#8217;s common stock.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the PSU grants is based on the Company&#8217;s closing stock price on the grant date. The number of PSUs that will ultimately be earned is based upon the Company&#8217;s performance as measured against specified targets over the measurement period. Expectations related to the achievement of performance goals associated with PSU grants is assessed as of each reporting period and is used to determine whether PSU grants are expected to vest. If performance-based milestones </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for all stock-based compensation awards, including stock options, RSUs, and PSUs granted to employees eligible for retirement, as defined within the award notice and allowing for continued vesting post-retirement, over the retirement notice period and continuously updates its estimate of expense over the notice period each reporting period if a retirement notice has not been provided. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense related to the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) based on the estimated fair value of the options on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of fair value using option-pricing models, as indicated above, is affected by the Company&#8217;s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company&#8217;s expected stock price volatility over the expected term of the awards. The Company determines the expected term of each award giving consideration to the contractual terms, vesting schedules, and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected term of the award. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. The expense is reduced for forfeitures as they occur.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic net loss per common share is computed by dividing reported net loss by the weighted average number of common shares outstanding during the period without consideration of potentially dilutive securities. Diluted net loss per share reflects the potential dilution that could occur if contracts to issue common stock were exercised or converted into common stock of the Company. Diluted net loss per share is the same as basic net loss per common share for all periods presented, since the effect of the potentially dilutive securities are anti-dilutive. Potential dilutive common share equivalents consist of the incremental common shares issuable upon exercise of vested stock options, RSUs, and PSUs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Financial Accounting Standards Board ("FASB") amended Accounting Standards Codification ("ASC") 848 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (issued under Accounting Standards Update ("ASU") 2020 - 4, Reference Rate Reform). The amendment in this update defers the sunset date of Topic 848 from December 31, 2022, to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. The Company has not yet assessed the impact of the deferral on its consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, FASB amended ASC 832, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (issued under ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosures by Business Entities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">bout Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). This amendment requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy, including, (1) the types of transactions; (2) the financial statement line items affected by the transaction: and (3) significant terms and conditions associated with the transactions. The Company adopted the guidance on January 1, 2022, and the adoption of ASU 2021-10 had no impact on the Company's consolidated financial condition, results of operations and an immaterial impact on disclosures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other ASUs issued and not yet effective as of December 31, 2022, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company&#8217;s current or future financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446600243312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for inventory write-down is for the years ended as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:44.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.140%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for inventory write-down</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The provision for inventory write-down for the year ended December&#160;31, 2021, included the Avive write-down of $1,251. The Avive write-down resulted from the Company announcing on May 17, 2021, it was suspending market availability of Avive effective June 1, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513607056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement <div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2022, and 2021:</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"/></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt derivative liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Level 3 liabilities measured at fair value on a recurring basis were as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"/><td style="width:74.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Derivative Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There were no changes in the levels or methodology of the measurement of financial assets or liabilities during the years ended December&#160;31, 2022, and 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of cash, restricted cash, accounts receivable, accounts payable and accrued expenses approximates the carrying values because of the short-term nature of these instruments. The carrying value and fair value of the Credit Facility were $45,712 and $50,293 at December&#160;31, 2022, respectively, $45,325 and $52,605 at December&#160;31, 2021, respectively. See Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees .</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The debt derivative liabilities are measured using a &#8216;with and without&#8217; valuation model to compare the fair value of each tranche of the Credit Facility including the identified embedded derivative feature and the fair value of a plain vanilla note with the same terms. The fair value of the Credit Facility including the embedded derivative features was determined using a probability-weighted expected return model based on four potential settlement scenarios for the Credit Facility included in the table below. The estimated settlement value of each scenario, which would include any required make-whole payment (see </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees ), is then discounted to present value using a discount rate that is derived based on the initial terms of the Credit Facility at issuance and corroborated utilizing a synthetic credit rating analysis. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant inputs that are included in the valuation of the debt derivative liability - first tranche include:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Input</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Remaining term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturity date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Coupon rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5% - 12.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue participation payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.90%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Probability of mandatory prepayment before 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated timing of mandatory prepayment event before 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Probability of mandatory prepayment 2024 or after</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated timing of mandatory prepayment event 2024 or after</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Probability of optional prepayment event</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated timing of optional prepayment event</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents a significant unobservable input.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant inputs that are included in the valuation of the debt derivative liability - second tranche include: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Input</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coupon rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5% - 12.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue participation payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of mandatory prepayment before 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated timing of mandatory prepayment event before 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of mandatory prepayment 2024 or after</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated timing of mandatory prepayment event 2024 or after</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of optional prepayment event</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated timing of optional prepayment event</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents a significant unobservable input.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513003360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases administrative, manufacturing, research and distribution facilities through operating leases. Several leases include fixed payments including rent and non-lease components such as common-area or other maintenance costs. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of total lease expense for the years ended were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the operating and financing leases is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except lease term and discount rate)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use operating assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_282ba7ce-3ef3-47fa-b090-df6bc8c1cb62"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_bf9cd539-7ed8-407f-9081-99b74e7abdea">Current maturities of long-term lease obligations</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_43b1e322-811d-4e24-9d5c-24c744c9ffc6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_90aa3a79-3bec-4569-a69a-52d996616d6a">Long-term lease obligations</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use financing leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_271319ea-950a-424e-8fc3-fea671d857ad"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_51dc3b73-6881-4d4b-ad5d-be166f123d9e">Current maturities of long-term lease obligations</span></span> </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_ad5ae935-b90b-46e6-8d03-aa77e93ca8d3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_d55777eb-f537-4f2f-82c6-3481b4ecb124">Long-term lease obligations</span></span> </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average operating lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average financing term (in years):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate financing leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Financing leases are included in property and equipment, net on the consolidated balance sheets. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating and financing leases as of December&#160;31, 2022, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,405&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease modifications</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for lease revisions as a lease modification in accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the modification effectively terminates the existing lease and creates a new lease.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2021, the Company entered into the Seventh Amendment to a License and Services Agreement ("Seventh Amendment") with Community Blood Center (doing business as Community Tissue Services) ("CTS"), with an effective date of February 22, 2021, pursuant to the original agreement dated August 6, 2015, as amended ("CTS Agreement"). The CTS Agreement is for processing of the Avance Nerve Graft in Dayton, Ohio. The Seventh Amendment extended the term of the agreement to December 31, 2023. Under the CTS Agreement, the Company pays CTS a facility fee for use of clean room/manufacturing, storage, and office space, which the Company accounts for as an embedded lease. The Company valued the CTS Agreement using a 6.3% incremental borrowing rate and recorded a right-of-use asset  and a lease liability of $272 as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, the Company entered into the First Amendment to Office Lease ("Heights Union First Amendment") with Cousins Heights Union, LLC (as successor in interest to Heights Union I, LLC), with an effective date of July 12, 2021, pursuant to the original lease dated September 20, 2018, as amended ("Heights Union Lease"). The Heights Union Lease is for the general office, medical laboratory, training, and meeting purposes located in Tampa, Florida. The Heights Union First Amendment revises the commencement date of the Heights Union Lease to mean October 30, 2020 and revises the termination date of the Heights Union Lease to be October 31, 2034. Pursuant to the Heights Union First Amendment, the Company was entitled to an additional 1.5 months of free rent. The Company valued the Height Union Lease using a 10.6% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $299 as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 13, 2021, the Company entered into a Sixth Amendment to Lease ("Sixth Amendment") with Alachua Copeland Park Investments, LLC (as successor in interest to Ology Bioservices Holdings, LLC, who was successor in interest to SNH Medical Office Properties Trust), with an effective date of July 13, 2021, pursuant to the original lease agreement dated February 6, 2007, as amended ("Alachua Lease"). The Alachua Lease is for the Company's corporate headquarters in Alachua, Florida. The Sixth Amendment extended the term of the Alachua Lease to October 31, 2026. The Company valued the Alachua Lease using a 10.6% incremental borrowing rate and recorded a right-of-use asset of $1,335 and a lease liability of $1,370 as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2022, the Company entered into a Commercial Lease Amendment ("Amendment") with JA-Cole L.P., with an effective date of February 1, 2022, pursuant to the original Commercial Lease dated April 21, 2015, as amended (the "2015 JA-Cole Lease"). The 2015 JA-Cole Lease is for the office and warehouse facility located in Burleson, Texas. The Amendment revised the commencement date to May 1, 2022, and the expiration date to April 30, 2027. The Company valued the 2015 JA-Cole Lease using a 11.3% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $641 as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2022, the Company entered into the First Amendment to Lease Agreement (the &#8220;First Amendment&#8221;) with JA-Cole, L.P. with an effective date of October 1, 2022, pursuant to the original Commercial Lease dated October 1, 2020, as amended (the "2020 JA-Cole Lease"). The 2020 JA-Cole Lease is for the office and warehouse facility located in Burleson, </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Texas. The First Amendment adds an additional 2,500 square feet to the Leased Premises, for a total of 5,000 square feet and revises the expiration date of the 2020 JA-Cole Lease to mean September 30, 2027. The Company valued the 2020 JA Cole Lease using a 12.8% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $221 as a result of this amendment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2022, the Company entered into the Second Amendment to Lease Agreement (the "Second Amendment") with SNH Medical Office Properties Trust n/k/a Nucleic Acids Licensing, LLC with an effective date of January 1, 2023, pursuant to the original lease agreement on November 19, 2018, as amended (the "2018 Nucleic Lease"). The 2018 Nucleic Lease is for medical laboratory space in Alachua, Florida. The Second Amendment extends the term of the 2018 Nucleic Lease one year; to December 31, 2023, with the option to extend the term for one additional year. The Company valued the 2018 Nucleic Lease using a 14.0% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $75 as a result of this amendment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases administrative, manufacturing, research and distribution facilities through operating leases. Several leases include fixed payments including rent and non-lease components such as common-area or other maintenance costs. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of total lease expense for the years ended were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the operating and financing leases is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except lease term and discount rate)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use operating assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_282ba7ce-3ef3-47fa-b090-df6bc8c1cb62"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_bf9cd539-7ed8-407f-9081-99b74e7abdea">Current maturities of long-term lease obligations</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_43b1e322-811d-4e24-9d5c-24c744c9ffc6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_90aa3a79-3bec-4569-a69a-52d996616d6a">Long-term lease obligations</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use financing leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_271319ea-950a-424e-8fc3-fea671d857ad"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_51dc3b73-6881-4d4b-ad5d-be166f123d9e">Current maturities of long-term lease obligations</span></span> </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_ad5ae935-b90b-46e6-8d03-aa77e93ca8d3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_d55777eb-f537-4f2f-82c6-3481b4ecb124">Long-term lease obligations</span></span> </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average operating lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average financing term (in years):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate financing leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Financing leases are included in property and equipment, net on the consolidated balance sheets. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating and financing leases as of December&#160;31, 2022, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,405&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease modifications</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for lease revisions as a lease modification in accordance with ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, when the modification effectively terminates the existing lease and creates a new lease.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2021, the Company entered into the Seventh Amendment to a License and Services Agreement ("Seventh Amendment") with Community Blood Center (doing business as Community Tissue Services) ("CTS"), with an effective date of February 22, 2021, pursuant to the original agreement dated August 6, 2015, as amended ("CTS Agreement"). The CTS Agreement is for processing of the Avance Nerve Graft in Dayton, Ohio. The Seventh Amendment extended the term of the agreement to December 31, 2023. Under the CTS Agreement, the Company pays CTS a facility fee for use of clean room/manufacturing, storage, and office space, which the Company accounts for as an embedded lease. The Company valued the CTS Agreement using a 6.3% incremental borrowing rate and recorded a right-of-use asset  and a lease liability of $272 as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, the Company entered into the First Amendment to Office Lease ("Heights Union First Amendment") with Cousins Heights Union, LLC (as successor in interest to Heights Union I, LLC), with an effective date of July 12, 2021, pursuant to the original lease dated September 20, 2018, as amended ("Heights Union Lease"). The Heights Union Lease is for the general office, medical laboratory, training, and meeting purposes located in Tampa, Florida. The Heights Union First Amendment revises the commencement date of the Heights Union Lease to mean October 30, 2020 and revises the termination date of the Heights Union Lease to be October 31, 2034. Pursuant to the Heights Union First Amendment, the Company was entitled to an additional 1.5 months of free rent. The Company valued the Height Union Lease using a 10.6% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $299 as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 13, 2021, the Company entered into a Sixth Amendment to Lease ("Sixth Amendment") with Alachua Copeland Park Investments, LLC (as successor in interest to Ology Bioservices Holdings, LLC, who was successor in interest to SNH Medical Office Properties Trust), with an effective date of July 13, 2021, pursuant to the original lease agreement dated February 6, 2007, as amended ("Alachua Lease"). The Alachua Lease is for the Company's corporate headquarters in Alachua, Florida. The Sixth Amendment extended the term of the Alachua Lease to October 31, 2026. The Company valued the Alachua Lease using a 10.6% incremental borrowing rate and recorded a right-of-use asset of $1,335 and a lease liability of $1,370 as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2022, the Company entered into a Commercial Lease Amendment ("Amendment") with JA-Cole L.P., with an effective date of February 1, 2022, pursuant to the original Commercial Lease dated April 21, 2015, as amended (the "2015 JA-Cole Lease"). The 2015 JA-Cole Lease is for the office and warehouse facility located in Burleson, Texas. The Amendment revised the commencement date to May 1, 2022, and the expiration date to April 30, 2027. The Company valued the 2015 JA-Cole Lease using a 11.3% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $641 as a result of this amendment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2022, the Company entered into the First Amendment to Lease Agreement (the &#8220;First Amendment&#8221;) with JA-Cole, L.P. with an effective date of October 1, 2022, pursuant to the original Commercial Lease dated October 1, 2020, as amended (the "2020 JA-Cole Lease"). The 2020 JA-Cole Lease is for the office and warehouse facility located in Burleson, </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Texas. The First Amendment adds an additional 2,500 square feet to the Leased Premises, for a total of 5,000 square feet and revises the expiration date of the 2020 JA-Cole Lease to mean September 30, 2027. The Company valued the 2020 JA Cole Lease using a 12.8% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $221 as a result of this amendment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2022, the Company entered into the Second Amendment to Lease Agreement (the "Second Amendment") with SNH Medical Office Properties Trust n/k/a Nucleic Acids Licensing, LLC with an effective date of January 1, 2023, pursuant to the original lease agreement on November 19, 2018, as amended (the "2018 Nucleic Lease"). The 2018 Nucleic Lease is for medical laboratory space in Alachua, Florida. The Second Amendment extends the term of the 2018 Nucleic Lease one year; to December 31, 2023, with the option to extend the term for one additional year. The Company valued the 2018 Nucleic Lease using a 14.0% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $75 as a result of this amendment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513648368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,482&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,952&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Processing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projects in process </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,660&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,296)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,614)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,923&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_2ffaa088-42a3-4658-a56e-41bcb91c69e1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_6ac65a1e-f9f2-4c6f-9b60-403fe0960398">projects in process</span></span> is a government grant received totaling $1,188 as of December 31, 2022 and December 31, 2021, which was recorded as an offset, and $11,429 and $5,274 of capitalized interest as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation expense is as follows for the years ended:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513768800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.477%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">License agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total amortizable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,258&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,086)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,484&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,284&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,635)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,945&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,086)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amortization expense is as follows for the years ended:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:44.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, future amortization of patents and license agreements are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">License Agreements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has multiple license agreements with the University of Florida Research Foundation and the University of Texas at Austin (the "License Agreements") in which the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the U.S. and international markets. The effective term of the License Agreements extends through the term of the related patents.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. Also, when the Company pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty fees included in sales and marketing on the consolidated statement of operations are as follows for the years ended:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:44.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty fees </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513686112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses&#8203;<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,520&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,863&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts payable and accrued expenses</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,443&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,459&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513588176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt&#8203;, Net of Debt Discount and Financing Fees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Debt&#8203;, Net of Debt Discount and Financing Fees</a></td>
<td class="text">Long-Term Debt, Net of Debt Discount and Financing Fees<div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of debt discount and financing fees consists of the following:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Facility - first tranche</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Facility - second tranche</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less - unamortized debt discount and deferred financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, net of debt discount and financing fees</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,712&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company entered into a seven-year financing agreement (the &#8220;Credit Facility&#8221;) with Oberland Capital and its affiliates TPC Investments II LP and Argo SA LLC (collectively, the "Lender") and obtained the first tranche of $35,000 at closing. On June 30, 2021, the second tranche of $15,000 was drawn down by the Company. The financing costs for this facility were $642 and were recorded as a contra liability to the long-term debt on the consolidated balance sheet. The financing costs were paid as of December&#160;31, 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each tranche under the Credit Facility requires quarterly interest payments for seven years. Interest is calculated as 7.5% plus the greater of the London Interbank Offered Rate ("LIBOR") or 2.0% (11.24% as of December&#160;31, 2022). Each tranche of the Credit Facility has a term of seven years from the date of issuance (with the first tranche issued on June 30, 2020, maturing on June 30, 2027, and the second tranche issued on June 30, 2021, maturing on June 30, 2028). In connection with the Credit Facility, the Company entered into a revenue participation agreement (the &#8220;Revenue Participation Agreement&#8221;) with the Lender, which provided that, among other things, a quarterly royalty payment as a percentage of the Company&#8217;s net revenues up to $70&#160;million in any given year, after April 1, 2021, ending on the date upon which all amounts owed under the Credit Facility have been paid in full. This structure results in approximately 1.0% per year of additional interest payments on the outstanding loan amount. The Company recorded $756 and $646 as interest expense for this Revenue Participation Agreement for the years ended December&#160;31, 2022, and 2021, respectively. The Company pays the quarterly debt interest on the last day of the quarter, and for the years ended December&#160;31, 2022, and 2021, paid $5,074 and $4,103, respectively, to the Lender. The Company capitalized interest of $6,155 and $4,277 for the years ended December&#160;31, 2022, and 2021, respectively, towards the costs to construct and retrofit its APC Facility in Vandalia, OH. See Note 14 - Commitments and Contingencies. To date, the Company has capitalized interest of $11,429 related to this project. The capitalized interest is recorded as part of property and equipment in the consolidated balance sheets. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Lender had the right to purchase up to $3,500 worth of the Company's common stock from the Company in one transaction at any time after closing of the Credit Facility until the later of (i) the date all amounts due under the Credit Facility are repaid and (ii) June 30, 2027 (the &#8220;Credit Facility Option&#8221;). The purchase price of the common stock was calculated based on the 45-day moving average of the closing stock price on the day prior to the purchase. On December 10, 2020, the Lender exercised in full its option under the Credit Facility Option. The exercise price was determined to be $14.13, resulting in gross proceeds to the Company of $3,500 and the issuance of 247,699 shares to a wholly owned subsidiary of the Lender. In conjunction with the issuance of the shares, the Lender received certain protective rights (including protection from down-round stock issuances) for a period of one year subsequent to the issuance. These rights expired on December 10, 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts outstanding under the Credit Facility may be accelerated upon certain events, including: (a) required mandatory prepayments upon an asset sale; (b) in the event the Company is subject to (i) any litigation brought by a Governmental Authority (as defined in the Credit Facility) including intervention after litigation is commenced by a Person (as defined in the Credit Facility), or (ii) any final administrative action by a Governmental Authority, in each case arising out of or in connection with any of the Company&#8217;s registry studies, payments made to doctors or training activities with respect to healthcare professionals (excluding certain final administrative actions that have been fully and finally resolved by the parties pursuant to a settlement agreement) or (c) upon the occurrence of an event of default (either automatically or at the option of the Lender depending on the nature of the event). In addition, the Company has the right to prepay any amounts outstanding under the Credit Facility. Upon maturity or upon such earlier repayment of the Credit Facility, the Company will repay the principal balance and provide a make-whole payment calculated to generate an internal rate of return to the Lender equal to 11.5%, less the total of all quarterly interest and royalty payments previously paid to the Lender. See Note 14 - Commitments and Contingencies for further information related to the make-whole payment calculation.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of an event of default, the interest rate incurred on amounts outstanding under the Credit Facility will be increased by 4%. The Credit Facility includes a financial covenant requiring the Company to achieve certain revenue targets each quarter. As of December&#160;31, 2022, the Company was in compliance with all the covenants. In the event of a failure to meet such covenant the Company may avoid a default by electing to be subject to a liquidity covenant and meeting all of the obligations required by such covenant. The borrowings under the Credit Facility are secured by substantially all of the assets of the Company. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that Credit Facility included separable embedded features on a combined basis as a single derivative feature. The Company estimated the fair value of these features as $2,387 as of the date of issuance of the Credit Facility and recorded this value as a debt derivative liability. As a result of the second tranche draw on June 30, 2021, the Company recorded an additional derivative and estimated the fair value to be $1,961, along with an increase of $1,076 related to the first tranche derivative. See Note 6 - Fair Value Measurement. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The debt derivative liabilities are recorded at fair value, with the change in fair value reported in change in the fair value of the derivative on the consolidated statements of operations at each reporting date. See Note 6 - Fair Value Measurement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unamortized Debt Discount and Financing Fees</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unamortized debt discount consists of the remaining initial fair values of the embedded derivatives related to the Credit Facility. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financing fees for the Credit Facility were $642 and were recorded as a contra liability to long-term debt on the consolidated balance sheet. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of debt discount and deferred financing fees for the years ended December&#160;31, 2022, 2021 and 2020, was $891, $831 and $232, respectively, and recorded in interest expense using the effective interest rate method.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Credit Facilities</span></div>The Company had restricted cash of $6,251 and $6,251 at December&#160;31, 2022, and 2021, respectively. The December&#160;31, 2022, and 2021 balances both include $6,000, which represents collateral for an irrevocable standby letter of credit. In March 2021, the Company entered into an agreement which required an additional irrevocable standby letter of credit in the amount of $250.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513829840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Loss per Common Share</a></td>
<td class="text">Basic and Diluted Loss per Common Share<div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two-class method as of:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted-average common shares outstanding (Basic)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,083,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,214,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,966,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding (Diluted)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,083,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,214,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,966,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per common share (Basic and Diluted)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-dilutive shares excluded from the calculation of diluted earnings per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,133,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,364,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,618,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> These common equivalent shares are not included in the diluted per share calculations as they would be anti-dilutive if the Company was in a net income position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513656544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation <div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains two stock-based incentive plans: the Axogen, Inc. 2019 Amended and Restated Long-Term Incentive Plan, as amended ("2019 Plan") approved by shareholders on May 25, 2022, which provides incentives through the grants of stock options, non-qualified stock options, PSUs and RSUs to employees, directors, and consultants which replaced the Company's 2010 Stock Incentive Plan ("2010 Plan") and the Axogen 2017 Employee Stock Purchase Plan (&#8220;2017 ESPP&#8221;).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the May 25, 2022, Annual Shareholder Meeting, approval was received to increase the number of shares available under the 2019 Plan by 2,500,000 to 8,000,000. The 2019 Plan replaced the 2010 Plan, accordingly, no new grants have been issued under the 2010 Plan.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there were 3,374,881 shares of common stock for future grant under the 2019 Plan.</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is included in the following line items in the accompanying consolidated statements of operations for the years ended:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Costs of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total  stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The options granted to employees prior to July 1, 2017, typically vest 25% one year after the grant date and 12.5% every six months thereafter for the remaining three-year period until fully vested after four years. The options granted to employees after July 1, 2017, typically vest 50% two years after the grant date and 12.5% every six months thereafter for the remaining two-year period until fully vested after four years. The options granted to directors and certain options granted from time to time to certain executive officers have vested ratably over three years or 25% per quarter over one year. Options typically have terms ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI3NjM_61ba867c-4dd3-4803-a6a5-10aa309ff564">seven</span> to ten years. The Company estimates the fair value of each option award on the date of grant using a multiple-point Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur. The value of the portion of the award that is ultimately expected to vest is recognized as </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used in the calculation of fair value for stock options granted for the following periods:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:54.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.667%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's stock option activity for the year ended December&#160;31, 2022:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value              (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,194,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,228,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(267,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(260,963)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,894,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,034,249&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.94</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of stock options granted during the years ended December&#160;31, 2022, 2021 and 2020 was $4.65, $10.53, $4.73, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised for the years ended December&#160;31, 2022, 2021 and 2020 was $2,643, $14,167 and $5,595, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was approximately $6,839 of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of 2.4 years. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted to employees have a requisite service period of four years. The RSUs granted to directors and certain RSUs granted from time to time to certain executive officers have a requisite service period of three years, while certain of these RSUs have a requisite service period of one year. The Company expenses the fair value of RSUs on a straight-line basis over the requisite service period. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for restricted stock units for the indicated periods:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:47.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding Restricted and Performance Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Units</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Fair Value at Date of Grant per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Vesting Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">967,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(265,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(254,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,861,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of restricted stock units granted during the years ended December&#160;31, 2022, 2021 and 2020 was $8.40, $20.13, $9.55, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was approximately $13,756 of total unrecognized compensation costs related to unvested restricted stock. These costs are expected to be recognized over a weighted-average period of 2.74 years. The total fair market value of restricted stock vested during the years ended December&#160;31, 2022, 2021 and 2020 was $2,288, $2,179 and $2,699, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Stock Units</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of the PSUs based on its closing stock price at the time of grant and its estimate of achieving such performance target and records compensation expense as the milestones are achieved. PSUs generally have a requisite service period of three years and are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses their fair value over the requisite service period. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense will be adjusted based upon the Company&#8217;s estimate of achieving such performance target. The number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on the actual performance metrics as set forth in the applicable PSU award agreement. The amount actually awarded will be based upon achievement of the performance measures.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for performance stock units for the indicated periods:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding Restricted and Performance Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Units</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Fair Value at Date of Grant per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Vesting Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">763,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">530,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of performance stock units during the years ended December&#160;31, 2022, 2021 and 2020 was $8.23, $20.70 and $9.58, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was approximately $1,723 of total unrecognized compensation costs related to unvested performance stock. These costs are expected to be recognized over a weighted-average period of 1.86 years. The total fair market value of performance stock vested during the years ended December&#160;31, 2022, 2021 and 2020 was $673, $2,302 and $1,112, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PSU Awards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2017, December 27, 2018, and December 17, 2019, the Compensation Committee of the Board of Directors approved PSU awards to certain employees related to their work on the Company&#8217;s Biologics License Application </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("BLA"). As of December&#160;31, 2022, 294,968 PSU awards were available to vest. The number of shares is allocated to certain milestones related to the BLA submission to and approval by the FDA. These awards are expected to vest beginning when the BLA is submitted to the FDA, which is not expected to be until the second half of 2023. The performance measure is based upon achieving each of the specific milestones and will vest 50% upon achieving each of the milestones and 50% one year later. No expense has been recognized on these awards. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 17, 2020, the Compensation Committee of the Board of Directors approved PSU awards of 144,300 shares tied to 2020 revenue. These awards were granted in mid-year with certain revenue targets adjusted for the impact of COVID-19. These 2020 awards granted in July reached 110% achievement of revenue targets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 16, 2021, the Compensation Committee of the Board of Directors approved PSU awards of 332,200 shares tied to 2022 revenue, with a payout ranging from 0% to 200% upon achievement of specific revenue goals. In the fourth quarter of 2021, it was determined that the performance metrics tied to 2022 revenue were no longer probable; therefore, stock compensation expense related to these awards of $1,831 was reversed in 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 16, 2022, the Compensation Committee of the Board of Directors approved PSU awards of 526,467 shares tied to revenue from 2022 to 2024 with a pay-out range from 0% to 150% upon achievement of specific revenue targets.At December&#160;31, 2022, the total future stock compensation expense related to non-vested performance awards is expected to be $1,693 for those awards issued on March 16, 2022. Future stock compensation expense has not been calculated on the awards for which expensing has not yet begun which include the BLA awards.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017 ESPP</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2017 ESPP allows eligible employees to acquire shares of the Company's common stock through payroll deductions at a discount to market price (currently 15.0%) of the lesser of the closing price of the Company&#8217;s common stock on the first day or last day of the offering period. The offering period is currently 6 months. Participants may not purchase more than $25 or 3,000 shares of the Company&#8217;s common stock in a calendar year through the ESPP. Stock-based compensation expense related to the 2017 ESPP, included in total stock-based compensation expense, was $844, $401 and $493 for the years ended December&#160;31, 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, there were 600,000 shares of the Company's common stock authorized for issuance under the 2017 ESPP and 69,155 shares remain available for issuance.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the weighted average assumptions used in the valuation of ESPP options for the years ended December 31:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"/><td style="width:43.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>The weighted-average grant-date fair value of ESPP options during the years ended December&#160;31, 2022, 2021 and 2020 was $2.87, $5.18, $5.24 respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513650368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities, as measured by enacted state and federal tax rates. Deferred tax assets and deferred tax liabilities are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charitable contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,049&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,744)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,740)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,673)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58,309)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,251)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is provided to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more-likely-than-not that a portion or none of the deferred tax assets will be realized. As of December&#160;31, 2022 and 2021, management assessed the realizability of deferred tax assets. After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management determined that a full valuation allowance was necessary as of December&#160;31, 2022 and2021. The valuation allowance increased by $5,058 during 2022, primarily as a result of the increase in the capitalized research and development costs. The valuation allowance increased by $6,734 during 2021, primarily as a result of the increase in the net operating loss carryforward. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Section 174 of the Tax Cuts and Jobs Act of 2017 ("TCJA") which requires taxpayers to capitalize and amortize research and development expenditures for the tax years beginning after December&#160;31, 2021. This rule became effective for the Company during 2022 and resulted in capitalized research and development costs of $6,357 being recorded to deferred tax assets as of December&#160;31, 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the financial statement income tax benefit and the income tax benefit using statutory rates is primarily due to the valuation allowance. The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate for the years ended December&#160;31, 2022, 2021, and 2020 as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes - net of Federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items and other deductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company had tax-effected net operating loss carryforwards of $42,716 to offset future taxable income. Net operating losses incurred in tax years beginning on or after January 1, 2018, are carried forward indefinitely. Net operating losses incurred in tax years prior to January 1, 2018, are subject to a twenty year carryforward before expiring. A portion of the net operating loss carryforwards may expire due to limitations imposed by Section 382 of the Internal Revenue Code. Future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section&#160;382 as a result of changes in ownership.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. In the normal course of business, the Company is subject to examination by taxing authorities throughout the U.S. These examinations could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with federal, state, and local laws. The Company&#8217;s remaining open tax years subject to examination by federal tax authorities include the years ended December&#160;31, 2019, through 2022. The Company's remaining open tax years subject to examination by state and foreign tax authorities include the years ended December&#160;31, 2018, through 2022. However, for tax years 2004 through 2017, federal and state taxing authorities may examine and adjust loss carryforwards in the years in which those loss carryforwards are ultimately utilized.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation enacted in 2018, titled the Tax Cuts and Jobs Act of 2017, subjects a U.S. shareholder to tax on global intangible low-taxed income (&#8220;GILTI&#8221;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Global Intangible Low-Taxed Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to account for GILTI in the year the tax is incurred.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no recorded income tax expense or income tax benefit for the years ended December&#160;31, 2022, 2021, and 2020 due to the generation of net operating losses, the benefits of which have been fully reserved. The Company does not believe there are any additional tax refund opportunities currently available.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513829840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan&#8203;<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan&#8203;</a></td>
<td class="text">Retirement PlanThe Company sponsors the Axogen 401(k) plan (the "401(k) Plan"), a defined contribution plan covering substantially all employees of the Company. All full-time employees who have attained the age of 18 are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of 3% on the first 3% of the employee&#8217;s annual salary and 1% on the next 2% of the employee&#8217;s annual salary as long as the employee participates in the 401(k) Plan. Both employee contributions and Company contributions vest immediately. Employer contributions to the 401(k) Plan were $1,409, $1,346, and $1,141 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513702048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Service Agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pays CTS a facility fee for the use of clean room/manufacturing, storage, and office space and for services in support of its product process including for routine sterilization of daily supplies, providing disposable supplies and microbial services, and office support. Pursuant to the CTS Agreement, the Company recorded expenses of $2,278, $2,466 and $1,739 for the years ended December&#160;31, 2022, 2021, and 2020, respectively, in sales and marketing expenses. The CTS Agreement terminates December 31, 2023, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#8217;s right to cure, in certain circumstances), or without cause upon 6 months prior notice. We expect to reduce our utilization of CTS in the second half of 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2011, the Company entered into a Master Services Agreement for Clinical Research and Related Services. The Company was required to pay $151 upon execution of this agreement and the remainder monthly based on activities associated with the execution of Axogen&#8217;s phase 3 pivotal clinical trial to support the BLA for Avance Nerve Graft. Payments made under this agreement were $1,254, $1,100 and $1,136 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Distribution and Supply Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2008, the Company entered into an exclusive distribution agreement with Cook Biotech to distribute the Axoguard Nerve Connector and Axoguard Nerve Protector products worldwide and the parties subsequently amended the agreement on February 26, 2018. Pursuant to the February 2018 amendment, the agreement expires on June 30, 2027. The Cook Biotech agreement establishes a formula for the transfer cost of the Axoguard products and requires certain minimum purchases by the Company, although, through mutual agreement, the parties have not established such minimums; and, to date, have not enforced such provision. Under the Cook Biotech agreement, the Company provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders. The agreement allows for termination provisions for both parties. The loss of the ability to sell the Axoguard</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products could have a material adverse effect on the Company's business until other replacement products would be available.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, the Company entered into the Nerve End Cap Supply Agreement (the "Supply Agreement") with Cook Biotech whereby Cook Biotech is the exclusive contract manufacturer of the Axoguard Nerve Cap and both parties have provided the other party the necessary licenses to their technologies for operation of the Supply Agreement. The Supply Agreement expires on August 27, 2027. Under the Supply Agreement the Company provides purchase orders to Cook Biotech and Cook Biotech fulfills the purchase orders.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Axogen Processing Center Facility</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on the continued availability of its processing facilities at the Community Blood Center facility (&#8220;CTS&#8221;) in Dayton, Ohio and could be harmed if the physical infrastructure of this facility is unavailable for any prolonged period of time. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2018, the Company purchased the APC Facility in Vandalia, Ohio, located near the CTS processing facility where Avance Nerve Graft is currently processed. The APC Facility, when and if operational, will be the new processing facility for Avance Nerve Graft to provide continued capacity for growth and to support the transition of Avance Nerve Graft from a Human Cellular and Tissue-based Product pursuant to Section 361 of the Public Health Service Act (PHSA) to a biologic product under section 351 of the PHSA. The APC Facility is comprised of a 107,000 square foot building on approximately 8.6 acres of land. The Company paid $731 for the land and this is recorded as land within Property and equipment, net on the consolidated balance sheets. The Company paid $4,300 for the building and this is recorded in projects in process within Property and equipment, net on the consolidated balance sheets. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 9, 2019, the Company&#160;entered into a Standard Form of Agreement Between Owner and Design-Builder (the &#8220;Design-Build Agreement&#8221;) with CRB Builders, L.L.C., a Missouri limited liability company (&#8220;CRB&#8221;), pursuant to which CRB will renovate and retrofit the APC Facility. The estimated cost pursuant to the Design-Build Agreement was $29,300. Additional costs associated with the renovation, validation and certification of the APC Facility are estimated to be $20,900. For the year ended December&#160;31, 2022, the Company has recorded $10,938 related to renovations and design and build in projects in progress. The Company has recorded $46,354 to date related to this project. In addition to these project costs, the Company has capitalized interest of $6,155 for the year ended December&#160;31, 2022. To date, the Company has capitalized interest of $11,429 related to this project. These items are recorded as projects in process in property and equipment, net on the consolidated balance sheet. The Company anticipates recording an additional $4,000 to $5,000 in 2023. The Company anticipates completion of construction, validation of systems and processes in the first half of 2023 and commence processing in mid- 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company obtained certain economic development grants from state and local authorities totaling up to $2,685 including $1,250 of cash grants to offset costs to acquire and develop the APC Facility. The economic development grants are subject to certain job creation milestones by 2023 and related contingencies. The Company received zero, $950 and $238 from these grants in the years ended December&#160;31, 2022, 2021 and 2020, respectively. These grants have claw back clauses if the Company does not meet these job creation milestones by 2023, the Company has sent requests to the grant authorities for extensions of the job creation milestones; however, the Company has not yet received a decision from the grant authorities regarding whether extensions will be granted. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fair Value of the Debt Derivative Liabilities  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the debt derivative liabilities is $4,518 as of December&#160;31, 2022. The fair value of the debt derivative liabilities was determined using a probability-weighted expected return model based upon the four potential settlement scenarios for the Credit Facility which are described in Note 2 - Summary of Significant Accounting Policies &#8211; Derivative Instruments. The estimated settlement value of each scenario, which includes any required make-whole payment see Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees , is then discounted to present value using a discount rate that is derived based upon the initial terms of the Credit Facility at issuance and corroborated utilizing a synthetic rating analysis. The calculated fair values under the four scenarios are then compared to the fair value of a plain vanilla note, with the difference reflecting the fair value of the Debt Derivative Liabilities. The Company estimated the make-whole payments required under each scenario according to the terms of the Credit Facility to generate an internal rate of return equal to 11.5% through the scheduled maturity dates, less the total of all quarterly interest and royalty payments previously paid to the Lender. The calculation utilized the XIRR function in Microsoft Excel as required by the Credit Facility. If the debt is not prepaid but instead is held to its scheduled maturities, the Company&#8217;s estimate of the make-whole payment for the first and second tranches of the Credit Facility due on June 30, 2027, and June 30, 2028, respectively, are approximately zero. The Company has consistently applied this approach since the inception of the debt agreement on June 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has become aware that the Lender may have an alternative interpretation of the calculation of the make-whole payments that the Company believes does not properly utilize the same methodology utilized by the XIRR function in Microsoft Excel as described in the Credit Facility. The Company estimates the top end of the range of the make-whole payments if the debt is held to scheduled maturity under an alternative interpretation to be approximately $9,000 for the first tranche of the Credit Facility on June 30, 2027, and approximately $4,000 for the second tranche of the Credit Facility on June 30, 2028. Further, if the debt is prepaid prior to the scheduled maturity dates and subject to the alternative interpretation, the make-whole payment would be larger than the amounts herein.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Commitments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive officers of the Company are parties to employment contracts. Such contracts have severance payments for certain conditions including change of control.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Legal Proceedings </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and may be subject to various claims, lawsuits, and proceedings in the ordinary course of the Company's business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Comp</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any's financial condition, results of operations or cash flows. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 9, 2019, Plaintiff Neil Einhorn, on behalf of himself and others similarly situated, filed a putative class action complaint in the United States District Court for the Middle District of Florida alleging violations of the federal securities laws against Axogen, Inc., certain of its directors and officers (&#8220;Individual Defendants&#8221;), and Axogen&#8217;s 2017 Offering Underwriters and 2018 Offering Underwriters (collectively, with the Individual Defendants, the &#8220;Defendants&#8221;), captioned Einhorn v. Axogen, Inc., et al., No. 8:19-cv-00069 (M.D. Fla.). Plaintiff asserts that Defendants made false or misleading statements in connection with the Company&#8217;s November 2017 registration statement issued regarding its secondary public offering in November 2017 and May 2018 registration statement issued regarding its secondary public offering in May 2018, and during a class period of August 7, 2017 to December 18, 2018. In particular, Plaintiff asserts that Defendants issued false and misleading statements and failed to disclose to investors: (1) that the Company aggressively increased prices to mask lower sales; (2) that the Company&#8217;s pricing alienated customers and threatened the Company&#8217;s future growth; (3) that ambulatory surgery centers form a significant part of the market for the Company&#8217;s products; (4) that such centers were especially sensitive to price increases; (5) that the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) that the Company&#8217;s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the Company&#8217;s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the Company&#8217;s key operating metrics, such as the number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. Axogen was served on January 15, 2019. On February 4, 2019, the Court granted the parties&#8217; stipulated motion which provided that Axogen is not required to file a response to the complaint until thirty days after Plaintiff files a consolidated amended complaint. On </span></div>June 19, 2019, Plaintiff filed an Amended Class Action Complaint, and on July 22, 2019, Defendants filed a motion to dismiss. Plaintiff filed opposing papers on August 12, 2019. The Court held a status hearing on September 11, 2019 and stayed all deadlines regarding the parties&#8217; obligations to file a case management report. On December 4, 2019, the parties presented oral arguments. On April 21, 2020, the Court dismissed the complaint without prejudice, finding the Plaintiff failed to state a claim upon which relief could be granted. The Plaintiff filed a Second Amended Class Action Complaint on June 22, 2020. Axogen filed a motion to dismiss on August 6, 2020. The Plaintiff filed an opposition on September 20, 2020. The Court held oral argument on February 25, 2021. On March 19, 2021, the Court dismissed the Second Amended Complaint with prejudice, finding again that the Plaintiff failed to state a claim upon which relief could be granted. On April 14, 2021, Plaintiff filed a notice of appeal. Plaintiff filed its opening brief on June 28, 2021. The Company filed its appellee brief on August 11, 2021. The Plaintiff filed a reply brief on September 14, 2021. The Eleventh Circuit heard oral argument the week of March 8, 2022. On August 1, 2022, the Eleventh Circuit affirmed the dismissal of the complaint with prejudice.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513647136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent EventSilicon Valley Bank (&#8220;SVB&#8221;) was closed on March 10, 2023 by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver. At the time of closing, the Company maintained approximately $8.0&#160;million of its cash in deposit accounts with SVB. The vast majority of the Company&#8217;s cash, cash equivalents and short-term investments reside in custodial accounts held by U.S. Bank for which SVB Asset Management is the advisor. The Company&#8217;s investment portfolio currently does not contain any securities of SVB. On March 12, 2023, the U.S. Treasury, Federal Reserve, and FDIC announced that SVB depositors will have access to all of their money starting March 13, 2023. As of March 14, 2023, the Company had access to all of its money held at SVB.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513607056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule II &#8211; Valuation and Qualifying Accounts - to </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AXOGEN, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II &#8211; VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THREE YEARS ENDED DECEMBER&#160;31, 2022, 2021 AND 2020</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.493%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at Beginning of Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deductions (Charge-offs)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at End of Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(676)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,932&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512183696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation The accompanying consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). All intercompany accounts and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant estimates affecting the amounts reported or disclosed in the consolidated financial statements include the realizable value of inventories, the valuation of stock-based compensation and the valuation of derivative instruments and the fair value of debt instruments. Other estimates that affect the amounts reported or disclosed in the consolidated financial statements include the allowance for doubtful accounts, the useful life and recoverability of long-lived assets, incremental borrowing rates for operating leases, accounting for income taxes including the realizability of deferred tax assets and the related valuation allowance. The Company bases its estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">ReclassificationsCertain prior year amounts have been reclassified for consistency with the current year presentation. Specifically, finance lease right-of-use assets which were presented separately in 2021, and are now included in property and equipment. In addition, the debt derivative liability was included in net operating loss carryforwards in deferred assets in 2021, it is presented separately as debt derivative liability in deferred tax assets. See Note 12 - Income Taxes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk and Uncertainties</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak of the COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020, and the virus has continued to spread through 2022. The related responses by public health and governmental authorities to contain and combat the outbreak and spread of the virus, have adversely impacted global commercial activity, hospital staffing, elective surgeries, supply chains and contributed to significant volatility in financial markets. The Company experienced a decrease in demand for its products and services during 2020 and 2021, due to the lack of access to hospitals and health care facilities and the reallocation of resources from surgical procedures to COVID-19 patient care as well as the related staffing shortages in health care had a material adverse effect on the Company's results of operations. This negative impact began to improve in 2022, particularly in the second half of the year; however, the inflationary pressure and the ensuing recession may have a negative effect on the demand for the Company's products, services and the Company's operating results.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on its suppliers, including single source suppliers, and the inability of these suppliers to deliver necessary components of its products in a timely manner at prices, quality levels and volumes acceptable to the </span></div>Company, or its inability to efficiently manage these components from these suppliers, could have a material adverse effect on its business, financial condition and operating results.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of acquisition. Certain of the Company's cash and cash equivalents balances exceed Federal Deposit Insurance Corporation ("FDIC") insured limits or are invested in money market accounts with investment banks that are not FDIC-insured. The Company places its cash and cash equivalents in what they believe to be credit-worthy financial institutions. As of December&#160;31, 2022, $15,034 of the cash and cash equivalents balance was in excess of FDIC limits. </span></div><div style="margin-top:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash </span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent those required to be set aside to meet contractual terms of a lease agreement held by the Company.See Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments consist of commercial paper and U.S. government securities, are classified as available-for-sale and have maturities less than one year as of each balance sheet date. Investments are carried at fair value based upon quoted market prices. The Company elected the fair value option ("FVO") for all of its available-for-sale investments. The FVO election results in all changes in unrealized gains and losses being included in investment income in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Account receivables are recorded at invoiced amounts and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or other security to support its receivables.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance for doubtful accounts is established for estimated uncollectible receivables based on the Company's assessment of the collectability of customer accounts and recognizes the provision in general and administrative on the consolidated statements of operations. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. Uncollectible receivables are written off against the allowance for doubtful accounts when all attempts to collect the receivable have been exhausted. The provision for bad debts is recorded as a component of general and administrative expenses on the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration Risk</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Risk</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions and trade receivables. </span></div>The Company's products are sold on an uncollateralized basis and on credit terms.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, consisting of materials, direct labor and manufacturing overhead, are stated at the lower of cost or net realizable value. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf-life. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage. To estimate the amount of inventory that will expire prior to being distributed, the Company reviews inventory quantities on hand, historical and projected distribution levels, and historical expiration trends. The Company&#8217;s calculation of the amount of inventory that will expire prior to distribution has two components: 1) a demand or consumption-based component that compares projected distribution to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being distributed. The Company&#8217;s model assumes that inventory will be distributed on a first-in, first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that significant portions of the Company&#8217;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written down involves significant judgments and estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net are stated at historical cost less accumulated depreciation and amortization. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset&#8217;s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg2NTE3MQ_1b1457ed-1497-471b-a70d-aa52a8985c35">three</span> to seven years. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains or losses on the disposition of property and equipment are recorded in the period incurred and recorded general and administrative expenses on the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCapitalizationPolicyPolicyTextBlock', window );">Capitalized Interest</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitalized Interest</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest cost on capital projects, including facilities build-outs, is capitalized and included in the cost of the project. Capitalization begins with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. For the years ended December&#160;31, 2022, and 2021, the Company capitalized $6,155 and $4,277, respectively, of interest expense into property and equipment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes long-lived assets (asset groups), including property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. The Company tests annually, in the third quarter, for impairments. An impairment is recognized when the estimated undiscounted cash flows generated by those assets is less than the carrying amounts of such assets. If it is determined that long-live asset (asset groups) is not recoverable, an impairment loss would be calculated based on the excess of the carrying value of the long-lived asset (asset groups) over the fair value of the long-lived asset (asset groups). There have been no impairments of long-lived assets during the years ended December&#160;31, 2022, 2021, and 2020. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are not subject to amortization, however, annually in the third quarter or whenever an event occurs or circumstances indicate that the indefinite-lived intangible assets may be impaired, the Company evaluates qualitative factors to determine whether it is more likely or not that the fair value of the indefinite lived asset is less than its carrying amount. The Company's qualitative evaluation includes an assessment of factors, including specific operating results as well as industry, market and general economic conditions. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets, net</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, net</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are recorded at cost and include patents and patent application costs, licenses, and trademarks. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives and reported net of accumulated </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortization. Amortization expense is recorded in general and administrative expenses on the consolidated statements of operations. The useful lives of intangible assets are as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">License agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: 17 to 20 years</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patents: up to 20 years. </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trademarks: indefinite lived</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company pays royalty fees based on net sales of the licensed products, which are recorded in sales and marketing on the consolidated statements of operation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Cash equivalents, investments and derivative instruments are recorded at fair value on a recurring basis. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for classification and disclosure of fair value measurements as follows:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its debt instruments in determining whether there are embedded derivative instruments, which are required to be bifurcated and accounted for separately as a derivative financial instrument. Embedded derivatives that are not clearly and closely related to the debt host are bifurcated and are recognized at fair value on the consolidated balance sheet with changes in fair value recognized as either a gain or loss on the consolidated statement of operations each reporting period. The fair value of embedded derivatives are measured based on equity markets and interest rates, as well as an estimate of the Company's nonperformance risk adjustment. This estimate includes an option adjusted spread and an estimate of the Company's risk-free rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if a contract contains a lease at the inception date and determines the lease classification, recognition, and measurement at commencement date. All operating lease commitments with a lease term greater than 12 months are recognized as right-of-use assets and obligations on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies a lease based on whether the arrangement is effectively a purchase of the underlying asset. Leases that transfer the control of the underlying asset are classified as finance leases and all others are classified as operating leases. Interest and amortization expense are recognized for operating leases on a straight-line basis. If a change to the lease term leads </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to a reassessment of the lease classification and remeasurement, assumptions such as the discount rate and variable rents based on a rate or index will be updated as of the remeasurement date. If an arrangement is modified, the Company will reassess whether the arrangement contains a lease. Any subsequent changes in lease payments are recognized when incurred, unless the change requires a remeasurement of the lease liability.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's leases include options for the Company to extend the lease term. The exercise of lease renewal option is generally at the Company's sole discretion. Certain of the Company's lease agreements include provisions for the Company to reimburse the lessor for common area maintenance, real estate taxes, and insurance, which the Company accounts for as variable lease costs. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection. Revenue is recognized when the Company transfers of control of the products and services to the Company&#8217;s customers when the product is shipped or when it is delivered to the customer depending on the agreement. Products are primarily transferred to customer at a point in time. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract. These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#8217;s cost. The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and therefore, the Company has determined it is appropriate to recognize revenue when: i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement. Determining the timing of revenue recognition for such contracts is subject to judgment, because an evaluation must be made regarding the distributor&#8217;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company. Changes in these assessments could have an impact on the timing of revenue recognition from sales to distributors. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing, and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#8217;s contracts vary; however, as a common business practice, payment terms are typically due in full within 30 days of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material. The Company has several contracts with distributors in international markets that include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Assistance</a></td>
<td class="text">Government Assistance<span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As there is no authoritative guidance under U.S. GAAP for accounting for grants to for-profit business entities, the Company accounts for the grants by analogy to International Accounting Standard ("IAS") 20 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20")</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span> Government assistance and grants are recognized when there is reasonable assurance that the Company has met the requirements of the assistance and there is reasonable assurance that the grant will be received. The Company received government grants of $158, $1,164 and $628 during the years ended December&#160;31, 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods Sold</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Costs of Goods Sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes direct labor and materials costs related to each product sold or produced, including processing, quality assurance labor and scrap, inbound freight costs, as well as facility and warehousing overhead supporting the Company's manufacturing operations. All of the Company's manufacturing costs are included in cost of goods sold on the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred. Costs of research and development activities relate to product development, clinical trial expenses for the improvement of existing products, and technical support of products. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment. The Company received certain government grants totaling $158, $214, and $390 which were recorded as an <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_53f04da6-b4de-4448-a842-3ba64e7044cf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_d6f381e2-5ace-449f-8744-bd43ca3d4c2a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_e7410970-08ee-44c3-807d-dbdd552f3cb6">offset to research and development</span></span></span> in the consolidated statement of operations during the years ended December&#160;31, 2022, 2021 and 2020, respectively</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Shipping and Handling </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All shipping and handling costs, including facility and warehousing overhead, directly related to bringing the Company&#8217;s products to their final selling destination are included in sales and marketing expenses on the consolidated statements of operations were $5,271, $4,883, and $3,912 for the December&#160;31, 2022, 2021, and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. </span></div>The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the consolidated balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation is in the form of stock options, restricted stock units ("RSU"), performance stock units ("PSU"), and recognized at, or above, the fair market value of the Company's common stock on the date of grant.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of each stock option award on the date of grant using a multiple-point Black-Scholes option-pricing model. In addition, the Company measures stock options granted to employees at a premium price based on market conditions, such as the trading price of the Company&#8217;s common stock, using a Monte Carlo Simulation option-pricing model in estimating the fair value at the grant date.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of RSU grants based upon the grant date closing market price of the Company&#8217;s common stock.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the PSU grants is based on the Company&#8217;s closing stock price on the grant date. The number of PSUs that will ultimately be earned is based upon the Company&#8217;s performance as measured against specified targets over the measurement period. Expectations related to the achievement of performance goals associated with PSU grants is assessed as of each reporting period and is used to determine whether PSU grants are expected to vest. If performance-based milestones </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for all stock-based compensation awards, including stock options, RSUs, and PSUs granted to employees eligible for retirement, as defined within the award notice and allowing for continued vesting post-retirement, over the retirement notice period and continuously updates its estimate of expense over the notice period each reporting period if a retirement notice has not been provided. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation expense related to the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) based on the estimated fair value of the options on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of fair value using option-pricing models, as indicated above, is affected by the Company&#8217;s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company&#8217;s expected stock price volatility over the expected term of the awards. The Company determines the expected term of each award giving consideration to the contractual terms, vesting schedules, and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected term of the award. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#8217;s consolidated statements of operations. The expense is reduced for forfeitures as they occur.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share&#8203;</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Basic net loss per common share is computed by dividing reported net loss by the weighted average number of common shares outstanding during the period without consideration of potentially dilutive securities. Diluted net loss per share reflects the potential dilution that could occur if contracts to issue common stock were exercised or converted into common stock of the Company. Diluted net loss per share is the same as basic net loss per common share for all periods presented, since the effect of the potentially dilutive securities are anti-dilutive. Potential dilutive common share equivalents consist of the incremental common shares issuable upon exercise of vested stock options, RSUs, and PSUs.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Financial Accounting Standards Board ("FASB") amended Accounting Standards Codification ("ASC") 848 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (issued under Accounting Standards Update ("ASU") 2020 - 4, Reference Rate Reform). The amendment in this update defers the sunset date of Topic 848 from December 31, 2022, to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. The Company has not yet assessed the impact of the deferral on its consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, FASB amended ASC 832, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (issued under ASU 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosures by Business Entities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">bout Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). This amendment requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy, including, (1) the types of transactions; (2) the financial statement line items affected by the transaction: and (3) significant terms and conditions associated with the transactions. The Company adopted the guidance on January 1, 2022, and the adoption of ASU 2021-10 had no impact on the Company's consolidated financial condition, results of operations and an immaterial impact on disclosures.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other ASUs issued and not yet effective as of December 31, 2022, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company&#8217;s current or future financial position or results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks And Uncertainties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342957-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCapitalizationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCapitalizationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513776896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of reconciliation of cash, cash equivalents and restricted cash</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same reported in the consolidated statements of cash flows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:72.183%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.886%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,535&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,007&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513650368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,905&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The provision for inventory write-down is for the years ended as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:44.036%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.137%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.140%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for inventory write-down</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515450832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value financial assets measured on a recurring basis</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables represent the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2022, and 2021:</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"/></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,669&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.895%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,249&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt derivative liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of fair value instruments classified Level 3</a></td>
<td class="text"><div style="margin-top:10pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Level 3 liabilities measured at fair value on a recurring basis were as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"><tr><td style="width:1.0%"/><td style="width:74.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Derivative Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant inputs in liability valuation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant inputs that are included in the valuation of the debt derivative liability - first tranche include:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Input</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Remaining term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturity date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">June 30, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Coupon rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5% - 12.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue participation payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.90%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Probability of mandatory prepayment before 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated timing of mandatory prepayment event before 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Probability of mandatory prepayment 2024 or after</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated timing of mandatory prepayment event 2024 or after</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Probability of optional prepayment event</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Estimated timing of optional prepayment event</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents a significant unobservable input.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant inputs that are included in the valuation of the debt derivative liability - second tranche include: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Input</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity date</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coupon rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5% - 12.7%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50%&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue participation payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum each year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of mandatory prepayment before 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated timing of mandatory prepayment event before 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of mandatory prepayment 2024 or after</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated timing of mandatory prepayment event 2024 or after</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Probability of optional prepayment event</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0%&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated timing of optional prepayment event</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%">1</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents a significant unobservable input.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446509516256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of total lease expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of total lease expense for the years ended were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance lease costs</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,104&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of supplemental balance sheet information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to the operating and financing leases is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except lease term and discount rate)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use operating assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_282ba7ce-3ef3-47fa-b090-df6bc8c1cb62"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_bf9cd539-7ed8-407f-9081-99b74e7abdea">Current maturities of long-term lease obligations</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_43b1e322-811d-4e24-9d5c-24c744c9ffc6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_90aa3a79-3bec-4569-a69a-52d996616d6a">Long-term lease obligations</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use financing leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_271319ea-950a-424e-8fc3-fea671d857ad"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_51dc3b73-6881-4d4b-ad5d-be166f123d9e">Current maturities of long-term lease obligations</span></span> </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_ad5ae935-b90b-46e6-8d03-aa77e93ca8d3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_d55777eb-f537-4f2f-82c6-3481b4ecb124">Long-term lease obligations</span></span> </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average operating lease term (in years):</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average financing term (in years):</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate financing leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table> (1) Financing leases are included in property and equipment, net on the consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of operating lease maturity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating and financing leases as of December&#160;31, 2022, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,405&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of finance lease maturity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under operating and financing leases as of December&#160;31, 2022, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,352&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: Current lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,405&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512595888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,482&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,952&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Processing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Projects in process </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,703&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,660&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,296)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,614)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,923&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_2ffaa088-42a3-4658-a56e-41bcb91c69e1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_6ac65a1e-f9f2-4c6f-9b60-403fe0960398">projects in process</span></span> is a government grant received totaling $1,188 as of December 31, 2022 and December 31, 2021, which was recorded as an offset, and $11,429 and $5,274 of capitalized interest as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation expense is as follows for the years ended:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:43.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.860%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512571136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of finite-lived intangible assets</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.477%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">License agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total amortizable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,258&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,086)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,484&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,284&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,635)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,945&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,086)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of indefinite-lived intangible assets</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:32.477%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amortizable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">License agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total amortizable intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,635)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,258&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,570&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,086)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,484&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unamortized intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,284&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,635)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,649&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,945&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,086)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of amortization expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The amortization expense is as follows for the years ended:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:44.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, future amortization of patents and license agreements are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:85.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,258&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_ScheduleOfRoyaltyExpensesTableTextBlock', window );">Schedule of royalty expenses</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty fees included in sales and marketing on the consolidated statement of operations are as follows for the years ended:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:44.312%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty fees </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ScheduleOfRoyaltyExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Royalty Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ScheduleOfRoyaltyExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515000896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses&#8203; (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued expenses</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,964&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,520&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,863&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts payable and accrued expenses</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,443&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,459&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446600282336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt&#8203;, Net of Debt Discount and Financing Fees (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of long-term debt, net of financing fees</a></td>
<td class="text"><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of debt discount and financing fees consists of the following:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Facility - first tranche</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Facility - second tranche</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less - unamortized debt discount and deferred financing fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,288)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term debt, net of debt discount and financing fees</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,712&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,821&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513826144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net loss per common share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two-class method as of:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,985)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted-average common shares outstanding (Basic)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,083,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,214,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,966,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding (Diluted)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,083,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,214,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,966,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per common share (Basic and Diluted)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.60)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-dilutive shares excluded from the calculation of diluted earnings per share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,133,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,364,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,618,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> These common equivalent shares are not included in the diluted per share calculations as they would be anti-dilutive if the Company was in a net income position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515705616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense of consolidated statements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is included in the following line items in the accompanying consolidated statements of operations for the years ended:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.014%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Costs of goods sold</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total  stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions for options granted</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following weighted-average assumptions were used in the calculation of fair value for stock options granted for the following periods:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:54.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.667%"/><td style="width:0.1%"/></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.88</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the weighted average assumptions used in the valuation of ESPP options for the years ended December 31:</span></div><div style="margin-top:10pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"/><td style="width:43.773%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.472%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.706%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's stock option activity for the year ended December&#160;31, 2022:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value              (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,194,738&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,228,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(267,839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(260,963)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,894,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2022</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,034,249&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.94</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of stock unit activity</a></td>
<td class="text">The following table summarizes the activity for restricted stock units for the indicated periods:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:47.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding Restricted and Performance Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Units</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Fair Value at Date of Grant per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Vesting Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">967,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.06&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(265,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(254,297)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,861,106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity for performance stock units for the indicated periods:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding Restricted and Performance Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stock Units</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average Fair Value at Date of Grant per Share</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Remaining Vesting Life (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">763,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">530,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112,031&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446517700864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective income tax basis</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities, as measured by enacted state and federal tax rates. Deferred tax assets and deferred tax liabilities are as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory write-down</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charitable contributions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued bonus</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,049&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,934&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,744)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,740)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,673)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58,309)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,251)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text">The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate for the years ended December&#160;31, 2022, 2021, and 2020 as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes - net of Federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items and other deductions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512237520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash and cash equivalents balance outside of FDIC limit</a></td>
<td class="nump">$ 15,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest costs capitalized</a></td>
<td class="nump">6,155<span></span>
</td>
<td class="nump">$ 4,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_ContributionsToCharitableOrganization', window );">Contributions to charitable organization</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Grants received</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 1,164<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">$ 80,228<span></span>
</td>
<td class="nump">$ 73,328<span></span>
</td>
<td class="nump">$ 69,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=axgn_ResearchAndDevelopmentGrantsMember', window );">Research and Development Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Grants received</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">$ 5,271<span></span>
</td>
<td class="nump">$ 4,883<span></span>
</td>
<td class="nump">$ 3,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period of intangible assets (in years)</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable', window );">Age of doubtful accounts</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period of intangible assets (in years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period of intangible assets (in years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the age of specific types of trade accounts and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ContributionsToCharitableOrganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contributions to Charitable Organization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ContributionsToCharitableOrganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=axgn_ResearchAndDevelopmentGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=axgn_ResearchAndDevelopmentGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512435360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,284<span></span>
</td>
<td class="nump">$ 32,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">6,251<span></span>
</td>
<td class="nump">6,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">$ 21,535<span></span>
</td>
<td class="nump">$ 39,007<span></span>
</td>
<td class="nump">$ 55,609<span></span>
</td>
<td class="nump">$ 41,724<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446514990464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 12,651<span></span>
</td>
<td class="nump">$ 11,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">5,228<span></span>
</td>
<td class="nump">4,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">18,905<span></span>
</td>
<td class="nump">16,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory write-down</a></td>
<td class="nump">$ 1,769<span></span>
</td>
<td class="nump">3,314<span></span>
</td>
<td class="nump">$ 2,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=axgn_AviveSoftTissueMembraneMember', window );">Avive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for inventory write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=axgn_AviveSoftTissueMembraneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=axgn_AviveSoftTissueMembraneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446508840608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 43,859<span></span>
</td>
<td class="nump">$ 73,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">4,518<span></span>
</td>
<td class="nump">5,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">10,354<span></span>
</td>
<td class="nump">22,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">12,316<span></span>
</td>
<td class="nump">12,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">21,189<span></span>
</td>
<td class="nump">39,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Debt derivative liabilities</a></td>
<td class="nump">4,518<span></span>
</td>
<td class="nump">5,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">22,669<span></span>
</td>
<td class="nump">34,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">10,354<span></span>
</td>
<td class="nump">22,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">12,316<span></span>
</td>
<td class="nump">12,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Debt derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">21,189<span></span>
</td>
<td class="nump">39,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">21,189<span></span>
</td>
<td class="nump">39,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Debt derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">4,518<span></span>
</td>
<td class="nump">5,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Debt derivative liabilities</a></td>
<td class="nump">$ 4,518<span></span>
</td>
<td class="nump">$ 5,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512176112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Fair Value of Instruments Classified as Level 3 (Details) - Level 3 - Recurring - Debt derivative liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 5,562<span></span>
</td>
<td class="nump">$ 2,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value included in net loss</a></td>
<td class="num">(1,044)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 4,518<span></span>
</td>
<td class="nump">$ 5,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446514915680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Narrative (Details) - Credit Facility - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 45,712<span></span>
</td>
<td class="nump">$ 45,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 50,293<span></span>
</td>
<td class="nump">$ 52,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515116432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Significant Inputs Included in the Valuation of the Debt Derivative Liability (Details) - Debt derivative liabilities<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">First Tranche | Remaining term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">First Tranche | Coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">First Tranche | Coupon rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">First Tranche | Coupon rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">First Tranche | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.1390<span></span>
</td>
<td class="nump">0.1072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">First Tranche | Mandatory Prepayment Rate | Probability of mandatory prepayment before 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.050<span></span>
</td>
<td class="nump">0.050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">First Tranche | Mandatory Prepayment Rate | Probability of mandatory prepayment 2024 or after</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.150<span></span>
</td>
<td class="nump">0.150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">First Tranche | Mandatory Prepayment Rate | Probability of optional prepayment event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.050<span></span>
</td>
<td class="nump">0.050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">Second Tranche | Remaining term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">Second Tranche | Coupon rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">Second Tranche | Coupon rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">Second Tranche | Coupon rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">Second Tranche | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.1756<span></span>
</td>
<td class="nump">0.1321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">Second Tranche | Mandatory Prepayment Rate | Probability of mandatory prepayment before 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.050<span></span>
</td>
<td class="nump">0.050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">Second Tranche | Mandatory Prepayment Rate | Probability of mandatory prepayment 2024 or after</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.150<span></span>
</td>
<td class="nump">0.150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">Second Tranche | Mandatory Prepayment Rate | Probability of optional prepayment event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.050<span></span>
</td>
<td class="nump">0.050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=axgn_MeasurementInputCouponRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=axgn_MeasurementInputCouponRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=axgn_MeasurementInputMandatoryPrepaymentRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=axgn_MeasurementInputMandatoryPrepaymentRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_PrepaymentProbabilityEventAxis=axgn_MandatoryPrepaymentEventBefore2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_PrepaymentProbabilityEventAxis=axgn_MandatoryPrepaymentEventBefore2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_PrepaymentProbabilityEventAxis=axgn_MandatoryPrepaymentEventIn2024OrAfterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_PrepaymentProbabilityEventAxis=axgn_MandatoryPrepaymentEventIn2024OrAfterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_PrepaymentProbabilityEventAxis=axgn_OptionalPrepaymentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_PrepaymentProbabilityEventAxis=axgn_OptionalPrepaymentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515628944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases- Components of Total Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Finance lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease obligations</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Operating lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">4,077<span></span>
</td>
<td class="nump">4,326<span></span>
</td>
<td class="nump">2,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 5,412<span></span>
</td>
<td class="nump">$ 5,104<span></span>
</td>
<td class="nump">$ 2,936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512334304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current maturities of long-term lease obligations<span></span>
</td>
<td class="text">Current maturities of long-term lease obligations<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-term lease obligations<span></span>
</td>
<td class="text">Long-term lease obligations<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Current maturities of long-term lease obligations<span></span>
</td>
<td class="text">Current maturities of long-term lease obligations<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Long-term lease obligations<span></span>
</td>
<td class="text">Long-term lease obligations<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_OperatingLeasesAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 14,369<span></span>
</td>
<td class="nump">$ 15,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturities of long-term lease obligations</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">20,387<span></span>
</td>
<td class="nump">20,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LeasesFinanceAbstract', window );"><strong>Financing Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current maturities of long-term lease obligations</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average operating lease term (in years):</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average financing term (in years):</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate operating leases</a></td>
<td class="nump">10.58%<span></span>
</td>
<td class="nump">10.32%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate financing leases</a></td>
<td class="nump">11.91%<span></span>
</td>
<td class="nump">7.23%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LeasesFinanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LeasesFinanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_OperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_OperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512329952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne', window );">2023</a></td>
<td class="nump">$ 3,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo', window );">2024</a></td>
<td class="nump">3,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree', window );">2025</a></td>
<td class="nump">3,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour', window );">2026</a></td>
<td class="nump">3,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive', window );">2027</a></td>
<td class="nump">2,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">20,931<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid', window );">Total</a></td>
<td class="nump">37,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(15,637)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_OperatingAndFinancingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">21,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_OperatingAndFinancingLeaseLiabilityCurrent', window );">Less: Current lease liability</a></td>
<td class="num">(1,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">$ 20,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Financing Lease, Liability, to be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Financing Lease, Liability, to be Paid, after Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Financing Lease, Liability, to be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Financing Lease, Liability, to be Paid, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Financing Lease, Liability, to be Paid, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Financing Lease, Liability, to be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Financing Lease, Liability, to be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating and Financing Lease, Liability, Undiscounted Excess Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_OperatingAndFinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and Financing Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_OperatingAndFinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_OperatingAndFinancingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and Financing Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_OperatingAndFinancingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_OperatingAndFinancingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating and Financing Lease, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_OperatingAndFinancingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446508671968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 22, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 27, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 12, 2021 </div>
<div>USD ($) </div>
<div>mo</div>
</th>
<th class="th">
<div>Feb. 22, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 14,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_CommercialLeaseWithJAColeLPMember', window );">Commercial Lease With JA-Cole L.P</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_OperatingLeaseIncrementalBorrowingRate', window );">Operating lease, incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
<td class="nump">$ 1,335<span></span>
</td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 641<span></span>
</td>
<td class="nump">$ 1,370<span></span>
</td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths', window );">Rent-free period (in months) | mo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember', window );">Commercial Lease With JA-Cole L.P, First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_OperatingLeaseIncrementalBorrowingRate', window );">Operating lease, incremental borrowing rate</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LesseeOperatingLeaseNumberOfRentFreeMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Rent-Free Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LesseeOperatingLeaseNumberOfRentFreeMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_OperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_OperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_CommercialLeaseWithJAColeLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_CommercialLeaseWithJAColeLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446514937920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net -Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease right-of-use assets</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property and equipment, at cost</a></td>
<td class="nump">89,590<span></span>
</td>
<td class="nump">70,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</a></td>
<td class="num">(10,296)<span></span>
</td>
<td class="num">(7,614)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">$ 79,294<span></span>
</td>
<td class="nump">$ 62,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration', window );">Government Assistance, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">Property and equipment, net<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_FurnitureAndOfficeEquipmentMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 5,316<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">15,482<span></span>
</td>
<td class="nump">14,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Processing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">4,227<span></span>
</td>
<td class="nump">3,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Projects in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 63,703<span></span>
</td>
<td class="nump">$ 45,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=axgn_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446514978928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmountCumulative', window );">Grants received</a></td>
<td class="nump">$ 1,188<span></span>
</td>
<td class="nump">$ 1,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2,827<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
<td class="nump">$ 1,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedCapitalizedInterestCosts', window );">Accumulated capitalized interest costs</a></td>
<td class="nump">$ 11,429<span></span>
</td>
<td class="nump">$ 5,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedCapitalizedInterestCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedCapitalizedInterestCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmountCumulative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342832&amp;loc=SL128342943-244231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmountCumulative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446508678512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Components of Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Amortizable intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 4,893<span></span>
</td>
<td class="nump">$ 3,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,635)<span></span>
</td>
<td class="num">(1,086)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">3,258<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Unamortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross</a></td>
<td class="nump">5,284<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,649<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Unamortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Carrying amount</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Amortizable intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">3,792<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(621)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">3,170<span></span>
</td>
<td class="nump">2,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Amortizable intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,014)<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513758256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 265<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 153<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512443344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Future Amortization of Patents and License Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 3,258<span></span>
</td>
<td class="nump">$ 2,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=axgn_PatentsAndLicenseAgreementsMember', window );">Patents And License Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 3,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=axgn_PatentsAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=axgn_PatentsAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515583072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Narrative (Details) - License agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_RoyaltyFeesPercentageUnderLicenseAgreements', window );">Royalty fees range under the license agreements</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_RoyaltyFeesPercentageUnderLicenseAgreements', window );">Royalty fees range under the license agreements</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors', window );">Royalty stack cap for royalties paid to more than one licensor for sales of the same product</a></td>
<td class="nump">3.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_RoyaltyFeesPercentageUnderLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty fees percentage under license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_RoyaltyFeesPercentageUnderLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515668480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Royalty Fees (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty fees</a></td>
<td class="nump">$ 3,103<span></span>
</td>
<td class="nump">$ 2,715<span></span>
</td>
<td class="nump">$ 2,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446517740608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses&#8203; (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 8,964<span></span>
</td>
<td class="nump">$ 5,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">4,520<span></span>
</td>
<td class="nump">6,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">8,959<span></span>
</td>
<td class="nump">9,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 22,443<span></span>
</td>
<td class="nump">$ 22,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512549968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt&#8203;, Net of Debt Discount and Financing Fees - Schedule of Carrying Values of Outstanding Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less - unamortized debt discount and deferred financing fees</a></td>
<td class="num">$ (4,288)<span></span>
</td>
<td class="num">$ (5,179)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of debt discount and financing fees</a></td>
<td class="nump">45,712<span></span>
</td>
<td class="nump">44,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember', window );">First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember', window );">Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446507718896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt&#8203;, Net of Debt Discount and Financing Fees - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 10, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 624<span></span>
</td>
<td class="nump">$ 1,356<span></span>
</td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest costs capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,155<span></span>
</td>
<td class="nump">4,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt discount and deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">891<span></span>
</td>
<td class="nump">831<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,251<span></span>
</td>
<td class="nump">6,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Collateral amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=axgn_RestrictedCashMember', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Collateral amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember', window );">Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_StockOptionMember', window );">Oberland Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="nump">$ 14.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_StockOptionMember', window );">Oberland Option | TPC Investments II LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">247,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityMember', window );">Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,712<span></span>
</td>
<td class="nump">45,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade', window );">Period for which quarterly interest payments are required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate at period end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty', window );">Threshold revenue achievement for payment of additional quarterly royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure', window );">Additional payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,074<span></span>
</td>
<td class="nump">4,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn', window );">Make-whole payment, minimum required internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease', window );">Interest rate increase in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityMember', window );">Credit Facility | Oberland Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Value of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_PurchasePriceOfCommonStockCalculationPeriod', window );">Moving average of closing stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds from warrant exercises</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityMember', window );">Credit Facility | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DebtInstrumentAdditionalInterestFloorRate', window );">Additional interest floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember', window );">First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember', window );">First Tranche | Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember', window );">Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember', window );">Second Tranche | Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DebtInstrumentAdditionalInterestFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Interest, Floor Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DebtInstrumentAdditionalInterestFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DebtInstrumentInterestRateEventOfDefaultIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Event of Default, Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DebtInstrumentInterestRateEventOfDefaultIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Minimum Required Internal Rate Of Return</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percentage Of Additional Payment On Outstanding Loan Based On Royalty Structure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Period For Which Quarterly Interest Payments Should Be Made</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_PurchasePriceOfCommonStockCalculationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Common Stock Calculation Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_PurchasePriceOfCommonStockCalculationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Participation Agreement, Threshold Revenue Achievement For Payment Of Additional Quarterly Royalty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=axgn_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=axgn_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512668576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Loss per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,948)<span></span>
</td>
<td class="num">$ (26,985)<span></span>
</td>
<td class="num">$ (23,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">42,083,125<span></span>
</td>
<td class="nump">41,214,889<span></span>
</td>
<td class="nump">39,966,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">42,083,125<span></span>
</td>
<td class="nump">41,214,889<span></span>
</td>
<td class="nump">39,966,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in USD per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in USD per share)</a></td>
<td class="num">$ (0.69)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">3,133,865<span></span>
</td>
<td class="nump">1,364,567<span></span>
</td>
<td class="nump">1,618,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">454,430<span></span>
</td>
<td class="nump">333,276<span></span>
</td>
<td class="nump">188,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted, Other Disclosure1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446517814032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Overview of Equity Incentive Plans Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 25, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>plan </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_ShareBasePaymentArrangementNumberOfPlans', window );">Number of share-based incentive plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized for future issuance (in shares)</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,374,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ShareBasePaymentArrangementNumberOfPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-base Payment Arrangement, Number Of Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ShareBasePaymentArrangementNumberOfPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512608320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of consolidated statements of operations (Details) - 2019 Plan - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 15,591<span></span>
</td>
<td class="nump">$ 10,919<span></span>
</td>
<td class="nump">$ 8,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember', window );">Costs of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,341<span></span>
</td>
<td class="nump">2,905<span></span>
</td>
<td class="nump">2,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,640<span></span>
</td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 10,395<span></span>
</td>
<td class="nump">$ 5,934<span></span>
</td>
<td class="nump">$ 4,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446507744288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Options Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 2,643<span></span>
</td>
<td class="nump">$ 14,167<span></span>
</td>
<td class="nump">$ 5,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition of unrecognized compensation expense</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember', window );">Prior Axogen Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember', window );">Prior Axogen Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to non-vested stock options and restricted stock awards</a></td>
<td class="nump">$ 6,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="nump">$ 10.53<span></span>
</td>
<td class="nump">$ 4.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Prior Axogen Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Prior Axogen Plan | One Year After Grant Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Prior Axogen Plan | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2017 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2017 ESPP | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2017 ESPP | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_DirectorsAndOfficersStockOptionsMember', window );">Directors And Officers Stock Options | Per Quarter, Over One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_DirectorsAndOfficersStockOptionsMember', window );">Directors And Officers Stock Options | 2017 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to non-vested stock options and restricted stock awards</a></td>
<td class="nump">$ 13,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition of unrecognized compensation expense</a></td>
<td class="text">2 years 8 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="nump">20.13<span></span>
</td>
<td class="nump">9.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to non-vested stock options and restricted stock awards</a></td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period of recognition of unrecognized compensation expense</a></td>
<td class="text">1 year 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 8.23<span></span>
</td>
<td class="nump">$ 20.70<span></span>
</td>
<td class="nump">$ 9.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axgn_AxoGen2010StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_DirectorsAndOfficersStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_DirectorsAndOfficersStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=axgn_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=axgn_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446514987520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted-Average Assumptions Used (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">61.17%<span></span>
</td>
<td class="nump">58.38%<span></span>
</td>
<td class="nump">58.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">1.02%<span></span>
</td>
<td class="nump">0.49%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515216544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - Stock options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">3,194,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,228,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(267,839)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(260,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">3,894,856<span></span>
</td>
<td class="nump">3,194,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,034,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in USD per share)</a></td>
<td class="nump">$ 15.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in USD per share)</a></td>
<td class="nump">14.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">4.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in USD per share)</a></td>
<td class="nump">14.38<span></span>
</td>
<td class="nump">$ 15.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share)</a></td>
<td class="nump">$ 16.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding (in years)</a></td>
<td class="text">6 years 9 months 10 days<span></span>
</td>
<td class="text">6 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable (in years)</a></td>
<td class="text">4 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 2,783<span></span>
</td>
<td class="nump">$ 2,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 1,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446507064528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted and Performance Stock Units Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2022</div></th>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Dec. 17, 2019</div></th>
<th class="th"><div>Dec. 27, 2018</div></th>
<th class="th"><div>Dec. 18, 2017</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 25, 2022</div></th>
<th class="th"><div>Jul. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="nump">$ 20.13<span></span>
</td>
<td class="nump">$ 9.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of restricted stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,288<span></span>
</td>
<td class="nump">$ 2,179<span></span>
</td>
<td class="nump">$ 2,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares available (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,861,106<span></span>
</td>
<td class="nump">967,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Directors And Certain Executive Officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Directors And Certain Executive Officers | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.23<span></span>
</td>
<td class="nump">$ 20.70<span></span>
</td>
<td class="nump">$ 9.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of restricted stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">$ 2,302<span></span>
</td>
<td class="nump">$ 1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares available (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,112,031<span></span>
</td>
<td class="nump">763,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_PerformanceSharesBiologicLicenseApplicationMember', window );">PSU - BLA Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_PerformanceSharesBiologicLicenseApplicationMember', window );">PSU - BLA Milestones | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_PerformanceSharesBiologicLicenseApplicationMember', window );">PSU - BLA Milestones | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyPerformanceShareUnitMember', window );">2020 PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_PercentageOfAchievementOfAwardIssued', window );">Achievement of award issued (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyOnePerformanceShareUnitMember', window );">2021 PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_ShareBasedCompensationExpenseForfeitedOrReversed', window );">Value of grants reversed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyOnePerformanceShareUnitMember', window );">2021 PSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_PerformanceStockUnitPayoutOpportunity', window );">Performance stock unit, payout opportunity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyOnePerformanceShareUnitMember', window );">2021 PSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_PerformanceStockUnitPayoutOpportunity', window );">Performance stock unit, payout opportunity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyTwoPerformanceShareUnitMember', window );">2022 PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">526,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyTwoPerformanceShareUnitMember', window );">2022 PSUs | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_PerformanceStockUnitPayoutOpportunity', window );">Performance stock unit, payout opportunity</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyTwoPerformanceShareUnitMember', window );">2022 PSUs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_PerformanceStockUnitPayoutOpportunity', window );">Performance stock unit, payout opportunity</a></td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_PercentageOfAchievementOfAwardIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Achievement Of Award Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_PercentageOfAchievementOfAwardIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_PerformanceStockUnitPayoutOpportunity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Unit, Payout Opportunity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_PerformanceStockUnitPayoutOpportunity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ShareBasedCompensationExpenseForfeitedOrReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Expense, Forfeited Or Reversed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ShareBasedCompensationExpenseForfeitedOrReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=axgn_DirectorsAndCertainExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=axgn_DirectorsAndCertainExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_PerformanceSharesBiologicLicenseApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_PerformanceSharesBiologicLicenseApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyPerformanceShareUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyPerformanceShareUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyOnePerformanceShareUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyOnePerformanceShareUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyTwoPerformanceShareUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=axgn_TwoThousandTwentyTwoPerformanceShareUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446509339376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted and Performance Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted and Performance Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">967,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,413,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(265,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(254,297)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">1,861,106<span></span>
</td>
<td class="nump">967,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning of the period (in USD per share)</a></td>
<td class="nump">$ 16.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">8.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in USD per share)</a></td>
<td class="nump">13.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="nump">12.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end of the period (in USD per share)</a></td>
<td class="nump">$ 11.13<span></span>
</td>
<td class="nump">$ 16.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Vesting Life (Years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 5 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 18,574<span></span>
</td>
<td class="nump">$ 9,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted and Performance Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">763,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">530,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(77,671)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(104,978)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">1,112,031<span></span>
</td>
<td class="nump">763,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning of the period (in USD per share)</a></td>
<td class="nump">$ 21.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">8.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in USD per share)</a></td>
<td class="nump">18.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="nump">16.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end of the period (in USD per share)</a></td>
<td class="nump">$ 15.90<span></span>
</td>
<td class="nump">$ 21.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Vesting Life (Years)</a></td>
<td class="text">1 year 10 months 9 days<span></span>
</td>
<td class="text">2 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 11,098<span></span>
</td>
<td class="nump">$ 7,156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446506971888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Employee Stock Purchase Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 5.18<span></span>
</td>
<td class="nump">$ 5.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember', window );">2017 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock', window );">Discount from market value on common stock</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_EmployeeStockPurchasePlanOfferingPeriod', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear', window );">Maximum amount available to participants per year</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares available (in shares)</a></td>
<td class="nump">69,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember', window );">2017 ESPP | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 844<span></span>
</td>
<td class="nump">$ 401<span></span>
</td>
<td class="nump">$ 493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Discount from Market Value on Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Amount Available to Participants Per Year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EmployeeStockPurchasePlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EmployeeStockPurchasePlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512188448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted-Average Assumptions Used For 2017 ESPP (Details) - 2017 ESPP<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Option Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">66.50%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">81.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=axgn_Axogen2017EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446514902688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Temporary Differences (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 42,716<span></span>
</td>
<td class="nump">$ 47,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory write-down</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DeferredTaxAssetsInterestLimitation', window );">Interest limitation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for doubtful accounts</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DeferredTaxAssetsLeaseObligations', window );">Lease obligations</a></td>
<td class="nump">5,643<span></span>
</td>
<td class="nump">5,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">5,274<span></span>
</td>
<td class="nump">3,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">6,357<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Debt derivative liability</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contributions</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses', window );">Accrued bonus</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">63,049<span></span>
</td>
<td class="nump">58,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(983)<span></span>
</td>
<td class="num">(692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Amortization</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="num">(3,744)<span></span>
</td>
<td class="num">(3,861)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome', window );">Contract liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(4,740)<span></span>
</td>
<td class="num">(4,673)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DeferredTaxAssetsLiabilities', window );">Net deferred tax assets</a></td>
<td class="nump">58,309<span></span>
</td>
<td class="nump">54,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (58,309)<span></span>
</td>
<td class="num">$ (53,251)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DeferredTaxAssetsInterestLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Interest Limitation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DeferredTaxAssetsInterestLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DeferredTaxAssetsLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from right-of-use liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DeferredTaxAssetsLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DeferredTaxAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DeferredTaxAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446509425536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">$ 5,058,000<span></span>
</td>
<td class="nump">$ 6,734,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">42,716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446517497968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes - net of Federal benefit</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Permanent items and other deductions</a></td>
<td class="num">(7.10%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(17.50%)<span></span>
</td>
<td class="num">(24.70%)<span></span>
</td>
<td class="num">(27.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515519600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan&#8203; (Details) - AxoGen 401K Plan<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan', window );">Age limit for eligibility to participate in the plan</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contributions</a></td>
<td class="nump">$ 1,409<span></span>
</td>
<td class="nump">$ 1,346<span></span>
</td>
<td class="nump">$ 1,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=axgn_Axogen401kPlanMember', window );">Employer's Contribution, First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contributions</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DefinedContributionPlanEmployeeContributionPercentMatched', window );">Employee contribution matched, percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=axgn_Axogen401kPlanMember', window );">Employer's Contribution, Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contributions</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DefinedContributionPlanEmployeeContributionPercentMatched', window );">Employee contribution matched, percent</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DefinedContributionPlanEmployeeContributionPercentMatched">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee contribution, as a percent of annual salary, that is matched by the employer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DefinedContributionPlanEmployeeContributionPercentMatched</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan minimum age limit for eligibility to participate in plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=axgn_Axogen401kPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=axgn_Axogen401kPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446512446048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Service Agreements Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_CommunityTissuesServicesAgreementMember', window );">CTS Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Service Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_LicenseFeeAmount', window );">License fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,278<span></span>
</td>
<td class="nump">$ 2,466<span></span>
</td>
<td class="nump">$ 1,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_NoticePeriodForTerminationOfAgreement', window );">Notice period for termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember', window );">Master Services Agreement For Clinical Research and Related Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems', window );"><strong>Service Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement', window );">Service agreement amount paid upon execution of agreement</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_PaymentForServiceFees', window );">Payment for service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,254<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_LicenseFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fee amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_LicenseFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_NoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the notice period for termination of the agreement by either parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_NoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_PaymentForServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for Service Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_PaymentForServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service Agreement Amount Paid Upon Execution Of Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_CommunityTissuesServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_CommunityTissuesServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446507920224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Axogen Processing Center Facility Narrative (Details)<br> ft&#178; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($) </div>
<div>a </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 09, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest costs capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,155<span></span>
</td>
<td class="nump">$ 4,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,703<span></span>
</td>
<td class="nump">45,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_DesignBuildAgreementMember', window );">Design Build Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_EstimatedCostRelatingToDesignBuildAgreement', window );">Estimated cost relating to design build agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement', window );">Additional costs associated with design build agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_DesignBuildAgreementMember', window );">Design Build Agreement | Construction in Progress | Subsequent Event | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne', window );">Anticipated costs associated with design build agreement, in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_DesignBuildAgreementMember', window );">Design Build Agreement | Construction in Progress | Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne', window );">Anticipated costs associated with design build agreement, in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_DesignBuildAgreementMember', window );">Design Build Agreement | Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Expenses related to improvements in current year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest costs capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedCapitalizedInterestCosts', window );">Accumulated capitalized interest costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=axgn_APCFacilityMember', window );">APC Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Size of building space | ft&#178;</a></td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land where building resides | a</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLandHeldForUse', window );">Payments to acquire Land</a></td>
<td class="nump">$ 731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBuildings', window );">Payments to acquire Building</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=axgn_APCFacilityMember', window );">APC Facility | Design Build Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Receivable economic development grants from state and local authorities (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_CashGrantsReceivable', window );">Cash grants receivable (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromGrantors', window );">Proceeds from grantors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 950<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_AdditionalCostsAssociatedWithDesignBuildAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Costs Associated with Design Build Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_AdditionalCostsAssociatedWithDesignBuildAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anticipated Costs Associated with Design Build Agreement, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_CashGrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of cash grants receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_CashGrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_EstimatedCostRelatingToDesignBuildAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Cost Relating to Design Build Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_EstimatedCostRelatingToDesignBuildAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedCapitalizedInterestCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedCapitalizedInterestCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of buildings (properties) whether for investment or use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLandHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of land for use; excludes purchases of land held as inventory or as investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLandHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromGrantors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from grantors during the current period related to operating activities. This element represents receipts from a guarantor for the amount of guarantee provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromGrantors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_DesignBuildAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=axgn_DesignBuildAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=axgn_APCFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=axgn_APCFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446515016000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Fair Value of Debt Derivative Liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>settlementScenario</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 4,518,000<span></span>
</td>
<td class="nump">$ 5,562,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityMember', window );">Credit Facility | Debt derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_NumberOfPotentialSettlementScenarios', window );">Number of potential settlement scenarios | settlementScenario</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios', window );">Make-whole payment required under each scenario, internal rate of return</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember', window );">First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DebtInstrumentHeldToMaturityMakeWholePayment', window );">Held to maturity make-whole payment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation', window );">Held to maturity make-whole payment, alternative interpretation</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember', window );">Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation', window );">Held to maturity make-whole payment, alternative interpretation</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DebtInstrumentHeldToMaturityMakeWholePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Held To Maturity Make-Whole Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DebtInstrumentHeldToMaturityMakeWholePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Held To Maturity Make-Whole Payment, Alternative Interpretation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Internal Rate Of Return Under Settlement Scenarios</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_NumberOfPotentialSettlementScenarios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Potential Settlement Scenarios</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_NumberOfPotentialSettlementScenarios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=axgn_DebtDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=axgn_CreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446513621504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 10, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation', window );">Cash previously deposited at bank closed by California Department of Financial Protection and Innovation</a></td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Deposited At Bank Closed By California Department Of Financial Protection And Innovation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>axgn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140446514908784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Year</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 1,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease', window );">Additions</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions (Charge-offs)</a></td>
<td class="num">(238)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
<td class="num">(676)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Year</a></td>
<td class="nump">650<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Valuation allowance for deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Year</a></td>
<td class="nump">53,251<span></span>
</td>
<td class="nump">46,517<span></span>
</td>
<td class="nump">39,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease', window );">Additions</a></td>
<td class="nump">5,073<span></span>
</td>
<td class="nump">6,734<span></span>
</td>
<td class="nump">6,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions (Charge-offs)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End of Year</a></td>
<td class="nump">$ 58,324<span></span>
</td>
<td class="nump">$ 53,251<span></span>
</td>
<td class="nump">$ 46,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>axgn-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:axgn="http://www.axogeninc.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="axgn-20221231.xsd" xlink:type="simple"/>
    <context id="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i065152e6a3b64f53bb6e652d3c07713d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib74c767cfa73403094e07d49b29033f0_I20230310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="idb63c57e724a4e6e8ad20ee65119370a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if17b0477fc984ecfa301826bf71b2eb6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf515d9a7de44eff9aae0e17da62fba2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11a07c1ba89f4e78b9f41a1b28db3e2e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i020f70d532cd4985bbe689c32516cea3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i91b861abf62b4326b086bd6c32bdcf69_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i70b02bce882f4530a644cf1f4de1281a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45cc08a71962457c8a2b55f8d7a4d39a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i988505ce34a844a09623ae3c12d8ec87_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8f968e20d3bf41eebd5e2ffa7bb615b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied6b9724c05f4cb3a66af446b51ae49e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i404b822cbf2e4fe08c667eb2554e74c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if0df7a1efdb049cfa90a2524886d1252_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48bde1d6124b4ea78c970234e62219ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie35d0ad377f844a4a7e48534c50caff4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8158cb4740e7427188f9ee3550c9230b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic23f7a20a5a44ab7b5e3f093917b8c03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81e2bc0aacfa402f813dddb588b6267f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec80f298a69e4799b67c597636a9f301_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6d3fa1437edd43a5b85f3cf6a86ed7df_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i64198b8113a54a908aaacc22c63099fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e263d574089497289c6eefc50c18244_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26cf5637ad1d4822b296d27f9963de73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5efaab989c6841568efb1406dbb75d6c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2097ff736d5343bda084880731e97ad9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie4725cd6d9b24bb59307c754dcac2d41_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2dd68d66cd4242ecb6935259bfbb0bfd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc7ba18f09ee45d587b2fe032937cda5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1bc6c9dfa31e4dfb90c5dc20212c1ca1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">axgn:ResearchAndDevelopmentGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic68f8ca16e14404a992ae8f0910b911c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">axgn:ResearchAndDevelopmentGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87f90b83c663430ea63bc4f87a3e3a3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">axgn:ResearchAndDevelopmentGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib7fac01f992a4a81b65d12402ff03e2f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i64abf6623fa944d6afd0f670cf3c2a34_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2511c05b8d24d5498026c37e476c019_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iead0e385765c4b64b8993cfd1f3c50a7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">axgn:AviveSoftTissueMembraneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8fdfd74ec77440a993b43f1ab043aec4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i070dcdc6ab0e4a87856b934b83e36f61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic4b7b03e5ad24c209c6e89b463f7c09d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d7786e6549f4f2b87fd1be253cbb057_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a1078ddd2ca4d68ba2298c4052ef876_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3763b8b0a3348d59cfaea1445d2bfc8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefef6bfa4d304246b2f3543fef3d3125_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6fcdd9ed764541c286b0eaaa84d984ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i981abdd294e44919817cd956d30d31a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i219c4cc0cbd547b3b68a43331493fb1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i20c791c3ff7e418ab95668e32cc7a1ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i93d0b4619b6c40f0b1a0de407ee760f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief216639aeea40978d9004092b61999b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i040b86ceb15544419c782b59216a1371_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idffd7fe48ee54e349aaddba79d4382e8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6cab5edf539940499d0c87a4b0bfaecf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa2057862cc54798a45830a2e34c7672_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i414b5edcb9214fef95168d989218cbd4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65aa335ff06f439d8115f7904b82f8aa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">axgn:PatentsAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib87452ca58634dbaa8dd73c32eb97477_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibd7f9133c7a74c2bbd041186bedf782a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i883e9d9eb9ba4b5980f84ab0473b72ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1cb615006a90448cae97a9c052e1adfb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i108f5fba334f442e831ebcd3d2adaee4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d98f50d860845f4a00f11fe83cde291_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i45579dc2f8964009928c3c2e3fef14d8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie9f0dbd08bf2403187833c72b32e0021_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73351972eccc4224be149e2d0b567b8c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d33c3cc49e343eb8a823bc5ad30dd10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia545915c6cee4044ae461b4e3af6a345_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id571ec182cbc48dbb46f0902fabfaa4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0fd5c952fe7147368209c3bdedede315_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe2f9c677cc94813913c444deda1a1fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie6afd80e6ff54416977b579d2a685207_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5149fc3ac5624e7ca71842bdab5b8b31_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5473e91ae2d416cae7554133eb8cbb1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i79d1a0dcac804c06a79caf26d3fdcdf2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43510f63e6ba4c3ca4047759ce1d9771_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia7965b9980ab4e319a9eb72458f4e891_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6626e08228454045ae1ff645428d36cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie1feb2a1c57d43a8a89b0469ed5f79d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7999f53613c34864ab3d0b6a7527bba5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i42db69a16e2a4860a246a776fd8ad30c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife046a9660e8491b9dca4c3123909056_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e456cfb65c14ed1ae258c526b1a5ce9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i614ad5e81ab442e19a8c5e1d2bb61b7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i699ff71d4b5f46c19f42ee43b4ff55ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ba0f9df4d9c44889d4cd22b2ac19083_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i690e6522ce7d426589cbba53994c7d97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id48f1ba541194d20abbd6444602c33bb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i12533576801f4002b10b0fe696102c65_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i134277d723964a98be276a7cfd374add_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7dc0ea19aecc4d6dbf7f2bb1e1acc8cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07a044804b5b4fb1af23926c78c8ce13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9df50280b6e4544bdb2b7df50822fa9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13c01632c18d4b0fa2a95b893eb9f178_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic339a73d39af4de797a3d83409a67e96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i233781a5f56440c3bd9431cd5d4497ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51dbdd80d2ef4fdcbf34d3331a1740c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f44c5f22b0f4c40813f276fb3c6827e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iefe9c570ebbd4043946a89fd045c1f82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7407c910a8640d8988cc07ab8eda26d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3799b9b46cfa4242a49caf62d6c4d193_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96fd23a1c75242caaecd4598b4ab2e33_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42df21d43bee4402a8975d2309e802f0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i05a09806c9ee410192e276bdee67d4ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i493945d3878542549477456e7e460b75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fb3c6271c204980bf4241e0ed97c838_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i112f623f3210421683f1756809d4475b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib01ca98fb65f484db7aa0441f172af4a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a72a93104ed4eccbc5523f4c0f05191_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7df814d0d49f44b38f0402eeabb3552c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02f73cc8149a450c9f9c913738431082_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie21ffd851ecc4537b177459b24c9a3d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac001b043861493599ed9f7cf962441d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventBefore2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia8843fd82eae4f4092d2b2e26e5f6403_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventBefore2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3218bc21e1b493a82d42491d73cb0ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventIn2024OrAfterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i920e8bfa648d41c7b399a5783bd68c3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventIn2024OrAfterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia49615132a2c496d981625ca85c9c943_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:OptionalPrepaymentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1cad8ff35f4474da61c3d70a7da989b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:OptionalPrepaymentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic393cbccf77f4f7f9ddd00e20e44bfa7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3313bb44c00d456ba559b7c53b18be3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac024fdbce484e7f8e49292e12eb03a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ac361d361b540cbba4353a8b20de144_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2532d10d99c4277927947329d695475_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputCouponRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a116e8bc9eb4403af53f80e4b35086c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e18c269659d4844ac0d512a92bcd2a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1958bf62020547a291e5c09e08fcc45f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventBefore2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if107145343dc4b0daddec46f6ccc3857_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventBefore2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d58523409ee484bae896a42cbecd8b1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventIn2024OrAfterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49673c1dce6f4f2496f2da68cd37b20b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:MandatoryPrepaymentEventIn2024OrAfterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic134f7c3e14d4cd7b7811f6e97064116_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:OptionalPrepaymentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81395195766a421e95d3757424963785_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">axgn:MeasurementInputMandatoryPrepaymentRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="axgn:PrepaymentProbabilityEventAxis">axgn:OptionalPrepaymentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ba9dcd463a4411d98f217af826e1ec3_D20210222-20210222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-22</startDate>
            <endDate>2021-02-22</endDate>
        </period>
    </context>
    <context id="ic07a04ab4a2a4b3fa3a573b41c2448a6_I20210222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-22</instant>
        </period>
    </context>
    <context id="i157567aac3fe47c883ab1353f6869f96_D20210712-20210712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-12</startDate>
            <endDate>2021-07-12</endDate>
        </period>
    </context>
    <context id="i955f3c4847e84499b9e5df9ed14d2f7a_I20210712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-12</instant>
        </period>
    </context>
    <context id="i0b56b68105574c4899488b9442a10226_D20210713-20210713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-13</startDate>
            <endDate>2021-07-13</endDate>
        </period>
    </context>
    <context id="i7c395685d2a24e03a092821152da1c30_I20210713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-13</instant>
        </period>
    </context>
    <context id="i0581e65b1022415ca3161ab6932a9f19_D20220127-20220127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-27</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <context id="i4097a733c1714381b903a1dfe340dafe_I20220127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-27</instant>
        </period>
    </context>
    <context id="i2e1fc63be79e43f2ab16a203a1d29645_I20220822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPFirstAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-22</instant>
        </period>
    </context>
    <context id="i099064cb7e584aca8bb8c8b521b1be3c_I20220822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-22</instant>
        </period>
    </context>
    <context id="icf7f7b402ec14835ba2971de3296cb0d_D20220822-20220822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPFirstAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-22</startDate>
            <endDate>2022-08-22</endDate>
        </period>
    </context>
    <context id="i41dbef148b97433ea98f9c4af34f62f1_D20221231-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPFirstAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic9a30248ed7b4f40a1fafee657210a01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">axgn:CommercialLeaseWithJAColeLPFirstAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i312f2d64cb674fdbad24a7fe51918409_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i104179cd76d94a2bb5b480f5d740f348_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe9a8770fa764d7891407778eae23958_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id591cfe573344db49a17900c7f2534ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6403d399211849738490229c7838d26e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if575cb76b14c473cbdc0a317a1e37598_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia7f2d0f52ae2425faca15b977fa1eb33_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i18a440d8b8744e8f9a6b185b93f909de_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id42e84f255884f7eb85ff88a32cfbec7_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if401beb532c24731a94a6c209f24f06f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icc88fe00a2b34650ba8c22e3a5248c9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia2d1964162f34aa9aff7b7bf6ccd1778_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i271d865b318a4f69926f6640eb4178a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i32bc87a417ec436cbde425177f4f1fca_I20201210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="i7229d1ab938d4b54a5c614ac06b82ab4_D20201210-20201210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-10</startDate>
            <endDate>2020-12-10</endDate>
        </period>
    </context>
    <context id="i232073fcc6e04d25aa02ac11cc331bfc_I20201210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">axgn:TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="i443dfc9e27ca43fa95f569f05a0bbe28_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1655c65194084245be81921c34c77204_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2861cc9701fe4e06bbe34f3f481d4cbb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8a546ce46a914aa785e30fa74d23ae15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">axgn:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6eb9268062cf4f6cbb9c740dbb809cea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">axgn:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2bda4fe5ea904b66952845b8d764cf1b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie6204757bdfb4234845eb99fcc2f5bde_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib00632d9ac6845ff94f04e3e98489229_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88b8752e11b545e6a8bef12b17eaa002_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6a16e53d518446cfbd2024ffdb8a8bf1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i36385a5cb9a84a35be78534b6035cd66_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i071fd4cf629e4e2280fd669b14f69dee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if01e2ccdaa54461098fe9e12370e82c8_D20220525-20220525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <startDate>2022-05-25</startDate>
            <endDate>2022-05-25</endDate>
        </period>
    </context>
    <context id="i1901933b221a4b9b954c7479477f3e4b_I20220525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
        </entity>
        <period>
            <instant>2022-05-25</instant>
        </period>
    </context>
    <context id="i23829077b773438fa1c9f990db81d62a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6ea41484f76d414e87f57fe619eda0d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i265deb6981db4caba802dff7098eaf78_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia017b12b6e4844b9ad5921672e3ad683_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic382dfac5eb34387894011ca21faacb1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a5e8c7dd95f4725be7b20b882541185_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad06ab740e97428ab5fa032137f4d319_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i353c868d857d4f78b75da6d08d6f5ce8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i82f76c354583477ba3582208c4de3e9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i906644212cb044e79417f0990512be9f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib865e7888f5b433f95e77cfab871debf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9648970fef2d49fbbf69cb19fe670983_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia7956fd5c1234348844e780e82ebc0c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib744e6a9173947e59255d4550e92de8b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iee39cce463fb44d0a4bfe365b6681f5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09c0b507e033470891c7ca7da0c6882b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2019LongTermIncentivePlanNewAxogenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9aca85efc69240e1a769914f9dcb9319_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2ec881302ae14b18b7a4033a56f38e41_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia801c2b2298a45dd968f3bc35b69132c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iab23cd73c6404992b546cccab3d848b9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8d35f388c73c4c55b667458fd456bb77_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie8fe5d68d40444db8d1a38fee238b7a9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0212c0badd7b46908abba199f97a351e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:DirectorsAndOfficersStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5e80010008dd494aa1fc37d1fd76468b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:DirectorsAndOfficersStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">axgn:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i289e4e30f0654ba2b3181339326c280d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic0b94c6006f54a3db47bc4394457d1e3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:AxoGen2010StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic51b16331d104e7e8fdcef21b100803f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id192a5d2ca61416498fadecd34072e03_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id1e45b0b246b467fbbfb1b6cd29a64b4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">axgn:DirectorsAndCertainExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i42d9032ded3e403885f2e9975a16f6ba_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">axgn:DirectorsAndCertainExecutiveOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id91fc5c40e6640dda04b21132c42f27c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4666913c7daa474b8bbb30f0335d78a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia34eb80cba6046728fa5e0562af47d00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36f58e081cfe4d2ba7361775fbbb25d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae4361a3f58144dc89e3af795773310b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd0c5b69b5984bf8bec833a99943f9a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie11aa559ad27461e8d53d7d3e811e707_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i59a311c65bd9478aab63c3835e9f72d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7b8b79e630c433d9fdf51406b61b52d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2655caad891648a1a7b5ffeb3d3a7654_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86095a926657489a9c0c27cdcf148b0a_D20181227-20181227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-27</startDate>
            <endDate>2018-12-27</endDate>
        </period>
    </context>
    <context id="i4efbb86d561c4296ac6a8acef41fa1c7_D20191217-20191217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-17</startDate>
            <endDate>2019-12-17</endDate>
        </period>
    </context>
    <context id="i51ad0d1614e74ceda868f8561214b5ae_D20171218-20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-18</startDate>
            <endDate>2017-12-18</endDate>
        </period>
    </context>
    <context id="i248e3d8e95cb446ea5448ffd760d6858_D20181227-20181227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-27</startDate>
            <endDate>2018-12-27</endDate>
        </period>
    </context>
    <context id="i717731af1dc14019834ae2cebf768ac6_D20191217-20191217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-17</startDate>
            <endDate>2019-12-17</endDate>
        </period>
    </context>
    <context id="i7a2ae8023341421386b40e9ae8b40f59_D20171218-20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:PerformanceSharesBiologicLicenseApplicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-18</startDate>
            <endDate>2017-12-18</endDate>
        </period>
    </context>
    <context id="i19da80c554e84b1f87236d2a9f78dea3_I20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyPerformanceShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="i8234a2e85537460db0ac834d843b9f53_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyPerformanceShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="ia3332793e1664f34a11a863a2ac0ea63_I20210316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyOnePerformanceShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="ifeb16850541e4351bd40387578338733_D20210316-20210316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyOnePerformanceShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="ib665842cd4a641bd996a4f540d05b968_D20210316-20210316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyOnePerformanceShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="id572945122984533aa8afff607ed6ec8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyOnePerformanceShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2216c948174746b58affe9e729448569_I20210316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyTwoPerformanceShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="ifc02d67a57a34782804ce01d01580755_D20220316-20220316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyTwoPerformanceShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-16</startDate>
            <endDate>2022-03-16</endDate>
        </period>
    </context>
    <context id="ia121473080d34c55a59059e23ecccb8d_D20220316-20220316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">axgn:TwoThousandTwentyTwoPerformanceShareUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-16</startDate>
            <endDate>2022-03-16</endDate>
        </period>
    </context>
    <context id="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0b64e28b97d45429f64b42130e5f1e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ad8aba17c754a17ae1c1742ee8271fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id23c516e6eac4ecd8e34c8640d264ee9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i961f19ca53be45ff97d7bd5885e51a53_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf36782fab8f4beda0e41e2bcb53023b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iea37731e57ec4ce89a11a90afef95441_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e8e5bdce3b54c78ae99fb00b50a85b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">axgn:Axogen2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9ff1fe87cd0546b8b116eabe76752894_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i181cd94e7d834b44b5b5a1f041d09d44_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieed0a63f9da94ba092fa792b834444ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05aa70972d464831a814056c33b271a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iefd130037ca64a11bb22c7512ae0a94d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanEmployerMatchingContributionTranche1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i182aaa761ab746c08c115aa520c8ef32_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">axgn:Axogen401kPlanEmployerMatchingContributionTranche2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i400f27a4e7ff431998cec2a000a877d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i236f63d48da94326b86bbf56915ef555_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">axgn:Axogen401kPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73105f432ef241c4a97fc1d3d88fe6a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:CommunityTissuesServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if781fbbca41e4e539d4a2af2b30d30b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:CommunityTissuesServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i07a9992aadca401c9da150aec1eb925d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:CommunityTissuesServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1fde54db694d4428af52e02f60a749f9_D20111201-20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-12-01</startDate>
            <endDate>2011-12-31</endDate>
        </period>
    </context>
    <context id="if5e477a79209414b9802cd7abd1b6b50_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7e0f3af02aa7447d8f475f07a758e898_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb046ec1c789420aa97b6546383d2a96_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:MasterServicesAgreementForClinicalResearchAndRelatedServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7981a723acd84152a08440913339b2eb_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="ic4c3c23c084b482f91cc7aa41dcd753c_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i7a73dc524bc0487f8a26096a8e638192_I20190709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-09</instant>
        </period>
    </context>
    <context id="i5d4755bb5df442e0bcbac343dd97c6a5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6c09353a39ab44c1abcd20449e840722_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7a632239217d41468fa2372519ffc0b1_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="ic9e769962cd54b3b97e7d9fd767e4375_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i6ca27fff32cc49c8b733f18e1fa356ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i240989f39b9840bca8e3655746971a82_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibc7bb6eff8634156ae51a0b363ee7e34_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1483ac9511a64c4ea92e59beedb6290d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">axgn:APCFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PurchaseCommitmentExcludingLongtermCommitmentAxis">axgn:DesignBuildAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i872b209a46c14c878edd3c5a93dc57b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">axgn:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">axgn:DebtDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63b272a784f043b28b8f70d792398c9d_I20230310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-10</instant>
        </period>
    </context>
    <context id="iace3449af19a43cd8d67c6135dea1c3f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1eadfa7371f84649a56fada99ffeb49f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i491dd34b56ac4fb6b8ba9809c9f8440d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3669aa557841487bb68d45ebfd6ac73d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if81dc6f294f4481ba24f6cf04a2a5b07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e2f4d63cb0a4bdbba2fe027bcca072d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i13a1d089805140e781df39c5f26229e1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief79fb6a5e3b43748ba8450f97233cc8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iff49c4d00f374dc3a6c840d2ead2e75c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i66448d92e4ed4bbdabf0e6233a2efd1f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc7ff5c961444d40b57c14dbf3857165_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia96693000e594bfcab99cf6f0f656103_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic01ee8be630348558bc989c9e8469302_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i682121d6bec448318e7178b60d411be4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000805928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="m">
        <measure>utr:M</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="plan">
        <measure>axgn:plan</measure>
    </unit>
    <unit id="acre">
        <measure>utr:acre</measure>
    </unit>
    <unit id="settlementscenario">
        <measure>axgn:settlementScenario</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV80L2ZyYWc6MGNiZjM3Nzc0OTE4NDAwNGI4Zjk4MzY3ZjlmZTFhYzUvdGFibGU6ZjRiNGFjM2M0YWZlNGViMGFlYjA3NGJiYTVhY2JmNGIvdGFibGVyYW5nZTpmNGI0YWMzYzRhZmU0ZWIwYWViMDc0YmJhNWFjYmY0Yl8wLTEtMS0xLTEwMjQzMQ_e7d81657-03b9-45a1-aa35-d1dc60737fb0">0000805928</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV80L2ZyYWc6MGNiZjM3Nzc0OTE4NDAwNGI4Zjk4MzY3ZjlmZTFhYzUvdGFibGU6ZjRiNGFjM2M0YWZlNGViMGFlYjA3NGJiYTVhY2JmNGIvdGFibGVyYW5nZTpmNGI0YWMzYzRhZmU0ZWIwYWViMDc0YmJhNWFjYmY0Yl8yLTEtMS0xLTEwMjQzMQ_f5bbdde5-c941-4d9c-8e7a-9a66d7064adc">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV80L2ZyYWc6MGNiZjM3Nzc0OTE4NDAwNGI4Zjk4MzY3ZjlmZTFhYzUvdGFibGU6ZjRiNGFjM2M0YWZlNGViMGFlYjA3NGJiYTVhY2JmNGIvdGFibGVyYW5nZTpmNGI0YWMzYzRhZmU0ZWIwYWViMDc0YmJhNWFjYmY0Yl8zLTEtMS0xLTEwMjQzMQ_67570d5c-4070-4abf-8bc2-d05df6d66a19">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV80L2ZyYWc6MGNiZjM3Nzc0OTE4NDAwNGI4Zjk4MzY3ZjlmZTFhYzUvdGFibGU6ZjRiNGFjM2M0YWZlNGViMGFlYjA3NGJiYTVhY2JmNGIvdGFibGVyYW5nZTpmNGI0YWMzYzRhZmU0ZWIwYWViMDc0YmJhNWFjYmY0Yl80LTEtMS0xLTEwMjQzMQ_3de4cf71-ea1c-4f3b-bbbf-704677e63628">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5efaab989c6841568efb1406dbb75d6c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg2NTE3MQ_1b1457ed-1497-471b-a70d-aa52a8985c35">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_53f04da6-b4de-4448-a842-3ba64e7044cf">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_d6f381e2-5ace-449f-8744-bd43ca3d4c2a">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_e7410970-08ee-44c3-807d-dbdd552f3cb6">http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_2ffaa088-42a3-4658-a56e-41bcb91c69e1">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_6ac65a1e-f9f2-4c6f-9b60-403fe0960398">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_282ba7ce-3ef3-47fa-b090-df6bc8c1cb62">http://www.axogeninc.com/20221231#LeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_bf9cd539-7ed8-407f-9081-99b74e7abdea">http://www.axogeninc.com/20221231#LeaseLiabilityCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_43b1e322-811d-4e24-9d5c-24c744c9ffc6">http://www.axogeninc.com/20221231#LeaseLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_90aa3a79-3bec-4569-a69a-52d996616d6a">http://www.axogeninc.com/20221231#LeaseLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_271319ea-950a-424e-8fc3-fea671d857ad">http://www.axogeninc.com/20221231#LeaseLiabilityCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_51dc3b73-6881-4d4b-ad5d-be166f123d9e">http://www.axogeninc.com/20221231#LeaseLiabilityCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_ad5ae935-b90b-46e6-8d03-aa77e93ca8d3">http://www.axogeninc.com/20221231#LeaseLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_d55777eb-f537-4f2f-82c6-3481b4ecb124">http://www.axogeninc.com/20221231#LeaseLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i289e4e30f0654ba2b3181339326c280d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI3NjM_61ba867c-4dd3-4803-a6a5-10aa309ff564">P7Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU0_1e42d764-f9e2-4192-a28e-4209692de150">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGFibGU6YmE2YzJiNjY1ZWQzNGU1M2JlYmQ4MzY1YjdlY2FmNmMvdGFibGVyYW5nZTpiYTZjMmI2NjVlZDM0ZTUzYmViZDgzNjViN2VjYWY2Y18wLTAtMS0xLTEwMjQzMQ_7131b5d4-38e5-4c2e-83ba-ad64b056099c">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8yODM_84342b8b-5d96-4bf9-a590-52fcb7df21a2">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8yODM_dc0bcaa2-e036-4b2a-a9b1-214bff2158d5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGFibGU6YzYwMGU4ZWM4MTkyNDQ3N2FlMTM5YTdhOWRkMzQxYTgvdGFibGVyYW5nZTpjNjAwZThlYzgxOTI0NDc3YWUxMzlhN2E5ZGQzNDFhOF8wLTAtMS0xLTEwMjQzMQ_4e2adfa6-cbff-466c-820f-422f30391222">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjYx_5da5044b-a95b-43fc-8e7a-8ad51521eb01">001-36046</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU1_48e727ad-5ac6-423e-b497-63550749d717">AXOGEN,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU2_465f9c89-afbc-49b1-9ffa-70e4d3412ee5">MN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjUw_44d59569-9ada-400d-b59e-9ba6e8712e92">13631 Progress Blvd., Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjUx_34e63d97-12aa-4a59-8c5f-44059455c35e">Alachua</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQ2_dde48038-1219-405d-b034-4e05de34e8c1">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU3_0fa1e76c-084b-45c4-8e6b-2885acc58088">41-1301878</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQ1_3ff57000-1fef-4755-a03a-ba86b4a1894a">32615</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjM4_2ebcc82e-052b-41af-b2bf-4aeafd3d30cd">386</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjM5_c5e57656-c3db-4091-a73c-8c5c38e8091e">462-6800</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGFibGU6ZTdmODYxZjNiZDU2NDkwNGI3ZDAwNDg2Nzg4ZDFmYTYvdGFibGVyYW5nZTplN2Y4NjFmM2JkNTY0OTA0YjdkMDA0ODY3ODhkMWZhNl8xLTAtMS0xLTEwMjQzMQ_0765fa90-2838-4b18-a371-69ec317df12f">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGFibGU6ZTdmODYxZjNiZDU2NDkwNGI3ZDAwNDg2Nzg4ZDFmYTYvdGFibGVyYW5nZTplN2Y4NjFmM2JkNTY0OTA0YjdkMDA0ODY3ODhkMWZhNl8xLTItMS0xLTEwMjQzMQ_380fc31b-0e03-4f6e-aa14-fd15c92c198b">AXGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGFibGU6ZTdmODYxZjNiZDU2NDkwNGI3ZDAwNDg2Nzg4ZDFmYTYvdGFibGVyYW5nZTplN2Y4NjFmM2JkNTY0OTA0YjdkMDA0ODY3ODhkMWZhNl8xLTQtMS0xLTEwMjQzMQ_546d2a6a-b9a9-43ed-bf97-eea18a7f89e4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjUz_1aa6c246-0101-431a-b68a-432c638e704d">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQw_891ae001-2e68-4d20-8bb5-8c27d428e42b">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQx_5953c45b-360c-403e-af92-c382c527d452">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU4_4c86a6f8-ed67-43f3-866f-ed37268c6283">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQz_01fa6268-6125-444b-b69f-c418978d2d14">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQ3_c1760eba-23e0-40ae-90e9-41c657e39d03">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjU5_cb5e12cb-87ae-4c1b-b419-a32ed2d368f7">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQ4_6abf1546-44e0-4fa9-a036-c21ab2405ef6">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjQ0_b9e746d6-3baa-421c-b0d1-fb4804ad93f2">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i065152e6a3b64f53bb6e652d3c07713d_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV81NDk3NTU4MTc1OTA_43f51233-eea0-4761-8f2c-32e9f5be1f13"
      unitRef="usd">221521729</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib74c767cfa73403094e07d49b29033f0_I20230310"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV81NDk3NTU4MTc2MjA_fc8ce4e1-cbc5-47c2-8bac-c251fe4d1b69"
      unitRef="shares">42601918</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xL2ZyYWc6NTI4Y2RjZTY5NjlkNDY5MWFlODQ2NDg2ZjEwZjRhMjEvdGV4dHJlZ2lvbjo1MjhjZGNlNjk2OWQ0NjkxYWU4NDY0ODZmMTBmNGEyMV8zNjYw_72505d69-aaa2-42dc-9364-f695205fd0f2">Portions of the Registrant&#x2019;s definitive proxy statement to be filed pursuant to Regulation 14A within 120 days after the end of the Registrant&#x2019;s fiscal year are incorporated by reference into Part&#160;III of this Form&#160;10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83My9mcmFnOmUzZWU4NDhiNTEzNTQ5M2U4NGY1OTUzZDJmYjMzYjczL3RhYmxlOjlhODZjYmU2YjMyMjQ1YWU5Zjc2YjFiZDM1NTM1ZTNmL3RhYmxlcmFuZ2U6OWE4NmNiZTZiMzIyNDVhZTlmNzZiMWJkMzU1MzVlM2ZfMi0wLTEtMS0xMDI0MzEvdGV4dHJlZ2lvbjozNzcyZmRlMmE4ZDc0ZDljODM0MmIwZmQ4YTA5ZGI4Y183NA_33cc46e0-6f0a-455d-a76d-cca3558fee53">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83Ni9mcmFnOmZhYWVjNTJjNGMyZjRmY2E4YzNhNWVjYTQ2MzBiMjgzL3RleHRyZWdpb246ZmFhZWM1MmM0YzJmNGZjYThjM2E1ZWNhNDYzMGIyODNfOTQwOA_cb819397-327a-48da-a63e-1d2482011a84">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83Ni9mcmFnOmZhYWVjNTJjNGMyZjRmY2E4YzNhNWVjYTQ2MzBiMjgzL3RleHRyZWdpb246ZmFhZWM1MmM0YzJmNGZjYThjM2E1ZWNhNDYzMGIyODNfOTQwOQ_c148733b-9959-4349-bdd4-5a3c58b096ce">Miami, Florida</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMy0xLTEtMS0xMDI0MzE_727c03af-7854-4db2-9474-48b01d0e1dad"
      unitRef="usd">15284000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMy0zLTEtMS0xMDI0MzE_65c41896-6b75-426b-8c4d-f50873845bc1"
      unitRef="usd">32756000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNC0xLTEtMS0xMDI0MzE_76afe812-3128-4829-b733-b34673ac0769"
      unitRef="usd">6251000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNC0zLTEtMS0xMDI0MzE_ed397614-46f7-4dcc-a28f-82457df6c72d"
      unitRef="usd">6251000</us-gaap:RestrictedCash>
    <us-gaap:ShortTermInvestments
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNS0xLTEtMS0xMDI0MzE_a9654362-6100-4575-b009-401d968ef1e8"
      unitRef="usd">33505000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNS0zLTEtMS0xMDI0MzE_6ceb5b00-114c-4e7e-bac0-13c27ccdadc7"
      unitRef="usd">51330000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNi0wLTEtMS0xMDI0MzEvdGV4dHJlZ2lvbjpmOTgxYTA5OTVjMDk0N2RmOTQ5ZTg0YmMwYmQ5NTNjYl82Nw_f2a1b32d-a00c-4a1c-9506-7443b4cf1ee6"
      unitRef="usd">650000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNi0wLTEtMS0xMDI0MzEvdGV4dHJlZ2lvbjpmOTgxYTA5OTVjMDk0N2RmOTQ5ZTg0YmMwYmQ5NTNjYl83NA_2a7c569b-0d0e-4bb9-b5a3-db4fcd68abc7"
      unitRef="usd">276000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNi0xLTEtMS0xMDI0MzE_8ef9b5e2-c795-4a34-aa75-b50ddec67320"
      unitRef="usd">22186000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNi0zLTEtMS0xMDI0MzE_f95f28ed-f9b0-4b71-be90-6678f53ce13f"
      unitRef="usd">18158000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNy0xLTEtMS0xMDI0MzE_313a0b55-8eb0-4e12-98fa-21315ab68ad9"
      unitRef="usd">18905000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfNy0zLTEtMS0xMDI0MzE_0e84d523-829a-4ca5-baf5-fe38e8d9e5ff"
      unitRef="usd">16693000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfOC0xLTEtMS0xMDI0MzE_8cf99c54-cfbd-4437-b60e-1ddcd09d0206"
      unitRef="usd">1944000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfOC0zLTEtMS0xMDI0MzE_4511d28e-1179-44ef-982a-1dd2a35c1061"
      unitRef="usd">1861000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfOS0xLTEtMS0xMDI0MzE_8e7deb34-4f44-4538-8bef-cc21bc973eb4"
      unitRef="usd">98075000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfOS0zLTEtMS0xMDI0MzE_6d77bad5-629c-4a69-af81-9d7d70dbb279"
      unitRef="usd">127049000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTAtMS0xLTEtMTAyNDMx_e6607ed9-04cb-45d5-8bb0-a02a80e6446c"
      unitRef="usd">79294000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTAtMy0xLTEtMTAyNDMx_e1898430-88d3-45a2-b33d-96f70ee9a4f7"
      unitRef="usd">62923000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTEtMS0xLTEtMTAyNDMx_0eeecafd-2b26-4b3e-9bcf-887ef5e04176"
      unitRef="usd">14369000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTEtMy0xLTEtMTAyNDMx_aca204c8-8ea2-4fd7-bf94-ceacd31cb852"
      unitRef="usd">15193000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTMtMS0xLTEtMTAyNDMx_bf25044b-3578-4de2-8670-114ef2f945d4"
      unitRef="usd">3649000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTMtMy0xLTEtMTAyNDMx_8aa0db78-4b6b-4e35-bbcb-d16137127d9f"
      unitRef="usd">2859000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Assets
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTQtMS0xLTEtMTAyNDMx_2f21bf40-bb17-4524-b747-0c2560ecd61a"
      unitRef="usd">195387000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTQtMy0xLTEtMTAyNDMx_234e30ee-dbb8-480d-84fd-2e09ff394910"
      unitRef="usd">208024000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTgtMS0xLTEtMTAyNDMx_ab6950e0-da9f-4a7c-a752-dcd0ed131e07"
      unitRef="usd">22443000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTgtMy0xLTEtMTAyNDMx_05aef2c0-66e6-441b-aa1d-88989aa580fe"
      unitRef="usd">22459000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <axgn:LeaseLiabilityCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTktMS0xLTEtMTAyNDMx_3456f161-d703-4b7a-a819-cb1f49dfa6da"
      unitRef="usd">1310000</axgn:LeaseLiabilityCurrent>
    <axgn:LeaseLiabilityCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMTktMy0xLTEtMTAyNDMx_c71c7198-abc0-4164-acee-3af9d716593e"
      unitRef="usd">1834000</axgn:LeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjAtMS0xLTEtMTAyNDMx_f339e8df-1078-4b89-a49c-4614d6a8bcc5"
      unitRef="usd">23753000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjAtMy0xLTEtMTAyNDMx_e31a202f-0ec6-43b6-ac0e-2b104cecc8d2"
      unitRef="usd">24293000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjItMS0xLTEtMTAyNDMx_3b26eba8-af57-434d-8cc3-050d93d329b6"
      unitRef="usd">45712000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjItMy0xLTEtMTAyNDMx_a4fa2744-2815-43eb-a63f-77e64cc0ea88"
      unitRef="usd">44821000</us-gaap:LongTermDebtNoncurrent>
    <axgn:LeaseLiabilitiesNoncurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjMtMS0xLTEtMTAyNDMx_90db9367-1171-468d-aeaa-d89f22e95b37"
      unitRef="usd">20405000</axgn:LeaseLiabilitiesNoncurrent>
    <axgn:LeaseLiabilitiesNoncurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjMtMy0xLTEtMTAyNDMx_46ac090c-9878-4702-b39b-a62135d53592"
      unitRef="usd">20798000</axgn:LeaseLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjQtMS0xLTEtMTAyNDMx_4035a704-8ee3-4ea8-8934-bbff138a657f"
      unitRef="usd">4518000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjQtMy0xLTEtMTAyNDMx_5ad8bbe2-be8a-4951-9d3d-36fb0d5dcdb1"
      unitRef="usd">5562000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjYtMS0xLTEtMTAyNDMx_8c02185b-f743-4316-948f-02e28d15736b"
      unitRef="usd">94388000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjYtMy0xLTEtMTAyNDMx_c63a7c91-bcff-49d7-897d-53ded37a9a6e"
      unitRef="usd">95474000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjgtMS0xLTEtMTAyNDMx_edd4c5d0-3c60-4f03-8020-7745eb512644"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMjgtMy0xLTEtMTAyNDMx_4cd8c0d8-94b4-4280-a587-bd5abe683450"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfMTg_a4fd23d6-1357-4e95-b511-7b36939e91eb"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfMTg_dc291027-212d-4f6c-b674-59657727485e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNDI_6e8d6e16-92dd-4ac5-85fd-8e4ee0467f76"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNDI_7a23e93b-00ad-41a0-b560-1d585de11de1"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNjQ_323be743-8480-4cba-8153-247dcb699b38"
      unitRef="shares">42445517</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNjQ_d118c35b-9b17-4077-9198-6606879997f2"
      unitRef="shares">42445517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNzE_7f73b344-9964-4d10-81ab-48e457aae899"
      unitRef="shares">41736950</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMC0xLTEtMTAyNDMxL3RleHRyZWdpb246OTcyYzIxZmRmNmVkNGFlYjg2YWJjNjUxYzFhOTI0NTBfNzE_da2191ed-42c9-46bb-a354-7bbfcea8fdcd"
      unitRef="shares">41736950</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMS0xLTEtMTAyNDMx_74ff4c8e-541c-4bab-8de9-f8b067d0465f"
      unitRef="usd">424000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzEtMy0xLTEtMTAyNDMx_40afa51a-6661-4b65-845e-215879ae04d6"
      unitRef="usd">417000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzItMS0xLTEtMTAyNDMx_a728f3b4-e2aa-4f7a-a05c-c2fd2e3985e3"
      unitRef="usd">360155000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzItMy0xLTEtMTAyNDMx_271b7c84-effe-464c-a383-eb055be5940e"
      unitRef="usd">342765000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzMtMS0xLTEtMTAyNDMx_f1828f09-9e11-4468-95c4-d70719e84290"
      unitRef="usd">-259580000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzMtMy0xLTEtMTAyNDMx_4e0ba9e8-2cfc-451a-a5a3-b5704b35aebb"
      unitRef="usd">-230632000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzQtMS0xLTEtMTAyNDMx_2d1760fe-fabe-443c-9d00-1624e2b58ea5"
      unitRef="usd">100999000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzQtMy0xLTEtMTAyNDMx_18762176-b457-40cf-8941-55ad5fe2c15f"
      unitRef="usd">112550000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzUtMS0xLTEtMTAyNDMx_9423556a-1f36-4598-b938-002b8920d6b1"
      unitRef="usd">195387000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV83OS9mcmFnOjhjMzAzZTA4NTAwMjQxYWI5ZGEyZjIzNjY5YmJlYWJhL3RhYmxlOjM5ZjlmZDY5NDljYTRlMDU5YmJlNmUwYTMwZmQwOTcyL3RhYmxlcmFuZ2U6MzlmOWZkNjk0OWNhNGUwNTliYmU2ZTBhMzBmZDA5NzJfMzUtMy0xLTEtMTAyNDMx_974d7a70-e5de-4904-abbd-4cb8ea361aa5"
      unitRef="usd">208024000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMS0xLTEtMS0xMDI0MzE_fc072238-ec48-45cf-b145-4edda981d0ad"
      unitRef="usd">138584000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMS0zLTEtMS0xMDI0MzE_b7c5bcb9-cf8b-4c00-970c-e2d451b5ed7a"
      unitRef="usd">127358000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMS01LTEtMS0xMDI0MzE_c0f3bbdb-2a23-43d2-9536-29af467c75cd"
      unitRef="usd">112300000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMi0xLTEtMS0xMDI0MzE_f223d375-e73b-4c4c-b82b-67ee665d4efc"
      unitRef="usd">24147000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMi0zLTEtMS0xMDI0MzE_9652658e-85c1-42a9-9f16-15db968944a9"
      unitRef="usd">22931000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMi01LTEtMS0xMDI0MzE_9732542d-5f46-4f74-9756-1a19a0913f59"
      unitRef="usd">21581000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMy0xLTEtMS0xMDI0MzE_c8469871-b775-416f-9225-bb7229375a49"
      unitRef="usd">114437000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMy0zLTEtMS0xMDI0MzE_5ac6e3ec-c092-4d33-adec-25486ae3b97a"
      unitRef="usd">104427000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMy01LTEtMS0xMDI0MzE_ffea8db7-9019-45f1-b95e-6d050eb255a2"
      unitRef="usd">90719000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNS0xLTEtMS0xMDI0MzE_be5bea32-cc1b-4c76-ad09-86e2b0fefd45"
      unitRef="usd">80228000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNS0zLTEtMS0xMDI0MzE_6794fb71-504c-41d7-b5f6-4d6f1a7e7058"
      unitRef="usd">73328000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNS01LTEtMS0xMDI0MzE_738b833b-541f-4d41-9866-42d1f15b521b"
      unitRef="usd">69659000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNi0xLTEtMS0xMDI0MzE_3a4debff-7055-45a7-9530-bdd69e7ab0cc"
      unitRef="usd">27158000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNi0zLTEtMS0xMDI0MzE_a799b220-8eb2-4693-aacf-62e1e8ff7d8a"
      unitRef="usd">24177000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNi01LTEtMS0xMDI0MzE_889d65c8-1ddd-41f2-a8e9-3664aaec302d"
      unitRef="usd">17846000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNy0xLTEtMS0xMDI0MzE_1f82f7ff-49eb-47da-920d-b47a326f1130"
      unitRef="usd">36758000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNy0zLTEtMS0xMDI0MzE_a724f7de-7ed0-47c2-a499-c329c8c9e2d7"
      unitRef="usd">32338000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfNy01LTEtMS0xMDI0MzE_5451ed91-508a-4843-a60c-d934c89d778c"
      unitRef="usd">26396000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOC0xLTEtMS0xMDI0MzE_3e1561ab-3634-4d34-9ab5-18b2743e0fe7"
      unitRef="usd">144144000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOC0zLTEtMS0xMDI0MzE_b0cf5324-632c-4282-99de-fd09a61657d8"
      unitRef="usd">129843000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOC01LTEtMS0xMDI0MzE_805255ff-1e6c-4605-9e87-5d4f40a589e2"
      unitRef="usd">113901000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOS0xLTEtMS0xMDI0MzE_f235fbef-48f1-4bf2-802e-a440a34be3c9"
      unitRef="usd">-29707000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOS0zLTEtMS0xMDI0MzE_c6c4d727-4b0e-46cd-b7d2-ad5fe2ab0a2f"
      unitRef="usd">-25416000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfOS01LTEtMS0xMDI0MzE_0752a88c-c154-4d6d-91b4-49e8681569a7"
      unitRef="usd">-23182000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTEtMS0xLTEtMTAyNDMx_f7c1c635-2737-46ac-bf72-7a8b954f861b"
      unitRef="usd">569000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTEtMy0xLTEtMTAyNDMx_b6903d1e-2921-434e-9977-169986b36558"
      unitRef="usd">93000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTEtNS0xLTEtMTAyNDMx_4b7d166b-ee4a-4e61-86f1-0836e603bb02"
      unitRef="usd">605000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTItMS0xLTEtMTAyNDMx_75eb3519-a37c-4b68-bd0a-8c501a7f8e36"
      unitRef="usd">624000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTItMy0xLTEtMTAyNDMx_5c36c5d4-9edd-4dd1-92e9-c204fd3caeb2"
      unitRef="usd">1356000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTItNS0xLTEtMTAyNDMx_e39d925b-14d1-4ca9-9bbf-f9c70abf9e87"
      unitRef="usd">1054000</us-gaap:InterestExpense>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTMtMS0xLTEtMTAyNDMx_c0ffd297-fcaf-48aa-93de-f453edc2c5b6"
      unitRef="usd">1044000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTMtMy0xLTEtMTAyNDMx_1bed0613-57ea-4df9-b117-a3b055d5095a"
      unitRef="usd">-28000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTMtNS0xLTEtMTAyNDMx_f98b8af2-81ce-4a0b-92e8-8807c480f69d"
      unitRef="usd">-117000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTUtMS0xLTEtMTAyNDMx_8578d1dc-b3b3-4dc5-a41c-98ee72e98989"
      unitRef="usd">-230000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTUtMy0xLTEtMTAyNDMx_11de82fd-f666-48f5-8128-5557982b7914"
      unitRef="usd">-278000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTUtNS0xLTEtMTAyNDMx_5089c735-9b36-43f3-802f-3cd5fdcba726"
      unitRef="usd">-38000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTYtMS0xLTEtMTAyNDMx_850dfbd3-e14f-4889-8b4c-35fc914af770"
      unitRef="usd">759000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTYtMy0xLTEtMTAyNDMx_73bc7637-e09c-4504-b2ea-2cc6893809f2"
      unitRef="usd">-1569000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTYtNS0xLTEtMTAyNDMx_ec0bdb5b-d7bf-4ba1-9f00-e481d6305744"
      unitRef="usd">-604000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTctMS0xLTEtMTAyNDMx_a80f770a-bc04-495d-8d35-8047859901b4"
      unitRef="usd">-28948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTctMy0xLTEtMTAyNDMx_07326441-74f6-45d2-ad5d-c1b3b1f76c2a"
      unitRef="usd">-26985000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTctNS0xLTEtMTAyNDMx_f7d02799-eb65-49ea-b948-669fa3230e59"
      unitRef="usd">-23786000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMS0xLTEtMTAyNDMx_2d448aa0-8bbf-4519-be72-34d2e6721c48"
      unitRef="shares">42083125</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMS0xLTEtMTAyNDMx_513e9d47-1a2b-4b26-b372-21e6bb23e38d"
      unitRef="shares">42083125</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMS0xLTEtMTAyNDMx_84179dbf-4da7-4e7f-b270-4d8a281f5bd1"
      unitRef="shares">42083125</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMS0xLTEtMTAyNDMx_b055903e-52ce-4473-9a18-8fcb0276264d"
      unitRef="shares">42083125</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMy0xLTEtMTAyNDMx_0f98db8a-b32b-454d-97c0-899d0c733c75"
      unitRef="shares">41214889</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktMy0xLTEtMTAyNDMx_e121a3d8-aaa8-4c90-b193-7140b912bed9"
      unitRef="shares">41214889</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktNS0xLTEtMTAyNDMx_385258be-71be-442a-ae66-afba20e3ad90"
      unitRef="shares">39966937</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMTktNS0xLTEtMTAyNDMx_a62741fb-290a-4852-a606-4d2c92e16914"
      unitRef="shares">39966937</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtMS0xLTEtMTAyNDMx_1ae5018d-3e61-411f-80a0-2a3c63c363af"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtMS0xLTEtMTAyNDMx_df915d32-3620-416a-8f2b-afbf0146b118"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtMy0xLTEtMTAyNDMx_18009c9a-81bc-4859-8651-d033587728e7"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtMy0xLTEtMTAyNDMx_1d16f6fd-ece4-43ea-97af-2f6c57fcd9fd"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtNS0xLTEtMTAyNDMx_8484f0db-6850-449c-9186-2f6b3c0c7f34"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84Mi9mcmFnOjZhN2IyY2E3MTAxZDRiZmI4ZDdiMzYyOGY2YWQ4Mzc5L3RhYmxlOmM4ZjcwODQ5MDNhYjRiMDY4Y2YzZWQwMzgwMDhiMjQwL3RhYmxlcmFuZ2U6YzhmNzA4NDkwM2FiNGIwNjhjZjNlZDAzODAwOGIyNDBfMjAtNS0xLTEtMTAyNDMx_8492cad2-44c4-444f-a507-c9df09b5e33f"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idf515d9a7de44eff9aae0e17da62fba2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMi0xLTEtMS0xMDI0MzE_1061258c-9d16-4a10-8f6f-836157471e1e"
      unitRef="shares">39590000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idf515d9a7de44eff9aae0e17da62fba2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMi0zLTEtMS0xMDI0MzE_004bf029-571b-43a4-8f8d-0772a12b039d"
      unitRef="usd">396000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i11a07c1ba89f4e78b9f41a1b28db3e2e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMi01LTEtMS0xMDI0MzE_31249b1a-63e7-48b1-8550-8051bfea984a"
      unitRef="usd">311618000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i020f70d532cd4985bbe689c32516cea3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMi03LTEtMS0xMDI0MzE_a0100628-36b0-43c7-a860-f418fdef21de"
      unitRef="usd">-179861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91b861abf62b4326b086bd6c32bdcf69_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMi05LTEtMS0xMDI0MzE_73256970-e6d3-4e37-a945-700e32a98376"
      unitRef="usd">132153000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNC01LTEtMS0xMDI0MzE_3a6db523-a627-43c0-99a3-2571a8693d9c"
      unitRef="usd">8470000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNC05LTEtMS0xMDI0MzE_806ebd56-096c-42c2-89ea-c6e57e3e84c3"
      unitRef="usd">8470000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS0xLTEtMS0xMTY4NzA_7430532d-1aa4-49e6-a4b0-9ab2b7a0ba76"
      unitRef="shares">249000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS0zLTEtMS0xMTY4NzY_88ed2c2d-f8c5-4b62-ac3a-447d16606495"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS01LTEtMS0xMTY4ODY_72b9580c-89fa-4c84-a2ee-e4f1d7dac2ea"
      unitRef="usd">-2000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS05LTEtMS0xMTY4OTg_949f0769-d629-4ee1-afbe-010cf9daa2e8"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi0xLTEtMS0xMTY5MDY_220dc78c-6677-4633-b9e5-2301da75827e"
      unitRef="shares">40000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi01LTEtMS0xMTY5MjI_da63131b-7b89-479e-99da-8aa02b397e15"
      unitRef="usd">670000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi05LTEtMS0xMTY5Mzg_cc93261d-7b21-4b06-8109-e39777d6f092"
      unitRef="usd">670000</us-gaap:StockRepurchasedDuringPeriodValue>
    <axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS0xLTEtMS0xMDI0MzE_67db38b5-590d-449d-8052-47712a080fcf"
      unitRef="shares">572000</axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS0zLTEtMS0xMDI0MzE_50aaff58-aef6-4ddb-9ff1-09fb07338c42"
      unitRef="usd">6000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS01LTEtMS0xMDI0MzE_a42ef17a-cd7d-478b-9e5e-f0e10da6ce8c"
      unitRef="usd">3294000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNS05LTEtMS0xMDI0MzE_3073232e-4ebe-4cbc-b19d-3dc1b4c5bca3"
      unitRef="usd">3300000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights
      contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi0xLTEtMS0xMDI0MzE_b4cf6932-b13a-4611-a81c-c91df6262972"
      unitRef="shares">248000</axgn:StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights>
    <axgn:StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue
      contextRef="i4818e5552ff14829a3083da6b472a6d8_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi0zLTEtMS0xMDI0MzE_db3d073a-7c35-4370-82e3-ef377e5a7d55"
      unitRef="usd">2000</axgn:StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue>
    <axgn:StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue
      contextRef="iadb35062c34f4114b195dc3f8fbfa055_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi01LTEtMS0xMDI0MzE_0c0388a3-8e7c-411f-9ed3-6c2c17e749a3"
      unitRef="usd">3680000</axgn:StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue>
    <axgn:StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNi05LTEtMS0xMDI0MzE_01aff42b-3af2-4f8b-9485-ed27fc2f6658"
      unitRef="usd">3682000</axgn:StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue>
    <us-gaap:NetIncomeLoss
      contextRef="i70b02bce882f4530a644cf1f4de1281a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNy03LTEtMS0xMDI0MzE_2976496c-41d8-4c42-b83a-398a2d921e6b"
      unitRef="usd">-23786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfNy05LTEtMS0xMDI0MzE_c5f0eacd-e8f8-455d-b60e-b42245635fe4"
      unitRef="usd">-23786000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i45cc08a71962457c8a2b55f8d7a4d39a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfOS0xLTEtMS0xMDI0MzE_e9d565c3-fed1-426b-b492-0d3360709d1c"
      unitRef="shares">40619000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i45cc08a71962457c8a2b55f8d7a4d39a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfOS0zLTEtMS0xMDI0MzE_8b9722bd-779a-4ae4-8c15-775554baa128"
      unitRef="usd">406000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i988505ce34a844a09623ae3c12d8ec87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfOS01LTEtMS0xMDI0MzE_46a33800-7d64-4c5e-8521-34b40b1afe0e"
      unitRef="usd">326390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f968e20d3bf41eebd5e2ffa7bb615b7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfOS03LTEtMS0xMDI0MzE_82bdcd1f-a7af-486e-8ed6-0be09dc266b0"
      unitRef="usd">-203647000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ied6b9724c05f4cb3a66af446b51ae49e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfOS05LTEtMS0xMDI0MzE_c84edd43-0da7-44d3-aac4-616d734cb038"
      unitRef="usd">123149000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i404b822cbf2e4fe08c667eb2554e74c4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTEtNS0xLTEtMTAyNDMx_5dbfae0a-5ac6-4dfe-be57-01cbbc351796"
      unitRef="usd">10919000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTEtOS0xLTEtMTAyNDMx_c417361c-84fd-4729-ade6-c8aff8a25489"
      unitRef="usd">10919000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="if0df7a1efdb049cfa90a2524886d1252_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTItMS0xLTEtMTAyNDMx_e3007f81-c994-4d9d-9eb0-a96dbfc643b8"
      unitRef="shares">254000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="if0df7a1efdb049cfa90a2524886d1252_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTItMy0xLTEtMTAyNDMx_1a81e9ad-b3d1-4697-b0e8-c75a4b7f62ca"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i404b822cbf2e4fe08c667eb2554e74c4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTItNS0xLTEtMTAyNDMx_0a77c2d4-1ab4-4a7e-b92e-f37c6929a65d"
      unitRef="usd">-2000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTItOS0xLTEtMTAyNDMx_6bff7f6c-4db1-4bd2-961a-e890ddd8a37c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="if0df7a1efdb049cfa90a2524886d1252_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTQtMS0xLTEtMTAyNDMx_84953b93-14cb-45c4-8e1e-1530813b6648"
      unitRef="shares">864000</axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="if0df7a1efdb049cfa90a2524886d1252_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTQtMy0xLTEtMTAyNDMx_d77e222a-decf-45fb-8771-88c03b2dbd91"
      unitRef="usd">9000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="i404b822cbf2e4fe08c667eb2554e74c4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTQtNS0xLTEtMTAyNDMx_79985777-e1ab-444c-a815-3637283c6e40"
      unitRef="usd">5458000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTQtOS0xLTEtMTAyNDMx_7b53e416-4ad6-4d72-83e4-b18316ebb2f9"
      unitRef="usd">5467000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="i48bde1d6124b4ea78c970234e62219ab_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTYtNy0xLTEtMTAyNDMx_ed6d1a1d-1861-475d-ba23-05a6d719492d"
      unitRef="usd">-26985000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTYtOS0xLTEtMTAyNDMx_39e49eb7-30dc-4424-b814-b8ef4847e9f0"
      unitRef="usd">-26985000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie35d0ad377f844a4a7e48534c50caff4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTgtMS0xLTEtMTAyNDMx_d07ef018-3543-4c77-bb2e-02e318fa3540"
      unitRef="shares">41737000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie35d0ad377f844a4a7e48534c50caff4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTgtMy0xLTEtMTAyNDMx_7cd85176-90d9-454c-96d6-498764f864cf"
      unitRef="usd">417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8158cb4740e7427188f9ee3550c9230b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTgtNS0xLTEtMTAyNDMx_e0f4c7ea-4109-45c4-b93e-3766e1fbeeb2"
      unitRef="usd">342765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic23f7a20a5a44ab7b5e3f093917b8c03_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTgtNy0xLTEtMTAyNDMx_7e4180c7-bb70-45a8-9d00-b95d8904a782"
      unitRef="usd">-230632000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMTgtOS0xLTEtMTAyNDMx_9fb1a56e-7980-4353-b82b-4c68ea5cfeb7"
      unitRef="usd">112550000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i81e2bc0aacfa402f813dddb588b6267f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjAtNS0xLTEtMTAyNDMx_c645b670-260f-4af6-ac36-8ef029d5206b"
      unitRef="usd">15591000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjAtOS0xLTEtMTAyNDMx_65371581-d027-4bc1-b0eb-d313e17c64e1"
      unitRef="usd">15591000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="iec80f298a69e4799b67c597636a9f301_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjEtMS0xLTEtMTAyNDMx_f26f55e7-6b37-40b3-bff8-b1e94662fda4"
      unitRef="shares">343000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="iec80f298a69e4799b67c597636a9f301_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjEtMy0xLTEtMTAyNDMx_dbb1a249-66ef-41a8-8898-67d32a604f0a"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i81e2bc0aacfa402f813dddb588b6267f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjEtNS0xLTEtMTAyNDMx_0c211a7b-98c0-497b-b704-95e47e6715f8"
      unitRef="usd">-3000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjEtOS0xLTEtMTAyNDMx_018d5eed-4505-41ea-9be2-b3ee09cf09cc"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="iec80f298a69e4799b67c597636a9f301_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjMtMS0xLTEtMTAyNDMx_d5678cc7-f4f0-4ff4-b243-5cc8cd06db1e"
      unitRef="shares">365000</axgn:StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="iec80f298a69e4799b67c597636a9f301_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjMtMy0xLTEtMTAyNDMx_e4f4cf16-e55f-4c4d-9455-d6897fb4c47f"
      unitRef="usd">4000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="i81e2bc0aacfa402f813dddb588b6267f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjMtNS0xLTEtMTAyNDMx_d0f2a974-ee2a-4ca4-950d-f16919e71a22"
      unitRef="usd">1802000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjMtOS0xLTEtMTAyNDMx_6801f60e-55da-495c-b0cb-680bff40dce7"
      unitRef="usd">1806000</axgn:StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="i6d3fa1437edd43a5b85f3cf6a86ed7df_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjUtNy0xLTEtMTAyNDMx_a7b10e5b-8a98-4b54-a4a8-5a250ec25abe"
      unitRef="usd">-28948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjUtOS0xLTEtMTAyNDMx_e6fa335c-b755-45ab-88d5-adfaa4d4cddb"
      unitRef="usd">-28948000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i64198b8113a54a908aaacc22c63099fa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjctMS0xLTEtMTAyNDMx_0c97ca34-6d83-4451-ada8-a264cf597d7b"
      unitRef="shares">42445000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i64198b8113a54a908aaacc22c63099fa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjctMy0xLTEtMTAyNDMx_edc0d993-9895-432e-b4d5-91bd89989a12"
      unitRef="usd">424000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e263d574089497289c6eefc50c18244_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjctNS0xLTEtMTAyNDMx_dfc36e00-5d53-4c9e-88fb-70003c25890e"
      unitRef="usd">360155000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i26cf5637ad1d4822b296d27f9963de73_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjctNy0xLTEtMTAyNDMx_a278f94c-3f54-43e3-848d-95bf9fa909a6"
      unitRef="usd">-259580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84NS9mcmFnOjhiYmE3NTk3YTU5YTQ1ZGRhZmRmYjc2MmIyODU4MGRhL3RhYmxlOmE2ZTdhNjgxMGUyNjQxMjZhOTQ1YWNmYzM3MWYxNTFiL3RhYmxlcmFuZ2U6YTZlN2E2ODEwZTI2NDEyNmE5NDVhY2ZjMzcxZjE1MWJfMjctOS0xLTEtMTAyNDMx_bbc27fbc-0471-4a6a-bf22-bda42deab64d"
      unitRef="usd">100999000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMi0xLTEtMS0xMDI0MzE_c6f4f912-ceec-4aa5-a1f2-85027feac5b7"
      unitRef="usd">-28948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMi0zLTEtMS0xMDI0MzE_fd3b2ba8-7267-4751-a29c-658e3fa394fc"
      unitRef="usd">-26985000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMi01LTEtMS0xMDI0MzE_f5e96c8c-45ab-4186-bf90-2cdc1086e067"
      unitRef="usd">-23786000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNC0xLTEtMS0xMDI0MzE_0180378a-853d-4ec8-87c5-680583eb961e"
      unitRef="usd">2827000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNC0zLTEtMS0xMDI0MzE_8b306db5-9a3c-4e61-931b-da739475fa1d"
      unitRef="usd">2744000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNC01LTEtMS0xMDI0MzE_54227d74-dc0c-4bf0-9e7c-903cdcd5d674"
      unitRef="usd">1530000</us-gaap:DepreciationDepletionAndAmortization>
    <axgn:RightOfUseAssetAmortization
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNS0xLTEtMS0xMDI0MzE_46c47474-d8c0-44a7-9053-8c64ceb7e772"
      unitRef="usd">1761000</axgn:RightOfUseAssetAmortization>
    <axgn:RightOfUseAssetAmortization
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNS0zLTEtMS0xMDI0MzE_56135db2-0a10-4124-8b35-79392e466f0a"
      unitRef="usd">1795000</axgn:RightOfUseAssetAmortization>
    <axgn:RightOfUseAssetAmortization
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNS01LTEtMS0xMDI0MzE_c5a16100-d4dc-474c-b919-73138669ff65"
      unitRef="usd">1777000</axgn:RightOfUseAssetAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNi0xLTEtMS0xMDI0MzE_4f770e4c-dfb1-46dc-b82e-0bb20a6a333b"
      unitRef="usd">265000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNi0zLTEtMS0xMDI0MzE_fba0c675-47c3-443e-8024-e53c2661f294"
      unitRef="usd">202000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNi01LTEtMS0xMDI0MzE_569fe9d4-3ffb-45c9-b04d-bdd3f514f846"
      unitRef="usd">153000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOC0xLTEtMS0xMDI0MzE_ae2a6e1b-45d7-496b-ab88-2a666c4c3427"
      unitRef="usd">891000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOC0zLTEtMS0xMDI0MzE_f11846c4-987f-4d07-90a6-69b9dcfec8e6"
      unitRef="usd">831000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOC01LTEtMS0xMDI0MzE_11128781-b7e2-41e6-8791-2aaa6061e227"
      unitRef="usd">232000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOS0xLTEtMS0xMDI0MzE_12bf95fa-b463-4abc-8b0b-00e9fc4d234c"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOS0zLTEtMS0xMDI0MzE_dceb88e4-c76b-4567-b880-80352dea40a4"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfOS01LTEtMS0xMDI0MzE_f3702fc4-0b3e-4eec-a553-9d7687fbff52"
      unitRef="usd">-3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTEtMS0xLTEtMTAyNDMx_1dde4aa4-96b7-47e7-8d44-dc9c1e6d8abe"
      unitRef="usd">612000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTEtMy0xLTEtMTAyNDMx_b25d0931-014b-4ba4-a303-2289905fce9d"
      unitRef="usd">-41000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTEtNS0xLTEtMTAyNDMx_e3354cb8-d616-4dc6-94ac-afe83f75673a"
      unitRef="usd">-105000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryWriteDown
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTItMS0xLTEtMTAyNDMx_039827a0-9299-45f5-ab29-84dba7bb82c9"
      unitRef="usd">1769000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTItMy0xLTEtMTAyNDMx_b2002297-8fe1-455f-86a3-58d171a5da38"
      unitRef="usd">3314000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTItNS0xLTEtMTAyNDMx_96ec12bf-d83e-41d3-a708-334864bbb080"
      unitRef="usd">2242000</us-gaap:InventoryWriteDown>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTMtMS0xLTEtMTAyNDMx_3847b3b8-b679-4b97-b5f7-7042696287d4"
      unitRef="usd">228000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTMtMy0xLTEtMTAyNDMx_ce84cae8-1400-4280-a309-1893951f3b5d"
      unitRef="usd">-68000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTMtNS0xLTEtMTAyNDMx_a561f563-ceae-461d-8a0b-2e627a450e93"
      unitRef="usd">47000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTQtMS0xLTEtMTAyNDMx_cff45f06-9288-4c5f-8f47-6397a8b5b76a"
      unitRef="usd">1044000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTQtMy0xLTEtMTAyNDMx_9022d5b8-836a-4753-a09e-49e04e26aa75"
      unitRef="usd">-28000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTQtNS0xLTEtMTAyNDMx_c9c52ec8-3bcc-42bb-92eb-d37b7fa54000"
      unitRef="usd">-117000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ShareBasedCompensation
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTUtMS0xLTEtMTAyNDMx_be1c65e1-7085-4dc4-834b-d23e5854cfd6"
      unitRef="usd">15591000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTUtMy0xLTEtMTAyNDMx_7ff27f0f-2ef7-4b2b-8f07-07d689ec5ee8"
      unitRef="usd">10919000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTUtNS0xLTEtMTAyNDMx_adcd4b18-6f91-4ea9-818a-27dd7a62c6b3"
      unitRef="usd">8470000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTctMS0xLTEtMTAyNDMx_c78daaaa-7a0a-40ef-9643-086e811a9031"
      unitRef="usd">4639000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTctMy0xLTEtMTAyNDMx_e195bf51-9df5-4933-898f-1273ccd1b7a1"
      unitRef="usd">499000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTctNS0xLTEtMTAyNDMx_c1931ed5-beea-4ed6-8544-725e31e4ed10"
      unitRef="usd">635000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTgtMS0xLTEtMTAyNDMx_8107e9b8-c9e0-4ed0-ac28-90fd4372831c"
      unitRef="usd">3656000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTgtMy0xLTEtMTAyNDMx_08315cfd-e376-4b4f-b678-919dda3b7a33"
      unitRef="usd">7478000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTgtNS0xLTEtMTAyNDMx_eb07af45-c77e-4b34-a052-2a861b3c4e19"
      unitRef="usd">910000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTktMS0xLTEtMTAyNDMx_29a5a43b-70ab-4272-875a-85b4e6183584"
      unitRef="usd">84000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTktMy0xLTEtMTAyNDMx_294cf3c8-7b4f-442c-8993-5e933eb3f5c1"
      unitRef="usd">-2435000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMTktNS0xLTEtMTAyNDMx_917fdf2b-a791-4217-8fa2-e99ce33f4b4f"
      unitRef="usd">2524000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjAtMS0xLTEtMTAyNDMx_87d9f6d0-34f2-4c2f-8baa-8c62a4d1c15f"
      unitRef="usd">660000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjAtMy0xLTEtMTAyNDMx_4b82767a-deb7-4350-bb9d-ffab232e014e"
      unitRef="usd">-270000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjAtNS0xLTEtMTAyNDMx_3c998379-0650-495d-8d39-395a0f251bae"
      unitRef="usd">4958000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <axgn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjEtMS0xLTEtMTAyNDMx_7c3c9005-ddb3-4b1b-9619-71a3aa05498f"
      unitRef="usd">1841000</axgn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <axgn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjEtMy0xLTEtMTAyNDMx_dfee9e78-c9c3-4d0a-b4d7-c30d7c6b6645"
      unitRef="usd">463000</axgn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <axgn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjEtNS0xLTEtMTAyNDMx_8776b6c5-f79d-4b7c-a924-0ffcceb72e1c"
      unitRef="usd">1086000</axgn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjItMS0xLTEtMTAyNDMx_ef566182-3741-43b0-b4a6-6e3691efe67e"
      unitRef="usd">2000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjItMy0xLTEtMTAyNDMx_04e188f7-f574-4615-90ef-7657795eb15a"
      unitRef="usd">2000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjItNS0xLTEtMTAyNDMx_ad3c9196-21f8-433d-959c-cf932ecb9de9"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjMtMS0xLTEtMTAyNDMx_b2ed0793-d779-4231-96cf-9ce688706cb0"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjMtMy0xLTEtMTAyNDMx_7a3e9a61-96d1-45be-afb9-d5a7dbfd726e"
      unitRef="usd">-3000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjMtNS0xLTEtMTAyNDMx_71164109-b72f-4f2c-9156-456961f83e9f"
      unitRef="usd">-12000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjQtMS0xLTEtMTAyNDMx_03f1241d-537e-4186-a2d0-068710f3c3dd"
      unitRef="usd">-16066000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjQtMy0xLTEtMTAyNDMx_d18a3d0e-0236-4220-8ffe-ce780ef83fd7"
      unitRef="usd">-13405000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjQtNS0xLTEtMTAyNDMx_c6ef31ea-22c0-4055-9ec7-0079de08ed15"
      unitRef="usd">-9626000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjctMS0xLTEtMTAyNDMx_36d803b4-a76c-4ef0-8461-ae398ddd3a7e"
      unitRef="usd">20078000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjctMy0xLTEtMTAyNDMx_9f831bfd-d7b0-44b3-b1c6-f7cc9685ae72"
      unitRef="usd">27811000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjctNS0xLTEtMTAyNDMx_4db2a703-7860-4d52-abf6-c46d753aa79f"
      unitRef="usd">21905000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <axgn:ProceedsFromGrantorsInvestingActivities
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjgtMS0xLTEtMTAyNDMx_eb4c7363-b96a-48b5-a58f-d926bbbbcb2b"
      unitRef="usd">0</axgn:ProceedsFromGrantorsInvestingActivities>
    <axgn:ProceedsFromGrantorsInvestingActivities
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjgtMy0xLTEtMTAyNDMx_8a386825-e280-427d-8c7b-1bfd7487beed"
      unitRef="usd">950000</axgn:ProceedsFromGrantorsInvestingActivities>
    <axgn:ProceedsFromGrantorsInvestingActivities
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjgtNS0xLTEtMTAyNDMx_4d61c5ae-65da-4cf5-a399-f541ce5b8a79"
      unitRef="usd">0</axgn:ProceedsFromGrantorsInvestingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjktMS0xLTEtMTAyNDMx_c750a55b-00c0-420c-81e6-7acc03196e54"
      unitRef="usd">39247000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjktMy0xLTEtMTAyNDMx_a7c20178-7203-44da-88db-028100caec33"
      unitRef="usd">68699000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMjktNS0xLTEtMTAyNDMx_3f931067-1399-43d1-9ccb-f4140566a041"
      unitRef="usd">77806000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzAtMS0xLTEtMTAyNDMx_5e5daff5-238c-4f5f-9957-613504cd9eaa"
      unitRef="usd">57300000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzAtMy0xLTEtMTAyNDMx_845c8931-c5d8-49c8-944d-66193fb277ea"
      unitRef="usd">72500000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzAtNS0xLTEtMTAyNDMx_c9eea86e-db89-4074-b5f9-410d5a95b38b"
      unitRef="usd">83440000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzEtMS0xLTEtMTAyNDMx_ad3c4ac8-62b0-4f90-b7f0-45a8b26a27a2"
      unitRef="usd">1175000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzEtMy0xLTEtMTAyNDMx_235133c1-c63b-4cdb-8c4f-6f1de18dfb2b"
      unitRef="usd">589000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzEtNS0xLTEtMTAyNDMx_bfde27f4-1448-4da8-9188-f3026eaf4b1d"
      unitRef="usd">692000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzItMS0xLTEtMTAyNDMx_1acf0a70-fd42-4c0a-b8a8-14373e60922c"
      unitRef="usd">-3200000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzItMy0xLTEtMTAyNDMx_c146cc2d-c19a-420f-b58d-57d872f62c0a"
      unitRef="usd">-23649000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzItNS0xLTEtMTAyNDMx_bc25d414-1353-4608-8f24-47ca6d4268f1"
      unitRef="usd">-16963000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzUtMS0xLTEtMTAyNDMx_b94f1169-9480-4679-86d8-45cca0a6e612"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzUtMy0xLTEtMTAyNDMx_5537ccd1-38fc-4684-9bee-524c2a0d628e"
      unitRef="usd">15000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzUtNS0xLTEtMTAyNDMx_a8c71295-f12b-4eeb-92ba-3cce17bc6b43"
      unitRef="usd">35000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzYtMS0xLTEtMTAyNDMx_78227440-aac0-4651-8b40-53e658860126"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzYtMy0xLTEtMTAyNDMx_a1d4aefe-716a-42cf-930a-4ff8f71c893e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzYtNS0xLTEtMTAyNDMx_896b1fde-d797-4406-8014-220a8bf587e9"
      unitRef="usd">7820000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzctMS0xLTEtMTAyNDMx_b8442098-b243-49da-92ae-0baf68d97651"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzctMy0xLTEtMTAyNDMx_ec955d55-5518-41cb-8adb-fc2e353784ca"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzctNS0xLTEtMTAyNDMx_bd881a11-f9de-402f-bcf1-20ff120a036f"
      unitRef="usd">7820000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzgtMS0xLTEtMTAyNDMx_e9b286e0-3e4a-48a7-92de-e1e78c273b2a"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzgtMy0xLTEtMTAyNDMx_0f6508be-cb48-4d5f-b8dc-dc291124c126"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzgtNS0xLTEtMTAyNDMx_cf5240e5-b223-4803-85b9-5a6d599b5d15"
      unitRef="usd">3500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzktMS0xLTEtMTAyNDMx_59a26f45-f95f-4e91-bfb3-33b80b1335cf"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzktMy0xLTEtMTAyNDMx_ab127bbf-ad4f-44bf-9a57-bd0b7d8f3afa"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfMzktNS0xLTEtMTAyNDMx_a453f86b-e923-4ed2-b52b-d3937a43a811"
      unitRef="usd">642000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDMtMS0xLTEtMTAyNDMx_b9c9aadd-84f2-4be3-ab7b-fcfd1a06620a"
      unitRef="usd">12000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDMtMy0xLTEtMTAyNDMx_2f19fb64-7140-4017-8965-3e32f10f23cb"
      unitRef="usd">15000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDMtNS0xLTEtMTAyNDMx_e7d0c4b0-838f-4624-956c-ef9a4c7e8114"
      unitRef="usd">14000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDQtMS0xLTEtMTAyNDMx_4a21efbf-3632-4fee-96ae-4f74e3504dfd"
      unitRef="usd">1806000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDQtMy0xLTEtMTAyNDMx_de93bfb4-2e29-4dbd-9994-759da24ac695"
      unitRef="usd">5467000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDQtNS0xLTEtMTAyNDMx_28956cdc-f0dc-4b01-a3a5-b4b2ce4accb3"
      unitRef="usd">3300000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDUtMS0xLTEtMTAyNDMx_0eba33a1-040d-4426-8fd7-c3009c5be078"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDUtMy0xLTEtMTAyNDMx_434478fc-4e48-4ff2-a5fb-e7ab690d041c"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDUtNS0xLTEtMTAyNDMx_1b579e3d-daa2-41cb-8c99-6af607b4689d"
      unitRef="usd">670000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDYtMS0xLTEtMTAyNDMx_a51587ec-9a68-40a5-b330-abc0f5d63a19"
      unitRef="usd">1794000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDYtMy0xLTEtMTAyNDMx_fc3b0a45-ed0f-4155-a95d-5c58e51b16c5"
      unitRef="usd">20452000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDYtNS0xLTEtMTAyNDMx_bfd89a5e-2bd8-4c5f-902c-8f2e787eaf15"
      unitRef="usd">40474000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDctMS0xLTEtMTAyNDMx_aeca7b96-d976-4bc9-8f35-a2618ef98c70"
      unitRef="usd">-17472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDctMy0xLTEtMTAyNDMx_12b22eee-588d-4836-aa99-a955d63b3e2e"
      unitRef="usd">-16602000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDctNS0xLTEtMTAyNDMx_9b5bec2a-1168-4a8e-a62f-5268d1f1e993"
      unitRef="usd">13885000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDgtMS0xLTEtMTAyNDMx_3410e33a-d553-42a0-82f4-5d125fd79514"
      unitRef="usd">39007000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ied6b9724c05f4cb3a66af446b51ae49e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDgtMy0xLTEtMTAyNDMx_5c86f527-7e35-4442-8e08-d27e7b925584"
      unitRef="usd">55609000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i91b861abf62b4326b086bd6c32bdcf69_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDgtNS0xLTEtMTAyNDMx_30040338-a2d3-4ac9-bf2f-bba6f0e052b7"
      unitRef="usd">41724000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDktMS0xLTEtMTAyNDMx_eb1cb457-71c9-4d41-9300-116506e05fd0"
      unitRef="usd">21535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDktMy0xLTEtMTAyNDMx_4815656f-f406-4d80-936a-ccf1eed35eb6"
      unitRef="usd">39007000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ied6b9724c05f4cb3a66af446b51ae49e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOjIzYzhkYjdhMzNkNTQ3MTM4YmRhZmEwZmVjMmVjZDRkL3RhYmxlcmFuZ2U6MjNjOGRiN2EzM2Q1NDcxMzhiZGFmYTBmZWMyZWNkNGRfNDktNS0xLTEtMTAyNDMx_54a8825d-4b93-46c5-b216-96a82ca7fb6e"
      unitRef="usd">55609000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfMi0xLTEtMS0xMDI0MzE_4f60bfba-7667-43d3-b607-7ec728a78a83"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfMi0zLTEtMS0xMDI0MzE_a20c0326-ec91-4ea6-a264-db9ad1919593"
      unitRef="usd">495000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfMi01LTEtMS0xMDI0MzE_6eb26768-91a1-44d5-a1ca-a0e0a13a1a8d"
      unitRef="usd">822000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNC0xLTEtMS0xMDI0MzE_ad8d9d19-7656-4be1-aaa1-b01b432c43a0"
      unitRef="usd">866000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNC0zLTEtMS0xMDI0MzE_47477324-386c-4fd7-8aac-ba71af2a1a27"
      unitRef="usd">1420000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNC01LTEtMS0xMDI0MzE_34ac8846-d7e7-4327-a191-16177b1049f3"
      unitRef="usd">1077000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNS0xLTEtMS0xMDI0MzE_762d2d35-245b-43c9-94cf-78ad1c41de67"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNS0zLTEtMS0xMDI0MzE_2cef6aac-dad4-4708-aeb5-447145c1ba41"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNS01LTEtMS0xMDI0MzE_7e0ebb43-9265-422a-8d8f-31e12ed8cae0"
      unitRef="usd">5250000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <axgn:EmbeddedDerivativeAssociatedWithTheLongTermDebt
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNi0xLTEtMS0xMDI0MzE_b8f5ee5d-4ac3-4337-92e9-d1044f4033a1"
      unitRef="usd">0</axgn:EmbeddedDerivativeAssociatedWithTheLongTermDebt>
    <axgn:EmbeddedDerivativeAssociatedWithTheLongTermDebt
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNi0zLTEtMS0xMDI0MzE_9c4bd0c4-3b63-4eb2-8b0a-178c1d1fca97"
      unitRef="usd">3037000</axgn:EmbeddedDerivativeAssociatedWithTheLongTermDebt>
    <axgn:EmbeddedDerivativeAssociatedWithTheLongTermDebt
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNi01LTEtMS0xMDI0MzE_360277f5-61c8-4dcc-9c6b-ada3e55731c3"
      unitRef="usd">2563000</axgn:EmbeddedDerivativeAssociatedWithTheLongTermDebt>
    <axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNy0xLTEtMS0xMDI0MzE_30d0e721-d5ab-4317-b0fb-4dea43d7a1cd"
      unitRef="usd">1018000</axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability>
    <axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNy0zLTEtMS0xMDI0MzE_0e71f64c-3199-4b51-9432-041b2baa8e75"
      unitRef="usd">1375000</axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability>
    <axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfNy01LTEtMS0xMDI0MzE_d3877d94-5d96-4524-b51e-d27a776f6194"
      unitRef="usd">14259000</axgn:NoncashRightOfUseAssetsAndOperatingLeaseLiability>
    <axgn:NoncashOrPartNoncashConversionOption
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOC0xLTEtMS0xMDI0MzE_2430b8a0-1cfd-497e-bb2f-7894f4ea0f8c"
      unitRef="usd">0</axgn:NoncashOrPartNoncashConversionOption>
    <axgn:NoncashOrPartNoncashConversionOption
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOC0zLTEtMS0xMDI0MzE_cf3a88db-2d6c-4671-b738-386bb4d66d36"
      unitRef="usd">0</axgn:NoncashOrPartNoncashConversionOption>
    <axgn:NoncashOrPartNoncashConversionOption
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOC01LTEtMS0xMDI0MzE_3c02b596-0e93-4c26-8198-2d55215f8814"
      unitRef="usd">182000</axgn:NoncashOrPartNoncashConversionOption>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOS0xLTEtMS0xMDI0MzE_f3eff573-2a0e-4734-8661-fcaef33157c6"
      unitRef="usd">299000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOS0zLTEtMS0xMDI0MzE_64978910-8bc4-4a90-81f3-dd0a2aef3dc6"
      unitRef="usd">418000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV84OC9mcmFnOmY2YzhmYWM3YzczNTQ2Y2Y5NmJkMjM4M2NlZGY1YjI2L3RhYmxlOmI0NDcxZDgzYzQ2NDQyMTU4YjQ3YjM1Mjk1OTdiNzc5L3RhYmxlcmFuZ2U6YjQ0NzFkODNjNDY0NDIxNThiNDdiMzUyOTU5N2I3NzlfOS01LTEtMS0xMDI0MzE_e34522ca-fb0a-4718-a53c-b4fb1f6de726"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NatureOfOperations
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV85NC9mcmFnOjk0Y2YxYTI4Yjk3MzQxYzNhZmQyNTllNjUyNmNmNjYyL3RleHRyZWdpb246OTRjZjFhMjhiOTczNDFjM2FmZDI1OWU2NTI2Y2Y2NjJfNTcy_2f6fecd1-7405-465e-bd8d-1ed68fe35638">Nature of Business &#160;&#160;&#160;&#160;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Axogen,&#160;Inc. (together with its wholly-owned subsidiaries, the &#x201c;Company&#x201d;) was incorporated in Minnesota and is the leader in the science, development and commercialization of the technologies used for the peripheral nerve regeneration and repair. The Company's products include Avance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Nerve Graft, Axoguard Nerve Connector&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Axoguard Nerve Protector&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Axoguard Nerve Cap&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Axotouch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Two-Point Discriminator&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is headquartered in Florida. The Company has processing, warehousing, and distribution facilities in Texas and Ohio.&lt;/span&gt;The Company manages its operations as a single operating segment. Substantially all of the Company's assets are maintained in the United States. The Company derives substantially all of its revenues from sales to customers in the United States.</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDE1_f4435292-fd0c-40dc-9c68-5023e6e62b53">Summary of Significant Accounting Policies &lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). All intercompany accounts and transactions have been eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant estimates affecting the amounts reported or disclosed in the consolidated financial statements include the realizable value of inventories, the valuation of stock-based compensation and the valuation of derivative instruments and the fair value of debt instruments. Other estimates that affect the amounts reported or disclosed in the consolidated financial statements include the allowance for doubtful accounts, the useful life and recoverability of long-lived assets, incremental borrowing rates for operating leases, accounting for income taxes including the realizability of deferred tax assets and the related valuation allowance. The Company bases its estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified for consistency with the current year presentation. Specifically, finance lease right-of-use assets which were presented separately in 2021, and are now included in property and equipment. In addition, the debt derivative liability was included in net operating loss carryforwards in deferred assets in 2021, it is presented separately as debt derivative liability in deferred tax assets. See Note 12 - Income Taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outbreak of the COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020, and the virus has continued to spread through 2022. The related responses by public health and governmental authorities to contain and combat the outbreak and spread of the virus, have adversely impacted global commercial activity, hospital staffing, elective surgeries, supply chains and contributed to significant volatility in financial markets. The Company experienced a decrease in demand for its products and services during 2020 and 2021, due to the lack of access to hospitals and health care facilities and the reallocation of resources from surgical procedures to COVID-19 patient care as well as the related staffing shortages in health care had a material adverse effect on the Company's results of operations. This negative impact began to improve in 2022, particularly in the second half of the year; however, the inflationary pressure and the ensuing recession may have a negative effect on the demand for the Company's products, services and the Company's operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on its suppliers, including single source suppliers, and the inability of these suppliers to deliver necessary components of its products in a timely manner at prices, quality levels and volumes acceptable to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company, or its inability to efficiently manage these components from these suppliers, could have a material adverse effect on its business, financial condition and operating results.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash and cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of acquisition. Certain of the Company's cash and cash equivalents balances exceed Federal Deposit Insurance Corporation ("FDIC") insured limits or are invested in money market accounts with investment banks that are not FDIC-insured. The Company places its cash and cash equivalents in what they believe to be credit-worthy financial institutions. As of December&#160;31, 2022, $15,034 of the cash and cash equivalents balance was in excess of FDIC limits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in restricted cash represent those required to be set aside to meet contractual terms of a lease agreement held by the Company.See Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Credit Facilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same reported in the consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments consist of commercial paper and U.S. government securities, are classified as available-for-sale and have maturities less than one year as of each balance sheet date. Investments are carried at fair value based upon quoted market prices. The Company elected the fair value option ("FVO") for all of its available-for-sale investments. The FVO election results in all changes in unrealized gains and losses being included in investment income in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Account receivables are recorded at invoiced amounts and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or other security to support its receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance for doubtful accounts is established for estimated uncollectible receivables based on the Company's assessment of the collectability of customer accounts and recognizes the provision in general and administrative on the consolidated statements of operations. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. Uncollectible receivables are written off against the allowance for doubtful accounts when all attempts to collect the receivable have been exhausted. The provision for bad debts is recorded as a component of general and administrative expenses on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions and trade receivables. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's products are sold on an uncollateralized basis and on credit terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of the Company's customers accounted for 10% or more of the consolidated revenues during the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, consisting of materials, direct labor and manufacturing overhead, are stated at the lower of cost or net realizable value. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf-life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage. To estimate the amount of inventory that will expire prior to being distributed, the Company reviews inventory quantities on hand, historical and projected distribution levels, and historical expiration trends. The Company&#x2019;s calculation of the amount of inventory that will expire prior to distribution has two components: 1) a demand or consumption-based component that compares projected distribution to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being distributed. The Company&#x2019;s model assumes that inventory will be distributed on a first-in, first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that significant portions of the Company&#x2019;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written down involves significant judgments and estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are stated at historical cost less accumulated depreciation and amortization. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset&#x2019;s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg2NTE3MQ_1b1457ed-1497-471b-a70d-aa52a8985c35"&gt;three&lt;/span&gt; to seven years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains or losses on the disposition of property and equipment are recorded in the period incurred and recorded general and administrative expenses on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capitalized Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest cost on capital projects, including facilities build-outs, is capitalized and included in the cost of the project. Capitalization begins with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. For the years ended December&#160;31, 2022, and 2021, the Company capitalized $6,155 and $4,277, respectively, of interest expense into property and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes long-lived assets (asset groups), including property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. The Company tests annually, in the third quarter, for impairments. An impairment is recognized when the estimated undiscounted cash flows generated by those assets is less than the carrying amounts of such assets. If it is determined that long-live asset (asset groups) is not recoverable, an impairment loss would be calculated based on the excess of the carrying value of the long-lived asset (asset groups) over the fair value of the long-lived asset (asset groups). There have been no impairments of long-lived assets during the years ended December&#160;31, 2022, 2021, and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are not subject to amortization, however, annually in the third quarter or whenever an event occurs or circumstances indicate that the indefinite-lived intangible assets may be impaired, the Company evaluates qualitative factors to determine whether it is more likely or not that the fair value of the indefinite lived asset is less than its carrying amount. The Company's qualitative evaluation includes an assessment of factors, including specific operating results as well as industry, market and general economic conditions. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are recorded at cost and include patents and patent application costs, licenses, and trademarks. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives and reported net of accumulated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortization. Amortization expense is recorded in general and administrative expenses on the consolidated statements of operations. The useful lives of intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;License agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: 17 to 20 years&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Patents: up to 20 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Trademarks: indefinite lived&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company pays royalty fees based on net sales of the licensed products, which are recorded in sales and marketing on the consolidated statements of operation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Global Nerve Foundation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Periodically, the Company may make contributions to the Global Nerve Foundation ("GNF"), a related party, due to certain executives of the Company being members of GNF's board of directors. The GNF was incorporated in 2021 exclusively for charitable, educational, and scientific purposes and qualifies under IRC 501(c)(3) as an exempt private foundation. Under its charter, the GNF engages in activities that focus on improving the awareness and care of patients with peripheral nerve injuries through grants, contributions and other appropriate means. The GNF is a separate legal entity and is not a subsidiary of the Company; therefore, its results are not included in the accompanying consolidated financial statements. The Company contributed $700 to the GNF during the year ended December&#160;31, 2022, no amounts were contributed previously. These contributions were recorded in sales and marketing expense on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Cash equivalents, investments and derivative instruments are recorded at fair value on a recurring basis. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for classification and disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its debt instruments in determining whether there are embedded derivative instruments, which are required to be bifurcated and accounted for separately as a derivative financial instrument. Embedded derivatives that are not clearly and closely related to the debt host are bifurcated and are recognized at fair value on the consolidated balance sheet with changes in fair value recognized as either a gain or loss on the consolidated statement of operations each reporting period. The fair value of embedded derivatives are measured based on equity markets and interest rates, as well as an estimate of the Company's nonperformance risk adjustment. This estimate includes an option adjusted spread and an estimate of the Company's risk-free rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if a contract contains a lease at the inception date and determines the lease classification, recognition, and measurement at commencement date. All operating lease commitments with a lease term greater than 12 months are recognized as right-of-use assets and obligations on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies a lease based on whether the arrangement is effectively a purchase of the underlying asset. Leases that transfer the control of the underlying asset are classified as finance leases and all others are classified as operating leases. Interest and amortization expense are recognized for operating leases on a straight-line basis. If a change to the lease term leads &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to a reassessment of the lease classification and remeasurement, assumptions such as the discount rate and variable rents based on a rate or index will be updated as of the remeasurement date. If an arrangement is modified, the Company will reassess whether the arrangement contains a lease. Any subsequent changes in lease payments are recognized when incurred, unless the change requires a remeasurement of the lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company's leases include options for the Company to extend the lease term. The exercise of lease renewal option is generally at the Company's sole discretion. Certain of the Company's lease agreements include provisions for the Company to reimburse the lessor for common area maintenance, real estate taxes, and insurance, which the Company accounts for as variable lease costs. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection. Revenue is recognized when the Company transfers of control of the products and services to the Company&#x2019;s customers when the product is shipped or when it is delivered to the customer depending on the agreement. Products are primarily transferred to customer at a point in time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract. These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#x2019;s cost. The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and therefore, the Company has determined it is appropriate to recognize revenue when: i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement. Determining the timing of revenue recognition for such contracts is subject to judgment, because an evaluation must be made regarding the distributor&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company. Changes in these assessments could have an impact on the timing of revenue recognition from sales to distributors. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing, and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#x2019;s contracts vary; however, as a common business practice, payment terms are typically due in full within 30 days of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material. The Company has several contracts with distributors in international markets that include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Government Assistance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As there is no authoritative guidance under U.S. GAAP for accounting for grants to for-profit business entities, the Company accounts for the grants by analogy to International Accounting Standard ("IAS") 20 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20")&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Government assistance and grants are recognized when there is reasonable assurance that the Company has met the requirements of the assistance and there is reasonable assurance that the grant will be received. The Company received government grants of $158, $1,164 and $628 during the years ended December&#160;31, 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Costs of Goods Sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold includes direct labor and materials costs related to each product sold or produced, including processing, quality assurance labor and scrap, inbound freight costs, as well as facility and warehousing overhead supporting the Company's manufacturing operations. All of the Company's manufacturing costs are included in cost of goods sold on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred. Costs of research and development activities relate to product development, clinical trial expenses for the improvement of existing products, and technical support of products. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment. The Company received certain government grants totaling $158, $214, and $390 which were recorded as an &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_53f04da6-b4de-4448-a842-3ba64e7044cf"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_d6f381e2-5ace-449f-8744-bd43ca3d4c2a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_e7410970-08ee-44c3-807d-dbdd552f3cb6"&gt;offset to research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; in the consolidated statement of operations during the years ended December&#160;31, 2022, 2021 and 2020, respectively&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Shipping and Handling &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All shipping and handling costs, including facility and warehousing overhead, directly related to bringing the Company&#x2019;s products to their final selling destination are included in sales and marketing expenses on the consolidated statements of operations were $5,271, $4,883, and $3,912 for the December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the consolidated balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation is in the form of stock options, restricted stock units ("RSU"), performance stock units ("PSU"), and recognized at, or above, the fair market value of the Company's common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of each stock option award on the date of grant using a multiple-point Black-Scholes option-pricing model. In addition, the Company measures stock options granted to employees at a premium price based on market conditions, such as the trading price of the Company&#x2019;s common stock, using a Monte Carlo Simulation option-pricing model in estimating the fair value at the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of RSU grants based upon the grant date closing market price of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the PSU grants is based on the Company&#x2019;s closing stock price on the grant date. The number of PSUs that will ultimately be earned is based upon the Company&#x2019;s performance as measured against specified targets over the measurement period. Expectations related to the achievement of performance goals associated with PSU grants is assessed as of each reporting period and is used to determine whether PSU grants are expected to vest. If performance-based milestones &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for all stock-based compensation awards, including stock options, RSUs, and PSUs granted to employees eligible for retirement, as defined within the award notice and allowing for continued vesting post-retirement, over the retirement notice period and continuously updates its estimate of expense over the notice period each reporting period if a retirement notice has not been provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense related to the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) based on the estimated fair value of the options on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of fair value using option-pricing models, as indicated above, is affected by the Company&#x2019;s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company&#x2019;s expected stock price volatility over the expected term of the awards. The Company determines the expected term of each award giving consideration to the contractual terms, vesting schedules, and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected term of the award. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#x2019;s consolidated statements of operations. The expense is reduced for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Basic net loss per common share is computed by dividing reported net loss by the weighted average number of common shares outstanding during the period without consideration of potentially dilutive securities. Diluted net loss per share reflects the potential dilution that could occur if contracts to issue common stock were exercised or converted into common stock of the Company. Diluted net loss per share is the same as basic net loss per common share for all periods presented, since the effect of the potentially dilutive securities are anti-dilutive. Potential dilutive common share equivalents consist of the incremental common shares issuable upon exercise of vested stock options, RSUs, and PSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Financial Accounting Standards Board ("FASB") amended Accounting Standards Codification ("ASC") 848 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (issued under Accounting Standards Update ("ASU") 2020 - 4, Reference Rate Reform). The amendment in this update defers the sunset date of Topic 848 from December 31, 2022, to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. The Company has not yet assessed the impact of the deferral on its consolidated financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, FASB amended ASC 832, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (issued under ASU 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosures by Business Entities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;bout Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). This amendment requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy, including, (1) the types of transactions; (2) the financial statement line items affected by the transaction: and (3) significant terms and conditions associated with the transactions. The Company adopted the guidance on January 1, 2022, and the adoption of ASU 2021-10 had no impact on the Company's consolidated financial condition, results of operations and an immaterial impact on disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other ASUs issued and not yet effective as of December 31, 2022, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company&#x2019;s current or future financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2Njk0MTU_bd2b59b3-8ea2-4250-b1d4-f20d46aa81f0">Basis of Presentation The accompanying consolidated financial statements of the Company are prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). All intercompany accounts and transactions have been eliminated in consolidation.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMjM_5f50ea9a-6349-4b21-a257-bf3e00503ea7">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The significant estimates affecting the amounts reported or disclosed in the consolidated financial statements include the realizable value of inventories, the valuation of stock-based compensation and the valuation of derivative instruments and the fair value of debt instruments. Other estimates that affect the amounts reported or disclosed in the consolidated financial statements include the allowance for doubtful accounts, the useful life and recoverability of long-lived assets, incremental borrowing rates for operating leases, accounting for income taxes including the realizability of deferred tax assets and the related valuation allowance. The Company bases its estimates on historical and anticipated results, trends, and various other assumptions that management believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3MjYzNzg_3b02c09f-40f7-4411-94db-72900d0b6682">ReclassificationsCertain prior year amounts have been reclassified for consistency with the current year presentation. Specifically, finance lease right-of-use assets which were presented separately in 2021, and are now included in property and equipment. In addition, the debt derivative liability was included in net operating loss carryforwards in deferred assets in 2021, it is presented separately as debt derivative liability in deferred tax assets. See Note 12 - Income Taxes.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <axgn:RisksAndUncertaintiesPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0MzQxODI_516e6727-e98a-4cbe-91ac-ebcf5a86e37b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risk and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outbreak of the COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020, and the virus has continued to spread through 2022. The related responses by public health and governmental authorities to contain and combat the outbreak and spread of the virus, have adversely impacted global commercial activity, hospital staffing, elective surgeries, supply chains and contributed to significant volatility in financial markets. The Company experienced a decrease in demand for its products and services during 2020 and 2021, due to the lack of access to hospitals and health care facilities and the reallocation of resources from surgical procedures to COVID-19 patient care as well as the related staffing shortages in health care had a material adverse effect on the Company's results of operations. This negative impact began to improve in 2022, particularly in the second half of the year; however, the inflationary pressure and the ensuing recession may have a negative effect on the demand for the Company's products, services and the Company's operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is dependent on its suppliers, including single source suppliers, and the inability of these suppliers to deliver necessary components of its products in a timely manner at prices, quality levels and volumes acceptable to the &lt;/span&gt;&lt;/div&gt;Company, or its inability to efficiently manage these components from these suppliers, could have a material adverse effect on its business, financial condition and operating results.</axgn:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3NTkxNjg_9f60166e-bbd9-4b22-adc1-92c2f2769df5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash and cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of acquisition. Certain of the Company's cash and cash equivalents balances exceed Federal Deposit Insurance Corporation ("FDIC") insured limits or are invested in money market accounts with investment banks that are not FDIC-insured. The Company places its cash and cash equivalents in what they believe to be credit-worthy financial institutions. As of December&#160;31, 2022, $15,034 of the cash and cash equivalents balance was in excess of FDIC limits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in restricted cash represent those required to be set aside to meet contractual terms of a lease agreement held by the Company.See Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Credit Facilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashUninsuredAmount
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzEwOTk1MTE4MDAyMTA_f8bca0c4-be8b-486d-b383-945779735bec"
      unitRef="usd">15034000</us-gaap:CashUninsuredAmount>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDA3_4e73b416-6745-4622-91d6-9e213acb3ca9">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents, and restricted cash reported in the consolidated balance sheets that sum to the total of the same reported in the consolidated statements of cash flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzEtMS0xLTEtMTAyNDMx_9ef34c7c-76d5-40f2-b395-24b64322cf3e"
      unitRef="usd">15284000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzEtMy0xLTEtMTAyNDMx_b3dfad29-2e9d-4d92-8a1f-60c3be77af81"
      unitRef="usd">32756000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzItMS0xLTEtMTAyNDMx_85c30433-a133-4797-8043-49db86a72679"
      unitRef="usd">6251000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzItMy0xLTEtMTAyNDMx_87b04915-21c5-4955-819e-62811513f6ac"
      unitRef="usd">6251000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzMtMS0xLTEtMTAyNDMx_adc2a537-52af-4199-af16-a7b5df11c948"
      unitRef="usd">21535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90YWJsZTo1YjFmNmEzMWI5Y2Y0ZWEyOWFjMGMwZmE5OGM2YzE3Mi90YWJsZXJhbmdlOjViMWY2YTMxYjljZjRlYTI5YWMwYzBmYTk4YzZjMTcyXzMtMy0xLTEtMTAyNDMx_53f01ff5-9f4b-4c9f-aa24-bf3d6a708c1e"
      unitRef="usd">39007000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMjY_35c94acf-5ead-4d99-945a-edeb8d2d4f8e">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments consist of commercial paper and U.S. government securities, are classified as available-for-sale and have maturities less than one year as of each balance sheet date. Investments are carried at fair value based upon quoted market prices. The Company elected the fair value option ("FVO") for all of its available-for-sale investments. The FVO election results in all changes in unrealized gains and losses being included in investment income in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMjc_d45df68d-90da-4fd1-8a3c-c3007eadcbf0">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Account receivables are recorded at invoiced amounts and do not bear interest. The Company grants credit to customers in the normal course of business, but generally does not require collateral or other security to support its receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance for doubtful accounts is established for estimated uncollectible receivables based on the Company's assessment of the collectability of customer accounts and recognizes the provision in general and administrative on the consolidated statements of operations. In determining the amount of the allowance, the Company considers aging of account balances, historical credit losses, customer-specific information, the current economic environment, supportable forecasts, and other relevant factors. Uncollectible receivables are written off against the allowance for doubtful accounts when all attempts to collect the receivable have been exhausted. The provision for bad debts is recorded as a component of general and administrative expenses on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3MjYzODE_0805a4fa-b6c9-42b0-9a00-4a301bf6b8f1">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, which are held at major financial institutions and trade receivables. &lt;/span&gt;&lt;/div&gt;The Company's products are sold on an uncollateralized basis and on credit terms.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDE4_311bc830-e22f-4f24-b367-4489865eb237">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, consisting of materials, direct labor and manufacturing overhead, are stated at the lower of cost or net realizable value. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf-life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors the shelf life of its products and historical expiration and spoilage trends and writes down inventory based on the estimated amount of inventory that may not be distributed before expiration or spoilage. To estimate the amount of inventory that will expire prior to being distributed, the Company reviews inventory quantities on hand, historical and projected distribution levels, and historical expiration trends. The Company&#x2019;s calculation of the amount of inventory that will expire prior to distribution has two components: 1) a demand or consumption-based component that compares projected distribution to inventory quantities on hand; and 2) an expiring inventory component that assesses the risk related to inventory that is near expiration by analyzing historical expiration trends to project inventory that will expire prior to being distributed. The Company&#x2019;s model assumes that inventory will be distributed on a first-in, first-out basis. Due to the nature of the inventory (surgical implants with expiration dates) and the fact that significant portions of the Company&#x2019;s inventory is at medical facility consignment locations, estimating the amount of inventory that will expire and the amount of inventory that should be written down involves significant judgments and estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMjk_1a47dd4a-e5b7-4749-bc7e-279efb88b6ff">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net are stated at historical cost less accumulated depreciation and amortization. Additions and improvements that extend the lives of the assets are capitalized, while expenditures for repairs and maintenance are expensed as incurred. Leasehold improvements are amortized on a straight-line basis over the shorter of the asset&#x2019;s estimated useful life or the remaining lease term. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg2NTE3MQ_1b1457ed-1497-471b-a70d-aa52a8985c35"&gt;three&lt;/span&gt; to seven years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains or losses on the disposition of property and equipment are recorded in the period incurred and recorded general and administrative expenses on the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2097ff736d5343bda084880731e97ad9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg2NTE3Mg_3865462a-ee02-4a5d-abf4-a31b5c596e3e">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InterestCapitalizationPolicyPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3MjYzODM_79585d1c-dd86-455c-831a-c1c2bcf66930">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capitalized Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest cost on capital projects, including facilities build-outs, is capitalized and included in the cost of the project. Capitalization begins with the first expenditure for the project and continues until the project is substantially complete and ready for its intended use. For the years ended December&#160;31, 2022, and 2021, the Company capitalized $6,155 and $4,277, respectively, of interest expense into property and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:InterestCapitalizationPolicyPolicyTextBlock>
    <us-gaap:InterestCostsCapitalized
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk2NTYzNQ_2aef9d37-3777-4587-8890-3fa80412ac30"
      unitRef="usd">6155000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk2NTYzOA_90cd61ae-c781-47e2-bc84-726728d90886"
      unitRef="usd">4277000</us-gaap:InterestCostsCapitalized>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3NDQ4NjQ_d4078e94-b884-4f76-8d56-9e971317a669">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes long-lived assets (asset groups), including property and equipment and definite-lived intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amounts may not be recoverable. The Company tests annually, in the third quarter, for impairments. An impairment is recognized when the estimated undiscounted cash flows generated by those assets is less than the carrying amounts of such assets. If it is determined that long-live asset (asset groups) is not recoverable, an impairment loss would be calculated based on the excess of the carrying value of the long-lived asset (asset groups) over the fair value of the long-lived asset (asset groups). There have been no impairments of long-lived assets during the years ended December&#160;31, 2022, 2021, and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are not subject to amortization, however, annually in the third quarter or whenever an event occurs or circumstances indicate that the indefinite-lived intangible assets may be impaired, the Company evaluates qualitative factors to determine whether it is more likely or not that the fair value of the indefinite lived asset is less than its carrying amount. The Company's qualitative evaluation includes an assessment of factors, including specific operating results as well as industry, market and general economic conditions. The Company may elect to bypass this qualitative evaluation and perform a quantitative test.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzA_0eb8e146-f502-48e3-8b1f-93806a4c796d">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are recorded at cost and include patents and patent application costs, licenses, and trademarks. Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives and reported net of accumulated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortization. Amortization expense is recorded in general and administrative expenses on the consolidated statements of operations. The useful lives of intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;License agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: 17 to 20 years&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Patents: up to 20 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Trademarks: indefinite lived&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company pays royalty fees based on net sales of the licensed products, which are recorded in sales and marketing on the consolidated statements of operation.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="ie4725cd6d9b24bb59307c754dcac2d41_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTkzMzUyNw_3429978c-5402-4359-b431-a1499b6d6ae8">P17Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i2dd68d66cd4242ecb6935259bfbb0bfd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTkzMzUzMg_5aacec6e-cbe0-4f19-af08-21c2c5bd9bae">P20Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="idc7ba18f09ee45d587b2fe032937cda5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTkwMjk2MQ_9c143285-a0ba-413f-8eaa-87bf30f35d2f">P20Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <axgn:ContributionsToCharitableOrganization
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTkwNDQ1OQ_72bade99-e337-4d29-ad1b-48fd7c08cf44"
      unitRef="usd">700000</axgn:ContributionsToCharitableOrganization>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3NDQ4NjU_ef569045-19f4-4924-8359-1725c499d581">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Cash equivalents, investments and derivative instruments are recorded at fair value on a recurring basis. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for classification and disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2013; Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDIz_3e1c7717-9a04-4f02-aa54-e7882e908745">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its debt instruments in determining whether there are embedded derivative instruments, which are required to be bifurcated and accounted for separately as a derivative financial instrument. Embedded derivatives that are not clearly and closely related to the debt host are bifurcated and are recognized at fair value on the consolidated balance sheet with changes in fair value recognized as either a gain or loss on the consolidated statement of operations each reporting period. The fair value of embedded derivatives are measured based on equity markets and interest rates, as well as an estimate of the Company's nonperformance risk adjustment. This estimate includes an option adjusted spread and an estimate of the Company's risk-free rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzM_8ebb20a9-279e-49b0-8f53-0827787918ac">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if a contract contains a lease at the inception date and determines the lease classification, recognition, and measurement at commencement date. All operating lease commitments with a lease term greater than 12 months are recognized as right-of-use assets and obligations on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies a lease based on whether the arrangement is effectively a purchase of the underlying asset. Leases that transfer the control of the underlying asset are classified as finance leases and all others are classified as operating leases. Interest and amortization expense are recognized for operating leases on a straight-line basis. If a change to the lease term leads &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to a reassessment of the lease classification and remeasurement, assumptions such as the discount rate and variable rents based on a rate or index will be updated as of the remeasurement date. If an arrangement is modified, the Company will reassess whether the arrangement contains a lease. Any subsequent changes in lease payments are recognized when incurred, unless the change requires a remeasurement of the lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company's leases include options for the Company to extend the lease term. The exercise of lease renewal option is generally at the Company's sole discretion. Certain of the Company's lease agreements include provisions for the Company to reimburse the lessor for common area maintenance, real estate taxes, and insurance, which the Company accounts for as variable lease costs. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDA5_ff8235ed-77b6-48fc-800f-327051429043">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts to sell and distribute products and services to hospitals and surgical facilities for use in caring for patients with peripheral nerve damage or transection. Revenue is recognized when the Company transfers of control of the products and services to the Company&#x2019;s customers when the product is shipped or when it is delivered to the customer depending on the agreement. Products are primarily transferred to customer at a point in time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the Company's product revenue is generated from consigned inventory maintained at hospitals and independent sales agencies, and also from inventory physically held by field sales representatives. For these types of product sales, the Company retains control until the product has been used or implanted, at which time revenue is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the case of products or services sold to a customer under a distribution or purchase agreement, the customers are granted exclusive distribution rights to sell the implants internationally in a territory defined by the contract. These international distributor agreements contain provisions that allow the Company to terminate the distribution agreement with the distributor, and upon termination, the right to repurchase inventory from the distributor at the distributor&#x2019;s cost. The Company has determined that its contractual rights to repurchase distributor inventory upon termination of the distributor agreement are not substantive and do not impact the timing of when control transfers; and therefore, the Company has determined it is appropriate to recognize revenue when: i) the product is shipped via common carrier; or ii) the product is delivered to the customer or distributor, depending on the terms of the agreement. Determining the timing of revenue recognition for such contracts is subject to judgment, because an evaluation must be made regarding the distributor&#x2019;s ability to direct the use of, and obtain substantially all of the remaining benefits from, the implants received from the Company. Changes in these assessments could have an impact on the timing of revenue recognition from sales to distributors. The Company accounts for shipping and handling activities as a fulfillment cost rather than a separate performance obligation. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying products is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in a single reportable segment of peripheral nerve repair, offers similar products to its customers, and enters into consistently structured arrangements with similar types of customers. As such, the Company does not disaggregate revenue from contracts with customers as the nature, amount, timing, and uncertainty of revenue and cash flows does not materially differ within and among the contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract with the customer states the final terms of the sale, including the description, quantity, and price of each implant distributed. The payment terms and conditions in the Company&#x2019;s contracts vary; however, as a common business practice, payment terms are typically due in full within 30 days of delivery. Since the customer agrees to a stated price in the contract that does not vary over the contract term, the contracts do not contain any material types of variable consideration, and contractual rights of return are not material. The Company has several contracts with distributors in international markets that include consideration paid to the customer in exchange for distinct marketing and other services. The Company records such consideration paid to the customer as a reduction to revenue from the contracts with those distributor customers.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <axgn:AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable
      contextRef="i2097ff736d5343bda084880731e97ad9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk1OTc1OA_1bad6082-9843-480f-adda-a3186cd7f538">P30D</axgn:AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable>
    <us-gaap:GovernmentAssistancePolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU3MjYzODQ_578f7e20-5fb0-4dfc-8b40-f4a92e64aa3d">Government Assistance&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As there is no authoritative guidance under U.S. GAAP for accounting for grants to for-profit business entities, the Company accounts for the grants by analogy to International Accounting Standard ("IAS") 20 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Accounting for Government Grants and Disclosures of Government Assistance ("IAS 20")&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt; Government assistance and grants are recognized when there is reasonable assurance that the Company has met the requirements of the assistance and there is reasonable assurance that the grant will be received. The Company received government grants of $158, $1,164 and $628 during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</us-gaap:GovernmentAssistancePolicyTextBlock>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MTg1NA_c2a41f2f-b2e4-4ed6-a48d-845bdc6649b3"
      unitRef="usd">158000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MTg1OQ_74b5598c-fb16-4875-bd98-58596b5ee9e8"
      unitRef="usd">1164000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MTg2Nw_893f7fea-2665-4d08-93e3-1ea5e696261c"
      unitRef="usd">628000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzQ_1bbbc0f3-588e-4e90-841c-7d2df3389ecb">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Costs of Goods Sold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold includes direct labor and materials costs related to each product sold or produced, including processing, quality assurance labor and scrap, inbound freight costs, as well as facility and warehousing overhead supporting the Company's manufacturing operations. All of the Company's manufacturing costs are included in cost of goods sold on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDE3_74c90991-6e79-407c-8cec-3eea930028c8">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred. Costs of research and development activities relate to product development, clinical trial expenses for the improvement of existing products, and technical support of products. Costs primarily consist of salaries, wages, consulting and depreciation and maintenance of research facilities and equipment. The Company received certain government grants totaling $158, $214, and $390 which were recorded as an &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_53f04da6-b4de-4448-a842-3ba64e7044cf"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_d6f381e2-5ace-449f-8744-bd43ca3d4c2a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxOTkwMjM0Njc0OTU_e7410970-08ee-44c3-807d-dbdd552f3cb6"&gt;offset to research and development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; in the consolidated statement of operations during the years ended December&#160;31, 2022, 2021 and 2020, respectively&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="i1bc6c9dfa31e4dfb90c5dc20212c1ca1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MjYxNg_f8f9b0a6-3ca0-40df-a84c-9e2f2a219936"
      unitRef="usd">158000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="ic68f8ca16e14404a992ae8f0910b911c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MjYyMQ_ea5e779e-1a72-46d0-89d7-0e71a594eca4"
      unitRef="usd">214000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="i87f90b83c663430ea63bc4f87a3e3a3e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTk3MjYyOQ_5ca20c8c-8a37-47a2-a58e-ce2995c5b718"
      unitRef="usd">390000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzU_2e68fdce-b300-4cc5-a081-e154d6903733">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Shipping and Handling &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All shipping and handling costs, including facility and warehousing overhead, directly related to bringing the Company&#x2019;s products to their final selling destination are included in sales and marketing expenses on the consolidated statements of operations were $5,271, $4,883, and $3,912 for the December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ib7fac01f992a4a81b65d12402ff03e2f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg4OTk3OA_99520c95-275a-4169-bf8b-bacfe309a5c5"
      unitRef="usd">5271000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i64abf6623fa944d6afd0f670cf3c2a34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg4OTk3NA_2fcbee68-9a32-4f26-b525-0196668bb561"
      unitRef="usd">4883000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ic2511c05b8d24d5498026c37e476c019_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzU0OTc1NTg4OTk3MQ_320f1bf0-c7af-4b17-9f23-a87762a90490"
      unitRef="usd">3912000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzY_75f28b22-aac5-4bea-adfa-41319e6143a2">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method to account for income taxes in accordance with the authoritative guidance for income taxes. Under this method, deferred tax assets and liabilities are determined based on future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that has a greater than 50% likelihood of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. &lt;/span&gt;&lt;/div&gt;The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the consolidated balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDE0_151150f2-173f-42f2-abb2-26a88e3c1785">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation is in the form of stock options, restricted stock units ("RSU"), performance stock units ("PSU"), and recognized at, or above, the fair market value of the Company's common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of each stock option award on the date of grant using a multiple-point Black-Scholes option-pricing model. In addition, the Company measures stock options granted to employees at a premium price based on market conditions, such as the trading price of the Company&#x2019;s common stock, using a Monte Carlo Simulation option-pricing model in estimating the fair value at the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of RSU grants based upon the grant date closing market price of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the PSU grants is based on the Company&#x2019;s closing stock price on the grant date. The number of PSUs that will ultimately be earned is based upon the Company&#x2019;s performance as measured against specified targets over the measurement period. Expectations related to the achievement of performance goals associated with PSU grants is assessed as of each reporting period and is used to determine whether PSU grants are expected to vest. If performance-based milestones &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to PSU grants are not met or not expected to be met, any compensation expense recognized associated with such grants will be reversed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for all stock-based compensation awards, including stock options, RSUs, and PSUs granted to employees eligible for retirement, as defined within the award notice and allowing for continued vesting post-retirement, over the retirement notice period and continuously updates its estimate of expense over the notice period each reporting period if a retirement notice has not been provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation expense related to the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) based on the estimated fair value of the options on the date of grant. The Company estimates the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option pricing model for each purchase period. The grant date fair value is expensed on a straight-line basis over the offering period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of fair value using option-pricing models, as indicated above, is affected by the Company&#x2019;s stock price, as well as assumptions regarding several subjective variables. These variables include, but are not limited to, the Company&#x2019;s expected stock price volatility over the expected term of the awards. The Company determines the expected term of each award giving consideration to the contractual terms, vesting schedules, and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected term of the award. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#x2019;s consolidated statements of operations. The expense is reduced for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzcxNDY4MjU2NTczMzk_533b504c-7745-4297-b395-fb7919f771d9">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Basic net loss per common share is computed by dividing reported net loss by the weighted average number of common shares outstanding during the period without consideration of potentially dilutive securities. Diluted net loss per share reflects the potential dilution that could occur if contracts to issue common stock were exercised or converted into common stock of the Company. Diluted net loss per share is the same as basic net loss per common share for all periods presented, since the effect of the potentially dilutive securities are anti-dilutive. Potential dilutive common share equivalents consist of the incremental common shares issuable upon exercise of vested stock options, RSUs, and PSUs.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDAvZnJhZzo2MjY5Y2VhYTk3MmY0Yjc3OTg5MGI4ODRmYTkxOTJhYi90ZXh0cmVnaW9uOjYyNjljZWFhOTcyZjRiNzc5ODkwYjg4NGZhOTE5MmFiXzIxNDIy_8c45e561-95ea-420c-b031-7113b94299e6">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Financial Accounting Standards Board ("FASB") amended Accounting Standards Codification ("ASC") 848 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (issued under Accounting Standards Update ("ASU") 2020 - 4, Reference Rate Reform). The amendment in this update defers the sunset date of Topic 848 from December 31, 2022, to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. The Company has not yet assessed the impact of the deferral on its consolidated financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, FASB amended ASC 832, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (issued under ASU 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosures by Business Entities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;bout Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). This amendment requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy, including, (1) the types of transactions; (2) the financial statement line items affected by the transaction: and (3) significant terms and conditions associated with the transactions. The Company adopted the guidance on January 1, 2022, and the adoption of ASU 2021-10 had no impact on the Company's consolidated financial condition, results of operations and an immaterial impact on disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All other ASUs issued and not yet effective as of December 31, 2022, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company&#x2019;s current or future financial position or results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90ZXh0cmVnaW9uOjJkMjg2NWEzNzMyYTQzOWFiMWM5ZjhiNjQyMDcyYmNmXzI1OQ_2cdd56ad-b61e-44e1-b752-5dc74e5a21d2">Inventory&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The provision for inventory write-down is for the years ended as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.140%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for inventory write-down&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The provision for inventory write-down for the year ended December&#160;31, 2021, included the Avive write-down of $1,251. The Avive write-down resulted from the Company announcing on May 17, 2021, it was suspending market availability of Avive effective June 1, 2021.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90ZXh0cmVnaW9uOjJkMjg2NWEzNzMyYTQzOWFiMWM5ZjhiNjQyMDcyYmNmXzI1OA_ad59c2b2-76c7-4eed-beb1-43a8e1e6fa5f">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The provision for inventory write-down is for the years ended as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.863%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.140%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for inventory write-down&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzEtMS0xLTEtMTAyNDMx_7edaf3b3-0d60-4483-ac62-663e75852c00"
      unitRef="usd">12651000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzEtMy0xLTEtMTAyNDMx_2a179898-0ad6-4781-9a6b-16629cc96272"
      unitRef="usd">11011000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzItMS0xLTEtMTAyNDMx_8f852d42-aa09-4f48-8555-801029f81228"
      unitRef="usd">1026000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzItMy0xLTEtMTAyNDMx_99f46ac8-d4a8-4e20-b96c-f4e257622c01"
      unitRef="usd">813000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzMtMS0xLTEtMTAyNDMx_f5e194f8-70e7-4c8a-b848-1f01249cd412"
      unitRef="usd">5228000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzMtMy0xLTEtMTAyNDMx_a92447de-9e8e-4af3-a769-c994bfe16722"
      unitRef="usd">4869000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzQtMS0xLTEtMTAyNDMx_e5b687d8-0a5b-4d64-90f6-c98445a0f820"
      unitRef="usd">18905000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpjYmU4NTkzNDI2MTE0ODFkOTEwOWUwMWY3ZmU1NjE1MC90YWJsZXJhbmdlOmNiZTg1OTM0MjYxMTQ4MWQ5MTA5ZTAxZjdmZTU2MTUwXzQtMy0xLTEtMTAyNDMx_c6665425-b5db-4707-ab35-348bf891578e"
      unitRef="usd">16693000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpiZmZhNzgzMTcwYjk0NjBkYjkzYjI3MGMyYWEwZjQ3ZS90YWJsZXJhbmdlOmJmZmE3ODMxNzBiOTQ2MGRiOTNiMjcwYzJhYTBmNDdlXzItMS0xLTEtMTExMDkz_1eab7fc5-1664-431f-9371-58e62fdaddd4"
      unitRef="usd">1769000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpiZmZhNzgzMTcwYjk0NjBkYjkzYjI3MGMyYWEwZjQ3ZS90YWJsZXJhbmdlOmJmZmE3ODMxNzBiOTQ2MGRiOTNiMjcwYzJhYTBmNDdlXzItMy0xLTEtMTExMDkz_e8f87198-c749-4dc3-be3c-b19d55998672"
      unitRef="usd">3314000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90YWJsZTpiZmZhNzgzMTcwYjk0NjBkYjkzYjI3MGMyYWEwZjQ3ZS90YWJsZXJhbmdlOmJmZmE3ODMxNzBiOTQ2MGRiOTNiMjcwYzJhYTBmNDdlXzItNS0xLTEtMTExMDkz_67b5555a-6ecc-4e40-85e3-91193e96a104"
      unitRef="usd">2242000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="iead0e385765c4b64b8993cfd1f3c50a7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDMvZnJhZzoyZDI4NjVhMzczMmE0MzlhYjFjOWY4YjY0MjA3MmJjZi90ZXh0cmVnaW9uOjJkMjg2NWEzNzMyYTQzOWFiMWM5ZjhiNjQyMDcyYmNmXzI1Ng_81df0635-f429-40a9-8f81-13f6ad7cb3fe"
      unitRef="usd">1251000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzMwNw_b22de966-6d51-4c85-afa2-c45b66728aec">Property and Equipment, Net&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Processing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Projects in process &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_2ffaa088-42a3-4658-a56e-41bcb91c69e1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_6ac65a1e-f9f2-4c6f-9b60-403fe0960398"&gt;projects in process&lt;/span&gt;&lt;/span&gt; is a government grant received totaling $1,188 as of December 31, 2022 and December 31, 2021, which was recorded as an offset, and $11,429 and $5,274 of capitalized interest as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation expense is as follows for the years ended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzMwOA_4c5a185e-5f87-4a33-81c0-2de038ebb3f5">&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Processing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Projects in process &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;89,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;70,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,296)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;79,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_2ffaa088-42a3-4658-a56e-41bcb91c69e1"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzIxOTkwMjMyNTk1MjQ_6ac65a1e-f9f2-4c6f-9b60-403fe0960398"&gt;projects in process&lt;/span&gt;&lt;/span&gt; is a government grant received totaling $1,188 as of December 31, 2022 and December 31, 2021, which was recorded as an offset, and $11,429 and $5,274 of capitalized interest as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation expense is as follows for the years ended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.860%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8fdfd74ec77440a993b43f1ab043aec4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzEtMS0xLTEtMTAyNDMx_23ccce70-3476-4923-a132-7799e6365784"
      unitRef="usd">5316000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i070dcdc6ab0e4a87856b934b83e36f61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzEtMy0xLTEtMTAyNDMx_4ac910cb-6eb5-4409-b648-6a064df093b2"
      unitRef="usd">5100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic4b7b03e5ad24c209c6e89b463f7c09d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzItMS0xLTEtMTAyNDMx_89a665cc-bac2-4607-bcc6-0f8126d32970"
      unitRef="usd">15482000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9d7786e6549f4f2b87fd1be253cbb057_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzItMy0xLTEtMTAyNDMx_9798e3a7-e2a7-476a-aeaa-1874a5640f73"
      unitRef="usd">14952000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4a1078ddd2ca4d68ba2298c4052ef876_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzMtMS0xLTEtMTAyNDMx_3a9e77ea-19c7-4c16-bf4b-d723313e0db5"
      unitRef="usd">4227000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia3763b8b0a3348d59cfaea1445d2bfc8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzMtMy0xLTEtMTAyNDMx_d1a4cbea-a544-4361-ac43-83e4adeafb71"
      unitRef="usd">3984000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iefef6bfa4d304246b2f3543fef3d3125_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzQtMS0xLTEtMTAyNDMx_17809717-788e-449b-bf3d-add13afc3dd4"
      unitRef="usd">731000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6fcdd9ed764541c286b0eaaa84d984ce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzQtMy0xLTEtMTAyNDMx_bb5f1013-a56a-432b-a2d0-d747e7c5290e"
      unitRef="usd">731000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzUtMS0xLTEtMTExNDM5_173624ae-8600-4764-9f37-e761bf6636a3"
      unitRef="usd">131000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzUtMy0xLTEtMTExNDU1_9234632a-d109-436c-b8e8-fb8e3ad3556e"
      unitRef="usd">110000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i981abdd294e44919817cd956d30d31a2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzUtMS0xLTEtMTAyNDMx_3a2f5cd1-44c9-4f33-bbf6-c334cc4e391d"
      unitRef="usd">63703000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i219c4cc0cbd547b3b68a43331493fb1d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzUtMy0xLTEtMTAyNDMx_2ba98659-44cd-42ec-91ef-b354e3ae98e4"
      unitRef="usd">45660000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzYtMS0xLTEtMTAyNDMx_90d0a345-19b3-4058-ab46-dcc2cb79a266"
      unitRef="usd">89590000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzYtMy0xLTEtMTAyNDMx_4975f35a-1695-44c9-9bec-2f21eeec4219"
      unitRef="usd">70536000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzctMS0xLTEtMTAyNDMx_a6e68b11-147e-45d5-ab97-e3da0f7793e6"
      unitRef="usd">10296000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzctMy0xLTEtMTAyNDMx_f922fe72-09ca-444a-ad08-9beed2afecc7"
      unitRef="usd">7614000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzgtMS0xLTEtMTAyNDMx_35e6857b-badc-4576-b250-0420997a1e55"
      unitRef="usd">79294000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZToxMTRiMmU0YTgwMWQ0YmYzYTY4OTg3ZmZhNDIwN2Q3OS90YWJsZXJhbmdlOjExNGIyZTRhODAxZDRiZjNhNjg5ODdmZmE0MjA3ZDc5XzgtMy0xLTEtMTAyNDMx_ce8fd659-a389-4d98-b0c7-105c6f4b90cc"
      unitRef="usd">62923000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzM1NzM0MTI3OTA2MzU3_37090f13-b11c-4f59-ac02-8c86d257b6de"
      unitRef="usd">1188000</us-gaap:GovernmentAssistanceAmountCumulative>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzM1NzM0MTI3OTA2MzU3_94556d80-0d70-43e6-961d-001f11fbddd0"
      unitRef="usd">1188000</us-gaap:GovernmentAssistanceAmountCumulative>
    <us-gaap:AccumulatedCapitalizedInterestCosts
      contextRef="i20c791c3ff7e418ab95668e32cc7a1ec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzU0OTc1NTgxNzQ2MQ_3e87801a-5e13-4c7d-9358-ffe04f136f83"
      unitRef="usd">11429000</us-gaap:AccumulatedCapitalizedInterestCosts>
    <us-gaap:AccumulatedCapitalizedInterestCosts
      contextRef="i93d0b4619b6c40f0b1a0de407ee760f7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90ZXh0cmVnaW9uOmYyNTBkZWI5ZmVmYjQ2Mzg4YmE0OTUyZTA1MjkwZmRiXzU0OTc1NTgxNzY4NQ_1082f4ec-3469-4e0e-a932-2e917f4b57f0"
      unitRef="usd">5274000</us-gaap:AccumulatedCapitalizedInterestCosts>
    <us-gaap:Depreciation
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZTowYjkyYjg1MzJjNDI0NDRiYWJkMTNmZjlhN2U1ZDE4NC90YWJsZXJhbmdlOjBiOTJiODUzMmM0MjQ0NGJhYmQxM2ZmOWE3ZTVkMTg0XzItMS0xLTEtMTExMDg5_882f482d-9c5e-4856-a35d-dc428606e757"
      unitRef="usd">2827000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZTowYjkyYjg1MzJjNDI0NDRiYWJkMTNmZjlhN2U1ZDE4NC90YWJsZXJhbmdlOjBiOTJiODUzMmM0MjQ0NGJhYmQxM2ZmOWE3ZTVkMTg0XzItMy0xLTEtMTExMDg5_c3b8af9d-2bca-475c-aa59-f68cce1b3eda"
      unitRef="usd">2744000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTIvZnJhZzpmMjUwZGViOWZlZmI0NjM4OGJhNDk1MmUwNTI5MGZkYi90YWJsZTowYjkyYjg1MzJjNDI0NDRiYWJkMTNmZjlhN2U1ZDE4NC90YWJsZXJhbmdlOjBiOTJiODUzMmM0MjQ0NGJhYmQxM2ZmOWE3ZTVkMTg0XzItNS0xLTEtMTExMDg5_a62a5706-2820-4150-a489-4bcb7528b33b"
      unitRef="usd">1530000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzM2Mjg_b25b05b9-f7e5-48f7-b8e9-2001ca32676d">Intangible Assets, Net &lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;License agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unamortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amortization expense is as follows for the years ended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2022, future amortization of patents and license agreements are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;License Agreements&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has multiple license agreements with the University of Florida Research Foundation and the University of Texas at Austin (the "License Agreements") in which the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the U.S. and international markets. The effective term of the License Agreements extends through the term of the related patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. Also, when the Company pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty fees included in sales and marketing on the consolidated statement of operations are as follows for the years ended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty fees &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzM2Mjk_240a4155-67bb-4ab1-9c76-edf8bc7f9876">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;License agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unamortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzM2Mjk_51bcfcb1-bb01-4c84-8faf-0565f697e2d3">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.317%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Amortizable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(621)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;License agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,014)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unamortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ief216639aeea40978d9004092b61999b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtMi0xLTEtMTAyNDMx_7578871c-8a51-4358-8488-af6a89b44aff"
      unitRef="usd">3792000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ief216639aeea40978d9004092b61999b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtNC0xLTEtMTAyNDMx_dca387ec-c7b9-49d5-998e-6f3900026631"
      unitRef="usd">621000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ief216639aeea40978d9004092b61999b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtNi0xLTEtMTAyNDMx_c7da22b0-4cd8-4f17-946a-3121404e95ff"
      unitRef="usd">3170000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i040b86ceb15544419c782b59216a1371_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtOC0xLTEtMTAyNDMx_73956ab4-36e9-459a-82c9-923766503dae"
      unitRef="usd">2469000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i040b86ceb15544419c782b59216a1371_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtMTAtMS0xLTEwMjQzMQ_00ebfb8d-1aeb-4459-be4a-1d812c1747e8"
      unitRef="usd">234000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i040b86ceb15544419c782b59216a1371_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzMtMTItMS0xLTEwMjQzMQ_c919e2d5-9873-4159-9049-a39630b6573f"
      unitRef="usd">2235000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idffd7fe48ee54e349aaddba79d4382e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtMi0xLTEtMTAyNDMx_9bba1feb-6a06-4a3f-ace8-4c1469a3a808"
      unitRef="usd">1101000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idffd7fe48ee54e349aaddba79d4382e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtNC0xLTEtMTAyNDMx_c8808253-0b38-4709-9e73-f1b6045e1600"
      unitRef="usd">1014000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idffd7fe48ee54e349aaddba79d4382e8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtNi0xLTEtMTAyNDMx_cf6031cb-85c1-4260-9934-e736ecb7fe3b"
      unitRef="usd">87000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6cab5edf539940499d0c87a4b0bfaecf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtOC0xLTEtMTAyNDMx_0f9d04ec-8c8e-457c-990f-70c82e55582f"
      unitRef="usd">1101000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6cab5edf539940499d0c87a4b0bfaecf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtMTAtMS0xLTEwMjQzMQ_c4b01498-96d5-40de-807d-b35de70ef8df"
      unitRef="usd">852000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6cab5edf539940499d0c87a4b0bfaecf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzQtMTItMS0xLTEwMjQzMQ_1202d54b-c477-46c2-ba0b-e15bc2d15d20"
      unitRef="usd">249000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtMi0xLTEtMTAyNDMx_25187651-a93d-4447-b220-7dc1a5ae7456"
      unitRef="usd">4893000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtNC0xLTEtMTAyNDMx_416ccdfc-e98f-4419-8e91-2159b7f6b3a4"
      unitRef="usd">1635000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtNi0xLTEtMTAyNDMx_12706ed5-76ff-4de3-bd0d-5496b01db7ca"
      unitRef="usd">3258000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtOC0xLTEtMTAyNDMx_08370c61-6f73-465d-8bb7-ac6df34238bc"
      unitRef="usd">3570000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtMTAtMS0xLTEwMjQzMQ_d18f5723-b254-4fc2-b9bc-b173559d776f"
      unitRef="usd">1086000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzUtMTItMS0xLTEwMjQzMQ_84d51ae0-554f-4772-9621-371e4dfb5149"
      unitRef="usd">2484000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ifa2057862cc54798a45830a2e34c7672_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzgtMi0xLTEtMTAyNDMx_8bf4ca13-c93b-4c76-a49c-c60ce3513d30"
      unitRef="usd">391000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ifa2057862cc54798a45830a2e34c7672_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzgtNi0xLTEtMTAyNDMx_1226a6a3-43e1-4dd9-88e9-15355dd78ccd"
      unitRef="usd">391000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i414b5edcb9214fef95168d989218cbd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzgtOC0xLTEtMTAyNDMx_16fe0bb3-f571-4a8e-97fd-9e09efe65280"
      unitRef="usd">375000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i414b5edcb9214fef95168d989218cbd4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzgtMTItMS0xLTEwMjQzMQ_799d205d-8c67-408d-91cd-34b0cfb254f4"
      unitRef="usd">375000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktMi0xLTEtMTAyNDMx_c9798524-25c9-43c6-aa12-bcee109aec47"
      unitRef="usd">5284000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktNC0xLTEtMTAyNDMx_db48da74-103e-42a5-a5b1-2da58025fb3d"
      unitRef="usd">1635000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktNi0xLTEtMTAyNDMx_db600225-ee36-4eff-b3a0-90e2b9dd666b"
      unitRef="usd">3649000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktOC0xLTEtMTAyNDMx_d937dabe-e51a-4429-aae3-3039231b02b1"
      unitRef="usd">3945000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktMTAtMS0xLTEwMjQzMQ_ba0a84d2-a6ee-4eb1-92b9-9fcc460d9793"
      unitRef="usd">1086000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTowOTNjNDI0YjVjMTc0NjZkODllZDIxZDVhZDdiZDk0MC90YWJsZXJhbmdlOjA5M2M0MjRiNWMxNzQ2NmQ4OWVkMjFkNWFkN2JkOTQwXzktMTItMS0xLTEwMjQzMQ_23328192-82a2-43a3-bb1b-ad055f5a1c07"
      unitRef="usd">2859000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0Xzg3OTYwOTMwMjcxMjI_93f49630-8da8-45ed-98c4-60695bbdb25b">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The amortization expense is as follows for the years ended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTo4ZTI4YWRkNTdhZWE0ODY2YmZmYjZiZDhiMTVjM2NhMC90YWJsZXJhbmdlOjhlMjhhZGQ1N2FlYTQ4NjZiZmZiNmJkOGIxNWMzY2EwXzItMS0xLTEtMTExMjYz_50f3e9a0-b462-42c9-bdfc-05ba66f7f455"
      unitRef="usd">265000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTo4ZTI4YWRkNTdhZWE0ODY2YmZmYjZiZDhiMTVjM2NhMC90YWJsZXJhbmdlOjhlMjhhZGQ1N2FlYTQ4NjZiZmZiNmJkOGIxNWMzY2EwXzItMy0xLTEtMTExMjY3_2f56eea9-48d0-4ecd-ad90-4f00c0b4b49b"
      unitRef="usd">202000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTo4ZTI4YWRkNTdhZWE0ODY2YmZmYjZiZDhiMTVjM2NhMC90YWJsZXJhbmdlOjhlMjhhZGQ1N2FlYTQ4NjZiZmZiNmJkOGIxNWMzY2EwXzItNS0xLTEtMTExMjcx_ea7ac959-93f6-40e2-8941-b416238dbb83"
      unitRef="usd">153000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzM2Mjc_67556e50-1e9b-47ec-b190-2675c88cfbcc">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2022, future amortization of patents and license agreements are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzEtMS0xLTEtMTAyNDMx_e1690428-f3d7-4b3e-85e8-d316fe48342f"
      unitRef="usd">250000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzItMS0xLTEtMTAyNDMx_e45628df-c9aa-4d8d-8953-6074d047b70b"
      unitRef="usd">181000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzMtMS0xLTEtMTAyNDMx_b5514337-483f-48b0-a0d1-93d5e579c1b2"
      unitRef="usd">181000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzQtMS0xLTEtMTAyNDMx_9021cfea-2ff0-4674-a052-f7dd24d9b999"
      unitRef="usd">180000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzUtMS0xLTEtMTAyNDMx_9567a67b-02e0-44e0-883f-fd00b0476155"
      unitRef="usd">176000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzYtMS0xLTEtMTAyNDMx_5d0adee4-8f0e-4ab0-8d85-91923823197c"
      unitRef="usd">2290000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i65aa335ff06f439d8115f7904b82f8aa_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTozOTJmMzczYmUzNTE0MTkxYTM4ODQzNTcyMGE1ZDVhMi90YWJsZXJhbmdlOjM5MmYzNzNiZTM1MTQxOTFhMzg4NDM1NzIwYTVkNWEyXzctMS0xLTEtMTAyNDMx_bcf6c0d9-31a9-4caa-b522-6700c78dd8a9"
      unitRef="usd">3258000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <axgn:RoyaltyFeesPercentageUnderLicenseAgreements
      contextRef="ie4725cd6d9b24bb59307c754dcac2d41_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzE1ODc_f4b34b9e-90ab-4b37-ae22-e3720d545f3d"
      unitRef="number">0.01</axgn:RoyaltyFeesPercentageUnderLicenseAgreements>
    <axgn:RoyaltyFeesPercentageUnderLicenseAgreements
      contextRef="i2dd68d66cd4242ecb6935259bfbb0bfd_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzE1OTM_978fa674-2d3a-4df9-ac36-e4c3c8e77f40"
      unitRef="number">0.03</axgn:RoyaltyFeesPercentageUnderLicenseAgreements>
    <axgn:PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors
      contextRef="i2dd68d66cd4242ecb6935259bfbb0bfd_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzIwMjM_74048cef-0d70-4561-abd8-862d25339529"
      unitRef="number">0.0375</axgn:PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors>
    <axgn:ScheduleOfRoyaltyExpensesTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90ZXh0cmVnaW9uOmIyOTNmNDExMDI2NTQ4YTM4MTVkZGFmNDcxNDAzMGY0XzkzNDU4NDg4NDEwMDk_a54a3779-2a97-4b84-ab92-0446ad0a9995">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty fees included in sales and marketing on the consolidated statement of operations are as follows for the years ended:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty fees &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</axgn:ScheduleOfRoyaltyExpensesTableTextBlock>
    <us-gaap:RoyaltyExpense
      contextRef="ib87452ca58634dbaa8dd73c32eb97477_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTpiOTZkZGM3YzQ4MmU0MWEyYTlkYTE2ZTNlYmNiZDVmNS90YWJsZXJhbmdlOmI5NmRkYzdjNDgyZTQxYTJhOWRhMTZlM2ViY2JkNWY1XzItMS0xLTEtMTExMjkz_a1e685d3-fe04-43f9-ba0a-635b33c4cc51"
      unitRef="usd">3103000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ibd7f9133c7a74c2bbd041186bedf782a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTpiOTZkZGM3YzQ4MmU0MWEyYTlkYTE2ZTNlYmNiZDVmNS90YWJsZXJhbmdlOmI5NmRkYzdjNDgyZTQxYTJhOWRhMTZlM2ViY2JkNWY1XzItMy0xLTEtMTExMjkz_e17ab038-f84b-4456-8ce1-be57ea32f838"
      unitRef="usd">2715000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i883e9d9eb9ba4b5980f84ab0473b72ff_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTUvZnJhZzpiMjkzZjQxMTAyNjU0OGEzODE1ZGRhZjQ3MTQwMzBmNC90YWJsZTpiOTZkZGM3YzQ4MmU0MWEyYTlkYTE2ZTNlYmNiZDVmNS90YWJsZXJhbmdlOmI5NmRkYzdjNDgyZTQxYTJhOWRhMTZlM2ViY2JkNWY1XzItNS0xLTEtMTExMjkz_82c64502-d6d7-4997-b139-9a2cb1b8f74f"
      unitRef="usd">2289000</us-gaap:RoyaltyExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzQ4Nzk_ddd76579-95c1-4e06-b824-d48fd58961c6">Fair Value Measurement &lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables represent the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2022, and 2021:&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"/&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in Level 3 liabilities measured at fair value on a recurring basis were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;There were no changes in the levels or methodology of the measurement of financial assets or liabilities during the years ended December&#160;31, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The fair value of cash, restricted cash, accounts receivable, accounts payable and accrued expenses approximates the carrying values because of the short-term nature of these instruments. The carrying value and fair value of the Credit Facility were $45,712 and $50,293 at December&#160;31, 2022, respectively, $45,325 and $52,605 at December&#160;31, 2021, respectively. See Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees .&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The debt derivative liabilities are measured using a &#x2018;with and without&#x2019; valuation model to compare the fair value of each tranche of the Credit Facility including the identified embedded derivative feature and the fair value of a plain vanilla note with the same terms. The fair value of the Credit Facility including the embedded derivative features was determined using a probability-weighted expected return model based on four potential settlement scenarios for the Credit Facility included in the table below. The estimated settlement value of each scenario, which would include any required make-whole payment (see &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees ), is then discounted to present value using a discount rate that is derived based on the initial terms of the Credit Facility at issuance and corroborated utilizing a synthetic credit rating analysis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant inputs that are included in the valuation of the debt derivative liability - first tranche include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Remaining term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;June 30, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;June 30, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Coupon rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5% - 12.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue participation payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maximum each year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maximum each year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.90%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Probability of mandatory prepayment before 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Estimated timing of mandatory prepayment event before 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Probability of mandatory prepayment 2024 or after&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Estimated timing of mandatory prepayment event 2024 or after&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Probability of optional prepayment event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Estimated timing of optional prepayment event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents a significant unobservable input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant inputs that are included in the valuation of the debt derivative liability - second tranche include: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remaining term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Coupon rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5% - 12.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue participation payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maximum each year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maximum each year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Probability of mandatory prepayment before 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated timing of mandatory prepayment event before 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Probability of mandatory prepayment 2024 or after&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated timing of mandatory prepayment event 2024 or after&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Probability of optional prepayment event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated timing of optional prepayment event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents a significant unobservable input.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzQ4ODI_3a8dc70a-36df-4c80-93ac-f318314168d1">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables represent the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of December&#160;31, 2022, and 2021:&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.895%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;39,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1cb615006a90448cae97a9c052e1adfb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzMtMS0xLTEtMTAyNDMx_baa9b789-8371-4e7d-9513-830fbe6f90af"
      unitRef="usd">10354000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i108f5fba334f442e831ebcd3d2adaee4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzMtMy0xLTEtMTAyNDMx_8d00112c-ca92-420b-94f1-4a371d4cd7ad"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2d98f50d860845f4a00f11fe83cde291_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzMtNS0xLTEtMTAyNDMx_5c9b2bc5-3e04-4f8b-8972-220a9e2385e8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i45579dc2f8964009928c3c2e3fef14d8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzMtNy0xLTEtMTAyNDMx_fe188fff-6e08-47ec-8c0a-b9f64ba78b50"
      unitRef="usd">10354000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie9f0dbd08bf2403187833c72b32e0021_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzQtMS0xLTEtMTAyNDMx_d71a8856-6e21-4efd-a8ff-f30ecd299a06"
      unitRef="usd">12316000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i73351972eccc4224be149e2d0b567b8c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzQtMy0xLTEtMTAyNDMx_cc657ba7-9112-45c2-8f66-f2f99523fa8d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4d33c3cc49e343eb8a823bc5ad30dd10_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzQtNS0xLTEtMTAyNDMx_8c3ebd3f-1f15-42e0-97ae-0febb0f748d1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia545915c6cee4044ae461b4e3af6a345_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzQtNy0xLTEtMTAyNDMx_ef7c41e3-43a2-4bab-8eea-daebf4d946d5"
      unitRef="usd">12316000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id571ec182cbc48dbb46f0902fabfaa4e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzYtMS0xLTEtMTAyNDMx_14dbde92-b716-4f4c-b4c9-2e61a6be4d14"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0fd5c952fe7147368209c3bdedede315_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzYtMy0xLTEtMTAyNDMx_08c80317-efe0-4aff-9ce0-333f4ca05409"
      unitRef="usd">21189000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibe2f9c677cc94813913c444deda1a1fd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzYtNS0xLTEtMTAyNDMx_938e5b60-92d9-405a-b898-e40cfdaf8b17"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie6afd80e6ff54416977b579d2a685207_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzYtNy0xLTEtMTAyNDMx_8b70cfba-2a71-44f4-bbb1-2c128a937d9e"
      unitRef="usd">21189000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5149fc3ac5624e7ca71842bdab5b8b31_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzctMS0xLTEtMTAyNDMx_747722c5-a0da-4649-abed-682dba142595"
      unitRef="usd">22669000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5473e91ae2d416cae7554133eb8cbb1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzctMy0xLTEtMTAyNDMx_9bac9c7b-3600-4e29-bc43-3a14cc3f02a4"
      unitRef="usd">21189000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i79d1a0dcac804c06a79caf26d3fdcdf2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzctNS0xLTEtMTAyNDMx_ee7b0152-5f9e-4a81-946a-20ce14a7fb3c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i43510f63e6ba4c3ca4047759ce1d9771_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzctNy0xLTEtMTAyNDMx_8a2922cd-7bc6-44ed-9318-c78dfc75afff"
      unitRef="usd">43859000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ia7965b9980ab4e319a9eb72458f4e891_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzExLTEtMS0xLTEwMjQzMQ_ea542e60-91dc-4abd-9b7a-8c9e70871ee3"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6626e08228454045ae1ff645428d36cd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzExLTMtMS0xLTEwMjQzMQ_a0f44ab9-2ca0-4e09-8228-61f9cdde18fa"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie1feb2a1c57d43a8a89b0469ed5f79d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzExLTUtMS0xLTEwMjQzMQ_c116eee9-a0a6-41da-bd01-5c738dc015a4"
      unitRef="usd">4518000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7999f53613c34864ab3d0b6a7527bba5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzExLTctMS0xLTEwMjQzMQ_cf03cc62-f771-4656-9942-be903519316e"
      unitRef="usd">4518000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i5149fc3ac5624e7ca71842bdab5b8b31_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzEyLTEtMS0xLTEwMjQzMQ_367b55b3-b925-4c7e-9e36-ab189031d2aa"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ib5473e91ae2d416cae7554133eb8cbb1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzEyLTMtMS0xLTEwMjQzMQ_38dba40e-daf9-41d9-b517-bc6e7897d595"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i79d1a0dcac804c06a79caf26d3fdcdf2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzEyLTUtMS0xLTEwMjQzMQ_452343a9-2bd9-4c9e-81f7-b8590f28605c"
      unitRef="usd">4518000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i43510f63e6ba4c3ca4047759ce1d9771_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphNWZhMzA1ZWUwYzg0M2NlYjM2MmYwYjAxNmQwMDlmNy90YWJsZXJhbmdlOmE1ZmEzMDVlZTBjODQzY2ViMzYyZjBiMDE2ZDAwOWY3XzEyLTctMS0xLTEwMjQzMQ_72ab6800-ee98-46d0-a3ec-d7c238f966fc"
      unitRef="usd">4518000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i42db69a16e2a4860a246a776fd8ad30c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzMtMS0xLTEtMTAyNDMx_3b96e12d-20bb-4c01-8f0d-b9e112d07da5"
      unitRef="usd">22012000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ife046a9660e8491b9dca4c3123909056_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzMtMy0xLTEtMTAyNDMx_26c1071c-9e71-4289-afda-a5d4ec9ae15b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6e456cfb65c14ed1ae258c526b1a5ce9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzMtNS0xLTEtMTAyNDMx_c2fcf7ca-bdad-43c5-9bf1-8f48df4d3540"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i614ad5e81ab442e19a8c5e1d2bb61b7f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzMtNy0xLTEtMTAyNDMx_81f22b80-b0b1-4d1b-bd43-341a511706e7"
      unitRef="usd">22012000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i699ff71d4b5f46c19f42ee43b4ff55ff_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzQtMS0xLTEtMTAyNDMx_233544f4-de31-4d71-a7ca-aafdf2e59178"
      unitRef="usd">12081000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3ba0f9df4d9c44889d4cd22b2ac19083_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzQtMy0xLTEtMTAyNDMx_d0f0d809-b039-4587-b1eb-2b97b68b3d66"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i690e6522ce7d426589cbba53994c7d97_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzQtNS0xLTEtMTAyNDMx_f94bf3ec-adca-4286-96fc-ba35cc993c90"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id48f1ba541194d20abbd6444602c33bb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzQtNy0xLTEtMTAyNDMx_3e5012ea-50d2-4944-aeb7-0528b45a683d"
      unitRef="usd">12081000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i12533576801f4002b10b0fe696102c65_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzYtMS0xLTEtMTAyNDMx_53b49c34-9167-4400-aefe-d826d1460652"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i134277d723964a98be276a7cfd374add_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzYtMy0xLTEtMTAyNDMx_0de0c71d-a729-450d-92e3-9030ed515fb7"
      unitRef="usd">39249000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7dc0ea19aecc4d6dbf7f2bb1e1acc8cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzYtNS0xLTEtMTAyNDMx_c0d0671b-2d9d-48ab-b823-4beb62b32601"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i07a044804b5b4fb1af23926c78c8ce13_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzYtNy0xLTEtMTAyNDMx_51fba7d6-7349-44c6-a037-0baacb9ce3c6"
      unitRef="usd">39249000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id9df50280b6e4544bdb2b7df50822fa9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctMS0xLTEtMTAyNDMx_091ae009-f7e0-42e4-bdbf-46be4995b40d"
      unitRef="usd">34093000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id9df50280b6e4544bdb2b7df50822fa9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctMS0xLTEtMTAyNDMx_f514860e-ea59-4917-b263-644efc696f13"
      unitRef="usd">34093000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i13c01632c18d4b0fa2a95b893eb9f178_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctMy0xLTEtMTAyNDMx_716bc0a8-b9e8-410e-b3a1-c1a8320403a5"
      unitRef="usd">39249000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i13c01632c18d4b0fa2a95b893eb9f178_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctMy0xLTEtMTAyNDMx_b35d2bf7-0ede-43f3-ac7c-cd45b81b3c71"
      unitRef="usd">39249000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic339a73d39af4de797a3d83409a67e96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctNS0xLTEtMTAyNDMx_4fe08155-6181-44d2-943a-44650c1c1b18"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic339a73d39af4de797a3d83409a67e96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctNS0xLTEtMTAyNDMx_e3bc5e51-7bec-4db8-9c6a-c5e5db575571"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i233781a5f56440c3bd9431cd5d4497ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctNy0xLTEtMTAyNDMx_2c53c075-54c2-46a8-8162-b63f77ac615b"
      unitRef="usd">73342000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i233781a5f56440c3bd9431cd5d4497ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzctNy0xLTEtMTAyNDMx_ec9f68df-f655-485b-a6c9-e68ee5174996"
      unitRef="usd">73342000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i51dbdd80d2ef4fdcbf34d3331a1740c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzExLTEtMS0xLTEwMjQzMQ_f5a7d407-adb9-45c3-a5b6-9a3489eedb8b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0f44c5f22b0f4c40813f276fb3c6827e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzExLTMtMS0xLTEwMjQzMQ_c64ced99-bbb1-4a5e-9a54-03ac95399643"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iefe9c570ebbd4043946a89fd045c1f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzExLTUtMS0xLTEwMjQzMQ_ac07a7c6-65a2-4e45-a631-dd9417e6498c"
      unitRef="usd">5562000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if7407c910a8640d8988cc07ab8eda26d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzExLTctMS0xLTEwMjQzMQ_3eb9cbc0-898a-4068-b01c-81ae5b893653"
      unitRef="usd">5562000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="id9df50280b6e4544bdb2b7df50822fa9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzEyLTEtMS0xLTEwMjQzMQ_ee6b439e-f7e8-4e19-b0c5-e25f5a5ce25e"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i13c01632c18d4b0fa2a95b893eb9f178_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzEyLTMtMS0xLTEwMjQzMQ_de49267c-6070-4e1d-925d-2d7d3b6e3e3c"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ic339a73d39af4de797a3d83409a67e96_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzEyLTUtMS0xLTEwMjQzMQ_443934f2-fa7d-4a93-9dbd-047c8701a13d"
      unitRef="usd">5562000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i233781a5f56440c3bd9431cd5d4497ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTpjMDY1NzkwNGQ3YjM0MTFlYTM4NGMwYzlkZGRjMjU2ZS90YWJsZXJhbmdlOmMwNjU3OTA0ZDdiMzQxMWVhMzg0YzBjOWRkZGMyNTZlXzEyLTctMS0xLTEwMjQzMQ_0813ac54-1af6-4753-ba9b-1d10249da1b9"
      unitRef="usd">5562000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzQ4ODM_e2fb25b8-afa5-4eed-bbe1-1ea2cd3147ef">&lt;div style="margin-top:10pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"/&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in Level 3 liabilities measured at fair value on a recurring basis were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.557%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Derivative Liabilities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,044)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3799b9b46cfa4242a49caf62d6c4d193_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzEtNC0xLTEtMTAyNDMx_b4ed9ac0-172c-45f3-b515-c40e4bc4fbe8"
      unitRef="usd">2497000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i96fd23a1c75242caaecd4598b4ab2e33_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzItNC0xLTEtMTAyNDMx_152827d8-cab7-421f-a3ae-68485fcdb361"
      unitRef="usd">3037000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i96fd23a1c75242caaecd4598b4ab2e33_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzMtNC0xLTEtMTAyNDMx_4747ac56-b1e3-40a2-94be-7bdc520215ab"
      unitRef="usd">-28000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iefe9c570ebbd4043946a89fd045c1f82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzUtNC0xLTEtMTAyNDMx_79ddf741-e5ed-4055-983b-0adad96cb66b"
      unitRef="usd">5562000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i42df21d43bee4402a8975d2309e802f0_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzctNC0xLTEtMTAyNDMx_80a47eaa-dc65-4390-9807-c3aacc4a1e33"
      unitRef="usd">1044000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie1feb2a1c57d43a8a89b0469ed5f79d3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTo4MzNiYmJkNjNkYzQ0YTA3YWMxODczMjcwMDNhZjM0MS90YWJsZXJhbmdlOjgzM2JiYmQ2M2RjNDRhMDdhYzE4NzMyNzAwM2FmMzQxXzgtNC0xLTEtMTAyNDMx_c13ced83-1e9f-4212-9a51-a4555c0e6bee"
      unitRef="usd">4518000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i05a09806c9ee410192e276bdee67d4ec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzIxOTkwMjMyNjA5MjA_73ad5050-b514-4d61-b3f3-e9f8f19774fa"
      unitRef="usd">45712000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="i05a09806c9ee410192e276bdee67d4ec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzEwOTk1MTE2MzI5NTA_8fcfc2f9-d4fd-4399-bd8d-e3a33dca0e6b"
      unitRef="usd">50293000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i493945d3878542549477456e7e460b75_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzU0OTc1NTgxOTIxNw_865b5f26-c870-488b-a236-d60b83839645"
      unitRef="usd">45325000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtFairValue
      contextRef="i493945d3878542549477456e7e460b75_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzU0OTc1NTgxOTIxMw_f17d9edf-af70-47e4-bb48-ebbeb999130b"
      unitRef="usd">52605000</us-gaap:LongTermDebtFairValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90ZXh0cmVnaW9uOmQwYzUzMzU2NTQ0MDRkNDM4MzkzNmM0YTY5MWQ5MTI0XzcxNDY4MjU1OTIzODc_885ced90-2356-4d81-9783-dd9828b6e3fc">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant inputs that are included in the valuation of the debt derivative liability - first tranche include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Remaining term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;June 30, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;June 30, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Coupon rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5% - 12.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Revenue participation payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maximum each year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maximum each year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.90%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Probability of mandatory prepayment before 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Estimated timing of mandatory prepayment event before 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Probability of mandatory prepayment 2024 or after&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Estimated timing of mandatory prepayment event 2024 or after&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Probability of optional prepayment event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:6pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Estimated timing of optional prepayment event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents a significant unobservable input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant inputs that are included in the valuation of the debt derivative liability - second tranche include: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Remaining term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Coupon rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5% - 12.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue participation payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maximum each year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maximum each year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Probability of mandatory prepayment before 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated timing of mandatory prepayment event before 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Probability of mandatory prepayment 2024 or after&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated timing of mandatory prepayment event 2024 or after&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Probability of optional prepayment event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0%&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated timing of optional prepayment event&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:115%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents a significant unobservable input.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i4fb3c6271c204980bf4241e0ed97c838_I20221231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzItMS0xLTEtMTIxNjA5_e2c9bc1e-3995-4f7b-af29-d79600d8981b"
      unitRef="number">4.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i112f623f3210421683f1756809d4475b_I20211231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzItMy0xLTEtMTIxNjA5_7b4a026c-9a6c-4497-901c-1a4b7bf95cce"
      unitRef="number">5.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ib01ca98fb65f484db7aa0441f172af4a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzQtMS0xLTEtMTIxNjA5L3RleHRyZWdpb246OWM2ZGNhMzI5NGJlNGVhNjg1ZDc5MTlkMjZhNDdkOTJfNTQ5NzU1ODEzOTA4_ec6585ba-84fe-49d2-bbad-8a934537959b"
      unitRef="number">0.095</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i6a72a93104ed4eccbc5523f4c0f05191_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzQtMS0xLTEtMTIxNjA5L3RleHRyZWdpb246OWM2ZGNhMzI5NGJlNGVhNjg1ZDc5MTlkMjZhNDdkOTJfNTQ5NzU1ODEzOTE2_8811d8ba-7c0f-4678-9ea1-3e45dbd9be60"
      unitRef="number">0.127</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i7df814d0d49f44b38f0402eeabb3552c_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzQtMy0xLTEtMTIxNjA5_55340763-daa0-45c0-93eb-1abc5df2a292"
      unitRef="number">0.0950</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i02f73cc8149a450c9f9c913738431082_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzYtMS0xLTEtMTIxNjA5_79a0f4b5-8986-4739-b8ff-d7dac53112f0"
      unitRef="number">0.1390</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ie21ffd851ecc4537b177459b24c9a3d5_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzYtMy0xLTEtMTIxNjA5_92d2021a-7c40-429b-92e1-74f5733fbd49"
      unitRef="number">0.1072</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="iac001b043861493599ed9f7cf962441d_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzctMS0xLTEtMTIxNjA5_abb6fbf7-3a75-4ffe-9b3c-8586b24672af"
      unitRef="number">0.050</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ia8843fd82eae4f4092d2b2e26e5f6403_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzctMy0xLTEtMTIxNjA5_d258bc39-1ad4-45d8-995b-2a1eea15c958"
      unitRef="number">0.050</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="if3218bc21e1b493a82d42491d73cb0ea_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzktMS0xLTEtMTIxNjA5_3bc1cb96-c88e-4bde-a105-39d2c58fe646"
      unitRef="number">0.150</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i920e8bfa648d41c7b399a5783bd68c3c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzktMy0xLTEtMTIxNjA5_f7bf2a96-1366-4eb7-8030-91db8f4f0bd8"
      unitRef="number">0.150</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ia49615132a2c496d981625ca85c9c943_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzExLTEtMS0xLTEyMTYwOQ_50f2e9f0-3903-4f53-93ae-078f2e234a58"
      unitRef="number">0.050</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ic1cad8ff35f4474da61c3d70a7da989b_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZToxNDA4Nzc0ODQ4MDA0ZjYwYmIzYzFlN2E5NjdlZmZiOC90YWJsZXJhbmdlOjE0MDg3NzQ4NDgwMDRmNjBiYjNjMWU3YTk2N2VmZmI4XzExLTMtMS0xLTEyMTYwOQ_2b798d57-5cce-4d39-bb18-c19a795d8a15"
      unitRef="number">0.050</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ic393cbccf77f4f7f9ddd00e20e44bfa7_I20221231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzItMS0xLTEtMTIxNjA5_3b5c841e-c249-4760-b8fc-c0ff9d7b395c"
      unitRef="number">5.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i3313bb44c00d456ba559b7c53b18be3d_I20211231"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzItMy0xLTEtMTIxNjA5_7cf8ae60-564e-41bf-aede-486fb780d38f"
      unitRef="number">6.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="iac024fdbce484e7f8e49292e12eb03a3_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzQtMS0xLTEtMTIxNjA5L3RleHRyZWdpb246Zjk0NjVhM2M0ZTI2NDU0YzgyNmE2Nzk0MzRmY2Y1ZjRfNTQ5NzU1ODEzOTA4_cb839e26-85f5-4898-bf3e-73e5b53002ba"
      unitRef="number">0.095</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i2ac361d361b540cbba4353a8b20de144_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzQtMS0xLTEtMTIxNjA5L3RleHRyZWdpb246Zjk0NjVhM2M0ZTI2NDU0YzgyNmE2Nzk0MzRmY2Y1ZjRfNTQ5NzU1ODEzOTE2_db519634-9bd3-4dc9-806c-3502e3e4ea68"
      unitRef="number">0.127</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="if2532d10d99c4277927947329d695475_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzQtMy0xLTEtMTIxNjA5_d7154a17-365f-4ccf-a4bc-9cb7eea6d680"
      unitRef="number">0.0950</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i5a116e8bc9eb4403af53f80e4b35086c_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzYtMS0xLTEtMTIxNjA5_5dd653b7-5951-4ad3-986d-c434ade24250"
      unitRef="number">0.1756</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i1e18c269659d4844ac0d512a92bcd2a2_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzYtMy0xLTEtMTIxNjA5_b51d71f9-3605-4037-82e7-01c48117b671"
      unitRef="number">0.1321</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i1958bf62020547a291e5c09e08fcc45f_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzctMS0xLTEtMTIxNjA5_c4124a9f-603b-4a86-9fe6-049c302826fe"
      unitRef="number">0.050</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="if107145343dc4b0daddec46f6ccc3857_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzctMy0xLTEtMTIxNjA5_22b0f8a2-90c9-4484-9ff4-149bea3392fe"
      unitRef="number">0.050</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i2d58523409ee484bae896a42cbecd8b1_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzktMS0xLTEtMTIxNjA5_2a0e868d-29f0-4c2c-92dc-48ec0a7ce5e2"
      unitRef="number">0.150</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i49673c1dce6f4f2496f2da68cd37b20b_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzktMy0xLTEtMTIxNjA5_a4e240a7-013e-4b3b-9d2b-086500a165c7"
      unitRef="number">0.150</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ic134f7c3e14d4cd7b7811f6e97064116_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzExLTEtMS0xLTEyMTYwOQ_3485ab32-943a-4ba8-8cc0-bdc8d548228c"
      unitRef="number">0.050</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i81395195766a421e95d3757424963785_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDYvZnJhZzpkMGM1MzM1NjU0NDA0ZDQzODM5MzZjNGE2OTFkOTEyNC90YWJsZTphMDRlZjNlM2EzOWY0ODQ2YTUyZjBiMjQ4ZjE0YzFhNS90YWJsZXJhbmdlOmEwNGVmM2UzYTM5ZjQ4NDZhNTJmMGIyNDhmMTRjMWE1XzExLTMtMS0xLTEyMTYwOQ_508fa3f6-614b-43ff-8e16-892e8cafcb7e"
      unitRef="number">0.050</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90ZXh0cmVnaW9uOjhlOTlkMGFjMGQ5ZTQ1ZDlhNGE3MmIwZjRkMzNlYmI0XzExMA_362d9b80-fdf1-44df-9676-f18a6f079b8d">Accounts Payable and Accrued Expenses&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90ZXh0cmVnaW9uOjhlOTlkMGFjMGQ5ZTQ1ZDlhNGE3MmIwZjRkMzNlYmI0XzExMQ_8e660596-642b-4805-90a5-4e650910a6b5">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzEtMS0xLTEtMTAyNDMx_89aabe29-72c8-4927-868b-f183dfe91b68"
      unitRef="usd">8964000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzEtMy0xLTEtMTAyNDMx_86f714ab-cafd-48c4-be7b-7041e3af5c6d"
      unitRef="usd">5923000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzItMS0xLTEtMTAyNDMx_83c4d3b2-af44-4b36-bba7-f34710c18655"
      unitRef="usd">4520000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzItMy0xLTEtMTAyNDMx_e0d39b4f-fc5f-49a9-a707-0454ae4d39ce"
      unitRef="usd">6863000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzMtMS0xLTEtMTAyNDMx_06187804-abe6-4363-8614-866c70775256"
      unitRef="usd">8959000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzMtMy0xLTEtMTAyNDMx_70a326b9-b28a-4359-a738-f99ce0710503"
      unitRef="usd">9673000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzQtMS0xLTEtMTAyNDMx_effb3b48-1695-4948-8fc3-f350026d1c96"
      unitRef="usd">22443000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMTgvZnJhZzo4ZTk5ZDBhYzBkOWU0NWQ5YTRhNzJiMGY0ZDMzZWJiNC90YWJsZTpmMjM4ZWJkZGY0NTc0ODRlODkyYzgyYjI4OGJiNjVjMS90YWJsZXJhbmdlOmYyMzhlYmRkZjQ1NzQ4NGU4OTJjODJiMjg4YmI2NWMxXzQtMy0xLTEtMTAyNDMx_dad34bca-7da1-4f35-ac2a-d3615ee3137a"
      unitRef="usd">22459000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzQyMA_0159b1f3-de3e-4d56-8b7e-fd6e089170d6">Leases &lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases administrative, manufacturing, research and distribution facilities through operating leases. Several leases include fixed payments including rent and non-lease components such as common-area or other maintenance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of total lease expense for the years ended were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to the operating and financing leases is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(In thousands, except lease term and discount rate)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use operating assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_282ba7ce-3ef3-47fa-b090-df6bc8c1cb62"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_bf9cd539-7ed8-407f-9081-99b74e7abdea"&gt;Current maturities of long-term lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_43b1e322-811d-4e24-9d5c-24c744c9ffc6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_90aa3a79-3bec-4569-a69a-52d996616d6a"&gt;Long-term lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financing Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use financing leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_271319ea-950a-424e-8fc3-fea671d857ad"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_51dc3b73-6881-4d4b-ad5d-be166f123d9e"&gt;Current maturities of long-term lease obligations&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_ad5ae935-b90b-46e6-8d03-aa77e93ca8d3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_d55777eb-f537-4f2f-82c6-3481b4ecb124"&gt;Long-term lease obligations&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average operating lease term (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average financing term (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Financing leases are included in property and equipment, net on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under operating and financing leases as of December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Current lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease modifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for lease revisions as a lease modification in accordance with ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when the modification effectively terminates the existing lease and creates a new lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 22, 2021, the Company entered into the Seventh Amendment to a License and Services Agreement ("Seventh Amendment") with Community Blood Center (doing business as Community Tissue Services) ("CTS"), with an effective date of February 22, 2021, pursuant to the original agreement dated August 6, 2015, as amended ("CTS Agreement"). The CTS Agreement is for processing of the Avance Nerve Graft in Dayton, Ohio. The Seventh Amendment extended the term of the agreement to December 31, 2023. Under the CTS Agreement, the Company pays CTS a facility fee for use of clean room/manufacturing, storage, and office space, which the Company accounts for as an embedded lease. The Company valued the CTS Agreement using a 6.3% incremental borrowing rate and recorded a right-of-use asset  and a lease liability of $272 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 12, 2021, the Company entered into the First Amendment to Office Lease ("Heights Union First Amendment") with Cousins Heights Union, LLC (as successor in interest to Heights Union I, LLC), with an effective date of July 12, 2021, pursuant to the original lease dated September 20, 2018, as amended ("Heights Union Lease"). The Heights Union Lease is for the general office, medical laboratory, training, and meeting purposes located in Tampa, Florida. The Heights Union First Amendment revises the commencement date of the Heights Union Lease to mean October 30, 2020 and revises the termination date of the Heights Union Lease to be October 31, 2034. Pursuant to the Heights Union First Amendment, the Company was entitled to an additional 1.5 months of free rent. The Company valued the Height Union Lease using a 10.6% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $299 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 13, 2021, the Company entered into a Sixth Amendment to Lease ("Sixth Amendment") with Alachua Copeland Park Investments, LLC (as successor in interest to Ology Bioservices Holdings, LLC, who was successor in interest to SNH Medical Office Properties Trust), with an effective date of July 13, 2021, pursuant to the original lease agreement dated February 6, 2007, as amended ("Alachua Lease"). The Alachua Lease is for the Company's corporate headquarters in Alachua, Florida. The Sixth Amendment extended the term of the Alachua Lease to October 31, 2026. The Company valued the Alachua Lease using a 10.6% incremental borrowing rate and recorded a right-of-use asset of $1,335 and a lease liability of $1,370 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 27, 2022, the Company entered into a Commercial Lease Amendment ("Amendment") with JA-Cole L.P., with an effective date of February 1, 2022, pursuant to the original Commercial Lease dated April 21, 2015, as amended (the "2015 JA-Cole Lease"). The 2015 JA-Cole Lease is for the office and warehouse facility located in Burleson, Texas. The Amendment revised the commencement date to May 1, 2022, and the expiration date to April 30, 2027. The Company valued the 2015 JA-Cole Lease using a 11.3% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $641 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 22, 2022, the Company entered into the First Amendment to Lease Agreement (the &#x201c;First Amendment&#x201d;) with JA-Cole, L.P. with an effective date of October 1, 2022, pursuant to the original Commercial Lease dated October 1, 2020, as amended (the "2020 JA-Cole Lease"). The 2020 JA-Cole Lease is for the office and warehouse facility located in Burleson, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Texas. The First Amendment adds an additional 2,500 square feet to the Leased Premises, for a total of 5,000 square feet and revises the expiration date of the 2020 JA-Cole Lease to mean September 30, 2027. The Company valued the 2020 JA Cole Lease using a 12.8% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $221 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;31, 2022, the Company entered into the Second Amendment to Lease Agreement (the "Second Amendment") with SNH Medical Office Properties Trust n/k/a Nucleic Acids Licensing, LLC with an effective date of January 1, 2023, pursuant to the original lease agreement on November 19, 2018, as amended (the "2018 Nucleic Lease"). The 2018 Nucleic Lease is for medical laboratory space in Alachua, Florida. The Second Amendment extends the term of the 2018 Nucleic Lease one year; to December 31, 2023, with the option to extend the term for one additional year. The Company valued the 2018 Nucleic Lease using a 14.0% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $75 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzQyMA_71cfc386-98e1-4791-8390-89cfd5909456">Leases &lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases administrative, manufacturing, research and distribution facilities through operating leases. Several leases include fixed payments including rent and non-lease components such as common-area or other maintenance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of total lease expense for the years ended were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to the operating and financing leases is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(In thousands, except lease term and discount rate)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use operating assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_282ba7ce-3ef3-47fa-b090-df6bc8c1cb62"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_bf9cd539-7ed8-407f-9081-99b74e7abdea"&gt;Current maturities of long-term lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_43b1e322-811d-4e24-9d5c-24c744c9ffc6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_90aa3a79-3bec-4569-a69a-52d996616d6a"&gt;Long-term lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financing Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use financing leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_271319ea-950a-424e-8fc3-fea671d857ad"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_51dc3b73-6881-4d4b-ad5d-be166f123d9e"&gt;Current maturities of long-term lease obligations&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_ad5ae935-b90b-46e6-8d03-aa77e93ca8d3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_d55777eb-f537-4f2f-82c6-3481b4ecb124"&gt;Long-term lease obligations&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average operating lease term (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average financing term (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Financing leases are included in property and equipment, net on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under operating and financing leases as of December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Current lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease modifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for lease revisions as a lease modification in accordance with ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, when the modification effectively terminates the existing lease and creates a new lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 22, 2021, the Company entered into the Seventh Amendment to a License and Services Agreement ("Seventh Amendment") with Community Blood Center (doing business as Community Tissue Services) ("CTS"), with an effective date of February 22, 2021, pursuant to the original agreement dated August 6, 2015, as amended ("CTS Agreement"). The CTS Agreement is for processing of the Avance Nerve Graft in Dayton, Ohio. The Seventh Amendment extended the term of the agreement to December 31, 2023. Under the CTS Agreement, the Company pays CTS a facility fee for use of clean room/manufacturing, storage, and office space, which the Company accounts for as an embedded lease. The Company valued the CTS Agreement using a 6.3% incremental borrowing rate and recorded a right-of-use asset  and a lease liability of $272 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 12, 2021, the Company entered into the First Amendment to Office Lease ("Heights Union First Amendment") with Cousins Heights Union, LLC (as successor in interest to Heights Union I, LLC), with an effective date of July 12, 2021, pursuant to the original lease dated September 20, 2018, as amended ("Heights Union Lease"). The Heights Union Lease is for the general office, medical laboratory, training, and meeting purposes located in Tampa, Florida. The Heights Union First Amendment revises the commencement date of the Heights Union Lease to mean October 30, 2020 and revises the termination date of the Heights Union Lease to be October 31, 2034. Pursuant to the Heights Union First Amendment, the Company was entitled to an additional 1.5 months of free rent. The Company valued the Height Union Lease using a 10.6% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $299 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 13, 2021, the Company entered into a Sixth Amendment to Lease ("Sixth Amendment") with Alachua Copeland Park Investments, LLC (as successor in interest to Ology Bioservices Holdings, LLC, who was successor in interest to SNH Medical Office Properties Trust), with an effective date of July 13, 2021, pursuant to the original lease agreement dated February 6, 2007, as amended ("Alachua Lease"). The Alachua Lease is for the Company's corporate headquarters in Alachua, Florida. The Sixth Amendment extended the term of the Alachua Lease to October 31, 2026. The Company valued the Alachua Lease using a 10.6% incremental borrowing rate and recorded a right-of-use asset of $1,335 and a lease liability of $1,370 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 27, 2022, the Company entered into a Commercial Lease Amendment ("Amendment") with JA-Cole L.P., with an effective date of February 1, 2022, pursuant to the original Commercial Lease dated April 21, 2015, as amended (the "2015 JA-Cole Lease"). The 2015 JA-Cole Lease is for the office and warehouse facility located in Burleson, Texas. The Amendment revised the commencement date to May 1, 2022, and the expiration date to April 30, 2027. The Company valued the 2015 JA-Cole Lease using a 11.3% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $641 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 22, 2022, the Company entered into the First Amendment to Lease Agreement (the &#x201c;First Amendment&#x201d;) with JA-Cole, L.P. with an effective date of October 1, 2022, pursuant to the original Commercial Lease dated October 1, 2020, as amended (the "2020 JA-Cole Lease"). The 2020 JA-Cole Lease is for the office and warehouse facility located in Burleson, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Texas. The First Amendment adds an additional 2,500 square feet to the Leased Premises, for a total of 5,000 square feet and revises the expiration date of the 2020 JA-Cole Lease to mean September 30, 2027. The Company valued the 2020 JA Cole Lease using a 12.8% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $221 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;31, 2022, the Company entered into the Second Amendment to Lease Agreement (the "Second Amendment") with SNH Medical Office Properties Trust n/k/a Nucleic Acids Licensing, LLC with an effective date of January 1, 2023, pursuant to the original lease agreement on November 19, 2018, as amended (the "2018 Nucleic Lease"). The 2018 Nucleic Lease is for medical laboratory space in Alachua, Florida. The Second Amendment extends the term of the 2018 Nucleic Lease one year; to December 31, 2023, with the option to extend the term for one additional year. The Company valued the 2018 Nucleic Lease using a 14.0% incremental borrowing rate and recorded a right-of-use asset and a lease liability of $75 as a result of this amendment.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzcxNDY4MjU1OTE5NTc_b3a6efee-3cb7-4d35-ba1b-8d8ecaad65cd">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of total lease expense for the years ended were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzMtMS0xLTEtMTIwNTY1_d922bc6d-a803-45ff-94b1-1a4dabf3302c"
      unitRef="usd">20000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzMtMy0xLTEtMTIwNTY1_749e710a-fbd6-4368-9df6-44837cfc160d"
      unitRef="usd">22000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzMtNS0xLTEtMTIwNTY1_2497e5e5-1d89-4aa9-8158-addd376e3e36"
      unitRef="usd">22000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzQtMS0xLTEtMTIwNTY1_ce708d9e-05a4-462e-95b4-0151af79d7c2"
      unitRef="usd">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzQtMy0xLTEtMTIwNTY1_7d8d5539-1e5c-47d8-8002-5b129034bbc1"
      unitRef="usd">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzQtNS0xLTEtMTIwNTY1_45204e41-bfef-4bdd-8358-6a8c3e87999c"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzYtMS0xLTEtMTIwNTY1_6acbe7d4-c1b7-4c48-b2d5-e595169bf1f9"
      unitRef="usd">4077000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzYtMy0xLTEtMTIwNTY1_8242c0b6-1b76-4c44-a5d0-188b6e1ec4ce"
      unitRef="usd">4326000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzYtNS0xLTEtMTIwNTY1_e6418dfe-5a8a-4221-9132-50a2d11c3aa6"
      unitRef="usd">2777000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzctMS0xLTEtMTIwNTY1_e16cb15c-f407-44d2-a9bb-3840e569f6b4"
      unitRef="usd">72000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzctMy0xLTEtMTIwNTY1_0d98dab1-fa96-4bc2-8bf2-be0f337cf9e5"
      unitRef="usd">10000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzctNS0xLTEtMTIwNTY1_661524ef-ac8e-403f-975a-db16e1274c07"
      unitRef="usd">116000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzgtMS0xLTEtMTIwNTY1_3fa2d6d3-cdde-479b-b3ca-c2585f106458"
      unitRef="usd">1241000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzgtMy0xLTEtMTIwNTY1_d5fa2358-8f91-4b90-b892-4a1e91003164"
      unitRef="usd">744000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzgtNS0xLTEtMTIwNTY1_679adb4b-30fa-4cb6-b423-dd49ad8964b9"
      unitRef="usd">18000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzktMS0xLTEtMTIwNTY1_ba4296e2-e028-448f-b1c2-e3eb728c3262"
      unitRef="usd">5412000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzktMy0xLTEtMTIwNTY1_1b5d7bee-4de8-4384-89ee-0c49549d3963"
      unitRef="usd">5104000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo4YTBlNDhkZWYyYzg0NmE3OTY5ZjFiNjEyOGM0ZjdmOC90YWJsZXJhbmdlOjhhMGU0OGRlZjJjODQ2YTc5NjlmMWI2MTI4YzRmN2Y4XzktNS0xLTEtMTIwNTY1_3ea4bd2d-17b1-4231-a2fc-5a308fbb1af8"
      unitRef="usd">2936000</us-gaap:LeaseCost>
    <axgn:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzkzNDU4NDg4NDAyOTI_6e1cb6b8-6092-4b2d-8dea-a486f50540cd">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to the operating and financing leases is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(In thousands, except lease term and discount rate)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use operating assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_282ba7ce-3ef3-47fa-b090-df6bc8c1cb62"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMC0xLTEtMTE0MDg4_bf9cd539-7ed8-407f-9081-99b74e7abdea"&gt;Current maturities of long-term lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_43b1e322-811d-4e24-9d5c-24c744c9ffc6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMC0xLTEtMTE0MDkw_90aa3a79-3bec-4569-a69a-52d996616d6a"&gt;Long-term lease obligations&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financing Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use financing leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_271319ea-950a-424e-8fc3-fea671d857ad"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMC0xLTEtMTE0MDk2_51dc3b73-6881-4d4b-ad5d-be166f123d9e"&gt;Current maturities of long-term lease obligations&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_ad5ae935-b90b-46e6-8d03-aa77e93ca8d3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMC0xLTEtMTE0MTAy_d55777eb-f537-4f2f-82c6-3481b4ecb124"&gt;Long-term lease obligations&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average operating lease term (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average financing term (in years):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate financing leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; (1) Financing leases are included in property and equipment, net on the consolidated balance sheets.</axgn:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzItMS0xLTEtMTEwNTU4_332ead80-84d5-412a-998a-2a8611ba8eda"
      unitRef="usd">14369000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzItMy0xLTEtMTEwNjUw_12f8362e-ec2b-40eb-b6e0-c24fb2d8b0fe"
      unitRef="usd">15193000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMS0xLTEtMTEwNTY2_ae84cc38-279d-48cd-aa4a-418d1465c013"
      unitRef="usd">1303000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzMtMy0xLTEtMTEwNjU0_b4d8fbcb-2c83-418f-bf97-4292428270ba"
      unitRef="usd">1825000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMS0xLTEtMTEwNTc0_7c2b0e22-2672-4eeb-a9b9-59f1187e80ef"
      unitRef="usd">20387000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzQtMy0xLTEtMTEwNjU4_d342f8e9-4fd7-4e87-8e7e-4d86f9ef263e"
      unitRef="usd">20794000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzYtMS0xLTEtMTEwNTgy_9e12c6fb-bcc3-4407-8f39-802ba145e60e"
      unitRef="usd">41000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzYtMy0xLTEtMTEwNjY0_ee2179c1-009c-4746-b140-b9bedb0efe02"
      unitRef="usd">42000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMS0xLTEtMTEwNTkw_d8d82436-24d4-40e7-9782-ebf4e85e897e"
      unitRef="usd">7000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzctMy0xLTEtMTEwNjcy_5537896f-109d-42ab-bc26-091071678d13"
      unitRef="usd">9000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMS0xLTEtMTEwNTk4_c15eebe6-7b81-4e8d-8e36-48f4059159d7"
      unitRef="usd">18000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzgtMy0xLTEtMTEwNjc2_47de2c5d-dd5e-44bb-89d6-c874259d4146"
      unitRef="usd">4000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzEwLTEtMS0xLTExMDYwNg_c12304e3-6a33-44b8-bd4e-37152d15345d">P11Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzEwLTMtMS0xLTExMDY4MA_e0426ffe-c37b-45c5-827f-ce6d2237d204">P12Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzExLTEtMS0xLTExMDYxNA_8bd07bc9-6d96-4761-acbd-f68852ccaf9b">P4Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzExLTMtMS0xLTExMDY4NA_24520201-2683-4991-bbaa-005b8edaa67a">P2Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzEzLTEtMS0xLTExMDYzNg_a08b7995-02b5-4f17-b68b-f2aa4c0e4f99"
      unitRef="number">0.1058</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzEzLTMtMS0xLTExMDY4OA_c53670b4-628f-4a8d-9054-fda68060c276"
      unitRef="number">0.1032</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzE0LTEtMS0xLTExMDY0Mg_926d4ef9-d3b1-4eec-9bca-e57619fc361c"
      unitRef="number">0.1191</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZToxN2RiNGZlN2JkNWU0ZGRjYmFmOGQxY2UwMDA3NGFkZS90YWJsZXJhbmdlOjE3ZGI0ZmU3YmQ1ZTRkZGNiYWY4ZDFjZTAwMDc0YWRlXzE0LTMtMS0xLTExMDY5Mg_d79d6a5f-9d05-4a60-9ee0-f1f30c182004"
      unitRef="number">0.0723</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzkzNDU4NDg4NDAyOTM_676d662e-1ce5-4cb9-9154-84fd8faf5899">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under operating and financing leases as of December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Current lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzkzNDU4NDg4NDAyOTM_e17ea2aa-fc22-4d92-8b1c-1d821ef1b617">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under operating and financing leases as of December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: Current lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzEtMS0xLTEtMTEwMTA2_5a0ac686-cc12-4c5c-9b22-c349bc77cc60"
      unitRef="usd">3519000</axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne>
    <axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzItMS0xLTEtMTEwMTA2_c6894fbb-8dfd-476d-bf6d-f6fbc9b66cb0"
      unitRef="usd">3297000</axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo>
    <axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzMtMS0xLTEtMTEwMTA2_6122bd9f-3883-4a25-940a-f61281ce6991"
      unitRef="usd">3336000</axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree>
    <axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzQtMS0xLTEtMTEwMTA2_07294201-449d-4726-8a45-dd6b9818e7b0"
      unitRef="usd">3348000</axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour>
    <axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzUtMS0xLTEtMTEwMTA2_81204ac8-950a-497b-88b5-ebca3bc2bf60"
      unitRef="usd">2921000</axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive>
    <axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzctMS0xLTEtMTEwMTA2_52a11026-3e48-4cd6-a128-beec3b1878ad"
      unitRef="usd">20931000</axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive>
    <axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaid
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzgtMS0xLTEtMTEwNDUy_d271ac02-de59-4ca2-9b83-06211b006f66"
      unitRef="usd">37352000</axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaid>
    <axgn:LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzktMS0xLTEtMTEwMTA2_89d91ea2-8566-4139-89f1-634aa7425c6f"
      unitRef="usd">15637000</axgn:LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount>
    <axgn:OperatingAndFinancingLeaseLiability
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzEwLTEtMS0xLTExMDQ2OA_694b207b-e297-4253-a65e-745d04efc4c4"
      unitRef="usd">21715000</axgn:OperatingAndFinancingLeaseLiability>
    <axgn:OperatingAndFinancingLeaseLiabilityCurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzExLTEtMS0xLTExMDEwNg_8b2e72cc-4acf-4648-81bd-034ea116b020"
      unitRef="usd">1310000</axgn:OperatingAndFinancingLeaseLiabilityCurrent>
    <axgn:OperatingAndFinancingLeaseLiabilityNoncurrent
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90YWJsZTo5YTM3YjE3MTBkMTM0ZjJmODYyMjY5ZjE1ZjUxOTQ1OC90YWJsZXJhbmdlOjlhMzdiMTcxMGQxMzRmMmY4NjIyNjlmMTVmNTE5NDU4XzEyLTEtMS0xLTExMDQ4NA_c25dbf24-9ca2-44a7-ae71-e9785c706688"
      unitRef="usd">20405000</axgn:OperatingAndFinancingLeaseLiabilityNoncurrent>
    <axgn:OperatingLeaseIncrementalBorrowingRate
      contextRef="i7ba9dcd463a4411d98f217af826e1ec3_D20210222-20210222"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTc4MQ_9e47e466-9d77-418b-8ef9-05e8d5fd88d7"
      unitRef="number">0.063</axgn:OperatingLeaseIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic07a04ab4a2a4b3fa3a573b41c2448a6_I20210222"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTc5MA_436563e9-d106-4026-9dcc-bb7316f86091"
      unitRef="usd">272000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic07a04ab4a2a4b3fa3a573b41c2448a6_I20210222"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTc5MA_823bf9fa-5709-4b77-b4a5-72ed91f8bae1"
      unitRef="usd">272000</us-gaap:OperatingLeaseRightOfUseAsset>
    <axgn:LesseeOperatingLeaseNumberOfRentFreeMonths
      contextRef="i157567aac3fe47c883ab1353f6869f96_D20210712-20210712"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTgzMw_f1d23b36-c64b-4536-9712-ccaef57f2ce3"
      unitRef="m">1.5</axgn:LesseeOperatingLeaseNumberOfRentFreeMonths>
    <axgn:OperatingLeaseIncrementalBorrowingRate
      contextRef="i157567aac3fe47c883ab1353f6869f96_D20210712-20210712"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg0MQ_dff6090a-21c2-4c62-8abe-8ca282b8cb08"
      unitRef="number">0.106</axgn:OperatingLeaseIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseLiability
      contextRef="i955f3c4847e84499b9e5df9ed14d2f7a_I20210712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg1MA_992e8b67-97a9-4e5c-9bd2-983a6299fb59"
      unitRef="usd">299000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i955f3c4847e84499b9e5df9ed14d2f7a_I20210712"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg1MA_efb0da20-0998-4f7c-9a57-01594df2278c"
      unitRef="usd">299000</us-gaap:OperatingLeaseRightOfUseAsset>
    <axgn:OperatingLeaseIncrementalBorrowingRate
      contextRef="i0b56b68105574c4899488b9442a10226_D20210713-20210713"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg4Mw_7e7f73bc-588f-40d0-8ff0-cf018bca582f"
      unitRef="number">0.106</axgn:OperatingLeaseIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7c395685d2a24e03a092821152da1c30_I20210713"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg3Mw_bf4dc910-cdce-4da7-bb98-534f5dd3ef84"
      unitRef="usd">1335000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7c395685d2a24e03a092821152da1c30_I20210713"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg2OQ_fde74962-e8e8-43ef-abf6-79958c195913"
      unitRef="usd">1370000</us-gaap:OperatingLeaseLiability>
    <axgn:OperatingLeaseIncrementalBorrowingRate
      contextRef="i0581e65b1022415ca3161ab6932a9f19_D20220127-20220127"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg4Nw_7d059a42-6bfd-4712-b3fb-ab4e87a8fd76"
      unitRef="number">0.113</axgn:OperatingLeaseIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4097a733c1714381b903a1dfe340dafe_I20220127"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg5MQ_b88f7e5f-1256-45f3-bd1f-d37a75f5db71"
      unitRef="usd">641000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4097a733c1714381b903a1dfe340dafe_I20220127"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMTg5MQ_f5465a31-3c6c-49fe-b44a-4c5effaf46d9"
      unitRef="usd">641000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i2e1fc63be79e43f2ab16a203a1d29645_I20220822"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzE4NjkxNjk3NjgxMDYy_3f239645-8c4f-4112-a82e-4064fcf146f0"
      unitRef="sqft">2500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i099064cb7e584aca8bb8c8b521b1be3c_I20220822"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzE4NjkxNjk3NjgxMTE3_d6b54d0d-e873-49ad-b213-c0730d61f680"
      unitRef="sqft">5000</us-gaap:AreaOfRealEstateProperty>
    <axgn:OperatingLeaseIncrementalBorrowingRate
      contextRef="icf7f7b402ec14835ba2971de3296cb0d_D20220822-20220822"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzE2OQ_e0b7547f-7252-4113-b0d8-6c23338a0a35"
      unitRef="number">0.128</axgn:OperatingLeaseIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2e1fc63be79e43f2ab16a203a1d29645_I20220822"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzE3Mw_10384ee1-c28d-4b5d-b391-3fda9e320bed"
      unitRef="usd">221000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2e1fc63be79e43f2ab16a203a1d29645_I20220822"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzE3Mw_c9417503-d307-44bf-8bf5-f24f4f08516f"
      unitRef="usd">221000</us-gaap:OperatingLeaseRightOfUseAsset>
    <axgn:OperatingLeaseIncrementalBorrowingRate
      contextRef="i41dbef148b97433ea98f9c4af34f62f1_D20221231-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzIwMg_75ee95ad-5384-4eac-82fa-92085684c059"
      unitRef="number">0.140</axgn:OperatingLeaseIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic9a30248ed7b4f40a1fafee657210a01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzE5OA_46bbd2ac-8ec4-4083-a5f7-5a30f3803f4b"
      unitRef="usd">75000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic9a30248ed7b4f40a1fafee657210a01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMDkvZnJhZzpmZDgyODFlMzZiMzY0NjFmOWI4MzA3ZWZjYTI1NjM3ZC90ZXh0cmVnaW9uOmZkODI4MWUzNmIzNjQ2MWY5YjgzMDdlZmNhMjU2MzdkXzU0OTc1NTgzMzE5OA_da17c0e9-c3ca-498a-a679-2db44c0ef850"
      unitRef="usd">75000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzk1Mjk_48615156-20b2-443a-b4df-00d55ba88053">Long-Term Debt, Net of Debt Discount and Financing Fees&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt, net of debt discount and financing fees consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Facility - first tranche&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Facility - second tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less - unamortized debt discount and deferred financing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, net of debt discount and financing fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2020, the Company entered into a seven-year financing agreement (the &#x201c;Credit Facility&#x201d;) with Oberland Capital and its affiliates TPC Investments II LP and Argo SA LLC (collectively, the "Lender") and obtained the first tranche of $35,000 at closing. On June 30, 2021, the second tranche of $15,000 was drawn down by the Company. The financing costs for this facility were $642 and were recorded as a contra liability to the long-term debt on the consolidated balance sheet. The financing costs were paid as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each tranche under the Credit Facility requires quarterly interest payments for seven years. Interest is calculated as 7.5% plus the greater of the London Interbank Offered Rate ("LIBOR") or 2.0% (11.24% as of December&#160;31, 2022). Each tranche of the Credit Facility has a term of seven years from the date of issuance (with the first tranche issued on June 30, 2020, maturing on June 30, 2027, and the second tranche issued on June 30, 2021, maturing on June 30, 2028). In connection with the Credit Facility, the Company entered into a revenue participation agreement (the &#x201c;Revenue Participation Agreement&#x201d;) with the Lender, which provided that, among other things, a quarterly royalty payment as a percentage of the Company&#x2019;s net revenues up to $70&#160;million in any given year, after April 1, 2021, ending on the date upon which all amounts owed under the Credit Facility have been paid in full. This structure results in approximately 1.0% per year of additional interest payments on the outstanding loan amount. The Company recorded $756 and $646 as interest expense for this Revenue Participation Agreement for the years ended December&#160;31, 2022, and 2021, respectively. The Company pays the quarterly debt interest on the last day of the quarter, and for the years ended December&#160;31, 2022, and 2021, paid $5,074 and $4,103, respectively, to the Lender. The Company capitalized interest of $6,155 and $4,277 for the years ended December&#160;31, 2022, and 2021, respectively, towards the costs to construct and retrofit its APC Facility in Vandalia, OH. See Note 14 - Commitments and Contingencies. To date, the Company has capitalized interest of $11,429 related to this project. The capitalized interest is recorded as part of property and equipment in the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Lender had the right to purchase up to $3,500 worth of the Company's common stock from the Company in one transaction at any time after closing of the Credit Facility until the later of (i) the date all amounts due under the Credit Facility are repaid and (ii) June 30, 2027 (the &#x201c;Credit Facility Option&#x201d;). The purchase price of the common stock was calculated based on the 45-day moving average of the closing stock price on the day prior to the purchase. On December 10, 2020, the Lender exercised in full its option under the Credit Facility Option. The exercise price was determined to be $14.13, resulting in gross proceeds to the Company of $3,500 and the issuance of 247,699 shares to a wholly owned subsidiary of the Lender. In conjunction with the issuance of the shares, the Lender received certain protective rights (including protection from down-round stock issuances) for a period of one year subsequent to the issuance. These rights expired on December 10, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts outstanding under the Credit Facility may be accelerated upon certain events, including: (a) required mandatory prepayments upon an asset sale; (b) in the event the Company is subject to (i) any litigation brought by a Governmental Authority (as defined in the Credit Facility) including intervention after litigation is commenced by a Person (as defined in the Credit Facility), or (ii) any final administrative action by a Governmental Authority, in each case arising out of or in connection with any of the Company&#x2019;s registry studies, payments made to doctors or training activities with respect to healthcare professionals (excluding certain final administrative actions that have been fully and finally resolved by the parties pursuant to a settlement agreement) or (c) upon the occurrence of an event of default (either automatically or at the option of the Lender depending on the nature of the event). In addition, the Company has the right to prepay any amounts outstanding under the Credit Facility. Upon maturity or upon such earlier repayment of the Credit Facility, the Company will repay the principal balance and provide a make-whole payment calculated to generate an internal rate of return to the Lender equal to 11.5%, less the total of all quarterly interest and royalty payments previously paid to the Lender. See Note 14 - Commitments and Contingencies for further information related to the make-whole payment calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of an event of default, the interest rate incurred on amounts outstanding under the Credit Facility will be increased by 4%. The Credit Facility includes a financial covenant requiring the Company to achieve certain revenue targets each quarter. As of December&#160;31, 2022, the Company was in compliance with all the covenants. In the event of a failure to meet such covenant the Company may avoid a default by electing to be subject to a liquidity covenant and meeting all of the obligations required by such covenant. The borrowings under the Credit Facility are secured by substantially all of the assets of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that Credit Facility included separable embedded features on a combined basis as a single derivative feature. The Company estimated the fair value of these features as $2,387 as of the date of issuance of the Credit Facility and recorded this value as a debt derivative liability. As a result of the second tranche draw on June 30, 2021, the Company recorded an additional derivative and estimated the fair value to be $1,961, along with an increase of $1,076 related to the first tranche derivative. See Note 6 - Fair Value Measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The debt derivative liabilities are recorded at fair value, with the change in fair value reported in change in the fair value of the derivative on the consolidated statements of operations at each reporting date. See Note 6 - Fair Value Measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unamortized Debt Discount and Financing Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unamortized debt discount consists of the remaining initial fair values of the embedded derivatives related to the Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financing fees for the Credit Facility were $642 and were recorded as a contra liability to long-term debt on the consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of debt discount and deferred financing fees for the years ended December&#160;31, 2022, 2021 and 2020, was $891, $831 and $232, respectively, and recorded in interest expense using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Credit Facilities&lt;/span&gt;&lt;/div&gt;The Company had restricted cash of $6,251 and $6,251 at December&#160;31, 2022, and 2021, respectively. The December&#160;31, 2022, and 2021 balances both include $6,000, which represents collateral for an irrevocable standby letter of credit. In March 2021, the Company entered into an agreement which required an additional irrevocable standby letter of credit in the amount of $250.</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzk1Mjc_63042330-6be4-4fb4-a57c-468253a8e289">&lt;div style="margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt, net of debt discount and financing fees consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Facility - first tranche&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Facility - second tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less - unamortized debt discount and deferred financing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-term debt, net of debt discount and financing fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i312f2d64cb674fdbad24a7fe51918409_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzEtMS0xLTEtMTAyNDMx_52b9c84f-e3df-4ac6-a34c-30af9bc70a22"
      unitRef="usd">35000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i104179cd76d94a2bb5b480f5d740f348_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzEtMy0xLTEtMTAyNDMx_15a3821d-30fc-4579-b54a-8b3e1b7dcd64"
      unitRef="usd">35000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibe9a8770fa764d7891407778eae23958_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzItMS0xLTEtMTAyNDMx_3a157a3f-c69b-49f2-a018-865f9a653a65"
      unitRef="usd">15000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id591cfe573344db49a17900c7f2534ed_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzItMy0xLTEtMTAyNDMx_2e986249-9614-4ffc-89c6-3600bfd163f1"
      unitRef="usd">15000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzMtMS0xLTEtMTAyNDMx_ca1534ec-385b-431e-95d9-a74c69cb5e69"
      unitRef="usd">4288000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzMtMy0xLTEtMTAyNDMx_af1fca65-38e7-442a-ad8b-b5a02faed250"
      unitRef="usd">5179000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzQtMS0xLTEtMTAyNDMx_fc85768c-6f85-46b8-a86c-0e14b57b5a22"
      unitRef="usd">45712000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90YWJsZTpjMjI3NjVlOGFmM2M0YWNkYWRhODRjMTRlNGMyZDgxMC90YWJsZXJhbmdlOmMyMjc2NWU4YWYzYzRhY2RhZGE4NGMxNGU0YzJkODEwXzQtMy0xLTEtMTAyNDMx_fe6330ba-2a6c-49c9-8167-77872f0f9844"
      unitRef="usd">44821000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentTerm
      contextRef="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzk1MjY_47f2f728-ef61-4715-ab67-77965382880a">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6403d399211849738490229c7838d26e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzI4Nw_0619661b-ef5d-4fc2-a058-613a86f529cd"
      unitRef="usd">35000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if575cb76b14c473cbdc0a317a1e37598_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzM0Mg_61b3514c-4454-4ab7-adb0-daad2e29ce30"
      unitRef="usd">15000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="ia7f2d0f52ae2425faca15b977fa1eb33_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzQxOQ_1f80427c-f6b5-4631-8c2c-9c2c94ba28b2"
      unitRef="usd">642000</us-gaap:DeferredFinanceCostsGross>
    <axgn:DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade
      contextRef="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzYwOA_2482f7e0-baf8-4f28-b898-b7dc945eaa2b">P7Y</axgn:DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i18a440d8b8744e8f9a6b185b93f909de_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzYzOA_a30e1591-f046-4a60-a76b-1ddfcf7ae1fb"
      unitRef="number">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <axgn:DebtInstrumentAdditionalInterestFloorRate
      contextRef="id42e84f255884f7eb85ff88a32cfbec7_D20200630-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzcwOA_fb2e43d5-df91-43d5-9fb8-44a46196ca29"
      unitRef="number">0.020</axgn:DebtInstrumentAdditionalInterestFloorRate>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i05a09806c9ee410192e276bdee67d4ec_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgzMDY0Nw_21fa732e-21a7-400a-9bc2-0e111314f28d"
      unitRef="number">0.1124</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:DebtInstrumentTerm
      contextRef="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzc3OA_205d735a-994a-4587-bc3a-4958e164fef2">P7Y</us-gaap:DebtInstrumentTerm>
    <axgn:RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty
      contextRef="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzEyMDI_a112e498-f01a-458b-a1f6-151ab994d623"
      unitRef="usd">70000000</axgn:RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty>
    <axgn:DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure
      contextRef="i4dbb66de6a8540f5a1a91719a6e23d5a_D20200630-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzE2MzM_67b18528-4624-4d18-94a7-ec81a7154858"
      unitRef="number">0.010</axgn:DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure>
    <us-gaap:InterestExpense
      contextRef="if401beb532c24731a94a6c209f24f06f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDU1Mg_b2ef07e4-9ea0-4a71-92c0-a127acf5e5a8"
      unitRef="usd">756000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icc88fe00a2b34650ba8c22e3a5248c9a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDU2MA_ecb662cf-90f5-4c8f-b8ea-6e3df8e62578"
      unitRef="usd">646000</us-gaap:InterestExpense>
    <us-gaap:InterestPaid
      contextRef="if401beb532c24731a94a6c209f24f06f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDYxMg_3963edbd-8939-491b-8292-c84eb9dab427"
      unitRef="usd">5074000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="icc88fe00a2b34650ba8c22e3a5248c9a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDYxNQ_7434ee33-ba83-42cf-b9a0-e3049244e270"
      unitRef="usd">4103000</us-gaap:InterestPaid>
    <us-gaap:InterestCostsCapitalized
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDYyNw_2aef9d37-3777-4587-8890-3fa80412ac30"
      unitRef="usd">6155000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDY0NQ_90cd61ae-c781-47e2-bc84-726728d90886"
      unitRef="usd">4277000</us-gaap:InterestCostsCapitalized>
    <us-gaap:AccumulatedCapitalizedInterestCosts
      contextRef="i20c791c3ff7e418ab95668e32cc7a1ec_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgzMjY0Mg_3e87801a-5e13-4c7d-9358-ffe04f136f83"
      unitRef="usd">11429000</us-gaap:AccumulatedCapitalizedInterestCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ia2d1964162f34aa9aff7b7bf6ccd1778_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzI0MTA_b53175ab-4aa5-42cd-b427-afa50ff268c5"
      unitRef="usd">3500000</us-gaap:WarrantsAndRightsOutstanding>
    <axgn:PurchasePriceOfCommonStockCalculationPeriod
      contextRef="i271d865b318a4f69926f6640eb4178a3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzk1Mjg_345625bc-e42e-4059-ae89-8c26cef3699d">P45D</axgn:PurchasePriceOfCommonStockCalculationPeriod>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i32bc87a417ec436cbde425177f4f1fca_I20201210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzI5NTY_c6ae716d-90a8-4aed-bc4b-40ced0464d7c"
      unitRef="usdPerShare">14.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i7229d1ab938d4b54a5c614ac06b82ab4_D20201210-20201210"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzMwMDY_9a8e0fac-2d39-43e2-a64f-aa642a37ff6d"
      unitRef="usd">3500000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i232073fcc6e04d25aa02ac11cc331bfc_I20201210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzMwMjk_b765c184-5eab-456a-9ff1-c5af65f447ae"
      unitRef="shares">247699</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <axgn:DebtInstrumentMinimumRequiredInternalRateOfReturn
      contextRef="i18a440d8b8744e8f9a6b185b93f909de_I20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzQ2Mjk_9cbe7eeb-4b3c-4dae-9a77-e95665ca20e2"
      unitRef="number">0.115</axgn:DebtInstrumentMinimumRequiredInternalRateOfReturn>
    <axgn:DebtInstrumentInterestRateEventOfDefaultIncrease
      contextRef="i18a440d8b8744e8f9a6b185b93f909de_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzQ5MDc_949676b9-251e-4211-8e5c-f255342c3e3e"
      unitRef="number">0.04</axgn:DebtInstrumentInterestRateEventOfDefaultIncrease>
    <us-gaap:DerivativeLiabilities
      contextRef="i443dfc9e27ca43fa95f569f05a0bbe28_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzcyMTk_9944c825-7fbe-455b-80ac-43301f036306"
      unitRef="usd">2387000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1655c65194084245be81921c34c77204_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDY2OQ_3868eebb-2c71-4e2f-94fb-665b23f30ecf"
      unitRef="usd">1961000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2861cc9701fe4e06bbe34f3f481d4cbb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDY1Mw_dae62985-26c9-467d-b482-b2f5fb6f7d93"
      unitRef="usd">1076000</us-gaap:DerivativeLiabilities>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i18a440d8b8744e8f9a6b185b93f909de_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNzQ4NQ_7ed47f01-df94-4f8b-88b1-d176fcc9c474"
      unitRef="usd">642000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyODAzNw_cf0de251-7e1b-4d33-8ed0-bc7c906fc9c9"
      unitRef="usd">891000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyODA0MQ_258917a1-9d21-44b3-9b7b-efced9205a4c"
      unitRef="usd">831000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyODIyNA_c5d0c0d1-969c-4c8d-9226-d9c8ebe63fe4"
      unitRef="usd">232000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:RestrictedCash
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzkyMzU_85c30433-a133-4797-8043-49db86a72679"
      unitRef="usd">6251000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzU0OTc1NTgyNDUwMg_ed397614-46f7-4dcc-a28f-82457df6c72d"
      unitRef="usd">6251000</us-gaap:RestrictedCash>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="i8a546ce46a914aa785e30fa74d23ae15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzkzMDk_127d150a-d056-4cd0-a3d1-25a5fd02fd2e"
      unitRef="usd">6000000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="i6eb9268062cf4f6cbb9c740dbb809cea_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3XzkzMDk_c995e120-9f53-4b2a-b013-5fffda4c2d2a"
      unitRef="usd">6000000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="i2bda4fe5ea904b66952845b8d764cf1b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjEvZnJhZzphYmRiOTNhZjc5ZjE0YzJjYmNhMzcwY2RiNzY1Y2ZhNy90ZXh0cmVnaW9uOmFiZGI5M2FmNzlmMTRjMmNiY2EzNzBjZGI3NjVjZmE3Xzk1MjM_3f63c8a0-48f9-41cb-a243-6bfa524b2358"
      unitRef="usd">250000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90ZXh0cmVnaW9uOjRjNjg0MjhlOTc2YzQ0NjM4NjA1NTIxMTc3ZGNjZDVjXzcxNDY4MjU1ODIwMTE_77482fbb-6e68-4c72-953d-93b5e66f8b08">Basic and Diluted Loss per Common Share&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two-class method as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Weighted-average common shares outstanding (Basic)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,083,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,214,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,966,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding (Diluted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,083,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,214,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,966,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss per common share (Basic and Diluted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Anti-dilutive shares excluded from the calculation of diluted earnings per share &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,133,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,364,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,618,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;454,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; These common equivalent shares are not included in the diluted per share calculations as they would be anti-dilutive if the Company was in a net income position.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90ZXh0cmVnaW9uOjRjNjg0MjhlOTc2YzQ0NjM4NjA1NTIxMTc3ZGNjZDVjXzcxNDY4MjU1ODIwMTM_f20f5aa1-5059-497b-9a33-b849e9624cc7">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following reflects the net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two-class method as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Weighted-average common shares outstanding (Basic)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,083,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,214,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,966,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding (Diluted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,083,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,214,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,966,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss per common share (Basic and Diluted)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Anti-dilutive shares excluded from the calculation of diluted earnings per share &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,133,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,364,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,618,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;454,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; These common equivalent shares are not included in the diluted per share calculations as they would be anti-dilutive if the Company was in a net income position.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzMtMi0xLTEtMTA1OTQ3_a80f770a-bc04-495d-8d35-8047859901b4"
      unitRef="usd">-28948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzMtNC0xLTEtMTA1OTQ3_07326441-74f6-45d2-ad5d-c1b3b1f76c2a"
      unitRef="usd">-26985000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzMtNi0xLTEtMTEyMTMw_f7d02799-eb65-49ea-b948-669fa3230e59"
      unitRef="usd">-23786000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtMi0xLTEtMTA1OTQ3_2d448aa0-8bbf-4519-be72-34d2e6721c48"
      unitRef="shares">42083125</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtMi0xLTEtMTA1OTQ3_513e9d47-1a2b-4b26-b372-21e6bb23e38d"
      unitRef="shares">42083125</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtMi0xLTEtMTA1OTQ3_84179dbf-4da7-4e7f-b270-4d8a281f5bd1"
      unitRef="shares">42083125</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtMi0xLTEtMTA1OTQ3_b055903e-52ce-4473-9a18-8fcb0276264d"
      unitRef="shares">42083125</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtNC0xLTEtMTA1OTQ3_0f98db8a-b32b-454d-97c0-899d0c733c75"
      unitRef="shares">41214889</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtNC0xLTEtMTA1OTQ3_e121a3d8-aaa8-4c90-b193-7140b912bed9"
      unitRef="shares">41214889</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtNi0xLTEtMTEyMTcx_385258be-71be-442a-ae66-afba20e3ad90"
      unitRef="shares">39966937</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzUtNi0xLTEtMTEyMTcx_a62741fb-290a-4852-a606-4d2c92e16914"
      unitRef="shares">39966937</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzYtMi0xLTEtMTA1OTQ3_18d93ce1-4fde-4a85-bea7-2e892f96b064"
      unitRef="shares">42083125</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzYtNC0xLTEtMTA1OTQ3_62fd2e09-725a-49ea-bc76-5802ef2862da"
      unitRef="shares">41214889</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzYtNi0xLTEtMTEyMTc5_358bb6f6-c305-4e3c-9388-f8d9a7b84f24"
      unitRef="shares">39966937</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctMi0xLTEtMTA1OTQ3_cbd0789b-9163-4653-96b0-af345323b1be"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctMi0xLTEtMTA1OTQ3_ccb9521c-9d44-45a8-841c-c15a24420787"
      unitRef="usdPerShare">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctNC0xLTEtMTA1OTQ3_441486ef-7d48-4599-acf7-75116327194d"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctNC0xLTEtMTA1OTQ3_e216db2e-6ed3-4003-bd8b-ab7b6029a076"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctNi0xLTEtMTEyMjI3_3b14e3c3-2fc4-44ef-837a-b981c55f419f"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzctNi0xLTEtMTEyMjI3_ff9db9ed-4c11-40d9-937d-842dfe5958a2"
      unitRef="usdPerShare">-0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie6204757bdfb4234845eb99fcc2f5bde_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzEwLTItMS0xLTEwNTk0Nw_baed45ce-9ed8-458e-ab5b-661483bee045"
      unitRef="shares">3133865</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib00632d9ac6845ff94f04e3e98489229_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzEwLTQtMS0xLTEwNTk0Nw_90de40af-bcb1-425d-bdab-1e3caf422c3c"
      unitRef="shares">1364567</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i88b8752e11b545e6a8bef12b17eaa002_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzEwLTYtMS0xLTExMjI3NQ_a1bee83a-ad42-4de5-8519-35f383ef8735"
      unitRef="shares">1618002</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6a16e53d518446cfbd2024ffdb8a8bf1_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzExLTItMS0xLTEwNTk0Nw_a6c52547-32d3-4f2b-8326-5d0f49fb6306"
      unitRef="shares">454430</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i36385a5cb9a84a35be78534b6035cd66_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzExLTQtMS0xLTEwNTk0Nw_9ce7e1d1-f877-4b7d-922e-0c40a022953f"
      unitRef="shares">333276</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i071fd4cf629e4e2280fd669b14f69dee_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjQvZnJhZzo0YzY4NDI4ZTk3NmM0NDYzODYwNTUyMTE3N2RjY2Q1Yy90YWJsZTowZjdhNjE1YWQxYTg0NmQ4YThhYzc3YjVkYzIxMzllNC90YWJsZXJhbmdlOjBmN2E2MTVhZDFhODQ2ZDhhOGFjNzdiNWRjMjEzOWU0XzExLTYtMS0xLTExMjI4Mw_edb9713f-593c-4a94-863e-98c3c4df00cb"
      unitRef="shares">188321</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzODU_caf72d51-2618-4168-b51d-000cc4b36979">Stock-Based Compensation &lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains two stock-based incentive plans: the Axogen, Inc. 2019 Amended and Restated Long-Term Incentive Plan, as amended ("2019 Plan") approved by shareholders on May 25, 2022, which provides incentives through the grants of stock options, non-qualified stock options, PSUs and RSUs to employees, directors, and consultants which replaced the Company's 2010 Stock Incentive Plan ("2010 Plan") and the Axogen 2017 Employee Stock Purchase Plan (&#x201c;2017 ESPP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the May 25, 2022, Annual Shareholder Meeting, approval was received to increase the number of shares available under the 2019 Plan by 2,500,000 to 8,000,000. The 2019 Plan replaced the 2010 Plan, accordingly, no new grants have been issued under the 2010 Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there were 3,374,881 shares of common stock for future grant under the 2019 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is included in the following line items in the accompanying consolidated statements of operations for the years ended:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Costs of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total  stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The options granted to employees prior to July 1, 2017, typically vest 25% one year after the grant date and 12.5% every six months thereafter for the remaining three-year period until fully vested after four years. The options granted to employees after July 1, 2017, typically vest 50% two years after the grant date and 12.5% every six months thereafter for the remaining two-year period until fully vested after four years. The options granted to directors and certain options granted from time to time to certain executive officers have vested ratably over three years or 25% per quarter over one year. Options typically have terms ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI3NjM_61ba867c-4dd3-4803-a6a5-10aa309ff564"&gt;seven&lt;/span&gt; to ten years. The Company estimates the fair value of each option award on the date of grant using a multiple-point Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company&#x2019;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur. The value of the portion of the award that is ultimately expected to vest is recognized as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expense over the requisite service periods in the Company&#x2019;s consolidated statements of operations. The expense has been reduced for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average assumptions were used in the calculation of fair value for stock options granted for the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:0pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's stock option activity for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value              (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,194,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,228,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(267,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(260,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,894,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,034,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of stock options granted during the years ended December&#160;31, 2022, 2021 and 2020 was $4.65, $10.53, $4.73, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised for the years ended December&#160;31, 2022, 2021 and 2020 was $2,643, $14,167 and $5,595, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was approximately $6,839 of total unrecognized compensation costs related to unvested stock options. These costs are expected to be recognized over a weighted-average period of 2.4 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted to employees have a requisite service period of four years. The RSUs granted to directors and certain RSUs granted from time to time to certain executive officers have a requisite service period of three years, while certain of these RSUs have a requisite service period of one year. The Company expenses the fair value of RSUs on a straight-line basis over the requisite service period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for restricted stock units for the indicated periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding Restricted and Performance Stock Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Fair Value at Date of Grant per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Vesting Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;967,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(265,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(254,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,861,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of restricted stock units granted during the years ended December&#160;31, 2022, 2021 and 2020 was $8.40, $20.13, $9.55, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was approximately $13,756 of total unrecognized compensation costs related to unvested restricted stock. These costs are expected to be recognized over a weighted-average period of 2.74 years. The total fair market value of restricted stock vested during the years ended December&#160;31, 2022, 2021 and 2020 was $2,288, $2,179 and $2,699, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Performance Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of the PSUs based on its closing stock price at the time of grant and its estimate of achieving such performance target and records compensation expense as the milestones are achieved. PSUs generally have a requisite service period of three years and are subject to graded vesting conditions based on revenue goals of the Company. The Company expenses their fair value over the requisite service period. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense will be adjusted based upon the Company&#x2019;s estimate of achieving such performance target. The number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on the actual performance metrics as set forth in the applicable PSU award agreement. The amount actually awarded will be based upon achievement of the performance measures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for performance stock units for the indicated periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding Restricted and Performance Stock Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Fair Value at Date of Grant per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Vesting Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;763,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;530,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of performance stock units during the years ended December&#160;31, 2022, 2021 and 2020 was $8.23, $20.70 and $9.58, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was approximately $1,723 of total unrecognized compensation costs related to unvested performance stock. These costs are expected to be recognized over a weighted-average period of 1.86 years. The total fair market value of performance stock vested during the years ended December&#160;31, 2022, 2021 and 2020 was $673, $2,302 and $1,112, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PSU Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 18, 2017, December 27, 2018, and December 17, 2019, the Compensation Committee of the Board of Directors approved PSU awards to certain employees related to their work on the Company&#x2019;s Biologics License Application &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("BLA"). As of December&#160;31, 2022, 294,968 PSU awards were available to vest. The number of shares is allocated to certain milestones related to the BLA submission to and approval by the FDA. These awards are expected to vest beginning when the BLA is submitted to the FDA, which is not expected to be until the second half of 2023. The performance measure is based upon achieving each of the specific milestones and will vest 50% upon achieving each of the milestones and 50% one year later. No expense has been recognized on these awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 17, 2020, the Compensation Committee of the Board of Directors approved PSU awards of 144,300 shares tied to 2020 revenue. These awards were granted in mid-year with certain revenue targets adjusted for the impact of COVID-19. These 2020 awards granted in July reached 110% achievement of revenue targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 16, 2021, the Compensation Committee of the Board of Directors approved PSU awards of 332,200 shares tied to 2022 revenue, with a payout ranging from 0% to 200% upon achievement of specific revenue goals. In the fourth quarter of 2021, it was determined that the performance metrics tied to 2022 revenue were no longer probable; therefore, stock compensation expense related to these awards of $1,831 was reversed in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 16, 2022, the Compensation Committee of the Board of Directors approved PSU awards of 526,467 shares tied to revenue from 2022 to 2024 with a pay-out range from 0% to 150% upon achievement of specific revenue targets.At December&#160;31, 2022, the total future stock compensation expense related to non-vested performance awards is expected to be $1,693 for those awards issued on March 16, 2022. Future stock compensation expense has not been calculated on the awards for which expensing has not yet begun which include the BLA awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2017 ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2017 ESPP allows eligible employees to acquire shares of the Company's common stock through payroll deductions at a discount to market price (currently 15.0%) of the lesser of the closing price of the Company&#x2019;s common stock on the first day or last day of the offering period. The offering period is currently 6 months. Participants may not purchase more than $25 or 3,000 shares of the Company&#x2019;s common stock in a calendar year through the ESPP. Stock-based compensation expense related to the 2017 ESPP, included in total stock-based compensation expense, was $844, $401 and $493 for the years ended December&#160;31, 2022, 2021 and 2020, respectively. As of December&#160;31, 2022, there were 600,000 shares of the Company's common stock authorized for issuance under the 2017 ESPP and 69,155 shares remain available for issuance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the weighted average assumptions used in the valuation of ESPP options for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted-average grant-date fair value of ESPP options during the years ended December&#160;31, 2022, 2021 and 2020 was $2.87, $5.18, $5.24 respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <axgn:ShareBasePaymentArrangementNumberOfPlans
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzYw_0e18381f-e388-4165-b14d-ed51512e4ab3"
      unitRef="plan">2</axgn:ShareBasePaymentArrangementNumberOfPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="if01e2ccdaa54461098fe9e12370e82c8_D20220525-20220525"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0Mjc2NQ_72f676e0-dce1-401d-b75d-3725d1ad59d5"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i1901933b221a4b9b954c7479477f3e4b_I20220525"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NTE4Mw_fd713148-b54b-404b-b390-61ec9064804b"
      unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i23829077b773438fa1c9f990db81d62a_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NTY3OA_19506bdc-175c-444e-ada2-2089f51c3795"
      unitRef="shares">3374881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzcxNDY4MjU2MDQ3NTA_2a4518d0-7389-4fa6-9114-7e38f0b62e19">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is included in the following line items in the accompanying consolidated statements of operations for the years ended:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Costs of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total  stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6ea41484f76d414e87f57fe619eda0d3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzItMi0xLTEtMTEzNTIy_6c87c499-e7d3-4611-9cea-e3ec4d8f0dc1"
      unitRef="usd">215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i265deb6981db4caba802dff7098eaf78_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzItNC0xLTEtMTEzNTIy_c2a05b42-bfac-466a-b634-87c365afc1eb"
      unitRef="usd">157000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia017b12b6e4844b9ad5921672e3ad683_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzItNi0xLTEtMTEzNTIy_69d7ba6a-9d2f-44f6-b08c-e59d3a6175ae"
      unitRef="usd">167000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic382dfac5eb34387894011ca21faacb1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzMtMi0xLTEtMTEzNTIy_d08dcf52-cc5b-4300-aeff-ac5dc552c0b8"
      unitRef="usd">2341000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8a5e8c7dd95f4725be7b20b882541185_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzMtNC0xLTEtMTEzNTIy_27d07a8d-9222-4831-b421-fef2af3a8aa9"
      unitRef="usd">2905000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iad06ab740e97428ab5fa032137f4d319_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzMtNi0xLTEtMTEzNTIy_3fa88b40-0aa8-446f-ad47-fdbb0d78a2ad"
      unitRef="usd">2585000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i353c868d857d4f78b75da6d08d6f5ce8_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzQtMi0xLTEtMTEzNTIy_cb0cd594-ce39-4207-b074-7496ca52b463"
      unitRef="usd">2640000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i82f76c354583477ba3582208c4de3e9f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzQtNC0xLTEtMTEzNTIy_b1f57b77-154a-4f1a-9641-5ef188fb2d33"
      unitRef="usd">1923000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i906644212cb044e79417f0990512be9f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzQtNi0xLTEtMTEzNTIy_fecfbccd-0664-44ba-b2b2-1eef970b81f0"
      unitRef="usd">1376000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib865e7888f5b433f95e77cfab871debf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzUtMi0xLTEtMTEzNTIy_d353ab87-7dbf-435b-820e-566418b3b804"
      unitRef="usd">10395000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9648970fef2d49fbbf69cb19fe670983_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzUtNC0xLTEtMTEzNTIy_505a9ff3-27cb-442e-a585-d93680d6fb32"
      unitRef="usd">5934000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia7956fd5c1234348844e780e82ebc0c1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzUtNi0xLTEtMTEzNTIy_90b93401-dd94-43d4-b8b7-2e7fc25fb6c0"
      unitRef="usd">4341000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib744e6a9173947e59255d4550e92de8b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzYtMi0xLTEtMTEzNTIy_89aee083-8160-403e-83b3-08f614d07150"
      unitRef="usd">15591000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee39cce463fb44d0a4bfe365b6681f5d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzYtNC0xLTEtMTEzNTIy_881da139-e3c5-4b6c-8fa8-1cef3b9c5f93"
      unitRef="usd">10919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i09c0b507e033470891c7ca7da0c6882b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTplODEwODhiMWQ3NDI0YjlkYTQwZTc0NGU2M2ZkZTFmZi90YWJsZXJhbmdlOmU4MTA4OGIxZDc0MjRiOWRhNDBlNzQ0ZTYzZmRlMWZmXzYtNi0xLTEtMTEzNTIy_a74877b8-5f0d-4aab-8e6f-ba2e6d5ba047"
      unitRef="usd">8470000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i9aca85efc69240e1a769914f9dcb9319_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzIyNDI_e35a5a33-dbff-47fe-9823-584b1355fd81"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9aca85efc69240e1a769914f9dcb9319_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzIyNDU_a445d788-4868-4de5-b7d4-4cc9c1edd18b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i2ec881302ae14b18b7a4033a56f38e41_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzIyNzM_b0746739-398e-4db3-a408-cb54032694be"
      unitRef="number">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2ec881302ae14b18b7a4033a56f38e41_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzODM_26bcee2d-8fb4-4406-b6eb-b421e83b240b">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia801c2b2298a45dd968f3bc35b69132c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzIzNjI_4fabd0ee-3fed-4da1-8537-b91793e4fead">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iab23cd73c6404992b546cccab3d848b9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI0MzM_abbd4fef-343d-4f33-a301-8cd654caea55"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iab23cd73c6404992b546cccab3d848b9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI0MzY_d00087d3-bd5f-4900-a667-6ab65ccf7388">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i8d35f388c73c4c55b667458fd456bb77_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI0NjQ_3a2e16ef-e0d1-40b5-a068-628f33ca3080"
      unitRef="number">0.125</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8d35f388c73c4c55b667458fd456bb77_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzODg_ad825771-7592-441b-a6b4-50573e512948">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie8fe5d68d40444db8d1a38fee238b7a9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI1NTM_81ed86ea-f5c7-45d4-af95-fd46b568b54a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0212c0badd7b46908abba199f97a351e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI2OTE_f17252cc-a88f-4b0e-8531-a614c7e3e28b">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i5e80010008dd494aa1fc37d1fd76468b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI2OTc_a8e163a2-b2c9-43f9-bbbe-1e07e080621e"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5e80010008dd494aa1fc37d1fd76468b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI3MTc_5fd5b7ba-ceea-44d4-8fcc-385c9b9b3a7d">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic0b94c6006f54a3db47bc4394457d1e3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzI3Njk_e9dc7e22-0299-473d-a7e9-c0a7ee7b88ff">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzcxNDY4MjU2MDQ3NTI_fcdc4fdd-7102-4bf7-947a-134e15fa1379">&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following weighted-average assumptions were used in the calculation of fair value for stock options granted for the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:0pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;61.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the weighted average assumptions used in the valuation of ESPP options for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.711%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzMtMi0xLTEtMTEyNDM1_4391b5ea-963f-4940-89c3-9db0fab1d7fc">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzMtNC0xLTEtMTEyNDM1_d6f03cef-ecae-425b-8378-6bec3c6d68a9">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzMtNi0xLTEtMTEyNDM1_17eaf099-b030-4e86-a292-9a9555b505e4">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzQtMi0xLTEtMTEyNDM1_3ed77748-4f1f-4d06-998c-0c7f227c631e"
      unitRef="number">0.6117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzQtNC0xLTEtMTEyNDM1_768737f6-b8a0-4633-aa14-b96a77793714"
      unitRef="number">0.5838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzQtNi0xLTEtMTEyNDM1_7bf895d9-ebe2-4c2c-8d25-916ae550c043"
      unitRef="number">0.5846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzUtMi0xLTEtMTEyNDM1_c311bd87-ef8b-425c-82b6-7800eb739654"
      unitRef="number">0.0231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzUtNC0xLTEtMTEyNDM1_915d7f37-e1a2-47c8-8f93-867dc0c95376"
      unitRef="number">0.0102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzUtNi0xLTEtMTEyNDM1_7ff6c3be-4af2-4f63-8231-5a62f2c5b3f5"
      unitRef="number">0.0049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzYtMi0xLTEtMTEyNDM1_7232c9b4-c35a-4316-b22c-a00f2c747d6d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzYtNC0xLTEtMTEyNDM1_d69b981f-988c-485a-9cef-dedc212d4e28"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo4ZmU5ZDA1Y2E0NjE0ZTMyYWQ4MGU3NDg1MmY2NmEyNC90YWJsZXJhbmdlOjhmZTlkMDVjYTQ2MTRlMzJhZDgwZTc0ODUyZjY2YTI0XzYtNi0xLTEtMTEyNDM1_d24ad8b3-6cb1-4a8b-a7f7-af9ce96d16a7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzODQ_03e9a32d-9a6d-4310-8f5a-0ae430e3d203">&lt;div style="margin-top:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's stock option activity for the year ended December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value              (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,194,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,228,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(267,839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(260,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,894,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,034,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic51b16331d104e7e8fdcef21b100803f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzUtMS0xLTEtMTAyNDMx_fd798028-ba29-4ce4-bcce-fbf2da7a46ad"
      unitRef="shares">3194738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic51b16331d104e7e8fdcef21b100803f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzUtMy0xLTEtMTAyNDMx_f011fb51-741e-43d7-ac2a-57a97e9b5a3c"
      unitRef="usdPerShare">15.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzUtNS0xLTEtMTAyNDMx_72c3bb45-d503-4fcc-a6ef-fc031ee31ee4">P6Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic51b16331d104e7e8fdcef21b100803f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzUtNy0xLTEtMTAyNDMx_b2d8bbfe-e211-4fda-b33f-1d919e2589ca"
      unitRef="usd">2236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzYtMS0xLTEtMTAyNDMx_cf77a471-417e-4bb1-974b-306a28efee2b"
      unitRef="shares">1228920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzYtMy0xLTEtMTAyNDMx_e469e27d-f573-4f49-aa6b-716b1c9456c0"
      unitRef="usdPerShare">9.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzctMS0xLTEtMTAyNDMx_e174c496-6353-48e8-85c8-cb3f21b3b5f9"
      unitRef="shares">267839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzctMy0xLTEtMTAyNDMx_5355195a-06f9-4dd0-8d10-29eb6b7f641c"
      unitRef="usdPerShare">14.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzgtMS0xLTEtMTAyNDMx_5408342f-0859-41d1-adc1-faec80abb6d3"
      unitRef="shares">260963</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzgtMy0xLTEtMTAyNDMx_8df062d8-cfe3-4fa2-b20b-e29b95082dd4"
      unitRef="usdPerShare">4.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id192a5d2ca61416498fadecd34072e03_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzktMS0xLTEtMTAyNDMx_1827f4b0-db2b-4a15-8dd3-ed7dff0d28cf"
      unitRef="shares">3894856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id192a5d2ca61416498fadecd34072e03_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzktMy0xLTEtMTAyNDMx_8719ee42-8746-4fa9-8faf-26d3b89e3002"
      unitRef="usdPerShare">14.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzktNS0xLTEtMTAyNDMx_aac64738-9737-43dd-9c34-f10ee83c2ba4">P6Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id192a5d2ca61416498fadecd34072e03_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzktNy0xLTEtMTAyNDMx_7c8b45da-2c7b-4d9b-8378-f7234b893e29"
      unitRef="usd">2783000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id192a5d2ca61416498fadecd34072e03_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzExLTEtMS0xLTEwMjQzMQ_89640a08-f726-451f-acde-452bbaed11ae"
      unitRef="shares">2034249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id192a5d2ca61416498fadecd34072e03_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzExLTMtMS0xLTEwMjQzMQ_abacf09b-f1cd-40a0-90f2-9dc859e6308c"
      unitRef="usdPerShare">16.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzExLTUtMS0xLTEwMjQzMQ_7d6f42af-400e-4793-8951-2359ff4dc610">P4Y11M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="id192a5d2ca61416498fadecd34072e03_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToyNGNjYzhmNTA3OGU0MzAxOGViMjFiMTUzZTExMWEzMC90YWJsZXJhbmdlOjI0Y2NjOGY1MDc4ZTQzMDE4ZWIyMWIxNTNlMTExYTMwXzExLTctMS0xLTEwMjQzMQ_27216d46-6868-4b88-8780-8db53a39d7f3"
      unitRef="usd">1462000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzEwOTk1MTE2NjA4NDg_a8c055ce-fbf4-492a-814b-0090e6767d86"
      unitRef="usdPerShare">4.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0556229d48e6417190b02c8bbd3a23ba_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzEwOTk1MTE2NjA4OTA_9927ff77-b8cc-459e-8540-7dcb76d314a8"
      unitRef="usdPerShare">10.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i82750687e0d54f7bb282bcc075267f29_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzEwOTk1MTE2NjA4OTM_b2ef5544-ba46-4b85-bd78-102a5f5780e3"
      unitRef="usdPerShare">4.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDM0Nw_7a97a95a-e2ca-4f6d-92c4-4c70c03c63fb"
      unitRef="usd">2643000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDM1Mg_eb178971-ea98-4bf8-b3be-081bb72d6c44"
      unitRef="usd">14167000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDM2MA_110cfe2c-521e-4eb8-9a52-bede2e8d5d6c"
      unitRef="usd">5595000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id192a5d2ca61416498fadecd34072e03_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDIzNQ_ef96b089-72bb-406b-b978-999d49f906b9"
      unitRef="usd">6839000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDI0NQ_dfca83f9-0931-4f7b-82bf-32c3713dd336">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzcxNDY4MjU1ODk5ODM_345caf88-7d92-471a-b62a-5dcec8d892ed">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id1e45b0b246b467fbbfb1b6cd29a64b4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzM2Nzk_cc4585dc-3564-4d1f-bce2-4b4cdc75617a">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i42d9032ded3e403885f2e9975a16f6ba_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzM3NDY_dc1d90f4-e2d1-45c1-8b95-46bb65dc59b4">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzODY_a891e6e1-d18a-4d7b-9552-8c76b070e0ca">The following table summarizes the activity for restricted stock units for the indicated periods:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding Restricted and Performance Stock Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Fair Value at Date of Grant per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Vesting Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;967,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(265,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(254,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,861,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity for performance stock units for the indicated periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding Restricted and Performance Stock Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Fair Value at Date of Grant per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Vesting Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;763,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;530,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77,671)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,112,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id91fc5c40e6640dda04b21132c42f27c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzYtMS0xLTEtMTAyNDMx_394efc51-4b45-4816-933a-0eeb59b32b3e"
      unitRef="shares">967068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id91fc5c40e6640dda04b21132c42f27c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzYtMy0xLTEtMTAyNDMx_16a4eb0c-526c-4164-909a-903d86a742f9"
      unitRef="usdPerShare">16.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i4666913c7daa474b8bbb30f0335d78a8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzYtNS0xLTEtMTAyNDMx_bfe06336-8e8d-4847-a785-a0d13aaf6b2f">P1Y5M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="id91fc5c40e6640dda04b21132c42f27c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzYtNy0xLTEtMTAyNDMx_dae9d092-55a4-498a-9dd9-a7746dc4d41c"
      unitRef="usd">9061000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzctMS0xLTEtMTAyNDMx_c9260d81-c8b9-4345-8ce1-7a54fd2f89bd"
      unitRef="shares">1413755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzctMy0xLTEtMTAyNDMx_aec53efc-02cf-4d24-9ad2-ebda88f91bab"
      unitRef="usdPerShare">8.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzgtMS0xLTEtMTAyNDMx_421a3a87-f912-458b-94bc-55bbae1a5732"
      unitRef="shares">265420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzgtMy0xLTEtMTAyNDMx_0f00569a-b7f0-48f8-80e0-2ea7e316381b"
      unitRef="usdPerShare">13.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzktMS0xLTEtMTAyNDMx_90a332c2-36d1-4710-bdee-d68388bd7b39"
      unitRef="shares">254297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzktMy0xLTEtMTAyNDMx_51f09a7d-3c61-42cb-ae49-eea2531f48df"
      unitRef="usdPerShare">12.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia34eb80cba6046728fa5e0562af47d00_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzEwLTEtMS0xLTEwMjQzMQ_ad4237e1-8cbb-4ad2-8fc6-c41107c08335"
      unitRef="shares">1861106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia34eb80cba6046728fa5e0562af47d00_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzEwLTMtMS0xLTEwMjQzMQ_a93f9305-bc43-4f60-8bbc-e6961aed0f4e"
      unitRef="usdPerShare">11.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzEwLTUtMS0xLTEwMjQzMQ_57ee8c8c-a202-49d6-b4ed-bd29fb262001">P1Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="ia34eb80cba6046728fa5e0562af47d00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo0MzZmMzcyZmRlZDQ0YTljYjE0NGY5NGIxZjhmZmNjZC90YWJsZXJhbmdlOjQzNmYzNzJmZGVkNDRhOWNiMTQ0Zjk0YjFmOGZmY2NkXzEwLTctMS0xLTEwMjQzMQ_bb328ab9-b8e1-4f2e-bff3-7f7dde5c5fe8"
      unitRef="usd">18574000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ2OA_e20e559d-e9e6-47c5-ad53-0c7cd2bb69d3"
      unitRef="usdPerShare">8.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4666913c7daa474b8bbb30f0335d78a8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ3Mg_71c77f68-7852-4eee-a007-a3029aac5d1f"
      unitRef="usdPerShare">20.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i36f58e081cfe4d2ba7361775fbbb25d5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ4Mg_46bb9d67-c5cc-43de-823f-7e603d3fe89a"
      unitRef="usdPerShare">9.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia34eb80cba6046728fa5e0562af47d00_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDkyOA_159f6c14-9849-45b7-9e0e-579ca76c1c27"
      unitRef="usd">13756000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNDkzMg_bfbe706d-5f6d-4ab9-8d41-2c953de4f52b">P2Y8M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjExMQ_c400c10b-d0b7-4cf7-a397-20a3d6ff467d"
      unitRef="usd">2288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i4666913c7daa474b8bbb30f0335d78a8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjExNg_17a3ba49-d611-4f4b-8de6-f30c13ef3a82"
      unitRef="usd">2179000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i36f58e081cfe4d2ba7361775fbbb25d5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjUwNQ_35247e57-5c0e-425d-bc97-646c784c8ab0"
      unitRef="usd">2699000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzQ1MTg_69916784-5360-4e97-8820-fbfe40781731">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icd0c5b69b5984bf8bec833a99943f9a5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzItMS0xLTEtMTE0MjIz_a2486409-919b-4862-b516-4f5b0aa34753"
      unitRef="shares">763697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="icd0c5b69b5984bf8bec833a99943f9a5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzItMy0xLTEtMTE0MjI5_37189a3b-9a5d-4136-8c41-57c775e1251d"
      unitRef="usdPerShare">21.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ie11aa559ad27461e8d53d7d3e811e707_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzItNS0xLTEtMTE0MjM3_e9ddfbbe-3f83-4dbd-b22e-061fd04bbb08">P2Y4M9D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="icd0c5b69b5984bf8bec833a99943f9a5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzItNy0xLTEtMTE0MjQz_94acd830-fd43-4888-b6d8-97bfe4a2a0ef"
      unitRef="usd">7156000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzMtMS0xLTEtMTE0MjIz_2ebdbc97-670b-4a51-b9aa-458ef9f2400d"
      unitRef="shares">530983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzMtMy0xLTEtMTE0MjI5_9602602d-18b7-49bc-b1b0-a98ec488bc9e"
      unitRef="usdPerShare">8.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzQtMS0xLTEtMTE0MjIz_b9014000-4572-4144-8027-c063f965959d"
      unitRef="shares">77671</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzQtMy0xLTEtMTE0MjI5_455418f4-78d9-418d-9032-d348a31edb20"
      unitRef="usdPerShare">18.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzUtMS0xLTEtMTE0MjIz_923a86da-c0f4-4fac-b139-34ec7ffdc6c6"
      unitRef="shares">104978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzUtMy0xLTEtMTE0MjI5_f362af69-e0fc-4349-9320-0c6dba6e5c3a"
      unitRef="usdPerShare">16.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i59a311c65bd9478aab63c3835e9f72d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzYtMS0xLTEtMTE0MjIz_080e09df-b9da-44cd-a79d-5c1f0a10ce2a"
      unitRef="shares">1112031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i59a311c65bd9478aab63c3835e9f72d2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzYtMy0xLTEtMTE0MjI5_a4e87ae7-2f2e-4e78-addd-fbe5abd45471"
      unitRef="usdPerShare">15.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzYtNS0xLTEtMTE0MjM3_1eabf1b1-8bca-4099-9107-ea630e72d5ae">P1Y10M9D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i59a311c65bd9478aab63c3835e9f72d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZTo1NjUzOTE1NTQ4MGY0ZTFiYWQwYjM2YmRkMzI4ZThmNC90YWJsZXJhbmdlOjU2NTM5MTU1NDgwZjRlMWJhZDBiMzZiZGQzMjhlOGY0XzYtNy0xLTEtMTE0MjQz_88c3b532-28cb-42f7-a88b-68f7763827e9"
      unitRef="usd">11098000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjMxMg_c0200d81-38fc-47e2-8bd0-f70342560a8b"
      unitRef="usdPerShare">8.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie11aa559ad27461e8d53d7d3e811e707_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ2MQ_595080ec-cae7-4d4c-bf2e-14ee975764fe"
      unitRef="usdPerShare">20.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id7b8b79e630c433d9fdf51406b61b52d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ2NA_03effe25-d863-4c00-886b-202e8732adfc"
      unitRef="usdPerShare">9.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i59a311c65bd9478aab63c3835e9f72d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNTYwMw_45109cbb-6d04-452c-aea7-942cc07a8610"
      unitRef="usd">1723000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNTYwNg_c3521ba7-1f97-4afc-96f8-2b3c78051d28">P1Y10M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iae4361a3f58144dc89e3af795773310b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ4OA_a445ca7a-b695-460c-b08d-21b8bf853841"
      unitRef="usd">673000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ie11aa559ad27461e8d53d7d3e811e707_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ5MQ_f6ba6823-2ae6-422e-bc33-9baeb21e6038"
      unitRef="usd">2302000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="id7b8b79e630c433d9fdf51406b61b52d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgzNjQ5Nw_92ea3a35-f8a9-4d49-b162-968be17b0951"
      unitRef="usd">1112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i2655caad891648a1a7b5ffeb3d3a7654_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0MzUwOA_5e9afd12-afb8-4850-bd67-60fecf1f41c8"
      unitRef="shares">294968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i86095a926657489a9c0c27cdcf148b0a_D20181227-20181227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU4OTE_02677928-a463-4cf1-bd02-7fad9064fb65"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i4efbb86d561c4296ac6a8acef41fa1c7_D20191217-20191217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU4OTE_8eb2dcb8-6432-4564-86b6-944a60a7b6d6"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i51ad0d1614e74ceda868f8561214b5ae_D20171218-20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU4OTE_9203d020-9222-4091-aaee-1b84eacf48e0"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i248e3d8e95cb446ea5448ffd760d6858_D20181227-20181227"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5MzY_120068d9-bd4e-4586-8a6c-3b85f8a05d1d"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i717731af1dc14019834ae2cebf768ac6_D20191217-20191217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5MzY_726a05dc-7d4a-4bd0-a319-d092e85075e2"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7a2ae8023341421386b40e9ae8b40f59_D20171218-20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5MzY_cf358f0d-f866-4181-81ac-0bdd0d013dfa"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i717731af1dc14019834ae2cebf768ac6_D20191217-20191217"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5Mzk_1d1851b3-a7cd-4045-a22f-68f90ebce28f">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7a2ae8023341421386b40e9ae8b40f59_D20171218-20171218"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5Mzk_3fd50f82-8dc5-465c-aba9-cc70ac5c3837">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i248e3d8e95cb446ea5448ffd760d6858_D20181227-20181227"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU5Mzk_dca8cb76-5ce7-4ead-99bd-41856488587d">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i19da80c554e84b1f87236d2a9f78dea3_I20200717"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3Xzc1ODY_ae90b4c4-7ec8-4857-aa47-97bee4f4a5fe"
      unitRef="shares">144300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <axgn:PercentageOfAchievementOfAwardIssued
      contextRef="i8234a2e85537460db0ac834d843b9f53_D20200701-20200731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3Xzc3NjQ_40b4156f-2399-407e-a286-b84b1226f118"
      unitRef="number">1.10</axgn:PercentageOfAchievementOfAwardIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia3332793e1664f34a11a863a2ac0ea63_I20210316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3Xzc4OTQ_574c759a-59e6-4025-a271-11ace65da7f7"
      unitRef="shares">332200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <axgn:PerformanceStockUnitPayoutOpportunity
      contextRef="ifeb16850541e4351bd40387578338733_D20210316-20210316"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NTY2Nw_b53e5016-5664-47ee-a633-9242a0447b6e"
      unitRef="number">0</axgn:PerformanceStockUnitPayoutOpportunity>
    <axgn:PerformanceStockUnitPayoutOpportunity
      contextRef="ib665842cd4a641bd996a4f540d05b968_D20210316-20210316"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3Xzc5NTg_bfc68709-fd63-4204-bcfe-7e67864f8afd"
      unitRef="number">2</axgn:PerformanceStockUnitPayoutOpportunity>
    <axgn:ShareBasedCompensationExpenseForfeitedOrReversed
      contextRef="id572945122984533aa8afff607ed6ec8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzgxOTQ_1c914019-7a0a-4cea-a9f4-d41ef6c021df"
      unitRef="usd">1831000</axgn:ShareBasedCompensationExpenseForfeitedOrReversed>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i2216c948174746b58affe9e729448569_I20210316"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NTQzNg_f84aebae-307b-4990-acfd-007df62dc6dc"
      unitRef="shares">526467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <axgn:PerformanceStockUnitPayoutOpportunity
      contextRef="ifc02d67a57a34782804ce01d01580755_D20220316-20220316"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzMxNzYz_233f41d1-d5a1-4abf-8b6b-295361607080"
      unitRef="number">0</axgn:PerformanceStockUnitPayoutOpportunity>
    <axgn:PerformanceStockUnitPayoutOpportunity
      contextRef="ia121473080d34c55a59059e23ecccb8d_D20220316-20220316"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NTYxNQ_59112cf3-9a31-4f37-8d7c-c141b4be0fec"
      unitRef="number">1.50</axgn:PerformanceStockUnitPayoutOpportunity>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i59a311c65bd9478aab63c3835e9f72d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzgzMjk_182c7a6e-0547-4d08-a034-f6cb2218ff69"
      unitRef="usd">1693000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <axgn:EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock
      contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjU0OQ_f05e9140-2823-4df9-ae76-335bc2d8a5ba"
      unitRef="number">0.150</axgn:EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock>
    <axgn:EmployeeStockPurchasePlanOfferingPeriod
      contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjcwNQ_500ace81-ae71-48b3-abb3-dcab09ef65d2">P6M</axgn:EmployeeStockPurchasePlanOfferingPeriod>
    <axgn:EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear
      contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjc5Ng_8fc35ed8-ad1f-48ed-b80f-27bd9e0f0092"
      unitRef="usd">25000</axgn:EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia0b64e28b97d45429f64b42130e5f1e9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzkzNDU4NDg4NjY2Mjc_cc0c747a-b704-4a10-81bb-cc705d445657"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ad8aba17c754a17ae1c1742ee8271fc_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjk2NQ_631f7563-41ca-4498-8516-5d1c867fb55d"
      unitRef="usd">844000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id23c516e6eac4ecd8e34c8640d264ee9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjk3MA_30be87d1-11ae-426c-bfa1-6f4ef25bec8f"
      unitRef="usd">401000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i961f19ca53be45ff97d7bd5885e51a53_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNjk3OA_379edf3e-7ad6-4232-b4ee-da4d1d1fdf89"
      unitRef="usd">493000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibf36782fab8f4beda0e41e2bcb53023b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNzA1Ng_acc05c68-6fee-48c0-9ed8-c64a10fed57c"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ibf36782fab8f4beda0e41e2bcb53023b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTgyNzE0NQ_82d484dd-a858-4db7-9c9e-42687198cf8e"
      unitRef="shares">69155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzMtMi0xLTEtMTEyMzc3_0f3f63e9-5eb1-43d7-a0bc-83e97259c09e">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iea37731e57ec4ce89a11a90afef95441_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzMtNC0xLTEtMTEyMzc3_cfd552c3-810b-44e5-a151-fc39cd057c95">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3e8e5bdce3b54c78ae99fb00b50a85b4_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzMtNi0xLTEtMTE0OTI4_02d8be47-e8a7-4e8f-9c42-7f91c0c4c332">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzQtMi0xLTEtMTEyMzc3_98b767bf-115e-4713-854a-b4c592af720d"
      unitRef="number">0.665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iea37731e57ec4ce89a11a90afef95441_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzQtNC0xLTEtMTEyMzc3_e1c3a723-0c66-422d-9931-50c0d8fc0683"
      unitRef="number">0.480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3e8e5bdce3b54c78ae99fb00b50a85b4_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzQtNi0xLTEtMTE0OTI4_af0c78a1-a414-4248-9e8b-aa9a10fc767a"
      unitRef="number">0.814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzUtMi0xLTEtMTEyMzc3_7be3dc15-2bc7-4866-8a91-e9911220997c"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iea37731e57ec4ce89a11a90afef95441_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzUtNC0xLTEtMTEyMzc3_a9901985-6f9c-4f76-8398-ac6b485e6234"
      unitRef="number">0.0010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3e8e5bdce3b54c78ae99fb00b50a85b4_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzUtNi0xLTEtMTE0OTI4_be948f65-f31c-427c-a768-7ec19f448460"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzYtMi0xLTEtMTEyMzc3_5ffc2116-6894-4de0-923c-3cf0384b15a7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iea37731e57ec4ce89a11a90afef95441_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzYtNC0xLTEtMTEyMzc3_b5b531ee-2fa2-4fd5-b765-c9dc938d3b47"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3e8e5bdce3b54c78ae99fb00b50a85b4_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90YWJsZToxMDVlZmEyYjU5ODI0YThjYWRmMWE4OWMyODE5NTAxOC90YWJsZXJhbmdlOjEwNWVmYTJiNTk4MjRhOGNhZGYxYTg5YzI4MTk1MDE4XzYtNi0xLTEtMTE0OTI4_6ce579d0-dcd9-4b75-982d-f4867f9eec9a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9ff1fe87cd0546b8b116eabe76752894_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzEwOTk1MTE2NjA5MDA_4423c98c-b15c-470b-a593-8d8b18847ca6"
      unitRef="usdPerShare">2.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i181cd94e7d834b44b5b5a1f041d09d44_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzEwOTk1MTE2NjA5MDQ_a5d00814-3b69-4846-858d-c3c87ebf0a45"
      unitRef="usdPerShare">5.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ieed0a63f9da94ba092fa792b834444ee_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMjcvZnJhZzpmOTUzYTViYjRkMTQ0YzA5OTk1MmMzZTQxZTFjNjk5Ny90ZXh0cmVnaW9uOmY5NTNhNWJiNGQxNDRjMDk5OTUyYzNlNDFlMWM2OTk3XzU0OTc1NTg0NzA0OA_b426fb02-6815-42b7-b458-ff59fba70814"
      unitRef="usdPerShare">5.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQ1NDE_ce468346-ef7f-4dfe-b20f-173d92e1c75a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities, as measured by enacted state and federal tax rates. Deferred tax assets and deferred tax liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charitable contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is provided to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more-likely-than-not that a portion or none of the deferred tax assets will be realized. As of December&#160;31, 2022 and 2021, management assessed the realizability of deferred tax assets. After consideration of all the evidence, including reversal of deferred tax liabilities, future taxable income and other factors, management determined that a full valuation allowance was necessary as of December&#160;31, 2022 and2021. The valuation allowance increased by $5,058 during 2022, primarily as a result of the increase in the capitalized research and development costs. The valuation allowance increased by $6,734 during 2021, primarily as a result of the increase in the net operating loss carryforward. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted Section 174 of the Tax Cuts and Jobs Act of 2017 ("TCJA") which requires taxpayers to capitalize and amortize research and development expenditures for the tax years beginning after December&#160;31, 2021. This rule became effective for the Company during 2022 and resulted in capitalized research and development costs of $6,357 being recorded to deferred tax assets as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between the financial statement income tax benefit and the income tax benefit using statutory rates is primarily due to the valuation allowance. The Company&#x2019;s effective income tax rate differs from the statutory federal income tax rate for the years ended December&#160;31, 2022, 2021, and 2020 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes - net of Federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items and other deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company had tax-effected net operating loss carryforwards of $42,716 to offset future taxable income. Net operating losses incurred in tax years beginning on or after January 1, 2018, are carried forward indefinitely. Net operating losses incurred in tax years prior to January 1, 2018, are subject to a twenty year carryforward before expiring. A portion of the net operating loss carryforwards may expire due to limitations imposed by Section 382 of the Internal Revenue Code. Future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section&#160;382 as a result of changes in ownership.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations. In the normal course of business, the Company is subject to examination by taxing authorities throughout the U.S. These examinations could include examining the timing and amount of deductions, the allocation of income among various tax jurisdictions and compliance with federal, state, and local laws. The Company&#x2019;s remaining open tax years subject to examination by federal tax authorities include the years ended December&#160;31, 2019, through 2022. The Company's remaining open tax years subject to examination by state and foreign tax authorities include the years ended December&#160;31, 2018, through 2022. However, for tax years 2004 through 2017, federal and state taxing authorities may examine and adjust loss carryforwards in the years in which those loss carryforwards are ultimately utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legislation enacted in 2018, titled the Tax Cuts and Jobs Act of 2017, subjects a U.S. shareholder to tax on global intangible low-taxed income (&#x201c;GILTI&#x201d;) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Global Intangible Low-Taxed Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to account for GILTI in the year the tax is incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no recorded income tax expense or income tax benefit for the years ended December&#160;31, 2022, 2021, and 2020 due to the generation of net operating losses, the benefits of which have been fully reserved. The Company does not believe there are any additional tax refund opportunities currently available.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQ1NDI_598b1d67-9b50-434f-bd56-e6d0c586a874">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes are accounted for using the balance sheet approach, which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities, as measured by enacted state and federal tax rates. Deferred tax assets and deferred tax liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory write-down&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charitable contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued bonus&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzItMS0xLTEtMTAyNDMx_e951dcf2-8428-4150-8653-ab1d50060a39"
      unitRef="usd">42716000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzItMy0xLTEtMTAyNDMx_ec299c50-e150-4722-b685-a85cceedd8c3"
      unitRef="usd">47049000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzMtMS0xLTEtMTAyNDMx_7d71fe4b-e06c-4719-b3e0-e709d0d9d1c5"
      unitRef="usd">503000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzMtMy0xLTEtMTAyNDMx_0b003da5-8e77-4b50-a11d-0517ffb149b2"
      unitRef="usd">653000</us-gaap:DeferredTaxAssetsInventory>
    <axgn:DeferredTaxAssetsInterestLimitation
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzYtMS0xLTEtMTAyNDMx_23edc4bb-e339-4783-a5dd-064775a446cd"
      unitRef="usd">0</axgn:DeferredTaxAssetsInterestLimitation>
    <axgn:DeferredTaxAssetsInterestLimitation
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzYtMy0xLTEtMTAyNDMx_336a9c94-d685-4548-ac59-008fc8faf658"
      unitRef="usd">453000</axgn:DeferredTaxAssetsInterestLimitation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzctMS0xLTEtMTAyNDMx_63982fbd-cbe1-4365-a35d-5bc86a4dfb23"
      unitRef="usd">169000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzctMy0xLTEtMTAyNDMx_74279027-0245-4470-a079-760e4310ba74"
      unitRef="usd">70000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <axgn:DeferredTaxAssetsLeaseObligations
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzgtMS0xLTEtMTAyNDMx_743cbe96-fc89-4328-91a7-faf18b9304cb"
      unitRef="usd">5643000</axgn:DeferredTaxAssetsLeaseObligations>
    <axgn:DeferredTaxAssetsLeaseObligations
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzgtMy0xLTEtMTAyNDMx_e1682cc9-657c-42c0-bb00-28567b423b9f"
      unitRef="usd">5736000</axgn:DeferredTaxAssetsLeaseObligations>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzktMS0xLTEtMTAyNDMx_557350ec-fded-4c7a-9dd6-303ac250a8b4"
      unitRef="usd">5274000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzktMy0xLTEtMTAyNDMx_0f4a044e-cc4c-4f28-b490-3ed6548d0b23"
      unitRef="usd">3985000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEwLTEtMS0xLTEwMjQzMQ_d9047ff9-bd7c-461e-a216-1ec9c25b5a07"
      unitRef="usd">6357000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEwLTMtMS0xLTEwMjQzMQ_1decbdba-1fd2-4374-8a06-9dd54d47af89"
      unitRef="usd">6000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzExLTEtMS0xLTEyODQ5OA_16df90ee-0741-459f-9514-1fab1d581b8a"
      unitRef="usd">1174000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsDerivativeInstruments
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzExLTMtMS0xLTEyODUwMA_5f51f969-348b-4a81-8531-9b85c2e894fd"
      unitRef="usd">-28000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEyLTEtMS0xLTEyODUwMg_7ccf7495-1470-4a88-b600-7cfbcaf49faa"
      unitRef="usd">203000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEyLTMtMS0xLTEyODUwNA_4f8a2ec6-cb1e-4fd2-b71b-e3724756d3d8"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEzLTEtMS0xLTE0MjIyNQ_92b3d2f8-8141-487a-a5ba-51324b0f3121"
      unitRef="usd">1010000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEzLTMtMS0xLTE0MjIzOQ_37429062-345f-47c3-bd8d-c081637dce1c"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzExLTEtMS0xLTEwMjQzMQ_a5b24140-9ad6-4e30-8011-f4a54572b946"
      unitRef="usd">63049000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzExLTMtMS0xLTEwMjQzMQ_1c1b4b1a-38a9-4e90-aa09-c7754b9586d8"
      unitRef="usd">58934000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEzLTEtMS0xLTEwMjQzMQ_448cebfb-b209-4cb5-a5fd-28260084b767"
      unitRef="usd">983000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzEzLTMtMS0xLTEwMjQzMQ_40d2266c-5b2b-4e66-84bc-fbd251c7b0b6"
      unitRef="usd">692000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE0LTEtMS0xLTEwMjQzMQ_76f5968c-12ee-41cf-8475-1777b0793530"
      unitRef="usd">17000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE0LTMtMS0xLTEwMjQzMQ_42ee2bd3-7576-4d5e-8663-09935951fb95"
      unitRef="usd">116000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <axgn:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE1LTEtMS0xLTEwMjQzMQ_4a7268b2-5159-4a1e-a6d9-52451d3bc3e4"
      unitRef="usd">3744000</axgn:DeferredTaxLiabilitiesRightOfUseAsset>
    <axgn:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE1LTMtMS0xLTEwMjQzMQ_1d731dd8-5b4a-4df9-a1ae-7aed1a2eb39c"
      unitRef="usd">3861000</axgn:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE2LTEtMS0xLTEwMjQzMQ_36dc46e7-0e43-4154-97d2-5101f3966dc7"
      unitRef="usd">-4000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE2LTMtMS0xLTEwMjQzMQ_68fbc230-cb9c-4e73-94be-ea7b0daf2ae5"
      unitRef="usd">4000</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE3LTEtMS0xLTEwMjQzMQ_536d557f-8918-4990-8b5f-7d586df46d51"
      unitRef="usd">4740000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE3LTMtMS0xLTEwMjQzMQ_26be3394-2cf2-49b5-b005-0b76415a13c6"
      unitRef="usd">4673000</us-gaap:DeferredIncomeTaxLiabilities>
    <axgn:DeferredTaxAssetsLiabilities
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE4LTEtMS0xLTEwMjQzMQ_f9bdc1af-65e3-4bbb-997b-026bba1265f1"
      unitRef="usd">58309000</axgn:DeferredTaxAssetsLiabilities>
    <axgn:DeferredTaxAssetsLiabilities
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE4LTMtMS0xLTEwMjQzMQ_4ad23510-3c26-4dc5-8b05-49f9f8195bb2"
      unitRef="usd">54261000</axgn:DeferredTaxAssetsLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE5LTEtMS0xLTEwMjQzMQ_b743db17-9dd3-43ba-8f70-88cdd242fe1f"
      unitRef="usd">58309000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if17b0477fc984ecfa301826bf71b2eb6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo0Zjg5NDdjMGEzZjE0MTc0YjE0OTkzYmFlYzI3ZDI5Ny90YWJsZXJhbmdlOjRmODk0N2MwYTNmMTQxNzRiMTQ5OTNiYWVjMjdkMjk3XzE5LTMtMS0xLTEwMjQzMQ_80528c89-d16b-42a6-9b6b-233ef0aeb717"
      unitRef="usd">53251000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3Xzk5MQ_56ba2b97-c625-4a5c-83ac-6a4271e0ecaf"
      unitRef="usd">5058000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzM1NzM0MTI3OTA4MDgw_0f086cb9-2d2a-482b-8c87-235fbe72cfc1"
      unitRef="usd">6734000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzU0OTc1NTgyMzQ1OA_d9047ff9-bd7c-461e-a216-1ec9c25b5a07"
      unitRef="usd">6357000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQ1NDM_cc069902-0e9d-47aa-b679-98ffb85b52d5">The Company&#x2019;s effective income tax rate differs from the statutory federal income tax rate for the years ended December&#160;31, 2022, 2021, and 2020 as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes - net of Federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items and other deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:5pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzItMS0xLTEtMTAyNDMx_b29d0636-8939-4519-a27a-ff915a0feb57"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzItMy0xLTEtMTAyNDMx_27e53e19-8a1a-44b4-ae70-4bbfff2c2595"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzItNS0xLTEtMTAyNDMx_3de65890-0103-4469-aeb3-b947191b7053"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzMtMS0xLTEtMTAyNDMx_7cf256e0-0ba6-4212-95f8-d29715b2d6ae"
      unitRef="number">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzMtMy0xLTEtMTAyNDMx_ec5bcc19-5238-4356-aebd-e743c9cc3fd5"
      unitRef="number">0.051</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzMtNS0xLTEtMTAyNDMx_ce9c8488-1dc8-40e3-ac3f-47400b7347be"
      unitRef="number">0.073</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzQtMS0xLTEtMTAyNDMx_4af27b40-5aaa-442e-b05e-27d2ef3d73a4"
      unitRef="number">-0.071</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzQtMy0xLTEtMTAyNDMx_3a95b0e3-7084-421b-8079-6a80622ec875"
      unitRef="number">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzQtNS0xLTEtMTAyNDMx_fce532e0-61ea-4d47-9c7f-3f806522d3d9"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtMS0xLTEtMTQxOTY4_7ce66956-d4ca-4356-9b6c-987d06a5c788"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtMy0xLTEtMTQxOTc4_61bc7b9f-ea23-426b-8134-eeefb3b0b291"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtNS0xLTEtMTQxOTg2_da3164c3-d3c9-4d42-9ca1-b63349e2c671"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtMS0xLTEtMTAyNDMx_24905a4f-8bbf-4b6d-a281-444c51ccd5a4"
      unitRef="number">-0.175</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtMy0xLTEtMTAyNDMx_0474a93e-ad56-488a-9d95-6f06dc7efcad"
      unitRef="number">-0.247</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzUtNS0xLTEtMTAyNDMx_1fd03116-b51a-414e-aa93-8a8b8837136a"
      unitRef="number">-0.277</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzYtMS0xLTEtMTAyNDMx_7c38ff95-4378-4b7b-b68c-28b4607a8330"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzYtMy0xLTEtMTAyNDMx_bdb0c94e-7376-480c-b3a0-f7c8d271a6e8"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90YWJsZTo3ZGZmNWU5ZWFiMzc0YTgwOGYwNGU5YzIzNjg0YmMwMC90YWJsZXJhbmdlOjdkZmY1ZTllYWIzNzRhODA4ZjA0ZTljMjM2ODRiYzAwXzYtNS0xLTEtMTAyNDMx_d5a9f134-0191-438d-9edd-a806e69b6ca8"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="idb63c57e724a4e6e8ad20ee65119370a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzIxNjA_cc12c7b7-9c36-4295-aba5-61ffdf48f0c7"
      unitRef="usd">42716000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1ad128b741c14b9797699a3555082a9d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQyNjA_07ab836d-b1c9-4c4c-85ac-4f08668e9993"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQyNjA_8bd51aad-ed84-4716-b360-279d1f19f1e5"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2a71040f35724ed39394a885f2fc991c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzAvZnJhZzphODkyNWMzN2ExOTc0MTRjYjFhMTExOGM0MzRiZmE5Ny90ZXh0cmVnaW9uOmE4OTI1YzM3YTE5NzQxNGNiMWExMTE4YzQzNGJmYTk3XzQyNjA_a609d776-3806-4688-b70c-14a31c908544"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzkwOA_61cc76c1-e7e9-4aa9-948f-698935086ffb">Retirement PlanThe Company sponsors the Axogen 401(k) plan (the "401(k) Plan"), a defined contribution plan covering substantially all employees of the Company. All full-time employees who have attained the age of 18 are eligible to participate in the 401(k) Plan. Eligibility is immediate upon employment and enrollment is available any time during employment. Participating employees may make annual pretax contributions to their accounts up to a maximum amount as limited by law. The 401(k) Plan requires the Company to make matching contributions of 3% on the first 3% of the employee&#x2019;s annual salary and 1% on the next 2% of the employee&#x2019;s annual salary as long as the employee participates in the 401(k) Plan. Both employee contributions and Company contributions vest immediately. Employer contributions to the 401(k) Plan were $1,409, $1,346, and $1,141 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <axgn:DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan
      contextRef="i05aa70972d464831a814056c33b271a3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzIyNQ_b6912c62-cacf-421d-863b-a7de68a1574c"
      unitRef="number">18</axgn:DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="iefd130037ca64a11bb22c7512ae0a94d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzU2NQ_529563c7-07f8-4c36-a7e9-878d6c501b0d"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <axgn:DefinedContributionPlanEmployeeContributionPercentMatched
      contextRef="iefd130037ca64a11bb22c7512ae0a94d_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzU4MQ_31404cb5-1a87-4090-a0d5-b6a1c9615e92"
      unitRef="number">0.03</axgn:DefinedContributionPlanEmployeeContributionPercentMatched>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i182aaa761ab746c08c115aa520c8ef32_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzYyMA_d2e732fa-840e-4936-a61a-7e233d459d13"
      unitRef="number">0.01</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <axgn:DefinedContributionPlanEmployeeContributionPercentMatched
      contextRef="i182aaa761ab746c08c115aa520c8ef32_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1XzYzNQ_341b1327-870a-458c-b140-9a7be32889c5"
      unitRef="number">0.02</axgn:DefinedContributionPlanEmployeeContributionPercentMatched>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i05aa70972d464831a814056c33b271a3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1Xzg0Ng_57ac059e-620b-454a-92d1-046c914b1158"
      unitRef="usd">1409000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i400f27a4e7ff431998cec2a000a877d7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1Xzg1MA_2f3cff34-eef9-4873-898d-99658eae1da2"
      unitRef="usd">1346000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i236f63d48da94326b86bbf56915ef555_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzMvZnJhZzo5MGQzMjdmMTViZTI0NDkxOGI3NjdmNmJjNDVmZGU1NS90ZXh0cmVnaW9uOjkwZDMyN2YxNWJlMjQ0OTE4Yjc2N2Y2YmM0NWZkZTU1Xzg1Nw_dd986ef3-f199-493c-b23b-7223359fd70c"
      unitRef="usd">1141000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzIwMjIw_36347bd7-fbc1-47b0-9969-d827ab67fe4a">Commitments and Contingencies&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Service Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company pays CTS a facility fee for the use of clean room/manufacturing, storage, and office space and for services in support of its product process including for routine sterilization of daily supplies, providing disposable supplies and microbial services, and office support. Pursuant to the CTS Agreement, the Company recorded expenses of $2,278, $2,466 and $1,739 for the years ended December&#160;31, 2022, 2021, and 2020, respectively, in sales and marketing expenses. The CTS Agreement terminates December 31, 2023, subject to earlier termination by either party at any time for cause (subject to the non-terminating party&#x2019;s right to cure, in certain circumstances), or without cause upon 6 months prior notice. We expect to reduce our utilization of CTS in the second half of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2011, the Company entered into a Master Services Agreement for Clinical Research and Related Services. The Company was required to pay $151 upon execution of this agreement and the remainder monthly based on activities associated with the execution of Axogen&#x2019;s phase 3 pivotal clinical trial to support the BLA for Avance Nerve Graft. Payments made under this agreement were $1,254, $1,100 and $1,136 for the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Distribution and Supply Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2008, the Company entered into an exclusive distribution agreement with Cook Biotech to distribute the Axoguard Nerve Connector and Axoguard Nerve Protector products worldwide and the parties subsequently amended the agreement on February 26, 2018. Pursuant to the February 2018 amendment, the agreement expires on June 30, 2027. The Cook Biotech agreement establishes a formula for the transfer cost of the Axoguard products and requires certain minimum purchases by the Company, although, through mutual agreement, the parties have not established such minimums; and, to date, have not enforced such provision. Under the Cook Biotech agreement, the Company provides purchase orders to Cook Biotech, and Cook Biotech fulfills the purchase orders. The agreement allows for termination provisions for both parties. The loss of the ability to sell the Axoguard&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;products could have a material adverse effect on the Company's business until other replacement products would be available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, the Company entered into the Nerve End Cap Supply Agreement (the "Supply Agreement") with Cook Biotech whereby Cook Biotech is the exclusive contract manufacturer of the Axoguard Nerve Cap and both parties have provided the other party the necessary licenses to their technologies for operation of the Supply Agreement. The Supply Agreement expires on August 27, 2027. Under the Supply Agreement the Company provides purchase orders to Cook Biotech and Cook Biotech fulfills the purchase orders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Axogen Processing Center Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on the continued availability of its processing facilities at the Community Blood Center facility (&#x201c;CTS&#x201d;) in Dayton, Ohio and could be harmed if the physical infrastructure of this facility is unavailable for any prolonged period of time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2018, the Company purchased the APC Facility in Vandalia, Ohio, located near the CTS processing facility where Avance Nerve Graft is currently processed. The APC Facility, when and if operational, will be the new processing facility for Avance Nerve Graft to provide continued capacity for growth and to support the transition of Avance Nerve Graft from a Human Cellular and Tissue-based Product pursuant to Section 361 of the Public Health Service Act (PHSA) to a biologic product under section 351 of the PHSA. The APC Facility is comprised of a 107,000 square foot building on approximately 8.6 acres of land. The Company paid $731 for the land and this is recorded as land within Property and equipment, net on the consolidated balance sheets. The Company paid $4,300 for the building and this is recorded in projects in process within Property and equipment, net on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 9, 2019, the Company&#160;entered into a Standard Form of Agreement Between Owner and Design-Builder (the &#x201c;Design-Build Agreement&#x201d;) with CRB Builders, L.L.C., a Missouri limited liability company (&#x201c;CRB&#x201d;), pursuant to which CRB will renovate and retrofit the APC Facility. The estimated cost pursuant to the Design-Build Agreement was $29,300. Additional costs associated with the renovation, validation and certification of the APC Facility are estimated to be $20,900. For the year ended December&#160;31, 2022, the Company has recorded $10,938 related to renovations and design and build in projects in progress. The Company has recorded $46,354 to date related to this project. In addition to these project costs, the Company has capitalized interest of $6,155 for the year ended December&#160;31, 2022. To date, the Company has capitalized interest of $11,429 related to this project. These items are recorded as projects in process in property and equipment, net on the consolidated balance sheet. The Company anticipates recording an additional $4,000 to $5,000 in 2023. The Company anticipates completion of construction, validation of systems and processes in the first half of 2023 and commence processing in mid- 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company obtained certain economic development grants from state and local authorities totaling up to $2,685 including $1,250 of cash grants to offset costs to acquire and develop the APC Facility. The economic development grants are subject to certain job creation milestones by 2023 and related contingencies. The Company received zero, $950 and $238 from these grants in the years ended December&#160;31, 2022, 2021 and 2020, respectively. These grants have claw back clauses if the Company does not meet these job creation milestones by 2023, the Company has sent requests to the grant authorities for extensions of the job creation milestones; however, the Company has not yet received a decision from the grant authorities regarding whether extensions will be granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Fair Value of the Debt Derivative Liabilities  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the debt derivative liabilities is $4,518 as of December&#160;31, 2022. The fair value of the debt derivative liabilities was determined using a probability-weighted expected return model based upon the four potential settlement scenarios for the Credit Facility which are described in Note 2 - Summary of Significant Accounting Policies &#x2013; Derivative Instruments. The estimated settlement value of each scenario, which includes any required make-whole payment see Note 9 - Long-Term Debt, Net of Debt Discount and Financing Fees , is then discounted to present value using a discount rate that is derived based upon the initial terms of the Credit Facility at issuance and corroborated utilizing a synthetic rating analysis. The calculated fair values under the four scenarios are then compared to the fair value of a plain vanilla note, with the difference reflecting the fair value of the Debt Derivative Liabilities. The Company estimated the make-whole payments required under each scenario according to the terms of the Credit Facility to generate an internal rate of return equal to 11.5% through the scheduled maturity dates, less the total of all quarterly interest and royalty payments previously paid to the Lender. The calculation utilized the XIRR function in Microsoft Excel as required by the Credit Facility. If the debt is not prepaid but instead is held to its scheduled maturities, the Company&#x2019;s estimate of the make-whole payment for the first and second tranches of the Credit Facility due on June 30, 2027, and June 30, 2028, respectively, are approximately zero. The Company has consistently applied this approach since the inception of the debt agreement on June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has become aware that the Lender may have an alternative interpretation of the calculation of the make-whole payments that the Company believes does not properly utilize the same methodology utilized by the XIRR function in Microsoft Excel as described in the Credit Facility. The Company estimates the top end of the range of the make-whole payments if the debt is held to scheduled maturity under an alternative interpretation to be approximately $9,000 for the first tranche of the Credit Facility on June 30, 2027, and approximately $4,000 for the second tranche of the Credit Facility on June 30, 2028. Further, if the debt is prepaid prior to the scheduled maturity dates and subject to the alternative interpretation, the make-whole payment would be larger than the amounts herein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain executive officers of the Company are parties to employment contracts. Such contracts have severance payments for certain conditions including change of control.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is and may be subject to various claims, lawsuits, and proceedings in the ordinary course of the Company's business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company. In the opinion of management, such claims are either adequately covered by insurance or otherwise indemnified, or are not expected, individually or in the aggregate, to result in a material, adverse effect on the Comp&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;any's financial condition, results of operations or cash flows. However, it is possible that the Company's results of operations, financial position and cash flows in a particular period could be materially affected by these contingencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 9, 2019, Plaintiff Neil Einhorn, on behalf of himself and others similarly situated, filed a putative class action complaint in the United States District Court for the Middle District of Florida alleging violations of the federal securities laws against Axogen, Inc., certain of its directors and officers (&#x201c;Individual Defendants&#x201d;), and Axogen&#x2019;s 2017 Offering Underwriters and 2018 Offering Underwriters (collectively, with the Individual Defendants, the &#x201c;Defendants&#x201d;), captioned Einhorn v. Axogen, Inc., et al., No. 8:19-cv-00069 (M.D. Fla.). Plaintiff asserts that Defendants made false or misleading statements in connection with the Company&#x2019;s November 2017 registration statement issued regarding its secondary public offering in November 2017 and May 2018 registration statement issued regarding its secondary public offering in May 2018, and during a class period of August 7, 2017 to December 18, 2018. In particular, Plaintiff asserts that Defendants issued false and misleading statements and failed to disclose to investors: (1) that the Company aggressively increased prices to mask lower sales; (2) that the Company&#x2019;s pricing alienated customers and threatened the Company&#x2019;s future growth; (3) that ambulatory surgery centers form a significant part of the market for the Company&#x2019;s products; (4) that such centers were especially sensitive to price increases; (5) that the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) that the Company&#x2019;s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the Company&#x2019;s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the Company&#x2019;s key operating metrics, such as the number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants&#x2019; positive statements about the Company&#x2019;s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis. Axogen was served on January 15, 2019. On February 4, 2019, the Court granted the parties&#x2019; stipulated motion which provided that Axogen is not required to file a response to the complaint until thirty days after Plaintiff files a consolidated amended complaint. On &lt;/span&gt;&lt;/div&gt;June 19, 2019, Plaintiff filed an Amended Class Action Complaint, and on July 22, 2019, Defendants filed a motion to dismiss. Plaintiff filed opposing papers on August 12, 2019. The Court held a status hearing on September 11, 2019 and stayed all deadlines regarding the parties&#x2019; obligations to file a case management report. On December 4, 2019, the parties presented oral arguments. On April 21, 2020, the Court dismissed the complaint without prejudice, finding the Plaintiff failed to state a claim upon which relief could be granted. The Plaintiff filed a Second Amended Class Action Complaint on June 22, 2020. Axogen filed a motion to dismiss on August 6, 2020. The Plaintiff filed an opposition on September 20, 2020. The Court held oral argument on February 25, 2021. On March 19, 2021, the Court dismissed the Second Amended Complaint with prejudice, finding again that the Plaintiff failed to state a claim upon which relief could be granted. On April 14, 2021, Plaintiff filed a notice of appeal. Plaintiff filed its opening brief on June 28, 2021. The Company filed its appellee brief on August 11, 2021. The Plaintiff filed a reply brief on September 14, 2021. The Eleventh Circuit heard oral argument the week of March 8, 2022. On August 1, 2022, the Eleventh Circuit affirmed the dismissal of the complaint with prejudice.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <axgn:LicenseFeeAmount
      contextRef="i73105f432ef241c4a97fc1d3d88fe6a3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0NjM_c24931f6-f198-4aaa-9845-cea33f887da5"
      unitRef="usd">2278000</axgn:LicenseFeeAmount>
    <axgn:LicenseFeeAmount
      contextRef="if781fbbca41e4e539d4a2af2b30d30b6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0Njc_899df575-684f-4199-ade0-590c0c9b8f14"
      unitRef="usd">2466000</axgn:LicenseFeeAmount>
    <axgn:LicenseFeeAmount
      contextRef="i07a9992aadca401c9da150aec1eb925d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0NzQ_bc4090dc-ff62-4671-9219-ebf89c7e7a04"
      unitRef="usd">1739000</axgn:LicenseFeeAmount>
    <axgn:NoticePeriodForTerminationOfAgreement
      contextRef="i73105f432ef241c4a97fc1d3d88fe6a3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU3ODA_3805ecf3-ac5d-4822-b82d-42c7019db45b">P6M</axgn:NoticePeriodForTerminationOfAgreement>
    <axgn:ServiceAgreementAmountPaidUponExecutionOfAgreement
      contextRef="i1fde54db694d4428af52e02f60a749f9_D20111201-20111231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU5NDQ_5b2a5579-a4a1-4c6f-9816-b1e8a22cc713"
      unitRef="usd">151000</axgn:ServiceAgreementAmountPaidUponExecutionOfAgreement>
    <axgn:PaymentForServiceFees
      contextRef="if5e477a79209414b9802cd7abd1b6b50_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg0OTM1Mg_6c931c25-187c-44cc-b033-07c00c59f1f0"
      unitRef="usd">1254000</axgn:PaymentForServiceFees>
    <axgn:PaymentForServiceFees
      contextRef="i7e0f3af02aa7447d8f475f07a758e898_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg0OTM1NQ_361a7800-9ef4-4323-8704-c9b587e4a92b"
      unitRef="usd">1100000</axgn:PaymentForServiceFees>
    <axgn:PaymentForServiceFees
      contextRef="ibb046ec1c789420aa97b6546383d2a96_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg0OTM1OA_8023b993-cbe4-4f3c-afa5-c9d74140d495"
      unitRef="usd">1136000</axgn:PaymentForServiceFees>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i7981a723acd84152a08440913339b2eb_I20180731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzcxNDY4MjU2MTgwOTQ_4baae2db-05bb-45b1-85b1-e5eca6720fde"
      unitRef="sqft">107000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfLand
      contextRef="i7981a723acd84152a08440913339b2eb_I20180731"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzkzNzQ_32fee55b-cadb-4172-9769-898f21886f72"
      unitRef="acre">8.6</us-gaap:AreaOfLand>
    <us-gaap:PaymentsToAcquireLandHeldForUse
      contextRef="ic4c3c23c084b482f91cc7aa41dcd753c_D20180701-20180731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2Xzk0MDk_6dcd011a-65ea-40ac-8562-abfe0038d8f2"
      unitRef="usd">731000</us-gaap:PaymentsToAcquireLandHeldForUse>
    <us-gaap:PaymentsToAcquireBuildings
      contextRef="ic4c3c23c084b482f91cc7aa41dcd753c_D20180701-20180731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2Xzk1MzY_a3be26a7-6e68-4e48-becc-e4fcb7f4220d"
      unitRef="usd">4300000</us-gaap:PaymentsToAcquireBuildings>
    <axgn:EstimatedCostRelatingToDesignBuildAgreement
      contextRef="i7a73dc524bc0487f8a26096a8e638192_I20190709"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEwMjc5_a7a0f219-e803-40df-bf74-2e137a570a7e"
      unitRef="usd">29300000</axgn:EstimatedCostRelatingToDesignBuildAgreement>
    <axgn:AdditionalCostsAssociatedWithDesignBuildAgreement
      contextRef="i7a73dc524bc0487f8a26096a8e638192_I20190709"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEwNDAx_f58bef83-a5b5-4e1a-9b46-2a1e35f1d07c"
      unitRef="usd">20900000</axgn:AdditionalCostsAssociatedWithDesignBuildAgreement>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i5d4755bb5df442e0bcbac343dd97c6a5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEwOTk1MTE2NjYzNjU_bfdc2729-ee5c-457b-9e9f-262952d33bb3"
      unitRef="usd">10938000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6c09353a39ab44c1abcd20449e840722_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MDgzMw_31b9488e-0ee8-4d07-a707-08574e26acd2"
      unitRef="usd">46354000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:InterestCostsCapitalized
      contextRef="i5d4755bb5df442e0bcbac343dd97c6a5_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MDg1Nw_b3f9d816-b464-44f1-a029-f778f9d66616"
      unitRef="usd">6155000</us-gaap:InterestCostsCapitalized>
    <us-gaap:AccumulatedCapitalizedInterestCosts
      contextRef="i6c09353a39ab44c1abcd20449e840722_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MDg0Nw_3ceef902-0f25-4d52-9625-f47b7ba7f950"
      unitRef="usd">11429000</us-gaap:AccumulatedCapitalizedInterestCosts>
    <axgn:AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne
      contextRef="i7a632239217d41468fa2372519ffc0b1_I20231231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MjQzNA_b74f7d6c-a67b-4bd5-a135-f930ce496ddb"
      unitRef="usd">4000000</axgn:AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne>
    <axgn:AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne
      contextRef="ic9e769962cd54b3b97e7d9fd767e4375_I20231231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MjQ0OQ_4ee9adae-ea0b-43f2-b72a-669d45d3b8da"
      unitRef="usd">5000000</axgn:AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne>
    <us-gaap:GrantsReceivable
      contextRef="i6ca27fff32cc49c8b733f18e1fa356ad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzExNjI5_712ea7ad-71d3-4b3c-8c5a-1919b08e0195"
      unitRef="usd">2685000</us-gaap:GrantsReceivable>
    <axgn:CashGrantsReceivable
      contextRef="i6ca27fff32cc49c8b733f18e1fa356ad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzExNjQy_fe6449b7-283e-426a-904d-0aed0a4523e0"
      unitRef="usd">1250000</axgn:CashGrantsReceivable>
    <us-gaap:ProceedsFromGrantors
      contextRef="i240989f39b9840bca8e3655746971a82_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MDk1OQ_793d8a36-b38d-45fa-b53e-70cfa45ca718"
      unitRef="usd">0</us-gaap:ProceedsFromGrantors>
    <us-gaap:ProceedsFromGrantors
      contextRef="ibc7bb6eff8634156ae51a0b363ee7e34_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzExODUy_7915b5ca-2b5a-4f68-abcd-88d8c24af947"
      unitRef="usd">950000</us-gaap:ProceedsFromGrantors>
    <us-gaap:ProceedsFromGrantors
      contextRef="i1483ac9511a64c4ea92e59beedb6290d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzExODU5_bbb62255-82bd-4ec9-84ed-8006238fede7"
      unitRef="usd">238000</us-gaap:ProceedsFromGrantors>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i43510f63e6ba4c3ca4047759ce1d9771_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MzE4NQ_72ab6800-ee98-46d0-a3ec-d7c238f966fc"
      unitRef="usd">4518000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <axgn:NumberOfPotentialSettlementScenarios
      contextRef="i872b209a46c14c878edd3c5a93dc57b8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEyMjcz_8ff68c64-62ae-4ec6-a738-a248ee25a716"
      unitRef="settlementscenario">4</axgn:NumberOfPotentialSettlementScenarios>
    <axgn:NumberOfPotentialSettlementScenarios
      contextRef="i872b209a46c14c878edd3c5a93dc57b8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEyNzI3_8ff68c64-62ae-4ec6-a738-a248ee25a716"
      unitRef="settlementscenario">4</axgn:NumberOfPotentialSettlementScenarios>
    <axgn:DebtInstrumentInternalRateOfReturnUnderSettlementScenarios
      contextRef="i872b209a46c14c878edd3c5a93dc57b8_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEzMDU0_5c248ea7-da9c-44c9-801e-91e3d4eba90e"
      unitRef="number">0.115</axgn:DebtInstrumentInternalRateOfReturnUnderSettlementScenarios>
    <axgn:DebtInstrumentHeldToMaturityMakeWholePayment
      contextRef="i312f2d64cb674fdbad24a7fe51918409_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzEzNTk1_f5af8bf9-e2b8-4b44-afc5-a6db443151fc"
      unitRef="usd">0</axgn:DebtInstrumentHeldToMaturityMakeWholePayment>
    <axgn:DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation
      contextRef="i312f2d64cb674fdbad24a7fe51918409_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MTQ2MQ_744261e7-6827-4c39-94a7-fe77766ac75f"
      unitRef="usd">9000000</axgn:DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation>
    <axgn:DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation
      contextRef="ibe9a8770fa764d7891407778eae23958_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xMzYvZnJhZzo2ZTY5YTA0MzU4MGM0NTA2YjcwMDQzMzk0N2Q4ZDM4Ni90ZXh0cmVnaW9uOjZlNjlhMDQzNTgwYzQ1MDZiNzAwNDMzOTQ3ZDhkMzg2XzU0OTc1NTg1MTQ2Ng_270889df-d458-425e-a5d0-d294eaff3b53"
      unitRef="usd">4000000</axgn:DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xNDUvZnJhZzo2OTllYjIwYzJmNzU0OTdiYTg0ZDhmMjVmNTczNzZkOS90ZXh0cmVnaW9uOjY5OWViMjBjMmY3NTQ5N2JhODRkOGYyNWY1NzM3NmQ5XzMyNQ_493256e0-247e-4336-911a-b7749e54c4b1">Subsequent EventSilicon Valley Bank (&#x201c;SVB&#x201d;) was closed on March 10, 2023 by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) as receiver. At the time of closing, the Company maintained approximately $8.0&#160;million of its cash in deposit accounts with SVB. The vast majority of the Company&#x2019;s cash, cash equivalents and short-term investments reside in custodial accounts held by U.S. Bank for which SVB Asset Management is the advisor. The Company&#x2019;s investment portfolio currently does not contain any securities of SVB. On March 12, 2023, the U.S. Treasury, Federal Reserve, and FDIC announced that SVB depositors will have access to all of their money starting March 13, 2023. As of March 14, 2023, the Company had access to all of its money held at SVB.</us-gaap:SubsequentEventsTextBlock>
    <axgn:CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation
      contextRef="i63b272a784f043b28b8f70d792398c9d_I20230310"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xNDUvZnJhZzo2OTllYjIwYzJmNzU0OTdiYTg0ZDhmMjVmNTczNzZkOS90ZXh0cmVnaW9uOjY5OWViMjBjMmY3NTQ5N2JhODRkOGYyNWY1NzM3NmQ5XzcxNDY4MjU1ODU2MjE_7e04e522-a0c0-4a59-a6f5-19a52f1235ad"
      unitRef="usd">8000000</axgn:CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90ZXh0cmVnaW9uOmM5ZjA1YjJmOWQyZDRkOWM5ZWFiN2ExYWU2N2FhMTVjXzE0Nw_72324d26-33e3-41f4-bb7c-d79af1656ed7">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Schedule II &#x2013; Valuation and Qualifying Accounts - to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;AXOGEN, INC.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II &#x2013; VALUATION AND QUALIFYING ACCOUNTS&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;THREE YEARS ENDED DECEMBER&#160;31, 2022, 2021 AND 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.493%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at Beginning of Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deductions (Charge-offs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at End of Year&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iace3449af19a43cd8d67c6135dea1c3f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzItMS0xLTEtMTAyNDMx_3e78763d-a5ac-4394-97f7-a549aa49b87b"
      unitRef="usd">1092000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="i1eadfa7371f84649a56fada99ffeb49f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzItMy0xLTEtMTAyNDMx_9bd8c40f-805e-4772-bbf7-b3a1d8999981"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i1eadfa7371f84649a56fada99ffeb49f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzItNS0xLTEtMTAyNDMx_6167469d-1d4e-47b2-b673-b29744f98171"
      unitRef="usd">676000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i491dd34b56ac4fb6b8ba9809c9f8440d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzItNy0xLTEtMTAyNDMx_0246ae01-5d97-4ea3-8877-1c4eeb99e77e"
      unitRef="usd">416000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i491dd34b56ac4fb6b8ba9809c9f8440d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzMtMS0xLTEtMTAyNDMx_9389338f-fd59-415a-a747-34c295b820c6"
      unitRef="usd">416000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="i3669aa557841487bb68d45ebfd6ac73d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzMtMy0xLTEtMTAyNDMx_933d10f3-ab88-4f08-bc19-203f7d52f56c"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i3669aa557841487bb68d45ebfd6ac73d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzMtNS0xLTEtMTAyNDMx_c73e6d5f-4be8-477b-a99f-49c9f9060aee"
      unitRef="usd">140000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if81dc6f294f4481ba24f6cf04a2a5b07_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzMtNy0xLTEtMTAyNDMx_a4b1aa9f-c71c-448e-bab9-d8a3376314f3"
      unitRef="usd">276000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if81dc6f294f4481ba24f6cf04a2a5b07_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzQtMS0xLTEtMTAyNDMx_1f060de5-0239-48c2-8bd4-ecbb2c1c055d"
      unitRef="usd">276000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="i3e2f4d63cb0a4bdbba2fe027bcca072d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzQtMy0xLTEtMTAyNDMx_d6945f24-fe3d-46d3-9bd2-a78a3158a36b"
      unitRef="usd">612000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i3e2f4d63cb0a4bdbba2fe027bcca072d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzQtNS0xLTEtMTAyNDMx_0660e681-3167-423f-899c-c35e9efd5055"
      unitRef="usd">238000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i13a1d089805140e781df39c5f26229e1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzQtNy0xLTEtMTAyNDMx_75918ad0-32c0-4e0e-8e31-0e4a93e7c194"
      unitRef="usd">650000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ief79fb6a5e3b43748ba8450f97233cc8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzctMS0xLTEtMTAyNDMx_87122a2f-916c-4655-8130-3e8a1c658cde"
      unitRef="usd">39932000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="iff49c4d00f374dc3a6c840d2ead2e75c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzctMy0xLTEtMTAyNDMx_af360efa-4da2-4b74-b3f1-bbedc4555807"
      unitRef="usd">6585000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iff49c4d00f374dc3a6c840d2ead2e75c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzctNS0xLTEtMTAyNDMx_c7aaed8e-a7ad-4613-a04d-23de09a18fed"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i66448d92e4ed4bbdabf0e6233a2efd1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzctNy0xLTEtMTAyNDMx_a719f736-b237-4478-9722-5fd57645687b"
      unitRef="usd">46517000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i66448d92e4ed4bbdabf0e6233a2efd1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzgtMS0xLTEtMTAyNDMx_ea857a4d-6878-4391-ba37-f86d5aa06d49"
      unitRef="usd">46517000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="ifc7ff5c961444d40b57c14dbf3857165_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzgtMy0xLTEtMTAyNDMx_b4972c86-850b-44a3-969b-6b76b8676f90"
      unitRef="usd">6734000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ifc7ff5c961444d40b57c14dbf3857165_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzgtNS0xLTEtMTAyNDMx_d4519035-717a-465c-af50-c62a56a48d08"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia96693000e594bfcab99cf6f0f656103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzgtNy0xLTEtMTAyNDMx_a1bbfb88-a4a0-4680-9b68-c1e747ff2055"
      unitRef="usd">53251000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia96693000e594bfcab99cf6f0f656103_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzktMS0xLTEtMTAyNDMx_436f4ce9-2b62-40ad-94e3-88231c321f5c"
      unitRef="usd">53251000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="ic01ee8be630348558bc989c9e8469302_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzktMy0xLTEtMTAyNDMx_bf314236-fe6f-498a-8aed-316b728d1854"
      unitRef="usd">5073000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ic01ee8be630348558bc989c9e8469302_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzktNS0xLTEtMTAyNDMx_25ebc5ee-81db-4597-b62a-ebf7d9f18ab5"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i682121d6bec448318e7178b60d411be4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNiMGY0YmNkNDRlMzQ2YTA5ZWIzZjYwZDI3NTFiY2RlL3NlYzozYjBmNGJjZDQ0ZTM0NmEwOWViM2Y2MGQyNzUxYmNkZV8xODEvZnJhZzpjOWYwNWIyZjlkMmQ0ZDljOWVhYjdhMWFlNjdhYTE1Yy90YWJsZTo4OTc4NWMyMjQ5NjE0YTU0OTIzMGJmM2IwOTFkNzBiNC90YWJsZXJhbmdlOjg5Nzg1YzIyNDk2MTRhNTQ5MjMwYmYzYjA5MWQ3MGI0XzktNy0xLTEtMTAyNDMx_a1a79755-2043-4464-b993-fa8f853a729d"
      unitRef="usd">58324000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>98
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MI@$7,!2I'I5G:*Y@%D-<H G/4B7>X#4T\[2K?WXT K06M0;H2*T*D)0 21.
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MAAX-,.EZ8A'S0C) FKAE33Q.FS=OS) ^,1+'ZS4B5K$@&NB02$N?9)P^KZH
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M#A$ 12**.SP %/9"#-/P&QK^((W?2R$EVI1BF2J(@&\-BK'KTBX# .:X+NG
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MZ$)4UD>Y]8,2F^IP\TDH)?+J=LV9[KX&H+\OA5 O#V: YD!]^B]02P,$%
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MR&)":4]W$0,]9!AZNE7TJ4TS=ROI>#:- #0C]X)V0@V2!;'=;Y JG/<L.,1
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MB(U^N6:I# I*(+]?"=$\OU$_L'\XZ/(?4$L#!!0    ( -"$;E8J@80170,
M "X'   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULC57;;MLX$/T50@6Z
MNX!KR;)[07P![&33]B&MT61W'XH^T-38(DIQU"$5)?WZ'5*R-NFF1E]L#F?F
MS)D+1XL6Z:LK ;RXJXQURZ3TOCY+4Z=*J*0;8PV6-7ND2GH6Z9"ZFD 6T:DR
M:9YEK])*:INL%O%N2ZL%-MYH"UL2KJDJ2?<;,-@NDTERO/BD#Z4/%^EJ4<L#
M7(/_J]X22^F 4N@*K--H!<%^F:PG9YM9L(\&?VMHW8.S")GL$+\&X7VQ3+)
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MV34;OWZ9".JV<R=XK.-&W*'G_1J/91RO8,#Z/7+I>R$$&#Z1JW\!4$L#!!0
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M.E*QL*:NJ4DV!S#++6^F;Q?#!O8.B&6>"A?LL'"40<4LAQX//YY'E*6+13\
MQ4(AS+H#40%1:K-EVVQ@<)"9N,Y9]L$M*AB4#B4/>^G:'M C*G78C9TKVB"
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M;+0)V4&HC.=ATMT2%&\=$AJ2U00_9AA#C.ST46-^%3$3\^VS%!P[ OT2%L6
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M=F#\_A;1M)864$VDWU+<4&8S>R+U"[\&V-*[Q;KVOY/#W7%85AY/=K7XXC>
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M#9ZO0620'B\!))\^O<Q,6G3QGJZF/0%%"58WBKL+G54'8P3X@0PBK27-BC#
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ME= $O)\:DY4/M,#R"\ZS_P%02P,$%     @ T(1N5B5^KR8Z P  2@<  !D
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M\)+9D:ZXPIVU-B5S.#6;L:T,9[D7*N4X#L/IN&1"!<L+OW9KEA>Z=E(H?FO
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MS4+\QL/)=$'K<3(9^'F<I/";R+!_(<[&<%YZB&@8A>B$:!A&>' ^ZQ;F:3R
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M7U([F U<.MY22[E68J:@C3L4^N=EEE$CHUM 1LK$EXP7#MS3L7T%(O5-(_%
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MCV*B!?A];M !\0LIJ/^?Q=5_ 5!+ P04    " #0A&Y6DM\(O+<#  !H"
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M >AAK@T+JSH_2S;*TF3R8D._ JB= GW?*F7'A7,P_5RL_P902P,$%     @
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MK5V-([5LURY8"D!0QB[7)Z0A- V\@DQT*35OL*$5W/&2X?4!%+9^][$OGKZ
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M8#J8D^9_M.S51A_M2AWNS;[+$8S:;@B4RQ+>K4W@PD^*5<']W9T,4]@/0YQ
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MI*WOHN*C5MNM'*KM#G%M3%PI4:IJ#MJ0_HH@YIG)?J !P4Q:.%@F[P+)UG/
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M-4][LD&!SU?&^.,F..C_?YC]"U!+ P04    " #0A&Y6%GT!Z)@3  #9-
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M(_H].3E)D30YO?@SD?1(((VI>(#SF8A++SU0MM@,LR0\X::=HZR#P,G54WY
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M<P@@\ .LB7&(#67,/YF,S_^C&Y/R,4JV,'E;LH_2H2"($D0!6BL)VS '?&9
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M&2T+T/W&4#MV&S;0O_;SOP%02P,$%     @ T(1N5KT>]HD\ P  /@<  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULK55A;]H\$/XKIVR:.BEM$@<"
M;0$I0+8BM;2#LO>MIGTPR06B)3&SG=']^]D.I""U[/WP?HGO?'?//7=VSKTM
MXS_$&E'"<Y&7HF^MI=Q<.8Z(UUA0<<$V6"I+RGA!I5+YRA$;CC0Q047N$-<-
MG()FI37HF;T'/NBQ2N99B0\<1%44E/\>8LZV?<NS]ANS;+66>L,9]#9TA7.4
MB\T#5YK3H"19@:7(6 D<T[X5>E?#EO8W#E\SW(H#&70E2\9^:&62]"U7$\(<
M8ZD1J%I^X0CS7 ,I&C]WF%:34@<>RGOT3Z9V5<N2"ARQ_)\LD>N^U;4@P916
MN9RQ[0WNZFEKO)CEPGQA6_L&@05Q)20K=L&*09&5]4J?=WTX".BZ;P2070 Q
MO.M$AN682CKH<;8%KKT5FA9,J29:D<M*?2ASR94U4W%R,%>GG%0YPF0"Y_"5
MYA6MNU4F\*6B>9;^SLH5A'',JE**GB-54AWJQ+L$PSH!>2.!1^".E7(M("H3
M3(X!',6VH4SVE(?D).(8XPOP/1N(2\@)/+]I@6_P_+=:$(U@WP8;/'+N7MI_
M[P1\"Y="<G6KOK_6E#IEZ_64^D^[$AL:8]]2OY) _@NMP8=W7N!>GRBHU134
M.H7^?YSIR02OTS_,^N%=EWC>]7_HXCE(!N&_]Y^CJ0V3Z>@"YJ.;:+RXC8YP
MPMM%^#BYGT(X'<.717@[^?0TF7Z&<#2Z7TP?Y_!X,XLB>(K"V1RBZ3@:PS@:
M17?#:-9<%?/U#((27#C+2I!K5@G%37R$(<UI&2-0"4-<966I>;(4GI!R"),D
MTW4(&*LBXUH\&ZTI7^$Y2]/C>'737R)S-?>,04U02%BUE&F5JVFT:X"A\AX\
MV[TD:C45DVLEG06=X*-:6UY0$Z_%(Q>OY6H7TC$N9">^A\#3\AGQN]H<M-W#
MDS@FA"ERC@E(^@Q4"'RAY%_:E[[&">QVMZW3*\'K-&1J39L[?NN(5]NW2=O;
M4]II2K#=CG_LV+5]TH+7[KQS,-,*5&W6DUN Z5H]WIK=YG$(ZYGXXEZ_+'?J
ME#)U7CFF*M2]Z+0MX/6TKA7)-F9"+IE4\]:(:_7 (=<.RIXR)O>*3M \F8,_
M4$L#!!0    ( -"$;E;S.)F0X"4  '1]   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;+U=6W/;5I+^*RA-=L:J@F21MF/'3EPEWS+:RDRT5IQYV-H'
MD#@D$8, @XMDYM=O?]U];B (V<[.OMB2")Q+G[Y\?3O\_JYN/K8;8[KDT[:L
MVA].-EVW>_[P8;O<F&W6GM<[4]$GJ[K99AW]VJP?MKO&9#F_M"T?SB\NOGVX
MS8KJY.7W_+?KYN7W==^5166NFZ3MM]NLV;\R97WWP\GLQ/[A?;'>=/C#PY??
M[[*UN3'=A]UU0[\]=*/DQ=94;5%726-6/YQ<SIZ_FC_#"_S$KX6Y:X.?$VQE
M4=<?\<M5_L/)!59D2K/L,$1&_]V:UZ8L,1*MXW<=],3-B1?#G^WH[WCSM)E%
MUIK7=?FO(N\V/YP\.TERL\KZLGM?W_W=Z(:>8+QE7;;\;W(GSS[Y]B19]FU7
M;_5E6L&VJ.3_[),2(GCAV<61%^;ZPIS7+1/Q*M]D7?;R^Z:^2QH\3:/A!]XJ
MOTV+*RJ<RDW7T*<%O=>]O)'32.I5<E.LJV)5++.J2RZ7R[JONJ):)]=U62P+
MTR8/[$^GWS_L:&H,\'"IT[R2:>9'IIG-DW_45;=ID[=5;O)X@(>T9K?PN5WX
MJ_GDB&_,\CQY-$N3^<5\/C'>(T>(1SS>HR/CC>WXOR\7;=<0X_S/V(YEO,?C
MXT&:GK>[;&E^."%Q:4US:TY>_O4OLV\O7DRL]K%;[>.IT5^^RMJBQ:%=8^RJ
MR\#B8XO\BF&27S:&I&59;W=9M0=!EG75$DWRK#-YLBJJK%H669FT]+PA">UX
MB([>>BWO)%EC$MKUCO[/DZ+BT9J<7C/$WMV&?U=B[YJ"1MN51.ZUJ4R3E>4>
MGYM=)^]BW ]5@=]N,"%/=KDU#7%J\N#DP_G->?+CY>7UR>EY<EF6]$IGFJ5=
MB$S4)EF5)W2459NQ-FB3379KDH4Q56+*@@0KT^G\7NFQ\XFC>N*.ZLDDC3^T
M!BM^VW;%%LL?.Z4O&X$/2,@K!T8?WG]$LC?H\:+;RS$XVI%^_;TOB =(M52D
MC/%&TM7TVT>3&#<OB)BUI,!W0L-NDW5)MEJ1AN5CHB75#1:0;87JM#!ZWBC]
MRR);%&71%3H47LF+=EG6;=\8W068 K,?>\_Q&K9J?Q[=L)UB;%6-N355K^LP
MG\C&M?1+WC=@2?\2,RAQ6IV?,]';0$4&9&$*V#?M+&[:NK&[] S].<>U+/O<
MZ&*RLO@C6Y0FN<W*GK==5+2#KFZ(*"D_A$\<.Y#=6'X\@[G*$\@"[4\^LT2)
MGLYIB[<9S",-2QJOCPFXRHK&3YR;11<^=I[\3 \U 3V&;/%OH AIB?J.]<D*
M@]7]HEOUI1-WH4C?&ORQ+%:&]]*897U+&H:9B4U>65?KLY+VG2N_I9BEX0EI
M\D7=D+#C8!O>&.8B/ 2IH[^5ALA+;P3*# _0 /665IE],G;-GJGD'-W\!!],
M QU)3X<<+P^73 M_4F[3PHQ6V>*4:29ZU1\!/;TI6K#'DO;!<DLK)#W+0Y*@
M$V@!E1I3Y=A"A7F(SWMZE4_S0,P#Q; @C4GRT[*:ISVU=<6\V9-I;^0PBV;9
M;^GL:+%"4Z5"."R),JF85=]!^"&/X*7+9=?3BG6%-.N>6(58J4E63;VEP8EG
M_#ZG]/.W3C]_.ZE=WYME2<MBL>:%C2GH+QSBM6DZ0L0P;L01>Y,U3@B\W6G<
M6^!X>@XB0(=FJJ7J9R9E3PQ"1.=!=H&9/D]N=F;)<Y+)3%5FC+!ET@"-GM6K
M,Q("RUEWFV*Y2>Z,&&<,1!.W8D8,65U:,(&IF; #SK8B2JK4L9SN&G _L2YK
M3;(8._##>7)%O)GG!58EDL<Z(M J5H/3OK(V&K(BQR,0J;IMDV76-'NBQUW6
MY&RVG)3H/MPZ"U)$[?A>:)KCBPC']))'!#4F^6=-9H7@ZAGMB@7Y%PCR%*,]
M=8SV=)I+BO:CB/<'.B=F$)BT,7:;'&@<6F+TP\%949 SMB Q_>A0VL^_7KTY
MFWW'AY&#"YFXR;JL%R1[I%1RLRV6R6+/C_^K;LH\^3OI+F+)GYMU5I$.$]-1
M)?_(&N*IF>#PB]3;EZ+IP>RMVO0>I*X3<1WIB:;NUQO&[J+,K+:C_>QJ-L8T
M^ZY?$!)/-C(UAEY#@5>JGK.>U$$CN(#&QD00.CQ')[?(Q/JXW>/O.K\2@A>9
MBDAF.8W<LAB06EUB+4H/&HO0)ELC]B&)@^B=NMT5G1BH%8G>.DW$TZ2A",VL
MC1CFMM_M:,CEAA;6ZLJJKBD6?:<$"1#%;4TT<!SJ;2 Y:!^9/T.M#]!"<]!A
MX^CH%!N6>V;M+29B6]1!/.J\7ZIA ;,42P]U<&C\@0A43B:>%@7:E-F2&090
MO&7ZVBW+2'HH2^B)5;8<XCJ8NK)>.HA!YUKW#69F/0X2L6FBU=$.^D:.T'$F
MV:D"6H^')R:Z([>=#4; *I;R24M<T)%Q8LT0KFN3@3:P% V?GAQQ8@2:U%7H
ML_RM=4:'EJLJB3@15"<E4YFU B3F#M+@) =8,OW>U R<F)M36CKAQF5/0B4J
M%7.TA#Q LZQ<6=Z#/G]!-+TCR]>(UBRJ5<F3PB&'9#,LMA0E"-<S%#$X$) 5
MQE%XUR\OWEO "O%6+5.DGB/L//XAKY>5,C$'%E >A"QS'!1-"&9C?B^(RJ'1
M;^D?@@?" .$C=DKB=(^)Z ]M\!1HG!M@M(9VB:V#.L"T=65=SXC-H0$2P@<0
M9=I]!3#3P1(S%/F=T 4F*HGLRLDD=H1D6W4Z&<FH#$PH_6=.Z3^;5/JOLU8T
M%__PEFPFX3F'KM\3DJ&%@9OQ^9@I^-KAW2=+_&""3Q1FL)L R3DC\=B21B/$
M0"0K"WHT9_>B[01X,Q8A1;NF<X(V(L FPLZGU9#1W$ILA]BLA+)0J.9]M&Q)
M@[:%P!8+CN*8P=]:6>GHDDD-,Y0DK;<T1*QW)D>D('E#'@4-2Z::1(71S^NZ
M(2=#U,Z#DW=OKEZ?G,);Z6'BX.AWO$QH!]FBP!#:@-FKHO5! ]ZXIP0MH_IH
MW1N&1UV"&<YT_%@\=J1!%9<?WQA-?;<10[6WN!K<MR#@1R,6W=D=G=!F'U@#
MN%Y%UZMRNN13>$."L5T0I]N 6)I\,WN27CQZ;*E\+VT5F3&%6QX46U.2G0\Y
M-;E4.!MBN<8_P[.0OR?03&&[!AERW6 +4K=%SAO>(@+-MC$3#P!,*0$$1;39
MFCB-CV%C"(\H.%%JGSOH]ATAMY_@UOU" Q!A%EV:_--T0B4"A&_(\<32F1CO
MA*JDH]X9.JLS=65?,^F3=]ZL3>&_[YPJ^&Y25J^\2(T)^F>_G(0_!\(<X)1=
MMH/: QI$B,>C)E@BE=Z4>3AP0>C\L]NL**$!S\ADG+7$(6+K860"N6<A)S$
M C3JWO!9F8S H&4HR2I !9Q'2^9I">/SG%T879!X14^:G?1T#3Y2B13M/0!
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M-NIZ4' 0EG[0@GL"(J0S;)JV\EC%A6519U&XPHT@4))IQH@]O/TNXST61S?
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M\ -+<6#+X]PH(\(@T!"\'([:6L'/N,#*QC^_)/8HF=GQ7KZ8BT<.3^RA:LK
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MO/$Q]N01VS-KL& RQU^[*V*]5T36%1&Z(AY*X*C$X006_Z-%4HEMJXT-SA1
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ME$>6A64QAR3,BCR<%Y>T*I(RC.,4'I FE%<.S7BW3G)2;#[/PSR+(2/7]+*
MI"S#C#KMX$GD9JHC?NOX,Q,H[<C>L9#*DEZ'+ ;ACJ2/5/HC*^.D2%;?Z?KI
M1 T;TMFKTO"M!Z'3M&62K,B<<)D?*XJD&H16&>ZP+MXZ'Z*CPYUTNO-7F*$L
M2,O].3_M3K?D=7\Y_##OK]C/3.\X,1:X)=?XXG(>@.ZOK?[%JM9?%1MEZ>+Q
MRSW=]*B= 7W?*F7'%Q=@^N^P_A=02P,$%     @ T(1N5GG);"[E!0  >!
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MA@J0EX>%LB'9RI3/#TRJ8MQ<+M4!"[@>H.[/&9/;AGY ?62;_@%02P,$%
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M[9A&6KAS;U>HE[Z=&<A5+6US/W76KF/>^$:Q9Y]0)VT:WP^:I@W?,4W[VX#
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M+$I?K@A>$*X&R+\O&1.O%^I.C_S.GNG_4$L#!!0    ( -"$;E93U3+620,
M +<+   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;*U6:T_;,!3]*U8V
M32"MY-FDL#82$-"0AH9@C\]N>MM8)'9FNRW;KY_ME-"F)O"A7QH_[CGV.;ZU
M[WC-^*,H "1ZJDHJ)DXA97WFNB(OH,+BA-5 U<R<\0I+U>4+5]0<\,R JM(-
M/"]V*TRHDX[-V!U/QVPI2T+ACB.QK"K,_UY R=83QW>>!^[)HI!ZP$W'-5[
M \B?]1U7/;=EF9$*J"",(@[SB7/NGV6^IP$FXA>!M=AJ(RUERMBC[MS,)HZG
M=P0EY%)38/59P264I692^_BS(77:-35PN_W,?FW$*S%3+."2E;_)3!839^2@
M&<SQLI3W;/T5-H*&FB]GI3"_:-W$)HF#\J60K-J U0XJ0ILO?MH8L07PXU<
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MIEFHRAJX#E#S<\;D<T<OT-;JZ7]02P,$%     @ T(1N5@&S$>8/!   &1,
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M6.@:HG,%J9SU(]AS<(:C.#SPGN*=4H>/IXQR6]ER1F<L9^K5Z0#OKSA.<'3
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M,).JZ.:JVA*WC:(X U,FJ&G /W?/4C_C'M6F>5>4.>&F#__:U'43.*]4-X[
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M%@E5$)&0YDS1A/W",<L4X&Z*A%PVW]%^0ZGPG+=;K]C3J Z^8UNO6&N*+S7
M7.L44A"SLN.2J*/(5/7)K5?KIFY4]C);ZV-L]JK>[ ]-U2E>4C%CF20)3)'2
M.NFA/E%U7]5$\;SL1VZYPNZF',;8L(+0 ?A\RKE:3?0&=0OL_P902P,$%
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MD(B&31P_$S$>/I,1[MW#)>J5[S8&,E5+VUS)[6K;T,Z;>_QW>-,-KYE><6E
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MI%,2S?!H#,5KVT[G7.GF;)>EGK<@C(,^7W"N-H8)T$WPY!]02P,$%     @
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MKCT^L#L[J439/ZI!3Q4T-,?9^_\Y.9G,@FZ'!0T 0&D42F-0&D?1S&/_;0#
MLP< ##4145:QI:JKDUEOWV6G#=46E!8VM(Y2'>?@0#:T6 JE,2B-HVBFN%H_
MW[.?(?BZU-1EGB[T>'@OLXT66+Q,],?:=*A&TV;0K!:"8K%(JAB4GK*WHZO*
M'T7:;XO9RQXL1>=@%C*;'.R'#:&%1E :A=(8E,91-%.(K:OOV5W]MZVVGA2G
M^[E8_Q1WO6.HG3=87%N:XYICJ-,5%]3"A](HE,:@-(ZBF>+:>W2.W<(_Y@DF
M=L1@/6&?F.,==GW=YY-$7L]Q ;_[$!-HO1B4QE$T4R2MX^Y9[=16)&N1],^L
MH!8[E!8VM'V%!)/9P;3*/[2BG(G7U0C4$H?2.(IF:J2UQ#V["_U!?)>O'_1\
M23Z-4J^J9]<EJ\UJ9RAL_89J(*LG['K>I&2Y4;W[8^W%#994T#^][BX$H:5&
M4!J%TAB4QE$T4WRM8>[9#7-S(9ADL9*BJ#Z0<BE)-7TOM^&:^OF6O7*#NND-
MK3MG\KMJ@^[NA](HE,:@-(ZBF6IK37?/;KIWMCV0?\D1^_WMS,$"@^[WA](B
M*(U":0Q*XRB:J</6V/>P^_T]J'</I8506@2E42B-06D<13,EV/KYGMW/_UND
M&W.;?[XIB^KY54EVUZM!J+_?T/;G]EYPZ'M!W7THC4)I#$KC*)KY:-76W??M
M[OZ'_+X*;(M[J<1=+;(XS8OJ4E'F\?<^==F)0]4%I86_N%L_( OQV!?KC*#U
MH% :@](XBF8JKK7\?;OESU1>%&2M\EC*14%N5;YZZMB(;$XV]>ZQ\ \-^,-^
MZ-)>^F ]0=U\*(U":0Q*XRB:J;'6S??M;O[AXN']U;M/GWM5!?7QH;002HN@
M- JE,2B-HVBF^EJ[W\<^*M^'6O]06@BE15 :A=(8E,91-%.">X_,MP<3]L*9
MN^UGMVF>JV?W!-F!@T7H]WISW3V,T$(C*(U":0Q*XRB:J:XV#.';PQ T45I/
M7_64+5[VBPD:5X#20B@M@M(HE,:@-(ZBF9IKHP_^%#NH0F,-4%H(I450&H72
M&)3&4313@FU(PK>')(XZ,6)G#-;=X=;W:LW;-=^.2Q;YA^\+Z$E&H;? H#2.
MHID2:*,!OGVSO#'RZ67EP*>;V>F#Q0$-#D!I$91&H30&I7$4S51D&QSPL2\4
M\*&Q 2@MA-(B*(U":0Q*XRB:^::N-H80V%WU@9V@G394@5!:"*5%4!J%TEA#
MVY\+.)-99[\F1Y5I*JN-%03V6,$7&>?9PK;2M ,&BPD:/(#2(BB-0FD,2N,H
MFBFZ-G@08-\P$$ C"%!:"*5%4!J%TAB4QE$T4X)M!"&P'Q@X:J5I9PS6'31L
M$!R>&'!Z%J3'):/0NK'@\*!"3Z$<5:@I@=;!#^P.OCGT#5]JVO&#U8&DA5!:
M!*51*(U!:1Q%,R6Y]TI>[-L$ NQK>;'OY85& : T"J4Q*(VC:*8$VRA  'V;
M@)TV6('0( "4%D%I%$ICP>&#BIRSJ=,=;Z'F_KA82EF&HA3S\Y54=_)2IFE!
MZM="7XRJM<#N*E'RMGKH]INW[FA\<#UTWE"GNCYN,?/SM;B3'X2Z2[*"I/)6
M(R<G,WV#*KE;[KZ4^?IBI-<R-WE9YJOZXU(*K=XJ@?[];9Z73U^J AYR];VN
M]OS_4$L#!!0    ( -"$;E:<^8K05 0  & 3   9    >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;,U8;6^C.!#^*Q:W.K72MF @A/222$WHZ5;:757-]?;#
MZ3ZXX"16 >=LD_3^_=F&$B .[:[0Z?JAX66>AWEF/,/@Z8&R9[[%6("7+,WY
MS-H*L;NQ;1YO<8;X-=WA7-Y94Y8A(4_9QN8[AE&B05EJNXX3V!DBN36?ZFOW
M;#ZEA4A)CN\9X$66(?;/ J?T,+.@]7KA@6RV0EVPY],=VN 5%H^[>R;/[)HE
M(1G..:$Y8'@]LV[A301'"J M_B#XP!O'0$EYHO19G7Q*9I:C/,(ICH6B0/)G
MCY<X3163]./OBM2JGZF S>-7]E^U>"GF"7&\I.DWDHCMS HMD. U*E+Q0 ^_
MX4J0=C"F*=?_P:&R=2P0%US0K )+#S*2E[_HI0I$ P"#,P"W KA=@'\&X%4
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MX.!>KJ-R0/SSLR0&GP3.^%_&%,!!4S D6S046SL%[C$%;N_R52FXJG/ CSG
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M ?O[5"GSO%+L8/VEG^'_4$L#!!0    ( -"$;E8E0'ZR_P(  '0)   9
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M:/[6'K;+C@;:;%V4V7([N-J"9;K:_!M_W3X1>P-TZYD!QG: <>P <SO /':
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MDR@]W!#L$RHKB-]72<)?3V0'Q3\J9O\!4$L#!!0    ( -"$;E:8-B@'S@0
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M[2]:.]O1*$#%4BI>-V#M04V8^\?/31RV /$A0-( DGW X "@WP#ZKP4,&L#
M1L9)L7'(L<+96/ U$L9:LYF!#:9%:_F$F;0_**%WB<:I[(85O ;T S^#1)_1
MUZH"FPGTLH'NL0)T#P5G!:$$VWR=Y* PH?+C.%3:#4,6%LV1E^[(Y,"1<8)N
M.5-SB;ZR$LI=@E#[WXI(-B(NDT[&'(H>ZL>?4!(EB<>AJ]?#8P\\?ST\ZE#3
M;U/2MWS]HRE!.9$%Y7(I /V^F$HE]#7YXXNX8QSX&4WI.)<+7, DT+5!@EA!
MD'UX%X^B+[YHO259_D9D.Y$<M)$<=+%GUU""P!0I'4JA/V)?Y!Q#[))KBN0J
MBWKF,UAMA^155ODQJQT1PU;$L%/$@S+73S47E.F7@%=HHVP*#"JB?,(<:QSO
M.!,-]I7YS8;[TOQF:=^O;=1J&W5JNP-=NADPA8B"6B+,2L35'(0NW>72O@S2
MIZV;]23MQ=%[7V6Z.@*,>R,_,#\"C#S G8BD;4323J;O1KU/<C=,.S \(#GU
M9BY*]A*<>KY=?W)/6RFGG3X]8KITCP6FNKO K/!>P&Z2DS@]J.P(,AGTT@/9
M/(9,/<B=&)RU,3CKI'IY3XFKZEVEZ*PK!4[R<9.\T\2)"+?ZA1K$S/9=$A5\
MR91[==O5MK6[L!W-WOJE;OE<A_9"X_K%6RQFA$E$H=*442_5!42X'LQ-%%_8
MKF3*E>YQ['"NVU80QD#O5YRKS<0<T#;"V7]02P,$%     @ T(1N5BQ/-:F6
M P  C!$  !D   !X;"]W;W)K<VAE971S+W-H965T-S N>&ULK9A;;YLP%(#_
MBL6F7:2N7)NF78+4E-TT5:K:79X=. G6C,ULIVG__6R@%"+*DLTO#79\OL/Y
MB%V;V9:+7S('4.B^H$S.G5RI\MQU99I#@>4Q+X'I;U9<%%CIIEB[LA2 LRJH
MH&[@>1.WP(0Y\:SJNQ;QC&\4)0RN!9*;HL#B80&4;^>.[SQVW)!UKDR'&\]*
MO(9;4-_+:Z%;;DO)2 %,$LZ0@-7<N?#/$S\T =6('P2VLG.-3"E+SG^9QI=L
M[GCFCH!"J@P"ZX\[N 1*#4G?Q^\&ZK0Y36#W^I'^L2I>%[/$$BXY_4DRE<^=
MJ8,R6.$-53=\^QF:@DX,+^545G_1MAX[T1G3C52\:()UNR"L_L3WC8A.0! \
M$Q T <&^ 6$3$.X;$#4!466F+J7RD&"%XYG@6R3,:$TS%Y7,*EJ73YAY[K=*
MZ&^)CE/Q#2@B0#](A:XI9J]>3 ,O?(_>)* PH?(M>H<N[ODG8"CR_*_5&/02
M$8:^Y7PC,<ODS%7Z/@S-39N<BSIG\$Q./T!7G*E<H@\L@ZP/<'4!;17!8Q6+
M8)280'J,0O\(!5X0H.^W"7KS\NW C5WNC_%',,G^&&\8TZLR;)]56''#9[DK
MW9.A!3!]53^P(?LU)1JFF(7D7)8XA;FC5PH)X@Z<^-4+?^*]'S)F$Y98@O7L
M1:V]:(P>7ZP!45)H;WJU1$#)FBP))>H!*8Y*+!1)28D5F!^WR@&5S]BMLTRJ
M+&95O8O]Z<R]ZSH;O9%#G5F"]9R=M,Y.1IU]*$K*'T"@5,]7098;LU8/SOB:
M<]*U$GEG.UX&!H71I#\H&1CD1WX[J%?'I*UCLE<=KR6Z[%1RA#X2(17Z)C#3
M_U"'ZAKE'CJ7;,(22[">S]/6YZF5E>C4ICV;L,02K&=OVMJ;COX:K[!*<\+6
M?Y]5-<</.I/!._;"G6DUFNU0,99@/3%GK9BS?:8I],3HW8[6!=D1*D&D>J,R
M).IL+U&CV0\590G6$^5[3]LV[]]6M%O0\K*Q)6V<?.BLM$I+;-'Z5CN;8=_*
MNM9@;"FT24MLT?H*@R>%@:7%K0'M3EI_9]*.YSO8CB5:W\[3#MX?W>+^QPK7
M@'=M!;NVK.[7;=%J6V[GF%J 6%?'?:E5;)BJSWIM;_M*X:(Z2._T+\RKANKX
M^X2IWU-<8;$F3"(**XWTCD_U/E+41_^ZH7A9'8:77.FC=769 \Y F 'Z^Q7G
MZK%A$K0O8.(_4$L#!!0    ( -"$;E91,0=@H0,  .80   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<Q+GAM;*U8;8_:.!#^*Z-<5;52;_-"".P6D'8AIZO4
MK59+>_?9FPQ@-8ESMEFV_[ZV$[*$#3F0_ 5B9Y['XWGLL2>3'>,_Q091PDN>
M%6+J;*0L;UQ7)!O,B;AB)1;JS8KQG$C5Y&M7E!Q):D!YY@:>%[DYH84SFYB^
M!SZ;L*W,:($/',0VSPG_=8<9VTT=W]EW/-+U1NH.=S8IR1J7*'^4#URUW(8E
MI3D6@K(".*ZFSJU_$_N>!AB+?RCNQ,$SZ*D\,?93-[ZD4\?3'F&&B=041/T]
MXQRS3#,I/_ZK29UF3 T\?-ZS_V4FKR;S1 3.6?8O3>5FZHP=2'%%MIE\9+N_
ML9[04/,E+!/F%W:UK>= LA62Y358>9#3HOHG+W4@#@"*IQL0U(#@&!"=  QJ
MP. 8$)X A#4@/!<PK %FZFXU=Q.X!9%D-N%L!UQ;*S;]8*)OT"I>M- +92FY
M>DL53L[F+,^I5,I+ :1(8<X*28LU%@E% 7_"$ODS31!NUQRQ,OM&."=:7OBP
M0$EH)CXJPQ_+!7QX]Q'> 2W@^X9MA:(3$U<J)_50;E([=%<Y%)QPR(=[Y<)&
M0%RDF';@Y_^##WH(7!6=)D3!/D1W02_C I,K&/B?(/!\O\NAL^%!T %?G _O
M&CT^'^[U!&/0K)>!X0M/K9?OR]>UT*5N+URGO1M1D@2GCLIK0BTN=&;O__ C
M[W-79&V2+6R2Q9;(6AJ$C0:A81^<T.#MGNP2(K0IA$VRA4VRV!)92XAA(\2P
M=S-\52H4 F&%""1GV^X=T<MQJ1 5V="0Z4O \RP(1N.)^WP8X ZC,(K:1O%;
M(W\TN&Z,6@&)FH!$O0'YQJ1>F"5RRE)0UQB0R-6I1<RE@*V ]*6.7NY+ ]7O
M: 2Y.22ZEJ=--V)+9"TU1HT:H]Y)WA.APK\_PL5KO@!UQX*Y,J<)R>!1#4QX
MLC'G_R-F1&+:@+ITZAWU4IULDBULDL66R%K2C1OIQA92_-BF$#;)%C;)8DMD
M+2&N&R&N>_?07H@F<=6)'DI"4]B6*JWA"R;;LQ+<]=N4._3;:7G>Z\ZE,M@D
MBRV1M63PO=<ZQ>L5XH'\,N'7AXJH15'G;G>%T4MUZ<:HV5JR!</PZ,SMLO(]
M[^C0[;0:1$>GKGM0S^7(UZ:0%I#HA5?5+4UO4ZS?FA+UJ'^NBWA3)[[25%\
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ME!9 :2&4%D%I,8K6E4GKDKIVF_0J5SSAV]W<YM2\]=:,4.9I1Z^RH'8JE!9
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M9EI6,<]'IG2+>G1*:6>/?JV#+Z1_4=*_J*5_S;6QY)MF$FO)*@ZUYL^-ZX;
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M9>G@^&%!-Q5JET#?UXKXVL"=GN[N2_\"4$L#!!0    ( -"$;E8. NN$Z@,
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M#//6=R)]E--'.9;E0L;5%\OCYL3FXYYI'(=A%&$K.AX['8RQ=8LB^'&K8=Z
M@>6!3*];:WRW\0IYO@ZP/7VN0K"9XI6(S11?:T#<ZP:,.';O-I8'&-@N8+4#
M^=UYH*;<G#"$7<6\87<PCL0QAD MNFLTBI#5B>#KWA_L+@G#.'8C@+D=A"&&
MP-V((Y@#\( A85B]!_?>1_[F/>5O_P<Y^@M02P,$%     @ T(1N5I>*NQS
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MJXU@>LLN:BN5L!9PO4>XWM-RY755<?,2P'+YH*1_&U>.38I"U\I) /D!@?Q
M"[E03_X";5[@N#S$!N8A+= EEX;=\;(6[+/@UO^RX0V0#M4&L3>N/9* S]<(
ML\6(6!<^(]GY?.&%<;5A\V^UW(4W_,F6HA,PS!<C8F$L?(ZC'L*'LHFU/L%X
M0X>)8D1LBM>^:-F*O_# & +I3YI:^(!^AYB8*D;$KKC6ZJ&_%J9B,W'OOC0A
M#,-*.&(S.)*,,%F,B&UQP:TLFA#.9%D['\)K;2WSCRB;ZJJ"F)@N1L2^R)TN
MOO8]K ?T7/Y.]M<4<(1I8T3LC84J="78FG_OCC28)4;$FK@53K8C,5N57'V!
MZ3)FBXC8%N&YDBY<9)L';^IK*E_>"%7(3O B3!H1L33R^MZ*;W4(WORI*[,(
M+3:(]9'[>VQJ/^HM%JS?.+>YI@GD/S5,YB-,(1&Q0M \ZDL$,3&71,0NP3%C
MB(FY)")VR<^$C[U;!^79/R 9IH^(6!^',[^#F)@^(F)]M"G@02S,&A&Q-9!<
M,+!"3$PD$7F]<2@?/!3-&/-*3.P5-#'LC#DQ9I:8NAS!$L,N)B::F%@T:&+8
MQ43GMJA%<R0Q?'TZ(28FFIA8-# _/-AQ,+W$Q'K!+9A 3,PU,;%K<,P48F*N
MB8E= V0]$X[+LOM#8[Z)B7USQ-9]UF:5$!/S34SLFZ.8;0.<L,9\DYQDULMC
M+KDQ'%8,">:;A-@WQW_TIA-!3,PW";%OVA2MWPSB6C7%H>_H:^UXR7P;Q,1\
MDQ#[YC63]-&K=[NR":4'O."^P"X$@RL^";J:0NR;GYB7=3/1_CFL9M85:\ZS
M%<3$S)-03Y+M,=LN(Y_$P4$SP;23$&L'2]+[>0$Q,>TDQ-I!:XD93(023$$)
M^439P5IBW^\A)J:@Y#0E3Y]-*FTZZT IIJ"46$%',=MN#S$Q!:7$"CJ*^<:4
M*::@E%A!1S%O]0LO.YB8@E)B!>%U+IRT2C$%I=0*0NO<#B:ZI'_*=9I.\9-B
M%DI/N4[3C29FH?1$ZS2^$]UT-Q*EF(52ZF7^XYBARH28F(528@MAF+X)[C?!
M+)016PB-9F>J*,,LE%$OZ:"8L MEF(4RZA6>XYBWPD(+99B%LE--O#71A.-F
MAEDHHU[A.8XYKW8EQ,0LE%%/P:'1A'-;&;JUC-A"G6G,/EL+G[.;,"<WD]MM
M9WC/, MEY%-P'<Q?BTN(B5DH^XV;!L+SZ$/8; -F;0/$Q"R4_>9]! =+]#$F
MH/$I=Q2P/L3$!#0F%A"*V?'D&!/0F'I#,XH)/3G&!#0FWV+0W:%Q^+'$W#.F
M=@^V5Z/[>V/N&3?N&307VT\?-V(KE=@L_4=8?[[@9;$R++RT>QN3-.PZVM9E
M.?7G;M2UYIO]OP[L_^WAT[]02P,$%     @ T(1N5F?\4D), @  :"P  !H
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MWCFW_\_QT[/L;3N\Y+/IG[7K/U!+ 0(4 Q0    ( -"$;E8'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ T(1N5N(=[H3N    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ T(1N5IE<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #0A&Y6
M\:F"&I,'   K+P  &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ T(1N5CVJ A,Y @  N@4  !@
M     ("!U@\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M -"$;E;06B2K_04  &87   8              " @442  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " #0A&Y6X:72MO$"   M"   &
M            @(%X&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ T(1N5A?>,7>*!0  7!<  !@              ("!GQL  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( -"$;E8?H\P#, <  "LQ
M   8              " @5\A  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " #0A&Y6>DW@NG$*   H-   &               @('%*
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ T(1N5BJ!A!%=
M P  +@<  !@              ("!;#,  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( -"$;E8Q0?6H3R<  %)[   8              "
M@?\V  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #0A&Y6
MF%(QSK "  #_!0  &0              @(&$7@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( -"$;E8-W3JN+P<  )\6   9
M      " @6MA  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ T(1N5F0F^S99"@  S3D  !D              ("!T6@  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #0A&Y6)7ZO)CH#  !*!P
M&0              @(%A<P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( -"$;E9P&1UH,P4  %X,   9              " @=)V  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ T(1N5OEK(6E]
M @  ^P4  !D              ("!/'P  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " #0A&Y6F,]->B0,  !S(0  &0
M@('P?@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( -"$
M;E:2WPB\MP,  &@(   9              " @4N+  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ T(1N5OSO&T9&#@  *BP  !D
M         ("!.8\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " #0A&Y6RH-LCP\*  !*&@  &0              @(&VG0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( -"$;E;_4,61G0,  $L(
M   9              " @?RG  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ T(1N5A9] >B8$P  V30  !D              ("!T*L
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #0A&Y6DQJQ
M++,#  #Y!P  &0              @(&?OP  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( -"$;E:]'O:)/ ,  #X'   9
M  " @8G#  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MT(1N5O,XF9#@)0  ='T  !D              ("!_,8  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " #0A&Y6"WZK+=<"  #+!@  &0
M            @($3[0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( -"$;E;>!>+.P (   H&   9              " @2'P  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ T(1N5K)D,^Q8!0
M;!(  !D              ("!&/,  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " #0A&Y6U /L39X$   E#@  &0              @(&G
M^   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( -"$;E9.
M.NBT30,  $,'   9              " @7S]  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ T(1N5J5!EGQ*!   1 X  !D
M     ("!  $! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -"$;E;S^OLE.@4   0,   9              "
M@6L5 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ T(1N
M5O'B+$YF!0  !!T  !D              ("!W!H! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " #0A&Y6<O=NS^T"  #""0  &0
M        @(%Y( $ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( -"$;E8.Q3_^2 ,  +X-   9              " @9TC 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ T(1N5MO4"*,!"   ?5<
M !D              ("!'"<! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " #0A&Y6M0*<4RT#  !K"   &0              @(%4+P$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( -"$;E9%$X-W
M? (   H&   9              " @;@R 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ T(1N5EX>C:/]!0  Y3,  !D
M ("!:S4! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #0
MA&Y64]4RUDD#  "W"P  &0              @(&?.P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( -"$;E8!LQ'F#P0  !D3   9
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M970T."YX;6Q02P$"% ,4    " #0A&Y6R)P(?O8#  #V$@  &0
M    @(&54P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M -"$;E;?)_L=A@(  +,&   9              " @<)7 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ T(1N5G^(]FH  P  00P  !D
M             ("!?UH! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " #0A&Y6PM71S*T"  #R!P  &0              @(&V70$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( -"$;E9N/*SWDP(
M ,T'   9              " @9I@ 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ T(1N5EQ&T=F+ @  " <  !D              ("!
M9&,! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #0A&Y6
MT]EQZHD#  !<$0  &0              @($F9@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( -"$;E:%&!WR]@L  &.'   9
M      " @>9I 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ T(1N5ISYBM!4!   8!,  !D              ("!$W8! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " #0A&Y6KGTVS  #  "#"@
M&0              @(&>>@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( -"$;E8FQ(GO\P,  &(4   9              " @=5] 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ T(1N5K,2,B<@
M"   ]4<  !D              ("!_X$! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " #0A&Y6)4!^LO\"  !T"0  &0
M@(%6B@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( -"$
M;E;S[0G$T 0  &H5   9              " @8R- 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ T(1N5M$VH;)3#0  7\P  !D
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M=#8W+GAM;%!+ 0(4 Q0    ( -"$;E; R5:_R@(  )P(   9
M  " @3^S 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @
MT(1N5H4CPK<S P  % L  !D              ("!0+8! 'AL+W=O<FMS:&5E
M=',O<VAE970V.2YX;6Q02P$"% ,4    " #0A&Y6+$\UJ98#  ",$0  &0
M            @(&JN0$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4
M Q0    ( -"$;E91,0=@H0,  .80   9              " @7>] 0!X;"]W
M;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ T(1N5@Y/JNOI!P
M=4H  !D              ("!3\$! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX
M;6Q02P$"% ,4    " #0A&Y6=GDK]>(#  "Z$0  &0              @(%O
MR0$ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( -"$;E;4
MC3NE/ (   <%   9              " @8C- 0!X;"]W;W)K<VAE971S+W-H
M965T-S0N>&UL4$L! A0#%     @ T(1N5@X"ZX3J P  B1   !D
M     ("!^\\! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4
M" #0A&Y6OR!%*44#  "0%   #0              @ $<U $ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( -"$;E:7BKL<P    !,"   +              "
M 8S7 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -"$;E9BQ]>LO 4  'HQ   /
M              "  778 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #0
MA&Y69_Q20DP"  !H+   &@              @ %>W@$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #0A&Y6AJ9C2 P"  !A*P  $P
M            @ 'BX $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     4P!3
+ +P6   ?XP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>288</ContextCount>
  <ElementCount>398</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>77</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Accounts Payable and Accrued Expenses???</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses???</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Long-Term Debt???, Net of Debt Discount and Financing Fees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFees</Role>
      <ShortName>Long-Term Debt???, Net of Debt Discount and Financing Fees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Basic and Diluted Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/BasicandDilutedLossperCommonShare</Role>
      <ShortName>Basic and Diluted Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Retirement Plan???</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan???</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/Inventory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/FairValueMeasurement</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/IntangibleAssetsNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Accounts Payable and Accrued Expenses??? (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses??? (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Long-Term Debt???, Net of Debt Discount and Financing Fees (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesTables</Role>
      <ShortName>Long-Term Debt???, Net of Debt Discount and Financing Fees (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFees</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Basic and Diluted Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareTables</Role>
      <ShortName>Basic and Diluted Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/BasicandDilutedLossperCommonShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/StockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/InventoryTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Fair Value Measurement - Fair Value of Instruments Classified as Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details</Role>
      <ShortName>Fair Value Measurement - Fair Value of Instruments Classified as Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Fair Value Measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>Fair Value Measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Fair Value Measurement - Significant Inputs Included in the Valuation of the Debt Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value Measurement - Significant Inputs Included in the Valuation of the Debt Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Leases- Components of Total Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails</Role>
      <ShortName>Leases- Components of Total Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Property and Equipment, Net -Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, Net -Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Intangible Assets, Net - Components of Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails</Role>
      <ShortName>Intangible Assets, Net - Components of Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Intangible Assets, Net - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IntangibleAssetsNetAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets, Net - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Intangible Assets, Net - Future Amortization of Patents and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails</Role>
      <ShortName>Intangible Assets, Net - Future Amortization of Patents and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Intangible Assets, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails</Role>
      <ShortName>Intangible Assets, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Intangible Assets, Net - Royalty Fees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails</Role>
      <ShortName>Intangible Assets, Net - Royalty Fees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Accounts Payable and Accrued Expenses??? (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses??? (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Long-Term Debt???, Net of Debt Discount and Financing Fees - Schedule of Carrying Values of Outstanding Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails</Role>
      <ShortName>Long-Term Debt???, Net of Debt Discount and Financing Fees - Schedule of Carrying Values of Outstanding Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Long-Term Debt???, Net of Debt Discount and Financing Fees - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails</Role>
      <ShortName>Long-Term Debt???, Net of Debt Discount and Financing Fees - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Basic and Diluted Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails</Role>
      <ShortName>Basic and Diluted Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Stock-Based Compensation - Overview of Equity Incentive Plans Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Overview of Equity Incentive Plans Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Stock-Based Compensation - Summary of consolidated statements of operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of consolidated statements of operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Stock-Based Compensation - Stock Options Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Options Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions Used (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted-Average Assumptions Used (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Stock-Based Compensation - Restricted and Performance Stock Units Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted and Performance Stock Units Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Stock-Based Compensation - Summary of Restricted and Performance Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted and Performance Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock-Based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions Used For 2017 ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted-Average Assumptions Used For 2017 ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Income Taxes - Temporary Differences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails</Role>
      <ShortName>Income Taxes - Temporary Differences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Retirement Plan??? (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/RetirementPlanDetails</Role>
      <ShortName>Retirement Plan??? (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/RetirementPlan</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Commitments and Contingencies - Service Agreements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Service Agreements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Commitments and Contingencies - Axogen Processing Center Facility Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Axogen Processing Center Facility Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Commitments and Contingencies - Fair Value of Debt Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Fair Value of Debt Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/SubsequentEvent</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="axgn-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccounts</ParentRole>
      <Position>75</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  axgn-20221231.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:DeferredTaxAssetsDerivativeInstruments has a value of -28000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:DeferredTaxAssetsDerivativeInstruments fact are: Context: if17b0477fc984ecfa301826bf71b2eb6_I20211231, Unit: usd, Rule Element Id: 3027. axgn-20221231.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome has a value of -4000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome fact are: Context: idb63c57e724a4e6e8ad20ee65119370a_I20221231, Unit: usd, Rule Element Id: 3247. axgn-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="axgn-20221231.htm">axgn-20221231.htm</File>
    <File>a2022consent.htm</File>
    <File>axgn-20221231.xsd</File>
    <File>axgn-20221231_cal.xml</File>
    <File>axgn-20221231_def.xml</File>
    <File>axgn-20221231_lab.xml</File>
    <File>axgn-20221231_pre.xml</File>
    <File>axgnfy21q4ex32.htm</File>
    <File>axgnfy22q4ex311.htm</File>
    <File>axgnfy22q4ex312.htm</File>
    <File>exhibit1023thirdamendmen.htm</File>
    <File>exhibit10253secondamendm.htm</File>
    <File>exhibit10301firstamendme.htm</File>
    <File>subsidiariesofaxogen123120.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>axgn-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="908">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>104
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "axgn-20221231.htm": {
   "axisCustom": 1,
   "axisStandard": 31,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 908,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 288,
   "dts": {
    "calculationLink": {
     "local": [
      "axgn-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "axgn-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "axgn-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "axgn-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "axgn-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "axgn-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 623,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 15,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 19
   },
   "keyCustom": 65,
   "keyStandard": 333,
   "memberCustom": 34,
   "memberStandard": 40,
   "nsprefix": "axgn",
   "nsuri": "http://www.axogeninc.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.axogeninc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.axogeninc.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Measurement",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.axogeninc.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.axogeninc.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.axogeninc.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Intangible Assets, Net",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.axogeninc.com/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Accounts Payable and Accrued Expenses\u200b",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.axogeninc.com/role/AccountsPayableandAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses\u200b",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Long-Term Debt\u200b, Net of Debt Discount and Financing Fees",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFees",
     "shortName": "Long-Term Debt\u200b, Net of Debt Discount and Financing Fees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Basic and Diluted Loss per Common Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShare",
     "shortName": "Basic and Diluted Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.axogeninc.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.axogeninc.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.axogeninc.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Retirement Plan\u200b",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.axogeninc.com/role/RetirementPlan",
     "shortName": "Retirement Plan\u200b",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.axogeninc.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Subsequent Event",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.axogeninc.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Inventory (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.axogeninc.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Fair Value Measurement (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.axogeninc.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.axogeninc.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.axogeninc.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Intangible Assets, Net (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.axogeninc.com/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Accounts Payable and Accrued Expenses\u200b (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses\u200b (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Long-Term Debt\u200b, Net of Debt Discount and Financing Fees (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesTables",
     "shortName": "Long-Term Debt\u200b, Net of Debt Discount and Financing Fees (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Basic and Diluted Loss per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareTables",
     "shortName": "Basic and Diluted Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.axogeninc.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.axogeninc.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Inventory (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.axogeninc.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i443dfc9e27ca43fa95f569f05a0bbe28_I20200630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i43510f63e6ba4c3ca4047759ce1d9771_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "iefe9c570ebbd4043946a89fd045c1f82_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Fair Value Measurement - Fair Value of Instruments Classified as Level 3 (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
     "shortName": "Fair Value Measurement - Fair Value of Instruments Classified as Level 3 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i3799b9b46cfa4242a49caf62d6c4d193_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i05a09806c9ee410192e276bdee67d4ec_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Fair Value Measurement - Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails",
     "shortName": "Fair Value Measurement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i05a09806c9ee410192e276bdee67d4ec_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i4fb3c6271c204980bf4241e0ed97c838_I20221231",
      "decimals": "1",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Fair Value Measurement - Significant Inputs Included in the Valuation of the Debt Derivative Liability (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
     "shortName": "Fair Value Measurement - Significant Inputs Included in the Valuation of the Debt Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i4fb3c6271c204980bf4241e0ed97c838_I20221231",
      "decimals": "1",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Leases- Components of Total Lease Expense (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails",
     "shortName": "Leases- Components of Total Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "axgn:AssetsAndLiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "axgn:AssetsAndLiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "axgn:LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "axgn:AssetsAndLiabilitiesLesseeTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.axogeninc.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i0581e65b1022415ca3161ab6932a9f19_D20220127-20220127",
      "decimals": "3",
      "lang": "en-US",
      "name": "axgn:OperatingLeaseIncrementalBorrowingRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Property and Equipment, Net -Schedule of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment, Net -Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GovernmentAssistanceAmountCumulative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.axogeninc.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GovernmentAssistanceAmountCumulative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Intangible Assets, Net - Components of Intangible Assets, Net (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails",
     "shortName": "Intangible Assets, Net - Components of Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Intangible Assets, Net - Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.axogeninc.com/role/IntangibleAssetsNetAmortizationExpenseDetails",
     "shortName": "Intangible Assets, Net - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Intangible Assets, Net - Future Amortization of Patents and License Agreements (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails",
     "shortName": "Intangible Assets, Net - Future Amortization of Patents and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i65aa335ff06f439d8115f7904b82f8aa_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ie4725cd6d9b24bb59307c754dcac2d41_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "axgn:RoyaltyFeesPercentageUnderLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Intangible Assets, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails",
     "shortName": "Intangible Assets, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ie4725cd6d9b24bb59307c754dcac2d41_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "axgn:RoyaltyFeesPercentageUnderLicenseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "axgn:ScheduleOfRoyaltyExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ib87452ca58634dbaa8dd73c32eb97477_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Intangible Assets, Net - Royalty Fees (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails",
     "shortName": "Intangible Assets, Net - Royalty Fees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "axgn:ScheduleOfRoyaltyExpensesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ib87452ca58634dbaa8dd73c32eb97477_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Accounts Payable and Accrued Expenses\u200b (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses\u200b (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Long-Term Debt\u200b, Net of Debt Discount and Financing Fees - Schedule of Carrying Values of Outstanding Debt (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails",
     "shortName": "Long-Term Debt\u200b, Net of Debt Discount and Financing Fees - Schedule of Carrying Values of Outstanding Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Long-Term Debt\u200b, Net of Debt Discount and Financing Fees - Narrative (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
     "shortName": "Long-Term Debt\u200b, Net of Debt Discount and Financing Fees - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i2bda4fe5ea904b66952845b8d764cf1b_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCollateralAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Basic and Diluted Loss per Common Share (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails",
     "shortName": "Basic and Diluted Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ie6204757bdfb4234845eb99fcc2f5bde_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "axgn:ShareBasePaymentArrangementNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Stock-Based Compensation - Overview of Equity Incentive Plans Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
     "shortName": "Stock-Based Compensation - Overview of Equity Incentive Plans Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "axgn:ShareBasePaymentArrangementNumberOfPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ib744e6a9173947e59255d4550e92de8b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Stock-Based Compensation - Summary of consolidated statements of operations (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails",
     "shortName": "Stock-Based Compensation - Summary of consolidated statements of operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ib744e6a9173947e59255d4550e92de8b_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idf515d9a7de44eff9aae0e17da62fba2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idf515d9a7de44eff9aae0e17da62fba2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Stock-Based Compensation - Stock Options Narrative (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
     "shortName": "Stock-Based Compensation - Stock Options Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions Used (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails",
     "shortName": "Stock-Based Compensation - Summary of Weighted-Average Assumptions Used (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ic51b16331d104e7e8fdcef21b100803f_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "ie0025fc2dc404d0dad01eadf1cb3b540_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i1901933b221a4b9b954c7479477f3e4b_I20220525",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Stock-Based Compensation - Restricted and Performance Stock Units Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
     "shortName": "Stock-Based Compensation - Restricted and Performance Stock Units Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "id91fc5c40e6640dda04b21132c42f27c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Stock-Based Compensation - Summary of Restricted and Performance Stock Units (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted and Performance Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i071af8baaf7e4728b2d69621b6fd0358_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i1901933b221a4b9b954c7479477f3e4b_I20220525",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
     "shortName": "Stock-Based Compensation - Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i9ff1fe87cd0546b8b116eabe76752894_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions Used For 2017 ESPP (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails",
     "shortName": "Stock-Based Compensation - Summary of Weighted-Average Assumptions Used For 2017 ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "id8cb6fc3f1954e2c85d4edbdecdcd533_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Income Taxes - Temporary Differences (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails",
     "shortName": "Income Taxes - Temporary Differences (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "idb63c57e724a4e6e8ad20ee65119370a_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.axogeninc.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i05aa70972d464831a814056c33b271a3_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "axgn:DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Retirement Plan\u200b (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.axogeninc.com/role/RetirementPlanDetails",
     "shortName": "Retirement Plan\u200b (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i05aa70972d464831a814056c33b271a3_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "axgn:DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i73105f432ef241c4a97fc1d3d88fe6a3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "axgn:LicenseFeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Commitments and Contingencies - Service Agreements Narrative (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails",
     "shortName": "Commitments and Contingencies - Service Agreements Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i73105f432ef241c4a97fc1d3d88fe6a3_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "axgn:LicenseFeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Commitments and Contingencies - Axogen Processing Center Facility Narrative (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
     "shortName": "Commitments and Contingencies - Axogen Processing Center Facility Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i7a73dc524bc0487f8a26096a8e638192_I20190709",
      "decimals": "-3",
      "lang": "en-US",
      "name": "axgn:EstimatedCostRelatingToDesignBuildAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i43510f63e6ba4c3ca4047759ce1d9771_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Commitments and Contingencies - Fair Value of Debt Derivative Liabilities (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Fair Value of Debt Derivative Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i872b209a46c14c878edd3c5a93dc57b8_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "axgn:NumberOfPotentialSettlementScenarios",
      "reportCount": 1,
      "unique": true,
      "unitRef": "settlementscenario",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i63b272a784f043b28b8f70d792398c9d_I20230310",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "axgn:CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Subsequent Event (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.axogeninc.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i63b272a784f043b28b8f70d792398c9d_I20230310",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "axgn:CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "if81dc6f294f4481ba24f6cf04a2a5b07_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "iace3449af19a43cd8d67c6135dea1c3f_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Nature of Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.axogeninc.com/role/NatureofBusiness",
     "shortName": "Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.axogeninc.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "axgn-20221231.htm",
      "contextRef": "i51c07a17dd5242a599a119aeb7c825d6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 77,
   "tag": {
    "axgn_APCFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APC Facility",
        "label": "APC Facility [Member]",
        "terseLabel": "APC Facility"
       }
      }
     },
     "localname": "APCFacilityMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_AdditionalCostsAssociatedWithDesignBuildAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Costs Associated with Design Build Agreement",
        "label": "Additional Costs Associated with Design Build Agreement",
        "terseLabel": "Additional costs associated with design build agreement"
       }
      }
     },
     "localname": "AdditionalCostsAssociatedWithDesignBuildAgreement",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the age of specific types of trade accounts and notes receivable.",
        "label": "Allowance for Doubtful Accounts Receivable Age of Accounts Receivable",
        "terseLabel": "Age of doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableAgeOfAccountsReceivable",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anticipated Costs Associated with Design Build Agreement, Year One",
        "label": "Anticipated Costs Associated with Design Build Agreement, Year One",
        "terseLabel": "Anticipated costs associated with design build agreement, in 2022"
       }
      }
     },
     "localname": "AnticipatedCostsAssociatedWithDesignBuildAgreementYearOne",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of supplemental balance sheet information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "axgn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.axogeninc.com/20221231",
     "xbrltype": "stringItemType"
    },
    "axgn_AviveSoftTissueMembraneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Avive Soft Tissue Membrane",
        "label": "Avive Soft Tissue Membrane [Member]",
        "terseLabel": "Avive"
       }
      }
     },
     "localname": "AviveSoftTissueMembraneMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_AxoGen2010StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The AxoGen 2010 Stock Incentive Plan.",
        "label": "Axo Gen2010 Stock Incentive Plan [Member]",
        "terseLabel": "Prior Axogen Plan"
       }
      }
     },
     "localname": "AxoGen2010StockIncentivePlanMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_Axogen2017EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AxoGen 2017 Employee Stock Purchase Plan [Member]",
        "label": "Axogen2017 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2017 ESPP"
       }
      }
     },
     "localname": "Axogen2017EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_Axogen2019LongTermIncentivePlanNewAxogenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information relating to New Axogen Plan",
        "label": "Axogen 2019 Long-Term Incentive Plan, New Axogen Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "Axogen2019LongTermIncentivePlanNewAxogenPlanMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_Axogen401kPlanEmployerMatchingContributionTranche1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the first tranche of the AxoGen 401K plan where the employer matches a percent of employee contributions.",
        "label": "Axogen401k Plan Employer Matching Contribution Tranche1 [Member]",
        "terseLabel": "Employer's Contribution, First Tranche"
       }
      }
     },
     "localname": "Axogen401kPlanEmployerMatchingContributionTranche1Member",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_Axogen401kPlanEmployerMatchingContributionTranche2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the second tranche of the AxoGen 401K plan where the employer matches a percent of employee contributions.",
        "label": "Axogen401k Plan Employer Matching Contribution Tranche2 [Member]",
        "terseLabel": "Employer's Contribution, Second Tranche"
       }
      }
     },
     "localname": "Axogen401kPlanEmployerMatchingContributionTranche2Member",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_Axogen401kPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the AxoGen 401K plan.",
        "label": "Axogen401k Plan [Member]",
        "terseLabel": "AxoGen 401K Plan"
       }
      }
     },
     "localname": "Axogen401kPlanMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Deposited At Bank Closed By California Department Of Financial Protection And Innovation",
        "label": "Cash Deposited At Bank Closed By California Department Of Financial Protection And Innovation",
        "terseLabel": "Cash previously deposited at bank closed by California Department of Financial Protection and Innovation"
       }
      }
     },
     "localname": "CashDepositedAtBankClosedByCaliforniaDepartmentOfFinancialProtectionAndInnovation",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_CashGrantsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of cash grants receivable.",
        "label": "Cash Grants Receivable",
        "terseLabel": "Cash grants receivable (up to)"
       }
      }
     },
     "localname": "CashGrantsReceivable",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_CommercialLeaseWithJAColeLPFirstAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Lease With JA-Cole L.P, First Amendment",
        "label": "Commercial Lease With JA-Cole L.P, First Amendment [Member]",
        "terseLabel": "Commercial Lease With JA-Cole L.P, First Amendment"
       }
      }
     },
     "localname": "CommercialLeaseWithJAColeLPFirstAmendmentMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_CommercialLeaseWithJAColeLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Lease With JA-Cole L.P",
        "label": "Commercial Lease With JA-Cole L.P [Member]",
        "terseLabel": "Commercial Lease With JA-Cole L.P"
       }
      }
     },
     "localname": "CommercialLeaseWithJAColeLPMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_CommunityTissuesServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Community Tissues Services Agreement",
        "label": "Community Tissues Services Agreement [Member]",
        "terseLabel": "CTS Agreement"
       }
      }
     },
     "localname": "CommunityTissuesServicesAgreementMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_ContributionsToCharitableOrganization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contributions to Charitable Organization",
        "label": "Contributions to Charitable Organization",
        "terseLabel": "Contributions to charitable organization"
       }
      }
     },
     "localname": "ContributionsToCharitableOrganization",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_CreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility",
        "label": "Credit Facility [Member]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_CreditFacilityTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Tranche One",
        "label": "Credit Facility, Tranche One [Member]",
        "terseLabel": "First Tranche"
       }
      }
     },
     "localname": "CreditFacilityTrancheOneMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_CreditFacilityTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility. Tranche Two",
        "label": "Credit Facility. Tranche Two [Member]",
        "terseLabel": "Second Tranche"
       }
      }
     },
     "localname": "CreditFacilityTrancheTwoMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_DebtDerivativeLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Derivative Liability",
        "label": "Debt Derivative Liability [Member]",
        "terseLabel": "Debt derivative liabilities"
       }
      }
     },
     "localname": "DebtDerivativeLiabilityMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_DebtInstrumentAdditionalInterestFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Additional Interest, Floor Rate",
        "label": "Debt Instrument, Additional Interest, Floor Rate",
        "terseLabel": "Additional interest floor rate"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalInterestFloorRate",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_DebtInstrumentHeldToMaturityMakeWholePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Held To Maturity Make-Whole Payment",
        "label": "Debt Instrument, Held To Maturity Make-Whole Payment",
        "terseLabel": "Held to maturity make-whole payment"
       }
      }
     },
     "localname": "DebtInstrumentHeldToMaturityMakeWholePayment",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Held To Maturity Make-Whole Payment, Alternative Interpretation",
        "label": "Debt Instrument Held To Maturity Make-Whole Payment, Alternative Interpretation",
        "terseLabel": "Held to maturity make-whole payment, alternative interpretation"
       }
      }
     },
     "localname": "DebtInstrumentHeldToMaturityMakeWholePaymentAlternativeInterpretation",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DebtInstrumentInterestRateEventOfDefaultIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Interest Rate, Event of Default, Increase",
        "label": "Debt Instrument, Interest Rate, Event of Default, Increase",
        "terseLabel": "Interest rate increase in the event of default"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEventOfDefaultIncrease",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_DebtInstrumentInternalRateOfReturnUnderSettlementScenarios": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Internal Rate Of Return Under Settlement Scenarios",
        "label": "Debt Instrument, Internal Rate Of Return Under Settlement Scenarios",
        "terseLabel": "Make-whole payment required under each scenario, internal rate of return"
       }
      }
     },
     "localname": "DebtInstrumentInternalRateOfReturnUnderSettlementScenarios",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_DebtInstrumentMinimumRequiredInternalRateOfReturn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Minimum Required Internal Rate Of Return",
        "label": "Debt Instrument, Minimum Required Internal Rate Of Return",
        "terseLabel": "Make-whole payment, minimum required internal rate of return"
       }
      }
     },
     "localname": "DebtInstrumentMinimumRequiredInternalRateOfReturn",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Percentage Of Additional Payment On Outstanding Loan Based On Royalty Structure",
        "label": "Debt Instrument, Percentage Of Additional Payment On Outstanding Loan Based On Royalty Structure",
        "terseLabel": "Additional payment percentage"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfAdditionalPaymentOnOutstandingLoanBasedOnRoyaltyStructure",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Period For Which Quarterly Interest Payments Should Be Made",
        "label": "Debt Instrument, Period For Which Quarterly Interest Payments Should Be Made",
        "terseLabel": "Period for which quarterly interest payments are required"
       }
      }
     },
     "localname": "DebtInstrumentPeriodForWhichQuarterlyInterestPaymentsShouldBeMade",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_DeferredTaxAssetsInterestLimitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Interest Limitation",
        "label": "Deferred Tax Assets, Interest Limitation",
        "terseLabel": "Interest limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestLimitation",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DeferredTaxAssetsLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from right-of-use liability.",
        "label": "Deferred Tax Assets, Lease Obligations",
        "terseLabel": "Lease obligations"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseObligations",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DeferredTaxAssetsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Assets (Liabilities)",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilities",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from right-of-use asset.",
        "label": "Deferred Tax Liabilities, Right-of-use Asset",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_DefinedContributionPlanEmployeeContributionPercentMatched": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee contribution, as a percent of annual salary, that is matched by the employer.",
        "label": "Defined Contribution Plan, Employee Contribution, Percent Matched",
        "terseLabel": "Employee contribution matched, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeeContributionPercentMatched",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan minimum age limit for eligibility to participate in plan.",
        "label": "Defined Contribution Plan Minimum Age Limit For Eligibility To Participate In Plan",
        "terseLabel": "Age limit for eligibility to participate in the plan"
       }
      }
     },
     "localname": "DefinedContributionPlanMinimumAgeLimitForEligibilityToParticipateInPlan",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "axgn_DesignBuildAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to design build agreement.",
        "label": "Design Build Agreement [Member]",
        "terseLabel": "Design Build Agreement"
       }
      }
     },
     "localname": "DesignBuildAgreementMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_DirectorsAndCertainExecutiveOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors And Certain Executive Officers",
        "label": "Directors And Certain Executive Officers [Member]",
        "terseLabel": "Directors And Certain Executive Officers"
       }
      }
     },
     "localname": "DirectorsAndCertainExecutiveOfficersMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_DirectorsAndOfficersStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an officer or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Directors And Officers Stock Options [Member]",
        "terseLabel": "Directors And Officers Stock Options"
       }
      }
     },
     "localname": "DirectorsAndOfficersStockOptionsMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic and Diluted, Other Disclosure1",
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosure1 [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosure1Abstract",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "axgn_EmbeddedDerivativeAssociatedWithTheLongTermDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Embedded Derivative Associated With The Long Term Debt",
        "label": "Embedded Derivative Associated With The Long Term Debt",
        "terseLabel": "Embedded derivative associated with the long-term debt"
       }
      }
     },
     "localname": "EmbeddedDerivativeAssociatedWithTheLongTermDebt",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Discount from Market Value on Common Stock",
        "label": "Employee Stock Purchase Plan, Discount from Market Value on Common Stock",
        "terseLabel": "Discount from market value on common stock"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanDiscountFromMarketValueOnCommonStock",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Maximum Amount Available to Participants Per Year",
        "label": "Employee Stock Purchase Plan, Maximum Amount Available to Participants Per Year",
        "terseLabel": "Maximum amount available to participants per year"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAmountAvailableToParticipantsPerYear",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_EmployeeStockPurchasePlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan, Offering Period",
        "label": "Employee Stock Purchase Plan, Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanOfferingPeriod",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_EstimatedCostRelatingToDesignBuildAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Cost Relating to Design Build Agreement",
        "label": "Estimated Cost Relating to Design Build Agreement",
        "terseLabel": "Estimated cost relating to design build agreement"
       }
      }
     },
     "localname": "EstimatedCostRelatingToDesignBuildAgreement",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment and tangible personal property commonly used in offices.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "negatedTerseLabel": "Operating lease obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LeaseLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Liabilities, Noncurrent",
        "label": "Lease Liabilities, Noncurrent",
        "terseLabel": "Long-term lease obligations"
       }
      }
     },
     "localname": "LeaseLiabilitiesNoncurrent",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Liability, Current",
        "label": "Lease Liability, Current",
        "terseLabel": "Current maturities of long-term lease obligations"
       }
      }
     },
     "localname": "LeaseLiabilityCurrent",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LeasesFinanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Leases Finance Abstract",
        "terseLabel": "Financing Leases"
       }
      }
     },
     "localname": "LeasesFinanceAbstract",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Financing Lease, Liability, to be Paid",
        "label": "Lessee, Operating and Financing Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingAndFinancingLeaseLiabilityToBePaid",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Financing Lease, Liability, to be Paid, after Year Five",
        "label": "Lessee, Operating and Financing Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingAndFinancingLeaseLiabilityToBePaidAfterYearFive",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Financing Lease, Liability, to be Paid, Year Five",
        "label": "Lessee, Operating and Financing Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFive",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Financing Lease, Liability, to be Paid, Year Four",
        "label": "Lessee, Operating and Financing Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearFour",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Financing Lease, Liability, to be Paid, Year One",
        "label": "Lessee, Operating and Financing Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearOne",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Financing Lease, Liability, to be Paid, Year Three",
        "label": "Lessee, Operating and Financing Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearThree",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "axgn_LesseeOperatingAndFinancingLeaseLiabilityToBePaid",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Financing Lease, Liability, to be Paid, Year Two",
        "label": "Lessee, Operating and Financing Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingAndFinancingLeaseLiabilityToBePaidYearTwo",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating and Financing Lease, Liability, Undiscounted Excess Amount",
        "label": "Lessee, Operating and Financing Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingAndFinancingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_LesseeOperatingLeaseNumberOfRentFreeMonths": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Rent-Free Months",
        "label": "Lessee, Operating Lease, Number Of Rent-Free Months",
        "terseLabel": "Rent-free period (in months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRentFreeMonths",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "axgn_LicenseFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License fee amount",
        "label": "License fee amount",
        "terseLabel": "License fee amount"
       }
      }
     },
     "localname": "LicenseFeeAmount",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_MandatoryPrepaymentEventBefore2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mandatory Prepayment Event Before 2024",
        "label": "Mandatory Prepayment Event Before 2024 [Member]",
        "terseLabel": "Probability of mandatory prepayment before 2024"
       }
      }
     },
     "localname": "MandatoryPrepaymentEventBefore2024Member",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_MandatoryPrepaymentEventIn2024OrAfterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mandatory Prepayment Event In 2024 Or After",
        "label": "Mandatory Prepayment Event In 2024 Or After [Member]",
        "terseLabel": "Probability of mandatory prepayment 2024 or after"
       }
      }
     },
     "localname": "MandatoryPrepaymentEventIn2024OrAfterMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_MasterServicesAgreementForClinicalResearchAndRelatedServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment for clinical research and related services.",
        "label": "Master Services Agreement For Clinical Research And Related Services [Member]",
        "terseLabel": "Master Services Agreement For Clinical Research and Related Services"
       }
      }
     },
     "localname": "MasterServicesAgreementForClinicalResearchAndRelatedServicesMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_MeasurementInputCouponRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input Coupon Rate",
        "label": "Measurement Input Coupon Rate [Member]",
        "terseLabel": "Coupon rate"
       }
      }
     },
     "localname": "MeasurementInputCouponRateMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_MeasurementInputMandatoryPrepaymentRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input Mandatory Prepayment Rate",
        "label": "Measurement Input Mandatory Prepayment Rate [Member]",
        "terseLabel": "Mandatory Prepayment Rate"
       }
      }
     },
     "localname": "MeasurementInputMandatoryPrepaymentRateMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_NoncashOrPartNoncashConversionOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or Part Noncash Conversion, Option",
        "label": "Noncash or Part Noncash Conversion, Option",
        "terseLabel": "Conversion of the Credit Facility option"
       }
      }
     },
     "localname": "NoncashOrPartNoncashConversionOption",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_NoncashRightOfUseAssetsAndOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the noncash amount of right of use assets and operating lease liability.",
        "label": "Noncash Right of Use Assets and Operating Lease Liability",
        "terseLabel": "Obtaining a right-of-use asset in exchange for a lease liability"
       }
      }
     },
     "localname": "NoncashRightOfUseAssetsAndOperatingLeaseLiability",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_NoticePeriodForTerminationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the notice period for termination of the agreement by either parties.",
        "label": "Notice Period For Termination Of Agreement",
        "terseLabel": "Notice period for termination of agreement"
       }
      }
     },
     "localname": "NoticePeriodForTerminationOfAgreement",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_NumberOfPotentialSettlementScenarios": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Potential Settlement Scenarios",
        "label": "Number Of Potential Settlement Scenarios",
        "terseLabel": "Number of potential settlement scenarios"
       }
      }
     },
     "localname": "NumberOfPotentialSettlementScenarios",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axgn_OperatingAndFinancingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and Financing Lease, Liability",
        "label": "Operating and Financing Lease, Liability",
        "totalLabel": "Total lease liability"
       }
      }
     },
     "localname": "OperatingAndFinancingLeaseLiability",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_OperatingAndFinancingLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "axgn_OperatingAndFinancingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and Financing Lease, Liability, Current",
        "label": "Operating and Financing Lease, Liability, Current",
        "negatedTerseLabel": "Less: Current lease liability"
       }
      }
     },
     "localname": "OperatingAndFinancingLeaseLiabilityCurrent",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_OperatingAndFinancingLeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "axgn_OperatingAndFinancingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and Financing Lease, Liability, Noncurrent",
        "label": "Operating and Financing Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingAndFinancingLeaseLiabilityNoncurrent",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_OperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Incremental Borrowing Rate",
        "label": "Operating Lease, Incremental Borrowing Rate",
        "terseLabel": "Operating lease, incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_OperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases",
        "label": "Operating Leases [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeasesAbstract",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "axgn_OptionalPrepaymentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Optional Prepayment Event",
        "label": "Optional Prepayment Event [Member]",
        "terseLabel": "Probability of optional prepayment event"
       }
      }
     },
     "localname": "OptionalPrepaymentEventMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_PatentsAndLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents And License Agreements [Member]",
        "label": "Patents And License Agreements [Member]",
        "terseLabel": "Patents And License Agreements"
       }
      }
     },
     "localname": "PatentsAndLicenseAgreementsMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_PaymentForServiceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Service Fees",
        "label": "Payment for Service Fees",
        "terseLabel": "Payment for service fees"
       }
      }
     },
     "localname": "PaymentForServiceFees",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_PercentageOfAchievementOfAwardIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Achievement Of Award Issued",
        "label": "Percentage Of Achievement Of Award Issued",
        "terseLabel": "Achievement of award issued (as a percent)"
       }
      }
     },
     "localname": "PercentageOfAchievementOfAwardIssued",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of royalty which may be paid for the sale of the same product, pursuant to a capping arrangement in the license agreements.",
        "label": "Percentage of Capping Royalties for Multiple Royalty Payments to Licensors",
        "terseLabel": "Royalty stack cap for royalties paid to more than one licensor for sales of the same product"
       }
      }
     },
     "localname": "PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_PerformanceSharesBiologicLicenseApplicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares or units awarded based on Biologic License Application milestones.",
        "label": "Performance Shares Biologic License Application [Member]",
        "terseLabel": "PSU - BLA Milestones"
       }
      }
     },
     "localname": "PerformanceSharesBiologicLicenseApplicationMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_PerformanceStockUnitPayoutOpportunity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Unit, Payout Opportunity",
        "label": "Performance Stock Unit, Payout Opportunity",
        "terseLabel": "Performance stock unit, payout opportunity"
       }
      }
     },
     "localname": "PerformanceStockUnitPayoutOpportunity",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_PrepaymentProbabilityEventAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Probability Event",
        "label": "Prepayment Probability Event [Axis]",
        "terseLabel": "Prepayment Probability Event [Axis]"
       }
      }
     },
     "localname": "PrepaymentProbabilityEventAxis",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "axgn_PrepaymentProbabilityEventDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Probability Event",
        "label": "Prepayment Probability Event [Domain]",
        "terseLabel": "Prepayment Probability Event [Domain]"
       }
      }
     },
     "localname": "PrepaymentProbabilityEventDomain",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_ProceedsFromGrantorsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Grantors, Investing Activities",
        "label": "Proceeds from Grantors, Investing Activities",
        "terseLabel": "Economic development grant proceeds"
       }
      }
     },
     "localname": "ProceedsFromGrantorsInvestingActivities",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_PurchasePriceOfCommonStockCalculationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Price Of Common Stock Calculation Period",
        "label": "Purchase Price Of Common Stock Calculation Period",
        "terseLabel": "Moving average of closing stock"
       }
      }
     },
     "localname": "PurchasePriceOfCommonStockCalculationPeriod",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "axgn_ResearchAndDevelopmentGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Grants",
        "label": "Research And Development Grants [Member]",
        "terseLabel": "Research and Development Grants"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrantsMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_RestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash",
        "label": "Restricted Cash [Member]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Participation Agreement, Threshold Revenue Achievement For Payment Of Additional Quarterly Royalty",
        "label": "Revenue Participation Agreement, Threshold Revenue Achievement For Payment Of Additional Quarterly Royalty",
        "terseLabel": "Threshold revenue achievement for payment of additional quarterly royalty"
       }
      }
     },
     "localname": "RevenueParticipationAgreementThresholdRevenueAchievementForPaymentOfAdditionalQuarterlyRoyalty",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_RightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset.",
        "label": "Right Of Use Asset Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetAmortization",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks And Uncertainties",
        "label": "Risks And Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "axgn_RoyaltyFeesPercentageUnderLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty fees percentage under license agreements.",
        "label": "Royalty Fees Percentage under License Agreements",
        "terseLabel": "Royalty fees range under the license agreements"
       }
      }
     },
     "localname": "RoyaltyFeesPercentageUnderLicenseAgreements",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "axgn_ScheduleOfRoyaltyExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Royalty Expenses",
        "label": "Schedule of Royalty Expenses [Table Text Block]",
        "terseLabel": "Schedule of royalty expenses"
       }
      }
     },
     "localname": "ScheduleOfRoyaltyExpensesTableTextBlock",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "axgn_ServiceAgreementAmountPaidUponExecutionOfAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Agreement Amount Paid Upon Execution Of Agreement",
        "label": "Service Agreement Amount Paid Upon Execution Of Agreement",
        "terseLabel": "Service agreement amount paid upon execution of agreement"
       }
      }
     },
     "localname": "ServiceAgreementAmountPaidUponExecutionOfAgreement",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_ShareBasePaymentArrangementNumberOfPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-base Payment Arrangement, Number Of Plans",
        "label": "Share-base Payment Arrangement, Number Of Plans",
        "terseLabel": "Number of share-based incentive plans"
       }
      }
     },
     "localname": "ShareBasePaymentArrangementNumberOfPlans",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "axgn_ShareBasedCompensationAwardTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Four [Member]",
        "terseLabel": "Per Quarter, Over One Year"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheFourMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_ShareBasedCompensationExpenseForfeitedOrReversed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Expense, Forfeited Or Reversed",
        "label": "Share-based Compensation Expense, Forfeited Or Reversed",
        "terseLabel": "Value of grants reversed"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseForfeitedOrReversed",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Settlement of Warrants and Rights, Value",
        "label": "Stock Issued During Period, Settlement of Warrants and Rights, Value",
        "terseLabel": "Exercise of Credit Facility Option, net of settlement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSettlementOfWarrantsAndRightsValue",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Settlement of Warrants and Rights",
        "label": "Stock Issued During Period, Shares, Settlement of Warrants and Rights",
        "terseLabel": "Exercise of Credit Facility Option, net of settlement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSettlementOfWarrantsAndRights",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "axgn_StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Options Exercised and Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Shares, Stock Options Exercised and Employee Stock Purchase Plan",
        "terseLabel": "Exercise of stock options and employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndEmployeeStockPurchasePlan",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "axgn_StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Value, Stock Options Exercised and Employee Stock Purchase Plan",
        "terseLabel": "Exercise of stock options and employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "axgn_TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TPC Investments II LP, A Wholly Owned Subsidiary Of Oberland Capital",
        "label": "TPC Investments II LP, A Wholly Owned Subsidiary Of Oberland Capital [Member]",
        "terseLabel": "TPC Investments II LP"
       }
      }
     },
     "localname": "TPCInvestmentsIILPAWhollyOwnedSubsidiaryOfOberlandCapitalMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_TwoThousandTwentyOnePerformanceShareUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty-One Performance Share Unit",
        "label": "Two Thousand Twenty-One Performance Share Unit [Member]",
        "terseLabel": "2021 PSUs"
       }
      }
     },
     "localname": "TwoThousandTwentyOnePerformanceShareUnitMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_TwoThousandTwentyPerformanceShareUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty Performance Share Unit",
        "label": "Two Thousand Twenty Performance Share Unit [Member]",
        "terseLabel": "2020 PSUs"
       }
      }
     },
     "localname": "TwoThousandTwentyPerformanceShareUnitMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "axgn_TwoThousandTwentyTwoPerformanceShareUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty-Two Performance Share Unit",
        "label": "Two Thousand Twenty-Two Performance Share Unit [Member]",
        "terseLabel": "2022 PSUs"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoPerformanceShareUnitMember",
     "nsuri": "http://www.axogeninc.com/20221231",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r408",
      "r566",
      "r576",
      "r613",
      "r614",
      "r647",
      "r659",
      "r665",
      "r717",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r408",
      "r566",
      "r576",
      "r613",
      "r614",
      "r647",
      "r659",
      "r665",
      "r717",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "auth_ref": [
      "r597",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of real estate property.",
        "label": "Real Estate, Type of Property [Axis]",
        "terseLabel": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r615",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Land and any structures permanently fixed to it.",
        "label": "Real Estate [Domain]",
        "terseLabel": "Real Estate [Domain]"
       }
      }
     },
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r262",
      "r569",
      "r648",
      "r664",
      "r712",
      "r713",
      "r718",
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r262",
      "r569",
      "r648",
      "r664",
      "r712",
      "r713",
      "r718",
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r357",
      "r408",
      "r445",
      "r446",
      "r447",
      "r542",
      "r566",
      "r576",
      "r613",
      "r614",
      "r647",
      "r659",
      "r665",
      "r711",
      "r717",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r357",
      "r408",
      "r445",
      "r446",
      "r447",
      "r542",
      "r566",
      "r576",
      "r613",
      "r614",
      "r647",
      "r659",
      "r665",
      "r711",
      "r717",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r612",
      "r617",
      "r627",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of property.",
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r612",
      "r617",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center.",
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r213",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r703",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails",
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/AccountsPayableandAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r17",
      "r663"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r265",
      "r266"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $650 and $276, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r22",
      "r630"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedCapitalizedInterestCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis.",
        "label": "Accumulated Capitalized Interest Costs",
        "terseLabel": "Accumulated capitalized interest costs"
       }
      }
     },
     "localname": "AccumulatedCapitalizedInterestCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r699",
      "r700",
      "r701",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r108",
      "r109",
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r180",
      "r267",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r31",
      "r327",
      "r513",
      "r687"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt discount and deferred financing fees"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r51",
      "r74",
      "r81"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.axogeninc.com/role/IntangibleAssetsNetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land",
        "verboseLabel": "Area of land where building resides"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Size of building space"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r143",
      "r160",
      "r178",
      "r203",
      "r253",
      "r256",
      "r260",
      "r271",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r483",
      "r485",
      "r501",
      "r663",
      "r715",
      "r716",
      "r822"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r171",
      "r183",
      "r203",
      "r271",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r483",
      "r485",
      "r501",
      "r663",
      "r715",
      "r716",
      "r822"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Acquisition of fixed assets in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r53",
      "r174",
      "r628"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r54",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r47",
      "r53",
      "r58"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Total cash and cash equivalents, and restricted cash shown in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r47",
      "r135"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Cash and cash equivalents balance outside of FDIC limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r26",
      "r151",
      "r165"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies - see Note 14"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r296",
      "r297",
      "r599",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r699",
      "r700",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r663"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value per share; 100,000,000 shares authorized; 42,445,517 and 41,736,950 shares issued and outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Differences between the carrying amount of assets and liabilities for financial reporting purposes"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r156",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r65",
      "r133",
      "r134",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress",
        "verboseLabel": "Projects in Process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r34",
      "r569"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Costs of goods sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods Sold"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r144",
      "r146",
      "r158",
      "r207",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r514",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r3",
      "r146",
      "r158",
      "r329"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt, gross",
        "verboseLabel": "Principal balance"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCollateralAmount": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets pledged to secure a debt instrument.",
        "label": "Debt Instrument, Collateral Amount",
        "terseLabel": "Collateral amount"
       }
      }
     },
     "localname": "DebtInstrumentCollateralAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r24",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "verboseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r25",
      "r207",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r514",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r25",
      "r94",
      "r95",
      "r96",
      "r97",
      "r138",
      "r139",
      "r141",
      "r155",
      "r207",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r514",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term of debt"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r140",
      "r318",
      "r330",
      "r643",
      "r644"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less - unamortized debt discount and deferred financing fees"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r5",
      "r6",
      "r145",
      "r157",
      "r466"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 2.0,
       "parentTag": "axgn_DeferredTaxAssetsLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.",
        "label": "Deferred Tax Assets, Charitable Contribution Carryforwards",
        "terseLabel": "Charitable contributions"
       }
      }
     },
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDerivativeInstruments": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.",
        "label": "Deferred Tax Assets, Derivative Instruments",
        "terseLabel": "Debt derivative liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsDerivativeInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 1.0,
       "parentTag": "axgn_DeferredTaxAssetsLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "negatedLabel": "Amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": {
     "auth_ref": [
      "r114",
      "r810"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.",
        "label": "Deferred Tax Liabilities, Tax Deferred Income",
        "negatedLabel": "Contract liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTemporaryDifferencesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r402"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "verboseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r51",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r51",
      "r251"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r812"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedTerseLabel": "Change in fair value of derivatives",
        "terseLabel": "Change in fair value of derivatives"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r184",
      "r185",
      "r500",
      "r634"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Debt derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Debt derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability, measurement input"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r125",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r419",
      "r450",
      "r451",
      "r453",
      "r458",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r194",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r227",
      "r229",
      "r231",
      "r232",
      "r233",
      "r237",
      "r489",
      "r490",
      "r572",
      "r574",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per common share - basic (in USD per share)",
        "verboseLabel": "Net loss per common share - basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails",
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r194",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r229",
      "r231",
      "r232",
      "r233",
      "r237",
      "r489",
      "r490",
      "r572",
      "r574",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per common share - diluted (in USD per share)",
        "verboseLabel": "Net loss per common share - diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails",
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share\u200b"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Basic and Diluted Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r204",
      "r462",
      "r477"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Federal tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r809",
      "r811"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r809",
      "r811"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "verboseLabel": "Permanent items and other deductions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r809",
      "r811"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r809",
      "r811"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes - net of Federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation costs related to non-vested stock options and restricted stock awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period of recognition of unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r808"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Processing equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r93",
      "r169",
      "r189",
      "r190",
      "r191",
      "r214",
      "r215",
      "r216",
      "r218",
      "r224",
      "r226",
      "r240",
      "r272",
      "r334",
      "r454",
      "r455",
      "r456",
      "r473",
      "r474",
      "r488",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r532",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r491",
      "r492",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of significant inputs in liability valuation"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value financial assets measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r320",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r492",
      "r539",
      "r540",
      "r541",
      "r643",
      "r644",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r491",
      "r492",
      "r494",
      "r495",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r320",
      "r360",
      "r365",
      "r492",
      "r539",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r320",
      "r360",
      "r365",
      "r492",
      "r540",
      "r643",
      "r644",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r320",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r492",
      "r541",
      "r643",
      "r644",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r130",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of fair value instruments classified Level 3"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value included in net loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Acquired"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r320",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r539",
      "r540",
      "r541",
      "r643",
      "r644",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r497",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r518",
      "r523",
      "r662"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r520",
      "r527"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "negatedLabel": "Cash paid for interest portion of finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current maturities of long-term lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "verboseLabel": "Schedule of finance lease maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r519",
      "r527"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Cash paid for debt portion of finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r518",
      "r523",
      "r662"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r816"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r529",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate financing leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r528",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average financing term (in years):"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r268",
      "r269",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r328",
      "r332",
      "r487",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r641",
      "r704",
      "r705",
      "r706",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r177",
      "r290"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r287",
      "r289",
      "r290",
      "r292",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r80",
      "r571"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets",
        "verboseLabel": "Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r75",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r80",
      "r570"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Amortization period of intangible assets (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Finite-Lived Intangible Assets [Roll Forward]",
        "terseLabel": "Amortizable intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of government assistance recognized.",
        "label": "Government Assistance, Amount",
        "terseLabel": "Grants received"
       }
      }
     },
     "localname": "GovernmentAssistanceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentAssistanceAmountCumulative": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative government assistance recognized.",
        "label": "Government Assistance, Amount, Cumulative",
        "terseLabel": "Grants received"
       }
      }
     },
     "localname": "GovernmentAssistanceAmountCumulative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "auth_ref": [
      "r509",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government assistance.",
        "label": "Government Assistance [Policy Text Block]",
        "terseLabel": "Government Assistance"
       }
      }
     },
     "localname": "GovernmentAssistancePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes government assistance.",
        "label": "Government Assistance, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Government Assistance, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes government assistance.",
        "label": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_GovernmentAssistanceTypeAxis": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of government assistance.",
        "label": "Government Assistance, Type [Axis]",
        "terseLabel": "Government Assistance, Type [Axis]"
       }
      }
     },
     "localname": "GovernmentAssistanceTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GovernmentAssistanceTypeDomain": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of government assistance.",
        "label": "Government Assistance, Type [Domain]",
        "terseLabel": "Government Assistance, Type [Domain]"
       }
      }
     },
     "localname": "GovernmentAssistanceTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Receivable economic development grants from state and local authorities (up to)"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r33",
      "r203",
      "r253",
      "r255",
      "r259",
      "r261",
      "r271",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r501",
      "r640",
      "r715"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r204",
      "r463",
      "r464",
      "r471",
      "r475",
      "r478",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r205",
      "r225",
      "r226",
      "r252",
      "r461",
      "r476",
      "r479",
      "r575"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r188",
      "r459",
      "r460",
      "r464",
      "r465",
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r567",
      "r686"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r288",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Carrying amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r76",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Indefinite-Lived Intangible Assets [Roll Forward]",
        "terseLabel": "Unamortized intangible assets:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r73",
      "r78"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCapitalizationPolicyPolicyTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for interest capitalization.",
        "label": "Interest Capitalization, Policy [Policy Text Block]",
        "terseLabel": "Capitalized Interest"
       }
      }
     },
     "localname": "InterestCapitalizationPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest costs capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r140",
      "r153",
      "r192",
      "r250",
      "r512"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r688"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r198",
      "r200",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest, net of capitalized interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r72",
      "r631"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r182",
      "r629",
      "r663"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.axogeninc.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r173",
      "r181",
      "r239",
      "r283",
      "r285",
      "r286",
      "r568",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r72",
      "r633"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r72",
      "r632"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Provision for inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.axogeninc.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r37",
      "r39"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r270",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r530",
      "r662"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of total lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Description [Abstract]",
        "terseLabel": "Finance lease costs"
       }
      }
     },
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of operating lease maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r203",
      "r271",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r484",
      "r485",
      "r486",
      "r501",
      "r639",
      "r715",
      "r822",
      "r823"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r148",
      "r164",
      "r663",
      "r691",
      "r707",
      "r815"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r172",
      "r203",
      "r271",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r484",
      "r485",
      "r486",
      "r501",
      "r663",
      "r715",
      "r822",
      "r823"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "License agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Interest rate at period end"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r146",
      "r161",
      "r319",
      "r331",
      "r643",
      "r644"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Long-term debt, net of debt discount and financing fees"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesScheduleofCarryingValuesofOutstandingDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of debt discount and financing fees"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]",
        "terseLabel": "Long-Term Debt\u200b, Net of Debt Discount and Financing Fees"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Remaining term (years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r241",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature\u200b of\u200b Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/NatureofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r47",
      "r49",
      "r52"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r52",
      "r152",
      "r166",
      "r170",
      "r186",
      "r187",
      "r191",
      "r203",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r230",
      "r253",
      "r255",
      "r259",
      "r261",
      "r271",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r490",
      "r501",
      "r640",
      "r715"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails",
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "terseLabel": "Acquisition of leasehold asset"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Acquisition of intangible assets in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r253",
      "r255",
      "r259",
      "r261",
      "r640"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r524",
      "r662"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturities of long-term lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.axogeninc.com/role/LeasesNarrativeDetails",
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r529",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r528",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average operating lease term (in years):"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r123",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payments for debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Payments of employee tax withholdings in exchange of common stock awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBuildings": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of buildings (properties) whether for investment or use.",
        "label": "Payments to Acquire Buildings",
        "terseLabel": "Payments to acquire Building"
       }
      }
     },
     "localname": "PaymentsToAcquireBuildings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Cash payments for intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLandHeldForUse": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of land for use; excludes purchases of land held as inventory or as investments.",
        "label": "Payments to Acquire Land Held-for-use",
        "terseLabel": "Payments to acquire Land"
       }
      }
     },
     "localname": "PaymentsToAcquireLandHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r357",
      "r359",
      "r365",
      "r382",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r400",
      "r401",
      "r402",
      "r415",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Plan\u200b"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r682"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromGrantors": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from grantors during the current period related to operating activities. This element represents receipts from a guarantor for the amount of guarantee provided.",
        "label": "Proceeds from Grantors",
        "terseLabel": "Proceeds from grantors"
       }
      }
     },
     "localname": "ProceedsFromGrantors",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r684"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from the paycheck protection program loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r41",
      "r71",
      "r196"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from exercise of stock options and ESPP stock purchases"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r683"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Gross proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Expenses related to improvements in current year"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r709",
      "r817",
      "r818"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedTerseLabel": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r710",
      "r818"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r678",
      "r708",
      "r816"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/LeasesNarrativeDetails",
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r600",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r86",
      "r175"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetDetails",
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/LeasesNarrativeDetails",
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r195",
      "r275"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debt"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "auth_ref": [
      "r4",
      "r147",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers.",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Axis]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "auth_ref": [
      "r4",
      "r147",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate.",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Domain]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Line Items]",
        "terseLabel": "Service Agreements"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentTable": {
     "auth_ref": [
      "r4",
      "r147",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required or determined to be disclosed about arrangements in which the entity has agreed to expend funds to procure goods or services from one or more suppliers. Such disclosure may include identification of the goods or services to be purchased, identity of the seller, pricing, effects on pricing for failing to reach minimum quantities required to be purchased (such as penalties), cancellation rights, and termination provisions.",
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Table]",
        "terseLabel": "Purchase Commitment, Excluding Long-term Commitment [Table]"
       }
      }
     },
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesServiceAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "verboseLabel": "Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r685"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Repayment of the paycheck protection program loan"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r110",
      "r168",
      "r830"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r677",
      "r689",
      "r831",
      "r833"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r98",
      "r163",
      "r580",
      "r581",
      "r663"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r169",
      "r214",
      "r215",
      "r216",
      "r218",
      "r224",
      "r226",
      "r272",
      "r454",
      "r455",
      "r456",
      "r473",
      "r474",
      "r488",
      "r577",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r659",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]",
        "terseLabel": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r659",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]",
        "terseLabel": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r99",
      "r100",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r403",
      "r404",
      "r414",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r99",
      "r100",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r402",
      "r403",
      "r404",
      "r414",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/RetirementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r193",
      "r203",
      "r248",
      "r249",
      "r254",
      "r257",
      "r258",
      "r262",
      "r263",
      "r264",
      "r271",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r501",
      "r573",
      "r715"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty fees"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/AccountsPayableandAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r25",
      "r94",
      "r95",
      "r96",
      "r97",
      "r138",
      "r139",
      "r141",
      "r155",
      "r643",
      "r645",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of long-term debt, net of financing fees"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective income tax basis"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of net loss per common share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense of consolidated statements"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r75",
      "r79",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetFutureAmortizationofPatentsandLicenseAgreementsDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetNarrativeDetails",
      "http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r75",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r14",
      "r15",
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/PropertyandEquipmentNetDetails",
      "http://www.axogeninc.com/role/PropertyandEquipmentNetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r416",
      "r418",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average assumptions for options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of future amortization"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetRoyaltyFeesDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)",
        "terseLabel": "Shares available (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted and Performance Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at the end of the period (in USD per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Vesting Life (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock Option Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofconsolidatedstatementsofoperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationOverviewofEquityIncentivePlansNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in USD per share)",
        "periodStartLabel": "Outstanding at the beginning of the period (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "One Year After Grant Date"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r423",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofRestrictedandPerformanceStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofWeightedAverageAssumptionsUsedFor2017ESPPDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r149",
      "r150",
      "r159",
      "r681"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r525",
      "r662"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r59",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r90",
      "r118",
      "r167",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r27",
      "r93",
      "r169",
      "r189",
      "r190",
      "r191",
      "r214",
      "r215",
      "r216",
      "r218",
      "r224",
      "r226",
      "r240",
      "r272",
      "r334",
      "r454",
      "r455",
      "r456",
      "r473",
      "r474",
      "r488",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r532",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r240",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of restricted and performance stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r93",
      "r98",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of restricted and performance stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Oberland Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r7",
      "r8",
      "r93",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Shares surrendered by employees to pay tax withholdings (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r7",
      "r8",
      "r93",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Shares surrendered by employees to pay tax withholdings"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r70",
      "r663",
      "r691",
      "r707",
      "r815"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r508",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r508",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r508",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r508",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesAxogenProcessingCenterFacilityNarrativeDetails",
      "http://www.axogeninc.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow activity:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IntangibleAssetsNetComponentsofIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r268",
      "r269",
      "r328",
      "r332",
      "r487",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r704",
      "r705",
      "r706",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CommitmentsandContingenciesFairValueofDebtDerivativeLiabilitiesDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementFairValueofInstrumentsClassifiedasLevel3Details",
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.axogeninc.com/role/FairValueMeasurementSignificantInputsIncludedintheValuationoftheDebtDerivativeLiabilityDetails",
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "US Government Debt Securities [Member]",
        "terseLabel": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/FairValueMeasurementScheduleofAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Investment losses (gains)"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r242",
      "r243",
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "Valuation allowance for deferred tax assets"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at End of Year",
        "periodStartLabel": "Balance at Beginning of Year"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Deductions (Charge-offs)"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r526",
      "r662"
     ],
     "calculation": {
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LeasesComponentsofTotalLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/StockBasedCompensationRestrictedandPerformanceStockUnitsNarrativeDetails",
      "http://www.axogeninc.com/role/StockBasedCompensationStockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Value of warrants outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/LongTermDebtNetofDebtDiscountandFinancingFeesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r228",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails",
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r227",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.axogeninc.com/role/BasicandDilutedLossperCommonShareDetails",
      "http://www.axogeninc.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342943-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342832&loc=SL128342957-244231",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Footnote": "5",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "5",
   "Subparagraph": "Schedule III",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r666": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r667": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r668": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r669": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r671": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r672": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r673": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r674": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r675": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e12803-110250",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>105
<FILENAME>0000805928-23-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000805928-23-000020-xbrl.zip
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M3SN;XVO^_?=>:*?6^OZ2W*' E@):N=U^RW>V-C[M4&"]_6$;=A:7]PF)Q\,
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M@*SN3J\$B\;Q*',V"-SZ0#JE+4H18UEQ&J=?K_[RK>&F<7N(@]?=.*K9?$E
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M"1VX5Q%=#9 [^V"9(7IYA\CEX)/"4G"RK,3CSA-ND2<1@N;!U*/6S:PC=VK
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M(H@L3*PM+7PP/W<OU!"T+ND_T23OP4"@R#F4858I53+6UZD,TZ3E,_D8VDO
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MKIL:;7%G1MN7:0HC289)EM)>7CF2)@J),<9@4TU!,P%/_XA DVP,.D>9N5.
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M"X^,U+-.I;4O2_+*%,=E28X5M+?J!W&OV=E]25W2:X;#DE<Z3G3E=Q6U/G*
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MCS6NC+T.2$N7_G/8/"CW^.OTZYG\EUWJL]YA+,JZTJ%+26[]N]LT?*J!-/G
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M!_#<.O!/7DBAN:J==I-8&T6NUWK>GV[UO;5S>G3Q^O9]&;7_KW]8P<T?_<8
M6WBPU^U@HS-TCK\WB/:,"D@W? \]*6S"YY/D];_=9R9DL1_TEH_29JS"1X$A
M4D=AQ90@6L!]KH((9#T\^IQDDBPFLAGVJXFS?S;N42JONT1EWQ10/E+"MJH^
M1H7*:*6K*!-)ACE>>2-C&0>(TJ*E'Y (FQ:5MC<;G9J>A(1I(R[7O]8F17V]
MYJ!)-QS->F$/4^/@L-<_+--?@VZ#SABR-RY^"_\L,6-)%EJ(@^=WU2,36%]O
MF/F5]?62/S4 -UI?_W/'E)2_=.5L-5;_3.6"'Y0I&"924UL/!HU^M]5,PRH%
M?XP/#HML7#[RG0S*$8:O'[AXV-6MP\GDK>9@5- "?=QKQ);O]V^0(7K+;KE4
MT^&Q=GS/#PGCYFD[=%N_71@@F_9N[PW?8B:%LC9.V<"3N%<V!FR0ISK>:Y)F
M?'%G7R<$_]!\C/W)M[KLA_+\ZM@T]NA7C(#=\U#&F&R<<A&&5JR6E'>TF&!G
M*[77%[=/=JB-.XOOZ+Q/QVNO5N3.XL)QN6;M\R[L+"ZWM[>VKRXF:*V);5C;
M7VZOBK\_K6T1-=Y:8-O[Z=/JX@+1Y&VYOKCW:?7#SMY:B]KX]6("1HPY>\<J
M8:6M('!;>6EXI1U&2;+)7.11@BKIPN:@&S_]WOA_V5/&&P>^USCRK4/\A24&
M]ZT8-S=U<]V\#]T<>[>1<YLKY@T4<^6J8DK+,FE@J!@R64'66'G/H<J)J^A$
MY,Z&DBSY:NW1ZM^/F<A<.[_G.9?&-&>4CWPU [*0H!HG/SZT K^]JL *=!)>
M^RHX[RJ0F*J0G:D0/;?>9.L0* [8P\::[R?_GY%W;93B/#CXKD[?Y3*T6X[2
M7UB&)*=G&=)/C4/MWLLXU)2-S*UU.SCU4U;G@Q'#<8AOS^[>$'0_D,SENTQH
M3GN"B6>=5*;2L1%.&W$/R?*T2UFPYD@5+BQ::/8;OG&,K5;UJ=,]IE:B[Q.:
M$AWH'Y;9+]]O),S-SFA-P\9A"T=K-X"I,\VZH)"D9$\;V_3A)U_]1\O?;_;2
MYZNB)YCO=]^S^Q](5O]31+4YEM3*4%"U].*WRN'Y_)%[KZ, 70V[#"0G;ZRM
MIT\B:FG1,$C%.%YUMQ,$I[[1FM][L%@W:^/*3YB-3G= O_SGL%F\+SG=7-:V
M]H8E(?K7>>/SA?K=WI6?OJS:_^*JYU;D7JW(^V[KL#/PO>%JV5[_T5F/M\<?
MK>,>RT)8@=I6D 2K; BJLE&8!,(BB#"W'G=@/8[W<+@$ZXH)^8V/E7Z/*$8Q
M'JGA6ZUS"W+1M 0<GT WOL::?&U +C"2LS"X&)5"6$K9CT:BHYW=X:EEMWH<
M3M9PT1A6]^HW?J.;4L#<Z!_&O49_KUN6<)Y5NACL^<'55SGV_:]-X?#B\=O\
MDWA4)S5^$Q=>.5#L32>%?7JA<M'P?+JR-&5\L^'NW,.6#%OJ^X.&8XWD3_M/
M[]]$C(NBC8K\E.&^@1\</D)+<?)1.24CJ%"6S,<*F,3*9R>J**V(JE@+)9Z\
M('\UE:9B$OYKK3L5KGL&K&2Q%&0DVLW!@&P+MLA8]+J=,H39.FW@$?9.&RLE
M*O9QN"!CT0_\J,K(%?OYY1X7J=E7X=P&[AZV1BG8F]56X[=RT/S1$%(\/0_X
MFL-E[0=E6?M]&])1J\]-(_;_^0"&[T)_ENX<V\%'9_C>P4>(5GN=;85)FU),
M1%96ZTQ?I1':1BVLG!N^N>&[#\,W')AJ4;.QX6,DP]?SQ7H5*U!&I3K7_DI!
M::>Z]D"_31:3GM([HS-D.-K4!Z>_%P9)MR.R5;IHM[';ZQX/]LX./R4NB<.V
M#4?!AD7/ALOA2L*XH-?\1@N'A_D?9Z=]=<+X^.]G)WRS?6<W*OQQ?.XWFGIV
MYJ5A.BY")<X&ZBYRX:>3*DDRZ4F%Z\'Y^GHYUD&;IZ4+UZ[3O5IWX'5S#+5;
MW#J=8'F0,G"]EP3$W6[O])KY[^%)0XC&\4DUG0J_57#[^2/CV6LB<Y7F0E50
M2L<%[7(5@5MG;!*)PY,7"U?U>CH8WTG-3.3FM[S\9+KOWI5P^+Y_'?;IR?W^
M;!6*OI7:R8^1&\TP^$I(9!4PCY5CZ"K@42N#TB4F?USFN1ZH7[J>K\XHYL_>
M]M7P95^.WG6._?-A!?4Q!H5<Q%!90["'R,GE '>5EP+)WTAML[DA]G^\+>OD
MPMW\G;"RK"J^X51K&0$<CON1ZRUSKH-NX[ _"DD)N,,M?*XKR$U1;7E6Z[0\
M_+A)CRXJUZ%7ZQ;_<]3L#UUYQW=BT[=*Y%,*)I:3RW[(R?=2OU$J)#;3MY*K
MY&_^G]=&EG7@_#]:9_BP@.'JEP:&Q[-F8SI1UK.440(_&& I<%F$1/(J94BI
M:7YW.)UTOL[=]_ODD\M/9S+$G'$XZMD95_PI5S:+V^@00(JA['5;C2Y%'Q=P
M\X7)##==/D<',+BP!G33]X*GVU;K)RT\'4[%_<95X]W3S;*KJA&Z+!C]9WGQ
M+V\YSNH++;+2%]"9F[WV:.SX@)[MRTD$Z&&V4AJVV!^FYF#<KI^&XD*/7NI6
M4KQ'_[(2<V^AO%VWM_!%QLLMOSM3N^C=BEG!1^U#Y@HTQ3*%667O2MD/747!
M?1# %&;]XSWPKEJ/*UNS'W1'YO9Y#\MTR1%^<[/VLQ3X+Y?XT.^V#@=?7_*C
M08?1OWOGV]8<D$Y7H8?^4^4SZ<MSWSKVI_TGS^8;R]=V8_E)497^EXP)LJD_
MN\#_FW3FHO/ZXC2&Y9='R0W=KU/+AN561NFFH\O&*1&Y-<R4H)]('CT\*^4[
M9%F]7DF2Z!:?<-3L'O9;IV<NX;JG/FV0^FLI?S15]&O0NEF?_W_?(!U3PDAN
M,F-3".50?EWBHR,1?)',&8XNR'KHM<^G=PMMB=WA##:QD]9IOSDB'9T2JI)%
MK8(O%+606.ST1W2F3#'3H6$BT/G3+Z+GG-Y<K5'8ZU^<JR:KC4<%;.=-&-/F
MBV _F_L&]I2SQ8H3Y+\"SLV$-U5AR<_/PO7W_G_VWH2Y;2W)$OXK"$W-M!1!
MJ;1Z*4]7A"S;KU3E16WI]9LO)B8J0."2Q#,(L !",NO7?WDR\RX@05GRLRS)
M1D=W/TO"<G&77$^>-'GNO/;-=8CP5JJ)A,+6/6(X[SZRA3GIG?ME\VOWG\/G
MA@RK],GVP1!4O?M[R?9P-]W;'@T/G^T>QNGS@]&7^Y?]=*G[!X[L/&;1_/>F
M,-'!KK3O'/ QSX%)3.,.2?P?Y'66-4M8DN>DCSD:81#%(%NC)#_U7PWWQI '
MQ>,QW0NY-.42.2D^MX^]+-GW@W>+#+_^F$C=.A3*?!'1@62]P!" $:P&>EJ7
M@0&043R;5>7GC ZMH:']2<7%&X;]T".;(A-AT=3I1EMZ[#Y!'QWS)#X8/CD<
M'1T,AT_,DZ/]]("$RM.]@_2?IRP]GASL;I"83.@5>?V?&[NK$N2,7=LW>1DO
MM5 LFNEV6K+=B;LW(G2E-?R,GTF<[+U_]8G&^^OANXMD[\/%\3\/#T9')(P/
M4&-)CMW3)WO;ST;[R?;!OGD^.AJ:O='>P<9?26 /CNC_GNX_M]+%+NM?(S$I
MFEE9^-TKD0)L2YIEL!PG;MOI!JNY=%/OT7+.DWB6S<FHE(+.]6"*VT2='M*)
M1^6J$"!B,NH)&7-TEIHY!P=Q^'2*.A@46[,6\PFD64HF:B6(_#@8\#E<>_#D
MC4MG;_CT,'GZY&DRBI\>'.X>[#XG#_]I>OA\N/]\]^!@M,MG[V#W8*]U]D[?
MO^E -_,@N2CWG%_UP7];?QR_<!SWW_U^_,]1\BPQAV9O.QDF1W0<D_WM9\,X
MV4[VC_9&YC#=&SYYOO'7P_W!D]V]P?.]9ZNG4=;XIF?GB]FLN\,J/*YTVZL/
M)[^^>_W^XCPZ?7_RX>/9AX_'%Z]?12__O^CCZS>O/[Y^?_+Z08N>[]##N/;]
MHDSZ<D'/-I4AQ_."7O02&)N?ZVRC=>#5/Y_N'^W2%#[?CM'<_7 _3;:?'SPY
MW!X]>7ZTOWLT2G?)<H\,B;\9RLH17O[K&8+_BHA<HPXL;O(2RK7\O/!QF%9I
M3PN6[E'H>X?'G+W*$'22VI>(@YV2LB"#</V;1QE$=;0P<<7!B"Q8=%B*E5UV
M9#G*Z(S,4>U+=WKJH.YO2!58S;7]CYNWJPM.TM$]]&A__GSGV='!US!7/G^V
M\WQW_9\[^!678N0'UW11;_/"T)516C:8%RM5.CEF6I08:T)B7Q,#_F/2_^&D
M!/!LEE<W"4;W:82?((VP9BGNWD2Y8>/SB^.7;U]''][<2<#G1HMR5[V9;C@!
M)Q_>7\!&^T;$U#?\Y(= J/R5:NG9SM/=Y]^<3/C9P<[^'7 4'Y* ?/8M*(IO
M0;GVU>QL;4+74 G?F$=-GG0_M*YGI+Z^3-OZ?&6>.CX.?'3=P/ROXU/Z1CJE
MZ[OO2[_=<BPWUV][3V@ICS]>J 7>H=O66YS/K[$X[^8$K3=3OWR6;[OQOKOY
M=(_;ZY9CN<7V>K[QUU-R.Z.]G35;JU^T![EHMGK@+E?-J:]N,<],I'=N**\A
M"NU:MSM\X\JZ%>6ME^S)]<*[/VH/\*CM[XM\U%#7<2\E']72?<SJ3]&;.)F7
MU0.6E/VJWFY5#_9Z2?I QG*+A3NREN;+7H@^JE7[M:A,7>; EY[/XQ'BK%/.
M%CY<B=K;GDMK>'38B\P',I9;+-PS%9G[O<1\5(MV5I4SS+'I1>0C$9'/>A'Y
M*$_;P9Z*R(->1#ZJ17MKQG$>D:!,#+-C]I+R<4A*K-W142\I'\A8;K%PARHI
M#WM)^:@6[1W=$IW'(S-?1*^R.LG+NJEZR_*QR,O#+\O+1Y2V[_$B#QPO<O"T
MA1?I 2.]1OJF^^MP5\V(H]Z,>%2+)A693(#641.BO:Y?<\WP@*[(N1J$"P$G
M90X*JW<@T*IJKC:6YFK165,ED[B6<F*Y-^@QTULHC\)"P>8XZK$I#V4LMUBX
M Q7%3WI1_*@6[:.A]U^:M!>0CT- 'O0"\G&>M2<J()_V O)1+=J[55Y61+Z:
MNLZ4S/4XH$9[XZCL3LHB%;I?7$-BMLF%2^_#S,B0>J/TD<A<V@5'3WN9^T#&
M<HMZ7!L?>-ICI>][++=;M?\"S40VYQI]EI_TB]S^'"0>HN-AV<R5X2D"PKJ7
MJ8]"IF*1GQST,O6!C.46"V<=_6>]2'U4B^8MTW-/]PO1>M[,9CG_'%<+[D[;
MR]#'(4-I59_T\)>',I9;%& >6C#U\UZ(/JY5.^$6.NBYPK*33-%X7!F5IK^A
MA<^Q]$&)F3F_L#]::EPOA;T5VXO;1R%N>?WI0;W ?2!CN<72'5EH]O,^$G#?
M8[GELH%(K:*%8?')&.VTAQP^'J&))>R%YN,\?8<AW\3SOE3ZOL=RR[7[P-UB
M3@MA2J=']3+SD<C,0\C,GECBH8SE-DOWU!J:)[VX?%S+)FK.N^6 IL85-])X
M4U;TQB+Z>U-E=9II\S3NE796F4OPI)\6]4R[JO5B]@<2LX^H*J&OAWG@]3 D
M7]H%,7U%3*_(OO$.L^G9O=W>_GA<R_8J0UO6LJH'T6O7&?6#[8R*Z->);8T2
M_8*.J,@D],F#1V)L8(7W=O=[G^Z!C.4V2V>AVWL],?5]C^66R^8%Z4G0H[J7
MF8]$9C[I9>9C/7R.R[_G"[SOL=QRV;1H>A%]N"K(\IQD,^YG1?,>9T7TTA2&
M3%(@6.3O;)GZ(AFM=EE;LMW+WD<B>Y_WLO>1'N*G^U;V]D2$]SV66RZ;E;(L
M0)%+(.E;MT3J147#E.[,]4 QB!(WB$[IK63CIJ8/"SP:,8M%[\7LXSROKHE
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M/])?.L"0Z28FE:C7+VV:_GQ__S4LW:%7QB2R:^BTV3^1B9;2D80V)@5+FM7
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M[SK.$=N<5/PL,O$.^R7\GI'RHA6=!A)D"I%M7"J,CGE5QLE$(]#+D2G1ZWT
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M?<.3\GRC8SIOO+/O<#*OV]FG%Z_?17L[T<M?ST_?OSX_7RM!'\*';/SU%U,
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MRT#8UHP/ FG3!6UBJ0)18D4*^8\B2L3IXM"$4 &XS1(B,WYJZ7#A.:P%8*8
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MH)'[V-Y=33U7L))#5I4P=LQT9ML5*<:?K9QFBB.Q]VQ[2F^9!'B9'RSV]\=
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M<'"L>E;A0;KL+^/B4QUM<IAM]\7Q\<5+_N?>BRV\HDCC*JW9JYC$*-()^HU
M+U0QXEWLGO>@@A!4L->#"GYN4,&79>4];<TJ](Y;\FQLBB03WE^$",C<6R</
M<2O)@2QG:4>S*XY74"]6&R\?!HZV.JA]X],I6.W8(;/">SBR9L,731#+G&N
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MT?==^$/U2>QI8D.?G@6E!,N-D:WYP-8"A%[=:3DDY6PA;2^7\)B(R\4C(V8
MEPF%-P?)/N[MF2H[*6R";39$Q)PGQZK18NVY$<9?)@]U=],W:-=-SKR2\([9
M+U)%EL$&D79<$E4TGV. O'A\:CN0[BI2;NSFNO*4U3@N%%H@OX? B7E"2-9D
M=6E1<X:>5BZ,!9H:IDX)/\FZH059%%F=Y"AJ#]J-69:J,LS+^P]F.U4Z1<C2
MZ#-<G'&*^ ]ZQ96:I)T),4Q[$"[*&JP!].*\J3W/E)V.FWXM^ER,K0>GB\!M
M?A=8E;C*F"0:Q4+B<&56-]/S)]E,EJCA>QX-]=0M)=5;:5KH>Z,]%,+W!S6I
M-V/#"%M):S/(X!C);OJUR& (:,7@&QIAEL:^0]8;= *3<Q1VS_SUS<<W#F%J
MK>7VH[B'% B'CS$['GCUZ\6Q,P;H%O!D</#?5-.@_F1UN((N0[67;Z?I>T6&
MO2XEE;Q8#NI*9$S.OIHN7?!1A)<[)LO&2#CNQ($XS#B[JX@SIE;\VR@7_UL=
MR!:R25@=0EB( Z_AU<[@DFZ &GCI&! G_M(VH7MXBTVNZ%A:H"TD1,F:K\I%
MG%O(/Y:4!T<+Y.-%FIK1]Z?M"0WR-QTSV<-.0MC)DQYVTL-.'HS^N*52/A,9
MTFOB6W["<>U3*'.-HF<UK.JI).7W=K?_P>*XO.)$1%RU^KY?.LDK.8FAU)%G
MB'*JVF&=XER/D"@*5VV/..2D:BBXMIT(V Q*CR=D*@>LW1;279G$9)=<9U^4
MH&)22L/R"H)_:XD!&(R4EJ1< QG<8S)4>ZL*LSTH;>X&5GE'7KX<KVM%?,2]
M<4JI!8_X 3;3;TO-[KH-& _"USD-$EA=)&"N(T3(0GFP$_W?EFL*BHAS?<K!
MT=[FIZW-IUMV;Y\Q47'T-T/&Q(0N8ZJ.://L;^=;T7$R7XXC,O\NCS#F!2VY
M.&IOGZ$KM:).[ '0UJ1VV-?4E.Z-#I\_3>]P_J-K7G[GBR_Y0\^CS=M^L#TU
M<:&=Q.PB<QAVF)&%1,.(P6%PUE1U$WM20EH861>9?991*\]NK<#0T!FQR4>5
M986G]>^XFZ2<D)0XRW$SW#_9UN;AUI8"%S+I-H "7,0?"V6/=$BV*QNSI#TT
MSC0PJ?)(4>9N]]C,4C!X(3O1X?CH.:>9DIQ<<LW:V)'N1&^R)<:1U])>G%,=
M7-U@_%3CV9IAT?X7OJU2"Y/.IH9GUE19IY_S-Z[^.#%YSC4(3)+*$GY;TO2V
M>89SH_YV<O'G,U_E)XBV0AR$-(12@0%!D%.<0PD3>NV\A'06ZH)20,Q+FOU*
MP_9&&_X&1"RV%)#K\\ZX@.]T$)V>\K><TG];Q8894\!H?S'W%Y+=2"P/'"-Q
M;FQTS6DC)TEX*%Q*Y&08GQC9"8\D.O)EZI.2=LE"L:1D!WSJD.NT.<'$H61[
MVEC$<3;B;&*;@0\^DZ8>.!)!7$OF6WHZL^JUJ%GN8<1,EBZ=N=1&Q#G_2TQ9
M83LGG\FLH7(4^K-"PXZ/&W1_'?T-,?D6SJKEB7KU'WP%<BB2_>"#*IFN-6#&
MS8V/_RN>SEZ\VM@*$T_+#68;YB><&K*24A?.=: )SB;C% H#(VX8-14/"S_;
M7I*G9XHAFRAW#5@-60K;:1:^\\:W;T-R1>5\&ZO,(A2 &"',Y(7K4/SM@IJ!
M>X[CXFCW]4IXKV.!AEC9"H;?(SE0M_1L+H)8/?\;9HX+MY^X4'WO^GQ%$!+;
MFQQ\&AUB29 >K8R\.@AJ?Z!(TEA_(98.]]LC&X'G)5J)H[GXWXXC>_?E@L%]
ML9#@-C;<?VFT-Y-#KI" D%Y%+MO1U!;*4,=3;CG&7-HC_CURY&)?"7%^L8@*
MNHJE<'A+UPWV[.$&UY-0T@ZCC-LXD4UB>%;&99FV$N8LXZZR&D@G$B"B>?GK
M+)NO_R8HUIC)=8#5*R7B"<;Z%'5TLV8>M%S$BR"0'9]&988+:3<Y0RPU&I+)
M,I=0;6;[T@JDK;$TRNI1+$TCIT:FQDT%OS$:Q7EMN*+5(PV9K8[32D80XZ7T
M4.F\.%$PEIUE3D(U8D*LY$N$- N*5($S8LZYAERW]@\?Q/&"- <)U&J6T)4S
MVMR@@Q0[7)8PW>2N9'8J#+]_"2H:M!19[4+&084@&:]$+*"GI1;7XW\8MD0/
M-]XN"$Z_SXY&>OB5>MN1%2,WJ:1DL*A!#]P!#6HE/_#MKT);W&67!.$'AL=%
M\$O>-R=E^2EZ*:AR3SBQ"M-J7:?6*4/:4'3K5D#YM8.56K8MX(^\/GD7!2CV
MN<+$!4YD&=1"J[T$'"O)G>IOY:IOJ;*_YZ[NUL;=?!V][OW#9@YKS,[9C7IH
MR+<BI@SH!P)N %6+R@":5=S-.5G0F44N4J,'@Y#*3QR9D4F-I4H$[J#%73 L
M4R4J;=E#VL2'N3&%ZV&NEUG@B",):(7WUN!25VK.YT&_;!?:5CTQC(M/MNS&
MDR#&28*2%]8/(41$7,[CXXN7C\2O^)(V=J$>\Y64(:TBS%"G#-05";0,TX/4
M,WCG6&NKG((-PJN6V?:KDE/W*NN"?^ZH#JW<0Z29<+O.RK;*<-L<2EXC;D@*
MC*R!UH(82]Q+>_5&1WN[FY^V)/NA&^B-[O0W9(0.HE=5,[:?7)-)08K^F-X6
MH@_>O&)?_01_\!#O_;WHY,W'Z(SL WG\L_U=%R[[+^VF?KZH@>/T\J\-$;?)
M@SR^JFT+":N&EC0]M'LYG NQ9]SZKF!:Z)C3@<0RA&0R=]/)Z.%'L9</1"N
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MW_.KDM<[ 5-6B8#Y7P!<UG@!*SQ'@;V)-G@^F+#E=TNH([566OBU0OIYCCS
MHQY699P*U]-ZU%PK2GSP9(F:H8^@K^9S&>0#PCF:\$1H,Y@]K_R<Z8_GRC>W
MC<!-NX\/7%" EN=L!3&?BH1965)=30R':8+N/E)Z'=<E.J0L!& I1DS&P=
M?F2/US$BN@J>E#ZQ$%C6_PN[.#E$-9];]XAH4RP=VX:>K*!KX.[]#KKE#GK7
M<L5.@Z.[W?II)O0KZJ)9AD(U$0>MZIH!])$@ZRU)G(8=F(->0E7A6]VB:]!
M0V/NU[::1DI*6N*EUGTKE(PACM@.D1NW87]KL".W34IM+Q]FOV&NOYJ9XX;Q
M'-T\G>-((^CWV[?'QJ%>N$PLK=%I8-<L[<)7AC9>+LVB] [MN2QYK15F38EF
MP?</19C*J.T9DW-*)$)H& ''J)U3J$T4?(P7,3D59(/6YM.0\;]0.F2C?W6K
M6UK+6MO>IB&/#$?2N56GCUO-)HL:Z;JBWJ(QE]S>$JS7C*\/<GMA 3?D)J0U
MES[1220C>WN[\],%#:_#E(,R:O)1)@!^-$5MQ6>BM-'V-Y8(%NH_TQ;@WC23
MJ>!4 SF]11 @=3R3=DH'P6T:?-;O$+MON!#[S74B9PN5KQN6*,_;//WX<LMW
MODG9E%$YM&SV.6<_9*]8.<"/R7+[4&AG2372.2,SGYMTT+++V0B[BDF='^Q&
MZ$(&IAK2](O:!B3D#$B$ V*Q'9?;B5Y9>0Q/()LJ%2V,;69\H-W'T<&FT%:#
MND9V:,Q5*G&X,#$2SU=WA)P\KFAR)T^V9E,X"\/PV:.C5_#C^18TO<7YDQ*0
M(3F9T[!M"'TY?[!D0)@F>39O40UIW%=G1%0%?:HO^8@SI*Y=K11]$[LLDBSG
MW Q7FM4N3*]EII9967@2,HMAP)RXB'V;&$Z;*:+E4<XL&IJGHX]5<FA0'SI*
M8,R!76NK'S%B7G>T.LRU3RD]S[7"Q 7=WZ(SL+0)6%=R=@9<T.PSX+)!*PW(
M83,,![@$+*(TV+/CYPI_R[6W_'P!0$QA\CWN4WG1HA0,"Z5B-BE4/"V[2LHH
MV#M!W\RDV-^SS$?1_NZ>)+M6_S\'Q-]JFJ&?_#N8_(.]_763OS9#$>0F^C6Y
MDS4Y7+LF$$RD1MZ3M#X.6X] C;^17PJZ@R29 C[B(+<4KB%?M]6OX)VLX)-U
M*_BAFJ'=#.?S^KF_@[D_VETW]6W";>E?<:ZV;;\4=[$4:^48W-2" ]>O?+]4
MLOA=I"&,+?2+<R>+LU9$G;9\^H_B+[Z$3]^OQ)VLQ+-U*_%+6::P?Z,ST"%E
M2LCXGEQ#>T[>NO+@Z/]*8N'_V>S!'W#4'@F&YJ5/$MIR(=>,-_#>-E^^/=ZB
MJ9Y/KN+UG=&_;>KP0<)MX/TZ^- U4\6<32[K6U:2<9(X@H!=)!@_"* Q*\"8
M03?V9AU<)MI4+J4GNWL[^UL,G)U&!T=/)K:UJU)\K)#O:)NHEROOJAVVD(,;
MUC+F#@UH^21-M"PB5?E$EA.D+6";PZP-HEE3N5S)C.P*5#%H(,E1/2&<PZW'
M' .0Q%QJ*2P(HDHV#-YJ.V C?,<\6AX-UUK8G*V'^IU,S!3A9AK/NQ68WHG-
MY&QNG+P[V=@*6@^U4SI!G+S%[FT=\/""UFP5"F&8Q0)]QW3__^R]:W?;5K(M
M^E<P?';O;8]+J2TY=I+.O7<,1;83=<=M;\MI[S/NN!] $I30!@$V0$I1__I3
M-:MJK5H *%F)W^:7[E@D\5B/6O68-2>_7ACRLH9F@,N%IW=>*&,8KR?];XS&
MVB$9QM:2D;9)%E*SZ(YMRA,^!2SB3%2%,QC7=+B"F;U[9_;3LQ<T5BD9V*F#
M,4)\VJ^KP<*<AJVVOEII\I/5O[JL*RZ >Q,%.,L+JAX(,INA8X>S=1=<TDC!
MN6%%&>9\HNICOX55">3ONK\JA1TKKS6-:PH- I:KK[#40I=0X-P+.^I2)9;.
M6GH49;7"$\LSE=(:P]>JJNT5N*_$UG;K8J5C&#JSMIHBXS@;-YJQ%T3K\MMS
MD>]L<'?MDN^B7=)+ B8V/S*[ (,!O#Z0(7H83$R'=FFTAG9*1&YG;]=8$<E?
M=*7&K/-Y[EVS]/N<[=-8;XD@>%=Z85, A$S69_\QZD/%]/<J9%KVZ?]4BC-\
M0D#N5.A/XV6,_HSG"V2*=.AMC^TF=.B=O/R1U02#?2([#CQT]%/*=1'+<$7Z
M"%:J+.:[5?9>6_(=/:2BX:TI2 APJVI/X3M5T?<G03,U8WZ7Z"'!$W(@#[,;
MC,YA6!"WBHTT;-"WATXOI-2 H0_J9]M7PU<)>/]^!WC_N@'O.QOX/D]:]J?M
M--5(F9L<%8_FL6"Q:9?BXL!;'.00A+4D8 KINWPJ2[C&,I8"!>E8&"^@J 9=
M<TK8)*BWT#"'O^:S-_D9HM_TSKO#\[TN' OAA:_#X]IFLH/#C'-@YE%(L7=6
MSL+D0CA] M#FRF%V $Z:9_.(FY7;[N;Y@\US*LRN&:JC^479\:?'@$JN"YL8
MFNF%(WG9S=/'G:=WD3R\7<:0<W\^:)[TH9$@E ZW&LBKNX9]WZX?D.[A>4+L
M+F+*G+GKUFU1GZW/)P+^#2EFI)MW]%;O>SGVTW-Z#GCCGP?1748&IO1H#G7=
MLR)OV8YP/4?_IYP-O67M;D2\\V7DE3D>BBZX3V]?ROL,QN]ZPH?A:#&Z>UH4
M=:1428CVA4(Z)=CO2K[(X?W[WP*J?'C_X'Y$BZMH,Y/K*\U9G?!X0<]$;+.0
M;[&'?):WP2&*NP B'WC@KLFJAO<,5Y/4SM(MQ,I:Z:%HE]KUOVAF:#>B1V#'
M/G]CUXZ='9)3YZ9< 6AK MTAG7ONM%2J^ VE<42++=R*T<S!\C/^DIL5:AL+
MT'B94D@B_;[8@"&M=WLN@RXB>XDYDO$;<<B90R<J,,P;P+*716&-4+4TXG;A
ME;8\JHP@UUWH<?@:Q6_<^0G&V#DT4&A-HU\/54/PD>G 0FZR%)!SE=>T+A;Z
MRE;EJL,KL'YA<1;HZE1H:<%=+/RF-SU\[U88*,CS*#_:1(<.4Z6](N20-6^*
MZ]X=%6#&SZ.@*6T(D%,WF#NK97*(OFZB*,PZD48:;JY40H;[*IOVC0WC6G#B
M\MS%V*OYTR*EX6,3UD:B2_S"%REQV$^DWE-V$I'\MI[<XLF_YIK;:^Z#7Z<R
M/\?(]6&91.C#$SK=-_YHL<;I.\<_/GEYYQY/P%\W-,]L(F5*IL7ZDJUM\F<F
M%BJ64Q:"@BT--M2G&9B@B*X:FFHVU3JVC<#!)<]2J+3$L((:P#:H$"1&1Q$A
MJJX_WN-;-P9&@8695/G8(EQ>1O.4PB2B.*[>GM_$67E_++&;O)2'YT88M?'.
M'+#-6(+0K-*W;/I[:/S*2+(XF7+I;OKY^-6?7VA%[%3#A >/#H2R:J24VOOF
MPP/S\EYLIN2Y9#\7>44#=\H2\_0 1WR G H 92:==8'+H&_/K".(W_Q#EV<C
MY.Z=N?M'G,+:MB$//TLG_\$^1N!ULMJ,W=4%@+8\'MX_N)O?NWMX[^Z/]VR=
M>"EO60P&*!G$C;S)G<9W1_\0LW%X<!!1'Y%--NE'@A:+"=?W+_3H_OV]1W2Q
MX&98EZ!&SIETS#X8M(E"AD>"WULBFVYSUB2C_NWAI[DTO__V_N&GM#2_?:AK
M\SR_\-);!A9BI>B</+.K3AK=V075'$'6B00B&^_^6KYV =HZ2D3CV5].;H8'
MDA0%FI'!"!+5K4<>1)B!RZ50^?:/HC&$UN )W X%@8 UX9G(ISCP&NVXIM;;
MOF^?@X#C%% [2@C%"2DAV'#R@+/SO#Y+Z12Y@]D&(2IC\*L()0\/DL9CW!#+
MIR%:2_%.D\$+:6:*?^5&2X_*9*R.8FA5Z$[NQQN7A<0^;2'\/ (=C$^";G!R
M2QC(APEQ#!_@\]&GI=O_GM&]X.UQ-5PBUR^"/W3N?1HGZ->0,'L=^ZBWGCJ]
MPR8]:&X^9]1GR\4/<S04M/8#_XVQ&9^^"&S&B.)\TS4R=W/;1?1-7MU'FS,&
MRY #?W -L=3[/M'>\5+YM,ZV;_:_><2#<3*$GO3U*J.CPQT0W_Y@3:H3$855
M#@6 J?[7P<-O#K[WY5\8;,"G\@0^11=]AOB.)OGAQ_-:OHHYYJ-[BQFXA-.@
M$#$+@+N"S0<?#BV'OF0 ,$FBI0NB$3O:YH&RJJ@9VH1MSX%Z7F\X,TB_^Q['
M8<!.:_&6-SHOC;C]5<.9_[A!U2;!R"'\ED2J^D#D@/##JZ$S]]G$@\N%DD&W
M^L3N^?AGWG, T%<R0I*&I,B1_7%_SU5S*2,1$'9X+58OD+_FZU"IQ%?R]@SC
MT[LO.2?LJ,GCDFUTU"YF%>L-LA<,365MA%FYDIA<$%+=\#*;%2ZV98*,H[4W
M09(R.;R_;^V6RL&P1U>3<8TS'.TQV0%Q#)H5KSV]&4 7]#SS/09OQ%^Z\OK8
MDCH\I"?6"UD31G=. SVWBAZ7!LL+2$7(G3A)P0E*FKDEKR]:':+L'16NUYL6
M\5:-P\KD:3@SL:01V^@:Q-S.F,%O* V.5HH3;>QPAV1XK "Z8R(BEB?7A6C,
M5Q@B1\V]VDR5V9U':C][^>3X^=_#*R=W\&NNV\#]Q(&\@#JUO5M7U*B2V]M-
M;OEZ^#Y(O5I90MA%/+ TV11F=&'S[&""SKX?WM_!!'<PP9O<D8^T.-=,87!P
MF"V7V=W5'B?3B^P_J_4/]_?O/R2W6UWXMS8VPN7$U9X9LZC!ZEQO5,"VEE@2
M,<&)/9&GO+_E(;^ ^/*+SM#ZDI=7W^KE"7J)4@D579:"ENFW![M,Y?O)5*),
MB_10JI.BGHO:@1>2Y$+WFV&U?$CV8.+"LTGV?+9NM*3V"+-[6JS65F4[/!17
M/KG!8Z_9Y6_A+O5PD(5DPR$D(*] #I?]MR:H3B5!-;Z43)O;G-K#P75_@?30
M0?]R)Q'&]@JB&__:<)_I?Y^>O+ISKZ>$Y;^</,9W[$0?K:W#PKXTB:26(<'6
MR>R$\CSZ<Z[+#L?7JQO,(CJPO_GN0=9,:=U<Z'[#53%@\\]U6]W_^-OJ_M9M
M=4)+N)BV%M)^MX_T[9:--K:F>TOIQE5-:THS)[]G/W!,QY2*R",GU>W+9LL*
MHD6M-*HN4\Y_Y6SW]4]OJW/;=?D*U[P#,H+KIGE#^Z G8RG'#/[(H]L5Z;5]
M&A&\FK,96Z6YEM7[%P.69K<[WLON\)B+[R:#W9&?<6XE/8QX68P?$OT-=,,"
MNNTF8+&[L<4*6)7<@/SC&>/<WGIMEEURI7>Z,C\?Z:#7@CYC8!8[%@GF)U;T
M^L?=EF)["F1,D2@CU<VWK8.YN\LLJ209+Y.N7ZQ-+ZK+ZLN8J*(^R\_@?MR,
M@.O-A1$>.LW).&;[$=9IG3R;=ORK/C_(7?@J^^2;"W*?8I4BJEP5H$A[O'E#
M0\.X0@9OJMQMW[6:A LL>2 "#-$TJS#Q7""?<I!<Y5?7N5*?STR_TI?FA3VL
MXAD>'D,PL5E3[3\I "JWB6,Z8?6!-EL4-&GYU5*1;Q$K6:W/L:,,9A:$;: 4
MS("VSN3B:<!=:Y==5EK7P?WKB_EV/;N&Z +K)<"8O<R9!V5#00T+&7SN:M<'
M#Z%(ET1:?+;:HC>VEYQ1^'#=<*3 5^.,^M$<TST']W2^NJ*XYN6S(XYK!' 4
M=>S&L+;8\_&J2[OJ6B_&BD4T8"5;;<N]\^63B]/B*M<JW";RJKQ2.!,TR9;-
MG,:9\>K@Z!?U9HA;!Q5Z*& OBCT6OLGI H!.BP2];%?%+UI'9U$A%]4Z0O:"
MH9\"F4#GNTG9^?ZC<Z4>#\M=J/'G+8,]-C67'$S-5-2GL-C@6XP^CI1A!H.A
M.%1Q!CK5'N?.HGPI$,70XF*@&LGYC\X"!ZN 46KOJV);*X"]:9RZU'Z7=8#F
M.TNZS2:DY3$QZ,QFSI><M_GEULGFO_L_S5KR_N@BBH%'VP$S7!5?+20:F_HU
MTW54)2W\2/$D?0M"&$4SB.GFA.SJ'#&99%*9"_X,Z(M+.ZI"797%*%# D_J4
M)M_(1*,M)^&^4GU%QW 2N;!8"*-D]A!RE\M5-:2UA],$PBPHIH$M*[9SQ(:5
MU1PIYK--.9?C]XYO)>):V;QH'5&R./C'!?3BQ<_7FBC_#0X*!)GPR=Z/J'TJ
MP6#WE^Q9*30]S_*Z7 4P,GW_YV;)+\WFY->NN,,[P<<JW]H(E%*^[8IYKSH*
MX)V^!(O<MJK](2_\7UUF9:PXEZN86Y._5:C;]@C39N<YDWK0'',&7NCG^A.N
MX4B8[9F.&W.0J>I"G2WUW9?NW4,U650'W*'.&W\HX_NU[T>@*0T$@$.5;JZ\
M3=#MI;7?G&U2]CI!/;+/-&A+2;\&-""MBK-6#/\ETN+L%Z>H0#BUPS^#^S$Z
M:=%ZC,"R\#AXFX-#I;)C#?9B02N!OVN'7O$;^55=>>'B;7;Q14W;SD%:K1T=
MJ15?!5\:N>&T$.%JL?H\=++27X9;ZB[]TI?8+7LM [7/*]C5CSXXWW^T$.6X
M?\+ 3JFFXE6B Q7D;SQFOI#&(8WGF1Z5<;_ ]5[P0D;D(1Z<_D-4KP(<>.P!
M1"LO@HM*=I69=)%A5 $-+5_7U+\@K+#WV#%<8/VO&5$)62Q^NO.B8@AWQUBB
M^(U 2_'V$<L.)?L.*+LP7R=!3X=7#F#83A',I$\1M!AV*M=0\ZQM-BLYMYN5
MBX,69=N)&)*L$UNU[ 2$Q2I)+;VJTV07&&X$LN6B#CEO.D[7M(QQE\-=L?_<
M03PW8.5U,JQ?)6#G8 ?8^;H!.SO#^>X-YTF=J>T\"9Q:Z :_P7)VV1G9F5HR
M'Q4#9-N!#642@:*(F:,(&%?-PL6F15=Y,*2<MA>SN3L^/](JN&89*$#XVL6
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M5A3=!?<_K),\^X73&WN/2RE@N/7""^2%%EFT?O&"G=SV@O_YRH)-6V)/6&'
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M\+J(A $ZZCP#OG9X;;F0I\KJA:+CU:L7HF*_B.5" 5QPP1:&,E0/F\T:2U6
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M3.R*/%XI."[ZE(V1?@,"RQT\/_[KW8=[!]\LE_<P+1R6RE\/'N[Q&-TSLIJ
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MH"*P(DW^,!<E)Z,6VAL9OT6WVM01;6G*\;1)(< Q-RYT\%$M=_OR(^W+Q]
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M:]K+2<I=VBMAQ+41<EI(#=68HIS&R6+!%;BY58!.7NQGCS?!(!C<#X\TT_.
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M6OM8XHBI,TA_VGG;+ANN,"X4\-JU*<.GJ#[S>OBP; <NX<V:G\NP.KE)0!9
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M@EFSL;0 =QU%/&A<X%?*2_Y\V,]"4@(2T?SK$'(J9=_W,;QVR,UP U88@U(
M85&H@D7]W],-M54M"U+2<2&W->&(M4Z:&3FC+%X0O0B#9*UF&7O&Y]A[0AD2
M\4L""V.SP'YPC@Z6B0!))N- $I]2'8-]I?GH]R?VBK,BN#SE4;A5&)C_9HZ*
M2CT@2X1M<Y(D%4WV[I%9;=+7$=T%UV S+!-RFF!CI%>270AS__+U,Z;0,#0.
MYTXLJ<4-0#RXNY9WA9D @W\>AJ<K4KN<W+MOB1-@PHA1'C? OPEMEZ% :6RZ
MMHT)/+VY_8-TFIA)*XP+.B1YBTJ&3\Y^Z3[J^0U][)6RAO&U1B]TLTS=%1VY
M]WS@3+)EV>+@(:7M^0Y*P#[EE("Q3O)F*?[XJO.D/"4KGO;A"+$EBG)N#6A_
MBGPFI6TK.UL0W'9EO]<IZ;=*"_M)SQ4M))>8NUES>SZ<J#=1D&?#I$+'#/^=
M)].[ZAI*GHH^09Q+BZ[D6JY 91^A94 :9Q#HTTEU[(]>4$0A ,.))B#%L:R?
MNG'\=[WF )M1IVLU(WH_7!>&K:B.044'_A![0VWRB-W,1?&!W5,](,):#&=&
MU49A4<V_>FBOXB\,![45^FZ?G);-M%M*NRX31MGSH)N%8]U6<91,Z[TLUB?U
M+.RSL+J2W/C "7 , !<)*J=(0\5G8:J)$PE<E2-CECRR^A(C*&Z>ZKPIG"^2
MCP#"D2\9>[%1W"DGRO'QNF+_U: I@I9KV9]HZ3R.YX?-@*#7PL/?:^]C&KO8
M4&X*W%A@CLR)'B'X PPC:[@ZC'94Q@^5E3MTI<6)*<&T:FX)?>WU9!/%(X/6
M"VG7M]<60YOW&Y%\*[=RCUF_4ED5IO8CG*R*$'/WX*0%&<N>G(#XD(FUW\U^
MCJ=GVC3C,65C%>OXLO2A#R47//R"3^)!!Y-3YMK\B'C>AD V7RI1YZ1-\+1V
M"]8AEXUD^XO6R+I<:UVNJ\(F(<&%9&GWA\+ICM*B#"]G#@7@_9MXI_J<C?U7
M1 ILS+K6==)!9G+8H#VR72F*T-HWQ234)+TH"%FU7M-,Y2&J8#=)?\/5L&5=
M%1M?$Y/2EZ]\(3;5@I94R@ %TV\%(P 3TZ=\H *>='/'!F[*>SIJ[B6$)K'I
MU_F'0M[/?%H-!=)9W#*'S(ZBT]B?.>%<EI.N,D@(YM&[$8Z^S<LB8471-.IK
MBRUG\TJOW'&ZP5.M*#D$3*[95*HX>AX*#F(<:RFCNB]@9)#A'O(GO!00'O;Y
MX. V7XFUYV?]D[R5G:N,[-$+1HXM?E_5XV^8<WR)?@[#="J10D/YXK#,X.5L
M:/5&NA7'BIB'K;=<K3U%5NP94,,R@O,=^MA&7ZB6DE<A-(F8SH4^P*LZN4T,
M\'0#3+1]:L+%9/@Y"5)*U7N\-N@ZO/F@DL_G6?#WZ%S$V1G!#+.(2TWY"09A
MPMBB8Y8/-Z@P0)R7"BO^;?R#R3-JL-)KS.A87;"AJD!&1/Q5^3O8V\7BD(?"
M2&'3<82IB;Z DXR"[;!DQ&+C0Q99"TP:,[)6SO-T(R8^_E5L!3U?[-Y ,#XO
M$DU%<+6KHG9"G$GKCY,2L"@\-"$>(Z"TXKG8+QPCL&1[D>5"=R=.84>X/$\V
M JO3]J?W3Y;W_1:I%:^%(\QAM2@U9-T087LKG#R?,AE?DCR/]#P,H1^PAO'D
M@-./SM?D&NS*QDM\/G*QVXA&>?S@#HURAT:Y67[4D#<NM2"15(UXI-D5V=]_
M_Y2/4TKFOQ:V_&Q?RF/BZ3^MN=MK'IR"</CDT\T8F275B8^;.DSACKSR'/_[
M\<\:@.S>Z_VG;^^'J)E?.S@&SXA@ZYF6>NJF_7-8.,>?+U8#$DN>))>224)F
MY>7AFVSOT>._/1D[0I38+9GI02**&_X8$3.JH3?(-D/_'"'GSM%FAZG7CO*V
M; <L=[QZR#G,Y>"YY!V&BAE(Y%SE]/M0%"N*[AD?4BP60XZ:7O;%IT<Q$Q<=
MFW^H?^UF!7&?T@[5SUGV+90RJB9B'=LPR+<I*!X;O6R!TF2;9GOS/DU!?W.F
M8VN"D,3S3S)2AE893)8U#3";Y24>)S;U#%*8XT7@A#^$F:F4LR$QBVF%77A(
M1BF&?+//WQX^R.[];^FX/(1HC6N2N>\R^;V66WMS2J[J?<[J9A$">NCDD3$*
M#W+/$Y62<M9]!IU RT<[@,LFD3$;7>JPTOYBKV1.G_&<^O:?>Z*.=Y]F^GE'
M4?>$%+Q>27*:S?_/":$H;S['F;U_#"ZA>Z]^?K=_GPW7^[P\"PM=COBB8Y+Y
M_?D\+QOF6;U%^^^W(FGS.$^\L/?'MZ9BF*3\O4XAC[?_#6\C4GQF4@(% X_3
M45M>8,M.3:Y,J] ("O(1#I^XY0 ?V/:JGMN (4QU T#*O55Y?#]KE]3,3HN;
M&I]AY)=="&MS]R[05J<T39B3U0D2K2R[CCZ50KN+8)>.\U6F<C'2Q2XRX\BC
MS1?%1U<<"XLFF K@> <O#^?DTT<@SN<E7D3R.48DFV LPQLA@4B_RI,7)!#4
MI5[N934PX/:X96LXM/.6P!C/A:OAY<LB28(Z^6:V-5:0^O6?C/VEG\4D3=)*
M97\ XW7I8?5V/T;HR'D+4) .R24HG1O+CCL*-7X_?(BXCLO6L6M<9DI)98-S
M/Y'#-TQ>.)16=)H]R9;+K0#D&VT@N?!\-:,UF)=\%<.B/V"F\I4@'6BI41VV
M/XV:SVV);UK9_/A/9MG"7D3\"MT@)RJ!%5];E9?)S41\1"K12@H!1H;-<K6N
M"0(_17$KO!.5/:LB[)]EOIO=L+C@(G3,&=!-B4'Z(SV(0R82:G[-N?H!OTOI
ME"I4>I7@9M3P_3610-X"LR"C\:GMCG^LP?%F+90K!I#/"D7>FR.54ILH@8[I
M"&LL;RG\6$>[84-Y943:S 93A^N,P+-8U0*KIR+:H,_7$1:!8'\*C=^(&1-*
M57)HM!UBXYB-4F4+!>IXIJ?XV3S"Z,>)]R9)A#2R4<M!CWNY3K$KQ?#2P8\&
MJDLZT6& B+?*-5O0/*"J(\UE@@Y(>M*@;)NO3QR49TD<5'(?W?O2L]V4K<!A
MRY8U;.D^<MT(D9@6OG:(<RJ.,L,ZXJC"UTW)IC"T8]1^P76D#-]1OJ9H9%&O
MXR[ZG;AHY,77D2K+C51PO98TH'P4^G+F2?X?FA'!^8ID(K^5&Y=2<M$)4"\N
MO*[M4/<5IC#A)RU(B+2_Q)"5&WF_WDH9-HP1Z4UN8HX&'$O.H\J@?Y0$ &S+
M-H!M$C = +)2%2[]D1_5I\6.J]LG[\H*;!\*E>T<PR*9QDQZH/2( %(<>]A7
M$\'^DS-[5CEERXDN!]?#0DMD6;--F-9-PZY3,!7EM&2J8?%TPJ;9T [WO%.#
M+(\!RV!4<B[*$TQ4YG^_IV!,NA+A('2_E+$6V,3 GGB1\YXD+;!(0E<"#R*Y
M]T3:?YA(3YJ(T",T4;J[MD]E7@17L 'A%VU'P#@4 \FVU)'0V8B5BN/BJ^]F
M[^*1+Y^=E\5BIJ-MO1B.=#3NT2'R@%M<M^A=TN^YG[.Z1DF*;#^=CLC^IBVC
M*? $>VD:#LAZ";B. */0S9EP3YT5C?9/0T,\4I"4JM.7,*[PM:QE;IE_8/TN
M+EK#7[>.%K46][Q$5)P!MK%+\@/O,TN,=8/'K.6<$407X@@5Q7&;/8YI+CT-
MK W+U"PU;$M.VS&W(Y41/=COM =TW8:S6$"+53 #I[W&1MKA89D0]D?T;!=S
M!58ZOYIJ]5&_/IU-$\1- =L"HTH$9Z,=TC5S6A@5#CTWIU)'K/CY[$Z.KDE_
M]3P,'__FIX95V9'%W_>B6Y/L!7".!X)="FN7H:(NX_N"-+<X.0FMK5_RL]:H
MH#@DTQ",!R+%&45*)5_MBPK>8>F@_8QC(Z*13<Y$;!Z<;Y?=*X9X,KMURJER
MG?QT=?6@+\)E>=X\Q?/4\1JJ54JJ$/)./*?\[?AE89S4HW>F,:IYQ=L.='Z[
MP7-%L>7X\,B3V3\G3#=!YW8KL#09CV!S3SGXS0&%[<K@(-^!?#S(9^\.Y','
M\ODJ*&?.^L%TV,N6R"9G6H7,1?YZPM6G?.HQIX(P-?'?U*5C%8'-10[9Y,^&
MC7X#OLTG(!L<H\QHQUAT^),VC=L,9W!#EDH,]L5I?*?3EG%T#2':6C'6@:>-
M\,$64\-AVM_C8F=/P^Q12ZW3YA#V\+YDE:C6QSI'"+D0:CKV2K@/+,Z:0GV'
M7.OLVZ2=2V/NQ!^@#;U.)]-N\H)57_DO]!E_O=V_9,^'WG)D%D0I+I6$X.%V
MJ6#X/326.Y$7E!7!EF3[PN16!8O0$#VBN7I,ML6-^=;6<.2=6_IGKIX<W:"?
MKM''M7Q'/^A.N9/$.Q5"(PN W;L)RP/+#)=@@/?=*O3I#\4FDC2U'95*H,W*
MK26U!M;QL2L<'C4GA22W%>6@T&@S)*U=+"Y5A1EO[&*2=EO/@PD#I%!F!U!"
M 2>EL85D'[FX,I?8XC99RA2W<\HLT&PK(@$^E^#+9K9#C3.;;)5OD*RJ@P,+
MJL\-TGS<AM+4BR*.,\AO*]5DA=D#S<8JMO5M'&7S4-?&,]:'0'E&E/>BZ6KB
MN;3FN)B;$F6(X@.=!G(+?C7>(GG3$$6:2JX,)+BW#,9P(-@D:\XI:@C I$_B
M(_%?"K6'=*Z8G 2K#!0?D<QD.WS4U/ELL4ETA,T&YF;I> NZ1Q\]F>Y)JY=V
M'(J47; "* ?<C^9ERJIP99K#0R>H.6K)T/&MO)YYU!ZW":(AF  T.^GQX0S;
ME>UKY\QIDI;N<^Z-"%OV-,W=^_?&5%S/?(.S DBA,-<(S\<&]C;9BK<\*,(!
M1D8W;>8;K$3;1)YM.ZXB)%JIT#)Q/8T,C.!Y0Y4.*XU^'%FZE&="04K_%OOA
M1V<P/5A(:7V- 4+E1(YCJ>)8/V)FKWW8T?JN"D9^2@$__241/U&78(I.W2<?
M;88=?$#C0N6+>W_9/]C_RWU^_/0B3@^=K$UUS/+OQ.&1)!*]IF+%XMYI@8:9
MO^3I[;3&B,S!]C\G$9&N\#HLRY&)71/> 2JI(2"CN*5-\D3U67 H:.?+$7L:
MYG1IV%-4TDZH"A%N$"\\.7>Y1-<YSBAQ$:'T%_Y>44)*N!)H'_;6V+*<[7"9
M,[G\X-,"EUV2EPU;@&T3?#ABRD(])8YV3/1S\C+>([EP6,7':!8E"JB'EY\"
M_L)>ZNYHRRE6$6F_+LJ3NIY)^9I&XT,A/9Y"^*Z4V^(6.9IJ\WD\8R;F/!A^
M:J19!4=P\,W1;W%!73VQ2$. A&)LKB=QII5H*^3'QT3^M\9._A][3QY,@JTB
MV!1403 9\;.1W;/WM?#.BP4]@7V1QE<"$R+RX[Y\*;%I!AH5+Y)7EWF8C(U_
MW;AUS$G1X3+&6&E[,3N7$VH=Z1JT&;O@K$#;L=$ EJ#K#T%"!X=:9VOW>OJ#
M'EZN?^E+-B>E]+=:0H%9%PBME&S)\BT*DSV"JE ,))0Q00VDT9-H.!Y]!R56
M,;X.GQZC\.6#MO-$&QMN=ES.:<70/4/HXXB3I#JW["IQ/+:>B#\?O+U5?H+S
MS;2VH^?SG./T<$RNQ=-B1Q:N5=A45(MG$#.<N(K8Z\AMB^?]D/5(JR7\F=SG
M%<1Y=SP== E_4O@+SV:D/&'YFAY'#^K=\30)P]RU $;[)B_RU1%DEVO2H2.\
M"JO#M)$=! <AE!#[D80_]YP@>EFU.,\G&L*2X\(P/G=3YE9=%-S/IM?;+78G
M*&^QYJ C*&&8N#&D+E1QUHV(R>.E/1JU2GD*H@5J>,.\FHS0YK_;I%9F>Y?H
M(PGA$+Y]CSVN=Z_VLX-ZQG'-_NPT?U7,\(O[A@(WHLBA$8A\E,0;TRV.<Z?5
MI@LPIO6R>S__?+CSYN5/:&SQ"U:WMO<5EP*9X*F>E42)Q@ER8$%%2";EFZ&Z
MCN7)::CAY1KLG1-)M-Z[5EYGRIGV87KOIA,GG&M/GHV((#)QJU"O#KH\8T-:
MVO^G7$9;<DU\OI_2.L74*L(7BQL_6N<+=5]-TJ=(J=CF+FZ?) N&H%OT=7$S
M9<.)H:S"D.]F3PN!-,P%WM6JVF4./HZZ"L.7]%9$?E8C6&UJ.A&]L61/: 9\
M&A-RYZN-LHQYO%[I7])Y^G.7\I.V$"[$#R1HZ9,\.F'?E=1H,BT8/&MTN:U#
M7B:\DT?H06%ZE(EJWDXB90K;P:Y:4<?N=,VVZTT?@NJF?3#:EL7W*1)VA&$?
MN&165U+"HI?J&J%U,JG%:3W#?\EW*"2_.M$!P%^ 86Q.Y2IMF*C\N.CE/V1-
M^Y4D":5"D5ST$[AJ;/1V>/22?JR8#L'Q,'QG,S\"UK.)J#[T@"D<E(8EX322
M*:U]T?;AH$43QZE"IR3=0J!Q!K3C;) /%F7)P?6$/JA/Y25)A'">!?LD GW9
M?HK3>]H4'PFG$*GS ,NA/E0H=HM2E$?ZU:H2QYV8X\TE=L914](^N)S#$)(G
M>_%W03/)X@)]:R6-9_Y%M<809>)ODR?YHI0 P>_3DM@(=/RUZ[AGE?H6 $E-
MN V8<F45WJI7*])MIG65)EOFL<KB:G]"(-E?)IIY]I_%W2B+S9>9YBNWU5QJ
ME#N(R&YZ8/MG7P"W$JWS\ ZM<X?6^58P( >)ZF6KAHODH+BHE/I&BK0A*QA^
M4-F;KI)$RY6X0FY</&&]I+$&+W(>5.-/]47A\8[K:G%^WZ-'(H-H&E5H/WAT
MD^')$_FT]@&N5"'^/;7H\+U31CC ?/3[N1?4T=X'K[*I(2=CV^U/LWR=HZ /
MS @[*Y5PE)J,(\FG;I(\]+^+>D7"+?\I^F ">;$QK1;V\2(*0!IKSU<IN]TK
M\SUS@"A*;DS45ENZJH+"#%8#DD#(W(ET"9LQX.K[#%\D//+XQW3E *6RXE*6
MT$BB^VS=^V+;US+S2W!+=T5XC)C.M77I&"U'WIOI6E(SJ,D5G\K5+BO:U21U
M7OAZPNB5!V/!H.P18?)=0;/#KE8FP5<LN6:^UNP.M?Q,Z/:T2S#NU!LR[3?=
M6*$<FL[]1W"=!/%>Y^RWN,7&N]",11Q7E2G6Z_J-*G6XK#RGJ:3GQ_SX5>XI
M.'J_>8'ZGFSK.2*(0T57.VBG\0(8N5,I\YJBT^!BDD\Y.R%LS%$=K"OJ@GW2
M *:%B&(J.A&^.T*M-]4B;<D4]#&ZJ2E;H1D2ZM_!4E.!0F&'=*UW^Z]_(N5M
MV'EZDM^)M&B^09ED_*&$]6Q)WL1J@1V06YZ(WBAMM^UKW(9HQDHSVT;<&MY&
M17.C%4&^*6YI,AT8,OIV<2J'75('$BT1N\'4:3F.-:^-/%Q,QY?_87[?FQ6&
M7UT8L"&/$H#7DKJBB5%9ZP 5ZXV.&359@AL[9LSS:@U&V%D7;BE<[[SK;@U/
M^8/OSQGB6/#2\:+%7N0-E2&:X[R2!=IF]Z0P?O#N32NU\/L32[F60K//^6J;
M**Y[$XEUK14GNT_80!2FU<W%,RV)2R[K5N1CIH<N*[4(4(X><."2)\W1HU!1
MO"0G;+&K]18Z'+Z<=DRP"?N$B6S<NYX:^-ZE9EBFYPN5X?$(/QV\_>(CL/=%
M1^!^/+@$^-X*P">M#;"C1J=C/8/FC+;F<=C$2&GB)L*V636D&KD:[B=>ZF0$
M^1OA<&[5JY10$Q^Y@+*F1R XB4ZTHKMG"I+N;TRIL(BN4E<%(U/BFNH=]"DS
M&(UJ=CJ>O/TK'Q54()"S7SN&G%X=;_J8B%?S0 ?V).M6:*>-'8_Z+$B"EF'J
M\V:L N&E2. U>6F[?,PX28I6)3OQLPAS#F*B476EL&M&$*B][Z)/YZA0(ZEW
MB/P6 *PK3-#-;;AZ6HQY,6C;,#_HTL\[&9E2#N]& @_&WPJM$:&[URD14K_:
M9QT$$_'=@%CS;H$$K>'DHL_/.SK@IWE#_:?=6FI2[OC/9MU:YL?W] :7]CAF
MVY&<5\^ 6KUG"R9%4A5%CF"A*FQPS=^%GI,*H<!M33=)# K?1(*LDLORP>\M
MR:L6#72@">*,Y+,381)(U@!1@]7!AO7?(2TD-*ZBRGPPHM(63LP8IWJ^KX@8
M'PE;D^KIC-X:TT<_1,%@&@BA-: _:$R(V>X%A><$FYH7V]YOX1HJ(B3^,S0#
MRJ/28UKK(=<9@W\X;&7Q()O>;DE,<[2+&#%N6,'.54O6'VR6_,&D]>BE=3'7
M-ZV5Y(I1 JISO89$PR)80T\,"IU(SO8,X21^1Q:@UN:YLQ5%;0 X!3N+IJH;
M-A%7Q=^-2@N/,AF-#'PJ[,J&=:2U8G#]!!W#QYRG2V9IXI\3X$,BO<S0_46N
MT,_8)! IH)W&$<M:[_WPPR,<SJ3$^_#!@R?D2%#NH J#"W->G(CRCG?PS@3H
M6VL:@*&^# GL<?4X&]P7]H8.K[0DE$WKJ[XZ/FTL$PMTCOZI_6N]WA@1368R
M^J))FE9%];P@,^7O(UDC:D0H@<20WA[Q1Y8,Y"!X"YD]GL[@ QZ7FLXDW$N1
M8%'*T18)B5^>T86RY[@"Z@**NVZZA4BSLS/@GI&-0JNE#T',C")C ,]-GX7[
MSK8_T8&4W'^BH$]4U=\J_'?X=.=^')_C)%^+.+1=Y\<,;@__(N AFR8#_;#2
MVZA5\L5]>;LY@%=V)8+>U,<%^U)X<ZQ=.E"G Q!"?S,)\Q[!1WA4"@!'>?I;
M8AJ=9"?!3I@3Y"#1#0%3PE.<%;,>VZB*7<D[D!W(E12)S_7Y*%4.;U]M2V!^
MN')5FNQV+\)RZEK1W6BG#8DJ;#POC,)*(^LQA4XK;FDU4JH%OT>\ZBCKF2B:
MBA:#E,,XI3%/Y8Q2=]^0IM3O@W%)+%'9DUN7FNPIW,CPQW]T"[)-#Q^0U^18
MT@]&5--A'@\("S:1M2E9F0-%A8%,G6%A3_&J(CS6_CU[%3R695A?KX*E6>G>
M UU[O:P%6OUK7SP1XQ?)K,IE#.#H>:7(Q*+TYOX=%6 QHUX*M<O=K3IT8PVL
MCPJRQ3(+-D$;Z#8BO\BM#8/E@R # ZU[1;%J8,'D7@<ZT?2:0VT7@R+:5^'Y
MMVO3U>WU&,%/4OQ )+T%ONY3& ", 6JXV2$00TT>28.3XN8,3PNKNW'G;?#O
M%1$V5F5)%=1\3PG>:E%/^S&RP[:.P?NBV%IR$ $S:88HDD>(A@R+Q<9,K-"4
M[[]_>J>*ED"P'MU!L.X@6#?K&'@O#JTZ?YSJ3>.8Q'4410JV*V4[:%S7QI5%
M?L9X!D*Q2E1G FIOR-ID[^T^W&$LYOKUF_?[L?R3.^)OP)4*"T"@;"P^>=>$
M4T,8!E10B^,Y6#9HF<.7D2 O?46??.07-)( $/K1RTY\[R;\AJ-%86K17&/5
M$X1>@=7A5Y2Z MU-9$_6]MI^,,992_!L2LLG%<X=IG\<IZ_>L:1PT%KHWHS;
MSP'ECX/B9U'(7CZX)W/'D3B6TT5IY GN4&D5DE FG6-&[2-G(F*EWA)"3\22
M(K ILF>-75CI6(N3?#%'L0'C6;81C"-E5O:1N5W5.&UX=0A7H\J?A0<I2B3Y
MM=%^[IO=SFCD65N[&7XY? 5.B']ORF:.#Y&"-.SBR-'*Y>?0 YY\MN2B4;'Z
M+H9J-I9KO$7.K2IF%-4QZ8U/K!X6VVN+L$GJ3<$J!5%^2FBMCFVQ\R^:0OB]
MX=PPEWI='=>XDC!:)9$L2%.*I#%3@DY"6!G$HR^ ?E14!7$<69Z;$TP)XHF^
M-T[*LIOM+]8G3&72PY=@!ZDQLGW.2>-*=,/4"!&VQ%U?WR^_O!7SQBHU9)P2
M6::G2RI!>-[3 4I@#Q<?35K<BX\0.\>FU6,$KFX"K]'D?MHP1 80E[_"Z-@#
M@-=;]$]Z5L.8=?J+2+ **4NTZT#Z+'34K^.)+*2MK,#6K$&(;[7'F5&MBJUE
M%0/&\TU\N8]6-X<YHSZ!M'H9&Y?5-%W:#!KHR.5*@*A%8&J(XJXAMVIQ[\)O
M&;W.B&.R]529#+;$69&4)^E>$P"_UN?WVD!5R1;4:=&#B-(T,4DN$4GI>3KA
M=TF@C+-ZM8X:[QP^I]7,J8B&U1F8W[%=*E0+\!"Y' *RA99A IEL(ZZ2VV3U
MWZQ[!.2%<*6)=Z>]XM@(IE4E7F6;F:>2-AKN)BR!,7GV(KQ4.<LG>/K_6Y.Z
MUP&A$NNF*G/>AZ_R9A,,W2RER.'NQ@F,%NK-4TJ+ 4$FO>*RTF,R[Q5E&J0K
M4DK3D8.,VR3/:8YTRA)3PEVN>]E@]=>LII'F+6F#AGE>HH+!E>=4T,GER>E8
M="\9G#>D.4*LSQI8 NSWI7:Z/(QO>*!"R^61^)KIIOE?* '$/ M(8-JD1Y<\
ML_R(:O2H2/<9_+8"4C)7UI9)L'41"^(\G/ON.8GC1@Z%J>S8KG78 W=AC_N@
M>(BI<+2BZZ5GE/V;+;5=U/1[6#B$SBVM:AOKF6)BSDLZWS"3\&FZN^L:1[V
M6T8Z5QQERJU7VW5@Y7K+\/4T=P\6X=#,7JI#UE,5.D<'EU$WWY86;B(8\"F:
M;4,]*5/XZ_5;?4&UM80VYKK\U9NUJ:YHFGY..#&E#R=\=9,44[@-(#K8PW:
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M$4(1QJ:8(>27=MEUH3Z ) 2DA00^LY[MKLK?J_:ZLT^X<VR5B)^CJS==KHY
M5)8[\8Y,(3Q$P*R$9 BEH?08_848EP6&^]?:U7<E\=EQ4D ?W!["-E7R-*X]
M(9_-5 B>N! H55X?+80(MQ6 6ZZA)#*>T%+D9_&^ ?==$UT3(8Y]^MC0#+8#
MZ;<'8<C",U5E3E:+6X#>RM3LA_&]!S+F!S\>'+S=QX][/]Z7$#<\ 6EP<X*Y
M9&3!/_*JH\VY-R'$Q0.D3CC!,\F>[_ZZ*\R-O 82P/98@LG/V&%PN/X3K#(2
ML)S(IL)T,;M<X"6E6@Z/O;<)_[ADJ9PXY+O9J_! M?;6AD_!NJFMD8FV"9;%
M(FX1)\'I;<,\<8P7IT'3791L"U=3M>IG]-6W\27>V;/;%/ST[.T[G0(NS=-O
MY)U:RZKYYMF$9E>V2BL>,CN5P924LXX@/$A=2#-:NG*Y+B^!1<^Y/87@JUS=
M74ZB$-W8'(D,MNG@7A.^(]MC2G=@FFS<W2;SD98XV:2S7J(F7,DHPDE?1X%"
MT6M/;NF&$D0F-I[8VEG3+0KC);%D6?\BGG 8,^]J3A,=)UJ5:: OV9V-R]VT
M&<O_Q&"?LD)57<6%VJ^WI,Q'<SJEZ%FZ%3W%X_\R>8NJHM-9$I9:LY(_NANL
M)9;<\,@TH'W88CXP; 3"B*T<4MA:$9V!M$  ANJXE TB!$N>C*.R'%C '%^5
MIC8<,XRJ!>R,C]>S,<5.9# E(TPWZ=81)N6J \N"XK:RY>BNJ)#H<R;!%A"]
M:%HUG+$8[[E"%K[)Q< FP_ZE6^47'/1&%RB_*7Q+GQP8<0SZ-OW>NCYF>=/^
MA8PKS.+H^]KUFL[%2#.9I/M+9?.020P+.+R#'9MR''*7<+(UD#GF>J3G/%()
M3S[N#/%(+S9)WHIOUW_^'F%Z'*+^Z5=ZM\O,43QH>P>L;"#)=&NIH5"/@9Q?
M[@$2?>?1QXU/N0UE>$<4\IG0+5+P2<C"2JW*]$.B-:46Z^6RJ^00;6,.$VEC
MEQ8RD="1+"?_*NY&#9<F@]5G@51$4B8]XA:&H2&UWX.?+IDK=';=K"5QOOGT
MX6Q2M PS,"4*=?)N!==.44C,O0F <U&7!":O*%MVFCIT1SJW* 26+2JETT8@
M8DX,320*4W*UAOW+-9-W)"Q'L GHQ'&Q"F 4JQ/*ODXMYRWN!D#NN]G/1&*.
M+L9%,5Q_**2(34SRC<%8LIF?;WE1ME&,4YVI6D,,HAHF[=N@^SFK.L0L8/G_
M-[$-4"G4Y=O#D*_*-9EX^JFAX@[%DR'&\*Z23YX+VE[=ON >CL0QRW"VU3.J
MLI^4G(&G+J>$ LJSV>=I$ITN1DGWR2#:T?Q*@_UO0-5HBNEKBI\22,WX)@9(
M5LT%TTUH538B:=EO=W_SGKNT@:J'W+3":S]#18/7D@R69'*(:#?5 @D+Z 2=
MO()Y+*KCL&N@KS2!+[9<,64116*+.F<7E>Y,]Y/FWA  +W;J^8X^4'S'".=V
M_<M<[=F2XTZ&A9U%)@(@I@[=3#9!"MP.5Y\N&,&",G :83IDNDN))=F)-]VZ
MY2[CQD1 Y/71S]ODW2P$,\RL0ZW'A1,OHM7%#U!<)O5W\?,DOC(#_*3ND!O
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MB?/92''G=GKSJ97D=>SR,<<.39_S+$E'S\ :$,L9TG+N:@'HJFZ0!1!T7&D
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M;X&%/G4^=78ZZ!D?@"T%IDD*5E<_12NS1ELC-Q0,R5?R-3!$.::*H5.TP<A
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MAG+ 1D!HSU=78$@_*I<L'.@^+9FP9L<#V8<2/+CL4MC2\FL&,ID"OB7:H00
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M8\VV+4\+71V!;>(HUH-8-W479)0:V/?.N&]#%.O+SZLR+EI^?EQ^GK$Y;)#
ML>D# QM> /S,$_ 63(;\;#++B0S=-9"????99I@%:V-OS"]%/<U&V'%SHB#U
M/@&+I0I^GZ?86MD=22N@'D1 S<D^\[D7\]"R-3NQX5^.Y6M^"%(JBDPCC +/
MXJ&]]2[P5=U;53AC:0;9H%C'"V;ZE5VGM$S_0$P_F[ 6>U[(8D=SS0!S4MQ
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M^9D)\ST_/(?U_OK0/3K=UP]/WR/"!:8$QJ85NYIA85XO#QP-3!Y#\T++#:R
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M;O_PU[9]N/OC\L#\D!Y^W+\\/.^>?S\_['W?W?YUM+M]>?1Q_^IP]WU2W:/
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M;2;F"645 #<7P$LPZPN EP;@FKT?F0F&"H<(!^QRG]MY.9=0,EYAZU+.O,L
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M+T"B%V"O%-@UP:X=RUTC! )1 _9QE 091AP*5L'D*I$L"1G8BB_J.&0!=O.
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M X7D".(2",EI&A%VCF(K+6,LEY^>O^EM\5 V%K,+#ST4S"X2L_5$0&>QETJ
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MC<RS0Q?O?'/ANG"!7."Z4+C6ZL$G8I*3'"G",>*8**2-%(A%!G_"B3+O<N6
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M'$29>ACW<?Z6S6F"^Y .:QM)"PO7+H465D0+MR5+\LQARP6* 2<P;X1 UHB
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M*ARS #%6.&;S..:VLB/441IS.TZM ^*:262M,5G>97>/8Y'F[IRR+7'AF.?
M,:L4=859UI=9:L+0..&BIQ81DEW)5D=D)4U(4*D#220:PX!96!LVI05%N9LG
M#-<O;O;R_NJOW7+QN-/KY7A:/[7.*@"6@T)WL&4BRF&N%)A?FD>?+,-$4^F2
M(HY&)__:NY]3?"Z2+)RW.,Z;4=R;<8(C8Q8%(1@":8^1IHDC 1NE2$$9D8]
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M0&O$I1";>$'O8P_6%4M>LHB^R-Q_6Q_:81R;K3"OBO_V-(0\>X'!=?+ _SX
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MRA8"\SP,RFHCB2V* N<"*Z-M]N"H\]LE7<6+YQ*+K(?L@.*P$23-D">D0*R
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MB_0T82*/4Y9OCMTZ0=:N7S&]:4;G N?_YW])@L5O@&76!V#E"A;D]F\Z-Q8
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MM4%CK*:7FR].*NN($L=MK5OKVI/XG>=48[!=%EJ]J4ZD.*9D)[;6XGS-0?=
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M,DY)Q"57N>'>JPCZNHYS=G=>1:P=)M((!K681@D5U*32E',>O%BM$A)L5FV
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M7*&#F<Q<851FN;/@T1*+K5[-2=0&)[X_.'&\_VWG\*"0A3*9SA$-WDQ0TZY
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M 92&)@AV &1C%[AWFQ6GWW_>1TK?FEIO]H3&3G@.6?B( !QKJS8A25[J7)B
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MY.:_ #S8N-&PZ/SO6Z@4KUWFJ>0BYY:9G!FI%+6%PP6U/-.B-9P>$$YHY_!
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M5AWWM9]^N?CEUXL[M8\JS*J^].OP8L/]4[SO8TM>;8G!V[^>MN/Q7D&Y-3I
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M2%F;LV81O,R !H'-B$\)A(><I<PU,BT3,GV8="MQ@9RH="\J'2 1F="2<X5
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M0C!AT2&<M2Z^M0A/!B;02)5FGO!H(P'C//&&"P(^><6]X(JR6A>_ !FFVE$
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MA:G58*T&7[8:Y$)HPYS,4@'0('Q$*&4AR@A@=:IK""T9_DU4[ @2[3@MB83
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M-(G9VL:8-3"29(J(V5(2:X0GU$47K0I>*;_8M*5']04L+:#7%+RFX-..C^:
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MGBV':<9$'6HO$W6>9#:'>6G9''^D?C^ES:^II/@<??DC.30YEB:N?>/@HIS
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M7-\-4BA-/1#%32;@3"262B"ES9"AB@:N527U8LX\CJ<N]2_]5&&4ZXRG3<_
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M>E\-Z\]J5)^..X-V^&=LVA!K!CJFF <7>]N'E&L@H!$C9U/NZP=4U&D#/U0
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M[@ C"&$D[PVAZ-%#^9RUOH$GT5^W&A,THX**:8YQ7!"[8?V_VCWUJ+K/,CG
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M0<C@/&ME(?NVW<X"/\B69^<"=.!ZZ_78?HL-%^%IA4T/ST^#=CN;_F"SY#W
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M9ED:W[4R)RCS3T8L9)@:U ?5B]GZSNRJ0I:MQO8-.713&V(1?9KYX7F[5>R
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M"):K.CD1I4S:83V=H.=% J/9F-Q]A&N"C<'PBP<KA!J!H]QH1-B?SS.H=P>
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MC0M%@2'"-I68S?1;$O]N0)K[LO.F'KDP55P4&9XN(9SWAD\3\VXH=/-SP/>
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M^7@(]H$T]X\. 8Z(!'Q"@DF,> 3$TIIBE!QL6UAIHF!);NI)6HA<EJ'>P)T
MA&6#%20XVP/?JC84(!*A,.;&=*$+XG8&BG+4@>UNJ"Z56EW?J1+T:US);F]%
MN3>\9%Q7R@\+=U#CK(A/S0,H0VWS;Z XIYVS2D7[QZ">%ZTV&/KM_M!AE-^L
M>'$PS5N]WJ!JM5..I33WYVI?<1_XC@T9U."J<CX&YYVS\0GX?_^E*5&_+:G\
MY;3-O%"(;=A6NJ4K ;"A==[*).#F 6='Q+C3(;O,9E]CM)I5O[8!&)+CXSJ-
MV7SLY6_W )S@[_WC1JNZ_/R\W?)%>S/ G(;-VMJP1R!G68/+=[&GG4&&PN+.
M,.W%1?#$R><7LU<A6/[N4)HF1V)[.35E:W(#FMO&;8&V;$]VXUJFY][X_"W:
M=&^EN_O#-K\C&&_A,N1CZ>YW<HM*O?H>;61+DL7ZGBWW&=.\'NR3&BQE=?N[
MNOU=W?YN[6>N;G_WP!-=M[^KV]\]D8S7GVI_]]R36CW86\))XX31W"7MHM>,
M66,,9\E843>Y>Y10:;)[\OG'WOX;LKO_@>=Q?LEC^?O#Q<$)/.T4[O/C/?^R
M?WRZ.Q,J_9GN[C=%<_\SV=TYNOAR N_V-XQCYY\M>%KKR[L//YHGQ^T]N.>_
M?[P?J^GR!C=/WO\XM)1KR;%!AAB'X'>*G" 2\20<MI9Q)=C&:R79IIQ3T^7)
M)W+5.2+/(T?DF@C,N\%=G;/Z+*#N<@+JQ"%31!O+'(*%#XB3W%K*<X*$\DJ)
M2*@@.>2!;/%G"'0O,6,U$F*M$+D$N^*21!T$"RJPJ F)"JNZQ=S+0H3="?+3
M9(?1A)"<BX@ES1 /+B!':418DA0P=\YAG4/[F*SS56LN<L=\U;MQD#I?]1GC
MT 0S^?#CT'#K@V88I9!K:6BMD9-!(Z-R?("E%L<$1M@FF1,B_\C)JB^H@'#=
M%.[VFFEWB42JF\(],X1KSKJ9:'2A#-14.%=.$P0Y8VUNF!&3212$#VPOP?"F
MT3]=+VB-:VF^+(RXH9C8SP%%W43M^4#%M)O&2$SA_P(B.F>F&.>1(PXC:W3T
MP(T 1F+.\:?/&2>>^CWJ)FHOX>QQR=X23XD=OL F:@\$^1]FV:$SF("$8:"#
MBB(.PH$TI@IY+%DR4AAA@!TJM2G5;+_TI]Q#[7G#P[/FA2^TZ]C#@<0T+^1"
M<*(31TH' R"A S*84108UY:1&!S%N:3;%JZ[CJWO/5Z:T[#N.O;<F.'+[#KV
M0+C_>98<&LJLEL$"&P3PY\EF?P#[_]E[]Z8X<F1]^*MT<,Z^OYD(Q$@JJ23-
M;#B",?:L-P;P!>\<SS^$KM!VT\WVQ1@^_9NIJNH[=S!@^L0)+]/=5:62,I]\
M,I7*-*00T:N4@B]]";A/Q;I1B\C_E+N._=@0\4.SP^?8I^O[0<0\-4P%%H8K
M#8DT874^88@I."74E\'9,DI?6("(\@ZHX2-&B:=^CV=]:N$N^G35YW +D,?0
M&^&IWGPDYFJ'91[::%P^@3?8CY8&/$/F2^F"$4I;Z\K"%[J0T23% W]R/;Q6
M]N%2^_!ID4)2;$]N0B+. (\4P@=BE0E$>I:H9=1'CO9AG3&^3HO%$..M^G;=
M2BM7QR-6*8GWQZ=O!H^KXQ$_!$C.DV@KHE8V*L*Q6X:(2A.0_4"2B]*Z(*10
MV+Q';IC%XOK/,K[ZA)SL1U<V;'4\XO$APL+Q"!:M2\PQHIT'VD0-GA*EBD1;
M%C2"@9 66_QMZ-7QB!47N>GQB)MQD-7QB!\8A^:/1VCM"R<+3KCVC@B.M:JU
M=J342:FRT%Q%@ZU&UZEY3%N_L\V\JNH<"RV]GFR-NZOW!#NOPMV#- -[-%L(
MSS2]^&YJ06]_VS[8]UC9.VA&"HU1?Q4Y$)5 25*T$%R6U&IW3J+PS?HYW>@\
M\4IV'IGLO./8J=9(# IZXM'C%4%XXM#M92)&HZ0J18JY&9A:='8O+U)_COP$
MY;13)@)[]J(H@DDA229HZ4KF) ^K?F!/0WYV-O=I 2PA<DF"+@LB/*5$Z]+A
MND6M"H[%;',_L&7=,V;*T/\ M=KOOQW873D)JW9@#Z<X>Y].MD_VA634> ?D
M/5!!A.2>V&@5,8)[3Y75)<,LSG6UQ&K?KAO8 @W]?NW [B#2MFH']A@$> =8
M9R$Y<R"Q+!E@#A:HIRF3)MP57FDJ6>!Z>5#LBNW %MVEA^@'=DL_Z?$TUEE!
M;^YANKNY;X60WBI+7&DD$24%SDMU("#.VB4M"RW8VHM27=M=NELWZ?&(SLJD
M7RI7$GRI5#I;:EX0;K$I-Q90<KXHB'$V.LZP0RY645HO*+]]PZ];^E KX7I*
MPK5SLF]XM(4M)$G:&G34#7&LY&!SM8M,.6HDJU-W?@Q/*]_QUS8(2]M?I0/8
MAX^MBNT]C=>[T)'<[4[R(IE&"L/4^N0CKO)'\ 6BQN27U<=F?=S<9^P-P'\<
MM8?#.&X5]GL/&^"@M]H&=C_L]6NO]"L0J7&#G 'R?Q_[0]ONMF)-O&><BJI)
MTDFO_Z5U3D^AW]LP9P?8EN=/H.O8SF>S:L63QS57L_NB78%Z@@3?4'C6Z;@W
MR!3]USP:$.Q)7Y5_S)8QK_/.Z.02ZP:]SFAX_B7W7OG\BG)@BKD)FOKWL#]I
M&'$ EJ8?[1=B$PSV5]LYL:>#M5]FI1]$?VX.SWO].44Y_^53NK>7KU0Q8'.Y
M+ N_CD K^_@K&(Y]-&-I'?;1'/]/NW T">>#$+$0I:4FNB*5%*B?9/!QW%=K
M+_9RAR%0.LS8 +GZYR_VQ;(%7MHG"IBBIX4'&Q"]<(%;Y7EB49:R+'F9:,4/
MX!KP>M&<PK+"=XP'QSG&Y4PHA&<L" F>C%/INGVE'D@%?EK[_<_-M9\W6A<'
MUZZ7#LU+"1Z #=JP4FC+K'(R)5BQ4%A52G'_Z=!5DO-NRM\.-D?#PU[_ZO&S
M9QQXIMMG'T_ B9/1V!08!\ASF@@M*7&A5*2D*?K$DF >R;81Z\"0%NGVE(T[
MP;"L_6K;G:R>8-4PSG!.>[LVV,E.I^<; ]A8QZD.E[/FL07BB\T*C]J# 0HF
M?)I;&&9C:SLM=YI_]7IKLPG#U<.:C\/E)H N@I;FKB,GA[$[OC^,*C]B./5<
MN.,Z_*KM#_'K;F\X']4; 5IT\D\'$7LFM@YM)^&K@NP7U>LOZ6F'-UMHA(<#
MBO!GPRZ0;+93V\\T_NS6G?3RBYRKK]TZ^W]&7W4)]-8:7I92"6VL\=1SY0,L
MM-".6G1VF&:<8]_NZH^K*.Y-LF2F^WR^1YP:@%N#) &,\%@_"7]^"BIV]U[M
M4UXJ9;@F5N3MH,1 *RDG*ME@:"F2*^4%65%+%U_$Y)PN@RR9%]R4UI=66Q]!
MQ9-E/H=1F&% -TGSQVKQ'V+Q=70\>$#C4A2<"%D*HDM7$B.$+2G8V#*4UUU\
MR6R@@95,1"5\#%:7.FD0!<Z$DS;FQ5?P7YHT?ZP6_R$6WW!:@*938CCGF"/+
MB+4Q$N:T -.0A(YT[85<S"*X_(-_7&1JYBS,]:2+PZB*H*.1W@E11BN%T"D%
M!<2]U%*O[,K#2Y?</ONT#[X +;'<C0LB8K'4DFA;>E(X+9.V5 9L67&]Q5=,
MJ8+9Q()G @R'+H2-W$>75 GVI5S9E4>R^(J7N,*>J" L$9C:9@MF2*"&1R#^
M2D9^[<6WW$8-1+<03'!6@*$2%%R*J.%_DS0KN_)(%M^G0NI$ TFZ++':%2.:
M64^H"T ,*"M"LC>V*Q?E*MP('NXH.C M$M6NR?),A),>>(JQ^RQ%X\L^"TQ+
MY@IBP14$RB$DL9PG3(<W-#H?N4X7G_RZ$0JLUO@[KG&1@J1)<Z*#Q[UZZ8EU
MUA#O%;5>8NZ;NGB-;\3Q5FO\'=<X>*N]4R61'G.0HPW$&(>=R<#1$QK62 &Y
M XJ?TWT6C]A=_-\MC,;U-UH[O1P PQVH0SMHN1B[,XEM.9HV#K]MM'Z,;<1_
MCSJG]<8@IW>X,3A)]+MBR)T9\-VIEU)$+1Q+6O&B#-R:I'2(ML@A=TK5U4CV
M*N1^_\KIV>[6IWT;#77""Z*BSW%V!7Z]4-B2)T:1A)5X0( )L5[0)4<$ZK#Y
ML%V%G7,*7C]^C=U1G(MWYS#\0=5:II4CZH&@OK=.VL/#<9R]OK8U!"6,F*T:
M4.?@"EC#++_MHV-X=MYDV_W/FRW"3/.<_.SZ85//R1K2QY!"O&[X0'/@A.B"
MR$(),"<.3!+0Q*!%X4R219V#H^H<'*IF]Y/&*3CV&V#'A/3OILT<ZLC2#/^!
M0WXS&(Q05)^O.^"+G<_O]@4((Y-E(KPP!CB?BL#Y=$D<@@KG96(,LT[9HBC^
MHPX@Y5E%^9@3I2>2%G,9X&_;OC]LL;+*>WU(Q+=%47!EBLC*4B30%,:L+@N@
MW)[BR?FJWQLM6+E"_$>B8F)W[]V^5,(K:2R1!M,8*4>W2C$"R^=C*8-5"2@W
MK.TZOQKB\T;5UBLLMZUC>]H;#5NX@!C/3?W>T36A-T7'@+U3*5@4!7B!0=!"
M*ZET ?]3%'5N+0@7629E"]#;;'-^P$3SC_#HMWF(N\?'O?X0AW+ZG+%WLON^
ML_>)[YSL.UE$26%R)>@V'CD%&"XQU94+;JD0RI7 "I:!,(C$]5;:E:74@OL@
M;"E@G8TIK4A2T$"E,Z5>K?2=0@#\]F#?)5]J10U) ;=Q.17$^12! Y9* YAK
MF[!#]!+UG]FK&9O:<3Y 8W,/>K X&ZTW50I#ZHWZ@ O_'=G^L,JVJ&Q7>YB/
M:X0(GQZ!L0- .;3#?,EL9L*PCPF&RR"GHI7=7JO3 V/1;X%=<YCF\5MU' _N
M :A4G2Z9.3[5N(JSR1P3M@ICO%:VME3<" D,Q6@AB\):F,*42N OH01B?>6C
M %F*EQO$5]60QV6Y=_OO80[Z@]6AO/.$_> ;VCOF30[P$F6I)<)'2\ K%22
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M^2E7N>V-X![A2N71'DGANRN2YYGJF:[_RU4K+MZ@;.73G1#V$*? 'G@6%DS
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MQ503HKMJ3U' W&-5DTZ<79?;](ZXX_X35QKB,]OPVXK'?4#&9UC2[CKI!O=
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M2^:]*CTC446@%M8:8H1.I#3:%$#PRI3<?/M58((B"5&H0(U(R>C"R[((0%$
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MN7JW]!L6D_;.$>.7O<'P?;/M&)Y*_M[W%N<#NG.P+Y7U5)I(2DX=B+.PQ/#
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M5EZ[,DACH;$@P'"S&UXU1KH1M!7%.E> =O> 9NV]XCN?/YWM?/ZX[U+P7'%
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M"H#OPA/MI27,,..HCI297'.FU$LX[J0RTO=<Z8SB+^W@<+745U_J=Z?[*99
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MSXC%VD#F'HXXC!G*C'%"D-.J4=[X+-,Y3_NM==@[P9;6BX_#X9[&X<3$V2S
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ML*>9N7=)O\L/A-1H<'T?KM'B:+";;'PX\FLWE61T4S]%S=FHA-;^NOQ8;U;
M$#U9?/=NRV!;)Y_JIY_/ZQ,;4SO_S.QNIG/_\;EVWCC[RE@SN4J^.%MR6V;5
M_G1=KTM?Z[7KEH2N@%/IM'Y2OSBN7T_G7F#?"S9-[&"RS%'C;0YXB^9"'4K@
MH"-W3I?T4_HN_P_D/>QWR>A=U&-#9%]ZGSTKTZ'P]@=+>  J:C=;.;:(_.U,
M,7#=JFFIJ!L,$OC_(/_A3&VH<B-E$,R^ISM55;$7OJU4U87O/?18U:P:KOZD
MQS[\GJD;ZQ^L7C6=ISUV X/5JJ9I[=)@G:4>>\1.+C^](!\H9__OC?YFK#FS
M0OAW6O]>4B>Q'&OCIT6$2\?KFQ!,0?^%%=?$0WA&D!;<4_D*K#8YCI(;FMX,
M=BJ\2K++W')D(!UC\^=>UA?S*R7)"I-5<*IO]FA=:D%6[7[(BW!*,96"523_
M<L)R2.0X#%>2@KU;DY+ U%DW\UE1>03]9@GX?)]2L*-W"19KR+S+%@*]7T$\
M] ;A<-PT8XD3LG 9,@6+:?K]@<2*(*5\1BN<JT?7^3G/$(/<W"!7EJ^,X'*7
MY&O"0)E4MY::GR+MPBS_S[.F6)Y:@D_=JKFMT N+^%0W#/3]N,30_< )+-NW
M5-T,*%%]/<1>6*K+W6ZE7ECZ=,.\L?LM1^>TU@NRKC]I=G,MU^)*WU'/W-<O
MOZ5_MV/CLNT;S2\7HXMO?YC-;W7E:QM;8S5^7GS\[?9":]Q=ML^^-W\>1\V3
M[#M__=;Q;H/NY;<;L_GS1OWZLS%JGG[7+MK7'6R-=?'MXN[K[5>80\V\^/*'
M?O&QH?SULS&X:"GWY^WZX*)=@\]?W/^C4]NQ+3V0B4E\V=!=0W;MT(8_88.)
MX7J.[;WYH%845UO0&>LY,H$(NJ)LK(394S\YC?L"H?84H51*@I#8NJV&CF'!
M23:MD 3$=<.0>H8;L@B!DD<(E.="U17C,&OT?&3%HZ>4_WL2N<+HG@;R3YK$
M K16!:W1%&BY7N#XAA+*CF)2V;!M3?8\ "U/)VK@N/ _#"1EJ3L"M@1L;=0C
MM[VX-7:8"$Q:$9.:TXJ4I5JV8;F!K 8&8I('F&39NNQIKFT8(2"2#9ADV=8,
M'LWXIP04"2C:M 9EN&H0Z(9G6L0W0L_R'(^XCN+Z+B"3H?!^Q\\&H,+&$^BS
M&OI,:T2*9EB$PK5@!JXM&Y3HLN/8MJSZ!J6>ZU+;IF\^&.HL^FQ.&SH$OS-&
M\)=>VSGSVS?,G#=%@9D",U\<,R]F75^N[KBZ[H1R&)BN;*@FD8EMV+)N^)IK
M>HZF^-9:,',^;KVHVO9(P$- T)Y"D&Y9+B&F:3N&:CBVYUE.8)C4"P/ )%L/
MF &IY@:D*AQ?VPU9,XXO70]4)=1EXCF.;(2*(WN^ZL)>ZJ$=F%IH6O[:'%\"
MM@1LO9;CZY5Q2SB^GHQ),XXOV!YJ!68H&QYUT!GOR>BPE W4>UW%4@@%TU,U
ME&<XO@04"2AZ)0TJ=-3 MT+--4+#<%2/:$9H^:%B$(V8GF(S(^[9 "2,N">B
MS[1&1 Q/)03@QK=57X8=H[)'/%<.'*+KMJ6K1JB_^:#-<;MO3ALZD(0P322$
M'4BP0&#F]F+F'[..+S4$K2R@IJQHNBL;CJ_)CA<8,O4]3_-57S'-8"V8*>*5
M H)>R_%%M= (+-WW%% ) @\P**2*9GN^3Q1;"^;6A*_?\26@:35HFE;G LLU
MS% SY)#J@6Q8@2Z[7J#)Q 9]3C7A'Y;WYH.EBF14 4V[X]QZ76P2SJTGX]&,
M<TNQ+(5:CBKKJF7+AJ:'LN.ZONSK)G5I&)B@*X&JI#LBJTM T?9K22HF2"N.
MZRBF:BC4!KLMU%T?;EQ+TURJ,D/MV0 D#+4GHL^T-F2;KNJ00)%US5=D@RI4
M=JBNR@HUB*M3VU== [0A<]:UOO&LKORW\I.:,9.\?KVF>,8./>,0/*,E9JG)
MHG3D1$1^QP&Y9UW;GUB6_LC=+IZQA<\XD%38Y4O$111UMQ5-&MINZ%G$I+IG
MZ+;A>,0Q3"5T;4W7?=\1)>);JH7ZL^$"QU8UC6BA[*J6+QN6:<J.JH-22AVB
M^I;I^ %]\T%W*Z[^;+><2/00$/5:0<O0<'TC4)00\"GP=6+YCJ$$&B7P_[;I
M;Z!&7$#7,Z%K)CLDU"V%AD0V J+)AF<;LJ>'JNQY-/ -TS0=Q08#NF(ZYOXA
MUW.>\<)BE,*D083>2/=I]*X7=3/68.'F?ATYF9/#20@-'"H3FV#83=5EHAB!
MK.D!55RB.B$-\&1-B8BX:,5%^SA"6)9A.(&K48,&AN<%Q L5:H$=0#0:!FJX
MYK(X<:&N$2AF+E1;=4-;MV1/TVW9,&Q'!I-.D\TP,&W+,"U&%V7 C:K:6W2C
M'H)?<:528Q'($Y@J,'4#F'HSZU^AQ#%M MH6@*>#%'Q@GQ! U]"Q I,0Q0H,
M=UV8*G(-!$2]EG_%M\/0]%U+-0PC,!3/M'W5"+Q0A^.N6N8&2I$%=#T3NJ;5
M0<\ [<]W+-DQ%0_40:++KN5ZLN79EN=8MA6Z"OI7;-T0R"602R#78XXL09RP
M%J":<7 %AJFZBF[*MFH3C&'Y,@E-1?8MC9@6 5U:<01CJ("JK9C;*E3LKF6Y
M.@R'FJ[AA3[Q7-</K5 )+=-2%7W-E7="F5HC1LWXUE3/"Y'7A1A$ 8QR%-GU
M+$?V56H;<"-I+-?<U"N:J6X11!U([M+RU<PB7B$P56#J!C#U^ZQOS="MT/"I
M*VN>I<F&0@+9-2B2H\+V^;JF@IZ_+DS=O@P  5%["E&^HE+J>-32%=UP3-/Q
M?-=Q?9<Z!D*7]DK5S@*ZU@A=,[ZU4%<-3;?DD%K(IN40V2$TP$I$S]:<0'5,
M Z"KHMBZ0"Z!7 *YA&_M58!JQK>FF=3S34IE1PT\V3!=6P9EB\C4"^W #56'
M>*8@)150M15S6R7' @^L&E@>]0W#T56'VJKM>)82&*KJ46/-Q=)"F5HC1LWZ
MUHCMVJ8)EXJARX9A&3)8]3J<,2=T3)W8FAN ,N54=.W9D<IUYZT=#8C7I?#O
M(/I1Y. VA[<@ /Z'_[ 7^<B\Y.A#,4KV.OR#'QC=4T+#\P,#C%_#(HI+/3V$
MDZS9I@HOTW]4QWA3_E8VNUN2W$0]WNU68;#WLD([T\1:4_XO7S,0A3AA8O0.
MUIHF^*DW'QKM^H6DFE6I_M>GQG&CW9)JS5/IK-&L-4\:M7.IU:[!)^K-MM0Z
M^50__7Q>;SU]A>PE5BC?=AE1_9WJY% ?P9A[@W<ROO+ZT*<QRAI2<))L8!,G
MUL6JNNP2/8MZ 'X1Z4JM 1G06UBB5"*]0)KSAM3R.Z#-=6DZNX,+]J(D;-^&
MZ2 *1Q.;L<&]:'>H%!9S3,>33^A_AQ%6@7LCJ0$OPN&&?9-(@I_OPNM13[HB
MR4!J-/C[#O9T'W2B5*KU>D-XV#7MQ_ ^W&UG<*-(JB+_7AVOG=2+!_ ,OSL,
MX&$=\H-*'J4]*;Z-!@/\6>J384KAB73$?A4_3_K]+F 4H) 4)^6/C(<;]?C]
MA7<JC*7X!1@N?NX$-'#LE$WP-Q;N.OP6C! ^G]!!7%VXS=E*&EK5-E'BXC1B
MN)#0+@S@!WU_%P6#3G[AE[[(P?6=,OX*\6!8P\'BKY2.D _CI,F&#HRJZ)/K
M4?[G"B"&^3C9MSH%24>?W%#92RCY+I,0YOB.=._(*'US-"E=(%I32[]HU6"6
MO@PKAS?HNW1X"X(Y>K_T71*&+[:0#]TE_R%SAT_O.Y$7#=YO?(!2)T&]]%^/
M[S)<5&TNK2%*W@ .[G^.R(=Y!VC%3=OFZ\W;HNM--W =ZOSHK'AA;<GM%*.U
M E.2,@%(V74P">P/WCIX5\#'XZ2/9YE?:0F2G%"D/,DNAO$=]9Q%8AKR&.43
M$!G4QKNDG])W^7^\#Z*TWR6C=U&/39E]*3_@V=6 H#:ED;.?XV^/\:ZJ<,S+
MXM[9+V=O5]E;4W9"]IY6-5QKX=M*57WB>Z[E/NF;#PW6,:JJ;B[UV$>2 +8B
MUN\^)L=L2S.9E<# \FBR! //"N6W.[0,IS3UDZB/5]#$&CR%WHO+(Y-?L(.9
M'BCA!%:I7%ZER'FUWWOZT9UKP,//OCYJJRBE>G6F_NM5CRN?>>&/>$7%#J:_
MW8K=PP/,%+O.8-!/WQT=W=W=56&<U9OXQU$M\3M@T:1'-+@AR1'83^3(44Q7
M<XY@N*II.KJM@%*O*JIE'M%[60_4:F< H%$#LPKO:;2KKBFS, .IAAN&5B H
MAHWB:D:;#5ZHW<<WM%?!-ZK2+XMO[D$LY2 )1P[_Y!;>+6SZB+GY[?>I],<0
MK%28X&B.:O!')3-FX;5F_(,BTDI614).H+?5.:KJ$Y'G9?!EWU%D)M--H,B!
MH(BBVZ[.443+4*2,"7,AY7C4)7?I\H"A+0*,DV&2H)MO"BX<^?<26ER0D:0)
MH-@&H#"$NG&80*'A?VJZ@T!AY.I&R5Y 7:)%_6$2#2*N:CQ!LS 6:Q8/>!R0
M1Q6_,J(DD3A8G5*?ZQ>ZRG&CA"9GU$M 30%(,? ]31&8LFE,$<K'06**ZB"F
M6,X1N;_IR2"F-N95T'M#<XFK$)=PE+FF-U$ZR$R6:QP8P,%-0ED,J2+Q\!+A
MF#.\&:8#2>-FA5F1/#JXPTC7!!BA*E-/4WHO?8GCH M_IM(93$MJ_%61SJM7
MR\/50KWF>7!E32@_L)02?]U^*Y!JDTCUOZHB])]#PRK5U57-5 &H3,LQC@)-
M=VW%"NB]JF1JT!7!8)MT'OFTE])'L$E'2580FD8,B"81"H!D[)[!MQ$ICF.2
M!/@(0$(6-F?!?RI][L&PDS0:C/"5-KV''VJ-4DP06 [ \#BO;IF-L>G2'\1C
M+XXJ%*G-PY,F $H 5 %0V@-NX=8 _D1@J=_[W6$*/S"+8-)=-.A(K:'79>]@
M8+A-D]MT$MG&%A534Q1K%7";!+$SV(4H(#A*RA2?,TRR9-]8R9)$21#(MC?(
MQH!-6(D'!FR9E6@!HEBJ45B)EF(K)D,WU3,\-<.X%OPV0 J#.@9=F?0_'?N:
M<56J8<NTBD3#D/J899@AWF_#[D@R<UMM&\#N>8H<FX^:&9_["79/H7O=,A3\
ME6VTO@0,ODHSHU436C:!G<JV9W\^/, ,.[/Q .+I@TZ4!"0#.8Y\;7SI18!/
M8D"P#VM4 /C>S ANHOV92QSNSUQRTP&#3L@9,T\_^)C[HI^J&.SC#;T[%S$Z
M6I:YAH4ULD?6R -N%CTS0:( PS6#J"<=1_& ^IT>3/=F))W2'[0;]]GEVNBE
M@V@P'% 4Y*%'!G'RF.>X1?L#'A_B@:V%#I92?.M%K0U=N%;V"LM$5H] LS&:
M&0\E$S>1OT!J1VDZI-)5$OLT96[A!= U=@W;#+F<9;TEYU%(FW0@?:*D.^@L
M#TT/I! )<-I1<!*.7P%.!3@]X.Y=!V!E47J7R__+HY6(4NT;6@G#\##12E-5
M2W/LHT 'X-(,CE;Z0A?M.L JRPWDM1':RX/50KOO>>F.ZFRZ(X^M:;N,:),,
M3AMB,IE+[[ ]]";&8GH3052R;?BY6:(200@A""'6@4V"$$(00NR[$6(*?^ZV
M7J(;<)F86;$F%E%%WI#9 8_43SWLK"V%F4[B^'L>["J12\ #ES8K3.$!V1OP
M8=@CW+6'B3WS'"!FN0*A2"YC(9IE\&BJ5GNACV/-B/12=9W[Z>C8&^ 2GML#
M ZZ'R] !O?10T35_'H1IJT,8UU%>2:EZ*5_MXM)T@6";1C!+F'V'AF"YV0<J
MEZE:8/:9NFVZO#A=X;AUCFW;YD,2SR:TEPT<?6E\;'VJ?:E(Y^<G*U28*T]B
M"RS Z+_\4QD>C7,A=65&IRIH!55#V(,;!B5%R4%IL_:@*#]Z=L'#>DU"39_6
MIQ@V[5 !R,NLQW2NI,I4S.Z+H'=%0FKW=.AC@D&<\$8<)$U!8-(5BDZG=<Q_
M"P-Y#Y%\K%X* WE+8?R%U4M=573==H\"PS!55YV K7F)F$SE?# 17-77"VZM
MYB?I@@9X6J3+,(Q\EC[5QP,$"]Q.,*KQ=%Q;D^VLS:(;3]W2!;IM ;H9 MT.
M#-T4PS)=U5!46S'5(Z(:LJF9QC_,]Q? _RW.WIQ N+'9J6T]MCU4O?<\=--G
MT(T[/ T!;EL ;J8 M\,"MS%YDJ$96HD\25<M[AXT MO/$.XL'B:#SJ-*7*:T
M6*L1'ZT;OXSG)(QD4W#VF>IH)Z!I[!^T!#0=(C2!"J0:JJODT(3N'UVY9[J7
M&V1):V=1N 0N%0H8CPEHR@+.E9>%)O<IJ6PEI:E0J$1?@NT!)_M P>E0(Q<*
M_T]-1:""E]+H?M#)&9X&@YB9=005G9SSY7X)@.+\BOIB0JAY>M,EXXXYCF)8
MG!\ 3:GT*>[BZ4E7C,!.9[/]>TE XJ.V^*@%&FV!%><<*!H=N*J$&6J::[->
MC^B9XM"3R_!50F^C%*91[R+'(<N#@&V;@J!:/XFZ@ 8/)J&]L.WV',,M&[_.
MQR_0: O0R!5H=*AH9)NJ,HE&YW2 65IC%MDQ9W:)ORZ#'T2)G4&>TO#5W4<?
M04OP."V!*6@)!"V!H"40M 3;5H\O: D$+<%N&@S_B[P$A^I,/72# 8/0INF6
M@M"F9MT'-%0-,J?E/'Q"D5J#V/^.?\--BD;$59? ^R252(DX+<F)T\KQ:8W[
M"*Q'S(-:OP\/BNZEVB+C .R-^Q&VS!APBV;*%R%BR-N#+,ZZ2]_6U?U&@,YK
M@X[BFHH*J .X8UBZ=N2KCN,8]/Z'Z]YI>;H+V/B %_7;?C<>45J"&0X[E_W)
MDMXE/0VN^SP^UQFB?U%5NQW@LN82-@$NNPHNN49C8W384,<:34X9H"J:0_/2
MVYSC=76\Z0^3=$A*S;Q>7S^:3+I[]4[W O@V'>!Q!9W H:%;5A%A*IIKJ/81
M44W9A;_SBH@L[AS?WM+$CT#J)U)=N%64Q4B6;G#_&Y%/XBX\Y+QZM4(+HC7$
MDC5>K6$*J-D"J!&D<0)J2E"3T\8% >@-PUL4]N5@YV51YUG6G4"=K4,=4=!^
M8*@S=D@[KE(VWQ0M:REO6U;@S%=T2FF^VF1R74Y#JZW8$SZ#H551:#T]SO2]
M[O>^8T@DBL\/$XD<17$-4YO*[%T,//I,T7F>E#8-.1/8@F_,P:#7,;?&0[5V
M/W]N;Q!'5(0?)N*XBF(8EE'H/JZB9Z[KT/&I9S\*048.01,<-NZ,SO,Z /04
M$DD^\$S_<2=<T*,LK.\*C-IX]:5[L*7AAUY]J;'391VQ0DM B!R+>/7E+7T,
MHZ:J+TFO1#VFS381>%&D>K#:LE1LF0V2HY(F" \WKR/A_QTH !VZDF0JBJ;K
MXY8 IN+J"BI)NN'9CAED-4^13WN .ZQ>*2_2?KBUDK5:= PA;MB+!B/IN!O'
M\#<KC)%^"8Z\(U)Z-VL9FP_B[?)PM9 -;"WLW.8\=FY3>,"W!^%$X.TP$0[,
M0%5QS0+AG"*#25<5.\_+GDL,M@+JC6E?%UF):P:^55((],56Y?.RFIP2ZDWW
M?W'?"M3;L%V)M]Z!HMZA&Y9(ZZ,8VI$_2%/Z S!ES.V3TUFS5]>&>,O3_;R\
MJK>29;H8P@07T'9@V%:'#*FN476;,6QC WQ&RI2AZ):J:8JN8/*"EW1\^"U#
MU6SC']3<Y"QKJH[#> :$Y5V M07NLI4 ; G\DEZ:R"R?D%E9H<O,'A\022P#
M+L/C;E9!EO+ ]F5D*98@2Q%D*8(L19"E;!M+B"!+.4RR%&%]OGS<0,1%M_2"
MWU3=LZ:IKN>227Z%9MR3=ZS465M8XD-X2" 1A<Y[A69(\*"*(*B LTDXTSW5
MH>XDG%W1!"0=IN/G8/:Y!ZA1NR/8'N[% :T((:X"9PO3.P2<[2><,3P[U/"F
MP+-%>&8HNJMFZMDU17\-:F&+42R/"!2"K[D/EC9F\(9O_$X B:2_"<R*?JM,
MP.&&=;N%G>,$&.XQ&!YJ$<&A@Z&#8&B-<WCM @RMT'>M8%*Y8R64&];PG@AK
MULMDL=D+8$V4;VX%K DR90%KD[#F4**;_B2L70/&))&/$+([@.8(LL&# C2$
M,]':[F#A3+2V6Z6UW:(3G^=$]&)V;AZ0C>=]4F#BJV&B:+!WL)@H&NP)A6RC
MX*.)XG<!/_*8BC6#"$ZTP;6O^;"S*#90601$G]BL4K1,X]XS6YL+W-D#W!'9
M&(>%.^7B3!5>"J,D'11UF8.8L?[(R 64^;;P_<GRIC(Z39'_#+NCC*.L5(M)
M;N/>31F>5JB(V?\%KHK5**W&*D5C^[\:<V[QRNPU+C56O,B?6IO,Q5O4)6_%
M]<T"4YHP&P[K^BZ;#:[M9&:#/AF'VE :>$',[F8&RO-YL5:A6,]_5@#3-@"3
ML"L$,"F!L3T!\J>CT\),1H%..X5..9V+MMF,[:(^57!2O2)/Q3AI6S/5<=*V
MK9B:4>J._J_:U56]>=KXZ_@?5U,L6YMMEVZ/6XMR'+H:PD^CIQ9A:-E&Z,=3
MH+(==N_VK?Z_Q<+,7Y@4(XCW(SB#<-#8O3F5XV#O?KZ5H(1YX$AFE#"VH(01
ME#""$D90PFP;%XJ@A#E,2IB=MA&+R+@I,G*V]1)]U2Z!>IX06 IV%\T55'=^
M*LXRZ7[/;7WS+)^YZ!*XE9 CG.8"<L9.\]G,FW)"(/=J;P44/<M!?B!0Y!'_
M^TT2PZ&1L_,:LO^]WQV,^I6#U#+>\T=GNXSV^805$["V?EC+QH-=VW489]P+
M>,92WL,!7WD,IO*&>[S?GKX^D-I+K-@=2."Q?D'ZL<OR_:RV5O /<[)VH<Q'
M^<<0MBB,BG!_EHC4Z 5#G\<LIF/_@!X>E6X2TLMTCHGH&ZH=2>1++0 #4!EN
MRKT\\Z97KU3/,/VS^ZFU[!H2"9Z.@T6B^0WV#)L$NJ-M$;<D#\[RMISV"C:6
MO8GV>0+4-NX5$EP=!PMIEN(8DW7IK0$@"J)4#F5CM#K.;*G+NQY(-P+/*4UA
M"^7C8=2%4<VIU')7;!-Z?2QE#TLKTGGUO'JR2@?0U;6MZ=(35Z#2-J 25[4$
M7\:AXI*JJ-:4T9<A1JX9N=)YW+N1VQ3D>%([8D""RA=#(<(TKAZC&4IYK6B.
M9REB14+9P-=@TJVEP;H[K\&Z4)6V!)00E71%H-(AHI+&"FKUO.S$S-2E)DT
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M/EQ*72IYU"?#%!X#$L)^;4!N0%82*F%E9A!DT:[B&6-ISG]/R,6FY*)U\NE
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MH+C1=:N.J3^EMM& P_BTTL:'GNKJ5<4P-E"$N!'UA\'%_ZZ@_&S]9"8X-@<
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MX4?18D'EBYB.^,SG4YBB_;#K."+R0^[/[H7''5B!&=-A"*<EZ6*;I 086<I
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ML?O:*(VC7+@6F1KE,2WZK*(72H>[CY2KNF;"%OB-H'C#4D4NZR' Z^KYW R
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MPQ/!F'QR_NW'9U__<NW[G^7JV]Q[_V3UMQ=?G8]O^B(]EC_YK]]?O4L?\3C
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M%30QU3EB;V(ER4!&JVX= G$/I"$=]C1E1TM1M(\A77-5C$>? _F7.MD *H<
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M-TJZ#]60BKFT9TD;8?1K5+P(XVYE O^.8;[LL)XMO$ND I<3G)73$X4P78]
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M0:"9AJ(%'=59AJ3D.I2B3[U&)_KNBDHW'GBPPJ)]:':TJX0;AN8N0<SS7.O
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MM#:!Y4R#TLK7AC8>4B%K0'-E7.XL>7$X;JUO/QT'M3;14I>4>CW\?#:=S"3
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MO3H;IHM>%\Y$&TKQP**CP\,8#<%@@*B$9<$'%;%UFX#E2/9OH!U.NZ/FJNG
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M[JP&X<&U"-E(H=NT"-E$&UU80"NN#@AI?&99@@U8UYTR( \(GA7#DD]&MN\
M_%@OJ>UDZ330S[%?4EMG+3\NJ:VB:0N"='GW9QOM'OLE-<%\8B8Q,$IXJ,WB
M(4CK06AMG',*LV[M$QX_4[>\I'8\1-U J:UGA=Q=>BZMD4$R!<5I TJ3B(+0
M##@+0B8FN8\+_2:>8-G_1NI;O^Q_$]D?<*K('S@>S_ WKNN_];E=%>[?O8"%
MRGPC7+$,<]2D6"D0@\X8C4_1BQ)E7&IZWWK"X:L-KO+?'D4NI3B(1>A:UY4
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MN]8Z)]9_YN/0?Y>"[J! ^-DX8\6$@Y>3*9U?[\8C0DT\C;0OD8/K (5,H&Q
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M/NPL\3TE8B[>%[SVJOR1IQ_B24YG@SPJR_Y@AW3-3L]KD=1IM^"%U(\4O(3
MZ3"Q23&??5$LN8"F)%:*T[V=GMR1"7'EX67F',J2@8G:SC@(\O!L*E!8L%QS
MK\G[VY<%L7.:Z-XG_#8>329UF*4I4CG@OM!ID%!!0*^ .QL*+[:$YBW,[T9T
M1.?E=LQ8VUC:7 %=]-">]<_+RW(8YS7$SV(\.ST;X#2G9Z>C\;3_/[/JM![G
M(O@8+63O:_UHH#T\: ',I6@%DUFSYJ/(ML3ZZ"BU%Z7MTXVCKS=9TXO\>9S)
MYI@I<7ASB:8()XJQ((2I]V<=6;;:!)(P?8U:<&2MFR'N85F/CL+'1H4.6OML
MN<0U%V=C3"$AR=U(6IS6'NC8D."3MV2_&V_9WL*K+1;T@^&=J;^#1.*VBZL7
M4-9<8>VGBRHF"-FQ6D&1ZZ"'7.>ALQ2L4Z*Y@=']JGZPO%LB=) I_6WT)8^'
MLR5-)OW)M"[I0TWEUA]=:T#];C29J?)E]8DG_3#(+X=GI[.: %J$<)YK4[.'
MCF>2<>9DYBL!@2ECM"GD*;>.3C<!_N@(NW]U-KQ*<[&(BX#)V[(ZV#M++1KM
MZYQB#9A*!!5# (\!@:$TEA4L(J]5Z+\![=;%MJ^\?L=\ZD05#RG/[V4)Q7K:
MCU&0;2VR V1.@7;(4L[>1>>?3IZ_&SILD?3?1"T'RMBN _%'TG]'U6Z1NMU&
M+P>BD);1.\]J777UA;(LX+C*$"TY0RZ9R%3K$O>'G/3OFCF;J*-UTO_5V9BD
M?#;.A.UM*?V8+Q%>--E3$85$#TYD0N<U;;G>"F V(2:G<_ +=X!69'OO?=01
M6<W;:F?4F6@[R&+,7,R3T2"]/OT\)@._(IM<0$.3>9C%O(,!93,"(BI@/$BA
MHDI9M0X(WP'G\3"CM>P[.$%NL93K['0D$#G7'O(A@B=?#8SB09B 48G6(:5'
MNS&TD'$'0?<W.$P7W1(P&8L\ 8NF@-+6@J?M"*SD17.+.HG6J>VKIS\^16\I
MV0Z"S\]'LY$NL<KS]9#6_6F<)Q=;3I98G$T)1*SWQ45-<5IRZ#EZVHR,5XJU
MON%V%Y['QX-FTE\9J]U+>5?[ JX]E&BM4X2E=?!:Z%Q,8 IS]+40B[LL',,D
M4*TJPMI?F97+K)C9B)6@Z(00&8*S$HK I*1EWO+6LU*[+[-:%E9^=EI;.#\_
MSW'TO^1>G1#I&*-%IWJ%"+.GLY%I**7:R2IQ6O\>D@"+N(YHC]J.)>O$^'=2
M1@<NR[7DUW/\W)_BH/\_.;T>3C-MI]/GH\ETTDN9H^$F@O;&U-E$D;;IH$'+
M8*2*7+/0NFG%&K >'5U:JZ(#3^9Z?K2GF/$A1@6TIT=0008(9'8!$SQGXV0Q
MOK4;<_WYCT[_6PNW _]E[?R!U"8I389;B74PC5<(/K( 7J#VSIF4FY='/,3,
MW@ZTZ$05QY+9^Q4'L\SW2<[3-_6OJWYF X^$98XS\NU8U*"XM("1*Z!]SFBI
MC C-+W^OPG+T.;R-%#_J0 $=G#3+<%T,,EL#64?YNM6H#I.F:Z.]-2BQ@^CW
M2P[-G'2<("DDIY_<? Y!A=KH!+,-MO@<6L\+VS<I[DG [9L3FTB\BQ93TY,\
M/F]T/ _^6(PFHC.@A>*U&9H#GQ.M4W!M,D8O3>M,RRT0^S=.6VEHL:/43N)=
MZ;"VC:V1CX3#3[4X[ASI'YG<I=//HV'- 8W*DE_O$';;_F$M(G*-EKH0K.-:
M)%EL+%(PA<DX@](ZS[W7M&MDV]O^L3O?"^M/\YO^EYDC?.,95]:U81Z3+04\
MSW'>FQ6)EI$E94,M4&_>5',=7 WNQ*UZQOO18/!J-/Z*X]1+:%.NU^=]X/1V
MT]L,F%P [5S((@OCK=C?ZJ\AV_\>V)PM2VZ\M59)-Y<I5Z$\O^QI1)1T))B:
M&1'UZ@8"6N.A)&Z$=-GKU#HY=1^FHR++UKI<GRZ;*Z(#V^D.?*NN;A9,+$4Z
M[E,QN4X(5>"+()O2A5)<K-U<6F=--D?YU,C40ED=!!'O0$P&0B\''WD=8$![
M<)T:F4D83#E(P>CL%6)JWIGM;D1/C3:;*J&#&HJK&-<=.,^C7"4FQGU!<#XZ
M4"&96JGNP8B2%(N&Q>85%>NCVU>LN7,+IR.%'$N\^8Y%_?K]=_SOT?CY ">3
M6;PD"GKE=,P0A55U]Y2 A=:7R%G*FK&23>L;)1O .WQ4NBU!UM^V=E+4?JVH
M*Z!_X.E%U=,Z<#N*7V\(]3!![<Y4OS[%FNGM".B6E"&7PD4P10=0=?I,\((!
M>F]U<,+$LD=G;W\TNR=,?JPLVT1=7=QV(B?BJG">:\^TE+G.Y*RW TT=[)XD
M)",#LU9'*UIG86\ ."J+?'=U+5YEVEK67=Q=Z<?ZY@P_/?LTSC=O3TC#H_0<
MI$YU=B<MT:$VM10E*"W)E]3-"]A7@7G<A&BC@PYVA=?#N:COWS"OW!";(^92
M!%AI39T4ZL'I8D@P-GH?I2NZM?V\#<Z.97/=CT>G># .(<M00#$RC7V=HEHP
MQ!@X3[%Y]XWUT>W_U>J<58OO5T>JZF WO@?IRV]Q<)9HH_AM-$I?^X-!#Z6T
MY%(),+G4Y+XOM.-$.D)D5 J+"+'Y#>1-,1X=P;;6]V:TVDU9'>SF5R[\/<CG
M$Y]S5E8R!=EE3V@+!V>%!DGGFO':\YA;7Q?8#.&^@F][WZ\Z5-2R</\A G(;
MR/2\=8 II2@;(*@ZT"Y$!HXQ^H>^C=QS6FEK;W9#B(</S+4GRV8;WDY*V[_U
MNM2,7P=R1T&Z+> >)E#7*0TVHUPS'1X)_;@V:!RGUY$K1EXDDH7 O &K:P2=
M:>-#ZS/W:&AW3^#NV%FWB>HZ8-O',:9\BN._+D('.@D6F$L0O?05CP"7>(%L
M@DG"D;W)6Y^8BQB.SO+?77&CAE(_7)7LJ[-9.YUK-2.C,H]*XC"=AZ/R53"J
M;=7LE@_OJ(JVA2@6JFH3"SG*5(LHHC+2TTZ48W#(6$E$MJ55M5O"V$.5+3I;
M)W5)"$CNBV+, #DS"GP*'$-"G>T>\TC-PG=WE55=T\++;Y^KY/\@%7_\F@=?
M+B;I2B:=BJ*0/R<RN7?: 1J2BDE!"H?2%MXZI+<;XJ.*H&_'KDTJXQJK<+_5
MNDO0_U?&\<>OHYY 6QCCM:BGNF^BM@U0M75L$$5JH[C99_'<:J!/GF[;*&S/
MI;XK0!-M<L\4)HK-#CAC 53$!-Z5",FEH.L_#EMG@+>$^H-I6REMOW6_*V"_
M&IV->RYZ'H(V((HGU-EJ",Q;\%E)>DF4L?JP1^D%TA],VT9E'50/;X&ZMMS!
M8(UQM64<&>8DJ*R@UO< REQ20M0J[;&P\PZD/XBVC<HZ&+ZQ&>K95)%+Z-IH
M&P49E0$#O2/&9? :+43OA5 N&!1[])ON@_OD*;>]\CH8L''/Y8W@HD:!];X8
MN2^JSLQUO-8'A=K[5'E;<@?##Q_*#9K.V;.I"FX3Q.SQ_HPJ+&HO)=0>8J L
M-W54%T)4(8E@A ZV=6>,!WI_9A>Z=*20AWA_1K/,BW3DA;BB0#F&@#$FR RM
M3=HFH?9X,?WXTO1M";+#_9E-%'4$%QK6@?OC_DP'JM_Q9L,V>CL"NCG!>-2*
M@Y/"@8HL@J^#7 72N:]L1&[WZ"T>31K^6%FVB;I:SWZ9)^J>+4G4S=/"&)2B
M;;T Q\1H2[?DPBI90"87'9*40ED8A+=B]LN]CSHJ4WQW38TZ$_/ALN]_X'@\
M:P+=-J]^ZV,[RIC?#7\A%RXU9]*0NUQ45+S8@*9X3$D:[3AG>5DN_-8#]I#E
M+D5S$17QQ3I5F^21PQ]1 -.<>TM,(H_N 66Y9^_+^]%W'$R_O\IY\HX,57I/
M\%/^DY0SOO7^]%PI)41&S@XY/_3FA$0V9W 0DC=!Y2+YXCSO%1O4!@\]JJUJ
M.RK<V)^ZDG?#Y//Y/GH)[FUYCI\_]X>?SJ'W\^35:/P[V6%]VH+FRWF'WV>0
M/X[.5S$:3WHF('.1-E;4?E;E%"#46VI:%6$D_<.<6.\XVQ7*8^/0?G73Z263
M>_W<; V7CFE@IG;'UBH29E>;16@MM8_)JM8YY@<:F=J&3ATKY-"1J<EXVGM/
M:YA/EHQ955^#-&XD*&D*A% LV,A<"$XG$M,Z5*)/O48C^NZ*0C<>^ "B2!LI
M<[2K4!ON))<@YD;].C VB?NLH^/VOM3]<9P=A+^HOATDUZ$BL4@77$9@WKG:
MSJR:.YR!89*,GD ^@5FK=NW0"EP1(6FOOTT$UEAOOY.D3L].YT!<2+232'J\
MH7_(Q9: CAE:6U')J!CB>JT@[M'<C8?NS[+;2>RC%C)K:.'/@."W:T RRF@L
M1W 2+:@8)808$'22M2^\4\RMU2;Y/N5=?^@#5-[6,MMOK/IVDR(G2]*TLZ"2
MD3Q)F2"@KE!C]C($Y'F/E9H/,-VVC:'4M:+V6YVYO.W9&G!_I-LZ4/VN[>JV
MT-L1I-NX5,E%.BFE%:(.]:W]$FHI,^809& FVCTV\W^0Z;9]LFP3=77 KM4=
ML]!*%83RX+UEU>Z6X# SJ%>!#4=?8O-KKP^X:]E&:ER[:]DF.CA<&NY:N+YM
M(F[)!W>4BKMO"8NSF9%QC%&%Z*Q*(H;B I9H3)1:66N6)>.6/&(?Z3A6!U-E
M#3E(\IY-T!"T).]9*NZE2TB_?$#IN(MGS(4Y+SGN*:-4Y,5 LJ'. *X%AYZV
M;JMX8BP;6VQKT_TF@J/:H+;3_N*NM(.(.[CDN8$;PAWJZ(( :UB=_"IJ)S)N
MJR%*"^;:!=NZD]M#S8;L0(^.%'+H;,A5_PLZ+O*'*4YGG_OF^AS *#P)35M@
M.1=07G):3PC 7!(R&9Y]!ZT"5\)Y (&!C0APJX-,&T5TTI=H*;3+;N?W@^NL
M =8=P [5ZJJ1&M>CQPXZV#M1L"1Z&5P B\[62>41</:>U YRQC.57>N*J0,0
MY-ZF5(?@QR:B[Z+$(P\&U>T;IM]Q_%>>TM=S<^NBI;ETAD>;P,:Z\CB;/Q4<
M8, 438B2OFMMRMR#Z1"MJ)JI<-&&:2G_/?G?;T;#3Q_S^/1%#E/R*D>E?O&B
M/XFCLWKV)CJ,<1AI)=71O#BC1^4YCL??Z:?_B8.S/!F5MV?32?US^M'L [;W
MV[L%U,+?WZ/(%N,$9$"7J#C:HI3S%AGGM84])VO(FVQZW4+;;7>JG_1Z."%K
M>_;:737D+3%EPRP$S Z4IC<N:.$@EE(2EQ@]:WUI=@647???FQ][(=1GIU7X
M/9NS9TD)8(G1,@6/X%5&R"QXS82+QK>.?]Z%9__[;@O]+^ZXS23>08CA)K8_
MAWA^MSVGB_?QW3B?]L].Z;B8_>ED<E8'AC\?3<YO,CMGM'16@TC6U5X>"7Q@
M-6&.+.9@:2]H'6K;$?)CY%2W>NLB W/M".A)>J8GHP(<B@0*I0:G8P)A!0D(
MH[6N==O:Z\]_'(386J(=% O<7-]Y."1F,@!J0B>9.BK!&0G><PNFH"-(*1G?
MNI' $AC[BD1V_\IO+M5CB3+>7,?,V95&Q.P$!QYX ,52!A>C!C(<DTPB)^-:
MNWRW41PJIKBS7N_DR<;R[6"WOXGH6@)Y'5P=A0M783I,I'!7G=U)@1T%OD]"
M1&V])PS@,Z\=NPS6?I<)"C)C$RI"WWI0_'Z)<$]$<%\\V$3.K>^[/Q_GU)^^
MPM@?]*??/X[)+CW);X<7X2=3@UC),Y".>U URA50(*C"@T\Y8?(+G1-6W Z\
M^SF'MOJV5<:H&TFVOB6Z%-K'KZ.+R80Y9NZYH)TQ$JF+X;1DY0&M=BZR+*R5
MVROY\CF/5LG;27+EFWS :&V+=@:[/7#OT=:-6B!$)I!+J8-46<44?!;,BF Q
MJE#OB&P636W<'&&5FU.435%Z3V=6L'7T,4*03D'AZ&PPAB-OG=W;2[2TRKFG
M,KJ0Z_0]6Z](2Y\!ZX V6>/=3$KC0^O6/K=1''IGVT[7][BTFTJW\WCH0JS6
MQ*ABD1FB=!I4TJQ>I Y@C2M*)"83=AO#.-;H>#L.["#Q3OR4DL=T_I[OH>?1
MT]_&H\FDEU2TA7,$ZYP@!]TQ"()Y,-%R^KEV7+0NAUH)YK'PH(6L&T8S9];7
MS96^R^/^*+T:C?]QTH\G_^<,Q],\'GQ_/:3_R9/I14.-#R>CLT'Z-?^.*?<T
M'=J.*[+TC"3;6^DZMM5(J)GZ)*R0NI2U3-V=H3QLGAQ '1TTG[^Y@ ND[W%Z
M7NN1KCJX]*)+P4:%H$L@VBM&>Y_4')2W-AK-L(38Z6ES%[J'S:6.M=&PE_P2
MUC]+:29J'%P ?C48C<85=8\%G@17'&0IDK;*P"%H8\#%HNI<,2]1;;'9W/'(
MATV$#L7;06/WNM:WY69 X#IIG\UWQ)?#U"-)I&(%[7.^#MEPTH!/D:3A4G2!
MQ2AC:Q=L W@/FS5=ZZ-AR_?SUG+Y2QZ>Y7=T/O9C__-YD>G%M;LZ_&=R,AJD
M^5\]BR=]^JK^BD[6^1GZMER]%I?G[/RR3,^GC*Q.K50"L?:7BK0T5J=NJ**E
MMD:RL-:FTRW.A\VY8U/D;8[:MH;V92.[*\ 7:QA>*_U[,\+AKSC)Z>UPOHP/
M]!FQSL/LJ:Q<T5F""-J#B@X!'1WA.5I4,263$VYG>N\.[A&P\= JNTU!M_NE
MA?/=^^("H!&&J1 YV(@,E"D>0KT%*(10+*?D8VY=F+  X6'SI(5<;ZO9MU+S
M.^RGGB#3G:<DP)]/B=(6,#,$GC7C119)*^U(Q_7YCTO!&TMT2=1NYR#N!9A9
M#.DY?NY/<5!K(WNE!.TT+4F0%U</. N!> >,F=JK![4+[6\=+<?RN-2^DZ27
M4&#GR.VS&,].SP;5B;\&ZP;<7I81@S 9G)6UT41&<NE3@>0D"<0DF4+K&.X:
ML!X',5K+?PE'=BY3_4=-AIZ/!'C?_W0RG5RS47HB,/+/+#$V< <J90[(G29K
M)*?"I4 96U_XN O/XV!%,XDOH</6H=GSSMEGXWA"-NF[<3]6GWYT>CH:?IB.
MXE_/<1 KD4G8Y]Y\C\62$J\]UWD@-ZF6S7OO#6AMLL!8;%G,_:SJ7[[^0Q^V
M_CL5\1(N[#RZ<];IZ&V9\_7M>,;6E]_(Q>E?+N""S//?3GC/8([!90_6"@XJ
MAWHMTV;(-L08E"RLM+8DMP+ZL,FT/QTM8=;.,=QWXU',.4U>D8SFZ"XP3WHH
MN(ZA3M_6K$Z#3)D,9\? )L,5]UD)V7J8]5UX'@=/FDE\"1UV'L6YE,1_G%4I
MO2T?<CP;]^OP!MHA!SG]^GV1SSUO).=>:MH>48$JD:PI0\:V"5HQXXGMJ743
MJ!TA/PY2[5-O2WC7,M8Z;SS]/O_SK#^>V^A#'-0$QMOR/D_/QL.>#<DI06:9
M,X77\[A \$E#9#G6_F_6R/7J=3=^],.FRQ[$O80=6X=!E\"]GL]Z^66607AQ
M?C_D]3".,]ES/9^XYME$T*+4^AS&P0D>P'/E,SG\Z*/;@ASW/_G1<:.QL)=0
M8^?0Z0LRT+_,2HC?]#'4E"=M<[V D4<4&@S6CN>9N!I,D)"98R)%LMA3^YK8
M)4 >-B/:R7A)&=S.4=7K8^]G_<_.R\K/8SG%216,9D#8]/DM)61&@&>82R@8
M;//&N7?A>1P\:";Q)738.<+ZGO8I<K)F ;[)20\+DI@C^55:U5[ 6,!+6G',
M(LF,K@C;VG6YB>!QJ'P'J2Y1<N.;_,]'@QK1'>-@7IXMR4?*64@0+F10AA,'
ME8^0C9>VA, RZ_8JQ"*BQT&"AE)?0HK&-:SG%]:+<00*Z7#*C#!)YL&G8LA
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MK.KFJAI@2]PHZ'IU07?K8(?N POMDX^\ENQUH>'FDR>NE"BRL(S[VN$G6,'
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MNJ\H49C4U1H!O=B J%='8;U(#$35>W[>MR/8Q0?I%J)LKJAIJIE8B<5*]+'
MR[-)4!JU"_$][^*<P9S+J*3LU'@G^?'49B7$K$M\)B+FJ:&A80KO1=:H@&3F
M5=C\YACK2F/H8\A,A/*-[U=Z5,4@^C3,$N:Q%<'P")'^BB3VE$Y*C5PCYL&$
M[$MH/T=>),O9$D^'WFKY12&[-,<EI4$E2@GF "^)VH]+FRW^":X+A6GSR[+N
MH46:]P>;3/O^?1R3-4^[/:4F6/:=A'%FQ5P*V] &*P+CI,ER;8FH3=N&A1:J
MG\::"D@NU46=JIAFA^VGWKS;3V[YU'W>NN;<6Q+014'<!+%Q'-@75D7\:AR?
M7^ 5&GR)8;]T)/7L5>&RQ<SY,Z*/$]6IU?/;&;9#S"ILW#^!K<=$Q)>_3(RU
M(4MZ6T)<7"D$8S]STHL6=:HV7J_C2B@;U$5IF@(>DXGR^'TE.RG/&L+W:YXL
MT/819F4RI:OZZ^.0GY5H=B(>-HZ=W6)(A^_7QJID.'O\Y&ASYN8W1'WL>GAJ
MW+"(;:J1?%OCE[^S$ZO*9R^/.YN%PMW=81Z5!@\@YMD\RBW$+TKQU_T*-[QP
MIXBSR3.#^7S=6-^'?(SXZB^Z[],W'S;3S<"LJU0?-;5IG.Y"%[=BFG;=JQV<
M6E<G4#I5O2?T3,X<ZM7<\YV%Q7'@%6(LUGA>F<0%]S&BT=[[4%BCEMM'Q;1$
MZ>9M.+^*MKR0_/SSV^'F8<A95O0X; >\%'A>>YZ)!+XX0(3>3')8<:LU5LB&
M*HQK<_VL?TA(P)2I_Z6#.@EU=T)5<8'CZ]3.SJQ2>5U9[$+'_II,_VQT<O_#
MJ ?W#8X+E.#"TF=6^JWF]M0[I($3U/'Z)#Z7Z*CWX:U/]Q.&CVO]2IQBCR:S
MAAU<[.E.2EE6 O2KB-$N]Y=%6EO3=?K<O57@_<X;-CG@U.MGSPZJ+\+OR16Y
M!<B=6H;TCE/HTWIKK8*IFDY;^9H^FE,K-#8VE@41XT)A"Q=N-%$K&Z)<=2%K
M>70YP*Y.=K%I;,-&@% TK^M2S#W?IVWO':FW?;0LD< C%DZLZ>IG\IV5<^8J
ML]Y] LYVW7AFO0N90B8?UCYY-18'WG#MF,/E)E@YAE&UYZ:U!JQL*3C5]2U?
MH[7R<+[EREW&P=NZ*"U>,'<WSM'AEKU0C:+[-$?\&C7<?$M =;G[6-+?:(ST
M<N_PA=CF]UJ]? Q^>T%!\]CDI>WN_,>YI;M*%D2V$J-M/PF),[ [G@2G2*WR
M9IMXH::+R5WE9I@W#))Z8BZS&+*)<">3L'0(&F WB_3<]X%6")"M2HQS\+N>
MDST3E35S(K$:2IMF*ZS*HE\[H*ZQ\QFKJ6(-D$XW5Y!^G$/1CL&*5JG^CD;1
MH4,N=!#=JZ4:N[;#)(A?D[?Z)K JSSIT=L;M8?K:@I;GO.AI[Z;0Q*H7"W>E
M+&P1@6)_VBULCIBKJ"IOD=];CZ%KEDO4?\%]C]U-:#'YTWB3H=ZH(S^]E1.V
MP<>&\:GM_KW'U*T#+9HD?5L/BK\+T)>)K-"W3*M9L/-'KZ_VS?FP03:V4R9_
MM@ IDXZ!'//N%HR%C+3E"8:U*J<KQ*L6N/AK)@(KL34W8#K8M/7\'=L1P^H0
MXJTY0@(=MRS:;_OL7%P$6T-IDZEI'FCRIT@\?"TH7^W(>$S8;L7]OJFJO*'!
M2G1Y/],?-Z1=G(2:%RI9QW.H/-Q!/"XZ7I0V*;-@=B(S,B]G&E7X@+@<F\S6
M_7PUQ:M0D1+=S4",.<_:BWW]0"W84.0->\3;3ZT*P^FYA99QZQN*\M^/K^68
MH(]S'WW4"M;L(W\YZ_8 0/6_KJ<^V"QFJ3_FEQ@YCZ_:?M)O57.;WGG\XOV7
MMYB#)$.8-VF3C:EHP:%O5"INW'3WL=:;%M<V!SI>S8;.W2XT.14DA'=T-4 V
M)_8Y:6ID*XJ=L*:[>.T!$@E;&4,<=YT+WQ'GS&-<+/Y]F85%27"3MA#Q9HJ:
M\[[:C(OU6IAOK4;8;/?E90M7]=@^AW_B^[HRV:HD]H"'G9Z;S)<2=B$F0I-N
M<,)0IY57L5<^15#:FD7&VP\3KU+ W%JK06&S;4IJ.PU<Z29% NQJ,\PANQ=.
MGQUP(SQ2(]:<-O)M2L_!<,"Y)G5J\>A#0]"KDFU\*YH0 GRC^#" (L>'8 /'
MC U<8R2M['VLMDRK,-,L&&Z3+9XSSWQ6"Y$*"V9:;N^M^_PS<X=A/29X)ZR6
M6T9ET &?Z;6A8'QS,\:*.3UXC;8 "4 @B'$9/%6]<::_W4FVKL_A*LS]B:?0
M4L8P"Y]]=4\8.(["(<B6&JA_" M1--]ZNJ82"C([@FYVJ@K1072<F0D%)FQ_
MQIDR9#VV%?1(.) ,7K7!X_)#\_O5T5$FSU>!0K$<X1Q=%V[[FJ$H!5U= (/.
M7[A*ZO$Z8G3M;# 1<7#84<R2O13/*8^GL5.Y,\B\GZ6N.&\5P?-Y6O;R+@VH
ME-3;DLYQ75G\E*AP(Y3L=&'Q@IX;+?K1Z.TZP^-UH7A43L'2$&;KZ(Z]FG'6
MB[%*\2AA%[_Y4]!Y06CJET&=%_63-DXF#>P=-/3!UI%/2ML6!@:_.;],'_-$
M<<C5V<:37WEPL#06WU7<.)M1T#U0]8HZ2O(R?%U:!_JM85I6/HB/<Z.9(I$4
MC[PRT743KU-6R Y1Q'7$(Q 95'@LK.K%OMHQVE+JECT]I\TW+V\Z;>OCH4>!
MZ"[>UGT,D9HB]/"2 U6.*7$XYW134Y7S]B2'SGHUW$PMU"Y/3CEY$<+G?H;%
MV8Y_>] XV+]*,DQ9S,@5T^.86!O?ZPKJ)H)*^-%V%S2$99IP93$[]JU]9SKM
M[EBGT3-)>1/FH(TV'$KKO\Z4/L*)E?SN+0L+LX'IJ?6W"&XVJZPDQ_L)8\?H
M7S@7]^;F?@IU>1 LSLV#/P\M9)*<%]V:M'.K)LSNP"3JN6)<!*BPDLN8"AD>
MK?IOS9W?OFJ<A>TC/+[6GN\BWE&O8(=.MB1!Y4(7LAU >'+/JEY\BL1?#B9\
M_HA"<.>9RXI.7+H.;=;4"9G/PV$!&XZ/50P=/!UE<XM[)7)T<,;.LG!9*U35
MNG'KO1<6=KR!QJ<&!O6UKUK[!#9KLTE+.U:]"G*R;0K=N%EQQ1S'9\3M-M&(
MY[AQ(LOG/.S$P&]'JCS=3%@JS7)FU.;FJXXD;8?\B QM1O;UL3SV,0B8:X-7
M)SAGYQF@[5O9A0**VOZB3UN'&9-;W7'9/G&"4+B*O?0.B_C4H6XF?83E<?T&
M,=% CETON=>K_267U*X.[?K)%/&0>G^"FG=&<VS^$9Y#F0*H6_0N<"2PA)X:
M&9]V!=E+>382N3)1[=$L74+X$MIB@&^\7-]*_,QA1"7!%0&5HV#,.QNH:8K:
M+_(+I"]YJ1"5'3@[GK01+75$M:U[%&Z@P'Z7QU=WX,RM_CIU 56?K+JTV&E!
M0N"T3E8Y-$^\2@ZPDE4T9Z!83^W6T;70V$PV-\'X:_NW;J4CLC X:.G9L!_\
MG:=L[B^7BP=%G4I5_+1.^C)'WMN")XSV]?(!HSNVK@Y[L-"T6BDC1BM$"//,
MRMXO8CJSW2XGQTY\!7'4A_1Y)=;Z53XYR>T2S?(GJ!.I,L!7LZ&0PSQ1.R+U
MY6%<C](;T'!N#DVMU>D"SR-N+3Q_8FJ?"668=3SSX"XH+UT[E^NB)PNTSUT(
M8BT6)X)[+8(@ Z 7,MO-]X8Z)Q3$7__[\@CJ!.(2:K9?I T4!1U4\6B_%J*\
MM2^=M5<%^HAN<J\"RC='+O*W,KV(R0@AKQ<TL[N:_O8PA4%C U4Z6ZMZOR+6
M;\A:C[)3N 6\CS/A 9%^-#HG&OUN>352C/'Q-PK_\A]N<GAU,/J,M+\\F=(B
M"H(,'+>$LA_)OGMS%HT$2K7W;74XD$!DKB02< .=L6G/@(Z+UY  ]< O)#!?
MNDDY^&\)>OP_L_"QMT<J4=* ,20:<3+>Y($$J#I3SR>%DTU-;;OLED.%>#.E
MG\SVQ#C=I\ PT(;4$++>#)\(].[^E(=CG1KI\K%>;Z5>CI3(]U!04M"1,I$Q
M;U;7@M5+#");T06+<"!YI6\1?>.@+<J[S,%;]7<=TC\;C/&_WHPHF)ZR$EXQ
M0$\[+K@T'G'5[!HXUU+-T+Y^8(M)[7Y2/(RM+GST;:XOH\C"P,:* YK=/''4
MEU<]:BAV2NC2_8$?1:?G-CH'"8P(C2/@I;\+E_[9^)@3#3X?AP<8N\6%<.2O
M3VY,49MZ]Z '.UEONO8:DQ 3^"TS4WZ:M/(D<[)#3S7[G*UYW<>A9!WEM?WE
MX9+5[C#=R^;L*B_FB<+M&LLL/=][$9+KTA3!V>*D/13QAM\S'Q;>^X)1UD5+
M R[5/45/U(5$W>+05!\YP2D(QIB<H<&-5I:Z,N\*$44RFKP'SI%=GRC0&N6\
MUV0M"-:S+A<M-&,GLP(_6F-@8Q(;$^^>E9K\ASB].BW=74>\'0=!2J]3K' "
MSC&MX+IK<E9H4_F\'NJRZ*MZJ$))OFKNK-^<7%G.R1)_9GZ9VU;40(M6LLAA
M3PE@0A_QPKC7''=#)X<$TKQR;Z]U?Y=L_;.1M4YTJ7E4IH[(39W;@BC"6;W0
M-"AKG_'O+7NVU7K/.145N[0G^'4VO&MPC)U& A+:HMP1..?O")S.J3=T/<-E
MSG7WDKD1/A>IE^N@]O _?D^M4MV@BY:E>)/O2GB@BVL>=9O ?R,HL?2!UDI#
MBI E24#F]15U>'L#",?4WFR!X?AENCTS//@RH%=O*:J08@IC/.$0"50X+L(P
MH*#%F+_5Q_W14/BA6"['Y88>O!0J*OCA@%ETX_YX,7,)LV-%U+U^6GW9I],^
M/G)'+E\/JD)5Y3QNZ)6W^_MK0= Q&4H&U5</B-]O)EQ0_@<=3TC0A9S/D5HN
MPRURY$O,5)POY+"D">!X-=OWX-]G.!_79VDMNG;(3BS=O)F=G9GK>![U 8N'
M3.29U&K"(?@_[+#6+NRL3/TN@W9;T[#QKS9U;%89LR 3+XLB"%I\'ZW 7B)F
M&!-M2E^WQ=O6);% <DS>0%#9QUP5%^M>Y#)U$:T=(*0!&N!*-.T[HW$L_?P?
M3Y?\[-+S.:VBXT(PAH5[5^WWM::;9]5=MY/-@VSBCC*1Q.M87S#/AO@@TDNI
M.,-9O[P\''*]@C1C0J6L9&1[].K7*E%\A@'5-"1@N T^PZE" F!&!(%/)L"A
M^1H=\'.%,Z2-3\L)!D]J+U@D^AH9J@ZWLKX@41,Y\))/.Q3CN%1%'QJ@L*$P
MS#+ZK#0'2Q6Y9;3O[R?# KU\8OMAPV" WX7FDD-&*RVFO;N;#%,@KT*:/WEZ
M/;E9^KP(:[;1PN:I3N#!B^\_,Y[S^PTOG)=D)(QFDE>\$LI2L8M)GI'3)A^^
MR$E% L(7X,MK4'?XOIPP K0/.CQ! J&.+>]U3_N$#R,EHXG@)_(W:Y\\Q*>U
M<CEO\W.1P/!MZ2U"]SCS1DD>":3>Z-[ P:O:K/^FJ+#6A00$HA'7^'='\'ZP
M^%-)\D][#;HO6:_74B][,_N"$6YTMR?T%\%E]DF0_WR?%/:)]-9Y2__4H80F
M@.ZB+Q0)+*XC =)MSY_@S2C0(E7XWVU!6=KZ'73_JB5<?;?07R.!ZKOA&4!P
MCEVS@89ID$"+.,7?#59I^_[8 /]%C0-D?C='3I& !1( Q<$MLD_TD4"*-!+P
M#!+XNU'31HQ7O_ZJ9XJ8&$<"FP@( @FP7D%D_X&6VS^,CCH_5DKXB]KHG["7
MQ/T=KW]:%,S8(_]?&!QGQAO>M:==+O?#W!FD'L +NJ2+)8(N:!5$3L-%$'UY
MM#$O K,BOV:$1'E\RG6RURBKD(J4&)-J4Y!0#W]+7U[F)2'>T!127+#4@>KD
M<+M)V>M--\(<EG)YPCRY9\0\X>\_#XO^_6?G74C.^;M-JZ<*X2H$?;<-8XLJ
MDXH6>=2@*M_J-0 )%,IK[+[RIY]>CY0^I\K!72>/&?J?F#8,S1E[+/^7 /NO
MV?Q_;38+8N\7=_SXND&B]FB9YA%()B6Y(.-EKDGU)V]IOD?NRD3<;-!VHQ\1
M;[X ??KN ']"U4&)[ @+"U6U3TY\30;", 6@R$J(>S^VGN(TP8G_<,?!QF;B
MG7#30BF\P6-L.T$Y:JC!/^.+3.[KMQ_>44_ P&!KWZE:!CJA[WD]A0\WJ9!
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MO4RR.$*7^'AC&UZKF$!]:RJ]+*P.[AC*0'B\D*@I&%*B!]R.!GW2>@18A]!
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MZX<)O)NI1MJ(7K^F?GC.5,/ZP'V7N@Z!_%?C.^%G?W#<B;]PW)2G[Y'V2H^
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MYTYE*D&XBDOAPSQ( %%>1T+K4Q( **;#?YA,4'*O)3_A_F$]<+0=A=Q%$<^
M8D6;>ZS@C+2QJ<WGYY7@2?+7?V&2R?^JF('.^?+2SI[Y-Q.6"H.J\"DGK&XD
M &Z&>YG?6?^98XF]!@F +% _VS_?0&"/_JX6ZB]P>E_^Q^&-O\18#&4M<6J1
M65T2!$T&EG59>]0K+3L?]DN_K/H ;I4M/OZ$9]$9A#R(%HSRSY85OOB>]>.=
MC\^Y@)P!3KL7, VOE61A]M)?ZL.@3*A&BL@,'R!JT^IT;L]T4PF4,8U>K2P.
M4G_Q_MJ@(PE@F7>D[K<HW31)<!P6>_&X^L+$%:2WZYL9Q)92SZ**S6Q-LF2-
M"D9?8V3+V\=N9G/^:*TZJ(/=:"_W)-9HC9)2^=;^SQ4.A.V8_>#2@&>.I:G_
M1?-N(=VEHAE/?'Y &^4M_@&IN*5H;5>>Y_&>51^_X(>R9.X<L;*>F@G5JRB$
M(+]J5?N^1T_ZOZ6P@J[_E.M&>+KUSX<N(UOVYD@ JF/WC2>0&71;<E3'G@O'
M395*O7#(FE9GNCON=)UYLF>_\>NJV@5J5N^P%/2K"B($JDBLREHC<@ZB%\DP
MJ&Y8,]DT??SM22#:'N+3M?Q@1U=!.2)BJ&GTR8RVYQB94N72-$%N*9R.;%D@
M2[Y_)R7,/15NKS'DF5T5-7;?>;,P>.#==S:(LT%XR5QRVJ=!A/4%A09<$4$>
M,[G"KI?Z9G)<C?N3&SP=6SE!+R^H7,EDNMA(O%8=T2LF!;EEV.D->?N.6S2
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M]_.1QW=?W#F+\BQ:%^8N9E-JIOHLLWEP.I:B472<U=<J8KKU(&32"'.C=/B
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M718OY+=_!$^9R1P>D<U+L)H46D?QK)E\,4X4;%2Z#$YYJW*M.@3+$KIZE=K
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M8:,BOQ%G-W^-6\^?LOS5R/AD)YS20<#53<UN:\ #@C(DCW(/(7+ 8(*_U;7
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MKV/$?1K.@S*FH\K=X[>1NQ!?0V-E-HX;F85T[A1K?JY9 0R&#S5_?RRDOSA
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M\41B%AV.2E3V #PG(X<W>P34OI=E*>76BKQ9BB9PM[$HVT(,3[\LV_V:R=3
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M?!WX][:O#%6MG]XM]>:@.HLHJ]OC+U_ILK&\/JR6C[+4]I:QK=XV.[TL8%&
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M=F>LNH/;[9L;,=+=6<?#L'?WUR=[@/3LXNXGW?3Z-5W+;=3:/-'6<L)"#L-
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ME4')<1"$22QQXF2\CRO^U*B]%4Z /^9+\,OGU^!!%K7W\_G,8%/X#*XZ3YW
MX(YX(+NO^OZI; G8$SAY<FL F+7!#K-=R4OCX%[#, ,M$*!!8OL4J+ 8_&AW
MX#$<]FQX*.&G<+@\\,!8GDX/+46_M?*#7+^BY=?;8O68Z]W2CT^_E*;H3E-#
M87EWP_6NJ%JBYPI1&@M!(!9,;TA4&D&6!!'$/ X3DJ4L2)A+P(%]UTYKU A!
M"5IRP+7HIHYQ);OA+=7*K3<?K>!N"Y;#6-@M-L,@//!"8< U4H/;/7#_:"37
M9/\GL!4>W%R&V9G:W1'S1,L.'8]*J>Z /*?#'BWTH[+WJ^7=%UG<&X?PMS0O
M3#)2.<^BD&.,8I@*&D 4X!A2Q#B4 I&(<I9QZ71/=[*7J1G11DBH.[H'0HLY
M TH+"AZ-I&Z,=!I2._*Y&JB!>:;"R @(7E<8&1FKQ,4>+<5.##PQQ^D^1B6)
M3C6?\T'WP[VS:9HC!LTFMZM%SO=+\D8RCD02QC"3>NHCCAED&<%04)9%F12)
M8DZ.1N>[FAH)["0%K:B]H[<Z +:\V/("V]#W4OT0ZY-L\P(8_A)NGNMH[*2;
M%Q0^D7CSTAM]*RD4N3ELK%PB7ZW*]5SA*.",2T@(2_2^1G,%80A!JK(L)214
M8>I8)N%9#U,CAE9 L*@<>+D6T;D<PG,0[5C@*F@&GOQ;5)H*ED8\GZ4(SFCN
MK<[ \_9'+B)P1KWC"@'G'NQYUF]\T+ZN%OJ-\LW?-OGZ:;LPX0 E <<9Y%$<
MZ94_P1!3S&$6)2C)$$XH<\JE?;ZKJ4WPZG2ID?2__P..PNR?@*PD=BPBWH&N
MY7&W%\R&/IK>$_(?02TFN%FOBYQMUA4EK%?@EA95.,D YL!ED'R=_9[O:-QS
MVHL*'YVI7GZCIWMO(1]H+M[4?@(F;8O)PU.GD=@FY>><(\4%3 +%(&(H@C1)
M$8P("E(6!&&6"2=7W\M]3HU1&I&W_A2[E$6.GK\6<-LQBV<0!Z:8%K]&W J^
M.AUK+?$ &?T= /+E*VS1X[A^P_80'/D0.[S:(]SVO=0MR6U5:]W^]CSTL,+U
ME]6/\E8+8L*#WN:/<I[2B :"<9BP6)-1:'*SDA3#-&6A3$A(.;<BH^O$F!H_
MZ6\Q<XCP[ ]_-SF-!^K0AZ.5#N;&O=&B8JS=W4NS1]JJ,C,F$I/ J#.K8]G>
MNN7/[3\D#N&WHPS-2(&X0P^16W3NU<AVQNGV;WV\B-VK$3B(W;V^-3^)CW9^
MK6$6HB1)!)2("8@D4A G>D\=9%AR',=*[ZU=K."S/4UM;3G*I _>K\JR<DLS
M$=:K9>VRY&8(G\?9SOSU@M[ B\BI%%.#./U>!&.@+%,OY*Y[4=U+>:9\.=J^
M6^KY)\NUX9^Y2E,NXHA#1,TN63)F'(405%0$&",:2!RZ99;:-3XU2FAE V:/
MX)HW:@\SN[G>%XF!I_<6A-JB>+<T 3?&\GA%'_(U7>1_EZ:^;_W0<SOEW;)-
M?CR$&\\IQ+SECMIK>N1D4<=*'6>'.O%,O\E=VQORT-KXH$5MCFFB$*611 E,
M0E-W*M!;4L(HA3'"L4A$H!1R<JRYT-_4*&#G8E/?HJW8(K^C/4J+7\+9CB,\
MHC<P;322GMB?[,3UQP26N'@BATN]C<H7EJH_IQ#;UZX-B3SM KV?+7U73;PL
M-_?USYX%V\4X"\),8HABIO0?00!)%*4P3 *4HDC_5E@5OQM&O*EQUGZTWK?&
MIQS2)EJ"[K0 :E6 5?/O.Y.-2#I:.9Z'V?*R\<4&;^@+RKUQZPB/.:@(,@-;
M%<&>CB,%7_H< ._AF%Z$>Z$ 39_ G@_9]-K+V$&<=1XHW>O-4CPK LQ$R 2G
M"I(DR"#*$KU'33(%19K0@ 0H2D4P3JCF>2&GMFBT_A!&X)Y%F0<92\LUX85'
M:."5H1X5(^4 ):"'Q.[%HQD[1/R=Q"Q>!ME?9*)%7SWO&Y22Y@!(UGFMO]#O
MG^A:?I(&/;WSJ 1\]=7(]V[Y6BJI]R!"/U1?Q.\6H<5B]<WL6N9*FG(L@L,H
M$7I#@,VI!"<21@J%DL5)*&0VUQ8O6UG?4_B5T(4\]N4<CD-V=B)MA72\R_ \
MAI8W("\W+D/?F[2:@2;YOA8;&.7 H78S4.MG@N!;#:MG:QWW-P"MEC-S%\.]
MGK ,- Z^KFP\2S?N1<\PT!Y=#PW43;\5X=6"EN5']=>J(./Z8_')G%-\J.H@
MZHW)-CW7*TU6)IJT>:YL'BSGH4))DD82$F32L= DA!0K!L-8<<RS($TUQ3C8
M^%?*,S5S_L/SBI*\$MP$67]K1*\RK]2_=4RY<NW8V3'_B",R,--7FIBQ:&0T
M948K(6=@-TY["1)?;<>J56K[AL?;,T_X>F+P:Z49E;$]0?><H7TUV]-&OW]8
MK)ZD_"R+Q[S)J7NTB_BPJFYT9;U5**NZG?N_-[$^'U;K_Y!KL[#<+<WM<)W=
MY.VJ:'YDG@OG-(EQ%(<4XD100^ 99&%*(,81BG!(0J2<\FF-*_[4^'Z;%:D]
MYW^HI#;$4NS$-O_=+(NM:H#OIVAJO/X==P7C?C66FX;)?@M#7R%<JH>P5;J]
M33!:ZI^NP9-<@YVBLR;?5G5'M*>LQPW%BXR1K_W&N,*/NQUYD8$YVJV\C!17
MW&*PCA.WYL"-=:<",Q<KSY* ?9+F]"U?WKU:+:M N U=F+0:X3QAA+-4ZO43
M"P)1&J50KZ$9C+A481*&J<S<[L3'UV&RBVB;6G K.=@3';S/E=PF)ZRN6<U.
MZDG2PG4C]1+?C<.%RG2_AA&7T7-9+!V36!HD3B2O//V%&3P\7_"\S%CZO/\9
M68/QKX=>9HA.WAZ]D"C7.IN]U<VOY?O\T:2>6VN!<Y.)NCK ?.9J)$DD5)P@
M&#,I(4H$,Q=(" :2QAE)12C#GAYEUC),;?7;=S]2E1)P8;0 ^58-XSTF7;/(
M]!D>5T^P04 ?T=VKEA]6"H"=!NT5SSC>7,X@>G?9LI?@A?RRG"$Z[WSEWE3?
MU!<K+J4H3864RK7+7.R7<Z:"% 51 B,<)Q#%461J4>E_84(T]X4\<R/ T]U,
MC>-:*8$99"#;S.'FFJ3RJFR]84WLRIO/M[?-CQ]T_U^I<X&1,]#;D=OU@ [,
M7X=8UEZIE8P^DUMT8> MG\7)3D9.8=&EZ''6BLZG^_'$3\6J+'7+*E_/XRC,
M.&<F?:;F!:1P!%G* Q@AG'&2(HYBY9(#?*]M)T88(<EW)9K)\*UE<YO=^X#9
M3>F>, P\CVL$;KL1<)ZZ)W3U-%_W6QYUDIY0Z?G,//7(T!G[S6XJ7V[TSYK8
M2[V ;?.WA9(BA(1>W EF>G'G!!)$8D@Y3F*1QE$LG+)>^A%K:F9!E8A>+5;?
MFL7L5))_QYQZGL;/CEC&'Y6!.:E'=8 9V.D&=LH-DLK/+]ZCUQ;H%&JB=0=L
M@.Q?D\"J=3<B%S*?O]&MKI\^R;O<-+5<&W_J><95@"F6,$B" *)(I>;H24'%
M>4*0$&$86D6GG.M@:N1:RPAV0@(CI1V;G@6QFQ=]0#,PPSFB8DU1EU0_03:E
MY'^^6SW^H%^M>4;_8T<O9QL<A2@NJ=-.^8O/]<C>MSNK^;1ZHHOU4Y,F\/EA
M94:"# >80R4"#%'&0T@%1S!-@C0(5:P4LTJ1X-+IU";Y_F%F40ON6)75"?+N
MZ3\4D",>"#<RMYE$G8Z ^\/JD&-O 'A'RJC7!;.G-'F.X'0FQ;-M:[P4>([:
M'22\<WVW!VV;BC/OEGH)J#ZF_RD7XLOJ9[HVSK-//]/?Y%^_:D7;B\N%)L<E
MK:,B]#\?"ME\_#S1>^6(IY S9/)<$0)Q1 14+"8X4V% 8GM2]R+2U"C?J&&2
M3=XWBNA__";A-Z.**=)=^QO2G3;F'G%/'0?Z\C.B%FO&Z.,T\(IB] $[A4 U
M9%]6H-4)&*5@I57KOS(#>XJ!=R\[9 [KT>A#-])J-=80NBUP7M'N7/[\]#3>
MXN@5F8.ETV_+/5UM-JR4?]OH'MX\FD#RG>F8DD11'%-(<:(@2@,*,:(IQ 0G
MB<(XHL2I>L+9GJ:V#.X$!96DCLXQ9P&U._GU M/0^YIG")4#Y8>]B(4O?Y6S
M_8SKE7))W2/?DXLO#)3#YURZB6U=R+WL0F8_P-=2O,[-F>U2F!CE>9C%/"51
M!G$J8H@HQI"FF,"414D2IV$B8N(UH<^U$D^-I%H9@6B$=/7A&WR(+>EN2@,W
M-&U>[X2^*W:[GQQN!K:?0ZMZE7=BQ)1"OH9IK/Q"5\L[K61#ON!WSCSDK>.>
M/DZK1VT65[V695ZN31Z+FWM3@70NL(B",,E@(E$*44((9"H.H0R2.",R3@1R
M"D<^W]74UH:?Z@P#A>32.*,Z.D&=1]2.T?W@-# 5[X0$.RGU-KN2TZ//U$4L
M?+E0G>]H7(^JBPH?.5A=?J.GF[1F%ST-?I8FV\*<JIB&B90PP1F%B"@%64PR
MR&46T(!G)").6<\/6I\: 33".?HV'^!E-]=[HS#P]&[D K_6DGG<DI[4V)??
M\D';X[HKGU+KR$OYY$-]G6ANA-!#7K[2__Q8?%E]6\XE)@$+4P4CQ4.(,A5
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M8P)1*#FD-$YABJE(:"20MJN=;K9ZB3$U;M+?8NIXP=4/?LN;K\%!'?I*K%(
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MB8M_ [*6U]$(.H4TX31E7$JHI$P@8OH/'*,8QBC+.<NI%(S.GAJGAC5=K<<
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M;!*: GG+19TEMEM[:8()51PB5I@@6H(@2[DP0;1YD20<<^246?6DAZDMNXV
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MM6JYJF91@A"+A( 89Y$IGX4@B^,$*IP1FM(LSQ*K7&5^Q)G:Q&\E!=6:\G\
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M58IADN<Y4;C@>>&T'>_M;6H4OQ,6&&FAWGRU\KHZS/9!;+=3]@9<8!Z_C%F
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MXCARRZYLW_?4B+$3'3PULM=^9K21OJMS[V@T.8U$@EDD8@YSJ1A$280AIEC
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MX6J';4>O7'!=+?@WLN9Z;%X^EZ(]&_U"-J+=/*<H8 %5TW1,0Z3F:D8AP9C
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MDH8LR8QJ;WC3:&Y4TVE<9S5U*ELF=U\_3&;+GDG!'YFO6EM 7]EZ<W8#.GO
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M>JBPMB1DKQNZ9:/.8RS-&/DZA,8^_-PK=P-:]3SV[SQKNJ\^GL<"INWG>=;
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M%S3AE"5J <EH3"$B4D<(HQR&- M)%..$Q(%=L,B!A#D&AS0*@K:N@&V]P-<
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MZ[$:^7MW@<GZHQ]&P=.'?T;(I!__L*&'!'#AZBLKH^_/S_;)QU3&/$$!AV%
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MQC'#C NC:BH7)<UN9FV*Q^H2'J_5;<N&V9;9/0?P\'3H%;:19S=GQ!S*[5Y
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M9RR+8A@++"#"40;S.$UA&*I5*0OB5/UOL3'?!$^@LQ4O3K")[DQN0H([>V\
MV0!6V"843S'FIDZI68WDR-3;67M3GQCJT=,1HYW)O9+7;1<64)L-"PF5X5T3
M*EK;#GK&@[[U]5/Z]OMT?TTV6-X\9N-K/+&3;;(A./;+32?Z^BY;76)Y&R]Q
MO]X5)E_@D E"*86QS+0'C^609D*MN2,2H2A)!&6978*VF6"'X]F1)Y5WI/H.
MGLBRC4;KRBL\Z1%13+*KF26:EA*69[6&PV$V47B$^$W::>UJ5W218@K?3Q<[
M=%S51NLR3".TSQH0^F9MLRX#,=0NR^#N*]MD]<Z1?U,2MZ7@]^LO0K=/4 O^
M7TBUK/Y8%[02Y;,NXW.W?MINU*\5$.JNFCC?D173[*K^^J58K3X6I8X/6R#.
MHI2R1)?VQQ 1GD",,@Y1S#'&/(@H=^NU-9;&<SN-V/>=NNG[8$!GM/Z*=V:#
MVNX;T+<<U*:#U[;?@)[UX$]M/V@!<.T -MHK9,C.<WHQQB;V^;P3[LW-QAXG
MWQW21M/W;=JLC0W_V5YMHPN^ML3M!RD%TR$;.R_K%[40?JU"7<QN7_(,Y2%!
M(LTASX,,(B0"2.((PY#C6$19R"2W<GM>H\S<)K!^!5?16:-6^MJ<.A*C5 :!
M\I5%KI5Q'8;.\'A]H@$9^^"]-Q8[0T!C21WEH6TYF!8FJJWKCJOWJKL.JKQ1
M/5YWT,Y7ZKWBF0[AS^^*QT>=ETQ636/@Y>;[_[E]I\#X]+F-_<0HPIA(!@F-
M$$1)&$+"\A#&(HQHAK(@I$:)?F;BYL:>>X7;\UBM,O@_MU K#3[][;-%X.UE
MK(?)T#^"(]/=1?!<PI<OHV@1K>P5S8F"D]U?2;LX9&-L!L..+S]ENBAC8XM>
M!16;W^78Y8U4W_7_Z]/T9[+24>=?=F$/^A>W:_[Z![TK&U^PFBI*K=M[T?Q7
M_7NUY6HY_^$'^ZYS"/44TDPLBT#B)$HC"=,T$6JMS"C$$1%0H("*6 J9<F3C
MB9U6_;DY97\7&_ 3;_7^62^KZ[_I"I1,F7I3_UE[:UN+&X]?+ZY%7V#9S6[:
M%\9LA3[?UV#L2:X>YMJ/\J$_S'MC07.)'O>#'[Z^HT$!=#" GSH@?M;.@Q8+
MT('1[!4:.#SV_'N38?353W!:Y:?M5?@F W/4!_%MM'#8V+2^FH]%^564STLF
M/@I1+1*6)RA@#")&:.,.H1R%,$DBBB(F""/FFYF3(N:V@>F<C=J]6S5J6C0_
M&H#28*]R-4!C!^/TL&DU!!]]8&.Q [D:HXEV'=98V6TV!F$8W&"<OG.Z3<6@
MYJ\V$L-77I> ^#H72?WK=:K2(F(D#.(<PSCG 42!I#"G/((L"$C*)):IR.TB
M7@PESS#DI5C7=7*O3T&\!+K9RMDGD&^=F*A_L/MMH[?_-$5#H#QG+%Z2^B;)
MBX90G,MC-+W=CINJ<M,[S]9.QR[2[__;DM52OJC%WBUCQ5:M"4]U:LUHQ!.1
M4\A2ID^<.89Y1F(HPSC-61BE).,FB[0K]9C;2F[G/+J[ Q#LS*GWE7N#0&>1
M&:5=.U;#%#?A"(SMN?OP#G26W( P@@&^ 7UWWL7Q&*]3KR>4A_A2B>AQI?K7
MGB>OE3X);WJ"J.-17X]S;.OQ^$2691V)6*JG/Q456=U+7?'BT_)9\#KFNMIM
MJ^_4UF#]3><Q-K\XW30NC3.6H22 &68$HBS+H5HPYI ',5,[9!9%U*@^\(@Z
MSHV/]R;NFN/6MC59&I9+RC'&U&SY^<8C-3)O]P>I!)U])P>L?\BZ-W/WRTDZ
M#(XW%KYZIHR@X;2]5L:#^*A'RXBB'%V-.U?F9_(DRM9?'F1I'"5!!C.9Z6)%
M7$(<1@R&2<#20"W&L\"JE/-)*7-C[YX7_4EK:>F".PFDH:?L6GBFB]JH%;P<
MI&'O91J"P)<SZ*2,:7TV0V8>N58&+W9.AUMN1,TVA_323[K[\$/7'!;_*4CY
M45V[0#1*XX +B/6*$&%"(<TBI*-K28JS+"(XMTH:<5)C;HRAWK#,.OW-!7XS
M&AD?U)%YIC&@78(=+KAN@%:\=I3WK;D!VA"@+?&:,7<%DOXRZ%R4F#JC[@J@
M3F387?,TUPXY[X0^_E_=K;GX\7_%RR(BA.8$Z]4/U;G &89Y$C,8I)DDC 88
M,Z,F=6<ES(W'&B5!JR6HU01*3]M..(= #M.6%WA&9B1K9!PZWIRQ_HI.-X=/
MG+C#S1F#CCO;G+O0;6ESJY[)EZNMCI3_JK.7:A?&[VITWQ>/9+E>$"3"4*88
M$DX(U+56(4E%"GD411G*!2.1D1?!5.#</O.^OF"O\ W0*H,_&Z4MDTTO@FZV
M=/$)Y<B4<"6*UFL14V@\K3HNBIMT?6%J_.%*PO@^-ZKY76E/JN_WY6=2;MI_
MW+)_;I=-H<"/RQ_=84[]TU+P<)&3G'$<(^W#U&<JC$&:B@PF<1S$E.B2?L*&
M?1QTF!TA[=75YZ]U/9'OQ8H#HO6V(R*7(3'CII&!'IFN6H7U6;?6'W3_[EEP
M VH;VG-MT%GAC\*N0- 3J[EH,"G170'1(?==\Z@KBY;\\M(FD-=1;:7XYU:L
MV<OMCV6UX&DL<QJF,"9,=P?,)<P#BF"8DX@A*9,HP$YE1\[+G!O=]?0$.T7!
MGUI5UQ(? X ;GAGYA7%D,G-"T+T@QF5,?)>T&)#X-D4I+D-PMJR$P:UN=/-%
M5$+=I#,+WHMGL2KJBG/MJ5#C'EN@A&=10D(8I &&*$<!Q#Q.89A@+*ANM"&M
MBB8;R)P;W70JU^%'/:7!NZ*R#48P@=R,<#P#.3+AG,6P57B:(  +S#P1DHG$
M20G) H)#0K*YU?'D:;4J_M*UX3X6Y3NUGEIN/A55U;J 4<P2C' $HT27;P\R
MJ4^3 \BS$,DD9ID,,ZM3IP%A<Z.@G:YUD@@OMG0CMRM K )2C5 V/&;RA-W(
MK',RM'2G^PUH5 =:]Q%<\28@^3IL&A(U[4&3@=%'ATPF]]@'RG\19/6ATGTH
M="7<TS5R>ZTN[V57A+=>]F<Q25F>4!A'40Y1'&801RB$/(]"GJ22R-0X5/XJ
M3>;&1?7Q;"'!KFBZS<;K^G$9)JA)T1[[Q,D2:*NH=B\@71'7?IW\R2+;O<#4
MCVWW\T#O,4MJCTG^2[&O[@C<T!\.:$)3!'F2)1"1E,(\0D3]+1 1IXSGB96/
MST+VW AO,)JF O0%U/J#V@"W8RB+@3$\CAH'[I$9SRO2/H.5SF$V?H32D>2Y
MA"6=@\0B%NGL(ZZM<UHW\/F%5(+K5O9J>]KD$)6E+H*A-ZU*]/Z:-GG\5I=:
MK<O_+0*29Y(A!I,@#R!BNHE!Q&*884[43E/M. /B5O3T2LWF1HW]-+U:;4BU
MWJ!O'.A;I[_A_H5=[8/:Q+8>IR5Y^AMV,VI]D\$<>Z-\-(Z_F([C+P[C>$4Q
M54^8>Z^L>JU>;U1FU1.<YVNN^A+@6L.C7#X3';RRZRO1\Z74!;@7 28BC)'B
M^3#4A8MD"G,419!3DA(>YT$86,63&,B<&XWO5=Y5[GBY 8\])^%2JVU;RN,R
M]F:,ZQG1D;FT!^:G/9A]C^O=()@.Q3N,X?%6N..RQ(F+=AA#<%RPP_Q6U]1
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M82OHC[W(PC\H<3Y=K'LC<*AVUF>([*NEM1,GYWM;GQ]BP";73K;L=KMVNR1
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MJJJ0$&>%@$14%%98%4G%4<6]^[CVSO80CMDP;+M]*X_ 863'9XUX.Q$;&,S
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M)SVY+Y=F&]29<31]W[5QO>R4HFROW2?]M^^_6_T?_8>IT_3]=_\%4$L#!!0
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M^+/Y_#3,WN.7Q7(]T<5;CBZ %M*#XLJ#3PHA9!F%8E9Y[9M(_NJJ>R% ](^
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MNM5S2&EY2G3<VN(D\<#I.B[ -'D0BKQLB#EY<"[GK+07+NVJ03@FRKX'>=W
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MKHTS")3:": #-/T-Y[@,LUK2FT^F\VGE3ZUI.-^.S5X6XP.8%"0HG>N;LV2
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MB6M.WK5BX&T64'@(,I8:+6[]SG,_-7MASO\@F&O$]!^\ OAZ)?2BU-CAX,7
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M\F$Q)Z6X^OGA#&<K4HMO_O=\^KTFWW_Y64<1K^<=&2MS3MI I*] Z< AQ,1
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M%ZOI_ZT%.>%<!!_7CD5MSF"JS@Z:?%67HA5,9LU:Z[=]]]JI]]<&CD<18 =
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ML3;!T$;$-HJ3_F,^3W].S\X(IG=7KJ-XS^;+^@+H:NAO"DDPTD%)K^NIC8;
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M:H:4L& D*$EF:PC%@HW,A>!TXGXKAY@^]0; Z+MK<-U:\&1J&7:2YOQ0UO:
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M@1PFU2<@L@>+.P#)N_DLS6>_S>@3 \[^\[[0+G*J]+S[[9?W'R]U8XRI.%Z
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MOY9LLO$>+_^A,=<6^'L H-O2MO6=MFXS54G.L^4%S3_J@,'\Y[R\^=_S=9O
MVK2*N/7A#&=TL2X6ZRKU \K>FJS;IB2N/0L:E<M=AX?7K].OMO8Q7_3/J"7=
M:T"&NOG+KL=7T;EDBB/+)D-F]1$3&2* J!,X,G8T3W1V6.L4XV$[;A<UOHRX
MWQ;IJ_I^\,NZ3>#REY_7?[/9QZL_<9$N;E6N?2Z).U(I FO5JH$@M0=GK=$Y
MT<$OK5G7;/,CS[@X'F8?CR@?4_P=V#-5(U5G9QV-6;=V2T8 $O> +D$)S@</
M,>H0G6."6],8NC?7[R5<>U0(W'UHOZ\\.L+2QG&67D1OLH,2:OOI2 861F&
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MY4.PJ=]^\Q>=_^DR+W^;77#@\WR%9[_-5HOI;#F-_\*S\SP10L:<I(>"/M7
M40!GBP92":$H@\%YU\OAV(&NSNNJ.STT0P&G@\-T52>3%S^FF_K>>RSZ8S[[
M02HC7VB/Y9KLF[^O3WO_F*_^)Z\^YCC_,EM/2\!,ZD1K(E_4]Q$ITU<));G9
MD2=MDT7=NGOP8,1T7A ^[+'I R(O^:Q<:).W\\7F1_7O^$0[$PRR#)$L49*9
MU^ E?5ND5R$'H7-L;9\=E\*1??P7>JH.!U,'1^W0J_H?](>KJWOZW[GZ?<3%
M'WE!7M_ZE[_B*K_%Z>+BUL8BDN!<@N:^%JUC!(]&0;)><63,"MVZ,>*12=SJ
ML)D7>MAZAM.I=7JZ'(]TAPNOELOS;Q?<^B?])\--B=INW:-,B-J#!9WTAS(6
M,?F:*PUUFD5Q$#B!E!4MHU1&!]GZN>]+Z0]E2S#6D7_'UVK(903DV8)/BEFO
MA8[8O)O)?_M#[8C9X?I#[2+^#NRHVVUC,,F4LDM03,U].A;H,D4+5I3(HLT)
M0^N7(R^R/]1.('BR/]0N$ND 3H,\35<\I1*SA,(]'6R,'(+/C$YW45XFC86U
MOHQ>>G^HG6!UC/Y0N\BX YP_WFJHZ*@Q&PW&A0PJ% Z^]FMG7#&F+9.V^5S-
MOU-_J)UPLG5_J%V$U@'Z&CC+*OA@0N:@=6WW4<ND0@@>4E*H@RL*>3>YW=UJ
M?DZ@*<8AYL&19=\+VO<I[+@*M]SPNVNK[=HFJ4[-XY-(YQL#4Y!DL;4?A2!.
M, &NH*Q]<*3'UBFHX:CI7-LWQF6KZI^V(.GEN.PCB*<X\:\YN>#3L^GJYT=R
MQ2<\FX*8/7A3<FUMEX@;18$6TBB7B#&NFVCX]F2=?,'0P0>H(]B\M)/T<;K\
MS]M%SK_-:(-YN5HS1&JF7! %B"\,E \:D#D)/I(-&EPR);1NPS\X42=?0=3-
M*3H8,B_M#%VJE5^G/Z8IS]*:(:@XKRW#(%I5&8*^MEEUQ!6?@RUD4C=OR#PX
M42=?3M3-&3H8,J>:?;T1Y'@55T3]ZN=P*=<G%CM*GG5;8OM(KJ:@A1')@C:2
M$_RR :?JX#,CT#IEG62MO<Z7DEP5(NFL<X;",^D571($)#7#D&GCH\Z6_S>Y
M.D1R=1?,#I=<W47\'1@_MW,N(DG,S#KBF:5;QVKR?A*+@ &12:$2FM;'_D4F
M5W<"P9/)U5TDT@&<!DFHH(Y<&F$!)?%094M?(=E"HFB&A7L?XW^'[^R67-T)
M5D<9OK.#C#O ^>-Y.M1<1:<%"&]JB2<&8BK=1X+I$)D5@N7_#M\Y$DZV3J[N
M(K0.T-? ^_7**,:+!W*"(RCFZ89*QM9QA2RPHK'(;MX&OKCDZB'FP9%E?\IH
MWQ2^OS]?+5<X2_7M_/SL[.U\47\YR5%(%,*#+7S=U<(#>FG <J^28)X42C>#
MU9^DI',MWQB/C5]%- #'RSHB?YQ?S"107C)%%J'*48,JVH-C4=9.AR$5I5#9
M;M*GCQ%QH@>C(3*'.RQ[P&3O<_)]_6+ITPH7JRY.R^V75/]8S)?+29:V]O9*
MH!+Y4LK6EGXL:8@V&LEYX3'T=IL\0,:)EA?T>V(.A<H+N%M(#"5/5^>+ZYX3
MD\*M0\5KJ\(LR "N<U%\LL"%I_]-CLGF8_(&(.-$RPCZ/2V'0F7WT^(O3LLL
M?ZD9AC;G93WF:;D\S^G7\\55BZ(UX;=FL%ZV8DD3ZYB*/"@(%HGGBM-7H;X-
M4S7;*XD%JKFQM?,N3S3A/R#:AQ5T'V!N;C%&--Y6$[&D.NC5*P[>>0F,>R-8
MDEF8;JKZ#W(L^FOZT:_B/PPF!SH6;V9]G)6-FJ@1P@T3K LH6.W\'UD )1DQ
M0<M:V\V=JJ-PM1ND]K\E$2?J4O01G3H,$B_ >;BA&.XTJKB\5#\LIC%7/58V
M>DPC<FFYA11\J?/#.01'&BU)BX(C:;-X]*>XS:D\4=>CCU,U,*C^/L=NXI(.
MRKH$4DO21K6S19U ",BMD#*;9)M/(#\2:2\F=CP(PL<YD#O![72BS8\FB[=I
MW'6;0260#5\+QJ,F\UV9','Q6C\N4(E85"S';P'7CKP3-24[/9,CP>X4;L?G
M6/- G/))_EA,&&J(GW$4Q!_GP45)RDM'\J[1Y>1:]RPZ-HTG:I">Z-D<$H O
MX8#>ZW+^)'>"YC'P8FI_2U)?46APC"= 4732S*0B6_?#.2Z%+R9T?Q*'<SCP
MG<+1;&3J1^.XSA[!1_J'Q!4 O1.@57#"NA"<ZRU#W-*S/(7D01>'<02XO;QT
MPY.LX9PX(0L#IKVKPP8=^=O$'U,<\SRP4D1OE8!;DG:BUV(?0=0AX/,"[K=7
M*:VG%>#9]6O6ZR>J*OMDN$P045M0&"0@J@P)%5<8BXAZJR''1SQ+3Q)THG=9
M'R>H'51Z.3?A>6:$G2_JC[D^_**?OY[/UJPYQ[/:]4Q,-"O(<F)0DC&@'"\0
M5.:0#2/%PKF*9I!,WW')/.U,1$.0MVJG=R3$O8!#^?@=_QB+^"3(C%X8 2K$
M ,H+ 0$C0F1<>L>$M[*;0;7[DWG:J8A^#^70B.OE4+9Q:>^,;329K&N.!:31
M&90,#@++&ECD.I0H1$C=M!E[CIC3SB<,?,!&1T\OQZB-IKG-"#Y1O@075 2I
M7 W)!@XN<@')J<(8=\7P0;RT0:@YT2#'*=U4A^#GQ'KW?<S$^FGM5D@ZY$->
ME/GB&\[B14N-?\ZFJ^4?2"Q<37_DYJW\]EA[R,Y^A[*BCT9_I-RU4-R!54;6
M?L<.O/06,I.6J2"LU:WS+"^ET9^2)C*/I&Z<).V3929G$#WP$@)#IVU6S<VM
M_S;ZVQ&SPS7ZVT7\'=A+M_M_L>BE2L1"DPI=4:RV44H.(3M!1'%6A&KMI;_(
M1G\[@>#)1G^[2*0#..W/N">:>S&3$$.=8.%%HG^B!<]$!&9+2(D9Z_Q_&_WM
MUNAO)U@=H]'?+C+N .?75MZU7??QTS\W?>-$1.YM-L 2>2'*9+J)?*"O0@C)
MEY2X:=U%[<D-=9XK&!PO\Z&$UP$2;[H8E8G+#1G*HDN,!<"8D!C$'&#)"-SS
M8+GS6MK6&'QD*YT'Q8^-OA8"&Q%WU2V_3\,OT_G9_,LTOIM&8G%^]?W[V32N
M.;VA+N:8:Y*LSOU0H+2IS: \V>J1%X-%%QGO.)3W_?_]EAY7^361]OQHK!\;
M6)__G'_^.C]?XBQ]_I/8^_,NN559;^AB4C@>LP6&7I,-(S7X' .DR'E!(;15
M82M([;#HN+JL.9B&8G=W,'H_RT^0E@1*I5T&3] @_I%)C)D50/+9DF3)N<+V
M0]*3ZXZ;S!H>3.V8WAV>Z =/D%84)_<J<D")=%2B5N!2G?<;R9K,:+3QSP:[
M]UAWW)S.\'AJQ_01\;1<K":?IZL:9?IMENILIW,\6_ODR=CBHO$0>*Q&I6/$
M,J,A9R5X(%[Y[;Q&6N&&M4[?75OJCR[^4EIH[Q-X:R.1WB#U[^GJZSIP7K.2
M7Z??/\_?S%9UNM2%!Y-C+"6Z!,Z40HP2$IQBIMJ(B9P7(:T?!&Q/;VL<6[T1
M )Z"4T-IC'T7_CI=Y$B_7Y);_#HO5K3_-W_E>%XSFN]+(2]D<:GZ;2A!H$5@
MVO'ZOE3194^>!Y,<7;8VF["=7;7]FATAJ*7,Y\,+H(-8UK_R<C6=?5D?/5T*
MLT%+,)C)=8V<CA[Q"TK(7 ?&@TBM.R??6'[D.K,N$E'[2J,?(&U.6F'&1\$-
M%%\]C9@+!*(<B@RA,*4\ZM8/N6]M8-P(U-YB?!@.>_"T T \<H[6!X7.$ITW
M<E8W2M,K%JV1$HJN71&",5!O>HA1"Y:ECYX=*=WXT/:Z -,^(-@NBWBP1$X"
M;.3);DC+OA 8R*YDT3!0*M9QPTR!L(&[X(AN<:0YZ@]M;URW\)A@VT\B(SM]
M'ZL5L%;L-AIC4E004I:@D@N UAK:='53BE&I;-42]AEW[FK!D<N'1X\7[,?Y
M'N!R&2VKG;AL$F!US6V[:"'D+,#)F%U4,B6O6P%F;,]L3V'=%?<>G!M9X+]/
M9]-OY]\N$SB8F%0R@I=U$#)Z2<Z@RN"5(C<Q9DY7:0.1WUIT9*'O([)Y"_Z-
M+7C\Z^;&&9GUIF(=!5G])7# ' +8R*03,0H?MGH0_9S@;RXZCN703/![\Z]?
M\W.7_@<V(D8>:V,.KD%Q$0%]\F -C]K[:)7IIH'ONYW&@ [7=:*+F,V197_*
M:%__LW$Q+AJR<6*]],'+ +Z.856*D:HPQ KF0BE*<^;T5E;1,7#_P/X[K_-L
MC+U6T#\4"*=\"+9IZKO^Y:^XRF]QNKAX%"R0[D^/!I*1JOKB2.PQ'!(RCD$Q
M'N*1HA9#D=AYT6JG1^D(<#KET_;F?\^GJY^_S9:KQ?G:$'B_^IH7G[_B;,.X
MJH5RNF3<Y_D*SZZYI#-*A2)!TC4 QE@!IVMN6LI:?><QF*.WBQZ$TA-M\C#R
MV3L>N$[Y"%[,2]H8Z<M7YZNO\\7T_W*:F)1LU"R!QCKGK(Z3"+E(T"P(0XX?
M>8O=G*['B#C1I@XC'YPFD#CE,_&LYOAC/ONQ5AZ;:6/<%.9E"J!=(#$Y4A:!
M:_JV&)=XY$+';CH*[4K<R?>N[//R.01"O9RM?=K"W'0N/U8[>$G7;ZR0^I(G
M7D>II#,D&S)YE?0(0:D F)- [Y0QS0M3!B%DJS-C7O*9&14:8U>$7F_[?7E%
MPLH_UG33-Y7"BU'(DZ"*EDQ%<*E$4-HR\#9$T#E+RQ4&\OJVJ@7=9K6M &E?
M&""'D<78X'J8F6_^JE_FS<";G-XO/A*EM&":,%1<.LT@V#IU2JS?YMH"40B9
MO$K6:[\5T'9=>2O0N9<(ND%E-#8 '^KA1?R;GZ_>?_\^7ZS.Z?N?DZP]]SP;
M<"&6.IA:@.>"G.A<T%O#M,MJ6_7V_');0<V_1*BUET8'UN6;;]_/YC]S_I07
M/Z:;EVWW^'ME0:]9N5S';V[^OK;'^F.^^I^\^ICC_,NLNK#7GW3Q']VURB?*
MH'.91V!H:ZXQULI*92#9Q.O[@!ATZRX1HQ&[77:,O;!3,SK;=\+8B?6]_'3^
M[1LN?L[+\UT?F_>]W&/M(?M>'LJ*/OI>.L6S(]\*1+TS5"+K!$L($*-QUG*7
M9/,&>"^E[V50-FOK:IV*-^14T(''& /DP(11F?D@FC^;^&_?RQTQ.US?RUW$
MWX')=;L=GI:Z")TR6"'HBN(V0#"&+E:/*%.*P3G3&+LOLN_E3B!XLN_E+A+I
M $Z#=!ESM$[*3@$FLO14K.5(/GAPW&KD2C!G^AG;?AI]+W>"U3'Z7NXBXPYP
M_G3K1&U"=L$@")[JR!7+P=G(H* 2Q4M?G&K=-?SOUO=R)[SLU/=R%^%U@,3'
MV@UEB:H$IVM_(6*0<PX0K8# BC+!9G*@6YNA?Y^^EX>@KX7 .L!=@S".4E:B
M\1Q4(#J5P A>$"LY9U%&+^F@=3,Z]]U.KRM.H$/4(2;JD65_RFC?OB#DX_SL
M[.UF)KA5538JTAW$' G'<0C663!6!*ZT<,EU\^YH+PH[MT@:X_?XU47[@NGO
M<=0VM5<"<W"%9"BUEJ!*DJ0"L=[G3M,=S+D:9I!9-^5[_1VP(R!\M%*_7>"V
M]SG\OBYJ_[3"Q:KSTWC[<<PD,J<=%@V2EU G<:A:>,_!!+0NAX*2M>YS=BS:
M.G> _@YG\0"PO>@K\?9;F(GUO@2M-;C:T$$Q)<'SX"#%($SDI;3O$'<LVD[T
M,=5+.H0'@&WW0^@O#N$L?ZFYP\Z/X55MX+6&BLIYK+V[71V2FAFQ24L&**QQ
MF?LD8NN"I".2=Z(/M%[283P,<B_\/-XUW='*G&1RX",R4E7) &**D#D&P6PJ
M/K;.B_?E*?;WT.LEG<5#X':@I_AF-O)9W+#@_?EJN<)9FLZ^W.F3L)DDGC\L
MIC%769:-+)W$<O$TR-<F=M5^<+55"1D.DA168+J?(.G>5)ZH[SARH/0XH'K1
MGN&53GJ^;4G,A=1F2(#2JSH?DKZJW?65+T)I[H4RW73!:4CWB898CW0VCG]Y
MM@7JWRX"^SS[I$VFD'<.C)-;0$QS0#)G-72F-%:7/733%:XU\2=Z#[^TPSXD
M9%_T=7X[]O8\XW26G@4RUHJR9+O)'"'XHB$&423F*$LZG=SHCL2?:*CXI9WU
M(2'[HL_Z)K1W3L!]GFO&("(I0S*'2J9_I(0@B'4RFQ1"CD$U?_+1!^4G&H-^
M::=\,+"^Z".^@]-CE! \1 DE\T1J,11PA2LH)ND:\,=TBDW*VASO_L+:+^UX
M#P344X]Z/\NW5RE-ZQ=X=OTJ]OJIJT)5I]0IT((54)8Q0.8#Q!*E2-H&:[MI
MTGD8J2=JB_=>*-P.7B_ZFGU<#7_,]2$0_?SU?+9FVCF>?<X+$GA0*2K&(@BK
M RBCZYQWM, E]SD%Q:SHYE7+$ PXT;#X,8_,T8[YT/CMY?"'YYD7=A?XER^+
M=;7*;\2AZ6PYC6L[Y09/)\(%7U2IW2;JC,3,$C@,&JQFZ(H3QK-N&I<VH/=$
M@^!C'^U30.>)-9RZZN)5?_OA?!&_TE_41[K-VTL]N]*0S:1V([.3UE'$3\^D
M!,NY)S>.%\#L"FCMBC)68?&M=>)+:1V5?<B\V 31E=H.E-R$P(E_W!@9F>0Q
M8G.W[K^MHW;$['"MHW81?P>6UV5/A'5#&<=R9JX@<9#5YH8.P6?!(;DHZC2C
M[$WK>O6;Z[^4QE$[0>!N8XE]Y=$1EC;]-:SB/&O4$!766":9+Z$@@LP)BRX!
M/;9.2O74JVE_23X"B3W8.G:[Z5=K&TDP;A\U@C:-4RRSUAF30,M$]KGR&H)P
M%ERD(Y,XRYC"<[;?;DOV@8Y]A#H?G,,=*)/;K<Z**)J1*P1210[*2PY>Y ")
MA<03U]S:UJU,=^]I> (-8PZYFO:72 =PVI]Q3W204J3(.1H%V1,/28E[\(75
MQQ[2Q^PRVG+TK.R)]S3<"5;'Z&FXBXP[P/FM6V"C^6/VI614Y FM!PAD(B%:
MA)Q3D8&99)N7_#ZPC<Y3"H-CX[$6]GL*J@.LM4BL^L@C)Q(C.>=T'QD#P6@!
M7)B M85IE*V;;!Z^ZY'3V5T8 T>6_=B.S.,QW.DRSL]GJ[<DI]]Q\9^\NHC@
MSX@MW^:S]=]/;)1"Y)A V1K#UUZ!E]Z"]A%-UEZ29[B5<W/0-CI7P(T!,Q]%
M>MWB]#U=+(OI[,NF34!AN7AO:W595J!,MH!B_4Q9:>N#=5)MYVYON>"))AV'
MQ-X!$ND69?]?>U_6W%:NI/D^_R4CL"\O':&RRW<<X;KVN%S=T4\,+ D7NV32
M34J^Y?GUDR I6=;F0Q*'!W1/1(5*MF0BD?D!N2"7W\+?\T_7GRX^U4-U\27,
M+ZNB^;!\%U97\S3_7.M^:+__B6$U,]YE$XH $8PCCC(%46*!X(4,2:5H[D^
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M6,8$Y+P[[I7EB;7N#? $*5-/-V_N<[9@>9_(N>G[%I'<(9Z RZ2))=I#"$5
M3$D*%T7FL75&QY/$3&OV-Q'UC^%S -_[ ]#N_M16,)1$>DK>@4J\)O]%1=]%
M8[(13(G6+<D?):0[X!PBY.>A<P#'ITZPJ&..-B=(>!FU*0KJ0SXH0<:B5Y)#
MUJ&85'0D7=LB8^)FP6F'][1.R#F(C3W(_@:R@2=O!:=#8 LHI3+XXBV@Q6"S
M<)SY08/FATA_:LOV0&'=%_<!G)O:#=^V.MP1SI&T(BI6RX-K!ZZ<(:#SD+$P
MXW+!' :U8/F1DWUWT8F%?HC(EBWX-[7@P]]W"$=DOB !/@B?:TV1)_7D)42O
MA,K$%QPVU/5'@K^[Z#3)(LT$?S#_.K *'ZBZ-[?5(-Y%IDI&",F3>6)\@L#1
M0/"N".5(%;)!M_XQF>)O]JH[MF=@$#1F? <0NEAA>%N^A8!NPC\S\K9LO>?
M)DNVLTBN/HE8H(LQR%*<,:(U@)ZBI;,$[P-EO1R!\=T Z$U8U,:?WHAB UB)
MK+[X%G!:!2A!H>#&9Q;&@4Q=O;.<Q98@V9NYDSY,WC[C;LL*UQ^6%^F_K^<K
MK-OXWWA92Z+_6..,YY*CR1X8(S-=.1;!%5]G']A4$YPDN]_4Y?B\BN=)ZBQC
MIPV$6HJA@^OFP78V26[SQ<?U3!KC=+ *T+M<,R\UQ!3(B%>R,.5<5KGUB*VG
MJ>GL&7LD+!W&_*G34$GASC_5PH9M%^'+4,L'/RP?2YJ<A<C('JQ68D[UH973
M\5"9E+.U(JN@7,9[;SM/Y*7NL6AGKSC'86=4CD^-I(N<YY5-X;)N;'VQ7B]K
MG0SF_YA?_?GH[K()R69B88R%+EF?//FI=%A2'8O(2,=++(/PM/?2G45E&Z!J
M7.[WH.R>RH2[V7EE7F'6.05,^0@J>>*;1 O,FZ),<K7SVZFR4V^IZLS?;Z3\
MV@JC9WC]8[5<KV?(T.KHR0<E_0VJ=O!SF0X+#T9X:YFWS8?#/$_1(%BYGP56
M^PNA TB]KGU#<'VUN9!?A,_SJW"YF=!@BK7H& =&7T$),A*]30Z\$#ZR%&UH
M/L#T*5H&P<B?&8R:,+X# -TI.[ZSB^]V-S.6":V)16Z7-I;!.<8@*JXP<F:\
M;EU".X"L85%*=F:X:BV/#B#VCQ7=M.OWF'#^9?,24)RR*<= SJJIG;,B[<05
M ]PF%H67TI36=]-]&H:!Y]QBW$=Q>FK?[D58__E@ X$';CQW@+ZF%:@BP-DH
M07H,4BE=2APV+?FQ3Q\&@G.)8;=A8@?WQ:8M&N;U*^+89B_+U9J0'%/T)@ J
M&T#IF"$X4JNL-O7,:(RX/S:[A7'\@(YAD#F[F/6Q')_Z[KA8W$P6S0-#$_^)
M8?5V03=D[1+@HP?A@@&5:QX#\0VXIV,A&09FTJ +YF 2AD'J7$+7)Q3'.7;!
M?!7FJW\/E]>X+"\Q7KW$%=W1M=7CFWG8S,FM+?5&:8&YS\JC][\\F V3-+_,
M CW7V4/1*$$Y;2$:75.?DHB"M*L?EMZW5V[/"9M?WDJ#SBEN%KPCAM\PU+5R
MK5M*UZL5T4&_\,_E8G7SQU_">K[>YO@4+P+6_K7&U#)AG@JX$.G:P,P%\BA2
M\S:AS8B?.NME+$3>5_;32+L#N[+>-*\WU7&WS8/(_I4R,P4FU0'D@3REF"."
M8SQ[5,($T?ID/Z1B6N!-!(<'8V>/DDUWZ*J5G;NBF$+[P. -9&83J%H_[(J/
M=3PS1L-"Y*KUB]%3M$R+M&-E_"QD#F3XU([+"UIO?G6O)V,4VGNE!##E: /9
M;D)[G/Z8<W)(]WX9UNORL4_O"0.'"FW9DH-]0> #N=_I3R1?Z*9F.]KH!)*"
M)\I!818U/55 49S%I%"$^W,I!X'A_CK3P**1!)_&PU'L[!(9'_ZUO!E*R(*,
M201(RM<YQ:(V#R8?7=027=+!B7Y\.#)NUYDFT?=4R#B,G1W8&Z_F"]K /%S>
M4ZG16)MKR,3K6IB#BJRP5#AH:4)0.DENF[M@CY,R;89X'W9M"REU +9Z6-:T
M<F7C=F@-L>AM>61WZUH.OG[\1SM5'XT0T4L#+-3!.8YI\*9VV227-B47BS"M
MFZ^UI']B=ZT%H):=2'=J!?MX[/%&T=#YMMZ0#1I-+5A3-16(&PZNYEXK+8/E
M;I!^?7:9:>$TG>B7H\BA@[OR5O'\\G6G9C;3OE:;YA9IVTXLTRG%VC\L6<V(
M4YMYTEH2NX+SDHN,L77EU@"RIJW'Z41A-Y9>3X!\;$.[H^MI%R'$>G21W"+O
M. 3C,B O-@C4M*U!+2H/ >339'42&6T%A:>@UD@NG4)M?7MB;QPMD9.M8]')
M=?,U0]*#,RY -MD+J4B+N-9=E(;0U0G86H%A -B.DDQ/:#M"8]S)=C")*>D4
M\501=PWI#Y=J$^VB4ZXQ(U(D';Y=OMFKZ<-H:22=:>^3(V)J5^:?U_4$ORWO
MEE<D+3+/?\>KJ\O-,?\]X2*LYLOU3*(*/N8 @<MZ@4@%&\-:F9",=RZ1$SG(
MHQFR6B?WZ>F1L!Q3+%/C[/L'G$U>^B)<O@]76)MK7%VO%G\L2+*/;5,[;R3/
MBHYS#;WG)&H#F "\\.!U4)S[8:68A]-P_B')!I@\D0C[0FKMP/!A^5N@[=7(
M0O@+_^-/6FQ783]S*DI;ZO3NE"006XF/P3D(,7!N#8O)#)MOOL^JY^]O-T=C
M0S'U8*#>Q,KN</:6[=_2NF:21QY$E(!6TK88IPURRT"J;#@J5PRV3D,:2-KY
M&Y7'071,29[3!7EQN=$2-3R[41A$\!8&LQ+(3XR97%'O:S$:<]MB-&368B3.
M.LF;WYQ/DC-M*X_I\3J18+M-Q;_75?J(U/HG/JE-JOP0,ANEOM];:OTMI[CH
M+*1PH'T@N#EK($8I0%K.A?66&]UZJM]3M+1N_[^)*W#'R$AP9+&*.A^MUI>$
MR#PY70ICT843H,?=7P=IYDVD_Z.N_WNSNP-3[:EI",)P45+)P$PRH(2,]4W3
M M(?BR*VT"4Y,FKVF35RLJ;_^\MXX*21?1C>)VYVT7K'DF%>)\!4R!3T1D,L
M14/BB7$OF(YB[/NF\TDC>XEZ\*21??C>'X!NDARYM2QQ#]:Y2(ZN*1 8\2=D
MZV/VQ7'>.HOOK":-["7D09-&]N%X?[#YYC4(EKP6*H"RSH-"9L A1\C:1ZMX
MC-ZW[LKY%"W31EO'UEB'L7QJI[\VB'B)GY?K^17FBZM?PN*O%Y?+->9?OKX(
ME_.R7"WF@7XAK#;%B'?RO=ZMEE>XF2M';NOKQ6+Y9>LG&A]"RK1[+*)6;EA>
M1R,Z8,X[%-+9H(:%]9N3UM7E=2!<[C?WF$YV_?KXZ4_,UY?X^G6-O6P^+RSR
M_[FN+/E:HRPI+:]KEN(1SO^>2S2*"ARSL2/#!756Q^VJ%X^M>NLZ,N9D$,6#
MMJ6.<%8U4+0)&66G<R$4E19#4(91<\QLE^=7^!;EW:H2Z51]F*W3\0J=Y>1J
MGH+A@+YH%:41Z ?5=1ZU[7M$33<4: 2LW!T;,YYH.K#EOFWN\G+Y+[JQL8:.
MWY/P5E]P?>LN*2Z4S=%!E+$.JJC)_F@D6!5#808]-F_#-XRR7E%W%"R6H\NH
M>^3M?*ULB#V:=B(+)YLY"@->!@O"1F>%*G1^6R?&#:%K6NMN##SL!;D#A-,!
MX&ZW\FJYVM9COEG>CJ>.1G%/[C;$S&HG>BG 1?+5M G.1"L<WN_5?GR?T6?H
MZ1E@ATC_?J?15J+H %8/F?6VO-R1\B'\O7V.W6U-2G+ 4'.0*0E0W"@(#G,=
M*:O)7K:D!EH'2/8@;]J8R>B@&TM0$T^%'&J'W D"N*(*5P88EZ%.V380/;G?
M"=$(IY7TP^8%-O(>)H[9G<:6&U]275Z%=X_P+^&R_M5,!.YJ2T5 P10HM 8<
M]P:$8=K4F=LEME:U@PCKWY4X$!A[V7:'2.E@Z'W&U7R9?[\*JZL3 /#=9K77
MB[3"L,:7N/W_++""R>H"9%I84!8#N*0<6(XR%A5<2JUKP@ZAL__;\13P;"##
M[B_*EYBOTV[*3*F-R6*DC;BP;9\=O)#@ YDZC"P?;5L_Y ^E;9H,\M[P>*"L
M]L>@WV)P@1]K+^,3JNN<T<3ZTEV,J:F@9=.UJD!&)ZV.C/ZF=0_!=NJZ>7IX
M;_@[1$I'JNM?%WG(B]KN!_5+I"OZW_[7_P-02P,$%     @ T(1N5G=D".X<
M!0  <A0  !(   !A>&=N9GDR,7$T97@S,BYH=&WM6%MSVC@4?M]?<4IG6S(#
MO@$) 9H9 LZ$;0H9<+;MONP(6PYJC>3*(H3]]7LDVPV$WJ>;[G3*@P?KW*3O
M.T<Z5N_1<#((7E_ZL%#+!"ZO3B]& ZC4;?ME8V#;PV (Y\&+"VA:C@N!)#QC
MB@E.$MOVQQ6H+)1*.[:]7J^M=<,2\MH.IK9VU;03(3)J12JJG/3T"#XIB4Y^
MZSVJUV$HPM62<@6AI$31"%89X]?P,J+96ZC7"ZV!2#>272\4>([7@)="OF4W
M))<KIA)Z4OKIV?E[SS9!>G,1;4YZ$;L!%CVK,#<ZC _;D1N';KOI>:WCR*&.
M=^C%U&M[M.7^[>(D;53/;3*U2>BSRI+Q^H+J^)VF9QVU4M5=LT@M.J[C_%XQ
MJB>]6'"%\23:YW]S-WO.%+U5=9*P:]XQ2ZKDIJ4X%(F0G<>.^76UI!Z3)4LV
MG:<!6](,QG0-4[$D_&DM0QKJ&94LSA4S]@_%.>'TS.LZG_(1^DD8I^427$]/
MVG]U/CH=!=#P=N>[O6PBKW'E2J1H@TZW9AXBU%3^H*D/_&DP.AL-^L%H,L94
MG<ZN^N, @@G,_($9.W8.87(&P;D/L_[TM#_V9_7)JPO_-?0'@99XCN-!=79U
M6EC,H-H_@/YX"-73 ZU0>G(;+:<&@_/^9>!/X;!AW(Z""Q_<=@VNQJ/ '\(L
MZ ?^# :3H7_P+6B^666*Q9M\B/$(P>VX[?2_3XWF!_$=<0@%YS34%0YKIA:@
M%A3ZG*]( E.:"JD )6="+L%UZL^AJN5/'K<]S^GF<O/B=@] Q-"_%=>4UV#$
M0VM'=2"6*>&;4K<&SXFD'/XB$97T#<*^8#0&_Y:&*\5N*$SBF(54 N$17$J:
M,8V4CJ!]%LYR(<7LA#\L>$$D(YS5MIS\B2ZVK+5Z'N>,<<)#ADLLX^QZK@$E
MX0)0@&0QFM4@7<EL1=")$I@.<&7-K($%LP*X/'5(!B02J=[:MM5+)9VI19@9
MD7/":5:?W"9T _W0+$UG:DU;:)4YS<S@@LHGCYM'W07+X"T7ZX1&UQ0U".+>
M:G=_@AQTK7(1#Q^]FY(HPE.HGM 81QRKI6$($/\B]^-5DFRP1I9I@GEP5R&2
MOELQ2?4YE&F:[C*A2K 2)+BM:G3PGF_,2(FG*'KP;\,%X4AA0;I[W&@BD\==
MG9X_ 9O>_Y)-QF/<P8BA"#<\1= RPE'#3DDU81*Y3G&_T*S6M)@D": 93@;W
M"A2D2#-*M%7\?@]!AY%ID<P.@UJK)$\*D5)I8F;W]A?KBX@^,B0J,D]H*9X+
MB1MF'>%,2)K13OFG&[$L3<BFP[@!Q1AU"V=SH918=G0O<Z-WM) D1>Z8G,G%
M19O3<CW+:^6!L;]141FYZ((LQ\AL%>T+F^W2](/B3]I^4NBUCTTK]OT]NX=?
M,6?;(")+C3+Q"K0BS(,D0W:?51J54J=(R(X#[DZ03ZAZZ:U6WBYQG<[WJ<M9
M>_@B-VWP4/?OYOS1QRZ>E&ZS9OKU]WG]^77N0/(PT/YD+)B^(#//W79JAX4/
M0]ML/SBTQ=YEMK84P1()BZ!$Z2MQ1R<_"/1=H/$;\".=:PWV.D\\7S!\>12<
M"B(C[:!Z*1D>)"F>)'M>#KZ 2K?YPZKD5PU_SQJ^_RGS!=RWW%]E_$VX[V&-
MA?@M'X[W"OA.KFWZ82A67.E;KH_7LVUZM<_W_)6/WCMMV=R[NDI%?G?7D30A
M>F5[EUEWK)H>T;DS(7.D=J7V33YS_U4\\]LX<R]X\B]02P,$%     @ T(1N
M5L].KKLO"   <28  !,   !A>&=N9GDR,G$T97@S,3$N:'1M[5KO;QLW$OU^
M?P6KX-($T&_)MBH[!F19082FMN$HE_2^'*A=KL1ZM=R07,GJ7]\WY*XE64IL
M]WJ.:UR!.M)R2 YG'M\\4GOTP^EY?_3KQ8!-[2QF%Q]/W@_[K%2IU3ZU^K7:
MZ>B4O1O]\IZUJ_4&&VF>&&FE2GA<JPW.2JPTM3;MUFJ+Q:*Z:%65GM1&ES4:
MJEV+E3*B&MJP='Q$3_!7\/#X'T<_5"KL5 793"26!5IP*T*6&9E,V*=0F"M6
MJ>16?94NM9Q,+6O6FRWV2>DK.>>^W4H;B^-BG*.:_WY4<Y,<C56X/#X*Y9S)
M\$U)[G5$<W^\WZH?C%OM*!*=5KW=WJ^W]Z..B#I!_3\-.%F#N>]C[#(6;THS
MF52F@N;OMIO5@[W4'BYD:*?=1KW^SY(S/3Z*5&(QGT9__]$/LS68%=>VPF,Y
M2;IN227?M6@.5*QT]T7=_7=(+96(SV2\[/XXDC-AV)E8L$LUX\F/98,T5(S0
M,O*&1OXNX!/<<U\7WN4#C!/+1!1+:#3)Z<'G=\.3X8BU&M7&IL?K"^=Z@K5;
ME:(7AEWS/4"PA?Y.SO<'EZ/AVV&_-QJ>G['SM^SB<GC6'U[TWK/!YT'_XVCX
MKP$>PV)P"2Q??OC8.QNQT3G[,.B[+JUZD[J-W@W8A][E2>]L\*%R_OG]X%?6
MZX^HI5FO-_],6'[+C)71TC^228@H=1N=]'^?Y?;.0 W+[&>N1<+^S4.AQ6]E
M%@A-#C([Y?;EB[W.X3-89:-:+.+Q9S],>1B"LBJQB/"D7MVC, S9E,\%TV(N
MQ0*L9J?2L%Z29#QFER)5VC*5L+=*SUBC7OF9J8CUKM5$)&4V3((J$O/3<TA,
M\\DEYH0;I .QGRW95:(6L0@GHNSSHWUB0@47$H62A!FX3!A/EBQ+K,X$5H B
MY>H5,L;9#-^T1$XC'N"19FHF+;/*VVT9)"(0QG"])),9OQ*8=VU,@V<AG,&4
ML2MVF(,, JE1W&"6H#L\P4YFBZD,ILQD]&?5?X$]G@]""YA)$Z,*4D%=2#O%
M DTJ N<@C9O"-15BF7-T"]EXN1Z&YP+!UM\'@H)%,D&2"2^KI):!/YBC6:^U
MRR0">7#28/@<Q%F(,0&<M0R6 3JIXR5+D7>"+$$YCE>8S.%@;DT-V(=.W)7)
M(HMA " JH,5-9YP_ 3=3%L5J80J4:C&1QD(96L;IH?<;7I;7P&8*9[:\?2YX
M:S\YO(TVDO/R1:?9.#@T.:)R.4 4H:)(XJM+VY!!-3B (.%R' M*)!- Y3B6
M9DKF9#8#/1)%TO=0FB!6)D,_(DZM8H^45*M A'ALV"L (Q1 FL_^X#J8\F0B
M6 ^<=)G%L&BT>*6Q]TJ\=ET;>Z'_YK]*4IR)1RB-SXBXUH#K@42^W'NB:&.B
M"!/1.F_#&194SA\FES9RT=J_&[25[XA:_G10VZC6#R@.I\(@4DB@*W)WHZM,
M]3?@F;E_%RJ$8P&DY#/YTJHRC0' 5W-I' O"2B1N'!+-*_Y<YV M8NZ@E]?6
M%7S*.3]3HP27PA>C8AFZTZ[)QD:&DFM)"Y!> ;BJD-!(F:&J[':J<27<<2:.
MTW (YUS7*>7 ?)#%G*@>RW).K*H[>GBML"YQ\&DLR!!LC/XB?!C[_JV@/7XZ
MT,X)>1/9]V:U+8#?GP_OC7/LC;D,";[<J(03\7,#Z)/T)$QS'1;X N(E'\M8
MVB5)@%W3TFYS4'0H\QMEPW1-NKKZ<ITO*,UT"I0;)UF"0.G0.>!$+ Y)4"(Q
MP(X6D=(N(A,(= ]H[#:9@N*?,:2#IP/I@JT'<QYGCM(HX2**("SE'*DR.P3B
MC0:Y!T7[K[LUHX,P.H)>C5>F8Y79KWMPGR+";ZP%R>[H[I,2&Q>"WNU*X2,!
M?QP":8+GB<+PZ:"P(%:?WVV<T D^EX"N92<8'T"G) -4$&2:T+!6<W>,.E/&
MXCE=EV(L$V"@+QE*-H9^]94N$6 -HKMEG3N.@Y=PEP]T+^'ND[Q?K[U74VYN
M! I1I-L&(G2UP\4CY_4EB^65B/.;B%OVY?\Z1 ^'_M,]T>T].9S_N1.=NY$,
MBRU27M$6L>@Z3%<,1D![@#[9TKXWKG'H7ZNTN9$$[@&&G,VDM4)\HT:,%40'
MM8<2_KE!7@',H&1#E(]_2847.U!\R23<=[LM2P)W8?'Z_P>WQY0"O1C"#K&2
M !\=G^D@'D@!M.3E_.8 M1#\BNJS%WJN0CN)ZFY2B_NF!V$P/^OXRXL=5,=#
M=#3BANF^BM=<V*(+0 ?]6?8BP4 AF&P&R"!*;C%YA=EY,_?,!<#3.UGU4.<C
M#6XI PC"T2&@Y*["<\R5?9F4R5S%<T&U,N&3_$9?YPPJ9FFLE@*MBZGRM,DW
M$ T$_B5"HGHO7+A-=63=82QO'@.10E<0ZIBG1G2+#X>@]S3FRZY,7,!<I\-\
ML+&R5LVZ].OUG&H$Q$4.+ <HWYS_L+W7:%:;>WYBC?_#8N;\=^]JW;75;+C=
MV.X477<V?[/O-QN;G9_<C^]__<B-_0?X7',1T85% <H\6G1*B$W*DS>E5JFP
MR<':K;/&QB3?,&VFUV2\OO\)ZK=3Y[/V^ 3@7GPXQ:9RM97]PC5HM]$NNQ<T
M;F!]]S(W(O(XD7UF27CYH@W2<7\W?^O?R,+NT+8ZCQ[:G+H<LZ4(%EV%LB)*
M#XP[!OE.0=\,]%@?]Z=21&QP+8*,;AW8N9?>97:A(6FH5#NUT)]R"7&0%'KW
MA,3M=J)JCKCOU@NEK[YVM-;GUIM+J?*O;G7]E?5<;+W+M$J5*QCU51<^1KXR
MN]WECM>?\K_^92SW6MCQ'U!+ P04    " #0A&Y6=;M/!4$(  !9*0  $P
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M- = I# 5N%KQU(K.XN(8Z3U5?-Z1B7.84SHN.@MTENE)A]ZX3ZE&@%P4P'*
M\LW%R_B]1K/:W/,#&_R/%B,7[^JK===6RZ+-QO;A0G5K\Q=UO]C8/#QR'PS\
M]3TW]I]@<\UYQ"PD%J LO$6[!&53GKPIM4H+F0*LG3IKW!GD"Z+-]):$U]<_
M0?U^Z'S4OGX"<!]K?. &R;;1+KM/299@?GAR=_SP=?SYS%S_\D4;J<;];KSD
MOQ.(G?%ND;-<2DOA+SH#90M'/='UZ.0;^?U/^-JSHEU&\K=S9_]6A#D=T[!_
M8:?"K@SX'_$:1ZUZ8REB=KZLFY=^.[/I\IJK<UO*Z+T/S5+MO[3K^-/ZJ=CX
M]&P%5E<KZRL5'@"Q>;:I\L#7:OYW;%:A&8E* ')Z4^$QL-3A:L;GMO3W?21W
MCV.6/JNYBXZK^8\.W>>/I_\%4$L#!!0    ( -"$;E9WI.W970$  &T$   <
M    97AH:6)I=#$P,C-T:&ER9&%M96YD;65N+FAT;=V43T_#(!C&[_L4R,$;
M]E_FH:5--)VNR>:,:30>:?NNQ7704'3.3R_MNL1L42^[Z($07G@>GO>7 )VF
M\UDTHM/)51S1,T)0+//7-0B-2A"@F(8"95OT)-6*OS&4B!P18@1IDLXF$;Q7
M/./:L5U/5UP5S"@+,ZBUVQ]1JW<>T>M%_(RR,I>U5"'>5%P#-N4X>42LYJ4(
M<6XN!;4OMGI;0XC73)5<D!J6VG=@'6QXH2O?L<?C ._R?A?!MIV+EZ;<I?WB
MV+"BX*(D6C:^:QR["Y/Y+6I5'N)?S##27'<F;<T+<##JXX2XRX-1!;RLM%EY
ME^.AC8C>+.Y2U/(/(S+GAPQ+*33IBK[3Z*!GX@]($+4Z242M3CZB]Q&=/B A
MVXH5$)GE03,ED$P!6Y$,EE*!S^H-V[:FJW.1M4VPMQFFGX&YIP3F'@-S_QLP
M[Y3 O&-@WM\#=C!US[[_!;IOYA-02P,$%     @ T(1N5L' %RE1 0  / ,
M !P   !E>&AI8FET,3 R-3-S96-O;F1A;65N9&TN:'1MU5--3X0P$+WS*VH/
MWBH?&SQ (=&PNB2[:@S1>"PP"W6A)5!=UU]OR[*)6:->O'B:S$S?FS<O4[K(
M5LO8HHOY11+3$T)0(HN7%H1"%0CHF8(2Y3OT*/L-?V4H%04B1 .R-%O.8WBK
M><Z5ZWC^;(!"BI)I;-E2>]^WJ#TR6_3R-GE">57(1O81WM9< =;E)'U K.&5
MB'"AAT)_* YJUT"$6]977) &UBIPH0VWO%1UX#J^'^*]WN\D.(Y[]MQ5>[6?
M&#M6EEQ41,DN\#2C&9BNKM'0%Q'^A0PCQ94A&1I>@HO1*"?"1@]&-?"J5CJ;
MG?O3&C&]NKW)T,#?-4B_GS2LI5#$% .W4^'H23!9@JAM(#&U#=RB=S%=W",A
MAYJ5$.OT:)D*2-X#VY <UK*'@#5;MAOT5J<B'[KP0#.%GPWS_M(P[ZMAWO\S
M["B8*QZ/VOR:#U!+ P04    " #0A&Y6X.H+U#X!   + @  '    &5X:&EB
M:70Q,#,P,69I<G-T86UE;F1M92YH=&V%4M%.@S 4?><K:A]\JX#+?(!"HF$Z
MDLT90S0^%KA ';2DK<[Y];9L2XS1^-3<TYYSS[FW=%FL5ZE'EXOK+*5GA*!,
M5F\#"(-:$*"8@1J5>_0LU9:_,Y2+"A%B"45>K!8I?'2\Y"8,9D'8<*4-L]1Z
M .H?[CWJ3\H>O=ED+ZAL*]E+E>!=QPU@"V?Y$V(];T6"*]L4U G49M]#@@>F
M6BY(#XV)0ACB':]-%X6SJWF,#W[_LA $X<7KV![<?E,<65UST1(CQ^C2*KJ&
M^?H.:54E^!\QC PW3D3WO(80H\E.@IT?C#K@;6=L%<SGQQ@IO=W<%TCS3TNR
M[X\>&BD,<6 4CB:>9A(=1X*H[R@I]1W=HP\I73XB(77':DAM^2-,"Z14P+:D
MA$8JB%B_8WMM4YV+4H_Q2>;WPRUEVI'[!%]02P,$%     @ T(1N5DYUGEZ%
M @  >PH  !X   !S=6)S:61I87)I97-O9F%X;V=E;C$R,S$R,"YH=&WM5MU/
MVS 0?]]?88(&+TT<-_U,0Z72%JC$ $$1V]/DQ)?&(HDCVR5T?_W<AHIUHQ.;
MQM1)R\,IMN_S=^?S!7NCR^'TT]48)3I+T=7M\?EDB"P;XSMOB/%H.D)GTP_G
MJ.&X!$TES1777.0TQ7A\82$KT;KP,2[+TBD]1\@9GE[CI:H&3H50X##-K'ZP
MW#$4*.N_"_9L&XU$-,\@URB20#4P-%<\GZ$[!NH>V?83UU 4"\EGB49UM^ZA
M.R'O^0.MSC77*?37>@)<K0.\,A*$@BWZ >,/B+,CBWMMKQ5YC)%NU&XTZIVP
M"6&KVXD]H#0F3?*9&">Q8:]DE%ZD<&1E/+<36-KWV_5"]TK.=.(3UWUO;?)1
M.3.LH=!:9+[KN)U"&XY8Y-IX(HWFZK<R\*.9#?%GV?5Y)%(A_7UW]?66)W9,
M,YXN_,,A37DH^6%-F<S8"B2/*P;%OX!/B'%ZM2RK*!I&/N4YK*,B]:8)Y6"?
MM-S>?[I.T]M@WWX1^_%CPD-NZILX9+-,?E8@/0V/VC;V9[D?F>H'^<=*IO$J
MMV]NCV\FH\G@>C*^09<G:/#Q\G1\44.3BZ'S^C"VWY$=NAT#A42,1A!!%H)$
M'JDMFY&A@T<Q@]S$G$<.2BA#.I$ 2(G4D'FH..-4<E '^\U.;VMX!67,=#X[
MA5C[7FN=6YXSDU??)G\_8.*\[45XR6IO X:NTVHMPZX0-J^ +(2DRW>GAJA)
M14I+*@%%S_L&X^Z_A'%]US >SZ4H )UFX9G!.$>#N=*2FY_O03:'[!<:U>Y!
M[^T:]%=21*!6X\\K*GU[>_UV4BE$-:?YTJC0_ &VSB[KH>59A(:FA<WU=I'?
M&7>>:#66K0;$_E=02P$"% ,4    " #0A&Y6TA6(338#  "("   $
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M;BTR,#(R,3(S,5]D968N>&UL4$L! A0#%     @ T(1N5K9B^="NFP  R<
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M,C%Q-&5X,S(N:'1M4$L! A0#%     @ T(1N5L].KKLO"   <28  !,
M         ( !-2 ' &%X9VYF>3(R<31E>#,Q,2YH=&U02P$"% ,4    " #0
MA&Y6=;M/!4$(  !9*0  $P              @ &5* < 87AG;F9Y,C)Q-&5X
M,S$R+FAT;5!+ 0(4 Q0    ( -"$;E9WI.W970$  &T$   <
M  "  0<Q!P!E>&AI8FET,3 R,W1H:7)D86UE;F1M96XN:'1M4$L! A0#%
M  @ T(1N5L' %RE1 0  / ,  !P              ( !GC(' &5X:&EB:70Q
M,#(U,W-E8V]N9&%M96YD;2YH=&U02P$"% ,4    " #0A&Y6X.H+U#X!   +
M @  '               @ $I- < 97AH:6)I=#$P,S Q9FER<W1A;65N9&UE
M+FAT;5!+ 0(4 Q0    ( -"$;E9.=9Y>A0(  'L*   >              "
M :$U!P!S=6)S:61I87)I97-O9F%X;V=E;C$R,S$R,"YH=&U02P4&      \
,#P#V P  8C@'

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
